words,sentence_id,labels
Antihypertensive,0,O
drugs,0,O
and,0,O
depression,0,B-Disease
:,0,O
a,0,O
reappraisal,0,O
.,0,O
Eighty-nine,1,O
new,1,O
referral,1,O
hypertensive,1,B-Disease
out-patients,1,O
and,1,O
46,1,O
new,1,O
referral,1,O
non-hypertensive,1,O
chronically,1,O
physically,1,O
ill,1,O
out-patients,1,O
completed,1,O
a,1,O
mood,1,O
rating,1,O
scale,1,O
at,1,O
regular,1,O
intervals,1,O
for,1,O
one,1,O
year,1,O
.,1,O
The,2,O
results,2,O
showed,2,O
a,2,O
high,2,O
prevalence,2,O
of,2,O
depression,2,B-Disease
in,2,O
both,2,O
groups,2,O
of,2,O
patients,2,O
",",2,O
with,2,O
no,2,O
preponderance,2,O
in,2,O
the,2,O
hypertensive,2,B-Disease
group,2,O
.,2,O
Hypertensive,3,B-Disease
patients,3,O
with,3,O
psychiatric,3,B-Disease
histories,3,O
had,3,O
a,3,O
higher,3,O
prevalence,3,O
of,3,O
depression,3,B-Disease
than,3,O
the,3,O
comparison,3,O
patients,3,O
.,3,O
This,4,O
was,4,O
accounted,4,O
for,4,O
by,4,O
a,4,O
significant,4,O
number,4,O
of,4,O
depressions,4,B-Disease
occurring,4,O
in,4,O
methyl,4,B-Chemical
dopa,4,I-Chemical
treated,4,O
patients,4,O
with,4,O
psychiatric,4,B-Disease
histories,4,O
.,4,O
Pharmacokinetic,5,O
and,5,O
clinical,5,O
studies,5,O
in,5,O
patients,5,O
with,5,O
cimetidine-associated,5,B-Chemical
mental,5,O
confusion,5,B-Disease
.,5,O
15,6,O
cases,6,O
of,6,O
cimetidine-associated,6,B-Chemical
mental,6,O
confusion,6,B-Disease
have,6,O
been,6,O
reported,6,O
.,6,O
In,7,O
order,7,O
that,7,O
this,7,O
syndrome,7,O
might,7,O
be,7,O
investigated,7,O
changes,7,O
in,7,O
mental,7,O
status,7,O
(,7,O
M.S,7,O
.,7,O
),7,O
were,8,O
correlated,8,O
with,8,O
serum,8,O
concentrations,8,O
and,8,O
renal,8,O
and,8,O
hepatic,8,O
function,8,O
in,8,O
36,8,O
patients,8,O
",",8,O
30,8,O
patients,8,O
had,8,O
no,8,O
M.S,8,O
.,8,O
change,9,O
on,9,O
cimetidine,9,B-Chemical
and,9,O
6,9,O
had,9,O
moderate,9,O
to,9,O
severe,9,O
changes,9,O
.,9,O
These,10,O
6,10,O
patients,10,O
had,10,O
both,10,O
renal,10,O
and,10,O
liver,10,O
dysfunction,10,O
(,10,O
P,10,O
less,10,O
than,10,O
0.05,10,O
),10,O
",",10,O
as,10,O
well,10,O
as,10,O
cimetidine,10,B-Chemical
trough-concentrations,10,O
of,10,O
more,10,O
than,10,O
1.25,10,O
microgram/ml,10,O
(,10,O
P,10,O
less,10,O
than,10,O
0.05,10,O
),10,O
.,10,O
The,11,O
severity,11,O
of,11,O
M.S,11,O
.,11,O
changes,12,O
increased,12,O
as,12,O
trough-concentrations,12,O
rose,12,O
",",12,O
5,12,O
patients,12,O
had,12,O
lumbar,12,O
puncture,12,O
.,12,O
The,13,O
cerebrospinal,13,O
fluid,13,O
:,13,O
serum,13,O
ratio,13,O
of,13,O
cimetidine,13,B-Chemical
concentrations,13,O
was,13,O
0.24:1,13,O
and,13,O
indicates,13,O
that,13,O
cimetidine,13,B-Chemical
passes,13,O
the,13,O
blood-brain,13,O
barrier,13,O
;,13,O
it,13,O
also,13,O
raises,13,O
the,13,O
possibility,13,O
that,13,O
M.S,13,O
.,13,O
changes,14,O
are,14,O
due,14,O
to,14,O
blockade,14,O
of,14,O
histamine,14,B-Chemical
H2-receptors,14,O
in,14,O
the,14,O
central,14,O
nervous,14,O
system,14,O
.,14,O
Patients,15,O
likely,15,O
to,15,O
have,15,O
both,15,O
raised,15,O
trough-concentrations,15,O
and,15,O
mental,15,O
confusion,15,B-Disease
are,15,O
those,15,O
with,15,O
both,15,O
severe,15,O
renal,15,O
and,15,O
hepatic,15,O
dysfunction,15,O
.,15,O
They,16,O
should,16,O
be,16,O
closely,16,O
observed,16,O
and,16,O
should,16,O
be,16,O
given,16,O
reduced,16,O
doses,16,O
of,16,O
cimetidine,16,B-Chemical
.,16,O
Alpha,17,O
and,17,O
beta,17,O
coma,17,B-Disease
in,17,O
drug,17,O
intoxication,17,O
uncomplicated,17,O
by,17,O
cerebral,17,B-Disease
hypoxia,17,I-Disease
.,17,O
Four,18,O
patients,18,O
who,18,O
were,18,O
rendered,18,O
comatose,18,B-Disease
or,18,O
stuporous,18,B-Disease
by,18,O
drug,18,O
intoxication,18,O
",",18,O
but,18,O
who,18,O
were,18,O
not,18,O
hypoxic,18,O
",",18,O
are,18,O
described,18,O
.,18,O
Three,19,O
patients,19,O
received,19,O
high,19,O
doses,19,O
of,19,O
chlormethiazole,19,B-Chemical
for,19,O
alcohol,19,B-Chemical
withdrawal,19,B-Disease
symptoms,19,I-Disease
",",19,O
and,19,O
one,19,O
took,19,O
a,19,O
suicidal,19,O
overdose,19,B-Disease
of,19,O
nitrazepam,19,B-Chemical
.,19,O
The,20,O
patient,20,O
with,20,O
nitrazepam,20,B-Chemical
overdose,20,B-Disease
and,20,O
two,20,O
of,20,O
those,20,O
with,20,O
chlormethiazole,20,B-Chemical
intoxication,20,O
conformed,20,O
to,20,O
the,20,O
criteria,20,O
of,20,O
'alpha,20,O
coma,20,B-Disease
',20,O
",",20,O
showing,20,O
non-reactive,20,O
generalized,20,O
or,20,O
frontally,20,O
predominant,20,O
alpha,20,O
activity,20,O
in,20,O
the,20,O
EEG,20,O
.,20,O
The,21,O
fourth,21,O
patient,21,O
who,21,O
was,21,O
unconscious,21,O
after,21,O
chlormethiazole,21,B-Chemical
administration,21,O
exhibite,21,O
generalized,21,O
non-reactive,21,O
activity,21,O
in,21,O
the,21,O
slow,21,O
beta,21,O
range,21,O
.,21,O
All,22,O
four,22,O
recovered,22,O
completely,22,O
without,22,O
neurological,22,B-Disease
sequelae,22,I-Disease
following,22,O
the,22,O
withdrawal,22,O
of,22,O
the,22,O
offending,22,O
agents,22,O
.,22,O
The,23,O
similarities,23,O
between,23,O
the,23,O
effects,23,O
of,23,O
structural,23,O
lesions,23,O
and,23,O
pharmacological,23,O
depression,23,B-Disease
of,23,O
the,23,O
brain,23,O
stem,23,O
reticular,23,O
formation,23,O
are,23,O
discussed,23,O
.,23,O
It,24,O
is,24,O
suggested,24,O
that,24,O
in,24,O
both,24,O
situations,24,O
disturbed,24,O
reticulo-thalamic,24,O
interactions,24,O
are,24,O
important,24,O
in,24,O
the,24,O
pathogenesis,24,O
of,24,O
alpha,24,O
coma,24,B-Disease
.,24,O
It,25,O
is,25,O
concluded,25,O
that,25,O
when,25,O
this,25,O
electroencephalographic,25,O
and,25,O
behavioural,25,O
picture,25,O
is,25,O
seen,25,O
in,25,O
drug,25,O
intoxication,25,O
",",25,O
in,25,O
the,25,O
absence,25,O
of,25,O
significant,25,O
hypoxaemia,25,B-Disease
",",25,O
a,25,O
favourable,25,O
outcome,25,O
may,25,O
be,25,O
anticipated,25,O
.,25,O
Effect,26,O
of,26,O
humoral,26,O
modulators,26,O
of,26,O
morphine-induced,26,B-Chemical
increase,26,B-Disease
in,26,I-Disease
locomotor,26,I-Disease
activity,26,I-Disease
of,26,O
mice,26,O
.,26,O
The,27,O
effect,27,O
of,27,O
humoral,27,O
modulators,27,O
on,27,O
the,27,O
morphine-induced,27,B-Chemical
increase,27,B-Disease
in,27,I-Disease
locomotor,27,I-Disease
activity,27,I-Disease
of,27,O
mice,27,O
was,27,O
studied,27,O
.,27,O
The,28,O
subcutaneous,28,O
administration,28,O
of,28,O
10,28,O
mg/kg,28,O
of,28,O
morphine-HC1,28,B-Chemical
produced,28,O
a,28,O
marked,28,O
increase,28,B-Disease
in,28,I-Disease
locomotor,28,I-Disease
activity,28,I-Disease
in,28,O
mice,28,O
.,28,O
The,29,O
morphine-induced,29,B-Chemical
hyperactivity,29,B-Disease
was,29,O
potentiated,29,O
by,29,O
scopolamine,29,B-Chemical
and,29,O
attenuated,29,O
by,29,O
physostigmine,29,B-Chemical
.,29,O
In,30,O
contrast,30,O
",",30,O
both,30,O
methscopolamine,30,B-Chemical
and,30,O
neostigmine,30,B-Chemical
",",30,O
which,30,O
do,30,O
not,30,O
penetrate,30,O
the,30,O
blood-brain,30,O
barrier,30,O
",",30,O
had,30,O
no,30,O
effect,30,O
on,30,O
the,30,O
hyperactivity,30,B-Disease
produced,30,O
by,30,O
morphine,30,B-Chemical
.,30,O
Pretreatment,31,O
of,31,O
mice,31,O
with,31,O
alpha-methyltyrosine,31,B-Chemical
(,31,O
20,31,O
mg/kg,31,O
i.p.,31,O
",",31,O
one,31,O
hour,31,O
),31,O
",",31,O
an,31,O
inhibitor,31,O
of,31,O
tyrosine,31,B-Chemical
hydroxylase,31,O
",",31,O
significantly,31,O
decreased,31,O
the,31,O
activity-increasing,31,O
effects,31,O
of,31,O
morphine,31,B-Chemical
.,31,O
On,32,O
the,32,O
other,32,O
hand,32,O
",",32,O
pretreatment,32,O
with,32,O
p-chlorophenylalamine,32,B-Chemical
(,32,O
3,32,O
X,32,O
320,32,O
mg/kg,32,O
i.p.,32,O
",",32,O
24,32,O
hr,32,O
),32,O
",",32,O
a,32,O
serotonin,32,B-Chemical
depletor,32,O
",",32,O
caused,32,O
no,32,O
significant,32,O
change,32,O
in,32,O
the,32,O
hyperactivity,32,B-Disease
.,32,O
The,33,O
study,33,O
suggests,33,O
that,33,O
the,33,O
activity-increasing,33,O
effects,33,O
of,33,O
morphine,33,B-Chemical
are,33,O
mediated,33,O
by,33,O
the,33,O
release,33,O
of,33,O
catecholamines,33,B-Chemical
from,33,O
adrenergic,33,O
neurons,33,O
in,33,O
the,33,O
brain,33,O
.,33,O
And,34,O
the,34,O
results,34,O
are,34,O
consistent,34,O
with,34,O
the,34,O
hypothesis,34,O
that,34,O
morphine,34,B-Chemical
acts,34,O
by,34,O
retarding,34,O
the,34,O
release,34,O
of,34,O
acetylcholine,34,B-Chemical
at,34,O
some,34,O
central,34,O
cholinergic,34,O
synapses,34,O
.,34,O
It,35,O
is,35,O
also,35,O
suggested,35,O
from,35,O
collected,35,O
evidence,35,O
that,35,O
the,35,O
activity-increasing,35,O
effects,35,O
of,35,O
morphine,35,B-Chemical
in,35,O
mice,35,O
are,35,O
mediated,35,O
by,35,O
mechanisms,35,O
different,35,O
from,35,O
those,35,O
which,35,O
mediate,35,O
the,35,O
activity-increasing,35,O
effects,35,O
of,35,O
morphine,35,B-Chemical
in,35,O
rats,35,O
.,35,O
A,36,O
pyridoxine-dependent,36,B-Chemical
behavioral,36,B-Disease
disorder,36,I-Disease
unmasked,36,O
by,36,O
isoniazid,36,B-Chemical
.,36,O
A,37,O
3-year-old,37,O
girl,37,O
had,37,O
behavioral,37,B-Disease
deterioration,37,I-Disease
",",37,O
with,37,O
hyperkinesis,37,B-Disease
",",37,O
irritability,37,B-Disease
",",37,O
and,37,O
sleeping,37,B-Disease
difficulties,37,I-Disease
after,37,O
the,37,O
therapeutic,37,O
administration,37,O
of,37,O
isoniazid,37,B-Chemical
.,37,O
The,38,O
administration,38,O
of,38,O
pharmacologic,38,O
doses,38,O
of,38,O
pyridoxine,38,B-Chemical
hydrochloride,38,I-Chemical
led,38,O
to,38,O
a,38,O
disappearance,38,O
of,38,O
symptoms,38,O
.,38,O
After,39,O
discontinuing,39,O
isoniazid,39,B-Chemical
therapy,39,O
a,39,O
similar,39,O
pattern,39,O
of,39,O
behavior,39,O
was,39,O
noted,39,O
that,39,O
was,39,O
controlled,39,O
by,39,O
pyridoxine,39,B-Chemical
.,39,O
A,40,O
placebo,40,O
had,40,O
no,40,O
effect,40,O
",",40,O
but,40,O
niacinamide,40,B-Chemical
was,40,O
as,40,O
effective,40,O
as,40,O
pyridoxine,40,B-Chemical
.,40,O
Periodic,41,O
withdrawal,41,O
of,41,O
pyridoxine,41,B-Chemical
was,41,O
associated,41,O
with,41,O
return,41,O
of,41,O
the,41,O
hyperkinesis,41,B-Disease
.,41,O
The,42,O
level,42,O
of,42,O
pyridoxal,42,B-Chemical
in,42,O
the,42,O
blood,42,O
was,42,O
normal,42,O
during,42,O
the,42,O
periods,42,O
of,42,O
relapse,42,O
.,42,O
Metabolic,43,O
studies,43,O
suggested,43,O
a,43,O
block,43,O
in,43,O
the,43,O
kynurenine,43,B-Chemical
pathway,43,O
of,43,O
tryptophan,43,B-Chemical
metabolism,43,O
.,43,O
The,44,O
patient,44,O
has,44,O
been,44,O
followed,44,O
for,44,O
six,44,O
years,44,O
and,44,O
has,44,O
required,44,O
pharmacologic,44,O
doses,44,O
of,44,O
pyridoxine,44,B-Chemical
to,44,O
control,44,O
her,44,O
behavior,44,O
.,44,O
Perhexiline,45,B-Chemical
maleate,45,I-Chemical
and,45,O
peripheral,45,B-Disease
neuropathy,45,I-Disease
.,45,O
Peripheral,46,B-Disease
neuropathy,46,I-Disease
has,46,O
been,46,O
noted,46,O
as,46,O
a,46,O
complication,46,O
of,46,O
therapy,46,O
with,46,O
perhexiline,46,B-Chemical
maleate,46,I-Chemical
",",46,O
a,46,O
drug,46,O
widely,46,O
used,46,O
in,46,O
France,46,O
(,46,O
and,46,O
in,46,O
clinical,46,O
trials,46,O
in,46,O
the,46,O
United,46,O
States,46,O
),46,O
for,46,O
the,46,O
prophylactic,46,O
treatment,46,O
of,46,O
angina,46,B-Disease
pectoris,46,I-Disease
.,46,O
In,47,O
24,47,O
patients,47,O
with,47,O
this,47,O
complication,47,O
",",47,O
the,47,O
marked,47,O
slowing,47,O
of,47,O
motor,47,O
nerve,47,O
conduction,47,O
velocity,47,O
and,47,O
the,47,O
electromyographic,47,O
changes,47,O
imply,47,O
mainly,47,O
a,47,O
demyelinating,47,B-Disease
disorder,47,I-Disease
.,47,O
Improvement,48,O
was,48,O
noted,48,O
with,48,O
cessation,48,O
of,48,O
therapy,48,O
.,48,O
In,49,O
a,49,O
few,49,O
cases,49,O
the,49,O
presence,49,O
of,49,O
active,49,O
denervation,49,O
signified,49,O
a,49,O
poor,49,O
prognosis,49,O
",",49,O
with,49,O
only,49,O
slight,49,O
improvement,49,O
.,49,O
The,50,O
underlying,50,O
mechanism,50,O
causing,50,O
the,50,O
neuropathy,50,B-Disease
is,50,O
not,50,O
yet,50,O
fully,50,O
known,50,O
",",50,O
although,50,O
some,50,O
evidence,50,O
indicates,50,O
that,50,O
it,50,O
may,50,O
be,50,O
a,50,O
lipid,50,O
storage,50,O
process,50,O
.,50,O
Naloxone,51,B-Chemical
reverses,51,O
the,51,O
antihypertensive,51,O
effect,51,O
of,51,O
clonidine,51,B-Chemical
.,51,O
In,52,O
unanesthetized,52,O
",",52,O
spontaneously,52,O
hypertensive,52,B-Disease
rats,52,O
the,52,O
decrease,52,O
in,52,O
blood,52,O
pressure,52,O
and,52,O
heart,52,O
rate,52,O
produced,52,O
by,52,O
intravenous,52,O
clonidine,52,B-Chemical
",",52,O
5,52,O
to,52,O
20,52,O
micrograms/kg,52,O
",",52,O
was,52,O
inhibited,52,O
or,52,O
reversed,52,O
by,52,O
nalozone,52,B-Chemical
",",52,O
0.2,52,O
to,52,O
2,52,O
mg/kg,52,O
.,52,O
The,53,O
hypotensive,53,B-Disease
effect,53,O
of,53,O
100,53,O
mg/kg,53,O
alpha-methyldopa,53,B-Chemical
was,53,O
also,53,O
partially,53,O
reversed,53,O
by,53,O
naloxone,53,B-Chemical
.,53,O
Naloxone,54,B-Chemical
alone,54,O
did,54,O
not,54,O
affect,54,O
either,54,O
blood,54,O
pressure,54,O
or,54,O
heart,54,O
rate,54,O
.,54,O
In,55,O
brain,55,O
membranes,55,O
from,55,O
spontaneously,55,O
hypertensive,55,B-Disease
rats,55,O
clonidine,55,B-Chemical
",",55,O
10,55,O
(,55,O
-8,55,O
),55,O
to,55,O
10,55,O
(,55,O
-5,55,O
),55,O
M,55,O
",",55,O
did,55,O
not,55,O
influence,55,O
stereoselective,55,O
binding,55,O
of,55,O
[,55,B-Chemical
3H,55,I-Chemical
],55,I-Chemical
-naloxone,55,I-Chemical
(,55,O
8,55,O
nM,55,O
),55,O
",",55,O
and,55,O
naloxone,55,B-Chemical
",",55,O
10,55,O
(,55,O
-8,55,O
),55,O
to,55,O
10,55,O
(,55,O
-4,55,O
),55,O
M,55,O
",",55,O
did,55,O
not,55,O
influence,55,O
clonidine-suppressible,55,B-Chemical
binding,55,O
of,55,O
[,55,B-Chemical
3H,55,I-Chemical
],55,I-Chemical
-dihydroergocryptine,55,I-Chemical
(,55,O
1,55,O
nM,55,O
),55,O
.,55,O
These,56,O
findings,56,O
indicate,56,O
that,56,O
in,56,O
spontaneously,56,O
hypertensive,56,B-Disease
rats,56,O
the,56,O
effects,56,O
of,56,O
central,56,O
alpha-adrenoceptor,56,O
stimulation,56,O
involve,56,O
activation,56,O
of,56,O
opiate,56,O
receptors,56,O
.,56,O
As,57,O
naloxone,57,B-Chemical
and,57,O
clonidine,57,B-Chemical
do,57,O
not,57,O
appear,57,O
to,57,O
interact,57,O
with,57,O
the,57,O
same,57,O
receptor,57,O
site,57,O
",",57,O
the,57,O
observed,57,O
functional,57,O
antagonism,57,O
suggests,57,O
the,57,O
release,57,O
of,57,O
an,57,O
endogenous,57,O
opiate,57,O
by,57,O
clonidine,57,B-Chemical
or,57,O
alpha-methyldopa,57,B-Chemical
and,57,O
the,57,O
possible,57,O
role,57,O
of,57,O
the,57,O
opiate,57,O
in,57,O
the,57,O
central,57,O
control,57,O
of,57,O
sympathetic,57,O
tone,57,O
.,57,O
Neurotoxicity,58,B-Disease
of,58,O
halogenated,58,B-Chemical
hydroxyquinolines,58,I-Chemical
:,58,O
clinical,58,O
analysis,58,O
of,58,O
cases,58,O
reported,58,O
outside,58,O
Japan,58,O
.,58,O
An,59,O
analysis,59,O
is,59,O
presented,59,O
of,59,O
220,59,O
cases,59,O
of,59,O
possible,59,O
neurotoxic,59,B-Disease
reactions,59,O
to,59,O
halogenated,59,B-Chemical
hydroxyquinolines,59,I-Chemical
reported,59,O
from,59,O
outside,59,O
Japan,59,O
.,59,O
In,60,O
80,60,O
cases,60,O
insufficient,60,O
information,60,O
was,60,O
available,60,O
for,60,O
adequate,60,O
comment,60,O
and,60,O
in,60,O
29,60,O
a,60,O
relationship,60,O
to,60,O
the,60,O
administration,60,O
of,60,O
clioquinol,60,B-Chemical
could,60,O
be,60,O
excluded,60,O
.,60,O
Of,61,O
the,61,O
remainder,61,O
",",61,O
a,61,O
relationship,61,O
to,61,O
clioquinol,61,B-Chemical
was,61,O
considered,61,O
probable,61,O
in,61,O
42,61,O
and,61,O
possible,61,O
in,61,O
69,61,O
cases,61,O
.,61,O
In,62,O
six,62,O
of,62,O
the,62,O
probable,62,O
cases,62,O
the,62,O
neurological,62,B-Disease
disturbance,62,I-Disease
consisted,62,O
of,62,O
an,62,O
acute,62,O
reversible,62,O
encephalopathy,62,B-Disease
usually,62,O
related,62,O
to,62,O
the,62,O
ingestion,62,O
of,62,O
a,62,O
high,62,O
dose,62,O
of,62,O
clioquinol,62,B-Chemical
over,62,O
a,62,O
short,62,O
period,62,O
.,62,O
The,63,O
most,63,O
common,63,O
manifestation,63,O
",",63,O
observed,63,O
in,63,O
15,63,O
further,63,O
cases,63,O
",",63,O
was,63,O
isolated,63,O
optic,63,B-Disease
atrophy,63,I-Disease
.,63,O
This,64,O
was,64,O
most,64,O
frequently,64,O
found,64,O
in,64,O
children,64,O
",",64,O
many,64,O
of,64,O
whom,64,O
had,64,O
received,64,O
clioquinol,64,B-Chemical
as,64,O
treatment,64,O
for,64,O
acrodermatitis,64,B-Disease
enteropathica,64,I-Disease
.,64,O
In,65,O
the,65,O
remaining,65,O
cases,65,O
",",65,O
a,65,O
combination,65,O
of,65,O
myelopathy,65,B-Disease
",",65,O
visual,65,B-Disease
disturbance,65,I-Disease
",",65,O
and,65,O
peripheral,65,B-Disease
neuropathy,65,I-Disease
was,65,O
the,65,O
most,65,O
common,65,O
manifestation,65,O
.,65,O
Isolated,66,O
myelopathy,66,B-Disease
or,66,O
peripheral,66,B-Disease
neuropathy,66,I-Disease
",",66,O
or,66,O
these,66,O
manifestations,66,O
occurring,66,O
together,66,O
",",66,O
were,66,O
infrequent,66,O
.,66,O
The,67,O
onset,67,O
of,67,O
all,67,O
manifestations,67,O
(,67,O
except,67,O
toxic,67,O
encephalopathy,67,B-Disease
),67,O
was,67,O
usually,67,O
subacute,67,O
",",67,O
with,67,O
subsequent,67,O
partial,67,O
recovery,67,O
.,67,O
Older,68,O
subjects,68,O
tended,68,O
to,68,O
display,68,O
more,68,O
side,68,O
effects,68,O
.,68,O
The,69,O
full,69,O
syndrome,69,O
of,69,O
subacute,69,O
myelo-optic,69,O
neuropathy,69,O
was,69,O
more,69,O
frequent,69,O
in,69,O
women,69,O
",",69,O
but,69,O
they,69,O
tended,69,O
to,69,O
have,69,O
taken,69,O
greater,69,O
quantities,69,O
of,69,O
the,69,O
drug,69,O
.,69,O
Effects,70,O
of,70,O
aminophylline,70,B-Chemical
on,70,O
the,70,O
threshold,70,O
for,70,O
initiating,70,O
ventricular,70,B-Disease
fibrillation,70,I-Disease
during,70,O
respiratory,70,B-Disease
failure,70,I-Disease
.,70,O
Cardiac,71,B-Disease
arrhythmias,71,I-Disease
have,71,O
frequently,71,O
been,71,O
reported,71,O
in,71,O
association,71,O
with,71,O
respiratory,71,B-Disease
failure,71,I-Disease
.,71,O
The,72,O
possible,72,O
additive,72,O
role,72,O
of,72,O
pharmacologic,72,O
agents,72,O
in,72,O
precipitating,72,O
cardiac,72,B-Disease
disturbances,72,I-Disease
in,72,O
patients,72,O
with,72,O
respiratory,72,B-Disease
failure,72,I-Disease
has,72,O
only,72,O
recently,72,O
been,72,O
emphasized,72,O
.,72,O
The,73,O
effects,73,O
of,73,O
aminophylline,73,B-Chemical
on,73,O
the,73,O
ventricular,73,B-Disease
fibrillation,73,I-Disease
threshold,73,O
during,73,O
normal,73,O
acid-base,73,O
conditions,73,O
and,73,O
during,73,O
respiratory,73,B-Disease
failure,73,I-Disease
were,73,O
studied,73,O
in,73,O
anesthetized,73,O
open,73,O
chest,73,O
dogs,73,O
.,73,O
The,74,O
ventricular,74,B-Disease
fibrillation,74,I-Disease
threshold,74,O
was,74,O
measured,74,O
by,74,O
passing,74,O
a,74,O
gated,74,O
train,74,O
of,74,O
12,74,O
constant,74,O
current,74,O
pulses,74,O
through,74,O
the,74,O
ventricular,74,O
myocardium,74,O
during,74,O
the,74,O
vulnerable,74,O
period,74,O
of,74,O
the,74,O
cardiac,74,O
cycle,74,O
.,74,O
During,75,O
the,75,O
infusion,75,O
of,75,O
aminophylline,75,B-Chemical
",",75,O
the,75,O
ventricular,75,B-Disease
fibrillation,75,I-Disease
threshold,75,O
was,75,O
reduced,75,O
by,75,O
30,75,O
to,75,O
40,75,O
percent,75,O
of,75,O
the,75,O
control,75,O
when,75,O
pH,75,O
and,75,O
partial,75,O
pressures,75,O
of,75,O
oxygen,75,B-Chemical
(,75,O
PO2,75,B-Chemical
),75,O
and,75,O
carbon,75,B-Chemical
dioxide,75,I-Chemical
(,75,O
CO2,75,B-Chemical
),75,O
were,75,O
kept,75,O
within,75,O
normal,75,O
limits,75,O
.,75,O
When,76,O
respiratory,76,B-Disease
failure,76,I-Disease
was,76,O
produced,76,O
by,76,O
hypoventilation,76,B-Disease
(,76,O
pH,76,O
7.05,76,O
to,76,O
7.25,76,O
;,76,O
PC02,76,O
70,76,O
to,76,O
100,76,O
mm,76,O
Hg,76,O
:,76,O
P02,76,O
20,76,O
to,76,O
40,76,O
mm,76,O
Hg,76,O
),76,O
",",76,O
infusion,76,O
of,76,O
aminophylline,76,B-Chemical
resulted,76,O
in,76,O
an,76,O
even,76,O
greater,76,O
decrease,76,O
in,76,O
ventricular,76,B-Disease
fibrillation,76,I-Disease
threshold,76,O
to,76,O
60,76,O
percent,76,O
of,76,O
the,76,O
control,76,O
level,76,O
.,76,O
These,77,O
experiments,77,O
suggest,77,O
that,77,O
although,77,O
many,77,O
factors,77,O
may,77,O
contribute,77,O
to,77,O
the,77,O
increased,77,O
incidence,77,O
of,77,O
ventricular,77,B-Disease
arrhythmias,77,I-Disease
in,77,O
respiratory,77,B-Disease
failure,77,I-Disease
",",77,O
pharmacologic,77,O
agents,77,O
",",77,O
particularly,77,O
aminophylline,77,B-Chemical
",",77,O
may,77,O
play,77,O
a,77,O
significant,77,O
role,77,O
.,77,O
Pulmonary,78,O
shunt,78,O
and,78,O
cardiovascular,78,O
responses,78,O
to,78,O
CPAP,78,O
during,78,O
nitroprusside-induced,78,B-Chemical
hypotension,78,B-Disease
.,78,O
The,79,O
effects,79,O
of,79,O
continuous,79,O
positive,79,O
airway,79,O
pressure,79,O
(,79,O
CPAP,79,O
),79,O
on,79,O
cardiovascular,79,O
dynamics,79,O
and,79,O
pulmonary,79,O
shunt,79,O
(,79,O
QS/QT,79,O
),79,O
were,79,O
investigated,79,O
in,79,O
12,79,O
dogs,79,O
before,79,O
and,79,O
during,79,O
sodium,79,B-Chemical
nitroprusside,79,I-Chemical
infusion,79,O
that,79,O
decreased,79,O
mean,79,O
arterial,79,O
blood,79,O
pressure,79,O
40-50,79,O
per,79,O
cent,79,O
.,79,O
Before,80,O
nitroprusside,80,B-Chemical
infusion,80,O
",",80,O
5,80,O
cm,80,O
H2O,80,B-Chemical
CPAP,80,O
significantly,80,O
",",80,O
P,80,O
less,80,O
than,80,O
.05,80,O
",",80,O
decreased,80,O
arterial,80,O
blood,80,O
pressure,80,O
",",80,O
but,80,O
did,80,O
not,80,O
significantly,80,O
alter,80,O
heart,80,O
rate,80,O
",",80,O
cardiac,80,O
output,80,O
",",80,O
systemic,80,O
vascular,80,O
resistance,80,O
",",80,O
or,80,O
QS/QT,80,O
.,80,O
Ten,81,O
cm,81,O
H2O,81,B-Chemical
CPAP,81,O
before,81,O
nitroprusside,81,B-Chemical
infusion,81,O
produced,81,O
a,81,O
further,81,O
decrease,81,B-Disease
in,81,I-Disease
arterial,81,I-Disease
blood,81,I-Disease
pressure,81,I-Disease
and,81,O
significantly,81,O
increased,81,O
heart,81,O
rate,81,O
and,81,O
decreased,81,B-Disease
cardiac,81,I-Disease
output,81,I-Disease
and,81,O
QS/QT,81,O
.,81,O
Nitroprusside,82,B-Chemical
caused,82,O
significant,82,O
decreases,82,B-Disease
in,82,I-Disease
arterial,82,I-Disease
blood,82,I-Disease
pressure,82,I-Disease
and,82,O
systemic,82,O
vascular,82,O
resistance,82,O
and,82,O
increases,82,O
in,82,O
heart,82,O
rate,82,O
",",82,O
but,82,O
did,82,O
not,82,O
change,82,O
cardiac,82,O
output,82,O
or,82,O
QS/QT,82,O
.,82,O
Five,83,O
cm,83,O
H2O,83,B-Chemical
CPAP,83,O
during,83,O
nitroprusside,83,B-Chemical
did,83,O
not,83,O
further,83,O
alter,83,O
any,83,O
of,83,O
the,83,O
above-mentioned,83,O
variables,83,O
.,83,O
However,84,O
",",84,O
10,84,O
cm,84,O
H2O,84,B-Chemical
CPAP,84,O
decreased,84,O
arterial,84,O
blood,84,O
pressure,84,O
",",84,O
cardiac,84,O
output,84,O
",",84,O
and,84,O
QS/QT,84,O
.,84,O
These,85,O
data,85,O
indicate,85,O
that,85,O
nitroprusside,85,B-Chemical
infusion,85,O
rates,85,O
that,85,O
decrease,85,O
mean,85,O
arterial,85,O
blood,85,O
pressure,85,O
by,85,O
40-50,85,O
per,85,O
cent,85,O
do,85,O
not,85,O
change,85,O
cardiac,85,O
output,85,O
or,85,O
QS/QT,85,O
.,85,O
During,86,O
nitroprusside,86,B-Chemical
infusion,86,O
low,86,O
levels,86,O
of,86,O
CPAP,86,O
do,86,O
not,86,O
markedly,86,O
alter,86,O
cardiovascular,86,O
dynamics,86,O
",",86,O
but,86,O
high,86,O
levels,86,O
of,86,O
CPAP,86,O
(,86,O
10,86,O
cm,86,O
H2O,86,B-Chemical
),86,O
",",86,O
while,86,O
decreasing,86,O
QS/QT,86,O
",",86,O
produce,86,O
marked,86,O
decreases,86,O
in,86,O
arterial,86,O
blood,86,O
pressure,86,O
and,86,O
cardiac,86,O
output,86,O
.,86,O
Clinical,87,O
experiences,87,O
in,87,O
an,87,O
open,87,O
and,87,O
a,87,O
double-blind,87,O
trial,87,O
.,87,O
A,88,O
total,88,O
of,88,O
sixty,88,O
patients,88,O
were,88,O
trated,88,O
with,88,O
bromperidol,88,B-Chemical
first,88,O
in,88,O
open,88,O
conditions,88,O
(,88,O
20,88,O
patients,88,O
),88,O
",",88,O
then,88,O
on,88,O
a,88,O
double,88,O
blind,88,O
basis,88,O
(,88,O
40,88,O
patients,88,O
),88,O
with,88,O
haloperidol,88,B-Chemical
as,88,O
the,88,O
reference,88,O
substance,88,O
.,88,O
The,89,O
open,89,O
study,89,O
lasted,89,O
for,89,O
four,89,O
weeks,89,O
;,89,O
the,89,O
drug,89,O
was,89,O
administrated,89,O
in,89,O
the,89,O
form,89,O
of,89,O
1,89,O
mg,89,O
tablets,89,O
.,89,O
The,90,O
daily,90,O
dose,90,O
(,90,O
initial,90,O
dose,90,O
:,90,O
1,90,O
mg,90,O
;,90,O
mean,90,O
dose,90,O
at,90,O
the,90,O
end,90,O
of,90,O
the,90,O
trial,90,O
:,90,O
4.47,90,O
mg,90,O
),90,O
was,90,O
always,90,O
administered,90,O
in,90,O
one,90,O
single,90,O
dose,90,O
.,90,O
Nineteen,91,O
patients,91,O
finished,91,O
the,91,O
trial,91,O
",",91,O
and,91,O
in,91,O
18,91,O
cases,91,O
the,91,O
therapeutic,91,O
result,91,O
was,91,O
considered,91,O
very,91,O
good,91,O
to,91,O
good,91,O
.,91,O
These,92,O
results,92,O
were,92,O
confirmed,92,O
by,92,O
statistical,92,O
analysis,92,O
.,92,O
Nine,93,O
patients,93,O
exhibited,93,O
mild,93,O
to,93,O
moderate,93,O
extrapyramidal,93,B-Disease
concomitant,93,I-Disease
symptoms,93,I-Disease
;,93,O
no,93,O
other,93,O
side,93,O
effects,93,O
were,93,O
observed,93,O
.,93,O
The,94,O
results,94,O
of,94,O
detailed,94,O
laboratory,94,O
tests,94,O
and,94,O
evaluations,94,O
of,94,O
various,94,O
quantitative,94,O
and,94,O
qualitative,94,O
tolerability,94,O
parameters,94,O
were,94,O
not,94,O
indicative,94,O
of,94,O
toxic,94,O
effects,94,O
.,94,O
In,95,O
the,95,O
double,95,O
blind,95,O
study,95,O
with,95,O
haloperidol,95,B-Chemical
",",95,O
both,95,O
substances,95,O
were,95,O
found,95,O
to,95,O
be,95,O
highly,95,O
effective,95,O
in,95,O
the,95,O
treatment,95,O
of,95,O
psychotic,95,B-Disease
syndromes,95,I-Disease
belonging,95,I-Disease
predominantly,95,I-Disease
to,95,I-Disease
the,95,I-Disease
schizophrenia,95,I-Disease
group,95,I-Disease
.,95,O
Certain,96,O
clues,96,O
",",96,O
including,96,O
the,96,O
onset,96,O
of,96,O
action,96,O
",",96,O
seem,96,O
to,96,O
be,96,O
indicative,96,O
of,96,O
the,96,O
superiority,96,O
of,96,O
bromperidol,96,B-Chemical
.,96,O
No,97,O
differences,97,O
were,97,O
observed,97,O
with,97,O
respect,97,O
to,97,O
side,97,O
effects,97,O
and,97,O
general,97,O
tolerability,97,O
.,97,O
Lidocaine-induced,98,B-Chemical
cardiac,98,B-Disease
asystole,98,I-Disease
.,98,O
Intravenous,99,O
administration,99,O
of,99,O
a,99,O
single,99,O
50-mg,99,O
bolus,99,O
of,99,O
lidocaine,99,B-Chemical
in,99,O
a,99,O
67-year-old,99,O
man,99,O
resulted,99,O
in,99,O
profound,99,O
depression,99,B-Disease
of,99,O
the,99,O
activity,99,O
of,99,O
the,99,O
sinoatrial,99,O
and,99,O
atrioventricular,99,O
nodal,99,O
pacemakers,99,O
.,99,O
The,100,O
patient,100,O
had,100,O
no,100,O
apparent,100,O
associated,100,O
conditions,100,O
which,100,O
might,100,O
have,100,O
predisposed,100,O
him,100,O
to,100,O
the,100,O
development,100,O
of,100,O
bradyarrhythmias,100,B-Disease
;,100,O
and,100,O
",",100,O
thus,100,O
",",100,O
this,100,O
probably,100,O
represented,100,O
a,100,O
true,100,O
idiosyncrasy,100,O
to,100,O
lidocaine,100,B-Chemical
.,100,O
Patterns,101,O
of,101,O
hepatic,101,B-Disease
injury,101,I-Disease
induced,101,O
by,101,O
methyldopa,101,B-Chemical
.,101,O
Twelve,102,O
patients,102,O
with,102,O
liver,102,B-Disease
disease,102,I-Disease
related,102,O
to,102,O
methyldopa,102,B-Chemical
were,102,O
seen,102,O
between,102,O
1967,102,O
and,102,O
1977,102,O
.,102,O
Illness,103,O
occurred,103,O
within,103,O
1,103,O
--,103,O
9,103,O
weeks,103,O
of,103,O
commencement,103,O
of,103,O
therapy,103,O
in,103,O
9,103,O
patients,103,O
",",103,O
the,103,O
remaining,103,O
3,103,O
patients,103,O
having,103,O
received,103,O
the,103,O
drug,103,O
for,103,O
13,103,O
months,103,O
",",103,O
15,103,O
months,103,O
and,103,O
7,103,O
years,103,O
before,103,O
experiencing,103,O
symptoms,103,O
.,103,O
Jaundice,104,B-Disease
with,104,O
tender,104,O
hepatomegaly,104,B-Disease
",",104,O
usually,104,O
preceded,104,O
by,104,O
symptoms,104,O
of,104,O
malaise,104,O
",",104,O
anorexia,104,B-Disease
",",104,O
nausea,104,B-Disease
and,104,O
vomiting,104,B-Disease
",",104,O
and,104,O
associated,104,O
with,104,O
upper,104,O
abdominal,104,B-Disease
pain,104,I-Disease
",",104,O
was,104,O
an,104,O
invariable,104,O
finding,104,O
in,104,O
all,104,O
patients,104,O
.,104,O
Biochemical,105,O
liver,105,O
function,105,O
tests,105,O
indicated,105,O
hepatocellular,105,O
necrosis,105,B-Disease
and,105,O
correlated,105,O
with,105,O
histopathological,105,O
evidence,105,O
of,105,O
hepatic,105,B-Disease
injury,105,I-Disease
",",105,O
the,105,O
spectrum,105,O
of,105,O
which,105,O
ranged,105,O
from,105,O
fatty,105,B-Disease
change,105,I-Disease
and,105,O
focal,105,O
hepatocellular,105,O
necrosis,105,B-Disease
to,105,O
massive,105,B-Disease
hepatic,105,I-Disease
necrosis,105,I-Disease
.,105,O
Most,106,O
patients,106,O
showed,106,O
moderate,106,O
to,106,O
severe,106,O
acute,106,B-Disease
hepatitis,106,I-Disease
or,106,O
chronic,106,B-Disease
active,106,I-Disease
hepatitis,106,I-Disease
with,106,O
associated,106,O
cholestasis,106,B-Disease
.,106,O
The,107,O
drug,107,O
was,107,O
withdrawn,107,O
on,107,O
presentation,107,O
to,107,O
hospital,107,O
in,107,O
11,107,O
patients,107,O
",",107,O
with,107,O
rapid,107,O
clinical,107,O
improvement,107,O
in,107,O
9,107,O
.,107,O
One,108,O
patient,108,O
died,108,O
",",108,O
having,108,O
presented,108,O
in,108,O
hepatic,108,B-Disease
failure,108,I-Disease
",",108,O
and,108,O
another,108,O
",",108,O
who,108,O
had,108,O
been,108,O
taking,108,O
methyldopa,108,B-Chemical
for,108,O
7,108,O
years,108,O
",",108,O
showed,108,O
slower,108,O
clinical,108,O
and,108,O
biochemical,108,O
resolution,108,O
over,108,O
a,108,O
period,108,O
of,108,O
several,108,O
months,108,O
.,108,O
The,109,O
remaining,109,O
patient,109,O
in,109,O
the,109,O
series,109,O
developed,109,O
fulminant,109,B-Disease
hepatitis,109,I-Disease
when,109,O
the,109,O
drug,109,O
was,109,O
accidentally,109,O
recommenced,109,O
1,109,O
year,109,O
after,109,O
a,109,O
prior,109,O
episode,109,O
of,109,O
methyldopa-induced,109,B-Chemical
hepatitis,109,B-Disease
.,109,O
In,110,O
this,110,O
latter,110,O
patient,110,O
",",110,O
and,110,O
in,110,O
2,110,O
others,110,O
",",110,O
the,110,O
causal,110,O
relationship,110,O
between,110,O
methyldopa,110,B-Chemical
and,110,O
hepatic,110,B-Disease
dysfunction,110,I-Disease
was,110,O
proved,110,O
with,110,O
the,110,O
recurrence,110,O
of,110,O
hepatitis,110,B-Disease
within,110,O
2,110,O
weeks,110,O
of,110,O
re-exposure,110,O
to,110,O
the,110,O
drug,110,O
.,110,O
Suxamethonium,111,B-Chemical
infusion,111,O
rate,111,O
and,111,O
observed,111,O
fasciculations,111,B-Disease
.,111,O
A,112,O
dose-response,112,O
study,112,O
.,112,O
Suxamethonium,113,B-Chemical
chloride,113,I-Chemical
(,113,O
Sch,113,B-Chemical
),113,O
was,113,O
administered,113,O
i.v,113,O
.,113,O
to,114,O
36,114,O
adult,114,O
males,114,O
at,114,O
six,114,O
rates,114,O
:,114,O
0.25,114,O
mg,114,O
s-1,114,O
to,114,O
20,114,O
mg,114,O
s-1,114,O
.,114,O
The,115,O
infusion,115,O
was,115,O
discontinued,115,O
either,115,O
when,115,O
there,115,O
was,115,O
no,115,O
muscular,115,O
response,115,O
to,115,O
tetanic,115,B-Disease
stimulation,115,O
of,115,O
the,115,O
ulnar,115,O
nerve,115,O
or,115,O
when,115,O
Sch,115,B-Chemical
120,115,O
mg,115,O
was,115,O
exceeded,115,O
.,115,O
Six,116,O
additional,116,O
patients,116,O
received,116,O
a,116,O
30-mg,116,O
i.v,116,O
.,116,O
bolus,117,O
dose,117,O
.,117,O
Fasciculations,118,B-Disease
in,118,O
six,118,O
areas,118,O
of,118,O
the,118,O
body,118,O
were,118,O
scored,118,O
from,118,O
0,118,O
to,118,O
3,118,O
and,118,O
summated,118,O
as,118,O
a,118,O
total,118,O
fasciculation,118,B-Disease
score,118,O
.,118,O
The,119,O
times,119,O
to,119,O
first,119,O
fasciculation,119,B-Disease
",",119,O
twitch,119,B-Disease
suppression,119,O
and,119,O
tetanus,119,B-Disease
suppression,119,O
were,119,O
inversely,119,O
related,119,O
to,119,O
the,119,O
infusion,119,O
rates,119,O
.,119,O
Fasciculations,120,B-Disease
in,120,O
the,120,O
six,120,O
areas,120,O
and,120,O
the,120,O
total,120,O
fasciculation,120,B-Disease
score,120,O
were,120,O
related,120,O
directly,120,O
to,120,O
the,120,O
rate,120,O
of,120,O
infusion,120,O
.,120,O
Total,121,O
fasciculation,121,B-Disease
scores,121,O
in,121,O
the,121,O
30-mg,121,O
bolus,121,O
group,121,O
and,121,O
the,121,O
5-mg,121,O
s-1,121,O
and,121,O
20-mg,121,O
s-1,121,O
infusion,121,O
groups,121,O
were,121,O
not,121,O
significantly,121,O
different,121,O
.,121,O
Angiosarcoma,122,O
of,122,O
the,122,O
liver,122,O
associated,122,O
with,122,O
diethylstilbestrol,122,B-Chemical
.,122,O
Angiosarcoma,123,O
of,123,O
the,123,O
liver,123,O
occurred,123,O
in,123,O
a,123,O
76-year-old,123,O
man,123,O
who,123,O
had,123,O
been,123,O
treated,123,O
for,123,O
a,123,O
well-differentiated,123,O
adenocarcinoma,123,O
of,123,O
the,123,O
liver,123,O
with,123,O
diethylstilbestrol,123,B-Chemical
for,123,O
13,123,O
years,123,O
.,123,O
Angiosarcoma,124,B-Disease
was,124,O
also,124,O
present,124,O
within,124,O
pulmonary,124,O
and,124,O
renal,124,O
arteries,124,O
.,124,O
The,125,O
possibility,125,O
that,125,O
the,125,O
intraarterial,125,B-Disease
lesions,125,I-Disease
might,125,O
represent,125,O
independent,125,O
primary,125,O
tumors,125,B-Disease
is,125,O
considered,125,O
.,125,O
Galanthamine,126,B-Chemical
hydrobromide,126,I-Chemical
",",126,O
a,126,O
longer,126,O
acting,126,O
anticholinesterase,126,O
drug,126,O
",",126,O
in,126,O
the,126,O
treatment,126,O
of,126,O
the,126,O
central,126,O
effects,126,O
of,126,O
scopolamine,126,B-Chemical
(,126,O
Hyoscine,126,B-Chemical
),126,O
.,126,O
Galanthamine,127,B-Chemical
hydrobromide,127,I-Chemical
",",127,O
an,127,O
anticholinesterase,127,O
drug,127,O
capable,127,O
of,127,O
penetrating,127,O
the,127,O
blood-brain,127,O
barrier,127,O
",",127,O
was,127,O
used,127,O
in,127,O
a,127,O
patient,127,O
demonstrating,127,O
central,127,O
effects,127,O
of,127,O
scopolamine,127,B-Chemical
(,127,O
hyoscine,127,B-Chemical
),127,O
overdosage,127,B-Disease
.,127,O
It,128,O
is,128,O
longer,128,O
acting,128,O
than,128,O
physostigmine,128,B-Chemical
and,128,O
is,128,O
used,128,O
in,128,O
anaesthesia,128,O
to,128,O
reverse,128,O
the,128,O
non-depolarizing,128,O
neuromuscular,128,O
block,128,O
.,128,O
However,129,O
",",129,O
studies,129,O
into,129,O
the,129,O
dose,129,O
necessary,129,O
to,129,O
combating,129,O
scopolamine,129,B-Chemical
intoxication,129,O
are,129,O
indicated,129,O
.,129,O
Reversal,130,O
by,130,O
phenylephrine,130,B-Chemical
of,130,O
the,130,O
beneficial,130,O
effects,130,O
of,130,O
intravenous,130,O
nitroglycerin,130,B-Chemical
in,130,O
patients,130,O
with,130,O
acute,130,B-Disease
myocardial,130,I-Disease
infarction,130,I-Disease
.,130,O
Nitroglycerin,131,B-Chemical
has,131,O
been,131,O
shown,131,O
to,131,O
reduce,131,O
ST-segment,131,O
elevation,131,O
during,131,O
acute,131,B-Disease
myocardial,131,I-Disease
infarction,131,I-Disease
",",131,O
an,131,O
effect,131,O
potentiated,131,O
in,131,O
the,131,O
dog,131,O
by,131,O
agents,131,O
that,131,O
reverse,131,O
nitroglycerin-induced,131,B-Chemical
hypotension,131,B-Disease
.,131,O
Our,132,O
study,132,O
was,132,O
designed,132,O
to,132,O
determine,132,O
the,132,O
effects,132,O
of,132,O
combined,132,O
nitroglycerin,132,B-Chemical
and,132,O
phenylephrine,132,B-Chemical
therapy,132,O
.,132,O
Ten,133,O
patients,133,O
with,133,O
acute,133,O
transmural,133,O
myocardial,133,B-Disease
infarctions,133,I-Disease
received,133,O
intravenous,133,O
nitroglycerin,133,B-Chemical
",",133,O
sufficient,133,O
to,133,O
reduce,133,O
mean,133,O
arterial,133,O
pressure,133,O
from,133,O
107,133,O
+/-,133,O
6,133,O
to,133,O
85,133,O
+/-,133,O
6,133,O
mm,133,O
Hg,133,O
(,133,O
P,133,O
less,133,O
than,133,O
0.001,133,O
),133,O
",",133,O
for,133,O
60,133,O
minutes,133,O
.,133,O
Left,134,O
ventricular,134,O
filling,134,O
pressure,134,O
decreased,134,O
from,134,O
19,134,O
+/-,134,O
2,134,O
to,134,O
11,134,O
+/-,134,O
2,134,O
mm,134,O
Hg,134,O
(,134,O
P,134,O
less,134,O
than,134,O
0.001,134,O
),134,O
.,134,O
SigmaST,135,O
",",135,O
the,135,O
sum,135,O
of,135,O
ST-segment,135,O
elevations,135,O
in,135,O
16,135,O
precordial,135,O
leads,135,O
",",135,O
decreased,135,O
(,135,O
P,135,O
less,135,O
than,135,O
0.02,135,O
),135,O
with,135,O
intravenous,135,O
nitroglycerin,135,B-Chemical
.,135,O
Subsequent,136,O
addition,136,O
of,136,O
phenylephrine,136,B-Chemical
infusion,136,O
",",136,O
sufficient,136,O
to,136,O
re-elevate,136,O
mean,136,O
arterial,136,O
pressure,136,O
to,136,O
106,136,O
+/-,136,O
4,136,O
mm,136,O
Hg,136,O
(,136,O
P,136,O
less,136,O
than,136,O
0.001,136,O
),136,O
for,136,O
30,136,O
minutes,136,O
",",136,O
increased,136,O
left,136,O
ventricular,136,O
filling,136,O
pressure,136,O
to,136,O
17,136,O
+/-,136,O
2,136,O
mm,136,O
Hg,136,O
(,136,O
P,136,O
less,136,O
than,136,O
0.05,136,O
),136,O
and,136,O
also,136,O
significantly,136,O
increased,136,O
sigmaST,136,O
(,136,O
P,136,O
less,136,O
than,136,O
0.05,136,O
),136,O
.,136,O
Our,137,O
results,137,O
suggest,137,O
that,137,O
addition,137,O
of,137,O
phenylephrine,137,B-Chemical
to,137,O
nitroglycerin,137,B-Chemical
is,137,O
not,137,O
beneficial,137,O
in,137,O
the,137,O
treatment,137,O
of,137,O
patients,137,O
with,137,O
acute,137,B-Disease
myocardial,137,I-Disease
infarction,137,I-Disease
.,137,O
Mediation,138,O
of,138,O
enhanced,138,O
reflex,138,O
vagal,138,O
bradycardia,138,B-Disease
by,138,O
L-dopa,138,B-Chemical
via,138,O
central,138,O
dopamine,138,B-Chemical
formation,138,O
in,138,O
dogs,138,O
.,138,O
L-Dopa,139,B-Chemical
(,139,O
5,139,O
mg/kg,139,O
i.v,139,O
.,139,O
),139,O
decreased,140,O
blood,140,O
pressure,140,O
and,140,O
heart,140,O
rate,140,O
after,140,O
extracerebral,140,O
decarboxylase,140,O
inhibition,140,O
with,140,O
MK-486,140,B-Chemical
(,140,O
25,140,O
mg/kg,140,O
i.v,140,O
.,140,O
),140,O
in,141,O
anesthetize,141,O
MAO-inhibited,141,B-Chemical
dogs,141,O
.,141,O
In,142,O
addition,142,O
",",142,O
reflex,142,O
bradycardia,142,B-Disease
caused,142,O
by,142,O
injected,142,O
norepinephrine,142,B-Chemical
was,142,O
significantly,142,O
enhanced,142,O
by,142,O
L-dopa,142,B-Chemical
",",142,O
DL-Threo-dihydroxyphenylserine,142,B-Chemical
had,142,O
no,142,O
effect,142,O
on,142,O
blood,142,O
pressure,142,O
",",142,O
heart,142,O
rate,142,O
or,142,O
reflex,142,O
responses,142,O
to,142,O
norepinephrine,142,B-Chemical
.,142,O
FLA-63,143,B-Chemical
",",143,O
a,143,O
dopamine-beta-oxidase,143,B-Chemical
inhibitor,143,O
",",143,O
did,143,O
not,143,O
have,143,O
any,143,O
effect,143,O
on,143,O
the,143,O
hypotension,143,B-Disease
",",143,O
bradycardia,143,B-Disease
or,143,O
reflex-enhancing,143,O
effect,143,O
of,143,O
L-dopa,143,B-Chemical
.,143,O
Pimozide,144,B-Chemical
did,144,O
not,144,O
affect,144,O
the,144,O
actions,144,O
of,144,O
L-dopa,144,B-Chemical
on,144,O
blood,144,O
pressure,144,O
and,144,O
heart,144,O
rate,144,O
but,144,O
completely,144,O
blocked,144,O
the,144,O
enhancement,144,O
of,144,O
reflexes,144,O
.,144,O
Removal,145,O
of,145,O
the,145,O
carotid,145,O
sinuses,145,O
caused,145,O
an,145,O
elevation,145,O
blood,145,O
pressure,145,O
and,145,O
heart,145,O
rate,145,O
and,145,O
abolished,145,O
the,145,O
negative,145,O
chronotropic,145,O
effect,145,O
of,145,O
norepinephrine,145,B-Chemical
.,145,O
However,146,O
",",146,O
L-dopa,146,B-Chemical
restored,146,O
the,146,O
bradycardia,146,B-Disease
caused,146,O
by,146,O
norepinephrine,146,B-Chemical
in,146,O
addition,146,O
to,146,O
decreasing,146,O
blood,146,O
pressure,146,O
and,146,O
heart,146,O
rate,146,O
.,146,O
5-HTP,147,B-Chemical
(,147,O
5,147,O
mg/kg,147,O
i.v,147,O
.,147,O
),147,O
decreased,148,O
blood,148,O
pressure,148,O
and,148,O
heart,148,O
rate,148,O
and,148,O
decreased,148,O
the,148,O
reflex,148,O
bradycardia,148,B-Disease
to,148,O
norepinephrine,148,B-Chemical
.,148,O
It,149,O
is,149,O
concluded,149,O
that,149,O
L-dopa,149,B-Chemical
enhances,149,O
reflex,149,O
bradycardia,149,B-Disease
through,149,O
central,149,O
alpha-receptor,149,O
stimulation,149,O
.,149,O
Furthermore,150,O
",",150,O
the,150,O
effects,150,O
are,150,O
mediated,150,O
through,150,O
dopamine,150,B-Chemical
rather,150,O
than,150,O
norepinephrine,150,B-Chemical
and,150,O
do,150,O
not,150,O
require,150,O
the,150,O
carotid,150,O
sinus,150,O
baroreceptors,150,O
.,150,O
Late,151,O
recovery,151,O
of,151,O
renal,151,O
function,151,O
in,151,O
a,151,O
woman,151,O
with,151,O
the,151,O
hemolytic,151,B-Disease
uremic,151,I-Disease
syndrome,151,I-Disease
.,151,O
A,152,O
case,152,O
is,152,O
reported,152,O
of,152,O
the,152,O
hemolytic,152,B-Disease
uremic,152,I-Disease
syndrome,152,I-Disease
(,152,O
HUS,152,B-Disease
),152,O
in,152,O
a,152,O
woman,152,O
taking,152,O
oral,152,B-Chemical
contraceptives,152,I-Chemical
.,152,O
She,153,O
was,153,O
treated,153,O
with,153,O
heparin,153,B-Chemical
",",153,O
dipyridamole,153,B-Chemical
and,153,O
hemodialysis,153,O
;,153,O
and,153,O
after,153,O
more,153,O
than,153,O
three,153,O
months,153,O
",",153,O
her,153,O
urinary,153,O
output,153,O
rose,153,O
above,153,O
500,153,O
ml,153,O
;,153,O
and,153,O
six,153,O
months,153,O
after,153,O
the,153,O
onset,153,O
of,153,O
anuria,153,B-Disease
",",153,O
dialysis,153,O
treatment,153,O
was,153,O
stopped,153,O
.,153,O
This,154,O
case,154,O
emphasizes,154,O
the,154,O
possibility,154,O
that,154,O
HUS,154,B-Disease
in,154,O
adults,154,O
is,154,O
not,154,O
invariably,154,O
irreversible,154,O
and,154,O
that,154,O
",",154,O
despite,154,O
prolonged,154,O
oliguria,154,B-Disease
",",154,O
recovery,154,O
of,154,O
renal,154,O
function,154,O
can,154,O
be,154,O
obtained,154,O
.,154,O
Therefore,155,O
",",155,O
in,155,O
adult,155,O
patients,155,O
affected,155,O
by,155,O
HUS,155,B-Disease
",",155,O
dialysis,155,O
should,155,O
not,155,O
be,155,O
discontinued,155,O
prematurely,155,O
;,155,O
moreover,155,O
",",155,O
bilateral,155,O
nephrectomy,155,O
",",155,O
for,155,O
treatment,155,O
of,155,O
severe,155,O
hypertension,155,B-Disease
and,155,O
microangiopathic,155,B-Disease
hemolytic,155,I-Disease
anemia,155,I-Disease
",",155,O
should,155,O
be,155,O
performed,155,O
with,155,O
caution,155,O
.,155,O
Effects,156,O
of,156,O
acetylsalicylic,156,B-Chemical
acid,156,I-Chemical
",",156,O
dipyridamole,156,B-Chemical
",",156,O
and,156,O
hydrocortisone,156,B-Chemical
on,156,O
epinephrine-induced,156,B-Chemical
myocardial,156,B-Disease
injury,156,I-Disease
in,156,O
dogs,156,O
.,156,O
A,157,O
reproducible,157,O
model,157,O
for,157,O
producing,157,O
diffuse,157,O
myocardial,157,B-Disease
injury,157,I-Disease
(,157,O
epinephrine,157,B-Chemical
infusion,157,O
),157,O
has,157,O
been,157,O
developed,157,O
to,157,O
study,157,O
the,157,O
cardioprotective,157,O
effects,157,O
of,157,O
agents,157,O
or,157,O
maneuvers,157,O
which,157,O
might,157,O
alter,157,O
the,157,O
evolution,157,O
of,157,O
acute,157,O
myocardial,157,B-Disease
infarction,157,I-Disease
.,157,O
Infusions,158,O
of,158,O
epinephrine,158,B-Chemical
(,158,O
4,158,O
mug,158,O
per,158,O
kilogram,158,O
per,158,O
minute,158,O
for,158,O
6,158,O
hours,158,O
),158,O
increased,158,O
radiocalcium,158,B-Chemical
uptakes,158,O
into,158,O
intact,158,O
myocardium,158,O
and,158,O
each,158,O
of,158,O
its,158,O
subcellular,158,O
components,158,O
with,158,O
the,158,O
mitochondrial,158,O
fraction,158,O
showing,158,O
the,158,O
most,158,O
consistent,158,O
changes,158,O
when,158,O
compared,158,O
to,158,O
saline-infused,158,O
control,158,O
animals,158,O
(,158,O
"4,957",158,O
vs.,158,O
827,158,O
counts,158,O
per,158,O
minute,158,O
per,158,O
gram,158,O
of,158,O
dried,158,O
tissue,158,O
or,158,O
fraction,158,O
),158,O
.,158,O
Myocardial,159,O
concentrations,159,O
of,159,O
calcium,159,B-Chemical
also,159,O
increased,159,O
significantly,159,O
(,159,O
12.0,159,O
vs.,159,O
5.0,159,O
mg.per,159,O
100,159,O
Gm,159,O
.,159,O
of,160,O
fat-free,160,O
dry,160,O
weight,160,O
),160,O
.,160,O
Infusions,161,O
of,161,O
calcium,161,B-Chemical
chloride,161,I-Chemical
sufficient,161,O
to,161,O
raise,161,O
serum,161,O
calcium,161,B-Chemical
concentrations,161,O
2,161,O
mEq,161,O
.,161,O
per,162,O
liter,162,O
failed,162,O
to,162,O
increase,162,O
calcium,162,B-Chemical
influx,162,O
into,162,O
the,162,O
myocardial,162,O
cell,162,O
.,162,O
Mitochondrial,163,O
radiocalcium,163,B-Chemical
uptakes,163,O
were,163,O
significantly,163,O
decreased,163,O
in,163,O
animals,163,O
pretreated,163,O
with,163,O
acetylsalicylic,163,B-Chemical
acid,163,I-Chemical
or,163,O
dipyridamole,163,B-Chemical
or,163,O
when,163,O
hydrocortisone,163,B-Chemical
was,163,O
added,163,O
to,163,O
the,163,O
epinephrine,163,B-Chemical
infusion,163,O
(,163,O
"2,682,2,803",163,O
",",163,O
and,163,O
"3,424",163,O
counts,163,O
per,163,O
minute,163,O
per,163,O
gram,163,O
of,163,O
dried,163,O
fraction,163,O
",",163,O
respectively,163,O
),163,O
.,163,O
Myocardial,164,O
calcium,164,B-Chemical
concentrations,164,O
also,164,O
were,164,O
decreased,164,O
(,164,O
11.2,164,O
",",164,O
8.3,164,O
",",164,O
and,164,O
8.9,164,O
mg.,164,O
per,164,O
100,164,O
Gm,164,O
.,164,O
of,165,O
fat-free,165,O
dry,165,O
weight,165,O
",",165,O
respectively,165,O
),165,O
in,165,O
the,165,O
three,165,O
treatment,165,O
groups,165,O
",",165,O
being,165,O
significantly,165,O
decreased,165,O
only,165,O
in,165,O
the,165,O
last,165,O
two,165,O
.,165,O
Evidence,166,O
of,166,O
microscopic,166,O
damage,166,O
was,166,O
graded,166,O
as,166,O
less,166,O
severe,166,O
in,166,O
the,166,O
three,166,O
treatment,166,O
groups,166,O
.,166,O
Acetylsalicylic,167,B-Chemical
acid,167,I-Chemical
",",167,O
dipyridamole,167,B-Chemical
",",167,O
and,167,O
hydrocortisone,167,B-Chemical
all,167,O
appear,167,O
to,167,O
have,167,O
cardioprotective,167,O
effects,167,O
when,167,O
tested,167,O
in,167,O
this,167,O
model,167,O
.,167,O
Further,168,O
studies,168,O
on,168,O
effects,168,O
of,168,O
irrigation,168,O
solutions,168,O
on,168,O
rat,168,O
bladders,168,O
.,168,O
Further,169,O
studies,169,O
on,169,O
the,169,O
effects,169,O
of,169,O
certain,169,O
irrigating,169,O
fluids,169,O
on,169,O
the,169,O
rat,169,O
bladder,169,O
for,169,O
18,169,O
hours,169,O
are,169,O
reported,169,O
.,169,O
The,170,O
results,170,O
have,170,O
shown,170,O
that,170,O
the,170,O
degradation,170,O
product,170,O
p-choloroaniline,170,B-Chemical
is,170,O
not,170,O
a,170,O
significant,170,O
factor,170,O
in,170,O
chlorhexidine-digluconate,170,B-Chemical
associated,170,O
erosive,170,O
cystitis,170,B-Disease
.,170,O
A,171,O
high,171,O
percentage,171,O
of,171,O
kanamycin-colistin,171,B-Chemical
and,171,O
povidone-iodine,171,B-Chemical
irrigations,171,O
were,171,O
associated,171,O
with,171,O
erosive,171,O
cystitis,171,B-Disease
and,171,O
suggested,171,O
a,171,O
possible,171,O
complication,171,O
with,171,O
human,171,O
usage,171,O
.,171,O
Picloxydine,172,B-Chemical
irrigations,172,O
appeared,172,O
to,172,O
have,172,O
a,172,O
lower,172,O
incidence,172,O
of,172,O
erosive,172,O
cystitis,172,B-Disease
but,172,O
further,172,O
studies,172,O
would,172,O
have,172,O
to,172,O
be,172,O
performed,172,O
before,172,O
it,172,O
could,172,O
be,172,O
recommended,172,O
for,172,O
use,172,O
in,172,O
urological,172,O
procedures,172,O
.,172,O
Neonatal,173,O
pyridoxine,173,B-Chemical
responsive,173,O
convulsions,173,B-Disease
due,173,O
to,173,O
isoniazid,173,B-Chemical
therapy,173,O
.,173,O
A,174,O
17-day-old,174,O
infant,174,O
on,174,O
isoniazid,174,B-Chemical
therapy,174,O
13,174,O
mg/kg,174,O
daily,174,O
from,174,O
birth,174,O
because,174,O
of,174,O
maternal,174,O
tuberculosis,174,B-Disease
was,174,O
admitted,174,O
after,174,O
4,174,O
days,174,O
of,174,O
clonic,174,B-Disease
fits,174,I-Disease
.,174,O
No,175,O
underlying,175,O
infective,175,O
or,175,O
biochemical,175,O
cause,175,O
could,175,O
be,175,O
found,175,O
.,175,O
The,176,O
fits,176,B-Disease
ceased,176,O
within,176,O
4,176,O
hours,176,O
of,176,O
administering,176,O
intramuscular,176,O
pyridoxine,176,B-Chemical
",",176,O
suggesting,176,O
an,176,O
aetiology,176,O
of,176,O
pyridoxine,176,B-Chemical
deficiency,176,O
secondary,176,O
to,176,O
isoniazid,176,B-Chemical
medication,176,O
.,176,O
Nephrotoxicity,177,B-Disease
of,177,O
combined,177,O
cephalothin-gentamicin,177,B-Chemical
regimen,177,O
.,177,O
Two,178,O
patients,178,O
developed,178,O
acute,178,B-Disease
tubular,178,I-Disease
necrosis,178,I-Disease
",",178,O
characterized,178,O
clinically,178,O
by,178,O
acute,178,O
oliguric,178,O
renal,178,O
failure,178,O
",",178,O
while,178,O
they,178,O
were,178,O
receiving,178,O
a,178,O
combination,178,O
of,178,O
cephalothin,178,B-Chemical
sodium,178,I-Chemical
and,178,O
gentamicin,178,B-Chemical
sulfate,178,I-Chemical
therapy,178,O
.,178,O
Patients,179,O
who,179,O
are,179,O
given,179,O
this,179,O
drug,179,O
regimen,179,O
should,179,O
be,179,O
observed,179,O
very,179,O
carefully,179,O
for,179,O
early,179,O
signs,179,O
of,179,O
nephrotoxicity,179,B-Disease
.,179,O
High,180,O
doses,180,O
of,180,O
this,180,O
antibiotic,180,O
combination,180,O
should,180,O
be,180,O
avoided,180,O
especially,180,O
in,180,O
elderly,180,O
patients,180,O
.,180,O
Patients,181,O
with,181,O
renal,181,B-Disease
insufficiency,181,I-Disease
should,181,O
not,181,O
be,181,O
given,181,O
this,181,O
regimen,181,O
.,181,O
Liver,182,B-Disease
disease,182,I-Disease
caused,182,O
by,182,O
propylthiouracil,182,B-Chemical
.,182,O
This,183,O
report,183,O
presents,183,O
the,183,O
clinical,183,O
",",183,O
laboratory,183,O
",",183,O
and,183,O
light,183,O
and,183,O
electron,183,O
microscopic,183,O
observations,183,O
on,183,O
a,183,O
patient,183,O
with,183,O
chronic,183,B-Disease
active,183,I-Disease
(,183,I-Disease
aggressive,183,I-Disease
),183,I-Disease
hepatitis,183,I-Disease
caused,183,O
by,183,O
the,183,O
administration,183,O
of,183,O
propylthiouracil,183,B-Chemical
.,183,O
This,184,O
is,184,O
an,184,O
addition,184,O
to,184,O
the,184,O
list,184,O
of,184,O
drugs,184,O
that,184,O
must,184,O
be,184,O
considered,184,O
in,184,O
the,184,O
evaluation,184,O
of,184,O
chronic,184,O
liver,184,B-Disease
disease,184,I-Disease
.,184,O
Effects,185,O
of,185,O
uninephrectomy,185,O
and,185,O
high,185,O
protein,185,O
feeding,185,O
on,185,O
lithium-induced,185,B-Chemical
chronic,185,B-Disease
renal,185,I-Disease
failure,185,I-Disease
in,185,O
rats,185,O
.,185,O
Rats,186,O
with,186,O
lithium-induced,186,B-Chemical
nephropathy,186,B-Disease
were,186,O
subjected,186,O
to,186,O
high,186,O
protein,186,O
(,186,O
HP,186,O
),186,O
feeding,186,O
",",186,O
uninephrectomy,186,O
(,186,O
NX,186,O
),186,O
or,186,O
a,186,O
combination,186,O
of,186,O
these,186,O
",",186,O
in,186,O
an,186,O
attempt,186,O
to,186,O
induce,186,O
glomerular,186,O
hyperfiltration,186,O
and,186,O
further,186,O
progression,186,O
of,186,O
renal,186,B-Disease
failure,186,I-Disease
.,186,O
Newborn,187,O
female,187,O
Wistar,187,O
rats,187,O
were,187,O
fed,187,O
a,187,O
lithium-containing,187,B-Chemical
diet,187,O
(,187,O
50,187,O
mmol/kg,187,O
),187,O
for,187,O
8,187,O
weeks,187,O
and,187,O
then,187,O
randomized,187,O
to,187,O
normal,187,O
diet,187,O
",",187,O
HP,187,O
diet,187,O
(,187,O
40,187,O
vs.,187,O
19,187,O
%,187,O
),187,O
",",187,O
NX,187,O
or,187,O
HP+NX,187,O
for,187,O
another,187,O
8,187,O
weeks,187,O
.,187,O
Corresponding,188,O
non-lithium,188,O
pretreated,188,O
groups,188,O
were,188,O
generated,188,O
.,188,O
When,189,O
comparing,189,O
all,189,O
lithium,189,B-Chemical
treated,189,O
versus,189,O
non-lithium-treated,189,O
groups,189,O
",",189,O
lithium,189,B-Chemical
caused,189,O
a,189,O
reduction,189,O
in,189,O
glomerular,189,O
filtration,189,O
rate,189,O
(,189,O
GFR,189,O
),189,O
without,189,O
significant,189,O
changes,189,O
in,189,O
effective,189,O
renal,189,O
plasma,189,O
flow,189,O
(,189,O
as,189,O
determined,189,O
by,189,O
a,189,O
marker,189,O
secreted,189,O
into,189,O
the,189,O
proximal,189,O
tubules,189,O
),189,O
or,189,O
lithium,189,B-Chemical
clearance,189,O
.,189,O
Consequently,190,O
",",190,O
lithium,190,B-Chemical
pretreatment,190,O
caused,190,O
a,190,O
fall,190,O
in,190,O
filtration,190,O
fraction,190,O
and,190,O
an,190,O
increase,190,O
in,190,O
fractional,190,O
Li,190,B-Chemical
excretion,190,O
.,190,O
Lithium,191,B-Chemical
also,191,O
caused,191,O
proteinuria,191,B-Disease
and,191,O
systolic,191,O
hypertension,191,B-Disease
in,191,O
absence,191,O
of,191,O
glomerulosclerosis,191,B-Disease
.,191,O
HP,192,O
failed,192,O
to,192,O
accentuante,192,O
progression,192,O
of,192,O
renal,192,B-Disease
failure,192,I-Disease
and,192,O
in,192,O
fact,192,O
tended,192,O
to,192,O
increase,192,O
GFR,192,O
and,192,O
decrease,192,O
plasma,192,O
creatinine,192,B-Chemical
levels,192,O
in,192,O
lithium,192,B-Chemical
pretreated,192,O
rats,192,O
.,192,O
NX,193,O
caused,193,O
an,193,O
additive,193,O
deterioration,193,O
in,193,O
GFR,193,O
which,193,O
",",193,O
however,193,O
",",193,O
was,193,O
ameliorated,193,O
by,193,O
HP,193,O
.,193,O
NX+HP,194,O
caused,194,O
a,194,O
further,194,O
rise,194,O
in,194,O
blood,194,O
pressure,194,O
in,194,O
Li-pretreated,194,B-Chemical
rats,194,O
.,194,O
The,195,O
results,195,O
indicate,195,O
that,195,O
Li-induced,195,B-Chemical
nephropathy,195,B-Disease
",",195,O
even,195,O
when,195,O
the,195,O
GFR,195,O
is,195,O
only,195,O
modestly,195,O
reduced,195,O
",",195,O
is,195,O
associated,195,O
with,195,O
proteinuria,195,B-Disease
and,195,O
arterial,195,O
systolic,195,O
hypertension,195,B-Disease
.,195,O
In,196,O
this,196,O
model,196,O
of,196,O
chronic,196,B-Disease
renal,196,I-Disease
failure,196,I-Disease
the,196,O
decline,196,O
in,196,O
GFR,196,O
is,196,O
not,196,O
accompanied,196,O
by,196,O
a,196,O
corresponding,196,O
fall,196,O
in,196,O
effective,196,O
renal,196,O
plasma,196,O
flow,196,O
",",196,O
which,196,O
may,196,O
be,196,O
the,196,O
functional,196,O
expression,196,O
of,196,O
the,196,O
formation,196,O
of,196,O
nonfiltrating,196,O
atubular,196,O
glomeruli,196,O
.,196,O
The,197,O
fractional,197,O
reabsorption,197,O
of,197,O
tubular,197,O
fluid,197,O
by,197,O
the,197,O
proximal,197,O
tubules,197,O
is,197,O
reduced,197,O
",",197,O
leaving,197,O
the,197,O
distal,197,O
delivery,197,O
unchanged,197,O
.,197,O
(,198,O
ABSTRACT,198,O
TRUNCATED,198,O
AT,198,O
250,198,O
WORDS,198,O
),198,O
Treatment,199,O
of,199,O
Crohn,199,B-Disease
's,199,I-Disease
disease,199,I-Disease
with,199,O
fusidic,199,B-Chemical
acid,199,I-Chemical
:,199,O
an,199,O
antibiotic,199,O
with,199,O
immunosuppressive,199,O
properties,199,O
similar,199,O
to,199,O
cyclosporin,199,B-Chemical
.,199,O
Fusidic,200,O
acid,200,O
is,200,O
an,200,O
antibiotic,200,O
with,200,O
T-cell,200,O
specific,200,O
immunosuppressive,200,O
effects,200,O
similar,200,O
to,200,O
those,200,O
of,200,O
cyclosporin,200,B-Chemical
.,200,O
Because,201,O
of,201,O
the,201,O
need,201,O
for,201,O
the,201,O
development,201,O
of,201,O
new,201,O
treatments,201,O
for,201,O
Crohn,201,B-Disease
's,201,I-Disease
disease,201,I-Disease
",",201,O
a,201,O
pilot,201,O
study,201,O
was,201,O
undertaken,201,O
to,201,O
estimate,201,O
the,201,O
pharmacodynamics,201,O
and,201,O
tolerability,201,O
of,201,O
fusidic,201,B-Chemical
acid,201,I-Chemical
treatment,201,O
in,201,O
chronic,201,O
active,201,O
",",201,O
therapy-resistant,201,O
patients,201,O
.,201,O
Eight,202,O
Crohn,202,B-Disease
's,202,I-Disease
disease,202,I-Disease
patients,202,O
were,202,O
included,202,O
.,202,O
Fusidic,203,B-Chemical
acid,203,I-Chemical
was,203,O
administered,203,O
orally,203,O
in,203,O
a,203,O
dose,203,O
of,203,O
500,203,O
mg,203,O
t.d.s,203,O
.,203,O
and,204,O
the,204,O
treatment,204,O
was,204,O
planned,204,O
to,204,O
last,204,O
8,204,O
weeks,204,O
.,204,O
The,205,O
disease,205,O
activity,205,O
was,205,O
primarily,205,O
measured,205,O
by,205,O
a,205,O
modified,205,O
individual,205,O
grading,205,O
score,205,O
.,205,O
Five,206,O
of,206,O
8,206,O
patients,206,O
(,206,O
63,206,O
%,206,O
),206,O
improved,206,O
during,206,O
fusidic,206,B-Chemical
acid,206,I-Chemical
treatment,206,O
:,206,O
3,206,O
at,206,O
two,206,O
weeks,206,O
and,206,O
2,206,O
after,206,O
four,206,O
weeks,206,O
.,206,O
There,207,O
were,207,O
no,207,O
serious,207,O
clinical,207,O
side,207,O
effects,207,O
",",207,O
but,207,O
dose,207,O
reduction,207,O
was,207,O
required,207,O
in,207,O
two,207,O
patients,207,O
because,207,O
of,207,O
nausea,207,B-Disease
.,207,O
Biochemically,208,O
",",208,O
an,208,O
increase,208,O
in,208,O
alkaline,208,O
phosphatases,208,O
was,208,O
noted,208,O
in,208,O
5,208,O
of,208,O
8,208,O
cases,208,O
(,208,O
63,208,O
%,208,O
),208,O
",",208,O
and,208,O
the,208,O
greatest,208,O
increases,208,O
were,208,O
seen,208,O
in,208,O
those,208,O
who,208,O
had,208,O
elevated,208,O
levels,208,O
prior,208,O
to,208,O
treatment,208,O
.,208,O
All,209,O
reversed,209,O
to,209,O
pre-treatment,209,O
levels,209,O
after,209,O
cessation,209,O
of,209,O
treatment,209,O
.,209,O
The,210,O
results,210,O
of,210,O
this,210,O
pilot,210,O
study,210,O
suggest,210,O
that,210,O
fusidic,210,B-Chemical
acid,210,I-Chemical
may,210,O
be,210,O
of,210,O
benefit,210,O
in,210,O
selected,210,O
chronic,210,O
active,210,O
Crohn,210,B-Disease
's,210,I-Disease
disease,210,I-Disease
patients,210,O
in,210,O
whom,210,O
conventional,210,O
treatment,210,O
is,210,O
ineffective,210,O
.,210,O
Because,211,O
there,211,O
seems,211,O
to,211,O
exist,211,O
a,211,O
scientific,211,O
rationale,211,O
for,211,O
the,211,O
use,211,O
of,211,O
fusidic,211,B-Chemical
acid,211,I-Chemical
at,211,O
the,211,O
cytokine,211,O
level,211,O
in,211,O
inflammatory,211,B-Disease
bowel,211,I-Disease
disease,211,I-Disease
",",211,O
we,211,O
suggest,211,O
that,211,O
the,211,O
role,211,O
of,211,O
this,211,O
treatment,211,O
should,211,O
be,211,O
further,211,O
investigated,211,O
.,211,O
Changes,212,O
in,212,O
depressive,212,B-Disease
status,212,O
associated,212,O
with,212,O
topical,212,O
beta-blockers,212,O
.,212,O
Depression,213,B-Disease
and,213,O
sexual,213,B-Disease
dysfunction,213,I-Disease
have,213,O
been,213,O
related,213,O
to,213,O
side,213,O
effects,213,O
of,213,O
topical,213,O
beta-blockers,213,O
.,213,O
We,214,O
performed,214,O
a,214,O
preliminary,214,O
study,214,O
in,214,O
order,214,O
to,214,O
determine,214,O
any,214,O
difference,214,O
between,214,O
a,214,O
non,214,O
selective,214,O
beta-blocker,214,O
(,214,O
timolol,214,B-Chemical
),214,O
and,214,O
a,214,O
selective,214,O
beta-blocker,214,O
(,214,O
betaxolol,214,B-Chemical
),214,O
regarding,214,O
CNS,214,O
side,214,O
effects,214,O
.,214,O
Eight,215,O
glaucomatous,215,B-Disease
patients,215,O
chronically,215,O
treated,215,O
with,215,O
timolol,215,B-Chemical
0.5,215,O
%,215,O
/12h,215,O
",",215,O
suffering,215,O
from,215,O
depression,215,B-Disease
diagnosed,215,O
through,215,O
DMS-III-R,215,O
criteria,215,O
",",215,O
were,215,O
included,215,O
in,215,O
the,215,O
study,215,O
.,215,O
During,216,O
the,216,O
six-month,216,O
follow,216,O
up,216,O
",",216,O
depression,216,B-Disease
was,216,O
quantified,216,O
through,216,O
the,216,O
Beck,216,O
and,216,O
Zung-Conde,216,O
scales,216,O
every,216,O
two,216,O
months,216,O
.,216,O
In,217,O
a,217,O
double,217,O
blind,217,O
cross-over,217,O
study,217,O
with,217,O
control,217,O
group,217,O
",",217,O
the,217,O
patients,217,O
under,217,O
timolol,217,B-Chemical
treatment,217,O
presented,217,O
higher,217,O
depression,217,B-Disease
values,217,O
measured,217,O
through,217,O
the,217,O
Beck,217,O
and,217,O
the,217,O
Zung-Conde,217,O
scales,217,O
(,217,O
p,217,O
<,217,O
0.001,217,O
vs,217,O
control,217,O
),217,O
.,217,O
These,218,O
results,218,O
suggest,218,O
that,218,O
betaxolol,218,B-Chemical
could,218,O
be,218,O
less,218,O
of,218,O
a,218,O
depression-inducer,218,B-Disease
than,218,O
timolol,218,B-Chemical
in,218,O
predisposed,218,O
patients,218,O
.,218,O
Protection,219,O
against,219,O
amphetamine-induced,219,B-Chemical
neurotoxicity,219,B-Disease
toward,219,O
striatal,219,O
dopamine,219,B-Chemical
neurons,219,O
in,219,O
rodents,219,O
by,219,O
LY274614,219,B-Chemical
",",219,O
an,219,O
excitatory,219,O
amino,219,B-Chemical
acid,219,I-Chemical
antagonist,219,O
.,219,O
LY274614,220,B-Chemical
",",220,O
"3SR,4aRS,6SR,8aRS-6-",220,B-Chemical
[,220,I-Chemical
phosphonomethyl,220,I-Chemical
],220,I-Chemical
decahydr,220,I-Chemical
oisoquinoline-3-,220,I-Chemical
carboxylic,220,I-Chemical
acid,220,I-Chemical
",",220,O
has,220,O
been,220,O
described,220,O
as,220,O
a,220,O
potent,220,O
antagonist,220,O
of,220,O
the,220,O
N-methyl-D-aspartate,220,B-Chemical
(,220,O
NMDA,220,B-Chemical
),220,O
subtype,220,O
of,220,O
glutamate,220,B-Chemical
receptor,220,O
.,220,O
Here,221,O
its,221,O
ability,221,O
to,221,O
antagonize,221,O
the,221,O
prolonged,221,O
depletion,221,O
of,221,O
dopamine,221,B-Chemical
in,221,O
the,221,O
striatum,221,O
by,221,O
amphetamine,221,B-Chemical
in,221,O
iprindole-treated,221,B-Chemical
rats,221,O
is,221,O
reported,221,O
.,221,O
A,222,O
single,222,O
18.4,222,O
mg/kg,222,O
(,222,O
i.p,222,O
.,222,O
),222,O
dose,223,O
of,223,O
(,223,O
+/-,223,O
),223,O
-amphetamine,223,O
hemisulfate,223,O
",",223,O
given,223,O
to,223,O
rats,223,O
pretreated,223,O
with,223,O
iprindole,223,B-Chemical
",",223,O
resulted,223,O
in,223,O
persistent,223,O
depletion,223,O
of,223,O
dopamine,223,B-Chemical
in,223,O
the,223,O
striatum,223,O
1,223,O
week,223,O
later,223,O
.,223,O
This,224,O
prolonged,224,O
depletion,224,O
of,224,O
dopamine,224,B-Chemical
in,224,O
the,224,O
striatum,224,O
was,224,O
antagonized,224,O
by,224,O
dizocilpine,224,B-Chemical
(,224,O
MK-801,224,B-Chemical
",",224,O
a,224,O
non-competitive,224,O
antagonist,224,O
of,224,O
NMDA,224,B-Chemical
receptors,224,O
),224,O
or,224,O
by,224,O
LY274614,224,B-Chemical
(,224,O
a,224,O
competitive,224,O
antagonist,224,O
of,224,O
NMDA,224,B-Chemical
receptors,224,O
),224,O
.,224,O
The,225,O
protective,225,O
effect,225,O
of,225,O
LY274614,225,B-Chemical
was,225,O
dose-dependent,225,O
",",225,O
being,225,O
maximum,225,O
at,225,O
10-40,225,O
mgkg,225,O
(,225,O
i.p,225,O
.,225,O
),225,O
.,225,O
A,226,O
10,226,O
mg/kg,226,O
dose,226,O
of,226,O
LY274614,226,B-Chemical
was,226,O
effective,226,O
in,226,O
antagonizing,226,O
the,226,O
depletion,226,O
of,226,O
dopamine,226,B-Chemical
in,226,O
the,226,O
striatum,226,O
",",226,O
when,226,O
given,226,O
as,226,O
long,226,O
as,226,O
8,226,O
hr,226,O
prior,226,O
to,226,O
amphetamine,226,B-Chemical
but,226,O
not,226,O
when,226,O
given,226,O
24,226,O
hr,226,O
prior,226,O
to,226,O
amphetamine,226,B-Chemical
.,226,O
Depletion,227,O
of,227,O
dopamine,227,B-Chemical
in,227,O
the,227,O
striatum,227,O
was,227,O
also,227,O
antagonized,227,O
when,227,O
LY274614,227,B-Chemical
was,227,O
given,227,O
after,227,O
the,227,O
injection,227,O
of,227,O
amphetamine,227,B-Chemical
;,227,O
LY274614,227,B-Chemical
protected,227,O
when,227,O
given,227,O
up,227,O
to,227,O
4,227,O
hr,227,O
after,227,O
but,227,O
not,227,O
when,227,O
given,227,O
8,227,O
or,227,O
24,227,O
hr,227,O
after,227,O
amphetamine,227,B-Chemical
.,227,O
The,228,O
prolonged,228,O
depletion,228,O
of,228,O
dopamine,228,B-Chemical
in,228,O
the,228,O
striatum,228,O
in,228,O
mice,228,O
",",228,O
given,228,O
multiple,228,O
injections,228,O
of,228,O
methamphetamine,228,B-Chemical
",",228,O
was,228,O
also,228,O
antagonized,228,O
dose-dependently,228,O
and,228,O
completely,228,O
by,228,O
LY274614,228,B-Chemical
.,228,O
The,229,O
data,229,O
strengthen,229,O
the,229,O
evidence,229,O
that,229,O
the,229,O
neurotoxic,229,B-Disease
effect,229,O
of,229,O
amphetamine,229,B-Chemical
and,229,O
related,229,O
compounds,229,O
toward,229,O
nigrostriatal,229,O
dopamine,229,B-Chemical
neurons,229,O
involves,229,O
NMDA,229,B-Chemical
receptors,229,O
and,229,O
that,229,O
LY274614,229,B-Chemical
is,229,O
an,229,O
NMDA,229,B-Chemical
receptor,229,O
antagonist,229,O
with,229,O
long-lasting,229,O
in,229,O
vivo,229,O
effects,229,O
in,229,O
rats,229,O
.,229,O
Hyperbaric,230,O
oxygen,230,B-Chemical
therapy,230,O
for,230,O
control,230,O
of,230,O
intractable,230,O
cyclophosphamide-induced,230,B-Chemical
hemorrhagic,230,O
cystitis,230,O
.,230,O
We,231,O
report,231,O
a,231,O
case,231,O
of,231,O
intractable,231,O
hemorrhagic,231,O
cystitis,231,O
due,231,O
to,231,O
cyclophosphamide,231,B-Chemical
therapy,231,O
for,231,O
Wegener,231,B-Disease
's,231,I-Disease
granulomatosis,231,I-Disease
.,231,O
Conservative,232,O
treatment,232,O
",",232,O
including,232,O
bladder,232,O
irrigation,232,O
with,232,O
physiological,232,O
saline,232,O
and,232,O
instillation,232,O
of,232,O
prostaglandin,232,B-Chemical
F2,232,I-Chemical
alpha,232,I-Chemical
",",232,O
failed,232,O
to,232,O
totally,232,O
control,232,O
hemorrhage,232,B-Disease
.,232,O
We,233,O
then,233,O
used,233,O
hyperbaric,233,O
oxygen,233,B-Chemical
at,233,O
an,233,O
absolute,233,O
pressure,233,O
of,233,O
2,233,O
atm,233,O
",",233,O
5,233,O
days,233,O
a,233,O
week,233,O
for,233,O
8,233,O
consecutive,233,O
weeks,233,O
.,233,O
The,234,O
bleeding,234,B-Disease
ceased,234,O
completely,234,O
by,234,O
the,234,O
end,234,O
of,234,O
treatment,234,O
and,234,O
the,234,O
patient,234,O
remained,234,O
free,234,O
of,234,O
hematuria,234,B-Disease
thereafter,234,O
.,234,O
No,235,O
side,235,O
effect,235,O
was,235,O
noted,235,O
during,235,O
the,235,O
course,235,O
of,235,O
therapy,235,O
.,235,O
In,236,O
future,236,O
",",236,O
this,236,O
form,236,O
of,236,O
therapy,236,O
can,236,O
offer,236,O
a,236,O
safe,236,O
alternative,236,O
in,236,O
the,236,O
treatment,236,O
of,236,O
cyclophosphamide-induced,236,B-Chemical
hemorrhagic,236,O
cystitis,236,O
.,236,O
Treatment,237,O
of,237,O
tinnitus,237,B-Disease
by,237,O
intratympanic,237,O
instillation,237,O
of,237,O
lignocaine,237,B-Chemical
(,237,O
lidocaine,237,B-Chemical
),237,O
2,237,O
per,237,O
cent,237,O
through,237,O
ventilation,237,O
tubes,237,O
.,237,O
Idiopathic,238,B-Disease
subjective,238,I-Disease
tinnitus,238,I-Disease
(,238,O
IST,238,B-Disease
),238,O
is,238,O
one,238,O
of,238,O
the,238,O
most,238,O
obscure,238,O
otological,238,O
pathologies,238,O
.,238,O
This,239,O
paper,239,O
presents,239,O
the,239,O
results,239,O
of,239,O
treating,239,O
IST,239,B-Disease
by,239,O
intratympanic,239,O
instillation,239,O
of,239,O
lignocaine,239,B-Chemical
(,239,O
lidocaine,239,B-Chemical
),239,O
2,239,O
per,239,O
cent,239,O
through,239,O
a,239,O
grommet,239,O
",",239,O
for,239,O
five,239,O
weekly,239,O
courses,239,O
.,239,O
Fifty-two,240,O
patients,240,O
suffering,240,O
from,240,O
intractable,240,O
tinnitus,240,B-Disease
entered,240,O
this,240,O
therapeutic,240,O
trial,240,O
",",240,O
but,240,O
only,240,O
nine,240,O
finished,240,O
all,240,O
five,240,O
courses,240,O
.,240,O
In,241,O
one,241,O
patient,241,O
",",241,O
the,241,O
tinnitus,241,B-Disease
was,241,O
almost,241,O
completely,241,O
abolished,241,O
",",241,O
but,241,O
in,241,O
all,241,O
the,241,O
nine,241,O
patients,241,O
the,241,O
decompensated,241,O
tinnitus,241,B-Disease
changed,241,O
to,241,O
a,241,O
compensated,241,O
one,241,O
.,241,O
We,242,O
suggest,242,O
this,242,O
mode,242,O
of,242,O
treatment,242,O
for,242,O
patients,242,O
that,242,O
were,242,O
previously,242,O
treated,242,O
by,242,O
drugs,242,O
",",242,O
acupuncture,242,O
and,242,O
biofeedback,242,O
",",242,O
with,242,O
disappointing,242,O
results,242,O
.,242,O
Patients,243,O
should,243,O
be,243,O
warned,243,O
about,243,O
the,243,O
side,243,O
effects,243,O
of,243,O
vertigo,243,B-Disease
and,243,O
vomiting,243,B-Disease
",",243,O
which,243,O
subsides,243,O
gradually,243,O
with,243,O
every,243,O
new,243,O
instillation,243,O
",",243,O
and,243,O
that,243,O
the,243,O
tinnitus,243,B-Disease
may,243,O
not,243,O
disappear,243,O
but,243,O
will,243,O
be,243,O
alleviated,243,O
",",243,O
enabling,243,O
them,243,O
to,243,O
cope,243,O
more,243,O
easily,243,O
with,243,O
the,243,O
disease,243,O
and,243,O
lead,243,O
a,243,O
more,243,O
normal,243,O
life,243,O
.,243,O
Optimization,244,O
of,244,O
levodopa,244,B-Chemical
therapy,244,O
.,244,O
While,245,O
there,245,O
is,245,O
no,245,O
single,245,O
correct,245,O
starting,245,O
dose,245,O
for,245,O
levodopa,245,B-Chemical
therapy,245,O
",",245,O
many,245,O
individuals,245,O
can,245,O
be,245,O
started,245,O
on,245,O
either,245,O
the,245,O
25/100,245,O
or,245,O
controlled-release,245,O
formula,245,O
",",245,O
following,245,O
the,245,O
general,245,O
rule,245,O
not,245,O
to,245,O
attempt,245,O
to,245,O
titrate,245,O
carbidopa-levodopa,245,B-Chemical
to,245,O
the,245,O
point,245,O
of,245,O
``,245,O
normality,245,O
",",245,O
'',245,O
which,245,O
can,245,O
lead,245,O
to,245,O
toxicity,245,B-Disease
.,245,O
The,246,O
physician,246,O
should,246,O
also,246,O
determine,246,O
the,246,O
proper,246,O
use,246,O
of,246,O
any,246,O
adjunctive,246,O
medications,246,O
;,246,O
such,246,O
combined,246,O
therapy,246,O
has,246,O
become,246,O
the,246,O
standard,246,O
approach,246,O
to,246,O
treatment,246,O
.,246,O
Following,247,O
the,247,O
initial,247,O
period,247,O
of,247,O
therapy,247,O
",",247,O
emerging,247,O
difficulties,247,O
require,247,O
a,247,O
reassessment,247,O
of,247,O
therapeutic,247,O
approaches,247,O
",",247,O
such,247,O
as,247,O
dosage,247,O
adjustment,247,O
or,247,O
introduction,247,O
of,247,O
a,247,O
dopamine,247,B-Chemical
agonist,247,O
.,247,O
Other,248,O
possible,248,O
adverse,248,O
effects,248,O
--,248,O
such,248,O
as,248,O
gastrointestinal,248,B-Disease
disorders,248,I-Disease
",",248,O
orthostatic,248,B-Disease
hypotension,248,I-Disease
",",248,O
levodopa-induced,248,B-Chemical
psychosis,248,B-Disease
",",248,O
sleep,248,B-Disease
disturbances,248,I-Disease
or,248,O
parasomnias,248,B-Disease
",",248,O
or,248,O
drug,248,O
interactions,248,O
--,248,O
also,248,O
require,248,O
carefully,248,O
monitored,248,O
individual,248,O
treatment,248,O
.,248,O
Nonpharmacologic,249,O
concerns,249,O
can,249,O
help,249,O
the,249,O
Parkinson,249,B-Disease
's,249,I-Disease
disease,249,I-Disease
patient,249,O
achieve,249,O
and,249,O
maintain,249,O
optimal,249,O
functioning,249,O
",",249,O
including,249,O
daily,249,O
exercise,249,O
",",249,O
physical,249,O
therapy,249,O
",",249,O
and,249,O
involvement,249,O
with,249,O
support,249,O
groups,249,O
.,249,O
Seizures,250,B-Disease
induced,250,O
by,250,O
the,250,O
cocaine,250,B-Chemical
metabolite,250,O
benzoylecgonine,250,B-Chemical
in,250,O
rats,250,O
.,250,O
The,251,O
half-life,251,O
(,251,O
t1/2,251,O
),251,O
of,251,O
cocaine,251,B-Chemical
is,251,O
relatively,251,O
short,251,O
",",251,O
but,251,O
some,251,O
of,251,O
the,251,O
consequences,251,O
of,251,O
its,251,O
use,251,O
",",251,O
such,251,O
as,251,O
seizures,251,B-Disease
and,251,O
strokes,251,B-Disease
",",251,O
can,251,O
occur,251,O
hours,251,O
after,251,O
exposure,251,O
.,251,O
This,252,O
led,252,O
us,252,O
to,252,O
hypothesize,252,O
that,252,O
a,252,O
metabolite,252,O
of,252,O
cocaine,252,B-Chemical
may,252,O
be,252,O
responsible,252,O
for,252,O
some,252,O
of,252,O
those,252,O
delayed,252,O
sequelae,252,O
.,252,O
We,253,O
evaluated,253,O
the,253,O
potential,253,O
of,253,O
the,253,O
major,253,O
metabolite,253,O
of,253,O
cocaine,253,B-Chemical
",",253,O
benzoylecgonine,253,B-Chemical
(,253,O
BE,253,B-Chemical
),253,O
",",253,O
to,253,O
cause,253,O
seizures,253,B-Disease
.,253,O
Two,254,O
separate,254,O
equimolar,254,O
doses,254,O
(,254,O
0.2,254,O
and,254,O
0.4,254,O
mumol,254,O
),254,O
of,254,O
either,254,O
cocaine,254,B-Chemical
or,254,O
BE,254,B-Chemical
were,254,O
injected,254,O
ventricularly,254,O
in,254,O
unanesthetized,254,O
juvenile,254,O
rats,254,O
.,254,O
Treated,255,O
rats,255,O
were,255,O
then,255,O
evaluated,255,O
for,255,O
incidence,255,O
",",255,O
latency,255,O
",",255,O
and,255,O
seizure,255,B-Disease
pattern,255,O
or,255,O
for,255,O
locomotor,255,O
activity,255,O
in,255,O
animals,255,O
without,255,O
seizures,255,B-Disease
.,255,O
BE-Induced,256,B-Chemical
seizures,256,B-Disease
occurred,256,O
more,256,O
frequently,256,O
and,256,O
had,256,O
significantly,256,O
longer,256,O
latencies,256,O
than,256,O
those,256,O
induced,256,O
by,256,O
equimolar,256,O
amounts,256,O
of,256,O
cocaine,256,B-Chemical
.,256,O
Whereas,257,O
cocaine-induced,257,B-Chemical
seizures,257,B-Disease
were,257,O
best,257,O
characterized,257,O
as,257,O
brief,257,O
",",257,O
generalized,257,O
",",257,O
and,257,O
tonic,257,O
and,257,O
resulted,257,O
in,257,O
death,257,B-Disease
",",257,O
those,257,O
induced,257,O
by,257,O
BE,257,B-Chemical
were,257,O
prolonged,257,O
",",257,O
often,257,O
multiple,257,O
and,257,O
mixed,257,O
in,257,O
type,257,O
",",257,O
and,257,O
rarely,257,O
resulted,257,O
in,257,O
death,257,B-Disease
.,257,O
Electrical,258,O
recordings,258,O
from,258,O
the,258,O
hippocampus,258,O
showed,258,O
a,258,O
rhythmic,258,O
progression,258,O
in,258,O
EEG,258,O
frequency,258,O
and,258,O
voltage,258,O
with,258,O
clinical,258,O
seizure,258,B-Disease
expression,258,O
.,258,O
BE-Injected,259,B-Chemical
rats,259,O
that,259,O
did,259,O
not,259,O
have,259,O
seizures,259,B-Disease
had,259,O
significantly,259,O
more,259,O
locomotor,259,O
activity,259,O
than,259,O
cocaine-injected,259,B-Chemical
animals,259,O
without,259,O
seizures,259,B-Disease
.,259,O
The,260,O
finding,260,O
that,260,O
cocaine-,260,B-Chemical
and,260,O
BE-induced,260,B-Chemical
seizures,260,B-Disease
differ,260,O
in,260,O
several,260,O
respects,260,O
suggests,260,O
more,260,O
than,260,O
one,260,O
mechanism,260,O
for,260,O
cocaine-induced,260,B-Chemical
seizures,260,B-Disease
and,260,O
emphasizes,260,O
the,260,O
importance,260,O
of,260,O
a,260,O
cocaine,260,B-Chemical
metabolite,260,O
",",260,O
BE,260,B-Chemical
.,260,O
Electrocardiographic,261,O
evidence,261,O
of,261,O
myocardial,261,B-Disease
injury,261,I-Disease
in,261,O
psychiatrically,261,O
hospitalized,261,O
cocaine,261,B-Chemical
abusers,261,O
.,261,O
The,262,O
electrocardiograms,262,O
(,262,O
ECG,262,O
),262,O
of,262,O
99,262,O
cocaine-abusing,262,B-Chemical
patients,262,O
were,262,O
compared,262,O
with,262,O
the,262,O
ECGs,262,O
of,262,O
50,262,O
schizophrenic,262,B-Disease
controls,262,O
.,262,O
Eleven,263,O
of,263,O
the,263,O
cocaine,263,B-Chemical
abusers,263,O
and,263,O
none,263,O
of,263,O
the,263,O
controls,263,O
had,263,O
ECG,263,O
evidence,263,O
of,263,O
significant,263,O
myocardial,263,B-Disease
injury,263,I-Disease
defined,263,O
as,263,O
myocardial,263,B-Disease
infarction,263,I-Disease
",",263,O
ischemia,263,B-Disease
",",263,O
and,263,O
bundle,263,B-Disease
branch,263,I-Disease
block,263,I-Disease
.,263,O
Learning,264,O
of,264,O
rats,264,O
under,264,O
amnesia,264,B-Disease
caused,264,O
by,264,O
pentobarbital,264,B-Chemical
.,264,O
Dissociated,265,O
learning,265,O
of,265,O
rats,265,O
in,265,O
the,265,O
normal,265,O
state,265,O
and,265,O
the,265,O
state,265,O
of,265,O
amnesia,265,B-Disease
produced,265,O
by,265,O
pentobarbital,265,B-Chemical
(,265,O
15,265,O
mg/kg,265,O
",",265,O
ip,265,O
),265,O
was,265,O
carried,265,O
out,265,O
.,265,O
Rats,266,O
were,266,O
trained,266,O
to,266,O
approach,266,O
a,266,O
shelf,266,O
where,266,O
they,266,O
received,266,O
food,266,O
reinforcement,266,O
.,266,O
In,267,O
Group,267,O
1,267,O
the,267,O
rats,267,O
were,267,O
trained,267,O
under,267,O
the,267,O
influence,267,O
of,267,O
pentobarbital,267,B-Chemical
to,267,O
run,267,O
to,267,O
the,267,O
same,267,O
shelf,267,O
as,267,O
in,267,O
the,267,O
normal,267,O
state,267,O
.,267,O
In,268,O
Group,268,O
2,268,O
the,268,O
rats,268,O
were,268,O
trained,268,O
to,268,O
approach,268,O
different,268,O
shelves,268,O
in,268,O
different,268,O
drug,268,O
states,268,O
.,268,O
It,269,O
was,269,O
shown,269,O
that,269,O
memory,269,B-Disease
dissociation,269,I-Disease
occurred,269,O
in,269,O
both,269,O
groups,269,O
.,269,O
Differences,270,O
in,270,O
the,270,O
parameters,270,O
of,270,O
training,270,O
under,270,O
the,270,O
influence,270,O
of,270,O
pentobarbital,270,B-Chemical
between,270,O
Groups,270,O
1,270,O
and,270,O
2,270,O
were,270,O
revealed,270,O
.,270,O
These,271,O
findings,271,O
show,271,O
that,271,O
the,271,O
brain-dissociated,271,O
state,271,O
induced,271,O
by,271,O
pentobarbital,271,B-Chemical
is,271,O
formed,271,O
with,271,O
the,271,O
participation,271,O
of,271,O
the,271,O
mechanisms,271,O
of,271,O
information,271,O
perception,271,O
.,271,O
Adverse,272,O
effect,272,O
of,272,O
the,272,O
calcium,272,B-Chemical
channel,272,O
blocker,272,O
nitrendipine,272,B-Chemical
on,272,O
nephrosclerosis,272,B-Disease
in,272,O
rats,272,O
with,272,O
renovascular,272,B-Disease
hypertension,272,I-Disease
.,272,O
The,273,O
effect,273,O
of,273,O
a,273,O
6-week,273,O
treatment,273,O
with,273,O
the,273,O
calcium,273,B-Chemical
channel,273,O
blocker,273,O
nitrendipine,273,B-Chemical
or,273,O
the,273,O
angiotensin,273,B-Chemical
converting,273,O
enzyme,273,O
inhibitor,273,O
enalapril,273,B-Chemical
on,273,O
blood,273,O
pressure,273,O
",",273,O
albuminuria,273,B-Disease
",",273,O
renal,273,O
hemodynamics,273,O
",",273,O
and,273,O
morphology,273,O
of,273,O
the,273,O
nonclipped,273,O
kidney,273,O
was,273,O
studied,273,O
in,273,O
rats,273,O
with,273,O
two-kidney,273,O
",",273,O
one,273,O
clip,273,O
renovascular,273,B-Disease
hypertension,273,I-Disease
.,273,O
Six,274,O
weeks,274,O
after,274,O
clipping,274,O
of,274,O
one,274,O
renal,274,O
artery,274,O
",",274,O
hypertensive,274,B-Disease
rats,274,O
(,274,O
178,274,O
+/-,274,O
4,274,O
mm,274,O
Hg,274,O
),274,O
were,274,O
randomly,274,O
assigned,274,O
to,274,O
three,274,O
groups,274,O
:,274,O
untreated,274,O
hypertensive,274,B-Disease
controls,274,O
(,274,O
n,274,O
=,274,O
8,274,O
),274,O
",",274,O
enalapril-treated,274,B-Chemical
(,274,O
n,274,O
=,274,O
8,274,O
),274,O
",",274,O
or,274,O
nitrendipine-treated,274,B-Chemical
(,274,O
n,274,O
=,274,O
10,274,O
),274,O
.,274,O
Sham-operated,275,O
rats,275,O
served,275,O
as,275,O
normotensive,275,O
controls,275,O
(,275,O
128,275,O
+/-,275,O
3,275,O
mm,275,O
Hg,275,O
",",275,O
n,275,O
=,275,O
8,275,O
),275,O
.,275,O
After,276,O
6,276,O
weeks,276,O
of,276,O
treatment,276,O
",",276,O
renal,276,O
hemodynamics,276,O
(,276,O
glomerular,276,O
filtration,276,O
rate,276,O
and,276,O
renal,276,O
plasma,276,O
flow,276,O
),276,O
were,276,O
measured,276,O
in,276,O
the,276,O
anesthetized,276,O
rats,276,O
.,276,O
Renal,277,O
tissue,277,O
was,277,O
obtained,277,O
for,277,O
determination,277,O
of,277,O
glomerular,277,O
size,277,O
and,277,O
sclerosis,277,O
.,277,O
Enalapril,278,B-Chemical
but,278,O
not,278,O
nitrendipine,278,B-Chemical
reduced,278,O
blood,278,O
pressure,278,O
significantly,278,O
.,278,O
After,279,O
6,279,O
weeks,279,O
of,279,O
therapy,279,O
",",279,O
glomerular,279,O
filtration,279,O
rate,279,O
was,279,O
not,279,O
different,279,O
among,279,O
the,279,O
studied,279,O
groups,279,O
.,279,O
Renal,280,O
plasma,280,O
flow,280,O
increased,280,O
",",280,O
but,280,O
albumin,280,O
excretion,280,O
and,280,O
glomerulosclerosis,280,B-Disease
did,280,O
not,280,O
change,280,O
after,280,O
enalapril,280,B-Chemical
treatment,280,O
.,280,O
In,281,O
contrast,281,O
",",281,O
in,281,O
the,281,O
nitrendipine-treated,281,B-Chemical
group,281,O
albuminuria,281,B-Disease
increased,281,O
from,281,O
12.8,281,O
+/-,281,O
2,281,O
progressively,281,O
to,281,O
163,281,O
+/-,281,O
55,281,O
compared,281,O
with,281,O
19.2,281,O
+/-,281,O
9,281,O
mg/24,281,O
hr,281,O
in,281,O
the,281,O
hypertensive,281,B-Disease
controls,281,O
.,281,O
Furthermore,282,O
",",282,O
glomerulosclerosis,282,B-Disease
index,282,O
was,282,O
significantly,282,O
increased,282,O
in,282,O
the,282,O
nitrendipine-treated,282,B-Chemical
group,282,O
compared,282,O
with,282,O
the,282,O
hypertensive,282,B-Disease
controls,282,O
(,282,O
0.38,282,O
+/-,282,O
0.1,282,O
versus,282,O
0.13,282,O
+/-,282,O
0.04,282,O
),282,O
.,282,O
In,283,O
addition,283,O
",",283,O
glomerular,283,O
size,283,O
was,283,O
higher,283,O
in,283,O
the,283,O
nitrendipine-treated,283,B-Chemical
group,283,O
(,283,O
14.9,283,O
+/-,283,O
0.17,283,O
10,283,O
(,283,O
-3,283,O
),283,O
mm2,283,O
),283,O
but,283,O
lower,283,O
in,283,O
the,283,O
enalapril-treated,283,B-Chemical
group,283,O
(,283,O
11.5,283,O
+/-,283,O
0.15,283,O
10,283,O
(,283,O
-3,283,O
),283,O
mm2,283,O
),283,O
compared,283,O
with,283,O
the,283,O
hypertensive,283,B-Disease
controls,283,O
(,283,O
12.1,283,O
+/-,283,O
0.17,283,O
10,283,O
(,283,O
-3,283,O
),283,O
mm2,283,O
),283,O
.,283,O
(,284,O
ABSTRACT,284,O
TRUNCATED,284,O
AT,284,O
250,284,O
WORDS,284,O
),284,O
Phase,285,O
II,285,O
study,285,O
of,285,O
the,285,O
amsacrine,285,B-Chemical
analogue,285,O
CI-921,285,B-Chemical
(,285,O
NSC,285,B-Chemical
343499,285,I-Chemical
),285,O
in,285,O
non-small,285,B-Disease
cell,285,I-Disease
lung,285,I-Disease
cancer,285,I-Disease
.,285,O
CI-921,286,B-Chemical
(,286,O
NSC,286,B-Chemical
343499,286,I-Chemical
;,286,O
9-,286,B-Chemical
[,286,I-Chemical
[,286,I-Chemical
2-methoxy-4-,286,I-Chemical
[,286,I-Chemical
(,286,I-Chemical
methylsulphonyl,286,I-Chemical
),286,I-Chemical
amino,286,I-Chemical
],286,I-Chemical
phenyl,286,I-Chemical
],286,I-Chemical
amino,286,I-Chemical
],286,I-Chemical
"-N,5-dimethyl-",286,I-Chemical
4-acridinecarboxamide,286,I-Chemical
),286,O
is,286,O
a,286,O
topoisomerase,286,O
II,286,O
poison,286,O
with,286,O
high,286,O
experimental,286,O
antitumour,286,O
activity,286,O
.,286,O
It,287,O
was,287,O
administered,287,O
by,287,O
15,287,O
min,287,O
infusion,287,O
to,287,O
16,287,O
evaluable,287,O
patients,287,O
with,287,O
non-small,287,B-Disease
cell,287,I-Disease
lung,287,I-Disease
cancer,287,I-Disease
(,287,O
NSCLC,287,B-Disease
),287,O
(,287,O
7,287,O
with,287,O
no,287,O
prior,287,O
treatment,287,O
",",287,O
9,287,O
patients,287,O
in,287,O
relapse,287,O
following,287,O
surgery/radiotherapy,287,O
),287,O
at,287,O
a,287,O
dose,287,O
(,287,O
648,287,O
mg/m2,287,O
divided,287,O
over,287,O
3,287,O
days,287,O
",",287,O
repeated,287,O
every,287,O
3,287,O
weeks,287,O
),287,O
determined,287,O
by,287,O
phase,287,O
I,287,O
trial,287,O
.,287,O
Patients,288,O
had,288,O
a,288,O
median,288,O
performance,288,O
status,288,O
of,288,O
1,288,O
(,288,O
WHO,288,O
),288,O
",",288,O
and,288,O
median,288,O
age,288,O
of,288,O
61,288,O
years,288,O
.,288,O
The,289,O
histology,289,O
comprised,289,O
squamous,289,B-Disease
carcinoma,289,I-Disease
(,289,O
11,289,O
),289,O
",",289,O
adenocarcinoma,289,B-Disease
(,289,O
1,289,O
),289,O
",",289,O
mixed,289,O
histology,289,O
(,289,O
2,289,O
),289,O
",",289,O
bronchio-alveolar,289,B-Disease
carcinoma,289,I-Disease
(,289,O
1,289,O
),289,O
and,289,O
large,289,O
cell,289,O
undifferentiated,289,B-Disease
carcinoma,289,I-Disease
(,289,O
1,289,O
),289,O
.,289,O
Neutropenia,290,B-Disease
grade,290,O
greater,290,O
than,290,O
or,290,O
equal,290,O
to,290,O
3,290,O
was,290,O
seen,290,O
in,290,O
15,290,O
patients,290,O
",",290,O
infections,290,B-Disease
with,290,O
recovery,290,O
in,290,O
3,290,O
",",290,O
and,290,O
grand,290,O
mal,290,O
seizures,290,B-Disease
in,290,O
1,290,O
patient,290,O
.,290,O
Grade,291,O
less,291,O
than,291,O
or,291,O
equal,291,O
to,291,O
2,291,O
nausea,291,B-Disease
and,291,O
vomiting,291,B-Disease
occurred,291,O
in,291,O
66,291,O
%,291,O
courses,291,O
and,291,O
phlebitis,291,B-Disease
in,291,O
the,291,O
infusion,291,O
arm,291,O
in,291,O
37,291,O
%,291,O
.,291,O
1,292,O
patient,292,O
with,292,O
squamous,292,B-Disease
cell,292,I-Disease
carcinoma,292,I-Disease
achieved,292,O
a,292,O
partial,292,O
response,292,O
lasting,292,O
5,292,O
months,292,O
.,292,O
Further,293,O
testing,293,O
in,293,O
this,293,O
and,293,O
other,293,O
tumour,293,B-Disease
types,293,O
using,293,O
multiple,293,O
daily,293,O
schedules,293,O
is,293,O
warranted,293,O
.,293,O
Long-term,294,O
follow-up,294,O
of,294,O
ifosfamide,294,B-Chemical
renal,294,B-Disease
toxicity,294,I-Disease
in,294,O
children,294,O
treated,294,O
for,294,O
malignant,294,B-Disease
mesenchymal,294,I-Disease
tumors,294,I-Disease
:,294,O
an,294,O
International,294,O
Society,294,O
of,294,O
Pediatric,294,O
Oncology,294,O
report,294,O
.,294,O
The,295,O
renal,295,O
function,295,O
of,295,O
74,295,O
children,295,O
with,295,O
malignant,295,B-Disease
mesenchymal,295,I-Disease
tumors,295,I-Disease
in,295,O
complete,295,O
remission,295,O
and,295,O
who,295,O
have,295,O
received,295,O
the,295,O
same,295,O
ifosfamide,295,B-Chemical
chemotherapy,295,O
protocol,295,O
(,295,O
International,295,O
Society,295,O
of,295,O
Pediatric,295,O
Oncology,295,O
Malignant,295,B-Disease
Mesenchymal,295,I-Disease
Tumor,295,I-Disease
Study,295,O
84,295,O
[,295,O
SIOP,295,O
MMT,295,O
84,295,O
],295,O
),295,O
were,295,O
studied,295,O
1,295,O
year,295,O
after,295,O
the,295,O
completion,295,O
of,295,O
treatment,295,O
.,295,O
Total,296,O
cumulative,296,O
doses,296,O
were,296,O
36,296,O
or,296,O
60,296,O
g/m2,296,O
of,296,O
ifosfamide,296,B-Chemical
(,296,O
six,296,O
or,296,O
10,296,O
cycles,296,O
of,296,O
ifosfamide,296,B-Chemical
",",296,I-Chemical
vincristine,296,I-Chemical
",",296,I-Chemical
and,296,I-Chemical
dactinomycin,296,I-Chemical
[,296,O
IVA,296,B-Chemical
],296,O
),296,O
.,296,O
None,297,O
of,297,O
them,297,O
had,297,O
received,297,O
cisplatin,297,B-Chemical
chemotherapy,297,O
.,297,O
Ages,298,O
ranged,298,O
from,298,O
4,298,O
months,298,O
to,298,O
17,298,O
years,298,O
;,298,O
58,298,O
patients,298,O
were,298,O
males,298,O
and,298,O
42,298,O
females,298,O
.,298,O
The,299,O
most,299,O
common,299,O
primary,299,O
tumor,299,B-Disease
site,299,O
was,299,O
the,299,O
head,299,O
and,299,O
neck,299,O
.,299,O
Renal,300,O
function,300,O
was,300,O
investigated,300,O
by,300,O
measuring,300,O
plasma,300,O
and,300,O
urinary,300,O
electrolytes,300,O
",",300,O
glucosuria,300,B-Disease
",",300,O
proteinuria,300,B-Disease
",",300,O
aminoaciduria,300,B-Disease
",",300,O
urinary,300,O
pH,300,O
",",300,O
osmolarity,300,O
",",300,O
creatinine,300,B-Chemical
clearance,300,O
",",300,O
phosphate,300,B-Chemical
tubular,300,O
reabsorption,300,O
",",300,O
beta,300,O
2,300,O
microglobulinuria,300,O
",",300,O
and,300,O
lysozymuria,300,O
.,300,O
Fifty-eight,301,O
patients,301,O
(,301,O
78,301,O
%,301,O
),301,O
had,301,O
normal,301,O
renal,301,O
tests,301,O
",",301,O
whereas,301,O
16,301,O
patients,301,O
(,301,O
22,301,O
%,301,O
),301,O
had,301,O
renal,301,B-Disease
abnormalities,301,I-Disease
.,301,O
Two,302,O
subsets,302,O
of,302,O
patients,302,O
were,302,O
identified,302,O
from,302,O
this,302,O
latter,302,O
group,302,O
:,302,O
the,302,O
first,302,O
included,302,O
four,302,O
patients,302,O
(,302,O
5,302,O
%,302,O
of,302,O
the,302,O
total,302,O
population,302,O
),302,O
who,302,O
developed,302,O
major,302,O
toxicity,302,B-Disease
resulting,302,O
in,302,O
Fanconi,302,B-Disease
's,302,I-Disease
syndrome,302,I-Disease
(,302,O
TDFS,302,B-Disease
),302,O
;,302,O
and,302,O
the,302,O
second,302,O
group,302,O
included,302,O
five,302,O
patients,302,O
with,302,O
elevated,302,O
beta,302,O
2,302,O
microglobulinuria,302,O
and,302,O
low,302,O
phosphate,302,B-Chemical
reabsorption,302,O
.,302,O
The,303,O
remaining,303,O
seven,303,O
patients,303,O
had,303,O
isolated,303,O
beta,303,O
2,303,O
microglobulinuria,303,O
.,303,O
Severe,304,O
toxicity,304,B-Disease
was,304,O
correlated,304,O
with,304,O
the,304,O
higher,304,O
cumulative,304,O
dose,304,O
of,304,O
60,304,O
g/m2,304,O
of,304,O
ifosfamide,304,B-Chemical
",",304,O
a,304,O
younger,304,O
age,304,O
(,304,O
less,304,O
than,304,O
2,304,O
1/2,304,O
years,304,O
old,304,O
),304,O
",",304,O
and,304,O
a,304,O
predominance,304,O
of,304,O
vesicoprostatic,304,O
tumor,304,B-Disease
involvement,304,O
.,304,O
This,305,O
low,305,O
percentage,305,O
(,305,O
5,305,O
%,305,O
),305,O
of,305,O
TDFS,305,O
must,305,O
be,305,O
evaluated,305,O
with,305,O
respect,305,O
to,305,O
the,305,O
efficacy,305,O
of,305,O
ifosfamide,305,B-Chemical
in,305,O
the,305,O
treatment,305,O
of,305,O
mesenchymal,305,B-Disease
tumors,305,I-Disease
in,305,O
children,305,O
.,305,O
Granulomatous,306,O
hepatitis,306,O
due,306,O
to,306,O
combination,306,B-Chemical
of,306,I-Chemical
amoxicillin,306,I-Chemical
and,306,I-Chemical
clavulanic,306,I-Chemical
acid,306,I-Chemical
.,306,O
We,307,O
report,307,O
the,307,O
case,307,O
of,307,O
a,307,O
patient,307,O
with,307,O
amoxicillin-clavulanic,307,B-Chemical
acid-induced,307,O
hepatitis,307,B-Disease
with,307,O
histologic,307,O
multiple,307,O
granulomas,307,B-Disease
.,307,O
This,308,O
type,308,O
of,308,O
lesion,308,O
broadens,308,O
the,308,O
spectrum,308,O
of,308,O
liver,308,B-Disease
injury,308,I-Disease
due,308,O
to,308,O
this,308,O
drug,308,O
combination,308,O
",",308,O
mainly,308,O
represented,308,O
by,308,O
a,308,O
benign,308,O
cholestatic,308,B-Disease
syndrome,308,I-Disease
.,308,O
The,309,O
association,309,O
of,309,O
granulomas,309,B-Disease
and,309,O
eosinophilia,309,B-Disease
favor,309,O
an,309,O
immunoallergic,309,O
mechanism,309,O
.,309,O
As,310,O
penicillin,310,B-Chemical
derivatives,310,O
and,310,O
amoxicillin,310,B-Chemical
alone,310,O
are,310,O
known,310,O
to,310,O
induce,310,O
such,310,O
types,310,O
of,310,O
lesions,310,O
",",310,O
the,310,O
amoxicillin,310,B-Chemical
component,310,O
",",310,O
with,310,O
or,310,O
without,310,O
a,310,O
potentiating,310,O
effect,310,O
of,310,O
clavulanic,310,B-Chemical
acid,310,I-Chemical
",",310,O
might,310,O
have,310,O
a,310,O
major,310,O
role,310,O
.,310,O
Dobutamine,311,B-Chemical
stress,311,O
echocardiography,311,O
:,311,O
a,311,O
sensitive,311,O
indicator,311,O
of,311,O
diminished,311,O
myocardial,311,O
function,311,O
in,311,O
asymptomatic,311,O
doxorubicin-treated,311,B-Chemical
long-term,311,O
survivors,311,O
of,311,O
childhood,311,O
cancer,311,B-Disease
.,311,O
Doxorubicin,312,B-Chemical
is,312,O
an,312,O
effective,312,O
anticancer,312,O
chemotherapeutic,312,O
agent,312,O
known,312,O
to,312,O
cause,312,O
acute,312,O
and,312,O
chronic,312,O
cardiomyopathy,312,B-Disease
.,312,O
To,313,O
develop,313,O
a,313,O
more,313,O
sensitive,313,O
echocardiographic,313,O
screening,313,O
test,313,O
for,313,O
cardiac,313,B-Disease
damage,313,I-Disease
due,313,O
to,313,O
doxorubicin,313,B-Chemical
",",313,O
a,313,O
cohort,313,O
study,313,O
was,313,O
performed,313,O
using,313,O
dobutamine,313,B-Chemical
infusion,313,O
to,313,O
differentiate,313,O
asymptomatic,313,O
long-term,313,O
survivors,313,O
of,313,O
childhood,313,O
cancer,313,B-Disease
treated,313,O
with,313,O
doxorubicin,313,B-Chemical
from,313,O
healthy,313,O
control,313,O
subjects,313,O
.,313,O
Echocardiographic,314,O
data,314,O
from,314,O
the,314,O
experimental,314,O
group,314,O
of,314,O
21,314,O
patients,314,O
(,314,O
mean,314,O
age,314,O
16,314,O
+/-,314,O
5,314,O
years,314,O
),314,O
treated,314,O
from,314,O
1.6,314,O
to,314,O
14.3,314,O
years,314,O
(,314,O
median,314,O
5.3,314,O
),314,O
before,314,O
this,314,O
study,314,O
with,314,O
27,314,O
to,314,O
532,314,O
mg/m2,314,O
of,314,O
doxorubicin,314,B-Chemical
(,314,O
mean,314,O
196,314,O
),314,O
were,314,O
compared,314,O
with,314,O
echocardiographic,314,O
data,314,O
from,314,O
12,314,O
normal,314,O
age-matched,314,O
control,314,O
subjects,314,O
.,314,O
Graded,315,O
dobutamine,315,B-Chemical
infusions,315,O
of,315,O
0.5,315,O
",",315,O
2.5,315,O
",",315,O
5,315,O
and,315,O
10,315,O
micrograms/kg,315,O
per,315,O
min,315,O
were,315,O
administered,315,O
.,315,O
Echocardiographic,316,O
Doppler,316,O
studies,316,O
were,316,O
performed,316,O
before,316,O
infusion,316,O
and,316,O
after,316,O
15,316,O
min,316,O
of,316,O
infusion,316,O
at,316,O
each,316,O
rate,316,O
.,316,O
Dobutamine,317,B-Chemical
infusion,317,O
at,317,O
10,317,O
micrograms/kg,317,O
per,317,O
min,317,O
was,317,O
discontinued,317,O
after,317,O
six,317,O
studies,317,O
secondary,317,O
to,317,O
a,317,O
50,317,O
%,317,O
incidence,317,O
rate,317,O
of,317,O
adverse,317,O
symptoms,317,O
.,317,O
The,318,O
most,318,O
important,318,O
findings,318,O
were,318,O
that,318,O
compared,318,O
with,318,O
values,318,O
in,318,O
control,318,O
subjects,318,O
",",318,O
end-systolic,318,O
left,318,O
ventricular,318,O
posterior,318,O
wall,318,O
dimension,318,O
and,318,O
percent,318,O
of,318,O
left,318,O
ventricular,318,O
posterior,318,O
wall,318,O
thickening,318,O
in,318,O
doxorubicin-treated,318,B-Chemical
patients,318,O
were,318,O
decreased,318,O
at,318,O
baseline,318,O
study,318,O
and,318,O
these,318,O
findings,318,O
were,318,O
more,318,O
clearly,318,O
delineated,318,O
with,318,O
dobutamine,318,B-Chemical
stimulation,318,O
.,318,O
End-systolic,319,O
left,319,O
ventricular,319,O
posterior,319,O
wall,319,O
dimension,319,O
at,319,O
baseline,319,O
for,319,O
the,319,O
doxorubicin-treated,319,B-Chemical
group,319,O
was,319,O
11,319,O
+/-,319,O
1.9,319,O
mm,319,O
versus,319,O
13.1,319,O
+/-,319,O
1.5,319,O
mm,319,O
for,319,O
control,319,O
subjects,319,O
(,319,O
p,319,O
less,319,O
than,319,O
0.01,319,O
),319,O
.,319,O
End-systolic,320,O
left,320,O
ventricular,320,O
posterior,320,O
wall,320,O
dimension,320,O
at,320,O
the,320,O
5-micrograms/kg,320,O
per,320,O
min,320,O
dobutamine,320,B-Chemical
infusion,320,O
for,320,O
the,320,O
doxorubicin-treated,320,B-Chemical
group,320,O
was,320,O
14.1,320,O
+/-,320,O
2.4,320,O
mm,320,O
versus,320,O
19.3,320,O
+/-,320,O
2.6,320,O
mm,320,O
for,320,O
control,320,O
subjects,320,O
(,320,O
p,320,O
less,320,O
than,320,O
0.01,320,O
),320,O
.,320,O
(,321,O
ABSTRACT,321,O
TRUNCATED,321,O
AT,321,O
250,321,O
WORDS,321,O
),321,O
Cocaine-induced,322,B-Chemical
myocardial,322,B-Disease
infarction,322,I-Disease
:,322,O
clinical,322,O
observations,322,O
and,322,O
pathogenetic,322,O
considerations,322,O
.,322,O
Clinical,323,O
and,323,O
experimental,323,O
data,323,O
published,323,O
to,323,O
date,323,O
suggest,323,O
several,323,O
possible,323,O
mechanisms,323,O
by,323,O
which,323,O
cocaine,323,B-Chemical
may,323,O
result,323,O
in,323,O
acute,323,B-Disease
myocardial,323,I-Disease
infarction,323,I-Disease
.,323,O
In,324,O
individuals,324,O
with,324,O
preexisting,324,O
",",324,O
high-grade,324,O
coronary,324,O
arterial,324,O
narrowing,324,O
",",324,O
acute,324,B-Disease
myocardial,324,I-Disease
infarction,324,I-Disease
may,324,O
result,324,O
from,324,O
an,324,O
increase,324,O
in,324,O
myocardial,324,O
oxygen,324,B-Chemical
demand,324,O
associated,324,O
with,324,O
cocaine-induced,324,B-Chemical
increase,324,O
in,324,O
rate-pressure,324,O
product,324,O
.,324,O
In,325,O
other,325,O
individuals,325,O
with,325,O
no,325,O
underlying,325,O
atherosclerotic,325,B-Disease
obstruction,325,I-Disease
",",325,O
coronary,325,B-Disease
occlusion,325,I-Disease
may,325,O
be,325,O
due,325,O
to,325,O
spasm,325,B-Disease
",",325,O
thrombus,325,B-Disease
",",325,O
or,325,O
both,325,O
.,325,O
With,326,O
regard,326,O
to,326,O
spasm,326,B-Disease
",",326,O
the,326,O
clinical,326,O
findings,326,O
are,326,O
largely,326,O
circumstantial,326,O
",",326,O
and,326,O
the,326,O
locus,326,O
of,326,O
cocaine-induced,326,B-Chemical
vasoconstriction,326,O
remains,326,O
speculative,326,O
.,326,O
Although,327,O
certain,327,O
clinical,327,O
and,327,O
experimental,327,O
findings,327,O
support,327,O
the,327,O
hypothesis,327,O
that,327,O
spasm,327,B-Disease
involves,327,O
the,327,O
epicardial,327,O
",",327,O
medium-size,327,O
vessels,327,O
",",327,O
other,327,O
data,327,O
suggest,327,O
intramural,327,O
vasoconstriction,327,O
.,327,O
Diffuse,328,O
intramural,328,O
vasoconstriction,328,O
is,328,O
not,328,O
consistent,328,O
with,328,O
reports,328,O
of,328,O
segmental,328,O
",",328,O
discrete,328,O
infarction,328,B-Disease
.,328,O
Whereas,329,O
certain,329,O
in,329,O
vivo,329,O
data,329,O
suggest,329,O
that,329,O
these,329,O
effects,329,O
are,329,O
alpha-mediated,329,O
",",329,O
other,329,O
in,329,O
vitro,329,O
data,329,O
suggest,329,O
the,329,O
opposite,329,O
.,329,O
The,330,O
finding,330,O
of,330,O
cocaine-induced,330,B-Chemical
vasoconstriction,330,O
in,330,O
segments,330,O
of,330,O
(,330,O
noninnervated,330,O
),330,O
human,330,O
umbilical,330,O
artery,330,O
suggests,330,O
that,330,O
the,330,O
presence,330,O
or,330,O
absence,330,O
of,330,O
intact,330,O
innervation,330,O
is,330,O
not,330,O
sufficient,330,O
to,330,O
explain,330,O
the,330,O
discrepant,330,O
data,330,O
involving,330,O
the,330,O
possibility,330,O
of,330,O
alpha-mediated,330,O
effects,330,O
.,330,O
Finally,331,O
",",331,O
the,331,O
contribution,331,O
of,331,O
a,331,O
primary,331,O
",",331,O
thrombotic,331,B-Disease
effect,331,O
of,331,O
cocaine,331,B-Chemical
has,331,O
not,331,O
been,331,O
excluded,331,O
.,331,O
Rabbit,332,B-Disease
syndrome,332,I-Disease
",",332,O
antidepressant,332,B-Chemical
use,332,O
",",332,O
and,332,O
cerebral,332,O
perfusion,332,O
SPECT,332,O
scan,332,O
findings,332,O
.,332,O
The,333,O
rabbit,333,B-Disease
syndrome,333,I-Disease
is,333,O
an,333,O
extrapyramidal,333,O
side,333,O
effect,333,O
associated,333,O
with,333,O
chronic,333,O
neuroleptic,333,O
therapy,333,O
.,333,O
Its,334,O
occurrence,334,O
in,334,O
a,334,O
patient,334,O
being,334,O
treated,334,O
with,334,O
imipramine,334,B-Chemical
is,334,O
described,334,O
",",334,O
representing,334,O
the,334,O
first,334,O
reported,334,O
case,334,O
of,334,O
this,334,O
syndrome,334,O
in,334,O
conjunction,334,O
with,334,O
antidepressants,334,B-Chemical
.,334,O
Repeated,335,O
cerebral,335,O
perfusion,335,O
SPECT,335,O
scans,335,O
revealed,335,O
decreased,335,B-Disease
basal,335,I-Disease
ganglia,335,I-Disease
perfusion,335,I-Disease
while,335,O
the,335,O
movement,335,B-Disease
disorder,335,I-Disease
was,335,O
present,335,O
",",335,O
and,335,O
a,335,O
return,335,O
to,335,O
normal,335,O
perfusion,335,O
when,335,O
the,335,O
rabbit,335,B-Disease
syndrome,335,I-Disease
resolved,335,O
.,335,O
Evidence,336,O
for,336,O
an,336,O
involvement,336,O
of,336,O
D1,336,O
and,336,O
D2,336,O
dopamine,336,B-Chemical
receptors,336,O
in,336,O
mediating,336,O
nicotine-induced,336,B-Chemical
hyperactivity,336,B-Disease
in,336,O
rats,336,O
.,336,O
Previous,337,O
studies,337,O
have,337,O
suggested,337,O
that,337,O
repeated,337,O
exposure,337,O
of,337,O
rats,337,O
to,337,O
the,337,O
drug,337,O
or,337,O
to,337,O
the,337,O
experimental,337,O
environment,337,O
is,337,O
necessary,337,O
to,337,O
observe,337,O
nicotine-induced,337,B-Chemical
locomotor,337,O
stimulation,337,O
.,337,O
In,338,O
the,338,O
present,338,O
study,338,O
the,338,O
role,338,O
of,338,O
habituation,338,O
to,338,O
the,338,O
experimental,338,O
environment,338,O
on,338,O
the,338,O
stimulant,338,O
effect,338,O
of,338,O
nicotine,338,B-Chemical
in,338,O
rats,338,O
was,338,O
examined,338,O
.,338,O
In,339,O
addition,339,O
",",339,O
the,339,O
role,339,O
of,339,O
dopamine,339,B-Chemical
receptors,339,O
in,339,O
mediating,339,O
nicotine-induced,339,B-Chemical
locomotor,339,O
stimulation,339,O
was,339,O
investigated,339,O
by,339,O
examining,339,O
the,339,O
effects,339,O
of,339,O
selective,339,O
D1,339,O
and,339,O
D2,339,O
dopamine,339,B-Chemical
receptor,339,O
antagonists,339,O
on,339,O
activity,339,O
induced,339,O
by,339,O
nicotine,339,B-Chemical
.,339,O
Locomotor,340,O
activity,340,O
was,340,O
assessed,340,O
in,340,O
male,340,O
Sprague-Dawley,340,O
rats,340,O
tested,340,O
in,340,O
photocell,340,O
cages,340,O
.,340,O
Nicotine,341,B-Chemical
(,341,O
1.0,341,O
mg/kg,341,O
),341,O
caused,341,O
a,341,O
significant,341,O
increase,341,B-Disease
in,341,I-Disease
locomotor,341,I-Disease
activity,341,I-Disease
in,341,O
rats,341,O
that,341,O
were,341,O
habituated,341,O
to,341,O
the,341,O
test,341,O
environment,341,O
",",341,O
but,341,O
had,341,O
only,341,O
a,341,O
weak,341,O
and,341,O
delayed,341,O
stimulant,341,O
action,341,O
in,341,O
rats,341,O
that,341,O
were,341,O
unfamiliar,341,O
with,341,O
the,341,O
test,341,O
environment,341,O
.,341,O
The,342,O
stimulant,342,O
action,342,O
of,342,O
nicotine,342,B-Chemical
was,342,O
blocked,342,O
by,342,O
the,342,O
central,342,O
nicotinic,342,O
antagonist,342,O
mecamylamine,342,B-Chemical
but,342,O
not,342,O
by,342,O
the,342,O
peripheral,342,O
nicotinic,342,O
blocker,342,O
hexamethonium,342,B-Chemical
",",342,O
indicating,342,O
that,342,O
the,342,O
response,342,O
is,342,O
probably,342,O
mediated,342,O
by,342,O
central,342,O
nicotinic,342,O
receptors,342,O
.,342,O
Nicotine-induced,343,B-Chemical
hyperactivity,343,B-Disease
was,343,O
blocked,343,O
by,343,O
the,343,O
selective,343,O
D1,343,O
antagonist,343,O
SCH,343,B-Chemical
23390,343,I-Chemical
",",343,O
the,343,O
selective,343,O
D2,343,O
antagonist,343,O
raclopride,343,B-Chemical
and,343,O
the,343,O
D1/D2,343,O
antagonist,343,O
fluphenazine,343,B-Chemical
.,343,O
Pretreatment,344,O
with,344,O
the,344,O
D2,344,O
agonist,344,O
PHNO,344,B-Chemical
enhanced,344,O
nicotine-induced,344,B-Chemical
hyperactivity,344,B-Disease
",",344,O
whereas,344,O
the,344,O
D1,344,O
agonist,344,O
SKF,344,B-Chemical
38393,344,I-Chemical
had,344,O
no,344,O
effect,344,O
.,344,O
The,345,O
results,345,O
indicate,345,O
that,345,O
acute,345,O
nicotine,345,B-Chemical
injection,345,O
induces,345,O
a,345,O
pronounced,345,O
hyperactivity,345,B-Disease
in,345,O
rats,345,O
habituated,345,O
to,345,O
the,345,O
test,345,O
environment,345,O
.,345,O
The,346,O
effect,346,O
appears,346,O
to,346,O
be,346,O
mediated,346,O
by,346,O
central,346,O
nicotine,346,B-Chemical
receptors,346,O
",",346,O
possibly,346,O
located,346,O
on,346,O
dopaminergic,346,O
neurons,346,O
",",346,O
and,346,O
also,346,O
requires,346,O
the,346,O
activation,346,O
of,346,O
both,346,O
D1,346,O
and,346,O
D2,346,O
dopamine,346,B-Chemical
receptors,346,O
.,346,O
Acute,347,O
bronchodilating,347,O
effects,347,O
of,347,O
ipratropium,347,B-Chemical
bromide,347,I-Chemical
and,347,O
theophylline,347,B-Chemical
in,347,O
chronic,347,B-Disease
obstructive,347,I-Disease
pulmonary,347,I-Disease
disease,347,I-Disease
.,347,O
The,348,O
bronchodilator,348,O
effects,348,O
of,348,O
a,348,O
single,348,O
dose,348,O
of,348,O
ipratropium,348,B-Chemical
bromide,348,I-Chemical
aerosol,348,O
(,348,O
36,348,O
micrograms,348,O
),348,O
and,348,O
short-acting,348,O
theophylline,348,B-Chemical
tablets,348,O
(,348,O
dose,348,O
titrated,348,O
to,348,O
produce,348,O
serum,348,O
levels,348,O
of,348,O
10-20,348,O
micrograms/mL,348,O
),348,O
were,348,O
compared,348,O
in,348,O
a,348,O
double-blind,348,O
",",348,O
placebo-controlled,348,O
crossover,348,O
study,348,O
in,348,O
21,348,O
patients,348,O
with,348,O
stable,348,O
",",348,O
chronic,348,B-Disease
obstructive,348,I-Disease
pulmonary,348,I-Disease
disease,348,I-Disease
.,348,O
Mean,349,O
peak,349,O
forced,349,O
expiratory,349,O
volume,349,O
in,349,O
1,349,O
second,349,O
(,349,O
FEV1,349,O
),349,O
increases,349,O
over,349,O
baseline,349,O
and,349,O
the,349,O
proportion,349,O
of,349,O
patients,349,O
attaining,349,O
at,349,O
least,349,O
a,349,O
15,349,O
%,349,O
increase,349,O
in,349,O
the,349,O
FEV1,349,O
(,349,O
responders,349,O
),349,O
were,349,O
31,349,O
%,349,O
and,349,O
90,349,O
%,349,O
",",349,O
respectively,349,O
",",349,O
for,349,O
ipratropium,349,B-Chemical
and,349,O
17,349,O
%,349,O
and,349,O
50,349,O
%,349,O
",",349,O
respectively,349,O
",",349,O
for,349,O
theophylline,349,B-Chemical
.,349,O
The,350,O
average,350,O
FEV1,350,O
increases,350,O
during,350,O
the,350,O
6-hour,350,O
observation,350,O
period,350,O
were,350,O
18,350,O
%,350,O
for,350,O
ipratropium,350,B-Chemical
and,350,O
8,350,O
%,350,O
for,350,O
theophylline,350,B-Chemical
.,350,O
The,351,O
mean,351,O
duration,351,O
of,351,O
action,351,O
was,351,O
3.8,351,O
hours,351,O
with,351,O
ipratropium,351,B-Chemical
and,351,O
2.4,351,O
hours,351,O
with,351,O
theophylline,351,B-Chemical
.,351,O
While,352,O
side,352,O
effects,352,O
were,352,O
rare,352,O
",",352,O
those,352,O
experienced,352,O
after,352,O
theophylline,352,B-Chemical
use,352,O
did,352,O
involve,352,O
the,352,O
cardiovascular,352,O
and,352,O
gastrointestinal,352,O
systems,352,O
.,352,O
These,353,O
results,353,O
show,353,O
that,353,O
ipratropium,353,B-Chemical
is,353,O
a,353,O
more,353,O
potent,353,O
bronchodilator,353,O
than,353,O
oral,353,O
theophylline,353,B-Chemical
in,353,O
patients,353,O
with,353,O
chronic,353,B-Disease
airflow,353,I-Disease
obstruction,353,I-Disease
.,353,O
Neuropsychiatric,354,O
side,354,O
effects,354,O
after,354,O
the,354,O
use,354,O
of,354,O
mefloquine,354,B-Chemical
.,354,O
This,355,O
study,355,O
describes,355,O
neuropsychiatric,355,O
side,355,O
effects,355,O
in,355,O
patients,355,O
after,355,O
treatment,355,O
with,355,O
mefloquine,355,B-Chemical
.,355,O
Reactions,356,O
consisted,356,O
mainly,356,O
of,356,O
seizures,356,B-Disease
",",356,O
acute,356,O
psychoses,356,B-Disease
",",356,O
anxiety,356,B-Disease
neurosis,356,I-Disease
",",356,O
and,356,O
major,356,O
disturbances,356,B-Disease
of,356,I-Disease
sleep-wake,356,I-Disease
rhythm,356,I-Disease
.,356,O
Side,357,O
effects,357,O
occurred,357,O
after,357,O
both,357,O
therapeutic,357,O
and,357,O
prophylactic,357,O
intake,357,O
and,357,O
were,357,O
graded,357,O
from,357,O
moderate,357,O
to,357,O
severe,357,O
.,357,O
In,358,O
a,358,O
risk,358,O
analysis,358,O
of,358,O
neuropsychiatric,358,O
side,358,O
effects,358,O
in,358,O
Germany,358,O
",",358,O
it,358,O
is,358,O
estimated,358,O
that,358,O
one,358,O
of,358,O
"8,000",358,O
mefloquine,358,B-Chemical
users,358,O
suffers,358,O
from,358,O
such,358,O
reactions,358,O
.,358,O
The,359,O
incidence,359,O
calculation,359,O
revealed,359,O
that,359,O
one,359,O
of,359,O
215,359,O
therapeutic,359,O
users,359,O
had,359,O
reactions,359,O
",",359,O
compared,359,O
with,359,O
one,359,O
of,359,O
"13,000",359,O
in,359,O
the,359,O
prophylaxis,359,O
group,359,O
",",359,O
making,359,O
the,359,O
risk,359,O
of,359,O
neuropsychiatric,359,O
reactions,359,O
after,359,O
mefloquine,359,B-Chemical
treatment,359,O
60,359,O
times,359,O
higher,359,O
than,359,O
after,359,O
prophylaxis,359,O
.,359,O
Therefore,360,O
",",360,O
certain,360,O
limitations,360,O
for,360,O
malaria,360,B-Disease
prophylaxis,360,O
and,360,O
treatment,360,O
with,360,O
mefloquine,360,B-Chemical
are,360,O
recommended,360,O
.,360,O
Irreversible,361,O
damage,361,O
to,361,O
the,361,O
medullary,361,O
interstitium,361,O
in,361,O
experimental,361,O
analgesic,361,O
nephropathy,361,B-Disease
in,361,O
F344,361,O
rats,361,O
.,361,O
Renal,362,B-Disease
papillary,362,I-Disease
necrosis,362,I-Disease
(,362,O
RPN,362,B-Disease
),362,O
and,362,O
a,362,O
decreased,362,O
urinary,362,O
concentrating,362,O
ability,362,O
developed,362,O
during,362,O
continuous,362,O
long-term,362,O
treatment,362,O
with,362,O
aspirin,362,B-Chemical
and,362,O
paracetamol,362,B-Chemical
in,362,O
female,362,O
Fischer,362,O
344,362,O
rats,362,O
.,362,O
Renal,363,O
structure,363,O
and,363,O
concentrating,363,O
ability,363,O
were,363,O
examined,363,O
after,363,O
a,363,O
recovery,363,O
period,363,O
of,363,O
up,363,O
to,363,O
18,363,O
weeks,363,O
",",363,O
when,363,O
no,363,O
analgesics,363,O
were,363,O
given,363,O
",",363,O
to,363,O
investigate,363,O
whether,363,O
the,363,O
analgesic-induced,363,O
changes,363,O
were,363,O
reversible,363,O
.,363,O
There,364,O
was,364,O
no,364,O
evidence,364,O
of,364,O
repair,364,O
to,364,O
the,364,O
damaged,364,O
medullary,364,O
interstitial,364,O
matrix,364,O
",",364,O
or,364,O
proliferation,364,O
of,364,O
remaining,364,O
undamaged,364,O
type,364,O
1,364,O
medullary,364,O
interstitial,364,O
cells,364,O
after,364,O
the,364,O
recovery,364,O
period,364,O
following,364,O
analgesic,364,O
treatment,364,O
.,364,O
The,365,O
recovery,365,O
of,365,O
urinary,365,O
concentrating,365,O
ability,365,O
was,365,O
related,365,O
to,365,O
the,365,O
length,365,O
of,365,O
analgesic,365,O
treatment,365,O
and,365,O
the,365,O
extent,365,O
of,365,O
the,365,O
resulting,365,O
inner,365,O
medullary,365,O
structural,365,O
damage,365,O
.,365,O
During,366,O
the,366,O
early,366,O
stages,366,O
of,366,O
analgesic,366,O
treatment,366,O
",",366,O
the,366,O
changes,366,O
in,366,O
urinary,366,O
concentrating,366,O
ability,366,O
were,366,O
reversible,366,O
",",366,O
but,366,O
after,366,O
prolonged,366,O
analgesic,366,O
treatment,366,O
",",366,O
maximum,366,O
urinary,366,O
concentrating,366,O
ability,366,O
failed,366,O
to,366,O
recover,366,O
.,366,O
This,367,O
study,367,O
shows,367,O
that,367,O
prolonged,367,O
analgesic,367,O
treatment,367,O
in,367,O
Fischer,367,O
344,367,O
rats,367,O
causes,367,O
progressive,367,O
and,367,O
irreversible,367,O
damage,367,O
to,367,O
the,367,O
interstitial,367,O
matrix,367,O
and,367,O
type,367,O
1,367,O
interstitial,367,O
cells,367,O
leading,367,O
to,367,O
RPN,367,B-Disease
.,367,O
The,368,O
associated,368,O
urinary,368,O
concentrating,368,O
defect,368,O
is,368,O
reversible,368,O
only,368,O
during,368,O
the,368,O
early,368,O
stages,368,O
of,368,O
structural,368,O
damage,368,O
to,368,O
the,368,O
inner,368,O
medulla,368,O
.,368,O
Sulpiride-induced,369,B-Chemical
tardive,369,B-Disease
dystonia,369,I-Disease
.,369,O
Sulpiride,370,B-Chemical
is,370,O
a,370,O
selective,370,O
D2-receptor,370,O
antagonist,370,O
with,370,O
antipsychotic,370,O
and,370,O
antidepressant,370,B-Chemical
properties,370,O
.,370,O
Although,371,O
initially,371,O
thought,371,O
to,371,O
be,371,O
free,371,O
of,371,O
extrapyramidal,371,O
side,371,O
effects,371,O
",",371,O
sulpiride-induced,371,B-Chemical
tardive,371,B-Disease
dyskinesia,371,I-Disease
and,371,O
parkinsonism,371,B-Disease
have,371,O
been,371,O
reported,371,O
occasionally,371,O
.,371,O
We,372,O
studied,372,O
a,372,O
37-year-old,372,O
man,372,O
who,372,O
developed,372,O
persistent,372,O
segmental,372,O
dystonia,372,B-Disease
within,372,O
2,372,O
months,372,O
after,372,O
starting,372,O
sulpiride,372,B-Chemical
therapy,372,O
.,372,O
We,373,O
could,373,O
not,373,O
find,373,O
any,373,O
previous,373,O
reports,373,O
of,373,O
sulpiride-induced,373,B-Chemical
tardive,373,B-Disease
dystonia,373,I-Disease
.,373,O
Less,374,O
frequent,374,O
lithium,374,B-Chemical
administration,374,O
and,374,O
lower,374,O
urine,374,O
volume,374,O
.,374,O
OBJECTIVE,375,O
:,375,O
This,375,O
study,375,O
was,375,O
designed,375,O
to,375,O
determine,375,O
whether,375,O
patients,375,O
maintained,375,O
on,375,O
a,375,O
regimen,375,O
of,375,O
lithium,375,B-Chemical
on,375,O
a,375,O
once-per-day,375,O
schedule,375,O
have,375,O
lower,375,O
urine,375,O
volumes,375,O
than,375,O
do,375,O
patients,375,O
receiving,375,O
multiple,375,O
doses,375,O
per,375,O
day,375,O
.,375,O
METHOD,376,O
:,376,O
This,376,O
was,376,O
a,376,O
cross-sectional,376,O
study,376,O
of,376,O
85,376,O
patients,376,O
from,376,O
a,376,O
lithium,376,B-Chemical
clinic,376,O
who,376,O
received,376,O
different,376,O
dose,376,O
schedules,376,O
.,376,O
Patients,377,O
were,377,O
admitted,377,O
to,377,O
the,377,O
hospital,377,O
for,377,O
measurement,377,O
of,377,O
lithium,377,B-Chemical
level,377,O
",",377,O
creatinine,377,B-Chemical
clearance,377,O
",",377,O
urine,377,O
volume,377,O
",",377,O
and,377,O
maximum,377,O
osmolality,377,O
.,377,O
RESULTS,378,O
:,378,O
Multiple,378,O
daily,378,O
doses,378,O
of,378,O
lithium,378,B-Chemical
were,378,O
associated,378,O
with,378,O
higher,378,O
urine,378,O
volumes,378,O
.,378,O
The,379,O
dosing,379,O
schedule,379,O
",",379,O
duration,379,O
of,379,O
lithium,379,B-Chemical
treatment,379,O
",",379,O
and,379,O
daily,379,O
dose,379,O
of,379,O
lithium,379,B-Chemical
did,379,O
not,379,O
affect,379,O
maximum,379,O
osmolality,379,O
or,379,O
creatinine,379,B-Chemical
clearance,379,O
.,379,O
CONCLUSIONS,380,O
:,380,O
Urine,380,O
volume,380,O
can,380,O
be,380,O
reduced,380,O
by,380,O
giving,380,O
lithium,380,B-Chemical
once,380,O
daily,380,O
and/or,380,O
by,380,O
lowering,380,O
the,380,O
total,380,O
daily,380,O
dose,380,O
.,380,O
Lithium-induced,381,B-Chemical
polyuria,381,B-Disease
seems,381,O
to,381,O
be,381,O
related,381,O
to,381,O
extrarenal,381,O
as,381,O
well,381,O
as,381,O
to,381,O
renal,381,O
effects,381,O
.,381,O
Hemolytic,382,B-Disease
anemia,382,I-Disease
associated,382,O
with,382,O
the,382,O
use,382,O
of,382,O
omeprazole,382,B-Chemical
.,382,O
Omeprazole,383,B-Chemical
is,383,O
the,383,O
first,383,O
drug,383,O
designed,383,O
to,383,O
block,383,O
the,383,O
final,383,O
step,383,O
in,383,O
the,383,O
acid,383,O
secretory,383,O
process,383,O
within,383,O
the,383,O
parietal,383,O
cell,383,O
.,383,O
It,384,O
has,384,O
been,384,O
shown,384,O
to,384,O
be,384,O
extremely,384,O
effective,384,O
in,384,O
the,384,O
treatment,384,O
of,384,O
peptic,384,B-Disease
ulcer,384,I-Disease
disease,384,I-Disease
",",384,O
reflux,384,B-Disease
esophagitis,384,I-Disease
",",384,O
and,384,O
the,384,O
Zollinger-Ellison,384,B-Disease
syndrome,384,I-Disease
.,384,O
Although,385,O
clinical,385,O
experience,385,O
with,385,O
omeprazole,385,B-Chemical
is,385,O
still,385,O
limited,385,O
",",385,O
many,385,O
controlled,385,O
studies,385,O
have,385,O
established,385,O
the,385,O
short-term,385,O
safety,385,O
of,385,O
this,385,O
drug,385,O
.,385,O
We,386,O
report,386,O
the,386,O
first,386,O
case,386,O
of,386,O
a,386,O
serious,386,O
short-term,386,O
adverse,386,O
reaction,386,O
with,386,O
the,386,O
use,386,O
of,386,O
omeprazole,386,B-Chemical
:,386,O
hemolytic,386,B-Disease
anemia,386,I-Disease
.,386,O
The,387,O
patient,387,O
developed,387,O
weakness,387,O
",",387,O
lethargy,387,B-Disease
",",387,O
and,387,O
shortness,387,B-Disease
of,387,I-Disease
breath,387,I-Disease
2,387,O
days,387,O
after,387,O
starting,387,O
therapy,387,O
with,387,O
omeprazole,387,B-Chemical
.,387,O
Two,388,O
weeks,388,O
after,388,O
the,388,O
initiation,388,O
of,388,O
therapy,388,O
",",388,O
her,388,O
hematocrit,388,O
had,388,O
decreased,388,O
from,388,O
44.1,388,O
%,388,O
to,388,O
20.4,388,O
%,388,O
",",388,O
and,388,O
she,388,O
had,388,O
a,388,O
positive,388,O
direct,388,O
Coombs,388,O
antiglobulin,388,O
test,388,O
and,388,O
an,388,O
elevated,388,O
indirect,388,O
bilirubin,388,B-Chemical
.,388,O
After,389,O
she,389,O
discontinued,389,O
the,389,O
omeprazole,389,B-Chemical
",",389,O
her,389,O
hemoglobin,389,O
and,389,O
hematocrit,389,O
gradually,389,O
returned,389,O
to,389,O
normal,389,O
.,389,O
The,390,O
mechanism,390,O
by,390,O
which,390,O
omeprazole,390,B-Chemical
caused,390,O
the,390,O
patient,390,O
's,390,O
hemolytic,390,B-Disease
anemia,390,I-Disease
is,390,O
uncertain,390,O
",",390,O
but,390,O
physicians,390,O
should,390,O
be,390,O
alerted,390,O
to,390,O
this,390,O
possible,390,O
adverse,390,O
effect,390,O
.,390,O
Effect,391,O
of,391,O
direct,391,O
intracoronary,391,O
administration,391,O
of,391,O
methylergonovine,391,B-Chemical
in,391,O
patients,391,O
with,391,O
and,391,O
without,391,O
variant,391,B-Disease
angina,391,I-Disease
.,391,O
The,392,O
effects,392,O
of,392,O
intracoronary,392,O
administration,392,O
of,392,O
methylergonovine,392,B-Chemical
were,392,O
studied,392,O
in,392,O
21,392,O
patients,392,O
with,392,O
variant,392,B-Disease
angina,392,I-Disease
and,392,O
22,392,O
patients,392,O
with,392,O
atypical,392,O
chest,392,B-Disease
pain,392,I-Disease
and,392,O
in,392,O
others,392,O
without,392,O
angina,392,B-Disease
pectoris,392,I-Disease
(,392,O
control,392,O
group,392,O
),392,O
.,392,O
Methylergonovine,393,B-Chemical
was,393,O
administered,393,O
continuously,393,O
at,393,O
a,393,O
rate,393,O
of,393,O
10,393,O
micrograms/min,393,O
up,393,O
to,393,O
50,393,O
micrograms,393,O
.,393,O
In,394,O
all,394,O
patients,394,O
with,394,O
variant,394,B-Disease
angina,394,I-Disease
",",394,O
coronary,394,B-Disease
spasm,394,I-Disease
was,394,O
provoked,394,O
at,394,O
a,394,O
mean,394,O
dose,394,O
of,394,O
28,394,O
+/-,394,O
13,394,O
micrograms,394,O
(,394,O
mean,394,O
+/-,394,O
SD,394,O
),394,O
.,394,O
In,395,O
the,395,O
control,395,O
group,395,O
neither,395,O
ischemic,395,O
ST,395,O
change,395,O
nor,395,O
localized,395,O
spasm,395,B-Disease
occurred,395,O
.,395,O
The,396,O
basal,396,O
tone,396,O
of,396,O
the,396,O
right,396,O
coronary,396,O
artery,396,O
was,396,O
significantly,396,O
lower,396,O
than,396,O
that,396,O
of,396,O
the,396,O
left,396,O
coronary,396,O
artery,396,O
.,396,O
The,397,O
percentage,397,O
of,397,O
vasoconstriction,397,O
of,397,O
the,397,O
right,397,O
coronary,397,O
artery,397,O
was,397,O
significantly,397,O
higher,397,O
than,397,O
that,397,O
of,397,O
the,397,O
left,397,O
coronary,397,O
artery,397,O
.,397,O
These,398,O
results,398,O
suggest,398,O
that,398,O
spasm,398,B-Disease
provocation,398,O
tests,398,O
",",398,O
which,398,O
use,398,O
an,398,O
intracoronary,398,O
injection,398,O
of,398,O
a,398,O
relatively,398,O
low,398,O
dose,398,O
of,398,O
methylergonovine,398,B-Chemical
",",398,O
have,398,O
a,398,O
high,398,O
sensitivity,398,O
in,398,O
variant,398,B-Disease
angina,398,I-Disease
and,398,O
the,398,O
vasoreactivity,398,O
of,398,O
the,398,O
right,398,O
coronary,398,O
artery,398,O
may,398,O
be,398,O
greater,398,O
than,398,O
that,398,O
of,398,O
the,398,O
other,398,O
coronary,398,O
arteries,398,O
.,398,O
Design,399,O
and,399,O
analysis,399,O
of,399,O
the,399,O
HYPREN-trial,399,O
:,399,O
safety,399,O
of,399,O
enalapril,399,B-Chemical
and,399,O
prazosin,399,B-Chemical
in,399,O
the,399,O
initial,399,O
treatment,399,O
phase,399,O
of,399,O
patients,399,O
with,399,O
congestive,399,B-Disease
heart,399,I-Disease
failure,399,I-Disease
.,399,O
Since,400,O
the,400,O
introduction,400,O
of,400,O
angiotensin,400,B-Chemical
converting,400,I-Chemical
enzyme,400,I-Chemical
(,400,I-Chemical
ACE,400,I-Chemical
),400,I-Chemical
inhibitors,400,I-Chemical
into,400,O
the,400,O
adjunctive,400,O
treatment,400,O
of,400,O
patients,400,O
with,400,O
congestive,400,B-Disease
heart,400,I-Disease
failure,400,I-Disease
",",400,O
cases,400,O
of,400,O
severe,400,O
hypotension,400,B-Disease
",",400,O
especially,400,O
on,400,O
the,400,O
first,400,O
day,400,O
of,400,O
treatment,400,O
",",400,O
have,400,O
occasionally,400,O
been,400,O
reported,400,O
.,400,O
To,401,O
assess,401,O
the,401,O
safety,401,O
of,401,O
the,401,O
ACE,401,B-Chemical
inhibitor,401,I-Chemical
enalapril,401,B-Chemical
a,401,O
multicenter,401,O
",",401,O
randomized,401,O
",",401,O
prazosin-controlled,401,B-Chemical
trial,401,O
was,401,O
designed,401,O
that,401,O
compared,401,O
the,401,O
incidence,401,O
and,401,O
severity,401,O
of,401,O
symptomatic,401,O
hypotension,401,B-Disease
on,401,O
the,401,O
first,401,O
day,401,O
of,401,O
treatment,401,O
.,401,O
Trial,402,O
medication,402,O
was,402,O
2.5,402,O
mg,402,O
enalapril,402,B-Chemical
or,402,O
0.5,402,O
prazosin,402,B-Chemical
.,402,O
Subjects,403,O
were,403,O
1210,403,O
inpatients,403,O
with,403,O
New,403,O
York,403,O
Heart,403,O
Association,403,O
(,403,O
NYHA,403,O
),403,O
functional,403,O
class,403,O
II,403,O
and,403,O
III,403,O
.,403,O
Patients,404,O
who,404,O
received,404,O
enalapril,404,B-Chemical
experienced,404,O
clinically,404,O
and,404,O
statistically,404,O
significantly,404,O
less,404,O
symptomatic,404,O
hypotension,404,B-Disease
(,404,O
5.2,404,O
%,404,O
),404,O
than,404,O
the,404,O
patients,404,O
who,404,O
received,404,O
prazosin,404,B-Chemical
(,404,O
12.9,404,O
%,404,O
),404,O
.,404,O
All,405,O
patients,405,O
recovered,405,O
.,405,O
It,406,O
was,406,O
concluded,406,O
that,406,O
treatment,406,O
with,406,O
enalapril,406,B-Chemical
was,406,O
well,406,O
tolerated,406,O
and,406,O
it,406,O
is,406,O
",",406,O
therefore,406,O
",",406,O
unreasonable,406,O
to,406,O
restrict,406,O
the,406,O
initiation,406,O
of,406,O
treatment,406,O
with,406,O
enalapril,406,B-Chemical
to,406,O
inpatients,406,O
.,406,O
Effect,407,O
of,407,O
adriamycin,407,B-Chemical
combined,407,O
with,407,O
whole,407,O
body,407,O
hyperthermia,407,B-Disease
on,407,O
tumor,407,B-Disease
and,407,O
normal,407,O
tissues,407,O
.,407,O
Thermal,408,O
enhancement,408,O
of,408,O
Adriamycin-mediated,408,B-Chemical
antitumor,408,O
activity,408,O
and,408,O
normal,408,O
tissue,408,O
toxicities,408,B-Disease
by,408,O
whole,408,O
body,408,O
hyperthermia,408,B-Disease
were,408,O
compared,408,O
using,408,O
a,408,O
F344,408,O
rat,408,O
model,408,O
.,408,O
Antitumor,409,O
activity,409,O
was,409,O
studied,409,O
using,409,O
a,409,O
tumor,409,B-Disease
growth,409,O
delay,409,O
assay,409,O
.,409,O
Acute,410,O
normal,410,O
tissue,410,O
toxicities,410,B-Disease
(,410,O
i.e.,410,O
",",410,O
leukopenia,410,B-Disease
and,410,O
thrombocytopenia,410,B-Disease
),410,O
and,410,O
late,410,O
normal,410,O
tissue,410,O
toxicities,410,B-Disease
(,410,O
i.e.,410,O
",",410,O
myocardial,410,O
and,410,O
kidney,410,O
injury,410,O
),410,O
were,410,O
evaluated,410,O
by,410,O
functional/physiological,410,O
assays,410,O
and,410,O
by,410,O
morphological,410,O
techniques,410,O
.,410,O
Whole,411,O
body,411,O
hyperthermia,411,B-Disease
(,411,O
120,411,O
min,411,O
at,411,O
41.5,411,O
degrees,411,O
C,411,O
),411,O
enhanced,411,O
both,411,O
Adriamycin-mediated,411,B-Chemical
antitumor,411,O
activity,411,O
and,411,O
toxic,411,O
side,411,O
effects,411,O
.,411,O
The,412,O
thermal,412,O
enhancement,412,O
ratio,412,O
calculated,412,O
for,412,O
antitumor,412,O
activity,412,O
was,412,O
1.6,412,O
.,412,O
Thermal,413,O
enhancement,413,O
ratios,413,O
estimated,413,O
for,413,O
``,413,O
acute,413,O
'',413,O
hematological,413,O
changes,413,O
were,413,O
1.3,413,O
",",413,O
whereas,413,O
those,413,O
estimated,413,O
for,413,O
``,413,O
late,413,O
'',413,O
damage,413,O
(,413,O
based,413,O
on,413,O
morphological,413,O
cardiac,413,O
and,413,O
renal,413,O
lesions,413,O
),413,O
varied,413,O
between,413,O
2.4,413,O
and,413,O
4.3,413,O
.,413,O
Thus,414,O
",",414,O
while,414,O
whole,414,O
body,414,O
hyperthermia,414,B-Disease
enhances,414,O
Adriamycin-mediated,414,B-Chemical
antitumor,414,O
effect,414,O
",",414,O
normal,414,O
tissue,414,O
toxicity,414,B-Disease
is,414,O
also,414,O
increased,414,O
",",414,O
and,414,O
the,414,O
potential,414,O
therapeutic,414,O
gain,414,O
of,414,O
the,414,O
combined,414,O
modality,414,O
treatment,414,O
is,414,O
eroded,414,O
.,414,O
Reduction,415,O
in,415,O
injection,415,O
pain,415,B-Disease
using,415,O
buffered,415,O
lidocaine,415,B-Chemical
as,415,O
a,415,O
local,415,O
anesthetic,415,O
before,415,O
cardiac,415,O
catheterization,415,O
.,415,O
Previous,416,O
reports,416,O
have,416,O
suggested,416,O
that,416,O
pain,416,B-Disease
associated,416,O
with,416,O
the,416,O
injection,416,O
of,416,O
lidocaine,416,B-Chemical
is,416,O
related,416,O
to,416,O
the,416,O
acidic,416,O
pH,416,O
of,416,O
the,416,O
solution,416,O
.,416,O
To,417,O
determine,417,O
if,417,O
the,417,O
addition,417,O
of,417,O
a,417,O
buffering,417,O
solution,417,O
to,417,O
adjust,417,O
the,417,O
pH,417,O
of,417,O
lidocaine,417,B-Chemical
into,417,O
the,417,O
physiologic,417,O
range,417,O
would,417,O
reduce,417,O
pain,417,B-Disease
during,417,O
injection,417,O
",",417,O
we,417,O
performed,417,O
a,417,O
blinded,417,O
randomized,417,O
study,417,O
in,417,O
patients,417,O
undergoing,417,O
cardiac,417,O
catheterization,417,O
.,417,O
Twenty,418,O
patients,418,O
were,418,O
asked,418,O
to,418,O
quantify,418,O
the,418,O
severity,418,O
of,418,O
pain,418,B-Disease
after,418,O
receiving,418,O
standard,418,O
lidocaine,418,B-Chemical
in,418,O
one,418,O
femoral,418,O
area,418,O
and,418,O
buffered,418,O
lidocaine,418,B-Chemical
in,418,O
the,418,O
opposite,418,O
femoral,418,O
area,418,O
.,418,O
The,419,O
mean,419,O
pain,419,B-Disease
score,419,O
for,419,O
buffered,419,O
lidocaine,419,B-Chemical
was,419,O
significantly,419,O
lower,419,O
than,419,O
the,419,O
mean,419,O
score,419,O
for,419,O
standard,419,O
lidocaine,419,B-Chemical
(,419,O
2.7,419,O
+/-,419,O
1.9,419,O
vs.,419,O
3.8,419,O
+/-,419,O
2.2,419,O
",",419,O
P,419,O
=,419,O
0.03,419,O
),419,O
.,419,O
The,420,O
pH,420,O
adjustment,420,O
of,420,O
standard,420,O
lidocaine,420,B-Chemical
can,420,O
be,420,O
accomplished,420,O
easily,420,O
in,420,O
the,420,O
catheterization,420,O
laboratory,420,O
before,420,O
injection,420,O
and,420,O
results,420,O
in,420,O
a,420,O
reduction,420,O
of,420,O
the,420,O
pain,420,B-Disease
occurring,420,O
during,420,O
the,420,O
infiltration,420,O
of,420,O
tissues,420,O
.,420,O
Effect,421,O
of,421,O
L-alpha-glyceryl-phosphorylcholine,421,B-Chemical
on,421,O
amnesia,421,B-Disease
caused,421,O
by,421,O
scopolamine,421,B-Chemical
.,421,O
The,422,O
present,422,O
study,422,O
was,422,O
carried,422,O
out,422,O
to,422,O
test,422,O
the,422,O
effects,422,O
of,422,O
L-alpha-glycerylphosphorylcholine,422,B-Chemical
(,422,O
L-alpha-GFC,422,B-Chemical
),422,O
on,422,O
memory,422,B-Disease
impairment,422,I-Disease
induced,422,O
by,422,O
scopolamine,422,B-Chemical
in,422,O
man,422,O
.,422,O
Thirty-two,423,O
healthy,423,O
young,423,O
volunteers,423,O
were,423,O
randomly,423,O
allocated,423,O
to,423,O
four,423,O
different,423,O
groups,423,O
.,423,O
They,424,O
were,424,O
given,424,O
a,424,O
ten,424,O
day,424,O
pretreatment,424,O
with,424,O
either,424,O
L-alpha-GFC,424,B-Chemical
or,424,O
placebo,424,O
",",424,O
p.o.,424,O
",",424,O
and,424,O
on,424,O
the,424,O
eleventh,424,O
day,424,O
either,424,O
scopolamine,424,B-Chemical
or,424,O
placebo,424,O
",",424,O
i.m,424,O
.,424,O
Before,425,O
and,425,O
0.5,425,O
",",425,O
1,425,O
",",425,O
2,425,O
",",425,O
3,425,O
",",425,O
and,425,O
6,425,O
h,425,O
after,425,O
injection,425,O
the,425,O
subjects,425,O
were,425,O
given,425,O
attention,425,O
and,425,O
mnemonic,425,O
tests,425,O
.,425,O
The,426,O
findings,426,O
of,426,O
this,426,O
study,426,O
indicate,426,O
that,426,O
the,426,O
drug,426,O
is,426,O
able,426,O
to,426,O
antagonize,426,O
impairment,426,B-Disease
of,426,I-Disease
attention,426,I-Disease
and,426,I-Disease
memory,426,I-Disease
induced,426,O
by,426,O
scopolamine,426,B-Chemical
.,426,O
Carmofur-induced,427,B-Chemical
organic,427,B-Disease
mental,427,I-Disease
disorders,427,I-Disease
.,427,O
Organic,428,B-Disease
mental,428,I-Disease
disorder,428,I-Disease
was,428,O
observed,428,O
in,428,O
a,428,O
29-year-old,428,O
female,428,O
in,428,O
the,428,O
prognostic,428,O
period,428,O
after,428,O
the,428,O
onset,428,O
of,428,O
carmofur-induced,428,B-Chemical
leukoencephalopathy,428,B-Disease
.,428,O
Symptoms,429,O
such,429,O
as,429,O
euphoria,429,O
",",429,O
emotional,429,O
lability,429,O
and,429,O
puerile,429,O
attitude,429,O
noted,429,O
in,429,O
the,429,O
patient,429,O
were,429,O
diagnosed,429,O
as,429,O
organic,429,B-Disease
personality,429,I-Disease
syndrome,429,I-Disease
according,429,O
to,429,O
the,429,O
criteria,429,O
defined,429,O
in,429,O
the,429,O
DSM-III-R,429,O
.,429,O
It,430,O
is,430,O
referred,430,O
to,430,O
as,430,O
a,430,O
frontal,430,B-Disease
lobe,430,I-Disease
syndrome,430,I-Disease
.,430,O
Brain,431,O
CT,431,O
revealed,431,O
a,431,O
periventricular,431,O
low,431,O
density,431,O
area,431,O
in,431,O
the,431,O
frontal,431,O
white,431,O
matter,431,O
and,431,O
moderate,431,O
dilatation,431,O
of,431,O
the,431,O
lateral,431,O
ventricles,431,O
especially,431,O
at,431,O
the,431,O
bilateral,431,O
anterior,431,O
horns,431,O
.,431,O
Consequently,432,O
",",432,O
carmofur-induced,432,B-Chemical
leukoencephalopathy,432,B-Disease
may,432,O
uncommonly,432,O
result,432,O
in,432,O
organic,432,B-Disease
personality,432,I-Disease
syndrome,432,I-Disease
in,432,O
the,432,O
residual,432,O
state,432,O
.,432,O
It,433,O
may,433,O
be,433,O
attributed,433,O
to,433,O
the,433,O
structural,433,B-Disease
damage,433,I-Disease
to,433,I-Disease
the,433,I-Disease
frontal,433,I-Disease
lobe,433,I-Disease
.,433,O
A,434,O
phase,434,O
I,434,O
study,434,O
of,434,O
4'-0-tetrahydropyranyladriamycin,434,B-Chemical
.,434,O
Clinical,435,O
pharmacology,435,O
and,435,O
pharmacokinetics,435,O
.,435,O
A,436,O
Phase,436,O
I,436,O
study,436,O
of,436,O
intravenous,436,O
(,436,O
IV,436,O
),436,O
bolus,436,O
4'-0-tetrahydropyranyladriamycin,436,B-Chemical
(,436,O
Pirarubicin,436,B-Chemical
),436,O
was,436,O
done,436,O
in,436,O
55,436,O
patients,436,O
in,436,O
good,436,O
performance,436,O
status,436,O
with,436,O
refractory,436,O
tumors,436,B-Disease
.,436,O
Twenty-six,437,O
had,437,O
minimal,437,O
prior,437,O
therapy,437,O
(,437,O
good,437,O
risk,437,O
),437,O
",",437,O
23,437,O
had,437,O
extensive,437,O
prior,437,O
therapy,437,O
(,437,O
poor,437,O
risk,437,O
),437,O
",",437,O
and,437,O
six,437,O
had,437,O
renal,437,O
and/or,437,O
hepatic,437,O
dysfunction,437,O
.,437,O
A,438,O
total,438,O
of,438,O
167,438,O
courses,438,O
at,438,O
doses,438,O
of,438,O
15,438,O
to,438,O
70,438,O
mg/m2,438,O
were,438,O
evaluable,438,O
.,438,O
Maximum,439,O
tolerated,439,O
dose,439,O
in,439,O
good-risk,439,O
patients,439,O
was,439,O
70,439,O
mg/m2,439,O
",",439,O
and,439,O
in,439,O
poor-risk,439,O
patients,439,O
",",439,O
60,439,O
mg/m2,439,O
.,439,O
The,440,O
dose-limiting,440,O
toxic,440,O
effect,440,O
was,440,O
transient,440,O
noncumulative,440,O
granulocytopenia,440,B-Disease
.,440,O
Granulocyte,441,O
nadir,441,O
was,441,O
on,441,O
day,441,O
14,441,O
(,441,O
range,441,O
",",441,O
4-22,441,O
),441,O
.,441,O
Less,442,O
frequent,442,O
toxic,442,O
effects,442,O
included,442,O
thrombocytopenia,442,B-Disease
",",442,O
anemia,442,B-Disease
",",442,O
nausea,442,B-Disease
",",442,O
mild,442,O
alopecia,442,B-Disease
",",442,O
phlebitis,442,B-Disease
",",442,O
and,442,O
mucositis,442,B-Disease
.,442,O
Myelosuppression,443,B-Disease
was,443,O
more,443,O
in,443,O
patients,443,O
with,443,O
hepatic,443,B-Disease
dysfunction,443,I-Disease
.,443,O
Pharmacokinetic,444,O
analyses,444,O
in,444,O
21,444,O
patients,444,O
revealed,444,O
Pirarubicin,444,B-Chemical
plasma,444,O
T,444,O
1/2,444,O
alpha,444,O
(,444,O
+/-,444,O
SE,444,O
),444,O
of,444,O
2.5,444,O
+/-,444,O
0.85,444,O
minutes,444,O
",",444,O
T,444,O
beta,444,O
1/2,444,O
of,444,O
25.6,444,O
+/-,444,O
6.5,444,O
minutes,444,O
",",444,O
and,444,O
T,444,O
1/2,444,O
gamma,444,O
of,444,O
23.6,444,O
+/-,444,O
7.6,444,O
hours,444,O
.,444,O
The,445,O
area,445,O
under,445,O
the,445,O
curve,445,O
was,445,O
537,445,O
+/-,445,O
149,445,O
ng/ml,445,O
x,445,O
hours,445,O
",",445,O
volume,445,O
of,445,O
distribution,445,O
(,445,O
Vd,445,O
),445,O
3504,445,O
+/-,445,O
644,445,O
l/m2,445,O
",",445,O
and,445,O
total,445,O
clearance,445,O
(,445,O
ClT,445,O
),445,O
was,445,O
204,445,O
+,445,O
39.3,445,O
l/hour/m2,445,O
.,445,O
Adriamycinol,446,B-Chemical
",",446,O
doxorubicin,446,B-Chemical
",",446,O
adriamycinone,446,B-Chemical
",",446,O
and,446,O
tetrahydropyranyladriamycinol,446,B-Chemical
were,446,O
the,446,O
metabolites,446,O
detected,446,O
in,446,O
plasma,446,O
and,446,O
the,446,O
amount,446,O
of,446,O
doxorubicin,446,B-Chemical
was,446,O
less,446,O
than,446,O
or,446,O
equal,446,O
to,446,O
10,446,O
%,446,O
of,446,O
the,446,O
total,446,O
metabolites,446,O
.,446,O
Urinary,447,O
excretion,447,O
of,447,O
Pirarubicin,447,B-Chemical
in,447,O
the,447,O
first,447,O
24,447,O
hours,447,O
was,447,O
less,447,O
than,447,O
or,447,O
equal,447,O
to,447,O
10,447,O
%,447,O
.,447,O
Activity,448,O
was,448,O
noted,448,O
in,448,O
mesothelioma,448,B-Disease
",",448,O
leiomyosarcoma,448,B-Disease
",",448,O
and,448,O
basal,448,B-Disease
cell,448,I-Disease
carcinoma,448,I-Disease
.,448,O
The,449,O
recommended,449,O
starting,449,O
dose,449,O
for,449,O
Phase,449,O
II,449,O
trials,449,O
is,449,O
60,449,O
mg/m2,449,O
IV,449,O
bolus,449,O
every,449,O
3,449,O
weeks,449,O
.,449,O
Ocular,450,O
and,450,O
auditory,450,O
toxicity,450,O
in,450,O
hemodialyzed,450,O
patients,450,O
receiving,450,O
desferrioxamine,450,B-Chemical
.,450,O
During,451,O
an,451,O
18-month,451,O
period,451,O
of,451,O
study,451,O
41,451,O
hemodialyzed,451,O
patients,451,O
receiving,451,O
desferrioxamine,451,B-Chemical
(,451,O
10-40,451,O
mg/kg,451,O
BW/3,451,O
times,451,O
weekly,451,O
),451,O
for,451,O
the,451,O
first,451,O
time,451,O
were,451,O
monitored,451,O
for,451,O
detection,451,O
of,451,O
audiovisual,451,B-Disease
toxicity,451,I-Disease
.,451,O
6,452,O
patients,452,O
presented,452,O
clinical,452,O
symptoms,452,O
of,452,O
visual,452,O
or,452,O
auditory,452,O
toxicity,452,O
.,452,O
Moreover,453,O
",",453,O
detailed,453,O
ophthalmologic,453,O
and,453,O
audiologic,453,O
studies,453,O
disclosed,453,O
abnormalities,453,O
in,453,O
7,453,O
more,453,O
asymptomatic,453,O
patients,453,O
.,453,O
Visual,454,B-Disease
toxicity,454,I-Disease
was,454,O
of,454,O
retinal,454,O
origin,454,O
and,454,O
was,454,O
characterized,454,O
by,454,O
a,454,O
tritan-type,454,O
dyschromatopsy,454,B-Disease
",",454,O
sometimes,454,O
associated,454,O
with,454,O
a,454,B-Disease
loss,454,I-Disease
of,454,I-Disease
visual,454,I-Disease
acuity,454,I-Disease
and,454,O
pigmentary,454,B-Disease
retinal,454,I-Disease
deposits,454,I-Disease
.,454,O
Auditory,455,B-Disease
toxicity,455,I-Disease
was,455,O
characterized,455,O
by,455,O
a,455,O
mid-,455,O
to,455,O
high-frequency,455,O
neurosensorial,455,B-Disease
hearing,455,I-Disease
loss,455,I-Disease
and,455,O
the,455,O
lesion,455,O
was,455,O
of,455,O
the,455,O
cochlear,455,O
type,455,O
.,455,O
Desferrioxamine,456,B-Chemical
withdrawal,456,O
resulted,456,O
in,456,O
a,456,O
complete,456,O
recovery,456,O
of,456,O
visual,456,O
function,456,O
in,456,O
1,456,O
patient,456,O
and,456,O
partial,456,O
recovery,456,O
in,456,O
3,456,O
",",456,O
and,456,O
a,456,O
complete,456,O
reversal,456,O
of,456,O
hearing,456,B-Disease
loss,456,I-Disease
in,456,O
3,456,O
patients,456,O
and,456,O
partial,456,O
recovery,456,O
in,456,O
3,456,O
.,456,O
This,457,O
toxicity,457,B-Disease
appeared,457,O
in,457,O
patients,457,O
receiving,457,O
the,457,O
higher,457,O
doses,457,O
of,457,O
desferrioxamine,457,B-Chemical
or,457,O
coincided,457,O
with,457,O
the,457,O
normalization,457,O
of,457,O
ferritin,457,O
or,457,O
aluminium,457,B-Chemical
serum,457,O
levels,457,O
.,457,O
The,458,O
data,458,O
indicate,458,O
that,458,O
audiovisual,458,B-Disease
toxicity,458,I-Disease
is,458,O
not,458,O
an,458,O
infrequent,458,O
complication,458,O
in,458,O
hemodialyzed,458,O
patients,458,O
receiving,458,O
desferrioxamine,458,B-Chemical
.,458,O
Periodical,459,O
audiovisual,459,O
monitoring,459,O
should,459,O
be,459,O
performed,459,O
on,459,O
hemodialyzed,459,O
patients,459,O
receiving,459,O
the,459,O
drug,459,O
in,459,O
order,459,O
to,459,O
detect,459,O
adverse,459,O
effects,459,O
as,459,O
early,459,O
as,459,O
possible,459,O
.,459,O
Serial,460,O
epilepsy,460,B-Disease
caused,460,O
by,460,O
levodopa/carbidopa,460,B-Chemical
administration,460,O
in,460,O
two,460,O
patients,460,O
on,460,O
hemodialysis,460,O
.,460,O
Two,461,O
patients,461,O
with,461,O
similar,461,O
clinical,461,O
features,461,O
are,461,O
presented,461,O
:,461,O
both,461,O
patients,461,O
had,461,O
chronic,461,B-Disease
renal,461,I-Disease
failure,461,I-Disease
",",461,O
on,461,O
hemodialysis,461,O
for,461,O
many,461,O
years,461,O
but,461,O
recently,461,O
begun,461,O
on,461,O
a,461,O
high-flux,461,O
dialyzer,461,O
;,461,O
both,461,O
had,461,O
been,461,O
receiving,461,O
a,461,O
carbidopa/levodopa,461,B-Chemical
preparation,461,O
;,461,O
and,461,O
both,461,O
had,461,O
the,461,O
onset,461,O
of,461,O
hallucinosis,461,B-Disease
and,461,O
recurrent,461,O
seizures,461,B-Disease
",",461,O
which,461,O
were,461,O
refractory,461,O
to,461,O
anticonvulsants,461,O
.,461,O
The,462,O
first,462,O
patient,462,O
died,462,O
without,462,O
a,462,O
diagnosis,462,O
;,462,O
the,462,O
second,462,O
patient,462,O
had,462,O
a,462,O
dramatic,462,O
recovery,462,O
following,462,O
the,462,O
administration,462,O
of,462,O
vitamin,462,B-Chemical
B6,462,I-Chemical
.,462,O
Neither,463,O
patient,463,O
was,463,O
considered,463,O
to,463,O
have,463,O
a,463,O
renal,463,O
state,463,O
sufficiently,463,O
severe,463,O
enough,463,O
to,463,O
explain,463,O
their,463,O
presentation,463,O
.,463,O
Randomized,464,O
",",464,O
double-blind,464,O
trial,464,O
of,464,O
mazindol,464,B-Chemical
in,464,O
Duchenne,464,B-Disease
dystrophy,464,I-Disease
.,464,O
There,465,O
is,465,O
evidence,465,O
that,465,O
growth,465,O
hormone,465,O
may,465,O
be,465,O
related,465,O
to,465,O
the,465,O
progression,465,O
of,465,O
weakness,465,B-Disease
in,465,O
Duchenne,465,B-Disease
dystrophy,465,I-Disease
.,465,O
We,466,O
conducted,466,O
a,466,O
12-month,466,O
controlled,466,O
trial,466,O
of,466,O
mazindol,466,B-Chemical
",",466,O
a,466,O
putative,466,O
growth,466,O
hormone,466,O
secretion,466,O
inhibitor,466,O
",",466,O
in,466,O
83,466,O
boys,466,O
with,466,O
Duchenne,466,B-Disease
dystrophy,466,I-Disease
.,466,O
Muscle,467,O
strength,467,O
",",467,O
contractures,467,O
",",467,O
functional,467,O
ability,467,O
and,467,O
pulmonary,467,O
function,467,O
were,467,O
tested,467,O
at,467,O
baseline,467,O
",",467,O
and,467,O
6,467,O
and,467,O
12,467,O
months,467,O
after,467,O
treatment,467,O
with,467,O
mazindol,467,B-Chemical
(,467,O
3,467,O
mg/d,467,O
),467,O
or,467,O
placebo,467,O
.,467,O
The,468,O
study,468,O
was,468,O
designed,468,O
to,468,O
have,468,O
a,468,O
power,468,O
of,468,O
greater,468,O
than,468,O
0.90,468,O
to,468,O
detect,468,O
a,468,O
slowing,468,O
to,468,O
25,468,O
%,468,O
of,468,O
the,468,O
expected,468,O
rate,468,O
of,468,O
progression,468,O
of,468,O
weakness,468,B-Disease
at,468,O
P,468,O
less,468,O
than,468,O
0.05,468,O
.,468,O
Mazindol,469,B-Chemical
did,469,O
not,469,O
benefit,469,O
strength,469,O
at,469,O
any,469,O
point,469,O
in,469,O
the,469,O
study,469,O
.,469,O
Side,470,O
effects,470,O
attributable,470,O
to,470,O
mazindol,470,B-Chemical
included,470,O
decreased,470,B-Disease
appetite,470,I-Disease
(,470,O
36,470,O
%,470,O
),470,O
",",470,O
dry,470,B-Disease
mouth,470,I-Disease
(,470,O
10,470,O
%,470,O
),470,O
",",470,O
behavioral,470,O
change,470,O
(,470,O
22,470,O
%,470,O
),470,O
",",470,O
and,470,O
gastrointestinal,470,B-Disease
symptoms,470,I-Disease
(,470,O
18,470,O
%,470,O
),470,O
;,470,O
mazindol,470,B-Chemical
dosage,470,O
was,470,O
reduced,470,O
in,470,O
43,470,O
%,470,O
of,470,O
patients,470,O
.,470,O
The,471,O
effect,471,O
of,471,O
mazindol,471,B-Chemical
on,471,O
GH,471,O
secretion,471,O
was,471,O
estimated,471,O
indirectly,471,O
by,471,O
comparing,471,O
the,471,O
postabsorptive,471,O
IGF-I,471,O
levels,471,O
obtained,471,O
following,471,O
3,471,O
",",471,O
6,471,O
",",471,O
9,471,O
",",471,O
and,471,O
12,471,O
months,471,O
in,471,O
the,471,O
mazindol,471,B-Chemical
treated,471,O
to,471,O
those,471,O
in,471,O
the,471,O
placebo,471,O
groups,471,O
.,471,O
Although,472,O
mazindol-treated,472,B-Chemical
patients,472,O
gained,472,O
less,472,O
weight,472,O
and,472,O
height,472,O
than,472,O
placebo-treated,472,O
patients,472,O
",",472,O
no,472,O
significant,472,O
effect,472,O
on,472,O
IGF-I,472,O
levels,472,O
was,472,O
observed,472,O
.,472,O
Mazindol,473,B-Chemical
doses,473,O
not,473,O
slow,473,O
the,473,O
progression,473,O
of,473,O
weakness,473,B-Disease
in,473,O
Duchenne,473,B-Disease
dystrophy,473,I-Disease
.,473,O
Facilitation,474,O
of,474,O
memory,474,O
retrieval,474,O
by,474,O
pre-test,474,O
morphine,474,B-Chemical
and,474,O
its,474,O
state,474,O
dependency,474,O
in,474,O
the,474,O
step-through,474,O
type,474,O
passive,474,O
avoidance,474,O
learning,474,O
test,474,O
in,474,O
mice,474,O
.,474,O
Amnesia,475,B-Disease
produced,475,O
by,475,O
scopolamine,475,B-Chemical
and,475,O
cycloheximide,475,B-Chemical
were,475,O
reversed,475,O
by,475,O
morphine,475,B-Chemical
given,475,O
30,475,O
min,475,O
before,475,O
the,475,O
test,475,O
trial,475,O
(,475,O
pre-test,475,O
),475,O
",",475,O
and,475,O
pre-test,475,O
morphine,475,B-Chemical
also,475,O
facilitated,475,O
the,475,O
memory,475,O
retrieval,475,O
in,475,O
the,475,O
animals,475,O
administered,475,O
naloxone,475,B-Chemical
during,475,O
the,475,O
training,475,O
trial,475,O
.,475,O
Similarly,476,O
",",476,O
pre-test,476,O
scopolamine,476,B-Chemical
partially,476,O
reversed,476,O
the,476,O
scopolamine-induced,476,B-Chemical
amnesia,476,B-Disease
",",476,O
but,476,O
not,476,O
significantly,476,O
;,476,O
and,476,O
pre-test,476,O
cycloheximide,476,B-Chemical
failed,476,O
to,476,O
reverse,476,O
the,476,O
cycloheximide-induced,476,B-Chemical
amnesia,476,B-Disease
.,476,O
These,477,O
results,477,O
suggest,477,O
that,477,O
the,477,O
facilitation,477,O
of,477,O
memory,477,O
retrieval,477,O
by,477,O
pre-test,477,O
morphine,477,B-Chemical
might,477,O
be,477,O
the,477,O
direct,477,O
action,477,O
of,477,O
morphine,477,B-Chemical
rather,477,O
than,477,O
a,477,O
state,477,O
dependent,477,O
effect,477,O
.,477,O
Prazosin-induced,478,B-Chemical
stress,478,B-Disease
incontinence,478,I-Disease
.,478,O
A,479,O
case,479,O
of,479,O
genuine,479,O
stress,479,B-Disease
incontinence,479,I-Disease
due,479,O
to,479,O
prazosin,479,B-Chemical
",",479,O
a,479,O
common,479,O
antihypertensive,479,O
drug,479,O
",",479,O
is,479,O
presented,479,O
.,479,O
Prazosin,480,B-Chemical
exerts,480,O
its,480,O
antihypertensive,480,O
effects,480,O
through,480,O
vasodilatation,480,O
caused,480,O
by,480,O
selective,480,O
blockade,480,O
of,480,O
postsynaptic,480,O
alpha-1,480,O
adrenergic,480,O
receptors,480,O
.,480,O
As,481,O
an,481,O
alpha-blocker,481,O
",",481,O
it,481,O
also,481,O
exerts,481,O
a,481,O
significant,481,O
relaxant,481,O
effect,481,O
on,481,O
the,481,O
bladder,481,O
neck,481,O
and,481,O
urethra,481,O
.,481,O
The,482,O
patient,482,O
's,482,O
clinical,482,O
course,482,O
is,482,O
described,482,O
and,482,O
correlated,482,O
with,482,O
initial,482,O
urodynamic,482,O
studies,482,O
while,482,O
on,482,O
prazosin,482,B-Chemical
and,482,O
subsequent,482,O
studies,482,O
while,482,O
taking,482,O
verapamil,482,B-Chemical
.,482,O
Her,483,O
incontinence,483,B-Disease
resolved,483,O
with,483,O
the,483,O
change,483,O
of,483,O
medication,483,O
.,483,O
The,484,O
restoration,484,O
of,484,O
continence,484,O
was,484,O
accompanied,484,O
by,484,O
a,484,O
substantial,484,O
rise,484,O
in,484,O
maximum,484,O
urethral,484,O
pressure,484,O
",",484,O
maximum,484,O
urethral,484,O
closure,484,O
pressure,484,O
",",484,O
and,484,O
functional,484,O
urethral,484,O
length,484,O
.,484,O
Patients,485,O
who,485,O
present,485,O
with,485,O
stress,485,B-Disease
incontinence,485,I-Disease
while,485,O
taking,485,O
prazosin,485,B-Chemical
should,485,O
change,485,O
their,485,O
antihypertensive,485,O
medication,485,O
before,485,O
considering,485,O
surgery,485,O
",",485,O
because,485,O
their,485,O
incontinence,485,B-Disease
may,485,O
resolve,485,O
spontaneously,485,O
with,485,O
a,485,O
change,485,O
in,485,O
drug,485,O
therapy,485,O
.,485,O
Myocardial,486,B-Disease
infarction,486,I-Disease
following,486,O
sublingual,486,O
administration,486,O
of,486,O
isosorbide,486,B-Chemical
dinitrate,486,I-Chemical
.,486,O
A,487,O
78-year-old,487,O
with,487,O
healed,487,O
septal,487,O
necrosis,487,B-Disease
suffered,487,O
a,487,O
recurrent,487,O
myocardial,487,B-Disease
infarction,487,I-Disease
of,487,O
the,487,O
anterior,487,O
wall,487,O
following,487,O
the,487,O
administration,487,O
of,487,O
isosorbide,487,B-Chemical
dinitrate,487,I-Chemical
5,487,O
mg,487,O
sublingually,487,O
.,487,O
After,488,O
detailing,488,O
the,488,O
course,488,O
of,488,O
events,488,O
",",488,O
we,488,O
discuss,488,O
the,488,O
role,488,O
of,488,O
paradoxical,488,O
coronary,488,O
spasm,488,B-Disease
and,488,O
hypotension-mediated,488,B-Disease
myocardial,488,B-Disease
ischemia,488,I-Disease
occurring,488,O
downstream,488,O
to,488,O
significant,488,O
coronary,488,B-Disease
arterial,488,I-Disease
stenosis,488,I-Disease
in,488,O
the,488,O
pathophysiology,488,O
of,488,O
acute,488,B-Disease
coronary,488,I-Disease
insufficiency,488,I-Disease
.,488,O
Comparison,489,O
of,489,O
the,489,O
respiratory,489,O
effects,489,O
of,489,O
i.v,489,O
.,489,O
infusions,490,O
of,490,O
morphine,490,B-Chemical
and,490,O
regional,490,O
analgesia,490,O
by,490,O
extradural,490,O
block,490,O
.,490,O
The,491,O
incidence,491,O
of,491,O
postoperative,491,O
respiratory,491,O
apnoea,491,B-Disease
was,491,O
compared,491,O
between,491,O
five,491,O
patients,491,O
receiving,491,O
a,491,O
continuous,491,O
i.v,491,O
.,491,O
infusion,492,O
of,492,O
morphine,492,B-Chemical
(,492,O
mean,492,O
73.6,492,O
mg,492,O
),492,O
and,492,O
five,492,O
patients,492,O
receiving,492,O
a,492,O
continuous,492,O
extradural,492,O
infusion,492,O
of,492,O
0.25,492,O
%,492,O
bupivacaine,492,B-Chemical
(,492,O
mean,492,O
192,492,O
mg,492,O
),492,O
in,492,O
the,492,O
24-h,492,O
period,492,O
following,492,O
upper,492,O
abdominal,492,O
surgery,492,O
.,492,O
Monitoring,493,O
consisted,493,O
of,493,O
airflow,493,O
detection,493,O
by,493,O
a,493,O
carbon,493,B-Chemical
dioxide,493,I-Chemical
analyser,493,O
",",493,O
chest,493,O
wall,493,O
movement,493,O
detected,493,O
by,493,O
pneumatic,493,O
capsules,493,O
",",493,O
and,493,O
continuous,493,O
electrocardiograph,493,O
recorded,493,O
with,493,O
a,493,O
Holter,493,O
ambulatory,493,O
monitor,493,O
.,493,O
Both,494,O
obstructive,494,O
(,494,O
P,494,O
less,494,O
than,494,O
0.05,494,O
),494,O
and,494,O
central,494,O
apnoea,494,O
(,494,O
P,494,O
less,494,O
than,494,O
0.05,494,O
),494,O
occurred,494,O
more,494,O
frequently,494,O
in,494,O
patients,494,O
who,494,O
had,494,O
a,494,O
morphine,494,B-Chemical
infusion,494,O
.,494,O
There,495,O
was,495,O
also,495,O
a,495,O
higher,495,O
incidence,495,O
of,495,O
tachyarrhythmias,495,B-Disease
(,495,O
P,495,O
less,495,O
than,495,O
0.05,495,O
),495,O
and,495,O
ventricular,495,B-Disease
ectopic,495,I-Disease
beats,495,I-Disease
(,495,O
P,495,O
less,495,O
than,495,O
0.05,495,O
),495,O
in,495,O
the,495,O
morphine,495,B-Chemical
infusion,495,O
group,495,O
.,495,O
Pentoxifylline,496,B-Chemical
(,496,O
Trental,496,B-Chemical
),496,O
does,496,O
not,496,O
inhibit,496,O
dipyridamole-induced,496,B-Chemical
coronary,496,O
hyperemia,496,B-Disease
:,496,O
implications,496,O
for,496,O
dipyridamole-thallium-201,496,B-Chemical
myocardial,496,O
imaging,496,O
.,496,O
Dipyridamole-thallium-201,497,B-Chemical
imaging,497,O
is,497,O
often,497,O
performed,497,O
in,497,O
patients,497,O
unable,497,O
to,497,O
exercise,497,O
because,497,O
of,497,O
peripheral,497,B-Disease
vascular,497,I-Disease
disease,497,I-Disease
.,497,O
Many,498,O
of,498,O
these,498,O
patients,498,O
are,498,O
taking,498,O
pentoxifylline,498,B-Chemical
(,498,O
Trental,498,B-Chemical
),498,O
",",498,O
a,498,O
methylxanthine,498,B-Chemical
derivative,498,O
which,498,O
may,498,O
improve,498,O
intermittent,498,B-Disease
claudication,498,I-Disease
.,498,O
Whether,499,O
pentoxifylline,499,B-Chemical
inhibits,499,O
dipyridamole-induced,499,B-Chemical
coronary,499,O
hyperemia,499,B-Disease
like,499,O
other,499,O
methylxanthines,499,B-Chemical
such,499,O
as,499,O
theophylline,499,B-Chemical
and,499,O
should,499,O
be,499,O
stopped,499,O
prior,499,O
to,499,O
dipyridamole-thallium-201,499,B-Chemical
imaging,499,O
is,499,O
unknown,499,O
.,499,O
Therefore,500,O
",",500,O
we,500,O
studied,500,O
the,500,O
hyperemic,500,O
response,500,O
to,500,O
dipyridamole,500,B-Chemical
in,500,O
seven,500,O
open-chest,500,O
anesthetized,500,O
dogs,500,O
after,500,O
pretreatment,500,O
with,500,O
either,500,O
pentoxifylline,500,B-Chemical
(,500,O
0,500,O
",",500,O
7.5,500,O
",",500,O
or,500,O
15,500,O
mg/kg,500,O
i.v,500,O
.,500,O
),500,O
or,501,O
theophylline,501,B-Chemical
(,501,O
3,501,O
mg/kg,501,O
i.v,501,O
.,501,O
),501,O
.,501,O
Baseline,502,O
circumflex,502,O
coronary,502,O
blood,502,O
flows,502,O
did,502,O
not,502,O
differ,502,O
significantly,502,O
among,502,O
treatment,502,O
groups,502,O
.,502,O
Dipyridamole,503,B-Chemical
significantly,503,O
increased,503,O
coronary,503,O
blood,503,O
flow,503,O
before,503,O
and,503,O
after,503,O
7.5,503,O
or,503,O
15,503,O
mm/kg,503,O
i.v,503,O
.,503,O
pentoxifylline,504,B-Chemical
(,504,O
p,504,O
less,504,O
than,504,O
0.002,504,O
),504,O
.,504,O
Neither,505,O
dose,505,O
of,505,O
pentoxifylline,505,B-Chemical
significantly,505,O
decreased,505,O
the,505,O
dipyridamole-induced,505,B-Chemical
hyperemia,505,B-Disease
",",505,O
while,505,O
peak,505,O
coronary,505,O
blood,505,O
flow,505,O
was,505,O
significantly,505,O
lower,505,O
after,505,O
theophylline,505,B-Chemical
(,505,O
p,505,O
less,505,O
than,505,O
0.01,505,O
),505,O
.,505,O
We,506,O
conclude,506,O
that,506,O
pentoxyifylline,506,B-Chemical
does,506,O
not,506,O
inhibit,506,O
dipyridamole-induced,506,B-Chemical
coronary,506,O
hyperemia,506,B-Disease
even,506,O
at,506,O
high,506,O
doses,506,O
.,506,O
Cause,507,O
of,507,O
death,507,B-Disease
among,507,O
patients,507,O
with,507,O
Parkinson,507,B-Disease
's,507,I-Disease
disease,507,I-Disease
:,507,O
a,507,O
rare,507,O
mortality,507,O
due,507,O
to,507,O
cerebral,507,B-Disease
haemorrhage,507,I-Disease
.,507,O
Causes,508,O
of,508,O
death,508,B-Disease
",",508,O
with,508,O
special,508,O
reference,508,O
to,508,O
cerebral,508,B-Disease
haemorrhage,508,I-Disease
",",508,O
among,508,O
240,508,O
patients,508,O
with,508,O
pathologically,508,O
verified,508,O
Parkinson,508,B-Disease
's,508,I-Disease
disease,508,I-Disease
were,508,O
investigated,508,O
using,508,O
the,508,O
Annuals,508,O
of,508,O
the,508,O
Pathological,508,O
Autopsy,508,O
Cases,508,O
in,508,O
Japan,508,O
from,508,O
1981,508,O
to,508,O
1985,508,O
.,508,O
The,509,O
leading,509,O
causes,509,O
of,509,O
death,509,B-Disease
were,509,O
pneumonia,509,B-Disease
and,509,O
bronchitis,509,B-Disease
(,509,O
44.1,509,O
%,509,O
),509,O
",",509,O
malignant,509,O
neoplasms,509,B-Disease
(,509,O
11.6,509,O
%,509,O
),509,O
",",509,O
heart,509,B-Disease
diseases,509,I-Disease
(,509,O
4.1,509,O
%,509,O
),509,O
",",509,O
cerebral,509,B-Disease
infarction,509,I-Disease
(,509,O
3.7,509,O
%,509,O
),509,O
and,509,O
septicaemia,509,B-Disease
(,509,O
3.3,509,O
%,509,O
),509,O
.,509,O
Cerebral,510,B-Disease
haemorrhage,510,I-Disease
was,510,O
the,510,O
11th,510,O
most,510,O
frequent,510,O
cause,510,O
of,510,O
death,510,B-Disease
",",510,O
accounting,510,O
for,510,O
only,510,O
0.8,510,O
%,510,O
of,510,O
deaths,510,B-Disease
among,510,O
the,510,O
patients,510,O
",",510,O
whereas,510,O
it,510,O
was,510,O
the,510,O
5th,510,O
most,510,O
common,510,O
cause,510,O
of,510,O
death,510,B-Disease
among,510,O
the,510,O
Japanese,510,O
general,510,O
population,510,O
in,510,O
1985,510,O
.,510,O
The,511,O
low,511,O
incidence,511,O
of,511,O
cerebral,511,B-Disease
haemorrhage,511,I-Disease
as,511,O
a,511,O
cause,511,O
of,511,O
death,511,B-Disease
in,511,O
patients,511,O
with,511,O
Parkinson,511,B-Disease
's,511,I-Disease
disease,511,I-Disease
may,511,O
reflect,511,O
the,511,O
hypotensive,511,B-Disease
effect,511,O
of,511,O
levodopa,511,B-Chemical
and,511,O
a,511,O
hypotensive,511,B-Disease
mechanism,511,O
due,511,O
to,511,O
reduced,511,O
noradrenaline,511,B-Chemical
levels,511,O
in,511,O
the,511,O
parkinsonian,511,B-Disease
brain,511,O
.,511,O
Possible,512,O
intramuscular,512,O
midazolam-associated,512,B-Chemical
cardiorespiratory,512,B-Disease
arrest,512,I-Disease
and,512,O
death,512,B-Disease
.,512,O
Midazolam,513,B-Chemical
hydrochloride,513,I-Chemical
is,513,O
commonly,513,O
used,513,O
for,513,O
dental,513,O
or,513,O
endoscopic,513,O
procedures,513,O
.,513,O
Although,514,O
generally,514,O
consisted,514,O
safe,514,O
when,514,O
given,514,O
intramuscularly,514,O
",",514,O
intravenous,514,O
administration,514,O
is,514,O
known,514,O
to,514,O
cause,514,O
respiratory,514,O
and,514,O
cardiovascular,514,O
depression,514,O
.,514,O
This,515,O
report,515,O
describes,515,O
the,515,O
first,515,O
published,515,O
case,515,O
of,515,O
cardiorespiratory,515,B-Disease
arrest,515,I-Disease
and,515,O
death,515,B-Disease
associated,515,O
with,515,O
intramuscular,515,O
administration,515,O
of,515,O
midazolam,515,B-Chemical
.,515,O
Information,516,O
regarding,516,O
midazolam,516,B-Chemical
use,516,O
is,516,O
reviewed,516,O
to,516,O
provide,516,O
recommendation,516,O
for,516,O
safe,516,O
administration,516,O
.,516,O
Myasthenia,517,B-Disease
gravis,517,I-Disease
presenting,517,O
as,517,O
weakness,517,O
after,517,O
magnesium,517,B-Chemical
administration,517,O
.,517,O
We,518,O
studied,518,O
a,518,O
patient,518,O
with,518,O
no,518,O
prior,518,O
history,518,O
of,518,O
neuromuscular,518,B-Disease
disease,518,I-Disease
who,518,O
became,518,O
virtually,518,O
quadriplegic,518,B-Disease
after,518,O
parenteral,518,O
magnesium,518,B-Chemical
administration,518,O
for,518,O
preeclampsia,518,B-Disease
.,518,O
The,519,O
serum,519,O
magnesium,519,B-Chemical
concentration,519,O
was,519,O
3.0,519,O
mEq/L,519,O
",",519,O
which,519,O
is,519,O
usually,519,O
well,519,O
tolerated,519,O
.,519,O
The,520,O
magnesium,520,B-Chemical
was,520,O
stopped,520,O
and,520,O
she,520,O
recovered,520,O
over,520,O
a,520,O
few,520,O
days,520,O
.,520,O
While,521,O
she,521,O
was,521,O
weak,521,O
",",521,O
2-Hz,521,O
repetitive,521,O
stimulation,521,O
revealed,521,O
a,521,O
decrement,521,O
without,521,O
significant,521,O
facilitation,521,O
at,521,O
rapid,521,O
rates,521,O
or,521,O
after,521,O
exercise,521,O
",",521,O
suggesting,521,O
postsynaptic,521,B-Disease
neuromuscular,521,I-Disease
blockade,521,I-Disease
.,521,O
After,522,O
her,522,O
strength,522,O
returned,522,O
",",522,O
repetitive,522,O
stimulation,522,O
was,522,O
normal,522,O
",",522,O
but,522,O
single,522,O
fiber,522,O
EMG,522,O
revealed,522,O
increased,522,O
jitter,522,O
and,522,O
blocking,522,O
.,522,O
Her,523,O
acetylcholine,523,B-Chemical
receptor,523,O
antibody,523,O
level,523,O
was,523,O
markedly,523,O
elevated,523,O
.,523,O
Although,524,O
paralysis,524,B-Disease
after,524,O
magnesium,524,B-Chemical
administration,524,O
has,524,O
been,524,O
described,524,O
in,524,O
patients,524,O
with,524,O
known,524,O
myasthenia,524,B-Disease
gravis,524,I-Disease
",",524,O
it,524,O
has,524,O
not,524,O
previously,524,O
been,524,O
reported,524,O
to,524,O
be,524,O
the,524,O
initial,524,O
or,524,O
only,524,O
manifestation,524,O
of,524,O
the,524,O
disease,524,O
.,524,O
Patients,525,O
who,525,O
are,525,O
unusually,525,O
sensitive,525,O
to,525,O
the,525,O
neuromuscular,525,O
effects,525,O
of,525,O
magnesium,525,B-Chemical
should,525,O
be,525,O
suspected,525,O
of,525,O
having,525,O
an,525,O
underlying,525,O
disorder,525,B-Disease
of,525,I-Disease
neuromuscular,525,I-Disease
transmission,525,I-Disease
.,525,O
No,526,O
enhancement,526,O
by,526,O
phenobarbital,526,B-Chemical
of,526,O
the,526,O
hepatocarcinogenicity,526,O
of,526,O
a,526,O
choline-devoid,526,B-Chemical
diet,526,O
in,526,O
the,526,O
rat,526,O
.,526,O
An,527,O
experiment,527,O
was,527,O
performed,527,O
to,527,O
test,527,O
whether,527,O
inclusion,527,O
of,527,O
phenobarbital,527,B-Chemical
in,527,O
a,527,O
choline-devoid,527,B-Chemical
diet,527,O
would,527,O
increase,527,O
the,527,O
hepatocarcinogenicity,527,O
of,527,O
the,527,O
diet,527,O
.,527,O
Groups,528,O
of,528,O
5-week,528,O
old,528,O
male,528,O
Fischer-344,528,O
rats,528,O
were,528,O
fed,528,O
for,528,O
7-25,528,O
months,528,O
semipurified,528,O
choline-devoid,528,B-Chemical
or,528,O
choline-supplemented,528,B-Chemical
diets,528,O
",",528,O
containing,528,O
or,528,O
not,528,O
0.06,528,O
%,528,O
phenobarbital,528,B-Chemical
.,528,O
No,529,O
hepatic,529,O
preneoplastic,529,O
nodules,529,O
or,529,O
hepatocellular,529,B-Disease
carcinomas,529,I-Disease
developed,529,O
in,529,O
rats,529,O
fed,529,O
the,529,O
plain,529,O
choline-supplemented,529,B-Chemical
diet,529,O
",",529,O
while,529,O
one,529,O
preneoplastic,529,O
nodule,529,O
and,529,O
one,529,O
hepatocellular,529,B-Disease
carcinoma,529,I-Disease
developed,529,O
in,529,O
two,529,O
rats,529,O
fed,529,O
the,529,O
same,529,O
diet,529,O
containing,529,O
phenobarbital,529,B-Chemical
.,529,O
The,530,O
incidence,530,O
of,530,O
preneoplastic,530,O
nodules,530,O
and,530,O
of,530,O
hepatocellular,530,B-Disease
carcinomas,530,I-Disease
was,530,O
10,530,O
%,530,O
and,530,O
37,530,O
%,530,O
",",530,O
respectively,530,O
",",530,O
in,530,O
rats,530,O
fed,530,O
the,530,O
plain,530,O
choline-devoid,530,B-Chemical
diet,530,O
",",530,O
and,530,O
17,530,O
%,530,O
and,530,O
30,530,O
%,530,O
",",530,O
in,530,O
rats,530,O
fed,530,O
the,530,O
phenobarbital-containing,530,B-Chemical
choline-devoid,530,B-Chemical
diet,530,O
.,530,O
The,531,O
results,531,O
evinced,531,O
no,531,O
enhancement,531,O
of,531,O
the,531,O
hepatocarcinogenicity,531,O
of,531,O
the,531,O
choline-devoid,531,B-Chemical
diet,531,O
by,531,O
phenobarbital,531,B-Chemical
.,531,O
Sporadic,532,O
neoplastic,532,O
lesions,532,O
were,532,O
observed,532,O
in,532,O
organs,532,O
other,532,O
than,532,O
the,532,O
liver,532,O
of,532,O
some,532,O
of,532,O
the,532,O
animals,532,O
",",532,O
irrespective,532,O
of,532,O
the,532,O
diet,532,O
fed,532,O
.,532,O
On,533,O
two,533,O
paradoxical,533,O
side-effects,533,O
of,533,O
prednisolone,533,B-Chemical
in,533,O
rats,533,O
",",533,O
ribosomal,533,O
RNA,533,O
biosyntheses,533,O
",",533,O
and,533,O
a,533,O
mechanism,533,O
of,533,O
action,533,O
.,533,O
Liver,534,B-Disease
enlargement,534,I-Disease
and,534,O
muscle,534,B-Disease
wastage,534,I-Disease
occurred,534,O
in,534,O
Wistar,534,O
rats,534,O
following,534,O
the,534,O
subcutaneous,534,O
administration,534,O
of,534,O
prednisolone,534,B-Chemical
.,534,O
In,535,O
the,535,O
liver,535,O
both,535,O
the,535,O
content,535,O
of,535,O
RNA,535,O
and,535,O
the,535,O
biosynthesis,535,O
of,535,O
ribosomal,535,O
RNA,535,O
increased,535,O
while,535,O
both,535,O
the,535,O
RNA,535,O
content,535,O
and,535,O
ribosomal,535,O
RNA,535,O
biosynthesis,535,O
were,535,O
reduced,535,O
in,535,O
the,535,O
gastrocnemius,535,O
muscle,535,O
.,535,O
It,536,O
is,536,O
suggested,536,O
that,536,O
the,536,O
drug,536,O
acted,536,O
in,536,O
a,536,O
selective,536,O
and,536,O
tissue-specific,536,O
manner,536,O
to,536,O
enhance,536,O
ribosomal,536,O
RNA,536,O
synthesis,536,O
in,536,O
the,536,O
liver,536,O
and,536,O
depress,536,O
such,536,O
synthesis,536,O
in,536,O
the,536,O
muscle,536,O
.,536,O
This,537,O
view,537,O
supports,537,O
the,537,O
contention,537,O
that,537,O
the,537,O
liver,537,O
and,537,O
muscle,537,O
are,537,O
independent,537,O
sites,537,O
of,537,O
prednisolone,537,B-Chemical
action,537,O
.,537,O
Differential,538,O
effects,538,O
of,538,O
gamma-hexachlorocyclohexane,538,B-Chemical
(,538,O
lindane,538,B-Chemical
),538,O
on,538,O
pharmacologically-induced,538,O
seizures,538,B-Disease
.,538,O
Gamma-hexachlorocyclohexane,539,B-Chemical
(,539,O
gamma-HCH,539,B-Chemical
),539,O
",",539,O
the,539,O
active,539,O
ingredient,539,O
of,539,O
the,539,O
insecticide,539,O
lindane,539,B-Chemical
",",539,O
has,539,O
been,539,O
shown,539,O
to,539,O
decrease,539,O
seizure,539,B-Disease
threshold,539,O
to,539,O
pentylenetrazol,539,O
(,539,O
PTZ,539,B-Chemical
),539,O
3,539,O
h,539,O
after,539,O
exposure,539,O
to,539,O
gamma-HCH,539,B-Chemical
and,539,O
conversely,539,O
increase,539,O
threshold,539,O
to,539,O
PTZ-induced,539,B-Chemical
seizures,539,B-Disease
24,539,O
h,539,O
after,539,O
exposure,539,O
to,539,O
gamma-HCH,539,B-Chemical
(,539,O
Vohland,539,O
et,539,O
al,539,O
.,539,O
1981,540,O
),540,O
.,540,O
In,541,O
this,541,O
study,541,O
",",541,O
the,541,O
severity,541,O
of,541,O
response,541,O
to,541,O
other,541,O
seizure-inducing,541,B-Disease
agents,541,O
was,541,O
tested,541,O
in,541,O
mice,541,O
1,541,O
and,541,O
24,541,O
h,541,O
after,541,O
intraperitoneal,541,O
administration,541,O
of,541,O
80,541,O
mg/kg,541,O
gamma-HCH,541,B-Chemical
.,541,O
One,542,O
hour,542,O
after,542,O
the,542,O
administration,542,O
of,542,O
gamma-HCH,542,B-Chemical
",",542,O
the,542,O
activity,542,O
of,542,O
seizure-inducing,542,B-Disease
agents,542,O
was,542,O
increased,542,O
",",542,O
regardless,542,O
of,542,O
their,542,O
mechanism,542,O
",",542,O
while,542,O
24,542,O
h,542,O
after,542,O
gamma-HCH,542,B-Chemical
a,542,O
differential,542,O
response,542,O
was,542,O
observed,542,O
.,542,O
Seizure,543,B-Disease
activity,543,O
due,543,O
to,543,O
PTZ,543,B-Chemical
and,543,O
picrotoxin,543,B-Chemical
(,543,O
PTX,543,B-Chemical
),543,O
was,543,O
significantly,543,O
decreased,543,O
;,543,O
however,543,O
",",543,O
seizure,543,B-Disease
activity,543,O
due,543,O
to,543,O
3-mercaptopropionic,543,B-Chemical
acid,543,I-Chemical
(,543,O
MPA,543,B-Chemical
),543,O
",",543,O
bicuculline,543,B-Chemical
(,543,O
BCC,543,B-Chemical
),543,O
",",543,O
methyl,543,B-Chemical
"6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate",543,I-Chemical
(,543,O
DMCM,543,B-Chemical
),543,O
",",543,O
or,543,O
strychnine,543,B-Chemical
(,543,O
STR,543,B-Chemical
),543,O
was,543,O
not,543,O
different,543,O
from,543,O
control,543,O
.,543,O
In,544,O
vitro,544,O
",",544,O
gamma-HCH,544,B-Chemical
",",544,O
pentylenetetrazol,544,B-Chemical
and,544,O
picrotoxin,544,B-Chemical
were,544,O
shown,544,O
to,544,O
inhibit,544,O
3H-TBOB,544,B-Chemical
binding,544,O
in,544,O
mouse,544,O
whole,544,O
brain,544,O
",",544,O
with,544,O
IC50,544,O
values,544,O
of,544,O
4.6,544,O
",",544,O
404,544,O
and,544,O
9.4,544,O
microM,544,O
",",544,O
respectively,544,O
.,544,O
MPA,545,B-Chemical
",",545,O
BCC,545,B-Chemical
",",545,O
DMCM,545,B-Chemical
",",545,O
and,545,O
STR,545,B-Chemical
showed,545,O
no,545,O
inhibition,545,O
of,545,O
3H-TBOB,545,B-Chemical
(,545,O
t-butyl,545,B-Chemical
bicyclo-orthobenzoate,545,I-Chemical
),545,O
binding,545,O
at,545,O
concentrations,545,O
of,545,O
100,545,O
micron,545,O
.,545,O
The,546,O
pharmacological,546,O
challenge,546,O
data,546,O
suggest,546,O
that,546,O
tolerance,546,O
may,546,O
occur,546,O
to,546,O
seizure,546,B-Disease
activity,546,O
induced,546,O
by,546,O
PTZ,546,B-Chemical
and,546,O
PTX,546,B-Chemical
24,546,O
h,546,O
after,546,O
gamma-HCH,546,B-Chemical
",",546,O
since,546,O
the,546,O
response,546,O
to,546,O
only,546,O
these,546,O
two,546,O
seizure-inducing,546,B-Disease
agents,546,O
is,546,O
decreased,546,O
.,546,O
The,547,O
in,547,O
vitro,547,O
data,547,O
suggest,547,O
that,547,O
the,547,O
site,547,O
responsible,547,O
for,547,O
the,547,O
decrease,547,O
in,547,O
seizure,547,B-Disease
activity,547,O
24,547,O
h,547,O
after,547,O
gamma-HCH,547,B-Chemical
may,547,O
be,547,O
the,547,O
GABA-A,547,B-Chemical
receptor-linked,547,O
chloride,547,O
channel,547,O
.,547,O
Tolerance,548,O
and,548,O
antiviral,548,O
effect,548,O
of,548,O
ribavirin,548,B-Chemical
in,548,O
patients,548,O
with,548,O
Argentine,548,B-Disease
hemorrhagic,548,I-Disease
fever,548,I-Disease
.,548,O
Tolerance,549,O
and,549,O
antiviral,549,O
effect,549,O
of,549,O
ribavirin,549,B-Chemical
was,549,O
studied,549,O
in,549,O
6,549,O
patients,549,O
with,549,O
Argentine,549,B-Disease
hemorrhagic,549,I-Disease
fever,549,I-Disease
(,549,O
AHF,549,B-Disease
),549,O
of,549,O
more,549,O
than,549,O
8,549,O
days,549,O
of,549,O
evolution,549,O
.,549,O
Administration,550,O
of,550,O
ribavirin,550,B-Chemical
resulted,550,O
in,550,O
a,550,O
neutralization,550,O
of,550,O
viremia,550,B-Disease
and,550,O
a,550,O
drop,550,O
of,550,O
endogenous,550,O
interferon,550,O
titers,550,O
.,550,O
The,551,O
average,551,O
time,551,O
of,551,O
death,551,B-Disease
was,551,O
delayed,551,O
.,551,O
A,552,O
reversible,552,O
anemia,552,B-Disease
was,552,O
the,552,O
only,552,O
adverse,552,O
effect,552,O
observed,552,O
.,552,O
From,553,O
these,553,O
results,553,O
",",553,O
we,553,O
conclude,553,O
that,553,O
ribavirin,553,B-Chemical
has,553,O
an,553,O
antiviral,553,O
effect,553,O
in,553,O
advanced,553,O
cases,553,O
of,553,O
AHF,553,B-Disease
",",553,O
and,553,O
that,553,O
anemia,553,B-Disease
",",553,O
the,553,O
only,553,O
secondary,553,O
reaction,553,O
observed,553,O
",",553,O
can,553,O
be,553,O
easily,553,O
managed,553,O
.,553,O
The,554,O
possible,554,O
beneficial,554,O
effect,554,O
of,554,O
ribavirin,554,B-Chemical
during,554,O
the,554,O
initial,554,O
days,554,O
of,554,O
AHF,554,B-Disease
is,554,O
discussed,554,O
.,554,O
Is,555,O
the,555,O
treatment,555,O
of,555,O
scabies,555,B-Disease
hazardous,555,O
?,555,O
Treatment,556,O
for,556,O
scabies,556,B-Disease
is,556,O
usually,556,O
initiated,556,O
by,556,O
general,556,O
practitioners,556,O
;,556,O
most,556,O
consider,556,O
lindane,556,B-Chemical
(,556,O
gamma,556,B-Chemical
benzene,556,I-Chemical
hexachloride,556,I-Chemical
),556,O
the,556,O
treatment,556,O
of,556,O
choice,556,O
.,556,O
Lindane,557,B-Chemical
is,557,O
also,557,O
widely,557,O
used,557,O
as,557,O
an,557,O
agricultural,557,O
and,557,O
industrial,557,O
pesticide,557,O
",",557,O
and,557,O
as,557,O
a,557,O
result,557,O
the,557,O
toxic,557,O
profile,557,O
of,557,O
this,557,O
insecticide,557,O
is,557,O
well,557,O
understood,557,O
.,557,O
Evidence,558,O
is,558,O
accumulating,558,O
that,558,O
lindane,558,B-Chemical
can,558,O
be,558,O
toxic,558,B-Disease
to,558,I-Disease
the,558,I-Disease
central,558,I-Disease
nervous,558,I-Disease
system,558,I-Disease
and,558,O
may,558,O
be,558,O
associated,558,O
with,558,O
aplastic,558,B-Disease
anaemia,558,I-Disease
.,558,O
Preparations,559,O
containing,559,O
lindane,559,B-Chemical
continue,559,O
to,559,O
be,559,O
sold,559,O
over,559,O
the,559,O
counter,559,O
and,559,O
may,559,O
represent,559,O
a,559,O
hazard,559,O
to,559,O
poorly,559,O
informed,559,O
patients,559,O
.,559,O
This,560,O
literature,560,O
review,560,O
suggests,560,O
that,560,O
general,560,O
practitioners,560,O
should,560,O
prescribe,560,O
scabicides,560,O
with,560,O
increased,560,O
caution,560,O
for,560,O
certain,560,O
at-risk,560,O
groups,560,O
",",560,O
and,560,O
give,560,O
adequate,560,O
warnings,560,O
regarding,560,O
potential,560,O
toxicity,560,B-Disease
.,560,O
Mouse,561,O
strain-dependent,561,O
effect,561,O
of,561,O
amantadine,561,B-Chemical
on,561,O
motility,561,O
and,561,O
brain,561,O
biogenic,561,O
amines,561,B-Chemical
.,561,O
The,562,O
effect,562,O
of,562,O
amantadine,562,B-Chemical
hydrochloride,562,I-Chemical
",",562,O
injected,562,O
i.p,562,O
.,562,O
in,563,O
6,563,O
increments,563,O
of,563,O
100,563,O
mg/kg,563,O
each,563,O
over,563,O
30,563,O
hr,563,O
",",563,O
on,563,O
mouse,563,O
motility,563,O
and,563,O
whole,563,O
brain,563,O
content,563,O
of,563,O
selected,563,O
biogenic,563,O
amines,563,B-Chemical
and,563,O
major,563,O
metabolites,563,O
was,563,O
studied,563,O
in,563,O
4,563,O
strains,563,O
of,563,O
mice,563,O
.,563,O
These,564,O
were,564,O
the,564,O
albino,564,O
Sprague-Dawley,564,O
ICR,564,O
and,564,O
BALB/C,564,O
",",564,O
the,564,O
black,564,O
C57BL/6,564,O
and,564,O
the,564,O
brown,564,O
CDF-I,564,O
mouse,564,O
strains,564,O
.,564,O
Amantadine,565,B-Chemical
treatment,565,O
produced,565,O
a,565,O
biphasic,565,O
effect,565,O
on,565,O
mouse,565,O
motility,565,O
.,565,O
The,566,O
initial,566,O
dose,566,O
of,566,O
amantadine,566,B-Chemical
depressed,566,B-Disease
locomotor,566,O
activity,566,O
in,566,O
all,566,O
mouse,566,O
strains,566,O
studied,566,O
with,566,O
the,566,O
BALB/C,566,O
mice,566,O
being,566,O
the,566,O
most,566,O
sensitive,566,O
.,566,O
Subsequent,567,O
amantadine,567,B-Chemical
treatments,567,O
produced,567,O
enhancement,567,O
of,567,O
motility,567,O
from,567,O
corresponding,567,O
control,567,O
in,567,O
all,567,O
mouse,567,O
strains,567,O
with,567,O
the,567,O
BALB/C,567,O
mice,567,O
being,567,O
the,567,O
least,567,O
sensitive,567,O
.,567,O
The,568,O
locomotor,568,O
activity,568,O
was,568,O
decreased,568,O
from,568,O
corresponding,568,O
controls,568,O
in,568,O
all,568,O
strains,568,O
studied,568,O
",",568,O
except,568,O
for,568,O
the,568,O
ICR,568,O
mice,568,O
",",568,O
during,568,O
an,568,O
overnight,568,O
drug-free,568,O
period,568,O
following,568,O
the,568,O
fourth,568,O
amantadine,568,B-Chemical
treatment,568,O
.,568,O
Readministration,569,O
of,569,O
amantadine,569,B-Chemical
",",569,O
after,569,O
a,569,O
drug-free,569,O
overnight,569,O
period,569,O
",",569,O
increased,569,O
motility,569,O
from,569,O
respective,569,O
saline,569,O
control,569,O
in,569,O
all,569,O
strains,569,O
with,569,O
exception,569,O
of,569,O
the,569,O
BALB/C,569,O
mice,569,O
where,569,O
suppression,569,B-Disease
of,569,I-Disease
motility,569,I-Disease
occurred,569,O
.,569,O
Treatment,570,O
with,570,O
amantadine,570,B-Chemical
did,570,O
not,570,O
alter,570,O
whole,570,O
brain,570,O
dopamine,570,B-Chemical
levels,570,O
but,570,O
decreased,570,O
the,570,O
amounts,570,O
of,570,O
"3,4-dihydroxyphenylacetic",570,B-Chemical
acid,570,I-Chemical
in,570,O
the,570,O
BALB/C,570,O
mice,570,O
compared,570,O
to,570,O
saline,570,O
control,570,O
.,570,O
Conversely,571,O
",",571,O
brain,571,O
normetanephrine,571,B-Chemical
concentration,571,O
was,571,O
increased,571,O
from,571,O
saline,571,O
control,571,O
by,571,O
amantadine,571,B-Chemical
in,571,O
the,571,O
BALB/C,571,O
mice,571,O
.,571,O
The,572,O
results,572,O
suggest,572,O
a,572,O
strain-dependent,572,O
effect,572,O
of,572,O
amantadine,572,B-Chemical
on,572,O
motility,572,O
and,572,O
indicate,572,O
a,572,O
differential,572,O
response,572,O
to,572,O
the,572,O
acute,572,O
and,572,O
multiple,572,O
dose,572,O
regimens,572,O
used,572,O
.,572,O
The,573,O
BALB/C,573,O
mouse,573,O
was,573,O
the,573,O
most,573,O
sensitive,573,O
strain,573,O
and,573,O
could,573,O
serve,573,O
as,573,O
the,573,O
strain,573,O
of,573,O
choice,573,O
for,573,O
evaluating,573,O
the,573,O
side,573,O
effects,573,O
of,573,O
amantadine,573,B-Chemical
.,573,O
The,574,O
biochemical,574,O
results,574,O
of,574,O
brain,574,O
biogenic,574,O
amines,574,B-Chemical
of,574,O
BALB/C,574,O
mouse,574,O
strain,574,O
suggest,574,O
a,574,O
probable,574,O
decrease,574,O
of,574,O
catecholamine,574,B-Chemical
turnover,574,O
rate,574,O
and/or,574,O
metabolism,574,O
by,574,O
monoamine,574,O
oxidase,574,O
and,574,O
a,574,O
resulting,574,O
increase,574,O
in,574,O
O-methylation,574,O
of,574,O
norepinephrine,574,B-Chemical
which,574,O
may,574,O
account,574,O
for,574,O
a,574,O
behavioral,574,B-Disease
depression,574,I-Disease
caused,574,O
by,574,O
amantadine,574,B-Chemical
in,574,O
the,574,O
BALB/C,574,O
mice,574,O
.,574,O
Chloroacetaldehyde,575,B-Chemical
and,575,O
its,575,O
contribution,575,O
to,575,O
urotoxicity,575,O
during,575,O
treatment,575,O
with,575,O
cyclophosphamide,575,B-Chemical
or,575,O
ifosfamide,575,B-Chemical
.,575,O
An,576,O
experimental,576,O
study/short,576,O
communication,576,O
.,576,O
Based,577,O
on,577,O
clinical,577,O
data,577,O
",",577,O
indicating,577,O
that,577,O
chloroacetaldehyde,577,B-Chemical
(,577,O
CAA,577,B-Chemical
),577,O
is,577,O
an,577,O
important,577,O
metabolite,577,O
of,577,O
oxazaphosphorine,577,O
cytostatics,577,O
",",577,O
an,577,O
experimental,577,O
study,577,O
was,577,O
carried,577,O
out,577,O
in,577,O
order,577,O
to,577,O
elucidate,577,O
the,577,O
role,577,O
of,577,O
CAA,577,B-Chemical
in,577,O
the,577,O
development,577,O
of,577,O
hemorrhagic,577,O
cystitis,577,O
.,577,O
The,578,O
data,578,O
demonstrate,578,O
that,578,O
CAA,578,B-Chemical
after,578,O
i.v,578,O
.,578,O
administration,579,O
does,579,O
not,579,O
contribute,579,O
to,579,O
bladder,579,B-Disease
damage,579,I-Disease
.,579,O
When,580,O
instilled,580,O
directly,580,O
into,580,O
the,580,O
bladder,580,O
",",580,O
CAA,580,B-Chemical
exerts,580,O
urotoxic,580,O
effects,580,O
",",580,O
it,580,O
is,580,O
",",580,O
however,580,O
",",580,O
susceptible,580,O
to,580,O
detoxification,580,O
with,580,O
mesna,580,B-Chemical
.,580,O
Source,581,O
of,581,O
pain,581,B-Disease
and,581,O
primitive,581,O
dysfunction,581,O
in,581,O
migraine,581,B-Disease
:,581,O
an,581,O
identical,581,O
site,581,O
?,581,O
Twenty,582,O
common,582,O
migraine,582,B-Disease
patients,582,O
received,582,O
a,582,O
one,582,O
sided,582,O
frontotemporal,582,O
application,582,O
of,582,O
nitroglycerin,582,B-Chemical
(,582,O
10,582,O
patients,582,O
),582,O
or,582,O
placebo,582,O
ointment,582,O
(,582,O
10,582,O
patients,582,O
),582,O
in,582,O
a,582,O
double,582,O
blind,582,O
study,582,O
.,582,O
Early,583,O
onset,583,O
migraine,583,B-Disease
attacks,583,O
were,583,O
induced,583,O
by,583,O
nitroglycerin,583,B-Chemical
in,583,O
seven,583,O
out,583,O
of,583,O
10,583,O
patients,583,O
versus,583,O
no,583,O
patient,583,O
in,583,O
the,583,O
placebo,583,O
group,583,O
.,583,O
Subsequently,584,O
20,584,O
migraine,584,B-Disease
patients,584,O
",",584,O
who,584,O
developed,584,O
an,584,O
early,584,O
onset,584,O
attack,584,O
with,584,O
frontotemporal,584,O
nitroglycerin,584,B-Chemical
",",584,O
received,584,O
the,584,O
drug,584,O
in,584,O
a,584,O
second,584,O
induction,584,O
test,584,O
at,584,O
other,584,O
body,584,O
areas,584,O
.,584,O
No,585,O
early,585,O
onset,585,O
migraine,585,B-Disease
was,585,O
observed,585,O
.,585,O
Thus,586,O
the,586,O
migraine-inducing,586,B-Disease
effect,586,O
of,586,O
nitroglycerin,586,B-Chemical
seems,586,O
to,586,O
depend,586,O
on,586,O
direct,586,O
stimulation,586,O
of,586,O
the,586,O
habitual,586,O
site,586,O
of,586,O
pain,586,B-Disease
",",586,O
suggesting,586,O
that,586,O
the,586,O
frontotemporal,586,O
region,586,O
is,586,O
of,586,O
crucial,586,O
importance,586,O
in,586,O
the,586,O
development,586,O
of,586,O
a,586,O
migraine,586,B-Disease
crisis,586,O
.,586,O
This,587,O
is,587,O
not,587,O
consistent,587,O
with,587,O
a,587,O
CNS,587,O
origin,587,O
of,587,O
migraine,587,B-Disease
attack,587,O
.,587,O
Hypersensitivity,588,B-Disease
to,588,O
carbamazepine,588,B-Chemical
presenting,588,O
with,588,O
a,588,O
leukemoid,588,B-Disease
reaction,588,I-Disease
",",588,O
eosinophilia,588,B-Disease
",",588,O
erythroderma,588,B-Disease
",",588,O
and,588,O
renal,588,B-Disease
failure,588,I-Disease
.,588,O
We,589,O
report,589,O
a,589,O
patient,589,O
in,589,O
whom,589,O
hypersensitivity,589,B-Disease
to,589,O
carbamazepine,589,B-Chemical
presented,589,O
with,589,O
generalized,589,O
erythroderma,589,B-Disease
",",589,O
a,589,O
severe,589,O
leukemoid,589,B-Disease
reaction,589,I-Disease
",",589,O
eosinophilia,589,B-Disease
",",589,O
hyponatremia,589,B-Disease
",",589,O
and,589,O
renal,589,B-Disease
failure,589,I-Disease
.,589,O
This,590,O
is,590,O
the,590,O
first,590,O
report,590,O
of,590,O
such,590,O
an,590,O
unusual,590,O
reaction,590,O
to,590,O
carbamazepine,590,B-Chemical
.,590,O
Fluoxetine-induced,591,B-Chemical
akathisia,591,B-Disease
:,591,O
clinical,591,O
and,591,O
theoretical,591,O
implications,591,O
.,591,O
Five,592,O
patients,592,O
receiving,592,O
fluoxetine,592,B-Chemical
for,592,O
the,592,O
treatment,592,O
of,592,O
obsessive,592,B-Disease
compulsive,592,I-Disease
disorder,592,I-Disease
or,592,O
major,592,B-Disease
depression,592,I-Disease
developed,592,O
akathisia,592,B-Disease
.,592,O
The,593,O
typical,593,O
fluoxetine-induced,593,B-Chemical
symptoms,593,O
of,593,O
restlessness,593,O
",",593,O
constant,593,O
pacing,593,O
",",593,O
purposeless,593,O
movements,593,O
of,593,O
the,593,O
feet,593,O
and,593,O
legs,593,O
",",593,O
and,593,O
marked,593,O
anxiety,593,B-Disease
were,593,O
indistinguishable,593,O
from,593,O
those,593,O
of,593,O
neuroleptic-induced,593,O
akathisia,593,B-Disease
.,593,O
Three,594,O
patients,594,O
who,594,O
had,594,O
experienced,594,O
neuroleptic-induced,594,O
akathisia,594,B-Disease
in,594,O
the,594,O
past,594,O
reported,594,O
that,594,O
the,594,O
symptoms,594,O
of,594,O
fluoxetine-induced,594,B-Chemical
akathisia,594,B-Disease
were,594,O
identical,594,O
",",594,O
although,594,O
somewhat,594,O
milder,594,O
.,594,O
Akathisia,595,B-Disease
appeared,595,O
to,595,O
be,595,O
a,595,O
common,595,O
side,595,O
effect,595,O
of,595,O
fluoxetine,595,B-Chemical
and,595,O
generally,595,O
responded,595,O
well,595,O
to,595,O
treatment,595,O
with,595,O
the,595,O
beta-adrenergic,595,O
antagonist,595,O
propranolol,595,B-Chemical
",",595,O
dose,595,O
reduction,595,O
",",595,O
or,595,O
both,595,O
.,595,O
The,596,O
authors,596,O
suggest,596,O
that,596,O
fluoxetine-induced,596,B-Chemical
akathisia,596,B-Disease
may,596,O
be,596,O
caused,596,O
by,596,O
serotonergically,596,O
mediated,596,O
inhibition,596,O
of,596,O
dopaminergic,596,O
neurotransmission,596,O
and,596,O
that,596,O
the,596,O
pathophysiology,596,O
of,596,O
fluoxetine-induced,596,B-Chemical
akathisia,596,B-Disease
and,596,O
tricyclic,596,O
antidepressant-induced,596,B-Chemical
``,596,O
jitteriness,596,O
'',596,O
may,596,O
be,596,O
identical,596,O
.,596,O
Effect,597,O
of,597,O
converting,597,O
enzyme,597,O
inhibition,597,O
on,597,O
the,597,O
course,597,O
of,597,O
adriamycin-induced,597,B-Chemical
nephropathy,597,B-Disease
.,597,O
The,598,O
effect,598,O
of,598,O
the,598,O
converting,598,O
enzyme,598,O
inhibitor,598,O
(,598,O
CEI,598,O
),598,O
enalapril,598,B-Chemical
was,598,O
assessed,598,O
in,598,O
Munich-Wistar,598,O
rats,598,O
with,598,O
established,598,O
adriamycin,598,B-Chemical
nephrosis,598,B-Disease
.,598,O
Rats,599,O
were,599,O
given,599,O
a,599,O
single,599,O
dose,599,O
of,599,O
adriamycin,599,B-Chemical
and,599,O
one,599,O
month,599,O
later,599,O
divided,599,O
into,599,O
four,599,O
groups,599,O
matched,599,O
for,599,O
albuminuria,599,B-Disease
",",599,O
blood,599,O
pressure,599,O
",",599,O
and,599,O
plasma,599,O
albumin,599,O
concentration,599,O
.,599,O
Groups,600,O
1,600,O
and,600,O
3,600,O
remained,600,O
untreated,600,O
while,600,O
groups,600,O
2,600,O
and,600,O
4,600,O
received,600,O
enalapril,600,B-Chemical
.,600,O
Groups,601,O
1,601,O
and,601,O
2,601,O
underwent,601,O
micropuncture,601,O
studies,601,O
after,601,O
10,601,O
days,601,O
.,601,O
These,602,O
short-term,602,O
studies,602,O
showed,602,O
that,602,O
enalapril,602,B-Chemical
reduced,602,O
arterial,602,O
blood,602,O
pressure,602,O
(,602,O
101,602,O
+/-,602,O
2,602,O
vs.,602,O
124,602,O
+/-,602,O
3,602,O
mm,602,O
Hg,602,O
",",602,O
group,602,O
2,602,O
vs.,602,O
1,602,O
",",602,O
P,602,O
less,602,O
than,602,O
0.05,602,O
),602,O
and,602,O
glomerular,602,O
capillary,602,O
pressure,602,O
(,602,O
54,602,O
+/-,602,O
1,602,O
vs.,602,O
61,602,O
+/-,602,O
2,602,O
mm,602,O
Hg,602,O
",",602,O
P,602,O
less,602,O
than,602,O
0.05,602,O
),602,O
without,602,O
reducing,602,O
albuminuria,602,B-Disease
(,602,O
617,602,O
+/-,602,O
50,602,O
vs.,602,O
570,602,O
+/-,602,O
47,602,O
mg/day,602,O
),602,O
or,602,O
GFR,602,O
(,602,O
1.03,602,O
+/-,602,O
0.04,602,O
vs.,602,O
1.04,602,O
+/-,602,O
0.11,602,O
ml/min,602,O
),602,O
.,602,O
Groups,603,O
3,603,O
and,603,O
4,603,O
were,603,O
studied,603,O
at,603,O
four,603,O
and,603,O
at,603,O
six,603,O
months,603,O
to,603,O
assess,603,O
the,603,O
effect,603,O
of,603,O
enalapril,603,B-Chemical
on,603,O
progression,603,O
of,603,O
renal,603,B-Disease
injury,603,I-Disease
in,603,O
adriamycin,603,B-Chemical
nephrosis,603,B-Disease
.,603,O
Chronic,604,O
enalapril,604,B-Chemical
treatment,604,O
reduced,604,O
blood,604,O
pressure,604,O
without,604,O
reducing,604,O
albuminuria,604,B-Disease
in,604,O
group,604,O
4,604,O
.,604,O
Untreated,605,O
group,605,O
3,605,O
rats,605,O
exhibited,605,O
a,605,O
progressive,605,O
reduction,605,O
in,605,O
GFR,605,O
(,605,O
0.35,605,O
+/-,605,O
0.08,605,O
ml/min,605,O
at,605,O
4,605,O
months,605,O
",",605,O
0.27,605,O
+/-,605,O
0.07,605,O
ml/min,605,O
at,605,O
6,605,O
months,605,O
),605,O
.,605,O
Enalapril,606,B-Chemical
treatment,606,O
blunted,606,O
but,606,O
did,606,O
not,606,O
prevent,606,O
reduction,606,O
in,606,O
GFR,606,O
in,606,O
group,606,O
4,606,O
(,606,O
0.86,606,O
+/-,606,O
0.15,606,O
ml/min,606,O
at,606,O
4,606,O
months,606,O
",",606,O
0.69,606,O
+/-,606,O
0.13,606,O
ml/min,606,O
at,606,O
6,606,O
months,606,O
",",606,O
both,606,O
P,606,O
less,606,O
than,606,O
0.05,606,O
vs.,606,O
group,606,O
3,606,O
),606,O
.,606,O
Reduction,607,O
in,607,O
GFR,607,O
was,607,O
associated,607,O
with,607,O
the,607,O
development,607,O
of,607,O
glomerular,607,B-Disease
sclerosis,607,I-Disease
in,607,O
both,607,O
treated,607,O
and,607,O
untreated,607,O
rats,607,O
.,607,O
(,608,O
ABSTRACT,608,O
TRUNCATED,608,O
AT,608,O
250,608,O
WORDS,608,O
),608,O
Clotiazepam-induced,609,B-Chemical
acute,609,O
hepatitis,609,B-Disease
.,609,O
We,610,O
report,610,O
the,610,O
case,610,O
of,610,O
a,610,O
patient,610,O
who,610,O
developed,610,O
acute,610,O
hepatitis,610,B-Disease
with,610,O
extensive,610,B-Disease
hepatocellular,610,I-Disease
necrosis,610,I-Disease
",",610,O
7,610,O
months,610,O
after,610,O
the,610,O
onset,610,O
of,610,O
administration,610,O
of,610,O
clotiazepam,610,B-Chemical
",",610,O
a,610,O
thienodiazepine,610,B-Chemical
derivative,610,O
.,610,O
Clotiazepam,611,B-Chemical
withdrawal,611,O
was,611,O
followed,611,O
by,611,O
prompt,611,O
recovery,611,O
.,611,O
The,612,O
administration,612,O
of,612,O
several,612,O
benzodiazepines,612,B-Chemical
",",612,O
chemically,612,O
related,612,O
to,612,O
clotiazepam,612,B-Chemical
",",612,O
did,612,O
not,612,O
interfere,612,O
with,612,O
recovery,612,O
and,612,O
did,612,O
not,612,O
induce,612,O
any,612,O
relapse,612,O
of,612,O
hepatitis,612,B-Disease
.,612,O
This,613,O
observation,613,O
shows,613,O
that,613,O
clotiazepam,613,B-Chemical
can,613,O
induce,613,O
acute,613,O
hepatitis,613,B-Disease
and,613,O
suggests,613,O
that,613,O
there,613,O
is,613,O
no,613,O
cross,613,O
hepatotoxicity,613,B-Disease
between,613,O
clotiazepam,613,B-Chemical
and,613,O
several,613,O
benzodiazepines,613,B-Chemical
.,613,O
5-azacytidine,614,B-Chemical
potentiates,614,O
initiation,614,B-Disease
induced,614,I-Disease
by,614,I-Disease
carcinogens,614,I-Disease
in,614,O
rat,614,O
liver,614,O
.,614,O
To,615,O
test,615,O
the,615,O
validity,615,O
of,615,O
the,615,O
hypothesis,615,O
that,615,O
hypomethylation,615,O
of,615,O
DNA,615,O
plays,615,O
an,615,O
important,615,O
role,615,O
in,615,O
the,615,O
initiation,615,B-Disease
of,615,I-Disease
carcinogenic,615,I-Disease
process,615,I-Disease
",",615,O
5-azacytidine,615,B-Chemical
(,615,O
5-AzC,615,B-Chemical
),615,O
(,615,O
10,615,O
mg/kg,615,O
),615,O
",",615,O
an,615,O
inhibitor,615,O
of,615,O
DNA,615,O
methylation,615,O
",",615,O
was,615,O
given,615,O
to,615,O
rats,615,O
during,615,O
the,615,O
phase,615,O
of,615,O
repair,615,O
synthesis,615,O
induced,615,O
by,615,O
the,615,O
three,615,O
carcinogens,615,O
",",615,O
benzo,615,B-Chemical
[,615,I-Chemical
a,615,I-Chemical
],615,I-Chemical
-pyrene,615,I-Chemical
(,615,O
200,615,O
mg/kg,615,O
),615,O
",",615,O
N-methyl-N-nitrosourea,615,B-Chemical
(,615,O
60,615,O
mg/kg,615,O
),615,O
and,615,O
"1,2-dimethylhydrazine",615,B-Chemical
(,615,O
"1,2-DMH",615,B-Chemical
),615,O
(,615,O
100,615,O
mg/kg,615,O
),615,O
.,615,O
The,616,O
initiated,616,O
hepatocytes,616,O
in,616,O
the,616,O
liver,616,O
were,616,O
assayed,616,O
as,616,O
the,616,O
gamma-glutamyltransferase,616,O
(,616,O
gamma-GT,616,O
),616,O
positive,616,O
foci,616,O
formed,616,O
following,616,O
a,616,O
2-week,616,O
selection,616,O
regimen,616,O
consisting,616,O
of,616,O
dietary,616,O
0.02,616,O
%,616,O
2-acetylaminofluorene,616,B-Chemical
coupled,616,O
with,616,O
a,616,O
necrogenic,616,O
dose,616,O
of,616,O
CCl4,616,B-Chemical
.,616,O
The,617,O
results,617,O
obtained,617,O
indicate,617,O
that,617,O
with,617,O
all,617,O
three,617,O
carcinogens,617,O
",",617,O
administration,617,O
of,617,O
5-AzC,617,B-Chemical
during,617,O
repair,617,O
synthesis,617,O
increased,617,O
the,617,O
incidence,617,O
of,617,O
initiated,617,O
hepatocytes,617,O
",",617,O
for,617,O
example,617,O
10-20,617,O
foci/cm2,617,O
in,617,O
5-AzC,617,B-Chemical
and,617,O
carcinogen-treated,617,O
rats,617,O
compared,617,O
with,617,O
3-5,617,O
foci/cm2,617,O
in,617,O
rats,617,O
treated,617,O
with,617,O
carcinogen,617,O
only,617,O
.,617,O
Administration,618,O
of,618,O
[,618,B-Chemical
3H,618,I-Chemical
],618,I-Chemical
-5-azadeoxycytidine,618,I-Chemical
during,618,O
the,618,O
repair,618,O
synthesis,618,O
induced,618,O
by,618,O
"1,2-DMH",618,B-Chemical
further,618,O
showed,618,O
that,618,O
0.019,618,O
mol,618,O
%,618,O
of,618,O
cytosine,618,B-Chemical
residues,618,O
in,618,O
DNA,618,O
were,618,O
substituted,618,O
by,618,O
the,618,O
analogue,618,O
",",618,O
indicating,618,O
that,618,O
incorporation,618,O
of,618,O
5-AzC,618,B-Chemical
occurs,618,O
during,618,O
repair,618,O
synthesis,618,O
.,618,O
In,619,O
the,619,O
absence,619,O
of,619,O
the,619,O
carcinogen,619,O
",",619,O
5-AzC,619,B-Chemical
given,619,O
after,619,O
a,619,O
two,619,O
thirds,619,O
partial,619,O
hepatectomy,619,O
",",619,O
when,619,O
its,619,O
incorporation,619,O
should,619,O
be,619,O
maximum,619,O
",",619,O
failed,619,O
to,619,O
induce,619,O
any,619,O
gamma-GT,619,O
positive,619,O
foci,619,O
.,619,O
The,620,O
results,620,O
suggest,620,O
that,620,O
hypomethylation,620,O
of,620,O
DNA,620,O
per,620,O
se,620,O
may,620,O
not,620,O
be,620,O
sufficient,620,O
for,620,O
initiation,620,O
.,620,O
Perhaps,621,O
two,621,O
events,621,O
might,621,O
be,621,O
necessary,621,O
for,621,O
initiation,621,O
",",621,O
the,621,O
first,621,O
caused,621,O
by,621,O
the,621,O
carcinogen,621,O
and,621,O
a,621,O
second,621,O
involving,621,O
hypomethylation,621,O
of,621,O
DNA,621,O
.,621,O
Chronic,622,B-Disease
active,622,I-Disease
hepatitis,622,I-Disease
associated,622,O
with,622,O
diclofenac,622,B-Chemical
sodium,622,I-Chemical
therapy,622,O
.,622,O
Diclofenac,623,B-Chemical
sodium,623,I-Chemical
(,623,O
Voltarol,623,B-Chemical
",",623,O
Geigy,623,O
Pharmaceuticals,623,O
),623,O
is,623,O
a,623,O
non-steroidal,623,O
anti-inflammatory,623,O
derivative,623,O
of,623,O
phenylacetic,623,B-Chemical
acid,623,I-Chemical
.,623,O
Although,624,O
generally,624,O
well-tolerated,624,O
",",624,O
asymptomatic,624,O
abnormalities,624,B-Disease
of,624,I-Disease
liver,624,I-Disease
function,624,I-Disease
have,624,O
been,624,O
recorded,624,O
and,624,O
",",624,O
less,624,O
commonly,624,O
",",624,O
severe,624,O
hepatitis,624,B-Disease
induced,624,O
by,624,O
diclofenac,624,B-Chemical
.,624,O
The,625,O
patient,625,O
described,625,O
developed,625,O
chronic,625,B-Disease
active,625,I-Disease
hepatitis,625,I-Disease
after,625,O
six,625,O
months,625,O
therapy,625,O
with,625,O
diclofenac,625,B-Chemical
sodium,625,I-Chemical
which,625,O
progressed,625,O
despite,625,O
the,625,O
withdrawal,625,O
of,625,O
the,625,O
drug,625,O
",",625,O
a,625,O
finding,625,O
not,625,O
previously,625,O
reported,625,O
.,625,O
Arterial,626,O
hypertension,626,B-Disease
as,626,O
a,626,O
complication,626,O
of,626,O
prolonged,626,O
ketoconazole,626,B-Chemical
treatment,626,O
.,626,O
Two,627,O
of,627,O
14,627,O
patients,627,O
with,627,O
Cushing,627,B-Disease
's,627,I-Disease
syndrome,627,I-Disease
treated,627,O
on,627,O
a,627,O
long-term,627,O
basis,627,O
with,627,O
ketoconazole,627,B-Chemical
developed,627,O
sustained,627,O
hypertension,627,B-Disease
.,627,O
In,628,O
both,628,O
cases,628,O
normal,628,O
plasma,628,O
and,628,O
urinary,628,O
free,628,O
cortisol,628,B-Chemical
levels,628,O
had,628,O
been,628,O
achieved,628,O
following,628,O
ketoconazole,628,B-Chemical
therapy,628,O
",",628,O
yet,628,O
continuous,628,O
blood,628,O
pressure,628,O
monitoring,628,O
demonstrated,628,O
hypertension,628,B-Disease
31,628,O
(,628,O
patient,628,O
1,628,O
),628,O
and,628,O
52,628,O
weeks,628,O
(,628,O
patient,628,O
2,628,O
),628,O
after,628,O
treatment,628,O
.,628,O
In,629,O
patient,629,O
1,629,O
",",629,O
plasma,629,O
levels,629,O
of,629,O
deoxycorticosterone,629,B-Chemical
and,629,O
11-deoxycortisol,629,B-Chemical
were,629,O
elevated,629,O
.,629,O
In,630,O
patient,630,O
2,630,O
",",630,O
in,630,O
addition,630,O
to,630,O
an,630,O
increase,630,O
in,630,O
both,630,O
deoxycorticosterone,630,B-Chemical
and,630,O
11-deoxycortisol,630,B-Chemical
levels,630,O
",",630,O
plasma,630,O
aldosterone,630,B-Chemical
values,630,O
were,630,O
raised,630,O
",",630,O
with,630,O
a,630,O
concomitant,630,O
suppression,630,O
of,630,O
renin,630,O
levels,630,O
.,630,O
Our,631,O
findings,631,O
show,631,O
that,631,O
long-term,631,O
treatment,631,O
with,631,O
high,631,O
doses,631,O
of,631,O
ketoconazole,631,B-Chemical
may,631,O
induce,631,O
enzyme,631,O
blockade,631,O
leading,631,O
to,631,O
mineralocorticoid-related,631,O
hypertension,631,B-Disease
.,631,O
Effects,632,O
of,632,O
an,632,O
inhibitor,632,O
of,632,O
angiotensin,632,B-Chemical
converting,632,O
enzyme,632,O
(,632,O
Captopril,632,B-Chemical
),632,O
on,632,O
pulmonary,632,O
and,632,O
renal,632,O
insufficiency,632,O
due,632,O
to,632,O
intravascular,632,B-Disease
coagulation,632,I-Disease
in,632,O
the,632,O
rat,632,O
.,632,O
Induction,633,O
of,633,O
intravascular,633,B-Disease
coagulation,633,I-Disease
and,633,O
inhibition,633,O
of,633,O
fibrinolysis,633,O
by,633,O
injection,633,O
of,633,O
thrombin,633,O
and,633,O
tranexamic,633,B-Chemical
acid,633,I-Chemical
(,633,O
AMCA,633,B-Chemical
),633,O
in,633,O
the,633,O
rat,633,O
gives,633,O
rise,633,O
to,633,O
pulmonary,633,O
and,633,O
renal,633,O
insufficiency,633,O
resembling,633,O
that,633,O
occurring,633,O
after,633,O
trauma,633,B-Disease
or,633,O
sepsis,633,B-Disease
in,633,O
man,633,O
.,633,O
Injection,634,O
of,634,O
Captopril,634,B-Chemical
(,634,O
1,634,O
mg/kg,634,O
),634,O
",",634,O
an,634,O
inhibitor,634,O
of,634,O
angiotensin,634,B-Chemical
converting,634,O
enzyme,634,O
(,634,O
ACE,634,O
),634,O
",",634,O
reduced,634,O
both,634,O
pulmonary,634,O
and,634,O
renal,634,O
insufficiency,634,O
in,634,O
this,634,O
rat,634,O
model,634,O
.,634,O
The,635,O
lung,635,O
weights,635,O
were,635,O
lower,635,O
and,635,O
PaO2,635,O
was,635,O
improved,635,O
in,635,O
rats,635,O
given,635,O
this,635,O
enzyme-blocking,635,O
agent,635,O
.,635,O
The,636,O
contents,636,O
of,636,O
albumin,636,O
in,636,O
the,636,O
lungs,636,O
were,636,O
not,636,O
changed,636,O
",",636,O
indicating,636,O
that,636,O
Captopril,636,B-Chemical
did,636,O
not,636,O
influence,636,O
the,636,O
extravasation,636,O
of,636,O
protein,636,O
.,636,O
Renal,637,B-Disease
damage,637,I-Disease
as,637,O
reflected,637,O
by,637,O
an,637,O
increase,637,O
in,637,O
serum,637,O
urea,637,B-Chemical
and,637,O
in,637,O
kidney,637,O
weight,637,O
was,637,O
prevented,637,O
by,637,O
Captopril,637,B-Chemical
.,637,O
The,638,O
amount,638,O
of,638,O
fibrin,638,O
in,638,O
the,638,O
kidneys,638,O
was,638,O
also,638,O
considerably,638,O
lower,638,O
than,638,O
in,638,O
animals,638,O
which,638,O
received,638,O
thrombin,638,O
and,638,O
AMCA,638,B-Chemical
alone,638,O
.,638,O
It,639,O
is,639,O
suggested,639,O
that,639,O
the,639,O
effects,639,O
of,639,O
Captopril,639,B-Chemical
on,639,O
the,639,O
lungs,639,O
may,639,O
be,639,O
attributable,639,O
to,639,O
a,639,O
vasodilatory,639,O
effect,639,O
due,639,O
to,639,O
a,639,O
reduction,639,O
in,639,O
the,639,O
circulating,639,O
level,639,O
of,639,O
Angiotension,639,B-Chemical
II,639,I-Chemical
and,639,O
an,639,O
increase,639,O
in,639,O
prostacyclin,639,B-Chemical
(,639,O
secondary,639,O
to,639,O
an,639,O
increase,639,O
in,639,O
bradykinin,639,B-Chemical
),639,O
.,639,O
Captopril,640,B-Chemical
may,640,O
",",640,O
by,640,O
the,640,O
same,640,O
mechanism,640,O
",",640,O
reduce,640,O
the,640,O
increase,640,O
in,640,O
glomerular,640,O
filtration,640,O
that,640,O
is,640,O
known,640,O
to,640,O
occur,640,O
after,640,O
an,640,O
injection,640,O
of,640,O
thrombin,640,O
",",640,O
thereby,640,O
diminishing,640,O
the,640,O
aggregation,640,O
of,640,O
fibrin,640,O
monomers,640,O
in,640,O
the,640,O
glomeruli,640,O
",",640,O
with,640,O
the,640,O
result,640,O
that,640,O
less,640,O
fibrin,640,O
will,640,O
be,640,O
deposited,640,O
and,640,O
thus,640,O
less,640,O
kidney,640,B-Disease
damage,640,I-Disease
will,640,O
be,640,O
produced,640,O
.,640,O
Stroke,641,B-Disease
associated,641,O
with,641,O
cocaine,641,B-Chemical
use,641,O
.,641,O
We,642,O
describe,642,O
eight,642,O
patients,642,O
in,642,O
whom,642,O
cocaine,642,B-Chemical
use,642,O
was,642,O
related,642,O
to,642,O
stroke,642,B-Disease
and,642,O
review,642,O
39,642,O
cases,642,O
from,642,O
the,642,O
literature,642,O
.,642,O
Among,643,O
these,643,O
47,643,O
patients,643,O
the,643,O
mean,643,O
(,643,O
+/-,643,O
SD,643,O
),643,O
age,643,O
was,643,O
32.5,643,O
+/-,643,O
12.1,643,O
years,643,O
;,643,O
76,643,O
%,643,O
(,643,O
34/45,643,O
),643,O
were,643,O
men,643,O
.,643,O
Stroke,644,B-Disease
followed,644,O
cocaine,644,B-Chemical
use,644,O
by,644,O
inhalation,644,O
",",644,O
intranasal,644,O
",",644,O
intravenous,644,O
",",644,O
and,644,O
intramuscular,644,O
routes,644,O
.,644,O
Intracranial,645,B-Disease
aneurysms,645,I-Disease
or,645,O
arteriovenous,645,B-Disease
malformations,645,I-Disease
were,645,O
present,645,O
in,645,O
17,645,O
of,645,O
32,645,O
patients,645,O
studied,645,O
angiographically,645,O
or,645,O
at,645,O
autopsy,645,O
;,645,O
cerebral,645,B-Disease
vasculitis,645,I-Disease
was,645,O
present,645,O
in,645,O
two,645,O
patients,645,O
.,645,O
Cerebral,646,B-Disease
infarction,646,I-Disease
occurred,646,O
in,646,O
10,646,O
patients,646,O
(,646,O
22,646,O
%,646,O
),646,O
",",646,O
intracerebral,646,B-Disease
hemorrhage,646,I-Disease
in,646,O
22,646,O
(,646,O
49,646,O
%,646,O
),646,O
",",646,O
and,646,O
subarachnoid,646,B-Disease
hemorrhage,646,I-Disease
in,646,O
13,646,O
(,646,O
29,646,O
%,646,O
),646,O
.,646,O
These,647,O
data,647,O
indicate,647,O
that,647,O
(,647,O
1,647,O
),647,O
the,647,O
apparent,647,O
incidence,647,O
of,647,O
stroke,647,B-Disease
related,647,O
to,647,O
cocaine,647,B-Chemical
use,647,O
is,647,O
increasing,647,O
;,647,O
(,647,O
2,647,O
),647,O
cocaine-associated,647,B-Chemical
stroke,647,B-Disease
occurs,647,O
primarily,647,O
in,647,O
young,647,O
adults,647,O
;,647,O
(,647,O
3,647,O
),647,O
stroke,647,B-Disease
may,647,O
follow,647,O
any,647,O
route,647,O
of,647,O
cocaine,647,B-Chemical
administration,647,O
;,647,O
(,647,O
4,647,O
),647,O
stroke,647,B-Disease
after,647,O
cocaine,647,B-Chemical
use,647,O
is,647,O
frequently,647,O
associated,647,O
with,647,O
intracranial,647,B-Disease
aneurysms,647,I-Disease
and,647,O
arteriovenous,647,B-Disease
malformations,647,I-Disease
;,647,O
and,647,O
(,647,O
5,647,O
),647,O
in,647,O
cocaine-associated,647,B-Chemical
stroke,647,B-Disease
",",647,O
the,647,O
frequency,647,O
of,647,O
intracranial,647,B-Disease
hemorrhage,647,I-Disease
exceeds,647,O
that,647,O
of,647,O
cerebral,647,B-Disease
infarction,647,I-Disease
.,647,O
A,648,O
randomized,648,O
comparison,648,O
of,648,O
labetalol,648,B-Chemical
and,648,O
nitroprusside,648,B-Chemical
for,648,O
induced,648,O
hypotension,648,B-Disease
.,648,O
In,649,O
a,649,O
randomized,649,O
study,649,O
",",649,O
labetalol-induced,649,B-Chemical
hypotension,649,B-Disease
and,649,O
nitroprusside-induced,649,B-Chemical
hypotension,649,B-Disease
were,649,O
compared,649,O
in,649,O
20,649,O
patients,649,O
(,649,O
10,649,O
in,649,O
each,649,O
group,649,O
),649,O
scheduled,649,O
for,649,O
major,649,O
orthopedic,649,O
procedures,649,O
.,649,O
Each,650,O
patient,650,O
was,650,O
subjected,650,O
to,650,O
an,650,O
identical,650,O
anesthetic,650,O
protocol,650,O
and,650,O
similar,650,O
drug-induced,650,O
reductions,650,B-Disease
in,650,I-Disease
mean,650,I-Disease
arterial,650,I-Disease
blood,650,I-Disease
pressure,650,I-Disease
(,650,O
BP,650,O
),650,O
(,650,O
50,650,O
to,650,O
55,650,O
mmHg,650,O
),650,O
.,650,O
Nitroprusside,651,O
infusion,651,O
was,651,O
associated,651,O
with,651,O
a,651,O
significant,651,O
(,651,O
p,651,O
less,651,O
than,651,O
0.05,651,O
),651,O
increase,651,B-Disease
in,651,I-Disease
heart,651,I-Disease
rate,651,I-Disease
and,651,I-Disease
cardiac,651,I-Disease
output,651,I-Disease
;,651,O
rebound,651,O
hypertension,651,B-Disease
was,651,O
observed,651,O
in,651,O
three,651,O
patients,651,O
after,651,O
discontinuation,651,O
of,651,O
nitroprusside,651,B-Chemical
.,651,O
Labetalol,652,B-Chemical
administration,652,O
was,652,O
not,652,O
associated,652,O
with,652,O
any,652,O
of,652,O
these,652,O
findings,652,O
.,652,O
Arterial,653,O
PO2,653,B-Chemical
decreased,653,O
in,653,O
both,653,O
groups,653,O
.,653,O
It,654,O
was,654,O
concluded,654,O
that,654,O
labetalol,654,B-Chemical
offers,654,O
advantages,654,O
over,654,O
nitroprusside,654,B-Chemical
.,654,O
Sodium,655,B-Chemical
status,655,O
influences,655,O
chronic,655,O
amphotericin,655,B-Chemical
B,655,I-Chemical
nephrotoxicity,655,B-Disease
in,655,O
rats,655,O
.,655,O
The,656,O
nephrotoxic,656,B-Disease
potential,656,O
of,656,O
amphotericin,656,B-Chemical
B,656,I-Chemical
(,656,O
5,656,O
mg/kg,656,O
per,656,O
day,656,O
intraperitoneally,656,O
for,656,O
3,656,O
weeks,656,O
),656,O
has,656,O
been,656,O
investigated,656,O
in,656,O
salt-depleted,656,O
",",656,O
normal-salt,656,O
",",656,O
and,656,O
salt-loaded,656,O
rats,656,O
.,656,O
In,657,O
salt-depleted,657,O
rats,657,O
",",657,O
amphotericin,657,B-Chemical
B,657,I-Chemical
decreased,657,O
creatinine,657,B-Chemical
clearance,657,O
linearly,657,O
with,657,O
time,657,O
",",657,O
with,657,O
an,657,O
85,657,O
%,657,O
reduction,657,O
by,657,O
week,657,O
3,657,O
.,657,O
In,658,O
contrast,658,O
",",658,O
in,658,O
normal-salt,658,O
rats,658,O
creatinine,658,B-Chemical
clearance,658,O
was,658,O
decreased,658,O
but,658,O
to,658,O
a,658,O
lesser,658,O
extent,658,O
at,658,O
week,658,O
2,658,O
and,658,O
3,658,O
",",658,O
and,658,O
in,658,O
salt-loaded,658,O
rats,658,O
creatinine,658,B-Chemical
clearance,658,O
did,658,O
not,658,O
change,658,O
for,658,O
2,658,O
weeks,658,O
and,658,O
was,658,O
decreased,658,O
by,658,O
43,658,O
%,658,O
at,658,O
week,658,O
3,658,O
.,658,O
All,659,O
rats,659,O
in,659,O
the,659,O
sodium-depleted,659,B-Chemical
group,659,O
had,659,O
histopathological,659,O
evidence,659,O
of,659,O
patchy,659,O
tubular,659,O
cytoplasmic,659,O
degeneration,659,O
in,659,O
tubules,659,O
that,659,O
was,659,O
not,659,O
observed,659,O
in,659,O
any,659,O
normal-salt,659,O
or,659,O
salt-loaded,659,O
rat,659,O
.,659,O
Concentrations,660,O
of,660,O
amphotericin,660,B-Chemical
B,660,I-Chemical
in,660,O
plasma,660,O
were,660,O
not,660,O
significantly,660,O
different,660,O
among,660,O
the,660,O
three,660,O
groups,660,O
at,660,O
any,660,O
time,660,O
during,660,O
the,660,O
study,660,O
.,660,O
However,661,O
",",661,O
at,661,O
the,661,O
end,661,O
of,661,O
3,661,O
weeks,661,O
",",661,O
amphotericin,661,B-Chemical
B,661,I-Chemical
levels,661,O
in,661,O
the,661,O
kidneys,661,O
and,661,O
liver,661,O
were,661,O
significantly,661,O
higher,661,O
in,661,O
salt-depleted,661,O
and,661,O
normal-salt,661,O
rats,661,O
than,661,O
those,661,O
in,661,O
salt-loaded,661,O
rats,661,O
",",661,O
with,661,O
plasma/kidney,661,O
ratios,661,O
of,661,O
21,661,O
",",661,O
14,661,O
",",661,O
and,661,O
8,661,O
in,661,O
salt-depleted,661,O
",",661,O
normal-salt,661,O
",",661,O
and,661,O
salt-loaded,661,O
rats,661,O
",",661,O
respectively,661,O
.,661,O
In,662,O
conclusion,662,O
",",662,O
reductions,662,O
in,662,O
creatinine,662,B-Chemical
clearance,662,O
and,662,O
renal,662,O
amphotericin,662,B-Chemical
B,662,I-Chemical
accumulation,662,O
after,662,O
chronic,662,O
amphotericin,662,B-Chemical
B,662,I-Chemical
administration,662,O
were,662,O
enhanced,662,O
by,662,O
salt,662,O
depletion,662,O
and,662,O
attenuated,662,O
by,662,O
sodium,662,B-Chemical
loading,662,O
in,662,O
rats,662,O
.,662,O
Flestolol,663,B-Chemical
:,663,O
an,663,O
ultra-short-acting,663,O
beta-adrenergic,663,O
blocking,663,O
agent,663,O
.,663,O
Flestolol,664,B-Chemical
(,664,O
ACC-9089,664,B-Chemical
),664,O
is,664,O
a,664,O
nonselective,664,O
",",664,O
competitive,664,O
",",664,O
ultra-short-acting,664,O
beta-adrenergic,664,O
blocking,664,O
agent,664,O
",",664,O
without,664,O
any,664,O
intrinsic,664,O
sympathomimetic,664,O
activity,664,O
.,664,O
Flestolol,665,B-Chemical
is,665,O
metabolized,665,O
by,665,O
plasma,665,O
esterases,665,O
and,665,O
has,665,O
an,665,O
elimination,665,O
half-life,665,O
of,665,O
approximately,665,O
6.5,665,O
minutes,665,O
.,665,O
This,666,O
agent,666,O
was,666,O
well,666,O
tolerated,666,O
in,666,O
healthy,666,O
volunteers,666,O
at,666,O
doses,666,O
up,666,O
to,666,O
100,666,O
micrograms/kg/min,666,O
.,666,O
In,667,O
long-term,667,O
infusion,667,O
studies,667,O
",",667,O
flestolol,667,B-Chemical
was,667,O
well,667,O
tolerated,667,O
at,667,O
the,667,O
effective,667,O
beta-blocking,667,O
dose,667,O
(,667,O
5,667,O
micrograms/kg/min,667,O
),667,O
for,667,O
up,667,O
to,667,O
seven,667,O
days,667,O
.,667,O
Flestolol,668,B-Chemical
blood,668,O
concentrations,668,O
increased,668,O
linearly,668,O
with,668,O
increasing,668,O
dose,668,O
and,668,O
good,668,O
correlation,668,O
exists,668,O
between,668,O
blood,668,O
concentrations,668,O
of,668,O
flestolol,668,B-Chemical
and,668,O
beta-adrenergic,668,O
blockade,668,O
.,668,O
Flestolol,669,B-Chemical
produced,669,O
a,669,O
dose-dependent,669,O
attenuation,669,O
of,669,O
isoproterenol-induced,669,B-Chemical
tachycardia,669,B-Disease
.,669,O
Electrophysiologic,670,O
and,670,O
hemodynamic,670,O
effects,670,O
of,670,O
flestolol,670,B-Chemical
are,670,O
similar,670,O
to,670,O
those,670,O
of,670,O
other,670,O
beta,670,O
blockers,670,O
.,670,O
In,671,O
contrast,671,O
with,671,O
other,671,O
beta,671,O
blockers,671,O
",",671,O
flestolol-induced,671,B-Chemical
effects,671,O
reverse,671,O
rapidly,671,O
(,671,O
within,671,O
30,671,O
minutes,671,O
),671,O
following,671,O
discontinuation,671,O
because,671,O
of,671,O
its,671,O
short,671,O
half-life,671,O
.,671,O
Flestolol,672,B-Chemical
effectively,672,O
reduced,672,O
heart,672,O
rate,672,O
in,672,O
patients,672,O
with,672,O
supraventricular,672,B-Disease
tachyarrhythmia,672,I-Disease
.,672,O
In,673,O
patients,673,O
with,673,O
unstable,673,B-Disease
angina,673,I-Disease
",",673,O
flestolol,673,B-Chemical
infusion,673,O
was,673,O
found,673,O
to,673,O
be,673,O
safe,673,O
and,673,O
effective,673,O
in,673,O
controlling,673,O
chest,673,B-Disease
pain,673,I-Disease
.,673,O
It,674,O
is,674,O
concluded,674,O
that,674,O
flestolol,674,B-Chemical
is,674,O
a,674,O
potent,674,O
",",674,O
well-tolerated,674,O
",",674,O
ultra-short-acting,674,O
beta-adrenergic,674,O
blocking,674,O
agent,674,O
.,674,O
Use,675,O
of,675,O
flestolol,675,B-Chemical
in,675,O
the,675,O
critical,675,O
care,675,O
setting,675,O
is,675,O
currently,675,O
undergoing,675,O
investigation,675,O
.,675,O
Immunohistochemical,676,O
",",676,O
electron,676,O
microscopic,676,O
and,676,O
morphometric,676,O
studies,676,O
of,676,O
estrogen-induced,676,B-Chemical
rat,676,O
prolactinomas,676,B-Disease
after,676,O
bromocriptine,676,B-Chemical
treatment,676,O
.,676,O
To,677,O
clarify,677,O
the,677,O
effects,677,O
of,677,O
bromocriptine,677,B-Chemical
on,677,O
prolactinoma,677,B-Disease
cells,677,O
in,677,O
vivo,677,O
",",677,O
immunohistochemical,677,O
",",677,O
ultrastructural,677,O
and,677,O
morphometrical,677,O
analyses,677,O
were,677,O
applied,677,O
to,677,O
estrogen-induced,677,B-Chemical
rat,677,O
prolactinoma,677,B-Disease
cells,677,O
1,677,O
h,677,O
and,677,O
6,677,O
h,677,O
after,677,O
injection,677,O
of,677,O
bromocriptine,677,B-Chemical
(,677,O
3,677,O
mg/kg,677,O
of,677,O
body,677,O
weight,677,O
),677,O
.,677,O
One,678,O
h,678,O
after,678,O
treatment,678,O
",",678,O
serum,678,O
prolactin,678,O
levels,678,O
decreased,678,O
markedly,678,O
.,678,O
Electron,679,O
microscopy,679,O
disclosed,679,O
many,679,O
secretory,679,O
granules,679,O
",",679,O
slightly,679,O
distorted,679,O
rough,679,O
endoplasmic,679,O
reticulum,679,O
",",679,O
and,679,O
partially,679,O
dilated,679,O
Golgi,679,O
cisternae,679,O
in,679,O
the,679,O
prolactinoma,679,B-Disease
cells,679,O
.,679,O
Morphometric,680,O
analysis,680,O
revealed,680,O
that,680,O
the,680,O
volume,680,O
density,680,O
of,680,O
secretory,680,O
granules,680,O
increased,680,O
",",680,O
while,680,O
the,680,O
volume,680,O
density,680,O
of,680,O
cytoplasmic,680,O
microtubules,680,O
decreased,680,O
.,680,O
These,681,O
findings,681,O
suggest,681,O
that,681,O
lowered,681,O
serum,681,O
prolactin,681,O
levels,681,O
in,681,O
the,681,O
early,681,O
phase,681,O
of,681,O
bromocriptine,681,B-Chemical
treatment,681,O
may,681,O
result,681,O
from,681,O
an,681,O
impaired,681,O
secretion,681,O
of,681,O
prolactin,681,O
due,681,O
to,681,O
decreasing,681,O
numbers,681,O
of,681,O
cytoplasmic,681,O
microtubules,681,O
.,681,O
At,682,O
6,682,O
h,682,O
after,682,O
injection,682,O
",",682,O
serum,682,O
prolactin,682,O
levels,682,O
were,682,O
still,682,O
considerably,682,O
lower,682,O
than,682,O
in,682,O
controls,682,O
.,682,O
The,683,O
prolactinoma,683,B-Disease
cells,683,O
at,683,O
this,683,O
time,683,O
were,683,O
well,683,O
granulated,683,O
",",683,O
with,683,O
vesiculated,683,O
rough,683,O
endoplasmic,683,O
reticulum,683,O
and,683,O
markedly,683,O
dilated,683,O
Golgi,683,O
cisternae,683,O
.,683,O
Electron,684,O
microscopical,684,O
immunohistochemistry,684,O
revealed,684,O
positive,684,O
reaction,684,O
products,684,O
noted,684,O
on,684,O
the,684,O
secretory,684,O
granules,684,O
",",684,O
Golgi,684,O
cisternae,684,O
",",684,O
and,684,O
endoplasmic,684,O
reticulum,684,O
of,684,O
the,684,O
untreated,684,O
rat,684,O
prolactinoma,684,B-Disease
cells,684,O
.,684,O
However,685,O
",",685,O
only,685,O
secretory,685,O
granules,685,O
showed,685,O
the,685,O
positive,685,O
reaction,685,O
products,685,O
for,685,O
prolactin,685,O
6,685,O
h,685,O
after,685,O
bromocriptine,685,B-Chemical
treatment,685,O
of,685,O
the,685,O
adenoma,685,B-Disease
cells,685,O
.,685,O
An,686,O
increase,686,O
in,686,O
the,686,O
volume,686,O
density,686,O
of,686,O
secretory,686,O
granules,686,O
and,686,O
a,686,O
decrease,686,O
in,686,O
the,686,O
volume,686,O
densities,686,O
of,686,O
rough,686,O
endoplasmic,686,O
reticulum,686,O
and,686,O
microtubules,686,O
was,686,O
determined,686,O
by,686,O
morphometric,686,O
analysis,686,O
",",686,O
suggesting,686,O
that,686,O
bromocriptine,686,B-Chemical
inhibits,686,O
protein,686,O
synthesis,686,O
as,686,O
well,686,O
as,686,O
bringing,686,O
about,686,O
a,686,O
disturbance,686,O
of,686,O
the,686,O
prolactin,686,O
secretion,686,O
.,686,O
Sulfasalazine-induced,687,B-Chemical
lupus,687,B-Disease
erythematosus,687,I-Disease
.,687,O
Pneumonitis,688,B-Disease
",",688,O
bilateral,688,O
pleural,688,B-Disease
effusions,688,I-Disease
",",688,O
echocardiographic,688,O
evidence,688,O
of,688,O
cardiac,688,B-Disease
tamponade,688,I-Disease
",",688,O
and,688,O
positive,688,O
autoantibodies,688,O
developed,688,O
in,688,O
a,688,O
43-year-old,688,O
man,688,O
",",688,O
who,688,O
was,688,O
receiving,688,O
long-term,688,O
sulfasalazine,688,B-Chemical
therapy,688,O
for,688,O
chronic,688,O
ulcerative,688,B-Disease
colitis,688,I-Disease
.,688,O
After,689,O
cessation,689,O
of,689,O
the,689,O
sulfasalazine,689,B-Chemical
and,689,O
completion,689,O
of,689,O
a,689,O
six-week,689,O
course,689,O
of,689,O
corticosteroids,689,O
",",689,O
these,689,O
problems,689,O
resolved,689,O
over,689,O
a,689,O
period,689,O
of,689,O
four,689,O
to,689,O
six,689,O
months,689,O
.,689,O
It,690,O
is,690,O
suggested,690,O
that,690,O
the,690,O
patient,690,O
had,690,O
sulfasalazine-induced,690,B-Chemical
lupus,690,B-Disease
",",690,O
which,690,O
manifested,690,O
with,690,O
serositis,690,B-Disease
and,690,O
pulmonary,690,O
parenchymal,690,O
involvement,690,O
in,690,O
the,690,O
absence,690,O
of,690,O
joint,690,O
symptoms,690,O
.,690,O
Physicians,691,O
who,691,O
use,691,O
sulfasalazine,691,B-Chemical
to,691,O
treat,691,O
patients,691,O
with,691,O
inflammatory,691,B-Disease
bowel,691,I-Disease
disease,691,I-Disease
should,691,O
be,691,O
aware,691,O
of,691,O
the,691,O
signs,691,O
of,691,O
sulfasalazine-induced,691,B-Chemical
lupus,691,B-Disease
syndrome,691,I-Disease
.,691,O
Chronic,692,O
carbamazepine,692,B-Chemical
treatment,692,O
in,692,O
the,692,O
rat,692,O
:,692,O
efficacy,692,O
",",692,O
toxicity,692,B-Disease
",",692,O
and,692,O
effect,692,O
on,692,O
plasma,692,O
and,692,O
tissue,692,O
folate,692,B-Chemical
concentrations,692,O
.,692,O
Folate,693,B-Chemical
depletion,693,O
has,693,O
often,693,O
been,693,O
a,693,O
problem,693,O
in,693,O
chronic,693,O
antiepileptic,693,O
drug,693,O
(,693,O
AED,693,O
),693,O
therapy,693,O
.,693,O
Carbamazepine,694,B-Chemical
(,694,O
CBZ,694,B-Chemical
),694,O
",",694,O
a,694,O
commonly,694,O
used,694,O
AED,694,O
",",694,O
has,694,O
been,694,O
implicated,694,O
in,694,O
some,694,O
clinical,694,O
studies,694,O
.,694,O
A,695,O
rat,695,O
model,695,O
was,695,O
developed,695,O
to,695,O
examine,695,O
the,695,O
effects,695,O
of,695,O
chronic,695,O
CBZ,695,B-Chemical
treatment,695,O
on,695,O
folate,695,B-Chemical
concentrations,695,O
in,695,O
the,695,O
rat,695,O
.,695,O
In,696,O
the,696,O
course,696,O
of,696,O
developing,696,O
this,696,O
model,696,O
",",696,O
a,696,O
common,696,O
vehicle,696,O
",",696,O
propylene,696,B-Chemical
glycol,696,I-Chemical
",",696,O
by,696,O
itself,696,O
in,696,O
high,696,O
doses,696,O
",",696,O
was,696,O
found,696,O
to,696,O
exhibit,696,O
protective,696,O
properties,696,O
against,696,O
induced,696,O
seizures,696,B-Disease
and,696,O
inhibited,696,O
weight,696,B-Disease
gain,696,I-Disease
.,696,O
Seizures,697,B-Disease
induced,697,O
by,697,O
hexafluorodiethyl,697,B-Chemical
ether,697,I-Chemical
(,697,O
HFDE,697,B-Chemical
),697,O
were,697,O
also,697,O
found,697,O
to,697,O
be,697,O
a,697,O
more,697,O
sensitive,697,O
measure,697,O
of,697,O
protection,697,O
by,697,O
CBZ,697,B-Chemical
than,697,O
seizures,697,B-Disease
induced,697,O
by,697,O
maximal,697,O
electroshock,697,O
(,697,O
MES,697,O
),697,O
.,697,O
Oral,698,O
administration,698,O
of,698,O
CBZ,698,B-Chemical
as,698,O
an,698,O
aqueous,698,O
suspension,698,O
every,698,O
8,698,O
h,698,O
at,698,O
a,698,O
dose,698,O
of,698,O
250,698,O
mg/kg,698,O
was,698,O
continuously,698,O
protective,698,O
against,698,O
HFDE-induced,698,B-Chemical
seizures,698,B-Disease
and,698,O
was,698,O
minimally,698,O
toxic,698,O
as,698,O
measured,698,O
by,698,O
weight,698,B-Disease
gain,698,I-Disease
over,698,O
8,698,O
weeks,698,O
of,698,O
treatment,698,O
.,698,O
The,699,O
CBZ,699,B-Chemical
levels,699,O
measured,699,O
in,699,O
plasma,699,O
and,699,O
brain,699,O
of,699,O
these,699,O
animals,699,O
",",699,O
however,699,O
",",699,O
were,699,O
below,699,O
those,699,O
normally,699,O
considered,699,O
protective,699,O
.,699,O
This,700,O
treatment,700,O
with,700,O
CBZ,700,B-Chemical
had,700,O
no,700,O
apparent,700,O
adverse,700,O
effect,700,O
on,700,O
folate,700,B-Chemical
concentrations,700,O
in,700,O
the,700,O
rat,700,O
",",700,O
and,700,O
",",700,O
indeed,700,O
",",700,O
the,700,O
folate,700,B-Chemical
concentration,700,O
increased,700,O
in,700,O
liver,700,O
after,700,O
6,700,O
weeks,700,O
of,700,O
treatment,700,O
and,700,O
in,700,O
plasma,700,O
at,700,O
8,700,O
weeks,700,O
of,700,O
treatment,700,O
.,700,O
Dipyridamole-induced,701,B-Chemical
myocardial,701,B-Disease
ischemia,701,I-Disease
.,701,O
Angina,702,B-Disease
and,702,O
ischemic,702,O
electrocardiographic,702,O
changes,702,O
occurred,702,O
after,702,O
administration,702,O
of,702,O
oral,702,O
dipyridamole,702,B-Chemical
in,702,O
four,702,O
patients,702,O
awaiting,702,O
urgent,702,O
myocardial,702,O
revascularization,702,O
procedures,702,O
.,702,O
To,703,O
our,703,O
knowledge,703,O
",",703,O
this,703,O
has,703,O
not,703,O
previously,703,O
been,703,O
reported,703,O
as,703,O
a,703,O
side,703,O
effect,703,O
of,703,O
preoperative,703,O
dipyridamole,703,B-Chemical
therapy,703,O
",",703,O
although,703,O
dipyridamole-induced,703,B-Chemical
myocardial,703,B-Disease
ischemia,703,I-Disease
has,703,O
been,703,O
demonstrated,703,O
to,703,O
occur,703,O
in,703,O
animals,703,O
and,703,O
humans,703,O
with,703,O
coronary,703,B-Disease
artery,703,I-Disease
disease,703,I-Disease
.,703,O
Epicardial,704,O
coronary,704,O
collateral,704,O
vessels,704,O
were,704,O
demonstrated,704,O
in,704,O
all,704,O
four,704,O
patients,704,O
;,704,O
a,704,O
coronary,704,O
``,704,O
steal,704,O
'',704,O
phenomenon,704,O
may,704,O
be,704,O
the,704,O
mechanism,704,O
of,704,O
the,704,O
dipyridamole-induced,704,B-Chemical
ischemia,704,B-Disease
observed,704,O
.,704,O
Inhibition,705,O
of,705,O
sympathoadrenal,705,O
activity,705,O
by,705,O
atrial,705,O
natriuretic,705,O
factor,705,O
in,705,O
dogs,705,O
.,705,O
In,706,O
six,706,O
conscious,706,O
",",706,O
trained,706,O
dogs,706,O
",",706,O
maintained,706,O
on,706,O
a,706,O
normal,706,O
sodium,706,B-Chemical
intake,706,O
of,706,O
2,706,O
to,706,O
4,706,O
mEq/kg/day,706,O
",",706,O
sympathetic,706,O
activity,706,O
was,706,O
assessed,706,O
as,706,O
the,706,O
release,706,O
rate,706,O
of,706,O
norepinephrine,706,B-Chemical
and,706,O
epinephrine,706,B-Chemical
during,706,O
15-minute,706,O
i.v,706,O
.,706,O
infusions,707,O
of,707,O
human,707,O
alpha-atrial,707,O
natriuretic,707,O
factor,707,O
.,707,O
Mean,708,O
arterial,708,O
pressure,708,O
(,708,O
as,708,O
a,708,O
percentage,708,O
of,708,O
control,708,O
+/-,708,O
SEM,708,O
),708,O
during,708,O
randomized,708,O
infusions,708,O
of,708,O
0.03,708,O
",",708,O
0.1,708,O
",",708,O
0.3,708,O
",",708,O
or,708,O
1.0,708,O
microgram/kg/min,708,O
was,708,O
99,708,O
+/-,708,O
1,708,O
",",708,O
95,708,O
+/-,708,O
1,708,O
(,708,O
p,708,O
less,708,O
than,708,O
0.05,708,O
),708,O
",",708,O
93,708,O
+/-,708,O
1,708,O
(,708,O
p,708,O
less,708,O
than,708,O
0.01,708,O
),708,O
",",708,O
or,708,O
79,708,O
+/-,708,O
6,708,O
%,708,O
(,708,O
p,708,O
less,708,O
than,708,O
0.001,708,O
),708,O
",",708,O
respectively,708,O
",",708,O
but,708,O
no,708,O
tachycardia,708,B-Disease
and,708,O
no,708,O
augmentation,708,O
of,708,O
the,708,O
norepinephrine,708,B-Chemical
release,708,O
rate,708,O
(,708,O
up,708,O
to,708,O
0.3,708,O
microgram/kg/min,708,O
),708,O
were,708,O
observed,708,O
",",708,O
which,708,O
is,708,O
in,708,O
contrast,708,O
to,708,O
comparable,708,O
hypotension,708,B-Disease
induced,708,O
by,708,O
hydralazine,708,B-Chemical
or,708,O
nitroglycerin,708,B-Chemical
.,708,O
The,709,O
release,709,O
rate,709,O
of,709,O
epinephrine,709,B-Chemical
(,709,O
control,709,O
",",709,O
6.7,709,O
+/-,709,O
0.6,709,O
ng/kg/min,709,O
),709,O
declined,709,O
immediately,709,O
during,709,O
infusions,709,O
of,709,O
atrial,709,O
natriuretic,709,O
factor,709,O
to,709,O
a,709,O
minimum,709,O
of,709,O
49,709,O
+/-,709,O
5,709,O
%,709,O
of,709,O
control,709,O
(,709,O
p,709,O
less,709,O
than,709,O
0.001,709,O
),709,O
during,709,O
0.1,709,O
microgram/kg/min,709,O
and,709,O
to,709,O
63,709,O
+/-,709,O
5,709,O
%,709,O
(,709,O
0.1,709,O
greater,709,O
than,709,O
p,709,O
greater,709,O
than,709,O
0.05,709,O
),709,O
or,709,O
95,709,O
+/-,709,O
13,709,O
%,709,O
(,709,O
not,709,O
significant,709,O
),709,O
during,709,O
0.3,709,O
or,709,O
1.0,709,O
microgram/kg/min,709,O
.,709,O
Steady,710,O
state,710,O
arterial,710,O
plasma,710,O
concentrations,710,O
of,710,O
atrial,710,O
natriuretic,710,O
factor,710,O
were,710,O
39,710,O
+/-,710,O
10,710,O
pg/ml,710,O
(,710,O
n,710,O
=,710,O
6,710,O
),710,O
during,710,O
infusions,710,O
of,710,O
saline,710,O
and,710,O
284,710,O
+/-,710,O
24,710,O
pg/ml,710,O
(,710,O
n,710,O
=,710,O
6,710,O
),710,O
and,710,O
1520,710,O
+/-,710,O
300,710,O
pg/ml,710,O
(,710,O
n,710,O
=,710,O
9,710,O
),710,O
during,710,O
0.03,710,O
and,710,O
0.1,710,O
microgram/kg/min,710,O
infusions,710,O
of,710,O
the,710,O
factor,710,O
.,710,O
(,711,O
ABSTRACT,711,O
TRUNCATED,711,O
AT,711,O
250,711,O
WORDS,711,O
),711,O
Inhibition,712,O
of,712,O
immunoreactive,712,O
corticotropin-releasing,712,O
factor,712,O
secretion,712,O
into,712,O
the,712,O
hypophysial-portal,712,O
circulation,712,O
by,712,O
delayed,712,O
glucocorticoid,712,O
feedback,712,O
.,712,O
Nitroprusside-induced,713,B-Chemical
hypotension,713,B-Disease
evokes,713,O
ACTH,713,O
secretion,713,O
which,713,O
is,713,O
primarily,713,O
mediated,713,O
by,713,O
enhanced,713,O
secretion,713,O
of,713,O
immunoreactive,713,O
corticotropin-releasing,713,O
factor,713,O
(,713,O
irCRF,713,O
),713,O
into,713,O
the,713,O
hypophysial-portal,713,O
circulation,713,O
.,713,O
Portal,714,O
plasma,714,O
concentrations,714,O
of,714,O
neither,714,O
arginine,714,B-Chemical
vasopressin,714,I-Chemical
nor,714,O
oxytocin,714,B-Chemical
are,714,O
significantly,714,O
altered,714,O
in,714,O
this,714,O
paradigm,714,O
.,714,O
Application,715,O
of,715,O
a,715,O
delayed,715,O
feedback,715,O
signal,715,O
",",715,O
in,715,O
the,715,O
form,715,O
of,715,O
a,715,O
2-h,715,O
systemic,715,O
corticosterone,715,B-Chemical
infusion,715,O
in,715,O
urethane-anesthetized,715,B-Chemical
rats,715,O
with,715,O
pharmacological,715,O
blockade,715,O
of,715,O
glucocorticoid,715,O
synthesis,715,O
",",715,O
is,715,O
without,715,O
effect,715,O
on,715,O
the,715,O
resting,715,O
secretion,715,O
of,715,O
arginine,715,B-Chemical
vasopressin,715,I-Chemical
and,715,O
oxytocin,715,B-Chemical
at,715,O
any,715,O
corticosterone,715,B-Chemical
feedback,715,O
dose,715,O
tested,715,O
.,715,O
Resting,716,O
irCRF,716,O
levels,716,O
are,716,O
suppressed,716,O
only,716,O
at,716,O
the,716,O
highest,716,O
corticosterone,716,B-Chemical
infusion,716,O
rate,716,O
",",716,O
which,716,O
resulted,716,O
in,716,O
systemic,716,O
corticosterone,716,B-Chemical
levels,716,O
of,716,O
40,716,O
micrograms/dl,716,O
.,716,O
Suppression,717,O
of,717,O
irCRF,717,O
secretion,717,O
in,717,O
response,717,O
to,717,O
nitroprusside-induced,717,B-Chemical
hypotension,717,B-Disease
is,717,O
observed,717,O
and,717,O
occurs,717,O
at,717,O
a,717,O
plasma,717,O
corticosterone,717,B-Chemical
level,717,O
between,717,O
8-12,717,O
micrograms/dl,717,O
.,717,O
These,718,O
studies,718,O
provide,718,O
further,718,O
evidence,718,O
for,718,O
a,718,O
strong,718,O
central,718,O
component,718,O
of,718,O
the,718,O
delayed,718,O
feedback,718,O
process,718,O
which,718,O
is,718,O
mediated,718,O
by,718,O
modulation,718,O
of,718,O
irCRF,718,O
release,718,O
.,718,O
Noradrenergic,719,O
involvement,719,O
in,719,O
catalepsy,719,B-Disease
induced,719,O
by,719,O
delta,719,B-Chemical
9-tetrahydrocannabinol,719,I-Chemical
.,719,O
In,720,O
order,720,O
to,720,O
elucidate,720,O
the,720,O
role,720,O
of,720,O
the,720,O
catecholaminergic,720,O
system,720,O
in,720,O
the,720,O
cataleptogenic,720,O
effect,720,O
of,720,O
delta,720,B-Chemical
9-tetrahydrocannabinol,720,I-Chemical
(,720,O
THC,720,B-Chemical
),720,O
",",720,O
the,720,O
effect,720,O
of,720,O
pretreatment,720,O
with,720,O
6-hydroxydopamine,720,B-Chemical
(,720,O
6-OHDA,720,B-Chemical
),720,O
or,720,O
with,720,O
desipramine,720,B-Chemical
and,720,O
6-OHDA,720,B-Chemical
and,720,O
lesions,720,O
of,720,O
the,720,O
locus,720,O
coeruleus,720,O
were,720,O
investigated,720,O
in,720,O
rats,720,O
.,720,O
The,721,O
cataleptogenic,721,O
effect,721,O
of,721,O
THC,721,B-Chemical
was,721,O
significantly,721,O
reduced,721,O
in,721,O
rats,721,O
treated,721,O
with,721,O
6-OHDA,721,B-Chemical
and,721,O
in,721,O
rats,721,O
with,721,O
lesions,721,O
of,721,O
the,721,O
locus,721,O
coeruleus,721,O
but,721,O
not,721,O
in,721,O
rats,721,O
treated,721,O
with,721,O
desipramine,721,B-Chemical
and,721,O
6-OHDA,721,B-Chemical
",",721,O
as,721,O
compared,721,O
with,721,O
control,721,O
rats,721,O
.,721,O
On,722,O
the,722,O
contrary,722,O
",",722,O
the,722,O
cataleptogenic,722,O
effect,722,O
of,722,O
haloperidol,722,B-Chemical
was,722,O
significantly,722,O
reduced,722,O
in,722,O
rats,722,O
treated,722,O
with,722,O
desipramine,722,B-Chemical
and,722,O
6-OHDA,722,B-Chemical
but,722,O
not,722,O
in,722,O
rats,722,O
treated,722,O
with,722,O
6-OHDA,722,B-Chemical
or,722,O
in,722,O
rats,722,O
with,722,O
lesions,722,O
of,722,O
the,722,O
locus,722,O
coeruleus,722,O
.,722,O
These,723,O
results,723,O
indicate,723,O
that,723,O
noradrenergic,723,O
neurons,723,O
have,723,O
an,723,O
important,723,O
role,723,O
in,723,O
the,723,O
manifestation,723,O
of,723,O
catalepsy,723,B-Disease
induced,723,O
by,723,O
THC,723,B-Chemical
",",723,O
whereas,723,O
dopaminergic,723,O
neurons,723,O
are,723,O
important,723,O
in,723,O
catalepsy,723,B-Disease
induced,723,O
by,723,O
haloperidol,723,B-Chemical
.,723,O
Reversibility,724,O
of,724,O
captopril-induced,724,B-Chemical
renal,724,B-Disease
insufficiency,724,I-Disease
after,724,O
prolonged,724,O
use,724,O
in,724,O
an,724,O
unusual,724,O
case,724,O
of,724,O
renovascular,724,B-Disease
hypertension,724,I-Disease
.,724,O
We,725,O
report,725,O
a,725,O
case,725,O
of,725,O
severe,725,O
hypertension,725,B-Disease
with,725,O
an,725,O
occluded,725,O
renal,725,O
artery,725,O
to,725,O
a,725,O
solitary,725,O
kidney,725,O
",",725,O
who,725,O
developed,725,O
sudden,725,B-Disease
deterioration,725,I-Disease
of,725,I-Disease
renal,725,I-Disease
function,725,I-Disease
following,725,O
treatment,725,O
with,725,O
captopril,725,B-Chemical
.,725,O
His,726,O
renal,726,O
function,726,O
remained,726,O
impaired,726,O
but,726,O
stable,726,O
during,726,O
2,726,O
years,726,O
',726,O
treatment,726,O
with,726,O
captopril,726,B-Chemical
but,726,O
returned,726,O
to,726,O
pre-treatment,726,O
levels,726,O
soon,726,O
after,726,O
cessation,726,O
of,726,O
the,726,O
drug,726,O
.,726,O
This,727,O
indicates,727,O
reversibility,727,O
in,727,O
captopril-induced,727,B-Chemical
renal,727,B-Disease
failure,727,I-Disease
even,727,O
after,727,O
its,727,O
prolonged,727,O
use,727,O
and,727,O
suggests,727,O
that,727,O
no,727,O
organic,727,O
damage,727,O
occurs,727,O
to,727,O
glomerular,727,O
arterioles,727,O
following,727,O
chronic,727,O
ACE,727,O
inhibition,727,O
.,727,O
HMG,728,O
CoA,728,O
reductase,728,O
inhibitors,728,O
.,728,O
Current,729,O
clinical,729,O
experience,729,O
.,729,O
Lovastatin,730,B-Chemical
and,730,O
simvastatin,730,B-Chemical
are,730,O
the,730,O
2,730,O
best-known,730,O
members,730,O
of,730,O
the,730,O
class,730,O
of,730,O
hypolipidaemic,730,O
agents,730,O
known,730,O
as,730,O
HMG,730,O
CoA,730,O
reductase,730,O
inhibitors,730,O
.,730,O
Clinical,731,O
experience,731,O
with,731,O
lovastatin,731,B-Chemical
includes,731,O
over,731,O
5000,731,O
patients,731,O
",",731,O
700,731,O
of,731,O
whom,731,O
have,731,O
been,731,O
treated,731,O
for,731,O
2,731,O
years,731,O
or,731,O
more,731,O
",",731,O
and,731,O
experience,731,O
with,731,O
simvastatin,731,B-Chemical
includes,731,O
over,731,O
3500,731,O
patients,731,O
",",731,O
of,731,O
whom,731,O
350,731,O
have,731,O
been,731,O
treated,731,O
for,731,O
18,731,O
months,731,O
or,731,O
more,731,O
.,731,O
Lovastatin,732,B-Chemical
has,732,O
been,732,O
marketed,732,O
in,732,O
the,732,O
United,732,O
States,732,O
for,732,O
over,732,O
6,732,O
months,732,O
.,732,O
Both,733,O
agents,733,O
show,733,O
substantial,733,O
clinical,733,O
efficacy,733,O
",",733,O
with,733,O
reductions,733,O
in,733,O
total,733,O
cholesterol,733,B-Chemical
of,733,O
over,733,O
30,733,O
%,733,O
and,733,O
in,733,O
LDL-cholesterol,733,O
of,733,O
40,733,O
%,733,O
in,733,O
clinical,733,O
studies,733,O
.,733,O
Modest,734,O
increases,734,O
in,734,O
HDL-cholesterol,734,O
levels,734,O
of,734,O
about,734,O
10,734,O
%,734,O
are,734,O
also,734,O
reported,734,O
.,734,O
Clinical,735,O
tolerability,735,O
of,735,O
both,735,O
agents,735,O
has,735,O
been,735,O
good,735,O
",",735,O
with,735,O
fewer,735,O
than,735,O
3,735,O
%,735,O
of,735,O
patients,735,O
withdrawn,735,O
from,735,O
treatment,735,O
because,735,O
of,735,O
clinical,735,O
adverse,735,O
experiences,735,O
.,735,O
Ophthalmological,736,O
examinations,736,O
in,736,O
over,736,O
1100,736,O
patients,736,O
treated,736,O
with,736,O
one,736,O
or,736,O
the,736,O
other,736,O
agent,736,O
have,736,O
revealed,736,O
no,736,O
evidence,736,O
of,736,O
significant,736,O
short,736,O
term,736,O
(,736,O
up,736,O
to,736,O
2,736,O
years,736,O
),736,O
cataractogenic,736,O
potential,736,O
.,736,O
One,737,O
to,737,O
2,737,O
%,737,O
of,737,O
patients,737,O
have,737,O
elevations,737,O
of,737,O
serum,737,O
transaminases,737,O
to,737,O
greater,737,O
than,737,O
3,737,O
times,737,O
the,737,O
upper,737,O
limit,737,O
of,737,O
normal,737,O
.,737,O
These,738,O
episodes,738,O
are,738,O
asymptomatic,738,O
and,738,O
reversible,738,O
when,738,O
therapy,738,O
is,738,O
discontinued,738,O
.,738,O
Minor,739,O
elevations,739,O
of,739,O
creatine,739,B-Chemical
kinase,739,O
levels,739,O
are,739,O
reported,739,O
in,739,O
about,739,O
5,739,O
%,739,O
of,739,O
patients,739,O
.,739,O
Myopathy,740,B-Disease
",",740,O
associated,740,O
in,740,O
some,740,O
cases,740,O
with,740,O
myoglobinuria,740,B-Disease
",",740,O
and,740,O
in,740,O
2,740,O
cases,740,O
with,740,O
transient,740,O
renal,740,B-Disease
failure,740,I-Disease
",",740,O
has,740,O
been,740,O
rarely,740,O
reported,740,O
with,740,O
lovastatin,740,B-Chemical
",",740,O
especially,740,O
in,740,O
patients,740,O
concomitantly,740,O
treated,740,O
with,740,O
cyclosporin,740,B-Chemical
",",740,O
gemfibrozil,740,B-Chemical
or,740,O
niacin,740,B-Chemical
.,740,O
Lovastatin,741,B-Chemical
and,741,O
simvastatin,741,B-Chemical
are,741,O
both,741,O
effective,741,O
and,741,O
well-tolerated,741,O
agents,741,O
for,741,O
lowering,741,O
elevated,741,O
levels,741,O
of,741,O
serum,741,O
cholesterol,741,B-Chemical
.,741,O
As,742,O
wider,742,O
use,742,O
confirms,742,O
their,742,O
safety,742,O
profile,742,O
",",742,O
they,742,O
will,742,O
gain,742,O
increasing,742,O
importance,742,O
in,742,O
the,742,O
therapeutic,742,O
approach,742,O
to,742,O
hypercholesterolaemia,742,B-Disease
and,742,O
its,742,O
consequences,742,O
.,742,O
Hepatic,743,O
reactions,743,O
associated,743,O
with,743,O
ketoconazole,743,B-Chemical
in,743,O
the,743,O
United,743,O
Kingdom,743,O
.,743,O
Ketoconazole,744,B-Chemical
was,744,O
introduced,744,O
in,744,O
the,744,O
United,744,O
Kingdom,744,O
in,744,O
1981,744,O
.,744,O
By,745,O
November,745,O
1984,745,O
the,745,O
Committee,745,O
on,745,O
Safety,745,O
of,745,O
Medicines,745,O
had,745,O
received,745,O
82,745,O
reports,745,O
of,745,O
possible,745,O
hepatotoxicity,745,B-Disease
associated,745,O
with,745,O
the,745,O
drug,745,O
",",745,O
including,745,O
five,745,O
deaths,745,B-Disease
.,745,O
An,746,O
analysis,746,O
of,746,O
the,746,O
75,746,O
cases,746,O
that,746,O
had,746,O
been,746,O
adequately,746,O
followed,746,O
up,746,O
suggested,746,O
that,746,O
16,746,O
",",746,O
including,746,O
three,746,O
deaths,746,B-Disease
",",746,O
were,746,O
probably,746,O
related,746,O
to,746,O
treatment,746,O
with,746,O
the,746,O
drug,746,O
.,746,O
Of,747,O
the,747,O
remainder,747,O
",",747,O
48,747,O
were,747,O
possibly,747,O
related,747,O
to,747,O
treatment,747,O
",",747,O
five,747,O
were,747,O
unlikely,747,O
to,747,O
be,747,O
so,747,O
",",747,O
and,747,O
six,747,O
were,747,O
unclassifiable,747,O
.,747,O
The,748,O
mean,748,O
age,748,O
of,748,O
patients,748,O
in,748,O
the,748,O
16,748,O
probable,748,O
cases,748,O
was,748,O
57.9,748,O
",",748,O
with,748,O
hepatotoxicity,748,B-Disease
being,748,O
more,748,O
common,748,O
in,748,O
women,748,O
.,748,O
The,749,O
average,749,O
duration,749,O
of,749,O
treatment,749,O
before,749,O
the,749,O
onset,749,O
of,749,O
jaundice,749,B-Disease
was,749,O
61,749,O
days,749,O
.,749,O
None,750,O
of,750,O
these,750,O
well,750,O
validated,750,O
cases,750,O
occurred,750,O
within,750,O
the,750,O
first,750,O
10,750,O
days,750,O
after,750,O
treatment,750,O
.,750,O
The,751,O
results,751,O
of,751,O
serum,751,O
liver,751,O
function,751,O
tests,751,O
suggested,751,O
hepatocellular,751,B-Disease
injury,751,I-Disease
in,751,O
10,751,O
(,751,O
63,751,O
%,751,O
),751,O
;,751,O
the,751,O
rest,751,O
showed,751,O
a,751,O
mixed,751,O
pattern,751,O
.,751,O
In,752,O
contrast,752,O
",",752,O
the,752,O
results,752,O
of,752,O
histological,752,O
examination,752,O
of,752,O
the,752,O
liver,752,O
often,752,O
showed,752,O
evidence,752,O
of,752,O
cholestasis,752,B-Disease
.,752,O
The,753,O
characteristics,753,O
of,753,O
the,753,O
48,753,O
patients,753,O
in,753,O
the,753,O
possible,753,O
cases,753,O
were,753,O
similar,753,O
.,753,O
Allergic,754,O
manifestations,754,O
such,754,O
as,754,O
rash,754,B-Disease
and,754,O
eosinophilia,754,B-Disease
were,754,O
rare,754,O
.,754,O
Hepatitis,755,B-Disease
was,755,O
usually,755,O
reversible,755,O
when,755,O
treatment,755,O
was,755,O
stopped,755,O
",",755,O
with,755,O
the,755,O
results,755,O
of,755,O
liver,755,O
function,755,O
tests,755,O
returning,755,O
to,755,O
normal,755,O
after,755,O
an,755,O
average,755,O
of,755,O
3.1,755,O
months,755,O
.,755,O
In,756,O
two,756,O
of,756,O
the,756,O
three,756,O
deaths,756,B-Disease
probably,756,O
associated,756,O
with,756,O
ketoconazole,756,B-Chemical
treatment,756,O
the,756,O
drug,756,O
had,756,O
been,756,O
continued,756,O
after,756,O
the,756,O
onset,756,O
of,756,O
jaundice,756,B-Disease
and,756,O
other,756,O
symptoms,756,O
of,756,O
hepatitis,756,B-Disease
.,756,O
Clinical,757,O
and,757,O
biochemical,757,O
monitoring,757,O
at,757,O
regular,757,O
intervals,757,O
for,757,O
evidence,757,O
of,757,O
hepatitis,757,B-Disease
is,757,O
advised,757,O
during,757,O
long,757,O
term,757,O
treatment,757,O
with,757,O
ketoconazole,757,B-Chemical
to,757,O
prevent,757,O
possible,757,O
serious,757,O
hepatic,757,B-Disease
injury,757,I-Disease
.,757,O
Glyburide-induced,758,B-Chemical
hepatitis,758,B-Disease
.,758,O
Drug-induced,759,O
hepatotoxicity,759,B-Disease
",",759,O
although,759,O
common,759,O
",",759,O
has,759,O
been,759,O
reported,759,O
only,759,O
infrequently,759,O
with,759,O
sulfonylureas,759,B-Chemical
.,759,O
For,760,O
glyburide,760,B-Chemical
",",760,O
a,760,O
second-generation,760,O
sulfonylurea,760,B-Chemical
",",760,O
only,760,O
two,760,O
brief,760,O
reports,760,O
of,760,O
hepatotoxicity,760,B-Disease
exist,760,O
.,760,O
Two,761,O
patients,761,O
with,761,O
type,761,B-Disease
II,761,I-Disease
diabetes,761,I-Disease
mellitus,761,I-Disease
developed,761,O
an,761,O
acute,761,B-Disease
hepatitis-like,761,I-Disease
syndrome,761,I-Disease
soon,761,O
after,761,O
initiation,761,O
of,761,O
glyburide,761,B-Chemical
therapy,761,O
.,761,O
There,762,O
was,762,O
no,762,O
serologic,762,O
evidence,762,O
of,762,O
viral,762,B-Disease
infection,762,I-Disease
",",762,O
and,762,O
a,762,O
liver,762,O
biopsy,762,O
sample,762,O
showed,762,O
a,762,O
histologic,762,O
pattern,762,O
consistent,762,O
with,762,O
drug-induced,762,B-Disease
hepatitis,762,I-Disease
.,762,O
Both,763,O
patients,763,O
recovered,763,O
quickly,763,O
after,763,O
stopping,763,O
glyburide,763,B-Chemical
therapy,763,O
and,763,O
have,763,O
remained,763,O
well,763,O
for,763,O
a,763,O
follow-up,763,O
period,763,O
of,763,O
1,763,O
year,763,O
.,763,O
Glyburide,764,B-Chemical
can,764,O
produce,764,O
an,764,O
acute,764,B-Disease
hepatitis-like,764,I-Disease
illness,764,I-Disease
in,764,O
some,764,O
persons,764,O
.,764,O
Intracranial,765,O
pressure,765,O
increases,765,O
during,765,O
alfentanil-induced,765,B-Chemical
rigidity,765,B-Disease
.,765,O
Intracranial,766,O
pressure,766,O
(,766,O
ICP,766,O
),766,O
was,766,O
measured,766,O
during,766,O
alfentanil-induced,766,B-Chemical
rigidity,766,B-Disease
in,766,O
rats,766,O
.,766,O
Ten,767,O
rats,767,O
had,767,O
arterial,767,O
",",767,O
central,767,O
venous,767,O
(,767,O
CVP,767,O
),767,O
",",767,O
and,767,O
subdural,767,O
cannulae,767,O
inserted,767,O
under,767,O
halothane,767,B-Chemical
anesthesia,767,O
.,767,O
The,768,O
animals,768,O
were,768,O
mechanically,768,O
ventilated,768,O
to,768,O
achieve,768,O
normocarbia,768,O
(,768,O
PCO2,768,O
=,768,O
42,768,O
+/-,768,O
1,768,O
mmHg,768,O
",",768,O
mean,768,O
+/-,768,O
SE,768,O
),768,O
.,768,O
Following,769,O
instrumentation,769,O
",",769,O
halothane,769,B-Chemical
was,769,O
discontinued,769,O
and,769,O
alfentanil,769,B-Chemical
(,769,O
125,769,O
mu/kg,769,O
),769,O
administered,769,O
iv,769,O
during,769,O
emergence,769,O
from,769,O
halothane,769,B-Chemical
anesthesia,769,O
.,769,O
In,770,O
the,770,O
five,770,O
rats,770,O
that,770,O
developed,770,O
somatic,770,B-Disease
rigidity,770,I-Disease
",",770,O
ICP,770,O
and,770,O
CVP,770,O
increased,770,O
significantly,770,O
above,770,O
baseline,770,O
(,770,O
delta,770,O
ICP,770,O
7.5,770,O
+/-,770,O
1.0,770,O
mmHg,770,O
",",770,O
delta,770,O
CVP,770,O
5.9,770,O
+/-,770,O
1.3,770,O
mmHg,770,O
),770,O
.,770,O
These,771,O
variables,771,O
returned,771,O
to,771,O
baseline,771,O
when,771,O
rigidity,771,B-Disease
was,771,O
abolished,771,O
with,771,O
metocurine,771,B-Chemical
.,771,O
In,772,O
five,772,O
rats,772,O
that,772,O
did,772,O
not,772,O
become,772,O
rigid,772,O
",",772,O
ICP,772,O
and,772,O
CVP,772,O
did,772,O
not,772,O
change,772,O
following,772,O
alfentanil,772,B-Chemical
.,772,O
These,773,O
observations,773,O
suggest,773,O
that,773,O
rigidity,773,B-Disease
should,773,O
be,773,O
prevented,773,O
when,773,O
alfentanil,773,B-Chemical
",",773,O
and,773,O
",",773,O
presumably,773,O
",",773,O
other,773,O
opiates,773,O
",",773,O
are,773,O
used,773,O
in,773,O
the,773,O
anesthetic,773,O
management,773,O
of,773,O
patients,773,O
with,773,O
ICP,773,O
problems,773,O
.,773,O
Verapamil,774,B-Chemical
withdrawal,774,O
as,774,O
a,774,O
possible,774,O
cause,774,O
of,774,O
myocardial,774,B-Disease
infarction,774,I-Disease
in,774,O
a,774,O
hypertensive,774,B-Disease
woman,774,O
with,774,O
a,774,O
normal,774,O
coronary,774,O
angiogram,774,O
.,774,O
Verapamil,775,B-Chemical
is,775,O
an,775,O
effective,775,O
and,775,O
relatively-safe,775,O
antihypertensive,775,O
drug,775,O
.,775,O
Serious,776,O
adverse,776,O
effects,776,O
are,776,O
uncommon,776,O
and,776,O
mainly,776,O
have,776,O
been,776,O
related,776,O
to,776,O
the,776,O
depression,776,B-Disease
of,776,O
cardiac,776,O
contractility,776,O
and,776,O
conduction,776,O
",",776,O
especially,776,O
when,776,O
the,776,O
drug,776,O
is,776,O
combined,776,O
with,776,O
beta-blocking,776,O
agents,776,O
.,776,O
We,777,O
report,777,O
a,777,O
case,777,O
in,777,O
which,777,O
myocardial,777,B-Disease
infarction,777,I-Disease
coincided,777,O
with,777,O
the,777,O
introduction,777,O
of,777,O
captopril,777,B-Chemical
and,777,O
the,777,O
withdrawal,777,O
of,777,O
verapamil,777,B-Chemical
in,777,O
a,777,O
previously,777,O
asymptomatic,777,O
woman,777,O
with,777,O
severe,777,O
hypertension,777,B-Disease
.,777,O
Possible,778,O
mechanisms,778,O
that,778,O
involve,778,O
a,778,O
verapamil-related,778,B-Chemical
increase,778,O
in,778,O
platelet,778,O
and/or,778,O
vascular,778,O
alpha,778,O
2-adrenoreceptor,778,O
affinity,778,O
for,778,O
catecholamines,778,B-Chemical
are,778,O
discussed,778,O
.,778,O
Haemolytic-uraemic,779,B-Disease
syndrome,779,I-Disease
after,779,O
treatment,779,O
with,779,O
metronidazole,779,B-Chemical
.,779,O
This,780,O
paper,780,O
describes,780,O
the,780,O
clinical,780,O
features,780,O
of,780,O
six,780,O
children,780,O
who,780,O
developed,780,O
the,780,O
haemolytic-uraemic,780,B-Disease
syndrome,780,I-Disease
after,780,O
treatment,780,O
with,780,O
metronidazole,780,B-Chemical
.,780,O
These,781,O
children,781,O
were,781,O
older,781,O
and,781,O
were,781,O
more,781,O
likely,781,O
to,781,O
have,781,O
undergone,781,O
recent,781,O
bowel,781,O
surgery,781,O
than,781,O
are,781,O
other,781,O
children,781,O
with,781,O
this,781,O
condition,781,O
.,781,O
While,782,O
the,782,O
involvement,782,O
of,782,O
metronidazole,782,B-Chemical
in,782,O
the,782,O
aetiology,782,O
of,782,O
the,782,O
haemolytic-uraemic,782,B-Disease
syndrome,782,I-Disease
is,782,O
not,782,O
established,782,O
firmly,782,O
",",782,O
the,782,O
action,782,O
of,782,O
this,782,O
drug,782,O
in,782,O
sensitizing,782,O
tissues,782,O
to,782,O
oxidation,782,O
injury,782,O
and,782,O
the,782,O
reported,782,O
evidence,782,O
of,782,O
oxidation,782,O
changes,782,O
in,782,O
the,782,O
haemolytic-uraemic,782,B-Disease
syndrome,782,I-Disease
suggest,782,O
a,782,O
possible,782,O
link,782,O
between,782,O
metronidazole,782,B-Chemical
treatment,782,O
and,782,O
some,782,O
cases,782,O
of,782,O
the,782,O
haemolytic-uraemic,782,B-Disease
syndrome,782,I-Disease
.,782,O
Adverse,783,O
cardiac,783,O
effects,783,O
during,783,O
induction,783,O
chemotherapy,783,O
treatment,783,O
with,783,O
cis-platin,783,B-Chemical
and,783,O
5-fluorouracil,783,B-Chemical
.,783,O
Survival,784,O
for,784,O
patients,784,O
with,784,O
advanced,784,O
head,784,B-Disease
and,784,I-Disease
neck,784,I-Disease
carcinoma,784,I-Disease
and,784,O
esophageal,784,B-Disease
carcinoma,784,I-Disease
is,784,O
poor,784,O
with,784,O
radiotherapy,784,O
and/or,784,O
surgery,784,O
.,784,O
Obviously,785,O
",",785,O
there,785,O
is,785,O
a,785,O
need,785,O
for,785,O
effective,785,O
chemotherapy,785,O
.,785,O
In,786,O
the,786,O
present,786,O
study,786,O
",",786,O
cis-platin,786,B-Chemical
(,786,O
80-120,786,O
mg/m2BSA,786,O
),786,O
and,786,O
5-FU,786,B-Chemical
(,786,O
1000,786,O
mg/m2BSA,786,O
daily,786,O
as,786,O
a,786,O
continuous,786,O
infusion,786,O
during,786,O
5,786,O
days,786,O
),786,O
were,786,O
given,786,O
to,786,O
76,786,O
patients,786,O
before,786,O
radiotherapy,786,O
and,786,O
surgery,786,O
.,786,O
The,787,O
aim,787,O
of,787,O
the,787,O
study,787,O
was,787,O
to,787,O
clarify,787,O
the,787,O
incidence,787,O
and,787,O
severity,787,O
of,787,O
adverse,787,O
cardiac,787,O
effects,787,O
to,787,O
this,787,O
treatment,787,O
.,787,O
Before,788,O
treatment,788,O
all,788,O
patients,788,O
had,788,O
a,788,O
cardiac,788,O
evaluation,788,O
and,788,O
during,788,O
treatment,788,O
serial,788,O
ECG,788,O
recordings,788,O
were,788,O
performed,788,O
.,788,O
In,789,O
the,789,O
pre-treatment,789,O
evaluation,789,O
",",789,O
signs,789,O
of,789,O
cardiovascular,789,B-Disease
disease,789,I-Disease
were,789,O
found,789,O
in,789,O
33,789,O
patients,789,O
(,789,O
43,789,O
%,789,O
),789,O
.,789,O
During,790,O
treatment,790,O
",",790,O
adverse,790,O
cardiac,790,O
effects,790,O
were,790,O
observed,790,O
in,790,O
14,790,O
patients,790,O
(,790,O
18,790,O
%,790,O
),790,O
.,790,O
The,791,O
mean,791,O
age,791,O
of,791,O
these,791,O
patients,791,O
was,791,O
the,791,O
same,791,O
as,791,O
for,791,O
the,791,O
entire,791,O
group,791,O
",",791,O
64,791,O
years,791,O
.,791,O
The,792,O
incidence,792,O
of,792,O
cardiotoxicity,792,B-Disease
was,792,O
not,792,O
higher,792,O
in,792,O
patients,792,O
with,792,O
signs,792,O
of,792,O
cardiovascular,792,B-Disease
disease,792,I-Disease
than,792,O
in,792,O
those,792,O
without,792,O
in,792,O
the,792,O
pre-treatment,792,O
evaluation,792,O
.,792,O
The,793,O
most,793,O
common,793,O
signs,793,O
of,793,O
cardiotoxicity,793,B-Disease
were,793,O
chest,793,B-Disease
pain,793,I-Disease
",",793,O
ST-T,793,O
wave,793,O
changes,793,O
and,793,O
atrial,793,B-Disease
fibrillation,793,I-Disease
.,793,O
This,794,O
was,794,O
followed,794,O
by,794,O
ventricular,794,B-Disease
fibrillation,794,I-Disease
in,794,O
one,794,O
patient,794,O
and,794,O
sudden,794,B-Disease
death,794,I-Disease
in,794,O
another,794,O
.,794,O
It,795,O
is,795,O
concluded,795,O
that,795,O
patients,795,O
on,795,O
5-FU,795,B-Chemical
treatment,795,O
should,795,O
be,795,O
under,795,O
close,795,O
supervision,795,O
and,795,O
that,795,O
the,795,O
treatment,795,O
should,795,O
be,795,O
discontinued,795,O
if,795,O
chest,795,B-Disease
pain,795,I-Disease
or,795,O
tachyarrhythmia,795,B-Disease
is,795,O
observed,795,O
.,795,O
Death,796,B-Disease
from,796,O
chemotherapy,796,O
in,796,O
gestational,796,B-Disease
trophoblastic,796,I-Disease
disease,796,I-Disease
.,796,O
Multiple,797,O
cytotoxic,797,O
drug,797,O
administration,797,O
is,797,O
the,797,O
generally,797,O
accepted,797,O
treatment,797,O
of,797,O
patients,797,O
with,797,O
a,797,O
high-risk,797,O
stage,797,O
of,797,O
choriocarcinoma,797,B-Disease
.,797,O
Based,798,O
on,798,O
this,798,O
principle,798,O
a,798,O
27-year,798,O
old,798,O
woman,798,O
",",798,O
classified,798,O
as,798,O
being,798,O
in,798,O
the,798,O
high-risk,798,O
group,798,O
(,798,O
Goldstein,798,O
and,798,O
Berkowitz,798,O
score,798,O
:,798,O
11,798,O
),798,O
",",798,O
was,798,O
treated,798,O
with,798,O
multiple,798,O
cytotoxic,798,O
drugs,798,O
.,798,O
The,799,O
multiple,799,O
drug,799,O
schema,799,O
consisted,799,O
of,799,O
:,799,O
Etoposide,799,B-Chemical
16.213,799,O
",",799,O
Methotrexate,799,B-Chemical
",",799,O
Cyclophosphamide,799,B-Chemical
",",799,O
Actomycin-D,799,B-Chemical
",",799,O
and,799,O
Cisplatin,799,B-Chemical
.,799,O
On,800,O
the,800,O
first,800,O
day,800,O
of,800,O
the,800,O
schedule,800,O
",",800,O
moderate,800,O
high,800,O
doses,800,O
of,800,O
Methotrexate,800,B-Chemical
",",800,O
Etoposide,800,B-Chemical
and,800,O
Cyclophosphamide,800,B-Chemical
were,800,O
administered,800,O
.,800,O
Within,801,O
8,801,O
hours,801,O
after,801,O
initiation,801,O
of,801,O
therapy,801,O
the,801,O
patient,801,O
died,801,O
with,801,O
a,801,O
clinical,801,O
picture,801,O
resembling,801,O
massive,801,O
pulmonary,801,B-Disease
obstruction,801,I-Disease
due,801,O
to,801,O
choriocarcinomic,801,O
tissue,801,O
plugs,801,O
",",801,O
probably,801,O
originating,801,O
from,801,O
the,801,O
uterus,801,O
.,801,O
Formation,802,O
of,802,O
these,802,O
plugs,802,O
was,802,O
probably,802,O
due,802,O
to,802,O
extensive,802,O
tumor,802,B-Disease
necrosis,802,B-Disease
at,802,O
the,802,O
level,802,O
of,802,O
the,802,O
walls,802,O
of,802,O
the,802,O
major,802,O
uterine,802,O
veins,802,O
",",802,O
which,802,O
resulted,802,O
in,802,O
an,802,O
open,802,O
exchange,802,O
of,802,O
tumor,802,B-Disease
plugs,802,O
to,802,O
the,802,O
vascular,802,O
spaces,802,O
;,802,O
decrease,802,O
in,802,O
tumor,802,B-Disease
tissue,802,O
coherence,802,O
secondary,802,O
to,802,O
chemotherapy,802,O
may,802,O
have,802,O
further,802,O
contributed,802,O
to,802,O
the,802,O
formation,802,O
of,802,O
tumor,802,B-Disease
emboli,802,O
.,802,O
In,803,O
view,803,O
of,803,O
the,803,O
close,803,O
time,803,O
association,803,O
between,803,O
the,803,O
start,803,O
of,803,O
chemotherapy,803,O
and,803,O
the,803,O
acute,803,O
onset,803,O
of,803,O
massive,803,O
embolism,803,B-Disease
other,803,O
explanations,803,O
",",803,O
such,803,O
as,803,O
spontaneous,803,O
necrosis,803,B-Disease
",",803,O
must,803,O
be,803,O
considered,803,O
less,803,O
likely,803,O
.,803,O
Patients,804,O
with,804,O
large,804,O
pelvic,804,B-Disease
tumor,804,I-Disease
loads,804,O
are,804,O
",",804,O
according,804,O
to,804,O
existing,804,O
classifications,804,O
",",804,O
at,804,O
high,804,O
risk,804,O
to,804,O
die,804,O
and,804,O
to,804,O
develop,804,O
drug,804,O
resistance,804,O
.,804,O
Notwithstanding,805,O
these,805,O
facts,805,O
our,805,O
findings,805,O
suggest,805,O
that,805,O
these,805,O
patients,805,O
might,805,O
benefit,805,O
from,805,O
relatively,805,O
mild,805,O
initial,805,O
treatment,805,O
",",805,O
especially,805,O
true,805,O
for,805,O
patients,805,O
not,805,O
previously,805,O
exposed,805,O
to,805,O
this,805,O
drug,805,O
.,805,O
Close,806,O
observation,806,O
of,806,O
the,806,O
response,806,O
status,806,O
both,806,O
clinically,806,O
and,806,O
with,806,O
beta-hCG,806,O
values,806,O
may,806,O
indicate,806,O
whether,806,O
and,806,O
when,806,O
more,806,O
agressive,806,O
combination,806,O
chemotherapy,806,O
should,806,O
be,806,O
started,806,O
.,806,O
(,807,O
ABSTRACT,807,O
TRUNCATED,807,O
AT,807,O
250,807,O
WORDS,807,O
),807,O
Systolic,808,O
pressure,808,O
variation,808,O
is,808,O
greater,808,O
during,808,O
hemorrhage,808,B-Disease
than,808,O
during,808,O
sodium,808,B-Chemical
nitroprusside-induced,808,O
hypotension,808,B-Disease
in,808,O
ventilated,808,O
dogs,808,O
.,808,O
The,809,O
systolic,809,O
pressure,809,O
variation,809,O
(,809,O
SPV,809,O
),809,O
",",809,O
which,809,O
is,809,O
the,809,O
difference,809,O
between,809,O
the,809,O
maximal,809,O
and,809,O
minimal,809,O
values,809,O
of,809,O
the,809,O
systolic,809,O
blood,809,O
pressure,809,O
(,809,O
SBP,809,O
),809,O
after,809,O
one,809,O
positive-pressure,809,O
breath,809,O
",",809,O
was,809,O
studied,809,O
in,809,O
ventilated,809,O
dogs,809,O
subjected,809,O
to,809,O
hypotension,809,B-Disease
.,809,O
Mean,810,O
arterial,810,O
pressure,810,O
was,810,O
decreased,810,O
to,810,O
50,810,O
mm,810,O
Hg,810,O
for,810,O
30,810,O
minutes,810,O
either,810,O
by,810,O
hemorrhage,810,B-Disease
(,810,O
HEM,810,B-Disease
",",810,O
n,810,O
=,810,O
7,810,O
),810,O
or,810,O
by,810,O
continuous,810,O
infusion,810,O
of,810,O
sodium,810,B-Chemical
nitroprusside,810,I-Chemical
(,810,O
SNP,810,B-Chemical
",",810,O
n,810,O
=,810,O
7,810,O
),810,O
.,810,O
During,811,O
HEM-induced,811,B-Disease
hypotension,811,B-Disease
the,811,O
cardiac,811,O
output,811,O
was,811,O
significantly,811,O
lower,811,O
and,811,O
systemic,811,O
vascular,811,O
resistance,811,O
higher,811,O
compared,811,O
with,811,O
that,811,O
in,811,O
the,811,O
SNP,811,B-Chemical
group,811,O
.,811,O
The,812,O
systemic,812,O
",",812,O
central,812,O
venous,812,O
",",812,O
pulmonary,812,O
capillary,812,O
wedge,812,O
pressures,812,O
",",812,O
and,812,O
heart,812,O
rates,812,O
",",812,O
were,812,O
similar,812,O
in,812,O
the,812,O
two,812,O
groups,812,O
.,812,O
Analysis,813,O
of,813,O
the,813,O
respiratory,813,O
changes,813,O
in,813,O
the,813,O
arterial,813,O
pressure,813,O
waveform,813,O
enabled,813,O
differentiation,813,O
between,813,O
the,813,O
two,813,O
groups,813,O
.,813,O
The,814,O
SPV,814,O
during,814,O
hypotension,814,B-Disease
was,814,O
15.7,814,O
+/-,814,O
6.7,814,O
mm,814,O
Hg,814,O
in,814,O
the,814,O
HEM,814,B-Disease
group,814,O
",",814,O
compared,814,O
with,814,O
9.1,814,O
+/-,814,O
2.0,814,O
mm,814,O
Hg,814,O
in,814,O
the,814,O
SNP,814,B-Chemical
group,814,O
(,814,O
P,814,O
less,814,O
than,814,O
0.02,814,O
),814,O
.,814,O
The,815,O
delta,815,O
down,815,O
",",815,O
which,815,O
is,815,O
the,815,O
measure,815,O
of,815,O
decrease,815,O
of,815,O
SBP,815,O
after,815,O
a,815,O
mechanical,815,O
breath,815,O
",",815,O
was,815,O
20.3,815,O
+/-,815,O
8.4,815,O
and,815,O
10.1,815,O
+/-,815,O
3.8,815,O
mm,815,O
Hg,815,O
in,815,O
the,815,O
HEM,815,B-Disease
and,815,O
SNP,815,B-Chemical
groups,815,O
",",815,O
respectively,815,O
",",815,O
during,815,O
hypotension,815,B-Disease
(,815,O
P,815,O
less,815,O
than,815,O
0.02,815,O
),815,O
.,815,O
It,816,O
is,816,O
concluded,816,O
that,816,O
increases,816,O
in,816,O
the,816,O
SPV,816,O
and,816,O
the,816,O
delta,816,O
down,816,O
are,816,O
characteristic,816,O
of,816,O
a,816,O
hypotensive,816,B-Disease
state,816,O
due,816,O
to,816,O
a,816,O
predominant,816,O
decrease,816,O
in,816,O
preload,816,O
.,816,O
They,817,O
are,817,O
thus,817,O
more,817,O
important,817,O
during,817,O
absolute,817,O
hypovolemia,817,B-Disease
than,817,O
during,817,O
deliberate,817,O
hypotension,817,B-Disease
.,817,O
Ventricular,818,B-Disease
tachyarrhythmias,818,I-Disease
during,818,O
cesarean,818,O
section,818,O
after,818,O
ritodrine,818,B-Chemical
therapy,818,O
:,818,O
interaction,818,O
with,818,O
anesthetics,818,O
.,818,O
This,819,O
case,819,O
illustrates,819,O
that,819,O
patients,819,O
receiving,819,O
ritodrine,819,B-Chemical
for,819,O
preterm,819,B-Disease
labor,819,I-Disease
may,819,O
risk,819,O
interactions,819,O
between,819,O
the,819,O
residual,819,O
betamimetic,819,O
effects,819,O
of,819,O
ritodrine,819,B-Chemical
and,819,O
the,819,O
effects,819,O
of,819,O
anesthetics,819,O
during,819,O
cesarean,819,O
section,819,O
.,819,O
Such,820,O
interactions,820,O
may,820,O
result,820,O
in,820,O
serious,820,O
cardiovascular,820,B-Disease
complications,820,I-Disease
even,820,O
after,820,O
cessation,820,O
of,820,O
an,820,O
infusion,820,O
of,820,O
ritodrine,820,B-Chemical
.,820,O
Preoperative,821,O
assessment,821,O
should,821,O
focus,821,O
on,821,O
cardiovascular,821,O
status,821,O
and,821,O
serum,821,O
potassium,821,B-Chemical
level,821,O
.,821,O
Delaying,822,O
induction,822,O
of,822,O
anesthesia,822,O
should,822,O
be,822,O
considered,822,O
whenever,822,O
possible,822,O
.,822,O
Careful,823,O
fluid,823,O
administration,823,O
and,823,O
cautious,823,O
use,823,O
of,823,O
titrated,823,O
doses,823,O
of,823,O
ephedrine,823,B-Chemical
are,823,O
advised,823,O
.,823,O
After,824,O
delivery,824,O
of,824,O
the,824,O
infant,824,O
",",824,O
there,824,O
should,824,O
be,824,O
no,824,O
contraindication,824,O
to,824,O
the,824,O
use,824,O
of,824,O
an,824,O
alpha-adrenergic,824,O
vasopressor,824,O
such,824,O
as,824,O
phenylephrine,824,B-Chemical
to,824,O
treat,824,O
hypotensive,824,B-Disease
patients,824,O
with,824,O
tachycardia,824,B-Disease
.,824,O
Verapamil-induced,825,B-Chemical
carbamazepine,825,B-Chemical
neurotoxicity,825,B-Disease
.,825,O
A,826,O
report,826,O
of,826,O
two,826,O
cases,826,O
.,826,O
Two,827,O
patients,827,O
with,827,O
signs,827,O
of,827,O
carbamazepine,827,B-Chemical
neurotoxicity,827,B-Disease
after,827,O
combined,827,O
treatment,827,O
with,827,O
verapamil,827,B-Chemical
showed,827,O
complete,827,O
recovery,827,O
after,827,O
discontinuation,827,O
of,827,O
the,827,O
calcium,827,B-Chemical
entry,827,O
blocker,827,O
.,827,O
Use,828,O
of,828,O
verapamil,828,B-Chemical
in,828,O
combination,828,O
with,828,O
carbamazepine,828,B-Chemical
should,828,O
either,828,O
be,828,O
avoided,828,O
or,828,O
prescribed,828,O
only,828,O
with,828,O
appropriate,828,O
adjustment,828,O
of,828,O
the,828,O
carbamazepine,828,B-Chemical
dose,828,O
(,828,O
usually,828,O
reduction,828,O
of,828,O
the,828,O
carbamazepine,828,B-Chemical
dose,828,O
by,828,O
one,828,O
half,828,O
),828,O
.,828,O
Paracetamol-associated,829,B-Chemical
coma,829,B-Disease
",",829,O
metabolic,829,B-Disease
acidosis,829,I-Disease
",",829,O
renal,829,O
and,829,O
hepatic,829,O
failure,829,O
.,829,O
A,830,O
case,830,O
of,830,O
metabolic,830,B-Disease
acidosis,830,I-Disease
",",830,O
acute,830,O
renal,830,O
failure,830,O
and,830,O
hepatic,830,O
failure,830,O
following,830,O
paracetamol,830,B-Chemical
ingestion,830,O
is,830,O
presented,830,O
.,830,O
The,831,O
diagnostic,831,O
difficulty,831,O
at,831,O
presentation,831,O
is,831,O
highlighted,831,O
.,831,O
Continuous,832,O
arteriovenous,832,O
haemofiltration,832,O
proved,832,O
a,832,O
valuable,832,O
means,832,O
of,832,O
maintaining,832,O
fluid,832,O
and,832,O
electrolyte,832,O
balance,832,O
.,832,O
The,833,O
patient,833,O
recovered,833,O
.,833,O
Sexual,834,B-Disease
dysfunction,834,I-Disease
among,834,O
patients,834,O
with,834,O
arthritis,834,B-Disease
.,834,O
The,835,O
relationship,835,O
of,835,O
arthritis,835,B-Disease
and,835,O
sexual,835,B-Disease
dysfunction,835,I-Disease
was,835,O
investigated,835,O
among,835,O
169,835,O
patients,835,O
with,835,O
rheumatoid,835,B-Disease
arthritis,835,I-Disease
",",835,O
osteoarthritis,835,B-Disease
and,835,O
spondyloarthropathy,835,B-Disease
",",835,O
130,835,O
of,835,O
whom,835,O
were,835,O
pair-matched,835,O
to,835,O
controls,835,O
.,835,O
Assessments,836,O
of,836,O
marital,836,O
happiness,836,O
and,836,O
depressed,836,B-Disease
mood,836,I-Disease
were,836,O
also,836,O
made,836,O
using,836,O
the,836,O
CES-D,836,O
and,836,O
the,836,O
Azrin,836,O
Marital,836,O
Happiness,836,O
Scale,836,O
(,836,O
AMHS,836,O
),836,O
.,836,O
Sexual,837,B-Disease
dysfunctions,837,I-Disease
were,837,O
found,837,O
to,837,O
be,837,O
common,837,O
among,837,O
patients,837,O
and,837,O
controls,837,O
",",837,O
the,837,O
majority,837,O
in,837,O
both,837,O
groups,837,O
reporting,837,O
one,837,O
or,837,O
more,837,O
dysfunctions,837,O
.,837,O
Impotence,838,B-Disease
was,838,O
more,838,O
common,838,O
among,838,O
male,838,O
patients,838,O
than,838,O
controls,838,O
and,838,O
was,838,O
found,838,O
to,838,O
be,838,O
associated,838,O
with,838,O
co-morbidity,838,O
and,838,O
the,838,O
taking,838,O
of,838,O
methotrexate,838,B-Chemical
.,838,O
Depressed,839,B-Disease
mood,839,I-Disease
was,839,O
more,839,O
common,839,O
among,839,O
patients,839,O
and,839,O
was,839,O
associated,839,O
with,839,O
certain,839,O
sexual,839,O
difficulties,839,O
",",839,O
but,839,O
not,839,O
with,839,O
impotence,839,B-Disease
.,839,O
Marital,840,O
unhappiness,840,O
",",840,O
as,840,O
indicated,840,O
by,840,O
AMHS,840,O
scores,840,O
",",840,O
was,840,O
not,840,O
associated,840,O
with,840,O
arthritis,840,B-Disease
but,840,O
was,840,O
associated,840,O
with,840,O
sexual,840,B-Disease
dysfunction,840,I-Disease
",",840,O
sexual,840,O
dissatisfaction,840,O
and,840,O
being,840,O
female,840,O
.,840,O
Does,841,O
paracetamol,841,B-Chemical
cause,841,O
urothelial,841,B-Disease
cancer,841,I-Disease
or,841,O
renal,841,B-Disease
papillary,841,I-Disease
necrosis,841,I-Disease
?,841,O
The,842,O
risk,842,O
of,842,O
developing,842,O
renal,842,B-Disease
papillary,842,I-Disease
necrosis,842,I-Disease
or,842,O
cancer,842,O
of,842,O
the,842,O
renal,842,O
pelvis,842,O
",",842,O
ureter,842,O
or,842,O
bladder,842,O
associated,842,O
with,842,O
consumption,842,O
of,842,O
either,842,O
phenacetin,842,B-Chemical
or,842,O
paracetamol,842,B-Chemical
was,842,O
calculated,842,O
from,842,O
data,842,O
acquired,842,O
by,842,O
questionnaire,842,O
from,842,O
381,842,O
cases,842,O
and,842,O
808,842,O
controls,842,O
.,842,O
The,843,O
risk,843,O
of,843,O
renal,843,B-Disease
papillary,843,I-Disease
necrosis,843,I-Disease
was,843,O
increased,843,O
nearly,843,O
20-fold,843,O
by,843,O
consumption,843,O
of,843,O
phenacetin,843,B-Chemical
",",843,O
which,843,O
also,843,O
increased,843,O
the,843,O
risk,843,O
for,843,O
cancer,843,O
of,843,O
the,843,O
renal,843,O
pelvis,843,O
and,843,O
bladder,843,O
but,843,O
not,843,O
for,843,O
ureteric,843,B-Disease
cancer,843,I-Disease
.,843,O
By,844,O
contrast,844,O
",",844,O
we,844,O
were,844,O
unable,844,O
to,844,O
substantiate,844,O
an,844,O
increased,844,O
risk,844,O
from,844,O
paracetamol,844,B-Chemical
consumption,844,O
for,844,O
renal,844,B-Disease
papillary,844,I-Disease
necrosis,844,I-Disease
or,844,O
any,844,O
of,844,O
these,844,O
cancers,844,B-Disease
although,844,O
there,844,O
was,844,O
a,844,O
suggestion,844,O
of,844,O
an,844,O
association,844,O
with,844,O
cancer,844,B-Disease
of,844,I-Disease
the,844,I-Disease
ureter,844,I-Disease
.,844,O
Dapsone-associated,845,B-Chemical
Heinz,845,O
body,845,O
hemolytic,845,B-Disease
anemia,845,I-Disease
in,845,O
a,845,O
Cambodian,845,O
woman,845,O
with,845,O
hemoglobin,845,O
E,845,O
trait,845,O
.,845,O
A,846,O
Cambodian,846,O
woman,846,O
with,846,O
hemoglobin,846,O
E,846,O
trait,846,O
(,846,O
AE,846,O
),846,O
and,846,O
leprosy,846,B-Disease
developed,846,O
a,846,O
Heinz,846,O
body,846,O
hemolytic,846,B-Disease
anemia,846,I-Disease
while,846,O
taking,846,O
a,846,O
dose,846,O
of,846,O
dapsone,846,B-Chemical
(,846,O
50,846,O
mg/day,846,O
),846,O
not,846,O
usually,846,O
associated,846,O
with,846,O
clinical,846,O
hemolysis,846,B-Disease
.,846,O
Her,847,O
red,847,O
blood,847,O
cells,847,O
(,847,O
RBCs,847,O
),847,O
had,847,O
increased,847,O
incubated,847,O
Heinz,847,O
body,847,O
formation,847,O
",",847,O
decreased,847,O
reduced,847,O
glutathione,847,B-Chemical
(,847,O
GSH,847,B-Chemical
),847,O
",",847,O
and,847,O
decreased,847,O
GSH,847,B-Chemical
stability,847,O
.,847,O
The,848,O
pentose,848,B-Chemical
phosphate,848,I-Chemical
shunt,848,O
activity,848,O
of,848,O
the,848,O
dapsone-exposed,848,B-Chemical
AE,848,O
RBCs,848,O
was,848,O
increased,848,O
compared,848,O
to,848,O
normal,848,O
RBCs,848,O
.,848,O
Although,849,O
the,849,O
AE,849,O
RBCs,849,O
from,849,O
an,849,O
individual,849,O
not,849,O
taking,849,O
dapsone,849,B-Chemical
had,849,O
increased,849,O
incubated,849,O
Heinz,849,O
body,849,O
formation,849,O
",",849,O
the,849,O
GSH,849,B-Chemical
content,849,O
and,849,O
GSH,849,B-Chemical
stability,849,O
were,849,O
normal,849,O
.,849,O
The,850,O
pentose,850,B-Chemical
phosphate,850,I-Chemical
shunt,850,O
activity,850,O
of,850,O
the,850,O
non-dapsone-exposed,850,O
AE,850,O
RBCs,850,O
was,850,O
decreased,850,O
compared,850,O
to,850,O
normal,850,O
RBCs,850,O
.,850,O
Thus,851,O
",",851,O
AE,851,O
RBCs,851,O
appear,851,O
to,851,O
have,851,O
an,851,O
increased,851,O
sensitivity,851,O
to,851,O
oxidant,851,O
stress,851,O
both,851,O
in,851,O
vitro,851,O
and,851,O
in,851,O
vivo,851,O
",",851,O
since,851,O
dapsone,851,B-Chemical
does,851,O
not,851,O
cause,851,O
hemolytic,851,B-Disease
anemia,851,I-Disease
at,851,O
this,851,O
dose,851,O
in,851,O
hematologically,851,O
normal,851,O
individuals,851,O
.,851,O
Given,852,O
the,852,O
influx,852,O
of,852,O
Southeast,852,O
Asians,852,O
into,852,O
the,852,O
United,852,O
States,852,O
",",852,O
oxidant,852,O
medications,852,O
should,852,O
be,852,O
used,852,O
with,852,O
caution,852,O
",",852,O
especially,852,O
if,852,O
an,852,O
infection,852,B-Disease
is,852,O
present,852,O
",",852,O
in,852,O
individuals,852,O
of,852,O
ethnic,852,O
backgrounds,852,O
that,852,O
have,852,O
an,852,O
increased,852,O
prevalence,852,O
of,852,O
hemoglobin,852,O
E,852,O
.,852,O
Severe,853,O
complications,853,O
of,853,O
antianginal,853,O
drug,853,O
therapy,853,O
in,853,O
a,853,O
patient,853,O
identified,853,O
as,853,O
a,853,O
poor,853,O
metabolizer,853,O
of,853,O
metoprolol,853,B-Chemical
",",853,O
propafenone,853,B-Chemical
",",853,O
diltiazem,853,B-Chemical
",",853,O
and,853,O
sparteine,853,B-Chemical
.,853,O
A,854,O
47-year-old,854,O
patient,854,O
suffering,854,O
from,854,O
coronary,854,B-Disease
artery,854,I-Disease
disease,854,I-Disease
was,854,O
admitted,854,O
to,854,O
the,854,O
CCU,854,O
in,854,O
shock,854,B-Disease
with,854,O
III,854,O
.,854,O
AV,855,B-Disease
block,855,I-Disease
",",855,O
severe,855,O
hypotension,855,B-Disease
",",855,O
and,855,O
impairment,855,B-Disease
of,855,I-Disease
ventricular,855,I-Disease
function,855,I-Disease
.,855,O
One,856,O
week,856,O
prior,856,O
to,856,O
admission,856,O
a,856,O
therapy,856,O
with,856,O
standard,856,O
doses,856,O
of,856,O
metoprolol,856,B-Chemical
(,856,O
100,856,O
mg,856,O
t.i.d,856,O
.,856,O
and,857,O
then,857,O
100,857,O
mg,857,O
b.i.d,857,O
.,857,O
),857,O
had,858,O
been,858,O
initiated,858,O
.,858,O
Two,859,O
days,859,O
before,859,O
admission,859,O
diltiazem,859,B-Chemical
(,859,O
60,859,O
mg,859,O
b.i.d,859,O
.,859,O
),859,O
was,860,O
prescribed,860,O
in,860,O
addition,860,O
.,860,O
Analyses,861,O
of,861,O
a,861,O
blood,861,O
sample,861,O
revealed,861,O
unusually,861,O
high,861,O
plasma,861,O
concentrations,861,O
of,861,O
metoprolol,861,B-Chemical
(,861,O
greater,861,O
than,861,O
3000,861,O
ng/ml,861,O
),861,O
and,861,O
diltiazem,861,B-Chemical
(,861,O
526,861,O
ng/ml,861,O
),861,O
.,861,O
The,862,O
patient,862,O
recovered,862,O
within,862,O
1,862,O
week,862,O
following,862,O
discontinuation,862,O
of,862,O
antianginal,862,O
therapy,862,O
.,862,O
Three,863,O
months,863,O
later,863,O
the,863,O
patient,863,O
was,863,O
exposed,863,O
to,863,O
a,863,O
single,863,O
dose,863,O
of,863,O
metoprolol,863,B-Chemical
",",863,O
diltiazem,863,B-Chemical
",",863,O
propafenone,863,B-Chemical
(,863,O
since,863,O
he,863,O
had,863,O
received,863,O
this,863,O
drug,863,O
in,863,O
the,863,O
past,863,O
),863,O
",",863,O
and,863,O
sparteine,863,B-Chemical
(,863,O
as,863,O
a,863,O
probe,863,O
for,863,O
the,863,O
debrisoquine/sparteine,863,B-Chemical
type,863,O
polymorphism,863,O
of,863,O
oxidative,863,O
drug,863,O
metabolism,863,O
),863,O
.,863,O
It,864,O
was,864,O
found,864,O
that,864,O
he,864,O
was,864,O
a,864,O
poor,864,O
metabolizer,864,O
of,864,O
all,864,O
four,864,O
drugs,864,O
",",864,O
indicating,864,O
that,864,O
their,864,O
metabolism,864,O
is,864,O
under,864,O
the,864,O
same,864,O
genetic,864,O
control,864,O
.,864,O
Therefore,865,O
",",865,O
patients,865,O
belonging,865,O
to,865,O
the,865,O
poor-metabolizer,865,O
phenotype,865,O
of,865,O
sparteine/debrisoquine,865,B-Chemical
polymorphism,865,O
in,865,O
drug,865,O
metabolism,865,O
",",865,O
which,865,O
constitutes,865,O
6.4,865,O
%,865,O
of,865,O
the,865,O
German,865,O
population,865,O
",",865,O
may,865,O
experience,865,O
adverse,865,B-Disease
drug,865,I-Disease
reactions,865,I-Disease
when,865,O
treated,865,O
with,865,O
standard,865,O
doses,865,O
of,865,O
one,865,O
of,865,O
these,865,O
drugs,865,O
alone,865,O
.,865,O
Moreover,866,O
",",866,O
the,866,O
coadministration,866,O
of,866,O
these,866,O
frequently,866,O
used,866,O
drugs,866,O
is,866,O
expected,866,O
to,866,O
be,866,O
especially,866,O
harmful,866,O
in,866,O
this,866,O
subgroup,866,O
of,866,O
patients,866,O
.,866,O
Prolonged,867,O
cholestasis,867,B-Disease
after,867,O
troleandomycin-induced,867,B-Chemical
acute,867,O
hepatitis,867,B-Disease
.,867,O
We,868,O
report,868,O
the,868,O
case,868,O
of,868,O
a,868,O
patient,868,O
in,868,O
whom,868,O
troleandomycin-induced,868,B-Chemical
hepatitis,868,B-Disease
was,868,O
followed,868,O
by,868,O
prolonged,868,O
anicteric,868,O
cholestasis,868,B-Disease
.,868,O
Jaundice,869,B-Disease
occurred,869,O
after,869,O
administration,869,O
of,869,O
troleandomycin,869,B-Chemical
for,869,O
7,869,O
days,869,O
and,869,O
was,869,O
associated,869,O
with,869,O
hypereosinophilia,869,B-Disease
.,869,O
Jaundice,870,B-Disease
disappeared,870,O
within,870,O
3,870,O
months,870,O
but,870,O
was,870,O
followed,870,O
by,870,O
prolonged,870,O
anicteric,870,O
cholestasis,870,B-Disease
marked,870,O
by,870,O
pruritus,870,B-Disease
and,870,O
high,870,O
levels,870,O
of,870,O
alkaline,870,O
phosphatase,870,O
and,870,O
gammaglutamyltransferase,870,O
activities,870,O
.,870,O
Finally,871,O
",",871,O
pruritus,871,B-Disease
disappeared,871,O
within,871,O
19,871,O
months,871,O
",",871,O
and,871,O
liver,871,O
tests,871,O
returned,871,O
to,871,O
normal,871,O
27,871,O
months,871,O
after,871,O
the,871,O
onset,871,O
of,871,O
hepatitis,871,B-Disease
.,871,O
This,872,O
observation,872,O
demonstrates,872,O
that,872,O
prolonged,872,O
cholestasis,872,B-Disease
can,872,O
follow,872,O
troleandomycin-induced,872,B-Chemical
acute,872,O
hepatitis,872,B-Disease
.,872,O
Serial,873,O
studies,873,O
of,873,O
auditory,873,B-Disease
neurotoxicity,873,I-Disease
in,873,O
patients,873,O
receiving,873,O
deferoxamine,873,B-Chemical
therapy,873,O
.,873,O
Visual,874,O
and,874,O
auditory,874,O
neurotoxicity,874,O
was,874,O
previously,874,O
documented,874,O
in,874,O
42,874,O
of,874,O
89,874,O
patients,874,O
with,874,O
transfusion-dependent,874,O
anemia,874,B-Disease
who,874,O
were,874,O
receiving,874,O
iron,874,B-Chemical
chelation,874,O
therapy,874,O
with,874,O
daily,874,O
subcutaneous,874,O
deferoxamine,874,B-Chemical
.,874,O
Twenty-two,875,O
patients,875,O
in,875,O
the,875,O
affected,875,O
group,875,O
had,875,O
abnormal,875,B-Disease
audiograms,875,I-Disease
with,875,I-Disease
deficits,875,I-Disease
mostly,875,I-Disease
in,875,I-Disease
the,875,I-Disease
high,875,I-Disease
frequency,875,I-Disease
range,875,I-Disease
of,875,I-Disease
"4,000",875,I-Disease
to,875,I-Disease
"8,000",875,I-Disease
Hz,875,I-Disease
and,875,O
in,875,O
the,875,O
hearing,875,O
threshold,875,O
levels,875,O
of,875,O
30,875,O
to,875,O
100,875,O
decibels,875,O
.,875,O
When,876,O
deferoxamine,876,B-Chemical
therapy,876,O
was,876,O
discontinued,876,O
and,876,O
serial,876,O
studies,876,O
were,876,O
performed,876,O
",",876,O
audiograms,876,O
in,876,O
seven,876,O
cases,876,O
reverted,876,O
to,876,O
normal,876,O
or,876,O
near,876,O
normal,876,O
within,876,O
two,876,O
to,876,O
three,876,O
weeks,876,O
",",876,O
and,876,O
nine,876,O
of,876,O
13,876,O
patients,876,O
with,876,O
symptoms,876,O
became,876,O
asymptomatic,876,O
.,876,O
Audiograms,877,O
from,877,O
15,877,O
patients,877,O
remained,877,O
abnormal,877,O
and,877,O
four,877,O
patients,877,O
required,877,O
hearing,877,O
aids,877,O
because,877,O
of,877,O
permanent,877,B-Disease
disability,877,I-Disease
.,877,O
Since,878,O
18,878,O
of,878,O
the,878,O
22,878,O
patients,878,O
were,878,O
initially,878,O
receiving,878,O
deferoxamine,878,B-Chemical
doses,878,O
in,878,O
excess,878,O
of,878,O
the,878,O
commonly,878,O
recommended,878,O
50,878,O
mg/kg,878,O
per,878,O
dose,878,O
",",878,O
therapy,878,O
was,878,O
restarted,878,O
with,878,O
lower,878,O
doses,878,O
",",878,O
usually,878,O
50,878,O
mg/kg,878,O
per,878,O
dose,878,O
or,878,O
less,878,O
depending,878,O
on,878,O
the,878,O
degree,878,O
of,878,O
auditory,878,B-Disease
abnormality,878,I-Disease
",",878,O
and,878,O
with,878,O
the,878,O
exception,878,O
of,878,O
two,878,O
cases,878,O
no,878,O
further,878,O
toxicity,878,B-Disease
was,878,O
demonstrated,878,O
.,878,O
Auditory,879,O
deterioration,879,O
and,879,O
improvement,879,O
",",879,O
demonstrated,879,O
serially,879,O
in,879,O
individual,879,O
patients,879,O
receiving,879,O
and,879,O
not,879,O
receiving,879,O
deferoxamine,879,B-Chemical
",",879,O
respectively,879,O
",",879,O
provided,879,O
convincing,879,O
evidence,879,O
for,879,O
a,879,O
cause-and-effect,879,O
relation,879,O
between,879,O
deferoxamine,879,B-Chemical
administration,879,O
and,879,O
ototoxicity,879,B-Disease
.,879,O
Based,880,O
on,880,O
these,880,O
data,880,O
",",880,O
a,880,O
plan,880,O
of,880,O
management,880,O
was,880,O
developed,880,O
that,880,O
allows,880,O
effective,880,O
yet,880,O
safe,880,O
administration,880,O
of,880,O
deferoxamine,880,B-Chemical
.,880,O
A,881,O
dose,881,O
of,881,O
50,881,O
mg/kg,881,O
is,881,O
recommended,881,O
in,881,O
those,881,O
without,881,O
audiogram,881,O
abnormalities,881,O
.,881,O
With,882,O
mild,882,O
toxicity,882,B-Disease
",",882,O
a,882,O
reduction,882,O
to,882,O
30,882,O
or,882,O
40,882,O
mg/kg,882,O
per,882,O
dose,882,O
should,882,O
result,882,O
in,882,O
a,882,O
reversal,882,O
of,882,O
the,882,O
abnormal,882,O
results,882,O
to,882,O
normal,882,O
within,882,O
four,882,O
weeks,882,O
.,882,O
Moderate,883,O
abnormalities,883,O
require,883,O
a,883,O
reduction,883,O
of,883,O
deferoxamine,883,B-Chemical
to,883,O
25,883,O
mg/kg,883,O
per,883,O
dose,883,O
with,883,O
careful,883,O
monitoring,883,O
.,883,O
In,884,O
those,884,O
with,884,O
symptoms,884,O
of,884,O
hearing,884,B-Disease
loss,884,I-Disease
",",884,O
the,884,O
drug,884,O
should,884,O
be,884,O
stopped,884,O
for,884,O
four,884,O
weeks,884,O
",",884,O
and,884,O
when,884,O
the,884,O
audiogram,884,O
is,884,O
stable,884,O
or,884,O
improved,884,O
",",884,O
therapy,884,O
should,884,O
be,884,O
restarted,884,O
at,884,O
10,884,O
to,884,O
25,884,O
mg/kg,884,O
per,884,O
dose,884,O
.,884,O
Serial,885,O
audiograms,885,O
should,885,O
be,885,O
performed,885,O
every,885,O
six,885,O
months,885,O
in,885,O
those,885,O
without,885,O
problems,885,O
and,885,O
more,885,O
frequently,885,O
in,885,O
young,885,O
patients,885,O
with,885,O
normal,885,O
serum,885,O
ferritin,885,O
values,885,O
and,885,O
in,885,O
those,885,O
with,885,O
auditory,885,B-Disease
dysfunction,885,I-Disease
.,885,O
Flurbiprofen,886,B-Chemical
in,886,O
the,886,O
treatment,886,O
of,886,O
juvenile,886,B-Disease
rheumatoid,886,I-Disease
arthritis,886,I-Disease
.,886,O
Thirty-four,887,O
patients,887,O
with,887,O
juvenile,887,B-Disease
rheumatoid,887,I-Disease
arthritis,887,I-Disease
",",887,O
who,887,O
were,887,O
treated,887,O
with,887,O
flurbiprofen,887,B-Chemical
at,887,O
a,887,O
maximum,887,O
dose,887,O
of,887,O
4,887,O
mg/kg/day,887,O
",",887,O
had,887,O
statistically,887,O
significant,887,O
decreases,887,O
from,887,O
baseline,887,O
in,887,O
6,887,O
arthritis,887,B-Disease
indices,887,O
after,887,O
12,887,O
weeks,887,O
of,887,O
treatment,887,O
.,887,O
Improvements,888,O
were,888,O
seen,888,O
in,888,O
the,888,O
number,888,O
of,888,O
tender,888,B-Disease
joints,888,I-Disease
",",888,O
the,888,O
severity,888,O
of,888,O
swelling,888,B-Disease
and,888,O
tenderness,888,B-Disease
",",888,O
the,888,O
time,888,O
of,888,O
walk,888,O
50,888,O
feet,888,O
",",888,O
the,888,O
duration,888,O
of,888,O
morning,888,B-Disease
stiffness,888,I-Disease
and,888,O
the,888,O
circumference,888,O
of,888,O
the,888,O
left,888,O
knee,888,O
.,888,O
The,889,O
most,889,O
frequently,889,O
observed,889,O
side,889,O
effect,889,O
was,889,O
fecal,889,B-Disease
occult,889,I-Disease
blood,889,I-Disease
(,889,O
25,889,O
%,889,O
of,889,O
patients,889,O
),889,O
;,889,O
however,889,O
",",889,O
there,889,O
was,889,O
no,889,O
other,889,O
evidence,889,O
of,889,O
gastrointestinal,889,B-Disease
(,889,I-Disease
GI,889,I-Disease
),889,I-Disease
bleeding,889,I-Disease
in,889,O
these,889,O
patients,889,O
.,889,O
One,890,O
patient,890,O
was,890,O
prematurely,890,O
discontinued,890,O
from,890,O
the,890,O
study,890,O
for,890,O
severe,890,O
headache,890,B-Disease
and,890,O
abdominal,890,B-Disease
pain,890,I-Disease
.,890,O
Most,891,O
side,891,O
effects,891,O
were,891,O
mild,891,O
and,891,O
related,891,O
to,891,O
the,891,O
GI,891,O
tract,891,O
.,891,O
Hyperkalemia,892,B-Disease
associated,892,O
with,892,O
sulindac,892,B-Chemical
therapy,892,O
.,892,O
Hyperkalemia,893,B-Disease
has,893,O
recently,893,O
been,893,O
recognized,893,O
as,893,O
a,893,O
complication,893,O
of,893,O
nonsteroidal,893,O
antiinflammatory,893,O
agents,893,O
(,893,O
NSAID,893,O
),893,O
such,893,O
as,893,O
indomethacin,893,B-Chemical
.,893,O
Several,894,O
recent,894,O
studies,894,O
have,894,O
stressed,894,O
the,894,O
renal,894,O
sparing,894,O
features,894,O
of,894,O
sulindac,894,B-Chemical
",",894,O
owing,894,O
to,894,O
its,894,O
lack,894,O
of,894,O
interference,894,O
with,894,O
renal,894,O
prostacyclin,894,B-Chemical
synthesis,894,O
.,894,O
We,895,O
describe,895,O
4,895,O
patients,895,O
in,895,O
whom,895,O
hyperkalemia,895,B-Disease
ranging,895,O
from,895,O
6.1,895,O
to,895,O
6.9,895,O
mEq/l,895,O
developed,895,O
within,895,O
3,895,O
to,895,O
8,895,O
days,895,O
of,895,O
sulindac,895,B-Chemical
administration,895,O
.,895,O
In,896,O
all,896,O
of,896,O
them,896,O
normal,896,O
serum,896,O
potassium,896,B-Chemical
levels,896,O
reached,896,O
within,896,O
2,896,O
to,896,O
4,896,O
days,896,O
of,896,O
stopping,896,O
sulindac,896,B-Chemical
.,896,O
As,897,O
no,897,O
other,897,O
medications,897,O
known,897,O
to,897,O
effect,897,O
serum,897,O
potassium,897,B-Chemical
had,897,O
been,897,O
given,897,O
concomitantly,897,O
",",897,O
this,897,O
course,897,O
of,897,O
events,897,O
is,897,O
suggestive,897,O
of,897,O
a,897,O
cause-and-effect,897,O
relationship,897,O
between,897,O
sulindac,897,B-Chemical
and,897,O
hyperkalemia,897,B-Disease
.,897,O
These,898,O
observations,898,O
indicate,898,O
that,898,O
initial,898,O
hopes,898,O
that,898,O
sulindac,898,B-Chemical
may,898,O
not,898,O
be,898,O
associated,898,O
with,898,O
the,898,O
adverse,898,O
renal,898,O
effects,898,O
of,898,O
other,898,O
NSAID,898,O
are,898,O
probably,898,O
not,898,O
justified,898,O
.,898,O
Drug-induced,899,O
arterial,899,O
spasm,899,B-Disease
relieved,899,O
by,899,O
lidocaine,899,B-Chemical
.,899,O
Case,900,O
report,900,O
.,900,O
Following,901,O
major,901,O
intracranial,901,O
surgery,901,O
in,901,O
a,901,O
35-year-old,901,O
man,901,O
",",901,O
sodium,901,B-Chemical
pentothal,901,I-Chemical
was,901,O
intravenously,901,O
infused,901,O
to,901,O
minimize,901,O
cerebral,901,B-Disease
ischaemia,901,I-Disease
.,901,O
Intense,902,O
vasospasm,902,B-Disease
with,902,O
threatened,902,O
gangrene,902,B-Disease
arose,902,O
in,902,O
the,902,O
arm,902,O
used,902,O
for,902,O
the,902,O
infusion,902,O
.,902,O
Since,903,O
the,903,O
cranial,903,O
condition,903,O
precluded,903,O
use,903,O
of,903,O
more,903,O
usual,903,O
methods,903,O
",",903,O
lidocaine,903,B-Chemical
was,903,O
given,903,O
intra-arterially,903,O
",",903,O
with,903,O
careful,903,O
cardiovascular,903,O
monitoring,903,O
",",903,O
to,903,O
counteract,903,O
the,903,O
vasospasm,903,B-Disease
.,903,O
The,904,O
treatment,904,O
was,904,O
rapidly,904,O
successful,904,O
.,904,O
Regional,905,O
localization,905,O
of,905,O
the,905,O
antagonism,905,O
of,905,O
amphetamine-induced,905,B-Chemical
hyperactivity,905,B-Disease
by,905,O
intracerebral,905,O
calcitonin,905,B-Chemical
injections,905,O
.,905,O
Calcitonin,906,B-Chemical
receptors,906,O
are,906,O
found,906,O
in,906,O
the,906,O
brain,906,O
",",906,O
and,906,O
intracerebral,906,O
infusions,906,O
of,906,O
calcitonin,906,B-Chemical
can,906,O
produce,906,O
behavioral,906,O
effects,906,O
.,906,O
Among,907,O
these,907,O
behavioral,907,O
effects,907,O
are,907,O
decreases,907,O
in,907,O
food,907,O
intake,907,O
and,907,O
decreases,907,O
in,907,O
amphetamine-induced,907,B-Chemical
locomotor,907,O
activity,907,O
.,907,O
In,908,O
previous,908,O
experiments,908,O
we,908,O
found,908,O
that,908,O
decreases,908,O
in,908,O
food,908,O
intake,908,O
were,908,O
induced,908,O
by,908,O
local,908,O
administration,908,O
of,908,O
calcitonin,908,B-Chemical
into,908,O
several,908,O
hypothalamic,908,O
sites,908,O
and,908,O
into,908,O
the,908,O
nucleus,908,O
accumbens,908,O
.,908,O
In,909,O
the,909,O
present,909,O
experiment,909,O
calcitonin,909,B-Chemical
decreased,909,O
locomotor,909,O
activity,909,O
when,909,O
locally,909,O
injected,909,O
into,909,O
the,909,O
same,909,O
sites,909,O
where,909,O
it,909,O
decreases,909,O
food,909,O
intake,909,O
.,909,O
The,910,O
areas,910,O
where,910,O
calcitonin,910,B-Chemical
is,910,O
most,910,O
effective,910,O
in,910,O
decreasing,910,O
locomotor,910,O
activity,910,O
are,910,O
located,910,O
in,910,O
the,910,O
hypothalamus,910,O
and,910,O
nucleus,910,O
accumbens,910,O
",",910,O
suggesting,910,O
that,910,O
these,910,O
areas,910,O
are,910,O
the,910,O
major,910,O
sites,910,O
of,910,O
action,910,O
of,910,O
calcitonin,910,B-Chemical
in,910,O
inhibiting,910,O
amphetamine-induced,910,B-Chemical
locomotor,910,O
activity,910,O
.,910,O
The,911,O
hematologic,911,O
effects,911,O
of,911,O
cefonicid,911,B-Chemical
and,911,O
cefazedone,911,B-Chemical
in,911,O
the,911,O
dog,911,O
:,911,O
a,911,O
potential,911,O
model,911,O
of,911,O
cephalosporin,911,B-Chemical
hematotoxicity,911,B-Disease
in,911,O
man,911,O
.,911,O
Cephalosporin,912,B-Chemical
antibiotics,912,O
cause,912,O
a,912,O
variety,912,O
of,912,O
hematologic,912,B-Disease
disturbances,912,I-Disease
in,912,O
man,912,O
",",912,O
the,912,O
pathogeneses,912,O
and,912,O
hematopathology,912,O
of,912,O
which,912,O
remain,912,O
poorly,912,O
characterized,912,O
.,912,O
There,913,O
is,913,O
a,913,O
need,913,O
for,913,O
a,913,O
well-defined,913,O
animal,913,O
model,913,O
in,913,O
which,913,O
these,913,O
blood,913,B-Disease
dyscrasias,913,I-Disease
can,913,O
be,913,O
studied,913,O
.,913,O
In,914,O
four,914,O
subacute,914,O
toxicity,914,B-Disease
studies,914,O
",",914,O
the,914,O
intravenous,914,O
administration,914,O
of,914,O
cefonicid,914,B-Chemical
or,914,O
cefazedone,914,B-Chemical
to,914,O
beagle,914,O
dogs,914,O
caused,914,O
a,914,O
dose-dependent,914,O
incidence,914,O
of,914,O
anemia,914,B-Disease
",",914,O
neutropenia,914,B-Disease
",",914,O
and,914,O
thrombocytopenia,914,B-Disease
after,914,O
1-3,914,O
months,914,O
of,914,O
treatment,914,O
.,914,O
A,915,O
nonregenerative,915,O
anemia,915,B-Disease
was,915,O
the,915,O
most,915,O
compromising,915,O
of,915,O
the,915,O
cytopenias,915,B-Disease
and,915,O
occurred,915,O
in,915,O
approximately,915,O
50,915,O
%,915,O
of,915,O
dogs,915,O
receiving,915,O
400-500,915,O
mg/kg,915,O
cefonicid,915,B-Chemical
or,915,O
540-840,915,O
mg/kg,915,O
cefazedone,915,B-Chemical
.,915,O
All,916,O
three,916,O
cytopenias,916,B-Disease
were,916,O
completely,916,O
reversible,916,O
following,916,O
cessation,916,O
of,916,O
treatment,916,O
;,916,O
the,916,O
time,916,O
required,916,O
for,916,O
recovery,916,O
of,916,O
the,916,O
erythron,916,O
(,916,O
approximately,916,O
1,916,O
month,916,O
),916,O
was,916,O
considerably,916,O
longer,916,O
than,916,O
that,916,O
of,916,O
the,916,O
granulocytes,916,O
and,916,O
platelets,916,O
(,916,O
hours,916,O
to,916,O
a,916,O
few,916,O
days,916,O
),916,O
.,916,O
Upon,917,O
rechallenge,917,O
with,917,O
either,917,O
cephalosporin,917,B-Chemical
",",917,O
the,917,O
hematologic,917,B-Disease
syndrome,917,I-Disease
was,917,O
reproduced,917,O
in,917,O
most,917,O
dogs,917,O
tested,917,O
;,917,O
cefonicid,917,B-Chemical
(,917,O
but,917,O
not,917,O
cefazedone,917,B-Chemical
),917,O
-treated,917,O
dogs,917,O
showed,917,O
a,917,O
substantially,917,O
reduced,917,O
induction,917,O
period,917,O
(,917,O
15,917,O
+/-,917,O
5,917,O
days,917,O
),917,O
compared,917,O
to,917,O
that,917,O
of,917,O
the,917,O
first,917,O
exposure,917,O
to,917,O
the,917,O
drug,917,O
(,917,O
61,917,O
+/-,917,O
24,917,O
days,917,O
),917,O
.,917,O
This,918,O
observation,918,O
",",918,O
along,918,O
with,918,O
the,918,O
rapid,918,O
rate,918,O
of,918,O
decline,918,O
in,918,O
red,918,O
cell,918,O
mass,918,O
parameters,918,O
of,918,O
affected,918,O
dogs,918,O
",",918,O
suggests,918,O
that,918,O
a,918,O
hemolytic,918,B-Disease
component,918,O
complicated,918,O
the,918,O
red,918,O
cell,918,O
production,918,O
problem,918,O
and,918,O
that,918,O
multiple,918,O
toxicologic,918,O
mechanisms,918,O
contributed,918,O
to,918,O
the,918,O
cytopenia,918,B-Disease
.,918,O
We,919,O
conclude,919,O
that,919,O
the,919,O
administration,919,O
of,919,O
high,919,O
doses,919,O
of,919,O
cefonicid,919,B-Chemical
or,919,O
cefazedone,919,B-Chemical
to,919,O
dogs,919,O
can,919,O
induce,919,O
hematotoxicity,919,B-Disease
similar,919,O
to,919,O
the,919,O
cephalosporin-induced,919,B-Chemical
blood,919,B-Disease
dyscrasias,919,I-Disease
described,919,O
in,919,O
man,919,O
and,919,O
thus,919,O
provides,919,O
a,919,O
useful,919,O
model,919,O
for,919,O
studying,919,O
the,919,O
mechanisms,919,O
of,919,O
these,919,O
disorders,919,O
.,919,O
Cerebral,920,O
blood,920,O
flow,920,O
and,920,O
metabolism,920,O
during,920,O
isoflurane-induced,920,B-Chemical
hypotension,920,B-Disease
in,920,O
patients,920,O
subjected,920,O
to,920,O
surgery,920,O
for,920,O
cerebral,920,B-Disease
aneurysms,920,I-Disease
.,920,O
Cerebral,921,O
blood,921,O
flow,921,O
and,921,O
cerebral,921,O
metabolic,921,O
rate,921,O
for,921,O
oxygen,921,B-Chemical
were,921,O
measured,921,O
during,921,O
isoflurane-induced,921,B-Chemical
hypotension,921,B-Disease
in,921,O
10,921,O
patients,921,O
subjected,921,O
to,921,O
craniotomy,921,O
for,921,O
clipping,921,O
of,921,O
a,921,O
cerebral,921,B-Disease
aneurysm,921,I-Disease
.,921,O
Flow,922,O
and,922,O
metabolism,922,O
were,922,O
measured,922,O
5-13,922,O
days,922,O
after,922,O
the,922,O
subarachnoid,922,B-Disease
haemorrhage,922,I-Disease
by,922,O
a,922,O
modification,922,O
of,922,O
the,922,O
classical,922,O
Kety-Schmidt,922,O
technique,922,O
using,922,O
xenon-133,922,B-Chemical
i.v,922,O
.,922,O
Anaesthesia,923,O
was,923,O
maintained,923,O
with,923,O
an,923,O
inspired,923,O
isoflurane,923,B-Chemical
concentration,923,O
of,923,O
0.75,923,O
%,923,O
(,923,O
plus,923,O
67,923,O
%,923,O
nitrous,923,B-Chemical
oxide,923,I-Chemical
in,923,O
oxygen,923,B-Chemical
),923,O
",",923,O
during,923,O
which,923,O
CBF,923,O
and,923,O
CMRO2,923,O
were,923,O
34.3,923,O
+/-,923,O
2.1,923,O
ml/100,923,O
g,923,O
min-1,923,O
and,923,O
2.32,923,O
+/-,923,O
0.16,923,O
ml/100,923,O
g,923,O
min-1,923,O
at,923,O
PaCO2,923,O
4.1,923,O
+/-,923,O
0.1,923,O
kPa,923,O
(,923,O
mean,923,O
+/-,923,O
SEM,923,O
),923,O
.,923,O
Controlled,924,O
hypotension,924,B-Disease
to,924,O
an,924,O
average,924,O
MAP,924,O
of,924,O
50-55,924,O
mm,924,O
Hg,924,B-Chemical
was,924,O
induced,924,O
by,924,O
increasing,924,O
the,924,O
dose,924,O
of,924,O
isoflurane,924,B-Chemical
",",924,O
and,924,O
maintained,924,O
at,924,O
an,924,O
inspired,924,O
concentration,924,O
of,924,O
2.2,924,O
+/-,924,O
0.2,924,O
%,924,O
.,924,O
This,925,O
resulted,925,O
in,925,O
a,925,O
significant,925,O
decrease,925,O
in,925,O
CMRO2,925,O
(,925,O
to,925,O
1.73,925,O
+/-,925,O
0.16,925,O
ml/100,925,O
g,925,O
min-1,925,O
),925,O
",",925,O
while,925,O
CBF,925,O
was,925,O
unchanged,925,O
.,925,O
After,926,O
the,926,O
clipping,926,O
of,926,O
the,926,O
aneurysm,926,B-Disease
the,926,O
isoflurane,926,B-Chemical
concentration,926,O
was,926,O
reduced,926,O
to,926,O
0.75,926,O
%,926,O
.,926,O
There,927,O
was,927,O
a,927,O
significant,927,O
increase,927,O
in,927,O
CBF,927,O
",",927,O
although,927,O
CMRO2,927,O
was,927,O
unchanged,927,O
",",927,O
compared,927,O
with,927,O
pre-hypotensive,927,O
values,927,O
.,927,O
These,928,O
changes,928,O
might,928,O
offer,928,O
protection,928,O
to,928,O
brain,928,O
tissue,928,O
during,928,O
periods,928,O
of,928,O
induced,928,O
hypotension,928,B-Disease
.,928,O
Triazolam-induced,929,B-Chemical
brief,929,O
episodes,929,O
of,929,O
secondary,929,O
mania,929,B-Disease
in,929,O
a,929,O
depressed,929,B-Disease
patient,929,O
.,929,O
Large,930,O
doses,930,O
of,930,O
triazolam,930,B-Chemical
repeatedly,930,O
induced,930,O
brief,930,O
episodes,930,O
of,930,O
mania,930,B-Disease
in,930,O
a,930,O
depressed,930,B-Disease
elderly,930,O
woman,930,O
.,930,O
Features,931,O
of,931,O
organic,931,B-Disease
mental,931,I-Disease
disorder,931,I-Disease
(,931,O
delirium,931,B-Disease
),931,O
were,931,O
not,931,O
present,931,O
.,931,O
Manic,932,B-Disease
excitement,932,O
was,932,O
coincident,932,O
with,932,O
the,932,O
duration,932,O
of,932,O
action,932,O
of,932,O
triazolam,932,B-Chemical
.,932,O
The,933,O
possible,933,O
contribution,933,O
of,933,O
the,933,O
triazolo,933,B-Chemical
group,933,O
to,933,O
changes,933,O
in,933,O
affective,933,O
status,933,O
is,933,O
discussed,933,O
.,933,O
The,934,O
correlation,934,O
between,934,O
neurotoxic,934,B-Disease
esterase,934,O
inhibition,934,O
and,934,O
mipafox-induced,934,B-Chemical
neuropathic,934,B-Disease
damage,934,I-Disease
in,934,O
rats,934,O
.,934,O
The,935,O
correlation,935,O
between,935,O
neuropathic,935,B-Disease
damage,935,I-Disease
and,935,O
inhibition,935,O
of,935,O
neurotoxic,935,B-Disease
esterase,935,O
or,935,O
neuropathy,935,B-Disease
target,935,O
enzyme,935,O
(,935,O
NTE,935,O
),935,O
was,935,O
examined,935,O
in,935,O
rats,935,O
acutely,935,O
exposed,935,O
to,935,O
Mipafox,935,B-Chemical
(,935,O
N,935,B-Chemical
",",935,I-Chemical
N'-diisopropylphosphorodiamidofluoridate,935,I-Chemical
),935,O
",",935,O
a,935,O
neurotoxic,935,B-Disease
organophosphate,935,B-Chemical
.,935,O
Brain,936,O
and,936,O
spinal,936,O
cord,936,O
NTE,936,O
activities,936,O
were,936,O
measured,936,O
in,936,O
Long-Evans,936,O
male,936,O
rats,936,O
1,936,O
hr,936,O
post-exposure,936,O
to,936,O
various,936,O
dosages,936,O
of,936,O
Mipafox,936,B-Chemical
(,936,O
ip,936,O
",",936,O
1-15,936,O
mg/kg,936,O
),936,O
.,936,O
These,937,O
data,937,O
were,937,O
correlated,937,O
with,937,O
histologically,937,O
scored,937,O
cervical,937,O
cord,937,B-Disease
damage,937,I-Disease
in,937,O
a,937,O
separate,937,O
group,937,O
of,937,O
similarly,937,O
dosed,937,O
rats,937,O
sampled,937,O
14-21,937,O
days,937,O
post-exposure,937,O
.,937,O
Those,938,O
dosages,938,O
(,938,O
greater,938,O
than,938,O
or,938,O
equal,938,O
to,938,O
10,938,O
mg/kg,938,O
),938,O
that,938,O
inhibited,938,O
mean,938,O
NTE,938,O
activity,938,O
in,938,O
the,938,O
spinal,938,O
cord,938,O
greater,938,O
than,938,O
or,938,O
equal,938,O
to,938,O
73,938,O
%,938,O
and,938,O
brain,938,O
greater,938,O
than,938,O
or,938,O
equal,938,O
to,938,O
67,938,O
%,938,O
of,938,O
control,938,O
values,938,O
produced,938,O
severe,938,O
(,938,O
greater,938,O
than,938,O
or,938,O
equal,938,O
to,938,O
3,938,O
),938,O
cervical,938,O
cord,938,O
pathology,938,O
in,938,O
85,938,O
%,938,O
of,938,O
the,938,O
rats,938,O
.,938,O
In,939,O
contrast,939,O
",",939,O
dosages,939,O
of,939,O
Mipafox,939,B-Chemical
(,939,O
less,939,O
than,939,O
or,939,O
equal,939,O
to,939,O
5,939,O
mg/kg,939,O
),939,O
which,939,O
inhibited,939,O
mean,939,O
NTE,939,O
activity,939,O
in,939,O
spinal,939,O
cord,939,O
less,939,O
than,939,O
or,939,O
equal,939,O
to,939,O
61,939,O
%,939,O
and,939,O
brain,939,O
less,939,O
than,939,O
or,939,O
equal,939,O
to,939,O
60,939,O
%,939,O
produced,939,O
this,939,O
degree,939,O
of,939,O
cord,939,B-Disease
damage,939,I-Disease
in,939,O
only,939,O
9,939,O
%,939,O
of,939,O
the,939,O
animals,939,O
.,939,O
These,940,O
data,940,O
indicate,940,O
that,940,O
a,940,O
critical,940,O
percentage,940,O
of,940,O
NTE,940,O
inhibition,940,O
in,940,O
brain,940,O
and,940,O
spinal,940,O
cord,940,O
sampled,940,O
shortly,940,O
after,940,O
Mipafox,940,B-Chemical
exposure,940,O
can,940,O
predict,940,O
neuropathic,940,B-Disease
damage,940,I-Disease
in,940,O
rats,940,O
several,940,O
weeks,940,O
later,940,O
.,940,O
Allergic,941,B-Disease
reaction,941,I-Disease
to,941,O
5-fluorouracil,941,B-Chemical
infusion,941,O
.,941,O
An,942,O
allergic,942,B-Disease
reaction,942,I-Disease
consisting,942,O
of,942,O
angioneurotic,942,B-Disease
edema,942,I-Disease
secondary,942,O
to,942,O
continuous,942,O
infusion,942,O
5-fluorouracil,942,B-Chemical
occurred,942,O
in,942,O
a,942,O
patient,942,O
with,942,O
recurrent,942,O
carcinoma,942,B-Disease
of,942,I-Disease
the,942,I-Disease
oral,942,I-Disease
cavity,942,I-Disease
",",942,O
cirrhosis,942,B-Disease
",",942,O
and,942,O
cisplatin-induced,942,B-Chemical
impaired,942,B-Disease
renal,942,I-Disease
function,942,I-Disease
.,942,O
This,943,O
reaction,943,O
occurred,943,O
during,943,O
the,943,O
sixth,943,O
and,943,O
seventh,943,O
courses,943,O
of,943,O
infusional,943,O
chemotherapy,943,O
.,943,O
Oral,944,O
diphenhydramine,944,B-Chemical
and,944,O
prednisone,944,B-Chemical
were,944,O
ineffective,944,O
in,944,O
preventing,944,O
the,944,O
recurrence,944,O
of,944,O
the,944,O
allergic,944,B-Disease
reaction,944,I-Disease
.,944,O
Discontinuance,945,O
of,945,O
effective,945,O
chemotherapy,945,O
in,945,O
this,945,O
patient,945,O
during,945,O
partial,945,O
remission,945,O
resulted,945,O
in,945,O
fatal,945,O
disease,945,O
progression,945,O
.,945,O
Myasthenia,946,B-Disease
gravis,946,I-Disease
caused,946,O
by,946,O
penicillamine,946,B-Chemical
and,946,O
chloroquine,946,B-Chemical
therapy,946,O
for,946,O
rheumatoid,946,B-Disease
arthritis,946,I-Disease
.,946,O
We,947,O
have,947,O
described,947,O
a,947,O
unique,947,O
patient,947,O
who,947,O
had,947,O
reversible,947,O
and,947,O
dose-related,947,O
myasthenia,947,B-Disease
gravis,947,I-Disease
after,947,O
penicillamine,947,B-Chemical
and,947,O
chloroquine,947,B-Chemical
therapy,947,O
for,947,O
rheumatoid,947,B-Disease
arthritis,947,I-Disease
.,947,O
Although,948,O
acetylcholine,948,B-Chemical
receptor,948,O
antibodies,948,O
were,948,O
not,948,O
detectable,948,O
",",948,O
the,948,O
time,948,O
course,948,O
was,948,O
consistent,948,O
with,948,O
an,948,O
autoimmune,948,O
process,948,O
.,948,O
On,949,O
the,949,O
mechanisms,949,O
of,949,O
the,949,O
development,949,O
of,949,O
tolerance,949,O
to,949,O
the,949,O
muscular,949,B-Disease
rigidity,949,I-Disease
produced,949,O
by,949,O
morphine,949,B-Chemical
in,949,O
rats,949,O
.,949,O
The,950,O
development,950,O
of,950,O
tolerance,950,O
to,950,O
the,950,O
muscular,950,B-Disease
rigidity,950,I-Disease
produced,950,O
by,950,O
morphine,950,B-Chemical
was,950,O
studied,950,O
in,950,O
rats,950,O
.,950,O
Saline-pretreated,951,O
controls,951,O
given,951,O
a,951,O
test,951,O
dose,951,O
of,951,O
morphine,951,B-Chemical
(,951,O
20,951,O
mg/kg,951,O
i.p,951,O
.,951,O
),951,O
showed,952,O
a,952,O
pronounced,952,O
rigidity,952,B-Disease
recorded,952,O
as,952,O
tonic,952,O
activity,952,O
in,952,O
the,952,O
electromyogram,952,O
.,952,O
Rats,953,O
treated,953,O
for,953,O
11,953,O
days,953,O
with,953,O
morphine,953,B-Chemical
and,953,O
withdrawn,953,O
for,953,O
36-40,953,O
h,953,O
showed,953,O
differences,953,O
in,953,O
the,953,O
development,953,O
of,953,O
tolerance,953,O
:,953,O
about,953,O
half,953,O
of,953,O
the,953,O
animals,953,O
showed,953,O
a,953,O
rigidity,953,B-Disease
after,953,O
the,953,O
test,953,O
dose,953,O
of,953,O
morphine,953,B-Chemical
that,953,O
was,953,O
not,953,O
significantly,953,O
less,953,O
than,953,O
in,953,O
the,953,O
controls,953,O
and,953,O
were,953,O
akinetic,953,B-Disease
(,953,O
A,953,O
group,953,O
),953,O
.,953,O
The,954,O
other,954,O
rats,954,O
showed,954,O
a,954,O
strong,954,O
decrease,954,O
in,954,O
the,954,O
rigidity,954,B-Disease
and,954,O
the,954,O
occurrence,954,O
of,954,O
stereotyped,954,O
(,954,O
S,954,O
),954,O
licking,954,O
and/or,954,O
gnawing,954,O
in,954,O
presence,954,O
of,954,O
akinetic,954,B-Disease
or,954,O
hyperkinetic,954,B-Disease
(,954,O
K,954,O
),954,O
behaviour,954,O
(,954,O
AS/KS,954,O
group,954,O
),954,O
",",954,O
suggesting,954,O
signs,954,O
of,954,O
dopaminergic,954,O
activation,954,O
.,954,O
The,955,O
rigidity,955,B-Disease
was,955,O
considerably,955,O
decreased,955,O
in,955,O
both,955,O
groups,955,O
after,955,O
20,955,O
days,955,O
',955,O
treatment,955,O
.,955,O
In,956,O
a,956,O
further,956,O
series,956,O
of,956,O
experiments,956,O
",",956,O
haloperidol,956,B-Chemical
(,956,O
0.2,956,O
mg/kg,956,O
i.p,956,O
.,956,O
),956,O
was,957,O
used,957,O
in,957,O
order,957,O
to,957,O
block,957,O
the,957,O
dopaminergic,957,O
activation,957,O
and,957,O
to,957,O
estimate,957,O
the,957,O
real,957,O
degree,957,O
of,957,O
the,957,O
tolerance,957,O
to,957,O
the,957,O
rigidity,957,B-Disease
without,957,O
any,957,O
dopaminergic,957,O
interference,957,O
.,957,O
Haloperidol,958,B-Chemical
enhanced,958,O
the,958,O
rigidity,958,B-Disease
in,958,O
the,958,O
A,958,O
group,958,O
.,958,O
However,959,O
",",959,O
the,959,O
level,959,O
in,959,O
the,959,O
AS/KS,959,O
group,959,O
remained,959,O
considerably,959,O
lower,959,O
than,959,O
in,959,O
the,959,O
A,959,O
group,959,O
.,959,O
The,960,O
results,960,O
suggest,960,O
that,960,O
rigidity,960,B-Disease
",",960,O
which,960,O
is,960,O
assumed,960,O
to,960,O
be,960,O
due,960,O
to,960,O
an,960,O
action,960,O
of,960,O
morphine,960,B-Chemical
in,960,O
the,960,O
striatum,960,O
",",960,O
can,960,O
be,960,O
antagonized,960,O
by,960,O
another,960,O
process,960,O
leading,960,O
to,960,O
dopaminergic,960,O
activation,960,O
in,960,O
the,960,O
striatum,960,O
.,960,O
Nevertheless,961,O
",",961,O
there,961,O
occurs,961,O
some,961,O
real,961,O
tolerance,961,O
to,961,O
this,961,O
effect,961,O
.,961,O
The,962,O
rapid,962,O
alternations,962,O
of,962,O
rigidity,962,B-Disease
and,962,O
the,962,O
signs,962,O
of,962,O
dopaminergic,962,O
activation,962,O
observed,962,O
in,962,O
the,962,O
animals,962,O
of,962,O
the,962,O
AS/KS,962,O
group,962,O
might,962,O
be,962,O
due,962,O
to,962,O
rapid,962,O
shifts,962,O
in,962,O
the,962,O
predominance,962,O
of,962,O
various,962,O
DA-innervated,962,O
structures,962,O
.,962,O
A,963,O
case,963,O
of,963,O
massive,963,O
rhabdomyolysis,963,B-Disease
following,963,O
molindone,963,B-Chemical
administration,963,O
.,963,O
Rhabdomyolysis,964,B-Disease
is,964,O
a,964,O
potentially,964,O
lethal,964,O
syndrome,964,O
that,964,O
psychiatric,964,B-Disease
patients,964,O
seem,964,O
predisposed,964,O
to,964,O
develop,964,O
.,964,O
The,965,O
clinical,965,O
signs,965,O
and,965,O
symptoms,965,O
",",965,O
typical,965,O
laboratory,965,O
features,965,O
",",965,O
and,965,O
complications,965,O
of,965,O
rhabdomyolysis,965,B-Disease
are,965,O
presented,965,O
.,965,O
The,966,O
case,966,O
of,966,O
a,966,O
schizophrenic,966,B-Disease
patient,966,O
is,966,O
reported,966,O
to,966,O
illustrate,966,O
massive,966,O
rhabdomyolysis,966,B-Disease
and,966,O
subsequent,966,O
acute,966,B-Disease
renal,966,I-Disease
failure,966,I-Disease
following,966,O
molindone,966,B-Chemical
administration,966,O
.,966,O
Physicians,967,O
who,967,O
prescribe,967,O
molindone,967,B-Chemical
should,967,O
be,967,O
aware,967,O
of,967,O
this,967,O
reaction,967,O
.,967,O
Compression,968,O
neuropathy,968,O
of,968,O
the,968,O
radial,968,O
nerve,968,O
due,968,O
to,968,O
pentazocine-induced,968,B-Chemical
fibrous,968,B-Disease
myopathy,968,I-Disease
.,968,O
Fibrous,969,B-Disease
myopathy,969,I-Disease
is,969,O
a,969,O
common,969,O
",",969,O
well-known,969,O
side,969,O
effect,969,O
of,969,O
repeated,969,O
pentazocine,969,B-Chemical
injection,969,O
.,969,O
However,970,O
",",970,O
compression,970,B-Disease
neuropathy,970,I-Disease
due,970,O
to,970,O
fibrotic,970,O
muscle,970,O
affected,970,O
by,970,O
pentazocine-induced,970,B-Chemical
myopathy,970,B-Disease
has,970,O
not,970,O
previously,970,O
been,970,O
reported,970,O
.,970,O
In,971,O
a,971,O
37-year-old,971,O
woman,971,O
with,971,O
documented,971,O
pentazocine-induced,971,B-Chemical
fibrous,971,B-Disease
myopathy,971,I-Disease
of,971,O
triceps,971,O
and,971,O
deltoid,971,O
muscles,971,O
bilaterally,971,O
and,971,O
a,971,O
three-week,971,O
history,971,O
of,971,O
right,971,O
wrist,971,O
drop,971,O
",",971,O
electrodiagnostic,971,O
examination,971,O
showed,971,O
a,971,O
severe,971,O
but,971,O
partial,971,O
lesion,971,O
of,971,O
the,971,O
right,971,O
radial,971,O
nerve,971,O
distal,971,O
to,971,O
the,971,O
branches,971,O
to,971,O
the,971,O
triceps,971,O
",",971,O
in,971,O
addition,971,O
to,971,O
the,971,O
fibrous,971,B-Disease
myopathy,971,I-Disease
.,971,O
Surgery,972,O
revealed,972,O
the,972,O
right,972,O
radial,972,O
nerve,972,O
to,972,O
be,972,O
severely,972,O
compressed,972,O
by,972,O
the,972,O
densely,972,O
fibrotic,972,O
lateral,972,O
head,972,O
of,972,O
the,972,O
triceps,972,O
.,972,O
Decompression,973,O
and,973,O
neurolysis,973,O
were,973,O
performed,973,O
with,973,O
good,973,O
subsequent,973,O
recovery,973,O
of,973,O
function,973,O
.,973,O
Recurrent,974,O
reversible,974,O
acute,974,B-Disease
renal,974,I-Disease
failure,974,I-Disease
from,974,O
amphotericin,974,B-Chemical
.,974,O
A,975,O
patient,975,O
with,975,O
cryptogenic,975,O
cirrhosis,975,B-Disease
and,975,O
disseminated,975,O
sporotrichosis,975,B-Disease
developed,975,O
acute,975,B-Disease
renal,975,I-Disease
failure,975,I-Disease
immediately,975,O
following,975,O
the,975,O
administration,975,O
of,975,O
amphotericin,975,B-Chemical
B,975,I-Chemical
on,975,O
four,975,O
separate,975,O
occasions,975,O
.,975,O
The,976,O
abruptness,976,O
of,976,O
the,976,O
renal,976,B-Disease
failure,976,I-Disease
and,976,O
its,976,O
reversibility,976,O
within,976,O
days,976,O
suggests,976,O
that,976,O
there,976,O
was,976,O
a,976,O
functional,976,O
component,976,O
to,976,O
the,976,O
renal,976,B-Disease
dysfunction,976,I-Disease
.,976,O
We,977,O
propose,977,O
that,977,O
amphotericin,977,B-Chemical
",",977,O
in,977,O
the,977,O
setting,977,O
of,977,O
reduced,977,O
effective,977,O
arterial,977,O
volume,977,O
",",977,O
may,977,O
activate,977,O
tubuloglomerular,977,O
feedback,977,O
",",977,O
thereby,977,O
contributing,977,O
to,977,O
acute,977,B-Disease
renal,977,I-Disease
failure,977,I-Disease
.,977,O
Cerebral,978,B-Disease
infarction,978,I-Disease
with,978,O
a,978,O
single,978,O
oral,978,O
dose,978,O
of,978,O
phenylpropanolamine,978,B-Chemical
.,978,O
Phenylpropanolamine,979,B-Chemical
(,979,O
PPA,979,B-Chemical
),979,O
",",979,O
a,979,O
synthetic,979,O
sympathomimetic,979,O
that,979,O
is,979,O
structurally,979,O
similar,979,O
to,979,O
amphetamine,979,B-Chemical
",",979,O
is,979,O
available,979,O
over,979,O
the,979,O
counter,979,O
in,979,O
anorectics,979,O
",",979,O
nasal,979,O
congestants,979,O
",",979,O
and,979,O
cold,979,O
preparations,979,O
.,979,O
Its,980,O
prolonged,980,O
use,980,O
or,980,O
overuse,980,O
has,980,O
been,980,O
associated,980,O
with,980,O
seizures,980,B-Disease
",",980,O
intracerebral,980,B-Disease
hemorrhage,980,I-Disease
",",980,O
neuropsychiatric,980,B-Disease
symptoms,980,I-Disease
",",980,O
and,980,O
nonhemorrhagic,980,O
cerebral,980,B-Disease
infarction,980,I-Disease
.,980,O
We,981,O
report,981,O
the,981,O
case,981,O
of,981,O
a,981,O
young,981,O
woman,981,O
who,981,O
suffered,981,O
a,981,O
cerebral,981,B-Disease
infarction,981,I-Disease
after,981,O
taking,981,O
a,981,O
single,981,O
oral,981,O
dose,981,O
of,981,O
PPA,981,B-Chemical
.,981,O
Remission,982,O
induction,982,O
of,982,O
meningeal,982,B-Disease
leukemia,982,I-Disease
with,982,O
high-dose,982,O
intravenous,982,O
methotrexate,982,B-Chemical
.,982,O
Twenty,983,O
children,983,O
with,983,O
acute,983,B-Disease
lymphoblastic,983,I-Disease
leukemia,983,I-Disease
who,983,O
developed,983,O
meningeal,983,B-Disease
disease,983,I-Disease
were,983,O
treated,983,O
with,983,O
a,983,O
high-dose,983,O
intravenous,983,O
methotrexate,983,B-Chemical
regimen,983,O
that,983,O
was,983,O
designed,983,O
to,983,O
achieve,983,O
and,983,O
maintain,983,O
CSF,983,O
methotrexate,983,B-Chemical
concentrations,983,O
of,983,O
10,983,O
(,983,O
-5,983,O
),983,O
mol/L,983,O
without,983,O
the,983,O
need,983,O
for,983,O
concomitant,983,O
intrathecal,983,O
dosing,983,O
.,983,O
The,984,O
methotrexate,984,B-Chemical
was,984,O
administered,984,O
as,984,O
a,984,O
loading,984,O
dose,984,O
of,984,O
"6,000",984,O
mg/m2,984,O
for,984,O
a,984,O
period,984,O
of,984,O
one,984,O
hour,984,O
followed,984,O
by,984,O
an,984,O
infusion,984,O
of,984,O
"1,200",984,O
mg/m2/h,984,O
for,984,O
23,984,O
hours,984,O
.,984,O
Leucovorin,985,B-Chemical
rescue,985,O
was,985,O
initiated,985,O
12,985,O
hours,985,O
after,985,O
the,985,O
end,985,O
of,985,O
the,985,O
infusion,985,O
with,985,O
a,985,O
loading,985,O
dose,985,O
of,985,O
200,985,O
mg/m2,985,O
followed,985,O
by,985,O
12,985,O
mg/m2,985,O
every,985,O
three,985,O
hours,985,O
for,985,O
six,985,O
doses,985,O
and,985,O
then,985,O
every,985,O
six,985,O
hours,985,O
until,985,O
the,985,O
plasma,985,O
methotrexate,985,B-Chemical
level,985,O
decreased,985,O
to,985,O
less,985,O
than,985,O
1,985,O
X,985,O
10,985,O
(,985,O
-7,985,O
),985,O
mol/L,985,O
.,985,O
The,986,O
mean,986,O
steady-state,986,O
plasma,986,O
and,986,O
CSF,986,O
methotrexate,986,B-Chemical
concentrations,986,O
achieved,986,O
were,986,O
1.1,986,O
X,986,O
10,986,O
(,986,O
-3,986,O
),986,O
mol/L,986,O
and,986,O
3.6,986,O
X,986,O
10,986,O
(,986,O
-5,986,O
),986,O
mol/L,986,O
",",986,O
respectively,986,O
.,986,O
All,987,O
20,987,O
patients,987,O
responded,987,O
to,987,O
this,987,O
regimen,987,O
",",987,O
16/20,987,O
(,987,O
80,987,O
%,987,O
),987,O
achieved,987,O
a,987,O
complete,987,O
remission,987,O
",",987,O
and,987,O
20,987,O
%,987,O
obtained,987,O
a,987,O
partial,987,O
remission,987,O
.,987,O
The,988,O
most,988,O
common,988,O
toxicities,988,B-Disease
encountered,988,O
were,988,O
transient,988,O
serum,988,O
transaminase,988,O
and,988,O
bilirubin,988,B-Chemical
elevations,988,O
",",988,O
neutropenia,988,B-Disease
",",988,O
and,988,O
mucositis,988,B-Disease
.,988,O
One,989,O
patient,989,O
had,989,O
focal,989,O
seizures,989,B-Disease
and,989,O
transient,989,B-Disease
hemiparesis,989,I-Disease
but,989,O
recovered,989,O
completely,989,O
.,989,O
High-dose,990,O
intravenous,990,O
methotrexate,990,B-Chemical
is,990,O
an,990,O
effective,990,O
treatment,990,O
for,990,O
the,990,O
induction,990,O
of,990,O
remission,990,O
after,990,O
meningeal,990,O
relapse,990,O
in,990,O
acute,990,B-Disease
lymphoblastic,990,I-Disease
leukemia,990,I-Disease
.,990,O
Interaction,991,O
of,991,O
cyclosporin,991,B-Chemical
A,991,I-Chemical
with,991,O
antineoplastic,991,O
agents,991,O
.,991,O
A,992,O
synergistic,992,O
effect,992,O
of,992,O
etoposide,992,B-Chemical
and,992,O
cyclosporin,992,B-Chemical
A,992,I-Chemical
was,992,O
observed,992,O
in,992,O
a,992,O
patient,992,O
with,992,O
acute,992,B-Disease
T-lymphocytic,992,I-Disease
leukemia,992,I-Disease
in,992,O
relapse,992,O
.,992,O
The,993,O
concomitant,993,O
administration,993,O
of,993,O
etoposide,993,B-Chemical
and,993,O
cyclosporin,993,B-Chemical
A,993,I-Chemical
resulted,993,O
in,993,O
eradication,993,O
of,993,O
hitherto,993,O
refractory,993,O
leukemic,993,B-Disease
infiltration,993,I-Disease
of,993,O
bone,993,O
marrow,993,O
.,993,O
Severe,994,O
side,994,O
effects,994,O
in,994,O
terms,994,O
of,994,O
mental,994,O
confusion,994,B-Disease
and,994,O
progressive,994,O
hyperbilirubinemia,994,B-Disease
",",994,O
however,994,O
",",994,O
point,994,O
to,994,O
an,994,O
enhancement,994,O
not,994,O
only,994,O
of,994,O
antineoplastic,994,O
effects,994,O
but,994,O
also,994,O
of,994,O
toxicity,994,B-Disease
in,994,O
normal,994,O
tissues,994,O
.,994,O
This,995,O
report,995,O
demonstrates,995,O
for,995,O
the,995,O
first,995,O
time,995,O
that,995,O
the,995,O
pharmacodynamic,995,O
properties,995,O
of,995,O
cyclosporin,995,B-Chemical
A,995,I-Chemical
may,995,O
not,995,O
be,995,O
confined,995,O
strictly,995,O
to,995,O
suppression,995,O
of,995,O
normal,995,O
T-cell,995,O
functions,995,O
.,995,O
Incidence,996,O
of,996,O
neoplasms,996,B-Disease
in,996,O
patients,996,O
with,996,O
rheumatoid,996,B-Disease
arthritis,996,I-Disease
exposed,996,O
to,996,O
different,996,O
treatment,996,O
regimens,996,O
.,996,O
Immunosuppressive,997,O
drugs,997,O
have,997,O
been,997,O
used,997,O
during,997,O
the,997,O
last,997,O
30,997,O
years,997,O
in,997,O
treatment,997,O
of,997,O
patients,997,O
with,997,O
severe,997,O
rheumatoid,997,B-Disease
arthritis,997,I-Disease
.,997,O
The,998,O
drugs,998,O
commonly,998,O
used,998,O
are,998,O
cyclophosphamide,998,B-Chemical
and,998,O
chlorambucil,998,B-Chemical
(,998,O
alkylating,998,B-Chemical
agents,998,I-Chemical
),998,O
",",998,O
azathioprine,998,B-Chemical
(,998,O
purine,998,B-Chemical
analogue,998,O
),998,O
",",998,O
and,998,O
methotrexate,998,B-Chemical
(,998,O
folic,998,B-Chemical
acid,998,I-Chemical
analogue,998,O
),998,O
.,998,O
There,999,O
is,999,O
evidence,999,O
that,999,O
all,999,O
four,999,O
immunosuppressive,999,O
drugs,999,O
can,999,O
reduce,999,O
synovitis,999,B-Disease
",",999,O
but,999,O
disease,999,O
activity,999,O
almost,999,O
always,999,O
recurs,999,O
after,999,O
therapy,999,O
is,999,O
stopped,999,O
.,999,O
Since,1000,O
adverse,1000,O
reactions,1000,O
are,1000,O
frequent,1000,O
",",1000,O
less,1000,O
than,1000,O
50,1000,O
percent,1000,O
of,1000,O
patients,1000,O
are,1000,O
able,1000,O
to,1000,O
continue,1000,O
a,1000,O
particular,1000,O
drug,1000,O
for,1000,O
more,1000,O
than,1000,O
one,1000,O
year,1000,O
.,1000,O
Since,1001,O
it,1001,O
takes,1001,O
three,1001,O
to,1001,O
12,1001,O
months,1001,O
to,1001,O
achieve,1001,O
maximal,1001,O
effects,1001,O
",",1001,O
those,1001,O
patients,1001,O
who,1001,O
are,1001,O
unable,1001,O
to,1001,O
continue,1001,O
the,1001,O
drug,1001,O
receive,1001,O
little,1001,O
benefit,1001,O
from,1001,O
it,1001,O
.,1001,O
Patients,1002,O
treated,1002,O
with,1002,O
alkylating,1002,B-Chemical
agents,1002,I-Chemical
have,1002,O
an,1002,O
increased,1002,O
risk,1002,O
of,1002,O
development,1002,O
of,1002,O
acute,1002,B-Disease
nonlymphocytic,1002,I-Disease
leukemia,1002,I-Disease
",",1002,O
and,1002,O
both,1002,O
alkylating,1002,B-Chemical
agents,1002,I-Chemical
and,1002,O
azathioprine,1002,B-Chemical
are,1002,O
associated,1002,O
with,1002,O
the,1002,O
development,1002,O
of,1002,O
non-Hodgkin,1002,B-Disease
's,1002,I-Disease
lymphoma,1002,I-Disease
.,1002,O
Cyclophosphamide,1003,B-Chemical
therapy,1003,O
increases,1003,O
the,1003,O
risk,1003,O
of,1003,O
carcinoma,1003,O
of,1003,O
the,1003,O
bladder,1003,O
.,1003,O
There,1004,O
have,1004,O
been,1004,O
several,1004,O
long-term,1004,O
studies,1004,O
of,1004,O
patients,1004,O
with,1004,O
rheumatoid,1004,B-Disease
arthritis,1004,I-Disease
treated,1004,O
with,1004,O
azathioprine,1004,B-Chemical
and,1004,O
cyclophosphamide,1004,B-Chemical
and,1004,O
the,1004,O
incidence,1004,O
of,1004,O
most,1004,O
of,1004,O
the,1004,O
common,1004,O
cancers,1004,B-Disease
is,1004,O
not,1004,O
increased,1004,O
.,1004,O
Data,1005,O
on,1005,O
the,1005,O
possible,1005,O
increased,1005,O
risk,1005,O
of,1005,O
malignancy,1005,B-Disease
in,1005,O
rheumatoid,1005,B-Disease
arthritis,1005,I-Disease
are,1005,O
still,1005,O
being,1005,O
collected,1005,O
",",1005,O
and,1005,O
until,1005,O
further,1005,O
information,1005,O
is,1005,O
available,1005,O
",",1005,O
the,1005,O
use,1005,O
of,1005,O
immunosuppressive,1005,O
drugs,1005,O
",",1005,O
particularly,1005,O
alkylating,1005,B-Chemical
agents,1005,I-Chemical
",",1005,O
in,1005,O
the,1005,O
treatment,1005,O
of,1005,O
rheumatoid,1005,B-Disease
arthritis,1005,I-Disease
should,1005,O
be,1005,O
reserved,1005,O
for,1005,O
patients,1005,O
with,1005,O
severe,1005,O
progressive,1005,O
disease,1005,O
or,1005,O
life-threatening,1005,O
complications,1005,O
.,1005,O
Warfarin-induced,1006,B-Chemical
iliopsoas,1006,O
hemorrhage,1006,B-Disease
with,1006,O
subsequent,1006,O
femoral,1006,B-Disease
nerve,1006,I-Disease
palsy,1006,I-Disease
.,1006,O
We,1007,O
present,1007,O
the,1007,O
case,1007,O
of,1007,O
a,1007,O
28-year-old,1007,O
man,1007,O
on,1007,O
chronic,1007,O
warfarin,1007,B-Chemical
therapy,1007,O
who,1007,O
sustained,1007,O
a,1007,O
minor,1007,O
muscle,1007,B-Disease
tear,1007,I-Disease
and,1007,O
developed,1007,O
increasing,1007,O
pain,1007,B-Disease
and,1007,O
a,1007,O
flexure,1007,O
contracture,1007,B-Disease
of,1007,O
the,1007,O
right,1007,O
hip,1007,O
.,1007,O
Surgical,1008,O
exploration,1008,O
revealed,1008,O
an,1008,O
iliopsoas,1008,O
hematoma,1008,B-Disease
and,1008,O
femoral,1008,O
nerve,1008,B-Disease
entrapment,1008,I-Disease
",",1008,O
resulting,1008,O
in,1008,O
a,1008,O
femoral,1008,B-Disease
nerve,1008,I-Disease
palsy,1008,I-Disease
and,1008,O
partial,1008,B-Disease
loss,1008,I-Disease
of,1008,I-Disease
quadriceps,1008,I-Disease
functions,1008,I-Disease
.,1008,O
Anticoagulant-induced,1009,O
femoral,1009,B-Disease
nerve,1009,I-Disease
palsy,1009,I-Disease
represents,1009,O
the,1009,O
most,1009,O
common,1009,O
form,1009,O
of,1009,O
warfarin-induced,1009,B-Chemical
peripheral,1009,B-Disease
neuropathy,1009,I-Disease
;,1009,O
it,1009,O
is,1009,O
characterized,1009,O
by,1009,O
severe,1009,O
pain,1009,B-Disease
in,1009,O
the,1009,O
inguinal,1009,O
region,1009,O
",",1009,O
varying,1009,O
degrees,1009,O
of,1009,O
motor,1009,B-Disease
and,1009,I-Disease
sensory,1009,I-Disease
impairment,1009,I-Disease
",",1009,O
and,1009,O
flexure,1009,O
contracture,1009,B-Disease
of,1009,O
the,1009,O
involved,1009,O
extremity,1009,O
.,1009,O
Pneumonitis,1010,O
with,1010,O
pleural,1010,O
and,1010,O
pericardial,1010,O
effusion,1010,O
and,1010,O
neuropathy,1010,B-Disease
during,1010,O
amiodarone,1010,B-Chemical
therapy,1010,O
.,1010,O
A,1011,O
patient,1011,O
with,1011,O
sinuatrial,1011,B-Disease
disease,1011,I-Disease
and,1011,O
implanted,1011,O
pacemaker,1011,O
was,1011,O
treated,1011,O
with,1011,O
amiodarone,1011,B-Chemical
(,1011,O
maximum,1011,O
dose,1011,O
1000,1011,O
mg,1011,O
",",1011,O
maintenance,1011,O
dose,1011,O
800,1011,O
mg,1011,O
daily,1011,O
),1011,O
for,1011,O
10,1011,O
months,1011,O
",",1011,O
for,1011,O
control,1011,O
of,1011,O
supraventricular,1011,B-Disease
tachyarrhythmias,1011,I-Disease
.,1011,O
He,1012,O
developed,1012,O
pneumonitis,1012,B-Disease
",",1012,O
pleural,1012,O
and,1012,O
pericardial,1012,O
effusions,1012,O
",",1012,O
and,1012,O
a,1012,O
predominantly,1012,O
proximal,1012,B-Disease
motor,1012,I-Disease
neuropathy,1012,I-Disease
.,1012,O
Immediate,1013,O
but,1013,O
gradual,1013,O
improvement,1013,O
followed,1013,O
withdrawal,1013,O
of,1013,O
amiodarone,1013,B-Chemical
and,1013,O
treatment,1013,O
with,1013,O
prednisolone,1013,B-Chemical
.,1013,O
Review,1014,O
of,1014,O
this,1014,O
and,1014,O
previously,1014,O
reported,1014,O
cases,1014,O
indicates,1014,O
the,1014,O
need,1014,O
for,1014,O
early,1014,O
diagnosis,1014,O
of,1014,O
amiodarone,1014,B-Chemical
pneumonitis,1014,B-Disease
",",1014,O
immediate,1014,O
withdrawal,1014,O
of,1014,O
amiodarone,1014,B-Chemical
",",1014,O
and,1014,O
prompt,1014,O
but,1014,O
continued,1014,O
steroid,1014,B-Chemical
therapy,1014,O
to,1014,O
ensure,1014,O
full,1014,O
recovery,1014,O
.,1014,O
Amiodarone-induced,1015,B-Chemical
sinoatrial,1015,B-Disease
block,1015,I-Disease
.,1015,O
We,1016,O
observed,1016,O
sinoatrial,1016,B-Disease
block,1016,I-Disease
due,1016,O
to,1016,O
chronic,1016,O
amiodarone,1016,B-Chemical
administration,1016,O
in,1016,O
a,1016,O
5-year-old,1016,O
boy,1016,O
with,1016,O
primary,1016,B-Disease
cardiomyopathy,1016,I-Disease
",",1016,O
Wolff-Parkinson-White,1016,B-Disease
syndrome,1016,I-Disease
and,1016,O
supraventricular,1016,B-Disease
tachycardia,1016,I-Disease
.,1016,O
Reduction,1017,O
in,1017,O
the,1017,O
dosage,1017,O
of,1017,O
amiodarone,1017,B-Chemical
resulted,1017,O
in,1017,O
the,1017,O
disappearance,1017,O
of,1017,O
the,1017,O
sinoatrial,1017,B-Disease
block,1017,I-Disease
and,1017,O
the,1017,O
persistence,1017,O
of,1017,O
asymptomatic,1017,O
sinus,1017,B-Disease
bradycardia,1017,I-Disease
.,1017,O
Desipramine-induced,1018,B-Chemical
delirium,1018,B-Disease
at,1018,O
``,1018,O
subtherapeutic,1018,O
'',1018,O
concentrations,1018,O
:,1018,O
a,1018,O
case,1018,O
report,1018,O
.,1018,O
An,1019,O
elderly,1019,O
patient,1019,O
treated,1019,O
with,1019,O
low,1019,O
dose,1019,O
Desipramine,1019,B-Chemical
developed,1019,O
a,1019,O
delirium,1019,B-Disease
while,1019,O
her,1019,O
plasma,1019,O
level,1019,O
was,1019,O
in,1019,O
the,1019,O
``,1019,O
subtherapeutic,1019,O
'',1019,O
range,1019,O
.,1019,O
Delirium,1020,B-Disease
",",1020,O
which,1020,O
may,1020,O
be,1020,O
induced,1020,O
by,1020,O
tricyclic,1020,O
drug,1020,O
therapy,1020,O
in,1020,O
the,1020,O
elderly,1020,O
",",1020,O
can,1020,O
be,1020,O
caused,1020,O
by,1020,O
tricyclics,1020,O
with,1020,O
low,1020,O
anticholinergic,1020,O
potency,1020,O
.,1020,O
Therapeutic,1021,O
ranges,1021,O
for,1021,O
antidepressants,1021,B-Chemical
that,1021,O
have,1021,O
been,1021,O
derived,1021,O
from,1021,O
general,1021,O
adult,1021,O
population,1021,O
studies,1021,O
may,1021,O
not,1021,O
be,1021,O
appropriate,1021,O
for,1021,O
the,1021,O
elderly,1021,O
.,1021,O
Further,1022,O
studies,1022,O
of,1022,O
specifically,1022,O
elderly,1022,O
patients,1022,O
are,1022,O
now,1022,O
required,1022,O
to,1022,O
establish,1022,O
safer,1022,O
and,1022,O
more,1022,O
appropriate,1022,O
guidelines,1022,O
for,1022,O
drug,1022,O
therapy,1022,O
.,1022,O
Indomethacin-induced,1023,B-Chemical
renal,1023,B-Disease
insufficiency,1023,I-Disease
:,1023,O
recurrence,1023,O
on,1023,O
rechallenge,1023,O
.,1023,O
We,1024,O
have,1024,O
reported,1024,O
a,1024,O
case,1024,O
of,1024,O
acute,1024,O
oliguric,1024,O
renal,1024,B-Disease
failure,1024,I-Disease
with,1024,O
hyperkalemia,1024,B-Disease
in,1024,O
a,1024,O
patient,1024,O
with,1024,O
cirrhosis,1024,B-Disease
",",1024,O
ascites,1024,B-Disease
",",1024,O
and,1024,O
cor,1024,B-Disease
pulmonale,1024,I-Disease
after,1024,O
indomethacin,1024,B-Chemical
therapy,1024,O
.,1024,O
Prompt,1025,O
restoration,1025,O
of,1025,O
renal,1025,O
function,1025,O
followed,1025,O
drug,1025,O
withdrawal,1025,O
",",1025,O
while,1025,O
re-exposure,1025,O
to,1025,O
a,1025,O
single,1025,O
dose,1025,O
of,1025,O
indomethacin,1025,B-Chemical
caused,1025,O
recurrence,1025,O
of,1025,O
acute,1025,O
reversible,1025,O
oliguria,1025,B-Disease
.,1025,O
Our,1026,O
case,1026,O
supports,1026,O
the,1026,O
hypothesis,1026,O
that,1026,O
endogenous,1026,O
renal,1026,O
prostaglandins,1026,B-Chemical
play,1026,O
a,1026,O
role,1026,O
in,1026,O
the,1026,O
maintenance,1026,O
of,1026,O
renal,1026,O
blood,1026,O
flow,1026,O
when,1026,O
circulating,1026,O
plasma,1026,O
volume,1026,O
is,1026,O
diminished,1026,O
.,1026,O
Since,1027,O
nonsteroidal,1027,O
anti-inflammatory,1027,O
agents,1027,O
interfere,1027,O
with,1027,O
this,1027,O
compensatory,1027,O
mechanism,1027,O
and,1027,O
may,1027,O
cause,1027,O
acute,1027,B-Disease
renal,1027,I-Disease
failure,1027,I-Disease
",",1027,O
they,1027,O
should,1027,O
be,1027,O
used,1027,O
with,1027,O
caution,1027,O
in,1027,O
such,1027,O
patients,1027,O
.,1027,O
Treatment,1028,O
of,1028,O
psoriasis,1028,B-Disease
with,1028,O
azathioprine,1028,B-Chemical
.,1028,O
Azathioprine,1029,B-Chemical
treatment,1029,O
benefited,1029,O
19,1029,O
(,1029,O
66,1029,O
%,1029,O
),1029,O
out,1029,O
of,1029,O
29,1029,O
patients,1029,O
suffering,1029,O
from,1029,O
severe,1029,O
psoriasis,1029,B-Disease
.,1029,O
Haematological,1030,O
complications,1030,O
were,1030,O
not,1030,O
troublesome,1030,O
and,1030,O
results,1030,O
of,1030,O
biochemical,1030,O
liver,1030,O
function,1030,O
tests,1030,O
remained,1030,O
normal,1030,O
.,1030,O
Minimal,1031,O
cholestasis,1031,B-Disease
was,1031,O
seen,1031,O
in,1031,O
two,1031,O
cases,1031,O
and,1031,O
portal,1031,O
fibrosis,1031,B-Disease
of,1031,O
a,1031,O
reversible,1031,O
degree,1031,O
in,1031,O
eight,1031,O
.,1031,O
Liver,1032,O
biopsies,1032,O
should,1032,O
be,1032,O
undertaken,1032,O
at,1032,O
regular,1032,O
intervals,1032,O
if,1032,O
azathioprine,1032,B-Chemical
therapy,1032,O
is,1032,O
continued,1032,O
so,1032,O
that,1032,O
structural,1032,O
liver,1032,B-Disease
damage,1032,I-Disease
may,1032,O
be,1032,O
detected,1032,O
at,1032,O
an,1032,O
early,1032,O
and,1032,O
reversible,1032,O
stage,1032,O
.,1032,O
Comparison,1033,O
of,1033,O
the,1033,O
subjective,1033,O
effects,1033,O
and,1033,O
plasma,1033,O
concentrations,1033,O
following,1033,O
oral,1033,O
and,1033,O
i.m,1033,O
.,1033,O
administration,1034,O
of,1034,O
flunitrazepam,1034,B-Chemical
in,1034,O
volunteers,1034,O
.,1034,O
Flunitrazepam,1035,B-Chemical
0.5,1035,O
",",1035,O
1.0,1035,O
or,1035,O
2.0,1035,O
mg,1035,O
was,1035,O
given,1035,O
by,1035,O
the,1035,O
oral,1035,O
or,1035,O
i.m,1035,O
.,1035,O
routes,1036,O
to,1036,O
groups,1036,O
of,1036,O
volunteers,1036,O
and,1036,O
its,1036,O
effects,1036,O
compared,1036,O
.,1036,O
Plasma,1037,O
concentrations,1037,O
of,1037,O
the,1037,O
drug,1037,O
were,1037,O
estimated,1037,O
by,1037,O
gas-liquid,1037,O
chromatography,1037,O
",",1037,O
in,1037,O
a,1037,O
smaller,1037,O
number,1037,O
of,1037,O
the,1037,O
subjects,1037,O
.,1037,O
The,1038,O
most,1038,O
striking,1038,O
effect,1038,O
was,1038,O
sedation,1038,O
which,1038,O
increased,1038,O
with,1038,O
the,1038,O
dose,1038,O
",",1038,O
2,1038,O
mg,1038,O
producing,1038,O
deep,1038,O
sleep,1038,O
although,1038,O
the,1038,O
subjects,1038,O
could,1038,O
still,1038,O
be,1038,O
aroused,1038,O
.,1038,O
The,1039,O
effects,1039,O
of,1039,O
i.m,1039,O
.,1039,O
administration,1040,O
were,1040,O
apparent,1040,O
earlier,1040,O
and,1040,O
sometimes,1040,O
lasted,1040,O
longer,1040,O
than,1040,O
those,1040,O
following,1040,O
oral,1040,O
administration,1040,O
.,1040,O
Dizziness,1041,B-Disease
was,1041,O
less,1041,O
marked,1041,O
than,1041,O
sedation,1041,O
",",1041,O
but,1041,O
increased,1041,O
with,1041,O
the,1041,O
dose,1041,O
.,1041,O
There,1042,O
was,1042,O
pain,1042,B-Disease
on,1042,O
i.m,1042,O
.,1042,O
injection,1043,O
of,1043,O
flunitrazepam,1043,B-Chemical
significantly,1043,O
more,1043,O
often,1043,O
than,1043,O
with,1043,O
isotonic,1043,O
saline,1043,O
.,1043,O
Plasma,1044,O
concentrations,1044,O
varied,1044,O
with,1044,O
dose,1044,O
and,1044,O
route,1044,O
and,1044,O
corresponded,1044,O
qualitatively,1044,O
with,1044,O
the,1044,O
subjective,1044,O
effects,1044,O
.,1044,O
The,1045,O
drug,1045,O
was,1045,O
still,1045,O
present,1045,O
in,1045,O
measurable,1045,O
quantities,1045,O
after,1045,O
24,1045,O
h,1045,O
even,1045,O
with,1045,O
the,1045,O
smallest,1045,O
dose,1045,O
.,1045,O
Possible,1046,O
teratogenicity,1046,O
of,1046,O
sulphasalazine,1046,B-Chemical
.,1046,O
Three,1047,O
infants,1047,O
",",1047,O
born,1047,O
of,1047,O
two,1047,O
mothers,1047,O
with,1047,O
inflammatory,1047,B-Disease
bowel,1047,I-Disease
disease,1047,I-Disease
who,1047,O
received,1047,O
treatment,1047,O
with,1047,O
sulphasalazine,1047,B-Chemical
throughout,1047,O
pregnancy,1047,O
",",1047,O
were,1047,O
found,1047,O
to,1047,O
have,1047,O
major,1047,O
congenital,1047,B-Disease
anomalies,1047,I-Disease
.,1047,O
In,1048,O
the,1048,O
singleton,1048,O
pregnancy,1048,O
",",1048,O
the,1048,O
mother,1048,O
had,1048,O
ulcerative,1048,B-Disease
colitis,1048,I-Disease
",",1048,O
and,1048,O
the,1048,O
infant,1048,O
",",1048,O
a,1048,O
male,1048,O
",",1048,O
had,1048,O
coarctation,1048,B-Disease
of,1048,I-Disease
the,1048,I-Disease
aorta,1048,I-Disease
and,1048,O
a,1048,O
ventricular,1048,B-Disease
septal,1048,I-Disease
defect,1048,I-Disease
.,1048,O
In,1049,O
the,1049,O
twin,1049,O
pregnancy,1049,O
",",1049,O
the,1049,O
mother,1049,O
had,1049,O
Crohn,1049,B-Disease
's,1049,I-Disease
disease,1049,I-Disease
.,1049,O
The,1050,O
first,1050,O
twin,1050,O
",",1050,O
a,1050,O
female,1050,O
",",1050,O
had,1050,O
a,1050,O
left,1050,O
Potter-type,1050,B-Disease
IIa,1050,I-Disease
polycystic,1050,I-Disease
kidney,1050,I-Disease
and,1050,O
a,1050,O
rudimentary,1050,B-Disease
left,1050,I-Disease
uterine,1050,I-Disease
cornu,1050,I-Disease
.,1050,O
The,1051,O
second,1051,O
twin,1051,O
",",1051,O
a,1051,O
male,1051,O
",",1051,O
had,1051,O
some,1051,O
features,1051,O
of,1051,O
Potter,1051,B-Disease
's,1051,I-Disease
facies,1051,I-Disease
",",1051,O
hypoplastic,1051,B-Disease
lungs,1051,I-Disease
",",1051,O
absent,1051,B-Disease
kidneys,1051,I-Disease
and,1051,I-Disease
ureters,1051,I-Disease
",",1051,O
and,1051,O
talipes,1051,B-Disease
equinovarus,1051,I-Disease
.,1051,O
Despite,1052,O
reports,1052,O
to,1052,O
the,1052,O
contrary,1052,O
",",1052,O
it,1052,O
is,1052,O
suggested,1052,O
that,1052,O
sulphasalazine,1052,B-Chemical
may,1052,O
be,1052,O
teratogenic,1052,O
.,1052,O
Thrombotic,1053,B-Disease
microangiopathy,1053,I-Disease
and,1053,O
renal,1053,B-Disease
failure,1053,I-Disease
associated,1053,O
with,1053,O
antineoplastic,1053,O
chemotherapy,1053,O
.,1053,O
Five,1054,O
patients,1054,O
with,1054,O
carcinoma,1054,B-Disease
developed,1054,O
thrombotic,1054,B-Disease
microangiopathy,1054,I-Disease
(,1054,O
characterized,1054,O
by,1054,O
renal,1054,B-Disease
insufficiency,1054,I-Disease
",",1054,O
microangiopathic,1054,B-Disease
hemolytic,1054,I-Disease
anemia,1054,I-Disease
",",1054,O
and,1054,O
usually,1054,O
thrombocytopenia,1054,B-Disease
),1054,O
after,1054,O
treatment,1054,O
with,1054,O
cisplatin,1054,B-Chemical
",",1054,O
bleomycin,1054,B-Chemical
",",1054,O
and,1054,O
a,1054,O
vinca,1054,B-Chemical
alkaloid,1054,I-Chemical
.,1054,O
One,1055,O
patient,1055,O
had,1055,O
thrombotic,1055,B-Disease
thrombocytopenic,1055,I-Disease
purpura,1055,I-Disease
",",1055,O
three,1055,O
the,1055,O
hemolytic-uremic,1055,B-Disease
syndrome,1055,I-Disease
",",1055,O
and,1055,O
one,1055,O
an,1055,O
apparent,1055,O
forme,1055,O
fruste,1055,O
of,1055,O
one,1055,O
of,1055,O
these,1055,O
disorders,1055,O
.,1055,O
Histologic,1056,O
examination,1056,O
of,1056,O
the,1056,O
renal,1056,O
tissue,1056,O
showed,1056,O
evidence,1056,O
of,1056,O
intravascular,1056,B-Disease
coagulation,1056,I-Disease
",",1056,O
primarily,1056,O
affecting,1056,O
the,1056,O
small,1056,O
arteries,1056,O
",",1056,O
arterioles,1056,O
",",1056,O
and,1056,O
glomeruli,1056,O
.,1056,O
Because,1057,O
each,1057,O
patient,1057,O
was,1057,O
tumor-free,1057,B-Disease
or,1057,O
had,1057,O
only,1057,O
a,1057,O
small,1057,O
tumor,1057,B-Disease
at,1057,O
the,1057,O
onset,1057,O
of,1057,O
this,1057,O
syndrome,1057,O
",",1057,O
the,1057,O
thrombotic,1057,B-Disease
microangiopathy,1057,I-Disease
may,1057,O
have,1057,O
been,1057,O
induced,1057,O
by,1057,O
chemotherapy,1057,O
.,1057,O
Diagnosis,1058,O
of,1058,O
this,1058,O
potentially,1058,O
fatal,1058,O
complication,1058,O
may,1058,O
be,1058,O
delayed,1058,O
or,1058,O
missed,1058,O
if,1058,O
renal,1058,O
tissue,1058,O
or,1058,O
the,1058,O
peripheral,1058,O
blood,1058,O
smear,1058,O
is,1058,O
not,1058,O
examined,1058,O
",",1058,O
because,1058,O
renal,1058,B-Disease
failure,1058,I-Disease
may,1058,O
be,1058,O
ascribed,1058,O
to,1058,O
cisplatin,1058,B-Chemical
nephrotoxicity,1058,B-Disease
and,1058,O
the,1058,O
anemia,1058,B-Disease
and,1058,O
thrombocytopenia,1058,B-Disease
to,1058,O
drug-induced,1058,O
bone,1058,B-Disease
marrow,1058,I-Disease
suppression,1058,I-Disease
.,1058,O
International,1059,O
mexiletine,1059,B-Chemical
and,1059,O
placebo,1059,O
antiarrhythmic,1059,O
coronary,1059,O
trial,1059,O
:,1059,O
I,1059,O
.,1059,O
Report,1060,O
on,1060,O
arrhythmia,1060,B-Disease
and,1060,O
other,1060,O
findings,1060,O
.,1060,O
Impact,1061,O
Research,1061,O
Group,1061,O
.,1061,O
The,1062,O
antiarrhythmic,1062,O
effects,1062,O
of,1062,O
the,1062,O
sustained,1062,O
release,1062,O
form,1062,O
of,1062,O
mexiletine,1062,B-Chemical
(,1062,O
Mexitil-Perlongets,1062,B-Chemical
),1062,O
were,1062,O
evaluated,1062,O
in,1062,O
a,1062,O
double-blind,1062,O
placebo,1062,O
trial,1062,O
in,1062,O
630,1062,O
patients,1062,O
with,1062,O
recent,1062,O
documented,1062,O
myocardial,1062,B-Disease
infarction,1062,I-Disease
.,1062,O
The,1063,O
primary,1063,O
response,1063,O
variable,1063,O
was,1063,O
based,1063,O
on,1063,O
central,1063,O
reading,1063,O
of,1063,O
24,1063,O
hour,1063,O
ambulatory,1063,O
electrocardiographic,1063,O
recordings,1063,O
and,1063,O
was,1063,O
defined,1063,O
as,1063,O
the,1063,O
occurrence,1063,O
of,1063,O
30,1063,O
or,1063,O
more,1063,O
single,1063,O
premature,1063,O
ventricular,1063,O
complexes,1063,O
in,1063,O
any,1063,O
two,1063,O
consecutive,1063,O
30,1063,O
minute,1063,O
blocks,1063,O
or,1063,O
one,1063,O
or,1063,O
more,1063,O
runs,1063,O
of,1063,O
two,1063,O
or,1063,O
more,1063,O
premature,1063,O
ventricular,1063,O
complexes,1063,O
in,1063,O
the,1063,O
entire,1063,O
24,1063,O
hour,1063,O
electrocardiographic,1063,O
recording,1063,O
.,1063,O
Large,1064,O
differences,1064,O
",",1064,O
regarded,1064,O
as,1064,O
statistically,1064,O
significant,1064,O
",",1064,O
between,1064,O
the,1064,O
mexiletine,1064,B-Chemical
and,1064,O
placebo,1064,O
groups,1064,O
were,1064,O
noted,1064,O
in,1064,O
that,1064,O
end,1064,O
point,1064,O
at,1064,O
months,1064,O
1,1064,O
and,1064,O
4,1064,O
",",1064,O
but,1064,O
only,1064,O
trends,1064,O
were,1064,O
observed,1064,O
at,1064,O
month,1064,O
12,1064,O
.,1064,O
These,1065,O
differences,1065,O
were,1065,O
observed,1065,O
even,1065,O
though,1065,O
the,1065,O
serum,1065,O
mexiletine,1065,B-Chemical
levels,1065,O
obtained,1065,O
in,1065,O
this,1065,O
study,1065,O
were,1065,O
generally,1065,O
lower,1065,O
than,1065,O
those,1065,O
observed,1065,O
in,1065,O
studies,1065,O
that,1065,O
have,1065,O
used,1065,O
the,1065,O
regular,1065,O
form,1065,O
of,1065,O
the,1065,O
drug,1065,O
.,1065,O
There,1066,O
were,1066,O
more,1066,O
deaths,1066,B-Disease
in,1066,O
the,1066,O
mexiletine,1066,B-Chemical
group,1066,O
(,1066,O
7.6,1066,O
%,1066,O
),1066,O
than,1066,O
in,1066,O
the,1066,O
placebo,1066,O
group,1066,O
(,1066,O
4.8,1066,O
%,1066,O
),1066,O
;,1066,O
the,1066,O
difference,1066,O
was,1066,O
not,1066,O
statistically,1066,O
significant,1066,O
.,1066,O
The,1067,O
incidence,1067,O
of,1067,O
coronary,1067,O
events,1067,O
was,1067,O
similar,1067,O
in,1067,O
both,1067,O
groups,1067,O
.,1067,O
Previously,1068,O
recognized,1068,O
side,1068,O
effects,1068,O
",",1068,O
particularly,1068,O
tremor,1068,B-Disease
and,1068,O
gastrointestinal,1068,B-Disease
problems,1068,I-Disease
",",1068,O
were,1068,O
more,1068,O
frequent,1068,O
in,1068,O
the,1068,O
mexiletine,1068,B-Chemical
group,1068,O
than,1068,O
in,1068,O
the,1068,O
placebo,1068,O
group,1068,O
.,1068,O
Changes,1069,O
in,1069,O
heart,1069,O
size,1069,O
during,1069,O
long-term,1069,O
timolol,1069,B-Chemical
treatment,1069,O
after,1069,O
myocardial,1069,B-Disease
infarction,1069,I-Disease
.,1069,O
The,1070,O
effect,1070,O
of,1070,O
long-term,1070,O
timolol,1070,B-Chemical
treatment,1070,O
on,1070,O
heart,1070,O
size,1070,O
after,1070,O
myocardial,1070,B-Disease
infarction,1070,I-Disease
was,1070,O
evaluated,1070,O
by,1070,O
X-ray,1070,O
in,1070,O
a,1070,O
double-blind,1070,O
study,1070,O
including,1070,O
241,1070,O
patients,1070,O
(,1070,O
placebo,1070,O
126,1070,O
",",1070,O
timolol,1070,B-Chemical
115,1070,O
),1070,O
.,1070,O
The,1071,O
follow-up,1071,O
period,1071,O
was,1071,O
12,1071,O
months,1071,O
.,1071,O
The,1072,O
timolol-treated,1072,B-Chemical
patients,1072,O
showed,1072,O
a,1072,O
small,1072,O
but,1072,O
significant,1072,O
increase,1072,O
in,1072,O
heart,1072,O
size,1072,O
from,1072,O
baseline,1072,O
in,1072,O
contrast,1072,O
to,1072,O
a,1072,O
decrease,1072,O
in,1072,O
the,1072,O
placebo,1072,O
group,1072,O
.,1072,O
These,1073,O
differences,1073,O
may,1073,O
be,1073,O
caused,1073,O
by,1073,O
timolol-induced,1073,B-Chemical
bradycardia,1073,B-Disease
and,1073,O
a,1073,O
compensatory,1073,O
increase,1073,O
in,1073,O
end-diastolic,1073,O
volume,1073,O
.,1073,O
The,1074,O
timolol-related,1074,B-Chemical
increase,1074,O
in,1074,O
heart,1074,O
size,1074,O
was,1074,O
observed,1074,O
only,1074,O
in,1074,O
patients,1074,O
with,1074,O
normal,1074,O
and,1074,O
borderline,1074,O
heart,1074,O
size,1074,O
.,1074,O
In,1075,O
patients,1075,O
with,1075,O
cardiomegaly,1075,B-Disease
",",1075,O
the,1075,O
increase,1075,O
in,1075,O
heart,1075,O
size,1075,O
was,1075,O
similar,1075,O
in,1075,O
both,1075,O
groups,1075,O
.,1075,O
After,1076,O
re-infarction,1076,O
",",1076,O
heart,1076,O
size,1076,O
increased,1076,O
in,1076,O
the,1076,O
placebo,1076,O
group,1076,O
and,1076,O
remained,1076,O
unchanged,1076,O
in,1076,O
the,1076,O
timolol,1076,B-Chemical
group,1076,O
.,1076,O
Vitamin,1077,B-Chemical
D3,1077,I-Chemical
toxicity,1077,B-Disease
in,1077,O
dairy,1077,O
cows,1077,O
.,1077,O
Large,1078,O
parenteral,1078,O
doses,1078,O
of,1078,O
vitamin,1078,B-Chemical
D3,1078,I-Chemical
(,1078,O
15,1078,O
to,1078,O
17.5,1078,O
x,1078,O
10,1078,O
(,1078,O
6,1078,O
),1078,O
IU,1078,O
vitamin,1078,B-Chemical
D3,1078,I-Chemical
),1078,O
were,1078,O
associated,1078,O
with,1078,O
prolonged,1078,O
hypercalcemia,1078,B-Disease
",",1078,O
hyperphosphatemia,1078,B-Disease
",",1078,O
and,1078,O
large,1078,O
increases,1078,O
of,1078,O
vitamin,1078,B-Chemical
D3,1078,I-Chemical
and,1078,O
its,1078,O
metabolites,1078,O
in,1078,O
the,1078,O
blood,1078,O
plasma,1078,O
of,1078,O
nonlactating,1078,O
nonpregnant,1078,O
and,1078,O
pregnant,1078,O
Jersey,1078,O
cows,1078,O
.,1078,O
Calcium,1079,B-Chemical
concentrations,1079,O
1,1079,O
day,1079,O
postpartum,1079,O
were,1079,O
higher,1079,O
in,1079,O
cows,1079,O
treated,1079,O
with,1079,O
vitamin,1079,B-Chemical
D3,1079,I-Chemical
about,1079,O
32,1079,O
days,1079,O
prepartum,1079,O
(,1079,O
8.8,1079,O
mg/100,1079,O
ml,1079,O
),1079,O
than,1079,O
in,1079,O
control,1079,O
cows,1079,O
(,1079,O
5.5,1079,O
mg/100,1079,O
ml,1079,O
),1079,O
.,1079,O
None,1080,O
of,1080,O
the,1080,O
cows,1080,O
treated,1080,O
with,1080,O
vitamin,1080,B-Chemical
D3,1080,I-Chemical
showed,1080,O
signs,1080,O
of,1080,O
milk,1080,B-Disease
fever,1080,I-Disease
during,1080,O
the,1080,O
peripartal,1080,O
period,1080,O
;,1080,O
however,1080,O
",",1080,O
22,1080,O
%,1080,O
of,1080,O
the,1080,O
control,1080,O
cows,1080,O
developed,1080,O
clinical,1080,O
signs,1080,O
of,1080,O
milk,1080,B-Disease
fever,1080,I-Disease
during,1080,O
this,1080,O
period,1080,O
.,1080,O
Signs,1081,O
of,1081,O
vitamin,1081,B-Chemical
D3,1081,I-Chemical
toxicity,1081,B-Disease
were,1081,O
not,1081,O
observed,1081,O
in,1081,O
nonlactating,1081,O
nonpregnant,1081,O
cows,1081,O
;,1081,O
however,1081,O
",",1081,O
pregnant,1081,O
cows,1081,O
commonly,1081,O
developed,1081,O
severe,1081,O
signs,1081,O
of,1081,O
vitamin,1081,B-Chemical
D3,1081,I-Chemical
toxicity,1081,B-Disease
and,1081,O
10,1081,O
of,1081,O
17,1081,O
cows,1081,O
died,1081,O
.,1081,O
There,1082,O
was,1082,O
widespread,1082,O
metastatic,1082,O
calcification,1082,O
in,1082,O
the,1082,O
cows,1082,O
that,1082,O
died,1082,O
.,1082,O
Because,1083,O
of,1083,O
the,1083,O
extreme,1083,O
toxicity,1083,B-Disease
of,1083,O
vitamin,1083,B-Chemical
D3,1083,I-Chemical
in,1083,O
pregnant,1083,O
Jersey,1083,O
cows,1083,O
and,1083,O
the,1083,O
low,1083,O
margin,1083,O
of,1083,O
safety,1083,O
between,1083,O
doses,1083,O
of,1083,O
vitamin,1083,B-Chemical
D3,1083,I-Chemical
that,1083,O
prevent,1083,O
milk,1083,B-Disease
fever,1083,I-Disease
and,1083,O
doses,1083,O
that,1083,O
induce,1083,O
milk,1083,B-Disease
fever,1083,I-Disease
",",1083,O
we,1083,O
concluded,1083,O
that,1083,O
vitamin,1083,B-Chemical
D3,1083,I-Chemical
can,1083,O
not,1083,O
be,1083,O
used,1083,O
practically,1083,O
to,1083,O
prevent,1083,O
milk,1083,B-Disease
fever,1083,I-Disease
when,1083,O
injected,1083,O
several,1083,O
weeks,1083,O
prepartum,1083,O
.,1083,O
Diseases,1084,B-Disease
of,1084,I-Disease
peripheral,1084,I-Disease
nerves,1084,I-Disease
as,1084,O
seen,1084,O
in,1084,O
the,1084,O
Nigerian,1084,O
African,1084,O
.,1084,O
The,1085,O
anatomical,1085,O
and,1085,O
aetiological,1085,O
diagnoses,1085,O
of,1085,O
peripheral,1085,B-Disease
nerve,1085,I-Disease
disease,1085,I-Disease
excluding,1085,O
its,1085,O
primary,1085,O
benign,1085,O
and,1085,O
malignant,1085,O
disorders,1085,O
",",1085,O
as,1085,O
seen,1085,O
in,1085,O
358,1085,O
Nigerians,1085,O
are,1085,O
presented,1085,O
.,1085,O
There,1086,O
is,1086,O
a,1086,O
male,1086,O
preponderance,1086,O
and,1086,O
the,1086,O
peak,1086,O
incidence,1086,O
is,1086,O
in,1086,O
the,1086,O
fourth,1086,O
decade,1086,O
.,1086,O
Sensori-motor,1087,B-Disease
neuropathy,1087,I-Disease
was,1087,O
the,1087,O
commonest,1087,O
presentation,1087,O
(,1087,O
50,1087,O
%,1087,O
),1087,O
.,1087,O
Guillain-Barr,1088,B-Disease
syndrome,1088,I-Disease
was,1088,O
the,1088,O
commonest,1088,O
identifiable,1088,O
cause,1088,O
(,1088,O
15.6,1088,O
%,1088,O
),1088,O
",",1088,O
accounting,1088,O
for,1088,O
half,1088,O
of,1088,O
the,1088,O
cases,1088,O
with,1088,O
motor,1088,B-Disease
neuropathy,1088,I-Disease
.,1088,O
Peripheral,1089,B-Disease
neuropathy,1089,I-Disease
due,1089,O
to,1089,O
nutritional,1089,B-Disease
deficiency,1089,I-Disease
of,1089,O
thiamine,1089,B-Chemical
and,1089,O
riboflavin,1089,B-Chemical
was,1089,O
common,1089,O
(,1089,O
10.1,1089,O
%,1089,O
),1089,O
and,1089,O
presented,1089,O
mainly,1089,O
as,1089,O
sensory,1089,O
and,1089,O
sensori-motor,1089,B-Disease
neuropathy,1089,I-Disease
.,1089,O
Diabetes,1090,B-Disease
mellitus,1090,I-Disease
was,1090,O
the,1090,O
major,1090,O
cause,1090,O
of,1090,O
autonomic,1090,B-Disease
neuropathy,1090,I-Disease
.,1090,O
Isoniazid,1091,B-Chemical
was,1091,O
the,1091,O
most,1091,O
frequent,1091,O
agent,1091,O
in,1091,O
drug-induced,1091,O
neuropathy,1091,B-Disease
.,1091,O
Migraine,1092,B-Disease
(,1092,O
20,1092,O
%,1092,O
),1092,O
was,1092,O
not,1092,O
an,1092,O
uncommon,1092,O
cause,1092,O
of,1092,O
cranial,1092,B-Disease
neuropathy,1092,I-Disease
although,1092,O
malignancies,1092,B-Disease
arising,1092,O
from,1092,O
the,1092,O
reticuloendothelial,1092,O
system,1092,O
or,1092,O
related,1092,O
structures,1092,O
of,1092,O
the,1092,O
head,1092,O
and,1092,O
neck,1092,O
were,1092,O
more,1092,O
frequent,1092,O
(,1092,O
26,1092,O
%,1092,O
),1092,O
.,1092,O
In,1093,O
26.5,1093,O
%,1093,O
of,1093,O
all,1093,O
the,1093,O
cases,1093,O
",",1093,O
the,1093,O
aetiology,1093,O
of,1093,O
the,1093,O
neuropathy,1093,B-Disease
was,1093,O
undetermined,1093,O
.,1093,O
Heredofamilial,1094,O
and,1094,O
connective,1094,B-Disease
tissue,1094,I-Disease
disorders,1094,I-Disease
were,1094,O
rare,1094,O
.,1094,O
Some,1095,O
of,1095,O
the,1095,O
factors,1095,O
related,1095,O
to,1095,O
the,1095,O
clinical,1095,O
presentation,1095,O
and,1095,O
pathogenesis,1095,O
of,1095,O
the,1095,O
neuropathies,1095,B-Disease
are,1095,O
briefly,1095,O
discussed,1095,O
.,1095,O
Reduction,1096,O
in,1096,O
caffeine,1096,B-Chemical
toxicity,1096,B-Disease
by,1096,O
acetaminophen,1096,B-Chemical
.,1096,O
A,1097,O
patient,1097,O
who,1097,O
allegedly,1097,O
consumed,1097,O
100,1097,O
tablets,1097,O
of,1097,O
an,1097,O
over-the-counter,1097,O
analgesic,1097,O
containing,1097,O
sodium,1097,B-Chemical
acetylsalicylate,1097,I-Chemical
",",1097,O
caffeine,1097,B-Chemical
",",1097,O
and,1097,O
acetaminophen,1097,B-Chemical
displayed,1097,O
no,1097,O
significant,1097,O
CNS,1097,O
stimulation,1097,O
despite,1097,O
the,1097,O
presence,1097,O
of,1097,O
175,1097,O
micrograms,1097,O
of,1097,O
caffeine,1097,B-Chemical
per,1097,O
mL,1097,O
of,1097,O
serum,1097,O
.,1097,O
Because,1098,O
salicylates,1098,O
have,1098,O
been,1098,O
reported,1098,O
to,1098,O
augment,1098,O
the,1098,O
stimulatory,1098,O
effects,1098,O
of,1098,O
caffeine,1098,B-Chemical
on,1098,O
the,1098,O
CNS,1098,O
",",1098,O
attention,1098,O
was,1098,O
focused,1098,O
on,1098,O
the,1098,O
possibility,1098,O
that,1098,O
the,1098,O
presence,1098,O
of,1098,O
acetaminophen,1098,B-Chemical
(,1098,O
52,1098,O
micrograms/mL,1098,O
),1098,O
reduced,1098,O
the,1098,O
CNS,1098,O
toxicity,1098,B-Disease
of,1098,O
caffeine,1098,B-Chemical
.,1098,O
Studies,1099,O
in,1099,O
DBA/2J,1099,O
mice,1099,O
showed,1099,O
that,1099,O
:,1099,O
1,1099,O
),1099,O
pretreatment,1099,O
with,1099,O
acetaminophen,1099,B-Chemical
(,1099,O
100,1099,O
mg/kg,1099,O
),1099,O
increased,1099,O
the,1099,O
interval,1099,O
between,1099,O
the,1099,O
administration,1099,O
of,1099,O
caffeine,1099,B-Chemical
(,1099,O
300,1099,O
to,1099,O
450,1099,O
mg/kg,1099,O
IP,1099,O
),1099,O
and,1099,O
the,1099,O
onset,1099,O
of,1099,O
fatal,1099,O
convulsions,1099,B-Disease
by,1099,O
a,1099,O
factor,1099,O
of,1099,O
about,1099,O
two,1099,O
;,1099,O
and,1099,O
2,1099,O
),1099,O
pretreatment,1099,O
with,1099,O
acetaminophen,1099,B-Chemical
(,1099,O
75,1099,O
mg/kg,1099,O
),1099,O
reduced,1099,O
the,1099,O
incidence,1099,O
of,1099,O
audiogenic,1099,O
seizures,1099,B-Disease
produced,1099,O
in,1099,O
the,1099,O
presence,1099,O
of,1099,O
caffeine,1099,B-Chemical
(,1099,O
12.5,1099,O
to,1099,O
75,1099,O
mg/kg,1099,O
IP,1099,O
),1099,O
.,1099,O
The,1100,O
frequency,1100,O
of,1100,O
sound-induced,1100,O
seizures,1100,B-Disease
after,1100,O
12.5,1100,O
or,1100,O
25,1100,O
mg/kg,1100,O
caffeine,1100,B-Chemical
was,1100,O
reduced,1100,O
from,1100,O
50,1100,O
to,1100,O
5,1100,O
%,1100,O
by,1100,O
acetaminophen,1100,B-Chemical
.,1100,O
In,1101,O
the,1101,O
absence,1101,O
of,1101,O
caffeine,1101,B-Chemical
",",1101,O
acetaminophen,1101,B-Chemical
(,1101,O
up,1101,O
to,1101,O
300,1101,O
mg/kg,1101,O
),1101,O
did,1101,O
not,1101,O
modify,1101,O
the,1101,O
seizures,1101,B-Disease
induced,1101,O
by,1101,O
maximal,1101,O
electroshock,1101,O
and,1101,O
did,1101,O
not,1101,O
alter,1101,O
the,1101,O
convulsant,1101,O
dose,1101,O
of,1101,O
pentylenetetrezol,1101,B-Chemical
in,1101,O
mice,1101,O
(,1101,O
tests,1101,O
performed,1101,O
by,1101,O
the,1101,O
Anticonvulsant,1101,O
Screening,1101,O
Project,1101,O
of,1101,O
NINCDS,1101,O
),1101,O
.,1101,O
Acetaminophen,1102,B-Chemical
(,1102,O
up,1102,O
to,1102,O
150,1102,O
micrograms/mL,1102,O
),1102,O
did,1102,O
not,1102,O
retard,1102,O
the,1102,O
incorporation,1102,O
of,1102,O
radioactive,1102,O
adenosine,1102,B-Chemical
into,1102,O
ATP,1102,B-Chemical
in,1102,O
slices,1102,O
of,1102,O
rat,1102,O
cerebral,1102,O
cortex,1102,O
.,1102,O
Thus,1103,O
the,1103,O
mechanism,1103,O
by,1103,O
which,1103,O
acetaminophen,1103,B-Chemical
antagonizes,1103,O
the,1103,O
actions,1103,O
of,1103,O
caffeine,1103,B-Chemical
in,1103,O
the,1103,O
CNS,1103,O
remains,1103,O
unknown,1103,O
.,1103,O
A,1104,O
double-blind,1104,O
study,1104,O
of,1104,O
the,1104,O
efficacy,1104,O
and,1104,O
safety,1104,O
of,1104,O
dothiepin,1104,B-Chemical
hydrochloride,1104,I-Chemical
in,1104,O
the,1104,O
treatment,1104,O
of,1104,O
major,1104,O
depressive,1104,B-Disease
disorder,1104,I-Disease
.,1104,O
In,1105,O
a,1105,O
6-week,1105,O
double-blind,1105,O
parallel,1105,O
treatment,1105,O
study,1105,O
",",1105,O
dothiepin,1105,B-Chemical
and,1105,O
amitriptyline,1105,B-Chemical
were,1105,O
compared,1105,O
to,1105,O
placebo,1105,O
in,1105,O
the,1105,O
treatment,1105,O
of,1105,O
33,1105,O
depressed,1105,B-Disease
outpatients,1105,O
.,1105,O
Dothiepin,1106,B-Chemical
and,1106,O
amitriptyline,1106,B-Chemical
were,1106,O
equally,1106,O
effective,1106,O
in,1106,O
alleviating,1106,O
the,1106,O
symptoms,1106,O
of,1106,O
depressive,1106,B-Disease
illness,1106,I-Disease
",",1106,O
and,1106,O
both,1106,O
were,1106,O
significantly,1106,O
superior,1106,O
to,1106,O
placebo,1106,O
.,1106,O
The,1107,O
overall,1107,O
incidence,1107,O
of,1107,O
side,1107,O
effects,1107,O
and,1107,O
the,1107,O
frequency,1107,O
and,1107,O
severity,1107,O
of,1107,O
blurred,1107,B-Disease
vision,1107,I-Disease
",",1107,O
dry,1107,B-Disease
mouth,1107,I-Disease
",",1107,O
and,1107,O
drowsiness,1107,O
were,1107,O
significantly,1107,O
less,1107,O
with,1107,O
dothiepin,1107,B-Chemical
than,1107,O
with,1107,O
amitriptyline,1107,B-Chemical
.,1107,O
Dothiepin,1108,B-Chemical
also,1108,O
produced,1108,O
fewer,1108,O
CNS,1108,O
and,1108,O
cardiovascular,1108,O
effects,1108,O
.,1108,O
There,1109,O
were,1109,O
no,1109,O
clinically,1109,O
important,1109,O
changes,1109,O
in,1109,O
laboratory,1109,O
parameters,1109,O
.,1109,O
Dothiepin,1110,B-Chemical
thus,1110,O
was,1110,O
found,1110,O
to,1110,O
be,1110,O
an,1110,O
effective,1110,O
antidepressant,1110,B-Chemical
drug,1110,O
associated,1110,O
with,1110,O
fewer,1110,O
side,1110,O
effects,1110,O
than,1110,O
amitriptyline,1110,B-Chemical
in,1110,O
the,1110,O
treatment,1110,O
of,1110,O
depressed,1110,B-Disease
outpatients,1110,O
.,1110,O
Behavioral,1111,O
effects,1111,O
of,1111,O
diazepam,1111,B-Chemical
and,1111,O
propranolol,1111,B-Chemical
in,1111,O
patients,1111,O
with,1111,O
panic,1111,B-Disease
disorder,1111,I-Disease
and,1111,O
agoraphobia,1111,B-Disease
.,1111,O
The,1112,O
effects,1112,O
of,1112,O
oral,1112,O
doses,1112,O
of,1112,O
diazepam,1112,B-Chemical
(,1112,O
single,1112,O
dose,1112,O
of,1112,O
10,1112,O
mg,1112,O
and,1112,O
a,1112,O
median,1112,O
dose,1112,O
of,1112,O
30,1112,O
mg/day,1112,O
for,1112,O
2,1112,O
weeks,1112,O
),1112,O
and,1112,O
propranolol,1112,B-Chemical
(,1112,O
single,1112,O
dose,1112,O
of,1112,O
80,1112,O
mg,1112,O
and,1112,O
a,1112,O
median,1112,O
dose,1112,O
of,1112,O
240,1112,O
mg/day,1112,O
for,1112,O
2,1112,O
weeks,1112,O
),1112,O
on,1112,O
psychological,1112,O
performance,1112,O
of,1112,O
patients,1112,O
with,1112,O
panic,1112,B-Disease
disorders,1112,I-Disease
and,1112,O
agoraphobia,1112,B-Disease
were,1112,O
investigated,1112,O
in,1112,O
a,1112,O
double-blind,1112,O
",",1112,O
randomized,1112,O
and,1112,O
crossover,1112,O
design,1112,O
.,1112,O
Both,1113,O
drugs,1113,O
impaired,1113,B-Disease
immediate,1113,I-Disease
free,1113,I-Disease
recall,1113,I-Disease
but,1113,O
the,1113,O
decrease,1113,O
was,1113,O
greater,1113,O
for,1113,O
diazepam,1113,B-Chemical
than,1113,O
propranolol,1113,B-Chemical
.,1113,O
Delayed,1114,B-Disease
free,1114,I-Disease
recall,1114,I-Disease
was,1114,I-Disease
also,1114,I-Disease
impaired,1114,I-Disease
but,1114,O
the,1114,O
two,1114,O
drugs,1114,O
did,1114,O
not,1114,O
differ,1114,O
.,1114,O
Patients,1115,O
tapped,1115,O
faster,1115,O
after,1115,O
propranolol,1115,B-Chemical
than,1115,O
diazepam,1115,B-Chemical
and,1115,O
they,1115,O
were,1115,O
more,1115,O
sedated,1115,O
after,1115,O
diazepam,1115,B-Chemical
than,1115,O
propranolol,1115,B-Chemical
.,1115,O
After,1116,O
2,1116,O
weeks,1116,O
of,1116,O
treatment,1116,O
",",1116,O
patients,1116,O
tested,1116,O
5-8,1116,O
h,1116,O
after,1116,O
the,1116,O
last,1116,O
dose,1116,O
of,1116,O
medication,1116,O
did,1116,O
not,1116,O
show,1116,O
any,1116,O
decrement,1116,O
of,1116,O
performance,1116,O
.,1116,O
These,1117,O
results,1117,O
are,1117,O
similar,1117,O
to,1117,O
those,1117,O
previously,1117,O
found,1117,O
in,1117,O
healthy,1117,O
subjects,1117,O
.,1117,O
Accumulation,1118,O
of,1118,O
drugs,1118,O
was,1118,O
not,1118,O
reflected,1118,O
in,1118,O
prolonged,1118,O
behavioral,1118,B-Disease
impairment,1118,I-Disease
.,1118,O
Comparison,1119,O
of,1119,O
i.v,1119,O
.,1119,O
glycopyrrolate,1120,B-Chemical
and,1120,O
atropine,1120,B-Chemical
in,1120,O
the,1120,O
prevention,1120,O
of,1120,O
bradycardia,1120,B-Disease
and,1120,O
arrhythmias,1120,B-Disease
following,1120,O
repeated,1120,O
doses,1120,O
of,1120,O
suxamethonium,1120,B-Chemical
in,1120,O
children,1120,O
.,1120,O
The,1121,O
effectiveness,1121,O
of,1121,O
administration,1121,O
of,1121,O
glycopyrrolate,1121,B-Chemical
5,1121,O
and,1121,O
10,1121,O
micrograms,1121,O
kg-1,1121,O
and,1121,O
atropine,1121,B-Chemical
10,1121,O
and,1121,O
20,1121,O
micrograms,1121,O
kg-1,1121,O
i.v,1121,O
.,1121,O
immediately,1122,O
before,1122,O
the,1122,O
induction,1122,O
of,1122,O
anaesthesia,1122,O
",",1122,O
to,1122,O
prevent,1122,O
arrhythmia,1122,B-Disease
and,1122,O
bradycardia,1122,B-Disease
following,1122,O
repeated,1122,O
doses,1122,O
of,1122,O
suxamethonium,1122,B-Chemical
in,1122,O
children,1122,O
",",1122,O
was,1122,O
studied,1122,O
.,1122,O
A,1123,O
control,1123,O
group,1123,O
was,1123,O
included,1123,O
for,1123,O
comparison,1123,O
with,1123,O
the,1123,O
lower,1123,O
dose,1123,O
range,1123,O
of,1123,O
glycopyrrolate,1123,B-Chemical
and,1123,O
atropine,1123,B-Chemical
.,1123,O
A,1124,O
frequency,1124,O
of,1124,O
bradycardia,1124,B-Disease
of,1124,O
50,1124,O
%,1124,O
was,1124,O
noted,1124,O
in,1124,O
the,1124,O
control,1124,O
group,1124,O
",",1124,O
but,1124,O
this,1124,O
was,1124,O
not,1124,O
significantly,1124,O
different,1124,O
from,1124,O
the,1124,O
frequency,1124,O
with,1124,O
the,1124,O
active,1124,O
drugs,1124,O
.,1124,O
Bradycardia,1125,B-Disease
(,1125,O
defined,1125,O
as,1125,O
a,1125,O
decrease,1125,O
in,1125,O
heart,1125,O
rate,1125,O
to,1125,O
less,1125,O
than,1125,O
50,1125,O
beat,1125,O
min-1,1125,O
),1125,O
was,1125,O
prevented,1125,O
when,1125,O
the,1125,O
larger,1125,O
dose,1125,O
of,1125,O
either,1125,O
active,1125,O
drug,1125,O
was,1125,O
used,1125,O
.,1125,O
It,1126,O
is,1126,O
recommended,1126,O
that,1126,O
either,1126,O
glycopyrrolate,1126,B-Chemical
10,1126,O
micrograms,1126,O
kg-1,1126,O
or,1126,O
atropine,1126,B-Chemical
20,1126,O
micrograms,1126,O
kg-1,1126,O
i.v,1126,O
.,1126,O
should,1127,O
immediately,1127,O
precede,1127,O
induction,1127,O
of,1127,O
anaesthesia,1127,O
",",1127,O
in,1127,O
children,1127,O
",",1127,O
if,1127,O
the,1127,O
repeated,1127,O
administration,1127,O
of,1127,O
suxamethonium,1127,B-Chemical
is,1127,O
anticipated,1127,O
.,1127,O
Veno-occlusive,1128,B-Disease
liver,1128,I-Disease
disease,1128,I-Disease
after,1128,O
dacarbazine,1128,B-Chemical
therapy,1128,O
(,1128,O
DTIC,1128,B-Chemical
),1128,O
for,1128,O
melanoma,1128,B-Disease
.,1128,O
A,1129,O
case,1129,O
of,1129,O
veno-occlusive,1129,B-Disease
disease,1129,I-Disease
of,1129,I-Disease
the,1129,I-Disease
liver,1129,I-Disease
with,1129,O
fatal,1129,O
outcome,1129,O
after,1129,O
dacarbazine,1129,B-Chemical
(,1129,O
DTIC,1129,B-Chemical
),1129,O
therapy,1129,O
for,1129,O
melanoma,1129,B-Disease
is,1129,O
reported,1129,O
.,1129,O
There,1130,O
was,1130,O
a,1130,O
fulminant,1130,O
clinical,1130,O
course,1130,O
from,1130,O
start,1130,O
of,1130,O
symptoms,1130,O
until,1130,O
death,1130,B-Disease
.,1130,O
At,1131,O
autopsy,1131,O
the,1131,O
liver,1131,O
was,1131,O
enlarged,1131,O
and,1131,O
firm,1131,O
with,1131,O
signs,1131,O
of,1131,O
venous,1131,B-Disease
congestion,1131,I-Disease
.,1131,O
Small-,1132,O
and,1132,O
medium-sized,1132,O
hepatic,1132,O
veins,1132,O
were,1132,O
blocked,1132,O
by,1132,O
thrombosis,1132,B-Disease
.,1132,O
Eosinophilic,1133,O
infiltrations,1133,O
were,1133,O
found,1133,O
around,1133,O
the,1133,O
vessels,1133,O
.,1133,O
Published,1134,O
cases,1134,O
from,1134,O
the,1134,O
literature,1134,O
are,1134,O
reviewed,1134,O
and,1134,O
pertinent,1134,O
features,1134,O
discussed,1134,O
.,1134,O
Maternal,1135,O
lithium,1135,B-Chemical
and,1135,O
neonatal,1135,O
Ebstein,1135,B-Disease
's,1135,I-Disease
anomaly,1135,I-Disease
:,1135,O
evaluation,1135,O
with,1135,O
cross-sectional,1135,O
echocardiography,1135,O
.,1135,O
Cross-sectional,1136,O
echocardiography,1136,O
was,1136,O
used,1136,O
to,1136,O
evaluate,1136,O
two,1136,O
neonates,1136,O
whose,1136,O
mothers,1136,O
ingested,1136,O
lithium,1136,B-Chemical
during,1136,O
pregnancy,1136,O
.,1136,O
In,1137,O
one,1137,O
infant,1137,O
",",1137,O
Ebstein,1137,B-Disease
's,1137,I-Disease
anomaly,1137,I-Disease
of,1137,O
the,1137,O
tricuspid,1137,O
valve,1137,O
was,1137,O
identified,1137,O
.,1137,O
In,1138,O
the,1138,O
other,1138,O
infant,1138,O
cross-sectional,1138,O
echocardiography,1138,O
provided,1138,O
reassurance,1138,O
that,1138,O
the,1138,O
infant,1138,O
did,1138,O
not,1138,O
have,1138,O
Ebstein,1138,B-Disease
's,1138,I-Disease
anomaly,1138,I-Disease
.,1138,O
Cross-sectional,1139,O
echocardiographic,1139,O
screening,1139,O
of,1139,O
newborns,1139,O
exposed,1139,O
to,1139,O
lithium,1139,B-Chemical
during,1139,O
gestation,1139,O
can,1139,O
provide,1139,O
highly,1139,O
accurate,1139,O
",",1139,O
noninvasive,1139,O
assessment,1139,O
of,1139,O
the,1139,O
presence,1139,O
or,1139,O
absence,1139,O
of,1139,O
lithium-induced,1139,B-Chemical
cardiac,1139,B-Disease
malformations,1139,I-Disease
.,1139,O
Effects,1140,O
of,1140,O
training,1140,O
on,1140,O
the,1140,O
extent,1140,O
of,1140,O
experimental,1140,O
myocardial,1140,B-Disease
infarction,1140,I-Disease
in,1140,O
aging,1140,O
rats,1140,O
.,1140,O
The,1141,O
effects,1141,O
of,1141,O
exercise,1141,O
on,1141,O
the,1141,O
severity,1141,O
of,1141,O
isoproterenol-induced,1141,B-Chemical
myocardial,1141,B-Disease
infarction,1141,I-Disease
were,1141,O
studied,1141,O
in,1141,O
female,1141,O
albino,1141,O
rats,1141,O
of,1141,O
"20,40,60",1141,O
and,1141,O
80,1141,O
weeks,1141,O
of,1141,O
age,1141,O
.,1141,O
The,1142,O
rats,1142,O
were,1142,O
trained,1142,O
to,1142,O
swim,1142,O
for,1142,O
a,1142,O
specific,1142,O
duration,1142,O
and,1142,O
for,1142,O
a,1142,O
particular,1142,O
period,1142,O
.,1142,O
The,1143,O
occurrence,1143,O
of,1143,O
infarcts,1143,B-Disease
were,1143,O
confirmed,1143,O
by,1143,O
histological,1143,O
methods,1143,O
.,1143,O
Elevations,1144,O
in,1144,O
the,1144,O
serum,1144,O
GOT,1144,O
and,1144,O
GPT,1144,O
were,1144,O
maximum,1144,O
in,1144,O
the,1144,O
sedentary-isoproterenols,1144,O
and,1144,O
minimum,1144,O
in,1144,O
the,1144,O
exercise-controls,1144,O
.,1144,O
These,1145,O
changes,1145,O
in,1145,O
the,1145,O
serum,1145,O
transaminases,1145,O
were,1145,O
associated,1145,O
with,1145,O
corresponding,1145,O
depletions,1145,O
in,1145,O
the,1145,O
cardiac,1145,O
GOT,1145,O
and,1145,O
GPT,1145,O
.,1145,O
However,1146,O
",",1146,O
age,1146,O
was,1146,O
seen,1146,O
to,1146,O
interfere,1146,O
with,1146,O
the,1146,O
responses,1146,O
exhibited,1146,O
by,1146,O
the,1146,O
young,1146,O
and,1146,O
old,1146,O
rats,1146,O
.,1146,O
Studies,1147,O
dealing,1147,O
with,1147,O
myocardial,1147,B-Disease
infarction,1147,I-Disease
are,1147,O
more,1147,O
informative,1147,O
when,1147,O
dealt,1147,O
with,1147,O
age,1147,O
.,1147,O
Effect,1148,O
of,1148,O
polyethylene,1148,B-Chemical
glycol,1148,I-Chemical
400,1148,I-Chemical
on,1148,O
adriamycin,1148,B-Chemical
toxicity,1148,B-Disease
in,1148,O
mice,1148,O
.,1148,O
The,1149,O
effect,1149,O
of,1149,O
a,1149,O
widely,1149,O
used,1149,O
organic,1149,O
solvent,1149,O
",",1149,O
polyethylene,1149,B-Chemical
glycol,1149,I-Chemical
400,1149,I-Chemical
(,1149,O
PEG,1149,B-Chemical
400,1149,I-Chemical
),1149,O
",",1149,O
on,1149,O
the,1149,O
toxic,1149,O
action,1149,O
of,1149,O
an,1149,O
acute,1149,O
or,1149,O
chronic,1149,O
treatment,1149,O
with,1149,O
adriamycin,1149,B-Chemical
(,1149,O
ADR,1149,B-Chemical
),1149,O
was,1149,O
evaluated,1149,O
in,1149,O
mice,1149,O
.,1149,O
PEG,1150,B-Chemical
400,1150,I-Chemical
impressively,1150,O
decreased,1150,O
both,1150,O
acute,1150,O
high-dose,1150,O
and,1150,O
chronic,1150,O
low-dose-ADR-associated,1150,O
lethality,1150,O
.,1150,O
Light,1151,O
microscopic,1151,O
analysis,1151,O
showed,1151,O
a,1151,O
significant,1151,O
protection,1151,O
against,1151,O
ADR-induced,1151,B-Chemical
cardiac,1151,B-Disease
morphological,1151,I-Disease
alterations,1151,I-Disease
.,1151,O
Such,1152,O
treatment,1152,O
did,1152,O
not,1152,O
diminish,1152,O
the,1152,O
ADR,1152,B-Chemical
antitumor,1152,O
activity,1152,O
in,1152,O
L1210,1152,B-Disease
leukemia,1152,I-Disease
and,1152,O
in,1152,O
Ehrlich,1152,B-Disease
ascites,1152,I-Disease
tumor,1152,I-Disease
.,1152,O
Sublingual,1153,O
absorption,1153,O
of,1153,O
the,1153,O
quaternary,1153,B-Chemical
ammonium,1153,I-Chemical
antiarrhythmic,1153,O
agent,1153,O
",",1153,O
UM-272,1153,B-Chemical
.,1153,O
UM-272,1154,B-Chemical
(,1154,O
N,1154,B-Chemical
",",1154,I-Chemical
N-dimethylpropranolol,1154,I-Chemical
),1154,O
",",1154,O
a,1154,O
quaternary,1154,O
antiarrhythmic,1154,O
agent,1154,O
",",1154,O
was,1154,O
administered,1154,O
sublingually,1154,O
to,1154,O
dogs,1154,O
with,1154,O
ouabain-induced,1154,B-Chemical
ventricular,1154,B-Disease
tachycardias,1154,I-Disease
.,1154,O
Both,1155,O
anti-arrhythmic,1155,O
efficacy,1155,O
and,1155,O
bioavailability,1155,O
were,1155,O
compared,1155,O
to,1155,O
oral,1155,O
drug,1155,O
.,1155,O
Sublingual,1156,O
UM-272,1156,B-Chemical
converted,1156,O
ventricular,1156,B-Disease
tachycardia,1156,I-Disease
to,1156,O
sinus,1156,O
rhythm,1156,O
in,1156,O
all,1156,O
5,1156,O
dogs,1156,O
.,1156,O
The,1157,O
area,1157,O
under,1157,O
the,1157,O
plasma,1157,O
concentration,1157,O
time,1157,O
curve,1157,O
at,1157,O
90,1157,O
min,1157,O
was,1157,O
4-12,1157,O
times,1157,O
greater,1157,O
than,1157,O
for,1157,O
oral,1157,O
drug,1157,O
",",1157,O
suggesting,1157,O
the,1157,O
existence,1157,O
of,1157,O
an,1157,O
absorption-limiting,1157,O
process,1157,O
in,1157,O
the,1157,O
intestine,1157,O
",",1157,O
and,1157,O
providing,1157,O
an,1157,O
alternate,1157,O
form,1157,O
of,1157,O
administration,1157,O
for,1157,O
quaternary,1157,O
drugs,1157,O
.,1157,O
Early,1158,O
adjuvant,1158,O
adriamycin,1158,B-Chemical
in,1158,O
superficial,1158,O
bladder,1158,O
carcinoma,1158,O
.,1158,O
A,1159,O
multicenter,1159,O
study,1159,O
was,1159,O
performed,1159,O
in,1159,O
110,1159,O
patients,1159,O
with,1159,O
superficial,1159,O
transitional,1159,O
cell,1159,O
carcinoma,1159,O
of,1159,O
the,1159,O
bladder,1159,O
.,1159,O
Adriamycin,1160,B-Chemical
(,1160,O
50,1160,O
mg/50,1160,O
ml,1160,O
),1160,O
was,1160,O
administered,1160,O
intravesically,1160,O
within,1160,O
24,1160,O
h,1160,O
after,1160,O
transurethral,1160,O
resection,1160,O
of,1160,O
TA-T1,1160,O
(,1160,O
O-A,1160,O
),1160,O
bladder,1160,B-Disease
tumors,1160,I-Disease
.,1160,O
Instillation,1161,O
was,1161,O
repeated,1161,O
twice,1161,O
during,1161,O
the,1161,O
first,1161,O
week,1161,O
",",1161,O
then,1161,O
weekly,1161,O
during,1161,O
the,1161,O
first,1161,O
month,1161,O
and,1161,O
afterwards,1161,O
monthly,1161,O
for,1161,O
1,1161,O
year,1161,O
.,1161,O
The,1162,O
tolerance,1162,O
was,1162,O
evaluated,1162,O
in,1162,O
these,1162,O
110,1162,O
patients,1162,O
",",1162,O
and,1162,O
29,1162,O
patients,1162,O
presented,1162,O
with,1162,O
local,1162,O
side-effects,1162,O
.,1162,O
In,1163,O
24,1163,O
of,1163,O
these,1163,O
patients,1163,O
chemical,1163,O
cystitis,1163,B-Disease
was,1163,O
severe,1163,O
enough,1163,O
for,1163,O
them,1163,O
to,1163,O
drop,1163,O
out,1163,O
of,1163,O
the,1163,O
study,1163,O
.,1163,O
No,1164,O
systemic,1164,O
side-effects,1164,O
were,1164,O
observed,1164,O
.,1164,O
Recurrence,1165,O
was,1165,O
studied,1165,O
in,1165,O
82,1165,O
evaluable,1165,O
patients,1165,O
after,1165,O
1,1165,O
year,1165,O
of,1165,O
follow-up,1165,O
and,1165,O
in,1165,O
72,1165,O
patients,1165,O
followed,1165,O
for,1165,O
2-3,1165,O
years,1165,O
(,1165,O
mean,1165,O
32,1165,O
months,1165,O
),1165,O
.,1165,O
Of,1166,O
the,1166,O
82,1166,O
patients,1166,O
studied,1166,O
after,1166,O
1,1166,O
year,1166,O
",",1166,O
23,1166,O
had,1166,O
primary,1166,O
and,1166,O
59,1166,O
recurrent,1166,O
disease,1166,O
.,1166,O
Of,1167,O
the,1167,O
82,1167,O
evaluable,1167,O
patients,1167,O
",",1167,O
50,1167,O
did,1167,O
not,1167,O
show,1167,O
any,1167,O
recurrence,1167,O
after,1167,O
1,1167,O
year,1167,O
(,1167,O
61,1167,O
%,1167,O
),1167,O
",",1167,O
while,1167,O
32,1167,O
presented,1167,O
with,1167,O
one,1167,O
or,1167,O
more,1167,O
recurrences,1167,O
(,1167,O
39,1167,O
%,1167,O
),1167,O
.,1167,O
Of,1168,O
these,1168,O
recurrences,1168,O
",",1168,O
27,1168,O
were,1168,O
T1,1168,O
tumors,1168,B-Disease
while,1168,O
five,1168,O
progressed,1168,O
to,1168,O
more,1168,O
highly,1168,O
invasive,1168,O
lesions,1168,O
.,1168,O
In,1169,O
patients,1169,O
that,1169,O
were,1169,O
free,1169,O
of,1169,O
recurrence,1169,O
during,1169,O
the,1169,O
first,1169,O
year,1169,O
",",1169,O
80,1169,O
%,1169,O
remained,1169,O
tumor-free,1169,B-Disease
during,1169,O
the,1169,O
2-,1169,O
to,1169,O
3-year,1169,O
follow-up,1169,O
period,1169,O
.,1169,O
Of,1170,O
the,1170,O
patients,1170,O
developing,1170,O
one,1170,O
or,1170,O
more,1170,O
recurrences,1170,O
during,1170,O
the,1170,O
first,1170,O
year,1170,O
",",1170,O
only,1170,O
50,1170,O
%,1170,O
presented,1170,O
with,1170,O
further,1170,O
recurrence,1170,O
once,1170,O
the,1170,O
instillations,1170,O
were,1170,O
stopped,1170,O
.,1170,O
The,1171,O
beneficial,1171,O
effect,1171,O
of,1171,O
Adriamycin,1171,B-Chemical
appears,1171,O
obvious,1171,O
and,1171,O
might,1171,O
be,1171,O
related,1171,O
to,1171,O
the,1171,O
drug,1171,O
itself,1171,O
",",1171,O
the,1171,O
early,1171,O
and,1171,O
repeated,1171,O
instillations,1171,O
after,1171,O
TUR,1171,O
",",1171,O
or,1171,O
both,1171,O
.,1171,O
D-penicillamine-induced,1172,B-Chemical
angiopathy,1172,B-Disease
in,1172,O
rats,1172,O
.,1172,O
The,1173,O
effect,1173,O
of,1173,O
high,1173,O
dose,1173,O
D-penicillamine,1173,B-Chemical
treatment,1173,O
on,1173,O
aortic,1173,O
permeability,1173,O
to,1173,O
albumin,1173,O
and,1173,O
on,1173,O
the,1173,O
ultrastructure,1173,O
of,1173,O
the,1173,O
vessel,1173,O
.,1173,O
Male,1174,O
Sprague-Dawley,1174,O
rats,1174,O
were,1174,O
treated,1174,O
with,1174,O
D-penicillamine,1174,B-Chemical
(,1174,O
D-pen,1174,B-Chemical
),1174,O
500,1174,O
mg/kg/day,1174,O
for,1174,O
10,1174,O
or,1174,O
42,1174,O
days,1174,O
.,1174,O
Pair,1175,O
fed,1175,O
rats,1175,O
served,1175,O
as,1175,O
controls,1175,O
.,1175,O
Changes,1176,O
in,1176,O
aortic,1176,O
morphology,1176,O
were,1176,O
examined,1176,O
by,1176,O
light-,1176,O
and,1176,O
transmission-electron,1176,O
microscopy,1176,O
(,1176,O
TEM,1176,O
),1176,O
.,1176,O
In,1177,O
addition,1177,O
",",1177,O
the,1177,O
endothelial,1177,O
permeability,1177,O
and,1177,O
the,1177,O
penetration,1177,O
through,1177,O
the,1177,O
aortic,1177,O
wall,1177,O
of,1177,O
albumin,1177,O
were,1177,O
studied,1177,O
10,1177,O
minutes,1177,O
",",1177,O
24,1177,O
and,1177,O
48,1177,O
hours,1177,O
after,1177,O
i.,1177,O
v.,1177,O
injection,1177,O
of,1177,O
human,1177,O
serum,1177,O
131I-albumin,1177,O
(,1177,O
131I-HSA,1177,O
),1177,O
.,1177,O
TEM,1178,O
revealed,1178,O
extensive,1178,O
elastolysis,1178,O
in,1178,O
the,1178,O
arterial,1178,O
wall,1178,O
of,1178,O
D-pen-treated,1178,B-Chemical
rats,1178,O
",",1178,O
consistent,1178,O
with,1178,O
an,1178,O
inhibitory,1178,O
effect,1178,O
on,1178,O
crosslink,1178,O
formation,1178,O
.,1178,O
In,1179,O
experimental,1179,O
animals,1179,O
excess,1179,O
deposition,1179,O
of,1179,O
collagen,1179,O
and,1179,O
glycoaminoglycans,1179,O
was,1179,O
observed,1179,O
in,1179,O
the,1179,O
subendothelial,1179,O
and,1179,O
medial,1179,O
layer,1179,O
of,1179,O
the,1179,O
aortic,1179,O
wall,1179,O
",",1179,O
together,1179,O
with,1179,O
prominent,1179,O
basal,1179,O
membrane,1179,O
substance,1179,O
around,1179,O
aortic,1179,O
smooth,1179,O
muscle,1179,O
cells,1179,O
.,1179,O
The,1180,O
aorta/serum-ratio,1180,O
and,1180,O
the,1180,O
radioactive,1180,O
build-up,1180,O
24,1180,O
and,1180,O
48,1180,O
hours,1180,O
after,1180,O
injection,1180,O
of,1180,O
131I-HSA,1180,O
was,1180,O
reduced,1180,O
in,1180,O
animals,1180,O
treated,1180,O
with,1180,O
D-pen,1180,B-Chemical
for,1180,O
42,1180,O
days,1180,O
",",1180,O
indicating,1180,O
an,1180,O
impeded,1180,O
transmural,1180,O
transport,1180,O
of,1180,O
tracer,1180,O
which,1180,O
may,1180,O
be,1180,O
caused,1180,O
by,1180,O
a,1180,O
steric,1180,O
exclusion,1180,O
effect,1180,O
of,1180,O
abundant,1180,O
hyaluronate,1180,B-Chemical
.,1180,O
The,1181,O
endothelial,1181,O
ultrastructure,1181,O
was,1181,O
unaffected,1181,O
by,1181,O
D-pen,1181,B-Chemical
",",1181,O
and,1181,O
no,1181,O
differences,1181,O
in,1181,O
aortic,1181,O
131I-HSA,1181,O
radioactivity,1181,O
or,1181,O
aorta/serum-ratio,1181,O
were,1181,O
recorded,1181,O
between,1181,O
experimental,1181,O
and,1181,O
control,1181,O
groups,1181,O
10,1181,O
minutes,1181,O
after,1181,O
tracer,1181,O
injection,1181,O
",",1181,O
indicating,1181,O
that,1181,O
the,1181,O
permeability,1181,O
of,1181,O
the,1181,O
endothelial,1181,O
barrier,1181,O
to,1181,O
albumin,1181,O
remained,1181,O
unaffected,1181,O
by,1181,O
D-pen,1181,B-Chemical
treatment,1181,O
.,1181,O
These,1182,O
observations,1182,O
support,1182,O
the,1182,O
hypothesis,1182,O
that,1182,O
treatment,1182,O
with,1182,O
high,1182,O
doses,1182,O
of,1182,O
D-pen,1182,B-Chemical
may,1182,O
induce,1182,O
a,1182,O
fibroproliferative,1182,O
response,1182,O
in,1182,O
rat,1182,O
aorta,1182,O
",",1182,O
possibly,1182,O
by,1182,O
an,1182,O
inhibitory,1182,O
effect,1182,O
on,1182,O
the,1182,O
cross-linking,1182,O
of,1182,O
collagen,1182,O
and,1182,O
elastin,1182,O
.,1182,O
Effect,1183,O
of,1183,O
aspirin,1183,B-Chemical
on,1183,O
N-,1183,B-Chemical
[,1183,I-Chemical
4-,1183,I-Chemical
(,1183,I-Chemical
5-nitro-2-furyl,1183,I-Chemical
),1183,I-Chemical
-2-thiazolyl,1183,I-Chemical
],1183,I-Chemical
-formamide-induced,1183,O
epithelial,1183,O
proliferation,1183,O
in,1183,O
the,1183,O
urinary,1183,O
bladder,1183,O
and,1183,O
forestomach,1183,O
of,1183,O
the,1183,O
rat,1183,O
.,1183,O
The,1184,O
co-administration,1184,O
of,1184,O
aspirin,1184,B-Chemical
with,1184,O
N-,1184,B-Chemical
[,1184,I-Chemical
4-,1184,I-Chemical
(,1184,I-Chemical
5-nitro-2-furyl,1184,I-Chemical
),1184,I-Chemical
-2-thiazolyl,1184,I-Chemical
],1184,I-Chemical
-formamide,1184,I-Chemical
(,1184,O
FANFT,1184,B-Chemical
),1184,O
to,1184,O
rats,1184,O
resulted,1184,O
in,1184,O
a,1184,O
reduced,1184,O
incidence,1184,O
of,1184,O
FANFT-induced,1184,B-Chemical
bladder,1184,B-Disease
carcinomas,1184,I-Disease
but,1184,O
a,1184,O
concomitant,1184,O
induction,1184,O
of,1184,O
forestomach,1184,B-Disease
tumors,1184,I-Disease
.,1184,O
An,1185,O
autoradiographic,1185,O
study,1185,O
was,1185,O
performed,1185,O
on,1185,O
male,1185,O
F-344,1185,O
rats,1185,O
fed,1185,O
diet,1185,O
containing,1185,O
FANFT,1185,B-Chemical
at,1185,O
a,1185,O
level,1185,O
of,1185,O
0.2,1185,O
%,1185,O
and/or,1185,O
aspirin,1185,B-Chemical
at,1185,O
a,1185,O
level,1185,O
of,1185,O
0.5,1185,O
%,1185,O
to,1185,O
evaluate,1185,O
the,1185,O
effect,1185,O
of,1185,O
aspirin,1185,B-Chemical
on,1185,O
the,1185,O
increased,1185,O
cell,1185,O
proliferation,1185,O
induced,1185,O
by,1185,O
FANFT,1185,B-Chemical
in,1185,O
the,1185,O
forestomach,1185,O
and,1185,O
bladder,1185,O
.,1185,O
FANFT-induced,1186,B-Chemical
cell,1186,O
proliferation,1186,O
in,1186,O
the,1186,O
bladder,1186,O
was,1186,O
significantly,1186,O
suppressed,1186,O
by,1186,O
aspirin,1186,B-Chemical
co-administration,1186,O
after,1186,O
4,1186,O
weeks,1186,O
but,1186,O
not,1186,O
after,1186,O
12,1186,O
weeks,1186,O
.,1186,O
In,1187,O
the,1187,O
forestomach,1187,O
",",1187,O
and,1187,O
also,1187,O
in,1187,O
the,1187,O
liver,1187,O
",",1187,O
aspirin,1187,B-Chemical
did,1187,O
not,1187,O
affect,1187,O
the,1187,O
FANFT-induced,1187,B-Chemical
increase,1187,O
in,1187,O
labeling,1187,O
index,1187,O
.,1187,O
The,1188,O
present,1188,O
results,1188,O
are,1188,O
consistent,1188,O
with,1188,O
the,1188,O
carcinogenicity,1188,O
experiment,1188,O
suggesting,1188,O
that,1188,O
different,1188,O
mechanisms,1188,O
are,1188,O
involved,1188,O
in,1188,O
FANFT,1188,B-Chemical
carcinogenesis,1188,B-Disease
in,1188,O
the,1188,O
bladder,1188,O
and,1188,O
forestomach,1188,O
",",1188,O
and,1188,O
that,1188,O
aspirin,1188,B-Chemical
's,1188,O
effect,1188,O
on,1188,O
FANFT,1188,B-Chemical
in,1188,O
the,1188,O
forestomach,1188,O
is,1188,O
not,1188,O
due,1188,O
to,1188,O
an,1188,O
irritant,1188,O
effect,1188,O
associated,1188,O
with,1188,O
increased,1188,O
cell,1188,O
proliferation,1188,O
.,1188,O
Also,1189,O
",",1189,O
there,1189,O
appears,1189,O
to,1189,O
be,1189,O
an,1189,O
adaptation,1189,O
by,1189,O
the,1189,O
rats,1189,O
to,1189,O
the,1189,O
chronic,1189,O
ingestion,1189,O
of,1189,O
aspirin,1189,B-Chemical
.,1189,O
A,1190,O
case,1190,O
of,1190,O
tardive,1190,B-Disease
dyskinesia,1190,I-Disease
caused,1190,O
by,1190,O
metoclopramide,1190,B-Chemical
.,1190,O
Abnormal,1191,B-Disease
involuntary,1191,I-Disease
movements,1191,I-Disease
appeared,1191,O
in,1191,O
the,1191,O
mouth,1191,O
",",1191,O
tongue,1191,O
",",1191,O
neck,1191,O
and,1191,O
abdomen,1191,O
of,1191,O
a,1191,O
64-year-old,1191,O
male,1191,O
patient,1191,O
after,1191,O
he,1191,O
took,1191,O
metoclopramide,1191,B-Chemical
for,1191,O
gastrointestinal,1191,B-Disease
disorder,1191,I-Disease
in,1191,O
a,1191,O
regimen,1191,O
of,1191,O
30,1191,O
mg,1191,O
per,1191,O
day,1191,O
for,1191,O
a,1191,O
total,1191,O
of,1191,O
about,1191,O
260,1191,O
days,1191,O
.,1191,O
The,1192,O
symptoms,1192,O
exacerbated,1192,O
to,1192,O
a,1192,O
maximum,1192,O
in,1192,O
a,1192,O
month,1192,O
.,1192,O
When,1193,O
the,1193,O
metoclopramide,1193,B-Chemical
administration,1193,O
was,1193,O
discontinued,1193,O
",",1193,O
the,1193,O
abnormal,1193,B-Disease
movements,1193,I-Disease
gradually,1193,O
improved,1193,O
to,1193,O
a,1193,O
considerable,1193,O
extent,1193,O
.,1193,O
Attention,1194,O
to,1194,O
the,1194,O
possible,1194,O
induction,1194,O
of,1194,O
specific,1194,O
tardive,1194,B-Disease
dyskinesia,1194,I-Disease
is,1194,O
called,1194,O
for,1194,O
in,1194,O
the,1194,O
use,1194,O
of,1194,O
this,1194,O
drug,1194,O
.,1194,O
Intra-arterial,1195,O
BCNU,1195,B-Chemical
chemotherapy,1195,O
for,1195,O
treatment,1195,O
of,1195,O
malignant,1195,B-Disease
gliomas,1195,I-Disease
of,1195,O
the,1195,O
central,1195,O
nervous,1195,O
system,1195,O
.,1195,O
Because,1196,O
of,1196,O
the,1196,O
rapid,1196,O
systemic,1196,O
clearance,1196,O
of,1196,O
BCNU,1196,B-Chemical
(,1196,O
"1,3-bis-",1196,B-Chemical
(,1196,I-Chemical
2-chloroethyl,1196,I-Chemical
),1196,I-Chemical
-1-nitrosourea,1196,I-Chemical
),1196,O
",",1196,O
intra-arterial,1196,O
administration,1196,O
should,1196,O
provide,1196,O
a,1196,O
substantial,1196,O
advantage,1196,O
over,1196,O
intravenous,1196,O
administration,1196,O
for,1196,O
the,1196,O
treatment,1196,O
of,1196,O
malignant,1196,B-Disease
gliomas,1196,I-Disease
.,1196,O
Thirty-six,1197,O
patients,1197,O
were,1197,O
treated,1197,O
with,1197,O
BCNU,1197,B-Chemical
every,1197,O
6,1197,O
to,1197,O
8,1197,O
weeks,1197,O
",",1197,O
either,1197,O
by,1197,O
transfemoral,1197,O
catheterization,1197,O
of,1197,O
the,1197,O
internal,1197,O
carotid,1197,O
or,1197,O
vertebral,1197,O
artery,1197,O
or,1197,O
through,1197,O
a,1197,O
fully,1197,O
implantable,1197,O
intracarotid,1197,O
drug,1197,O
delivery,1197,O
system,1197,O
",",1197,O
beginning,1197,O
with,1197,O
a,1197,O
dose,1197,O
of,1197,O
200,1197,O
mg/sq,1197,O
m,1197,O
body,1197,O
surface,1197,O
area,1197,O
.,1197,O
Twelve,1198,O
patients,1198,O
with,1198,O
Grade,1198,O
III,1198,O
or,1198,O
IV,1198,O
astrocytomas,1198,B-Disease
were,1198,O
treated,1198,O
after,1198,O
partial,1198,O
resection,1198,O
of,1198,O
the,1198,O
tumor,1198,B-Disease
without,1198,O
prior,1198,O
radiation,1198,O
therapy,1198,O
.,1198,O
After,1199,O
two,1199,O
to,1199,O
seven,1199,O
cycles,1199,O
of,1199,O
chemotherapy,1199,O
",",1199,O
nine,1199,O
patients,1199,O
showed,1199,O
a,1199,O
decrease,1199,O
in,1199,O
tumor,1199,B-Disease
size,1199,O
and,1199,O
surrounding,1199,O
edema,1199,B-Disease
on,1199,O
contrast-enhanced,1199,O
computerized,1199,O
tomography,1199,O
scans,1199,O
.,1199,O
In,1200,O
the,1200,O
nine,1200,O
responders,1200,O
",",1200,O
median,1200,O
duration,1200,O
of,1200,O
chemotherapy,1200,O
response,1200,O
from,1200,O
the,1200,O
time,1200,O
of,1200,O
operation,1200,O
was,1200,O
25,1200,O
weeks,1200,O
(,1200,O
range,1200,O
12,1200,O
to,1200,O
more,1200,O
than,1200,O
91,1200,O
weeks,1200,O
),1200,O
.,1200,O
The,1201,O
median,1201,O
duration,1201,O
of,1201,O
survival,1201,O
in,1201,O
the,1201,O
12,1201,O
patients,1201,O
was,1201,O
54,1201,O
weeks,1201,O
(,1201,O
range,1201,O
21,1201,O
to,1201,O
more,1201,O
than,1201,O
156,1201,O
weeks,1201,O
),1201,O
",",1201,O
with,1201,O
an,1201,O
18-month,1201,O
survival,1201,O
rate,1201,O
of,1201,O
42,1201,O
%,1201,O
.,1201,O
Twenty-four,1202,O
patients,1202,O
with,1202,O
recurrent,1202,O
Grade,1202,O
I,1202,O
to,1202,O
IV,1202,O
astrocytomas,1202,B-Disease
",",1202,O
whose,1202,O
resection,1202,O
and,1202,O
irradiation,1202,O
therapy,1202,O
had,1202,O
failed,1202,O
",",1202,O
received,1202,O
two,1202,O
to,1202,O
eight,1202,O
courses,1202,O
of,1202,O
intra-arterial,1202,O
BCNU,1202,B-Chemical
therapy,1202,O
.,1202,O
Seventeen,1203,O
of,1203,O
these,1203,O
had,1203,O
a,1203,O
response,1203,O
or,1203,O
were,1203,O
stable,1203,O
for,1203,O
a,1203,O
median,1203,O
of,1203,O
20,1203,O
weeks,1203,O
(,1203,O
range,1203,O
6,1203,O
to,1203,O
more,1203,O
than,1203,O
66,1203,O
weeks,1203,O
),1203,O
.,1203,O
The,1204,O
catheterization,1204,O
procedure,1204,O
is,1204,O
safe,1204,O
",",1204,O
with,1204,O
no,1204,O
immediate,1204,O
complication,1204,O
in,1204,O
111,1204,O
infusions,1204,O
of,1204,O
BCNU,1204,B-Chemical
.,1204,O
A,1205,O
delayed,1205,O
complication,1205,O
in,1205,O
nine,1205,O
patients,1205,O
has,1205,O
been,1205,O
unilateral,1205,O
loss,1205,B-Disease
of,1205,I-Disease
vision,1205,I-Disease
secondary,1205,O
to,1205,O
a,1205,O
retinal,1205,B-Disease
vasculitis,1205,I-Disease
.,1205,O
The,1206,O
frequency,1206,O
of,1206,O
visual,1206,B-Disease
loss,1206,I-Disease
decreased,1206,O
after,1206,O
the,1206,O
concentration,1206,O
of,1206,O
the,1206,O
ethanol,1206,B-Chemical
diluent,1206,O
was,1206,O
lowered,1206,O
.,1206,O
Provocation,1207,O
of,1207,O
postural,1207,O
hypotension,1207,B-Disease
by,1207,O
nitroglycerin,1207,B-Chemical
in,1207,O
diabetic,1207,B-Disease
autonomic,1207,I-Disease
neuropathy,1207,I-Disease
?,1207,O
The,1208,O
effect,1208,O
of,1208,O
nitroglycerin,1208,B-Chemical
on,1208,O
heart,1208,O
rate,1208,O
and,1208,O
systolic,1208,O
blood,1208,O
pressure,1208,O
was,1208,O
compared,1208,O
in,1208,O
5,1208,O
normal,1208,O
subjects,1208,O
",",1208,O
12,1208,O
diabetic,1208,B-Disease
subjects,1208,O
without,1208,O
autonomic,1208,B-Disease
neuropathy,1208,I-Disease
",",1208,O
and,1208,O
5,1208,O
diabetic,1208,B-Disease
subjects,1208,O
with,1208,O
autonomic,1208,B-Disease
neuropathy,1208,I-Disease
.,1208,O
The,1209,O
magnitude,1209,O
and,1209,O
time,1209,O
course,1209,O
of,1209,O
the,1209,O
increase,1209,O
in,1209,O
heart,1209,O
rate,1209,O
and,1209,O
the,1209,O
decrease,1209,O
in,1209,O
systolic,1209,O
blood,1209,O
pressure,1209,O
after,1209,O
nitroglycerin,1209,B-Chemical
were,1209,O
similar,1209,O
in,1209,O
the,1209,O
normal,1209,O
and,1209,O
diabetic,1209,B-Disease
subjects,1209,O
without,1209,O
autonomic,1209,B-Disease
neuropathy,1209,I-Disease
",",1209,O
whereas,1209,O
a,1209,O
lesser,1209,O
increase,1209,O
in,1209,O
heart,1209,O
rate,1209,O
and,1209,O
a,1209,O
greater,1209,O
decrease,1209,O
in,1209,O
systolic,1209,O
blood,1209,O
pressure,1209,O
occurred,1209,O
in,1209,O
the,1209,O
diabetic,1209,B-Disease
subjects,1209,O
with,1209,O
autonomic,1209,B-Disease
neuropathy,1209,I-Disease
.,1209,O
It,1210,O
is,1210,O
therefore,1210,O
suggested,1210,O
that,1210,O
caution,1210,O
should,1210,O
be,1210,O
exercised,1210,O
when,1210,O
prescribing,1210,O
vasodilator,1210,O
drugs,1210,O
in,1210,O
diabetic,1210,B-Disease
patients,1210,O
",",1210,O
particularly,1210,O
those,1210,O
with,1210,O
autonomic,1210,B-Disease
neuropathy,1210,I-Disease
.,1210,O
Blood,1211,O
pressure,1211,O
response,1211,O
to,1211,O
chronic,1211,O
low-dose,1211,O
intrarenal,1211,O
noradrenaline,1211,B-Chemical
infusion,1211,O
in,1211,O
conscious,1211,O
rats,1211,O
.,1211,O
Sodium,1212,B-Chemical
chloride,1212,I-Chemical
solution,1212,O
(,1212,O
0.9,1212,O
%,1212,O
),1212,O
or,1212,O
noradrenaline,1212,B-Chemical
in,1212,O
doses,1212,O
of,1212,O
4,1212,O
",",1212,O
12,1212,O
and,1212,O
36,1212,O
micrograms,1212,O
h-1,1212,O
kg-1,1212,O
was,1212,O
infused,1212,O
for,1212,O
five,1212,O
consecutive,1212,O
days,1212,O
",",1212,O
either,1212,O
intrarenally,1212,O
(,1212,O
by,1212,O
a,1212,O
new,1212,O
technique,1212,O
),1212,O
or,1212,O
intravenously,1212,O
into,1212,O
rats,1212,O
with,1212,O
one,1212,O
kidney,1212,O
removed,1212,O
.,1212,O
Intrarenal,1213,O
infusion,1213,O
of,1213,O
noradrenaline,1213,B-Chemical
caused,1213,O
hypertension,1213,B-Disease
at,1213,O
doses,1213,O
which,1213,O
did,1213,O
not,1213,O
do,1213,O
so,1213,O
when,1213,O
infused,1213,O
intravenously,1213,O
.,1213,O
Intrarenal,1214,O
compared,1214,O
with,1214,O
intravenous,1214,O
infusion,1214,O
of,1214,O
noradrenaline,1214,B-Chemical
caused,1214,O
higher,1214,O
plasma,1214,O
noradrenaline,1214,B-Chemical
concentrations,1214,O
and,1214,O
a,1214,O
shift,1214,O
of,1214,O
the,1214,O
plasma,1214,O
noradrenaline,1214,B-Chemical
concentration-blood,1214,O
pressure,1214,O
effect,1214,O
curve,1214,O
towards,1214,O
lower,1214,O
plasma,1214,O
noradrenaline,1214,B-Chemical
levels,1214,O
.,1214,O
These,1215,O
results,1215,O
suggest,1215,O
that,1215,O
hypertension,1215,B-Disease
after,1215,O
chronic,1215,O
intrarenal,1215,O
noradrenaline,1215,B-Chemical
infusion,1215,O
is,1215,O
produced,1215,O
by,1215,O
relatively,1215,O
higher,1215,O
levels,1215,O
of,1215,O
circulating,1215,O
noradrenaline,1215,B-Chemical
and,1215,O
by,1215,O
triggering,1215,O
of,1215,O
an,1215,O
additional,1215,O
intrarenal,1215,O
pressor,1215,O
mechanism,1215,O
.,1215,O
Characterization,1216,O
of,1216,O
estrogen-induced,1216,B-Chemical
adenohypophyseal,1216,B-Disease
tumors,1216,I-Disease
in,1216,O
the,1216,O
Fischer,1216,O
344,1216,O
rat,1216,O
.,1216,O
Pituitary,1217,B-Disease
tumors,1217,I-Disease
were,1217,O
induced,1217,O
in,1217,O
F344,1217,O
female,1217,O
rats,1217,O
by,1217,O
chronic,1217,O
treatment,1217,O
with,1217,O
diethylstilbestrol,1217,B-Chemical
(,1217,O
DES,1217,B-Chemical
",",1217,O
8-10,1217,O
mg,1217,O
),1217,O
implanted,1217,O
subcutaneously,1217,O
in,1217,O
silastic,1217,O
capsules,1217,O
.,1217,O
Over,1218,O
a,1218,O
range,1218,O
of,1218,O
1-150,1218,O
days,1218,O
of,1218,O
DES,1218,B-Chemical
treatment,1218,O
",",1218,O
pairs,1218,O
of,1218,O
control,1218,O
and,1218,O
DES-treated,1218,B-Chemical
rats,1218,O
were,1218,O
sacrificed,1218,O
",",1218,O
and,1218,O
their,1218,O
pituitaries,1218,O
dissociated,1218,O
enzymatically,1218,O
into,1218,O
single-cell,1218,O
preparations,1218,O
.,1218,O
The,1219,O
cell,1219,O
populations,1219,O
were,1219,O
examined,1219,O
regarding,1219,O
total,1219,O
cell,1219,O
recovery,1219,O
correlated,1219,O
with,1219,O
gland,1219,O
weight,1219,O
",",1219,O
intracellular,1219,O
prolactin,1219,O
(,1219,O
PRL,1219,O
),1219,O
content,1219,O
and,1219,O
subsequent,1219,O
release,1219,O
in,1219,O
primary,1219,O
culture,1219,O
",",1219,O
immunocytochemical,1219,O
PRL,1219,O
staining,1219,O
",",1219,O
density,1219,O
and/or,1219,O
size,1219,O
alterations,1219,O
via,1219,O
separation,1219,O
on,1219,O
Ficoll-Hypaque,1219,O
and,1219,O
by,1219,O
unit,1219,O
gravity,1219,O
sedimentation,1219,O
",",1219,O
and,1219,O
cell,1219,O
cycle,1219,O
analysis,1219,O
",",1219,O
after,1219,O
acriflavine,1219,B-Chemical
DNA,1219,O
staining,1219,O
",",1219,O
by,1219,O
laser,1219,O
flow,1219,O
cytometry,1219,O
.,1219,O
Total,1220,O
cell,1220,O
yields,1220,O
from,1220,O
DES-treated,1220,B-Chemical
pituitaries,1220,O
increased,1220,O
from,1220,O
1.3,1220,O
times,1220,O
control,1220,O
yields,1220,O
at,1220,O
8,1220,O
days,1220,O
of,1220,O
treatment,1220,O
to,1220,O
58.9,1220,O
times,1220,O
control,1220,O
values,1220,O
by,1220,O
day,1220,O
150,1220,O
.,1220,O
Intracellular,1221,O
PRL,1221,O
content,1221,O
ranged,1221,O
from,1221,O
1.9,1221,O
to,1221,O
9.4,1221,O
times,1221,O
control,1221,O
levels,1221,O
",",1221,O
and,1221,O
PRL,1221,O
release,1221,O
in,1221,O
vitro,1221,O
was,1221,O
significantly,1221,O
and,1221,O
consistently,1221,O
higher,1221,O
than,1221,O
controls,1221,O
",",1221,O
after,1221,O
at,1221,O
least,1221,O
8,1221,O
days,1221,O
of,1221,O
DES,1221,B-Chemical
exposure,1221,O
.,1221,O
Beyond,1222,O
8,1222,O
days,1222,O
of,1222,O
DES,1222,B-Chemical
exposure,1222,O
",",1222,O
the,1222,O
immunochemically,1222,O
PRL-positive,1222,O
proportion,1222,O
of,1222,O
cells,1222,O
increased,1222,O
to,1222,O
over,1222,O
50,1222,O
%,1222,O
of,1222,O
the,1222,O
total,1222,O
population,1222,O
.,1222,O
Increased,1223,O
density,1223,O
and/or,1223,O
size,1223,O
and,1223,O
PRL,1223,O
content,1223,O
were,1223,O
indicated,1223,O
for,1223,O
the,1223,O
majority,1223,O
of,1223,O
the,1223,O
PRL,1223,O
cell,1223,O
population,1223,O
in,1223,O
both,1223,O
types,1223,O
of,1223,O
separation,1223,O
protocols,1223,O
.,1223,O
All,1224,O
these,1224,O
effects,1224,O
of,1224,O
DES,1224,B-Chemical
were,1224,O
more,1224,O
pronounced,1224,O
among,1224,O
previously,1224,O
ovariectomized,1224,O
animals,1224,O
.,1224,O
The,1225,O
data,1225,O
extend,1225,O
the,1225,O
findings,1225,O
of,1225,O
other,1225,O
investigators,1225,O
",",1225,O
further,1225,O
establishing,1225,O
the,1225,O
DES-induced,1225,B-Chemical
tumor,1225,B-Disease
as,1225,O
a,1225,O
model,1225,O
for,1225,O
study,1225,O
of,1225,O
PRL,1225,O
cellular,1225,O
control,1225,O
mechanisms,1225,O
.,1225,O
Age,1226,O
and,1226,O
renal,1226,O
clearance,1226,O
of,1226,O
cimetidine,1226,B-Chemical
.,1226,O
In,1227,O
35,1227,O
patients,1227,O
(,1227,O
ages,1227,O
20,1227,O
to,1227,O
86,1227,O
yr,1227,O
),1227,O
receiving,1227,O
cimetidine,1227,B-Chemical
therapeutically,1227,O
two,1227,O
serum,1227,O
samples,1227,O
and,1227,O
all,1227,O
urine,1227,O
formed,1227,O
in,1227,O
the,1227,O
interim,1227,O
were,1227,O
collected,1227,O
for,1227,O
analysis,1227,O
of,1227,O
cimetidine,1227,B-Chemical
by,1227,O
high-pressure,1227,O
liquid,1227,O
chromatography,1227,O
and,1227,O
for,1227,O
creatinine,1227,B-Chemical
.,1227,O
Cimetidine,1228,B-Chemical
clearance,1228,O
decreased,1228,O
with,1228,O
age,1228,O
.,1228,O
The,1229,O
extrapolated,1229,O
6-hr,1229,O
serum,1229,O
concentration,1229,O
of,1229,O
cimetidine,1229,B-Chemical
per,1229,O
unit,1229,O
dose,1229,O
",",1229,O
after,1229,O
intravenous,1229,O
cimetidine,1229,B-Chemical
",",1229,O
increased,1229,O
with,1229,O
age,1229,O
of,1229,O
the,1229,O
patients,1229,O
.,1229,O
The,1230,O
ratio,1230,O
of,1230,O
cimetidine,1230,B-Chemical
clearance,1230,O
to,1230,O
creatinine,1230,B-Chemical
clearance,1230,O
(,1230,O
Rc,1230,O
),1230,O
averaged,1230,O
4.8,1230,O
+/-,1230,O
2.0,1230,O
",",1230,O
indicating,1230,O
net,1230,O
tubular,1230,O
secretion,1230,O
for,1230,O
cimetidine,1230,B-Chemical
.,1230,O
Rc,1231,O
seemed,1231,O
to,1231,O
be,1231,O
independent,1231,O
of,1231,O
age,1231,O
and,1231,O
decreased,1231,O
with,1231,O
increasing,1231,O
serum,1231,O
concentration,1231,O
of,1231,O
cimetidine,1231,B-Chemical
",",1231,O
suggesting,1231,O
that,1231,O
secretion,1231,O
of,1231,O
cimetidine,1231,B-Chemical
is,1231,O
a,1231,O
saturable,1231,O
process,1231,O
.,1231,O
There,1232,O
was,1232,O
only,1232,O
one,1232,O
case,1232,O
of,1232,O
dementia,1232,B-Disease
possibly,1232,O
due,1232,O
to,1232,O
cimetidine,1232,B-Chemical
(,1232,O
with,1232,O
a,1232,O
drug,1232,O
level,1232,O
of,1232,O
1.9,1232,O
microgram/ml,1232,O
6,1232,O
hr,1232,O
after,1232,O
a,1232,O
dose,1232,O
),1232,O
in,1232,O
a,1232,O
group,1232,O
of,1232,O
13,1232,O
patients,1232,O
without,1232,O
liver,1232,O
or,1232,O
kidney,1232,O
disease,1232,O
who,1232,O
had,1232,O
cimetidine,1232,B-Chemical
levels,1232,O
above,1232,O
1.25,1232,O
microgram/ml,1232,O
.,1232,O
Thus,1233,O
",",1233,O
high,1233,O
cimetidine,1233,B-Chemical
levels,1233,O
alone,1233,O
do,1233,O
not,1233,O
always,1233,O
induce,1233,O
dementia,1233,B-Disease
.,1233,O
Further,1234,O
observations,1234,O
on,1234,O
the,1234,O
electrophysiologic,1234,O
effects,1234,O
of,1234,O
oral,1234,O
amiodarone,1234,B-Chemical
therapy,1234,O
.,1234,O
A,1235,O
case,1235,O
is,1235,O
presented,1235,O
of,1235,O
a,1235,O
reversible,1235,O
intra-Hisian,1235,B-Disease
block,1235,I-Disease
occurring,1235,O
under,1235,O
amiodarone,1235,B-Chemical
treatment,1235,O
for,1235,O
atrial,1235,B-Disease
tachycardia,1235,I-Disease
in,1235,O
a,1235,O
patient,1235,O
without,1235,O
clear,1235,O
intraventricular,1235,B-Disease
conduction,1235,I-Disease
abnormalities,1235,I-Disease
.,1235,O
His,1236,O
bundle,1236,O
recordings,1236,O
showed,1236,O
an,1236,O
atrial,1236,B-Disease
tachycardia,1236,I-Disease
with,1236,O
intermittent,1236,O
exit,1236,O
block,1236,O
and,1236,O
greatly,1236,O
prolonged,1236,O
BH,1236,O
and,1236,O
HV,1236,O
intervals,1236,O
(,1236,O
40,1236,O
and,1236,O
100,1236,O
msec,1236,O
",",1236,O
respectively,1236,O
),1236,O
.,1236,O
Thirty,1237,O
days,1237,O
after,1237,O
amiodarone,1237,B-Chemical
discontinuation,1237,O
",",1237,O
His,1237,O
bundle,1237,O
electrograms,1237,O
showed,1237,O
atrial,1237,B-Disease
flutter,1237,I-Disease
without,1237,O
intra-Hisian,1237,O
or,1237,O
infra-Hisian,1237,O
delay,1237,O
.,1237,O
Amiodarone,1238,B-Chemical
should,1238,O
be,1238,O
used,1238,O
with,1238,O
caution,1238,O
during,1238,O
long-term,1238,O
oral,1238,O
therapy,1238,O
in,1238,O
patients,1238,O
with,1238,O
or,1238,O
without,1238,O
clear,1238,O
intraventricular,1238,O
conduction,1238,O
defects,1238,O
.,1238,O
Development,1239,O
of,1239,O
clear,1239,B-Disease
cell,1239,I-Disease
adenocarcinoma,1239,I-Disease
in,1239,O
DES-exposed,1239,B-Chemical
offspring,1239,O
under,1239,O
observation,1239,O
.,1239,O
Two,1240,O
cases,1240,O
of,1240,O
clear,1240,O
cell,1240,O
adenocarcinoma,1240,O
of,1240,O
the,1240,O
vagina,1240,O
detected,1240,O
at,1240,O
follow-up,1240,O
in,1240,O
young,1240,O
women,1240,O
exposed,1240,O
in,1240,O
utero,1240,O
to,1240,O
diethylstilbestrol,1240,B-Chemical
are,1240,O
reported,1240,O
.,1240,O
One,1241,O
patient,1241,O
",",1241,O
aged,1241,O
23,1241,O
",",1241,O
had,1241,O
been,1241,O
followed,1241,O
for,1241,O
2,1241,O
years,1241,O
before,1241,O
carcinoma,1241,B-Disease
was,1241,O
diagnosed,1241,O
;,1241,O
the,1241,O
second,1241,O
patient,1241,O
",",1241,O
aged,1241,O
22,1241,O
",",1241,O
had,1241,O
been,1241,O
seen,1241,O
on,1241,O
a,1241,O
regular,1241,O
basis,1241,O
for,1241,O
5,1241,O
years,1241,O
",",1241,O
8,1241,O
months,1241,O
.,1241,O
In,1242,O
both,1242,O
instances,1242,O
",",1242,O
suspicion,1242,O
of,1242,O
the,1242,O
presence,1242,O
of,1242,O
carcinoma,1242,B-Disease
was,1242,O
aroused,1242,O
by,1242,O
the,1242,O
palpation,1242,O
of,1242,O
a,1242,O
small,1242,O
nodule,1242,O
in,1242,O
the,1242,O
vaginal,1242,O
fornix,1242,O
.,1242,O
Hysterosalpingography,1243,O
was,1243,O
performed,1243,O
on,1243,O
both,1243,O
patients,1243,O
and,1243,O
",",1243,O
in,1243,O
1,1243,O
instance,1243,O
",",1243,O
an,1243,O
abnormal,1243,O
x-ray,1243,O
film,1243,O
was,1243,O
reflected,1243,O
by,1243,O
the,1243,O
gross,1243,O
appearance,1243,O
of,1243,O
the,1243,O
uterine,1243,O
cavity,1243,O
found,1243,O
in,1243,O
the,1243,O
surgical,1243,O
specimen,1243,O
.,1243,O
Neurologic,1244,O
effects,1244,O
of,1244,O
subarachnoid,1244,O
administration,1244,O
of,1244,O
2-chloroprocaine-CE,1244,B-Chemical
",",1244,O
bupivacaine,1244,B-Chemical
",",1244,O
and,1244,O
low,1244,O
pH,1244,O
normal,1244,O
saline,1244,O
in,1244,O
dogs,1244,O
.,1244,O
The,1245,O
purpose,1245,O
of,1245,O
this,1245,O
study,1245,O
was,1245,O
to,1245,O
evaluate,1245,O
the,1245,O
neurologic,1245,O
consequences,1245,O
of,1245,O
deliberate,1245,O
subarachnoid,1245,O
injection,1245,O
of,1245,O
large,1245,O
volumes,1245,O
of,1245,O
2-chloroprocaine-CE,1245,B-Chemical
in,1245,O
experimental,1245,O
animals,1245,O
.,1245,O
The,1246,O
possible,1246,O
role,1246,O
of,1246,O
low,1246,O
pH,1246,O
as,1246,O
well,1246,O
as,1246,O
total,1246,O
volume,1246,O
as,1246,O
potential,1246,O
factors,1246,O
in,1246,O
causing,1246,O
neurotoxicity,1246,B-Disease
was,1246,O
evaluated,1246,O
.,1246,O
The,1247,O
65,1247,O
dogs,1247,O
in,1247,O
the,1247,O
study,1247,O
received,1247,O
injections,1247,O
in,1247,O
the,1247,O
subarachnoid,1247,O
space,1247,O
as,1247,O
follows,1247,O
:,1247,O
6,1247,O
to,1247,O
8,1247,O
ml,1247,O
of,1247,O
bupivacaine,1247,B-Chemical
(,1247,O
N,1247,O
=,1247,O
15,1247,O
),1247,O
",",1247,O
2-chloroprocaine-CE,1247,B-Chemical
(,1247,O
N,1247,O
=,1247,O
20,1247,O
),1247,O
",",1247,O
low,1247,O
pH,1247,O
normal,1247,O
saline,1247,O
(,1247,O
pH,1247,O
3.0,1247,O
),1247,O
(,1247,O
N,1247,O
=,1247,O
20,1247,O
),1247,O
",",1247,O
or,1247,O
normal,1247,O
saline,1247,O
(,1247,O
N,1247,O
=,1247,O
10,1247,O
),1247,O
.,1247,O
Of,1248,O
the,1248,O
20,1248,O
animals,1248,O
that,1248,O
received,1248,O
subarachnoid,1248,O
injection,1248,O
of,1248,O
2-chloroprocaine-CE,1248,B-Chemical
seven,1248,O
(,1248,O
35,1248,O
%,1248,O
),1248,O
developed,1248,O
hind-limb,1248,O
paralysis,1248,B-Disease
.,1248,O
None,1249,O
of,1249,O
the,1249,O
animals,1249,O
that,1249,O
received,1249,O
bupivacaine,1249,B-Chemical
",",1249,O
normal,1249,O
saline,1249,O
",",1249,O
or,1249,O
normal,1249,O
saline,1249,O
titrated,1249,O
to,1249,O
a,1249,O
pH,1249,O
3.0,1249,O
developed,1249,O
hind-limb,1249,O
paralysis,1249,B-Disease
.,1249,O
Of,1250,O
the,1250,O
15,1250,O
spinal,1250,O
cords,1250,O
of,1250,O
the,1250,O
animals,1250,O
that,1250,O
received,1250,O
2-chloroprocaine-CE,1250,B-Chemical
",",1250,O
13,1250,O
showed,1250,O
subpial,1250,B-Disease
necrosis,1250,I-Disease
;,1250,O
the,1250,O
nerve,1250,O
roots,1250,O
and,1250,O
subarachnoid,1250,O
vessels,1250,O
were,1250,O
normal,1250,O
.,1250,O
The,1251,O
spinal,1251,O
cords,1251,O
of,1251,O
the,1251,O
animals,1251,O
that,1251,O
received,1251,O
bupivacaine,1251,B-Chemical
",",1251,O
low,1251,O
pH,1251,O
normal,1251,O
saline,1251,O
(,1251,O
pH,1251,O
3.0,1251,O
),1251,O
",",1251,O
or,1251,O
normal,1251,O
saline,1251,O
did,1251,O
not,1251,O
show,1251,O
abnormal,1251,O
findings,1251,O
.,1251,O
Procainamide-induced,1252,B-Chemical
polymorphous,1252,O
ventricular,1252,B-Disease
tachycardia,1252,I-Disease
.,1252,O
Seven,1253,O
cases,1253,O
of,1253,O
procainamide-induced,1253,B-Chemical
polymorphous,1253,O
ventricular,1253,B-Disease
tachycardia,1253,I-Disease
are,1253,O
presented,1253,O
.,1253,O
In,1254,O
four,1254,O
patients,1254,O
",",1254,O
polymorphous,1254,O
ventricular,1254,B-Disease
tachycardia,1254,I-Disease
appeared,1254,O
after,1254,O
intravenous,1254,O
administration,1254,O
of,1254,O
200,1254,O
to,1254,O
400,1254,O
mg,1254,O
of,1254,O
procainamide,1254,B-Chemical
for,1254,O
the,1254,O
treatment,1254,O
of,1254,O
sustained,1254,O
ventricular,1254,B-Disease
tachycardia,1254,I-Disease
.,1254,O
In,1255,O
the,1255,O
remaining,1255,O
three,1255,O
patients,1255,O
",",1255,O
procainamide,1255,B-Chemical
was,1255,O
administered,1255,O
orally,1255,O
for,1255,O
treatment,1255,O
of,1255,O
chronic,1255,O
premature,1255,B-Disease
ventricular,1255,I-Disease
contractions,1255,I-Disease
or,1255,O
atrial,1255,B-Disease
flutter,1255,I-Disease
.,1255,O
These,1256,O
patients,1256,O
had,1256,O
Q-T,1256,B-Disease
prolongation,1256,I-Disease
and,1256,O
recurrent,1256,O
syncope,1256,B-Disease
due,1256,O
to,1256,O
polymorphous,1256,O
ventricular,1256,B-Disease
tachycardia,1256,I-Disease
.,1256,O
In,1257,O
four,1257,O
patients,1257,O
",",1257,O
the,1257,O
arrhythmia,1257,B-Disease
was,1257,O
rapidly,1257,O
diagnosed,1257,O
and,1257,O
treated,1257,O
with,1257,O
disappearance,1257,O
of,1257,O
further,1257,O
episodes,1257,O
of,1257,O
the,1257,O
arrhythmia,1257,B-Disease
.,1257,O
In,1258,O
two,1258,O
patients,1258,O
",",1258,O
the,1258,O
arrhythmia,1258,B-Disease
degenerated,1258,O
into,1258,O
irreversible,1258,O
ventricular,1258,B-Disease
fibrillation,1258,I-Disease
and,1258,O
both,1258,O
patients,1258,O
died,1258,O
.,1258,O
In,1259,O
the,1259,O
seventh,1259,O
patient,1259,O
",",1259,O
a,1259,O
permanent,1259,O
ventricular,1259,O
pacemaker,1259,O
was,1259,O
inserted,1259,O
and,1259,O
",",1259,O
despite,1259,O
continuation,1259,O
of,1259,O
procainamide,1259,B-Chemical
therapy,1259,O
",",1259,O
polymorphous,1259,O
ventricular,1259,B-Disease
tachycardia,1259,I-Disease
did,1259,O
not,1259,O
reoccur,1259,O
.,1259,O
These,1260,O
seven,1260,O
cases,1260,O
demonstrate,1260,O
that,1260,O
procainamide,1260,B-Chemical
can,1260,O
produce,1260,O
an,1260,O
acquired,1260,O
prolonged,1260,B-Disease
Q-T,1260,I-Disease
syndrome,1260,I-Disease
with,1260,O
polymorphous,1260,O
ventricular,1260,B-Disease
tachycardia,1260,I-Disease
.,1260,O
Phenobarbitone-induced,1261,B-Chemical
enlargement,1261,B-Disease
of,1261,I-Disease
the,1261,I-Disease
liver,1261,I-Disease
in,1261,O
the,1261,O
rat,1261,O
:,1261,O
its,1261,O
relationship,1261,O
to,1261,O
carbon,1261,B-Chemical
tetrachloride-induced,1261,O
cirrhosis,1261,B-Disease
.,1261,O
The,1262,O
yield,1262,O
of,1262,O
severe,1262,O
cirrhosis,1262,B-Disease
of,1262,I-Disease
the,1262,I-Disease
liver,1262,I-Disease
(,1262,O
defined,1262,O
as,1262,O
a,1262,O
shrunken,1262,O
finely,1262,O
nodular,1262,O
liver,1262,O
with,1262,O
micronodular,1262,O
histology,1262,O
",",1262,O
ascites,1262,B-Disease
greater,1262,O
than,1262,O
30,1262,O
ml,1262,O
",",1262,O
plasma,1262,O
albumin,1262,O
less,1262,O
than,1262,O
2.2,1262,O
g/dl,1262,O
",",1262,O
splenomegaly,1262,B-Disease
2-3,1262,O
times,1262,O
normal,1262,O
",",1262,O
and,1262,O
testicular,1262,O
atrophy,1262,B-Disease
approximately,1262,O
half,1262,O
normal,1262,O
weight,1262,O
),1262,O
after,1262,O
12,1262,O
doses,1262,O
of,1262,O
carbon,1262,B-Chemical
tetrachloride,1262,I-Chemical
given,1262,O
intragastrically,1262,O
in,1262,O
the,1262,O
phenobarbitone-primed,1262,B-Chemical
rat,1262,O
was,1262,O
increased,1262,O
from,1262,O
25,1262,O
%,1262,O
to,1262,O
56,1262,O
%,1262,O
by,1262,O
giving,1262,O
the,1262,O
initial,1262,O
``,1262,O
calibrating,1262,O
'',1262,O
dose,1262,O
of,1262,O
carbon,1262,B-Chemical
tetrachloride,1262,I-Chemical
at,1262,O
the,1262,O
peak,1262,O
of,1262,O
the,1262,O
phenobarbitone-induced,1262,B-Chemical
enlargement,1262,B-Disease
of,1262,I-Disease
the,1262,I-Disease
liver,1262,I-Disease
.,1262,O
At,1263,O
this,1263,O
point,1263,O
it,1263,O
was,1263,O
assumed,1263,O
that,1263,O
the,1263,O
cytochrome,1263,O
P450/CCl4,1263,O
toxic,1263,O
state,1263,O
was,1263,O
both,1263,O
maximal,1263,O
and,1263,O
stable,1263,O
.,1263,O
The,1264,O
optimal,1264,O
rat,1264,O
size,1264,O
to,1264,O
begin,1264,O
phenobarbitone,1264,B-Chemical
was,1264,O
determined,1264,O
as,1264,O
100,1264,O
g,1264,O
",",1264,O
and,1264,O
this,1264,O
size,1264,O
as,1264,O
a,1264,O
group,1264,O
had,1264,O
a,1264,O
mean,1264,O
maximum,1264,O
relative,1264,O
liver,1264,O
weight,1264,O
increase,1264,O
47,1264,O
%,1264,O
greater,1264,O
than,1264,O
normal,1264,O
rats,1264,O
of,1264,O
the,1264,O
same,1264,O
body,1264,O
weight,1264,O
.,1264,O
The,1265,O
optimal,1265,O
time,1265,O
for,1265,O
the,1265,O
initial,1265,O
dose,1265,O
of,1265,O
carbon,1265,B-Chemical
tetrachloride,1265,I-Chemical
was,1265,O
after,1265,O
14,1265,O
days,1265,O
on,1265,O
phenobarbitone,1265,B-Chemical
.,1265,O
Triamterene,1266,B-Chemical
nephrolithiasis,1266,B-Disease
complicating,1266,O
dyazide,1266,B-Chemical
therapy,1266,O
.,1266,O
A,1267,O
case,1267,O
of,1267,O
triamterene,1267,B-Chemical
nephrolithiasis,1267,B-Disease
is,1267,O
reported,1267,O
in,1267,O
a,1267,O
man,1267,O
after,1267,O
4,1267,O
years,1267,O
of,1267,O
hydrochlorothiazide-triamterene,1267,B-Chemical
therapy,1267,O
for,1267,O
hypertension,1267,B-Disease
.,1267,O
The,1268,O
stone,1268,O
passed,1268,O
spontaneously,1268,O
and,1268,O
was,1268,O
found,1268,O
to,1268,O
contain,1268,O
a,1268,O
triamterene,1268,B-Chemical
metabolite,1268,O
admixed,1268,O
with,1268,O
uric,1268,B-Chemical
acid,1268,I-Chemical
salts,1268,I-Chemical
.,1268,O
Factors,1269,O
affecting,1269,O
triamterene,1269,B-Chemical
nephrolithiasis,1269,B-Disease
are,1269,O
discussed,1269,O
and,1269,O
2,1269,O
previously,1269,O
reported,1269,O
cases,1269,O
are,1269,O
reviewed,1269,O
.,1269,O
Busulfan-induced,1270,B-Chemical
hemorrhagic,1270,O
cystitis,1270,O
.,1270,O
A,1271,O
case,1271,O
of,1271,O
a,1271,O
busulfan-induced,1271,B-Chemical
hemorrhage,1271,O
cystitis,1271,O
is,1271,O
reported,1271,O
.,1271,O
Spontaneous,1272,O
resolution,1272,O
occurred,1272,O
following,1272,O
cessation,1272,O
of,1272,O
the,1272,O
drug,1272,O
.,1272,O
The,1273,O
similarity,1273,O
between,1273,O
the,1273,O
histologic,1273,O
appearances,1273,O
of,1273,O
busulfan,1273,B-Chemical
cystitis,1273,B-Disease
and,1273,O
both,1273,O
radiation,1273,O
and,1273,O
cyclophosphamide-induced,1273,B-Chemical
cystitis,1273,B-Disease
is,1273,O
discussed,1273,O
and,1273,O
the,1273,O
world,1273,O
literature,1273,O
reviewed,1273,O
.,1273,O
In,1274,O
view,1274,O
of,1274,O
the,1274,O
known,1274,O
tendency,1274,O
of,1274,O
busulfan,1274,B-Chemical
to,1274,O
induce,1274,O
cellular,1274,O
atypia,1274,O
and,1274,O
carcinoma,1274,B-Disease
in,1274,O
other,1274,O
sites,1274,O
",",1274,O
periodic,1274,O
urinary,1274,O
cytology,1274,O
is,1274,O
suggested,1274,O
in,1274,O
patients,1274,O
on,1274,O
long-term,1274,O
therapy,1274,O
.,1274,O
Variant,1275,O
ventricular,1275,B-Disease
tachycardia,1275,I-Disease
in,1275,O
desipramine,1275,B-Chemical
toxicity,1275,B-Disease
.,1275,O
We,1276,O
report,1276,O
a,1276,O
case,1276,O
of,1276,O
variant,1276,O
ventricular,1276,B-Disease
tachycardia,1276,I-Disease
induced,1276,O
by,1276,O
desipramine,1276,B-Chemical
toxicity,1276,B-Disease
.,1276,O
Unusual,1277,O
features,1277,O
of,1277,O
the,1277,O
arrhythmia,1277,B-Disease
are,1277,O
repetitive,1277,O
group,1277,O
beating,1277,O
",",1277,O
progressive,1277,O
shortening,1277,O
of,1277,O
the,1277,O
R-R,1277,O
interval,1277,O
",",1277,O
progressive,1277,O
widening,1277,O
of,1277,O
the,1277,O
QRS,1277,O
complex,1277,O
with,1277,O
eventual,1277,O
failure,1277,O
of,1277,O
intraventricular,1277,O
conduction,1277,O
",",1277,O
and,1277,O
changes,1277,O
in,1277,O
direction,1277,O
of,1277,O
the,1277,O
QRS,1277,O
axis,1277,O
.,1277,O
Recognition,1278,O
of,1278,O
variant,1278,O
ventricular,1278,B-Disease
tachycardia,1278,I-Disease
is,1278,O
important,1278,O
because,1278,O
therapy,1278,O
differs,1278,O
from,1278,O
that,1278,O
of,1278,O
classic,1278,O
ventricular,1278,B-Disease
tachycardia,1278,I-Disease
.,1278,O
Rebound,1279,O
hypertensive,1279,B-Disease
after,1279,O
sodium,1279,B-Chemical
nitroprusside,1279,I-Chemical
prevented,1279,O
by,1279,O
saralasin,1279,B-Chemical
in,1279,O
rats,1279,O
.,1279,O
The,1280,O
role,1280,O
of,1280,O
the,1280,O
renin,1280,O
--,1280,O
angiotensin,1280,B-Chemical
system,1280,O
in,1280,O
the,1280,O
maintenance,1280,O
of,1280,O
blood,1280,O
pressure,1280,O
during,1280,O
halothane,1280,B-Chemical
anesthesia,1280,O
and,1280,O
sodium,1280,B-Chemical
nitroprusside,1280,I-Chemical
(,1280,O
SNP,1280,B-Chemical
),1280,O
-induced,1280,O
hypotension,1280,B-Disease
was,1280,O
evaluated,1280,O
.,1280,O
Control,1281,O
rats,1281,O
received,1281,O
halothane,1281,B-Chemical
anesthesia,1281,O
(,1281,O
1,1281,O
MAC,1281,O
),1281,O
for,1281,O
one,1281,O
hour,1281,O
",",1281,O
followed,1281,O
by,1281,O
SNP,1281,B-Chemical
infusion,1281,O
",",1281,O
40,1281,O
microgram/kg/min,1281,O
",",1281,O
for,1281,O
30,1281,O
min,1281,O
",",1281,O
followed,1281,O
by,1281,O
a,1281,O
30-min,1281,O
recovery,1281,O
period,1281,O
.,1281,O
A,1282,O
second,1282,O
group,1282,O
of,1282,O
rats,1282,O
was,1282,O
treated,1282,O
identically,1282,O
and,1282,O
",",1282,O
in,1282,O
addition,1282,O
",",1282,O
received,1282,O
an,1282,O
infusion,1282,O
of,1282,O
saralasin,1282,B-Chemical
(,1282,O
a,1282,O
competitive,1282,O
inhibitor,1282,O
of,1282,O
angiotensin,1282,B-Chemical
II,1282,I-Chemical
),1282,O
throughout,1282,O
the,1282,O
experimental,1282,O
period,1282,O
.,1282,O
In,1283,O
each,1283,O
group,1283,O
",",1283,O
SNP,1283,B-Chemical
infusion,1283,O
resulted,1283,O
in,1283,O
an,1283,O
initial,1283,O
decrease,1283,O
in,1283,O
blood,1283,O
pressure,1283,O
from,1283,O
86,1283,O
torr,1283,O
and,1283,O
83,1283,O
torr,1283,O
",",1283,O
respectively,1283,O
",",1283,O
to,1283,O
48,1283,O
torr,1283,O
.,1283,O
During,1284,O
the,1284,O
SNP,1284,B-Chemical
infusion,1284,O
the,1284,O
control,1284,O
animals,1284,O
demonstrated,1284,O
a,1284,O
progressive,1284,O
increase,1284,B-Disease
in,1284,I-Disease
blood,1284,I-Disease
pressure,1284,I-Disease
to,1284,O
61,1284,O
torr,1284,O
",",1284,O
whereas,1284,O
the,1284,O
saralasin-treated,1284,B-Chemical
animals,1284,O
showed,1284,O
no,1284,O
change,1284,O
.,1284,O
Following,1285,O
discontinuation,1285,O
of,1285,O
SNP,1285,B-Chemical
",",1285,O
blood,1285,O
pressure,1285,O
in,1285,O
the,1285,O
control,1285,O
animals,1285,O
rebounded,1285,O
to,1285,O
94,1285,O
torr,1285,O
",",1285,O
as,1285,O
compared,1285,O
with,1285,O
78,1285,O
torr,1285,O
in,1285,O
the,1285,O
saralasin-treated,1285,B-Chemical
rats,1285,O
.,1285,O
This,1286,O
study,1286,O
indicates,1286,O
that,1286,O
with,1286,O
stable,1286,O
halothane,1286,B-Chemical
anesthesia,1286,O
",",1286,O
the,1286,O
partial,1286,O
recovery,1286,O
of,1286,O
blood,1286,O
pressure,1286,O
during,1286,O
SNP,1286,B-Chemical
infusion,1286,O
and,1286,O
the,1286,O
post-SNP,1286,O
rebound,1286,O
of,1286,O
blood,1286,O
pressure,1286,O
can,1286,O
be,1286,O
completely,1286,O
blocked,1286,O
by,1286,O
saralasin,1286,B-Chemical
.,1286,O
This,1287,O
demonstrates,1287,O
the,1287,O
participation,1287,O
of,1287,O
the,1287,O
renin,1287,O
--,1287,O
angiotensin,1287,B-Chemical
system,1287,O
in,1287,O
antagonizing,1287,O
the,1287,O
combined,1287,O
hypotensive,1287,B-Disease
effects,1287,O
of,1287,O
halothane,1287,B-Chemical
and,1287,O
SNP,1287,B-Chemical
.,1287,O
Clinical,1288,O
nephrotoxicity,1288,B-Disease
of,1288,O
tobramycin,1288,B-Chemical
and,1288,O
gentamicin,1288,B-Chemical
.,1288,O
A,1289,O
prospective,1289,O
study,1289,O
.,1289,O
Nearly,1290,O
3.2,1290,O
million,1290,O
people,1290,O
in,1290,O
this,1290,O
country,1290,O
receive,1290,O
aminoglycoside,1290,B-Chemical
antibiotics,1290,O
annually,1290,O
.,1290,O
Gentamicin,1291,B-Chemical
sulfate,1291,I-Chemical
and,1291,O
tobramycin,1291,B-Chemical
sulfate,1291,I-Chemical
continue,1291,O
to,1291,O
demonstrate,1291,O
ototoxicity,1291,B-Disease
and,1291,O
nephrotoxicity,1291,B-Disease
in,1291,O
both,1291,O
animal,1291,O
and,1291,O
clinical,1291,O
studies,1291,O
.,1291,O
In,1292,O
this,1292,O
study,1292,O
",",1292,O
62,1292,O
patients,1292,O
with,1292,O
confirmed,1292,O
initial,1292,O
normal,1292,O
renal,1292,O
function,1292,O
and,1292,O
treated,1292,O
with,1292,O
2,1292,O
to,1292,O
5,1292,O
mg/kg/day,1292,O
of,1292,O
gentamicin,1292,B-Chemical
sulfate,1292,I-Chemical
or,1292,O
tobramycin,1292,B-Chemical
sulfate,1292,I-Chemical
for,1292,O
a,1292,O
minimum,1292,O
of,1292,O
seven,1292,O
days,1292,O
were,1292,O
followed,1292,O
up,1292,O
prospectively,1292,O
for,1292,O
the,1292,O
development,1292,O
of,1292,O
aminoglycoside-related,1292,B-Chemical
renal,1292,B-Disease
failure,1292,I-Disease
",",1292,O
defined,1292,O
as,1292,O
at,1292,O
least,1292,O
a,1292,O
one-third,1292,O
reduction,1292,O
in,1292,O
renal,1292,O
function,1292,O
.,1292,O
In,1293,O
these,1293,O
62,1293,O
patients,1293,O
",",1293,O
no,1293,O
other,1293,O
causes,1293,O
for,1293,O
renal,1293,B-Disease
failure,1293,I-Disease
could,1293,O
be,1293,O
identified,1293,O
.,1293,O
Five,1294,O
of,1294,O
33,1294,O
(,1294,O
15,1294,O
%,1294,O
),1294,O
of,1294,O
the,1294,O
tobramycin-treated,1294,B-Chemical
patients,1294,O
and,1294,O
16,1294,O
of,1294,O
29,1294,O
(,1294,O
55.2,1294,O
%,1294,O
),1294,O
of,1294,O
the,1294,O
gentamicin-treated,1294,B-Chemical
patients,1294,O
had,1294,O
renal,1294,B-Disease
failure,1294,I-Disease
.,1294,O
Thus,1295,O
",",1295,O
gentamicin,1295,B-Chemical
was,1295,O
associated,1295,O
with,1295,O
renal,1295,B-Disease
failure,1295,I-Disease
more,1295,O
than,1295,O
three,1295,O
times,1295,O
as,1295,O
often,1295,O
as,1295,O
was,1295,O
tobramycin,1295,B-Chemical
.,1295,O
Metabolic,1296,O
involvement,1296,O
in,1296,O
adriamycin,1296,B-Chemical
cardiotoxicity,1296,B-Disease
.,1296,O
The,1297,O
cardiotoxic,1297,B-Disease
effects,1297,O
of,1297,O
adriamycin,1297,B-Chemical
were,1297,O
studied,1297,O
in,1297,O
mammalian,1297,O
myocardial,1297,O
cells,1297,O
in,1297,O
culture,1297,O
as,1297,O
a,1297,O
model,1297,O
system,1297,O
.,1297,O
Adriamycin,1298,B-Chemical
inhibited,1298,O
cell,1298,O
growth,1298,O
and,1298,O
the,1298,O
rhythmic,1298,O
contractions,1298,O
characteristic,1298,O
of,1298,O
myocardial,1298,O
cells,1298,O
in,1298,O
culture,1298,O
.,1298,O
A,1299,O
possible,1299,O
involvement,1299,O
of,1299,O
energy,1299,O
metabolism,1299,O
was,1299,O
suggested,1299,O
previously,1299,O
",",1299,O
and,1299,O
in,1299,O
this,1299,O
study,1299,O
the,1299,O
adenylate,1299,O
energy,1299,O
charge,1299,O
and,1299,O
phosphorylcreatine,1299,B-Chemical
mole,1299,O
fraction,1299,O
were,1299,O
determined,1299,O
in,1299,O
the,1299,O
adriamycin-treated,1299,B-Chemical
cells,1299,O
.,1299,O
The,1300,O
adenylate,1300,O
energy,1300,O
charge,1300,O
was,1300,O
found,1300,O
to,1300,O
be,1300,O
significantly,1300,O
decreased,1300,O
",",1300,O
while,1300,O
the,1300,O
phophorylcreatine,1300,B-Chemical
mole,1300,O
fraction,1300,O
was,1300,O
unchanged,1300,O
.,1300,O
Such,1301,O
disparity,1301,O
suggests,1301,O
an,1301,O
inhibition,1301,O
of,1301,O
creatine,1301,B-Chemical
phosphokinase,1301,O
.,1301,O
The,1302,O
addition,1302,O
of,1302,O
1,1302,O
mM,1302,O
adenosine,1302,B-Chemical
to,1302,O
the,1302,O
myocardial,1302,O
cell,1302,O
cultures,1302,O
markedly,1302,O
increases,1302,O
the,1302,O
ATP,1302,B-Chemical
concentration,1302,O
through,1302,O
a,1302,O
pathway,1302,O
reportedly,1302,O
leading,1302,O
to,1302,O
a,1302,O
compartmentalized,1302,O
ATP,1302,B-Chemical
pool,1302,O
.,1302,O
In,1303,O
the,1303,O
adriamycin-treated,1303,B-Chemical
cells,1303,O
",",1303,O
the,1303,O
addition,1303,O
of,1303,O
adenosine,1303,B-Chemical
increased,1303,O
the,1303,O
adenylate,1303,O
charge,1303,O
and,1303,O
",",1303,O
concomitant,1303,O
with,1303,O
this,1303,O
inrcease,1303,O
",",1303,O
the,1303,O
cells,1303,O
',1303,O
functional,1303,O
integrity,1303,O
",",1303,O
in,1303,O
terms,1303,O
of,1303,O
percentage,1303,O
of,1303,O
beating,1303,O
cells,1303,O
and,1303,O
rate,1303,O
of,1303,O
contractions,1303,O
",",1303,O
was,1303,O
maintained,1303,O
.,1303,O
Age-dependent,1304,O
sensitivity,1304,O
of,1304,O
the,1304,O
rat,1304,O
to,1304,O
neurotoxic,1304,B-Disease
effects,1304,O
of,1304,O
streptomycin,1304,B-Chemical
.,1304,O
Streptomycin,1305,B-Chemical
sulfate,1305,O
(,1305,O
300,1305,O
mg/kg,1305,O
s.c.,1305,O
),1305,O
was,1305,O
injected,1305,O
for,1305,O
various,1305,O
periods,1305,O
into,1305,O
preweanling,1305,O
rats,1305,O
and,1305,O
for,1305,O
3,1305,O
weeks,1305,O
into,1305,O
weanling,1305,O
rats,1305,O
.,1305,O
Beginning,1306,O
at,1306,O
8,1306,O
days,1306,O
of,1306,O
age,1306,O
",",1306,O
body,1306,O
movement,1306,O
and,1306,O
hearing,1306,O
were,1306,O
examined,1306,O
for,1306,O
6,1306,O
and,1306,O
up,1306,O
to,1306,O
17,1306,O
weeks,1306,O
",",1306,O
respectively,1306,O
.,1306,O
Abnormal,1307,B-Disease
movements,1307,I-Disease
and,1307,O
deafness,1307,B-Disease
occurred,1307,O
only,1307,O
in,1307,O
rats,1307,O
treated,1307,O
during,1307,O
the,1307,O
preweaning,1307,O
period,1307,O
;,1307,O
within,1307,O
this,1307,O
period,1307,O
the,1307,O
greatest,1307,O
sensitivities,1307,O
for,1307,O
these,1307,O
abnormalities,1307,O
occurred,1307,O
from,1307,O
2,1307,O
to,1307,O
11-17,1307,O
and,1307,O
5,1307,O
to,1307,O
11,1307,O
days,1307,O
of,1307,O
age,1307,O
",",1307,O
respectively,1307,O
",",1307,O
indicating,1307,O
that,1307,O
the,1307,O
cochlea,1307,O
is,1307,O
more,1307,O
sensitive,1307,O
to,1307,O
streptomycin,1307,B-Chemical
than,1307,O
the,1307,O
site,1307,O
(,1307,O
vestibular,1307,O
or,1307,O
central,1307,O
),1307,O
responsible,1307,O
for,1307,O
the,1307,O
dyskinesias,1307,B-Disease
.,1307,O
Late,1308,O
",",1308,O
late,1308,O
doxorubicin,1308,B-Chemical
cardiotoxicity,1308,B-Disease
.,1308,O
Cardiac,1309,B-Disease
toxicity,1309,I-Disease
is,1309,O
a,1309,O
major,1309,O
complication,1309,O
which,1309,O
limits,1309,O
the,1309,O
use,1309,O
of,1309,O
adriamycin,1309,B-Chemical
as,1309,O
a,1309,O
chemotherapeutic,1309,O
agent,1309,O
.,1309,O
Cardiomyopathy,1310,B-Disease
is,1310,O
frequent,1310,O
when,1310,O
the,1310,O
total,1310,O
dose,1310,O
exceeds,1310,O
600,1310,O
mg/m2,1310,O
and,1310,O
occurs,1310,O
within,1310,O
one,1310,O
to,1310,O
six,1310,O
months,1310,O
after,1310,O
cessation,1310,O
of,1310,O
therapy,1310,O
.,1310,O
A,1311,O
patient,1311,O
is,1311,O
reported,1311,O
who,1311,O
developed,1311,O
progressive,1311,O
cardiomyopathy,1311,B-Disease
two,1311,O
and,1311,O
one-half,1311,O
years,1311,O
after,1311,O
receiving,1311,O
580,1311,O
mg/m2,1311,O
which,1311,O
apparently,1311,O
represents,1311,O
late,1311,O
",",1311,O
late,1311,O
cardiotoxicity,1311,B-Disease
.,1311,O
Attenuation,1312,O
of,1312,O
the,1312,O
lithium-induced,1312,B-Chemical
diabetes-insipidus-like,1312,B-Disease
syndrome,1312,I-Disease
by,1312,O
amiloride,1312,B-Chemical
in,1312,O
rats,1312,O
.,1312,O
The,1313,O
effect,1313,O
of,1313,O
amiloride,1313,B-Chemical
on,1313,O
lithium-induced,1313,B-Chemical
polydipsia,1313,B-Disease
and,1313,O
polyuria,1313,B-Disease
and,1313,O
on,1313,O
the,1313,O
lithium,1313,B-Chemical
concentration,1313,O
in,1313,O
the,1313,O
plasma,1313,O
",",1313,O
brain,1313,O
",",1313,O
kidney,1313,O
",",1313,O
thyroid,1313,O
and,1313,O
red,1313,O
blood,1313,O
cells,1313,O
was,1313,O
investigated,1313,O
in,1313,O
rats,1313,O
",",1313,O
chronically,1313,O
treated,1313,O
with,1313,O
LiCl,1313,B-Chemical
.,1313,O
Amiloride,1314,B-Chemical
reduced,1314,O
the,1314,O
drinking,1314,O
and,1314,O
urine,1314,O
volume,1314,O
of,1314,O
rats,1314,O
in,1314,O
an,1314,O
acute,1314,O
(,1314,O
6,1314,O
or,1314,O
12,1314,O
h,1314,O
),1314,O
and,1314,O
a,1314,O
subacute,1314,O
(,1314,O
3,1314,O
days,1314,O
),1314,O
experiment,1314,O
.,1314,O
6,1315,O
h,1315,O
after,1315,O
the,1315,O
administration,1315,O
of,1315,O
amiloride,1315,B-Chemical
",",1315,O
a,1315,O
reduction,1315,O
was,1315,O
observed,1315,O
in,1315,O
the,1315,O
lithium,1315,B-Chemical
content,1315,O
of,1315,O
the,1315,O
renal,1315,O
medulla,1315,O
but,1315,O
not,1315,O
in,1315,O
the,1315,O
other,1315,O
organs,1315,O
studied,1315,O
.,1315,O
At,1316,O
12,1316,O
h,1316,O
",",1316,O
all,1316,O
the,1316,O
tissues,1316,O
showed,1316,O
a,1316,O
slight,1316,O
increase,1316,O
in,1316,O
lithium,1316,B-Chemical
levels,1316,O
.,1316,O
After,1317,O
3,1317,O
days,1317,O
of,1317,O
combined,1317,O
treatment,1317,O
",",1317,O
a,1317,O
marked,1317,O
elevation,1317,O
in,1317,O
plasma,1317,O
and,1317,O
tissue,1317,O
lithium,1317,B-Chemical
levels,1317,O
accompanied,1317,O
a,1317,O
reduction,1317,O
in,1317,O
water,1317,O
intake,1317,O
.,1317,O
In,1318,O
all,1318,O
the,1318,O
experiments,1318,O
",",1318,O
the,1318,O
attenuation,1318,O
of,1318,O
the,1318,O
lithium-induced,1318,B-Chemical
diabetes-insipidus-like,1318,B-Disease
syndrome,1318,I-Disease
by,1318,O
amiloride,1318,B-Chemical
was,1318,O
accompanied,1318,O
by,1318,O
a,1318,O
reduction,1318,O
of,1318,O
the,1318,O
ratio,1318,O
between,1318,O
the,1318,O
lithium,1318,B-Chemical
concentration,1318,O
in,1318,O
the,1318,O
renal,1318,O
medulla,1318,O
and,1318,O
its,1318,O
levels,1318,O
in,1318,O
the,1318,O
blood,1318,O
and,1318,O
an,1318,O
elevation,1318,O
in,1318,O
the,1318,O
plasma,1318,O
potassium,1318,B-Chemical
level,1318,O
.,1318,O
It,1319,O
is,1319,O
concluded,1319,O
that,1319,O
acute,1319,O
amiloride,1319,B-Chemical
administration,1319,O
to,1319,O
lithium-treated,1319,B-Chemical
patients,1319,O
suffering,1319,O
from,1319,O
polydipsia,1319,B-Disease
and,1319,O
polyuria,1319,B-Disease
might,1319,O
relieve,1319,O
these,1319,O
patients,1319,O
but,1319,O
prolonged,1319,O
amiloride,1319,B-Chemical
supplementation,1319,O
would,1319,O
result,1319,O
in,1319,O
elevated,1319,O
lithium,1319,B-Chemical
levels,1319,O
and,1319,O
might,1319,O
be,1319,O
hazardous,1319,O
.,1319,O
Cardiovascular,1320,B-Disease
complications,1320,I-Disease
associated,1320,O
with,1320,O
terbutaline,1320,B-Chemical
treatment,1320,O
for,1320,O
preterm,1320,B-Disease
labor,1320,I-Disease
.,1320,O
Severe,1321,O
cardiovascular,1321,B-Disease
complications,1321,I-Disease
occurred,1321,O
in,1321,O
eight,1321,O
of,1321,O
160,1321,O
patients,1321,O
treated,1321,O
with,1321,O
terbutaline,1321,B-Chemical
for,1321,O
preterm,1321,B-Disease
labor,1321,I-Disease
.,1321,O
Associated,1322,O
corticosteroid,1322,O
therapy,1322,O
and,1322,O
twin,1322,O
gestations,1322,O
appear,1322,O
to,1322,O
be,1322,O
predisposing,1322,O
factors,1322,O
.,1322,O
Potential,1323,O
mechanisms,1323,O
of,1323,O
the,1323,O
pathophysiology,1323,O
are,1323,O
briefly,1323,O
discussed,1323,O
.,1323,O
Toxic,1324,B-Disease
hepatitis,1324,I-Disease
induced,1324,O
by,1324,O
antithyroid,1324,O
drugs,1324,O
:,1324,O
four,1324,O
cases,1324,O
including,1324,O
one,1324,O
with,1324,O
cross-reactivity,1324,O
between,1324,O
carbimazole,1324,B-Chemical
and,1324,O
benzylthiouracil,1324,B-Chemical
.,1324,O
OBJECTIVE,1325,O
:,1325,O
This,1325,O
study,1325,O
was,1325,O
conducted,1325,O
to,1325,O
assess,1325,O
the,1325,O
occurrence,1325,O
of,1325,O
hepatic,1325,B-Disease
adverse,1325,I-Disease
effects,1325,I-Disease
encountered,1325,O
with,1325,O
antithyroid,1325,O
drugs,1325,O
.,1325,O
METHODS,1326,O
:,1326,O
Retrospective,1326,O
review,1326,O
of,1326,O
medical,1326,O
records,1326,O
of,1326,O
236,1326,O
patients,1326,O
with,1326,O
hyperthyroidism,1326,B-Disease
admitted,1326,O
in,1326,O
our,1326,O
department,1326,O
(,1326,O
in-,1326,O
or,1326,O
out-patients,1326,O
),1326,O
from,1326,O
1986,1326,O
to,1326,O
1992,1326,O
.,1326,O
RESULTS,1327,O
:,1327,O
Four,1327,O
patients,1327,O
(,1327,O
1.7,1327,O
%,1327,O
),1327,O
were,1327,O
identified,1327,O
with,1327,O
toxic,1327,B-Disease
hepatitis,1327,I-Disease
which,1327,O
could,1327,O
reasonably,1327,O
be,1327,O
attributed,1327,O
to,1327,O
the,1327,O
use,1327,O
of,1327,O
antithyroid,1327,O
agent,1327,O
.,1327,O
Two,1328,O
patients,1328,O
had,1328,O
a,1328,O
cholestatic,1328,O
hepatitis,1328,O
induced,1328,O
by,1328,O
carbimazole,1328,B-Chemical
(,1328,O
N,1328,B-Chemical
omercazole,1328,I-Chemical
),1328,O
.,1328,O
Two,1329,O
others,1329,O
had,1329,O
a,1329,O
mixed,1329,O
(,1329,O
cholestatic,1329,B-Disease
and,1329,O
cytolytic,1329,O
),1329,O
hepatitis,1329,B-Disease
following,1329,O
carbimazole,1329,B-Chemical
.,1329,O
One,1330,O
of,1330,O
the,1330,O
latter,1330,O
two,1330,O
patients,1330,O
further,1330,O
experienced,1330,O
a,1330,O
cytolytic,1330,O
hepatitis,1330,B-Disease
which,1330,O
appeared,1330,O
after,1330,O
Benzylthiouracil,1330,B-Chemical
(,1330,O
Basd,1330,B-Chemical
ne,1330,I-Chemical
),1330,O
had,1330,O
replaced,1330,O
carbimazole,1330,B-Chemical
.,1330,O
Biological,1331,O
features,1331,O
of,1331,O
hepatitis,1331,B-Disease
disappeared,1331,O
in,1331,O
all,1331,O
cases,1331,O
after,1331,O
cessation,1331,O
of,1331,O
the,1331,O
incriminated,1331,O
drug,1331,O
",",1331,O
while,1331,O
biliary,1331,O
",",1331,O
viral,1331,O
and,1331,O
immunological,1331,O
searches,1331,O
were,1331,O
negative,1331,O
.,1331,O
Only,1332,O
2,1332,O
patients,1332,O
of,1332,O
our,1332,O
retrospective,1332,O
study,1332,O
experienced,1332,O
a,1332,O
mild,1332,O
or,1332,O
severe,1332,O
neutropenia,1332,B-Disease
.,1332,O
CONCLUSION,1333,O
:,1333,O
Toxic,1333,B-Disease
hepatitis,1333,I-Disease
is,1333,O
a,1333,O
potential,1333,O
adverse,1333,O
effect,1333,O
of,1333,O
antithyroid,1333,O
drugs,1333,O
which,1333,O
warrants,1333,O
",",1333,O
as,1333,O
for,1333,O
haematological,1333,O
disturbances,1333,O
",",1333,O
a,1333,O
pre-therapeutic,1333,O
determination,1333,O
and,1333,O
a,1333,O
careful,1333,O
follow-up,1333,O
of,1333,O
relevant,1333,O
biological,1333,O
markers,1333,O
.,1333,O
Moreover,1334,O
",",1334,O
hepatotoxicity,1334,B-Disease
may,1334,O
not,1334,O
be,1334,O
restricted,1334,O
to,1334,O
one,1334,O
class,1334,O
of,1334,O
antithyroid,1334,O
agents,1334,O
.,1334,O
Interactive,1335,O
effects,1335,O
of,1335,O
variations,1335,O
in,1335,O
[,1335,O
Na,1335,B-Chemical
],1335,O
o,1335,O
and,1335,O
[,1335,O
Ca,1335,B-Chemical
],1335,O
o,1335,O
on,1335,O
rat,1335,O
atrial,1335,O
spontaneous,1335,O
frequency,1335,O
.,1335,O
The,1336,O
effects,1336,O
of,1336,O
varying,1336,O
the,1336,O
extracellular,1336,O
concentrations,1336,O
of,1336,O
Na,1336,B-Chemical
and,1336,O
Ca,1336,B-Chemical
(,1336,O
[,1336,O
Na,1336,B-Chemical
],1336,O
o,1336,O
and,1336,O
[,1336,O
Ca,1336,B-Chemical
],1336,O
o,1336,O
),1336,O
on,1336,O
both,1336,O
",",1336,O
the,1336,O
spontaneous,1336,O
beating,1336,O
and,1336,O
the,1336,O
negative,1336,O
chronotropic,1336,O
action,1336,O
of,1336,O
verapamil,1336,B-Chemical
",",1336,O
were,1336,O
studied,1336,O
in,1336,O
the,1336,O
isolated,1336,O
rat,1336,O
atria,1336,O
.,1336,O
Basal,1337,O
frequency,1337,O
(,1337,O
BF,1337,O
),1337,O
evaluated,1337,O
by,1337,O
surface,1337,O
electrogram,1337,O
was,1337,O
223,1337,O
+/-,1337,O
4,1337,O
beats/min,1337,O
.,1337,O
in,1338,O
control,1338,O
Krebs-Ringer,1338,O
containing,1338,O
137,1338,O
mM,1338,O
Na,1338,B-Chemical
and,1338,O
1.35,1338,O
mM,1338,O
Ca,1338,B-Chemical
(,1338,O
N,1338,O
),1338,O
.,1338,O
It,1339,O
decreased,1339,O
by,1339,O
16,1339,O
+/-,1339,O
3,1339,O
%,1339,O
by,1339,O
lowering,1339,O
[,1339,O
Na,1339,B-Chemical
],1339,O
o,1339,O
to,1339,O
78,1339,O
mM,1339,O
(,1339,O
LNa,1339,O
),1339,O
",",1339,O
23,1339,O
+/-,1339,O
2,1339,O
%,1339,O
by,1339,O
lowering,1339,O
simultaneously,1339,O
[,1339,O
Na,1339,B-Chemical
],1339,O
o,1339,O
to,1339,O
78,1339,O
mM,1339,O
and,1339,O
[,1339,O
Ca,1339,B-Chemical
],1339,O
o,1339,O
to,1339,O
0.675,1339,O
mM,1339,O
(,1339,O
LNa+LCa,1339,O
),1339,O
and,1339,O
31,1339,O
+/-,1339,O
5,1339,O
%,1339,O
by,1339,O
lowering,1339,O
[,1339,O
Na,1339,B-Chemical
],1339,O
o,1339,O
to,1339,O
78,1339,O
mM,1339,O
plus,1339,O
increasing,1339,O
[,1339,O
Ca,1339,B-Chemical
],1339,O
o,1339,O
to,1339,O
3.6,1339,O
mM,1339,O
(,1339,O
LNa+HCa,1339,O
),1339,O
.,1339,O
At,1340,O
normal,1340,O
[,1340,O
Na,1340,B-Chemical
],1340,O
o,1340,O
",",1340,O
decrease,1340,O
(,1340,O
0.675,1340,O
mM,1340,O
),1340,O
or,1340,O
increase,1340,O
(,1340,O
3.6,1340,O
mM,1340,O
),1340,O
of,1340,O
[,1340,O
Ca,1340,B-Chemical
],1340,O
o,1340,O
did,1340,O
not,1340,O
modify,1340,O
BF,1340,O
;,1340,O
a,1340,O
reduction,1340,O
of,1340,O
ten,1340,O
times,1340,O
(,1340,O
0.135,1340,O
mM,1340,O
of,1340,O
normal,1340,O
[,1340,O
Ca,1340,B-Chemical
],1340,O
o,1340,O
was,1340,O
effective,1340,O
to,1340,O
reduce,1340,O
BF,1340,O
by,1340,O
40,1340,O
+/-,1340,O
13,1340,O
%,1340,O
.,1340,O
All,1341,O
negative,1341,O
chronotropic,1341,O
effects,1341,O
were,1341,O
BF-dependent,1341,O
.,1341,O
Dose-dependent,1342,O
bradycardia,1342,B-Disease
induced,1342,O
by,1342,O
verapamil,1342,B-Chemical
was,1342,O
potentiated,1342,O
by,1342,O
LNa,1342,O
",",1342,O
LCa,1342,O
",",1342,O
and,1342,O
HCa,1342,O
.,1342,O
Independent,1343,O
but,1343,O
not,1343,O
additive,1343,O
effects,1343,O
of,1343,O
Na,1343,B-Chemical
and,1343,O
Ca,1343,B-Chemical
are,1343,O
shown,1343,O
by,1343,O
decreases,1343,O
in,1343,O
the,1343,O
values,1343,O
of,1343,O
[,1343,O
verapamil,1343,B-Chemical
],1343,O
o,1343,O
needed,1343,O
to,1343,O
reduce,1343,O
BF,1343,O
by,1343,O
30,1343,O
%,1343,O
(,1343,O
IC30,1343,O
),1343,O
with,1343,O
the,1343,O
following,1343,O
order,1343,O
of,1343,O
inhibitory,1343,O
potency,1343,O
:,1343,O
LNa,1343,O
>,1343,O
LCa,1343,O
>,1343,O
HCa,1343,O
>,1343,O
N,1343,O
",",1343,O
resulting,1343,O
LNa+HCa,1343,O
similar,1343,O
to,1343,O
LNa,1343,O
.,1343,O
The,1344,O
[,1344,O
verapamil,1344,B-Chemical
],1344,O
o,1344,O
that,1344,O
arrested,1344,O
atrial,1344,O
beating,1344,O
(,1344,O
AC,1344,O
),1344,O
was,1344,O
also,1344,O
potentiated,1344,O
with,1344,O
the,1344,O
order,1344,O
LNa,1344,O
=,1344,O
LNa+LCa,1344,O
=,1344,O
LNa+HCa,1344,O
=,1344,O
LCa,1344,O
>,1344,O
HCa,1344,O
=,1344,O
N.,1344,O
The,1344,O
results,1344,O
indicate,1344,O
that,1344,O
rat,1344,O
atrial,1344,O
spontaneous,1344,O
beating,1344,O
is,1344,O
more,1344,O
dependent,1344,O
on,1344,O
[,1344,O
Na,1344,B-Chemical
],1344,O
o,1344,O
than,1344,O
on,1344,O
[,1344,O
Ca,1344,B-Chemical
],1344,O
o,1344,O
in,1344,O
a,1344,O
range,1344,O
of,1344,O
+/-,1344,O
50,1344,O
%,1344,O
of,1344,O
their,1344,O
normal,1344,O
concentration,1344,O
.,1344,O
Also,1345,O
the,1345,O
enhancement,1345,O
of,1345,O
verapamil,1345,B-Chemical
effects,1345,O
on,1345,O
atrial,1345,O
beating,1345,O
was,1345,O
more,1345,O
pronounced,1345,O
at,1345,O
LNa,1345,O
than,1345,O
at,1345,O
LCa,1345,O
.,1345,O
(,1346,O
ABSTRACT,1346,O
TRUNCATED,1346,O
AT,1346,O
250,1346,O
WORDS,1346,O
),1346,O
Pseudo-allergic,1347,O
reactions,1347,I-Disease
to,1347,O
corticosteroids,1347,B-Chemical
:,1347,O
diagnosis,1347,O
and,1347,O
alternatives,1347,O
.,1347,O
Two,1348,O
patients,1348,O
treated,1348,O
with,1348,O
parenteral,1348,O
paramethasone,1348,B-Chemical
(,1348,O
Triniol,1348,O
),1348,O
and,1348,O
dexamethasone,1348,B-Chemical
(,1348,O
Sedionbel,1348,O
),1348,O
are,1348,O
described,1348,O
.,1348,O
A,1349,O
few,1349,O
minutes,1349,O
after,1349,O
administration,1349,O
of,1349,O
the,1349,O
drugs,1349,O
",",1349,O
they,1349,O
presented,1349,O
urticaria,1349,B-Disease
(,1349,O
patients,1349,O
1,1349,O
and,1349,O
2,1349,O
),1349,O
and,1349,O
conjunctivitis,1349,B-Disease
(,1349,O
patient,1349,O
1,1349,O
),1349,O
.,1349,O
The,1350,O
purpose,1350,O
of,1350,O
our,1350,O
study,1350,O
was,1350,O
to,1350,O
determine,1350,O
the,1350,O
cause,1350,O
of,1350,O
the,1350,O
patients,1350,O
',1350,O
reactions,1350,O
",",1350,O
the,1350,O
immunological,1350,O
mechanisms,1350,O
involved,1350,O
and,1350,O
whether,1350,O
these,1350,O
patients,1350,O
would,1350,O
be,1350,O
able,1350,O
to,1350,O
tolerate,1350,O
any,1350,O
kind,1350,O
of,1350,O
corticoid,1350,O
.,1350,O
Clinical,1351,O
examinations,1351,O
and,1351,O
skin,1351,O
",",1351,O
oral,1351,O
and,1351,O
parenteral,1351,O
challenges,1351,O
with,1351,O
different,1351,O
corticosteroids,1351,B-Chemical
and,1351,O
ELISA,1351,O
tests,1351,O
were,1351,O
performed,1351,O
.,1351,O
In,1352,O
the,1352,O
two,1352,O
patients,1352,O
",",1352,O
skin,1352,O
and,1352,O
ELISA,1352,O
tests,1352,O
with,1352,O
paramethasone,1352,B-Chemical
were,1352,O
negative,1352,O
",",1352,O
as,1352,O
was,1352,O
the,1352,O
prick,1352,O
test,1352,O
with,1352,O
each,1352,O
of,1352,O
its,1352,O
excipients,1352,O
.,1352,O
A,1353,O
single-blind,1353,O
parenteral,1353,O
challenge,1353,O
with,1353,O
Triniol,1353,O
was,1353,O
positive,1353,O
in,1353,O
both,1353,O
patients,1353,O
after,1353,O
the,1353,O
administration,1353,O
of,1353,O
1,1353,O
ml,1353,O
of,1353,O
the,1353,O
drug,1353,O
",",1353,O
and,1353,O
negative,1353,O
with,1353,O
its,1353,O
excipients,1353,O
.,1353,O
We,1354,O
also,1354,O
carried,1354,O
out,1354,O
oral,1354,O
and,1354,O
parenteral,1354,O
challenges,1354,O
with,1354,O
other,1354,O
corticosteroids,1354,B-Chemical
and,1354,O
found,1354,O
intolerance,1354,O
to,1354,O
some,1354,O
of,1354,O
them,1354,O
.,1354,O
These,1355,O
results,1355,O
suggest,1355,O
that,1355,O
paramethasone,1355,B-Chemical
caused,1355,O
pseudoallergic,1355,O
reactions,1355,O
in,1355,O
our,1355,O
patients,1355,O
.,1355,O
Corticosteroids,1356,O
different,1356,O
from,1356,O
paramethasone,1356,B-Chemical
also,1356,O
produced,1356,O
hypersensitivity,1356,B-Disease
reactions,1356,O
in,1356,O
these,1356,O
patients,1356,O
;,1356,O
however,1356,O
",",1356,O
a,1356,O
few,1356,O
of,1356,O
them,1356,O
were,1356,O
tolerated,1356,O
.,1356,O
The,1357,O
basic,1357,O
mechanisms,1357,O
of,1357,O
those,1357,O
reactions,1357,O
are,1357,O
not,1357,O
yet,1357,O
fully,1357,O
understood,1357,O
.,1357,O
To,1358,O
our,1358,O
knowledge,1358,O
",",1358,O
this,1358,O
is,1358,O
the,1358,O
first,1358,O
report,1358,O
of,1358,O
a,1358,O
pseudo-allergy,1358,O
caused,1358,O
by,1358,O
paramethasone,1358,B-Chemical
.,1358,O
Study,1359,O
of,1359,O
the,1359,O
role,1359,O
of,1359,O
vitamin,1359,B-Chemical
B12,1359,I-Chemical
and,1359,O
folinic,1359,B-Chemical
acid,1359,I-Chemical
supplementation,1359,O
in,1359,O
preventing,1359,O
hematologic,1359,O
toxicity,1359,B-Disease
of,1359,O
zidovudine,1359,B-Chemical
.,1359,O
A,1360,O
prospective,1360,O
",",1360,O
randomized,1360,O
study,1360,O
was,1360,O
conducted,1360,O
to,1360,O
evaluate,1360,O
the,1360,O
role,1360,O
of,1360,O
vitamin,1360,B-Chemical
B12,1360,I-Chemical
and,1360,O
folinic,1360,B-Chemical
acid,1360,I-Chemical
supplementation,1360,O
in,1360,O
preventing,1360,O
zidovudine,1360,B-Chemical
(,1360,O
ZDV,1360,B-Chemical
),1360,O
-induced,1360,O
bone,1360,B-Disease
marrow,1360,I-Disease
suppression,1360,I-Disease
.,1360,O
Seventy-five,1361,O
human,1361,B-Disease
immunodeficiency,1361,I-Disease
virus,1361,I-Disease
(,1361,I-Disease
HIV,1361,I-Disease
),1361,I-Disease
-infected,1361,I-Disease
patients,1361,O
with,1361,O
CD4+,1361,O
cell,1361,O
counts,1361,O
<,1361,O
500/mm3,1361,O
were,1361,O
randomized,1361,O
to,1361,O
receive,1361,O
either,1361,O
ZDV,1361,B-Chemical
(,1361,O
500,1361,O
mg,1361,O
daily,1361,O
),1361,O
alone,1361,O
(,1361,O
group,1361,O
I,1361,O
",",1361,O
n,1361,O
=,1361,O
38,1361,O
),1361,O
or,1361,O
in,1361,O
combination,1361,O
with,1361,O
folinic,1361,B-Chemical
acid,1361,I-Chemical
(,1361,O
15,1361,O
mg,1361,O
daily,1361,O
),1361,O
and,1361,O
intramascular,1361,O
vitamin,1361,B-Chemical
B12,1361,I-Chemical
(,1361,O
1000,1361,O
micrograms,1361,O
monthly,1361,O
),1361,O
(,1361,O
group,1361,O
II,1361,O
",",1361,O
n,1361,O
=,1361,O
37,1361,O
),1361,O
.,1361,O
Finally,1362,O
",",1362,O
15,1362,O
patients,1362,O
were,1362,O
excluded,1362,O
from,1362,O
the,1362,O
study,1362,O
(,1362,O
noncompliance,1362,O
14,1362,O
",",1362,O
death,1362,B-Disease
1,1362,O
),1362,O
;,1362,O
thus,1362,O
",",1362,O
60,1362,O
patients,1362,O
(,1362,O
31,1362,O
in,1362,O
group,1362,O
I,1362,O
and,1362,O
29,1362,O
in,1362,O
group,1362,O
II,1362,O
),1362,O
were,1362,O
eligible,1362,O
for,1362,O
analysis,1362,O
.,1362,O
No,1363,O
significant,1363,O
differences,1363,O
between,1363,O
groups,1363,O
were,1363,O
found,1363,O
at,1363,O
enrollment,1363,O
.,1363,O
During,1364,O
the,1364,O
study,1364,O
",",1364,O
vitamin,1364,B-Chemical
B12,1364,I-Chemical
and,1364,O
folate,1364,B-Chemical
levels,1364,O
were,1364,O
significantly,1364,O
higher,1364,O
in,1364,O
group,1364,O
II,1364,O
patients,1364,O
;,1364,O
however,1364,O
",",1364,O
no,1364,O
differences,1364,O
in,1364,O
hemoglobin,1364,O
",",1364,O
hematocrit,1364,O
",",1364,O
mean,1364,O
corpuscular,1364,O
volume,1364,O
",",1364,O
and,1364,O
white-cell,1364,O
",",1364,O
neutrophil,1364,O
and,1364,O
platelet,1364,O
counts,1364,O
were,1364,O
observed,1364,O
between,1364,O
groups,1364,O
at,1364,O
3,1364,O
",",1364,O
6,1364,O
",",1364,O
9,1364,O
and,1364,O
12,1364,O
months,1364,O
.,1364,O
Severe,1365,O
hematologic,1365,O
toxicity,1365,B-Disease
(,1365,O
neutrophil,1365,O
count,1365,O
<,1365,O
1000/mm3,1365,O
and/or,1365,O
hemoglobin,1365,O
<,1365,O
8,1365,O
g/dl,1365,O
),1365,O
occurred,1365,O
in,1365,O
4,1365,O
patients,1365,O
assigned,1365,O
to,1365,O
group,1365,O
I,1365,O
and,1365,O
7,1365,O
assigned,1365,O
to,1365,O
group,1365,O
II,1365,O
.,1365,O
There,1366,O
was,1366,O
no,1366,O
correlation,1366,O
between,1366,O
vitamin,1366,B-Chemical
B12,1366,I-Chemical
or,1366,O
folate,1366,B-Chemical
levels,1366,O
and,1366,O
development,1366,O
of,1366,O
myelosuppression,1366,B-Disease
.,1366,O
Vitamin,1367,B-Chemical
B12,1367,I-Chemical
and,1367,O
folinic,1367,B-Chemical
acid,1367,I-Chemical
supplementation,1367,O
of,1367,O
ZDV,1367,B-Chemical
therapy,1367,O
does,1367,O
not,1367,O
seem,1367,O
useful,1367,O
in,1367,O
preventing,1367,O
or,1367,O
reducing,1367,O
ZDV-induced,1367,B-Chemical
myelotoxicity,1367,B-Disease
in,1367,O
the,1367,O
overall,1367,O
treated,1367,O
population,1367,O
",",1367,O
although,1367,O
a,1367,O
beneficial,1367,O
effect,1367,O
in,1367,O
certain,1367,O
subgroups,1367,O
of,1367,O
patients,1367,O
can,1367,O
not,1367,O
be,1367,O
excluded,1367,O
.,1367,O
Safety,1368,O
and,1368,O
side-effects,1368,O
of,1368,O
alprazolam,1368,B-Chemical
.,1368,O
Controlled,1369,O
study,1369,O
in,1369,O
agoraphobia,1369,B-Disease
with,1369,O
panic,1369,B-Disease
disorder,1369,I-Disease
.,1369,O
BACKGROUND,1370,O
:,1370,O
The,1370,O
widespread,1370,O
use,1370,O
of,1370,O
benzodiazepines,1370,B-Chemical
has,1370,O
led,1370,O
to,1370,O
increasing,1370,O
recognition,1370,O
of,1370,O
their,1370,O
unwanted,1370,O
effects,1370,O
.,1370,O
The,1371,O
efficacy,1371,O
of,1371,O
alprazolam,1371,B-Chemical
and,1371,O
placebo,1371,O
in,1371,O
panic,1371,B-Disease
disorder,1371,I-Disease
with,1371,O
agoraphobia,1371,B-Disease
",",1371,O
and,1371,O
the,1371,O
side-effect,1371,O
and,1371,O
adverse,1371,O
effect,1371,O
profiles,1371,O
of,1371,O
both,1371,O
drug,1371,O
groups,1371,O
were,1371,O
measured,1371,O
.,1371,O
METHOD,1372,O
:,1372,O
In,1372,O
London,1372,O
and,1372,O
Toronto,1372,O
154,1372,O
patients,1372,O
who,1372,O
met,1372,O
DSM-III,1372,O
criteria,1372,O
for,1372,O
panic,1372,B-Disease
disorder,1372,I-Disease
with,1372,O
agoraphobia,1372,B-Disease
were,1372,O
randomised,1372,O
to,1372,O
alprazolam,1372,B-Chemical
or,1372,O
placebo,1372,O
.,1372,O
Subjects,1373,O
in,1373,O
each,1373,O
drug,1373,O
group,1373,O
also,1373,O
received,1373,O
either,1373,O
exposure,1373,O
or,1373,O
relaxation,1373,O
.,1373,O
Treatment,1374,O
was,1374,O
from,1374,O
weeks,1374,O
0,1374,O
to,1374,O
8,1374,O
and,1374,O
was,1374,O
then,1374,O
tapered,1374,O
from,1374,O
weeks,1374,O
8,1374,O
to,1374,O
16,1374,O
.,1374,O
RESULTS,1375,O
:,1375,O
Mean,1375,O
alprazolam,1375,B-Chemical
dose,1375,O
was,1375,O
5,1375,O
mg,1375,O
daily,1375,O
.,1375,O
Compared,1376,O
with,1376,O
placebo,1376,O
subjects,1376,O
",",1376,O
alprazolam,1376,B-Chemical
patients,1376,O
developed,1376,O
more,1376,O
adverse,1376,O
reactions,1376,O
(,1376,O
21,1376,O
%,1376,O
v.,1376,O
0,1376,O
%,1376,O
),1376,O
of,1376,O
depression,1376,B-Disease
",",1376,O
enuresis,1376,B-Disease
",",1376,O
disinhibition,1376,O
and,1376,O
aggression,1376,B-Disease
;,1376,O
and,1376,O
more,1376,O
side-effects,1376,O
",",1376,O
particularly,1376,O
sedation,1376,O
",",1376,O
irritability,1376,B-Disease
",",1376,O
impaired,1376,B-Disease
memory,1376,I-Disease
",",1376,O
weight,1376,B-Disease
loss,1376,I-Disease
and,1376,O
ataxia,1376,B-Disease
.,1376,O
Side-effects,1377,O
tended,1377,O
to,1377,O
diminish,1377,O
during,1377,O
treatment,1377,O
but,1377,O
remained,1377,O
significant,1377,O
at,1377,O
week,1377,O
8,1377,O
.,1377,O
Despite,1378,O
this,1378,O
",",1378,O
the,1378,O
drop-out,1378,O
rate,1378,O
was,1378,O
low,1378,O
.,1378,O
CONCLUSIONS,1379,O
:,1379,O
Alprazolam,1379,B-Chemical
caused,1379,O
side-effects,1379,O
and,1379,O
adverse,1379,O
effects,1379,O
during,1379,O
treatment,1379,O
but,1379,O
many,1379,O
patients,1379,O
were,1379,O
willing,1379,O
to,1379,O
accept,1379,O
these,1379,O
.,1379,O
Crescentic,1380,O
fibrillary,1380,O
glomerulonephritis,1380,B-Disease
associated,1380,O
with,1380,O
intermittent,1380,O
rifampin,1380,B-Chemical
therapy,1380,O
for,1380,O
pulmonary,1380,B-Disease
tuberculosis,1380,I-Disease
.,1380,O
This,1381,O
case,1381,O
study,1381,O
reveals,1381,O
an,1381,O
unusual,1381,O
finding,1381,O
of,1381,O
rapidly,1381,O
proliferative,1381,O
crescentic,1381,O
glomerulonephritis,1381,B-Disease
in,1381,O
a,1381,O
patient,1381,O
treated,1381,O
with,1381,O
rifampin,1381,B-Chemical
who,1381,O
had,1381,O
no,1381,O
other,1381,O
identifiable,1381,O
causes,1381,O
for,1381,O
developing,1381,O
this,1381,O
disease,1381,O
.,1381,O
This,1382,O
patient,1382,O
underwent,1382,O
a,1382,O
10-month,1382,O
regimen,1382,O
of,1382,O
rifampin,1382,B-Chemical
and,1382,O
isoniazid,1382,B-Chemical
for,1382,O
pulmonary,1382,B-Disease
tuberculosis,1382,I-Disease
and,1382,O
was,1382,O
discovered,1382,O
to,1382,O
have,1382,O
developed,1382,O
signs,1382,O
of,1382,O
severe,1382,O
renal,1382,B-Disease
failure,1382,I-Disease
five,1382,O
weeks,1382,O
after,1382,O
completion,1382,O
of,1382,O
therapy,1382,O
.,1382,O
Renal,1383,O
biopsy,1383,O
revealed,1383,O
severe,1383,O
glomerulonephritis,1383,B-Disease
with,1383,O
crescents,1383,O
",",1383,O
electron,1383,O
dense,1383,O
fibrillar,1383,O
deposits,1383,O
and,1383,O
moderate,1383,O
lymphocytic,1383,O
interstitial,1383,O
infiltrate,1383,O
.,1383,O
Other,1384,O
possible,1384,O
causes,1384,O
of,1384,O
rapidly,1384,O
progressive,1384,O
glomerulonephritis,1384,B-Disease
were,1384,O
investigated,1384,O
and,1384,O
ruled,1384,O
out,1384,O
.,1384,O
This,1385,O
report,1385,O
documents,1385,O
the,1385,O
unusual,1385,O
occurrence,1385,O
of,1385,O
rapidly,1385,O
progressive,1385,O
glomerulonephritis,1385,B-Disease
with,1385,O
crescents,1385,O
and,1385,O
fibrillar,1385,O
glomerulonephritis,1385,B-Disease
in,1385,O
a,1385,O
patient,1385,O
treated,1385,O
with,1385,O
rifampin,1385,B-Chemical
.,1385,O
Acute,1386,O
confusion,1386,B-Disease
induced,1386,O
by,1386,O
a,1386,O
high-dose,1386,O
infusion,1386,O
of,1386,O
5-fluorouracil,1386,B-Chemical
and,1386,O
folinic,1386,B-Chemical
acid,1386,I-Chemical
.,1386,O
A,1387,O
61-year-old,1387,O
man,1387,O
was,1387,O
treated,1387,O
with,1387,O
combination,1387,O
chemotherapy,1387,O
incorporating,1387,O
cisplatinum,1387,B-Chemical
",",1387,O
etoposide,1387,B-Chemical
",",1387,O
high-dose,1387,O
5-fluorouracil,1387,B-Chemical
(,1387,O
"2,250",1387,O
mg/m2/24,1387,O
hours,1387,O
),1387,O
and,1387,O
folinic,1387,B-Chemical
acid,1387,I-Chemical
for,1387,O
an,1387,O
inoperable,1387,O
gastric,1387,B-Disease
adenocarcinoma,1387,I-Disease
.,1387,O
He,1388,O
developed,1388,O
acute,1388,O
neurologic,1388,O
symptoms,1388,O
of,1388,O
mental,1388,O
confusion,1388,B-Disease
",",1388,O
disorientation,1388,B-Disease
and,1388,O
irritability,1388,B-Disease
",",1388,O
and,1388,O
then,1388,O
lapsed,1388,O
into,1388,O
a,1388,O
deep,1388,O
coma,1388,B-Disease
",",1388,O
lasting,1388,O
for,1388,O
approximately,1388,O
40,1388,O
hours,1388,O
during,1388,O
the,1388,O
first,1388,O
dose,1388,O
(,1388,O
day,1388,O
2,1388,O
),1388,O
of,1388,O
5-fluorouracil,1388,B-Chemical
and,1388,O
folinic,1388,B-Chemical
acid,1388,I-Chemical
infusion,1388,O
.,1388,O
This,1389,O
complication,1389,O
reappeared,1389,O
on,1389,O
day,1389,O
25,1389,O
during,1389,O
the,1389,O
second,1389,O
dose,1389,O
of,1389,O
5-fluorouracil,1389,B-Chemical
and,1389,O
folinic,1389,B-Chemical
acid,1389,I-Chemical
",",1389,O
which,1389,O
were,1389,O
then,1389,O
the,1389,O
only,1389,O
drugs,1389,O
given,1389,O
.,1389,O
Because,1390,O
folinic,1390,B-Chemical
acid,1390,I-Chemical
was,1390,O
unlikely,1390,O
to,1390,O
be,1390,O
associated,1390,O
with,1390,O
this,1390,O
condition,1390,O
",",1390,O
neurotoxicity,1390,B-Disease
due,1390,O
to,1390,O
high-dose,1390,O
5-fluorouracil,1390,B-Chemical
was,1390,O
highly,1390,O
suspected,1390,O
.,1390,O
The,1391,O
pathogenesis,1391,O
of,1391,O
5-fluorouracil,1391,B-Chemical
neurotoxicity,1391,B-Disease
may,1391,O
be,1391,O
due,1391,O
to,1391,O
a,1391,O
Krebs,1391,O
cycle,1391,O
blockade,1391,O
by,1391,O
fluoroacetate,1391,B-Chemical
and,1391,O
fluorocitrate,1391,B-Chemical
",",1391,O
thiamine,1391,B-Chemical
deficiency,1391,O
",",1391,O
or,1391,O
dihydrouracil,1391,B-Chemical
dehydrogenase,1391,O
deficiency,1391,O
.,1391,O
High-dose,1392,O
5-fluorouracil/folinic,1392,B-Chemical
acid,1392,I-Chemical
infusion,1392,O
therapy,1392,O
has,1392,O
recently,1392,O
become,1392,O
a,1392,O
popular,1392,O
regimen,1392,O
for,1392,O
various,1392,O
cancers,1392,B-Disease
.,1392,O
It,1393,O
is,1393,O
necessary,1393,O
that,1393,O
both,1393,O
oncologists,1393,O
and,1393,O
neurologists,1393,O
be,1393,O
fully,1393,O
aware,1393,O
of,1393,O
this,1393,O
unusual,1393,O
complication,1393,O
.,1393,O
Effect,1394,O
of,1394,O
switching,1394,O
carbamazepine,1394,B-Chemical
to,1394,O
oxcarbazepine,1394,B-Chemical
on,1394,O
the,1394,O
plasma,1394,O
levels,1394,O
of,1394,O
neuroleptics,1394,O
.,1394,O
A,1395,O
case,1395,O
report,1395,O
.,1395,O
Carbamazepine,1396,B-Chemical
was,1396,O
switched,1396,O
to,1396,O
its,1396,O
10-keto,1396,O
analogue,1396,O
oxcarbazepine,1396,B-Chemical
among,1396,O
six,1396,O
difficult-to-treat,1396,O
schizophrenic,1396,B-Disease
or,1396,O
organic,1396,B-Disease
psychotic,1396,I-Disease
patients,1396,O
using,1396,O
concomitantly,1396,O
haloperidol,1396,B-Chemical
",",1396,O
chlorpromazine,1396,B-Chemical
or,1396,O
clozapine,1396,B-Chemical
.,1396,O
This,1397,O
change,1397,O
resulted,1397,O
within,1397,O
2-4,1397,O
weeks,1397,O
in,1397,O
the,1397,O
50-200,1397,O
%,1397,O
increase,1397,O
in,1397,O
the,1397,O
plasma,1397,O
levels,1397,O
of,1397,O
these,1397,O
neuroleptics,1397,O
and,1397,O
the,1397,O
appearance,1397,O
of,1397,O
extrapyramidal,1397,B-Disease
symptoms,1397,I-Disease
.,1397,O
None,1398,O
of,1398,O
the,1398,O
patients,1398,O
showed,1398,O
any,1398,O
clinical,1398,O
deteriotation,1398,O
during,1398,O
the,1398,O
following,1398,O
3-6,1398,O
months,1398,O
.,1398,O
The,1399,O
results,1399,O
of,1399,O
this,1399,O
case,1399,O
report,1399,O
support,1399,O
the,1399,O
idea,1399,O
that,1399,O
in,1399,O
contrast,1399,O
with,1399,O
carbamazepine,1399,B-Chemical
oxcarbazepine,1399,B-Chemical
does,1399,O
not,1399,O
induce,1399,O
the,1399,O
hepatic,1399,O
microsomal,1399,O
enzyme,1399,O
systems,1399,O
regulating,1399,O
the,1399,O
inactivation,1399,O
of,1399,O
antipsychotic,1399,O
drugs,1399,O
.,1399,O
Time,1400,O
course,1400,O
of,1400,O
lipid,1400,O
peroxidation,1400,O
in,1400,O
puromycin,1400,B-Chemical
aminonucleoside-induced,1400,O
nephropathy,1400,B-Disease
.,1400,O
Reactive,1401,O
oxygen,1401,B-Chemical
species,1401,O
have,1401,O
been,1401,O
implicated,1401,O
in,1401,O
the,1401,O
pathogenesis,1401,O
of,1401,O
acute,1401,O
puromycin,1401,B-Chemical
aminonucleoside,1401,I-Chemical
(,1401,O
PAN,1401,B-Chemical
),1401,O
-induced,1401,O
nephropathy,1401,B-Disease
",",1401,O
with,1401,O
antioxidants,1401,O
significantly,1401,O
reducing,1401,O
the,1401,O
proteinuria,1401,B-Disease
.,1401,O
The,1402,O
temporal,1402,O
relationship,1402,O
between,1402,O
lipid,1402,O
peroxidation,1402,O
in,1402,O
the,1402,O
kidney,1402,O
and,1402,O
proteinuria,1402,B-Disease
was,1402,O
examined,1402,O
in,1402,O
this,1402,O
study,1402,O
.,1402,O
Rats,1403,O
were,1403,O
treated,1403,O
with,1403,O
a,1403,O
single,1403,O
IV,1403,O
injection,1403,O
of,1403,O
puromycin,1403,B-Chemical
aminonucleoside,1403,I-Chemical
",",1403,O
(,1403,O
PAN,1403,B-Chemical
",",1403,O
7.5,1403,O
mg/kg,1403,O
),1403,O
and,1403,O
24,1403,O
hour,1403,O
urine,1403,O
samples,1403,O
were,1403,O
obtained,1403,O
prior,1403,O
to,1403,O
sacrifice,1403,O
on,1403,O
days,1403,O
"3,5,7,10,17,27,41",1403,O
(,1403,O
N,1403,O
=,1403,O
5-10,1403,O
per,1403,O
group,1403,O
),1403,O
.,1403,O
The,1404,O
kidneys,1404,O
were,1404,O
removed,1404,O
",",1404,O
flushed,1404,O
with,1404,O
ice,1404,O
cold,1404,O
TRIS,1404,O
buffer,1404,O
.,1404,O
Kidney,1405,O
cortices,1405,O
from,1405,O
each,1405,O
animal,1405,O
were,1405,O
used,1405,O
to,1405,O
prepare,1405,O
homogenates,1405,O
.,1405,O
Tissue,1406,O
lipid,1406,O
peroxidation,1406,O
was,1406,O
measured,1406,O
in,1406,O
whole,1406,O
homogenates,1406,O
as,1406,O
well,1406,O
as,1406,O
in,1406,O
lipid,1406,O
extracts,1406,O
from,1406,O
homogenates,1406,O
as,1406,O
thiobarbituric,1406,B-Chemical
acid,1406,I-Chemical
reactive,1406,O
substances,1406,O
.,1406,O
Proteinuria,1407,B-Disease
was,1407,O
evident,1407,O
at,1407,O
day,1407,O
5,1407,O
",",1407,O
peaked,1407,O
at,1407,O
day,1407,O
7,1407,O
and,1407,O
persisted,1407,O
to,1407,O
day,1407,O
27,1407,O
.,1407,O
Lipid,1408,O
peroxidation,1408,O
in,1408,O
homogenates,1408,O
was,1408,O
maximal,1408,O
at,1408,O
day,1408,O
3,1408,O
and,1408,O
declined,1408,O
rapidly,1408,O
to,1408,O
control,1408,O
levels,1408,O
by,1408,O
day,1408,O
17,1408,O
.,1408,O
This,1409,O
study,1409,O
supports,1409,O
the,1409,O
role,1409,O
of,1409,O
lipid,1409,O
peroxidation,1409,O
in,1409,O
mediating,1409,O
the,1409,O
proteinuric,1409,B-Disease
injury,1409,I-Disease
in,1409,O
PAN,1409,B-Chemical
nephropathy,1409,B-Disease
.,1409,O
Composition,1410,O
of,1410,O
gall,1410,B-Disease
bladder,1410,I-Disease
stones,1410,I-Disease
associated,1410,O
with,1410,O
octreotide,1410,B-Chemical
:,1410,O
response,1410,O
to,1410,O
oral,1410,O
ursodeoxycholic,1410,B-Chemical
acid,1410,I-Chemical
.,1410,O
Octreotide,1411,B-Chemical
",",1411,O
an,1411,O
effective,1411,O
treatment,1411,O
for,1411,O
acromegaly,1411,B-Disease
",",1411,O
induces,1411,O
gall,1411,B-Disease
bladder,1411,I-Disease
stones,1411,I-Disease
in,1411,O
13-60,1411,O
%,1411,O
of,1411,O
patients,1411,O
.,1411,O
Because,1412,O
knowledge,1412,O
of,1412,O
stone,1412,O
composition,1412,O
is,1412,O
essential,1412,O
for,1412,O
studies,1412,O
of,1412,O
their,1412,O
pathogenesis,1412,O
",",1412,O
treatment,1412,O
",",1412,O
and,1412,O
prevention,1412,O
",",1412,O
this,1412,O
was,1412,O
investigated,1412,O
by,1412,O
direct,1412,O
and,1412,O
indirect,1412,O
methods,1412,O
in,1412,O
14,1412,O
octreotide,1412,B-Chemical
treated,1412,O
acromegalic,1412,B-Disease
patients,1412,O
with,1412,O
gall,1412,B-Disease
stones,1412,I-Disease
.,1412,O
Chemical,1413,O
analysis,1413,O
of,1413,O
gall,1413,B-Disease
stones,1413,I-Disease
retrieved,1413,O
at,1413,O
cholecystectomy,1413,O
from,1413,O
two,1413,O
patients,1413,O
",",1413,O
showed,1413,O
that,1413,O
they,1413,O
contained,1413,O
71,1413,O
%,1413,O
and,1413,O
87,1413,O
%,1413,O
cholesterol,1413,B-Chemical
by,1413,O
weight,1413,O
.,1413,O
In,1414,O
the,1414,O
remaining,1414,O
12,1414,O
patients,1414,O
",",1414,O
localised,1414,O
computed,1414,O
tomography,1414,O
of,1414,O
the,1414,O
gall,1414,O
bladder,1414,O
showed,1414,O
that,1414,O
eight,1414,O
had,1414,O
stones,1414,O
with,1414,O
maximum,1414,O
attenuation,1414,O
scores,1414,O
of,1414,O
<,1414,O
100,1414,O
Hounsfield,1414,O
units,1414,O
(,1414,O
values,1414,O
of,1414,O
<,1414,O
100,1414,O
HU,1414,O
predict,1414,O
cholesterol,1414,B-Chemical
rich,1414,O
",",1414,O
dissolvable,1414,O
stones,1414,O
),1414,O
.,1414,O
Gall,1415,O
bladder,1415,O
bile,1415,O
was,1415,O
obtained,1415,O
by,1415,O
ultrasound,1415,O
guided,1415,O
",",1415,O
fine,1415,O
needle,1415,O
puncture,1415,O
from,1415,O
six,1415,O
patients,1415,O
.,1415,O
All,1416,O
six,1416,O
patients,1416,O
had,1416,O
supersaturated,1416,O
bile,1416,O
(,1416,O
mean,1416,O
(,1416,O
SEM,1416,O
),1416,O
cholesterol,1416,B-Chemical
saturation,1416,O
index,1416,O
of,1416,O
1.19,1416,O
(,1416,O
0.08,1416,O
),1416,O
(,1416,O
range,1416,O
1.01-1.53,1416,O
),1416,O
),1416,O
and,1416,O
all,1416,O
had,1416,O
abnormally,1416,O
rapid,1416,O
cholesterol,1416,B-Chemical
microcrystal,1416,O
nucleation,1416,O
times,1416,O
(,1416,O
<,1416,O
4,1416,O
days,1416,O
(,1416,O
range,1416,O
1-4,1416,O
),1416,O
),1416,O
",",1416,O
whilst,1416,O
in,1416,O
four,1416,O
",",1416,O
the,1416,O
bile,1416,O
contained,1416,O
cholesterol,1416,B-Chemical
microcrystals,1416,O
immediately,1416,O
after,1416,O
sampling,1416,O
.,1416,O
Of,1417,O
the,1417,O
12,1417,O
patients,1417,O
considered,1417,O
for,1417,O
oral,1417,O
ursodeoxycholic,1417,B-Chemical
acid,1417,I-Chemical
(,1417,O
UDCA,1417,B-Chemical
),1417,O
treatment,1417,O
",",1417,O
two,1417,O
had,1417,O
a,1417,O
blocked,1417,O
cystic,1417,O
duct,1417,O
and,1417,O
were,1417,O
not,1417,O
started,1417,O
on,1417,O
UDCA,1417,B-Chemical
while,1417,O
one,1417,O
was,1417,O
lost,1417,O
to,1417,O
follow,1417,O
up,1417,O
.,1417,O
After,1418,O
one,1418,O
year,1418,O
of,1418,O
treatment,1418,O
",",1418,O
five,1418,O
of,1418,O
the,1418,O
remaining,1418,O
nine,1418,O
patients,1418,O
showed,1418,O
either,1418,O
partial,1418,O
(,1418,O
n,1418,O
=,1418,O
3,1418,O
),1418,O
or,1418,O
complete,1418,O
(,1418,O
n,1418,O
=,1418,O
2,1418,O
),1418,O
gall,1418,B-Disease
stone,1418,I-Disease
dissolution,1418,O
",",1418,O
suggesting,1418,O
that,1418,O
their,1418,O
stones,1418,O
were,1418,O
cholesterol,1418,B-Chemical
rich,1418,O
.,1418,O
This,1419,O
corresponds,1419,O
",",1419,O
by,1419,O
actuarial,1419,O
(,1419,O
life,1419,O
table,1419,O
),1419,O
analysis,1419,O
",",1419,O
to,1419,O
a,1419,O
combined,1419,O
gall,1419,B-Disease
stone,1419,I-Disease
dissolution,1419,O
rate,1419,O
of,1419,O
58.3,1419,O
(,1419,O
15.9,1419,O
%,1419,O
),1419,O
.,1419,O
In,1420,O
conclusion,1420,O
",",1420,O
octreotide,1420,B-Chemical
induced,1420,O
gall,1420,B-Disease
stones,1420,I-Disease
are,1420,O
generally,1420,O
small,1420,O
",",1420,O
multiple,1420,O
",",1420,O
and,1420,O
cholesterol,1420,B-Chemical
rich,1420,O
although,1420,O
",",1420,O
in,1420,O
common,1420,O
with,1420,O
spontaneous,1420,O
gall,1420,B-Disease
stone,1420,I-Disease
disease,1420,I-Disease
",",1420,O
at,1420,O
presentation,1420,O
some,1420,O
patients,1420,O
will,1420,O
have,1420,O
a,1420,O
blocked,1420,O
cystic,1420,O
duct,1420,O
and,1420,O
some,1420,O
gall,1420,B-Disease
stones,1420,I-Disease
containing,1420,O
calcium,1420,B-Chemical
.,1420,O
Erythema,1421,B-Disease
multiforme,1421,I-Disease
and,1421,O
hypersensitivity,1421,B-Disease
myocarditis,1421,I-Disease
caused,1421,O
by,1421,O
ampicillin,1421,B-Chemical
.,1421,O
OBJECTIVE,1422,O
:,1422,O
To,1422,O
report,1422,O
a,1422,O
case,1422,O
of,1422,O
erythema,1422,B-Disease
multiforme,1422,I-Disease
and,1422,O
hypersensitivity,1422,B-Disease
myocarditis,1422,I-Disease
caused,1422,O
by,1422,O
ampicillin,1422,B-Chemical
.,1422,O
CASE,1423,O
SUMMARY,1423,O
:,1423,O
A,1423,O
13-year-old,1423,O
boy,1423,O
was,1423,O
treated,1423,O
with,1423,O
ampicillin,1423,B-Chemical
and,1423,O
gentamicin,1423,B-Chemical
because,1423,O
of,1423,O
suspected,1423,O
septicemia,1423,B-Disease
.,1423,O
Medications,1424,O
were,1424,O
discontinued,1424,O
when,1424,O
erythema,1424,B-Disease
multiforme,1424,I-Disease
and,1424,O
congestive,1424,B-Disease
heart,1424,I-Disease
failure,1424,I-Disease
caused,1424,O
by,1424,O
myocarditis,1424,B-Disease
occurred,1424,O
.,1424,O
The,1425,O
patient,1425,O
was,1425,O
treated,1425,O
with,1425,O
methylprednisolone,1425,B-Chemical
and,1425,O
gradually,1425,O
improved,1425,O
.,1425,O
Macrophage-migration,1426,O
inhibition,1426,O
(,1426,O
MIF,1426,O
),1426,O
test,1426,O
with,1426,O
ampicillin,1426,B-Chemical
was,1426,O
positive,1426,O
.,1426,O
DISCUSSION,1427,O
:,1427,O
After,1427,O
most,1427,O
infections,1427,B-Disease
causing,1427,O
erythema,1427,B-Disease
multiforme,1427,I-Disease
and,1427,O
myocarditis,1427,B-Disease
were,1427,O
ruled,1427,O
out,1427,O
",",1427,O
a,1427,O
drug-induced,1427,B-Disease
allergic,1427,I-Disease
reaction,1427,I-Disease
was,1427,O
suspected,1427,O
.,1427,O
Positive,1428,O
MIF,1428,O
test,1428,O
for,1428,O
ampicillin,1428,B-Chemical
showed,1428,O
sensitization,1428,O
of,1428,O
the,1428,O
patient,1428,O
's,1428,O
lymphocytes,1428,O
to,1428,O
ampicillin,1428,B-Chemical
.,1428,O
CONCLUSIONS,1429,O
:,1429,O
Hypersensitivity,1429,B-Disease
myocarditis,1429,I-Disease
is,1429,O
a,1429,O
rare,1429,O
and,1429,O
dangerous,1429,O
manifestation,1429,O
of,1429,O
allergy,1429,B-Disease
to,1429,O
penicillins,1429,B-Chemical
.,1429,O
Clomipramine-induced,1430,B-Chemical
sleep,1430,B-Disease
disturbance,1430,I-Disease
does,1430,O
not,1430,O
impair,1430,O
its,1430,O
prolactin-releasing,1430,O
action,1430,O
.,1430,O
The,1431,O
present,1431,O
study,1431,O
was,1431,O
undertaken,1431,O
to,1431,O
examine,1431,O
the,1431,O
role,1431,O
of,1431,O
sleep,1431,B-Disease
disturbance,1431,I-Disease
",",1431,O
induced,1431,O
by,1431,O
clomipramine,1431,B-Chemical
administration,1431,O
",",1431,O
on,1431,O
the,1431,O
secretory,1431,O
rate,1431,O
of,1431,O
prolactin,1431,O
(,1431,O
PRL,1431,O
),1431,O
in,1431,O
addition,1431,O
to,1431,O
the,1431,O
direct,1431,O
drug,1431,O
effect,1431,O
.,1431,O
Two,1432,O
groups,1432,O
of,1432,O
supine,1432,O
subjects,1432,O
were,1432,O
studied,1432,O
under,1432,O
placebo-controlled,1432,O
conditions,1432,O
",",1432,O
one,1432,O
during,1432,O
the,1432,O
night,1432,O
",",1432,O
when,1432,O
sleeping,1432,O
(,1432,O
n,1432,O
=,1432,O
7,1432,O
),1432,O
and,1432,O
the,1432,O
other,1432,O
at,1432,O
daytime,1432,O
",",1432,O
when,1432,O
awake,1432,O
(,1432,O
n,1432,O
=,1432,O
6,1432,O
),1432,O
.,1432,O
Each,1433,O
subject,1433,O
received,1433,O
a,1433,O
single,1433,O
50,1433,O
mg,1433,O
dose,1433,O
of,1433,O
clomipramine,1433,B-Chemical
given,1433,O
orally,1433,O
2,1433,O
hours,1433,O
before,1433,O
blood,1433,O
collection,1433,O
.,1433,O
Plasma,1434,O
PRL,1434,O
concentrations,1434,O
were,1434,O
analysed,1434,O
at,1434,O
10,1434,O
min,1434,O
intervals,1434,O
and,1434,O
underlying,1434,O
secretory,1434,O
rates,1434,O
calculated,1434,O
by,1434,O
a,1434,O
deconvolution,1434,O
procedure,1434,O
.,1434,O
For,1435,O
both,1435,O
experiments,1435,O
the,1435,O
drug,1435,O
intake,1435,O
led,1435,O
to,1435,O
significant,1435,O
increases,1435,O
in,1435,O
PRL,1435,O
secretion,1435,O
",",1435,O
acting,1435,O
preferentially,1435,O
on,1435,O
tonic,1435,O
secretion,1435,O
as,1435,O
pulse,1435,O
amplitude,1435,O
and,1435,O
frequency,1435,O
did,1435,O
not,1435,O
differ,1435,O
significantly,1435,O
from,1435,O
corresponding,1435,O
control,1435,O
values,1435,O
.,1435,O
During,1436,O
the,1436,O
night,1436,O
clomipramine,1436,B-Chemical
ingestion,1436,O
altered,1436,O
the,1436,O
complete,1436,O
sleep,1436,O
architecture,1436,O
in,1436,O
that,1436,O
it,1436,O
suppressed,1436,O
REM,1436,O
sleep,1436,O
and,1436,O
the,1436,O
sleep,1436,O
cycles,1436,O
and,1436,O
induced,1436,O
increased,1436,O
wakefulness,1436,O
.,1436,O
As,1437,O
the,1437,O
relative,1437,O
increase,1437,O
in,1437,O
PRL,1437,O
secretion,1437,O
expressed,1437,O
as,1437,O
a,1437,O
percentage,1437,O
of,1437,O
the,1437,O
mean,1437,O
did,1437,O
not,1437,O
significantly,1437,O
differ,1437,O
between,1437,O
the,1437,O
night,1437,O
and,1437,O
day,1437,O
time,1437,O
studies,1437,O
(,1437,O
46,1437,O
+/-,1437,O
19,1437,O
%,1437,O
vs,1437,O
34,1437,O
+/-,1437,O
10,1437,O
%,1437,O
),1437,O
",",1437,O
it,1437,O
can,1437,O
be,1437,O
concluded,1437,O
that,1437,O
the,1437,O
observed,1437,O
sleep,1437,B-Disease
disturbance,1437,I-Disease
did,1437,O
not,1437,O
interfere,1437,O
with,1437,O
the,1437,O
drug,1437,O
action,1437,O
per,1437,O
se,1437,O
.,1437,O
The,1438,O
presence,1438,O
of,1438,O
REM,1438,O
sleep,1438,O
was,1438,O
shown,1438,O
not,1438,O
to,1438,O
be,1438,O
a,1438,O
determining,1438,O
factor,1438,O
either,1438,O
for,1438,O
secretory,1438,O
pulse,1438,O
amplitude,1438,O
and,1438,O
frequency,1438,O
",",1438,O
as,1438,O
",",1438,O
for,1438,O
both,1438,O
",",1438,O
mean,1438,O
nocturnal,1438,O
values,1438,O
were,1438,O
similar,1438,O
with,1438,O
and,1438,O
without,1438,O
prior,1438,O
clomipramine,1438,B-Chemical
ingestion,1438,O
.,1438,O
Survey,1439,O
of,1439,O
complications,1439,O
of,1439,O
indocyanine,1439,B-Chemical
green,1439,I-Chemical
angiography,1439,O
in,1439,O
Japan,1439,O
.,1439,O
PURPOSE,1440,O
:,1440,O
We,1440,O
evaluated,1440,O
the,1440,O
safety,1440,O
of,1440,O
indocyanine,1440,B-Chemical
green,1440,I-Chemical
for,1440,O
use,1440,O
in,1440,O
fundus,1440,O
angiography,1440,O
.,1440,O
METHODS,1441,O
:,1441,O
We,1441,O
sent,1441,O
a,1441,O
questionnaire,1441,O
concerning,1441,O
complications,1441,O
of,1441,O
indocyanine,1441,B-Chemical
green,1441,I-Chemical
to,1441,O
32,1441,O
institutions,1441,O
in,1441,O
Japan,1441,O
",",1441,O
which,1441,O
were,1441,O
selected,1441,O
on,1441,O
the,1441,O
basis,1441,O
of,1441,O
the,1441,O
client,1441,O
list,1441,O
from,1441,O
the,1441,O
Topcon,1441,O
Company,1441,O
",",1441,O
which,1441,O
manufactures,1441,O
the,1441,O
indocyanine,1441,B-Chemical
green,1441,I-Chemical
fundus,1441,O
camera,1441,O
.,1441,O
RESULTS,1442,O
:,1442,O
Ophthalmologists,1442,O
at,1442,O
15,1442,O
institutions,1442,O
responded,1442,O
",",1442,O
reporting,1442,O
a,1442,O
total,1442,O
of,1442,O
"3,774",1442,O
indocyanine,1442,B-Chemical
green,1442,I-Chemical
angiograms,1442,O
performed,1442,O
on,1442,O
"2,820",1442,O
patients,1442,O
between,1442,O
June,1442,O
1984,1442,O
and,1442,O
September,1442,O
1992,1442,O
.,1442,O
Before,1443,O
angiography,1443,O
",",1443,O
intradermal,1443,O
or,1443,O
intravenous,1443,O
indocyanine,1443,B-Chemical
green,1443,I-Chemical
testing,1443,O
",",1443,O
or,1443,O
both,1443,O
was,1443,O
performed,1443,O
at,1443,O
13,1443,O
of,1443,O
15,1443,O
institutions,1443,O
.,1443,O
For,1444,O
three,1444,O
patients,1444,O
",",1444,O
the,1444,O
decision,1444,O
was,1444,O
made,1444,O
not,1444,O
to,1444,O
proceed,1444,O
with,1444,O
angiography,1444,O
after,1444,O
positive,1444,O
preangiographic,1444,O
testing,1444,O
.,1444,O
The,1445,O
dosage,1445,O
of,1445,O
indocyanine,1445,B-Chemical
green,1445,I-Chemical
used,1445,O
for,1445,O
angiography,1445,O
varied,1445,O
from,1445,O
25,1445,O
to,1445,O
75,1445,O
mg,1445,O
",",1445,O
depending,1445,O
upon,1445,O
the,1445,O
institution,1445,O
.,1445,O
There,1446,O
were,1446,O
13,1446,O
cases,1446,O
of,1446,O
adverse,1446,O
reactions,1446,O
(,1446,O
0.34,1446,O
%,1446,O
),1446,O
",",1446,O
ten,1446,O
of,1446,O
which,1446,O
were,1446,O
mild,1446,O
reactions,1446,O
such,1446,O
as,1446,O
nausea,1446,B-Disease
",",1446,O
exanthema,1446,B-Disease
",",1446,O
urtication,1446,B-Disease
",",1446,O
itchiness,1446,B-Disease
",",1446,O
and,1446,O
urgency,1446,O
to,1446,O
defecate,1446,O
",",1446,O
and,1446,O
did,1446,O
not,1446,O
require,1446,O
treatment,1446,O
.,1446,O
Also,1447,O
recorded,1447,O
were,1447,O
one,1447,O
case,1447,O
of,1447,O
pain,1447,B-Disease
of,1447,O
the,1447,O
vein,1447,O
",",1447,O
which,1447,O
required,1447,O
treatment,1447,O
",",1447,O
and,1447,O
two,1447,O
cases,1447,O
of,1447,O
hypotension,1447,B-Disease
.,1447,O
The,1448,O
two,1448,O
hypotensive,1448,B-Disease
patients,1448,O
required,1448,O
treatment,1448,O
for,1448,O
shock,1448,B-Disease
.,1448,O
CONCLUSIONS,1449,O
:,1449,O
A,1449,O
comparison,1449,O
of,1449,O
frequency,1449,O
of,1449,O
adverse,1449,O
reactions,1449,O
to,1449,O
indocyanine,1449,B-Chemical
green,1449,I-Chemical
with,1449,O
the,1449,O
previously,1449,O
reported,1449,O
frequency,1449,O
of,1449,O
such,1449,O
reactions,1449,O
to,1449,O
fluorescein,1449,B-Chemical
sodium,1449,I-Chemical
indicated,1449,O
that,1449,O
indocyanine,1449,B-Chemical
green,1449,I-Chemical
is,1449,O
a,1449,O
safe,1449,O
as,1449,O
fluorescein,1449,B-Chemical
for,1449,O
use,1449,O
in,1449,O
angiography,1449,O
.,1449,O
Angioedema,1450,B-Disease
following,1450,O
the,1450,O
intravenous,1450,O
administration,1450,O
of,1450,O
metoprolol,1450,B-Chemical
.,1450,O
A,1451,O
72-year-old,1451,O
woman,1451,O
was,1451,O
admitted,1451,O
to,1451,O
the,1451,O
hospital,1451,O
with,1451,O
``,1451,O
flash,1451,O
'',1451,O
pulmonary,1451,B-Disease
edema,1451,I-Disease
",",1451,O
preceded,1451,O
by,1451,O
chest,1451,B-Disease
pain,1451,I-Disease
",",1451,O
requiring,1451,O
intubation,1451,O
.,1451,O
Her,1452,O
medical,1452,O
history,1452,O
included,1452,O
coronary,1452,B-Disease
artery,1452,I-Disease
disease,1452,I-Disease
with,1452,O
previous,1452,O
myocardial,1452,B-Disease
infarctions,1452,I-Disease
",",1452,O
hypertension,1452,B-Disease
",",1452,O
and,1452,O
diabetes,1452,B-Disease
mellitus,1452,I-Disease
.,1452,O
A,1453,O
history,1453,O
of,1453,O
angioedema,1453,B-Disease
secondary,1453,O
to,1453,O
lisinopril,1453,B-Chemical
therapy,1453,O
was,1453,O
elicited,1453,O
.,1453,O
Current,1454,O
medications,1454,O
did,1454,O
not,1454,O
include,1454,O
angiotensin-converting,1454,B-Chemical
enzyme,1454,O
inhibitors,1454,O
or,1454,O
beta-blockers,1454,O
.,1454,O
She,1455,O
had,1455,O
no,1455,O
previous,1455,O
beta-blocking,1455,O
drug,1455,O
exposure,1455,O
.,1455,O
During,1456,O
the,1456,O
first,1456,O
day,1456,O
of,1456,O
hospitalization,1456,O
(,1456,O
while,1456,O
intubated,1456,O
),1456,O
",",1456,O
intravenous,1456,O
metoprolol,1456,B-Chemical
was,1456,O
given,1456,O
",",1456,O
resulting,1456,O
in,1456,O
severe,1456,O
angioedema,1456,B-Disease
.,1456,O
The,1457,O
angioedema,1457,B-Disease
resolved,1457,O
after,1457,O
therapy,1457,O
with,1457,O
intravenous,1457,O
steroids,1457,B-Chemical
and,1457,O
diphenhydramine,1457,B-Chemical
hydrochloride,1457,O
.,1457,O
Effect,1458,O
of,1458,O
coniine,1458,B-Chemical
on,1458,O
the,1458,O
developing,1458,O
chick,1458,O
embryo,1458,O
.,1458,O
Coniine,1459,B-Chemical
",",1459,O
an,1459,O
alkaloid,1459,O
from,1459,O
Conium,1459,O
maculatum,1459,O
(,1459,O
poison,1459,O
hemlock,1459,O
),1459,O
",",1459,O
has,1459,O
been,1459,O
shown,1459,O
to,1459,O
be,1459,O
teratogenic,1459,O
in,1459,O
livestock,1459,O
.,1459,O
The,1460,O
major,1460,O
teratogenic,1460,O
outcome,1460,O
is,1460,O
arthrogryposis,1460,B-Disease
",",1460,O
presumably,1460,O
due,1460,O
to,1460,O
nicotinic,1460,O
receptor,1460,O
blockade,1460,O
.,1460,O
However,1461,O
",",1461,O
coniine,1461,B-Chemical
has,1461,O
failed,1461,O
to,1461,O
produce,1461,O
arthrogryposis,1461,B-Disease
in,1461,O
rats,1461,O
or,1461,O
mice,1461,O
and,1461,O
is,1461,O
only,1461,O
weakly,1461,O
teratogenic,1461,O
in,1461,O
rabbits,1461,O
.,1461,O
The,1462,O
purpose,1462,O
of,1462,O
this,1462,O
study,1462,O
was,1462,O
to,1462,O
evaluate,1462,O
and,1462,O
compare,1462,O
the,1462,O
effects,1462,O
of,1462,O
coniine,1462,B-Chemical
and,1462,O
nicotine,1462,B-Chemical
in,1462,O
the,1462,O
developing,1462,O
chick,1462,O
.,1462,O
Concentrations,1463,O
of,1463,O
coniine,1463,B-Chemical
and,1463,O
nicotine,1463,B-Chemical
sulfate,1463,O
were,1463,O
0.015,1463,O
%,1463,O
",",1463,O
0.03,1463,O
%,1463,O
",",1463,O
0.075,1463,O
%,1463,O
",",1463,O
0.15,1463,O
%,1463,O
",",1463,O
0.75,1463,O
%,1463,O
",",1463,O
1.5,1463,O
%,1463,O
",",1463,O
3,1463,O
%,1463,O
",",1463,O
and,1463,O
6,1463,O
%,1463,O
and,1463,O
1,1463,O
%,1463,O
",",1463,O
5,1463,O
%,1463,O
",",1463,O
and,1463,O
10,1463,O
%,1463,O
",",1463,O
respectively,1463,O
.,1463,O
Both,1464,O
compounds,1464,O
caused,1464,O
deformations,1464,B-Disease
and,1464,O
lethality,1464,O
in,1464,O
a,1464,O
dose-dependent,1464,O
manner,1464,O
.,1464,O
All,1465,O
concentrations,1465,O
of,1465,O
nicotine,1465,B-Chemical
sulfate,1465,O
caused,1465,O
some,1465,O
lethality,1465,O
but,1465,O
a,1465,O
no,1465,O
effect,1465,O
level,1465,O
for,1465,O
coniine,1465,B-Chemical
lethality,1465,O
was,1465,O
0.75,1465,O
%,1465,O
.,1465,O
The,1466,O
deformations,1466,B-Disease
caused,1466,O
by,1466,O
both,1466,O
coniine,1466,B-Chemical
and,1466,O
nicotine,1466,B-Chemical
sulfate,1466,O
were,1466,O
excessive,1466,B-Disease
flexion,1466,I-Disease
or,1466,I-Disease
extension,1466,I-Disease
of,1466,I-Disease
one,1466,I-Disease
or,1466,I-Disease
more,1466,I-Disease
toes,1466,I-Disease
.,1466,O
No,1467,O
histopathological,1467,O
alterations,1467,O
or,1467,O
differences,1467,O
in,1467,O
bone,1467,O
formation,1467,O
were,1467,O
seen,1467,O
in,1467,O
the,1467,O
limbs,1467,O
or,1467,O
toes,1467,O
of,1467,O
any,1467,O
chicks,1467,O
from,1467,O
any,1467,O
group,1467,O
;,1467,O
however,1467,O
",",1467,O
extensive,1467,O
cranial,1467,B-Disease
hemorrhage,1467,I-Disease
occurred,1467,O
in,1467,O
all,1467,O
nicotine,1467,B-Chemical
sulfate-treated,1467,O
chicks,1467,O
.,1467,O
There,1468,O
was,1468,O
a,1468,O
statistically,1468,O
significant,1468,O
(,1468,O
P,1468,O
<,1468,O
or,1468,O
=,1468,O
0.01,1468,O
),1468,O
decrease,1468,O
in,1468,O
movement,1468,O
in,1468,O
coniine,1468,B-Chemical
and,1468,O
nicotine,1468,B-Chemical
sulfate,1468,O
treated,1468,O
chicks,1468,O
as,1468,O
determined,1468,O
by,1468,O
ultrasound,1468,O
.,1468,O
Control,1469,O
chicks,1469,O
were,1469,O
in,1469,O
motion,1469,O
an,1469,O
average,1469,O
of,1469,O
33.67,1469,O
%,1469,O
of,1469,O
the,1469,O
time,1469,O
",",1469,O
while,1469,O
coniine-treated,1469,B-Chemical
chicks,1469,O
were,1469,O
only,1469,O
moving,1469,O
8.95,1469,O
%,1469,O
of,1469,O
a,1469,O
5-min,1469,O
interval,1469,O
",",1469,O
and,1469,O
no,1469,O
movement,1469,O
was,1469,O
observed,1469,O
for,1469,O
nicotine,1469,B-Chemical
sulfate,1469,O
treated,1469,O
chicks,1469,O
.,1469,O
In,1470,O
summary,1470,O
",",1470,O
the,1470,O
chick,1470,O
embryo,1470,O
provides,1470,O
a,1470,O
reliable,1470,O
and,1470,O
simple,1470,O
experimental,1470,O
animal,1470,O
model,1470,O
of,1470,O
coniine-induced,1470,B-Chemical
arthrogryposis,1470,B-Disease
.,1470,O
Data,1471,O
from,1471,O
this,1471,O
model,1471,O
support,1471,O
a,1471,O
mechanism,1471,O
involving,1471,O
nicotinic,1471,O
receptor,1471,O
blockade,1471,O
with,1471,O
subsequent,1471,O
decreased,1471,O
fetal,1471,O
movement,1471,O
.,1471,O
Immediate,1472,O
allergic,1472,B-Disease
reactions,1472,I-Disease
to,1472,O
amoxicillin,1472,B-Chemical
.,1472,O
A,1473,O
large,1473,O
group,1473,O
of,1473,O
patients,1473,O
with,1473,O
suspected,1473,O
allergic,1473,B-Disease
reactions,1473,I-Disease
to,1473,O
beta-lactam,1473,B-Chemical
antibiotics,1473,O
was,1473,O
evaluated,1473,O
.,1473,O
A,1474,O
detailed,1474,O
clinical,1474,O
history,1474,O
",",1474,O
together,1474,O
with,1474,O
skin,1474,O
tests,1474,O
",",1474,O
RAST,1474,O
(,1474,O
radioallergosorbent,1474,O
test,1474,O
),1474,O
",",1474,O
and,1474,O
controlled,1474,O
challenge,1474,O
tests,1474,O
",",1474,O
was,1474,O
used,1474,O
to,1474,O
establish,1474,O
whether,1474,O
patients,1474,O
allergic,1474,B-Disease
to,1474,O
beta-lactam,1474,B-Chemical
antibiotics,1474,O
had,1474,O
selective,1474,O
immediate,1474,O
allergic,1474,B-Disease
responses,1474,O
to,1474,O
amoxicillin,1474,B-Chemical
(,1474,O
AX,1474,B-Chemical
),1474,O
or,1474,O
were,1474,O
cross-reacting,1474,O
with,1474,O
other,1474,O
penicillin,1474,B-Chemical
derivatives,1474,O
.,1474,O
Skin,1475,O
tests,1475,O
were,1475,O
performed,1475,O
with,1475,O
benzylpenicilloyl-poly-L-lysine,1475,B-Chemical
(,1475,O
BPO-PLL,1475,B-Chemical
),1475,O
",",1475,O
benzylpenicilloate,1475,B-Chemical
",",1475,O
benzylpenicillin,1475,B-Chemical
(,1475,O
PG,1475,B-Chemical
),1475,O
",",1475,O
ampicillin,1475,B-Chemical
(,1475,O
AMP,1475,B-Chemical
),1475,O
",",1475,O
and,1475,O
AX,1475,B-Chemical
.,1475,O
RAST,1476,O
for,1476,O
BPO-PLL,1476,B-Chemical
and,1476,O
AX-PLL,1476,B-Chemical
was,1476,O
done,1476,O
.,1476,O
When,1477,O
both,1477,O
skin,1477,O
test,1477,O
and,1477,O
RAST,1477,O
for,1477,O
BPO,1477,B-Chemical
were,1477,O
negative,1477,O
",",1477,O
single-blind,1477,O
",",1477,O
placebo-controlled,1477,O
challenge,1477,O
tests,1477,O
were,1477,O
done,1477,O
to,1477,O
ensure,1477,O
tolerance,1477,O
of,1477,O
PG,1477,B-Chemical
or,1477,O
sensitivity,1477,O
to,1477,O
AX,1477,B-Chemical
.,1477,O
A,1478,O
total,1478,O
of,1478,O
177,1478,O
patients,1478,O
were,1478,O
diagnosed,1478,O
as,1478,O
allergic,1478,B-Disease
to,1478,O
beta-lactam,1478,B-Chemical
antibiotics,1478,O
.,1478,O
We,1479,O
selected,1479,O
the,1479,O
54,1479,O
(,1479,O
30.5,1479,O
%,1479,O
),1479,O
cases,1479,O
of,1479,O
immediate,1479,O
AX,1479,B-Chemical
allergy,1479,B-Disease
with,1479,O
good,1479,O
tolerance,1479,O
of,1479,O
PG,1479,B-Chemical
.,1479,O
Anaphylaxis,1480,B-Disease
was,1480,O
seen,1480,O
in,1480,O
37,1480,O
patients,1480,O
(,1480,O
69,1480,O
%,1480,O
),1480,O
",",1480,O
the,1480,O
other,1480,O
17,1480,O
(,1480,O
31,1480,O
%,1480,O
),1480,O
having,1480,O
urticaria,1480,B-Disease
and/or,1480,O
angioedema,1480,B-Disease
.,1480,O
All,1481,O
the,1481,O
patients,1481,O
were,1481,O
skin,1481,O
test,1481,O
negative,1481,O
to,1481,O
BPO,1481,B-Chemical
;,1481,O
49,1481,O
of,1481,O
51,1481,O
(,1481,O
96,1481,O
%,1481,O
),1481,O
were,1481,O
also,1481,O
negative,1481,O
to,1481,O
MDM,1481,B-Disease
",",1481,O
and,1481,O
44,1481,O
of,1481,O
46,1481,O
(,1481,O
96,1481,O
%,1481,O
),1481,O
to,1481,O
PG,1481,B-Chemical
.,1481,O
Skin,1482,O
tests,1482,O
with,1482,O
AX,1482,B-Chemical
were,1482,O
positive,1482,O
in,1482,O
34,1482,O
(,1482,O
63,1482,O
%,1482,O
),1482,O
patients,1482,O
.,1482,O
RAST,1483,O
was,1483,O
positive,1483,O
for,1483,O
AX,1483,B-Chemical
in,1483,O
22,1483,O
patients,1483,O
(,1483,O
41,1483,O
%,1483,O
),1483,O
and,1483,O
to,1483,O
BPO,1483,B-Chemical
in,1483,O
just,1483,O
5,1483,O
(,1483,O
9,1483,O
%,1483,O
),1483,O
.,1483,O
None,1484,O
of,1484,O
the,1484,O
sera,1484,O
with,1484,O
negative,1484,O
RAST,1484,O
for,1484,O
AX,1484,B-Chemical
were,1484,O
positive,1484,O
to,1484,O
BPO,1484,B-Chemical
.,1484,O
Challenge,1485,O
tests,1485,O
with,1485,O
AX,1485,B-Chemical
were,1485,O
performed,1485,O
in,1485,O
23,1485,O
subjects,1485,O
(,1485,O
43,1485,O
%,1485,O
),1485,O
to,1485,O
establish,1485,O
the,1485,O
diagnosis,1485,O
of,1485,O
immediate,1485,O
allergic,1485,B-Disease
reaction,1485,I-Disease
to,1485,O
AX,1485,B-Chemical
",",1485,O
and,1485,O
in,1485,O
15,1485,O
cases,1485,O
(,1485,O
28,1485,O
%,1485,O
),1485,O
both,1485,O
skin,1485,O
test,1485,O
and,1485,O
RAST,1485,O
for,1485,O
AX,1485,B-Chemical
were,1485,O
negative,1485,O
.,1485,O
PG,1486,B-Chemical
was,1486,O
well,1486,O
tolerated,1486,O
by,1486,O
all,1486,O
54,1486,O
patients,1486,O
.,1486,O
We,1487,O
describe,1487,O
the,1487,O
largest,1487,O
group,1487,O
of,1487,O
AX-allergic,1487,B-Chemical
patients,1487,O
who,1487,O
have,1487,O
tolerated,1487,O
PG,1487,B-Chemical
reported,1487,O
so,1487,O
far,1487,O
.,1487,O
Diagnosis,1488,O
of,1488,O
these,1488,O
patients,1488,O
can,1488,O
be,1488,O
achieved,1488,O
only,1488,O
if,1488,O
specific,1488,O
AX-related,1488,B-Chemical
reagents,1488,O
are,1488,O
employed,1488,O
.,1488,O
Further,1489,O
studies,1489,O
are,1489,O
necessary,1489,O
to,1489,O
determine,1489,O
the,1489,O
exact,1489,O
extent,1489,O
of,1489,O
this,1489,O
problem,1489,O
and,1489,O
to,1489,O
improve,1489,O
the,1489,O
efficacy,1489,O
of,1489,O
diagnostic,1489,O
methods,1489,O
.,1489,O
Acetazolamide-induced,1490,B-Chemical
nephrolithiasis,1490,B-Disease
:,1490,O
implications,1490,O
for,1490,O
treatment,1490,O
of,1490,O
neuromuscular,1490,B-Disease
disorders,1490,I-Disease
.,1490,O
Carbonic,1491,O
anhydrase,1491,O
inhibitors,1491,O
can,1491,O
cause,1491,O
nephrolithiasis,1491,B-Disease
.,1491,O
We,1492,O
studied,1492,O
20,1492,O
patients,1492,O
receiving,1492,O
long-term,1492,O
carbonic,1492,O
anhydrase,1492,O
inhibitor,1492,O
treatment,1492,O
for,1492,O
periodic,1492,O
paralysis,1492,B-Disease
and,1492,O
myotonia,1492,B-Disease
.,1492,O
Three,1493,O
patients,1493,O
on,1493,O
acetazolamide,1493,B-Chemical
(,1493,O
15,1493,O
%,1493,O
),1493,O
developed,1493,O
renal,1493,B-Disease
calculi,1493,I-Disease
.,1493,O
Extracorporeal,1494,O
lithotripsy,1494,O
successfully,1494,O
removed,1494,O
a,1494,O
renal,1494,B-Disease
calculus,1494,I-Disease
in,1494,O
one,1494,O
patient,1494,O
and,1494,O
surgery,1494,O
removed,1494,O
a,1494,O
staghorn,1494,O
calculus,1494,B-Disease
in,1494,O
another,1494,O
",",1494,O
permitting,1494,O
continued,1494,O
treatment,1494,O
.,1494,O
Renal,1495,O
function,1495,O
remained,1495,O
normal,1495,O
in,1495,O
all,1495,O
patients,1495,O
.,1495,O
Nephrolithiasis,1496,B-Disease
is,1496,O
a,1496,O
complication,1496,O
of,1496,O
acetazolamide,1496,B-Chemical
but,1496,O
does,1496,O
not,1496,O
preclude,1496,O
its,1496,O
use,1496,O
.,1496,O
Effects,1497,O
of,1497,O
calcium,1497,B-Chemical
channel,1497,O
blockers,1497,O
on,1497,O
bupivacaine-induced,1497,B-Chemical
toxicity,1497,B-Disease
.,1497,O
The,1498,O
purpose,1498,O
of,1498,O
this,1498,O
study,1498,O
was,1498,O
to,1498,O
investigate,1498,O
the,1498,O
influence,1498,O
of,1498,O
calcium,1498,B-Chemical
channel,1498,O
blockers,1498,O
on,1498,O
bupivacaine-induced,1498,B-Chemical
acute,1498,O
toxicity,1498,B-Disease
.,1498,O
For,1499,O
each,1499,O
of,1499,O
the,1499,O
three,1499,O
tested,1499,O
calcium,1499,B-Chemical
channel,1499,O
blockers,1499,O
(,1499,O
diltiazem,1499,B-Chemical
",",1499,O
verapamil,1499,B-Chemical
and,1499,O
bepridil,1499,B-Chemical
),1499,O
6,1499,O
groups,1499,O
of,1499,O
mice,1499,O
were,1499,O
treated,1499,O
by,1499,O
two,1499,O
different,1499,O
doses,1499,O
",",1499,O
i.e,1499,O
.,1499,O
2,1500,O
and,1500,O
10,1500,O
mg/kg/i.p.,1500,O
",",1500,O
or,1500,O
an,1500,O
equal,1500,O
volume,1500,O
of,1500,O
saline,1500,O
for,1500,O
the,1500,O
control,1500,O
group,1500,O
(,1500,O
n,1500,O
=,1500,O
20,1500,O
),1500,O
;,1500,O
15,1500,O
minutes,1500,O
later,1500,O
",",1500,O
all,1500,O
the,1500,O
animals,1500,O
were,1500,O
injected,1500,O
with,1500,O
a,1500,O
single,1500,O
50,1500,O
mg/kg/i.p,1500,O
.,1500,O
dose,1501,O
of,1501,O
bupivacaine,1501,B-Chemical
.,1501,O
The,1502,O
convulsant,1502,O
activity,1502,O
",",1502,O
the,1502,O
time,1502,O
of,1502,O
latency,1502,O
to,1502,O
convulse,1502,O
and,1502,O
the,1502,O
mortality,1502,O
rate,1502,O
were,1502,O
assessed,1502,O
in,1502,O
each,1502,O
group,1502,O
.,1502,O
The,1503,O
local,1503,O
anesthetic-induced,1503,O
mortality,1503,O
was,1503,O
significantly,1503,O
increased,1503,O
by,1503,O
the,1503,O
three,1503,O
different,1503,O
calcium,1503,B-Chemical
channel,1503,O
blockers,1503,O
.,1503,O
The,1504,O
convulsant,1504,O
activity,1504,O
of,1504,O
bupivacaine,1504,B-Chemical
was,1504,O
not,1504,O
significantly,1504,O
modified,1504,O
but,1504,O
calcium,1504,B-Chemical
channel,1504,O
blockers,1504,O
decreased,1504,O
the,1504,O
time,1504,O
of,1504,O
latency,1504,O
to,1504,O
obtain,1504,O
bupivacaine-induced,1504,B-Chemical
convulsions,1504,B-Disease
;,1504,O
this,1504,O
effect,1504,O
was,1504,O
less,1504,O
pronounced,1504,O
with,1504,O
bepridil,1504,B-Chemical
.,1504,O
Epidural,1505,O
blood,1505,O
flow,1505,O
during,1505,O
prostaglandin,1505,B-Chemical
E1,1505,I-Chemical
or,1505,O
trimethaphan,1505,B-Chemical
induced,1505,O
hypotension,1505,B-Disease
.,1505,O
To,1506,O
evaluate,1506,O
the,1506,O
effect,1506,O
of,1506,O
prostaglandin,1506,B-Chemical
E1,1506,I-Chemical
(,1506,O
PGE1,1506,B-Chemical
),1506,O
or,1506,O
trimethaphan,1506,B-Chemical
(,1506,O
TMP,1506,B-Chemical
),1506,O
induced,1506,O
hypotension,1506,B-Disease
on,1506,O
epidural,1506,O
blood,1506,O
flow,1506,O
(,1506,O
EBF,1506,O
),1506,O
during,1506,O
spinal,1506,O
surgery,1506,O
",",1506,O
EBF,1506,O
was,1506,O
measured,1506,O
using,1506,O
the,1506,O
heat,1506,O
clearance,1506,O
method,1506,O
in,1506,O
30,1506,O
patients,1506,O
who,1506,O
underwent,1506,O
postero-lateral,1506,O
interbody,1506,O
fusion,1506,O
under,1506,O
isoflurane,1506,B-Chemical
anaesthesia,1506,O
.,1506,O
An,1507,O
initial,1507,O
dose,1507,O
of,1507,O
0.1,1507,O
microgram.kg-1.min-1,1507,O
of,1507,O
PGE1,1507,B-Chemical
(,1507,O
15,1507,O
patients,1507,O
),1507,O
",",1507,O
or,1507,O
10,1507,O
micrograms.kg-1.min-1,1507,O
of,1507,O
TMP,1507,B-Chemical
(,1507,O
15,1507,O
patients,1507,O
),1507,O
was,1507,O
administered,1507,O
intravenously,1507,O
after,1507,O
the,1507,O
dural,1507,O
opening,1507,O
and,1507,O
the,1507,O
dose,1507,O
was,1507,O
adjusted,1507,O
to,1507,O
maintain,1507,O
the,1507,O
mean,1507,O
arterial,1507,O
blood,1507,O
pressure,1507,O
(,1507,O
MAP,1507,O
),1507,O
at,1507,O
about,1507,O
60,1507,O
mmHg,1507,O
.,1507,O
The,1508,O
hypotensive,1508,B-Disease
drug,1508,O
was,1508,O
discontinued,1508,O
at,1508,O
the,1508,O
completion,1508,O
of,1508,O
the,1508,O
operative,1508,O
procedure,1508,O
.,1508,O
After,1509,O
starting,1509,O
PGE1,1509,B-Chemical
or,1509,O
TMP,1509,B-Chemical
",",1509,O
MAP,1509,O
and,1509,O
rate,1509,O
pressure,1509,O
product,1509,O
(,1509,O
RPP,1509,O
),1509,O
decreased,1509,O
significantly,1509,O
compared,1509,O
with,1509,O
preinfusion,1509,O
values,1509,O
(,1509,O
P,1509,O
<,1509,O
0.01,1509,O
),1509,O
",",1509,O
and,1509,O
the,1509,O
degree,1509,O
of,1509,O
hypotension,1509,B-Disease
due,1509,O
to,1509,O
PGE1,1509,B-Chemical
remained,1509,O
constant,1509,O
until,1509,O
60,1509,O
min,1509,O
after,1509,O
its,1509,O
discontinuation,1509,O
.,1509,O
Heart,1510,O
rate,1510,O
(,1510,O
HR,1510,O
),1510,O
did,1510,O
not,1510,O
change,1510,O
in,1510,O
either,1510,O
group,1510,O
.,1510,O
EBFF,1511,O
did,1511,O
not,1511,O
change,1511,O
during,1511,O
PGE1,1511,B-Chemical
infusion,1511,O
whereas,1511,O
in,1511,O
the,1511,O
TMP,1511,B-Chemical
group,1511,O
",",1511,O
EBF,1511,O
decreased,1511,O
significantly,1511,O
at,1511,O
30,1511,O
and,1511,O
60,1511,O
min,1511,O
after,1511,O
the,1511,O
start,1511,O
of,1511,O
TMP,1511,B-Chemical
(,1511,O
preinfusion,1511,O
:,1511,O
45.9,1511,O
+/-,1511,O
13.9,1511,O
ml/100g/min,1511,O
.,1511,O
30,1512,O
min,1512,O
:,1512,O
32.3,1512,O
+/-,1512,O
9.9,1512,O
ml/100,1512,O
g/min,1512,O
(,1512,O
P,1512,O
<,1512,O
0.05,1512,O
),1512,O
.,1512,O
60,1513,O
min,1513,O
:,1513,O
30,1513,O
+/-,1513,O
7.5,1513,O
ml/100,1513,O
g/min,1513,O
(,1513,O
P,1513,O
<,1513,O
0.05,1513,O
),1513,O
),1513,O
.,1513,O
These,1514,O
results,1514,O
suggest,1514,O
that,1514,O
PGE1,1514,B-Chemical
may,1514,O
be,1514,O
preferable,1514,O
to,1514,O
TMP,1514,B-Chemical
for,1514,O
hypotensive,1514,B-Disease
anaesthesia,1514,O
in,1514,O
spinal,1514,O
surgery,1514,O
because,1514,O
TMP,1514,B-Chemical
decreased,1514,O
EBF,1514,O
.,1514,O
Dup,1515,B-Chemical
753,1515,I-Chemical
prevents,1515,O
the,1515,O
development,1515,O
of,1515,O
puromycin,1515,B-Chemical
aminonucleoside-induced,1515,O
nephrosis,1515,B-Disease
.,1515,O
The,1516,O
appearance,1516,O
of,1516,O
nephrotic,1516,B-Disease
syndromes,1516,I-Disease
such,1516,O
as,1516,O
proteinuria,1516,B-Disease
",",1516,O
hypoalbuminemia,1516,B-Disease
",",1516,O
hypercholesterolemia,1516,B-Disease
and,1516,O
increase,1516,O
in,1516,O
blood,1516,B-Chemical
nitrogen,1516,I-Chemical
urea,1516,I-Chemical
",",1516,O
induced,1516,O
in,1516,O
rats,1516,O
by,1516,O
injection,1516,O
of,1516,O
puromycin,1516,B-Chemical
aminonucleoside,1516,I-Chemical
was,1516,O
markedly,1516,O
inhibited,1516,O
by,1516,O
oral,1516,O
administration,1516,O
of,1516,O
Dup,1516,B-Chemical
753,1516,I-Chemical
(,1516,O
losartan,1516,B-Chemical
),1516,O
",",1516,O
a,1516,O
novel,1516,O
angiotensin,1516,B-Chemical
II,1516,I-Chemical
receptor,1516,O
antagonist,1516,O
",",1516,O
at,1516,O
a,1516,O
dose,1516,O
of,1516,O
1,1516,O
or,1516,O
2,1516,O
mg/kg,1516,O
per,1516,O
day,1516,O
.,1516,O
The,1517,O
results,1517,O
suggest,1517,O
a,1517,O
possible,1517,O
involvement,1517,O
of,1517,O
the,1517,O
renin-angiotensin,1517,O
system,1517,O
in,1517,O
the,1517,O
development,1517,O
of,1517,O
puromycin,1517,B-Chemical
aminonucleoside-induced,1517,O
nephrosis,1517,B-Disease
.,1517,O
Neuroplasticity,1518,O
of,1518,O
the,1518,O
adult,1518,O
primate,1518,O
auditory,1518,O
cortex,1518,O
following,1518,O
cochlear,1518,O
hearing,1518,B-Disease
loss,1518,I-Disease
.,1518,O
Tonotopic,1519,O
organization,1519,O
is,1519,O
an,1519,O
essential,1519,O
feature,1519,O
of,1519,O
the,1519,O
primary,1519,O
auditory,1519,O
area,1519,O
(,1519,O
A1,1519,O
),1519,O
of,1519,O
primate,1519,O
cortex,1519,O
.,1519,O
In,1520,O
A1,1520,O
of,1520,O
macaque,1520,O
monkeys,1520,O
",",1520,O
low,1520,O
frequencies,1520,O
are,1520,O
represented,1520,O
rostrolaterally,1520,O
and,1520,O
high,1520,O
frequencies,1520,O
are,1520,O
represented,1520,O
caudomedially,1520,O
.,1520,O
The,1521,O
purpose,1521,O
of,1521,O
this,1521,O
study,1521,O
was,1521,O
to,1521,O
determine,1521,O
if,1521,O
changes,1521,O
occur,1521,O
in,1521,O
this,1521,O
tonotopic,1521,O
organization,1521,O
following,1521,O
cochlear,1521,O
hearing,1521,B-Disease
loss,1521,I-Disease
.,1521,O
Under,1522,O
anesthesia,1522,O
",",1522,O
the,1522,O
superior,1522,O
temporal,1522,O
gyrus,1522,O
of,1522,O
adult,1522,O
macaque,1522,O
monkeys,1522,O
was,1522,O
exposed,1522,O
",",1522,O
and,1522,O
the,1522,O
tonotopic,1522,O
organization,1522,O
of,1522,O
A1,1522,O
was,1522,O
mapped,1522,O
using,1522,O
conventional,1522,O
microelectrode,1522,O
recording,1522,O
techniques,1522,O
.,1522,O
Following,1523,O
recovery,1523,O
",",1523,O
the,1523,O
monkeys,1523,O
were,1523,O
selectively,1523,O
deafened,1523,O
for,1523,O
high,1523,O
frequencies,1523,O
using,1523,O
kanamycin,1523,B-Chemical
and,1523,O
furosemide,1523,B-Chemical
.,1523,O
The,1524,O
actual,1524,O
frequencies,1524,O
deafened,1524,O
were,1524,O
determined,1524,O
by,1524,O
the,1524,O
loss,1524,O
of,1524,O
tone-burst,1524,O
elicited,1524,O
auditory,1524,O
brainstem,1524,O
responses,1524,O
.,1524,O
Three,1525,O
months,1525,O
after,1525,O
deafening,1525,O
",",1525,O
A1,1525,O
was,1525,O
remapped,1525,O
.,1525,O
Postmortem,1526,O
cytoarchitectural,1526,O
features,1526,O
identifying,1526,O
A1,1526,O
were,1526,O
correlated,1526,O
with,1526,O
the,1526,O
electrophysiologic,1526,O
data,1526,O
.,1526,O
The,1527,O
results,1527,O
indicate,1527,O
that,1527,O
the,1527,O
deprived,1527,O
area,1527,O
of,1527,O
A1,1527,O
undergoes,1527,O
extensive,1527,O
reorganization,1527,O
and,1527,O
becomes,1527,O
responsive,1527,O
to,1527,O
intact,1527,O
cochlear,1527,O
frequencies,1527,O
.,1527,O
The,1528,O
region,1528,O
of,1528,O
cortex,1528,O
that,1528,O
represents,1528,O
the,1528,O
low,1528,O
frequencies,1528,O
was,1528,O
not,1528,O
obviously,1528,O
affected,1528,O
by,1528,O
the,1528,O
cochlear,1528,O
hearing,1528,B-Disease
loss,1528,I-Disease
.,1528,O
Sodium,1529,B-Chemical
bicarbonate,1529,I-Chemical
alleviates,1529,O
penile,1529,B-Disease
pain,1529,I-Disease
induced,1529,O
by,1529,O
intracavernous,1529,O
injections,1529,O
for,1529,O
erectile,1529,B-Disease
dysfunction,1529,I-Disease
.,1529,O
In,1530,O
an,1530,O
attempt,1530,O
to,1530,O
determine,1530,O
whether,1530,O
penile,1530,B-Disease
pain,1530,I-Disease
associated,1530,O
with,1530,O
intracorporeal,1530,O
injections,1530,O
could,1530,O
be,1530,O
due,1530,O
to,1530,O
the,1530,O
acidity,1530,O
of,1530,O
the,1530,O
medication,1530,O
",",1530,O
we,1530,O
performed,1530,O
a,1530,O
randomized,1530,O
study,1530,O
comparing,1530,O
the,1530,O
incidence,1530,O
of,1530,O
penile,1530,B-Disease
pain,1530,I-Disease
following,1530,O
intracorporeal,1530,O
injections,1530,O
with,1530,O
or,1530,O
without,1530,O
the,1530,O
addition,1530,O
of,1530,O
sodium,1530,B-Chemical
bicarbonate,1530,I-Chemical
to,1530,O
the,1530,O
intracorporeal,1530,O
medications,1530,O
.,1530,O
A,1531,O
total,1531,O
of,1531,O
38,1531,O
consecutive,1531,O
patients,1531,O
who,1531,O
presented,1531,O
to,1531,O
our,1531,O
clinic,1531,O
with,1531,O
impotence,1531,B-Disease
received,1531,O
0.2,1531,O
ml,1531,O
.,1531,O
of,1532,O
a,1532,O
combination,1532,O
of,1532,O
3,1532,O
drugs,1532,O
:,1532,O
6,1532,O
mg.,1532,O
papaverine,1532,B-Chemical
",",1532,O
100,1532,O
micrograms,1532,O
.,1532,O
phentolamine,1533,B-Chemical
and,1533,O
10,1533,O
micrograms,1533,O
.,1533,O
prostaglandin,1534,B-Chemical
E1,1534,I-Chemical
with,1534,O
(,1534,O
pH,1534,O
7.05,1534,O
),1534,O
or,1534,O
without,1534,O
(,1534,O
pH,1534,O
4.17,1534,O
),1534,O
the,1534,O
addition,1534,O
of,1534,O
sodium,1534,B-Chemical
bicarbonate,1534,I-Chemical
(,1534,O
0.03,1534,O
mEq,1534,O
.,1534,O
),1534,O
.,1534,O
Of,1535,O
the,1535,O
19,1535,O
patients,1535,O
without,1535,O
sodium,1535,B-Chemical
bicarbonate,1535,I-Chemical
added,1535,O
to,1535,O
the,1535,O
medication,1535,O
11,1535,O
(,1535,O
58,1535,O
%,1535,O
),1535,O
complained,1535,O
of,1535,O
penile,1535,B-Disease
pain,1535,I-Disease
due,1535,O
to,1535,O
the,1535,O
medication,1535,O
",",1535,O
while,1535,O
only,1535,O
1,1535,O
of,1535,O
the,1535,O
19,1535,O
men,1535,O
(,1535,O
5,1535,O
%,1535,O
),1535,O
who,1535,O
received,1535,O
sodium,1535,B-Chemical
bicarbonate,1535,I-Chemical
complained,1535,O
of,1535,O
penile,1535,B-Disease
pain,1535,I-Disease
.,1535,O
From,1536,O
these,1536,O
data,1536,O
we,1536,O
conclude,1536,O
that,1536,O
the,1536,O
penile,1536,B-Disease
pain,1536,I-Disease
following,1536,O
intracorporeal,1536,O
injections,1536,O
is,1536,O
most,1536,O
likely,1536,O
due,1536,O
to,1536,O
the,1536,O
acidity,1536,O
of,1536,O
the,1536,O
medication,1536,O
",",1536,O
which,1536,O
can,1536,O
be,1536,O
overcome,1536,O
by,1536,O
elevating,1536,O
the,1536,O
pH,1536,O
to,1536,O
a,1536,O
neutral,1536,O
level,1536,O
.,1536,O
The,1537,O
use,1537,O
and,1537,O
toxicity,1537,B-Disease
of,1537,O
didanosine,1537,B-Chemical
(,1537,O
ddI,1537,B-Chemical
),1537,O
in,1537,O
HIV,1537,B-Disease
antibody-positive,1537,I-Disease
individuals,1537,O
intolerant,1537,O
to,1537,O
zidovudine,1537,B-Chemical
(,1537,O
AZT,1537,B-Chemical
),1537,O
One,1537,O
hundred,1537,O
and,1537,O
fifty-one,1537,O
patients,1537,O
intolerant,1537,O
to,1537,O
zidovudine,1537,B-Chemical
(,1537,O
AZT,1537,B-Chemical
),1537,O
received,1537,O
didanosine,1537,B-Chemical
(,1537,O
ddI,1537,B-Chemical
),1537,O
to,1537,O
a,1537,O
maximum,1537,O
dose,1537,O
of,1537,O
12.5,1537,O
mg/kg/day,1537,O
.,1537,O
Patient,1538,O
response,1538,O
was,1538,O
assessed,1538,O
using,1538,O
changes,1538,O
in,1538,O
CD4+,1538,O
lymphocyte,1538,O
subset,1538,O
count,1538,O
",",1538,O
HIV,1538,O
p24,1538,O
antigen,1538,O
",",1538,O
weight,1538,O
",",1538,O
and,1538,O
quality,1538,O
of,1538,O
life,1538,O
.,1538,O
Seventy,1539,O
patients,1539,O
developed,1539,O
major,1539,O
opportunistic,1539,B-Disease
infections,1539,I-Disease
whilst,1539,O
on,1539,O
therapy,1539,O
;,1539,O
this,1539,O
was,1539,O
the,1539,O
first,1539,O
AIDS,1539,B-Disease
diagnosis,1539,O
in,1539,O
17,1539,O
.,1539,O
Only,1540,O
minor,1540,O
changes,1540,O
in,1540,O
CD4+,1540,O
lymphocyte,1540,O
subset,1540,O
count,1540,O
were,1540,O
observed,1540,O
in,1540,O
AIDS,1540,B-Disease
patients,1540,O
",",1540,O
although,1540,O
a,1540,O
more,1540,O
significant,1540,O
rise,1540,O
occurred,1540,O
in,1540,O
those,1540,O
with,1540,O
earlier,1540,O
stages,1540,O
of,1540,O
disease,1540,O
.,1540,O
Of,1541,O
those,1541,O
positive,1541,O
for,1541,O
p24,1541,O
antigen,1541,O
at,1541,O
the,1541,O
commencement,1541,O
of,1541,O
the,1541,O
study,1541,O
67,1541,O
%,1541,O
showed,1541,O
a,1541,O
positive,1541,O
response,1541,O
",",1541,O
and,1541,O
this,1541,O
was,1541,O
most,1541,O
likely,1541,O
in,1541,O
those,1541,O
with,1541,O
CD4+,1541,O
lymphocyte,1541,O
subset,1541,O
counts,1541,O
above,1541,O
100,1541,O
mm3,1541,O
.,1541,O
A,1542,O
positive,1542,O
weight,1542,O
response,1542,O
was,1542,O
seen,1542,O
in,1542,O
16,1542,O
%,1542,O
of,1542,O
patients,1542,O
.,1542,O
Most,1543,O
patients,1543,O
showed,1543,O
improvement,1543,O
in,1543,O
individual,1543,O
parameters,1543,O
and,1543,O
global,1543,O
score,1543,O
of,1543,O
quality,1543,O
of,1543,O
life,1543,O
.,1543,O
Adverse,1544,O
reactions,1544,O
possibly,1544,O
attributable,1544,O
to,1544,O
didanosine,1544,B-Chemical
were,1544,O
common,1544,O
.,1544,O
The,1545,O
most,1545,O
common,1545,O
side-effect,1545,O
was,1545,O
diarrhoea,1545,B-Disease
",",1545,O
which,1545,O
resulted,1545,O
in,1545,O
cessation,1545,O
of,1545,O
therapy,1545,O
in,1545,O
19,1545,O
individuals,1545,O
.,1545,O
Peripheral,1546,B-Disease
neuropathy,1546,I-Disease
occurred,1546,O
in,1546,O
12,1546,O
patients,1546,O
and,1546,O
pancreatitis,1546,B-Disease
in,1546,O
six,1546,O
.,1546,O
Thirteen,1547,O
patients,1547,O
developed,1547,O
a,1547,O
raised,1547,O
serum,1547,O
amylase,1547,O
without,1547,O
abdominal,1547,B-Disease
pain,1547,I-Disease
.,1547,O
Seven,1548,O
patients,1548,O
developed,1548,O
glucose,1548,B-Disease
tolerance,1548,I-Disease
curves,1548,I-Disease
characteristic,1548,O
of,1548,O
diabetes,1548,B-Disease
but,1548,O
these,1548,O
were,1548,O
mild,1548,O
",",1548,O
did,1548,O
not,1548,O
require,1548,O
treatment,1548,O
and,1548,O
returned,1548,O
to,1548,O
normal,1548,O
on,1548,O
ceasing,1548,O
didanosine,1548,B-Chemical
.,1548,O
Immunohistochemical,1549,O
studies,1549,O
with,1549,O
antibodies,1549,O
to,1549,O
neurofilament,1549,O
proteins,1549,O
on,1549,O
axonal,1549,B-Disease
damage,1549,I-Disease
in,1549,O
experimental,1549,O
focal,1549,O
lesions,1549,O
in,1549,O
rat,1549,O
.,1549,O
Immunohistochemistry,1550,O
with,1550,O
monoclonal,1550,O
antibodies,1550,O
against,1550,O
neurofilament,1550,O
(,1550,O
NF,1550,O
),1550,O
proteins,1550,O
of,1550,O
middle,1550,O
and,1550,O
high,1550,O
molecular,1550,O
weight,1550,O
class,1550,O
",",1550,O
NF-M,1550,O
and,1550,O
NF-H,1550,O
",",1550,O
was,1550,O
used,1550,O
to,1550,O
study,1550,O
axonal,1550,B-Disease
injury,1550,I-Disease
in,1550,O
the,1550,O
borderzone,1550,O
of,1550,O
focal,1550,O
lesions,1550,O
in,1550,O
rats,1550,O
.,1550,O
Focal,1551,O
injury,1551,B-Disease
in,1551,I-Disease
the,1551,I-Disease
cortex,1551,I-Disease
was,1551,O
produced,1551,O
by,1551,O
infusion,1551,O
of,1551,O
lactate,1551,B-Chemical
at,1551,O
acid,1551,O
pH,1551,O
or,1551,O
by,1551,O
stab,1551,O
caused,1551,O
by,1551,O
needle,1551,O
insertion,1551,O
.,1551,O
Infarcts,1552,B-Disease
in,1552,I-Disease
substantia,1552,I-Disease
nigra,1552,I-Disease
pars,1552,I-Disease
reticulata,1552,I-Disease
were,1552,O
evoked,1552,O
by,1552,O
prolonged,1552,O
pilocarpine-induced,1552,B-Chemical
status,1552,B-Disease
epilepticus,1552,I-Disease
.,1552,O
Immunohistochemical,1553,O
staining,1553,O
for,1553,O
NFs,1553,O
showed,1553,O
characteristic,1553,O
terminal,1553,O
clubs,1553,O
of,1553,O
axons,1553,O
in,1553,O
the,1553,O
borderzone,1553,O
of,1553,O
lesions,1553,O
.,1553,O
Differences,1554,O
in,1554,O
the,1554,O
labelling,1554,O
pattern,1554,O
occurred,1554,O
with,1554,O
different,1554,O
antibodies,1554,O
which,1554,O
apparently,1554,O
depended,1554,O
on,1554,O
molecular,1554,O
weight,1554,O
class,1554,O
of,1554,O
NFs,1554,O
and,1554,O
phosphorylation,1554,O
state,1554,O
.,1554,O
These,1555,O
immunohistochemical,1555,O
changes,1555,O
of,1555,O
NFs,1555,O
can,1555,O
serve,1555,O
as,1555,O
a,1555,O
marker,1555,O
for,1555,O
axonal,1555,B-Disease
damage,1555,I-Disease
in,1555,O
various,1555,O
experimental,1555,O
traumatic,1555,B-Disease
or,1555,O
ischemic,1555,O
lesions,1555,O
.,1555,O
Prospective,1556,O
study,1556,O
of,1556,O
the,1556,O
long-term,1556,O
effects,1556,O
of,1556,O
somatostatin,1556,O
analog,1556,O
(,1556,O
octreotide,1556,B-Chemical
),1556,O
on,1556,O
gallbladder,1556,O
function,1556,O
and,1556,O
gallstone,1556,B-Disease
formation,1556,O
in,1556,O
Chinese,1556,O
acromegalic,1556,B-Disease
patients,1556,O
.,1556,O
This,1557,O
article,1557,O
reports,1557,O
the,1557,O
changes,1557,O
in,1557,O
gallbladder,1557,O
function,1557,O
examined,1557,O
by,1557,O
ultrasonography,1557,O
in,1557,O
20,1557,O
Chinese,1557,O
patients,1557,O
with,1557,O
active,1557,O
acromegaly,1557,B-Disease
treated,1557,O
with,1557,O
sc,1557,O
injection,1557,O
of,1557,O
the,1557,O
somatostatin,1557,O
analog,1557,O
octreotide,1557,B-Chemical
in,1557,O
dosages,1557,O
of,1557,O
300-1500,1557,O
micrograms/day,1557,O
for,1557,O
a,1557,O
mean,1557,O
of,1557,O
24.2,1557,O
+/-,1557,O
13.9,1557,O
months,1557,O
.,1557,O
During,1558,O
treatment,1558,O
with,1558,O
octreotide,1558,B-Chemical
",",1558,O
17,1558,O
patients,1558,O
developed,1558,O
sludge,1558,O
",",1558,O
10,1558,O
had,1558,O
gallstones,1558,B-Disease
",",1558,O
and,1558,O
1,1558,O
developed,1558,O
acute,1558,B-Disease
cholecystitis,1558,I-Disease
requiring,1558,O
surgery,1558,O
.,1558,O
In,1559,O
all,1559,O
of,1559,O
7,1559,O
patients,1559,O
examined,1559,O
acutely,1559,O
",",1559,O
gallbladder,1559,O
contractility,1559,O
was,1559,O
inhibited,1559,O
after,1559,O
a,1559,O
single,1559,O
100-micrograms,1559,O
injection,1559,O
.,1559,O
In,1560,O
8,1560,O
patients,1560,O
followed,1560,O
for,1560,O
24,1560,O
weeks,1560,O
",",1560,O
gallbladder,1560,O
contractility,1560,O
remained,1560,O
depressed,1560,B-Disease
throughout,1560,O
therapy,1560,O
.,1560,O
After,1561,O
withdrawal,1561,O
of,1561,O
octreotide,1561,B-Chemical
in,1561,O
10,1561,O
patients,1561,O
without,1561,O
gallstones,1561,B-Disease
",",1561,O
8,1561,O
patients,1561,O
assessed,1561,O
had,1561,O
return,1561,O
of,1561,O
normal,1561,O
gallbladder,1561,O
contractility,1561,O
within,1561,O
1,1561,O
month,1561,O
.,1561,O
In,1562,O
8,1562,O
of,1562,O
the,1562,O
remaining,1562,O
10,1562,O
patients,1562,O
who,1562,O
developed,1562,O
gallstones,1562,B-Disease
during,1562,O
treatment,1562,O
",",1562,O
gallbladder,1562,O
contractility,1562,O
normalized,1562,O
in,1562,O
5,1562,O
patients,1562,O
(,1562,O
3,1562,O
of,1562,O
whom,1562,O
has,1562,O
disappearance,1562,O
of,1562,O
their,1562,O
stones,1562,O
within,1562,O
3,1562,O
weeks,1562,O
),1562,O
",",1562,O
and,1562,O
remained,1562,O
depressed,1562,B-Disease
in,1562,O
3,1562,O
(,1562,O
2,1562,O
of,1562,O
whom,1562,O
had,1562,O
stones,1562,O
present,1562,O
at,1562,O
6,1562,O
months,1562,O
),1562,O
.,1562,O
Our,1563,O
results,1563,O
suggest,1563,O
that,1563,O
the,1563,O
suppression,1563,O
of,1563,O
gallbladder,1563,O
contractility,1563,O
is,1563,O
the,1563,O
cause,1563,O
of,1563,O
the,1563,O
successive,1563,O
formation,1563,O
of,1563,O
bile,1563,O
sludge,1563,O
",",1563,O
gallstones,1563,B-Disease
",",1563,O
and,1563,O
cholecystitis,1563,B-Disease
during,1563,O
octreotide,1563,B-Chemical
therapy,1563,O
in,1563,O
Chinese,1563,O
acromegalic,1563,B-Disease
patients,1563,O
.,1563,O
It,1564,O
is,1564,O
therefore,1564,O
very,1564,O
important,1564,O
to,1564,O
follow,1564,O
the,1564,O
changes,1564,O
of,1564,O
gallbladder,1564,O
function,1564,O
during,1564,O
long-term,1564,O
octreotide,1564,B-Chemical
therapy,1564,O
of,1564,O
acromegalic,1564,B-Disease
patients,1564,O
.,1564,O
Increase,1565,O
of,1565,O
Parkinson,1565,B-Disease
disability,1565,I-Disease
after,1565,O
fluoxetine,1565,B-Chemical
medication,1565,O
.,1565,O
Depression,1566,B-Disease
is,1566,O
a,1566,O
major,1566,O
clinical,1566,O
feature,1566,O
of,1566,O
Parkinson,1566,B-Disease
's,1566,I-Disease
disease,1566,I-Disease
.,1566,O
We,1567,O
report,1567,O
the,1567,O
increased,1567,O
amount,1567,O
of,1567,O
motor,1567,B-Disease
disability,1567,I-Disease
in,1567,O
four,1567,O
patients,1567,O
with,1567,O
idiopathic,1567,B-Disease
Parkinson,1567,I-Disease
's,1567,I-Disease
disease,1567,I-Disease
after,1567,O
exposure,1567,O
to,1567,O
the,1567,O
antidepressant,1567,B-Chemical
fluoxetine,1567,B-Chemical
.,1567,O
The,1568,O
possibility,1568,O
of,1568,O
a,1568,O
clinically,1568,O
relevant,1568,O
dopamine-antagonistic,1568,B-Chemical
capacity,1568,O
of,1568,O
fluoxetine,1568,B-Chemical
in,1568,O
Parkinson,1568,B-Disease
's,1568,I-Disease
disease,1568,I-Disease
patients,1568,O
must,1568,O
be,1568,O
considered,1568,O
.,1568,O
Sinus,1569,B-Disease
arrest,1569,I-Disease
associated,1569,O
with,1569,O
continuous-infusion,1569,O
cimetidine,1569,B-Chemical
.,1569,O
The,1570,O
administration,1570,O
of,1570,O
intermittent,1570,O
intravenous,1570,O
infusions,1570,O
of,1570,O
cimetidine,1570,B-Chemical
is,1570,O
infrequently,1570,O
associated,1570,O
with,1570,O
the,1570,O
development,1570,O
of,1570,O
bradyarrhythmias,1570,B-Disease
.,1570,O
A,1571,O
40-year-old,1571,O
man,1571,O
with,1571,O
leukemia,1571,B-Disease
and,1571,O
no,1571,O
history,1571,O
of,1571,O
cardiac,1571,B-Disease
disease,1571,I-Disease
developed,1571,O
recurrent,1571,O
",",1571,O
brief,1571,O
episodes,1571,O
of,1571,O
apparent,1571,O
sinus,1571,B-Disease
arrest,1571,I-Disease
while,1571,O
receiving,1571,O
continuous-infusion,1571,O
cimetidine,1571,B-Chemical
50,1571,O
mg/hour,1571,O
.,1571,O
The,1572,O
arrhythmias,1572,B-Disease
were,1572,O
temporally,1572,O
related,1572,O
to,1572,O
cimetidine,1572,B-Chemical
administration,1572,O
",",1572,O
disappeared,1572,O
after,1572,O
dechallenge,1572,O
",",1572,O
and,1572,O
did,1572,O
not,1572,O
recur,1572,O
during,1572,O
ranitidine,1572,B-Chemical
treatment,1572,O
.,1572,O
This,1573,O
is,1573,O
the,1573,O
first,1573,O
reported,1573,O
case,1573,O
of,1573,O
sinus,1573,B-Disease
arrest,1573,I-Disease
associated,1573,O
with,1573,O
continuous-infusion,1573,O
cimetidine,1573,B-Chemical
.,1573,O
Phase,1574,O
II,1574,O
trial,1574,O
of,1574,O
vinorelbine,1574,B-Chemical
in,1574,O
metastatic,1574,O
squamous,1574,B-Disease
cell,1574,I-Disease
esophageal,1574,I-Disease
carcinoma,1574,I-Disease
.,1574,O
European,1575,O
Organization,1575,O
for,1575,O
Research,1575,O
and,1575,O
Treatment,1575,O
of,1575,O
Cancer,1575,B-Disease
Gastrointestinal,1575,O
Treat,1575,O
Cancer,1575,B-Disease
Cooperative,1575,O
Group,1575,O
.,1575,O
PURPOSE,1576,O
:,1576,O
To,1576,O
evaluate,1576,O
the,1576,O
response,1576,O
rate,1576,O
and,1576,O
toxic,1576,O
effects,1576,O
of,1576,O
vinorelbine,1576,B-Chemical
(,1576,O
VNB,1576,B-Chemical
),1576,O
administered,1576,O
as,1576,O
a,1576,O
single,1576,O
agent,1576,O
in,1576,O
metastatic,1576,O
squamous,1576,B-Disease
cell,1576,I-Disease
esophageal,1576,I-Disease
carcinoma,1576,I-Disease
.,1576,O
PATIENTS,1577,O
AND,1577,O
METHODS,1577,O
:,1577,O
Forty-six,1577,O
eligible,1577,O
patients,1577,O
with,1577,O
measurable,1577,O
lesions,1577,O
were,1577,O
included,1577,O
and,1577,O
were,1577,O
stratified,1577,O
according,1577,O
to,1577,O
previous,1577,O
chemotherapy,1577,O
.,1577,O
Thirty,1578,O
patients,1578,O
without,1578,O
prior,1578,O
chemotherapy,1578,O
and,1578,O
16,1578,O
pretreated,1578,O
with,1578,O
cisplatin-based,1578,B-Chemical
chemotherapy,1578,O
were,1578,O
assessable,1578,O
for,1578,O
toxicity,1578,B-Disease
and,1578,O
response,1578,O
.,1578,O
VNB,1579,B-Chemical
was,1579,O
administered,1579,O
weekly,1579,O
as,1579,O
a,1579,O
25-mg/m2,1579,O
short,1579,O
intravenous,1579,O
(,1579,O
i.v,1579,O
.,1579,O
),1579,O
infusion,1580,O
.,1580,O
RESULTS,1581,O
:,1581,O
Six,1581,O
of,1581,O
30,1581,O
patients,1581,O
(,1581,O
20,1581,O
%,1581,O
),1581,O
without,1581,O
prior,1581,O
chemotherapy,1581,O
achieved,1581,O
a,1581,O
partial,1581,O
response,1581,O
(,1581,O
PR,1581,O
),1581,O
(,1581,O
95,1581,O
%,1581,O
confidence,1581,O
interval,1581,O
[,1581,O
CI,1581,O
],1581,O
",",1581,O
8,1581,O
%,1581,O
to,1581,O
39,1581,O
%,1581,O
),1581,O
.,1581,O
The,1582,O
median,1582,O
duration,1582,O
of,1582,O
response,1582,O
was,1582,O
21,1582,O
weeks,1582,O
(,1582,O
range,1582,O
",",1582,O
17,1582,O
to,1582,O
28,1582,O
),1582,O
.,1582,O
One,1583,O
of,1583,O
16,1583,O
patients,1583,O
(,1583,O
6,1583,O
%,1583,O
),1583,O
with,1583,O
prior,1583,O
chemotherapy,1583,O
had,1583,O
a,1583,O
complete,1583,O
response,1583,O
(,1583,O
CR,1583,O
),1583,O
of,1583,O
31,1583,O
weeks,1583,O
',1583,O
duration,1583,O
(,1583,O
95,1583,O
%,1583,O
CI,1583,O
",",1583,O
0,1583,O
%,1583,O
to,1583,O
30,1583,O
%,1583,O
),1583,O
.,1583,O
The,1584,O
overall,1584,O
response,1584,O
rate,1584,O
(,1584,O
World,1584,O
Health,1584,O
Organization,1584,O
[,1584,O
WHO,1584,O
],1584,O
criteria,1584,O
),1584,O
was,1584,O
15,1584,O
%,1584,O
(,1584,O
CR,1584,O
",",1584,O
2,1584,O
%,1584,O
;,1584,O
PR,1584,O
13,1584,O
%,1584,O
;,1584,O
95,1584,O
%,1584,O
CI,1584,O
",",1584,O
6,1584,O
%,1584,O
to,1584,O
29,1584,O
%,1584,O
),1584,O
.,1584,O
The,1585,O
median,1585,O
dose-intensity,1585,O
(,1585,O
DI,1585,O
),1585,O
was,1585,O
20,1585,O
mg/m2/wk,1585,O
.,1585,O
VNB,1586,B-Chemical
was,1586,O
well,1586,O
tolerated,1586,O
and,1586,O
zero,1586,O
instances,1586,O
of,1586,O
WHO,1586,O
grade,1586,O
4,1586,O
nonhematologic,1586,O
toxicity,1586,B-Disease
occurred,1586,O
.,1586,O
At,1587,O
least,1587,O
one,1587,O
episode,1587,O
of,1587,O
grade,1587,O
3,1587,O
or,1587,O
4,1587,O
granulocytopenia,1587,B-Disease
was,1587,O
seen,1587,O
in,1587,O
59,1587,O
%,1587,O
of,1587,O
patients,1587,O
.,1587,O
A,1588,O
grade,1588,O
2,1588,O
or,1588,O
3,1588,O
infection,1588,B-Disease
occurred,1588,O
in,1588,O
16,1588,O
%,1588,O
of,1588,O
patients,1588,O
",",1588,O
but,1588,O
no,1588,O
toxic,1588,O
deaths,1588,B-Disease
occurred,1588,O
.,1588,O
Other,1589,O
side,1589,O
effects,1589,O
were,1589,O
rare,1589,O
",",1589,O
and,1589,O
peripheral,1589,B-Disease
neurotoxicity,1589,I-Disease
has,1589,O
been,1589,O
minor,1589,O
(,1589,O
26,1589,O
%,1589,O
grade,1589,O
1,1589,O
),1589,O
.,1589,O
CONCLUSION,1590,O
:,1590,O
These,1590,O
data,1590,O
indicate,1590,O
that,1590,O
VNB,1590,B-Chemical
is,1590,O
an,1590,O
active,1590,O
agent,1590,O
in,1590,O
metastatic,1590,O
esophageal,1590,B-Disease
squamous,1590,I-Disease
cell,1590,I-Disease
carcinoma,1590,I-Disease
.,1590,O
Given,1591,O
its,1591,O
excellent,1591,O
tolerance,1591,O
profile,1591,O
and,1591,O
low,1591,O
toxicity,1591,B-Disease
",",1591,O
further,1591,O
evaluation,1591,O
of,1591,O
VNB,1591,B-Chemical
in,1591,O
combination,1591,O
therapy,1591,O
is,1591,O
warranted,1591,O
.,1591,O
Evaluation,1592,O
of,1592,O
adverse,1592,O
reactions,1592,O
of,1592,O
aponidine,1592,B-Chemical
hydrochloride,1592,I-Chemical
ophthalmic,1592,O
solution,1592,O
.,1592,O
We,1593,O
prospectively,1593,O
evaluated,1593,O
the,1593,O
adverse,1593,O
reactions,1593,O
of,1593,O
apraclonidine,1593,B-Chemical
in,1593,O
20,1593,O
normal,1593,O
volunteers,1593,O
by,1593,O
instilling,1593,O
a,1593,O
single,1593,O
drop,1593,O
of,1593,O
1,1593,O
%,1593,O
apraclonidine,1593,B-Chemical
in,1593,O
their,1593,O
right,1593,O
eyes,1593,O
.,1593,O
Examinations,1594,O
",",1594,O
including,1594,O
blood,1594,O
pressure,1594,O
",",1594,O
pulse,1594,O
rate,1594,O
",",1594,O
conjunctiva,1594,O
and,1594,O
cornea,1594,O
",",1594,O
intraocular,1594,O
pressure,1594,O
(,1594,O
IOP,1594,O
),1594,O
",",1594,O
pupil,1594,O
diameter,1594,O
",",1594,O
basal,1594,O
tear,1594,O
secretion,1594,O
and,1594,O
margin,1594,O
reflex,1594,O
distance,1594,O
of,1594,O
both,1594,O
upper,1594,O
and,1594,O
lower,1594,O
eyelids,1594,O
",",1594,O
were,1594,O
performed,1594,O
prior,1594,O
to,1594,O
entry,1594,O
and,1594,O
at,1594,O
1,1594,O
",",1594,O
3,1594,O
",",1594,O
5,1594,O
and,1594,O
7,1594,O
hours,1594,O
after,1594,O
instillation,1594,O
.,1594,O
The,1595,O
ocular,1595,B-Disease
hypotensive,1595,I-Disease
effects,1595,O
were,1595,O
statistically,1595,O
significant,1595,O
for,1595,O
apraclonidine-treated,1595,B-Chemical
eyes,1595,O
throughout,1595,O
the,1595,O
study,1595,O
and,1595,O
also,1595,O
statistically,1595,O
significant,1595,O
for,1595,O
contralateral,1595,O
eyes,1595,O
from,1595,O
three,1595,O
hours,1595,O
after,1595,O
topical,1595,O
administration,1595,O
of,1595,O
1,1595,O
%,1595,O
apraclonidine,1595,B-Chemical
.,1595,O
Decreases,1596,B-Disease
in,1596,I-Disease
systolic,1596,I-Disease
blood,1596,I-Disease
pressure,1596,I-Disease
were,1596,O
statistically,1596,O
",",1596,O
but,1596,O
not,1596,O
clinically,1596,O
",",1596,O
significant,1596,O
.,1596,O
No,1597,O
significant,1597,O
changes,1597,O
in,1597,O
diastolic,1597,O
blood,1597,O
pressure,1597,O
",",1597,O
pulse,1597,O
rate,1597,O
and,1597,O
basal,1597,O
tear,1597,O
secretion,1597,O
were,1597,O
noted,1597,O
.,1597,O
Conjunctival,1598,B-Disease
blanching,1598,I-Disease
and,1598,O
mydriasis,1598,B-Disease
were,1598,O
commonly,1598,O
found,1598,O
.,1598,O
Upper,1599,O
lid,1599,O
retraction,1599,O
was,1599,O
frequently,1599,O
noted,1599,O
.,1599,O
While,1600,O
the,1600,O
elevations,1600,O
of,1600,O
the,1600,O
upper,1600,O
lid,1600,O
margin,1600,O
in,1600,O
most,1600,O
subjects,1600,O
were,1600,O
not,1600,O
more,1600,O
than,1600,O
2,1600,O
mm,1600,O
and,1600,O
did,1600,O
not,1600,O
cause,1600,O
noticeable,1600,O
change,1600,O
in,1600,O
appearance,1600,O
",",1600,O
one,1600,O
subject,1600,O
suffered,1600,O
from,1600,O
mechanical,1600,O
entropion,1600,B-Disease
and,1600,O
marked,1600,O
corneal,1600,B-Disease
abrasion,1600,I-Disease
3,1600,O
hours,1600,O
after,1600,O
instillation,1600,O
of,1600,O
the,1600,O
medication,1600,O
.,1600,O
This,1601,O
may,1601,O
well,1601,O
be,1601,O
a,1601,O
particularly,1601,O
notable,1601,O
finding,1601,O
in,1601,O
Asian,1601,O
people,1601,O
.,1601,O
Thiopentone,1602,B-Chemical
pretreatment,1602,O
for,1602,O
propofol,1602,B-Chemical
injection,1602,O
pain,1602,B-Disease
in,1602,O
ambulatory,1602,O
patients,1602,O
.,1602,O
This,1603,O
study,1603,O
investigated,1603,O
propofol,1603,B-Chemical
injection,1603,O
pain,1603,B-Disease
in,1603,O
patients,1603,O
undergoing,1603,O
ambulatory,1603,O
anaesthesia,1603,O
.,1603,O
In,1604,O
a,1604,O
randomized,1604,O
",",1604,O
double-blind,1604,O
trial,1604,O
",",1604,O
90,1604,O
women,1604,O
were,1604,O
allocated,1604,O
to,1604,O
receive,1604,O
one,1604,O
of,1604,O
three,1604,O
treatments,1604,O
prior,1604,O
to,1604,O
induction,1604,O
of,1604,O
anaesthesia,1604,O
with,1604,O
propofol,1604,B-Chemical
.,1604,O
Patients,1605,O
in,1605,O
Group,1605,O
C,1605,O
received,1605,O
2,1605,O
ml,1605,O
normal,1605,O
saline,1605,O
",",1605,O
Group,1605,O
L,1605,O
",",1605,O
2,1605,O
ml,1605,O
",",1605,O
lidocaine,1605,B-Chemical
2,1605,O
%,1605,O
(,1605,O
40,1605,O
mg,1605,O
),1605,O
and,1605,O
Group,1605,O
T,1605,O
",",1605,O
2,1605,O
ml,1605,O
thiopentone,1605,B-Chemical
2.5,1605,O
%,1605,O
(,1605,O
50,1605,O
mg,1605,O
),1605,O
.,1605,O
Venous,1606,O
discomfort,1606,O
was,1606,O
assessed,1606,O
with,1606,O
a,1606,O
visual,1606,O
analogue,1606,O
scale,1606,O
(,1606,O
VAS,1606,O
),1606,O
5-15,1606,O
sec,1606,O
after,1606,O
commencing,1606,O
propofol,1606,B-Chemical
administration,1606,O
using,1606,O
an,1606,O
infusion,1606,O
pump,1606,O
(,1606,O
rate,1606,O
1000,1606,O
micrograms.kg-1.min-1,1606,O
),1606,O
.,1606,O
Loss,1607,B-Disease
of,1607,I-Disease
consciousness,1607,I-Disease
occurred,1607,O
in,1607,O
60-90,1607,O
sec,1607,O
.,1607,O
Visual,1608,O
analogue,1608,O
scores,1608,O
(,1608,O
mean,1608,O
+/-,1608,O
SD,1608,O
),1608,O
during,1608,O
induction,1608,O
were,1608,O
lower,1608,O
in,1608,O
Groups,1608,O
L,1608,O
(,1608,O
3.3,1608,O
+/-,1608,O
2.5,1608,O
),1608,O
and,1608,O
T,1608,O
(,1608,O
4.1,1608,O
+/-,1608,O
2.7,1608,O
),1608,O
than,1608,O
in,1608,O
Group,1608,O
C,1608,O
(,1608,O
5.6,1608,O
+/-,1608,O
2.3,1608,O
),1608,O
;,1608,O
P,1608,O
=,1608,O
0.0031,1608,O
.,1608,O
The,1609,O
incidence,1609,O
of,1609,O
venous,1609,O
discomfort,1609,O
was,1609,O
lower,1609,O
in,1609,O
Group,1609,O
L,1609,O
(,1609,O
76.6,1609,O
%,1609,O
;,1609,O
P,1609,O
<,1609,O
0.05,1609,O
),1609,O
than,1609,O
in,1609,O
Group,1609,O
C,1609,O
(,1609,O
100,1609,O
%,1609,O
),1609,O
but,1609,O
not,1609,O
different,1609,O
from,1609,O
Group,1609,O
T,1609,O
(,1609,O
90,1609,O
%,1609,O
),1609,O
.,1609,O
The,1610,O
VAS,1610,O
scores,1610,O
for,1610,O
recall,1610,O
of,1610,O
pain,1610,B-Disease
in,1610,O
the,1610,O
recovery,1610,O
room,1610,O
were,1610,O
correlated,1610,O
with,1610,O
the,1610,O
VAS,1610,O
scores,1610,O
during,1610,O
induction,1610,O
(,1610,O
r,1610,O
=,1610,O
0.7045,1610,O
;,1610,O
P,1610,O
<,1610,O
0.0001,1610,O
),1610,O
.,1610,O
Recovery,1611,O
room,1611,O
discharge,1611,O
times,1611,O
were,1611,O
similar,1611,O
:,1611,O
C,1611,O
(,1611,O
75.9,1611,O
+/-,1611,O
19.4,1611,O
min,1611,O
),1611,O
;,1611,O
L,1611,O
73.6,1611,O
+/-,1611,O
21.6,1611,O
min,1611,O
),1611,O
;,1611,O
T,1611,O
(,1611,O
77.1,1611,O
+/-,1611,O
18.9,1611,O
min,1611,O
),1611,O
.,1611,O
Assessing,1612,O
their,1612,O
overall,1612,O
satisfaction,1612,O
",",1612,O
89.7,1612,O
%,1612,O
would,1612,O
choose,1612,O
propofol,1612,B-Chemical
anaesthesia,1612,O
again,1612,O
.,1612,O
We,1613,O
conclude,1613,O
that,1613,O
lidocaine,1613,B-Chemical
reduces,1613,O
the,1613,O
incidence,1613,O
and,1613,O
severity,1613,O
of,1613,O
propofol,1613,B-Chemical
injection,1613,O
pain,1613,B-Disease
in,1613,O
ambulatory,1613,O
patients,1613,O
whereas,1613,O
thiopentone,1613,B-Chemical
only,1613,O
reduces,1613,O
its,1613,O
severity,1613,O
.,1613,O
Persistent,1614,O
paralysis,1614,B-Disease
after,1614,O
prolonged,1614,O
use,1614,O
of,1614,O
atracurium,1614,B-Chemical
in,1614,O
the,1614,O
absence,1614,O
of,1614,O
corticosteroids,1614,O
.,1614,O
Neuromuscular,1615,O
blocking,1615,O
agents,1615,O
(,1615,O
NMBAs,1615,O
),1615,O
are,1615,O
often,1615,O
used,1615,O
for,1615,O
patients,1615,O
requiring,1615,O
prolonged,1615,O
mechanical,1615,O
ventilation,1615,O
.,1615,O
Reports,1616,O
of,1616,O
persistent,1616,O
paralysis,1616,B-Disease
after,1616,O
the,1616,O
discontinuance,1616,O
of,1616,O
these,1616,O
drugs,1616,O
have,1616,O
most,1616,O
often,1616,O
involved,1616,O
aminosteroid-based,1616,O
NMBAs,1616,O
such,1616,O
as,1616,O
vecuronium,1616,B-Chemical
bromide,1616,I-Chemical
",",1616,O
especially,1616,O
when,1616,O
used,1616,O
in,1616,O
conjunction,1616,O
with,1616,O
corticosteroids,1616,O
.,1616,O
Atracurium,1617,B-Chemical
besylate,1617,I-Chemical
",",1617,O
a,1617,O
short-acting,1617,O
benzylisoquinolinium,1617,B-Chemical
NMBA,1617,O
that,1617,O
is,1617,O
eliminated,1617,O
independently,1617,O
of,1617,O
renal,1617,O
or,1617,O
hepatic,1617,O
function,1617,O
",",1617,O
has,1617,O
also,1617,O
been,1617,O
associated,1617,O
with,1617,O
persistent,1617,O
paralysis,1617,B-Disease
",",1617,O
but,1617,O
only,1617,O
when,1617,O
used,1617,O
with,1617,O
corticosteroids,1617,O
.,1617,O
We,1618,O
report,1618,O
a,1618,O
case,1618,O
of,1618,O
atracurium-related,1618,B-Chemical
paralysis,1618,B-Disease
persisting,1618,O
for,1618,O
approximately,1618,O
50,1618,O
hours,1618,O
in,1618,O
a,1618,O
patient,1618,O
who,1618,O
was,1618,O
not,1618,O
treated,1618,O
with,1618,O
corticosteroids,1618,O
.,1618,O
A,1619,O
phase,1619,O
I/II,1619,O
study,1619,O
of,1619,O
paclitaxel,1619,B-Chemical
plus,1619,O
cisplatin,1619,B-Chemical
as,1619,O
first-line,1619,O
therapy,1619,O
for,1619,O
head,1619,B-Disease
and,1619,I-Disease
neck,1619,I-Disease
cancers,1619,I-Disease
:,1619,O
preliminary,1619,O
results,1619,O
.,1619,O
Improved,1620,O
outcomes,1620,O
among,1620,O
patients,1620,O
with,1620,O
head,1620,B-Disease
and,1620,I-Disease
neck,1620,I-Disease
carcinomas,1620,I-Disease
require,1620,O
investigations,1620,O
of,1620,O
new,1620,O
drugs,1620,O
for,1620,O
induction,1620,O
therapy,1620,O
.,1620,O
Preliminary,1621,O
results,1621,O
of,1621,O
an,1621,O
Eastern,1621,O
Cooperative,1621,O
Oncology,1621,O
Group,1621,O
study,1621,O
of,1621,O
single-agent,1621,O
paclitaxel,1621,B-Chemical
(,1621,O
Taxol,1621,B-Chemical
;,1621,O
Bristol-Myers,1621,O
Squibb,1621,O
Company,1621,O
",",1621,O
Princeton,1621,O
",",1621,O
NJ,1621,O
),1621,O
reported,1621,O
a,1621,O
37,1621,O
%,1621,O
response,1621,O
rate,1621,O
in,1621,O
patients,1621,O
with,1621,O
head,1621,B-Disease
and,1621,I-Disease
neck,1621,I-Disease
cancer,1621,I-Disease
",",1621,O
and,1621,O
the,1621,O
paclitaxel/cisplatin,1621,B-Chemical
combination,1621,O
has,1621,O
been,1621,O
used,1621,O
successfully,1621,O
and,1621,O
has,1621,O
significantly,1621,O
improved,1621,O
median,1621,O
response,1621,O
duration,1621,O
in,1621,O
ovarian,1621,B-Disease
cancer,1621,I-Disease
patients,1621,O
.,1621,O
We,1622,O
initiated,1622,O
a,1622,O
phase,1622,O
I/II,1622,O
trial,1622,O
to,1622,O
determine,1622,O
the,1622,O
response,1622,O
and,1622,O
toxicity,1622,B-Disease
of,1622,O
escalating,1622,O
paclitaxel,1622,B-Chemical
doses,1622,O
combined,1622,O
with,1622,O
fixed-dose,1622,O
cisplatin,1622,B-Chemical
with,1622,O
granulocyte,1622,O
colony-stimulating,1622,O
factor,1622,O
support,1622,O
in,1622,O
patients,1622,O
with,1622,O
untreated,1622,O
locally,1622,O
advanced,1622,O
inoperable,1622,O
head,1622,B-Disease
and,1622,I-Disease
neck,1622,I-Disease
carcinoma,1622,I-Disease
.,1622,O
To,1623,O
date,1623,O
",",1623,O
23,1623,O
men,1623,O
with,1623,O
a,1623,O
median,1623,O
age,1623,O
of,1623,O
50,1623,O
years,1623,O
and,1623,O
good,1623,O
performance,1623,O
status,1623,O
have,1623,O
entered,1623,O
the,1623,O
trial,1623,O
.,1623,O
Primary,1624,O
tumor,1624,B-Disease
sites,1624,O
were,1624,O
oropharynx,1624,O
",",1624,O
10,1624,O
patients,1624,O
;,1624,O
hypopharynx,1624,O
",",1624,O
four,1624,O
;,1624,O
larynx,1624,O
",",1624,O
two,1624,O
;,1624,O
oral,1624,O
cavity,1624,O
",",1624,O
three,1624,O
;,1624,O
unknown,1624,O
primary,1624,O
",",1624,O
two,1624,O
;,1624,O
and,1624,O
nasal,1624,O
cavity,1624,O
and,1624,O
parotid,1624,O
gland,1624,O
",",1624,O
one,1624,O
each,1624,O
.,1624,O
Of,1625,O
20,1625,O
patients,1625,O
evaluable,1625,O
for,1625,O
toxicity,1625,B-Disease
",",1625,O
four,1625,O
had,1625,O
stage,1625,O
III,1625,O
and,1625,O
16,1625,O
had,1625,O
stage,1625,O
IV,1625,O
disease,1625,O
.,1625,O
Treatment,1626,O
",",1626,O
given,1626,O
every,1626,O
21,1626,O
days,1626,O
for,1626,O
a,1626,O
maximum,1626,O
of,1626,O
three,1626,O
cycles,1626,O
",",1626,O
consisted,1626,O
of,1626,O
paclitaxel,1626,B-Chemical
by,1626,O
3-hour,1626,O
infusion,1626,O
followed,1626,O
the,1626,O
next,1626,O
day,1626,O
by,1626,O
a,1626,O
fixed,1626,O
dose,1626,O
of,1626,O
cisplatin,1626,B-Chemical
(,1626,O
75,1626,O
mg/m2,1626,O
),1626,O
.,1626,O
The,1627,O
dose,1627,O
levels,1627,O
incorporate,1627,O
escalating,1627,O
paclitaxel,1627,B-Chemical
doses,1627,O
",",1627,O
and,1627,O
intrapatient,1627,O
escalations,1627,O
within,1627,O
a,1627,O
given,1627,O
dose,1627,O
level,1627,O
are,1627,O
permitted,1627,O
if,1627,O
toxicity,1627,B-Disease
permits,1627,O
.,1627,O
At,1628,O
the,1628,O
time,1628,O
of,1628,O
this,1628,O
writing,1628,O
",",1628,O
dose,1628,O
level,1628,O
4,1628,O
(,1628,O
260,1628,O
",",1628,O
270,1628,O
",",1628,O
and,1628,O
280,1628,O
mg/m2,1628,O
),1628,O
is,1628,O
being,1628,O
evaluated,1628,O
;,1628,O
three,1628,O
patients,1628,O
from,1628,O
this,1628,O
level,1628,O
are,1628,O
evaluable,1628,O
.,1628,O
With,1629,O
paclitaxel,1629,B-Chemical
doses,1629,O
of,1629,O
200,1629,O
mg/m2,1629,O
and,1629,O
higher,1629,O
",",1629,O
granulocyte,1629,O
colony-stimulating,1629,O
factor,1629,O
5,1629,O
micrograms/kg/d,1629,O
is,1629,O
given,1629,O
(,1629,O
days,1629,O
4,1629,O
through,1629,O
12,1629,O
),1629,O
.,1629,O
Of,1630,O
18,1630,O
patients,1630,O
evaluable,1630,O
for,1630,O
response,1630,O
",",1630,O
seven,1630,O
(,1630,O
39,1630,O
%,1630,O
),1630,O
achieved,1630,O
a,1630,O
complete,1630,O
response,1630,O
and,1630,O
six,1630,O
(,1630,O
33,1630,O
%,1630,O
),1630,O
achieved,1630,O
a,1630,O
partial,1630,O
response,1630,O
.,1630,O
Three,1631,O
patients,1631,O
had,1631,O
no,1631,O
change,1631,O
and,1631,O
disease,1631,O
progressed,1631,O
in,1631,O
two,1631,O
.,1631,O
The,1632,O
overall,1632,O
response,1632,O
rate,1632,O
is,1632,O
72,1632,O
%,1632,O
.,1632,O
Eleven,1633,O
responding,1633,O
patients,1633,O
had,1633,O
subsequent,1633,O
surgery/radiotherapy,1633,O
or,1633,O
radical,1633,O
radiotherapy,1633,O
.,1633,O
Two,1634,O
pathologic,1634,O
complete,1634,O
responses,1634,O
were,1634,O
observed,1634,O
in,1634,O
patients,1634,O
who,1634,O
had,1634,O
achieved,1634,O
clinical,1634,O
complete,1634,O
responses,1634,O
.,1634,O
Alopecia,1635,B-Disease
",",1635,O
paresthesias,1635,B-Disease
",",1635,O
and,1635,O
arthralgias/myalgias,1635,B-Disease
have,1635,O
occurred,1635,O
frequently,1635,O
",",1635,O
but,1635,O
with,1635,O
one,1635,O
exception,1635,O
(,1635,O
a,1635,O
grade,1635,O
3,1635,O
myalgia,1635,B-Disease
),1635,O
they,1635,O
have,1635,O
been,1635,O
grade,1635,O
1,1635,O
or,1635,O
2,1635,O
.,1635,O
No,1636,O
dose-limiting,1636,O
hematologic,1636,O
toxicity,1636,B-Disease
has,1636,O
been,1636,O
seen,1636,O
.,1636,O
Paclitaxel/cisplatin,1637,B-Chemical
is,1637,O
an,1637,O
effective,1637,O
first-line,1637,O
regimen,1637,O
for,1637,O
locoregionally,1637,O
advanced,1637,O
head,1637,B-Disease
and,1637,I-Disease
neck,1637,I-Disease
cancer,1637,I-Disease
and,1637,O
continued,1637,O
study,1637,O
is,1637,O
warranted,1637,O
.,1637,O
Results,1638,O
thus,1638,O
far,1638,O
suggest,1638,O
no,1638,O
dose-response,1638,O
effect,1638,O
for,1638,O
paclitaxel,1638,B-Chemical
doses,1638,O
above,1638,O
200,1638,O
mg/m2,1638,O
.,1638,O
Improvement,1639,O
of,1639,O
levodopa-induced,1639,B-Chemical
dyskinesia,1639,B-Disease
by,1639,O
propranolol,1639,B-Chemical
in,1639,O
Parkinson,1639,B-Disease
's,1639,I-Disease
disease,1639,I-Disease
.,1639,O
Seven,1640,O
patients,1640,O
suffering,1640,O
from,1640,O
Parkinson,1640,B-Disease
's,1640,I-Disease
disease,1640,I-Disease
(,1640,O
PD,1640,B-Disease
),1640,O
with,1640,O
severely,1640,O
disabling,1640,O
dyskinesia,1640,B-Disease
received,1640,O
low-dose,1640,O
propranolol,1640,B-Chemical
as,1640,O
an,1640,O
adjunct,1640,O
to,1640,O
the,1640,O
currently,1640,O
used,1640,O
medical,1640,O
treatment,1640,O
.,1640,O
There,1641,O
was,1641,O
a,1641,O
significant,1641,O
40,1641,O
%,1641,O
improvement,1641,O
in,1641,O
the,1641,O
dyskinesia,1641,B-Disease
score,1641,O
without,1641,O
increase,1641,O
of,1641,O
parkinsonian,1641,B-Disease
motor,1641,B-Disease
disability,1641,I-Disease
.,1641,O
Ballistic,1642,O
and,1642,O
choreic,1642,O
dyskinesia,1642,B-Disease
were,1642,O
markedly,1642,O
ameliorated,1642,O
",",1642,O
whereas,1642,O
dystonia,1642,B-Disease
was,1642,O
not,1642,O
.,1642,O
This,1643,O
study,1643,O
suggests,1643,O
that,1643,O
administration,1643,O
of,1643,O
low,1643,O
doses,1643,O
of,1643,O
beta-blockers,1643,O
may,1643,O
improve,1643,O
levodopa-induced,1643,B-Chemical
ballistic,1643,O
and,1643,O
choreic,1643,O
dyskinesia,1643,B-Disease
in,1643,O
PD,1643,B-Disease
.,1643,O
Habitual,1644,O
use,1644,O
of,1644,O
acetaminophen,1644,B-Chemical
as,1644,O
a,1644,O
risk,1644,O
factor,1644,O
for,1644,O
chronic,1644,B-Disease
renal,1644,I-Disease
failure,1644,I-Disease
:,1644,O
a,1644,O
comparison,1644,O
with,1644,O
phenacetin,1644,B-Chemical
.,1644,O
Six,1645,O
epidemiologic,1645,O
studies,1645,O
in,1645,O
the,1645,O
United,1645,O
States,1645,O
and,1645,O
Europe,1645,O
indicate,1645,O
that,1645,O
habitual,1645,O
use,1645,O
of,1645,O
phenacetin,1645,B-Chemical
is,1645,O
associated,1645,O
with,1645,O
the,1645,O
development,1645,O
of,1645,O
chronic,1645,B-Disease
renal,1645,I-Disease
failure,1645,I-Disease
and,1645,O
end-stage,1645,B-Disease
renal,1645,I-Disease
disease,1645,I-Disease
(,1645,O
ESRD,1645,B-Disease
),1645,O
",",1645,O
with,1645,O
a,1645,O
relative,1645,O
risk,1645,O
in,1645,O
the,1645,O
range,1645,O
of,1645,O
4,1645,O
to,1645,O
19,1645,O
.,1645,O
As,1646,O
a,1646,O
result,1646,O
of,1646,O
these,1646,O
and,1646,O
other,1646,O
studies,1646,O
",",1646,O
phenacetin,1646,B-Chemical
has,1646,O
now,1646,O
been,1646,O
withdrawn,1646,O
from,1646,O
the,1646,O
market,1646,O
in,1646,O
most,1646,O
countries,1646,O
.,1646,O
However,1647,O
",",1647,O
three,1647,O
case,1647,O
control,1647,O
studies,1647,O
",",1647,O
one,1647,O
each,1647,O
in,1647,O
North,1647,O
Carolina,1647,O
",",1647,O
northern,1647,O
Maryland,1647,O
",",1647,O
and,1647,O
West,1647,O
Berlin,1647,O
",",1647,O
Germany,1647,O
",",1647,O
showed,1647,O
that,1647,O
habitual,1647,O
use,1647,O
of,1647,O
acetaminophen,1647,B-Chemical
is,1647,O
also,1647,O
associated,1647,O
with,1647,O
chronic,1647,B-Disease
renal,1647,I-Disease
failure,1647,I-Disease
and,1647,O
ESRD,1647,B-Disease
",",1647,O
with,1647,O
a,1647,O
relative,1647,O
risk,1647,O
in,1647,O
the,1647,O
range,1647,O
of,1647,O
2,1647,O
to,1647,O
4,1647,O
.,1647,O
These,1648,O
studies,1648,O
suggest,1648,O
that,1648,O
both,1648,O
phenacetin,1648,B-Chemical
and,1648,O
acetaminophen,1648,B-Chemical
may,1648,O
contribute,1648,O
to,1648,O
the,1648,O
burden,1648,O
of,1648,O
ESRD,1648,B-Disease
",",1648,O
with,1648,O
the,1648,O
risk,1648,O
of,1648,O
the,1648,O
latter,1648,O
being,1648,O
somewhat,1648,O
less,1648,O
than,1648,O
that,1648,O
of,1648,O
the,1648,O
former,1648,O
.,1648,O
This,1649,O
apparent,1649,O
difference,1649,O
in,1649,O
risk,1649,O
may,1649,O
not,1649,O
be,1649,O
due,1649,O
to,1649,O
differences,1649,O
in,1649,O
nephrotoxic,1649,B-Disease
potential,1649,O
of,1649,O
the,1649,O
drugs,1649,O
themselves,1649,O
.,1649,O
A,1650,O
lower,1650,O
relative,1650,O
risk,1650,O
would,1650,O
be,1650,O
expected,1650,O
for,1650,O
acetaminophen,1650,B-Chemical
if,1650,O
the,1650,O
risk,1650,O
of,1650,O
both,1650,O
drugs,1650,O
in,1650,O
combination,1650,O
with,1650,O
other,1650,O
analgesics,1650,O
was,1650,O
higher,1650,O
than,1650,O
the,1650,O
risk,1650,O
of,1650,O
either,1650,O
agent,1650,O
alone,1650,O
.,1650,O
Thus,1651,O
",",1651,O
acetaminophen,1651,B-Chemical
has,1651,O
been,1651,O
used,1651,O
both,1651,O
as,1651,O
a,1651,O
single,1651,O
agent,1651,O
and,1651,O
in,1651,O
combination,1651,O
with,1651,O
other,1651,O
analgesics,1651,O
",",1651,O
whereas,1651,O
phenacetin,1651,B-Chemical
was,1651,O
available,1651,O
only,1651,O
in,1651,O
combinations,1651,O
.,1651,O
The,1652,O
possibility,1652,O
that,1652,O
habitual,1652,O
use,1652,O
of,1652,O
acetaminophen,1652,B-Chemical
alone,1652,O
increases,1652,O
the,1652,O
risk,1652,O
of,1652,O
ESRD,1652,B-Disease
has,1652,O
not,1652,O
been,1652,O
clearly,1652,O
demonstrated,1652,O
",",1652,O
but,1652,O
can,1652,O
not,1652,O
be,1652,O
dismissed,1652,O
.,1652,O
Acetaminophen-induced,1653,B-Chemical
hypotension,1653,B-Disease
.,1653,O
Through,1654,O
30,1654,O
years,1654,O
of,1654,O
widespread,1654,O
use,1654,O
",",1654,O
acetaminophen,1654,B-Chemical
has,1654,O
been,1654,O
shown,1654,O
to,1654,O
be,1654,O
a,1654,O
remarkably,1654,O
safe,1654,O
medication,1654,O
in,1654,O
therapeutic,1654,O
dosages,1654,O
.,1654,O
The,1655,O
potential,1655,O
for,1655,O
acetaminophen,1655,B-Chemical
to,1655,O
produce,1655,O
cardiovascular,1655,B-Disease
toxicities,1655,I-Disease
is,1655,O
very,1655,O
low,1655,O
.,1655,O
However,1656,O
",",1656,O
acetaminophen,1656,B-Chemical
has,1656,O
been,1656,O
demonstrated,1656,O
to,1656,O
produce,1656,O
symptoms,1656,O
of,1656,O
anaphylaxis,1656,B-Disease
",",1656,O
including,1656,O
hypotension,1656,B-Disease
",",1656,O
in,1656,O
sensitive,1656,O
individuals,1656,O
.,1656,O
This,1657,O
article,1657,O
describes,1657,O
two,1657,O
critically,1657,B-Disease
ill,1657,I-Disease
patients,1657,O
in,1657,O
whom,1657,O
transient,1657,O
episodes,1657,O
of,1657,O
hypotension,1657,B-Disease
reproducibly,1657,O
developed,1657,O
after,1657,O
administration,1657,O
of,1657,O
acetaminophen,1657,B-Chemical
.,1657,O
Other,1658,O
symptoms,1658,O
of,1658,O
allergic,1658,B-Disease
reactions,1658,I-Disease
were,1658,O
not,1658,O
clinically,1658,O
detectable,1658,O
.,1658,O
The,1659,O
hypotensive,1659,B-Disease
episodes,1659,O
were,1659,O
severe,1659,O
enough,1659,O
to,1659,O
require,1659,O
vasopressor,1659,O
administration,1659,O
.,1659,O
The,1660,O
reports,1660,O
illustrate,1660,O
the,1660,O
need,1660,O
for,1660,O
clinicians,1660,O
to,1660,O
consider,1660,O
acetaminophen,1660,B-Chemical
in,1660,O
patients,1660,O
with,1660,O
hypotension,1660,B-Disease
of,1660,O
unknown,1660,O
origin,1660,O
.,1660,O
Reduction,1661,O
of,1661,O
heparan,1661,B-Chemical
sulphate-associated,1661,O
anionic,1661,O
sites,1661,O
in,1661,O
the,1661,O
glomerular,1661,O
basement,1661,O
membrane,1661,O
of,1661,O
rats,1661,O
with,1661,O
streptozotocin-induced,1661,B-Chemical
diabetic,1661,B-Disease
nephropathy,1661,I-Disease
.,1661,O
Heparan,1662,B-Chemical
sulphate-associated,1662,O
anionic,1662,O
sites,1662,O
in,1662,O
the,1662,O
glomerular,1662,O
basement,1662,O
membrane,1662,O
were,1662,O
studied,1662,O
in,1662,O
rats,1662,O
8,1662,O
months,1662,O
after,1662,O
induction,1662,O
of,1662,O
diabetes,1662,B-Disease
by,1662,O
streptozotocin,1662,B-Chemical
and,1662,O
in,1662,O
age-,1662,O
adn,1662,O
sex-matched,1662,O
control,1662,O
rats,1662,O
",",1662,O
employing,1662,O
the,1662,O
cationic,1662,O
dye,1662,O
cuprolinic,1662,B-Chemical
blue,1662,I-Chemical
.,1662,O
Morphometric,1663,O
analysis,1663,O
at,1663,O
the,1663,O
ultrastructural,1663,O
level,1663,O
was,1663,O
performed,1663,O
using,1663,O
a,1663,O
computerized,1663,O
image,1663,O
processor,1663,O
.,1663,O
The,1664,O
heparan,1664,B-Chemical
sulphate,1664,I-Chemical
specificity,1664,O
of,1664,O
the,1664,O
cuprolinic,1664,B-Chemical
blue,1664,I-Chemical
staining,1664,O
was,1664,O
demonstrated,1664,O
by,1664,O
glycosaminoglycan-degrading,1664,B-Chemical
enzymes,1664,O
",",1664,O
showing,1664,O
that,1664,O
pretreatment,1664,O
of,1664,O
the,1664,O
sections,1664,O
with,1664,O
heparitinase,1664,O
abolished,1664,O
all,1664,O
staining,1664,O
",",1664,O
whereas,1664,O
chondroitinase,1664,O
ABC,1664,O
had,1664,O
no,1664,O
effect,1664,O
.,1664,O
The,1665,O
majority,1665,O
of,1665,O
anionic,1665,O
sites,1665,O
(,1665,O
74,1665,O
%,1665,O
in,1665,O
diabetic,1665,B-Disease
and,1665,O
81,1665,O
%,1665,O
in,1665,O
control,1665,O
rats,1665,O
),1665,O
were,1665,O
found,1665,O
within,1665,O
the,1665,O
lamina,1665,O
rara,1665,O
externa,1665,O
of,1665,O
the,1665,O
glomerular,1665,O
basement,1665,O
membrane,1665,O
.,1665,O
A,1666,O
minority,1666,O
of,1666,O
anionic,1666,O
sites,1666,O
were,1666,O
scattered,1666,O
throughout,1666,O
the,1666,O
lamina,1666,O
densa,1666,O
and,1666,O
lamina,1666,O
rara,1666,O
interna,1666,O
",",1666,O
and,1666,O
were,1666,O
significantly,1666,O
smaller,1666,O
than,1666,O
those,1666,O
in,1666,O
the,1666,O
lamina,1666,O
rara,1666,O
externa,1666,O
of,1666,O
the,1666,O
glomerular,1666,O
basement,1666,O
membrane,1666,O
(,1666,O
p,1666,O
<,1666,O
0.001,1666,O
and,1666,O
p,1666,O
<,1666,O
0.01,1666,O
for,1666,O
diabetic,1666,B-Disease
and,1666,O
control,1666,O
rats,1666,O
",",1666,O
respectively,1666,O
),1666,O
.,1666,O
Diabetic,1667,B-Disease
rats,1667,O
progressively,1667,O
developed,1667,O
albuminuria,1667,B-Disease
reaching,1667,O
40.3,1667,O
(,1667,O
32.2-62.0,1667,O
),1667,O
mg/24,1667,O
h,1667,O
after,1667,O
8,1667,O
months,1667,O
in,1667,O
contrast,1667,O
to,1667,O
the,1667,O
control,1667,O
animals,1667,O
(,1667,O
0.8,1667,O
(,1667,O
0.2-0.9,1667,O
),1667,O
mg/24,1667,O
h,1667,O
",",1667,O
p,1667,O
<,1667,O
0.002,1667,O
),1667,O
.,1667,O
At,1668,O
the,1668,O
same,1668,O
time,1668,O
",",1668,O
the,1668,O
number,1668,O
of,1668,O
heparan,1668,B-Chemical
sulphate,1668,I-Chemical
anionic,1668,O
sites,1668,O
and,1668,O
the,1668,O
total,1668,O
anionic,1668,O
site,1668,O
surface,1668,O
(,1668,O
number,1668,O
of,1668,O
anionic,1668,O
sites,1668,O
x,1668,O
mean,1668,O
anionic,1668,O
site,1668,O
surface,1668,O
),1668,O
in,1668,O
the,1668,O
lamina,1668,O
rara,1668,O
externa,1668,O
of,1668,O
the,1668,O
glomerular,1668,O
basement,1668,O
membrane,1668,O
was,1668,O
reduced,1668,O
by,1668,O
19,1668,O
%,1668,O
(,1668,O
p,1668,O
<,1668,O
0.021,1668,O
),1668,O
and,1668,O
by,1668,O
26,1668,O
%,1668,O
(,1668,O
p,1668,O
<,1668,O
0.02,1668,O
),1668,O
",",1668,O
respectively,1668,O
.,1668,O
Number,1669,O
and,1669,O
total,1669,O
anionic,1669,O
site,1669,O
surface,1669,O
in,1669,O
the,1669,O
remaining,1669,O
part,1669,O
of,1669,O
the,1669,O
glomerular,1669,O
basement,1669,O
membrane,1669,O
(,1669,O
lamina,1669,O
densa,1669,O
and,1669,O
lamina,1669,O
rara,1669,O
interna,1669,O
),1669,O
were,1669,O
not,1669,O
significantly,1669,O
changed,1669,O
.,1669,O
We,1670,O
conclude,1670,O
that,1670,O
in,1670,O
streptozotocin-diabetic,1670,B-Chemical
rats,1670,O
with,1670,O
an,1670,O
increased,1670,O
urinary,1670,O
albumin,1670,O
excretion,1670,O
",",1670,O
a,1670,O
reduced,1670,O
heparan,1670,B-Chemical
sulphate,1670,I-Chemical
charge,1670,O
barrier/density,1670,O
is,1670,O
found,1670,O
at,1670,O
the,1670,O
lamina,1670,O
rara,1670,O
externa,1670,O
of,1670,O
the,1670,O
glomerular,1670,O
basement,1670,O
membrane,1670,O
.,1670,O
Microangiopathic,1671,B-Disease
hemolytic,1671,I-Disease
anemia,1671,I-Disease
complicating,1671,O
FK506,1671,B-Chemical
(,1671,O
tacrolimus,1671,B-Chemical
),1671,O
therapy,1671,O
.,1671,O
We,1672,O
describe,1672,O
3,1672,O
episodes,1672,O
of,1672,O
microangiopathic,1672,B-Disease
hemolytic,1672,I-Disease
anemia,1672,I-Disease
(,1672,O
MAHA,1672,B-Disease
),1672,O
in,1672,O
2,1672,O
solid,1672,O
organ,1672,O
recipients,1672,O
under,1672,O
FK506,1672,B-Chemical
(,1672,O
tacrolimus,1672,B-Chemical
),1672,O
therapy,1672,O
.,1672,O
In,1673,O
both,1673,O
cases,1673,O
",",1673,O
discontinuation,1673,O
of,1673,O
FK506,1673,B-Chemical
and,1673,O
treatment,1673,O
with,1673,O
plasma,1673,O
exchange,1673,O
",",1673,O
fresh,1673,O
frozen,1673,O
plasma,1673,O
replacement,1673,O
",",1673,O
corticosteroids,1673,B-Chemical
",",1673,O
aspirin,1673,B-Chemical
",",1673,O
and,1673,O
dipyridamole,1673,B-Chemical
led,1673,O
to,1673,O
resolution,1673,O
of,1673,O
MAHA,1673,B-Disease
.,1673,O
In,1674,O
one,1674,O
patient,1674,O
",",1674,O
reintroduction,1674,O
of,1674,O
FK506,1674,B-Chemical
led,1674,O
to,1674,O
rapid,1674,O
recurrence,1674,O
of,1674,O
MAHA,1674,B-Disease
.,1674,O
FK506-associated,1675,B-Chemical
MAHA,1675,B-Disease
is,1675,O
probably,1675,O
rare,1675,O
but,1675,O
physicians,1675,O
must,1675,O
be,1675,O
aware,1675,O
of,1675,O
this,1675,O
severe,1675,O
complication,1675,O
.,1675,O
In,1676,O
our,1676,O
experience,1676,O
and,1676,O
according,1676,O
to,1676,O
the,1676,O
literature,1676,O
",",1676,O
FK506,1676,B-Chemical
does,1676,O
not,1676,O
seem,1676,O
to,1676,O
cross-react,1676,O
with,1676,O
cyclosporin,1676,B-Chemical
A,1676,I-Chemical
(,1676,O
CyA,1676,B-Chemical
),1676,O
",",1676,O
an,1676,O
immuno-suppressive,1676,O
drug,1676,O
already,1676,O
known,1676,O
to,1676,O
induce,1676,O
MAHA,1676,B-Disease
.,1676,O
Effect,1677,O
of,1677,O
some,1677,O
anticancer,1677,O
drugs,1677,O
and,1677,O
combined,1677,O
chemotherapy,1677,O
on,1677,O
renal,1677,B-Disease
toxicity,1677,I-Disease
.,1677,O
The,1678,O
nephrotoxic,1678,B-Disease
action,1678,O
of,1678,O
anticancer,1678,O
drugs,1678,O
such,1678,O
as,1678,O
nitrogranulogen,1678,B-Chemical
(,1678,O
NG,1678,B-Chemical
),1678,O
",",1678,O
methotrexate,1678,B-Chemical
(,1678,O
MTX,1678,B-Chemical
),1678,O
",",1678,O
5-fluorouracil,1678,B-Chemical
(,1678,O
5-FU,1678,B-Chemical
),1678,O
and,1678,O
cyclophosphamide,1678,B-Chemical
(,1678,O
CY,1678,B-Chemical
),1678,O
administered,1678,O
alone,1678,O
or,1678,O
in,1678,O
combination,1678,O
[,1678,O
MTX,1678,B-Chemical
+,1678,O
5-FU,1678,B-Chemical
+,1678,O
CY,1678,B-Chemical
(,1678,O
CMF,1678,O
),1678,O
],1678,O
was,1678,O
evaluated,1678,O
in,1678,O
experiments,1678,O
on,1678,O
Wistar,1678,O
rats,1678,O
.,1678,O
After,1679,O
drug,1679,O
administration,1679,O
",",1679,O
creatinine,1679,B-Chemical
concentrations,1679,O
in,1679,O
the,1679,O
plasma,1679,O
and,1679,O
in,1679,O
the,1679,O
urine,1679,O
of,1679,O
the,1679,O
rats,1679,O
were,1679,O
determined,1679,O
",",1679,O
as,1679,O
well,1679,O
as,1679,O
creatinine,1679,B-Chemical
clearance,1679,O
.,1679,O
Histopathologic,1680,O
evaluation,1680,O
of,1680,O
the,1680,O
kidneys,1680,O
was,1680,O
also,1680,O
performed,1680,O
.,1680,O
After,1681,O
MTX,1681,B-Chemical
administration,1681,O
a,1681,O
significant,1681,O
increase,1681,O
(,1681,O
p,1681,O
=,1681,O
0.0228,1681,O
),1681,O
in,1681,O
the,1681,O
plasma,1681,O
creatinine,1681,B-Chemical
concentration,1681,O
and,1681,O
a,1681,O
significant,1681,O
(,1681,O
p,1681,O
=,1681,O
0.0001,1681,O
),1681,O
decrease,1681,O
in,1681,O
creatinine,1681,B-Chemical
clearance,1681,O
was,1681,O
noted,1681,O
compared,1681,O
to,1681,O
controls,1681,O
.,1681,O
After,1682,O
the,1682,O
administration,1682,O
of,1682,O
NG,1682,B-Chemical
",",1682,O
5-FU,1682,B-Chemical
and,1682,O
CY,1682,B-Chemical
neither,1682,O
a,1682,O
statistically,1682,O
significant,1682,O
increase,1682,O
in,1682,O
creatinine,1682,B-Chemical
concentration,1682,O
nor,1682,O
an,1682,O
increase,1682,O
in,1682,O
creatinine,1682,B-Chemical
clearance,1682,O
was,1682,O
observed,1682,O
compared,1682,O
to,1682,O
the,1682,O
group,1682,O
receiving,1682,O
no,1682,O
cytostatics,1682,O
.,1682,O
Following,1683,O
polytherapy,1683,O
according,1683,O
to,1683,O
the,1683,O
CMF,1683,O
regimen,1683,O
",",1683,O
a,1683,O
statistically,1683,O
significant,1683,O
decrease,1683,O
(,1683,O
p,1683,O
=,1683,O
0.0343,1683,O
),1683,O
in,1683,O
creatinine,1683,B-Chemical
clearance,1683,O
was,1683,O
found,1683,O
",",1683,O
but,1683,O
creatinine,1683,B-Chemical
concentration,1683,O
did,1683,O
not,1683,O
increase,1683,O
significantly,1683,O
compared,1683,O
to,1683,O
controls,1683,O
.,1683,O
CY,1684,B-Chemical
caused,1684,O
hemorrhagic,1684,O
cystitis,1684,O
in,1684,O
40,1684,O
%,1684,O
of,1684,O
rats,1684,O
",",1684,O
but,1684,O
it,1684,O
did,1684,O
not,1684,O
cause,1684,O
this,1684,O
complication,1684,O
when,1684,O
combined,1684,O
with,1684,O
5-FU,1684,B-Chemical
and,1684,O
MTX,1684,B-Chemical
.,1684,O
Histologic,1685,O
changes,1685,O
were,1685,O
found,1685,O
in,1685,O
rat,1685,O
kidneys,1685,O
after,1685,O
administration,1685,O
of,1685,O
MTX,1685,B-Chemical
",",1685,O
CY,1685,B-Chemical
and,1685,O
NG,1685,B-Chemical
",",1685,O
while,1685,O
no,1685,O
such,1685,O
change,1685,O
was,1685,O
observed,1685,O
after,1685,O
5-FU,1685,B-Chemical
and,1685,O
joint,1685,O
administration,1685,O
of,1685,O
MTX,1685,B-Chemical
+,1685,O
5-FU,1685,B-Chemical
+,1685,O
CY,1685,B-Chemical
compared,1685,O
to,1685,O
controls,1685,O
.,1685,O
Our,1686,O
studies,1686,O
indicate,1686,O
that,1686,O
nephrotoxicity,1686,B-Disease
of,1686,O
MTX,1686,B-Chemical
+,1686,O
5-FU,1686,B-Chemical
+,1686,O
CY,1686,B-Chemical
administered,1686,O
jointly,1686,O
is,1686,O
lower,1686,O
than,1686,O
in,1686,O
monotherapy,1686,O
.,1686,O
The,1687,O
interpeduncular,1687,O
nucleus,1687,O
regulates,1687,O
nicotine,1687,B-Chemical
's,1687,O
effects,1687,O
on,1687,O
free-field,1687,O
activity,1687,O
.,1687,O
Partial,1688,O
lesions,1688,O
were,1688,O
made,1688,O
with,1688,O
kainic,1688,B-Chemical
acid,1688,I-Chemical
in,1688,O
the,1688,O
interpeduncular,1688,O
nucleus,1688,O
of,1688,O
the,1688,O
ventral,1688,O
midbrain,1688,O
of,1688,O
the,1688,O
rat,1688,O
.,1688,O
Compared,1689,O
with,1689,O
sham-operated,1689,O
controls,1689,O
",",1689,O
lesions,1689,O
significantly,1689,O
(,1689,O
p,1689,O
<,1689,O
0.25,1689,O
),1689,O
blunted,1689,O
the,1689,O
early,1689,O
(,1689,O
<,1689,O
60,1689,O
min,1689,O
),1689,O
free-field,1689,O
locomotor,1689,B-Disease
hypoactivity,1689,I-Disease
caused,1689,O
by,1689,O
nicotine,1689,B-Chemical
(,1689,O
0.5,1689,O
mg,1689,O
kg,1689,O
(,1689,O
-1,1689,O
),1689,O
",",1689,O
i.m,1689,O
.,1689,O
),1690,O
",",1690,O
enhanced,1690,O
the,1690,O
later,1690,O
(,1690,O
60-120,1690,O
min,1690,O
),1690,O
nicotine-induced,1690,O
hyperactivity,1690,O
",",1690,O
and,1690,O
raised,1690,O
spontaneous,1690,O
nocturnal,1690,O
activity,1690,O
.,1690,O
Lesions,1691,O
reduced,1691,O
the,1691,O
extent,1691,O
of,1691,O
immunohistological,1691,O
staining,1691,O
for,1691,O
choline,1691,O
acetyltransferase,1691,O
in,1691,O
the,1691,O
interpeduncular,1691,O
nucleus,1691,O
(,1691,O
p,1691,O
<,1691,O
0.025,1691,O
),1691,O
",",1691,O
but,1691,O
not,1691,O
for,1691,O
tyrosine,1691,O
hydroxylase,1691,O
in,1691,O
the,1691,O
surrounding,1691,O
catecholaminergic,1691,O
A10,1691,O
region,1691,O
.,1691,O
We,1692,O
conclude,1692,O
that,1692,O
the,1692,O
interpeduncular,1692,O
nucleus,1692,O
mediates,1692,O
nicotinic,1692,O
depression,1692,O
of,1692,O
locomotor,1692,O
activity,1692,O
and,1692,O
dampens,1692,O
nicotinic,1692,O
arousal,1692,O
mechanisms,1692,O
located,1692,O
elsewhere,1692,O
in,1692,O
the,1692,O
brain,1692,O
.,1692,O
Lithium-associated,1693,B-Chemical
cognitive,1693,B-Disease
and,1693,I-Disease
functional,1693,I-Disease
deficits,1693,I-Disease
reduced,1693,O
by,1693,O
a,1693,O
switch,1693,O
to,1693,O
divalproex,1693,B-Chemical
sodium,1693,I-Chemical
:,1693,O
a,1693,O
case,1693,O
series,1693,O
.,1693,O
BACKGROUND,1694,O
:,1694,O
Lithium,1694,B-Chemical
remains,1694,O
a,1694,O
first-line,1694,O
treatment,1694,O
for,1694,O
the,1694,O
acute,1694,O
and,1694,O
maintenance,1694,O
treatment,1694,O
of,1694,O
bipolar,1694,B-Disease
disorder,1694,I-Disease
.,1694,O
Although,1695,O
much,1695,O
has,1695,O
been,1695,O
written,1695,O
about,1695,O
the,1695,O
management,1695,O
of,1695,O
the,1695,O
more,1695,O
common,1695,O
adverse,1695,O
effects,1695,O
of,1695,O
lithium,1695,B-Chemical
",",1695,O
such,1695,O
as,1695,O
polyuria,1695,B-Disease
and,1695,O
tremor,1695,B-Disease
",",1695,O
more,1695,O
subtle,1695,O
lithium,1695,B-Chemical
side,1695,O
effects,1695,O
such,1695,O
as,1695,O
cognitive,1695,B-Disease
deficits,1695,I-Disease
",",1695,O
loss,1695,B-Disease
of,1695,I-Disease
creativity,1695,I-Disease
",",1695,O
and,1695,O
functional,1695,B-Disease
impairments,1695,I-Disease
remain,1695,O
understudied,1695,O
.,1695,O
This,1696,O
report,1696,O
summarizes,1696,O
our,1696,O
experience,1696,O
in,1696,O
switching,1696,O
bipolar,1696,B-Disease
patients,1696,O
from,1696,O
lithium,1696,B-Chemical
to,1696,O
divalproex,1696,B-Chemical
sodium,1696,I-Chemical
to,1696,O
alleviate,1696,O
such,1696,O
cognitive,1696,B-Disease
and,1696,I-Disease
functional,1696,I-Disease
impairments,1696,I-Disease
.,1696,O
METHOD,1697,O
:,1697,O
Open,1697,O
",",1697,O
case,1697,O
series,1697,O
design,1697,O
.,1697,O
RESULTS,1698,O
:,1698,O
We,1698,O
report,1698,O
seven,1698,O
cases,1698,O
where,1698,O
substitution,1698,O
of,1698,O
lithium,1698,B-Chemical
",",1698,O
either,1698,O
fully,1698,O
or,1698,O
partially,1698,O
",",1698,O
with,1698,O
divalproex,1698,B-Chemical
sodium,1698,I-Chemical
was,1698,O
extremely,1698,O
helpful,1698,O
in,1698,O
reducing,1698,O
the,1698,O
cognitive,1698,B-Disease
",",1698,I-Disease
motivational,1698,I-Disease
",",1698,I-Disease
or,1698,I-Disease
creative,1698,I-Disease
deficits,1698,I-Disease
attributed,1698,O
to,1698,O
lithium,1698,B-Chemical
in,1698,O
our,1698,O
bipolar,1698,B-Disease
patients,1698,O
.,1698,O
CONCLUSION,1699,O
:,1699,O
In,1699,O
this,1699,O
preliminary,1699,O
report,1699,O
",",1699,O
divalproex,1699,B-Chemical
sodium,1699,I-Chemical
was,1699,O
a,1699,O
superior,1699,O
alternative,1699,O
to,1699,O
lithium,1699,B-Chemical
in,1699,O
bipolar,1699,B-Disease
patients,1699,O
experiencing,1699,O
cognitive,1699,B-Disease
deficits,1699,I-Disease
",",1699,O
loss,1699,B-Disease
of,1699,I-Disease
creativity,1699,I-Disease
",",1699,O
and,1699,O
functional,1699,B-Disease
impairments,1699,I-Disease
.,1699,O
Effect,1700,O
of,1700,O
nifedipine,1700,B-Chemical
on,1700,O
renal,1700,O
function,1700,O
in,1700,O
liver,1700,O
transplant,1700,O
recipients,1700,O
receiving,1700,O
tacrolimus,1700,B-Chemical
.,1700,O
The,1701,O
effect,1701,O
of,1701,O
nifedipine,1701,B-Chemical
on,1701,O
renal,1701,O
function,1701,O
in,1701,O
liver,1701,O
transplant,1701,O
recipients,1701,O
who,1701,O
were,1701,O
receiving,1701,O
tacrolimus,1701,B-Chemical
was,1701,O
evaluated,1701,O
between,1701,O
January,1701,O
1992,1701,O
and,1701,O
January,1701,O
1996,1701,O
.,1701,O
Two,1702,O
groups,1702,O
of,1702,O
patients,1702,O
receiving,1702,O
tacrolimus,1702,B-Chemical
were,1702,O
compared,1702,O
over,1702,O
a,1702,O
period,1702,O
of,1702,O
1,1702,O
year,1702,O
",",1702,O
one,1702,O
group,1702,O
comprising,1702,O
hypertensive,1702,B-Disease
patients,1702,O
who,1702,O
were,1702,O
receiving,1702,O
nifedipine,1702,B-Chemical
",",1702,O
and,1702,O
the,1702,O
other,1702,O
comprising,1702,O
nonhypertensive,1702,O
patients,1702,O
not,1702,O
receiving,1702,O
nifedipine,1702,B-Chemical
.,1702,O
The,1703,O
time,1703,O
from,1703,O
transplant,1703,O
to,1703,O
baseline,1703,O
was,1703,O
similar,1703,O
in,1703,O
all,1703,O
patients,1703,O
.,1703,O
Nifedipine,1704,B-Chemical
significantly,1704,O
improved,1704,O
kidney,1704,O
function,1704,O
as,1704,O
indicated,1704,O
by,1704,O
a,1704,O
significant,1704,O
lowering,1704,O
of,1704,O
serum,1704,O
creatinine,1704,B-Chemical
levels,1704,O
at,1704,O
6,1704,O
and,1704,O
12,1704,O
months,1704,O
.,1704,O
The,1705,O
observed,1705,O
positive,1705,O
impact,1705,O
of,1705,O
nifedipine,1705,B-Chemical
on,1705,O
reducing,1705,O
the,1705,O
nephrotoxicity,1705,B-Disease
associated,1705,O
with,1705,O
tacrolimus,1705,B-Chemical
in,1705,O
liver,1705,O
transplant,1705,O
recipients,1705,O
should,1705,O
be,1705,O
an,1705,O
important,1705,O
factor,1705,O
in,1705,O
selecting,1705,O
an,1705,O
agent,1705,O
to,1705,O
treat,1705,O
hypertension,1705,B-Disease
in,1705,O
this,1705,O
population,1705,O
.,1705,O
Magnetic,1706,O
resonance,1706,O
volumetry,1706,O
of,1706,O
the,1706,O
cerebellum,1706,O
in,1706,O
epileptic,1706,B-Disease
patients,1706,O
after,1706,O
phenytoin,1706,B-Chemical
overdosages,1706,B-Disease
.,1706,O
The,1707,O
aim,1707,O
of,1707,O
this,1707,O
study,1707,O
was,1707,O
to,1707,O
evaluate,1707,O
the,1707,O
relationship,1707,O
between,1707,O
phenytoin,1707,B-Chemical
medication,1707,O
and,1707,O
cerebellar,1707,B-Disease
atrophy,1707,I-Disease
in,1707,O
patients,1707,O
who,1707,O
had,1707,O
experienced,1707,O
clinical,1707,O
intoxication,1707,O
.,1707,O
Five,1708,O
females,1708,O
and,1708,O
6,1708,O
males,1708,O
",",1708,O
21-59,1708,O
years,1708,O
of,1708,O
age,1708,O
",",1708,O
were,1708,O
examined,1708,O
with,1708,O
a,1708,O
1.5-T,1708,O
whole-body,1708,O
system,1708,O
using,1708,O
a,1708,O
circular,1708,O
polarized,1708,O
head,1708,O
coil,1708,O
.,1708,O
Conventional,1709,O
spin,1709,O
echo,1709,O
images,1709,O
were,1709,O
acquired,1709,O
in,1709,O
the,1709,O
sagittal,1709,O
and,1709,O
transverse,1709,O
orientation,1709,O
.,1709,O
In,1710,O
addition,1710,O
",",1710,O
we,1710,O
performed,1710,O
a,1710,O
high-resolution,1710,O
3D,1710,O
gradient,1710,O
echo,1710,O
",",1710,O
T1-weighted,1710,O
sequences,1710,O
at,1710,O
a,1710,O
1-mm,1710,O
slice,1710,O
thickness,1710,O
.,1710,O
The,1711,O
images,1711,O
were,1711,O
subsequently,1711,O
processed,1711,O
to,1711,O
obtain,1711,O
volumetric,1711,O
data,1711,O
for,1711,O
the,1711,O
cerebellum,1711,O
.,1711,O
Cerebellar,1712,O
volume,1712,O
for,1712,O
the,1712,O
patient,1712,O
group,1712,O
ranged,1712,O
between,1712,O
67.66,1712,O
and,1712,O
131.08,1712,O
ml,1712,O
(,1712,O
mean,1712,O
108.9,1712,O
ml,1712,O
),1712,O
.,1712,O
In,1713,O
addition,1713,O
3D,1713,O
gradient,1713,O
echo,1713,O
data,1713,O
sets,1713,O
from,1713,O
10,1713,O
healthy,1713,O
male,1713,O
and,1713,O
10,1713,O
healthy,1713,O
female,1713,O
age-matched,1713,O
volunteers,1713,O
were,1713,O
used,1713,O
to,1713,O
compare,1713,O
cerebellar,1713,O
volumes,1713,O
.,1713,O
Using,1714,O
linear,1714,O
regression,1714,O
we,1714,O
found,1714,O
that,1714,O
no,1714,O
correlation,1714,O
exists,1714,O
between,1714,O
seizure,1714,B-Disease
duration,1714,O
",",1714,O
elevation,1714,O
of,1714,O
phenytoin,1714,B-Chemical
serum,1714,O
levels,1714,O
and,1714,O
cerebellar,1714,O
volume,1714,O
.,1714,O
However,1715,O
",",1715,O
multiple,1715,O
regression,1715,O
for,1715,O
the,1715,O
daily,1715,O
dosage,1715,O
",",1715,O
duration,1715,O
of,1715,O
phenytoin,1715,B-Chemical
treatment,1715,O
and,1715,O
cerebellar,1715,O
volume,1715,O
revealed,1715,O
a,1715,O
correlation,1715,O
of,1715,O
these,1715,O
parameters,1715,O
.,1715,O
We,1716,O
conclude,1716,O
that,1716,O
phenytoin,1716,B-Chemical
overdosage,1716,B-Disease
does,1716,O
not,1716,O
necessarily,1716,O
result,1716,O
in,1716,O
cerebellar,1716,B-Disease
atrophy,1716,I-Disease
and,1716,O
it,1716,O
is,1716,O
unlikely,1716,O
that,1716,O
phenytoin,1716,B-Chemical
medication,1716,O
was,1716,O
the,1716,O
only,1716,O
cause,1716,O
of,1716,O
cerebellar,1716,B-Disease
atrophy,1716,I-Disease
in,1716,O
the,1716,O
remaining,1716,O
patients,1716,O
.,1716,O
Quantitative,1717,O
morphometric,1717,O
studies,1717,O
of,1717,O
the,1717,O
cerebellum,1717,O
provide,1717,O
valuable,1717,O
insights,1717,O
into,1717,O
the,1717,O
pathogenesis,1717,O
of,1717,O
cerebellar,1717,B-Disease
disorders,1717,I-Disease
.,1717,O
Morphological,1718,O
features,1718,O
of,1718,O
encephalopathy,1718,B-Disease
after,1718,O
chronic,1718,O
administration,1718,O
of,1718,O
the,1718,O
antiepileptic,1718,O
drug,1718,O
valproate,1718,B-Chemical
to,1718,O
rats,1718,O
.,1718,O
A,1719,O
transmission,1719,O
electron,1719,O
microscopic,1719,O
study,1719,O
of,1719,O
capillaries,1719,O
in,1719,O
the,1719,O
cerebellar,1719,O
cortex,1719,O
.,1719,O
Long-term,1720,O
intragastric,1720,O
application,1720,O
of,1720,O
the,1720,O
antiepileptic,1720,O
drug,1720,O
sodium,1720,B-Chemical
valproate,1720,I-Chemical
(,1720,O
Vupral,1720,O
``,1720,O
Polfa,1720,O
'',1720,O
),1720,O
at,1720,O
the,1720,O
effective,1720,O
dose,1720,O
of,1720,O
200,1720,O
mg/kg,1720,O
b.,1720,O
w.,1720,O
once,1720,O
daily,1720,O
to,1720,O
rats,1720,O
for,1720,O
1,1720,O
",",1720,O
3,1720,O
",",1720,O
6,1720,O
",",1720,O
9,1720,O
and,1720,O
12,1720,O
months,1720,O
revealed,1720,O
neurological,1720,B-Disease
disorders,1720,I-Disease
indicating,1720,O
cerebellum,1720,B-Disease
damage,1720,I-Disease
(,1720,O
``,1720,O
valproate,1720,I-Chemical
encephalopathy,1720,B-Disease
'',1720,O
),1720,O
.,1720,O
The,1721,O
first,1721,O
ultrastructural,1721,O
changes,1721,O
in,1721,O
structural,1721,O
elements,1721,O
of,1721,O
the,1721,O
blood-brain-barrier,1721,O
(,1721,O
BBB,1721,O
),1721,O
in,1721,O
the,1721,O
cerebellar,1721,O
cortex,1721,O
were,1721,O
detectable,1721,O
after,1721,O
3,1721,O
months,1721,O
of,1721,O
the,1721,O
experiment,1721,O
.,1721,O
They,1722,O
became,1722,O
more,1722,O
severe,1722,O
in,1722,O
the,1722,O
later,1722,O
months,1722,O
of,1722,O
the,1722,O
experiment,1722,O
",",1722,O
and,1722,O
were,1722,O
most,1722,O
severe,1722,O
after,1722,O
12,1722,O
months,1722,O
",",1722,O
located,1722,O
mainly,1722,O
in,1722,O
the,1722,O
molecular,1722,O
layer,1722,O
of,1722,O
the,1722,O
cerebellar,1722,O
cortex,1722,O
.,1722,O
Lesions,1723,O
of,1723,O
the,1723,O
capillary,1723,O
included,1723,O
necrosis,1723,B-Disease
of,1723,O
endothelial,1723,O
cells,1723,O
.,1723,O
Organelles,1724,O
of,1724,O
these,1724,O
cells,1724,O
",",1724,O
in,1724,O
particular,1724,O
the,1724,O
mitochondria,1724,O
(,1724,O
increased,1724,O
number,1724,O
and,1724,O
size,1724,O
",",1724,O
distinct,1724,O
degeneration,1724,O
of,1724,O
their,1724,O
matrix,1724,O
and,1724,O
cristae,1724,O
),1724,O
and,1724,O
Golgi,1724,O
apparatus,1724,O
were,1724,O
altered,1724,O
.,1724,O
Reduced,1725,O
size,1725,O
of,1725,O
capillary,1725,O
lumen,1725,O
and,1725,O
occlusion,1725,O
were,1725,O
caused,1725,O
by,1725,O
swollen,1725,O
endothelial,1725,O
cells,1725,O
which,1725,O
had,1725,O
luminal,1725,B-Chemical
protrusions,1725,O
and,1725,O
swollen,1725,O
microvilli,1725,O
.,1725,O
Pressure,1726,O
on,1726,O
the,1726,O
vessel,1726,O
wall,1726,O
was,1726,O
produced,1726,O
by,1726,O
enlarged,1726,O
perivascular,1726,O
astrocytic,1726,O
processes,1726,O
.,1726,O
Fragments,1727,O
of,1727,O
necrotic,1727,B-Disease
endothelial,1727,O
cells,1727,O
were,1727,O
in,1727,O
the,1727,O
vascular,1727,O
lumens,1727,O
and,1727,O
in,1727,O
these,1727,O
there,1727,O
was,1727,O
loosening,1727,O
and,1727,O
breaking,1727,O
of,1727,O
tight,1727,O
cellular,1727,O
junctions,1727,O
.,1727,O
Damage,1728,O
to,1728,O
the,1728,O
vascular,1728,O
basement,1728,O
lamina,1728,O
was,1728,O
also,1728,O
observed,1728,O
.,1728,O
Damage,1729,O
to,1729,O
the,1729,O
capillary,1729,O
was,1729,O
accompanied,1729,O
by,1729,O
marked,1729,O
damage,1729,O
to,1729,O
neuroglial,1729,O
cells,1729,O
",",1729,O
mainly,1729,O
to,1729,O
perivascular,1729,O
processes,1729,O
of,1729,O
astrocytes,1729,O
.,1729,O
The,1730,O
proliferation,1730,O
of,1730,O
astrocytes,1730,O
(,1730,O
Bergmann,1730,O
's,1730,O
in,1730,O
particular,1730,O
),1730,O
and,1730,O
occasionally,1730,O
of,1730,O
oligodendrocytes,1730,O
was,1730,O
found,1730,O
.,1730,O
Alterations,1731,O
in,1731,O
the,1731,O
structural,1731,O
elements,1731,O
of,1731,O
the,1731,O
BBB,1731,O
coexisted,1731,O
with,1731,O
marked,1731,O
lesions,1731,O
of,1731,O
neurons,1731,O
of,1731,O
the,1731,O
cerebellum,1731,O
(,1731,O
Purkinje,1731,O
cells,1731,O
are,1731,O
earliest,1731,O
),1731,O
.,1731,O
In,1732,O
electron,1732,O
micrographs,1732,O
both,1732,O
luminal,1732,B-Chemical
and,1732,O
antiluminal,1732,O
sides,1732,O
of,1732,O
the,1732,O
BBB,1732,O
of,1732,O
the,1732,O
cerebellar,1732,O
cortex,1732,O
had,1732,O
similar,1732,O
lesions,1732,O
.,1732,O
The,1733,O
possible,1733,O
influence,1733,O
of,1733,O
the,1733,O
hepatic,1733,B-Disease
damage,1733,I-Disease
",",1733,O
mainly,1733,O
hyperammonemia,1733,B-Disease
",",1733,O
upon,1733,O
the,1733,O
development,1733,O
of,1733,O
valproate,1733,B-Chemical
encephalopathy,1733,B-Disease
is,1733,O
discussed,1733,O
.,1733,O
Fatal,1734,O
intracranial,1734,B-Disease
bleeding,1734,I-Disease
associated,1734,O
with,1734,O
prehospital,1734,O
use,1734,O
of,1734,O
epinephrine,1734,B-Chemical
.,1734,O
We,1735,O
present,1735,O
a,1735,O
case,1735,O
of,1735,O
paramedic,1735,O
misjudgment,1735,O
in,1735,O
the,1735,O
execution,1735,O
of,1735,O
a,1735,O
protocol,1735,O
for,1735,O
the,1735,O
treatment,1735,O
of,1735,O
allergic,1735,B-Disease
reaction,1735,I-Disease
in,1735,O
a,1735,O
case,1735,O
of,1735,O
pulmonary,1735,B-Disease
edema,1735,I-Disease
with,1735,O
wheezing,1735,B-Disease
.,1735,O
The,1736,O
sudden,1736,O
onset,1736,O
of,1736,O
respiratory,1736,B-Disease
distress,1736,I-Disease
",",1736,O
rash,1736,B-Disease
",",1736,O
and,1736,O
a,1736,O
history,1736,O
of,1736,O
a,1736,O
new,1736,O
medicine,1736,O
led,1736,O
the,1736,O
two,1736,O
paramedics,1736,O
on,1736,O
the,1736,O
scene,1736,O
to,1736,O
administer,1736,O
subcutaneous,1736,O
epinephrine,1736,B-Chemical
.,1736,O
Subsequently,1737,O
",",1737,O
acute,1737,O
cardiac,1737,B-Disease
arrest,1737,I-Disease
and,1737,O
fatal,1737,O
subarachnoid,1737,B-Disease
hemorrhage,1737,I-Disease
occurred,1737,O
.,1737,O
Epinephrine,1738,B-Chemical
has,1738,O
a,1738,O
proven,1738,O
role,1738,O
in,1738,O
cardiac,1738,B-Disease
arrest,1738,I-Disease
in,1738,O
prehospital,1738,O
care,1738,O
;,1738,O
however,1738,O
",",1738,O
use,1738,O
by,1738,O
paramedics,1738,O
in,1738,O
patients,1738,O
with,1738,O
suspected,1738,O
allergic,1738,B-Disease
reaction,1738,I-Disease
and,1738,O
severe,1738,O
hypertension,1738,B-Disease
should,1738,O
be,1738,O
viewed,1738,O
with,1738,O
caution,1738,O
.,1738,O
Role,1739,O
of,1739,O
activation,1739,O
of,1739,O
bradykinin,1739,B-Chemical
B2,1739,O
receptors,1739,O
in,1739,O
disruption,1739,O
of,1739,O
the,1739,O
blood-brain,1739,O
barrier,1739,O
during,1739,O
acute,1739,O
hypertension,1739,B-Disease
.,1739,O
Cellular,1740,O
mechanisms,1740,O
which,1740,O
account,1740,O
for,1740,O
disruption,1740,O
the,1740,O
blood-brain,1740,O
barrier,1740,O
during,1740,O
acute,1740,O
hypertension,1740,B-Disease
are,1740,O
not,1740,O
clear,1740,O
.,1740,O
The,1741,O
goal,1741,O
of,1741,O
this,1741,O
study,1741,O
was,1741,O
to,1741,O
determine,1741,O
the,1741,O
role,1741,O
of,1741,O
synthesis/release,1741,O
of,1741,O
bradykinin,1741,B-Chemical
to,1741,O
activate,1741,O
B2,1741,O
receptors,1741,O
in,1741,O
disruption,1741,O
of,1741,O
the,1741,O
blood-brain,1741,O
barrier,1741,O
during,1741,O
acute,1741,O
hypertension,1741,B-Disease
.,1741,O
Permeability,1742,O
of,1742,O
the,1742,O
blood-brain,1742,O
barrier,1742,O
was,1742,O
quantitated,1742,O
by,1742,O
clearance,1742,O
of,1742,O
fluorescent-labeled,1742,O
dextran,1742,B-Chemical
before,1742,O
and,1742,O
during,1742,O
phenylephrine-induced,1742,B-Chemical
acute,1742,O
hypertension,1742,B-Disease
in,1742,O
rats,1742,O
treated,1742,O
with,1742,O
vehicle,1742,O
and,1742,O
Hoe-140,1742,B-Chemical
(,1742,O
0.1,1742,O
microM,1742,O
),1742,O
.,1742,O
Phenylephrine,1743,B-Chemical
infusion,1743,O
increased,1743,O
arterial,1743,O
pressure,1743,O
",",1743,O
arteriolar,1743,O
diameter,1743,O
and,1743,O
clearance,1743,O
of,1743,O
fluorescent,1743,O
dextran,1743,B-Chemical
by,1743,O
a,1743,O
similar,1743,O
magnitude,1743,O
in,1743,O
both,1743,O
groups,1743,O
.,1743,O
These,1744,O
findings,1744,O
suggest,1744,O
that,1744,O
disruption,1744,O
of,1744,O
the,1744,O
blood-brain,1744,O
barrier,1744,O
during,1744,O
acute,1744,O
hypertension,1744,B-Disease
is,1744,O
not,1744,O
related,1744,O
to,1744,O
the,1744,O
synthesis/release,1744,O
of,1744,O
bradykinin,1744,B-Chemical
to,1744,O
activate,1744,O
B2,1744,O
receptors,1744,O
.,1744,O
Risk,1745,O
factors,1745,O
of,1745,O
sensorineural,1745,B-Disease
hearing,1745,I-Disease
loss,1745,I-Disease
in,1745,O
preterm,1745,O
infants,1745,O
.,1745,O
Among,1746,O
547,1746,O
preterm,1746,O
infants,1746,O
of,1746,O
<,1746,O
or,1746,O
=,1746,O
34,1746,O
weeks,1746,O
gestation,1746,O
born,1746,O
between,1746,O
1987,1746,O
and,1746,O
1991,1746,O
",",1746,O
8,1746,O
children,1746,O
(,1746,O
1.46,1746,O
%,1746,O
),1746,O
developed,1746,O
severe,1746,O
progressive,1746,O
and,1746,O
bilateral,1746,O
sensorineural,1746,B-Disease
hearing,1746,I-Disease
loss,1746,I-Disease
.,1746,O
Perinatal,1747,O
risk,1747,O
factors,1747,O
of,1747,O
infants,1747,O
with,1747,O
hearing,1747,B-Disease
loss,1747,I-Disease
were,1747,O
compared,1747,O
with,1747,O
those,1747,O
of,1747,O
two,1747,O
control,1747,O
groups,1747,O
matched,1747,O
for,1747,O
gestation,1747,O
and,1747,O
birth,1747,O
weight,1747,O
and,1747,O
for,1747,O
perinatal,1747,O
complications,1747,O
.,1747,O
Our,1748,O
observations,1748,O
demonstrated,1748,O
an,1748,O
association,1748,O
of,1748,O
hearing,1748,B-Disease
loss,1748,I-Disease
with,1748,O
a,1748,O
higher,1748,O
incidence,1748,O
of,1748,O
perinatal,1748,O
complications,1748,O
.,1748,O
Ototoxicity,1749,B-Disease
appeared,1749,O
closely,1749,O
related,1749,O
to,1749,O
a,1749,O
prolonged,1749,O
administration,1749,O
and,1749,O
higher,1749,O
total,1749,O
dose,1749,O
of,1749,O
ototoxic,1749,B-Disease
drugs,1749,O
",",1749,O
particularly,1749,O
aminoglycosides,1749,B-Chemical
and,1749,O
furosemide,1749,B-Chemical
.,1749,O
Finally,1750,O
",",1750,O
we,1750,O
strongly,1750,O
recommend,1750,O
to,1750,O
prospectively,1750,O
and,1750,O
regularly,1750,O
perform,1750,O
audiologic,1750,O
assessment,1750,O
in,1750,O
sick,1750,O
preterm,1750,O
children,1750,O
as,1750,O
hearing,1750,B-Disease
loss,1750,I-Disease
is,1750,O
of,1750,O
delayed,1750,O
onset,1750,O
and,1750,O
in,1750,O
most,1750,O
cases,1750,O
bilateral,1750,O
and,1750,O
severe,1750,O
.,1750,O
Seizure,1751,B-Disease
resulting,1751,O
from,1751,O
a,1751,O
venlafaxine,1751,B-Chemical
overdose,1751,B-Disease
.,1751,O
OBJECTIVE,1752,O
:,1752,O
To,1752,O
report,1752,O
a,1752,O
case,1752,O
of,1752,O
venlafaxine,1752,B-Chemical
overdose,1752,B-Disease
.,1752,O
CASE,1753,O
SUMMARY,1753,O
:,1753,O
A,1753,O
40-year-old,1753,O
woman,1753,O
with,1753,O
major,1753,B-Disease
depression,1753,I-Disease
took,1753,O
an,1753,O
overdose,1753,B-Disease
of,1753,O
venlafaxine,1753,B-Chemical
in,1753,O
an,1753,O
apparent,1753,O
suicide,1753,O
attempt,1753,O
.,1753,O
After,1754,O
the,1754,O
ingestion,1754,O
of,1754,O
26,1754,O
venlafaxine,1754,B-Chemical
50-mg,1754,O
tablets,1754,O
",",1754,O
the,1754,O
patient,1754,O
experienced,1754,O
a,1754,O
witnessed,1754,O
generalized,1754,O
seizure,1754,B-Disease
.,1754,O
She,1755,O
was,1755,O
admitted,1755,O
to,1755,O
the,1755,O
medical,1755,O
intensive,1755,O
care,1755,O
unit,1755,O
",",1755,O
venlafaxine,1755,B-Chemical
was,1755,O
discontinued,1755,O
",",1755,O
and,1755,O
no,1755,O
further,1755,O
sequelae,1755,O
were,1755,O
seen,1755,O
.,1755,O
DISCUSSION,1756,O
:,1756,O
To,1756,O
our,1756,O
knowledge,1756,O
",",1756,O
this,1756,O
is,1756,O
the,1756,O
first,1756,O
reported,1756,O
case,1756,O
of,1756,O
venlafaxine,1756,B-Chemical
overdose,1756,B-Disease
that,1756,O
resulted,1756,O
in,1756,O
a,1756,O
generalized,1756,O
seizure,1756,B-Disease
.,1756,O
Based,1757,O
on,1757,O
nonoverdose,1757,O
pharmacokinetics,1757,O
and,1757,O
pharmacodynamics,1757,O
of,1757,O
venlafaxine,1757,B-Chemical
and,1757,O
the,1757,O
potential,1757,O
risks,1757,O
of,1757,O
available,1757,O
interventions,1757,O
",",1757,O
no,1757,O
emergent,1757,O
therapy,1757,O
was,1757,O
instituted,1757,O
.,1757,O
CONCLUSIONS,1758,O
:,1758,O
The,1758,O
venlafaxine,1758,B-Chemical
overdose,1758,B-Disease
in,1758,O
our,1758,O
patient,1758,O
resulted,1758,O
in,1758,O
a,1758,O
single,1758,O
episode,1758,O
of,1758,O
generalized,1758,O
seizure,1758,B-Disease
but,1758,O
elicited,1758,O
no,1758,O
further,1758,O
sequelae,1758,O
.,1758,O
Combined,1759,O
effects,1759,O
of,1759,O
prolonged,1759,O
prostaglandin,1759,B-Chemical
E1-induced,1759,O
hypotension,1759,B-Disease
and,1759,O
haemodilution,1759,B-Disease
on,1759,O
human,1759,O
hepatic,1759,O
function,1759,O
.,1759,O
Combined,1760,O
effects,1760,O
of,1760,O
prolonged,1760,O
prostaglandin,1760,B-Chemical
E1,1760,I-Chemical
(,1760,O
PGE1,1760,B-Chemical
),1760,O
-induced,1760,O
hypotension,1760,B-Disease
and,1760,O
haemodilution,1760,B-Disease
on,1760,O
hepatic,1760,O
function,1760,O
were,1760,O
studied,1760,O
in,1760,O
30,1760,O
patients,1760,O
undergoing,1760,O
hip,1760,O
surgery,1760,O
.,1760,O
The,1761,O
patients,1761,O
were,1761,O
randomly,1761,O
allocated,1761,O
to,1761,O
one,1761,O
of,1761,O
three,1761,O
groups,1761,O
;,1761,O
those,1761,O
in,1761,O
group,1761,O
A,1761,O
(,1761,O
n,1761,O
=,1761,O
10,1761,O
),1761,O
were,1761,O
subjected,1761,O
to,1761,O
controlled,1761,O
hypotension,1761,B-Disease
alone,1761,O
",",1761,O
those,1761,O
in,1761,O
group,1761,O
B,1761,O
(,1761,O
n,1761,O
=,1761,O
10,1761,O
),1761,O
to,1761,O
haemodilution,1761,B-Disease
alone,1761,O
and,1761,O
those,1761,O
in,1761,O
group,1761,O
C,1761,O
(,1761,O
n,1761,O
=,1761,O
10,1761,O
),1761,O
to,1761,O
both,1761,O
controlled,1761,O
hypotension,1761,B-Disease
and,1761,O
haemodilution,1761,B-Disease
.,1761,O
Haemodilution,1762,B-Disease
in,1762,O
groups,1762,O
B,1762,O
and,1762,O
C,1762,O
was,1762,O
produced,1762,O
by,1762,O
withdrawing,1762,O
approximately,1762,O
1000,1762,O
mL,1762,O
of,1762,O
blood,1762,O
and,1762,O
replacing,1762,O
it,1762,O
with,1762,O
the,1762,O
same,1762,O
amount,1762,O
of,1762,O
dextran,1762,B-Chemical
solution,1762,O
",",1762,O
and,1762,O
final,1762,O
haematocrit,1762,O
values,1762,O
were,1762,O
21,1762,O
or,1762,O
22,1762,O
%,1762,O
.,1762,O
Controlled,1763,O
hypotension,1763,B-Disease
in,1763,O
groups,1763,O
A,1763,O
and,1763,O
C,1763,O
was,1763,O
induced,1763,O
with,1763,O
PGE1,1763,B-Chemical
to,1763,O
maintain,1763,O
mean,1763,O
arterial,1763,O
blood,1763,O
pressure,1763,O
at,1763,O
55,1763,O
mmHg,1763,O
for,1763,O
180,1763,O
min,1763,O
.,1763,O
Measurements,1764,O
included,1764,O
arterial,1764,O
ketone,1764,O
body,1764,O
ratio,1764,O
(,1764,O
AKBR,1764,O
",",1764,O
aceto-acetate/3-hydroxybutyrate,1764,B-Chemical
),1764,O
and,1764,O
clinical,1764,O
hepatic,1764,O
function,1764,O
parameters,1764,O
.,1764,O
AKBR,1765,O
and,1765,O
biological,1765,O
hepatic,1765,O
function,1765,O
tests,1765,O
showed,1765,O
no,1765,O
change,1765,O
throughout,1765,O
the,1765,O
time,1765,O
course,1765,O
in,1765,O
groups,1765,O
A,1765,O
and,1765,O
B,1765,O
.,1765,O
In,1766,O
group,1766,O
C,1766,O
",",1766,O
AKBR,1766,O
showed,1766,O
a,1766,O
significant,1766,O
decrease,1766,O
at,1766,O
120,1766,O
min,1766,O
(,1766,O
-40,1766,O
%,1766,O
),1766,O
and,1766,O
at,1766,O
180,1766,O
min,1766,O
(,1766,O
-49,1766,O
%,1766,O
),1766,O
after,1766,O
the,1766,O
start,1766,O
of,1766,O
hypotension,1766,B-Disease
and,1766,O
at,1766,O
60,1766,O
min,1766,O
(,1766,O
-32,1766,O
%,1766,O
),1766,O
after,1766,O
recovery,1766,O
of,1766,O
normotension,1766,O
",",1766,O
and,1766,O
SGOT,1766,O
",",1766,O
SGPT,1766,O
",",1766,O
LDH,1766,O
and,1766,O
total,1766,O
bilirubin,1766,B-Chemical
showed,1766,O
significant,1766,O
increases,1766,O
after,1766,O
operation,1766,O
.,1766,O
The,1767,O
results,1767,O
suggest,1767,O
that,1767,O
a,1767,O
prolonged,1767,O
combination,1767,O
of,1767,O
more,1767,O
than,1767,O
120,1767,O
min,1767,O
of,1767,O
PGE1-induced,1767,B-Chemical
hypotension,1767,B-Disease
and,1767,O
moderate,1767,O
haemodilution,1767,B-Disease
would,1767,O
cause,1767,O
impairment,1767,B-Disease
of,1767,I-Disease
hepatic,1767,I-Disease
function,1767,I-Disease
.,1767,O
Cardiovascular,1768,B-Disease
alterations,1768,I-Disease
in,1768,O
rat,1768,O
fetuses,1768,O
exposed,1768,O
to,1768,O
calcium,1768,B-Chemical
channel,1768,O
blockers,1768,O
.,1768,O
Preclinical,1769,O
toxicologic,1769,O
investigation,1769,O
suggested,1769,O
that,1769,O
a,1769,O
new,1769,O
calcium,1769,B-Chemical
channel,1769,O
blocker,1769,O
",",1769,O
Ro,1769,B-Chemical
40-5967,1769,I-Chemical
",",1769,O
induced,1769,O
cardiovascular,1769,B-Disease
alterations,1769,I-Disease
in,1769,O
rat,1769,O
fetuses,1769,O
exposed,1769,O
to,1769,O
this,1769,O
agent,1769,O
during,1769,O
organogenesis,1769,O
.,1769,O
The,1770,O
present,1770,O
study,1770,O
was,1770,O
designed,1770,O
to,1770,O
investigate,1770,O
the,1770,O
hypothesis,1770,O
that,1770,O
calcium,1770,B-Chemical
channel,1770,O
blockers,1770,O
in,1770,O
general,1770,O
induce,1770,O
cardiovascular,1770,B-Disease
malformations,1770,I-Disease
indicating,1770,O
a,1770,O
pharmacologic,1770,O
class,1770,O
effect,1770,O
.,1770,O
We,1771,O
studied,1771,O
three,1771,O
calcium,1771,B-Chemical
channel,1771,O
blockers,1771,O
of,1771,O
different,1771,O
structure,1771,O
",",1771,O
nifedipine,1771,B-Chemical
",",1771,O
diltiazem,1771,B-Chemical
",",1771,O
and,1771,O
verapamil,1771,B-Chemical
",",1771,O
along,1771,O
with,1771,O
the,1771,O
new,1771,O
agent,1771,O
.,1771,O
Pregnant,1772,O
rats,1772,O
were,1772,O
administered,1772,O
one,1772,O
of,1772,O
these,1772,O
calcium,1772,B-Chemical
channel,1772,O
blockers,1772,O
during,1772,O
the,1772,O
period,1772,O
of,1772,O
cardiac,1772,O
morphogenesis,1772,O
and,1772,O
the,1772,O
offspring,1772,O
examined,1772,O
on,1772,O
day,1772,O
20,1772,O
of,1772,O
gestation,1772,O
for,1772,O
cardiovascular,1772,B-Disease
malformations,1772,I-Disease
.,1772,O
A,1773,O
low,1773,O
incidence,1773,O
of,1773,O
cardiovascular,1773,B-Disease
malformations,1773,I-Disease
was,1773,O
observed,1773,O
after,1773,O
exposure,1773,O
to,1773,O
each,1773,O
of,1773,O
the,1773,O
four,1773,O
calcium,1773,B-Chemical
channel,1773,O
blockers,1773,O
",",1773,O
but,1773,O
this,1773,O
incidence,1773,O
was,1773,O
statistically,1773,O
significant,1773,O
only,1773,O
for,1773,O
verapamil,1773,B-Chemical
and,1773,O
nifedipine,1773,B-Chemical
.,1773,O
All,1774,O
four,1774,O
agents,1774,O
were,1774,O
associated,1774,O
with,1774,O
aortic,1774,O
arch,1774,O
branching,1774,O
variants,1774,O
",",1774,O
although,1774,O
significantly,1774,O
increased,1774,O
only,1774,O
for,1774,O
Ro,1774,B-Chemical
40-5967,1774,I-Chemical
and,1774,O
verapamil,1774,B-Chemical
.,1774,O
The,1775,O
site,1775,O
of,1775,O
common,1775,O
side,1775,O
effects,1775,O
of,1775,O
sumatriptan,1775,B-Chemical
.,1775,O
Atypical,1776,B-Disease
sensations,1776,I-Disease
following,1776,O
the,1776,O
use,1776,O
of,1776,O
subcutaneous,1776,O
sumatriptan,1776,B-Chemical
are,1776,O
common,1776,O
",",1776,O
but,1776,O
of,1776,O
uncertain,1776,O
origin,1776,O
.,1776,O
They,1777,O
are,1777,O
almost,1777,O
always,1777,O
benign,1777,O
",",1777,O
but,1777,O
can,1777,O
be,1777,O
mistaken,1777,O
for,1777,O
a,1777,O
serious,1777,O
adverse,1777,O
event,1777,O
by,1777,O
the,1777,O
patient,1777,O
.,1777,O
Two,1778,O
patients,1778,O
are,1778,O
presented,1778,O
with,1778,O
tingling,1778,B-Disease
or,1778,I-Disease
burning,1778,I-Disease
sensations,1778,I-Disease
limited,1778,O
to,1778,O
areas,1778,O
of,1778,O
heat,1778,O
exposure,1778,O
or,1778,O
sunburn,1778,B-Disease
.,1778,O
In,1779,O
these,1779,O
individuals,1779,O
",",1779,O
side,1779,O
effects,1779,O
are,1779,O
most,1779,O
likely,1779,O
generated,1779,O
superficially,1779,O
in,1779,O
the,1779,O
skin,1779,O
.,1779,O
Macula,1780,O
toxicity,1780,B-Disease
after,1780,O
intravitreal,1780,O
amikacin,1780,B-Chemical
.,1780,O
BACKGROUND,1781,O
:,1781,O
Although,1781,O
intravitreal,1781,O
aminoglycosides,1781,B-Chemical
have,1781,O
substantially,1781,O
improved,1781,O
visual,1781,O
prognosis,1781,O
in,1781,O
endophthalmitis,1781,B-Disease
",",1781,O
macular,1781,O
infarction,1781,B-Disease
may,1781,O
impair,1781,O
full,1781,O
visual,1781,O
recovery,1781,O
.,1781,O
METHODS,1782,O
:,1782,O
We,1782,O
present,1782,O
a,1782,O
case,1782,O
of,1782,O
presumed,1782,O
amikacin,1782,B-Chemical
retinal,1782,B-Disease
toxicity,1782,I-Disease
following,1782,O
treatment,1782,O
with,1782,O
amikacin,1782,B-Chemical
and,1782,O
vancomycin,1782,B-Chemical
for,1782,O
alpha-haemolytic,1782,O
streptococcal,1782,B-Disease
endophthalmitis,1782,I-Disease
.,1782,O
RESULTS,1783,O
:,1783,O
Endophthalmitis,1783,B-Disease
resolved,1783,O
with,1783,O
improvement,1783,O
in,1783,O
visual,1783,O
acuity,1783,O
to,1783,O
6/24,1783,O
at,1783,O
three,1783,O
months,1783,O
.,1783,O
Fundus,1784,O
fluorescein,1784,B-Chemical
angiography,1784,O
confirmed,1784,O
macular,1784,O
capillary,1784,O
closure,1784,O
and,1784,O
telangiectasis,1784,B-Disease
.,1784,O
CONCLUSIONS,1785,O
:,1785,O
Currently,1785,O
accepted,1785,O
intravitreal,1785,O
antibiotic,1785,O
regimens,1785,O
may,1785,O
cause,1785,O
retinal,1785,B-Disease
toxicity,1785,I-Disease
and,1785,O
macular,1785,O
ischaemia,1785,B-Disease
.,1785,O
Treatment,1786,O
strategies,1786,O
aimed,1786,O
at,1786,O
avoiding,1786,O
retinal,1786,B-Disease
toxicity,1786,I-Disease
are,1786,O
discussed,1786,O
.,1786,O
The,1787,O
role,1787,O
of,1787,O
nicotine,1787,B-Chemical
in,1787,O
smoking-related,1787,O
cardiovascular,1787,B-Disease
disease,1787,I-Disease
.,1787,O
Nicotine,1788,B-Chemical
activates,1788,O
the,1788,O
sympathetic,1788,O
nervous,1788,O
system,1788,O
and,1788,O
in,1788,O
this,1788,O
way,1788,O
could,1788,O
contribute,1788,O
to,1788,O
cardiovascular,1788,B-Disease
disease,1788,I-Disease
.,1788,O
Animal,1789,O
studies,1789,O
and,1789,O
mechanistic,1789,O
studies,1789,O
indicate,1789,O
that,1789,O
nicotine,1789,B-Chemical
could,1789,O
play,1789,O
a,1789,O
role,1789,O
in,1789,O
accelerating,1789,O
atherosclerosis,1789,B-Disease
",",1789,O
but,1789,O
evidence,1789,O
among,1789,O
humans,1789,O
is,1789,O
too,1789,O
inadequate,1789,O
to,1789,O
be,1789,O
definitive,1789,O
about,1789,O
such,1789,O
an,1789,O
effect,1789,O
.,1789,O
Almost,1790,O
certainly,1790,O
",",1790,O
nicotine,1790,B-Chemical
via,1790,O
its,1790,O
hemodynamic,1790,O
effects,1790,O
contributes,1790,O
to,1790,O
acute,1790,O
cardiovascular,1790,O
events,1790,O
",",1790,O
although,1790,O
current,1790,O
evidence,1790,O
suggests,1790,O
that,1790,O
the,1790,O
effects,1790,O
of,1790,O
nicotine,1790,B-Chemical
are,1790,O
much,1790,O
less,1790,O
important,1790,O
than,1790,O
are,1790,O
the,1790,O
prothrombotic,1790,O
effects,1790,O
of,1790,O
cigarette,1790,O
smoking,1790,O
or,1790,O
the,1790,O
effects,1790,O
of,1790,O
carbon,1790,B-Chemical
monoxide,1790,I-Chemical
.,1790,O
Nicotine,1791,B-Chemical
does,1791,O
not,1791,O
appear,1791,O
to,1791,O
enhance,1791,O
thrombosis,1791,B-Disease
among,1791,O
humans,1791,O
.,1791,O
Clinical,1792,O
studies,1792,O
of,1792,O
pipe,1792,O
smokers,1792,O
and,1792,O
people,1792,O
using,1792,O
transdermal,1792,O
nicotine,1792,B-Chemical
support,1792,O
the,1792,O
idea,1792,O
that,1792,O
toxins,1792,O
other,1792,O
than,1792,O
nicotine,1792,B-Chemical
are,1792,O
the,1792,O
most,1792,O
important,1792,O
causes,1792,O
of,1792,O
acute,1792,O
cardiovascular,1792,O
events,1792,O
.,1792,O
Finally,1793,O
",",1793,O
the,1793,O
dose,1793,O
response,1793,O
for,1793,O
cardiovascular,1793,O
events,1793,O
of,1793,O
nicotine,1793,B-Chemical
appears,1793,O
to,1793,O
be,1793,O
flat,1793,O
",",1793,O
suggesting,1793,O
that,1793,O
if,1793,O
nicotine,1793,B-Chemical
is,1793,O
involved,1793,O
",",1793,O
adverse,1793,O
effects,1793,O
might,1793,O
be,1793,O
seen,1793,O
with,1793,O
relatively,1793,O
low-level,1793,O
cigarette,1793,O
exposures,1793,O
.,1793,O
Iatrogenically,1794,O
induced,1794,O
intractable,1794,O
atrioventricular,1794,B-Disease
reentrant,1794,I-Disease
tachycardia,1794,I-Disease
after,1794,O
verapamil,1794,B-Chemical
and,1794,O
catheter,1794,O
ablation,1794,O
in,1794,O
a,1794,O
patient,1794,O
with,1794,O
Wolff-Parkinson-White,1794,B-Disease
syndrome,1794,I-Disease
and,1794,O
idiopathic,1794,B-Disease
dilated,1794,I-Disease
cardiomyopathy,1794,I-Disease
.,1794,O
In,1795,O
a,1795,O
patient,1795,O
with,1795,O
WPW,1795,B-Disease
syndrome,1795,I-Disease
and,1795,O
idiopathic,1795,B-Disease
dilated,1795,I-Disease
cardiomyopathy,1795,I-Disease
",",1795,O
intractable,1795,O
atrioventricular,1795,B-Disease
reentrant,1795,I-Disease
tachycardia,1795,I-Disease
(,1795,O
AVRT,1795,B-Disease
),1795,O
was,1795,O
iatrogenically,1795,O
induced,1795,O
.,1795,O
QRS,1796,O
without,1796,O
preexcitation,1796,O
",",1796,O
caused,1796,O
by,1796,O
junctional,1796,O
escape,1796,O
beats,1796,O
after,1796,O
verapamil,1796,B-Chemical
or,1796,O
unidirectional,1796,O
antegrade,1796,O
block,1796,O
of,1796,O
accessory,1796,O
pathway,1796,O
after,1796,O
catheter,1796,O
ablation,1796,O
",",1796,O
established,1796,O
frequent,1796,O
AVRT,1796,B-Disease
attack,1796,O
.,1796,O
Epidemic,1797,O
of,1797,O
liver,1797,B-Disease
disease,1797,I-Disease
caused,1797,O
by,1797,O
hydrochlorofluorocarbons,1797,B-Chemical
used,1797,O
as,1797,O
ozone-sparing,1797,B-Chemical
substitutes,1797,O
of,1797,O
chlorofluorocarbons,1797,B-Chemical
.,1797,O
BACKGROUND,1798,O
:,1798,O
Hydrochlorofluorocarbons,1798,B-Chemical
(,1798,O
HCFCs,1798,B-Chemical
),1798,O
are,1798,O
used,1798,O
increasingly,1798,O
in,1798,O
industry,1798,O
as,1798,O
substitutes,1798,O
for,1798,O
ozone-depleting,1798,B-Chemical
chlorofluorocarbons,1798,B-Chemical
(,1798,O
CFCs,1798,B-Chemical
),1798,O
.,1798,O
Limited,1799,O
studies,1799,O
in,1799,O
animals,1799,O
indicate,1799,O
potential,1799,O
hepatotoxicity,1799,B-Disease
of,1799,O
some,1799,O
of,1799,O
these,1799,O
compounds,1799,O
.,1799,O
We,1800,O
investigated,1800,O
an,1800,O
epidemic,1800,O
of,1800,O
liver,1800,B-Disease
disease,1800,I-Disease
in,1800,O
nine,1800,O
industrial,1800,O
workers,1800,O
who,1800,O
had,1800,O
had,1800,O
repeated,1800,O
accidental,1800,O
exposure,1800,O
to,1800,O
a,1800,O
mixture,1800,O
of,1800,O
"1,1-dichloro-2,2,2-trifluoroethane",1800,B-Chemical
(,1800,O
HCFC,1800,B-Chemical
123,1800,I-Chemical
),1800,O
and,1800,O
"1-chloro-1,2,2,2-tetrafluoroethane",1800,B-Chemical
(,1800,O
HCFC,1800,B-Chemical
124,1800,I-Chemical
),1800,O
.,1800,O
All,1801,O
nine,1801,O
exposed,1801,O
workers,1801,O
were,1801,O
affected,1801,O
to,1801,O
various,1801,O
degrees,1801,O
.,1801,O
Both,1802,O
compounds,1802,O
are,1802,O
metabolised,1802,O
in,1802,O
the,1802,O
same,1802,O
way,1802,O
as,1802,O
"1-bromo-1-chloro-2,2,2-trifluoroethane",1802,B-Chemical
(,1802,O
halothane,1802,B-Chemical
),1802,O
to,1802,O
form,1802,O
reactive,1802,O
trifluoroacetyl,1802,B-Chemical
halide,1802,O
intermediates,1802,O
",",1802,O
which,1802,O
have,1802,O
been,1802,O
implicated,1802,O
in,1802,O
the,1802,O
hepatotoxicity,1802,B-Disease
of,1802,O
halothane,1802,B-Chemical
.,1802,O
We,1803,O
aimed,1803,O
to,1803,O
test,1803,O
whether,1803,O
HCFCs,1803,O
123,1803,O
and,1803,O
124,1803,O
can,1803,O
result,1803,O
in,1803,O
serious,1803,O
liver,1803,B-Disease
disease,1803,I-Disease
.,1803,O
METHODS,1804,O
:,1804,O
For,1804,O
one,1804,O
severely,1804,O
affected,1804,O
worker,1804,O
liver,1804,O
biopsy,1804,O
and,1804,O
immunohistochemical,1804,O
stainings,1804,O
for,1804,O
the,1804,O
presence,1804,O
of,1804,O
trifluoroacetyl,1804,B-Chemical
protein,1804,O
adducts,1804,O
were,1804,O
done,1804,O
.,1804,O
The,1805,O
serum,1805,O
of,1805,O
six,1805,O
affected,1805,O
workers,1805,O
and,1805,O
five,1805,O
controls,1805,O
was,1805,O
tested,1805,O
for,1805,O
autoantibodies,1805,O
that,1805,O
react,1805,O
with,1805,O
human,1805,O
liver,1805,O
cytochrome-P450,1805,O
2E1,1805,O
(,1805,O
P450,1805,O
2E1,1805,O
),1805,O
and,1805,O
P58,1805,O
protein,1805,O
disulphide,1805,O
isomerase,1805,O
isoform,1805,O
(,1805,O
P58,1805,O
),1805,O
.,1805,O
FINDINGS,1806,O
:,1806,O
The,1806,O
liver,1806,O
biopsy,1806,O
sample,1806,O
showed,1806,O
hepatocellular,1806,O
necrosis,1806,B-Disease
which,1806,O
was,1806,O
prominent,1806,O
in,1806,O
perivenular,1806,O
zone,1806,O
three,1806,O
and,1806,O
extended,1806,O
focally,1806,O
from,1806,O
portal,1806,O
tracts,1806,O
to,1806,O
portal,1806,O
tracts,1806,O
and,1806,O
centrilobular,1806,O
areas,1806,O
(,1806,O
bridging,1806,O
necrosis,1806,B-Disease
),1806,O
.,1806,O
Trifluoroacetyl-adducted,1807,B-Chemical
proteins,1807,O
were,1807,O
detected,1807,O
in,1807,O
surviving,1807,O
hepatocytes,1807,O
.,1807,O
Autoantibodies,1808,O
against,1808,O
P450,1808,O
2E1,1808,O
or,1808,O
P58,1808,O
",",1808,O
previously,1808,O
associated,1808,O
with,1808,O
halothane,1808,B-Disease
hepatitis,1808,I-Disease
",",1808,O
were,1808,O
detected,1808,O
in,1808,O
the,1808,O
serum,1808,O
of,1808,O
five,1808,O
affected,1808,O
workers,1808,O
.,1808,O
INTERPRETATION,1809,O
:,1809,O
Repeated,1809,O
exposure,1809,O
of,1809,O
human,1809,O
beings,1809,O
to,1809,O
HCFCs,1809,O
123,1809,O
and,1809,O
124,1809,O
can,1809,O
result,1809,O
in,1809,O
serious,1809,O
liver,1809,B-Disease
injury,1809,I-Disease
in,1809,O
a,1809,O
large,1809,O
proportion,1809,O
of,1809,O
the,1809,O
exposed,1809,O
population,1809,O
.,1809,O
Although,1810,O
the,1810,O
exact,1810,O
mechanism,1810,O
of,1810,O
hepatotoxicity,1810,B-Disease
of,1810,O
these,1810,O
agents,1810,O
is,1810,O
not,1810,O
known,1810,O
",",1810,O
the,1810,O
results,1810,O
suggest,1810,O
that,1810,O
trifluoroacetyl-altered,1810,B-Chemical
liver,1810,O
proteins,1810,O
are,1810,O
involved,1810,O
.,1810,O
In,1811,O
view,1811,O
of,1811,O
the,1811,O
potentially,1811,O
widespread,1811,O
use,1811,O
of,1811,O
these,1811,O
compounds,1811,O
",",1811,O
there,1811,O
is,1811,O
an,1811,O
urgent,1811,O
need,1811,O
to,1811,O
develop,1811,O
safer,1811,O
alternatives,1811,O
.,1811,O
Bile,1812,O
duct,1812,O
hamartoma,1812,O
occurring,1812,O
in,1812,O
association,1812,O
with,1812,O
long-term,1812,O
treatment,1812,O
with,1812,O
danazol,1812,B-Chemical
.,1812,O
We,1813,O
report,1813,O
a,1813,O
case,1813,O
of,1813,O
bile,1813,O
duct,1813,O
hamartoma,1813,O
which,1813,O
developed,1813,O
in,1813,O
a,1813,O
patient,1813,O
who,1813,O
had,1813,O
been,1813,O
on,1813,O
long-term,1813,O
danazol,1813,B-Chemical
treatment,1813,O
.,1813,O
Such,1814,O
patients,1814,O
should,1814,O
be,1814,O
under,1814,O
close,1814,O
follow-up,1814,O
",",1814,O
preferably,1814,O
with,1814,O
periodic,1814,O
ultrasound,1814,O
examination,1814,O
of,1814,O
the,1814,O
liver,1814,O
.,1814,O
If,1815,O
the,1815,O
patient,1815,O
develops,1815,O
a,1815,O
liver,1815,B-Disease
mass,1815,I-Disease
",",1815,O
because,1815,O
of,1815,O
non-specific,1815,O
clinical,1815,O
features,1815,O
and,1815,O
imaging,1815,O
appearances,1815,O
",",1815,O
biopsy,1815,O
may,1815,O
be,1815,O
the,1815,O
only,1815,O
way,1815,O
to,1815,O
achieve,1815,O
a,1815,O
definitive,1815,O
diagnosis,1815,O
.,1815,O
Endocrine,1816,O
screening,1816,O
in,1816,O
"1,022",1816,O
men,1816,O
with,1816,O
erectile,1816,B-Disease
dysfunction,1816,I-Disease
:,1816,O
clinical,1816,O
significance,1816,O
and,1816,O
cost-effective,1816,O
strategy,1816,O
.,1816,O
PURPOSE,1817,O
:,1817,O
We,1817,O
reviewed,1817,O
the,1817,O
results,1817,O
of,1817,O
serum,1817,O
testosterone,1817,B-Chemical
and,1817,O
prolactin,1817,O
determination,1817,O
in,1817,O
"1,022",1817,O
patients,1817,O
referred,1817,O
because,1817,O
of,1817,O
erectile,1817,B-Disease
dysfunction,1817,I-Disease
and,1817,O
compared,1817,O
the,1817,O
data,1817,O
with,1817,O
history,1817,O
",",1817,O
results,1817,O
of,1817,O
physical,1817,O
examination,1817,O
",",1817,O
other,1817,O
etiological,1817,O
investigations,1817,O
and,1817,O
effects,1817,O
of,1817,O
endocrine,1817,O
therapy,1817,O
to,1817,O
refine,1817,O
the,1817,O
rules,1817,O
of,1817,O
cost-effective,1817,O
endocrine,1817,O
screening,1817,O
and,1817,O
to,1817,O
pinpoint,1817,O
actual,1817,O
responsibility,1817,O
for,1817,O
hormonal,1817,O
abnormalities,1817,O
.,1817,O
MATERIALS,1818,O
AND,1818,O
METHODS,1818,O
:,1818,O
Testosterone,1818,B-Chemical
and,1818,O
prolactin,1818,O
were,1818,O
determined,1818,O
by,1818,O
radioimmunoassay,1818,O
.,1818,O
Every,1819,O
patient,1819,O
was,1819,O
screened,1819,O
for,1819,O
testosterone,1819,B-Chemical
and,1819,O
451,1819,O
were,1819,O
screened,1819,O
for,1819,O
prolactin,1819,O
on,1819,O
the,1819,O
basis,1819,O
of,1819,O
low,1819,B-Disease
sexual,1819,I-Disease
desire,1819,I-Disease
",",1819,O
gynecomastia,1819,B-Disease
or,1819,O
testosterone,1819,B-Chemical
less,1819,O
than,1819,O
4,1819,O
ng./ml,1819,O
.,1819,O
Determination,1820,O
was,1820,O
repeated,1820,O
in,1820,O
case,1820,O
of,1820,O
abnormal,1820,O
first,1820,O
results,1820,O
.,1820,O
Prolactin,1821,O
results,1821,O
were,1821,O
compared,1821,O
with,1821,O
those,1821,O
of,1821,O
a,1821,O
previous,1821,O
personal,1821,O
cohort,1821,O
of,1821,O
"1,340",1821,O
patients,1821,O
with,1821,O
erectile,1821,B-Disease
dysfunction,1821,I-Disease
and,1821,O
systematic,1821,O
prolactin,1821,O
determination,1821,O
.,1821,O
Main,1822,O
clinical,1822,O
criteria,1822,O
tested,1822,O
regarding,1822,O
efficiency,1822,O
in,1822,O
hormone,1822,O
determination,1822,O
were,1822,O
low,1822,B-Disease
sexual,1822,I-Disease
desire,1822,I-Disease
",",1822,O
small,1822,O
testes,1822,O
and,1822,O
gynecomastia,1822,B-Disease
.,1822,O
Endocrine,1823,O
therapy,1823,O
consisted,1823,O
of,1823,O
testosterone,1823,B-Chemical
heptylate,1823,I-Chemical
or,1823,O
human,1823,O
chorionic,1823,O
gonadotropin,1823,O
for,1823,O
hypogonadism,1823,B-Disease
and,1823,O
bromocriptine,1823,B-Chemical
for,1823,O
hyperprolactinemia,1823,B-Disease
.,1823,O
RESULTS,1824,O
:,1824,O
Testosterone,1824,B-Chemical
was,1824,O
less,1824,O
than,1824,O
3,1824,O
ng./ml,1824,O
.,1824,O
in,1825,O
107,1825,O
patients,1825,O
but,1825,O
normal,1825,O
in,1825,O
40,1825,O
%,1825,O
at,1825,O
repeat,1825,O
determination,1825,O
.,1825,O
The,1826,O
prevalence,1826,O
of,1826,O
repeatedly,1826,O
low,1826,O
testosterone,1826,B-Chemical
increased,1826,O
with,1826,O
age,1826,O
(,1826,O
4,1826,O
%,1826,O
before,1826,O
age,1826,O
50,1826,O
years,1826,O
and,1826,O
9,1826,O
%,1826,O
50,1826,O
years,1826,O
or,1826,O
older,1826,O
),1826,O
.,1826,O
Two,1827,O
pituitary,1827,B-Disease
tumors,1827,I-Disease
were,1827,O
discovered,1827,O
after,1827,O
testosterone,1827,B-Chemical
determination,1827,O
.,1827,O
Most,1828,O
of,1828,O
the,1828,O
other,1828,O
low,1828,O
testosterone,1828,B-Chemical
levels,1828,O
seemed,1828,O
to,1828,O
result,1828,O
from,1828,O
nonorganic,1828,O
hypothalamic,1828,B-Disease
dysfunction,1828,I-Disease
because,1828,O
of,1828,O
normal,1828,O
serum,1828,O
luteinizing,1828,O
hormone,1828,O
and,1828,O
prolactin,1828,O
and,1828,O
to,1828,O
have,1828,O
only,1828,O
a,1828,O
small,1828,O
role,1828,O
in,1828,O
erectile,1828,B-Disease
dysfunction,1828,I-Disease
(,1828,O
definite,1828,O
improvement,1828,O
in,1828,O
only,1828,O
16,1828,O
of,1828,O
44,1828,O
[,1828,O
36,1828,O
%,1828,O
],1828,O
after,1828,O
androgen,1828,O
therapy,1828,O
",",1828,O
normal,1828,O
morning,1828,O
or,1828,O
nocturnal,1828,O
erections,1828,O
in,1828,O
30,1828,O
%,1828,O
and,1828,O
definite,1828,O
vasculogenic,1828,O
contributions,1828,O
in,1828,O
42,1828,O
%,1828,O
),1828,O
.,1828,O
Determining,1829,O
testosterone,1829,B-Chemical
only,1829,O
in,1829,O
cases,1829,O
of,1829,O
low,1829,B-Disease
sexual,1829,I-Disease
desire,1829,I-Disease
or,1829,O
abnormal,1829,O
physical,1829,O
examination,1829,O
would,1829,O
have,1829,O
missed,1829,O
40,1829,O
%,1829,O
of,1829,O
the,1829,O
cases,1829,O
with,1829,O
low,1829,O
testosterone,1829,B-Chemical
",",1829,O
including,1829,O
37,1829,O
%,1829,O
of,1829,O
those,1829,O
subsequently,1829,O
improved,1829,O
by,1829,O
androgen,1829,O
therapy,1829,O
.,1829,O
Prolactin,1830,O
exceeded,1830,O
20,1830,O
ng./ml,1830,O
.,1830,O
in,1831,O
5,1831,O
men,1831,O
and,1831,O
was,1831,O
normal,1831,O
in,1831,O
2,1831,O
at,1831,O
repeat,1831,O
determination,1831,O
.,1831,O
Only,1832,O
1,1832,O
prolactinoma,1832,B-Disease
was,1832,O
discovered,1832,O
.,1832,O
These,1833,O
data,1833,O
are,1833,O
lower,1833,O
than,1833,O
those,1833,O
we,1833,O
found,1833,O
during,1833,O
the,1833,O
last,1833,O
2,1833,O
decades,1833,O
(,1833,O
overall,1833,O
prolactin,1833,O
greater,1833,O
than,1833,O
20,1833,O
ng./ml,1833,O
.,1833,O
in,1834,O
1.86,1834,O
%,1834,O
of,1834,O
"1,821",1834,O
patients,1834,O
",",1834,O
prolactinomas,1834,B-Disease
in,1834,O
7,1834,O
",",1834,O
0.38,1834,O
%,1834,O
),1834,O
.,1834,O
Bromocriptine,1835,B-Chemical
was,1835,O
definitely,1835,O
effective,1835,O
in,1835,O
cases,1835,O
with,1835,O
prolactin,1835,O
greater,1835,O
than,1835,O
35,1835,O
ng./ml,1835,O
.,1835,O
(,1836,O
8,1836,O
of,1836,O
12,1836,O
compared,1836,O
to,1836,O
only,1836,O
9,1836,O
of,1836,O
22,1836,O
cases,1836,O
with,1836,O
prolactin,1836,O
between,1836,O
20,1836,O
and,1836,O
35,1836,O
ng./ml,1836,O
.,1836,O
),1836,O
.,1836,O
Testosterone,1837,B-Chemical
was,1837,O
low,1837,O
in,1837,O
less,1837,O
than,1837,O
50,1837,O
%,1837,O
of,1837,O
cases,1837,O
with,1837,O
prolactin,1837,O
greater,1837,O
than,1837,O
35,1837,O
ng./ml,1837,O
.,1837,O
CONCLUSIONS,1838,O
:,1838,O
Low,1838,O
prevalences,1838,O
and,1838,O
effects,1838,O
of,1838,O
low,1838,O
testosterone,1838,B-Chemical
and,1838,O
high,1838,O
prolactin,1838,O
in,1838,O
erectile,1838,B-Disease
dysfunction,1838,I-Disease
can,1838,O
not,1838,O
justify,1838,O
their,1838,O
routine,1838,O
determination,1838,O
.,1838,O
However,1839,O
",",1839,O
cost-effective,1839,O
screening,1839,O
strategies,1839,O
recommended,1839,O
so,1839,O
far,1839,O
missed,1839,O
40,1839,O
to,1839,O
50,1839,O
%,1839,O
of,1839,O
cases,1839,O
improved,1839,O
with,1839,O
endocrine,1839,O
therapy,1839,O
and,1839,O
the,1839,O
pituitary,1839,B-Disease
tumors,1839,I-Disease
.,1839,O
We,1840,O
now,1840,O
advocate,1840,O
that,1840,O
before,1840,O
age,1840,O
50,1840,O
years,1840,O
testosterone,1840,B-Chemical
be,1840,O
determined,1840,O
only,1840,O
in,1840,O
cases,1840,O
of,1840,O
low,1840,B-Disease
sexual,1840,I-Disease
desire,1840,I-Disease
and,1840,O
abnormal,1840,O
physical,1840,O
examination,1840,O
but,1840,O
that,1840,O
it,1840,O
be,1840,O
measured,1840,O
in,1840,O
all,1840,O
men,1840,O
older,1840,O
than,1840,O
50,1840,O
years,1840,O
.,1840,O
Prolactin,1841,O
should,1841,O
be,1841,O
determined,1841,O
only,1841,O
in,1841,O
cases,1841,O
of,1841,O
low,1841,B-Disease
sexual,1841,I-Disease
desire,1841,I-Disease
",",1841,O
gynecomastia,1841,B-Disease
and/or,1841,O
testosterone,1841,B-Chemical
less,1841,O
than,1841,O
4,1841,O
ng./ml,1841,O
.,1841,O
Extrapyramidal,1842,O
side,1842,O
effects,1842,O
with,1842,O
risperidone,1842,B-Chemical
and,1842,O
haloperidol,1842,B-Chemical
at,1842,O
comparable,1842,O
D2,1842,O
receptor,1842,O
occupancy,1842,O
levels,1842,O
.,1842,O
Risperidone,1843,B-Chemical
is,1843,O
an,1843,O
antipsychotic,1843,O
drug,1843,O
with,1843,O
high,1843,O
affinity,1843,O
at,1843,O
dopamine,1843,B-Chemical
D2,1843,O
and,1843,O
serotonin,1843,B-Chemical
5-HT2,1843,I-Chemical
receptors,1843,O
.,1843,O
Previous,1844,O
clinical,1844,O
studies,1844,O
have,1844,O
proposed,1844,O
that,1844,O
risperidone,1844,B-Chemical
's,1844,O
pharmacologic,1844,O
profile,1844,O
may,1844,O
produce,1844,O
improved,1844,O
efficacy,1844,O
for,1844,O
negative,1844,O
psychotic,1844,B-Disease
symptoms,1844,I-Disease
and,1844,O
decreased,1844,O
propensity,1844,O
for,1844,O
extrapyramidal,1844,O
side,1844,O
effects,1844,O
;,1844,O
features,1844,O
shared,1844,O
by,1844,O
so-called,1844,O
'atypical,1844,O
',1844,O
neuroleptics,1844,O
.,1844,O
To,1845,O
determine,1845,O
if,1845,O
routine,1845,O
risperidone,1845,B-Chemical
treatment,1845,O
is,1845,O
associated,1845,O
with,1845,O
a,1845,O
unique,1845,O
degree,1845,O
of,1845,O
D2,1845,O
receptor,1845,O
occupancy,1845,O
and,1845,O
pattern,1845,O
of,1845,O
clinical,1845,O
effects,1845,O
",",1845,O
we,1845,O
used,1845,O
[,1845,O
123I,1845,O
],1845,O
IBZM,1845,O
SPECT,1845,O
to,1845,O
determine,1845,O
D2,1845,O
occupancy,1845,O
in,1845,O
subjects,1845,O
treated,1845,O
with,1845,O
routine,1845,O
clinical,1845,O
doses,1845,O
of,1845,O
risperidone,1845,B-Chemical
(,1845,O
n,1845,O
=,1845,O
12,1845,O
),1845,O
or,1845,O
haloperidol,1845,B-Chemical
(,1845,O
n,1845,O
=,1845,O
7,1845,O
),1845,O
.,1845,O
Both,1846,O
risperidone,1846,B-Chemical
and,1846,O
haloperidol,1846,B-Chemical
produced,1846,O
D2,1846,O
occupancy,1846,O
levels,1846,O
between,1846,O
approximately,1846,O
60,1846,O
and,1846,O
90,1846,O
%,1846,O
at,1846,O
standard,1846,O
clinical,1846,O
doses,1846,O
.,1846,O
There,1847,O
was,1847,O
no,1847,O
significant,1847,O
difference,1847,O
between,1847,O
occupancy,1847,O
levels,1847,O
obtained,1847,O
with,1847,O
haloperidol,1847,B-Chemical
or,1847,O
risperidone,1847,B-Chemical
.,1847,O
Drug-induced,1848,B-Disease
parkinsonism,1848,I-Disease
was,1848,O
observed,1848,O
in,1848,O
subjects,1848,O
treated,1848,O
with,1848,O
risperidone,1848,B-Chemical
(,1848,O
42,1848,O
%,1848,O
),1848,O
and,1848,O
haloperidol,1848,B-Chemical
(,1848,O
29,1848,O
%,1848,O
),1848,O
and,1848,O
was,1848,O
observed,1848,O
at,1848,O
occupancy,1848,O
levels,1848,O
above,1848,O
60,1848,O
%,1848,O
.,1848,O
Based,1849,O
on,1849,O
these,1849,O
observations,1849,O
",",1849,O
it,1849,O
is,1849,O
concluded,1849,O
that,1849,O
5-HT2,1849,O
blockade,1849,O
obtained,1849,O
with,1849,O
risperidone,1849,B-Chemical
at,1849,O
D2,1849,O
occupancy,1849,O
rates,1849,O
of,1849,O
60,1849,O
%,1849,O
and,1849,O
above,1849,O
does,1849,O
not,1849,O
appear,1849,O
to,1849,O
protect,1849,O
against,1849,O
the,1849,O
risk,1849,O
for,1849,O
extrapyramidal,1849,O
side,1849,O
effects,1849,O
.,1849,O
Treatment,1850,O
of,1850,O
previously,1850,O
treated,1850,O
metastatic,1850,O
breast,1850,B-Disease
cancer,1850,I-Disease
by,1850,O
mitoxantrone,1850,B-Chemical
and,1850,O
48-hour,1850,O
continuous,1850,O
infusion,1850,O
of,1850,O
high-dose,1850,O
5-FU,1850,B-Chemical
and,1850,O
leucovorin,1850,B-Chemical
(,1850,O
MFL,1850,B-Chemical
),1850,O
:,1850,O
low,1850,O
palliative,1850,O
benefit,1850,O
and,1850,O
high,1850,O
treatment-related,1850,O
toxicity,1850,B-Disease
.,1850,O
For,1851,O
previously,1851,O
treated,1851,O
advanced,1851,O
breast,1851,B-Disease
cancer,1851,I-Disease
",",1851,O
there,1851,O
is,1851,O
no,1851,O
standard,1851,O
second-line,1851,O
therapy,1851,O
.,1851,O
Combination,1852,O
chemotherapy,1852,O
with,1852,O
mitoxantrone,1852,B-Chemical
",",1852,O
high-dose,1852,O
5-fluorouracil,1852,B-Chemical
(,1852,O
5-FU,1852,B-Chemical
),1852,O
and,1852,O
leucovorin,1852,B-Chemical
(,1852,O
MFL,1852,B-Chemical
regimen,1852,I-Chemical
),1852,O
had,1852,O
been,1852,O
reported,1852,O
as,1852,O
an,1852,O
effective,1852,O
and,1852,O
well,1852,O
tolerated,1852,O
regimen,1852,O
.,1852,O
From,1853,O
October,1853,O
1993,1853,O
to,1853,O
November,1853,O
1995,1853,O
",",1853,O
we,1853,O
treated,1853,O
13,1853,O
patients,1853,O
with,1853,O
previously,1853,O
chemotherapy-treated,1853,O
metastatic,1853,O
breast,1853,B-Disease
cancer,1853,I-Disease
by,1853,O
mitoxantrone,1853,B-Chemical
",",1853,O
12,1853,O
mg/m2,1853,O
",",1853,O
on,1853,O
day,1853,O
1,1853,O
and,1853,O
continuous,1853,O
infusion,1853,O
of,1853,O
5-FU,1853,B-Chemical
",",1853,O
3000,1853,O
mg/m2,1853,O
",",1853,O
together,1853,O
with,1853,O
leucovorin,1853,B-Chemical
",",1853,O
300,1853,O
mg/m2,1853,O
",",1853,O
for,1853,O
48,1853,O
h,1853,O
from,1853,O
day,1853,O
1,1853,O
to,1853,O
2,1853,O
.,1853,O
Each,1854,O
course,1854,O
of,1854,O
chemotherapy,1854,O
was,1854,O
given,1854,O
every,1854,O
4,1854,O
weeks,1854,O
.,1854,O
Most,1855,O
of,1855,O
these,1855,O
patients,1855,O
had,1855,O
more,1855,O
than,1855,O
two,1855,O
metastatic,1855,O
sites,1855,O
",",1855,O
with,1855,O
lung,1855,O
metastasis,1855,O
predominant,1855,O
.,1855,O
Seven,1856,O
patients,1856,O
had,1856,O
been,1856,O
treated,1856,O
with,1856,O
anthracycline,1856,B-Chemical
.,1856,O
Seven,1857,O
patients,1857,O
had,1857,O
previously,1857,O
received,1857,O
radiotherapy,1857,O
and,1857,O
seven,1857,O
had,1857,O
received,1857,O
hormone,1857,O
therapy,1857,O
.,1857,O
Median,1858,O
number,1858,O
of,1858,O
courses,1858,O
of,1858,O
MFL,1858,B-Chemical
regimen,1858,I-Chemical
given,1858,O
was,1858,O
six,1858,O
and,1858,O
the,1858,O
median,1858,O
cumulative,1858,O
dose,1858,O
of,1858,O
mitoxantrone,1858,B-Chemical
was,1858,O
68.35,1858,O
mg/m2,1858,O
.,1858,O
One,1859,O
patient,1859,O
had,1859,O
complete,1859,O
response,1859,O
",",1859,O
seven,1859,O
had,1859,O
stable,1859,O
disease,1859,O
",",1859,O
none,1859,O
had,1859,O
partial,1859,O
response,1859,O
and,1859,O
five,1859,O
had,1859,O
progressive,1859,O
disease,1859,O
.,1859,O
The,1860,O
overall,1860,O
objective,1860,O
response,1860,O
rate,1860,O
was,1860,O
7.6,1860,O
%,1860,O
.,1860,O
The,1861,O
median,1861,O
follow-up,1861,O
period,1861,O
was,1861,O
14,1861,O
months,1861,O
.,1861,O
Median,1862,O
survival,1862,O
was,1862,O
16,1862,O
months,1862,O
.,1862,O
Median,1863,O
progression-free,1863,O
survival,1863,O
was,1863,O
5,1863,O
months,1863,O
.,1863,O
A,1864,O
complete,1864,O
responder,1864,O
had,1864,O
relapse-free,1864,O
survival,1864,O
up,1864,O
to,1864,O
17,1864,O
months,1864,O
.,1864,O
Major,1865,O
toxicities,1865,B-Disease
were,1865,O
cardiotoxicity,1865,B-Disease
and,1865,O
leukopenia,1865,B-Disease
.,1865,O
Eight,1866,O
patients,1866,O
were,1866,O
dead,1866,O
in,1866,O
the,1866,O
last,1866,O
follow-up,1866,O
;,1866,O
two,1866,O
of,1866,O
them,1866,O
died,1866,O
of,1866,O
treatment-related,1866,O
toxicity,1866,B-Disease
.,1866,O
The,1867,O
MFL,1867,B-Chemical
regimen,1867,I-Chemical
achieves,1867,O
little,1867,O
palliative,1867,O
benefit,1867,O
and,1867,O
induces,1867,O
severe,1867,O
toxicity,1867,B-Disease
at,1867,O
a,1867,O
fairly,1867,O
high,1867,O
rate,1867,O
.,1867,O
Administration,1868,O
of,1868,O
this,1868,O
regimen,1868,O
to,1868,O
breast,1868,B-Disease
cancer,1868,I-Disease
patients,1868,O
who,1868,O
have,1868,O
been,1868,O
treated,1868,O
by,1868,O
chemotherapy,1868,O
and,1868,O
those,1868,O
with,1868,O
impaired,1868,B-Disease
heart,1868,I-Disease
function,1868,I-Disease
requires,1868,O
careful,1868,O
attention,1868,O
.,1868,O
Ticlopidine-induced,1869,B-Chemical
aplastic,1869,B-Disease
anemia,1869,I-Disease
:,1869,O
report,1869,O
of,1869,O
three,1869,O
Chinese,1869,O
patients,1869,O
and,1869,O
review,1869,O
of,1869,O
the,1869,O
literature,1869,O
.,1869,O
In,1870,O
this,1870,O
study,1870,O
",",1870,O
three,1870,O
Chinese,1870,O
patients,1870,O
with,1870,O
ticlopidine-induced,1870,B-Chemical
aplastic,1870,B-Disease
anemia,1870,I-Disease
were,1870,O
reported,1870,O
and,1870,O
another,1870,O
13,1870,O
patients,1870,O
in,1870,O
the,1870,O
English,1870,O
literature,1870,O
were,1870,O
reviewed,1870,O
.,1870,O
We,1871,O
attempted,1871,O
to,1871,O
find,1871,O
underlying,1871,O
similarities,1871,O
",",1871,O
evaluate,1871,O
the,1871,O
risk,1871,O
factors,1871,O
",",1871,O
and,1871,O
identify,1871,O
appropriate,1871,O
treatment,1871,O
for,1871,O
this,1871,O
complication,1871,O
.,1871,O
All,1872,O
but,1872,O
one,1872,O
of,1872,O
the,1872,O
patients,1872,O
were,1872,O
over,1872,O
60,1872,O
years,1872,O
old,1872,O
",",1872,O
and,1872,O
the,1872,O
6,1872,O
who,1872,O
died,1872,O
were,1872,O
all,1872,O
older,1872,O
than,1872,O
65,1872,O
.,1872,O
Therefore,1873,O
",",1873,O
old,1873,O
age,1873,O
may,1873,O
be,1873,O
a,1873,O
risk,1873,O
factor,1873,O
for,1873,O
developing,1873,O
this,1873,O
complication,1873,O
.,1873,O
Agranulocytosis,1874,B-Disease
occurred,1874,O
3-20,1874,O
weeks,1874,O
after,1874,O
initiation,1874,O
of,1874,O
ticlopidine,1874,B-Chemical
",",1874,O
so,1874,O
frequent,1874,O
examination,1874,O
of,1874,O
white,1874,O
cell,1874,O
count,1874,O
during,1874,O
treatment,1874,O
is,1874,O
recommended,1874,O
.,1874,O
There,1875,O
seemed,1875,O
to,1875,O
be,1875,O
no,1875,O
direct,1875,O
correlation,1875,O
between,1875,O
the,1875,O
dose,1875,O
or,1875,O
duration,1875,O
used,1875,O
and,1875,O
the,1875,O
severity,1875,O
of,1875,O
bone,1875,B-Disease
marrow,1875,I-Disease
suppression,1875,I-Disease
.,1875,O
Treatment,1876,O
for,1876,O
ticlopidine-induced,1876,B-Chemical
aplastic,1876,B-Disease
anemia,1876,I-Disease
with,1876,O
colony-stimulating,1876,O
factors,1876,O
seemed,1876,O
to,1876,O
have,1876,O
little,1876,O
effect,1876,O
.,1876,O
The,1877,O
fact,1877,O
that,1877,O
5,1877,O
of,1877,O
the,1877,O
6,1877,O
patients,1877,O
who,1877,O
received,1877,O
concurrent,1877,O
calcium,1877,B-Chemical
channel,1877,O
blockers,1877,O
died,1877,O
",",1877,O
should,1877,O
alert,1877,O
clinicians,1877,O
to,1877,O
be,1877,O
more,1877,O
cautious,1877,O
when,1877,O
using,1877,O
these,1877,O
two,1877,O
drugs,1877,O
simultaneously,1877,O
.,1877,O
Upregulation,1878,O
of,1878,O
the,1878,O
expression,1878,O
of,1878,O
vasopressin,1878,B-Chemical
gene,1878,O
in,1878,O
the,1878,O
paraventricular,1878,O
and,1878,O
supraoptic,1878,O
nuclei,1878,O
of,1878,O
the,1878,O
lithium-induced,1878,B-Chemical
diabetes,1878,B-Disease
insipidus,1878,I-Disease
rat,1878,O
.,1878,O
The,1879,O
expression,1879,O
of,1879,O
arginine,1879,B-Chemical
vasopressin,1879,I-Chemical
(,1879,O
AVP,1879,B-Chemical
),1879,O
gene,1879,O
in,1879,O
the,1879,O
paraventricular,1879,O
(,1879,O
PVN,1879,O
),1879,O
and,1879,O
supraoptic,1879,O
nuclei,1879,O
(,1879,O
SON,1879,O
),1879,O
was,1879,O
investigated,1879,O
in,1879,O
rats,1879,O
with,1879,O
lithium,1879,B-Chemical
(,1879,O
Li,1879,B-Chemical
),1879,O
-induced,1879,O
polyuria,1879,B-Disease
",",1879,O
using,1879,O
in,1879,O
situ,1879,O
hybridization,1879,O
histochemistry,1879,O
and,1879,O
radioimmunoassay,1879,O
.,1879,O
The,1880,O
male,1880,O
Wistar,1880,O
rats,1880,O
consuming,1880,O
a,1880,O
diet,1880,O
that,1880,O
contained,1880,O
LiCl,1880,B-Chemical
(,1880,O
60,1880,O
mmol/kg,1880,O
),1880,O
for,1880,O
4,1880,O
weeks,1880,O
developed,1880,O
marked,1880,O
polyuria,1880,B-Disease
.,1880,O
The,1881,O
Li-treated,1881,B-Chemical
rats,1881,O
produced,1881,O
a,1881,O
large,1881,O
volume,1881,O
of,1881,O
hypotonic,1881,O
urine,1881,O
with,1881,O
low,1881,O
ionic,1881,O
concentrations,1881,O
.,1881,O
Plasma,1882,O
sodium,1882,B-Chemical
concentrations,1882,O
were,1882,O
found,1882,O
to,1882,O
be,1882,O
slightly,1882,O
increased,1882,O
in,1882,O
the,1882,O
Li-treated,1882,B-Chemical
rats,1882,O
compared,1882,O
with,1882,O
those,1882,O
in,1882,O
controls,1882,O
.,1882,O
Plasma,1883,O
concentration,1883,O
of,1883,O
AVP,1883,B-Chemical
and,1883,O
transcripts,1883,O
of,1883,O
AVP,1883,B-Chemical
gene,1883,O
in,1883,O
the,1883,O
PVN,1883,O
and,1883,O
SON,1883,O
were,1883,O
significantly,1883,O
increased,1883,O
in,1883,O
the,1883,O
Li-treated,1883,B-Chemical
rats,1883,O
compared,1883,O
with,1883,O
controls,1883,O
.,1883,O
These,1884,O
results,1884,O
suggest,1884,O
that,1884,O
dehydration,1884,B-Disease
and/or,1884,O
the,1884,O
activation,1884,O
of,1884,O
visceral,1884,O
afferent,1884,O
inputs,1884,O
may,1884,O
contribute,1884,O
to,1884,O
the,1884,O
elevation,1884,O
of,1884,O
plasma,1884,O
AVP,1884,B-Chemical
and,1884,O
the,1884,O
upregulation,1884,O
of,1884,O
AVP,1884,B-Chemical
gene,1884,O
expression,1884,O
in,1884,O
the,1884,O
PVN,1884,O
and,1884,O
the,1884,O
SON,1884,O
of,1884,O
the,1884,O
Li-induced,1884,B-Chemical
diabetes,1884,B-Disease
insipidus,1884,I-Disease
rat,1884,O
.,1884,O
Antinociceptive,1885,O
and,1885,O
antiamnesic,1885,O
properties,1885,O
of,1885,O
the,1885,O
presynaptic,1885,O
cholinergic,1885,O
amplifier,1885,O
PG-9,1885,B-Chemical
.,1885,O
The,1886,O
antinociceptive,1886,O
effect,1886,O
of,1886,O
3,1886,B-Chemical
alpha-tropyl,1886,I-Chemical
2-,1886,I-Chemical
(,1886,I-Chemical
p-bromophenyl,1886,I-Chemical
),1886,I-Chemical
propionate,1886,I-Chemical
[,1886,O
(,1886,O
+/-,1886,O
),1886,O
-PG-9,1886,O
],1886,O
(,1886,O
10-40,1886,O
mg,1886,O
kg-1,1886,O
s.c.,1886,O
;,1886,O
30-60,1886,O
mg,1886,O
kg-1,1886,O
p.o,1886,O
.,1886,O
;,1887,O
10-30,1887,O
mg,1887,O
kg-1,1887,O
i.v,1887,O
.,1887,O
;,1888,O
10-30,1888,O
micrograms/mouse,1888,O
i.c.v,1888,O
.,1888,O
),1888,O
was,1889,O
examined,1889,O
in,1889,O
mice,1889,O
",",1889,O
rats,1889,O
and,1889,O
guinea,1889,O
pigs,1889,O
by,1889,O
use,1889,O
of,1889,O
the,1889,O
hot-plate,1889,O
",",1889,O
abdominal-constriction,1889,O
",",1889,O
tail-flick,1889,O
and,1889,O
paw-pressure,1889,O
tests,1889,O
.,1889,O
(,1890,O
+/-,1890,O
),1890,B-Chemical
-PG-9,1890,O
antinociception,1890,O
peaked,1890,O
15,1890,O
min,1890,O
after,1890,O
injection,1890,O
and,1890,O
then,1890,O
slowly,1890,O
diminished,1890,O
.,1890,O
The,1891,O
antinociception,1891,O
produced,1891,O
by,1891,O
(,1891,O
+/-,1891,O
),1891,B-Chemical
-PG-9,1891,O
was,1891,O
prevented,1891,O
by,1891,O
the,1891,O
unselective,1891,O
muscarinic,1891,O
antagonist,1891,O
atropine,1891,O
",",1891,O
the,1891,O
M1-selective,1891,O
antagonists,1891,O
pirenzepine,1891,O
and,1891,O
dicyclomine,1891,O
and,1891,O
the,1891,O
acetylcholine,1891,O
depletor,1891,O
hemicholinium-3,1891,O
",",1891,O
but,1891,O
not,1891,O
by,1891,O
the,1891,O
opioid,1891,O
antagonist,1891,O
naloxone,1891,O
",",1891,O
the,1891,O
gamma-aminobutyric,1891,I-Chemical
acidB,1891,O
antagonist,1891,O
3-aminopropyl-diethoxy-methyl-phosphinic,1891,I-Chemical
acid,1891,O
",",1891,O
the,1891,O
H3,1891,O
agonist,1891,O
R-,1891,I-Chemical
(,1891,I-Chemical
alpha,1891,I-Chemical
),1891,I-Chemical
-methylhistamine,1891,O
",",1891,O
the,1891,O
D2,1891,O
antagonist,1891,O
quinpirole,1891,O
",",1891,O
the,1891,O
5-hydroxytryptamine4,1891,O
antagonist,1891,O
2-methoxy-4-amino-5-chlorobenzoic,1891,I-Chemical
acid,1891,I-Chemical
2-,1891,I-Chemical
(,1891,I-Chemical
diethylamino,1891,I-Chemical
),1891,I-Chemical
ethyl,1891,I-Chemical
ester,1891,O
hydrochloride,1891,O
",",1891,O
the,1891,O
5-hydroxytryptamin1A,1891,O
antagonist,1891,O
1-,1891,I-Chemical
(,1891,I-Chemical
2-methoxyphenyl,1891,I-Chemical
),1891,I-Chemical
-4-,1891,I-Chemical
[,1891,I-Chemical
4-,1891,I-Chemical
(,1891,I-Chemical
2-phthalimido,1891,I-Chemical
),1891,I-Chemical
butyl,1891,I-Chemical
],1891,I-Chemical
piperazine,1891,O
hydrobromide,1891,O
and,1891,O
the,1891,O
polyamines,1891,O
depletor,1891,O
reserpine,1891,O
.,1891,O
Based,1892,O
on,1892,O
these,1892,O
data,1892,O
",",1892,O
it,1892,O
can,1892,O
be,1892,O
postulated,1892,O
that,1892,O
(,1892,O
+/-,1892,O
),1892,B-Chemical
-PG-9,1892,O
exerted,1892,O
an,1892,O
antinociceptive,1892,O
effect,1892,O
mediated,1892,O
by,1892,O
a,1892,O
central,1892,O
potentiation,1892,O
of,1892,O
cholinergic,1892,O
transmission,1892,O
.,1892,O
(,1893,O
+/-,1893,O
),1893,B-Chemical
-PG-9,1893,O
(,1893,O
10-40,1893,O
mg,1893,O
kg-1,1893,O
i.p,1893,O
.,1893,O
),1893,O
was,1894,O
able,1894,O
to,1894,O
prevent,1894,O
amnesia,1894,O
induced,1894,O
by,1894,O
scopolamine,1894,O
(,1894,O
1,1894,O
mg,1894,O
kg-1,1894,O
i.p,1894,O
.,1894,O
),1894,O
and,1895,O
dicyclomine,1895,O
(,1895,O
2,1895,O
mg,1895,O
kg-1,1895,O
i.p,1895,O
.,1895,O
),1895,O
in,1896,O
the,1896,O
mouse,1896,O
passive-avoidance,1896,O
test,1896,O
.,1896,O
Affinity,1897,O
profiles,1897,O
of,1897,O
(,1897,O
+/-,1897,O
),1897,B-Chemical
-PG-9,1897,O
for,1897,O
muscarinic,1897,O
receptor,1897,O
subtypes,1897,O
",",1897,O
determined,1897,O
by,1897,O
functional,1897,O
studies,1897,O
(,1897,O
rabbit,1897,O
vas,1897,O
deferens,1897,O
for,1897,O
M1,1897,O
",",1897,O
guinea,1897,O
pig,1897,O
atrium,1897,O
for,1897,O
M2,1897,O
",",1897,O
guinea,1897,O
pig,1897,O
ileum,1897,O
for,1897,O
M3,1897,O
and,1897,O
immature,1897,O
guinea,1897,O
pig,1897,O
uterus,1897,O
for,1897,O
putative,1897,O
M4,1897,O
),1897,O
",",1897,O
have,1897,O
shown,1897,O
an,1897,O
M4/M1,1897,O
selectivity,1897,O
ratio,1897,O
of,1897,O
10.2,1897,O
that,1897,O
might,1897,O
be,1897,O
responsible,1897,O
for,1897,O
the,1897,O
antinociception,1897,O
and,1897,O
the,1897,O
anti-amnesic,1897,O
effect,1897,O
induced,1897,O
by,1897,O
(,1897,O
+/-,1897,O
),1897,B-Chemical
-PG-9,1897,O
through,1897,O
an,1897,O
increase,1897,O
in,1897,O
acetylcholine,1897,O
extracellular,1897,O
levels,1897,O
.,1897,O
In,1898,O
the,1898,O
antinociceptive,1898,O
and,1898,O
antiamnesic,1898,O
dose,1898,O
range,1898,O
",",1898,O
(,1898,O
+/-,1898,O
),1898,B-Chemical
-PG-9,1898,O
did,1898,O
not,1898,O
impair,1898,O
mouse,1898,O
performance,1898,O
evaluated,1898,O
by,1898,O
the,1898,O
rota-rod,1898,O
test,1898,O
and,1898,O
Animex,1898,O
apparatus,1898,O
.,1898,O
The,1899,O
effect,1899,O
of,1899,O
different,1899,O
anaesthetic,1899,O
agents,1899,O
in,1899,O
hearing,1899,B-Disease
loss,1899,I-Disease
following,1899,O
spinal,1899,O
anaesthesia,1899,O
.,1899,O
The,1900,O
cause,1900,O
of,1900,O
hearing,1900,B-Disease
loss,1900,I-Disease
after,1900,O
spinal,1900,O
anaesthesia,1900,O
is,1900,O
unknown,1900,O
.,1900,O
Up,1901,O
until,1901,O
now,1901,O
",",1901,O
the,1901,O
only,1901,O
factor,1901,O
studied,1901,O
has,1901,O
been,1901,O
the,1901,O
effect,1901,O
of,1901,O
the,1901,O
diameter,1901,O
of,1901,O
the,1901,O
spinal,1901,O
needle,1901,O
on,1901,O
post-operative,1901,O
sensorineural,1901,B-Disease
hearing,1901,I-Disease
loss,1901,I-Disease
.,1901,O
The,1902,O
aim,1902,O
of,1902,O
this,1902,O
study,1902,O
was,1902,O
to,1902,O
describe,1902,O
this,1902,O
hearing,1902,B-Disease
loss,1902,I-Disease
and,1902,O
to,1902,O
investigate,1902,O
other,1902,O
factors,1902,O
influencing,1902,O
the,1902,O
degree,1902,O
of,1902,O
hearing,1902,B-Disease
loss,1902,I-Disease
.,1902,O
Two,1903,O
groups,1903,O
of,1903,O
22,1903,O
similar,1903,O
patients,1903,O
were,1903,O
studied,1903,O
:,1903,O
one,1903,O
group,1903,O
received,1903,O
6,1903,O
mL,1903,O
prilocaine,1903,B-Chemical
2,1903,O
%,1903,O
;,1903,O
and,1903,O
the,1903,O
other,1903,O
received,1903,O
3,1903,O
mL,1903,O
bupivacaine,1903,B-Chemical
0.5,1903,O
%,1903,O
.,1903,O
Patients,1904,O
given,1904,O
prilocaine,1904,B-Chemical
were,1904,O
more,1904,O
likely,1904,O
to,1904,O
develop,1904,O
hearing,1904,B-Disease
loss,1904,I-Disease
(,1904,O
10,1904,O
out,1904,O
of,1904,O
22,1904,O
),1904,O
than,1904,O
those,1904,O
given,1904,O
bupivacaine,1904,B-Chemical
(,1904,O
4,1904,O
out,1904,O
of,1904,O
22,1904,O
),1904,O
(,1904,O
P,1904,O
<,1904,O
0.05,1904,O
),1904,O
.,1904,O
The,1905,O
average,1905,O
hearing,1905,B-Disease
loss,1905,I-Disease
for,1905,O
speech,1905,O
frequencies,1905,O
was,1905,O
about,1905,O
10,1905,O
dB,1905,O
after,1905,O
prilocaine,1905,B-Chemical
and,1905,O
15,1905,O
dB,1905,O
after,1905,O
bupivacaine,1905,B-Chemical
.,1905,O
None,1906,O
of,1906,O
the,1906,O
patients,1906,O
complained,1906,O
of,1906,O
subjective,1906,O
hearing,1906,B-Disease
loss,1906,I-Disease
.,1906,O
Long-term,1907,O
follow-up,1907,O
of,1907,O
the,1907,O
patients,1907,O
was,1907,O
not,1907,O
possible,1907,O
.,1907,O
A,1908,O
transient,1908,O
neurological,1908,B-Disease
deficit,1908,I-Disease
following,1908,O
intrathecal,1908,O
injection,1908,O
of,1908,O
1,1908,O
%,1908,O
hyperbaric,1908,O
bupivacaine,1908,B-Chemical
for,1908,O
unilateral,1908,O
spinal,1908,O
anaesthesia,1908,O
.,1908,O
We,1909,O
describe,1909,O
a,1909,O
case,1909,O
of,1909,O
transient,1909,O
neurological,1909,B-Disease
deficit,1909,I-Disease
that,1909,O
occurred,1909,O
after,1909,O
unilateral,1909,O
spinal,1909,O
anaesthesia,1909,O
with,1909,O
8,1909,O
mg,1909,O
of,1909,O
1,1909,O
%,1909,O
hyperbaric,1909,O
bupivacaine,1909,B-Chemical
slowly,1909,O
injected,1909,O
through,1909,O
a,1909,O
25-gauge,1909,O
pencil-point,1909,O
spinal,1909,O
needle,1909,O
.,1909,O
The,1910,O
surgery,1910,O
and,1910,O
anaesthesia,1910,O
were,1910,O
uneventful,1910,O
",",1910,O
but,1910,O
3,1910,O
days,1910,O
after,1910,O
surgery,1910,O
",",1910,O
the,1910,O
patient,1910,O
reported,1910,O
an,1910,O
area,1910,O
of,1910,O
hypoaesthesia,1910,O
over,1910,O
L3-L4,1910,O
dermatomes,1910,O
of,1910,O
the,1910,O
leg,1910,O
which,1910,O
had,1910,O
been,1910,O
operated,1910,O
on,1910,O
(,1910,O
loss,1910,B-Disease
of,1910,I-Disease
pinprick,1910,I-Disease
sensation,1910,I-Disease
),1910,O
without,1910,O
reduction,1910,O
in,1910,O
muscular,1910,O
strength,1910,O
.,1910,O
Sensation,1911,O
in,1911,O
this,1911,O
area,1911,O
returned,1911,O
to,1911,O
normal,1911,O
over,1911,O
the,1911,O
following,1911,O
2,1911,O
weeks,1911,O
.,1911,O
Prospective,1912,O
multicentre,1912,O
studies,1912,O
with,1912,O
a,1912,O
large,1912,O
population,1912,O
and,1912,O
a,1912,O
long,1912,O
follow-up,1912,O
should,1912,O
be,1912,O
performed,1912,O
in,1912,O
order,1912,O
to,1912,O
evaluate,1912,O
the,1912,O
incidence,1912,O
of,1912,O
this,1912,O
unusual,1912,O
side,1912,O
effect,1912,O
.,1912,O
However,1913,O
",",1913,O
we,1913,O
suggest,1913,O
that,1913,O
a,1913,O
low,1913,O
solution,1913,O
concentration,1913,O
should,1913,O
be,1913,O
preferred,1913,O
for,1913,O
unilateral,1913,O
spinal,1913,O
anaesthesia,1913,O
with,1913,O
a,1913,O
hyperbaric,1913,O
anaesthetic,1913,O
solution,1913,O
(,1913,O
if,1913,O
pencil-point,1913,O
needle,1913,O
and,1913,O
slow,1913,O
injection,1913,O
rate,1913,O
are,1913,O
employed,1913,O
),1913,O
",",1913,O
in,1913,O
order,1913,O
to,1913,O
minimize,1913,O
the,1913,O
risk,1913,O
of,1913,O
a,1913,O
localized,1913,O
high,1913,O
peak,1913,O
anaesthetic,1913,O
concentration,1913,O
",",1913,O
which,1913,O
might,1913,O
lead,1913,O
to,1913,O
a,1913,O
transient,1913,O
neurological,1913,B-Disease
deficit,1913,I-Disease
.,1913,O
Transient,1914,B-Disease
neurologic,1914,I-Disease
symptoms,1914,I-Disease
after,1914,O
spinal,1914,O
anesthesia,1914,O
:,1914,O
a,1914,O
lower,1914,O
incidence,1914,O
with,1914,O
prilocaine,1914,B-Chemical
and,1914,O
bupivacaine,1914,B-Chemical
than,1914,O
with,1914,O
lidocaine,1914,B-Chemical
.,1914,O
BACKGROUND,1915,O
:,1915,O
Recent,1915,O
evidence,1915,O
suggests,1915,O
that,1915,O
transient,1915,B-Disease
neurologic,1915,I-Disease
symptoms,1915,I-Disease
(,1915,O
TNSs,1915,B-Disease
),1915,O
frequently,1915,O
follow,1915,O
lidocaine,1915,B-Chemical
spinal,1915,O
anesthesia,1915,O
but,1915,O
are,1915,O
infrequent,1915,O
with,1915,O
bupivacaine,1915,B-Chemical
.,1915,O
However,1916,O
",",1916,O
identification,1916,O
of,1916,O
a,1916,O
short-acting,1916,O
local,1916,O
anesthetic,1916,O
to,1916,O
substitute,1916,O
for,1916,O
lidocaine,1916,B-Chemical
for,1916,O
brief,1916,O
surgical,1916,O
procedures,1916,O
remains,1916,O
an,1916,O
important,1916,O
goal,1916,O
.,1916,O
Prilocaine,1917,B-Chemical
is,1917,O
an,1917,O
amide,1917,O
local,1917,O
anesthetic,1917,O
with,1917,O
a,1917,O
duration,1917,O
of,1917,O
action,1917,O
similar,1917,O
to,1917,O
that,1917,O
of,1917,O
lidocaine,1917,B-Chemical
.,1917,O
Accordingly,1918,O
",",1918,O
the,1918,O
present,1918,O
",",1918,O
prospective,1918,O
double-blind,1918,O
study,1918,O
compares,1918,O
prilocaine,1918,B-Chemical
with,1918,O
lidocaine,1918,B-Chemical
and,1918,O
bupivacaine,1918,B-Chemical
with,1918,O
respect,1918,O
to,1918,O
duration,1918,O
of,1918,O
action,1918,O
and,1918,O
relative,1918,O
risk,1918,O
of,1918,O
TNSs,1918,B-Disease
.,1918,O
METHODS,1919,O
:,1919,O
Ninety,1919,O
patients,1919,O
classified,1919,O
as,1919,O
American,1919,O
Society,1919,O
of,1919,O
Anesthesiologists,1919,O
physical,1919,O
status,1919,O
I,1919,O
or,1919,O
II,1919,O
who,1919,O
were,1919,O
scheduled,1919,O
for,1919,O
short,1919,O
gynecologic,1919,O
procedures,1919,O
under,1919,O
spinal,1919,O
anesthesia,1919,O
were,1919,O
randomly,1919,O
allocated,1919,O
to,1919,O
receive,1919,O
2.5,1919,O
ml,1919,O
2,1919,O
%,1919,O
lidocaine,1919,B-Chemical
in,1919,O
7.5,1919,O
%,1919,O
glucose,1919,B-Chemical
",",1919,O
2,1919,O
%,1919,O
prilocaine,1919,B-Chemical
in,1919,O
7.5,1919,O
%,1919,O
glucose,1919,B-Chemical
",",1919,O
or,1919,O
0.5,1919,O
%,1919,O
bupivacaine,1919,B-Chemical
in,1919,O
7.5,1919,O
%,1919,O
glucose,1919,B-Chemical
.,1919,O
All,1920,O
solutions,1920,O
were,1920,O
provided,1920,O
in,1920,O
blinded,1920,O
vials,1920,O
by,1920,O
the,1920,O
hospital,1920,O
pharmacy,1920,O
.,1920,O
Details,1921,O
of,1921,O
spinal,1921,O
puncture,1921,O
",",1921,O
extension,1921,O
and,1921,O
regression,1921,O
of,1921,O
spinal,1921,O
block,1921,O
",",1921,O
and,1921,O
the,1921,O
times,1921,O
to,1921,O
reach,1921,O
discharge,1921,O
criteria,1921,O
were,1921,O
noted,1921,O
.,1921,O
In,1922,O
the,1922,O
evening,1922,O
of,1922,O
postoperative,1922,O
day,1922,O
1,1922,O
",",1922,O
patients,1922,O
were,1922,O
evaluated,1922,O
for,1922,O
TNSs,1922,B-Disease
by,1922,O
a,1922,O
physician,1922,O
unaware,1922,O
of,1922,O
the,1922,O
drug,1922,O
administered,1922,O
and,1922,O
the,1922,O
details,1922,O
of,1922,O
the,1922,O
anesthetic,1922,O
procedure,1922,O
.,1922,O
RESULTS,1923,O
:,1923,O
Nine,1923,O
of,1923,O
30,1923,O
patients,1923,O
receiving,1923,O
lidocaine,1923,B-Chemical
experienced,1923,O
TNSs,1923,B-Disease
",",1923,O
1,1923,O
of,1923,O
30,1923,O
patients,1923,O
receiving,1923,O
prilocaine,1923,B-Chemical
(,1923,O
P,1923,O
=,1923,O
0.03,1923,O
),1923,O
had,1923,O
them,1923,O
",",1923,O
and,1923,O
none,1923,O
of,1923,O
30,1923,O
patients,1923,O
receiving,1923,O
bupivacaine,1923,B-Chemical
had,1923,O
TNSs,1923,B-Disease
.,1923,O
Times,1924,O
to,1924,O
ambulate,1924,O
and,1924,O
to,1924,O
void,1924,O
were,1924,O
similar,1924,O
after,1924,O
lidocaine,1924,B-Chemical
and,1924,O
prilocaine,1924,B-Chemical
(,1924,O
150,1924,O
vs.,1924,O
165,1924,O
min,1924,O
and,1924,O
238,1924,O
vs.,1924,O
253,1924,O
min,1924,O
",",1924,O
respectively,1924,O
),1924,O
but,1924,O
prolonged,1924,O
after,1924,O
bupivacaine,1924,B-Chemical
(,1924,O
200,1924,O
and,1924,O
299,1924,O
min,1924,O
",",1924,O
respectively,1924,O
;,1924,O
P,1924,O
<,1924,O
0.05,1924,O
),1924,O
.,1924,O
CONCLUSIONS,1925,O
:,1925,O
Prilocaine,1925,B-Chemical
may,1925,O
be,1925,O
preferable,1925,O
to,1925,O
lidocaine,1925,B-Chemical
for,1925,O
short,1925,O
surgical,1925,O
procedures,1925,O
because,1925,O
it,1925,O
has,1925,O
a,1925,O
similar,1925,O
duration,1925,O
of,1925,O
action,1925,O
but,1925,O
a,1925,O
lower,1925,O
incidence,1925,O
of,1925,O
TNSs,1925,B-Disease
.,1925,O
Suxamethonium-induced,1926,B-Chemical
cardiac,1926,B-Disease
arrest,1926,I-Disease
and,1926,O
death,1926,B-Disease
following,1926,O
5,1926,O
days,1926,O
of,1926,O
immobilization,1926,O
.,1926,O
The,1927,O
present,1927,O
report,1927,O
describes,1927,O
a,1927,O
case,1927,O
of,1927,O
cardiac,1927,B-Disease
arrest,1927,I-Disease
and,1927,O
subsequent,1927,O
death,1927,B-Disease
as,1927,O
a,1927,O
result,1927,O
of,1927,O
hyperkalaemia,1927,B-Disease
following,1927,O
the,1927,O
use,1927,O
of,1927,O
suxamethonium,1927,B-Chemical
in,1927,O
a,1927,O
23-year-old,1927,O
Malawian,1927,O
woman,1927,O
.,1927,O
Five,1928,O
days,1928,O
after,1928,O
the,1928,O
onset,1928,O
of,1928,O
the,1928,O
symptoms,1928,O
of,1928,O
meningitis,1928,B-Disease
",",1928,O
the,1928,O
patient,1928,O
aspirated,1928,O
stomach,1928,O
contents,1928,O
and,1928,O
needed,1928,O
endotracheal,1928,O
intubation,1928,O
.,1928,O
Forty,1929,O
seconds,1929,O
after,1929,O
injection,1929,O
of,1929,O
suxamethonium,1929,B-Chemical
",",1929,O
bradycardia,1929,B-Disease
and,1929,O
cardiac,1929,B-Disease
arrest,1929,I-Disease
occurred,1929,O
.,1929,O
Attempts,1930,O
to,1930,O
resuscitate,1930,O
the,1930,O
patient,1930,O
were,1930,O
not,1930,O
successful,1930,O
.,1930,O
The,1931,O
serum,1931,O
level,1931,O
of,1931,O
potassium,1931,B-Chemical
was,1931,O
observed,1931,O
to,1931,O
be,1931,O
8.4,1931,O
mequiv,1931,O
L-1,1931,O
.,1931,O
Apart,1932,O
from,1932,O
the,1932,O
reduction,1932,O
in,1932,O
the,1932,O
patient,1932,O
's,1932,O
level,1932,O
of,1932,O
consciousness,1932,O
",",1932,O
there,1932,O
were,1932,O
no,1932,O
signs,1932,O
of,1932,O
motor,1932,O
neurone,1932,O
damage,1932,O
or,1932,O
of,1932,O
any,1932,O
of,1932,O
the,1932,O
other,1932,O
known,1932,O
predisposing,1932,O
conditions,1932,O
for,1932,O
hyperkalaemia,1932,B-Disease
following,1932,O
the,1932,O
administration,1932,O
of,1932,O
suxamethonium,1932,B-Chemical
.,1932,O
It,1933,O
is,1933,O
postulated,1933,O
that,1933,O
her,1933,O
death,1933,B-Disease
was,1933,O
caused,1933,O
by,1933,O
hypersensitivity,1933,B-Disease
to,1933,O
suxamethonium,1933,B-Chemical
",",1933,O
associated,1933,O
with,1933,O
her,1933,O
5-day,1933,O
immobilization,1933,O
.,1933,O
Acute,1934,O
hepatitis,1934,B-Disease
",",1934,O
autoimmune,1934,B-Disease
hemolytic,1934,I-Disease
anemia,1934,I-Disease
",",1934,O
and,1934,O
erythroblastocytopenia,1934,B-Disease
induced,1934,O
by,1934,O
ceftriaxone,1934,B-Chemical
.,1934,O
An,1935,O
80-yr-old,1935,O
man,1935,O
developed,1935,O
acute,1935,O
hepatitis,1935,B-Disease
shortly,1935,O
after,1935,O
ingesting,1935,O
oral,1935,O
ceftriaxone,1935,B-Chemical
.,1935,O
Although,1936,O
the,1936,O
transaminases,1936,O
gradually,1936,O
returned,1936,O
to,1936,O
baseline,1936,O
after,1936,O
withholding,1936,O
the,1936,O
beta,1936,B-Chemical
lactam,1936,I-Chemical
antibiotic,1936,O
",",1936,O
there,1936,O
was,1936,O
a,1936,O
gradual,1936,O
increase,1936,O
in,1936,O
serum,1936,O
bilirubin,1936,B-Chemical
and,1936,O
a,1936,O
decrease,1936,O
in,1936,O
hemoglobin,1936,O
concentration,1936,O
caused,1936,O
by,1936,O
an,1936,O
autoimmune,1936,B-Disease
hemolytic,1936,I-Disease
anemia,1936,I-Disease
and,1936,O
erythroblastocytopenia,1936,B-Disease
.,1936,O
These,1937,O
responded,1937,O
to,1937,O
systemic,1937,O
steroids,1937,B-Chemical
and,1937,O
immunoglobulins,1937,O
.,1937,O
Despite,1938,O
the,1938,O
widespread,1938,O
use,1938,O
of,1938,O
these,1938,O
agents,1938,O
this,1938,O
triad,1938,O
of,1938,O
side,1938,O
effects,1938,O
has,1938,O
not,1938,O
previously,1938,O
been,1938,O
reported,1938,O
in,1938,O
connection,1938,O
with,1938,O
beta,1938,B-Chemical
lactam,1938,I-Chemical
antibiotics,1938,O
.,1938,O
Thyroxine,1939,B-Chemical
abuse,1939,O
:,1939,O
an,1939,O
unusual,1939,O
case,1939,O
of,1939,O
thyrotoxicosis,1939,B-Disease
in,1939,O
pregnancy,1939,O
.,1939,O
Eating,1940,B-Disease
disorders,1940,I-Disease
and,1940,O
the,1940,O
associated,1940,O
behavioural,1940,O
problems,1940,O
and,1940,O
drug,1940,B-Disease
abuse,1940,I-Disease
are,1940,O
uncommon,1940,O
in,1940,O
pregnancy,1940,O
.,1940,O
When,1941,O
they,1941,O
do,1941,O
occur,1941,O
they,1941,O
are,1941,O
often,1941,O
unrecognized,1941,O
because,1941,O
of,1941,O
denial,1941,O
but,1941,O
when,1941,O
significant,1941,O
may,1941,O
pose,1941,O
a,1941,O
risk,1941,O
to,1941,O
both,1941,O
the,1941,O
mother,1941,O
and,1941,O
her,1941,O
fetus,1941,O
.,1941,O
This,1942,O
case,1942,O
illustrates,1942,O
a,1942,O
number,1942,O
of,1942,O
problems,1942,O
that,1942,O
may,1942,O
be,1942,O
encountered,1942,O
in,1942,O
women,1942,O
with,1942,O
eating,1942,B-Disease
disorders,1942,I-Disease
in,1942,O
pregnancy,1942,O
",",1942,O
including,1942,O
prolonged,1942,O
and,1942,O
recurrent,1942,O
metabolic,1942,O
disturbances,1942,O
and,1942,O
diuretic,1942,O
abuse,1942,O
.,1942,O
In,1943,O
particular,1943,O
it,1943,O
illustrates,1943,O
the,1943,O
derangements,1943,O
of,1943,O
thyroid,1943,O
function,1943,O
seen,1943,O
in,1943,O
pregnant,1943,O
women,1943,O
with,1943,O
eating,1943,B-Disease
disorders,1943,I-Disease
and,1943,O
reminds,1943,O
us,1943,O
that,1943,O
when,1943,O
a,1943,O
cause,1943,O
for,1943,O
thyrotoxicosis,1943,B-Disease
remains,1943,O
obscure,1943,O
",",1943,O
thyroxine,1943,B-Chemical
abuse,1943,O
should,1943,O
be,1943,O
considered,1943,O
and,1943,O
explored,1943,O
.,1943,O
Repeated,1944,O
trimipramine,1944,B-Chemical
induces,1944,O
dopamine,1944,B-Chemical
D2/D3,1944,O
and,1944,O
alpha1-adrenergic,1944,O
up-regulation,1944,O
.,1944,O
Trimipramine,1945,B-Chemical
(,1945,O
TRI,1945,B-Chemical
),1945,O
",",1945,O
which,1945,O
shows,1945,O
a,1945,O
clinical,1945,O
antidepressant,1945,B-Chemical
activity,1945,O
",",1945,O
is,1945,O
chemically,1945,O
related,1945,O
to,1945,O
imipramine,1945,B-Chemical
but,1945,O
does,1945,O
not,1945,O
inhibit,1945,O
the,1945,O
reuptake,1945,O
of,1945,O
noradrenaline,1945,B-Chemical
and,1945,O
5-hydroxytryptamine,1945,B-Chemical
",",1945,O
nor,1945,O
does,1945,O
it,1945,O
induce,1945,O
beta-adrenergic,1945,O
down-regulation,1945,O
.,1945,O
The,1946,O
mechanism,1946,O
of,1946,O
its,1946,O
antidepressant,1946,B-Chemical
activity,1946,O
is,1946,O
still,1946,O
unknown,1946,O
.,1946,O
The,1947,O
aim,1947,O
of,1947,O
the,1947,O
present,1947,O
study,1947,O
was,1947,O
to,1947,O
find,1947,O
out,1947,O
whether,1947,O
TRI,1947,B-Chemical
given,1947,O
repeatedly,1947,O
was,1947,O
able,1947,O
to,1947,O
induce,1947,O
adaptive,1947,O
changes,1947,O
in,1947,O
the,1947,O
dopaminergic,1947,O
and,1947,O
alpha1-adrenergic,1947,O
systems,1947,O
",",1947,O
demonstrated,1947,O
by,1947,O
us,1947,O
previously,1947,O
for,1947,O
various,1947,O
antidepressants,1947,B-Chemical
.,1947,O
TRI,1948,B-Chemical
was,1948,O
given,1948,O
to,1948,O
male,1948,O
Wistar,1948,O
rats,1948,O
and,1948,O
male,1948,O
Albino,1948,O
Swiss,1948,O
mice,1948,O
perorally,1948,O
twice,1948,O
daily,1948,O
for,1948,O
14,1948,O
days,1948,O
.,1948,O
In,1949,O
the,1949,O
acute,1949,O
experiment,1949,O
TRI,1949,B-Chemical
(,1949,O
given,1949,O
i.p,1949,O
.,1949,O
),1949,O
does,1950,O
not,1950,O
antagonize,1950,O
the,1950,O
reserpine,1950,B-Chemical
hypothermia,1950,B-Disease
in,1950,O
mice,1950,O
and,1950,O
does,1950,O
not,1950,O
potentiate,1950,O
the,1950,O
5-hydroxytryptophan,1950,B-Chemical
head,1950,O
twitches,1950,O
in,1950,O
rats,1950,O
.,1950,O
TRI,1951,B-Chemical
given,1951,O
repeatedly,1951,O
to,1951,O
rats,1951,O
increases,1951,O
the,1951,O
locomotor,1951,O
hyperactivity,1951,B-Disease
induced,1951,O
by,1951,O
d-amphetamine,1951,B-Chemical
",",1951,O
quinpirole,1951,B-Chemical
and,1951,O
(,1951,O
+,1951,O
),1951,O
-7-hydroxy-dipropyloaminotetralin,1951,O
(,1951,O
dopamine,1951,B-Chemical
D2,1951,O
and,1951,O
D3,1951,O
effects,1951,O
),1951,O
.,1951,O
The,1952,O
stereotypies,1952,O
induced,1952,O
by,1952,O
d-amphetamine,1952,B-Chemical
or,1952,O
apomorphine,1952,B-Chemical
are,1952,O
not,1952,O
potentiated,1952,O
by,1952,O
TRI,1952,B-Chemical
.,1952,O
It,1953,O
increases,1953,O
the,1953,O
behaviour,1953,O
stimulation,1953,O
evoked,1953,O
by,1953,O
phenylephrine,1953,B-Chemical
(,1953,O
given,1953,O
intraventricularly,1953,O
),1953,O
in,1953,O
rats,1953,O
",",1953,O
evaluated,1953,O
in,1953,O
the,1953,O
open,1953,O
field,1953,O
test,1953,O
as,1953,O
well,1953,O
as,1953,O
the,1953,O
aggressiveness,1953,B-Disease
evoked,1953,O
by,1953,O
clonidine,1953,B-Chemical
in,1953,O
mice,1953,O
",",1953,O
both,1953,O
these,1953,O
effects,1953,O
being,1953,O
mediated,1953,O
by,1953,O
an,1953,O
alpha1-adrenergic,1953,O
receptor,1953,O
.,1953,O
It,1954,O
may,1954,O
be,1954,O
concluded,1954,O
that,1954,O
",",1954,O
like,1954,O
other,1954,O
tricyclic,1954,O
antidepressants,1954,B-Chemical
studied,1954,O
previously,1954,O
",",1954,O
TRI,1954,B-Chemical
given,1954,O
repeatedly,1954,O
increases,1954,O
the,1954,O
responsiveness,1954,O
of,1954,O
brain,1954,O
dopamine,1954,B-Chemical
D2,1954,O
and,1954,O
D3,1954,O
(,1954,O
locomotor,1954,O
activity,1954,O
but,1954,O
not,1954,O
stereotypy,1954,O
),1954,O
as,1954,O
well,1954,O
as,1954,O
alpha1-adrenergic,1954,O
receptors,1954,O
to,1954,O
their,1954,O
agonists,1954,O
.,1954,O
A,1955,O
question,1955,O
arises,1955,O
whether,1955,O
the,1955,O
reuptake,1955,O
inhibition,1955,O
is,1955,O
of,1955,O
any,1955,O
importance,1955,O
to,1955,O
the,1955,O
adaptive,1955,O
changes,1955,O
induced,1955,O
by,1955,O
repeated,1955,O
antidepressants,1955,B-Chemical
",",1955,O
suggested,1955,O
to,1955,O
be,1955,O
responsible,1955,O
for,1955,O
the,1955,O
antidepressant,1955,B-Chemical
activity,1955,O
.,1955,O
Pethidine-associated,1956,B-Chemical
seizure,1956,B-Disease
in,1956,O
a,1956,O
healthy,1956,O
adolescent,1956,O
receiving,1956,O
pethidine,1956,B-Chemical
for,1956,O
postoperative,1956,B-Disease
pain,1956,I-Disease
control,1956,O
.,1956,O
A,1957,O
healthy,1957,O
17-year-old,1957,O
male,1957,O
received,1957,O
standard,1957,O
intermittent,1957,O
doses,1957,O
of,1957,O
pethidine,1957,B-Chemical
via,1957,O
a,1957,O
patient-controlled,1957,O
analgesia,1957,O
(,1957,O
PCA,1957,O
),1957,O
pump,1957,O
for,1957,O
management,1957,O
of,1957,O
postoperative,1957,B-Disease
pain,1957,I-Disease
control,1957,O
.,1957,O
Twenty-three,1958,O
h,1958,O
postoperatively,1958,O
he,1958,O
developed,1958,O
a,1958,O
brief,1958,O
self-limited,1958,O
seizure,1958,B-Disease
.,1958,O
Both,1959,O
plasma,1959,O
pethidine,1959,B-Chemical
and,1959,O
norpethidine,1959,B-Chemical
were,1959,O
elevated,1959,O
in,1959,O
the,1959,O
range,1959,O
associated,1959,O
with,1959,O
clinical,1959,O
manifestations,1959,O
of,1959,O
central,1959,O
nervous,1959,O
system,1959,O
excitation,1959,O
.,1959,O
No,1960,O
other,1960,O
risk,1960,O
factors,1960,O
for,1960,O
CNS,1960,O
toxicity,1960,B-Disease
were,1960,O
identified,1960,O
.,1960,O
This,1961,O
method,1961,O
allowed,1961,O
frequent,1961,O
self-dosing,1961,O
of,1961,O
pethidine,1961,B-Chemical
at,1961,O
short,1961,O
time,1961,O
intervals,1961,O
and,1961,O
rapid,1961,O
accumulation,1961,O
of,1961,O
pethidine,1961,B-Chemical
and,1961,O
norpethidine,1961,B-Chemical
.,1961,O
The,1962,O
routine,1962,O
use,1962,O
of,1962,O
pethidine,1962,B-Chemical
via,1962,O
PCA,1962,O
even,1962,O
for,1962,O
a,1962,O
brief,1962,O
postoperative,1962,O
analgesia,1962,O
should,1962,O
be,1962,O
reconsidered,1962,O
.,1962,O
An,1963,O
unusual,1963,O
toxic,1963,O
reaction,1963,O
to,1963,O
axillary,1963,O
block,1963,O
by,1963,O
mepivacaine,1963,B-Chemical
with,1963,O
adrenaline,1963,B-Chemical
.,1963,O
An,1964,O
increase,1964,B-Disease
in,1964,I-Disease
blood,1964,I-Disease
pressure,1964,I-Disease
",",1964,O
accompanied,1964,O
by,1964,O
atrial,1964,B-Disease
fibrillation,1964,I-Disease
",",1964,O
agitation,1964,B-Disease
",",1964,O
incomprehensible,1964,B-Disease
shouts,1964,I-Disease
and,1964,O
loss,1964,B-Disease
of,1964,I-Disease
consciousness,1964,I-Disease
",",1964,O
was,1964,O
observed,1964,O
in,1964,O
an,1964,O
elderly,1964,O
",",1964,O
ASA,1964,O
classification,1964,O
group,1964,O
II,1964,O
",",1964,O
cardiovascularly,1964,O
medicated,1964,O
male,1964,O
",",1964,O
12,1964,O
min,1964,O
after,1964,O
performance,1964,O
of,1964,O
axillary,1964,O
block,1964,O
with,1964,O
mepivacaine,1964,B-Chemical
850,1964,O
mg,1964,O
containing,1964,O
adrenaline,1964,B-Chemical
0.225,1964,O
mg,1964,O
",",1964,O
for,1964,O
correction,1964,O
of,1964,O
Dupuytren,1964,B-Disease
's,1964,I-Disease
contracture,1964,I-Disease
.,1964,O
After,1965,O
intravenous,1965,O
administration,1965,O
of,1965,O
labetalol,1965,B-Chemical
",",1965,O
metoprolol,1965,B-Chemical
and,1965,O
midazolam,1965,B-Chemical
the,1965,O
patient,1965,O
's,1965,O
condition,1965,O
improved,1965,O
",",1965,O
and,1965,O
15,1965,O
min,1965,O
later,1965,O
he,1965,O
woke,1965,O
up,1965,O
.,1965,O
The,1966,O
block,1966,O
was,1966,O
successful,1966,O
and,1966,O
surgery,1966,O
was,1966,O
conducted,1966,O
as,1966,O
scheduled,1966,O
despite,1966,O
persisting,1966,O
atrial,1966,B-Disease
fibrillation,1966,I-Disease
.,1966,O
Postoperatively,1967,O
",",1967,O
the,1967,O
patient,1967,O
refused,1967,O
DC,1967,O
cardioversion,1967,O
and,1967,O
was,1967,O
treated,1967,O
medically,1967,O
.,1967,O
Both,1968,O
the,1968,O
temporal,1968,O
relationship,1968,O
of,1968,O
events,1968,O
and,1968,O
the,1968,O
response,1968,O
to,1968,O
treatment,1968,O
suggest,1968,O
that,1968,O
a,1968,O
rapid,1968,O
systemic,1968,O
absorption,1968,O
of,1968,O
mepivacaine,1968,B-Chemical
with,1968,O
adrenaline,1968,B-Chemical
and/or,1968,O
interaction,1968,O
of,1968,O
these,1968,O
drugs,1968,O
with,1968,O
the,1968,O
patient,1968,O
's,1968,O
cardiovascular,1968,O
medications,1968,O
were,1968,O
responsible,1968,O
for,1968,O
the,1968,O
perioperative,1968,O
complications,1968,O
.,1968,O
Drug-associated,1969,O
acute-onset,1969,O
vanishing,1969,B-Disease
bile,1969,I-Disease
duct,1969,I-Disease
and,1969,O
Stevens-Johnson,1969,B-Disease
syndromes,1969,I-Disease
in,1969,O
a,1969,O
child,1969,O
.,1969,O
Acute,1970,O
vanishing,1970,B-Disease
bile,1970,I-Disease
duct,1970,I-Disease
syndrome,1970,O
is,1970,O
a,1970,O
rare,1970,O
but,1970,O
established,1970,O
cause,1970,O
of,1970,O
progressive,1970,O
cholestasis,1970,B-Disease
in,1970,O
adults,1970,O
",",1970,O
is,1970,O
most,1970,O
often,1970,O
drug,1970,O
or,1970,O
toxin,1970,O
related,1970,O
",",1970,O
and,1970,O
is,1970,O
of,1970,O
unknown,1970,O
pathogenesis,1970,O
.,1970,O
It,1971,O
has,1971,O
not,1971,O
been,1971,O
reported,1971,O
previously,1971,O
in,1971,O
children,1971,O
.,1971,O
Stevens-Johnson,1972,B-Disease
syndrome,1972,I-Disease
is,1972,O
a,1972,O
well-recognized,1972,O
immune,1972,O
complex-mediated,1972,O
hypersensitivity,1972,B-Disease
reaction,1972,O
that,1972,O
affects,1972,O
all,1972,O
age,1972,O
groups,1972,O
",",1972,O
is,1972,O
drug,1972,O
or,1972,O
infection,1972,B-Disease
induced,1972,O
",",1972,O
and,1972,O
has,1972,O
classic,1972,O
systemic,1972,O
",",1972,O
mucosal,1972,O
",",1972,O
and,1972,O
dermatologic,1972,O
manifestations,1972,O
.,1972,O
A,1973,O
previously,1973,O
healthy,1973,O
child,1973,O
who,1973,O
developed,1973,O
acute,1973,O
",",1973,O
severe,1973,O
",",1973,O
rapidly,1973,O
progressive,1973,O
vanishing,1973,B-Disease
bile,1973,I-Disease
duct,1973,I-Disease
syndrome,1973,I-Disease
shortly,1973,O
after,1973,O
Stevens-Johnson,1973,B-Disease
syndrome,1973,I-Disease
is,1973,O
described,1973,O
;,1973,O
this,1973,O
was,1973,O
temporally,1973,O
associated,1973,O
with,1973,O
ibuprofen,1973,B-Chemical
use,1973,O
.,1973,O
Despite,1974,O
therapy,1974,O
with,1974,O
ursodeoxycholic,1974,B-Chemical
acid,1974,I-Chemical
",",1974,O
prednisone,1974,B-Chemical
",",1974,O
and,1974,O
then,1974,O
tacrolimus,1974,B-Chemical
",",1974,O
her,1974,O
cholestatic,1974,B-Disease
disease,1974,I-Disease
was,1974,O
unrelenting,1974,O
",",1974,O
with,1974,O
cirrhosis,1974,B-Disease
shown,1974,O
by,1974,O
biopsy,1974,O
6,1974,O
months,1974,O
after,1974,O
presentation,1974,O
.,1974,O
This,1975,O
case,1975,O
documents,1975,O
acute,1975,O
drug-related,1975,O
vanishing,1975,B-Disease
bile,1975,I-Disease
duct,1975,I-Disease
syndrome,1975,I-Disease
in,1975,O
the,1975,O
pediatric,1975,O
age,1975,O
group,1975,O
and,1975,O
suggests,1975,O
shared,1975,O
immune,1975,O
mechanisms,1975,O
in,1975,O
the,1975,O
pathogenesis,1975,O
of,1975,O
both,1975,O
Stevens-Johnson,1975,B-Disease
syndrome,1975,I-Disease
and,1975,O
vanishing,1975,B-Disease
bile,1975,I-Disease
duct,1975,I-Disease
syndrome,1975,I-Disease
.,1975,O
High,1976,O
incidence,1976,O
of,1976,O
primary,1976,B-Disease
pulmonary,1976,I-Disease
hypertension,1976,I-Disease
associated,1976,O
with,1976,O
appetite,1976,B-Chemical
suppressants,1976,I-Chemical
in,1976,O
Belgium,1976,O
.,1976,O
Primary,1977,B-Disease
pulmonary,1977,I-Disease
hypertension,1977,I-Disease
is,1977,O
a,1977,O
rare,1977,O
",",1977,O
progressive,1977,O
and,1977,O
incurable,1977,O
disease,1977,O
",",1977,O
which,1977,O
has,1977,O
been,1977,O
associated,1977,O
with,1977,O
the,1977,O
intake,1977,O
of,1977,O
appetite,1977,B-Chemical
suppressant,1977,I-Chemical
drugs,1977,O
.,1977,O
The,1978,O
importance,1978,O
of,1978,O
this,1978,O
association,1978,O
was,1978,O
evaluated,1978,O
in,1978,O
Belgium,1978,O
while,1978,O
this,1978,O
country,1978,O
still,1978,O
had,1978,O
no,1978,O
restriction,1978,O
on,1978,O
the,1978,O
prescription,1978,O
of,1978,O
appetite,1978,B-Chemical
suppressants,1978,I-Chemical
.,1978,O
Thirty-five,1979,O
patients,1979,O
with,1979,O
primary,1979,B-Disease
pulmonary,1979,I-Disease
hypertension,1979,I-Disease
and,1979,O
85,1979,O
matched,1979,O
controls,1979,O
were,1979,O
recruited,1979,O
over,1979,O
32,1979,O
months,1979,O
(,1979,O
1992-1994,1979,O
),1979,O
in,1979,O
Belgium,1979,O
.,1979,O
Exposure,1980,O
to,1980,O
appetite-suppressants,1980,B-Chemical
was,1980,O
assessed,1980,O
on,1980,O
the,1980,O
basis,1980,O
of,1980,O
hospital,1980,O
records,1980,O
and,1980,O
standardized,1980,O
interview,1980,O
.,1980,O
Twenty-three,1981,O
of,1981,O
the,1981,O
patients,1981,O
had,1981,O
previously,1981,O
taken,1981,O
appetite,1981,B-Chemical
suppressants,1981,I-Chemical
",",1981,O
mainly,1981,O
fenfluramines,1981,B-Chemical
",",1981,O
as,1981,O
compared,1981,O
with,1981,O
only,1981,O
5,1981,O
of,1981,O
the,1981,O
controls,1981,O
(,1981,O
66,1981,O
versus,1981,O
6,1981,O
%,1981,O
",",1981,O
p,1981,O
<,1981,O
0.0001,1981,O
),1981,O
.,1981,O
Five,1982,O
patients,1982,O
died,1982,O
before,1982,O
the,1982,O
interview,1982,O
",",1982,O
all,1982,O
of,1982,O
them,1982,O
had,1982,O
taken,1982,O
appetite,1982,B-Chemical
suppressants,1982,I-Chemical
.,1982,O
In,1983,O
8,1983,O
patients,1983,O
the,1983,O
diagnosis,1983,O
of,1983,O
primary,1983,B-Disease
pulmonary,1983,I-Disease
hypertension,1983,I-Disease
was,1983,O
uncertain,1983,O
",",1983,O
5,1983,O
of,1983,O
them,1983,O
had,1983,O
taken,1983,O
appetite,1983,B-Chemical
suppressants,1983,I-Chemical
.,1983,O
The,1984,O
patients,1984,O
who,1984,O
had,1984,O
been,1984,O
exposed,1984,O
to,1984,O
appetite,1984,B-Chemical
suppressants,1984,I-Chemical
tended,1984,O
to,1984,O
be,1984,O
on,1984,O
average,1984,O
more,1984,O
severely,1984,O
ill,1984,O
",",1984,O
and,1984,O
to,1984,O
have,1984,O
a,1984,O
shorter,1984,O
median,1984,O
delay,1984,O
between,1984,O
onset,1984,O
of,1984,O
symptoms,1984,O
and,1984,O
diagnosis,1984,O
.,1984,O
A,1985,O
policy,1985,O
of,1985,O
unrestricted,1985,O
prescription,1985,O
of,1985,O
appetite,1985,B-Chemical
suppressants,1985,I-Chemical
may,1985,O
lead,1985,O
to,1985,O
a,1985,O
high,1985,O
incidence,1985,O
of,1985,O
associated,1985,O
primary,1985,B-Disease
pulmonary,1985,I-Disease
hypertension,1985,I-Disease
.,1985,O
Intake,1986,O
of,1986,O
appetite,1986,B-Chemical
suppressants,1986,I-Chemical
may,1986,O
accelerate,1986,O
the,1986,O
progression,1986,O
of,1986,O
the,1986,O
disease,1986,O
.,1986,O
Inappropriate,1987,O
use,1987,O
of,1987,O
carbamazepine,1987,B-Chemical
and,1987,O
vigabatrin,1987,B-Chemical
in,1987,O
typical,1987,O
absence,1987,B-Disease
seizures,1987,I-Disease
.,1987,O
Carbamazepine,1988,B-Chemical
and,1988,O
vigabatrin,1988,B-Chemical
are,1988,O
contraindicated,1988,O
in,1988,O
typical,1988,O
absence,1988,B-Disease
seizures,1988,I-Disease
.,1988,O
Of,1989,O
18,1989,O
consecutive,1989,O
referrals,1989,O
of,1989,O
children,1989,O
with,1989,O
resistant,1989,O
typical,1989,O
absences,1989,O
only,1989,O
",",1989,O
eight,1989,O
were,1989,O
erroneously,1989,O
treated,1989,O
with,1989,O
carbamazepine,1989,B-Chemical
either,1989,O
as,1989,O
monotherapy,1989,O
or,1989,O
as,1989,O
an,1989,O
add-on,1989,O
.,1989,O
Vigabatrin,1990,B-Chemical
was,1990,O
also,1990,O
used,1990,O
in,1990,O
the,1990,O
treatment,1990,O
of,1990,O
two,1990,O
children,1990,O
.,1990,O
Frequency,1991,O
of,1991,O
absences,1991,O
increased,1991,O
in,1991,O
four,1991,O
children,1991,O
treated,1991,O
with,1991,O
carbamazepine,1991,B-Chemical
and,1991,O
two,1991,O
of,1991,O
these,1991,O
developed,1991,O
myoclonic,1991,B-Disease
jerks,1991,I-Disease
",",1991,O
which,1991,O
resolved,1991,O
on,1991,O
withdrawal,1991,O
of,1991,O
carbamazepine,1991,B-Chemical
.,1991,O
Absences,1992,O
were,1992,O
aggravated,1992,O
in,1992,O
both,1992,O
cases,1992,O
where,1992,O
vigabatrin,1992,B-Chemical
was,1992,O
added,1992,O
on,1992,O
to,1992,O
concurrent,1992,O
treatment,1992,O
.,1992,O
Optimal,1993,O
control,1993,O
of,1993,O
the,1993,O
absences,1993,O
was,1993,O
achieved,1993,O
with,1993,O
sodium,1993,B-Chemical
valproate,1993,I-Chemical
",",1993,O
lamotrigine,1993,B-Chemical
",",1993,O
or,1993,O
ethosuximide,1993,B-Chemical
alone,1993,O
or,1993,O
in,1993,O
combination,1993,O
.,1993,O
Choreoathetoid,1994,B-Disease
movements,1994,I-Disease
associated,1994,O
with,1994,O
rapid,1994,O
adjustment,1994,O
to,1994,O
methadone,1994,B-Chemical
.,1994,O
Choreatiform,1995,O
hyperkinesias,1995,O
are,1995,O
known,1995,O
to,1995,O
be,1995,O
occasional,1995,O
movement,1995,B-Disease
abnormalities,1995,I-Disease
during,1995,O
intoxications,1995,O
with,1995,O
cocaine,1995,B-Chemical
but,1995,O
not,1995,O
opiates,1995,O
.,1995,O
This,1996,O
is,1996,O
a,1996,O
case,1996,O
report,1996,O
of,1996,O
euphoria,1996,O
and,1996,O
choreoathetoid,1996,B-Disease
movements,1996,I-Disease
both,1996,O
transiently,1996,O
induced,1996,O
by,1996,O
rapid,1996,O
adjustment,1996,O
to,1996,O
the,1996,O
selective,1996,O
mu-opioid,1996,O
receptor,1996,O
agonist,1996,O
methadone,1996,B-Chemical
in,1996,O
an,1996,O
inpatient,1996,O
previously,1996,O
abusing,1996,O
heroine,1996,B-Chemical
and,1996,O
cocaine,1996,B-Chemical
.,1996,O
In,1997,O
addition,1997,O
",",1997,O
minor,1997,O
EEG,1997,O
abnormalities,1997,O
occurred,1997,O
.,1997,O
Possible,1998,O
underlying,1998,O
neurobiological,1998,O
phenomena,1998,O
are,1998,O
discussed,1998,O
.,1998,O
Adverse,1999,O
effects,1999,O
of,1999,O
the,1999,O
atypical,1999,O
antipsychotics,1999,O
.,1999,O
Collaborative,2000,O
Working,2000,O
Group,2000,O
on,2000,O
Clinical,2000,O
Trial,2000,O
Evaluations,2000,O
.,2000,O
Adverse,2001,O
effects,2001,O
of,2001,O
antipsychotics,2001,O
often,2001,O
lead,2001,O
to,2001,O
noncompliance,2001,O
.,2001,O
Thus,2002,O
",",2002,O
clinicians,2002,O
should,2002,O
address,2002,O
patients,2002,O
',2002,O
concerns,2002,O
about,2002,O
adverse,2002,O
effects,2002,O
and,2002,O
attempt,2002,O
to,2002,O
choose,2002,O
medications,2002,O
that,2002,O
will,2002,O
improve,2002,O
their,2002,O
patients,2002,O
',2002,O
quality,2002,O
of,2002,O
life,2002,O
as,2002,O
well,2002,O
as,2002,O
overall,2002,O
health,2002,O
.,2002,O
The,2003,O
side,2003,O
effect,2003,O
profiles,2003,O
of,2003,O
the,2003,O
atypical,2003,O
antipsychotics,2003,O
are,2003,O
more,2003,O
advantageous,2003,O
than,2003,O
those,2003,O
of,2003,O
the,2003,O
conventional,2003,O
neuroleptics,2003,O
.,2003,O
Conventional,2004,O
agents,2004,O
are,2004,O
associated,2004,O
with,2004,O
unwanted,2004,O
central,2004,O
nervous,2004,O
system,2004,O
effects,2004,O
",",2004,O
including,2004,O
extrapyramidal,2004,B-Disease
symptoms,2004,I-Disease
(,2004,O
EPS,2004,B-Disease
),2004,O
",",2004,O
tardive,2004,B-Disease
dyskinesia,2004,I-Disease
",",2004,O
sedation,2004,O
",",2004,O
and,2004,O
possible,2004,O
impairment,2004,O
of,2004,O
some,2004,O
cognitive,2004,O
measures,2004,O
",",2004,O
as,2004,O
well,2004,O
as,2004,O
cardiac,2004,O
effects,2004,O
",",2004,O
orthostatic,2004,B-Disease
hypotension,2004,I-Disease
",",2004,O
hepatic,2004,O
changes,2004,O
",",2004,O
anticholinergic,2004,O
side,2004,O
effects,2004,O
",",2004,O
sexual,2004,B-Disease
dysfunction,2004,I-Disease
",",2004,O
and,2004,O
weight,2004,B-Disease
gain,2004,I-Disease
.,2004,O
The,2005,O
newer,2005,O
atypical,2005,O
agents,2005,O
have,2005,O
a,2005,O
lower,2005,O
risk,2005,O
of,2005,O
EPS,2005,B-Disease
",",2005,O
but,2005,O
are,2005,O
associated,2005,O
in,2005,O
varying,2005,O
degrees,2005,O
with,2005,O
sedation,2005,O
",",2005,O
cardiovascular,2005,O
effects,2005,O
",",2005,O
anticholinergic,2005,O
effects,2005,O
",",2005,O
weight,2005,B-Disease
gain,2005,I-Disease
",",2005,O
sexual,2005,B-Disease
dysfunction,2005,I-Disease
",",2005,O
hepatic,2005,O
effects,2005,O
",",2005,O
lowered,2005,O
seizure,2005,B-Disease
threshold,2005,O
(,2005,O
primarily,2005,O
clozapine,2005,B-Chemical
),2005,O
",",2005,O
and,2005,O
agranulocytosis,2005,B-Disease
(,2005,O
clozapine,2005,B-Chemical
only,2005,O
),2005,O
.,2005,O
Since,2006,O
the,2006,O
incidence,2006,O
and,2006,O
severity,2006,O
of,2006,O
specific,2006,O
adverse,2006,O
effects,2006,O
differ,2006,O
among,2006,O
the,2006,O
various,2006,O
atypicals,2006,O
",",2006,O
the,2006,O
clinician,2006,O
should,2006,O
carefully,2006,O
consider,2006,O
which,2006,O
side,2006,O
effects,2006,O
are,2006,O
most,2006,O
likely,2006,O
to,2006,O
lead,2006,O
to,2006,O
the,2006,O
individual,2006,O
's,2006,O
dissatisfaction,2006,O
and,2006,O
noncompliance,2006,O
before,2006,O
choosing,2006,O
an,2006,O
antipsychotic,2006,O
for,2006,O
a,2006,O
particular,2006,O
patient,2006,O
.,2006,O
A,2007,O
randomized,2007,O
",",2007,O
placebo-controlled,2007,O
dose-comparison,2007,O
trial,2007,O
of,2007,O
haloperidol,2007,B-Chemical
for,2007,O
psychosis,2007,B-Disease
and,2007,O
disruptive,2007,B-Disease
behaviors,2007,I-Disease
in,2007,O
Alzheimer,2007,B-Disease
's,2007,I-Disease
disease,2007,I-Disease
.,2007,O
OBJECTIVE,2008,O
:,2008,O
The,2008,O
goal,2008,O
of,2008,O
this,2008,O
study,2008,O
was,2008,O
to,2008,O
compare,2008,O
the,2008,O
efficacy,2008,O
and,2008,O
side,2008,O
effects,2008,O
of,2008,O
two,2008,O
doses,2008,O
of,2008,O
haloperidol,2008,B-Chemical
and,2008,O
placebo,2008,O
in,2008,O
the,2008,O
treatment,2008,O
of,2008,O
psychosis,2008,B-Disease
and,2008,O
disruptive,2008,B-Disease
behaviors,2008,I-Disease
in,2008,O
patients,2008,O
with,2008,O
Alzheimer,2008,B-Disease
's,2008,I-Disease
disease,2008,I-Disease
.,2008,O
METHOD,2009,O
:,2009,O
In,2009,O
a,2009,O
6-week,2009,O
random-assignment,2009,O
",",2009,O
double-blind,2009,O
",",2009,O
placebo-controlled,2009,O
trial,2009,O
(,2009,O
phase,2009,O
A,2009,O
),2009,O
",",2009,O
haloperidol,2009,B-Chemical
",",2009,O
2-3,2009,O
mg/day,2009,O
(,2009,O
standard,2009,O
dose,2009,O
),2009,O
",",2009,O
and,2009,O
haloperidol,2009,B-Chemical
",",2009,O
0.50-0.75,2009,O
mg/day,2009,O
(,2009,O
low,2009,O
dose,2009,O
),2009,O
",",2009,O
were,2009,O
compared,2009,O
in,2009,O
71,2009,O
outpatients,2009,O
with,2009,O
Alzheimer,2009,B-Disease
's,2009,I-Disease
disease,2009,I-Disease
.,2009,O
For,2010,O
the,2010,O
subsequent,2010,O
6-week,2010,O
double-blind,2010,O
crossover,2010,O
phase,2010,O
(,2010,O
phase,2010,O
B,2010,O
),2010,O
",",2010,O
patients,2010,O
taking,2010,O
standard-,2010,O
or,2010,O
low-dose,2010,O
haloperidol,2010,B-Chemical
were,2010,O
switched,2010,O
to,2010,O
placebo,2010,O
",",2010,O
and,2010,O
patients,2010,O
taking,2010,O
placebo,2010,O
were,2010,O
randomly,2010,O
assigned,2010,O
to,2010,O
standard-,2010,O
or,2010,O
low-dose,2010,O
haloperidol,2010,B-Chemical
.,2010,O
RESULTS,2011,O
:,2011,O
For,2011,O
the,2011,O
60,2011,O
patients,2011,O
who,2011,O
completed,2011,O
phase,2011,O
A,2011,O
",",2011,O
standard-dose,2011,O
haloperidol,2011,B-Chemical
was,2011,O
efficacious,2011,O
and,2011,O
superior,2011,O
to,2011,O
both,2011,O
low-dose,2011,O
haloperidol,2011,B-Chemical
and,2011,O
placebo,2011,O
for,2011,O
scores,2011,O
on,2011,O
the,2011,O
Brief,2011,O
Psychiatric,2011,O
Rating,2011,O
Scale,2011,O
psychosis,2011,B-Disease
factor,2011,O
and,2011,O
on,2011,O
psychomotor,2011,B-Disease
agitation,2011,I-Disease
.,2011,O
Response,2012,O
rates,2012,O
according,2012,O
to,2012,O
three,2012,O
sets,2012,O
of,2012,O
criteria,2012,O
were,2012,O
greater,2012,O
with,2012,O
the,2012,O
standard,2012,O
dose,2012,O
(,2012,O
55,2012,O
%,2012,O
-60,2012,O
%,2012,O
),2012,O
than,2012,O
the,2012,O
low,2012,O
dose,2012,O
(,2012,O
25,2012,O
%,2012,O
-35,2012,O
%,2012,O
),2012,O
and,2012,O
placebo,2012,O
(,2012,O
25,2012,O
%,2012,O
-30,2012,O
%,2012,O
),2012,O
.,2012,O
The,2013,O
advantage,2013,O
of,2013,O
standard,2013,O
dose,2013,O
over,2013,O
low,2013,O
dose,2013,O
was,2013,O
replicated,2013,O
in,2013,O
phase,2013,O
B,2013,O
.,2013,O
In,2014,O
phase,2014,O
A,2014,O
",",2014,O
extrapyramidal,2014,B-Disease
signs,2014,I-Disease
tended,2014,O
to,2014,O
be,2014,O
greater,2014,O
with,2014,O
the,2014,O
standard,2014,O
dose,2014,O
than,2014,O
in,2014,O
the,2014,O
other,2014,O
two,2014,O
conditions,2014,O
",",2014,O
primarily,2014,O
because,2014,O
of,2014,O
a,2014,O
subgroup,2014,O
(,2014,O
20,2014,O
%,2014,O
),2014,O
who,2014,O
developed,2014,O
moderate,2014,O
to,2014,O
severe,2014,O
signs,2014,O
.,2014,O
Low-dose,2015,O
haloperidol,2015,B-Chemical
did,2015,O
not,2015,O
differ,2015,O
from,2015,O
placebo,2015,O
on,2015,O
any,2015,O
measure,2015,O
of,2015,O
efficacy,2015,O
or,2015,O
side,2015,O
effects,2015,O
.,2015,O
CONCLUSIONS,2016,O
:,2016,O
The,2016,O
results,2016,O
indicated,2016,O
a,2016,O
favorable,2016,O
therapeutic,2016,O
profile,2016,O
for,2016,O
haloperidol,2016,B-Chemical
in,2016,O
doses,2016,O
of,2016,O
2-3,2016,O
mg/day,2016,O
",",2016,O
although,2016,O
a,2016,O
subgroup,2016,O
developed,2016,O
moderate,2016,O
to,2016,O
severe,2016,O
extrapyramidal,2016,B-Disease
signs,2016,I-Disease
.,2016,O
A,2017,O
starting,2017,O
dose,2017,O
of,2017,O
1,2017,O
mg/day,2017,O
with,2017,O
gradual,2017,O
",",2017,O
upward,2017,O
dose,2017,O
titration,2017,O
is,2017,O
recommended,2017,O
.,2017,O
The,2018,O
narrow,2018,O
therapeutic,2018,O
window,2018,O
observed,2018,O
with,2018,O
haloperidol,2018,B-Chemical
may,2018,O
also,2018,O
apply,2018,O
to,2018,O
other,2018,O
neuroleptics,2018,O
used,2018,O
in,2018,O
Alzheimer,2018,B-Disease
's,2018,I-Disease
disease,2018,I-Disease
patients,2018,O
with,2018,O
psychosis,2018,B-Disease
and,2018,O
disruptive,2018,B-Disease
behaviors,2018,I-Disease
.,2018,O
Clinical,2019,O
and,2019,O
histopathologic,2019,O
examination,2019,O
of,2019,O
renal,2019,O
allografts,2019,O
treated,2019,O
with,2019,O
tacrolimus,2019,B-Chemical
(,2019,O
FK506,2019,B-Chemical
),2019,O
for,2019,O
at,2019,O
least,2019,O
one,2019,O
year,2019,O
.,2019,O
BACKGROUND,2020,O
:,2020,O
We,2020,O
clinically,2020,O
and,2020,O
pathologically,2020,O
analyzed,2020,O
renal,2020,O
allografts,2020,O
from,2020,O
1,2020,O
9,2020,O
renal,2020,O
transplant,2020,O
patients,2020,O
treated,2020,O
with,2020,O
tacrolimus,2020,B-Chemical
(,2020,O
FK506,2020,B-Chemical
),2020,O
for,2020,O
more,2020,O
than,2020,O
1,2020,O
year,2020,O
.,2020,O
METHODS,2021,O
:,2021,O
Twenty-six,2021,O
renal,2021,O
allograft,2021,O
biopsy,2021,O
specimens,2021,O
from,2021,O
1,2021,O
9,2021,O
renal,2021,O
transplant,2021,O
patients,2021,O
who,2021,O
underwent,2021,O
transplantations,2021,O
between,2021,O
1991,2021,O
and,2021,O
1993,2021,O
were,2021,O
evaluated,2021,O
.,2021,O
Thirteen,2022,O
biopsies,2022,O
were,2022,O
performed,2022,O
from,2022,O
stable,2022,O
functioning,2022,O
renal,2022,O
allografts,2022,O
with,2022,O
informed,2022,O
consent,2022,O
(,2022,O
nonepisode,2022,O
biopsy,2022,O
),2022,O
and,2022,O
the,2022,O
other,2022,O
13,2022,O
were,2022,O
from,2022,O
dysfunctional,2022,O
renal,2022,O
allografts,2022,O
with,2022,O
a,2022,O
clinical,2022,O
indication,2022,O
for,2022,O
biopsy,2022,O
(,2022,O
episode,2022,O
biopsy,2022,O
),2022,O
.,2022,O
RESULTS,2023,O
:,2023,O
The,2023,O
main,2023,O
pathologic,2023,O
diagnoses,2023,O
(,2023,O
some,2023,O
overlap,2023,O
),2023,O
were,2023,O
acute,2023,O
rejection,2023,O
(,2023,O
AR,2023,O
;,2023,O
n,2023,O
=,2023,O
4,2023,O
),2023,O
",",2023,O
chronic,2023,O
rejection,2023,O
(,2023,O
CR,2023,O
;,2023,O
n=5,2023,O
),2023,O
",",2023,O
AR+CR,2023,O
(,2023,O
n,2023,O
=4,2023,O
),2023,O
",",2023,O
recurrent,2023,O
IgA,2023,B-Disease
nephropathy,2023,I-Disease
(,2023,O
n,2023,O
=5,2023,O
),2023,O
",",2023,O
normal,2023,O
findings,2023,O
(,2023,O
n,2023,O
=2,2023,O
),2023,O
",",2023,O
minimal-type,2023,O
chronic,2023,O
FK506,2023,B-Chemical
nephropathy,2023,B-Disease
(,2023,O
n,2023,O
=,2023,O
9,2023,O
),2023,O
",",2023,O
and,2023,O
mild-type,2023,O
FK506,2023,B-Chemical
nephropathy,2023,B-Disease
(,2023,O
n,2023,O
=,2023,O
11,2023,O
),2023,O
.,2023,O
Of,2024,O
the,2024,O
nonepisode,2024,O
biopsies,2024,O
",",2024,O
7,2024,O
and,2024,O
4,2024,O
biopsies,2024,O
showed,2024,O
minimal-type,2024,O
and,2024,O
mild-type,2024,O
chronic,2024,O
FK506,2024,B-Chemical
nephropathy,2024,B-Disease
",",2024,O
respectively,2024,O
.,2024,O
Chronic,2025,O
FK506,2025,B-Chemical
nephropathy,2025,B-Disease
consisted,2025,O
of,2025,O
rough,2025,O
and,2025,O
foamy,2025,O
tubular,2025,O
vacuolization,2025,O
(,2025,O
5,2025,O
biopsies,2025,O
),2025,O
",",2025,O
arteriolopathy,2025,O
(,2025,O
angiodegeneration,2025,O
of,2025,O
the,2025,O
arteriolar,2025,O
wall,2025,O
;,2025,O
20,2025,O
biopsies,2025,O
),2025,O
",",2025,O
focal,2025,B-Disease
segmental,2025,I-Disease
glomerulosclerosis,2025,I-Disease
(,2025,O
4,2025,O
biopsies,2025,O
),2025,O
and,2025,O
the,2025,O
striped,2025,O
form,2025,O
of,2025,O
interstitial,2025,B-Disease
fibrosis,2025,I-Disease
(,2025,O
11,2025,O
biopsies,2025,O
),2025,O
.,2025,O
The,2026,O
serum,2026,O
creatinine,2026,B-Chemical
levels,2026,O
of,2026,O
patients,2026,O
in,2026,O
the,2026,O
mild-type,2026,O
chronic,2026,O
FK506,2026,B-Chemical
nephropathy,2026,B-Disease
group,2026,O
",",2026,O
which,2026,O
included,2026,O
7,2026,O
episode,2026,O
biopsies,2026,O
",",2026,O
were,2026,O
statistically,2026,O
higher,2026,O
than,2026,O
those,2026,O
in,2026,O
the,2026,O
minimum-type,2026,O
chronic,2026,O
FK506-nephropathy,2026,B-Chemical
group,2026,O
(,2026,O
P,2026,O
<,2026,O
0.001,2026,O
),2026,O
.,2026,O
CONCLUSIONS,2027,O
:,2027,O
This,2027,O
study,2027,O
demonstrates,2027,O
that,2027,O
chronic,2027,O
FK506,2027,B-Chemical
nephropathy,2027,B-Disease
consists,2027,O
primarily,2027,O
of,2027,O
arteriolopathy,2027,O
manifesting,2027,O
as,2027,O
insudative,2027,O
hyalinosis,2027,O
of,2027,O
the,2027,O
arteriolar,2027,O
wall,2027,O
",",2027,O
and,2027,O
suggests,2027,O
that,2027,O
mild-type,2027,O
chronic,2027,O
FK506,2027,B-Chemical
nephropathy,2027,B-Disease
is,2027,O
a,2027,O
condition,2027,O
which,2027,O
may,2027,O
lead,2027,O
to,2027,O
deterioration,2027,O
of,2027,O
renal,2027,O
allograft,2027,O
function,2027,O
.,2027,O
Different,2028,O
lobular,2028,O
distributions,2028,O
of,2028,O
altered,2028,O
hepatocyte,2028,O
tight,2028,O
junctions,2028,O
in,2028,O
rat,2028,O
models,2028,O
of,2028,O
intrahepatic,2028,O
and,2028,O
extrahepatic,2028,O
cholestasis,2028,O
.,2028,O
Hepatocyte,2029,O
tight,2029,O
junctions,2029,O
(,2029,O
TJs,2029,O
),2029,O
",",2029,O
the,2029,O
only,2029,O
intercellular,2029,O
barrier,2029,O
between,2029,O
the,2029,O
sinusoidal,2029,O
and,2029,O
the,2029,O
canalicular,2029,O
spaces,2029,O
",",2029,O
play,2029,O
a,2029,O
key,2029,O
role,2029,O
in,2029,O
bile,2029,O
formation,2029,O
.,2029,O
Although,2030,O
hepatocyte,2030,O
TJs,2030,O
are,2030,O
impaired,2030,O
in,2030,O
cholestasis,2030,B-Disease
",",2030,O
attempts,2030,O
to,2030,O
localize,2030,O
the,2030,O
precise,2030,O
site,2030,O
of,2030,O
hepatocyte,2030,O
TJ,2030,O
damage,2030,O
by,2030,O
freeze-fracture,2030,O
electron,2030,O
microscopy,2030,O
have,2030,O
produced,2030,O
limited,2030,O
information,2030,O
.,2030,O
Recently,2031,O
",",2031,O
several,2031,O
TJ-associated,2031,O
proteins,2031,O
like,2031,O
ZO-1,2031,O
and,2031,O
7H6,2031,O
have,2031,O
been,2031,O
identified,2031,O
and,2031,O
characterized,2031,O
.,2031,O
Immunolocalization,2032,O
of,2032,O
7H6,2032,O
appears,2032,O
to,2032,O
closely,2032,O
correlate,2032,O
with,2032,O
paracellular,2032,O
permeability,2032,O
.,2032,O
We,2033,O
used,2033,O
rat,2033,O
models,2033,O
of,2033,O
intrahepatic,2033,B-Disease
cholestasis,2033,I-Disease
by,2033,O
ethinyl,2033,B-Chemical
estradiol,2033,I-Chemical
(,2033,O
EE,2033,B-Chemical
),2033,O
treatment,2033,O
and,2033,O
extrahepatic,2033,B-Disease
cholestasis,2033,I-Disease
by,2033,O
bile,2033,O
duct,2033,O
ligation,2033,O
(,2033,O
BDL,2033,O
),2033,O
to,2033,O
precisely,2033,O
determine,2033,O
the,2033,O
site,2033,O
of,2033,O
TJ,2033,O
damage,2033,O
.,2033,O
Alterations,2034,O
in,2034,O
hepatocyte,2034,O
TJs,2034,O
were,2034,O
assessed,2034,O
by,2034,O
double-immunolabeling,2034,O
for,2034,O
7H6,2034,O
and,2034,O
ZO-1,2034,O
using,2034,O
a,2034,O
confocal,2034,O
laser,2034,O
scanning,2034,O
microscope,2034,O
.,2034,O
In,2035,O
control,2035,O
rats,2035,O
",",2035,O
immunostaining,2035,O
for,2035,O
7H6,2035,O
and,2035,O
ZO-1,2035,O
colocalized,2035,O
to,2035,O
outline,2035,O
bile,2035,O
canaliculi,2035,O
in,2035,O
a,2035,O
continuous,2035,O
fashion,2035,O
.,2035,O
In,2036,O
contrast,2036,O
",",2036,O
7H6,2036,O
and,2036,O
ZO-1,2036,O
immunostaining,2036,O
was,2036,O
more,2036,O
discontinuous,2036,O
",",2036,O
outlining,2036,O
the,2036,O
bile,2036,O
canaliculi,2036,O
after,2036,O
BDL,2036,O
.,2036,O
Immunostaining,2037,O
for,2037,O
7H6,2037,O
",",2037,O
not,2037,O
ZO-1,2037,O
",",2037,O
decreased,2037,O
and,2037,O
predominantly,2037,O
appeared,2037,O
as,2037,O
discrete,2037,O
signals,2037,O
in,2037,O
the,2037,O
submembranous,2037,O
cytoplasm,2037,O
of,2037,O
periportal,2037,O
hepatocytes,2037,O
after,2037,O
BDL,2037,O
.,2037,O
After,2038,O
EE,2038,B-Chemical
treatment,2038,O
",",2038,O
changes,2038,O
in,2038,O
immunostaining,2038,O
for,2038,O
7H6,2038,O
and,2038,O
ZO-1,2038,O
were,2038,O
similar,2038,O
to,2038,O
those,2038,O
seen,2038,O
in,2038,O
periportal,2038,O
hepatocytes,2038,O
after,2038,O
BDL,2038,O
",",2038,O
but,2038,O
distributed,2038,O
more,2038,O
diffusely,2038,O
throughout,2038,O
the,2038,O
lobule,2038,O
.,2038,O
This,2039,O
study,2039,O
is,2039,O
the,2039,O
first,2039,O
to,2039,O
demonstrate,2039,O
that,2039,O
impairment,2039,O
of,2039,O
hepatocyte,2039,O
TJs,2039,O
occurs,2039,O
heterogenously,2039,O
in,2039,O
the,2039,O
liver,2039,O
lobule,2039,O
after,2039,O
BDL,2039,O
and,2039,O
suggests,2039,O
that,2039,O
BDL,2039,O
and,2039,O
EE,2039,B-Chemical
treatments,2039,O
produce,2039,O
different,2039,O
lobular,2039,O
distributions,2039,O
of,2039,O
increased,2039,O
paracellular,2039,O
permeability,2039,O
.,2039,O
Memory,2040,O
facilitation,2040,O
and,2040,O
stimulation,2040,O
of,2040,O
endogenous,2040,O
nerve,2040,O
growth,2040,O
factor,2040,O
synthesis,2040,O
by,2040,O
the,2040,O
acetylcholine,2040,B-Chemical
releaser,2040,O
PG-9,2040,B-Chemical
.,2040,O
The,2041,O
effects,2041,O
of,2041,O
PG-9,2041,B-Chemical
(,2041,O
3alpha-tropyl,2041,B-Chemical
2-,2041,I-Chemical
(,2041,I-Chemical
p-bromophenyl,2041,I-Chemical
),2041,I-Chemical
propionate,2041,I-Chemical
),2041,O
",",2041,O
the,2041,O
acetylcholine,2041,B-Chemical
releaser,2041,O
",",2041,O
on,2041,O
memory,2041,O
processes,2041,O
and,2041,O
nerve,2041,O
growth,2041,O
factor,2041,O
(,2041,O
NGF,2041,O
),2041,O
synthesis,2041,O
were,2041,O
evaluated,2041,O
.,2041,O
In,2042,O
the,2042,O
mouse,2042,O
passive-avoidance,2042,O
test,2042,O
",",2042,O
PG-9,2042,B-Chemical
(,2042,O
10-30,2042,O
mg/kg,2042,O
",",2042,O
i.p,2042,O
.,2042,O
),2043,O
",",2043,O
administered,2043,O
20,2043,O
min,2043,O
before,2043,O
the,2043,O
training,2043,O
session,2043,O
",",2043,O
prevented,2043,O
amnesia,2043,O
induced,2043,O
by,2043,O
both,2043,O
the,2043,O
non,2043,O
selective,2043,O
antimuscarinic,2043,O
drug,2043,O
scopolamine,2043,O
and,2043,O
the,2043,O
M1-selective,2043,O
antagonist,2043,O
S-,2043,I-Chemical
(,2043,I-Chemical
-,2043,I-Chemical
),2043,I-Chemical
-ET-126,2043,O
.,2043,O
In,2044,O
the,2044,O
same,2044,O
experimental,2044,O
conditions,2044,O
",",2044,O
PG-9,2044,O
(,2044,O
5-20,2044,O
microg,2044,O
per,2044,O
mouse,2044,O
",",2044,O
i.c.v,2044,O
.,2044,O
),2044,O
was,2045,O
also,2045,O
able,2045,O
to,2045,O
prevent,2045,O
antimuscarine-induced,2045,O
amnesia,2045,O
",",2045,O
demonstrating,2045,O
a,2045,O
central,2045,O
localization,2045,O
of,2045,O
the,2045,O
activity,2045,O
.,2045,O
At,2046,O
the,2046,O
highest,2046,O
effective,2046,O
doses,2046,O
",",2046,O
PG-9,2046,O
did,2046,O
not,2046,O
produce,2046,O
any,2046,O
collateral,2046,O
symptoms,2046,O
as,2046,O
revealed,2046,O
by,2046,O
the,2046,O
Irwin,2046,O
test,2046,O
",",2046,O
and,2046,O
it,2046,O
did,2046,O
not,2046,O
modify,2046,O
spontaneous,2046,O
motility,2046,O
and,2046,O
inspection,2046,O
activity,2046,O
",",2046,O
as,2046,O
revealed,2046,O
by,2046,O
the,2046,O
hole-board,2046,O
test,2046,O
.,2046,O
PG-9,2047,O
was,2047,O
also,2047,O
able,2047,O
to,2047,O
increase,2047,O
the,2047,O
amount,2047,O
of,2047,O
NGF,2047,O
secreted,2047,O
in,2047,O
vitro,2047,O
by,2047,O
astrocytes,2047,O
in,2047,O
a,2047,O
dose-dependent,2047,O
manner,2047,O
.,2047,O
The,2048,O
maximal,2048,O
NGF,2048,O
contents,2048,O
obtained,2048,O
by,2048,O
PG-9,2048,O
were,2048,O
17.6-fold,2048,O
of,2048,O
the,2048,O
control,2048,O
value,2048,O
.,2048,O
During,2049,O
culture,2049,O
",",2049,O
no,2049,O
morphological,2049,O
changes,2049,O
were,2049,O
found,2049,O
at,2049,O
effective,2049,O
concentrations,2049,O
of,2049,O
PG-9,2049,O
.,2049,O
The,2050,O
current,2050,O
work,2050,O
indicates,2050,O
the,2050,O
ability,2050,O
of,2050,O
PG-9,2050,O
to,2050,O
induce,2050,O
beneficial,2050,O
effects,2050,O
on,2050,O
cognitive,2050,O
processes,2050,O
and,2050,O
stimulate,2050,O
activity,2050,O
of,2050,O
NGF,2050,O
synthesis,2050,O
in,2050,O
astroglial,2050,O
cells,2050,O
.,2050,O
Therefore,2051,O
",",2051,O
PG-9,2051,O
could,2051,O
represent,2051,O
a,2051,O
potential,2051,O
useful,2051,O
drug,2051,O
able,2051,O
to,2051,O
improve,2051,O
the,2051,O
function,2051,O
of,2051,O
impaired,2051,O
cognitive,2051,O
processes,2051,O
.,2051,O
Mechanisms,2052,O
of,2052,O
FK,2052,B-Chemical
506-induced,2052,O
hypertension,2052,B-Disease
in,2052,O
the,2052,O
rat,2052,O
.,2052,O
-Tacrolimus,2053,O
(,2053,O
FK,2053,B-Chemical
506,2053,I-Chemical
),2053,O
is,2053,O
a,2053,O
powerful,2053,O
",",2053,O
widely,2053,O
used,2053,O
immunosuppressant,2053,O
.,2053,O
The,2054,O
clinical,2054,O
utility,2054,O
of,2054,O
FK,2054,B-Chemical
506,2054,I-Chemical
is,2054,O
complicated,2054,O
by,2054,O
substantial,2054,O
hypertension,2054,B-Disease
and,2054,O
nephrotoxicity,2054,B-Disease
.,2054,O
To,2055,O
clarify,2055,O
the,2055,O
mechanisms,2055,O
of,2055,O
FK,2055,B-Chemical
506-induced,2055,O
hypertension,2055,B-Disease
",",2055,O
we,2055,O
studied,2055,O
the,2055,O
chronic,2055,O
effects,2055,O
of,2055,O
FK,2055,B-Chemical
506,2055,I-Chemical
on,2055,O
the,2055,O
synthesis,2055,O
of,2055,O
endothelin-1,2055,O
(,2055,O
ET-1,2055,O
),2055,O
",",2055,O
the,2055,O
expression,2055,O
of,2055,O
mRNA,2055,O
of,2055,O
ET-1,2055,O
and,2055,O
endothelin-converting,2055,O
enzyme-1,2055,O
(,2055,O
ECE-1,2055,O
),2055,O
",",2055,O
the,2055,O
endothelial,2055,O
nitric,2055,B-Chemical
oxide,2055,I-Chemical
synthase,2055,O
(,2055,O
eNOS,2055,O
),2055,O
activity,2055,O
",",2055,O
and,2055,O
the,2055,O
expression,2055,O
of,2055,O
mRNA,2055,O
of,2055,O
eNOS,2055,O
and,2055,O
C-type,2055,O
natriuretic,2055,O
peptide,2055,O
(,2055,O
CNP,2055,O
),2055,O
in,2055,O
rat,2055,O
blood,2055,O
vessels,2055,O
.,2055,O
In,2056,O
addition,2056,O
",",2056,O
the,2056,O
effect,2056,O
of,2056,O
the,2056,O
specific,2056,O
endothelin,2056,O
type,2056,O
A,2056,O
receptor,2056,O
antagonist,2056,O
FR,2056,B-Chemical
139317,2056,I-Chemical
on,2056,O
FK,2056,B-Chemical
506-induced,2056,O
hypertension,2056,B-Disease
in,2056,O
rats,2056,O
was,2056,O
studied,2056,O
.,2056,O
FK,2057,B-Chemical
506,2057,I-Chemical
",",2057,O
5,2057,O
mg.,2057,O
kg-1,2057,O
.,2057,O
d-1,2058,O
given,2058,O
for,2058,O
4,2058,O
weeks,2058,O
",",2058,O
elevated,2058,O
blood,2058,O
pressure,2058,O
from,2058,O
102+/-13,2058,O
to,2058,O
152+/-15,2058,O
mm,2058,O
Hg,2058,O
and,2058,O
increased,2058,O
the,2058,O
synthesis,2058,O
of,2058,O
ET-1,2058,O
and,2058,O
the,2058,O
levels,2058,O
of,2058,O
ET-1,2058,O
mRNA,2058,O
in,2058,O
the,2058,O
mesenteric,2058,O
artery,2058,O
(,2058,O
240,2058,O
%,2058,O
and,2058,O
230,2058,O
%,2058,O
",",2058,O
respectively,2058,O
),2058,O
.,2058,O
Little,2059,O
change,2059,O
was,2059,O
observed,2059,O
in,2059,O
the,2059,O
expression,2059,O
of,2059,O
ECE-1,2059,O
mRNA,2059,O
and,2059,O
CNP,2059,O
mRNA,2059,O
.,2059,O
FK,2060,B-Chemical
506,2060,I-Chemical
decreased,2060,O
eNOS,2060,O
activity,2060,O
and,2060,O
the,2060,O
levels,2060,O
of,2060,O
eNOS,2060,O
mRNA,2060,O
in,2060,O
the,2060,O
aorta,2060,O
(,2060,O
48,2060,O
%,2060,O
and,2060,O
55,2060,O
%,2060,O
",",2060,O
respectively,2060,O
),2060,O
.,2060,O
The,2061,O
administration,2061,O
of,2061,O
FR,2061,B-Chemical
139317,2061,I-Chemical
(,2061,O
10,2061,O
mg.,2061,O
kg-1,2061,O
.,2061,O
d-1,2062,O
),2062,O
prevented,2062,O
FK,2062,B-Chemical
506-induced,2062,O
hypertension,2062,B-Disease
in,2062,O
rats,2062,O
.,2062,O
These,2063,O
results,2063,O
indicate,2063,O
that,2063,O
FK,2063,B-Chemical
506,2063,I-Chemical
may,2063,O
increase,2063,O
blood,2063,O
pressure,2063,O
not,2063,O
only,2063,O
by,2063,O
increasing,2063,O
ET-1,2063,O
production,2063,O
but,2063,O
also,2063,O
by,2063,O
decreasing,2063,O
NO,2063,B-Chemical
synthesis,2063,O
in,2063,O
the,2063,O
vasculature,2063,O
.,2063,O
Selegiline-induced,2064,B-Chemical
postural,2064,B-Disease
hypotension,2064,I-Disease
in,2064,O
Parkinson,2064,B-Disease
's,2064,I-Disease
disease,2064,I-Disease
:,2064,O
a,2064,O
longitudinal,2064,O
study,2064,O
on,2064,O
the,2064,O
effects,2064,O
of,2064,O
drug,2064,O
withdrawal,2064,O
.,2064,O
OBJECTIVES,2065,O
:,2065,O
The,2065,O
United,2065,O
Kingdom,2065,O
Parkinson,2065,B-Disease
's,2065,I-Disease
Disease,2065,I-Disease
Research,2065,O
Group,2065,O
(,2065,O
UKPDRG,2065,O
),2065,O
trial,2065,O
found,2065,O
an,2065,O
increased,2065,O
mortality,2065,O
in,2065,O
patients,2065,O
with,2065,O
Parkinson,2065,B-Disease
's,2065,I-Disease
disease,2065,I-Disease
(,2065,O
PD,2065,B-Disease
),2065,O
randomized,2065,O
to,2065,O
receive,2065,O
10,2065,O
mg,2065,O
selegiline,2065,B-Chemical
per,2065,O
day,2065,O
and,2065,O
L-dopa,2065,B-Chemical
compared,2065,O
with,2065,O
those,2065,O
taking,2065,O
L-dopa,2065,B-Chemical
alone,2065,O
.,2065,O
Recently,2066,O
",",2066,O
we,2066,O
found,2066,O
that,2066,O
therapy,2066,O
with,2066,O
selegiline,2066,B-Chemical
and,2066,O
L-dopa,2066,B-Chemical
was,2066,O
associated,2066,O
with,2066,O
selective,2066,O
systolic,2066,B-Disease
orthostatic,2066,I-Disease
hypotension,2066,I-Disease
which,2066,O
was,2066,O
abolished,2066,O
by,2066,O
withdrawal,2066,O
of,2066,O
selegiline,2066,B-Chemical
.,2066,O
This,2067,O
unwanted,2067,O
effect,2067,O
on,2067,O
postural,2067,O
blood,2067,O
pressure,2067,O
was,2067,O
not,2067,O
the,2067,O
result,2067,O
of,2067,O
underlying,2067,O
autonomic,2067,O
failure,2067,O
.,2067,O
The,2068,O
aims,2068,O
of,2068,O
this,2068,O
study,2068,O
were,2068,O
to,2068,O
confirm,2068,O
our,2068,O
previous,2068,O
findings,2068,O
in,2068,O
a,2068,O
separate,2068,O
cohort,2068,O
of,2068,O
patients,2068,O
and,2068,O
to,2068,O
determine,2068,O
the,2068,O
time,2068,O
course,2068,O
of,2068,O
the,2068,O
cardiovascular,2068,O
consequences,2068,O
of,2068,O
stopping,2068,O
selegiline,2068,B-Chemical
in,2068,O
the,2068,O
expectation,2068,O
that,2068,O
this,2068,O
might,2068,O
shed,2068,O
light,2068,O
on,2068,O
the,2068,O
mechanisms,2068,O
by,2068,O
which,2068,O
the,2068,O
drug,2068,O
causes,2068,O
orthostatic,2068,B-Disease
hypotension,2068,I-Disease
.,2068,O
METHODS,2069,O
:,2069,O
The,2069,O
cardiovascular,2069,O
responses,2069,O
to,2069,O
standing,2069,O
and,2069,O
head-up,2069,O
tilt,2069,O
were,2069,O
studied,2069,O
repeatedly,2069,O
in,2069,O
PD,2069,B-Disease
patients,2069,O
receiving,2069,O
selegiline,2069,B-Chemical
and,2069,O
as,2069,O
the,2069,O
drug,2069,O
was,2069,O
withdrawn,2069,O
.,2069,O
RESULTS,2070,O
:,2070,O
Head-up,2070,O
tilt,2070,O
caused,2070,O
systolic,2070,B-Disease
orthostatic,2070,I-Disease
hypotension,2070,I-Disease
which,2070,O
was,2070,O
marked,2070,O
in,2070,O
six,2070,O
of,2070,O
20,2070,O
PD,2070,B-Disease
patients,2070,O
on,2070,O
selegiline,2070,B-Chemical
",",2070,O
one,2070,O
of,2070,O
whom,2070,O
lost,2070,O
consciousness,2070,O
with,2070,O
unrecordable,2070,O
blood,2070,O
pressures,2070,O
.,2070,O
A,2071,O
lesser,2071,O
degree,2071,O
of,2071,O
orthostatic,2071,B-Disease
hypotension,2071,I-Disease
occurred,2071,O
with,2071,O
standing,2071,O
.,2071,O
Orthostatic,2072,B-Disease
hypotension,2072,I-Disease
was,2072,O
ameliorated,2072,O
4,2072,O
days,2072,O
after,2072,O
withdrawal,2072,O
of,2072,O
selegiline,2072,B-Chemical
and,2072,O
totally,2072,O
abolished,2072,O
7,2072,O
days,2072,O
after,2072,O
discontinuation,2072,O
of,2072,O
the,2072,O
drug,2072,O
.,2072,O
Stopping,2073,O
selegiline,2073,B-Chemical
also,2073,O
significantly,2073,O
reduced,2073,B-Disease
the,2073,I-Disease
supine,2073,I-Disease
systolic,2073,I-Disease
and,2073,I-Disease
diastolic,2073,I-Disease
blood,2073,I-Disease
pressures,2073,I-Disease
consistent,2073,O
with,2073,O
a,2073,O
previously,2073,O
undescribed,2073,O
supine,2073,O
pressor,2073,O
action,2073,O
.,2073,O
CONCLUSION,2074,O
:,2074,O
This,2074,O
study,2074,O
confirms,2074,O
our,2074,O
previous,2074,O
finding,2074,O
that,2074,O
selegiline,2074,B-Chemical
in,2074,O
combination,2074,O
with,2074,O
L-dopa,2074,B-Chemical
is,2074,O
associated,2074,O
with,2074,O
selective,2074,O
orthostatic,2074,B-Disease
hypotension,2074,I-Disease
.,2074,O
The,2075,O
possibilities,2075,O
that,2075,O
these,2075,O
cardiovascular,2075,O
findings,2075,O
might,2075,O
be,2075,O
the,2075,O
result,2075,O
of,2075,O
non-selective,2075,O
inhibition,2075,O
of,2075,O
monoamine,2075,O
oxidase,2075,O
or,2075,O
of,2075,O
amphetamine,2075,B-Chemical
and,2075,O
metamphetamine,2075,B-Chemical
are,2075,O
discussed,2075,O
.,2075,O
Effects,2076,O
of,2076,O
tetrandrine,2076,B-Chemical
and,2076,O
fangchinoline,2076,B-Chemical
on,2076,O
experimental,2076,O
thrombosis,2076,B-Disease
in,2076,O
mice,2076,O
and,2076,O
human,2076,O
platelet,2076,B-Disease
aggregation,2076,I-Disease
.,2076,O
Tetrandrine,2077,B-Chemical
(,2077,O
TET,2077,B-Chemical
),2077,O
and,2077,O
fangchinoline,2077,B-Chemical
(,2077,O
FAN,2077,B-Chemical
),2077,O
are,2077,O
two,2077,O
naturally,2077,O
occurring,2077,O
analogues,2077,O
with,2077,O
a,2077,O
bisbenzylisoquinoline,2077,B-Chemical
structure,2077,O
.,2077,O
The,2078,O
present,2078,O
study,2078,O
was,2078,O
undertaken,2078,O
to,2078,O
investigate,2078,O
the,2078,O
effects,2078,O
of,2078,O
TET,2078,B-Chemical
and,2078,O
FAN,2078,B-Chemical
on,2078,O
the,2078,O
experimental,2078,O
thrombosis,2078,B-Disease
induced,2078,O
by,2078,O
collagen,2078,O
plus,2078,O
epinephrine,2078,B-Chemical
(,2078,O
EP,2078,B-Chemical
),2078,O
in,2078,O
mice,2078,O
",",2078,O
and,2078,O
platelet,2078,B-Disease
aggregation,2078,I-Disease
and,2078,O
blood,2078,B-Disease
coagulation,2078,I-Disease
in,2078,O
vitro,2078,O
.,2078,O
In,2079,O
the,2079,O
in,2079,O
vivo,2079,O
study,2079,O
",",2079,O
the,2079,O
administration,2079,O
(,2079,O
50,2079,O
mg/kg,2079,O
",",2079,O
i.p,2079,O
.,2079,O
),2079,O
of,2080,O
TET,2080,B-Chemical
and,2080,O
FAN,2080,B-Chemical
in,2080,O
mice,2080,O
showed,2080,O
the,2080,O
inhibition,2080,O
of,2080,O
thrombosis,2080,B-Disease
by,2080,O
55,2080,O
%,2080,O
and,2080,O
35,2080,O
%,2080,O
",",2080,O
respectively,2080,O
",",2080,O
while,2080,O
acetylsalicylic,2080,B-Chemical
acid,2080,I-Chemical
(,2080,O
ASA,2080,B-Chemical
",",2080,O
50,2080,O
mg/kg,2080,O
",",2080,O
i.p,2080,O
.,2080,O
),2081,O
",",2081,O
a,2081,O
positive,2081,O
control,2081,O
",",2081,O
showed,2081,O
only,2081,O
30,2081,O
%,2081,O
inhibition,2081,O
.,2081,O
In,2082,O
the,2082,O
vitro,2082,O
human,2082,O
platelet,2082,I-Disease
aggregations,2082,O
induced,2082,O
by,2082,O
the,2082,O
agonists,2082,O
used,2082,O
in,2082,O
tests,2082,O
",",2082,O
TET,2082,O
and,2082,O
FAN,2082,O
showed,2082,O
the,2082,O
inhibitions,2082,O
dose,2082,O
dependently,2082,O
.,2082,O
In,2083,O
addition,2083,O
",",2083,O
neither,2083,O
TET,2083,O
nor,2083,O
FAN,2083,O
showed,2083,O
any,2083,O
anticoagulation,2083,O
activities,2083,O
in,2083,O
the,2083,O
measurement,2083,O
of,2083,O
the,2083,O
activated,2083,O
partial,2083,O
thromboplastin,2083,O
time,2083,O
(,2083,O
APTT,2083,O
),2083,O
",",2083,O
prothrombin,2083,O
time,2083,O
(,2083,O
PT,2083,O
),2083,O
and,2083,O
thrombin,2083,O
time,2083,O
(,2083,O
TT,2083,O
),2083,O
using,2083,O
human-citrated,2083,O
plasma,2083,O
.,2083,O
These,2084,O
results,2084,O
suggest,2084,O
that,2084,O
antithrombosis,2084,O
of,2084,O
TET,2084,O
and,2084,O
FAN,2084,O
in,2084,O
mice,2084,O
may,2084,O
be,2084,O
mainly,2084,O
related,2084,O
to,2084,O
the,2084,O
antiplatelet,2084,O
aggregation,2084,O
activities,2084,O
.,2084,O
Angioedema,2085,B-Disease
due,2085,O
to,2085,O
ACE,2085,B-Chemical
inhibitors,2085,I-Chemical
:,2085,O
common,2085,O
and,2085,O
inadequately,2085,O
diagnosed,2085,O
.,2085,O
The,2086,O
estimated,2086,O
incidence,2086,O
of,2086,O
angioedema,2086,B-Disease
during,2086,O
angiotensin-converting,2086,B-Chemical
enzyme,2086,I-Chemical
(,2086,I-Chemical
ACE,2086,I-Chemical
),2086,I-Chemical
inhibitor,2086,I-Chemical
treatment,2086,O
is,2086,O
between,2086,O
1,2086,O
and,2086,O
7,2086,O
per,2086,O
thousand,2086,O
patients,2086,O
.,2086,O
This,2087,O
potentially,2087,O
serious,2087,O
adverse,2087,O
effect,2087,O
is,2087,O
often,2087,O
preceded,2087,O
by,2087,O
minor,2087,O
manifestations,2087,O
that,2087,O
may,2087,O
serve,2087,O
as,2087,O
a,2087,O
warning,2087,O
.,2087,O
Cocaine-induced,2088,B-Chemical
mood,2088,B-Disease
disorder,2088,I-Disease
:,2088,O
prevalence,2088,O
rates,2088,O
and,2088,O
psychiatric,2088,B-Disease
symptoms,2088,O
in,2088,O
an,2088,O
outpatient,2088,O
cocaine-dependent,2088,B-Chemical
sample,2088,O
.,2088,O
This,2089,O
paper,2089,O
attempts,2089,O
to,2089,O
examine,2089,O
and,2089,O
compare,2089,O
prevalence,2089,O
rates,2089,O
and,2089,O
symptom,2089,O
patterns,2089,O
of,2089,O
DSM,2089,O
substance-induced,2089,O
and,2089,O
other,2089,O
mood,2089,B-Disease
disorders,2089,I-Disease
.,2089,O
243,2090,O
cocaine-dependent,2090,B-Chemical
outpatients,2090,O
with,2090,O
cocaine-induced,2090,B-Chemical
mood,2090,B-Disease
disorder,2090,I-Disease
(,2090,O
CIMD,2090,B-Disease
),2090,O
",",2090,O
other,2090,O
mood,2090,B-Disease
disorders,2090,I-Disease
",",2090,O
or,2090,O
no,2090,O
mood,2090,B-Disease
disorder,2090,I-Disease
were,2090,O
compared,2090,O
on,2090,O
measures,2090,O
of,2090,O
psychiatric,2090,B-Disease
symptoms,2090,O
.,2090,O
The,2091,O
prevalence,2091,O
rate,2091,O
for,2091,O
CIMD,2091,B-Disease
was,2091,O
12,2091,O
%,2091,O
at,2091,O
baseline,2091,O
.,2091,O
Introduction,2092,O
of,2092,O
the,2092,O
DSM-IV,2092,O
diagnosis,2092,O
of,2092,O
CIMD,2092,B-Disease
did,2092,O
not,2092,O
substantially,2092,O
affect,2092,O
rates,2092,O
of,2092,O
the,2092,O
other,2092,O
depressive,2092,B-Disease
disorders,2092,I-Disease
.,2092,O
Patients,2093,O
with,2093,O
CIMD,2093,B-Disease
had,2093,O
symptom,2093,O
severity,2093,O
levels,2093,O
between,2093,O
those,2093,O
of,2093,O
patients,2093,O
with,2093,O
and,2093,O
without,2093,O
a,2093,O
mood,2093,B-Disease
disorder,2093,I-Disease
.,2093,O
These,2094,O
findings,2094,O
suggest,2094,O
some,2094,O
validity,2094,O
for,2094,O
the,2094,O
new,2094,O
DSM-IV,2094,O
diagnosis,2094,O
of,2094,O
CIMD,2094,B-Disease
",",2094,O
but,2094,O
also,2094,O
suggest,2094,O
that,2094,O
it,2094,O
requires,2094,O
further,2094,O
specification,2094,O
and,2094,O
replication,2094,O
.,2094,O
Effect,2095,O
of,2095,O
fucoidan,2095,B-Chemical
treatment,2095,O
on,2095,O
collagenase-induced,2095,O
intracerebral,2095,B-Disease
hemorrhage,2095,I-Disease
in,2095,O
rats,2095,O
.,2095,O
Inflammatory,2096,O
cells,2096,O
are,2096,O
postulated,2096,O
to,2096,O
mediate,2096,O
some,2096,O
of,2096,O
the,2096,O
brain,2096,B-Disease
damage,2096,I-Disease
following,2096,O
ischemic,2096,B-Disease
stroke,2096,I-Disease
.,2096,O
Intracerebral,2097,B-Disease
hemorrhage,2097,I-Disease
is,2097,O
associated,2097,O
with,2097,O
more,2097,O
inflammation,2097,B-Disease
than,2097,O
ischemic,2097,B-Disease
stroke,2097,I-Disease
.,2097,O
We,2098,O
tested,2098,O
the,2098,O
sulfated,2098,O
polysaccharide,2098,O
fucoidan,2098,B-Chemical
",",2098,O
which,2098,O
has,2098,O
been,2098,O
reported,2098,O
to,2098,O
reduce,2098,O
inflammatory,2098,O
brain,2098,B-Disease
damage,2098,I-Disease
",",2098,O
in,2098,O
a,2098,O
rat,2098,O
model,2098,O
of,2098,O
intracerebral,2098,B-Disease
hemorrhage,2098,I-Disease
induced,2098,O
by,2098,O
injection,2098,O
of,2098,O
bacterial,2098,O
collagenase,2098,O
into,2098,O
the,2098,O
caudate,2098,O
nucleus,2098,O
.,2098,O
Rats,2099,O
were,2099,O
treated,2099,O
with,2099,O
seven,2099,O
day,2099,O
intravenous,2099,O
infusion,2099,O
of,2099,O
fucoidan,2099,B-Chemical
(,2099,O
30,2099,O
micrograms,2099,O
h-1,2099,O
),2099,O
or,2099,O
vehicle,2099,O
.,2099,O
The,2100,O
hematoma,2100,B-Disease
was,2100,O
assessed,2100,O
in,2100,O
vivo,2100,O
by,2100,O
magnetic,2100,O
resonance,2100,O
imaging,2100,O
.,2100,O
Motor,2101,O
behavior,2101,O
",",2101,O
passive,2101,O
avoidance,2101,O
",",2101,O
and,2101,O
skilled,2101,O
forelimb,2101,O
function,2101,O
were,2101,O
tested,2101,O
repeatedly,2101,O
for,2101,O
six,2101,O
weeks,2101,O
.,2101,O
Fucoidan-treated,2102,B-Chemical
rats,2102,O
exhibited,2102,O
evidence,2102,O
of,2102,O
impaired,2102,B-Disease
blood,2102,I-Disease
clotting,2102,I-Disease
and,2102,O
hemodilution,2102,B-Disease
",",2102,O
had,2102,O
larger,2102,O
hematomas,2102,B-Disease
",",2102,O
and,2102,O
tended,2102,O
to,2102,O
have,2102,O
less,2102,O
inflammation,2102,B-Disease
in,2102,O
the,2102,O
vicinity,2102,O
of,2102,O
the,2102,O
hematoma,2102,B-Disease
after,2102,O
three,2102,O
days,2102,O
.,2102,O
They,2103,O
showed,2103,O
significantly,2103,O
more,2103,O
rapid,2103,O
improvement,2103,O
of,2103,O
motor,2103,O
function,2103,O
in,2103,O
the,2103,O
first,2103,O
week,2103,O
following,2103,O
hemorrhage,2103,B-Disease
and,2103,O
better,2103,O
memory,2103,O
retention,2103,O
in,2103,O
the,2103,O
passive,2103,O
avoidance,2103,O
test,2103,O
.,2103,O
Acute,2104,O
white,2104,B-Disease
matter,2104,I-Disease
edema,2104,I-Disease
and,2104,O
eventual,2104,O
neuronal,2104,B-Disease
loss,2104,I-Disease
in,2104,O
the,2104,O
striatum,2104,O
adjacent,2104,O
to,2104,O
the,2104,O
hematoma,2104,B-Disease
did,2104,O
not,2104,O
differ,2104,O
between,2104,O
the,2104,O
two,2104,O
groups,2104,O
.,2104,O
Investigation,2105,O
of,2105,O
more,2105,O
specific,2105,O
anti-inflammatory,2105,O
agents,2105,O
and,2105,O
hemodiluting,2105,O
agents,2105,O
are,2105,O
warranted,2105,O
in,2105,O
intracerebral,2105,B-Disease
hemorrhage,2105,I-Disease
.,2105,O
Recurarization,2106,O
in,2106,O
the,2106,O
recovery,2106,O
room,2106,O
.,2106,O
A,2107,O
case,2107,O
of,2107,O
recurarization,2107,O
in,2107,O
the,2107,O
recovery,2107,O
room,2107,O
is,2107,O
reported,2107,O
.,2107,O
Accumulation,2108,O
of,2108,O
atracurium,2108,B-Chemical
in,2108,O
the,2108,O
intravenous,2108,O
line,2108,O
led,2108,O
to,2108,O
recurarization,2108,O
after,2108,O
flushing,2108,O
the,2108,O
line,2108,O
in,2108,O
the,2108,O
recovery,2108,O
room,2108,O
.,2108,O
A,2109,O
respiratory,2109,B-Disease
arrest,2109,I-Disease
with,2109,O
severe,2109,O
desaturation,2109,B-Disease
and,2109,O
bradycardia,2109,B-Disease
occurred,2109,O
.,2109,O
Circumstances,2110,O
leading,2110,O
to,2110,O
this,2110,O
event,2110,O
and,2110,O
the,2110,O
mechanisms,2110,O
enabling,2110,O
a,2110,O
neuromuscular,2110,B-Disease
blockade,2110,I-Disease
to,2110,O
occur,2110,O
",",2110,O
following,2110,O
the,2110,O
administration,2110,O
of,2110,O
a,2110,O
small,2110,O
dose,2110,O
of,2110,O
relaxant,2110,O
",",2110,O
are,2110,O
discussed,2110,O
.,2110,O
The,2111,O
haemodynamic,2111,O
effects,2111,O
of,2111,O
propofol,2111,B-Chemical
in,2111,O
combination,2111,O
with,2111,O
ephedrine,2111,B-Chemical
in,2111,O
elderly,2111,O
patients,2111,O
(,2111,O
ASA,2111,O
groups,2111,O
3,2111,O
and,2111,O
4,2111,O
),2111,O
.,2111,O
The,2112,O
marked,2112,O
vasodilator,2112,O
and,2112,O
negative,2112,O
inotropic,2112,O
effects,2112,O
of,2112,O
propofol,2112,B-Chemical
are,2112,O
disadvantages,2112,O
in,2112,O
frail,2112,O
elderly,2112,O
patients,2112,O
.,2112,O
We,2113,O
investigated,2113,O
the,2113,O
safety,2113,O
and,2113,O
efficacy,2113,O
of,2113,O
adding,2113,O
different,2113,O
doses,2113,O
of,2113,O
ephedrine,2113,B-Chemical
to,2113,O
propofol,2113,B-Chemical
in,2113,O
order,2113,O
to,2113,O
obtund,2113,O
the,2113,O
hypotensive,2113,B-Disease
response,2113,O
.,2113,O
The,2114,O
haemodynamic,2114,O
effects,2114,O
of,2114,O
adding,2114,O
15,2114,O
",",2114,O
20,2114,O
or,2114,O
25,2114,O
mg,2114,O
of,2114,O
ephedrine,2114,B-Chemical
to,2114,O
200,2114,O
mg,2114,O
of,2114,O
propofol,2114,B-Chemical
were,2114,O
compared,2114,O
to,2114,O
control,2114,O
in,2114,O
40,2114,O
ASA,2114,O
3/4,2114,O
patients,2114,O
over,2114,O
60,2114,O
years,2114,O
presenting,2114,O
for,2114,O
genito-urinary,2114,O
surgery,2114,O
.,2114,O
The,2115,O
addition,2115,O
of,2115,O
ephedrine,2115,B-Chemical
to,2115,O
propofol,2115,B-Chemical
appears,2115,O
to,2115,O
be,2115,O
an,2115,O
effective,2115,O
method,2115,O
of,2115,O
obtunding,2115,O
the,2115,O
hypotensive,2115,B-Disease
response,2115,O
to,2115,O
propofol,2115,B-Chemical
at,2115,O
all,2115,O
doses,2115,O
used,2115,O
in,2115,O
this,2115,O
study,2115,O
.,2115,O
However,2116,O
",",2116,O
marked,2116,O
tachycardia,2116,B-Disease
associated,2116,O
with,2116,O
the,2116,O
use,2116,O
of,2116,O
ephedrine,2116,B-Chemical
in,2116,O
combination,2116,O
with,2116,O
propofol,2116,B-Chemical
occurred,2116,O
in,2116,O
the,2116,O
majority,2116,O
of,2116,O
patients,2116,O
",",2116,O
occasionally,2116,O
reaching,2116,O
high,2116,O
levels,2116,O
in,2116,O
individual,2116,O
patients,2116,O
.,2116,O
Due,2117,O
to,2117,O
the,2117,O
risk,2117,O
of,2117,O
this,2117,O
tachycardia,2117,B-Disease
inducing,2117,O
myocardial,2117,B-Disease
ischemia,2117,I-Disease
",",2117,O
we,2117,O
would,2117,O
not,2117,O
recommend,2117,O
the,2117,O
use,2117,O
in,2117,O
elderly,2117,O
patients,2117,O
of,2117,O
any,2117,O
of,2117,O
the,2117,O
ephedrine/propofol/mixtures,2117,B-Chemical
studied,2117,O
.,2117,O
Gemcitabine,2118,B-Chemical
plus,2118,O
vinorelbine,2118,B-Chemical
in,2118,O
nonsmall,2118,B-Disease
cell,2118,I-Disease
lung,2118,I-Disease
carcinoma,2118,I-Disease
patients,2118,O
age,2118,O
70,2118,O
years,2118,O
or,2118,O
older,2118,O
or,2118,O
patients,2118,O
who,2118,O
can,2118,O
not,2118,O
receive,2118,O
cisplatin,2118,B-Chemical
.,2118,O
Oncopaz,2119,O
Cooperative,2119,O
Group,2119,O
.,2119,O
BACKGROUND,2120,O
:,2120,O
Although,2120,O
the,2120,O
prevalence,2120,O
of,2120,O
nonsmall,2120,B-Disease
cell,2120,I-Disease
lung,2120,I-Disease
carcinoma,2120,I-Disease
(,2120,O
NSCLC,2120,B-Disease
),2120,O
is,2120,O
high,2120,O
among,2120,O
elderly,2120,O
patients,2120,O
",",2120,O
few,2120,O
data,2120,O
are,2120,O
available,2120,O
regarding,2120,O
the,2120,O
efficacy,2120,O
and,2120,O
toxicity,2120,B-Disease
of,2120,O
chemotherapy,2120,O
in,2120,O
this,2120,O
group,2120,O
of,2120,O
patients,2120,O
.,2120,O
Recent,2121,O
reports,2121,O
indicate,2121,O
that,2121,O
single,2121,O
agent,2121,O
therapy,2121,O
with,2121,O
vinorelbine,2121,B-Chemical
(,2121,O
VNB,2121,B-Chemical
),2121,O
or,2121,O
gemcitabine,2121,B-Chemical
(,2121,O
GEM,2121,B-Chemical
),2121,O
may,2121,O
obtain,2121,O
a,2121,O
response,2121,O
rate,2121,O
of,2121,O
20-30,2121,O
%,2121,O
in,2121,O
elderly,2121,O
patients,2121,O
",",2121,O
with,2121,O
acceptable,2121,O
toxicity,2121,B-Disease
and,2121,O
improvement,2121,O
in,2121,O
symptoms,2121,O
and,2121,O
quality,2121,O
of,2121,O
life,2121,O
.,2121,O
In,2122,O
the,2122,O
current,2122,O
study,2122,O
the,2122,O
efficacy,2122,O
and,2122,O
toxicity,2122,B-Disease
of,2122,O
the,2122,O
combination,2122,O
of,2122,O
GEM,2122,B-Chemical
and,2122,O
VNB,2122,B-Chemical
in,2122,O
elderly,2122,O
patients,2122,O
with,2122,O
advanced,2122,O
NSCLC,2122,B-Disease
or,2122,O
those,2122,O
with,2122,O
some,2122,O
contraindication,2122,O
to,2122,O
receiving,2122,O
cisplatin,2122,B-Chemical
were,2122,O
assessed,2122,O
.,2122,O
METHODS,2123,O
:,2123,O
Forty-nine,2123,O
patients,2123,O
with,2123,O
advanced,2123,O
NSCLC,2123,B-Disease
were,2123,O
included,2123,O
",",2123,O
38,2123,O
of,2123,O
whom,2123,O
were,2123,O
age,2123,O
>,2123,O
/=,2123,O
70,2123,O
years,2123,O
and,2123,O
11,2123,O
were,2123,O
age,2123,O
<,2123,O
70,2123,O
years,2123,O
but,2123,O
who,2123,O
had,2123,O
some,2123,O
contraindication,2123,O
to,2123,O
receiving,2123,O
cisplatin,2123,B-Chemical
.,2123,O
All,2124,O
patients,2124,O
were,2124,O
evaluable,2124,O
for,2124,O
response,2124,O
and,2124,O
toxicity,2124,B-Disease
.,2124,O
Treatment,2125,O
was,2125,O
comprised,2125,O
of,2125,O
VNB,2125,B-Chemical
",",2125,O
25,2125,O
mg/m,2125,O
(,2125,O
2,2125,O
),2125,O
",",2125,O
plus,2125,O
GEM,2125,B-Chemical
",",2125,O
1000,2125,O
mg/m,2125,O
(,2125,O
2,2125,O
),2125,O
",",2125,O
both,2125,O
on,2125,O
Days,2125,O
1,2125,O
",",2125,O
8,2125,O
",",2125,O
and,2125,O
15,2125,O
every,2125,O
28,2125,O
days,2125,O
.,2125,O
Patients,2126,O
received,2126,O
a,2126,O
minimum,2126,O
of,2126,O
three,2126,O
courses,2126,O
unless,2126,O
progressive,2126,O
disease,2126,O
was,2126,O
detected,2126,O
.,2126,O
RESULTS,2127,O
:,2127,O
One,2127,O
hundred,2127,O
sixty-five,2127,O
courses,2127,O
were,2127,O
administered,2127,O
",",2127,O
with,2127,O
a,2127,O
median,2127,O
of,2127,O
3,2127,O
.,2127,O
6,2128,O
courses,2128,O
per,2128,O
patient,2128,O
.,2128,O
The,2129,O
overall,2129,O
response,2129,O
rate,2129,O
was,2129,O
26,2129,O
%,2129,O
(,2129,O
95,2129,O
%,2129,O
confidence,2129,O
interval,2129,O
",",2129,O
15-41,2129,O
%,2129,O
),2129,O
.,2129,O
Two,2130,O
patients,2130,O
attained,2130,O
a,2130,O
complete,2130,O
response,2130,O
(,2130,O
4,2130,O
%,2130,O
),2130,O
and,2130,O
11,2130,O
patients,2130,O
(,2130,O
22,2130,O
%,2130,O
),2130,O
achieved,2130,O
a,2130,O
partial,2130,O
response,2130,O
.,2130,O
Eastern,2131,O
Cooperative,2131,O
Oncology,2131,O
Group,2131,O
performance,2131,O
status,2131,O
improved,2131,O
in,2131,O
35,2131,O
%,2131,O
of,2131,O
those,2131,O
patients,2131,O
with,2131,O
an,2131,O
initial,2131,O
value,2131,O
>,2131,O
0,2131,O
",",2131,O
whereas,2131,O
relief,2131,O
of,2131,O
at,2131,O
least,2131,O
1,2131,O
symptom,2131,O
without,2131,O
worsening,2131,O
of,2131,O
other,2131,O
symptoms,2131,O
was,2131,O
noted,2131,O
in,2131,O
27,2131,O
patients,2131,O
(,2131,O
55,2131,O
%,2131,O
),2131,O
.,2131,O
The,2132,O
median,2132,O
time,2132,O
to,2132,O
progression,2132,O
was,2132,O
16,2132,O
weeks,2132,O
and,2132,O
the,2132,O
1-year,2132,O
survival,2132,O
rate,2132,O
was,2132,O
33,2132,O
%,2132,O
.,2132,O
Toxicity,2133,B-Disease
was,2133,O
mild,2133,O
.,2133,O
Six,2134,O
patients,2134,O
(,2134,O
12,2134,O
%,2134,O
),2134,O
had,2134,O
World,2134,O
Health,2134,O
Organization,2134,O
Grade,2134,O
3-4,2134,O
neutropenia,2134,B-Disease
",",2134,O
2,2134,O
patients,2134,O
(,2134,O
4,2134,O
%,2134,O
),2134,O
had,2134,O
Grade,2134,O
3-4,2134,O
thrombocytopenia,2134,B-Disease
",",2134,O
and,2134,O
2,2134,O
patients,2134,O
(,2134,O
4,2134,O
%,2134,O
),2134,O
had,2134,O
Grade,2134,O
3,2134,O
neurotoxicity,2134,B-Disease
.,2134,O
Three,2135,O
patients,2135,O
with,2135,O
severe,2135,O
neutropenia,2135,B-Disease
(,2135,O
6,2135,O
%,2135,O
),2135,O
died,2135,O
of,2135,O
sepsis,2135,B-Disease
.,2135,O
The,2136,O
median,2136,O
age,2136,O
of,2136,O
those,2136,O
patients,2136,O
developing,2136,O
Grade,2136,O
3-4,2136,O
neutropenia,2136,B-Disease
was,2136,O
significantly,2136,O
higher,2136,O
than,2136,O
that,2136,O
of,2136,O
the,2136,O
remaining,2136,O
patients,2136,O
(,2136,O
75,2136,O
years,2136,O
vs.,2136,O
72,2136,O
years,2136,O
;,2136,O
P,2136,O
=,2136,O
0.047,2136,O
),2136,O
.,2136,O
CONCLUSIONS,2137,O
:,2137,O
The,2137,O
combination,2137,O
of,2137,O
GEM,2137,B-Chemical
and,2137,O
VNB,2137,B-Chemical
is,2137,O
moderately,2137,O
active,2137,O
and,2137,O
well,2137,O
tolerated,2137,O
except,2137,O
in,2137,O
patients,2137,O
age,2137,O
>,2137,O
/=,2137,O
75,2137,O
years,2137,O
.,2137,O
This,2138,O
age,2138,O
group,2138,O
had,2138,O
an,2138,O
increased,2138,O
risk,2138,O
of,2138,O
myelosuppression,2138,B-Disease
.,2138,O
Therefore,2139,O
the,2139,O
prophylactic,2139,O
use,2139,O
of,2139,O
granulocyte-colony,2139,O
stimulating,2139,O
factor,2139,O
should,2139,O
be,2139,O
considered,2139,O
with,2139,O
this,2139,O
treatment,2139,O
.,2139,O
New,2140,O
chemotherapy,2140,O
combinations,2140,O
with,2140,O
higher,2140,O
activity,2140,O
and,2140,O
lower,2140,O
toxicity,2140,B-Disease
are,2140,O
needed,2140,O
for,2140,O
elderly,2140,O
patients,2140,O
with,2140,O
advanced,2140,O
NSCLC,2140,B-Disease
.,2140,O
A,2141,O
selective,2141,O
dopamine,2141,B-Chemical
D4,2141,O
receptor,2141,O
antagonist,2141,O
",",2141,O
NRA0160,2141,B-Chemical
:,2141,O
a,2141,O
preclinical,2141,O
neuropharmacological,2141,O
profile,2141,O
.,2141,O
NRA0160,2142,B-Chemical
",",2142,O
5,2142,B-Chemical
-,2142,I-Chemical
[,2142,I-Chemical
2-,2142,I-Chemical
(,2142,I-Chemical
4-,2142,I-Chemical
(,2142,I-Chemical
3,2142,I-Chemical
-,2142,I-Chemical
fluorobenzylidene,2142,I-Chemical
),2142,I-Chemical
piperidin-1-yl,2142,I-Chemical
),2142,I-Chemical
ethyl,2142,I-Chemical
],2142,I-Chemical
-,2142,I-Chemical
4,2142,I-Chemical
-,2142,I-Chemical
(,2142,I-Chemical
4-fluorophenyl,2142,I-Chemical
),2142,I-Chemical
thiazole-2-carboxamide,2142,I-Chemical
",",2142,O
has,2142,O
a,2142,O
high,2142,O
affinity,2142,O
for,2142,O
human,2142,O
cloned,2142,O
dopamine,2142,B-Chemical
D4.2,2142,O
",",2142,O
D4.4,2142,O
and,2142,O
D4.7,2142,O
receptors,2142,O
",",2142,O
with,2142,O
Ki,2142,O
values,2142,O
of,2142,O
0.5,2142,O
",",2142,O
0.9,2142,O
and,2142,O
2.7,2142,O
nM,2142,O
",",2142,O
respectively,2142,O
.,2142,O
NRA0160,2143,B-Chemical
is,2143,O
over,2143,O
"20,000fold",2143,O
more,2143,O
potent,2143,O
at,2143,O
the,2143,O
dopamine,2143,B-Chemical
D4.2,2143,O
receptor,2143,O
compared,2143,O
with,2143,O
the,2143,O
human,2143,O
cloned,2143,O
dopamine,2143,B-Chemical
D2L,2143,O
receptor,2143,O
.,2143,O
NRA0160,2144,B-Chemical
has,2144,O
negligible,2144,O
affinity,2144,O
for,2144,O
the,2144,O
human,2144,O
cloned,2144,O
dopamine,2144,B-Chemical
D3,2144,O
receptor,2144,O
(,2144,O
Ki=39,2144,O
nM,2144,O
),2144,O
",",2144,O
rat,2144,O
serotonin,2144,B-Chemical
(,2144,O
5-HT,2144,B-Chemical
),2144,O
2A,2144,O
receptors,2144,O
(,2144,O
Ki=180,2144,O
nM,2144,O
),2144,O
and,2144,O
rat,2144,O
alpha1,2144,O
adrenoceptor,2144,O
(,2144,O
Ki=237,2144,O
nM,2144,O
),2144,O
.,2144,O
NRA0160,2145,B-Chemical
and,2145,O
clozapine,2145,B-Chemical
antagonized,2145,O
locomotor,2145,O
hyperactivity,2145,B-Disease
induced,2145,O
by,2145,O
methamphetamine,2145,B-Chemical
(,2145,O
MAP,2145,B-Chemical
),2145,O
in,2145,O
mice,2145,O
.,2145,O
NRA0160,2146,B-Chemical
and,2146,O
clozapine,2146,B-Chemical
antagonized,2146,O
MAP-induced,2146,B-Chemical
stereotyped,2146,O
behavior,2146,O
in,2146,O
mice,2146,O
",",2146,O
although,2146,O
their,2146,O
effects,2146,O
did,2146,O
not,2146,O
exceed,2146,O
50,2146,O
%,2146,O
inhibition,2146,O
",",2146,O
even,2146,O
at,2146,O
the,2146,O
highest,2146,O
dose,2146,O
given,2146,O
.,2146,O
NRA0160,2147,B-Chemical
and,2147,O
clozapine,2147,B-Chemical
significantly,2147,O
induced,2147,O
catalepsy,2147,B-Disease
in,2147,O
rats,2147,O
",",2147,O
although,2147,O
their,2147,O
effects,2147,O
did,2147,O
not,2147,O
exceed,2147,O
50,2147,O
%,2147,O
induction,2147,O
even,2147,O
at,2147,O
the,2147,O
highest,2147,O
dose,2147,O
given,2147,O
.,2147,O
NRA0160,2148,B-Chemical
and,2148,O
clozapine,2148,B-Chemical
significantly,2148,O
reversed,2148,O
the,2148,O
disruption,2148,O
of,2148,O
prepulse,2148,O
inhibition,2148,O
(,2148,O
PPI,2148,O
),2148,O
in,2148,O
rats,2148,O
produced,2148,O
by,2148,O
apomorphine,2148,B-Chemical
.,2148,O
NRA0160,2149,B-Chemical
and,2149,O
clozapine,2149,B-Chemical
significantly,2149,O
shortened,2149,O
the,2149,O
phencyclidine,2149,B-Chemical
(,2149,O
PCP,2149,B-Chemical
),2149,O
-induced,2149,O
prolonged,2149,O
swimming,2149,O
latency,2149,O
in,2149,O
rats,2149,O
in,2149,O
a,2149,O
water,2149,O
maze,2149,O
task,2149,O
.,2149,O
These,2150,O
findings,2150,O
suggest,2150,O
that,2150,O
NRA0160,2150,B-Chemical
may,2150,O
have,2150,O
unique,2150,O
antipsychotic,2150,O
activities,2150,O
without,2150,O
the,2150,O
liability,2150,O
of,2150,O
motor,2150,O
side,2150,O
effects,2150,O
typical,2150,O
of,2150,O
classical,2150,O
antipsychotics,2150,O
.,2150,O
Warfarin-induced,2151,B-Chemical
artery,2151,B-Disease
calcification,2151,I-Disease
is,2151,O
accelerated,2151,O
by,2151,O
growth,2151,O
and,2151,O
vitamin,2151,B-Chemical
D.,2151,O
The,2151,O
present,2151,O
studies,2151,O
demonstrate,2151,O
that,2151,O
growth,2151,O
and,2151,O
vitamin,2151,B-Chemical
D,2151,I-Chemical
treatment,2151,O
enhance,2151,O
the,2151,O
extent,2151,O
of,2151,O
artery,2151,B-Disease
calcification,2151,I-Disease
in,2151,O
rats,2151,O
given,2151,O
sufficient,2151,O
doses,2151,O
of,2151,O
Warfarin,2151,B-Chemical
to,2151,O
inhibit,2151,O
gamma-carboxylation,2151,O
of,2151,O
matrix,2151,O
Gla,2151,O
protein,2151,O
",",2151,O
a,2151,O
calcification,2151,B-Disease
inhibitor,2151,O
known,2151,O
to,2151,O
be,2151,O
expressed,2151,O
by,2151,O
smooth,2151,O
muscle,2151,O
cells,2151,O
and,2151,O
macrophages,2151,O
in,2151,O
the,2151,O
artery,2151,O
wall,2151,O
.,2151,O
The,2152,O
first,2152,O
series,2152,O
of,2152,O
experiments,2152,O
examined,2152,O
the,2152,O
influence,2152,O
of,2152,O
age,2152,O
and,2152,O
growth,2152,O
status,2152,O
on,2152,O
artery,2152,B-Disease
calcification,2152,I-Disease
in,2152,O
Warfarin-treated,2152,B-Chemical
rats,2152,O
.,2152,O
Treatment,2153,O
for,2153,O
2,2153,O
weeks,2153,O
with,2153,O
Warfarin,2153,B-Chemical
caused,2153,O
massive,2153,O
focal,2153,O
calcification,2153,B-Disease
of,2153,I-Disease
the,2153,I-Disease
artery,2153,I-Disease
media,2153,O
in,2153,O
20-day-old,2153,O
rats,2153,O
and,2153,O
less,2153,O
extensive,2153,O
focal,2153,O
calcification,2153,B-Disease
in,2153,O
42-day-old,2153,O
rats,2153,O
.,2153,O
In,2154,O
contrast,2154,O
",",2154,O
no,2154,O
artery,2154,B-Disease
calcification,2154,I-Disease
could,2154,O
be,2154,O
detected,2154,O
in,2154,O
10-month-old,2154,O
adult,2154,O
rats,2154,O
even,2154,O
after,2154,O
4,2154,O
weeks,2154,O
of,2154,O
Warfarin,2154,B-Chemical
treatment,2154,O
.,2154,O
To,2155,O
directly,2155,O
examine,2155,O
the,2155,O
importance,2155,O
of,2155,O
growth,2155,O
to,2155,O
Warfarin-induced,2155,B-Chemical
artery,2155,B-Disease
calcification,2155,I-Disease
in,2155,O
animals,2155,O
of,2155,O
the,2155,O
same,2155,O
age,2155,O
",",2155,O
20-day-old,2155,O
rats,2155,O
were,2155,O
fed,2155,O
for,2155,O
2,2155,O
weeks,2155,O
either,2155,O
an,2155,O
ad,2155,O
libitum,2155,O
diet,2155,O
or,2155,O
a,2155,O
6-g/d,2155,O
restricted,2155,O
diet,2155,O
that,2155,O
maintains,2155,O
weight,2155,O
but,2155,O
prevents,2155,O
growth,2155,O
.,2155,O
Concurrent,2156,O
treatment,2156,O
of,2156,O
both,2156,O
dietary,2156,O
groups,2156,O
with,2156,O
Warfarin,2156,B-Chemical
produced,2156,O
massive,2156,O
focal,2156,O
calcification,2156,B-Disease
of,2156,I-Disease
the,2156,I-Disease
artery,2156,I-Disease
media,2156,O
in,2156,O
the,2156,O
ad,2156,O
libitum-fed,2156,O
rats,2156,O
but,2156,O
no,2156,O
detectable,2156,O
artery,2156,B-Disease
calcification,2156,I-Disease
in,2156,O
the,2156,O
restricted-diet,2156,O
",",2156,O
growth-inhibited,2156,O
group,2156,O
.,2156,O
Although,2157,O
the,2157,O
explanation,2157,O
for,2157,O
the,2157,O
association,2157,O
between,2157,O
artery,2157,B-Disease
calcification,2157,I-Disease
and,2157,O
growth,2157,O
status,2157,O
can,2157,O
not,2157,O
be,2157,O
determined,2157,O
from,2157,O
the,2157,O
present,2157,O
study,2157,O
",",2157,O
there,2157,O
was,2157,O
a,2157,O
relationship,2157,O
between,2157,O
higher,2157,O
serum,2157,O
phosphate,2157,B-Chemical
and,2157,O
susceptibility,2157,O
to,2157,O
artery,2157,B-Disease
calcification,2157,I-Disease
",",2157,O
with,2157,O
30,2157,O
%,2157,O
higher,2157,O
levels,2157,O
of,2157,O
serum,2157,O
phosphate,2157,B-Chemical
in,2157,O
young,2157,O
",",2157,O
ad,2157,O
libitum-fed,2157,O
rats,2157,O
compared,2157,O
with,2157,O
either,2157,O
of,2157,O
the,2157,O
groups,2157,O
that,2157,O
was,2157,O
resistant,2157,O
to,2157,O
Warfarin-induced,2157,B-Chemical
artery,2157,B-Disease
calcification,2157,I-Disease
",",2157,O
ie,2157,O
",",2157,O
the,2157,O
10-month-old,2157,O
rats,2157,O
and,2157,O
the,2157,O
restricted-diet,2157,O
",",2157,O
growth-inhibited,2157,O
young,2157,O
rats,2157,O
.,2157,O
This,2158,O
observation,2158,O
suggests,2158,O
that,2158,O
increased,2158,O
susceptibility,2158,O
to,2158,O
Warfarin-induced,2158,B-Chemical
artery,2158,B-Disease
calcification,2158,I-Disease
could,2158,O
be,2158,O
related,2158,O
to,2158,O
higher,2158,O
serum,2158,O
phosphate,2158,B-Chemical
levels,2158,O
.,2158,O
The,2159,O
second,2159,O
set,2159,O
of,2159,O
experiments,2159,O
examined,2159,O
the,2159,O
possible,2159,O
synergy,2159,O
between,2159,O
vitamin,2159,B-Chemical
D,2159,I-Chemical
and,2159,O
Warfarin,2159,B-Chemical
in,2159,O
artery,2159,B-Disease
calcification,2159,I-Disease
.,2159,O
High,2160,O
doses,2160,O
of,2160,O
vitamin,2160,B-Chemical
D,2160,I-Chemical
are,2160,O
known,2160,O
to,2160,O
cause,2160,O
calcification,2160,B-Disease
of,2160,I-Disease
the,2160,I-Disease
artery,2160,I-Disease
media,2160,O
in,2160,O
as,2160,O
little,2160,O
as,2160,O
3,2160,O
to,2160,O
4,2160,O
days,2160,O
.,2160,O
High,2161,O
doses,2161,O
of,2161,O
the,2161,O
vitamin,2161,B-Chemical
K,2161,I-Chemical
antagonist,2161,O
Warfarin,2161,B-Chemical
are,2161,O
also,2161,O
known,2161,O
to,2161,O
cause,2161,O
calcification,2161,B-Disease
of,2161,I-Disease
the,2161,I-Disease
artery,2161,I-Disease
media,2161,O
",",2161,O
but,2161,O
at,2161,O
treatment,2161,O
times,2161,O
of,2161,O
2,2161,O
weeks,2161,O
or,2161,O
longer,2161,O
yet,2161,O
not,2161,O
at,2161,O
1,2161,O
week,2161,O
.,2161,O
In,2162,O
the,2162,O
current,2162,O
study,2162,O
",",2162,O
we,2162,O
investigated,2162,O
the,2162,O
synergy,2162,O
between,2162,O
these,2162,O
2,2162,O
treatments,2162,O
and,2162,O
found,2162,O
that,2162,O
concurrent,2162,O
Warfarin,2162,B-Chemical
administration,2162,O
dramatically,2162,O
increased,2162,O
the,2162,O
extent,2162,O
of,2162,O
calcification,2162,B-Disease
in,2162,O
the,2162,O
media,2162,O
of,2162,O
vitamin,2162,B-Chemical
D-treated,2162,O
rats,2162,O
at,2162,O
3,2162,O
and,2162,O
4,2162,O
days,2162,O
.,2162,O
There,2163,O
was,2163,O
a,2163,O
close,2163,O
parallel,2163,O
between,2163,O
the,2163,O
effect,2163,O
of,2163,O
vitamin,2163,B-Chemical
D,2163,I-Chemical
dose,2163,O
on,2163,O
artery,2163,B-Disease
calcification,2163,I-Disease
and,2163,O
the,2163,O
effect,2163,O
of,2163,O
vitamin,2163,B-Chemical
D,2163,I-Chemical
dose,2163,O
on,2163,O
the,2163,O
elevation,2163,O
of,2163,O
serum,2163,O
calcium,2163,B-Chemical
",",2163,O
which,2163,O
suggests,2163,O
that,2163,O
vitamin,2163,B-Chemical
D,2163,I-Chemical
may,2163,O
induce,2163,O
artery,2163,B-Disease
calcification,2163,I-Disease
through,2163,O
its,2163,O
effect,2163,O
on,2163,O
serum,2163,O
calcium,2163,B-Chemical
.,2163,O
Because,2164,O
Warfarin,2164,B-Chemical
treatment,2164,O
had,2164,O
no,2164,O
effect,2164,O
on,2164,O
the,2164,O
elevation,2164,O
in,2164,O
serum,2164,O
calcium,2164,B-Chemical
produced,2164,O
by,2164,O
vitamin,2164,B-Chemical
D,2164,I-Chemical
",",2164,O
the,2164,O
synergy,2164,O
between,2164,O
Warfarin,2164,B-Chemical
and,2164,O
vitamin,2164,B-Chemical
D,2164,I-Chemical
is,2164,O
probably,2164,O
best,2164,O
explained,2164,O
by,2164,O
the,2164,O
hypothesis,2164,O
that,2164,O
Warfarin,2164,B-Chemical
inhibits,2164,O
the,2164,O
activity,2164,O
of,2164,O
matrix,2164,O
Gla,2164,O
protein,2164,O
as,2164,O
a,2164,O
calcification,2164,B-Disease
inhibitor,2164,O
.,2164,O
High,2165,O
levels,2165,O
of,2165,O
matrix,2165,O
Gla,2165,O
protein,2165,O
are,2165,O
found,2165,O
at,2165,O
sites,2165,O
of,2165,O
artery,2165,B-Disease
calcification,2165,I-Disease
in,2165,O
rats,2165,O
treated,2165,O
with,2165,O
vitamin,2165,B-Chemical
D,2165,I-Chemical
plus,2165,O
Warfarin,2165,B-Chemical
",",2165,O
and,2165,O
chemical,2165,O
analysis,2165,O
showed,2165,O
that,2165,O
the,2165,O
protein,2165,O
that,2165,O
accumulated,2165,O
was,2165,O
indeed,2165,O
not,2165,O
gamma-carboxylated,2165,B-Chemical
.,2165,O
These,2166,O
observations,2166,O
indicate,2166,O
that,2166,O
although,2166,O
the,2166,O
gamma-carboxyglutamate,2166,B-Chemical
residues,2166,O
of,2166,O
matrix,2166,O
Gla,2166,O
protein,2166,O
are,2166,O
apparently,2166,O
required,2166,O
for,2166,O
its,2166,O
function,2166,O
as,2166,O
a,2166,O
calcification,2166,B-Disease
inhibitor,2166,O
",",2166,O
they,2166,O
are,2166,O
not,2166,O
required,2166,O
for,2166,O
its,2166,O
accumulation,2166,O
at,2166,O
calcification,2166,B-Disease
sites,2166,O
.,2166,O
Test,2167,O
conditions,2167,O
influence,2167,O
the,2167,O
response,2167,O
to,2167,O
a,2167,O
drug,2167,O
challenge,2167,O
in,2167,O
rodents,2167,O
.,2167,O
These,2168,O
studies,2168,O
were,2168,O
conducted,2168,O
to,2168,O
examine,2168,O
the,2168,O
differential,2168,O
response,2168,O
to,2168,O
a,2168,O
drug,2168,O
challenge,2168,O
under,2168,O
varied,2168,O
experimental,2168,O
test,2168,O
conditions,2168,O
routinely,2168,O
employed,2168,O
to,2168,O
study,2168,O
drug-induced,2168,O
behavioral,2168,O
and,2168,O
neurophysiological,2168,O
responses,2168,O
in,2168,O
rodents,2168,O
.,2168,O
Apomorphine,2169,B-Chemical
",",2169,O
a,2169,O
nonselective,2169,O
dopamine,2169,B-Chemical
agonist,2169,I-Chemical
",",2169,O
was,2169,O
selected,2169,O
due,2169,O
to,2169,O
its,2169,O
biphasic,2169,O
behavioral,2169,O
effects,2169,O
",",2169,O
its,2169,O
ability,2169,O
to,2169,O
induce,2169,O
hypothermia,2169,B-Disease
",",2169,O
and,2169,O
to,2169,O
produce,2169,O
distinct,2169,O
changes,2169,O
to,2169,O
dopamine,2169,B-Chemical
turnover,2169,O
in,2169,O
the,2169,O
rodent,2169,O
brain,2169,O
.,2169,O
From,2170,O
such,2170,O
experiments,2170,O
there,2170,O
is,2170,O
evidence,2170,O
that,2170,O
characterization,2170,O
and,2170,O
detection,2170,O
of,2170,O
apomorphine-induced,2170,B-Chemical
activity,2170,O
in,2170,O
rodents,2170,O
critically,2170,O
depends,2170,O
upon,2170,O
the,2170,O
test,2170,O
conditions,2170,O
employed,2170,O
.,2170,O
In,2171,O
rats,2171,O
",",2171,O
detection,2171,O
of,2171,O
apomorphine-induced,2171,B-Chemical
hyperactivity,2171,B-Disease
was,2171,O
facilitated,2171,O
by,2171,O
a,2171,O
period,2171,O
of,2171,O
acclimatization,2171,O
to,2171,O
the,2171,O
test,2171,O
conditions,2171,O
.,2171,O
Moreover,2172,O
",",2172,O
test,2172,O
conditions,2172,O
can,2172,O
impact,2172,O
upon,2172,O
other,2172,O
physiological,2172,O
responses,2172,O
to,2172,O
apomorphine,2172,B-Chemical
such,2172,O
as,2172,O
drug-induced,2172,O
hypothermia,2172,B-Disease
.,2172,O
In,2173,O
mice,2173,O
",",2173,O
apomorphine,2173,B-Chemical
produced,2173,O
qualitatively,2173,O
different,2173,O
responses,2173,O
under,2173,O
novel,2173,O
conditions,2173,O
when,2173,O
compared,2173,O
to,2173,O
those,2173,O
behaviors,2173,O
elicited,2173,O
in,2173,O
the,2173,O
home,2173,O
test,2173,O
cage,2173,O
.,2173,O
Drug-induced,2174,O
gross,2174,O
activity,2174,O
counts,2174,O
were,2174,O
increased,2174,O
in,2174,O
the,2174,O
novel,2174,O
exploratory,2174,O
box,2174,O
only,2174,O
",",2174,O
while,2174,O
measures,2174,O
of,2174,O
stereotypic,2174,O
behavior,2174,O
were,2174,O
similar,2174,O
in,2174,O
both,2174,O
.,2174,O
By,2175,O
contrast,2175,O
",",2175,O
apomorphine-induced,2175,B-Chemical
locomotion,2175,O
was,2175,O
more,2175,O
prominent,2175,O
in,2175,O
the,2175,O
novel,2175,O
exploratory,2175,O
box,2175,O
.,2175,O
Dopamine,2176,B-Chemical
turnover,2176,O
ratios,2176,O
(,2176,O
DOPAC,2176,B-Chemical
:,2176,O
DA,2176,B-Chemical
and,2176,O
HVA,2176,B-Chemical
:,2176,O
DA,2176,B-Chemical
),2176,O
were,2176,O
found,2176,O
to,2176,O
be,2176,O
lower,2176,O
in,2176,O
those,2176,O
animals,2176,O
exposed,2176,O
to,2176,O
the,2176,O
exploratory,2176,O
box,2176,O
when,2176,O
compared,2176,O
to,2176,O
their,2176,O
home,2176,O
cage,2176,O
counterparts,2176,O
.,2176,O
However,2177,O
",",2177,O
apomorphine-induced,2177,B-Chemical
reductions,2177,O
in,2177,O
striatal,2177,O
dopamine,2177,B-Chemical
turnover,2177,O
were,2177,O
detected,2177,O
in,2177,O
both,2177,O
novel,2177,O
and,2177,O
home,2177,O
cage,2177,O
environments,2177,O
.,2177,O
The,2178,O
implications,2178,O
of,2178,O
these,2178,O
findings,2178,O
are,2178,O
discussed,2178,O
with,2178,O
particular,2178,O
emphasis,2178,O
upon,2178,O
conducting,2178,O
psychopharmacological,2178,O
challenge,2178,O
tests,2178,O
in,2178,O
rodents,2178,O
.,2178,O
Hemolysis,2179,B-Disease
of,2179,O
human,2179,O
erythrocytes,2179,O
induced,2179,O
by,2179,O
tamoxifen,2179,B-Chemical
is,2179,O
related,2179,O
to,2179,O
disruption,2179,O
of,2179,O
membrane,2179,O
structure,2179,O
.,2179,O
Tamoxifen,2180,B-Chemical
(,2180,O
TAM,2180,B-Chemical
),2180,O
",",2180,O
the,2180,O
antiestrogenic,2180,O
drug,2180,O
most,2180,O
widely,2180,O
prescribed,2180,O
in,2180,O
the,2180,O
chemotherapy,2180,O
of,2180,O
breast,2180,B-Disease
cancer,2180,I-Disease
",",2180,O
induces,2180,O
changes,2180,O
in,2180,O
normal,2180,O
discoid,2180,O
shape,2180,O
of,2180,O
erythrocytes,2180,O
and,2180,O
hemolytic,2180,B-Disease
anemia,2180,I-Disease
.,2180,O
This,2181,O
work,2181,O
evaluates,2181,O
the,2181,O
effects,2181,O
of,2181,O
TAM,2181,B-Chemical
on,2181,O
isolated,2181,O
human,2181,O
erythrocytes,2181,O
",",2181,O
attempting,2181,O
to,2181,O
identify,2181,O
the,2181,O
underlying,2181,O
mechanisms,2181,O
on,2181,O
TAM-induced,2181,B-Chemical
hemolytic,2181,B-Disease
anemia,2181,I-Disease
and,2181,O
the,2181,O
involvement,2181,O
of,2181,O
biomembranes,2181,O
in,2181,O
its,2181,O
cytostatic,2181,O
action,2181,O
mechanisms,2181,O
.,2181,O
TAM,2182,B-Chemical
induces,2182,O
hemolysis,2182,B-Disease
of,2182,O
erythrocytes,2182,O
as,2182,O
a,2182,O
function,2182,O
of,2182,O
concentration,2182,O
.,2182,O
The,2183,O
extension,2183,O
of,2183,O
hemolysis,2183,B-Disease
is,2183,O
variable,2183,O
with,2183,O
erythrocyte,2183,O
samples,2183,O
",",2183,O
but,2183,O
12.5,2183,O
microM,2183,O
TAM,2183,B-Chemical
induces,2183,O
total,2183,O
hemolysis,2183,B-Disease
of,2183,O
all,2183,O
tested,2183,O
suspensions,2183,O
.,2183,O
Despite,2184,O
inducing,2184,O
extensive,2184,O
erythrocyte,2184,O
lysis,2184,O
",",2184,O
TAM,2184,B-Chemical
does,2184,O
not,2184,O
shift,2184,O
the,2184,O
osmotic,2184,O
fragility,2184,O
curves,2184,O
of,2184,O
erythrocytes,2184,O
.,2184,O
The,2185,O
hemolytic,2185,B-Disease
effect,2185,O
of,2185,O
TAM,2185,B-Chemical
is,2185,O
prevented,2185,O
by,2185,O
low,2185,O
concentrations,2185,O
of,2185,O
alpha-tocopherol,2185,B-Chemical
(,2185,O
alpha-T,2185,B-Chemical
),2185,O
and,2185,O
alpha-tocopherol,2185,B-Chemical
acetate,2185,I-Chemical
(,2185,O
alpha-TAc,2185,B-Chemical
),2185,O
(,2185,O
inactivated,2185,O
functional,2185,O
hydroxyl,2185,B-Chemical
),2185,O
indicating,2185,O
that,2185,O
TAM-induced,2185,B-Chemical
hemolysis,2185,B-Disease
is,2185,O
not,2185,O
related,2185,O
to,2185,O
oxidative,2185,O
membrane,2185,O
damage,2185,O
.,2185,O
This,2186,O
was,2186,O
further,2186,O
evidenced,2186,O
by,2186,O
absence,2186,O
of,2186,O
oxygen,2186,B-Chemical
consumption,2186,O
and,2186,O
hemoglobin,2186,O
oxidation,2186,O
both,2186,O
determined,2186,O
in,2186,O
parallel,2186,O
with,2186,O
TAM-induced,2186,B-Chemical
hemolysis,2186,B-Disease
.,2186,O
Furthermore,2187,O
",",2187,O
it,2187,O
was,2187,O
observed,2187,O
that,2187,O
TAM,2187,B-Chemical
inhibits,2187,O
the,2187,O
peroxidation,2187,O
of,2187,O
human,2187,O
erythrocytes,2187,O
induced,2187,O
by,2187,O
AAPH,2187,B-Chemical
",",2187,O
thus,2187,O
ruling,2187,O
out,2187,O
TAM-induced,2187,B-Chemical
cell,2187,O
oxidative,2187,O
stress,2187,O
.,2187,O
Hemolysis,2188,B-Disease
caused,2188,O
by,2188,O
TAM,2188,B-Chemical
was,2188,O
not,2188,O
preceded,2188,O
by,2188,O
the,2188,O
leakage,2188,O
of,2188,O
K,2188,B-Chemical
(,2188,O
+,2188,O
),2188,O
from,2188,O
the,2188,O
cells,2188,O
",",2188,O
also,2188,O
excluding,2188,O
a,2188,O
colloid-osmotic,2188,O
type,2188,O
mechanism,2188,O
of,2188,O
hemolysis,2188,B-Disease
",",2188,O
according,2188,O
to,2188,O
the,2188,O
effects,2188,O
on,2188,O
osmotic,2188,O
fragility,2188,O
curves,2188,O
.,2188,O
However,2189,O
",",2189,O
TAM,2189,B-Chemical
induces,2189,O
release,2189,O
of,2189,O
peripheral,2189,O
proteins,2189,O
of,2189,O
membrane-cytoskeleton,2189,O
and,2189,O
cytosol,2189,O
proteins,2189,O
essentially,2189,O
bound,2189,O
to,2189,O
band,2189,O
3,2189,O
.,2189,O
Either,2190,O
alpha-T,2190,B-Chemical
or,2190,O
alpha-TAc,2190,B-Chemical
increases,2190,O
membrane,2190,O
packing,2190,O
and,2190,O
prevents,2190,O
TAM,2190,B-Chemical
partition,2190,O
into,2190,O
model,2190,O
membranes,2190,O
.,2190,O
These,2191,O
effects,2191,O
suggest,2191,O
that,2191,O
the,2191,O
protection,2191,O
from,2191,O
hemolysis,2191,B-Disease
by,2191,O
tocopherols,2191,B-Chemical
is,2191,O
related,2191,O
to,2191,O
a,2191,O
decreased,2191,O
TAM,2191,B-Chemical
incorporation,2191,O
in,2191,O
condensed,2191,O
membranes,2191,O
and,2191,O
the,2191,O
structural,2191,O
damage,2191,O
of,2191,O
the,2191,O
erythrocyte,2191,O
membrane,2191,O
is,2191,O
consequently,2191,O
avoided,2191,O
.,2191,O
Therefore,2192,O
",",2192,O
TAM-induced,2192,B-Chemical
hemolysis,2192,B-Disease
results,2192,O
from,2192,O
a,2192,O
structural,2192,O
perturbation,2192,O
of,2192,O
red,2192,O
cell,2192,O
membrane,2192,O
",",2192,O
leading,2192,O
to,2192,O
changes,2192,O
in,2192,O
the,2192,O
framework,2192,O
of,2192,O
the,2192,O
erythrocyte,2192,O
membrane,2192,O
and,2192,O
its,2192,O
cytoskeleton,2192,O
caused,2192,O
by,2192,O
its,2192,O
high,2192,O
partition,2192,O
in,2192,O
the,2192,O
membrane,2192,O
.,2192,O
These,2193,O
defects,2193,O
explain,2193,O
the,2193,O
abnormal,2193,O
erythrocyte,2193,O
shape,2193,O
and,2193,O
decreased,2193,O
mechanical,2193,O
stability,2193,O
promoted,2193,O
by,2193,O
TAM,2193,B-Chemical
",",2193,O
resulting,2193,O
in,2193,O
hemolytic,2193,B-Disease
anemia,2193,I-Disease
.,2193,O
Additionally,2194,O
",",2194,O
since,2194,O
membrane,2194,O
leakage,2194,O
is,2194,O
a,2194,O
final,2194,O
stage,2194,O
of,2194,O
cytotoxicity,2194,O
",",2194,O
the,2194,O
disruption,2194,O
of,2194,O
the,2194,O
structural,2194,O
characteristics,2194,O
of,2194,O
biomembranes,2194,O
by,2194,O
TAM,2194,B-Chemical
may,2194,O
contribute,2194,O
to,2194,O
the,2194,O
multiple,2194,O
mechanisms,2194,O
of,2194,O
its,2194,O
anticancer,2194,O
action,2194,O
.,2194,O
Changes,2195,O
of,2195,O
sodium,2195,B-Chemical
and,2195,O
ATP,2195,B-Chemical
affinities,2195,O
of,2195,O
the,2195,O
cardiac,2195,O
(,2195,O
Na,2195,B-Chemical
",",2195,O
K,2195,B-Chemical
),2195,O
-ATPase,2195,O
during,2195,O
and,2195,O
after,2195,O
nitric,2195,B-Chemical
oxide,2195,I-Chemical
deficient,2195,O
hypertension,2195,B-Disease
.,2195,O
In,2196,O
the,2196,O
cardiovascular,2196,O
system,2196,O
",",2196,O
NO,2196,B-Chemical
is,2196,O
involved,2196,O
in,2196,O
the,2196,O
regulation,2196,O
of,2196,O
a,2196,O
variety,2196,O
of,2196,O
functions,2196,O
.,2196,O
Inhibition,2197,O
of,2197,O
NO,2197,B-Chemical
synthesis,2197,O
induces,2197,O
sustained,2197,O
hypertension,2197,B-Disease
.,2197,O
In,2198,O
several,2198,O
models,2198,O
of,2198,O
hypertension,2198,B-Disease
",",2198,O
elevation,2198,O
of,2198,O
intracellular,2198,O
sodium,2198,B-Chemical
level,2198,O
was,2198,O
documented,2198,O
in,2198,O
cardiac,2198,O
tissue,2198,O
.,2198,O
To,2199,O
assess,2199,O
the,2199,O
molecular,2199,O
basis,2199,O
of,2199,O
disturbances,2199,O
in,2199,O
transmembraneous,2199,O
transport,2199,O
of,2199,O
Na+,2199,B-Chemical
",",2199,O
we,2199,O
studied,2199,O
the,2199,O
response,2199,O
of,2199,O
cardiac,2199,O
(,2199,O
Na,2199,B-Chemical
",",2199,O
K,2199,B-Chemical
),2199,O
-ATPase,2199,O
to,2199,O
NO-deficient,2199,B-Chemical
hypertension,2199,B-Disease
induced,2199,O
in,2199,O
rats,2199,O
by,2199,O
NO-synthase,2199,B-Chemical
inhibition,2199,O
with,2199,O
40,2199,O
mg/kg/day,2199,O
N,2199,B-Chemical
(,2199,I-Chemical
G,2199,I-Chemical
),2199,I-Chemical
-nitro-L-arginine,2199,I-Chemical
methyl,2199,I-Chemical
ester,2199,I-Chemical
(,2199,O
L-NAME,2199,B-Chemical
),2199,O
for,2199,O
4,2199,O
four,2199,O
weeks,2199,O
.,2199,O
After,2200,O
4-week,2200,O
administration,2200,O
of,2200,O
L-NAME,2200,B-Chemical
",",2200,O
the,2200,O
systolic,2200,O
blood,2200,O
pressure,2200,O
(,2200,O
SBP,2200,O
),2200,O
increased,2200,O
by,2200,O
36,2200,O
%,2200,O
.,2200,O
Two,2201,O
weeks,2201,O
after,2201,O
terminating,2201,O
the,2201,O
treatment,2201,O
",",2201,O
the,2201,O
SBP,2201,O
recovered,2201,O
to,2201,O
control,2201,O
value,2201,O
.,2201,O
When,2202,O
activating,2202,O
the,2202,O
(,2202,O
Na,2202,B-Chemical
",",2202,O
K,2202,B-Chemical
),2202,O
-ATPase,2202,O
with,2202,O
its,2202,O
substrate,2202,O
ATP,2202,B-Chemical
",",2202,O
no,2202,O
changes,2202,O
in,2202,O
Km,2202,O
and,2202,O
Vmax,2202,O
values,2202,O
were,2202,O
observed,2202,O
in,2202,O
NO-deficient,2202,B-Chemical
rats,2202,O
.,2202,O
During,2203,O
activation,2203,O
with,2203,O
Na+,2203,B-Chemical
",",2203,O
the,2203,O
Vmax,2203,O
remained,2203,O
unchanged,2203,O
",",2203,O
however,2203,O
the,2203,O
K,2203,B-Chemical
(,2203,O
Na,2203,B-Chemical
),2203,O
increased,2203,O
by,2203,O
50,2203,O
%,2203,O
",",2203,O
indicating,2203,O
a,2203,O
profound,2203,O
decrease,2203,O
in,2203,O
the,2203,O
affinity,2203,O
of,2203,O
the,2203,O
Na+-binding,2203,B-Chemical
site,2203,O
in,2203,O
NO-deficient,2203,B-Chemical
rats,2203,O
.,2203,O
After,2204,O
recovery,2204,O
from,2204,O
hypertension,2204,B-Disease
",",2204,O
the,2204,O
activity,2204,O
of,2204,O
(,2204,O
Na,2204,B-Chemical
",",2204,O
K,2204,B-Chemical
),2204,O
-ATPase,2204,O
increased,2204,O
",",2204,O
due,2204,O
to,2204,O
higher,2204,O
affinity,2204,O
of,2204,O
the,2204,O
ATP-binding,2204,B-Chemical
site,2204,O
",",2204,O
as,2204,O
revealed,2204,O
from,2204,O
the,2204,O
lowered,2204,O
Km,2204,O
value,2204,O
for,2204,O
ATP,2204,B-Chemical
.,2204,O
The,2205,O
K,2205,B-Chemical
(,2205,O
Na,2205,B-Chemical
),2205,O
value,2205,O
for,2205,O
Na+,2205,B-Chemical
returned,2205,O
to,2205,O
control,2205,O
value,2205,O
.,2205,O
Inhibition,2206,O
of,2206,O
NO-synthase,2206,B-Chemical
induced,2206,O
a,2206,O
reversible,2206,O
hypertension,2206,B-Disease
accompanied,2206,O
by,2206,O
depressed,2206,B-Disease
Na+-extrusion,2206,B-Chemical
from,2206,O
cardiac,2206,O
cells,2206,O
as,2206,O
a,2206,O
consequence,2206,O
of,2206,O
deteriorated,2206,O
Na+-binding,2206,B-Chemical
properties,2206,O
of,2206,O
the,2206,O
(,2206,O
Na,2206,B-Chemical
",",2206,O
K,2206,B-Chemical
),2206,O
-ATPase,2206,O
.,2206,O
After,2207,O
recovery,2207,O
of,2207,O
blood,2207,O
pressure,2207,O
to,2207,O
control,2207,O
values,2207,O
",",2207,O
the,2207,O
extrusion,2207,O
of,2207,O
Na+,2207,B-Chemical
from,2207,O
cardiac,2207,O
cells,2207,O
was,2207,O
normalized,2207,O
",",2207,O
as,2207,O
revealed,2207,O
by,2207,O
restoration,2207,O
of,2207,O
the,2207,O
(,2207,O
Na,2207,B-Chemical
",",2207,O
K,2207,B-Chemical
),2207,O
-ATPase,2207,O
activity,2207,O
.,2207,O
Effects,2208,O
of,2208,O
long-term,2208,O
pretreatment,2208,O
with,2208,O
isoproterenol,2208,B-Chemical
on,2208,O
bromocriptine-induced,2208,B-Chemical
tachycardia,2208,B-Disease
in,2208,O
conscious,2208,O
rats,2208,O
.,2208,O
It,2209,O
has,2209,O
been,2209,O
shown,2209,O
that,2209,O
bromocriptine-induced,2209,B-Chemical
tachycardia,2209,B-Disease
",",2209,O
which,2209,O
persisted,2209,O
after,2209,O
adrenalectomy,2209,O
",",2209,O
is,2209,O
(,2209,O
i,2209,O
),2209,O
mediated,2209,O
by,2209,O
central,2209,O
dopamine,2209,B-Chemical
D2,2209,O
receptor,2209,O
activation,2209,O
and,2209,O
(,2209,O
ii,2209,O
),2209,O
reduced,2209,O
by,2209,O
5-day,2209,O
isoproterenol,2209,B-Chemical
pretreatment,2209,O
",",2209,O
supporting,2209,O
therefore,2209,O
the,2209,O
hypothesis,2209,O
that,2209,O
this,2209,O
effect,2209,O
is,2209,O
dependent,2209,O
on,2209,O
sympathetic,2209,O
outflow,2209,O
to,2209,O
the,2209,O
heart,2209,O
.,2209,O
This,2210,O
study,2210,O
was,2210,O
conducted,2210,O
to,2210,O
examine,2210,O
whether,2210,O
prolonged,2210,O
pretreatment,2210,O
with,2210,O
isoproterenol,2210,B-Chemical
could,2210,O
abolish,2210,O
bromocriptine-induced,2210,B-Chemical
tachycardia,2210,B-Disease
in,2210,O
conscious,2210,O
rats,2210,O
.,2210,O
Isoproterenol,2211,B-Chemical
pretreatment,2211,O
for,2211,O
15,2211,O
days,2211,O
caused,2211,O
cardiac,2211,B-Disease
hypertrophy,2211,I-Disease
without,2211,O
affecting,2211,O
baseline,2211,O
blood,2211,O
pressure,2211,O
and,2211,O
heart,2211,O
rate,2211,O
.,2211,O
In,2212,O
control,2212,O
rats,2212,O
",",2212,O
intravenous,2212,O
bromocriptine,2212,B-Chemical
(,2212,O
150,2212,O
microg/kg,2212,O
),2212,O
induced,2212,O
significant,2212,O
hypotension,2212,B-Disease
and,2212,O
tachycardia,2212,B-Disease
.,2212,O
Bromocriptine-induced,2213,B-Chemical
hypotension,2213,B-Disease
was,2213,O
unaffected,2213,O
by,2213,O
isoproterenol,2213,B-Chemical
pretreatment,2213,O
",",2213,O
while,2213,O
tachycardia,2213,B-Disease
was,2213,O
reversed,2213,O
to,2213,O
significant,2213,O
bradycardia,2213,B-Disease
",",2213,O
an,2213,O
effect,2213,O
that,2213,O
was,2213,O
partly,2213,O
reduced,2213,O
by,2213,O
i.v,2213,O
.,2213,O
domperidone,2214,B-Chemical
(,2214,O
0.5,2214,O
mg/kg,2214,O
),2214,O
.,2214,O
Neither,2215,O
cardiac,2215,O
vagal,2215,O
nor,2215,O
sympathetic,2215,O
tone,2215,O
was,2215,O
altered,2215,O
by,2215,O
isoproterenol,2215,B-Chemical
pretreatment,2215,O
.,2215,O
In,2216,O
isolated,2216,O
perfused,2216,O
heart,2216,O
preparations,2216,O
from,2216,O
isoproterenol-pretreated,2216,B-Chemical
rats,2216,O
",",2216,O
the,2216,O
isoproterenol-induced,2216,B-Chemical
maximal,2216,O
increase,2216,O
in,2216,O
left,2216,O
ventricular,2216,O
systolic,2216,O
pressure,2216,O
was,2216,O
significantly,2216,O
reduced,2216,O
",",2216,O
compared,2216,O
with,2216,O
saline-pretreated,2216,O
rats,2216,O
(,2216,O
the,2216,O
EC50,2216,O
of,2216,O
the,2216,O
isoproterenol-induced,2216,B-Chemical
increase,2216,O
in,2216,O
left,2216,O
ventricular,2216,O
systolic,2216,O
pressure,2216,O
was,2216,O
enhanced,2216,O
approximately,2216,O
22-fold,2216,O
),2216,O
.,2216,O
These,2217,O
results,2217,O
show,2217,O
that,2217,O
15-day,2217,O
isoproterenol,2217,B-Chemical
pretreatment,2217,O
not,2217,O
only,2217,O
abolished,2217,O
but,2217,O
reversed,2217,O
bromocriptine-induced,2217,B-Chemical
tachycardia,2217,B-Disease
to,2217,O
bradycardia,2217,B-Disease
",",2217,O
an,2217,O
effect,2217,O
that,2217,O
is,2217,O
mainly,2217,O
related,2217,O
to,2217,O
further,2217,O
cardiac,2217,O
beta-adrenoceptor,2217,O
desensitization,2217,O
rather,2217,O
than,2217,O
to,2217,O
impairment,2217,O
of,2217,O
autonomic,2217,O
regulation,2217,O
of,2217,O
the,2217,O
heart,2217,O
.,2217,O
They,2218,O
suggest,2218,O
that,2218,O
",",2218,O
in,2218,O
normal,2218,O
conscious,2218,O
rats,2218,O
",",2218,O
the,2218,O
central,2218,O
tachycardia,2218,B-Disease
of,2218,O
bromocriptine,2218,B-Chemical
appears,2218,O
to,2218,O
predominate,2218,O
and,2218,O
to,2218,O
mask,2218,O
the,2218,O
bradycardia,2218,B-Disease
of,2218,O
this,2218,O
agonist,2218,O
at,2218,O
peripheral,2218,O
dopamine,2218,B-Chemical
D2,2218,O
receptors,2218,O
.,2218,O
A,2219,O
developmental,2219,O
analysis,2219,O
of,2219,O
clonidine,2219,B-Chemical
's,2219,O
effects,2219,O
on,2219,O
cardiac,2219,O
rate,2219,O
and,2219,O
ultrasound,2219,O
production,2219,O
in,2219,O
infant,2219,O
rats,2219,O
.,2219,O
Under,2220,O
controlled,2220,O
conditions,2220,O
",",2220,O
infant,2220,O
rats,2220,O
emit,2220,O
ultrasonic,2220,O
vocalizations,2220,O
during,2220,O
extreme,2220,O
cold,2220,O
exposure,2220,O
and,2220,O
after,2220,O
administration,2220,O
of,2220,O
the,2220,O
alpha,2220,O
(,2220,O
2,2220,O
),2220,O
adrenoceptor,2220,O
agonist,2220,O
",",2220,O
clonidine,2220,B-Chemical
.,2220,O
Previous,2221,O
investigations,2221,O
have,2221,O
determined,2221,O
that,2221,O
",",2221,O
in,2221,O
response,2221,O
to,2221,O
clonidine,2221,B-Chemical
",",2221,O
ultrasound,2221,O
production,2221,O
increases,2221,O
through,2221,O
the,2221,O
2nd-week,2221,O
postpartum,2221,O
and,2221,O
decreases,2221,O
thereafter,2221,O
.,2221,O
Given,2222,O
that,2222,O
sympathetic,2222,O
neural,2222,O
dominance,2222,O
exhibits,2222,O
a,2222,O
similar,2222,O
developmental,2222,O
pattern,2222,O
",",2222,O
and,2222,O
given,2222,O
that,2222,O
clonidine,2222,B-Chemical
induces,2222,O
sympathetic,2222,O
withdrawal,2222,O
and,2222,O
bradycardia,2222,B-Disease
",",2222,O
we,2222,O
hypothesized,2222,O
that,2222,O
clonidine,2222,B-Chemical
's,2222,O
developmental,2222,O
effects,2222,O
on,2222,O
cardiac,2222,O
rate,2222,O
and,2222,O
ultrasound,2222,O
production,2222,O
would,2222,O
mirror,2222,O
each,2222,O
other,2222,O
.,2222,O
Therefore,2223,O
",",2223,O
in,2223,O
the,2223,O
present,2223,O
experiment,2223,O
",",2223,O
the,2223,O
effects,2223,O
of,2223,O
clonidine,2223,B-Chemical
administration,2223,O
(,2223,O
0.5,2223,O
mg/kg,2223,O
),2223,O
on,2223,O
cardiac,2223,O
rate,2223,O
and,2223,O
ultrasound,2223,O
production,2223,O
were,2223,O
examined,2223,O
in,2223,O
2-,2223,O
",",2223,O
8-,2223,O
",",2223,O
15-,2223,O
",",2223,O
and,2223,O
20-day-old,2223,O
rats,2223,O
.,2223,O
Age-related,2224,O
changes,2224,O
in,2224,O
ultrasound,2224,O
production,2224,O
corresponded,2224,O
with,2224,O
changes,2224,O
in,2224,O
cardiovascular,2224,O
variables,2224,O
",",2224,O
including,2224,O
baseline,2224,O
cardiac,2224,O
rate,2224,O
and,2224,O
clonidine-induced,2224,B-Chemical
bradycardia,2224,B-Disease
.,2224,O
This,2225,O
experiment,2225,O
is,2225,O
discussed,2225,O
with,2225,O
regard,2225,O
to,2225,O
the,2225,O
hypothesis,2225,O
that,2225,O
ultrasound,2225,O
production,2225,O
is,2225,O
the,2225,O
acoustic,2225,O
by-product,2225,O
of,2225,O
a,2225,O
physiological,2225,O
maneuver,2225,O
that,2225,O
compensates,2225,O
for,2225,O
clonidine,2225,B-Chemical
's,2225,O
detrimental,2225,O
effects,2225,O
on,2225,O
cardiovascular,2225,O
function,2225,O
.,2225,O
Recurrent,2226,O
use,2226,O
of,2226,O
newer,2226,O
oral,2226,B-Chemical
contraceptives,2226,I-Chemical
and,2226,O
the,2226,O
risk,2226,O
of,2226,O
venous,2226,B-Disease
thromboembolism,2226,I-Disease
.,2226,O
The,2227,O
epidemiological,2227,O
studies,2227,O
that,2227,O
assessed,2227,O
the,2227,O
risk,2227,O
of,2227,O
venous,2227,B-Disease
thromboembolism,2227,I-Disease
(,2227,O
VTE,2227,B-Disease
),2227,O
associated,2227,O
with,2227,O
newer,2227,O
oral,2227,B-Chemical
contraceptives,2227,I-Chemical
(,2227,O
OC,2227,B-Chemical
),2227,O
did,2227,O
not,2227,O
distinguish,2227,O
between,2227,O
patterns,2227,O
of,2227,O
OC,2227,B-Chemical
use,2227,O
",",2227,O
namely,2227,O
first-time,2227,O
users,2227,O
",",2227,O
repeaters,2227,O
and,2227,O
switchers,2227,O
.,2227,O
Data,2228,O
from,2228,O
a,2228,O
Transnational,2228,O
case-control,2228,O
study,2228,O
were,2228,O
used,2228,O
to,2228,O
assess,2228,O
the,2228,O
risk,2228,O
of,2228,O
VTE,2228,B-Disease
for,2228,O
the,2228,O
latter,2228,O
patterns,2228,O
of,2228,O
use,2228,O
",",2228,O
while,2228,O
accounting,2228,O
for,2228,O
duration,2228,O
of,2228,O
use,2228,O
.,2228,O
Over,2229,O
the,2229,O
period,2229,O
1993-1996,2229,O
",",2229,O
551,2229,O
cases,2229,O
of,2229,O
VTE,2229,B-Disease
were,2229,O
identified,2229,O
in,2229,O
Germany,2229,O
and,2229,O
the,2229,O
UK,2229,O
along,2229,O
with,2229,O
2066,2229,O
controls,2229,O
.,2229,O
Totals,2230,O
of,2230,O
128,2230,O
cases,2230,O
and,2230,O
650,2230,O
controls,2230,O
were,2230,O
analysed,2230,O
for,2230,O
repeat,2230,O
use,2230,O
and,2230,O
135,2230,O
cases,2230,O
and,2230,O
622,2230,O
controls,2230,O
for,2230,O
switching,2230,O
patterns,2230,O
.,2230,O
The,2231,O
adjusted,2231,O
rate,2231,O
ratio,2231,O
of,2231,O
VTE,2231,B-Disease
for,2231,O
repeat,2231,O
users,2231,O
of,2231,O
third,2231,O
generation,2231,O
OC,2231,B-Chemical
was,2231,O
0.6,2231,O
(,2231,O
95,2231,O
%,2231,O
CI:0.3-1.2,2231,O
),2231,O
relative,2231,O
to,2231,O
repeat,2231,O
users,2231,O
of,2231,O
second,2231,O
generation,2231,O
pills,2231,O
",",2231,O
whereas,2231,O
it,2231,O
was,2231,O
1.3,2231,O
(,2231,O
95,2231,O
%,2231,O
CI:0.7-2.4,2231,O
),2231,O
for,2231,O
switchers,2231,O
from,2231,O
second,2231,O
to,2231,O
third,2231,O
generation,2231,O
pills,2231,O
relative,2231,O
to,2231,O
switchers,2231,O
from,2231,O
third,2231,O
to,2231,O
second,2231,O
generation,2231,O
pills,2231,O
.,2231,O
We,2232,O
conclude,2232,O
that,2232,O
second,2232,O
and,2232,O
third,2232,O
generation,2232,O
agents,2232,O
are,2232,O
associated,2232,O
with,2232,O
equivalent,2232,O
risks,2232,O
of,2232,O
VTE,2232,B-Disease
when,2232,O
the,2232,O
same,2232,O
agent,2232,O
is,2232,O
used,2232,O
repeatedly,2232,O
after,2232,O
interruption,2232,O
periods,2232,O
or,2232,O
when,2232,O
users,2232,O
are,2232,O
switched,2232,O
between,2232,O
the,2232,O
two,2232,O
generations,2232,O
of,2232,O
pills,2232,O
.,2232,O
These,2233,O
analyses,2233,O
suggest,2233,O
that,2233,O
the,2233,O
higher,2233,O
risk,2233,O
observed,2233,O
for,2233,O
the,2233,O
newer,2233,O
OC,2233,B-Chemical
in,2233,O
other,2233,O
studies,2233,O
may,2233,O
be,2233,O
the,2233,O
result,2233,O
of,2233,O
inadequate,2233,O
comparisons,2233,O
of,2233,O
pill,2233,O
users,2233,O
with,2233,O
different,2233,O
patterns,2233,O
of,2233,O
pill,2233,O
use,2233,O
.,2233,O
Differential,2234,O
effects,2234,O
of,2234,O
systemically,2234,O
administered,2234,O
ketamine,2234,B-Chemical
and,2234,O
lidocaine,2234,B-Chemical
on,2234,O
dynamic,2234,O
and,2234,O
static,2234,O
hyperalgesia,2234,B-Disease
induced,2234,O
by,2234,O
intradermal,2234,O
capsaicin,2234,B-Chemical
in,2234,O
humans,2234,O
.,2234,O
We,2235,O
have,2235,O
examined,2235,O
the,2235,O
effect,2235,O
of,2235,O
systemic,2235,O
administration,2235,O
of,2235,O
ketamine,2235,B-Chemical
and,2235,O
lidocaine,2235,B-Chemical
on,2235,O
brush-evoked,2235,O
(,2235,O
dynamic,2235,O
),2235,O
pain,2235,B-Disease
and,2235,O
punctate-evoked,2235,O
(,2235,O
static,2235,O
),2235,O
hyperalgesia,2235,B-Disease
induced,2235,O
by,2235,O
capsaicin,2235,B-Chemical
.,2235,O
In,2236,O
a,2236,O
randomized,2236,O
",",2236,O
double-blind,2236,O
",",2236,O
placebo-controlled,2236,O
",",2236,O
crossover,2236,O
study,2236,O
",",2236,O
we,2236,O
studied,2236,O
12,2236,O
volunteers,2236,O
in,2236,O
three,2236,O
experiments,2236,O
.,2236,O
Capsaicin,2237,B-Chemical
100,2237,O
micrograms,2237,O
was,2237,O
injected,2237,O
intradermally,2237,O
on,2237,O
the,2237,O
volar,2237,O
forearm,2237,O
followed,2237,O
by,2237,O
an,2237,O
i.v,2237,O
.,2237,O
infusion,2238,O
of,2238,O
ketamine,2238,B-Chemical
(,2238,O
bolus,2238,O
0.1,2238,O
mg,2238,O
kg-1,2238,O
over,2238,O
10,2238,O
min,2238,O
followed,2238,O
by,2238,O
infusion,2238,O
of,2238,O
7,2238,O
micrograms,2238,O
kg-1,2238,O
min-1,2238,O
),2238,O
",",2238,O
lidocaine,2238,B-Chemical
5,2238,O
mg,2238,O
kg-1,2238,O
or,2238,O
saline,2238,O
for,2238,O
50,2238,O
min,2238,O
.,2238,O
Infusion,2239,O
started,2239,O
15,2239,O
min,2239,O
after,2239,O
injection,2239,O
of,2239,O
capsaicin,2239,B-Chemical
.,2239,O
The,2240,O
following,2240,O
were,2240,O
measured,2240,O
:,2240,O
spontaneous,2240,O
pain,2240,B-Disease
",",2240,O
pain,2240,B-Disease
evoked,2240,O
by,2240,O
punctate,2240,O
and,2240,O
brush,2240,O
stimuli,2240,O
(,2240,O
VAS,2240,O
),2240,O
",",2240,O
and,2240,O
areas,2240,O
of,2240,O
brush-evoked,2240,O
and,2240,O
punctate-evoked,2240,O
hyperalgesia,2240,B-Disease
.,2240,O
Ketamine,2241,B-Chemical
reduced,2241,O
both,2241,O
the,2241,O
area,2241,O
of,2241,O
brush-evoked,2241,O
and,2241,O
punctate-evoked,2241,O
hyperalgesia,2241,B-Disease
significantly,2241,O
and,2241,O
it,2241,O
tended,2241,O
to,2241,O
reduce,2241,O
brush-evoked,2241,O
pain,2241,B-Disease
.,2241,O
Lidocaine,2242,B-Chemical
reduced,2242,O
the,2242,O
area,2242,O
of,2242,O
punctate-evoked,2242,O
hyperalgesia,2242,B-Disease
significantly,2242,O
.,2242,O
It,2243,O
tended,2243,O
to,2243,O
reduce,2243,O
VAS,2243,O
scores,2243,O
of,2243,O
spontaneous,2243,O
pain,2243,B-Disease
but,2243,O
had,2243,O
no,2243,O
effect,2243,O
on,2243,O
evoked,2243,O
pain,2243,B-Disease
.,2243,O
The,2244,O
differential,2244,O
effects,2244,O
of,2244,O
ketamine,2244,B-Chemical
and,2244,O
lidocaine,2244,B-Chemical
on,2244,O
static,2244,O
and,2244,O
dynamic,2244,O
hyperalgesia,2244,B-Disease
suggest,2244,O
that,2244,O
the,2244,O
two,2244,O
types,2244,O
of,2244,O
hyperalgesia,2244,B-Disease
are,2244,O
mediated,2244,O
by,2244,O
separate,2244,O
mechanisms,2244,O
and,2244,O
have,2244,O
a,2244,O
distinct,2244,O
pharmacology,2244,O
.,2244,O
Development,2245,O
of,2245,O
apomorphine-induced,2245,B-Chemical
aggressive,2245,B-Disease
behavior,2245,I-Disease
:,2245,O
comparison,2245,O
of,2245,O
adult,2245,O
male,2245,O
and,2245,O
female,2245,O
Wistar,2245,O
rats,2245,O
.,2245,O
The,2246,O
development,2246,O
of,2246,O
apomorphine-induced,2246,B-Chemical
(,2246,O
1.0,2246,O
mg/kg,2246,O
s.c.,2246,O
once,2246,O
daily,2246,O
),2246,O
aggressive,2246,B-Disease
behavior,2246,I-Disease
of,2246,O
adult,2246,O
male,2246,O
and,2246,O
female,2246,O
Wistar,2246,O
rats,2246,O
obtained,2246,O
from,2246,O
the,2246,O
same,2246,O
breeder,2246,O
was,2246,O
studied,2246,O
in,2246,O
two,2246,O
consecutive,2246,O
sets,2246,O
.,2246,O
In,2247,O
male,2247,O
animals,2247,O
",",2247,O
repeated,2247,O
apomorphine,2247,B-Chemical
treatment,2247,O
induced,2247,O
a,2247,O
gradual,2247,O
development,2247,O
of,2247,O
aggressive,2247,B-Disease
behavior,2247,I-Disease
as,2247,O
evidenced,2247,O
by,2247,O
the,2247,O
increased,2247,O
intensity,2247,O
of,2247,O
aggressiveness,2247,B-Disease
and,2247,O
shortened,2247,O
latency,2247,O
before,2247,O
the,2247,O
first,2247,O
attack,2247,O
toward,2247,O
the,2247,O
opponent,2247,O
.,2247,O
In,2248,O
female,2248,O
rats,2248,O
",",2248,O
only,2248,O
a,2248,O
weak,2248,O
tendency,2248,O
toward,2248,O
aggressiveness,2248,B-Disease
was,2248,O
found,2248,O
.,2248,O
In,2249,O
conclusion,2249,O
",",2249,O
the,2249,O
present,2249,O
study,2249,O
demonstrates,2249,O
gender,2249,O
differences,2249,O
in,2249,O
the,2249,O
development,2249,O
of,2249,O
the,2249,O
apomorphine-induced,2249,B-Chemical
aggressive,2249,B-Disease
behavior,2249,I-Disease
and,2249,O
indicates,2249,O
that,2249,O
the,2249,O
female,2249,O
rats,2249,O
do,2249,O
not,2249,O
fill,2249,O
the,2249,O
validation,2249,O
criteria,2249,O
for,2249,O
use,2249,O
in,2249,O
this,2249,O
method,2249,O
.,2249,O
Intracranial,2250,B-Disease
aneurysms,2250,I-Disease
and,2250,O
cocaine,2250,B-Disease
abuse,2250,I-Disease
:,2250,O
analysis,2250,O
of,2250,O
prognostic,2250,O
indicators,2250,O
.,2250,O
OBJECTIVE,2251,O
:,2251,O
The,2251,O
outcome,2251,O
of,2251,O
subarachnoid,2251,B-Disease
hemorrhage,2251,I-Disease
associated,2251,O
with,2251,O
cocaine,2251,B-Disease
abuse,2251,I-Disease
is,2251,O
reportedly,2251,O
poor,2251,O
.,2251,O
However,2252,O
",",2252,O
no,2252,O
study,2252,O
in,2252,O
the,2252,O
literature,2252,O
has,2252,O
reported,2252,O
the,2252,O
use,2252,O
of,2252,O
a,2252,O
statistical,2252,O
model,2252,O
to,2252,O
analyze,2252,O
the,2252,O
variables,2252,O
that,2252,O
influence,2252,O
outcome,2252,O
.,2252,O
METHODS,2253,O
:,2253,O
A,2253,O
review,2253,O
of,2253,O
admissions,2253,O
during,2253,O
a,2253,O
6-year,2253,O
period,2253,O
revealed,2253,O
14,2253,O
patients,2253,O
with,2253,O
cocaine-related,2253,B-Chemical
aneurysms,2253,B-Disease
.,2253,O
This,2254,O
group,2254,O
was,2254,O
compared,2254,O
with,2254,O
a,2254,O
control,2254,O
group,2254,O
of,2254,O
135,2254,O
patients,2254,O
with,2254,O
ruptured,2254,B-Disease
aneurysms,2254,I-Disease
and,2254,O
no,2254,O
history,2254,O
of,2254,O
cocaine,2254,B-Disease
abuse,2254,I-Disease
.,2254,O
Age,2255,O
at,2255,O
presentation,2255,O
",",2255,O
time,2255,O
of,2255,O
ictus,2255,O
after,2255,O
intoxication,2255,O
",",2255,O
Hunt,2255,O
and,2255,O
Hess,2255,O
grade,2255,O
of,2255,O
subarachnoid,2255,B-Disease
hemorrhage,2255,I-Disease
",",2255,O
size,2255,O
of,2255,O
the,2255,O
aneurysm,2255,B-Disease
",",2255,O
location,2255,O
of,2255,O
the,2255,O
aneurysm,2255,B-Disease
",",2255,O
and,2255,O
the,2255,O
Glasgow,2255,O
Outcome,2255,O
Scale,2255,O
score,2255,O
were,2255,O
assessed,2255,O
and,2255,O
compared,2255,O
.,2255,O
RESULTS,2256,O
:,2256,O
The,2256,O
patients,2256,O
in,2256,O
the,2256,O
study,2256,O
group,2256,O
were,2256,O
significantly,2256,O
younger,2256,O
than,2256,O
the,2256,O
patients,2256,O
in,2256,O
the,2256,O
control,2256,O
group,2256,O
(,2256,O
P,2256,O
<,2256,O
0.002,2256,O
),2256,O
.,2256,O
In,2257,O
patients,2257,O
in,2257,O
the,2257,O
study,2257,O
group,2257,O
",",2257,O
all,2257,O
aneurysms,2257,B-Disease
were,2257,O
located,2257,O
in,2257,O
the,2257,O
anterior,2257,O
circulation,2257,O
.,2257,O
The,2258,O
majority,2258,O
of,2258,O
these,2258,O
aneurysms,2258,B-Disease
were,2258,O
smaller,2258,O
than,2258,O
those,2258,O
of,2258,O
the,2258,O
control,2258,O
group,2258,O
(,2258,O
8,2258,O
+/-,2258,O
6.08,2258,O
mm,2258,O
versus,2258,O
11,2258,O
+/-,2258,O
5.4,2258,O
mm,2258,O
;,2258,O
P,2258,O
=,2258,O
0.05,2258,O
),2258,O
.,2258,O
The,2259,O
differences,2259,O
in,2259,O
mortality,2259,O
and,2259,O
morbidity,2259,O
between,2259,O
the,2259,O
two,2259,O
groups,2259,O
were,2259,O
not,2259,O
significant,2259,O
.,2259,O
Hunt,2260,O
and,2260,O
Hess,2260,O
grade,2260,O
(,2260,O
P,2260,O
<,2260,O
0.005,2260,O
),2260,O
and,2260,O
age,2260,O
(,2260,O
P,2260,O
<,2260,O
0.007,2260,O
),2260,O
were,2260,O
significant,2260,O
predictors,2260,O
of,2260,O
outcome,2260,O
for,2260,O
the,2260,O
patients,2260,O
with,2260,O
cocaine-related,2260,B-Chemical
aneurysms,2260,B-Disease
.,2260,O
CONCLUSION,2261,O
:,2261,O
Cocaine,2261,B-Chemical
use,2261,O
predisposed,2261,O
aneurysmal,2261,B-Disease
rupture,2261,I-Disease
at,2261,O
a,2261,O
significantly,2261,O
earlier,2261,O
age,2261,O
and,2261,O
in,2261,O
much,2261,O
smaller,2261,O
aneurysms,2261,B-Disease
.,2261,O
Contrary,2262,O
to,2262,O
the,2262,O
published,2262,O
literature,2262,O
",",2262,O
this,2262,O
group,2262,O
did,2262,O
reasonably,2262,O
well,2262,O
with,2262,O
aggressive,2262,O
management,2262,O
.,2262,O
Effect,2263,O
of,2263,O
intravenous,2263,O
nimodipine,2263,B-Chemical
on,2263,O
blood,2263,O
pressure,2263,O
and,2263,O
outcome,2263,O
after,2263,O
acute,2263,B-Disease
stroke,2263,I-Disease
.,2263,O
BACKGROUND,2264,O
AND,2264,O
PURPOSE,2264,O
:,2264,O
The,2264,O
Intravenous,2264,O
Nimodipine,2264,B-Chemical
West,2264,O
European,2264,O
Stroke,2264,B-Disease
Trial,2264,O
(,2264,O
INWEST,2264,O
),2264,O
found,2264,O
a,2264,O
correlation,2264,O
between,2264,O
nimodipine-induced,2264,B-Chemical
reduction,2264,B-Disease
in,2264,I-Disease
blood,2264,I-Disease
pressure,2264,I-Disease
(,2264,O
BP,2264,O
),2264,O
and,2264,O
an,2264,O
unfavorable,2264,O
outcome,2264,O
in,2264,O
acute,2264,B-Disease
stroke,2264,I-Disease
.,2264,O
We,2265,O
sought,2265,O
to,2265,O
confirm,2265,O
this,2265,O
correlation,2265,O
with,2265,O
and,2265,O
without,2265,O
adjustment,2265,O
for,2265,O
prognostic,2265,O
variables,2265,O
and,2265,O
to,2265,O
investigate,2265,O
outcome,2265,O
in,2265,O
subgroups,2265,O
with,2265,O
increasing,2265,O
levels,2265,O
of,2265,O
BP,2265,B-Disease
reduction,2265,I-Disease
.,2265,O
METHODS,2266,O
:,2266,O
Patients,2266,O
with,2266,O
a,2266,O
clinical,2266,O
diagnosis,2266,O
of,2266,O
ischemic,2266,B-Disease
stroke,2266,I-Disease
(,2266,O
within,2266,O
24,2266,O
hours,2266,O
),2266,O
were,2266,O
consecutively,2266,O
allocated,2266,O
to,2266,O
receive,2266,O
placebo,2266,O
(,2266,O
n=100,2266,O
),2266,O
",",2266,O
1,2266,O
mg/h,2266,O
(,2266,O
low-dose,2266,O
),2266,O
nimodipine,2266,B-Chemical
(,2266,O
n=101,2266,O
),2266,O
",",2266,O
or,2266,O
2,2266,O
mg/h,2266,O
(,2266,O
high-dose,2266,O
),2266,O
nimodipine,2266,B-Chemical
(,2266,O
n=94,2266,O
),2266,O
.,2266,O
The,2267,O
correlation,2267,O
between,2267,O
average,2267,O
BP,2267,O
change,2267,O
during,2267,O
the,2267,O
first,2267,O
2,2267,O
days,2267,O
and,2267,O
the,2267,O
outcome,2267,O
at,2267,O
day,2267,O
21,2267,O
was,2267,O
analyzed,2267,O
.,2267,O
RESULTS,2268,O
:,2268,O
Two,2268,O
hundred,2268,O
sixty-five,2268,O
patients,2268,O
were,2268,O
included,2268,O
in,2268,O
this,2268,O
analysis,2268,O
(,2268,O
n=92,2268,O
",",2268,O
93,2268,O
",",2268,O
and,2268,O
80,2268,O
for,2268,O
placebo,2268,O
",",2268,O
low,2268,O
dose,2268,O
",",2268,O
and,2268,O
high,2268,O
dose,2268,O
",",2268,O
respectively,2268,O
),2268,O
.,2268,O
Nimodipine,2269,B-Chemical
treatment,2269,O
resulted,2269,O
in,2269,O
a,2269,O
statistically,2269,O
significant,2269,O
reduction,2269,B-Disease
in,2269,I-Disease
systolic,2269,I-Disease
BP,2269,I-Disease
(,2269,O
SBP,2269,O
),2269,O
and,2269,O
diastolic,2269,O
BP,2269,O
(,2269,O
DBP,2269,O
),2269,O
from,2269,O
baseline,2269,O
compared,2269,O
with,2269,O
placebo,2269,O
during,2269,O
the,2269,O
first,2269,O
few,2269,O
days,2269,O
.,2269,O
In,2270,O
multivariate,2270,O
analysis,2270,O
",",2270,O
a,2270,O
significant,2270,O
correlation,2270,O
between,2270,O
DBP,2270,B-Disease
reduction,2270,I-Disease
and,2270,O
worsening,2270,O
of,2270,O
the,2270,O
neurological,2270,O
score,2270,O
was,2270,O
found,2270,O
for,2270,O
the,2270,O
high-dose,2270,O
group,2270,O
(,2270,O
beta=0.49,2270,O
",",2270,O
P=0,2270,O
.,2270,O
048,2271,O
),2271,O
.,2271,O
Patients,2272,O
with,2272,O
a,2272,O
DBP,2272,B-Disease
reduction,2272,I-Disease
of,2272,O
>,2272,O
or,2272,O
=20,2272,O
%,2272,O
in,2272,O
the,2272,O
high-dose,2272,O
group,2272,O
had,2272,O
a,2272,O
significantly,2272,O
increased,2272,O
adjusted,2272,O
OR,2272,O
for,2272,O
the,2272,O
compound,2272,O
outcome,2272,O
variable,2272,O
death,2272,B-Disease
or,2272,O
dependency,2272,O
(,2272,O
Barthel,2272,O
Index,2272,O
<,2272,O
60,2272,O
),2272,O
(,2272,O
n/N=25/26,2272,O
",",2272,O
OR,2272,O
10,2272,O
.,2272,O
16,2273,O
",",2273,O
95,2273,O
%,2273,O
CI,2273,O
1.02,2273,O
to,2273,O
101.74,2273,O
),2273,O
and,2273,O
death,2273,B-Disease
alone,2273,O
(,2273,O
n/N=9/26,2273,O
",",2273,O
OR,2273,O
4.336,2273,O
",",2273,O
95,2273,O
%,2273,O
CI,2273,O
1.131,2273,O
16.619,2273,O
),2273,O
compared,2273,O
with,2273,O
all,2273,O
placebo,2273,O
patients,2273,O
(,2273,O
n/N=62/92,2273,O
and,2273,O
14/92,2273,O
",",2273,O
respectively,2273,O
),2273,O
.,2273,O
There,2274,O
was,2274,O
no,2274,O
correlation,2274,O
between,2274,O
SBP,2274,O
change,2274,O
and,2274,O
outcome,2274,O
.,2274,O
CONCLUSIONS,2275,O
:,2275,O
DBP,2275,O
",",2275,O
but,2275,O
not,2275,O
SBP,2275,O
",",2275,O
reduction,2275,O
was,2275,O
associated,2275,O
with,2275,O
neurological,2275,O
worsening,2275,O
after,2275,O
the,2275,O
intravenous,2275,O
administration,2275,O
of,2275,O
high-dose,2275,O
nimodipine,2275,B-Chemical
after,2275,O
acute,2275,B-Disease
stroke,2275,I-Disease
.,2275,O
For,2276,O
low-dose,2276,O
nimodipine,2276,B-Chemical
",",2276,O
the,2276,O
results,2276,O
were,2276,O
not,2276,O
conclusive,2276,O
.,2276,O
These,2277,O
results,2277,O
do,2277,O
not,2277,O
confirm,2277,O
or,2277,O
exclude,2277,O
a,2277,O
neuroprotective,2277,O
property,2277,O
of,2277,O
nimodipine,2277,B-Chemical
.,2277,O
Ketamine,2278,B-Chemical
sedation,2278,O
for,2278,O
the,2278,O
reduction,2278,O
of,2278,O
children,2278,O
's,2278,O
fractures,2278,B-Disease
in,2278,O
the,2278,O
emergency,2278,O
department,2278,O
.,2278,O
BACKGROUND,2279,O
:,2279,O
There,2279,O
recently,2279,O
has,2279,O
been,2279,O
a,2279,O
resurgence,2279,O
in,2279,O
the,2279,O
utilization,2279,O
of,2279,O
ketamine,2279,B-Chemical
",",2279,O
a,2279,O
unique,2279,O
anesthetic,2279,O
",",2279,O
for,2279,O
emergency-department,2279,O
procedures,2279,O
requiring,2279,O
sedation,2279,O
.,2279,O
The,2280,O
purpose,2280,O
of,2280,O
the,2280,O
present,2280,O
study,2280,O
was,2280,O
to,2280,O
examine,2280,O
the,2280,O
safety,2280,O
and,2280,O
efficacy,2280,O
of,2280,O
ketamine,2280,B-Chemical
for,2280,O
sedation,2280,O
in,2280,O
the,2280,O
treatment,2280,O
of,2280,O
children,2280,O
's,2280,O
fractures,2280,B-Disease
in,2280,O
the,2280,O
emergency,2280,O
department,2280,O
.,2280,O
METHODS,2281,O
:,2281,O
One,2281,O
hundred,2281,O
and,2281,O
fourteen,2281,O
children,2281,O
(,2281,O
average,2281,O
age,2281,O
",",2281,O
5.3,2281,O
years,2281,O
;,2281,O
range,2281,O
",",2281,O
twelve,2281,O
months,2281,O
to,2281,O
ten,2281,O
years,2281,O
and,2281,O
ten,2281,O
months,2281,O
),2281,O
who,2281,O
underwent,2281,O
closed,2281,O
reduction,2281,O
of,2281,O
an,2281,O
isolated,2281,O
fracture,2281,B-Disease
or,2281,O
dislocation,2281,B-Disease
in,2281,O
the,2281,O
emergency,2281,O
department,2281,O
at,2281,O
a,2281,O
level-I,2281,O
trauma,2281,B-Disease
center,2281,O
were,2281,O
prospectively,2281,O
evaluated,2281,O
.,2281,O
Ketamine,2282,B-Chemical
hydrochloride,2282,I-Chemical
was,2282,O
administered,2282,O
intravenously,2282,O
(,2282,O
at,2282,O
a,2282,O
dose,2282,O
of,2282,O
two,2282,O
milligrams,2282,O
per,2282,O
kilogram,2282,O
of,2282,O
body,2282,O
weight,2282,O
),2282,O
in,2282,O
ninety-nine,2282,O
of,2282,O
the,2282,O
patients,2282,O
and,2282,O
intramuscularly,2282,O
(,2282,O
at,2282,O
a,2282,O
dose,2282,O
of,2282,O
four,2282,O
milligrams,2282,O
per,2282,O
kilogram,2282,O
of,2282,O
body,2282,O
weight,2282,O
),2282,O
in,2282,O
the,2282,O
other,2282,O
fifteen,2282,O
.,2282,O
A,2283,O
board-certified,2283,O
emergency,2283,O
physician,2283,O
skilled,2283,O
in,2283,O
airway,2283,O
management,2283,O
supervised,2283,O
administration,2283,O
of,2283,O
the,2283,O
anesthetic,2283,O
",",2283,O
and,2283,O
the,2283,O
patients,2283,O
were,2283,O
monitored,2283,O
by,2283,O
a,2283,O
registered,2283,O
nurse,2283,O
.,2283,O
Any,2284,O
pain,2284,B-Disease
during,2284,O
the,2284,O
reduction,2284,O
was,2284,O
rated,2284,O
by,2284,O
the,2284,O
orthopaedic,2284,O
surgeon,2284,O
treating,2284,O
the,2284,O
patient,2284,O
according,2284,O
to,2284,O
the,2284,O
Children,2284,O
's,2284,O
Hospital,2284,O
of,2284,O
Eastern,2284,O
Ontario,2284,O
Pain,2284,B-Disease
Scale,2284,O
(,2284,O
CHEOPS,2284,O
),2284,O
.,2284,O
RESULTS,2285,O
:,2285,O
The,2285,O
average,2285,O
time,2285,O
from,2285,O
intravenous,2285,O
administration,2285,O
of,2285,O
ketamine,2285,B-Chemical
to,2285,O
manipulation,2285,O
of,2285,O
the,2285,O
fracture,2285,B-Disease
or,2285,O
dislocation,2285,B-Disease
was,2285,O
one,2285,O
minute,2285,O
and,2285,O
thirty-six,2285,O
seconds,2285,O
(,2285,O
range,2285,O
",",2285,O
twenty,2285,O
seconds,2285,O
to,2285,O
five,2285,O
minutes,2285,O
),2285,O
",",2285,O
and,2285,O
the,2285,O
average,2285,O
time,2285,O
from,2285,O
intramuscular,2285,O
administration,2285,O
to,2285,O
manipulation,2285,O
was,2285,O
four,2285,O
minutes,2285,O
and,2285,O
forty-two,2285,O
seconds,2285,O
(,2285,O
range,2285,O
",",2285,O
sixty,2285,O
seconds,2285,O
to,2285,O
fifteen,2285,O
minutes,2285,O
),2285,O
.,2285,O
The,2286,O
average,2286,O
score,2286,O
according,2286,O
to,2286,O
the,2286,O
Children,2286,O
's,2286,O
Hospital,2286,O
of,2286,O
Eastern,2286,O
Ontario,2286,O
Pain,2286,B-Disease
Scale,2286,O
was,2286,O
6.4,2286,O
points,2286,O
(,2286,O
range,2286,O
",",2286,O
5,2286,O
to,2286,O
10,2286,O
points,2286,O
),2286,O
",",2286,O
reflecting,2286,O
minimal,2286,O
or,2286,O
no,2286,O
pain,2286,B-Disease
during,2286,O
fracture,2286,B-Disease
reduction,2286,O
.,2286,O
Adequate,2287,O
fracture,2287,B-Disease
reduction,2287,O
was,2287,O
obtained,2287,O
in,2287,O
111,2287,O
of,2287,O
the,2287,O
children,2287,O
.,2287,O
Ninety-nine,2288,O
percent,2288,O
(,2288,O
sixty-eight,2288,O
),2288,O
of,2288,O
the,2288,O
sixty-nine,2288,O
parents,2288,O
present,2288,O
during,2288,O
the,2288,O
reduction,2288,O
were,2288,O
pleased,2288,O
with,2288,O
the,2288,O
sedation,2288,O
and,2288,O
would,2288,O
allow,2288,O
it,2288,O
to,2288,O
be,2288,O
used,2288,O
again,2288,O
in,2288,O
a,2288,O
similar,2288,O
situation,2288,O
.,2288,O
Patency,2289,O
of,2289,O
the,2289,O
airway,2289,O
and,2289,O
independent,2289,O
respiration,2289,O
were,2289,O
maintained,2289,O
in,2289,O
all,2289,O
of,2289,O
the,2289,O
patients,2289,O
.,2289,O
Blood,2290,O
pressure,2290,O
and,2290,O
heart,2290,O
rate,2290,O
remained,2290,O
stable,2290,O
.,2290,O
Minor,2291,O
side,2291,O
effects,2291,O
included,2291,O
nausea,2291,B-Disease
(,2291,O
thirteen,2291,O
patients,2291,O
),2291,O
",",2291,O
emesis,2291,B-Disease
(,2291,O
eight,2291,O
of,2291,O
the,2291,O
thirteen,2291,O
patients,2291,O
with,2291,O
nausea,2291,B-Disease
),2291,O
",",2291,O
clumsiness,2291,B-Disease
(,2291,O
evident,2291,O
as,2291,O
ataxic,2291,B-Disease
movements,2291,I-Disease
in,2291,O
ten,2291,O
patients,2291,O
),2291,O
",",2291,O
and,2291,O
dysphoric,2291,B-Disease
reaction,2291,I-Disease
(,2291,O
one,2291,O
patient,2291,O
),2291,O
.,2291,O
No,2292,O
long-term,2292,O
sequelae,2292,O
were,2292,O
noted,2292,O
",",2292,O
and,2292,O
no,2292,O
patients,2292,O
had,2292,O
hallucinations,2292,B-Disease
or,2292,O
nightmares,2292,O
.,2292,O
CONCLUSIONS,2293,O
:,2293,O
Ketamine,2293,B-Chemical
reliably,2293,O
",",2293,O
safely,2293,O
",",2293,O
and,2293,O
quickly,2293,O
provided,2293,O
adequate,2293,O
sedation,2293,O
to,2293,O
effectively,2293,O
facilitate,2293,O
the,2293,O
reduction,2293,O
of,2293,O
children,2293,O
's,2293,O
fractures,2293,B-Disease
in,2293,O
the,2293,O
emergency,2293,O
department,2293,O
at,2293,O
our,2293,O
institution,2293,O
.,2293,O
Ketamine,2294,B-Chemical
should,2294,O
only,2294,O
be,2294,O
used,2294,O
in,2294,O
an,2294,O
environment,2294,O
such,2294,O
as,2294,O
the,2294,O
emergency,2294,O
department,2294,O
",",2294,O
where,2294,O
proper,2294,O
one-on-one,2294,O
monitoring,2294,O
is,2294,O
used,2294,O
and,2294,O
board-certified,2294,O
physicians,2294,O
skilled,2294,O
in,2294,O
airway,2294,O
management,2294,O
are,2294,O
directly,2294,O
involved,2294,O
in,2294,O
the,2294,O
care,2294,O
of,2294,O
the,2294,O
patient,2294,O
.,2294,O
Cyclosporine,2295,B-Chemical
and,2295,O
tacrolimus-associated,2295,B-Chemical
thrombotic,2295,B-Disease
microangiopathy,2295,I-Disease
.,2295,O
The,2296,O
development,2296,O
of,2296,O
thrombotic,2296,B-Disease
microangiopathy,2296,I-Disease
(,2296,O
TMA,2296,B-Disease
),2296,O
associated,2296,O
with,2296,O
the,2296,O
use,2296,O
of,2296,O
cyclosporine,2296,B-Chemical
has,2296,O
been,2296,O
well,2296,O
documented,2296,O
.,2296,O
Treatments,2297,O
have,2297,O
included,2297,O
discontinuation,2297,O
or,2297,O
reduction,2297,O
of,2297,O
cyclosporine,2297,B-Chemical
dose,2297,O
with,2297,O
or,2297,O
without,2297,O
concurrent,2297,O
plasma,2297,O
exchange,2297,O
",",2297,O
plasma,2297,O
infusion,2297,O
",",2297,O
anticoagulation,2297,O
",",2297,O
and,2297,O
intravenous,2297,O
immunoglobulin,2297,O
G,2297,O
infusion,2297,O
.,2297,O
However,2298,O
",",2298,O
for,2298,O
recipients,2298,O
of,2298,O
organ,2298,O
transplantation,2298,O
",",2298,O
removing,2298,O
the,2298,O
inciting,2298,O
agent,2298,O
is,2298,O
not,2298,O
without,2298,O
the,2298,O
attendant,2298,O
risk,2298,O
of,2298,O
precipitating,2298,O
acute,2298,O
rejection,2298,O
and,2298,O
graft,2298,O
loss,2298,O
.,2298,O
The,2299,O
last,2299,O
decade,2299,O
has,2299,O
seen,2299,O
the,2299,O
emergence,2299,O
of,2299,O
tacrolimus,2299,B-Chemical
as,2299,O
a,2299,O
potent,2299,O
immunosuppressive,2299,O
agent,2299,O
with,2299,O
mechanisms,2299,O
of,2299,O
action,2299,O
virtually,2299,O
identical,2299,O
to,2299,O
those,2299,O
of,2299,O
cyclosporine,2299,B-Chemical
.,2299,O
As,2300,O
a,2300,O
result,2300,O
",",2300,O
switching,2300,O
to,2300,O
tacrolimus,2300,B-Chemical
has,2300,O
been,2300,O
reported,2300,O
to,2300,O
be,2300,O
a,2300,O
viable,2300,O
therapeutic,2300,O
option,2300,O
in,2300,O
the,2300,O
setting,2300,O
of,2300,O
cyclosporine-induced,2300,B-Chemical
TMA,2300,B-Disease
.,2300,O
With,2301,O
the,2301,O
more,2301,O
widespread,2301,O
application,2301,O
of,2301,O
tacrolimus,2301,B-Chemical
in,2301,O
organ,2301,O
transplantation,2301,O
",",2301,O
tacrolimus-associated,2301,B-Chemical
TMA,2301,B-Disease
has,2301,O
also,2301,O
been,2301,O
recognized,2301,O
.,2301,O
However,2302,O
",",2302,O
literature,2302,O
regarding,2302,O
the,2302,O
incidence,2302,O
of,2302,O
the,2302,O
recurrence,2302,O
of,2302,O
TMA,2302,B-Disease
in,2302,O
patients,2302,O
exposed,2302,O
sequentially,2302,O
to,2302,O
cyclosporine,2302,B-Chemical
and,2302,O
tacrolimus,2302,B-Chemical
is,2302,O
limited,2302,O
.,2302,O
We,2303,O
report,2303,O
a,2303,O
case,2303,O
of,2303,O
a,2303,O
living,2303,O
donor,2303,O
renal,2303,O
transplant,2303,O
recipient,2303,O
who,2303,O
developed,2303,O
cyclosporine-induced,2303,B-Chemical
TMA,2303,B-Disease
that,2303,O
responded,2303,O
to,2303,O
the,2303,O
withdrawal,2303,O
of,2303,O
cyclosporine,2303,B-Chemical
in,2303,O
conjunction,2303,O
with,2303,O
plasmapheresis,2303,O
and,2303,O
fresh,2303,O
frozen,2303,O
plasma,2303,O
replacement,2303,O
therapy,2303,O
.,2303,O
Introduction,2304,O
of,2304,O
tacrolimus,2304,B-Chemical
as,2304,O
an,2304,O
alternative,2304,O
immunosuppressive,2304,O
agent,2304,O
resulted,2304,O
in,2304,O
the,2304,O
recurrence,2304,O
of,2304,O
TMA,2304,B-Disease
and,2304,O
the,2304,O
subsequent,2304,O
loss,2304,O
of,2304,O
the,2304,O
renal,2304,O
allograft,2304,O
.,2304,O
Patients,2305,O
who,2305,O
are,2305,O
switched,2305,O
from,2305,O
cyclosporine,2305,B-Chemical
to,2305,O
tacrolimus,2305,B-Chemical
or,2305,O
vice,2305,O
versa,2305,O
should,2305,O
be,2305,O
closely,2305,O
monitored,2305,O
for,2305,O
the,2305,O
signs,2305,O
and,2305,O
symptoms,2305,O
of,2305,O
recurrent,2305,O
TMA,2305,B-Disease
.,2305,O
Analgesic,2306,O
effect,2306,O
of,2306,O
intravenous,2306,O
ketamine,2306,B-Chemical
in,2306,O
cancer,2306,B-Disease
patients,2306,O
on,2306,O
morphine,2306,B-Chemical
therapy,2306,O
:,2306,O
a,2306,O
randomized,2306,O
",",2306,O
controlled,2306,O
",",2306,O
double-blind,2306,O
",",2306,O
crossover,2306,O
",",2306,O
double-dose,2306,O
study,2306,O
.,2306,O
Pain,2307,B-Disease
not,2307,O
responsive,2307,O
to,2307,O
morphine,2307,B-Chemical
is,2307,O
often,2307,O
problematic,2307,O
.,2307,O
Animal,2308,O
and,2308,O
clinical,2308,O
studies,2308,O
have,2308,O
suggested,2308,O
that,2308,O
N-methyl-D-aspartate,2308,B-Chemical
(,2308,O
NMDA,2308,B-Chemical
),2308,O
antagonists,2308,O
",",2308,O
such,2308,O
as,2308,O
ketamine,2308,B-Chemical
",",2308,O
may,2308,O
be,2308,O
effective,2308,O
in,2308,O
improving,2308,O
opioid,2308,O
analgesia,2308,O
in,2308,O
difficult,2308,O
pain,2308,B-Disease
syndromes,2308,O
",",2308,O
such,2308,O
as,2308,O
neuropathic,2308,B-Disease
pain,2308,I-Disease
.,2308,O
A,2309,O
slow,2309,O
bolus,2309,O
of,2309,O
subhypnotic,2309,O
doses,2309,O
of,2309,O
ketamine,2309,B-Chemical
(,2309,O
0.25,2309,O
mg/kg,2309,O
or,2309,O
0.50,2309,O
mg/kg,2309,O
),2309,O
was,2309,O
given,2309,O
to,2309,O
10,2309,O
cancer,2309,B-Disease
patients,2309,O
whose,2309,O
pain,2309,B-Disease
was,2309,O
unrelieved,2309,O
by,2309,O
morphine,2309,B-Chemical
in,2309,O
a,2309,O
randomized,2309,O
",",2309,O
double-blind,2309,O
",",2309,O
crossover,2309,O
",",2309,O
double-dose,2309,O
study,2309,O
.,2309,O
Pain,2310,B-Disease
intensity,2310,O
on,2310,O
a,2310,O
0,2310,O
to,2310,O
10,2310,O
numerical,2310,O
scale,2310,O
;,2310,O
nausea,2310,B-Disease
and,2310,O
vomiting,2310,B-Disease
",",2310,O
drowsiness,2310,O
",",2310,O
confusion,2310,B-Disease
",",2310,O
and,2310,O
dry,2310,B-Disease
mouth,2310,I-Disease
",",2310,O
using,2310,O
a,2310,O
scale,2310,O
from,2310,O
0,2310,O
to,2310,O
3,2310,O
(,2310,O
not,2310,O
at,2310,O
all,2310,O
",",2310,O
slight,2310,O
",",2310,O
a,2310,O
lot,2310,O
",",2310,O
awful,2310,O
),2310,O
;,2310,O
Mini-Mental,2310,O
State,2310,O
Examination,2310,O
(,2310,O
MMSE,2310,O
),2310,O
(,2310,O
0-30,2310,O
),2310,O
;,2310,O
and,2310,O
arterial,2310,O
pressure,2310,O
were,2310,O
recorded,2310,O
before,2310,O
administration,2310,O
of,2310,O
drugs,2310,O
(,2310,O
T0,2310,O
),2310,O
and,2310,O
after,2310,O
30,2310,O
minutes,2310,O
(,2310,O
T30,2310,O
),2310,O
",",2310,O
60,2310,O
minutes,2310,O
(,2310,O
T60,2310,O
),2310,O
",",2310,O
120,2310,O
minutes,2310,O
(,2310,O
T120,2310,O
),2310,O
",",2310,O
and,2310,O
180,2310,O
minutes,2310,O
(,2310,O
T180,2310,O
),2310,O
.,2310,O
Ketamine,2311,B-Chemical
",",2311,O
but,2311,O
not,2311,O
saline,2311,O
solution,2311,O
",",2311,O
significantly,2311,O
reduced,2311,O
the,2311,O
pain,2311,B-Disease
intensity,2311,O
in,2311,O
almost,2311,O
all,2311,O
the,2311,O
patients,2311,O
at,2311,O
both,2311,O
doses,2311,O
.,2311,O
This,2312,O
effect,2312,O
was,2312,O
more,2312,O
relevant,2312,O
in,2312,O
patients,2312,O
treated,2312,O
with,2312,O
higher,2312,O
doses,2312,O
.,2312,O
Hallucinations,2313,B-Disease
occurred,2313,O
in,2313,O
4,2313,O
patients,2313,O
",",2313,O
and,2313,O
an,2313,O
unpleasant,2313,O
sensation,2313,O
(,2313,O
``,2313,O
empty,2313,O
head,2313,O
'',2313,O
),2313,O
was,2313,O
also,2313,O
reported,2313,O
by,2313,O
2,2313,O
patients,2313,O
.,2313,O
These,2314,O
episodes,2314,O
reversed,2314,O
after,2314,O
the,2314,O
administration,2314,O
of,2314,O
diazepam,2314,B-Chemical
1,2314,O
mg,2314,O
intravenously,2314,O
.,2314,O
Significant,2315,O
increases,2315,O
in,2315,O
drowsiness,2315,O
were,2315,O
reported,2315,O
in,2315,O
patients,2315,O
treated,2315,O
with,2315,O
ketamine,2315,B-Chemical
in,2315,O
both,2315,O
groups,2315,O
and,2315,O
were,2315,O
more,2315,O
marked,2315,O
with,2315,O
ketamine,2315,B-Chemical
0.50,2315,O
mg/kg,2315,O
.,2315,O
A,2316,O
significant,2316,O
difference,2316,O
in,2316,O
MMSE,2316,O
was,2316,O
observed,2316,O
at,2316,O
T30,2316,O
in,2316,O
patients,2316,O
who,2316,O
received,2316,O
0.50,2316,O
mg/kg,2316,O
of,2316,O
ketamine,2316,B-Chemical
.,2316,O
Ketamine,2317,B-Chemical
can,2317,O
improve,2317,O
morphine,2317,B-Chemical
analgesia,2317,O
in,2317,O
difficult,2317,O
pain,2317,B-Disease
syndromes,2317,O
",",2317,O
such,2317,O
as,2317,O
neuropathic,2317,B-Disease
pain,2317,I-Disease
.,2317,O
However,2318,O
",",2318,O
the,2318,O
occurrence,2318,O
of,2318,O
central,2318,O
adverse,2318,O
effects,2318,O
should,2318,O
be,2318,O
taken,2318,O
into,2318,O
account,2318,O
",",2318,O
especially,2318,O
when,2318,O
using,2318,O
higher,2318,O
doses,2318,O
.,2318,O
This,2319,O
observation,2319,O
should,2319,O
be,2319,O
tested,2319,O
in,2319,O
studies,2319,O
of,2319,O
prolonged,2319,O
ketamine,2319,B-Chemical
administration,2319,O
.,2319,O
Paclitaxel,2320,B-Chemical
",",2320,O
cisplatin,2320,B-Chemical
",",2320,O
and,2320,O
gemcitabine,2320,B-Chemical
combination,2320,O
chemotherapy,2320,O
within,2320,O
a,2320,O
multidisciplinary,2320,O
therapeutic,2320,O
approach,2320,O
in,2320,O
metastatic,2320,O
nonsmall,2320,B-Disease
cell,2320,I-Disease
lung,2320,I-Disease
carcinoma,2320,I-Disease
.,2320,O
BACKGROUND,2321,O
:,2321,O
Cisplatin-based,2321,B-Chemical
chemotherapy,2321,O
combinations,2321,O
improve,2321,O
quality,2321,O
of,2321,O
life,2321,O
and,2321,O
survival,2321,O
in,2321,O
advanced,2321,O
nonsmall,2321,B-Disease
cell,2321,I-Disease
lung,2321,I-Disease
carcinoma,2321,I-Disease
(,2321,O
NSCLC,2321,B-Disease
),2321,O
.,2321,O
The,2322,O
emergence,2322,O
of,2322,O
new,2322,O
active,2322,O
drugs,2322,O
might,2322,O
translate,2322,O
into,2322,O
more,2322,O
effective,2322,O
regimens,2322,O
for,2322,O
the,2322,O
treatment,2322,O
of,2322,O
this,2322,O
disease,2322,O
.,2322,O
METHODS,2323,O
:,2323,O
The,2323,O
objective,2323,O
of,2323,O
this,2323,O
study,2323,O
was,2323,O
to,2323,O
determine,2323,O
the,2323,O
feasibility,2323,O
",",2323,O
response,2323,O
rate,2323,O
",",2323,O
and,2323,O
toxicity,2323,B-Disease
of,2323,O
a,2323,O
paclitaxel,2323,B-Chemical
",",2323,O
cisplatin,2323,B-Chemical
",",2323,O
and,2323,O
gemcitabine,2323,B-Chemical
combination,2323,O
to,2323,O
treat,2323,O
metastatic,2323,O
NSCLC,2323,B-Disease
.,2323,O
Thirty-five,2324,O
consecutive,2324,O
chemotherapy-naive,2324,O
patients,2324,O
with,2324,O
Stage,2324,O
IV,2324,O
NSCLC,2324,B-Disease
and,2324,O
an,2324,O
Eastern,2324,O
Cooperative,2324,O
Oncology,2324,O
Group,2324,O
performance,2324,O
status,2324,O
of,2324,O
0-2,2324,O
were,2324,O
treated,2324,O
with,2324,O
a,2324,O
combination,2324,O
of,2324,O
paclitaxel,2324,B-Chemical
(,2324,O
135,2324,O
mg/m,2324,O
(,2324,O
2,2324,O
),2324,O
given,2324,O
intravenously,2324,O
in,2324,O
3,2324,O
hours,2324,O
),2324,O
on,2324,O
Day,2324,O
1,2324,O
",",2324,O
cisplatin,2324,B-Chemical
(,2324,O
120,2324,O
mg/m,2324,O
(,2324,O
2,2324,O
),2324,O
given,2324,O
intravenously,2324,O
in,2324,O
6,2324,O
hours,2324,O
),2324,O
on,2324,O
Day,2324,O
1,2324,O
",",2324,O
and,2324,O
gemcitabine,2324,B-Chemical
(,2324,O
800,2324,O
mg/m,2324,O
(,2324,O
2,2324,O
),2324,O
given,2324,O
intravenously,2324,O
in,2324,O
30,2324,O
minutes,2324,O
),2324,O
on,2324,O
Days,2324,O
1,2324,O
and,2324,O
8,2324,O
",",2324,O
every,2324,O
4,2324,O
weeks,2324,O
.,2324,O
Although,2325,O
responding,2325,O
patients,2325,O
were,2325,O
scheduled,2325,O
to,2325,O
receive,2325,O
consolidation,2325,O
radiotherapy,2325,O
and,2325,O
24,2325,O
patients,2325,O
received,2325,O
preplanned,2325,O
second-line,2325,O
chemotherapy,2325,O
after,2325,O
disease,2325,O
progression,2325,O
",",2325,O
the,2325,O
response,2325,O
and,2325,O
toxicity,2325,B-Disease
rates,2325,O
reported,2325,O
refer,2325,O
only,2325,O
to,2325,O
the,2325,O
chemotherapy,2325,O
regimen,2325,O
given,2325,O
.,2325,O
RESULTS,2326,O
:,2326,O
All,2326,O
the,2326,O
patients,2326,O
were,2326,O
examined,2326,O
for,2326,O
toxicity,2326,B-Disease
;,2326,O
34,2326,O
were,2326,O
examinable,2326,O
for,2326,O
response,2326,O
.,2326,O
An,2327,O
objective,2327,O
response,2327,O
was,2327,O
observed,2327,O
in,2327,O
73.5,2327,O
%,2327,O
of,2327,O
the,2327,O
patients,2327,O
(,2327,O
95,2327,O
%,2327,O
confidence,2327,O
interval,2327,O
[,2327,O
CI,2327,O
],2327,O
",",2327,O
55.6-87.1,2327,O
%,2327,O
),2327,O
",",2327,O
including,2327,O
4,2327,O
complete,2327,O
responses,2327,O
(,2327,O
11.7,2327,O
%,2327,O
),2327,O
.,2327,O
According,2328,O
to,2328,O
intention-to-treat,2328,O
",",2328,O
the,2328,O
overall,2328,O
response,2328,O
rate,2328,O
was,2328,O
71.4,2328,O
%,2328,O
(,2328,O
95,2328,O
%,2328,O
CI,2328,O
",",2328,O
53,2328,O
.,2328,O
7-85.4,2329,O
%,2329,O
),2329,O
.,2329,O
After,2330,O
154,2330,O
courses,2330,O
of,2330,O
therapy,2330,O
",",2330,O
the,2330,O
median,2330,O
dose,2330,O
intensity,2330,O
was,2330,O
131,2330,O
mg/m,2330,O
(,2330,O
2,2330,O
),2330,O
for,2330,O
paclitaxel,2330,B-Chemical
(,2330,O
97.3,2330,O
%,2330,O
),2330,O
",",2330,O
117,2330,O
mg/m,2330,O
(,2330,O
2,2330,O
),2330,O
for,2330,O
cisplatin,2330,B-Chemical
(,2330,O
97.3,2330,O
%,2330,O
),2330,O
",",2330,O
and,2330,O
1378,2330,O
mg/m,2330,O
(,2330,O
2,2330,O
),2330,O
for,2330,O
gemcitabine,2330,B-Chemical
(,2330,O
86.2,2330,O
%,2330,O
),2330,O
.,2330,O
World,2331,O
Health,2331,O
Organization,2331,O
Grade,2331,O
3-4,2331,O
neutropenia,2331,B-Disease
and,2331,O
thrombocytopenia,2331,B-Disease
occurred,2331,O
in,2331,O
39.9,2331,O
%,2331,O
and,2331,O
11.4,2331,O
%,2331,O
of,2331,O
patients,2331,O
",",2331,O
respectively,2331,O
.,2331,O
There,2332,O
was,2332,O
one,2332,O
treatment-related,2332,O
death,2332,B-Disease
.,2332,O
Nonhematologic,2333,O
toxicities,2333,B-Disease
were,2333,O
mild,2333,O
.,2333,O
After,2334,O
a,2334,O
median,2334,O
follow-up,2334,O
of,2334,O
22,2334,O
months,2334,O
",",2334,O
the,2334,O
median,2334,O
progression,2334,O
free,2334,O
survival,2334,O
rate,2334,O
was,2334,O
7,2334,O
months,2334,O
",",2334,O
and,2334,O
the,2334,O
median,2334,O
survival,2334,O
time,2334,O
was,2334,O
16,2334,O
months,2334,O
.,2334,O
CONCLUSIONS,2335,O
:,2335,O
The,2335,O
combination,2335,O
of,2335,O
paclitaxel,2335,B-Chemical
",",2335,O
cisplatin,2335,B-Chemical
",",2335,O
and,2335,O
gemcitabine,2335,B-Chemical
is,2335,O
well,2335,O
tolerated,2335,O
and,2335,O
shows,2335,O
high,2335,O
activity,2335,O
in,2335,O
metastatic,2335,O
NSCLC,2335,B-Disease
.,2335,O
This,2336,O
treatment,2336,O
merits,2336,O
further,2336,O
comparison,2336,O
with,2336,O
other,2336,O
cisplatin-based,2336,B-Chemical
regimens,2336,O
.,2336,O
Serotonergic,2337,B-Chemical
antidepressants,2337,I-Chemical
and,2337,O
urinary,2337,B-Disease
incontinence,2337,I-Disease
.,2337,O
Many,2338,O
new,2338,O
serotonergic,2338,B-Chemical
antidepressants,2338,I-Chemical
have,2338,O
been,2338,O
introduced,2338,O
over,2338,O
the,2338,O
past,2338,O
decade,2338,O
.,2338,O
Although,2339,O
urinary,2339,B-Disease
incontinence,2339,I-Disease
is,2339,O
listed,2339,O
as,2339,O
one,2339,O
side,2339,O
effect,2339,O
of,2339,O
these,2339,O
drugs,2339,O
in,2339,O
their,2339,O
package,2339,O
inserts,2339,O
there,2339,O
is,2339,O
only,2339,O
one,2339,O
report,2339,O
in,2339,O
the,2339,O
literature,2339,O
.,2339,O
This,2340,O
concerns,2340,O
2,2340,O
male,2340,O
patients,2340,O
who,2340,O
experienced,2340,O
incontinence,2340,B-Disease
while,2340,O
taking,2340,O
venlafaxine,2340,B-Chemical
.,2340,O
In,2341,O
the,2341,O
present,2341,O
paper,2341,O
the,2341,O
authors,2341,O
describe,2341,O
2,2341,O
female,2341,O
patients,2341,O
who,2341,O
developed,2341,O
incontinence,2341,B-Disease
secondary,2341,O
to,2341,O
the,2341,O
selective,2341,O
serotonin,2341,B-Chemical
reuptake,2341,O
inhibitors,2341,O
paroxetine,2341,B-Chemical
and,2341,O
sertraline,2341,B-Chemical
",",2341,O
as,2341,O
well,2341,O
as,2341,O
a,2341,O
third,2341,O
who,2341,O
developed,2341,O
this,2341,O
side,2341,O
effect,2341,O
on,2341,O
venlafaxine,2341,B-Chemical
.,2341,O
In,2342,O
2,2342,O
of,2342,O
the,2342,O
3,2342,O
cases,2342,O
the,2342,O
patients,2342,O
were,2342,O
also,2342,O
taking,2342,O
lithium,2342,B-Chemical
carbonate,2342,I-Chemical
and,2342,O
beta-blockers,2342,O
",",2342,O
both,2342,O
of,2342,O
which,2342,O
could,2342,O
have,2342,O
contributed,2342,O
to,2342,O
the,2342,O
incontinence,2342,B-Disease
.,2342,O
Animal,2343,O
studies,2343,O
suggest,2343,O
that,2343,O
incontinence,2343,B-Disease
secondary,2343,O
to,2343,O
serotonergic,2343,B-Chemical
antidepressants,2343,I-Chemical
could,2343,O
be,2343,O
mediated,2343,O
by,2343,O
the,2343,O
5HT4,2343,O
receptors,2343,O
found,2343,O
on,2343,O
the,2343,O
bladder,2343,O
.,2343,O
Further,2344,O
research,2344,O
is,2344,O
needed,2344,O
to,2344,O
delineate,2344,O
the,2344,O
frequency,2344,O
of,2344,O
this,2344,O
troubling,2344,O
side,2344,O
effect,2344,O
and,2344,O
how,2344,O
best,2344,O
to,2344,O
treat,2344,O
it,2344,O
.,2344,O
Acute,2345,O
cocaine-induced,2345,B-Chemical
seizures,2345,B-Disease
:,2345,O
differential,2345,O
sensitivity,2345,O
of,2345,O
six,2345,O
inbred,2345,O
mouse,2345,O
strains,2345,O
.,2345,O
Mature,2346,O
male,2346,O
and,2346,O
female,2346,O
mice,2346,O
from,2346,O
six,2346,O
inbred,2346,O
stains,2346,O
were,2346,O
tested,2346,O
for,2346,O
susceptibility,2346,O
to,2346,O
behavioral,2346,O
seizures,2346,B-Disease
induced,2346,O
by,2346,O
a,2346,O
single,2346,O
injection,2346,O
of,2346,O
cocaine,2346,B-Chemical
.,2346,O
Cocaine,2347,B-Chemical
was,2347,O
injected,2347,O
ip,2347,O
over,2347,O
a,2347,O
range,2347,O
of,2347,O
doses,2347,O
(,2347,O
50-100,2347,O
mg/kg,2347,O
),2347,O
and,2347,O
behavior,2347,O
was,2347,O
monitored,2347,O
for,2347,O
20,2347,O
minutes,2347,O
.,2347,O
Seizure,2348,B-Disease
end,2348,O
points,2348,O
included,2348,O
latency,2348,O
to,2348,O
forelimb,2348,O
or,2348,O
hindlimb,2348,O
clonus,2348,O
",",2348,O
latency,2348,O
to,2348,O
clonic,2348,O
running,2348,O
seizure,2348,B-Disease
and,2348,O
latency,2348,O
to,2348,O
jumping,2348,O
bouncing,2348,O
seizure,2348,B-Disease
.,2348,O
A,2349,O
range,2349,O
of,2349,O
strain,2349,O
specific,2349,O
sensitivities,2349,O
was,2349,O
documented,2349,O
with,2349,O
A/J,2349,O
and,2349,O
SJL,2349,O
mice,2349,O
being,2349,O
most,2349,O
sensitive,2349,O
and,2349,O
C57BL/6J,2349,O
most,2349,O
resistant,2349,O
.,2349,O
DBA/2J,2350,O
",",2350,O
BALB/cByJ,2350,O
and,2350,O
NZW/LacJ,2350,O
strains,2350,O
exhibited,2350,O
intermediate,2350,O
sensitivity,2350,O
.,2350,O
EEG,2351,O
recordings,2351,O
were,2351,O
made,2351,O
in,2351,O
SJL,2351,O
",",2351,O
A/J,2351,O
and,2351,O
C57BL/6J,2351,O
mice,2351,O
revealing,2351,O
a,2351,O
close,2351,O
correspondence,2351,O
between,2351,O
electrical,2351,O
activity,2351,O
and,2351,O
behavior,2351,O
.,2351,O
Additionally,2352,O
",",2352,O
levels,2352,O
of,2352,O
cocaine,2352,B-Chemical
determined,2352,O
in,2352,O
hippocampus,2352,O
and,2352,O
cortex,2352,O
were,2352,O
not,2352,O
different,2352,O
between,2352,O
sensitive,2352,O
and,2352,O
resistant,2352,O
strains,2352,O
.,2352,O
Additional,2353,O
studies,2353,O
of,2353,O
these,2353,O
murine,2353,O
strains,2353,O
may,2353,O
be,2353,O
useful,2353,O
for,2353,O
investigating,2353,O
genetic,2353,O
influences,2353,O
on,2353,O
cocaine-induced,2353,B-Chemical
seizures,2353,B-Disease
.,2353,O
Hypotension,2354,B-Disease
following,2354,O
the,2354,O
initiation,2354,O
of,2354,O
tizanidine,2354,B-Chemical
in,2354,O
a,2354,O
patient,2354,O
treated,2354,O
with,2354,O
an,2354,O
angiotensin,2354,B-Chemical
converting,2354,O
enzyme,2354,O
inhibitor,2354,O
for,2354,O
chronic,2354,O
hypertension,2354,B-Disease
.,2354,O
Centrally,2355,O
acting,2355,O
alpha-2,2355,O
adrenergic,2355,O
agonists,2355,O
are,2355,O
one,2355,O
of,2355,O
several,2355,O
pharmacologic,2355,O
agents,2355,O
used,2355,O
in,2355,O
the,2355,O
treatment,2355,O
of,2355,O
spasticity,2355,B-Disease
related,2355,O
to,2355,O
disorders,2355,B-Disease
of,2355,I-Disease
the,2355,I-Disease
central,2355,I-Disease
nervous,2355,I-Disease
system,2355,I-Disease
.,2355,O
In,2356,O
addition,2356,O
to,2356,O
their,2356,O
effects,2356,O
on,2356,O
spasticity,2356,B-Disease
",",2356,O
certain,2356,O
adverse,2356,O
cardiorespiratory,2356,O
effects,2356,O
have,2356,O
been,2356,O
reported,2356,O
.,2356,O
Adults,2357,O
chronically,2357,O
treated,2357,O
with,2357,O
angiotensin,2357,B-Chemical
converting,2357,O
enzyme,2357,O
inhibitors,2357,O
may,2357,O
have,2357,O
a,2357,O
limited,2357,O
ability,2357,O
to,2357,O
respond,2357,O
to,2357,O
hypotension,2357,B-Disease
when,2357,O
the,2357,O
sympathetic,2357,O
response,2357,O
is,2357,O
simultaneously,2357,O
blocked,2357,O
.,2357,O
The,2358,O
authors,2358,O
present,2358,O
a,2358,O
10-year-old,2358,O
boy,2358,O
chronically,2358,O
treated,2358,O
with,2358,O
lisinopril,2358,B-Chemical
",",2358,O
an,2358,O
angiotensin,2358,B-Chemical
converting,2358,O
enzyme,2358,O
inhibitor,2358,O
",",2358,O
to,2358,O
control,2358,O
hypertension,2358,B-Disease
who,2358,O
developed,2358,O
hypotension,2358,B-Disease
following,2358,O
the,2358,O
addition,2358,O
of,2358,O
tizanidine,2358,B-Chemical
",",2358,O
an,2358,O
alpha-2,2358,O
agonist,2358,O
",",2358,O
for,2358,O
the,2358,O
treatment,2358,O
of,2358,O
spasticity,2358,B-Disease
.,2358,O
The,2359,O
possible,2359,O
interaction,2359,O
of,2359,O
tizanidine,2359,B-Chemical
and,2359,O
other,2359,O
antihypertensive,2359,O
agents,2359,O
should,2359,O
be,2359,O
kept,2359,O
in,2359,O
mind,2359,O
when,2359,O
prescribing,2359,O
therapy,2359,O
to,2359,O
treat,2359,O
either,2359,O
hypertension,2359,B-Disease
or,2359,O
spasticity,2359,B-Disease
in,2359,O
such,2359,O
patients,2359,O
.,2359,O
Two,2360,O
mouse,2360,O
lines,2360,O
selected,2360,O
for,2360,O
differential,2360,O
sensitivities,2360,O
to,2360,O
beta-carboline-induced,2360,B-Chemical
seizures,2360,B-Disease
are,2360,O
also,2360,O
differentially,2360,O
sensitive,2360,O
to,2360,O
various,2360,O
pharmacological,2360,O
effects,2360,O
of,2360,O
other,2360,O
GABA,2360,B-Chemical
(,2360,O
A,2360,O
),2360,O
receptor,2360,O
ligands,2360,O
.,2360,O
Two,2361,O
mouse,2361,O
lines,2361,O
were,2361,O
selectively,2361,O
bred,2361,O
according,2361,O
to,2361,O
their,2361,O
sensitivity,2361,O
(,2361,O
BS,2361,O
line,2361,O
),2361,O
or,2361,O
resistance,2361,O
(,2361,O
BR,2361,O
line,2361,O
),2361,O
to,2361,O
seizures,2361,B-Disease
induced,2361,O
by,2361,O
a,2361,O
single,2361,O
i.p,2361,O
.,2361,O
injection,2362,O
of,2362,O
methyl,2362,B-Chemical
beta-carboline-3-carboxylate,2362,I-Chemical
(,2362,O
beta-CCM,2362,B-Chemical
),2362,O
",",2362,O
an,2362,O
inverse,2362,O
agonist,2362,O
of,2362,O
the,2362,O
GABA,2362,B-Chemical
(,2362,O
A,2362,O
),2362,O
receptor,2362,O
benzodiazepine,2362,B-Chemical
site,2362,O
.,2362,O
Our,2363,O
aim,2363,O
was,2363,O
to,2363,O
characterize,2363,O
both,2363,O
lines,2363,O
',2363,O
sensitivities,2363,O
to,2363,O
various,2363,O
physiological,2363,O
effects,2363,O
of,2363,O
other,2363,O
ligands,2363,O
of,2363,O
the,2363,O
GABA,2363,B-Chemical
(,2363,O
A,2363,O
),2363,O
receptor,2363,O
.,2363,O
We,2364,O
measured,2364,O
diazepam-induced,2364,B-Chemical
anxiolysis,2364,O
with,2364,O
the,2364,O
elevated,2364,O
plus-maze,2364,O
test,2364,O
",",2364,O
diazepam-induced,2364,B-Chemical
sedation,2364,O
by,2364,O
recording,2364,O
the,2364,O
vigilance,2364,O
states,2364,O
",",2364,O
and,2364,O
picrotoxin-,2364,B-Chemical
and,2364,O
pentylenetetrazol-induced,2364,B-Chemical
seizures,2364,B-Disease
after,2364,O
i.p,2364,O
.,2364,O
injections,2365,O
.,2365,O
Results,2366,O
presented,2366,O
here,2366,O
show,2366,O
that,2366,O
the,2366,O
differential,2366,O
sensitivities,2366,O
of,2366,O
BS,2366,O
and,2366,O
BR,2366,O
lines,2366,O
to,2366,O
beta-CCM,2366,B-Chemical
can,2366,O
be,2366,O
extended,2366,O
to,2366,O
diazepam,2366,B-Chemical
",",2366,O
picrotoxin,2366,B-Chemical
",",2366,O
and,2366,O
pentylenetetrazol,2366,B-Chemical
",",2366,O
suggesting,2366,O
a,2366,O
genetic,2366,O
selection,2366,O
of,2366,O
a,2366,O
general,2366,O
sensitivity,2366,O
and,2366,O
resistance,2366,O
to,2366,O
several,2366,O
ligands,2366,O
of,2366,O
the,2366,O
GABA,2366,B-Chemical
(,2366,O
A,2366,O
),2366,O
receptor,2366,O
.,2366,O
Propylthiouracil-induced,2367,B-Chemical
perinuclear-staining,2367,O
antineutrophil,2367,O
cytoplasmic,2367,O
autoantibody-positive,2367,O
vasculitis,2367,B-Disease
in,2367,O
conjunction,2367,O
with,2367,O
pericarditis,2367,B-Disease
.,2367,O
OBJECTIVE,2368,O
:,2368,O
To,2368,O
describe,2368,O
a,2368,O
case,2368,O
of,2368,O
propylthiouracil-induced,2368,B-Chemical
vasculitis,2368,B-Disease
manifesting,2368,O
with,2368,O
pericarditis,2368,B-Disease
.,2368,O
METHODS,2369,O
:,2369,O
We,2369,O
present,2369,O
the,2369,O
first,2369,O
case,2369,O
report,2369,O
of,2369,O
a,2369,O
woman,2369,O
with,2369,O
hyperthyroidism,2369,B-Disease
treated,2369,O
with,2369,O
propylthiouracil,2369,B-Chemical
in,2369,O
whom,2369,O
a,2369,O
syndrome,2369,O
of,2369,O
pericarditis,2369,B-Disease
",",2369,O
fever,2369,B-Disease
",",2369,O
and,2369,O
glomerulonephritis,2369,B-Disease
developed,2369,O
.,2369,O
Serologic,2370,O
testing,2370,O
and,2370,O
immunologic,2370,O
studies,2370,O
were,2370,O
done,2370,O
",",2370,O
and,2370,O
a,2370,O
pericardial,2370,O
biopsy,2370,O
was,2370,O
performed,2370,O
.,2370,O
RESULTS,2371,O
:,2371,O
A,2371,O
25-year-old,2371,O
woman,2371,O
with,2371,O
Graves,2371,B-Disease
',2371,I-Disease
disease,2371,I-Disease
had,2371,O
a,2371,O
febrile,2371,B-Disease
illness,2371,I-Disease
and,2371,O
evidence,2371,O
of,2371,O
pericarditis,2371,B-Disease
",",2371,O
which,2371,O
was,2371,O
confirmed,2371,O
by,2371,O
biopsy,2371,O
.,2371,O
Serologic,2372,O
evaluation,2372,O
revealed,2372,O
the,2372,O
presence,2372,O
of,2372,O
perinuclear-staining,2372,O
antineutrophil,2372,O
cytoplasmic,2372,O
autoantibodies,2372,O
(,2372,O
pANCA,2372,O
),2372,O
against,2372,O
myeloperoxidase,2372,O
(,2372,O
MPO,2372,O
),2372,O
.,2372,O
Propylthiouracil,2373,B-Chemical
therapy,2373,O
was,2373,O
withdrawn,2373,O
",",2373,O
and,2373,O
she,2373,O
was,2373,O
treated,2373,O
with,2373,O
a,2373,O
1-month,2373,O
course,2373,O
of,2373,O
prednisone,2373,B-Chemical
",",2373,O
which,2373,O
alleviated,2373,O
her,2373,O
symptoms,2373,O
.,2373,O
A,2374,O
literature,2374,O
review,2374,O
revealed,2374,O
no,2374,O
prior,2374,O
reports,2374,O
of,2374,O
pericarditis,2374,B-Disease
in,2374,O
anti-MPO,2374,O
pANCA-positive,2374,O
vasculitis,2374,B-Disease
associated,2374,O
with,2374,O
propylthio-,2374,B-Chemical
uracil,2374,I-Chemical
therapy,2374,O
.,2374,O
CONCLUSION,2375,O
:,2375,O
Pericarditis,2375,B-Disease
may,2375,O
be,2375,O
the,2375,O
initial,2375,O
manifestation,2375,O
of,2375,O
drug-induced,2375,O
vasculitis,2375,B-Disease
attributable,2375,O
to,2375,O
propylthio-,2375,B-Chemical
uracil,2375,I-Chemical
therapy,2375,O
.,2375,O
Repeated,2376,O
transient,2376,O
anuria,2376,B-Disease
following,2376,O
losartan,2376,B-Chemical
administration,2376,O
in,2376,O
a,2376,O
patient,2376,O
with,2376,O
a,2376,O
solitary,2376,O
kidney,2376,O
.,2376,O
We,2377,O
report,2377,O
the,2377,O
case,2377,O
of,2377,O
a,2377,O
70-year-old,2377,O
hypertensive,2377,B-Disease
man,2377,O
with,2377,O
a,2377,O
solitary,2377,O
kidney,2377,O
and,2377,O
chronic,2377,B-Disease
renal,2377,I-Disease
insufficiency,2377,I-Disease
who,2377,O
developed,2377,O
two,2377,O
episodes,2377,O
of,2377,O
transient,2377,O
anuria,2377,B-Disease
after,2377,O
losartan,2377,B-Chemical
administration,2377,O
.,2377,O
He,2378,O
was,2378,O
hospitalized,2378,O
for,2378,O
a,2378,O
myocardial,2378,B-Disease
infarction,2378,I-Disease
with,2378,O
pulmonary,2378,B-Disease
edema,2378,I-Disease
",",2378,O
treated,2378,O
with,2378,O
high-dose,2378,O
diuretics,2378,O
.,2378,O
Due,2379,O
to,2379,O
severe,2379,O
systolic,2379,B-Disease
dysfunction,2379,I-Disease
losartan,2379,B-Chemical
was,2379,O
prescribed,2379,O
.,2379,O
Surprisingly,2380,O
",",2380,O
the,2380,O
first,2380,O
dose,2380,O
of,2380,O
50,2380,O
mg,2380,O
of,2380,O
losartan,2380,B-Chemical
resulted,2380,O
in,2380,O
a,2380,O
sudden,2380,O
anuria,2380,B-Disease
",",2380,O
which,2380,O
lasted,2380,O
eight,2380,O
hours,2380,O
despite,2380,O
high-dose,2380,O
furosemide,2380,B-Chemical
and,2380,O
amine,2380,B-Chemical
infusion,2380,O
.,2380,O
One,2381,O
week,2381,O
later,2381,O
",",2381,O
by,2381,O
mistake,2381,O
",",2381,O
losartan,2381,B-Chemical
was,2381,O
prescribed,2381,O
again,2381,O
and,2381,O
after,2381,O
the,2381,O
second,2381,O
dose,2381,O
of,2381,O
50,2381,O
mg,2381,O
",",2381,O
the,2381,O
patient,2381,O
developed,2381,O
a,2381,O
second,2381,O
episode,2381,O
of,2381,O
transient,2381,O
anuria,2381,B-Disease
lasting,2381,O
10,2381,O
hours,2381,O
.,2381,O
During,2382,O
these,2382,O
two,2382,O
episodes,2382,O
",",2382,O
his,2382,O
blood,2382,O
pressure,2382,O
diminished,2382,O
but,2382,O
no,2382,O
severe,2382,O
hypotension,2382,B-Disease
was,2382,O
noted,2382,O
.,2382,O
Ultimately,2383,O
",",2383,O
an,2383,O
arteriography,2383,O
showed,2383,O
a,2383,O
70-80,2383,O
%,2383,O
renal,2383,B-Disease
artery,2383,I-Disease
stenosis,2383,I-Disease
.,2383,O
In,2384,O
this,2384,O
patient,2384,O
",",2384,O
renal,2384,B-Disease
artery,2384,I-Disease
stenosis,2384,I-Disease
combined,2384,O
with,2384,O
heart,2384,B-Disease
failure,2384,I-Disease
and,2384,O
diuretic,2384,O
therapy,2384,O
certainly,2384,O
resulted,2384,O
in,2384,O
a,2384,O
strong,2384,O
activation,2384,O
of,2384,O
the,2384,O
renin-angiotensin,2384,O
system,2384,O
(,2384,O
RAS,2384,O
),2384,O
.,2384,O
Under,2385,O
such,2385,O
conditions,2385,O
",",2385,O
angiotensin,2385,B-Chemical
II,2385,I-Chemical
receptor,2385,O
blockade,2385,O
by,2385,O
losartan,2385,B-Chemical
probably,2385,O
induced,2385,O
a,2385,O
critical,2385,O
fall,2385,O
in,2385,O
glomerular,2385,O
filtration,2385,O
pressure,2385,O
.,2385,O
This,2386,O
case,2386,O
report,2386,O
highlights,2386,O
the,2386,O
fact,2386,O
that,2386,O
the,2386,O
angiotensin,2386,B-Chemical
II,2386,I-Chemical
receptor,2386,O
antagonist,2386,O
losartan,2386,B-Chemical
can,2386,O
cause,2386,O
serious,2386,O
unexpected,2386,O
complications,2386,O
in,2386,O
patients,2386,O
with,2386,O
renovascular,2386,B-Disease
disease,2386,I-Disease
and,2386,O
should,2386,O
be,2386,O
used,2386,O
with,2386,O
extreme,2386,O
caution,2386,O
in,2386,O
this,2386,O
setting,2386,O
.,2386,O
Calcineurin-inhibitor,2387,O
induced,2387,O
pain,2387,B-Disease
syndrome,2387,O
(,2387,O
CIPS,2387,B-Disease
),2387,O
:,2387,O
a,2387,O
severe,2387,O
disabling,2387,O
complication,2387,O
after,2387,O
organ,2387,O
transplantation,2387,O
.,2387,O
Bone,2388,O
pain,2388,B-Disease
after,2388,O
transplantation,2388,O
is,2388,O
a,2388,O
frequent,2388,O
complication,2388,O
that,2388,O
can,2388,O
be,2388,O
caused,2388,O
by,2388,O
several,2388,O
diseases,2388,O
.,2388,O
Treatment,2389,O
strategies,2389,O
depend,2389,O
on,2389,O
the,2389,O
correct,2389,O
diagnosis,2389,O
of,2389,O
the,2389,O
pain,2389,B-Disease
.,2389,O
Nine,2390,O
patients,2390,O
with,2390,O
severe,2390,O
pain,2390,B-Disease
in,2390,O
their,2390,O
feet,2390,O
",",2390,O
which,2390,O
was,2390,O
registered,2390,O
after,2390,O
transplantation,2390,O
",",2390,O
were,2390,O
investigated,2390,O
.,2390,O
Bone,2391,O
scans,2391,O
showed,2391,O
an,2391,O
increased,2391,O
tracer,2391,O
uptake,2391,O
of,2391,O
the,2391,O
foot,2391,O
bones,2391,O
.,2391,O
Magnetic,2392,O
resonance,2392,O
imaging,2392,O
demonstrated,2392,O
bone,2392,O
marrow,2392,O
oedema,2392,O
in,2392,O
the,2392,O
painful,2392,O
bones,2392,O
.,2392,O
Pain,2393,B-Disease
was,2393,O
not,2393,O
explained,2393,O
by,2393,O
other,2393,O
diseases,2393,O
causing,2393,O
foot,2393,O
pain,2393,B-Disease
",",2393,O
like,2393,O
reflex,2393,B-Disease
sympathetic,2393,I-Disease
dystrophy,2393,I-Disease
",",2393,O
polyneuropathy,2393,B-Disease
",",2393,O
Morton,2393,B-Disease
's,2393,I-Disease
neuralgia,2393,I-Disease
",",2393,O
gout,2393,B-Disease
",",2393,O
osteoporosis,2393,B-Disease
",",2393,O
avascular,2393,B-Disease
necrosis,2393,I-Disease
",",2393,O
intermittent,2393,B-Disease
claudication,2393,I-Disease
",",2393,O
orthopaedic,2393,O
foot,2393,B-Disease
deformities,2393,I-Disease
",",2393,O
stress,2393,B-Disease
fractures,2393,I-Disease
",",2393,O
and,2393,O
hyperparathyroidism,2393,B-Disease
.,2393,O
The,2394,O
reduction,2394,O
of,2394,O
cyclosporine-,2394,B-Chemical
or,2394,O
tacrolimus,2394,B-Chemical
trough,2394,O
levels,2394,O
and,2394,O
the,2394,O
administration,2394,O
of,2394,O
calcium,2394,B-Chemical
channel,2394,O
blockers,2394,O
led,2394,O
to,2394,O
relief,2394,O
of,2394,O
pain,2394,B-Disease
.,2394,O
The,2395,O
Calcineurin-inhibitor,2395,O
Induced,2395,O
Pain,2395,B-Disease
Syndrome,2395,O
(,2395,O
CIPS,2395,B-Disease
),2395,O
is,2395,O
a,2395,O
rare,2395,O
but,2395,O
severe,2395,O
side,2395,O
effect,2395,O
of,2395,O
cyclosporine,2395,B-Chemical
or,2395,O
tacrolimus,2395,B-Chemical
and,2395,O
is,2395,O
accurately,2395,O
diagnosed,2395,O
by,2395,O
its,2395,O
typical,2395,O
presentation,2395,O
",",2395,O
magnetic,2395,O
resonance,2395,O
imaging,2395,O
and,2395,O
bone,2395,O
scans,2395,O
.,2395,O
Incorrect,2396,O
diagnosis,2396,O
of,2396,O
the,2396,O
syndrome,2396,O
will,2396,O
lead,2396,O
to,2396,O
a,2396,O
significant,2396,O
reduction,2396,O
of,2396,O
life,2396,O
quality,2396,O
in,2396,O
patients,2396,O
suffering,2396,O
from,2396,O
CIPS,2396,B-Disease
.,2396,O
Brain,2397,O
natriuretic,2397,O
peptide,2397,O
is,2397,O
a,2397,O
predictor,2397,O
of,2397,O
anthracycline-induced,2397,B-Chemical
cardiotoxicity,2397,B-Disease
.,2397,O
Anthracyclines,2398,B-Chemical
are,2398,O
effective,2398,O
antineoplastic,2398,O
drugs,2398,O
",",2398,O
but,2398,O
they,2398,O
frequently,2398,O
cause,2398,O
dose-related,2398,O
cardiotoxicity,2398,B-Disease
.,2398,O
The,2399,O
cardiotoxicity,2399,B-Disease
of,2399,O
conventional,2399,O
anthracycline,2399,B-Chemical
therapy,2399,O
highlights,2399,O
a,2399,O
need,2399,O
to,2399,O
search,2399,O
for,2399,O
methods,2399,O
that,2399,O
are,2399,O
highly,2399,O
sensitive,2399,O
and,2399,O
capable,2399,O
of,2399,O
predicting,2399,O
cardiac,2399,B-Disease
dysfunction,2399,I-Disease
.,2399,O
We,2400,O
measured,2400,O
the,2400,O
plasma,2400,O
level,2400,O
of,2400,O
brain,2400,O
natriuretic,2400,O
peptide,2400,O
(,2400,O
BNP,2400,O
),2400,O
to,2400,O
determine,2400,O
whether,2400,O
BNP,2400,O
might,2400,O
serve,2400,O
as,2400,O
a,2400,O
simple,2400,O
diagnostic,2400,O
indicator,2400,O
of,2400,O
anthracycline-induced,2400,B-Chemical
cardiotoxicity,2400,B-Disease
in,2400,O
patients,2400,O
with,2400,O
acute,2400,B-Disease
leukemia,2400,I-Disease
treated,2400,O
with,2400,O
a,2400,O
daunorubicin,2400,B-Chemical
(,2400,O
DNR,2400,B-Chemical
),2400,O
-containing,2400,O
regimen,2400,O
.,2400,O
Thirteen,2401,O
patients,2401,O
with,2401,O
acute,2401,B-Disease
leukemia,2401,I-Disease
were,2401,O
treated,2401,O
with,2401,O
a,2401,O
DNR-containing,2401,B-Chemical
regimen,2401,O
.,2401,O
Cardiac,2402,O
functions,2402,O
were,2402,O
evaluated,2402,O
with,2402,O
radionuclide,2402,O
angiography,2402,O
before,2402,O
chemotherapies,2402,O
.,2402,O
The,2403,O
plasma,2403,O
levels,2403,O
of,2403,O
atrial,2403,O
natriuretic,2403,O
peptide,2403,O
(,2403,O
ANP,2403,O
),2403,O
and,2403,O
BNP,2403,O
were,2403,O
measured,2403,O
at,2403,O
the,2403,O
time,2403,O
of,2403,O
radionuclide,2403,O
angiography,2403,O
.,2403,O
Three,2404,O
patients,2404,O
developed,2404,O
congestive,2404,B-Disease
heart,2404,I-Disease
failure,2404,I-Disease
after,2404,O
the,2404,O
completion,2404,O
of,2404,O
chemotherapy,2404,O
.,2404,O
Five,2405,O
patients,2405,O
were,2405,O
diagnosed,2405,O
as,2405,O
having,2405,O
subclinical,2405,O
heart,2405,B-Disease
failure,2405,I-Disease
after,2405,O
the,2405,O
completion,2405,O
of,2405,O
chemotherapy,2405,O
.,2405,O
The,2406,O
plasma,2406,O
levels,2406,O
of,2406,O
BNP,2406,O
in,2406,O
all,2406,O
the,2406,O
patients,2406,O
with,2406,O
clinical,2406,O
and,2406,O
subclinical,2406,O
heart,2406,B-Disease
failure,2406,I-Disease
increased,2406,O
above,2406,O
the,2406,O
normal,2406,O
limit,2406,O
(,2406,O
40,2406,O
pg/ml,2406,O
),2406,O
before,2406,O
the,2406,O
detection,2406,O
of,2406,O
clinical,2406,O
or,2406,O
subclinical,2406,O
heart,2406,B-Disease
failure,2406,I-Disease
by,2406,O
radionuclide,2406,O
angiography,2406,O
.,2406,O
On,2407,O
the,2407,O
other,2407,O
hand,2407,O
",",2407,O
BNP,2407,O
did,2407,O
not,2407,O
increase,2407,O
in,2407,O
the,2407,O
patients,2407,O
without,2407,O
heart,2407,B-Disease
failure,2407,I-Disease
given,2407,O
DNR,2407,B-Chemical
",",2407,O
even,2407,O
at,2407,O
more,2407,O
than,2407,O
700,2407,O
mg/m,2407,O
(,2407,O
2,2407,O
),2407,O
.,2407,O
The,2408,O
plasma,2408,O
level,2408,O
of,2408,O
ANP,2408,O
did,2408,O
not,2408,O
always,2408,O
increase,2408,O
in,2408,O
all,2408,O
the,2408,O
patients,2408,O
with,2408,O
clinical,2408,O
and,2408,O
subclinical,2408,O
heart,2408,B-Disease
failure,2408,I-Disease
.,2408,O
These,2409,O
preliminary,2409,O
results,2409,O
suggest,2409,O
that,2409,O
BNP,2409,O
may,2409,O
be,2409,O
useful,2409,O
as,2409,O
an,2409,O
early,2409,O
and,2409,O
sensitive,2409,O
indicator,2409,O
of,2409,O
anthracycline-induced,2409,B-Chemical
cardiotoxicity,2409,B-Disease
.,2409,O
In,2410,O
vivo,2410,O
protection,2410,O
of,2410,O
dna,2410,O
damage,2410,O
associated,2410,O
apoptotic,2410,O
and,2410,O
necrotic,2410,B-Disease
cell,2410,O
deaths,2410,O
during,2410,O
acetaminophen-induced,2410,B-Chemical
nephrotoxicity,2410,B-Disease
",",2410,O
amiodarone-induced,2410,B-Chemical
lung,2410,B-Disease
toxicity,2410,I-Disease
and,2410,O
doxorubicin-induced,2410,B-Chemical
cardiotoxicity,2410,B-Disease
by,2410,O
a,2410,O
novel,2410,O
IH636,2410,B-Chemical
grape,2410,I-Chemical
seed,2410,I-Chemical
proanthocyanidin,2410,I-Chemical
extract,2410,I-Chemical
.,2410,O
Grape,2411,B-Chemical
seed,2411,I-Chemical
extract,2411,I-Chemical
",",2411,O
primarily,2411,O
a,2411,O
mixture,2411,O
of,2411,O
proanthocyanidins,2411,B-Chemical
",",2411,O
has,2411,O
been,2411,O
shown,2411,O
to,2411,O
modulate,2411,O
a,2411,O
wide-range,2411,O
of,2411,O
biological,2411,O
",",2411,O
pharmacological,2411,O
and,2411,O
toxicological,2411,O
effects,2411,O
which,2411,O
are,2411,O
mainly,2411,O
cytoprotective,2411,O
.,2411,O
This,2412,O
study,2412,O
assessed,2412,O
the,2412,O
ability,2412,O
of,2412,O
IH636,2412,B-Chemical
grape,2412,I-Chemical
seed,2412,I-Chemical
proanthocyanidin,2412,I-Chemical
extract,2412,I-Chemical
(,2412,O
GSPE,2412,B-Chemical
),2412,O
to,2412,O
prevent,2412,O
acetaminophen,2412,B-Chemical
(,2412,O
AAP,2412,B-Chemical
),2412,O
-induced,2412,O
nephrotoxicity,2412,B-Disease
",",2412,O
amiodarone,2412,B-Chemical
(,2412,O
AMI,2412,B-Chemical
),2412,O
-induced,2412,O
lung,2412,B-Disease
toxicity,2412,I-Disease
",",2412,O
and,2412,O
doxorubicin,2412,B-Chemical
(,2412,O
DOX,2412,B-Chemical
),2412,O
-induced,2412,O
cardiotoxicity,2412,B-Disease
in,2412,O
mice,2412,O
.,2412,O
Experimental,2413,O
design,2413,O
consisted,2413,O
of,2413,O
four,2413,O
groups,2413,O
:,2413,O
control,2413,O
(,2413,O
vehicle,2413,O
alone,2413,O
),2413,O
",",2413,O
GSPE,2413,B-Chemical
alone,2413,O
",",2413,O
drug,2413,O
alone,2413,O
and,2413,O
GSPE+drug,2413,B-Chemical
.,2413,O
For,2414,O
the,2414,O
cytoprotection,2414,O
study,2414,O
",",2414,O
animals,2414,O
were,2414,O
orally,2414,O
gavaged,2414,O
100,2414,O
mg/Kg,2414,O
GSPE,2414,B-Chemical
for,2414,O
7-10,2414,O
days,2414,O
followed,2414,O
by,2414,O
i.p,2414,O
.,2414,O
injections,2415,O
of,2415,O
organ,2415,O
specific,2415,O
three,2415,O
drugs,2415,O
(,2415,O
AAP,2415,B-Chemical
:,2415,O
500,2415,O
mg/Kg,2415,O
for,2415,O
24,2415,O
h,2415,O
;,2415,O
AMI,2415,B-Chemical
:,2415,O
50,2415,O
mg/Kg/day,2415,O
for,2415,O
four,2415,O
days,2415,O
;,2415,O
DOX,2415,B-Chemical
:,2415,O
20,2415,O
mg/Kg,2415,O
for,2415,O
48,2415,O
h,2415,O
),2415,O
.,2415,O
Parameters,2416,O
of,2416,O
study,2416,O
included,2416,O
analysis,2416,O
of,2416,O
serum,2416,O
chemistry,2416,O
(,2416,O
ALT,2416,O
",",2416,O
BUN,2416,O
and,2416,O
CPK,2416,O
),2416,O
",",2416,O
and,2416,O
orderly,2416,O
fragmentation,2416,O
of,2416,O
genomic,2416,O
DNA,2416,O
(,2416,O
both,2416,O
endonuclease-dependent,2416,O
and,2416,O
independent,2416,O
),2416,O
in,2416,O
addition,2416,O
to,2416,O
microscopic,2416,O
evaluation,2416,O
of,2416,O
damage,2416,O
and/or,2416,O
protection,2416,O
in,2416,O
corresponding,2416,O
PAS,2416,O
stained,2416,O
tissues,2416,O
.,2416,O
Results,2417,O
indicate,2417,O
that,2417,O
GSPE,2417,B-Chemical
preexposure,2417,O
prior,2417,O
to,2417,O
AAP,2417,B-Chemical
",",2417,O
AMI,2417,B-Chemical
and,2417,O
DOX,2417,B-Chemical
",",2417,O
provided,2417,O
near,2417,O
complete,2417,O
protection,2417,O
in,2417,O
terms,2417,O
of,2417,O
serum,2417,O
chemistry,2417,O
changes,2417,O
(,2417,O
ALT,2417,O
",",2417,O
BUN,2417,O
and,2417,O
CPK,2417,O
),2417,O
",",2417,O
and,2417,O
significantly,2417,O
reduced,2417,O
DNA,2417,O
fragmentation,2417,O
.,2417,O
Histopathological,2418,O
examination,2418,O
of,2418,O
kidney,2418,O
",",2418,O
heart,2418,O
and,2418,O
lung,2418,O
sections,2418,O
revealed,2418,O
moderate,2418,O
to,2418,O
massive,2418,O
tissue,2418,B-Disease
damage,2418,I-Disease
with,2418,O
a,2418,O
variety,2418,O
of,2418,O
morphological,2418,O
aberrations,2418,O
by,2418,O
all,2418,O
the,2418,O
three,2418,O
drugs,2418,O
in,2418,O
the,2418,O
absence,2418,O
of,2418,O
GSPE,2418,B-Chemical
preexposure,2418,O
than,2418,O
in,2418,O
its,2418,O
presence,2418,O
.,2418,O
GSPE+drug,2419,B-Chemical
exposed,2419,O
tissues,2419,O
exhibited,2419,O
minor,2419,O
residual,2419,O
damage,2419,O
or,2419,O
near,2419,O
total,2419,O
recovery,2419,O
.,2419,O
Additionally,2420,O
",",2420,O
histopathological,2420,O
alterations,2420,O
mirrored,2420,O
both,2420,O
serum,2420,O
chemistry,2420,O
changes,2420,O
and,2420,O
the,2420,O
pattern,2420,O
of,2420,O
DNA,2420,O
fragmentation,2420,O
.,2420,O
Interestingly,2421,O
",",2421,O
all,2421,O
the,2421,O
drugs,2421,O
",",2421,O
such,2421,O
as,2421,O
",",2421,O
AAP,2421,B-Chemical
",",2421,O
AMI,2421,B-Chemical
and,2421,O
DOX,2421,B-Chemical
induced,2421,O
apoptotic,2421,O
death,2421,O
in,2421,O
addition,2421,O
to,2421,O
necrosis,2421,B-Disease
in,2421,O
the,2421,O
respective,2421,O
organs,2421,O
which,2421,O
was,2421,O
very,2421,O
effectively,2421,O
blocked,2421,O
by,2421,O
GSPE,2421,B-Chemical
.,2421,O
Since,2422,O
AAP,2422,B-Chemical
",",2422,O
AMI,2422,B-Chemical
and,2422,O
DOX,2422,B-Chemical
undergo,2422,O
biotransformation,2422,O
and,2422,O
are,2422,O
known,2422,O
to,2422,O
produce,2422,O
damaging,2422,O
radicals,2422,O
in,2422,O
vivo,2422,O
",",2422,O
the,2422,O
protection,2422,O
by,2422,O
GSPE,2422,B-Chemical
may,2422,O
be,2422,O
linked,2422,O
to,2422,O
both,2422,O
inhibition,2422,O
of,2422,O
metabolism,2422,O
and/or,2422,O
detoxification,2422,O
of,2422,O
cytotoxic,2422,O
radicals,2422,O
.,2422,O
In,2423,O
addition,2423,O
",",2423,O
its,2423,O
',2423,O
presumed,2423,O
contribution,2423,O
to,2423,O
DNA,2423,O
repair,2423,O
may,2423,O
be,2423,O
another,2423,O
important,2423,O
attribute,2423,O
",",2423,O
which,2423,O
played,2423,O
a,2423,O
role,2423,O
in,2423,O
the,2423,O
chemoprevention,2423,O
process,2423,O
.,2423,O
Additionally,2424,O
",",2424,O
this,2424,O
may,2424,O
have,2424,O
been,2424,O
the,2424,O
first,2424,O
report,2424,O
on,2424,O
AMI-induced,2424,B-Chemical
apoptotic,2424,O
death,2424,O
in,2424,O
the,2424,O
lung,2424,O
tissue,2424,O
.,2424,O
Taken,2425,O
together,2425,O
",",2425,O
these,2425,O
events,2425,O
undoubtedly,2425,O
establish,2425,O
GSPE,2425,B-Chemical
's,2425,O
abundant,2425,O
bioavailability,2425,O
",",2425,O
and,2425,O
the,2425,O
power,2425,O
to,2425,O
defend,2425,O
multiple,2425,O
target,2425,O
organs,2425,O
from,2425,O
toxic,2425,O
assaults,2425,O
induced,2425,O
by,2425,O
structurally,2425,O
diverse,2425,O
and,2425,O
functionally,2425,O
different,2425,O
entities,2425,O
in,2425,O
vivo,2425,O
.,2425,O
Antidepressant-induced,2426,B-Chemical
mania,2426,B-Disease
in,2426,O
bipolar,2426,B-Disease
patients,2426,O
:,2426,O
identification,2426,O
of,2426,O
risk,2426,O
factors,2426,O
.,2426,O
BACKGROUND,2427,O
:,2427,O
Concerns,2427,O
about,2427,O
possible,2427,O
risks,2427,O
of,2427,O
switching,2427,O
to,2427,O
mania,2427,B-Disease
associated,2427,O
with,2427,O
antidepressants,2427,B-Chemical
continue,2427,O
to,2427,O
interfere,2427,O
with,2427,O
the,2427,O
establishment,2427,O
of,2427,O
an,2427,O
optimal,2427,O
treatment,2427,O
paradigm,2427,O
for,2427,O
bipolar,2427,B-Disease
depression,2427,I-Disease
.,2427,O
METHOD,2428,O
:,2428,O
The,2428,O
response,2428,O
of,2428,O
44,2428,O
patients,2428,O
meeting,2428,O
DSM-IV,2428,O
criteria,2428,O
for,2428,O
bipolar,2428,B-Disease
disorder,2428,I-Disease
to,2428,O
naturalistic,2428,O
treatment,2428,O
was,2428,O
assessed,2428,O
for,2428,O
at,2428,O
least,2428,O
6,2428,O
weeks,2428,O
using,2428,O
the,2428,O
Montgomery-Asberg,2428,O
Depression,2428,O
Rating,2428,O
Scale,2428,O
and,2428,O
the,2428,O
Bech-Rafaelson,2428,O
Mania,2428,O
Rating,2428,O
Scale,2428,O
.,2428,O
Patients,2429,O
who,2429,O
experienced,2429,O
a,2429,O
manic,2429,B-Disease
or,2429,O
hypomanic,2429,B-Disease
switch,2429,O
were,2429,O
compared,2429,O
with,2429,O
those,2429,O
who,2429,O
did,2429,O
not,2429,O
on,2429,O
several,2429,O
variables,2429,O
including,2429,O
age,2429,O
",",2429,O
sex,2429,O
",",2429,O
diagnosis,2429,O
(,2429,O
DSM-IV,2429,B-Disease
bipolar,2429,I-Disease
I,2429,I-Disease
vs.,2429,O
bipolar,2429,B-Disease
II,2429,I-Disease
),2429,O
",",2429,O
number,2429,O
of,2429,O
previous,2429,O
manic,2429,B-Disease
episodes,2429,O
",",2429,O
type,2429,O
of,2429,O
antidepressant,2429,B-Chemical
therapy,2429,O
used,2429,O
(,2429,O
electroconvulsive,2429,O
therapy,2429,O
vs.,2429,O
antidepressant,2429,B-Chemical
drugs,2429,O
and,2429,O
",",2429,O
more,2429,O
particularly,2429,O
",",2429,O
selective,2429,O
serotonin,2429,B-Chemical
reuptake,2429,I-Chemical
inhibitors,2429,I-Chemical
[,2429,O
SSRIs,2429,B-Chemical
],2429,O
),2429,O
",",2429,O
use,2429,O
and,2429,O
type,2429,O
of,2429,O
mood,2429,O
stabilizers,2429,O
(,2429,O
lithium,2429,B-Chemical
vs.,2429,O
anticonvulsants,2429,O
),2429,O
",",2429,O
and,2429,O
temperament,2429,O
of,2429,O
the,2429,O
patient,2429,O
",",2429,O
assessed,2429,O
during,2429,O
a,2429,O
normothymic,2429,O
period,2429,O
using,2429,O
the,2429,O
hyperthymia,2429,O
component,2429,O
of,2429,O
the,2429,O
Semi-structured,2429,O
Affective,2429,O
Temperament,2429,O
Interview,2429,O
.,2429,O
RESULTS,2430,O
:,2430,O
Switches,2430,O
to,2430,O
hypomania,2430,B-Disease
or,2430,O
mania,2430,B-Disease
occurred,2430,O
in,2430,O
27,2430,O
%,2430,O
of,2430,O
all,2430,O
patients,2430,O
(,2430,O
N,2430,O
=,2430,O
12,2430,O
),2430,O
(,2430,O
and,2430,O
in,2430,O
24,2430,O
%,2430,O
of,2430,O
the,2430,O
subgroup,2430,O
of,2430,O
patients,2430,O
treated,2430,O
with,2430,O
SSRIs,2430,B-Chemical
[,2430,O
8/33,2430,O
],2430,O
),2430,O
;,2430,O
16,2430,O
%,2430,O
(,2430,O
N,2430,O
=,2430,O
7,2430,O
),2430,O
experienced,2430,O
manic,2430,B-Disease
episodes,2430,O
",",2430,O
and,2430,O
11,2430,O
%,2430,O
(,2430,O
N,2430,O
=,2430,O
5,2430,O
),2430,O
experienced,2430,O
hypomanic,2430,B-Disease
episodes,2430,O
.,2430,O
Sex,2431,O
",",2431,O
age,2431,O
",",2431,O
diagnosis,2431,O
(,2431,O
bipolar,2431,B-Disease
I,2431,I-Disease
vs.,2431,O
bipolar,2431,B-Disease
II,2431,I-Disease
),2431,O
",",2431,O
and,2431,O
additional,2431,O
treatment,2431,O
did,2431,O
not,2431,O
affect,2431,O
the,2431,O
risk,2431,O
of,2431,O
switching,2431,O
.,2431,O
The,2432,O
incidence,2432,O
of,2432,O
mood,2432,O
switches,2432,O
seemed,2432,O
not,2432,O
to,2432,O
differ,2432,O
between,2432,O
patients,2432,O
receiving,2432,O
an,2432,O
anticonvulsant,2432,O
and,2432,O
those,2432,O
receiving,2432,O
no,2432,O
mood,2432,O
stabilizer,2432,O
.,2432,O
In,2433,O
contrast,2433,O
",",2433,O
mood,2433,O
switches,2433,O
were,2433,O
less,2433,O
frequent,2433,O
in,2433,O
patients,2433,O
receiving,2433,O
lithium,2433,B-Chemical
(,2433,O
15,2433,O
%,2433,O
",",2433,O
4/26,2433,O
),2433,O
than,2433,O
in,2433,O
patients,2433,O
not,2433,O
treated,2433,O
with,2433,O
lithium,2433,B-Chemical
(,2433,O
44,2433,O
%,2433,O
",",2433,O
8/18,2433,O
;,2433,O
p,2433,O
=,2433,O
.04,2433,O
),2433,O
.,2433,O
The,2434,O
number,2434,O
of,2434,O
previous,2434,O
manic,2434,B-Disease
episodes,2434,O
did,2434,O
not,2434,O
affect,2434,O
the,2434,O
probability,2434,O
of,2434,O
switching,2434,O
",",2434,O
whereas,2434,O
a,2434,O
high,2434,O
score,2434,O
on,2434,O
the,2434,O
hyperthymia,2434,O
component,2434,O
of,2434,O
the,2434,O
Semistructured,2434,O
Affective,2434,O
Temperament,2434,O
Interview,2434,O
was,2434,O
associated,2434,O
with,2434,O
a,2434,O
greater,2434,O
risk,2434,O
of,2434,O
switching,2434,O
(,2434,O
p,2434,O
=,2434,O
.008,2434,O
),2434,O
.,2434,O
CONCLUSION,2435,O
:,2435,O
The,2435,O
frequency,2435,O
of,2435,O
mood,2435,O
switching,2435,O
associated,2435,O
with,2435,O
acute,2435,O
antidepressant,2435,B-Chemical
therapy,2435,O
may,2435,O
be,2435,O
reduced,2435,O
by,2435,O
lithium,2435,B-Chemical
treatment,2435,O
.,2435,O
Particular,2436,O
attention,2436,O
should,2436,O
be,2436,O
paid,2436,O
to,2436,O
patients,2436,O
with,2436,O
a,2436,O
hyperthymic,2436,O
temperament,2436,O
",",2436,O
who,2436,O
have,2436,O
a,2436,O
greater,2436,O
risk,2436,O
of,2436,O
mood,2436,O
switches,2436,O
.,2436,O
Peritubular,2437,O
capillary,2437,O
basement,2437,O
membrane,2437,O
reduplication,2437,O
in,2437,O
allografts,2437,O
and,2437,O
native,2437,O
kidney,2437,B-Disease
disease,2437,I-Disease
:,2437,O
a,2437,O
clinicopathologic,2437,O
study,2437,O
of,2437,O
278,2437,O
consecutive,2437,O
renal,2437,O
specimens,2437,O
.,2437,O
BACKGROUND,2438,O
:,2438,O
An,2438,O
association,2438,O
has,2438,O
been,2438,O
found,2438,O
between,2438,O
transplant,2438,B-Disease
glomerulopathy,2438,I-Disease
(,2438,O
TG,2438,B-Disease
),2438,O
and,2438,O
reduplication,2438,O
of,2438,O
peritubular,2438,O
capillary,2438,O
basement,2438,O
membranes,2438,O
(,2438,O
PTCR,2438,O
),2438,O
.,2438,O
Although,2439,O
such,2439,O
an,2439,O
association,2439,O
is,2439,O
of,2439,O
practical,2439,O
and,2439,O
theoretical,2439,O
importance,2439,O
",",2439,O
only,2439,O
one,2439,O
prospective,2439,O
study,2439,O
has,2439,O
tried,2439,O
to,2439,O
confirm,2439,O
it,2439,O
.,2439,O
METHODS,2440,O
:,2440,O
We,2440,O
examined,2440,O
278,2440,O
consecutive,2440,O
renal,2440,O
specimens,2440,O
(,2440,O
from,2440,O
135,2440,O
transplants,2440,O
and,2440,O
143,2440,O
native,2440,O
kidneys,2440,O
),2440,O
for,2440,O
ultrastructural,2440,O
evidence,2440,O
of,2440,O
PTCR,2440,O
.,2440,O
In,2441,O
addition,2441,O
to,2441,O
renal,2441,O
allografts,2441,O
with,2441,O
TG,2441,B-Disease
",",2441,O
we,2441,O
also,2441,O
examined,2441,O
grafts,2441,O
with,2441,O
acute,2441,O
rejection,2441,O
",",2441,O
recurrent,2441,O
glomerulonephritis,2441,B-Disease
",",2441,O
chronic,2441,B-Disease
allograft,2441,I-Disease
nephropathy,2441,I-Disease
and,2441,O
stable,2441,O
grafts,2441,O
(,2441,O
``,2441,O
protocol,2441,O
biopsies,2441,O
'',2441,O
),2441,O
.,2441,O
Native,2442,O
kidney,2442,O
specimens,2442,O
included,2442,O
a,2442,O
wide,2442,O
range,2442,O
of,2442,O
glomerulopathies,2442,B-Disease
as,2442,O
well,2442,O
as,2442,O
cases,2442,O
of,2442,O
thrombotic,2442,B-Disease
microangiopathy,2442,I-Disease
",",2442,O
malignant,2442,B-Disease
hypertension,2442,I-Disease
",",2442,O
acute,2442,O
interstitial,2442,B-Disease
nephritis,2442,I-Disease
",",2442,O
and,2442,O
acute,2442,B-Disease
tubular,2442,I-Disease
necrosis,2442,I-Disease
.,2442,O
RESULTS,2443,O
:,2443,O
We,2443,O
found,2443,O
PTCR,2443,O
in,2443,O
14,2443,O
of,2443,O
15,2443,O
cases,2443,O
of,2443,O
TG,2443,B-Disease
",",2443,O
in,2443,O
7,2443,O
transplant,2443,O
biopsy,2443,O
specimens,2443,O
without,2443,O
TG,2443,B-Disease
",",2443,O
and,2443,O
in,2443,O
13,2443,O
of,2443,O
143,2443,O
native,2443,O
kidney,2443,O
biopsy,2443,O
specimens,2443,O
.,2443,O
These,2444,O
13,2444,O
included,2444,O
cases,2444,O
of,2444,O
malignant,2444,B-Disease
hypertension,2444,I-Disease
",",2444,O
thrombotic,2444,B-Disease
microangiopathy,2444,I-Disease
",",2444,O
lupus,2444,B-Disease
nephritis,2444,I-Disease
",",2444,O
Henoch-Schonlein,2444,B-Disease
nephritis,2444,I-Disease
",",2444,O
crescentic,2444,O
glomerulonephritis,2444,B-Disease
",",2444,O
and,2444,O
cocaine-related,2444,B-Chemical
acute,2444,B-Disease
renal,2444,I-Disease
failure,2444,I-Disease
.,2444,O
Mild,2445,O
PTCR,2445,O
in,2445,O
allografts,2445,O
without,2445,O
TG,2445,B-Disease
did,2445,O
not,2445,O
predict,2445,O
renal,2445,B-Disease
failure,2445,I-Disease
or,2445,O
significant,2445,O
proteinuria,2445,B-Disease
after,2445,O
follow-up,2445,O
periods,2445,O
of,2445,O
between,2445,O
3,2445,O
months,2445,O
and,2445,O
1,2445,O
year,2445,O
.,2445,O
CONCLUSIONS,2446,O
:,2446,O
We,2446,O
conclude,2446,O
that,2446,O
in,2446,O
transplants,2446,O
",",2446,O
there,2446,O
is,2446,O
a,2446,O
strong,2446,O
association,2446,O
between,2446,O
well-developed,2446,O
PTCR,2446,O
and,2446,O
TG,2446,B-Disease
",",2446,O
while,2446,O
the,2446,O
significance,2446,O
of,2446,O
mild,2446,O
PTCR,2446,O
and,2446,O
its,2446,O
predictive,2446,O
value,2446,O
in,2446,O
the,2446,O
absence,2446,O
of,2446,O
TG,2446,B-Disease
is,2446,O
unclear,2446,O
.,2446,O
PTCR,2447,O
also,2447,O
occurs,2447,O
in,2447,O
certain,2447,O
native,2447,O
kidney,2447,B-Disease
diseases,2447,I-Disease
",",2447,O
though,2447,O
the,2447,O
association,2447,O
is,2447,O
not,2447,O
as,2447,O
strong,2447,O
as,2447,O
that,2447,O
for,2447,O
TG,2447,B-Disease
.,2447,O
We,2448,O
suggest,2448,O
that,2448,O
repeated,2448,O
endothelial,2448,B-Disease
injury,2448,I-Disease
",",2448,O
including,2448,O
immunologic,2448,B-Disease
injury,2448,I-Disease
",",2448,O
may,2448,O
be,2448,O
the,2448,O
cause,2448,O
of,2448,O
this,2448,O
lesion,2448,O
both,2448,O
in,2448,O
allografts,2448,O
and,2448,O
native,2448,O
kidneys,2448,O
.,2448,O
Caffeine-induced,2449,B-Chemical
cardiac,2449,B-Disease
arrhythmia,2449,I-Disease
:,2449,O
an,2449,O
unrecognised,2449,O
danger,2449,O
of,2449,O
healthfood,2449,O
products,2449,O
.,2449,O
We,2450,O
describe,2450,O
a,2450,O
25-year-old,2450,O
woman,2450,O
with,2450,O
pre-existing,2450,O
mitral,2450,B-Disease
valve,2450,I-Disease
prolapse,2450,I-Disease
who,2450,O
developed,2450,O
intractable,2450,O
ventricular,2450,B-Disease
fibrillation,2450,I-Disease
after,2450,O
consuming,2450,O
a,2450,O
``,2450,O
natural,2450,O
energy,2450,O
'',2450,O
guarana,2450,O
health,2450,O
drink,2450,O
containing,2450,O
a,2450,O
high,2450,O
concentration,2450,O
of,2450,O
caffeine,2450,B-Chemical
.,2450,O
This,2451,O
case,2451,O
highlights,2451,O
the,2451,O
need,2451,O
for,2451,O
adequate,2451,O
labelling,2451,O
and,2451,O
regulation,2451,O
of,2451,O
such,2451,O
products,2451,O
.,2451,O
Conformationally,2452,O
restricted,2452,O
analogs,2452,O
of,2452,O
BD1008,2452,B-Chemical
and,2452,O
an,2452,O
antisense,2452,O
oligodeoxynucleotide,2452,B-Chemical
targeting,2452,O
sigma1,2452,O
receptors,2452,O
produce,2452,O
anti-cocaine,2452,O
effects,2452,O
in,2452,O
mice,2452,O
.,2452,O
Cocaine,2453,B-Chemical
's,2453,O
ability,2453,O
to,2453,O
interact,2453,O
with,2453,O
sigma,2453,O
receptors,2453,O
suggests,2453,O
that,2453,O
these,2453,O
proteins,2453,O
mediate,2453,O
some,2453,O
of,2453,O
its,2453,O
behavioral,2453,O
effects,2453,O
.,2453,O
Therefore,2454,O
",",2454,O
three,2454,O
novel,2454,O
sigma,2454,O
receptor,2454,O
ligands,2454,O
with,2454,O
antagonist,2454,O
activity,2454,O
were,2454,O
evaluated,2454,O
in,2454,O
Swiss,2454,O
Webster,2454,O
mice,2454,O
:,2454,O
BD1018,2454,B-Chemical
(,2454,O
3S-1-,2454,B-Chemical
[,2454,I-Chemical
2-,2454,I-Chemical
(,2454,I-Chemical
"3,4-dichlorophenyl",2454,I-Chemical
),2454,I-Chemical
ethyl,2454,I-Chemical
],2454,I-Chemical
"-1,4-diazabicyclo",2454,I-Chemical
[,2454,I-Chemical
4.3.0,2454,I-Chemical
],2454,I-Chemical
nonane,2454,I-Chemical
),2454,O
",",2454,O
BD1063,2454,B-Chemical
(,2454,O
1-,2454,B-Chemical
[,2454,I-Chemical
2-,2454,I-Chemical
(,2454,I-Chemical
"3,4-dichlorophenyl",2454,I-Chemical
),2454,I-Chemical
ethyl,2454,I-Chemical
],2454,I-Chemical
-4-methylpiperazine,2454,I-Chemical
),2454,O
",",2454,O
and,2454,O
LR132,2454,B-Chemical
(,2454,O
"1R,2S-",2454,O
(,2454,O
+,2454,O
),2454,O
-cis-N-,2454,O
[,2454,O
2-,2454,O
(,2454,O
"3,4-dichlorophenyl",2454,O
),2454,O
ethyl,2454,O
],2454,O
-2-,2454,O
(,2454,O
1-pyrrolidinyl,2454,O
),2454,O
cyclohexylamine,2454,O
),2454,O
.,2454,O
Competition,2455,O
binding,2455,O
assays,2455,O
demonstrated,2455,O
that,2455,O
all,2455,O
three,2455,O
compounds,2455,O
have,2455,O
high,2455,O
affinities,2455,O
for,2455,O
sigma1,2455,O
receptors,2455,O
.,2455,O
The,2456,O
three,2456,O
compounds,2456,O
vary,2456,O
in,2456,O
their,2456,O
affinities,2456,O
for,2456,O
sigma2,2456,O
receptors,2456,O
and,2456,O
exhibit,2456,O
negligible,2456,O
affinities,2456,O
for,2456,O
dopamine,2456,B-Chemical
",",2456,O
opioid,2456,O
",",2456,O
GABA,2456,B-Chemical
(,2456,O
A,2456,O
),2456,O
and,2456,O
NMDA,2456,B-Chemical
receptors,2456,O
.,2456,O
In,2457,O
behavioral,2457,O
studies,2457,O
",",2457,O
pre-treatment,2457,O
of,2457,O
mice,2457,O
with,2457,O
BD1018,2457,B-Chemical
",",2457,O
BD1063,2457,B-Chemical
",",2457,O
or,2457,O
LR132,2457,B-Chemical
significantly,2457,O
attenuated,2457,O
cocaine-induced,2457,B-Chemical
convulsions,2457,B-Disease
and,2457,O
lethality,2457,O
.,2457,O
Moreover,2458,O
",",2458,O
post-treatment,2458,O
with,2458,O
LR132,2458,B-Chemical
prevented,2458,O
cocaine-induced,2458,B-Chemical
lethality,2458,O
in,2458,O
a,2458,O
significant,2458,O
proportion,2458,O
of,2458,O
animals,2458,O
.,2458,O
In,2459,O
contrast,2459,O
to,2459,O
the,2459,O
protection,2459,O
provided,2459,O
by,2459,O
the,2459,O
putative,2459,O
antagonists,2459,O
",",2459,O
the,2459,O
well-characterized,2459,O
sigma,2459,O
receptor,2459,O
agonist,2459,O
di-o-tolylguanidine,2459,B-Chemical
(,2459,O
DTG,2459,B-Chemical
),2459,O
and,2459,O
the,2459,O
novel,2459,O
sigma,2459,O
receptor,2459,O
agonist,2459,O
BD1031,2459,B-Chemical
(,2459,O
3R-1-,2459,B-Chemical
[,2459,I-Chemical
2-,2459,I-Chemical
(,2459,I-Chemical
"3,4-dichlorophenyl",2459,I-Chemical
),2459,I-Chemical
ethyl,2459,I-Chemical
],2459,I-Chemical
"-1,4-diazabicyclo",2459,I-Chemical
[,2459,I-Chemical
4.3.0,2459,I-Chemical
],2459,I-Chemical
nonane,2459,I-Chemical
),2459,O
each,2459,O
worsened,2459,O
the,2459,O
behavioral,2459,O
toxicity,2459,B-Disease
of,2459,O
cocaine,2459,B-Chemical
.,2459,O
At,2460,O
doses,2460,O
where,2460,O
alone,2460,O
",",2460,O
they,2460,O
produced,2460,O
no,2460,O
significant,2460,O
effects,2460,O
on,2460,O
locomotion,2460,O
",",2460,O
BD1018,2460,B-Chemical
",",2460,O
BD1063,2460,B-Chemical
and,2460,O
LR132,2460,B-Chemical
significantly,2460,O
attenuated,2460,O
the,2460,O
locomotor,2460,O
stimulatory,2460,O
effects,2460,O
of,2460,O
cocaine,2460,B-Chemical
.,2460,O
To,2461,O
further,2461,O
validate,2461,O
the,2461,O
hypothesis,2461,O
that,2461,O
the,2461,O
anti-cocaine,2461,O
effects,2461,O
of,2461,O
the,2461,O
novel,2461,O
ligands,2461,O
involved,2461,O
antagonism,2461,O
of,2461,O
sigma,2461,O
receptors,2461,O
",",2461,O
an,2461,O
antisense,2461,O
oligodeoxynucleotide,2461,B-Chemical
against,2461,O
sigma1,2461,O
receptors,2461,O
was,2461,O
also,2461,O
shown,2461,O
to,2461,O
significantly,2461,O
attenuate,2461,O
the,2461,O
convulsive,2461,B-Disease
and,2461,O
locomotor,2461,O
stimulatory,2461,O
effects,2461,O
of,2461,O
cocaine,2461,B-Chemical
.,2461,O
Together,2462,O
",",2462,O
the,2462,O
data,2462,O
suggests,2462,O
that,2462,O
functional,2462,O
antagonism,2462,O
of,2462,O
sigma,2462,O
receptors,2462,O
is,2462,O
capable,2462,O
of,2462,O
attenuating,2462,O
a,2462,O
number,2462,O
of,2462,O
cocaine-induced,2462,B-Chemical
behaviors,2462,O
.,2462,O
Ranitidine-induced,2463,B-Chemical
acute,2463,O
interstitial,2463,B-Disease
nephritis,2463,I-Disease
in,2463,O
a,2463,O
cadaveric,2463,O
renal,2463,O
allograft,2463,O
.,2463,O
Ranitidine,2464,B-Chemical
frequently,2464,O
is,2464,O
used,2464,O
for,2464,O
preventing,2464,O
peptic,2464,O
ulceration,2464,O
after,2464,O
renal,2464,O
transplantation,2464,O
.,2464,O
This,2465,O
drug,2465,O
occasionally,2465,O
has,2465,O
been,2465,O
associated,2465,O
with,2465,O
acute,2465,O
interstitial,2465,B-Disease
nephritis,2465,I-Disease
in,2465,O
native,2465,O
kidneys,2465,O
.,2465,O
There,2466,O
are,2466,O
no,2466,O
similar,2466,O
reports,2466,O
with,2466,O
renal,2466,O
transplantation,2466,O
.,2466,O
We,2467,O
report,2467,O
a,2467,O
case,2467,O
of,2467,O
ranitidine-induced,2467,B-Chemical
acute,2467,O
interstitial,2467,B-Disease
nephritis,2467,I-Disease
in,2467,O
a,2467,O
recipient,2467,O
of,2467,O
a,2467,O
cadaveric,2467,O
renal,2467,O
allograft,2467,O
presenting,2467,O
with,2467,O
acute,2467,O
allograft,2467,O
dysfunction,2467,O
within,2467,O
48,2467,O
hours,2467,O
of,2467,O
exposure,2467,O
to,2467,O
the,2467,O
drug,2467,O
.,2467,O
The,2468,O
biopsy,2468,O
specimen,2468,O
showed,2468,O
pathognomonic,2468,O
features,2468,O
",",2468,O
including,2468,O
eosinophilic,2468,O
infiltration,2468,O
of,2468,O
the,2468,O
interstitial,2468,O
compartment,2468,O
.,2468,O
Allograft,2469,O
function,2469,O
improved,2469,O
rapidly,2469,O
and,2469,O
returned,2469,O
to,2469,O
baseline,2469,O
after,2469,O
stopping,2469,O
the,2469,O
drug,2469,O
.,2469,O
Withdrawal-emergent,2470,O
rabbit,2470,O
syndrome,2470,O
during,2470,O
dose,2470,O
reduction,2470,O
of,2470,O
risperidone,2470,B-Chemical
.,2470,O
Rabbit,2471,B-Disease
syndrome,2471,I-Disease
(,2471,O
RS,2471,B-Disease
),2471,O
is,2471,O
a,2471,O
rare,2471,O
extrapyramidal,2471,O
side,2471,O
effect,2471,O
caused,2471,O
by,2471,O
prolonged,2471,O
neuroleptic,2471,O
medication,2471,O
.,2471,O
Here,2472,O
we,2472,O
present,2472,O
a,2472,O
case,2472,O
of,2472,O
withdrawal-emergent,2472,O
RS,2472,O
",",2472,O
which,2472,O
is,2472,O
the,2472,O
first,2472,O
of,2472,O
its,2472,O
kind,2472,O
to,2472,O
be,2472,O
reported,2472,O
.,2472,O
The,2473,O
patient,2473,O
developed,2473,O
RS,2473,B-Disease
during,2473,O
dose,2473,O
reduction,2473,O
of,2473,O
risperidone,2473,B-Chemical
.,2473,O
The,2474,O
symptom,2474,O
was,2474,O
treated,2474,O
successfully,2474,O
with,2474,O
trihexyphenidyl,2474,B-Chemical
anticholinergic,2474,O
therapy,2474,O
.,2474,O
The,2475,O
underlying,2475,O
mechanism,2475,O
of,2475,O
withdrawal-emergent,2475,O
RS,2475,O
in,2475,O
the,2475,O
present,2475,O
case,2475,O
may,2475,O
have,2475,O
been,2475,O
related,2475,O
to,2475,O
the,2475,O
pharmacological,2475,O
profile,2475,O
of,2475,O
risperidone,2475,B-Chemical
",",2475,O
a,2475,O
serotonin-dopamine,2475,B-Chemical
antagonist,2475,O
",",2475,O
suggesting,2475,O
the,2475,O
pathophysiologic,2475,O
influence,2475,O
of,2475,O
the,2475,O
serotonin,2475,B-Chemical
system,2475,O
in,2475,O
the,2475,O
development,2475,O
of,2475,O
RS,2475,B-Disease
.,2475,O
Pharmacokinetic/pharmacodynamic,2476,O
assessment,2476,O
of,2476,O
the,2476,O
effects,2476,O
of,2476,O
E4031,2476,B-Chemical
",",2476,O
cisapride,2476,B-Chemical
",",2476,O
terfenadine,2476,B-Chemical
and,2476,O
terodiline,2476,B-Chemical
on,2476,O
monophasic,2476,O
action,2476,O
potential,2476,O
duration,2476,O
in,2476,O
dog,2476,O
.,2476,O
1,2477,O
.,2477,O
Torsades,2478,B-Disease
de,2478,I-Disease
pointes,2478,I-Disease
(,2478,O
TDP,2478,B-Disease
),2478,O
is,2478,O
a,2478,O
potentially,2478,O
fatal,2478,O
ventricular,2478,B-Disease
tachycardia,2478,I-Disease
associated,2478,O
with,2478,O
increases,2478,O
in,2478,O
QT,2478,O
interval,2478,O
and,2478,O
monophasic,2478,O
action,2478,O
potential,2478,O
duration,2478,O
(,2478,O
MAPD,2478,O
),2478,O
.,2478,O
TDP,2479,B-Disease
is,2479,O
a,2479,O
side-effect,2479,O
that,2479,O
has,2479,O
led,2479,O
to,2479,O
withdrawal,2479,O
of,2479,O
several,2479,O
drugs,2479,O
from,2479,O
the,2479,O
market,2479,O
(,2479,O
e.g,2479,O
.,2479,O
terfenadine,2480,B-Chemical
and,2480,O
terodiline,2480,B-Chemical
),2480,O
.,2480,O
2,2481,O
.,2481,O
The,2482,O
potential,2482,O
of,2482,O
compounds,2482,O
to,2482,O
cause,2482,O
TDP,2482,B-Disease
was,2482,O
evaluated,2482,O
by,2482,O
monitoring,2482,O
their,2482,O
effects,2482,O
on,2482,O
MAPD,2482,O
in,2482,O
dog,2482,O
.,2482,O
Four,2483,O
compounds,2483,O
known,2483,O
to,2483,O
increase,2483,O
QT,2483,O
interval,2483,O
and,2483,O
cause,2483,O
TDP,2483,B-Disease
were,2483,O
investigated,2483,O
:,2483,O
terfenadine,2483,B-Chemical
",",2483,O
terodiline,2483,B-Chemical
",",2483,O
cisapride,2483,B-Chemical
and,2483,O
E4031,2483,B-Chemical
.,2483,O
On,2484,O
the,2484,O
basis,2484,O
that,2484,O
only,2484,O
free,2484,O
drug,2484,O
in,2484,O
the,2484,O
systemic,2484,O
circulation,2484,O
will,2484,O
elicit,2484,O
a,2484,O
pharmacological,2484,O
response,2484,O
target,2484,O
",",2484,O
free,2484,O
concentrations,2484,O
in,2484,O
plasma,2484,O
were,2484,O
selected,2484,O
to,2484,O
mimic,2484,O
the,2484,O
free,2484,O
drug,2484,O
exposures,2484,O
in,2484,O
man,2484,O
.,2484,O
Infusion,2485,O
regimens,2485,O
were,2485,O
designed,2485,O
that,2485,O
rapidly,2485,O
achieved,2485,O
and,2485,O
maintained,2485,O
target-free,2485,O
concentrations,2485,O
of,2485,O
these,2485,O
drugs,2485,O
in,2485,O
plasma,2485,O
and,2485,O
data,2485,O
on,2485,O
the,2485,O
relationship,2485,O
between,2485,O
free,2485,O
concentration,2485,O
and,2485,O
changes,2485,O
in,2485,O
MAPD,2485,O
were,2485,O
obtained,2485,O
for,2485,O
these,2485,O
compounds,2485,O
.,2485,O
3,2486,O
.,2486,O
These,2487,O
data,2487,O
indicate,2487,O
that,2487,O
the,2487,O
free,2487,O
ED50,2487,O
in,2487,O
plasma,2487,O
for,2487,O
terfenadine,2487,B-Chemical
(,2487,O
1.9,2487,O
nM,2487,O
),2487,O
",",2487,O
terodiline,2487,B-Chemical
(,2487,O
76,2487,O
nM,2487,O
),2487,O
",",2487,O
cisapride,2487,B-Chemical
(,2487,O
11,2487,O
nM,2487,O
),2487,O
and,2487,O
E4031,2487,B-Chemical
(,2487,O
1.9,2487,O
nM,2487,O
),2487,O
closely,2487,O
correlate,2487,O
with,2487,O
the,2487,O
free,2487,O
concentration,2487,O
in,2487,O
man,2487,O
causing,2487,O
QT,2487,O
effects,2487,O
.,2487,O
For,2488,O
compounds,2488,O
that,2488,O
have,2488,O
shown,2488,O
TDP,2488,B-Disease
in,2488,O
the,2488,O
clinic,2488,O
(,2488,O
terfenadine,2488,B-Chemical
",",2488,O
terodiline,2488,B-Chemical
",",2488,O
cisapride,2488,B-Chemical
),2488,O
there,2488,O
is,2488,O
little,2488,O
differentiation,2488,O
between,2488,O
the,2488,O
dog,2488,O
ED50,2488,O
and,2488,O
the,2488,O
efficacious,2488,O
free,2488,O
plasma,2488,O
concentrations,2488,O
in,2488,O
man,2488,O
(,2488,O
<,2488,O
10-fold,2488,O
),2488,O
reflecting,2488,O
their,2488,O
limited,2488,O
safety,2488,O
margins,2488,O
.,2488,O
These,2489,O
data,2489,O
underline,2489,O
the,2489,O
need,2489,O
to,2489,O
maximize,2489,O
the,2489,O
therapeutic,2489,O
ratio,2489,O
with,2489,O
respect,2489,O
to,2489,O
TDP,2489,B-Disease
in,2489,O
potential,2489,O
development,2489,O
candidates,2489,O
and,2489,O
the,2489,O
importance,2489,O
of,2489,O
using,2489,O
free,2489,O
drug,2489,O
concentrations,2489,O
in,2489,O
pharmacokinetic/pharmacodynamic,2489,O
studies,2489,O
.,2489,O
Bladder,2490,O
retention,2490,B-Disease
of,2490,I-Disease
urine,2490,I-Disease
as,2490,O
a,2490,O
result,2490,O
of,2490,O
continuous,2490,O
intravenous,2490,O
infusion,2490,O
of,2490,O
fentanyl,2490,B-Chemical
:,2490,O
2,2490,O
case,2490,O
reports,2490,O
.,2490,O
Sedation,2491,O
has,2491,O
been,2491,O
commonly,2491,O
used,2491,O
in,2491,O
the,2491,O
neonate,2491,O
to,2491,O
decrease,2491,O
the,2491,O
stress,2491,O
and,2491,O
pain,2491,B-Disease
from,2491,O
the,2491,O
noxious,2491,O
stimuli,2491,O
and,2491,O
invasive,2491,O
procedures,2491,O
in,2491,O
the,2491,O
neonatal,2491,O
intensive,2491,O
care,2491,O
unit,2491,O
",",2491,O
as,2491,O
well,2491,O
as,2491,O
to,2491,O
facilitate,2491,O
synchrony,2491,O
between,2491,O
ventilator,2491,O
and,2491,O
spontaneous,2491,O
breaths,2491,O
.,2491,O
Fentanyl,2492,B-Chemical
",",2492,O
an,2492,O
opioid,2492,O
analgesic,2492,O
",",2492,O
is,2492,O
frequently,2492,O
used,2492,O
in,2492,O
the,2492,O
neonatal,2492,O
intensive,2492,O
care,2492,O
unit,2492,O
setting,2492,O
for,2492,O
these,2492,O
very,2492,O
purposes,2492,O
.,2492,O
Various,2493,O
reported,2493,O
side,2493,O
effects,2493,O
of,2493,O
fentanyl,2493,B-Chemical
administration,2493,O
include,2493,O
chest,2493,B-Disease
wall,2493,I-Disease
rigidity,2493,I-Disease
",",2493,O
hypotension,2493,B-Disease
",",2493,O
respiratory,2493,B-Disease
depression,2493,I-Disease
",",2493,O
and,2493,O
bradycardia,2493,B-Disease
.,2493,O
Here,2494,O
",",2494,O
2,2494,O
cases,2494,O
of,2494,O
urinary,2494,B-Disease
bladder,2494,I-Disease
retention,2494,I-Disease
leading,2494,O
to,2494,O
renal,2494,O
pelvocalyceal,2494,O
dilatation,2494,O
mimicking,2494,O
hydronephrosis,2494,B-Disease
as,2494,O
a,2494,O
result,2494,O
of,2494,O
continuous,2494,O
infusion,2494,O
of,2494,O
fentanyl,2494,B-Chemical
are,2494,O
reported,2494,O
.,2494,O
Fatal,2495,O
myeloencephalopathy,2495,B-Disease
due,2495,O
to,2495,O
accidental,2495,O
intrathecal,2495,O
vincristin,2495,B-Chemical
administration,2495,O
:,2495,O
a,2495,O
report,2495,O
of,2495,O
two,2495,O
cases,2495,O
.,2495,O
We,2496,O
report,2496,O
on,2496,O
two,2496,O
fatal,2496,O
cases,2496,O
of,2496,O
accidental,2496,O
intrathecal,2496,O
vincristine,2496,B-Chemical
instillation,2496,O
in,2496,O
a,2496,O
5-year,2496,O
old,2496,O
girl,2496,O
with,2496,O
recurrent,2496,O
acute,2496,B-Disease
lymphoblastic,2496,I-Disease
leucemia,2496,I-Disease
and,2496,O
a,2496,O
57-year,2496,O
old,2496,O
man,2496,O
with,2496,O
lymphoblastic,2496,B-Disease
lymphoma,2496,I-Disease
.,2496,O
The,2497,O
girl,2497,O
died,2497,O
seven,2497,O
days,2497,O
",",2497,O
the,2497,O
man,2497,O
four,2497,O
weeks,2497,O
after,2497,O
intrathecal,2497,O
injection,2497,O
of,2497,O
vincristine,2497,B-Chemical
.,2497,O
Clinically,2498,O
",",2498,O
the,2498,O
onset,2498,O
was,2498,O
characterized,2498,O
by,2498,O
the,2498,O
signs,2498,O
of,2498,O
opistothonus,2498,O
",",2498,O
sensory,2498,O
and,2498,O
motor,2498,O
dysfunction,2498,O
and,2498,O
ascending,2498,O
paralysis,2498,B-Disease
.,2498,O
Histological,2499,O
and,2499,O
immunohistochemical,2499,O
investigations,2499,O
(,2499,O
HE-LFB,2499,O
",",2499,O
CD-68,2499,O
",",2499,O
Neurofilament,2499,O
),2499,O
revealed,2499,O
degeneration,2499,O
of,2499,O
myelin,2499,O
and,2499,O
axons,2499,O
as,2499,O
well,2499,O
as,2499,O
pseudocystic,2499,B-Disease
transformation,2499,I-Disease
in,2499,O
areas,2499,O
exposed,2499,O
to,2499,O
vincristine,2499,B-Chemical
",",2499,O
accompanied,2499,O
by,2499,O
secondary,2499,O
changes,2499,O
with,2499,O
numerous,2499,O
prominent,2499,O
macrophages,2499,O
.,2499,O
The,2500,O
clinical,2500,O
course,2500,O
and,2500,O
histopathological,2500,O
results,2500,O
of,2500,O
the,2500,O
two,2500,O
cases,2500,O
are,2500,O
presented,2500,O
.,2500,O
A,2501,O
review,2501,O
of,2501,O
all,2501,O
reported,2501,O
cases,2501,O
in,2501,O
the,2501,O
literature,2501,O
is,2501,O
given,2501,O
.,2501,O
A,2502,O
better,2502,O
controlled,2502,O
regimen,2502,O
for,2502,O
administering,2502,O
vincristine,2502,B-Chemical
and,2502,O
intrathecal,2502,O
chemotherapy,2502,O
is,2502,O
recommended,2502,O
.,2502,O
Palpebral,2503,B-Disease
twitching,2503,I-Disease
in,2503,O
a,2503,O
depressed,2503,B-Disease
adolescent,2503,O
on,2503,O
citalopram,2503,B-Chemical
.,2503,O
Current,2504,O
estimates,2504,O
suggest,2504,O
that,2504,O
between,2504,O
0.4,2504,O
%,2504,O
and,2504,O
8.3,2504,O
%,2504,O
of,2504,O
children,2504,O
and,2504,O
adolescents,2504,O
are,2504,O
affected,2504,O
by,2504,O
major,2504,B-Disease
depression,2504,I-Disease
.,2504,O
We,2505,O
report,2505,O
a,2505,O
favorable,2505,O
response,2505,O
to,2505,O
treatment,2505,O
with,2505,O
citalopram,2505,B-Chemical
by,2505,O
a,2505,O
15-year-old,2505,O
boy,2505,O
with,2505,O
major,2505,B-Disease
depression,2505,I-Disease
who,2505,O
exhibited,2505,O
palpebral,2505,B-Disease
twitching,2505,I-Disease
during,2505,O
his,2505,O
first,2505,O
2,2505,O
weeks,2505,O
of,2505,O
treatment,2505,O
.,2505,O
This,2506,O
may,2506,O
have,2506,O
been,2506,O
a,2506,O
side,2506,O
effect,2506,O
of,2506,O
citalopram,2506,B-Chemical
as,2506,O
it,2506,O
remitted,2506,O
with,2506,O
redistribution,2506,O
of,2506,O
doses,2506,O
.,2506,O
The,2507,O
3-week,2507,O
sulphasalazine,2507,B-Chemical
syndrome,2507,O
strikes,2507,O
again,2507,O
.,2507,O
A,2508,O
34-year-old,2508,O
lady,2508,O
developed,2508,O
a,2508,O
constellation,2508,O
of,2508,O
dermatitis,2508,B-Disease
",",2508,O
fever,2508,B-Disease
",",2508,O
lymphadenopathy,2508,B-Disease
and,2508,O
hepatitis,2508,B-Disease
",",2508,O
beginning,2508,O
on,2508,O
the,2508,O
17th,2508,O
day,2508,O
of,2508,O
a,2508,O
course,2508,O
of,2508,O
oral,2508,O
sulphasalazine,2508,B-Chemical
for,2508,O
sero-negative,2508,O
rheumatoid,2508,B-Disease
arthritis,2508,I-Disease
.,2508,O
Cervical,2509,O
and,2509,O
inguinal,2509,O
lymph,2509,O
node,2509,O
biopsies,2509,O
showed,2509,O
the,2509,O
features,2509,O
of,2509,O
severe,2509,O
necrotising,2509,O
lymphadenitis,2509,B-Disease
",",2509,O
associated,2509,O
with,2509,O
erythrophagocytosis,2509,O
and,2509,O
prominent,2509,O
eosinophilic,2509,O
infiltrates,2509,O
",",2509,O
without,2509,O
viral,2509,O
inclusion,2509,O
bodies,2509,O
",",2509,O
suggestive,2509,O
of,2509,O
an,2509,O
adverse,2509,B-Disease
drug,2509,I-Disease
reaction.A,2509,O
week,2509,O
later,2509,O
",",2509,O
fulminant,2509,O
drug-induced,2509,B-Disease
hepatitis,2509,I-Disease
",",2509,O
associated,2509,O
with,2509,O
the,2509,O
presence,2509,O
of,2509,O
anti-nuclear,2509,O
autoantibodies,2509,O
(,2509,O
but,2509,O
not,2509,O
with,2509,O
other,2509,O
markers,2509,O
of,2509,O
autoimmunity,2509,B-Disease
),2509,O
",",2509,O
and,2509,O
accompanied,2509,O
by,2509,O
multi-organ,2509,B-Disease
failure,2509,I-Disease
and,2509,O
sepsis,2509,B-Disease
",",2509,O
supervened,2509,O
.,2509,O
She,2510,O
subsequently,2510,O
died,2510,O
some,2510,O
5,2510,O
weeks,2510,O
after,2510,O
the,2510,O
commencement,2510,O
of,2510,O
her,2510,O
drug,2510,O
therapy.Post-mortem,2510,O
examination,2510,O
showed,2510,O
evidence,2510,O
of,2510,O
massive,2510,B-Disease
hepatocellular,2510,I-Disease
necrosis,2510,I-Disease
",",2510,O
acute,2510,O
hypersensitivity,2510,O
myocarditis,2510,B-Disease
",",2510,O
focal,2510,O
acute,2510,O
tubulo-interstitial,2510,O
nephritis,2510,B-Disease
and,2510,O
extensive,2510,O
bone,2510,B-Disease
marrow,2510,I-Disease
necrosis,2510,I-Disease
",",2510,O
with,2510,O
no,2510,O
evidence,2510,O
of,2510,O
malignancy,2510,B-Disease
.,2510,O
It,2511,O
is,2511,O
thought,2511,O
that,2511,O
the,2511,O
clinico-pathological,2511,O
features,2511,O
and,2511,O
chronology,2511,O
of,2511,O
this,2511,O
case,2511,O
bore,2511,O
the,2511,O
hallmarks,2511,O
of,2511,O
the,2511,O
so-called,2511,O
``,2511,O
3-week,2511,O
sulphasalazine,2511,B-Chemical
syndrome,2511,O
'',2511,O
",",2511,O
a,2511,O
rare,2511,O
",",2511,O
but,2511,O
often,2511,O
fatal,2511,O
",",2511,O
immunoallergic,2511,O
reaction,2511,O
to,2511,O
sulphasalazine,2511,B-Chemical
.,2511,O
Intravenous,2512,O
administration,2512,O
of,2512,O
prochlorperazine,2512,B-Chemical
by,2512,O
15-minute,2512,O
infusion,2512,O
versus,2512,O
2-minute,2512,O
bolus,2512,O
does,2512,O
not,2512,O
affect,2512,O
the,2512,O
incidence,2512,O
of,2512,O
akathisia,2512,B-Disease
:,2512,O
a,2512,O
prospective,2512,O
",",2512,O
randomized,2512,O
",",2512,O
controlled,2512,O
trial,2512,O
.,2512,O
STUDY,2513,O
OBJECTIVE,2513,O
:,2513,O
We,2513,O
sought,2513,O
to,2513,O
compare,2513,O
the,2513,O
rate,2513,O
of,2513,O
akathisia,2513,B-Disease
after,2513,O
administration,2513,O
of,2513,O
intravenous,2513,O
prochlorperazine,2513,B-Chemical
as,2513,O
a,2513,O
2-minute,2513,O
bolus,2513,O
or,2513,O
15-minute,2513,O
infusion,2513,O
.,2513,O
METHODS,2514,O
:,2514,O
We,2514,O
conducted,2514,O
a,2514,O
prospective,2514,O
",",2514,O
randomized,2514,O
",",2514,O
double-blind,2514,O
study,2514,O
in,2514,O
the,2514,O
emergency,2514,O
department,2514,O
of,2514,O
a,2514,O
central-city,2514,O
teaching,2514,O
hospital,2514,O
.,2514,O
Patients,2515,O
aged,2515,O
18,2515,O
years,2515,O
or,2515,O
older,2515,O
treated,2515,O
with,2515,O
prochlorperazine,2515,B-Chemical
for,2515,O
headache,2515,B-Disease
",",2515,O
nausea,2515,B-Disease
",",2515,O
or,2515,O
vomiting,2515,B-Disease
were,2515,O
eligible,2515,O
for,2515,O
inclusion,2515,O
.,2515,O
Study,2516,O
participants,2516,O
were,2516,O
randomized,2516,O
to,2516,O
receive,2516,O
10,2516,O
mg,2516,O
of,2516,O
prochlorperazine,2516,B-Chemical
administered,2516,O
intravenously,2516,O
by,2516,O
means,2516,O
of,2516,O
2-minute,2516,O
push,2516,O
(,2516,O
bolus,2516,O
group,2516,O
),2516,O
or,2516,O
10,2516,O
mg,2516,O
diluted,2516,O
in,2516,O
50,2516,O
mL,2516,O
of,2516,O
normal,2516,O
saline,2516,O
solution,2516,O
administered,2516,O
by,2516,O
means,2516,O
of,2516,O
intravenous,2516,O
infusion,2516,O
during,2516,O
a,2516,O
15-minute,2516,O
period,2516,O
(,2516,O
infusion,2516,O
group,2516,O
),2516,O
.,2516,O
The,2517,O
main,2517,O
outcome,2517,O
was,2517,O
the,2517,O
number,2517,O
of,2517,O
study,2517,O
participants,2517,O
experiencing,2517,O
akathisia,2517,B-Disease
within,2517,O
60,2517,O
minutes,2517,O
of,2517,O
administration,2517,O
.,2517,O
Akathisia,2518,O
was,2518,O
defined,2518,O
as,2518,O
either,2518,O
a,2518,O
spontaneous,2518,O
report,2518,O
of,2518,O
restlessness,2518,O
or,2518,O
agitation,2518,B-Disease
or,2518,O
a,2518,O
change,2518,O
of,2518,O
2,2518,O
or,2518,O
more,2518,O
in,2518,O
the,2518,O
patient-reported,2518,O
akathisia,2518,B-Disease
rating,2518,O
scale,2518,O
and,2518,O
a,2518,O
change,2518,O
of,2518,O
at,2518,O
least,2518,O
1,2518,O
in,2518,O
the,2518,O
investigator-observed,2518,O
akathisia,2518,B-Disease
rating,2518,O
scale,2518,O
.,2518,O
The,2519,O
intensity,2519,O
of,2519,O
headache,2519,B-Disease
and,2519,O
nausea,2519,B-Disease
was,2519,O
measured,2519,O
with,2519,O
a,2519,O
100-mm,2519,O
visual,2519,O
analog,2519,O
scale,2519,O
.,2519,O
RESULTS,2520,O
:,2520,O
One,2520,O
hundred,2520,O
patients,2520,O
were,2520,O
enrolled,2520,O
.,2520,O
One,2521,O
study,2521,O
participant,2521,O
was,2521,O
excluded,2521,O
after,2521,O
protocol,2521,O
violation,2521,O
.,2521,O
Seventy-three,2522,O
percent,2522,O
(,2522,O
73/99,2522,O
),2522,O
of,2522,O
the,2522,O
study,2522,O
participants,2522,O
were,2522,O
treated,2522,O
for,2522,O
headache,2522,B-Disease
and,2522,O
70,2522,O
%,2522,O
(,2522,O
70/99,2522,O
),2522,O
for,2522,O
nausea,2522,B-Disease
.,2522,O
In,2523,O
the,2523,O
bolus,2523,O
group,2523,O
",",2523,O
26.0,2523,O
%,2523,O
(,2523,O
13/50,2523,O
),2523,O
had,2523,O
akathisia,2523,B-Disease
compared,2523,O
with,2523,O
32.7,2523,O
%,2523,O
(,2523,O
16/49,2523,O
),2523,O
in,2523,O
the,2523,O
infusion,2523,O
group,2523,O
(,2523,O
Delta=-6.7,2523,O
%,2523,O
;,2523,O
95,2523,O
%,2523,O
confidence,2523,O
interval,2523,O
[,2523,O
CI,2523,O
],2523,O
-24.6,2523,O
%,2523,O
to,2523,O
11.2,2523,O
%,2523,O
),2523,O
.,2523,O
The,2524,O
difference,2524,O
between,2524,O
the,2524,O
bolus,2524,O
and,2524,O
infusion,2524,O
groups,2524,O
in,2524,O
the,2524,O
percentage,2524,O
of,2524,O
participants,2524,O
who,2524,O
saw,2524,O
a,2524,O
50,2524,O
%,2524,O
reduction,2524,O
in,2524,O
their,2524,O
headache,2524,B-Disease
intensity,2524,O
within,2524,O
30,2524,O
minutes,2524,O
was,2524,O
11.8,2524,O
%,2524,O
(,2524,O
95,2524,O
%,2524,O
CI,2524,O
-9.6,2524,O
%,2524,O
to,2524,O
33.3,2524,O
%,2524,O
),2524,O
.,2524,O
The,2525,O
difference,2525,O
in,2525,O
the,2525,O
percentage,2525,O
of,2525,O
patients,2525,O
with,2525,O
a,2525,O
50,2525,O
%,2525,O
reduction,2525,O
in,2525,O
their,2525,O
nausea,2525,B-Disease
was,2525,O
12.6,2525,O
%,2525,O
(,2525,O
95,2525,O
%,2525,O
CI,2525,O
-4.6,2525,O
%,2525,O
to,2525,O
29.8,2525,O
%,2525,O
),2525,O
.,2525,O
CONCLUSION,2526,O
:,2526,O
A,2526,O
50,2526,O
%,2526,O
reduction,2526,O
in,2526,O
the,2526,O
incidence,2526,O
of,2526,O
akathisia,2526,B-Disease
when,2526,O
prochlorperazine,2526,B-Chemical
was,2526,O
administered,2526,O
by,2526,O
means,2526,O
of,2526,O
15-minute,2526,O
intravenous,2526,O
infusion,2526,O
versus,2526,O
a,2526,O
2-minute,2526,O
intravenous,2526,O
push,2526,O
was,2526,O
not,2526,O
detected,2526,O
.,2526,O
The,2527,O
efficacy,2527,O
of,2527,O
prochlorperazine,2527,B-Chemical
in,2527,O
the,2527,O
treatment,2527,O
of,2527,O
headache,2527,B-Disease
and,2527,O
nausea,2527,B-Disease
likewise,2527,O
did,2527,O
not,2527,O
appear,2527,O
to,2527,O
be,2527,O
affected,2527,O
by,2527,O
the,2527,O
rate,2527,O
of,2527,O
administration,2527,O
",",2527,O
although,2527,O
no,2527,O
formal,2527,O
statistical,2527,O
comparisons,2527,O
were,2527,O
made,2527,O
.,2527,O
Combined,2528,O
antiretroviral,2528,O
therapy,2528,O
causes,2528,O
cardiomyopathy,2528,B-Disease
and,2528,O
elevates,2528,O
plasma,2528,O
lactate,2528,B-Chemical
in,2528,O
transgenic,2528,O
AIDS,2528,B-Disease
mice,2528,O
.,2528,O
Highly,2529,O
active,2529,O
antiretroviral,2529,O
therapy,2529,O
(,2529,O
HAART,2529,O
),2529,O
is,2529,O
implicated,2529,O
in,2529,O
cardiomyopathy,2529,B-Disease
(,2529,O
CM,2529,B-Disease
),2529,O
and,2529,O
in,2529,O
elevated,2529,O
plasma,2529,O
lactate,2529,B-Chemical
(,2529,O
LA,2529,B-Chemical
),2529,O
in,2529,O
AIDS,2529,B-Disease
through,2529,O
mechanisms,2529,O
of,2529,O
mitochondrial,2529,B-Disease
dysfunction,2529,I-Disease
.,2529,O
To,2530,O
determine,2530,O
mitochondrial,2530,O
events,2530,O
from,2530,O
HAART,2530,O
in,2530,O
vivo,2530,O
",",2530,O
8-week-old,2530,O
hemizygous,2530,O
transgenic,2530,O
AIDS,2530,B-Disease
mice,2530,O
(,2530,O
NL4-3Delta,2530,O
gag/pol,2530,O
;,2530,O
TG,2530,O
),2530,O
and,2530,O
wild-type,2530,O
FVB/n,2530,O
littermates,2530,O
were,2530,O
treated,2530,O
with,2530,O
the,2530,O
HAART,2530,O
combination,2530,O
of,2530,O
zidovudine,2530,B-Chemical
",",2530,O
lamivudine,2530,B-Chemical
",",2530,O
and,2530,O
indinavir,2530,B-Chemical
or,2530,O
vehicle,2530,O
control,2530,O
for,2530,O
10,2530,O
days,2530,O
or,2530,O
35,2530,O
days,2530,O
.,2530,O
At,2531,O
termination,2531,O
of,2531,O
the,2531,O
experiments,2531,O
",",2531,O
mice,2531,O
underwent,2531,O
echocardiography,2531,O
",",2531,O
quantitation,2531,O
of,2531,O
abundance,2531,O
of,2531,O
molecular,2531,O
markers,2531,O
of,2531,O
CM,2531,B-Disease
(,2531,O
ventricular,2531,O
mRNA,2531,O
encoding,2531,O
atrial,2531,O
natriuretic,2531,O
factor,2531,O
[,2531,O
ANF,2531,O
],2531,O
and,2531,O
sarcoplasmic,2531,O
calcium,2531,B-Chemical
ATPase,2531,O
[,2531,O
SERCA2,2531,O
],2531,O
),2531,O
",",2531,O
and,2531,O
determination,2531,O
of,2531,O
plasma,2531,O
LA,2531,B-Chemical
.,2531,O
Myocardial,2532,O
histologic,2532,O
features,2532,O
were,2532,O
analyzed,2532,O
semiquantitatively,2532,O
and,2532,O
results,2532,O
were,2532,O
confirmed,2532,O
by,2532,O
transmission,2532,O
electron,2532,O
microscopy,2532,O
.,2532,O
After,2533,O
35,2533,O
days,2533,O
in,2533,O
the,2533,O
TG,2533,O
+,2533,O
HAART,2533,O
cohort,2533,O
",",2533,O
left,2533,O
ventricular,2533,O
mass,2533,O
increased,2533,O
160,2533,O
%,2533,O
by,2533,O
echocardiography,2533,O
.,2533,O
Molecularly,2534,O
",",2534,O
ANF,2534,O
mRNA,2534,O
increased,2534,O
250,2534,O
%,2534,O
and,2534,O
SERCA2,2534,O
mRNA,2534,O
decreased,2534,O
57,2534,O
%,2534,O
.,2534,O
Biochemically,2535,O
",",2535,O
LA,2535,B-Chemical
was,2535,O
elevated,2535,O
(,2535,O
8.5,2535,O
+/-,2535,O
2.0,2535,O
mM,2535,O
),2535,O
.,2535,O
Pathologically,2536,O
",",2536,O
granular,2536,O
cytoplasmic,2536,O
changes,2536,O
were,2536,O
found,2536,O
in,2536,O
cardiac,2536,O
myocytes,2536,O
",",2536,O
indicating,2536,O
enlarged,2536,O
",",2536,O
damaged,2536,O
mitochondria,2536,O
.,2536,O
Findings,2537,O
were,2537,O
confirmed,2537,O
ultrastructurally,2537,O
.,2537,O
No,2538,O
changes,2538,O
were,2538,O
found,2538,O
in,2538,O
other,2538,O
cohorts,2538,O
.,2538,O
After,2539,O
10,2539,O
days,2539,O
",",2539,O
only,2539,O
ANF,2539,O
was,2539,O
elevated,2539,O
",",2539,O
and,2539,O
only,2539,O
in,2539,O
the,2539,O
TG,2539,O
+,2539,O
HAART,2539,O
cohort,2539,O
.,2539,O
Results,2540,O
show,2540,O
that,2540,O
cumulative,2540,O
HAART,2540,O
caused,2540,O
mitochondrial,2540,O
CM,2540,B-Disease
with,2540,O
elevated,2540,O
LA,2540,B-Chemical
in,2540,O
AIDS,2540,B-Disease
transgenic,2540,O
mice,2540,O
.,2540,O
A,2541,O
Phase,2541,O
II,2541,O
trial,2541,O
of,2541,O
cisplatin,2541,B-Chemical
plus,2541,O
WR-2721,2541,B-Chemical
(,2541,O
amifostine,2541,B-Chemical
),2541,O
for,2541,O
metastatic,2541,O
breast,2541,B-Disease
carcinoma,2541,I-Disease
:,2541,O
an,2541,O
Eastern,2541,O
Cooperative,2541,O
Oncology,2541,O
Group,2541,O
Study,2541,O
(,2541,O
E8188,2541,O
),2541,O
.,2541,O
BACKGROUND,2542,O
:,2542,O
Cisplatin,2542,B-Chemical
has,2542,O
minimal,2542,O
antitumor,2542,O
activity,2542,O
when,2542,O
used,2542,O
as,2542,O
second-,2542,O
or,2542,O
third-line,2542,O
treatment,2542,O
of,2542,O
metastatic,2542,O
breast,2542,B-Disease
carcinoma,2542,I-Disease
.,2542,O
Older,2543,O
reports,2543,O
suggest,2543,O
an,2543,O
objective,2543,O
response,2543,O
rate,2543,O
of,2543,O
8,2543,O
%,2543,O
when,2543,O
60-120,2543,O
mg/m2,2543,O
of,2543,O
cisplatin,2543,B-Chemical
is,2543,O
administered,2543,O
every,2543,O
3-4,2543,O
weeks,2543,O
.,2543,O
Although,2544,O
a,2544,O
dose-response,2544,O
effect,2544,O
has,2544,O
been,2544,O
observed,2544,O
with,2544,O
cisplatin,2544,B-Chemical
",",2544,O
the,2544,O
dose-limiting,2544,O
toxicities,2544,B-Disease
associated,2544,O
with,2544,O
cisplatin,2544,B-Chemical
(,2544,O
e.g.,2544,O
",",2544,O
nephrotoxicity,2544,B-Disease
",",2544,O
ototoxicity,2544,B-Disease
",",2544,O
and,2544,O
neurotoxicity,2544,B-Disease
),2544,O
have,2544,O
limited,2544,O
its,2544,O
use,2544,O
as,2544,O
a,2544,O
treatment,2544,O
for,2544,O
breast,2544,B-Disease
carcinoma,2544,I-Disease
.,2544,O
WR-2721,2545,B-Chemical
or,2545,O
amifostine,2545,B-Chemical
initially,2545,O
was,2545,O
developed,2545,O
to,2545,O
protect,2545,O
military,2545,O
personnel,2545,O
in,2545,O
the,2545,O
event,2545,O
of,2545,O
nuclear,2545,O
war,2545,O
.,2545,O
Amifostine,2546,B-Chemical
subsequently,2546,O
was,2546,O
shown,2546,O
to,2546,O
protect,2546,O
normal,2546,O
tissues,2546,O
from,2546,O
the,2546,O
toxic,2546,O
effects,2546,O
of,2546,O
alkylating,2546,B-Chemical
agents,2546,I-Chemical
and,2546,O
cisplatin,2546,B-Chemical
without,2546,O
decreasing,2546,O
the,2546,O
antitumor,2546,O
effect,2546,O
of,2546,O
the,2546,O
chemotherapy,2546,O
.,2546,O
Early,2547,O
trials,2547,O
of,2547,O
cisplatin,2547,B-Chemical
and,2547,O
amifostine,2547,B-Chemical
also,2547,O
suggested,2547,O
that,2547,O
the,2547,O
incidence,2547,O
and,2547,O
severity,2547,O
of,2547,O
cisplatin-induced,2547,B-Chemical
nephrotoxicity,2547,B-Disease
",",2547,O
ototoxicity,2547,B-Disease
",",2547,O
and,2547,O
neuropathy,2547,B-Disease
were,2547,O
reduced,2547,O
.,2547,O
METHODS,2548,O
:,2548,O
A,2548,O
Phase,2548,O
II,2548,O
study,2548,O
of,2548,O
the,2548,O
combination,2548,O
of,2548,O
cisplatin,2548,B-Chemical
plus,2548,O
amifostine,2548,B-Chemical
was,2548,O
conducted,2548,O
in,2548,O
patients,2548,O
with,2548,O
progressive,2548,O
metastatic,2548,O
breast,2548,B-Disease
carcinoma,2548,I-Disease
who,2548,O
had,2548,O
received,2548,O
one,2548,O
",",2548,O
but,2548,O
not,2548,O
more,2548,O
than,2548,O
one,2548,O
",",2548,O
chemotherapy,2548,O
regimen,2548,O
for,2548,O
metastatic,2548,O
disease,2548,O
.,2548,O
Patients,2549,O
received,2549,O
amifostine,2549,B-Chemical
",",2549,O
910,2549,O
mg/m2,2549,O
intravenously,2549,O
over,2549,O
15,2549,O
minutes,2549,O
.,2549,O
After,2550,O
completion,2550,O
of,2550,O
the,2550,O
amifostine,2550,B-Chemical
infusion,2550,O
",",2550,O
cisplatin,2550,B-Chemical
120,2550,O
mg/m2,2550,O
was,2550,O
administered,2550,O
over,2550,O
30,2550,O
minutes,2550,O
.,2550,O
Intravenous,2551,O
hydration,2551,O
and,2551,O
mannitol,2551,B-Chemical
was,2551,O
administered,2551,O
before,2551,O
and,2551,O
after,2551,O
cisplatin,2551,B-Chemical
.,2551,O
Treatment,2552,O
was,2552,O
administered,2552,O
every,2552,O
3,2552,O
weeks,2552,O
until,2552,O
disease,2552,O
progression,2552,O
.,2552,O
RESULTS,2553,O
:,2553,O
Forty-four,2553,O
patients,2553,O
were,2553,O
enrolled,2553,O
in,2553,O
the,2553,O
study,2553,O
of,2553,O
which,2553,O
7,2553,O
(,2553,O
16,2553,O
%,2553,O
),2553,O
were,2553,O
ineligible,2553,O
.,2553,O
A,2554,O
median,2554,O
of,2554,O
2,2554,O
cycles,2554,O
of,2554,O
therapy,2554,O
was,2554,O
administered,2554,O
to,2554,O
the,2554,O
37,2554,O
eligible,2554,O
patients,2554,O
.,2554,O
Six,2555,O
partial,2555,O
responses,2555,O
were,2555,O
observed,2555,O
for,2555,O
an,2555,O
overall,2555,O
response,2555,O
rate,2555,O
of,2555,O
16,2555,O
%,2555,O
.,2555,O
Most,2556,O
patients,2556,O
(,2556,O
57,2556,O
%,2556,O
),2556,O
stopped,2556,O
treatment,2556,O
because,2556,O
of,2556,O
disease,2556,O
progression,2556,O
.,2556,O
Neurologic,2557,B-Disease
toxicity,2557,I-Disease
was,2557,O
reported,2557,O
in,2557,O
52,2557,O
%,2557,O
of,2557,O
patients,2557,O
.,2557,O
Seven,2558,O
different,2558,O
life-threatening,2558,O
toxicities,2558,B-Disease
were,2558,O
observed,2558,O
in,2558,O
patients,2558,O
while,2558,O
receiving,2558,O
treatment,2558,O
.,2558,O
CONCLUSIONS,2559,O
:,2559,O
The,2559,O
combination,2559,O
of,2559,O
cisplatin,2559,B-Chemical
and,2559,O
amifostine,2559,B-Chemical
in,2559,O
this,2559,O
study,2559,O
resulted,2559,O
in,2559,O
an,2559,O
overall,2559,O
response,2559,O
rate,2559,O
of,2559,O
16,2559,O
%,2559,O
.,2559,O
Neither,2560,O
a,2560,O
tumor-protective,2560,B-Disease
effect,2560,O
nor,2560,O
reduced,2560,O
toxicity,2560,B-Disease
to,2560,O
normal,2560,O
tissues,2560,O
was,2560,O
observed,2560,O
with,2560,O
the,2560,O
addition,2560,O
of,2560,O
amifostine,2560,B-Chemical
to,2560,O
cisplatin,2560,B-Chemical
in,2560,O
this,2560,O
trial,2560,O
.,2560,O
Oral,2561,B-Chemical
contraceptives,2561,I-Chemical
and,2561,O
the,2561,O
risk,2561,O
of,2561,O
myocardial,2561,B-Disease
infarction,2561,I-Disease
.,2561,O
BACKGROUND,2562,O
:,2562,O
An,2562,O
association,2562,O
between,2562,O
the,2562,O
use,2562,O
of,2562,O
oral,2562,B-Chemical
contraceptives,2562,I-Chemical
and,2562,O
the,2562,O
risk,2562,O
of,2562,O
myocardial,2562,B-Disease
infarction,2562,I-Disease
has,2562,O
been,2562,O
found,2562,O
in,2562,O
some,2562,O
",",2562,O
but,2562,O
not,2562,O
all,2562,O
",",2562,O
studies,2562,O
.,2562,O
We,2563,O
investigated,2563,O
this,2563,O
association,2563,O
",",2563,O
according,2563,O
to,2563,O
the,2563,O
type,2563,O
of,2563,O
progestagen,2563,B-Chemical
included,2563,O
in,2563,O
third-generation,2563,O
(,2563,O
i.e.,2563,O
",",2563,O
desogestrel,2563,B-Chemical
or,2563,O
gestodene,2563,B-Chemical
),2563,O
and,2563,O
second-generation,2563,O
(,2563,O
i.e.,2563,O
",",2563,O
levonorgestrel,2563,B-Chemical
),2563,O
oral,2563,B-Chemical
contraceptives,2563,I-Chemical
",",2563,O
the,2563,O
dose,2563,O
of,2563,O
estrogen,2563,B-Chemical
",",2563,O
and,2563,O
the,2563,O
presence,2563,O
or,2563,O
absence,2563,O
of,2563,O
prothrombotic,2563,O
mutations,2563,O
METHODS,2563,O
:,2563,O
In,2563,O
a,2563,O
nationwide,2563,O
",",2563,O
population-based,2563,O
",",2563,O
case-control,2563,O
study,2563,O
",",2563,O
we,2563,O
identified,2563,O
and,2563,O
enrolled,2563,O
248,2563,O
women,2563,O
18,2563,O
through,2563,O
49,2563,O
years,2563,O
of,2563,O
age,2563,O
who,2563,O
had,2563,O
had,2563,O
a,2563,O
first,2563,O
myocardial,2563,B-Disease
infarction,2563,I-Disease
between,2563,O
1990,2563,O
and,2563,O
1995,2563,O
and,2563,O
925,2563,O
control,2563,O
women,2563,O
who,2563,O
had,2563,O
not,2563,O
had,2563,O
a,2563,O
myocardial,2563,B-Disease
infarction,2563,I-Disease
and,2563,O
who,2563,O
were,2563,O
matched,2563,O
for,2563,O
age,2563,O
",",2563,O
calendar,2563,O
year,2563,O
of,2563,O
the,2563,O
index,2563,O
event,2563,O
",",2563,O
and,2563,O
area,2563,O
of,2563,O
residence,2563,O
.,2563,O
Subjects,2564,O
supplied,2564,O
information,2564,O
on,2564,O
oral-contraceptive,2564,B-Chemical
use,2564,O
and,2564,O
major,2564,O
cardiovascular,2564,O
risk,2564,O
factors,2564,O
.,2564,O
An,2565,O
analysis,2565,O
for,2565,O
factor,2565,O
V,2565,O
Leiden,2565,O
and,2565,O
the,2565,O
G20210A,2565,O
mutation,2565,O
in,2565,O
the,2565,O
prothrombin,2565,O
gene,2565,O
was,2565,O
conducted,2565,O
in,2565,O
217,2565,O
patients,2565,O
and,2565,O
763,2565,O
controls,2565,O
RESULTS,2565,O
:,2565,O
The,2565,O
odds,2565,O
ratio,2565,O
for,2565,O
myocardial,2565,B-Disease
infarction,2565,I-Disease
among,2565,O
women,2565,O
who,2565,O
used,2565,O
any,2565,O
type,2565,O
of,2565,O
combined,2565,O
oral,2565,B-Chemical
contraceptive,2565,I-Chemical
",",2565,O
as,2565,O
compared,2565,O
with,2565,O
nonusers,2565,O
",",2565,O
was,2565,O
2.0,2565,O
(,2565,O
95,2565,O
percent,2565,O
confidence,2565,O
interval,2565,O
",",2565,O
1.5,2565,O
to,2565,O
2.8,2565,O
),2565,O
.,2565,O
The,2566,O
adjusted,2566,O
odds,2566,O
ratio,2566,O
was,2566,O
2.5,2566,O
(,2566,O
95,2566,O
percent,2566,O
confidence,2566,O
interval,2566,O
",",2566,O
1.5,2566,O
to,2566,O
4.1,2566,O
),2566,O
among,2566,O
women,2566,O
who,2566,O
used,2566,O
second-generation,2566,O
oral,2566,B-Chemical
contraceptives,2566,I-Chemical
and,2566,O
1.3,2566,O
(,2566,O
95,2566,O
percent,2566,O
confidence,2566,O
interval,2566,O
",",2566,O
0.7,2566,O
to,2566,O
2.5,2566,O
),2566,O
among,2566,O
those,2566,O
who,2566,O
used,2566,O
third-generation,2566,O
oral,2566,B-Chemical
contraceptives,2566,I-Chemical
.,2566,O
Among,2567,O
women,2567,O
who,2567,O
used,2567,O
oral,2567,B-Chemical
contraceptives,2567,I-Chemical
",",2567,O
the,2567,O
odds,2567,O
ratio,2567,O
was,2567,O
2.1,2567,O
(,2567,O
95,2567,O
percent,2567,O
confidence,2567,O
interval,2567,O
",",2567,O
1.5,2567,O
to,2567,O
3.0,2567,O
),2567,O
for,2567,O
those,2567,O
without,2567,O
a,2567,O
prothrombotic,2567,O
mutation,2567,O
and,2567,O
1.9,2567,O
(,2567,O
95,2567,O
percent,2567,O
confidence,2567,O
interval,2567,O
",",2567,O
0.6,2567,O
to,2567,O
5.5,2567,O
),2567,O
for,2567,O
those,2567,O
with,2567,O
a,2567,O
mutation,2567,O
CONCLUSIONS,2567,O
:,2567,O
The,2567,O
risk,2567,O
of,2567,O
myocardial,2567,B-Disease
infarction,2567,I-Disease
was,2567,O
increased,2567,O
among,2567,O
women,2567,O
who,2567,O
used,2567,O
second-generation,2567,O
oral,2567,B-Chemical
contraceptives,2567,I-Chemical
.,2567,O
The,2568,O
results,2568,O
with,2568,O
respect,2568,O
to,2568,O
the,2568,O
use,2568,O
of,2568,O
third-generation,2568,O
oral,2568,B-Chemical
contraceptives,2568,I-Chemical
were,2568,O
inconclusive,2568,O
but,2568,O
suggested,2568,O
that,2568,O
the,2568,O
risk,2568,O
was,2568,O
lower,2568,O
than,2568,O
the,2568,O
risk,2568,O
associated,2568,O
with,2568,O
second-generation,2568,O
oral,2568,B-Chemical
contraceptives,2568,I-Chemical
.,2568,O
The,2569,O
risk,2569,O
of,2569,O
myocardial,2569,B-Disease
infarction,2569,I-Disease
was,2569,O
similar,2569,O
among,2569,O
women,2569,O
who,2569,O
used,2569,O
oral,2569,B-Chemical
contraceptives,2569,I-Chemical
whether,2569,O
or,2569,O
not,2569,O
they,2569,O
had,2569,O
a,2569,O
prothrombotic,2569,O
mutation,2569,O
.,2569,O
End-stage,2570,B-Disease
renal,2570,I-Disease
disease,2570,I-Disease
(,2570,O
ESRD,2570,B-Disease
),2570,O
after,2570,O
orthotopic,2570,O
liver,2570,O
transplantation,2570,O
(,2570,O
OLTX,2570,O
),2570,O
using,2570,O
calcineurin-based,2570,O
immunotherapy,2570,O
:,2570,O
risk,2570,O
of,2570,O
development,2570,O
and,2570,O
treatment,2570,O
.,2570,O
BACKGROUND,2571,O
:,2571,O
The,2571,O
calcineurin,2571,O
inhibitors,2571,O
cyclosporine,2571,B-Chemical
and,2571,O
tacrolimus,2571,B-Chemical
are,2571,O
both,2571,O
known,2571,O
to,2571,O
be,2571,O
nephrotoxic,2571,B-Disease
.,2571,O
Their,2572,O
use,2572,O
in,2572,O
orthotopic,2572,O
liver,2572,O
transplantation,2572,O
(,2572,O
OLTX,2572,O
),2572,O
has,2572,O
dramatically,2572,O
improved,2572,O
success,2572,O
rates,2572,O
.,2572,O
Recently,2573,O
",",2573,O
however,2573,O
",",2573,O
we,2573,O
have,2573,O
had,2573,O
an,2573,O
increase,2573,O
of,2573,O
patients,2573,O
who,2573,O
are,2573,O
presenting,2573,O
after,2573,O
OLTX,2573,O
with,2573,O
end-stage,2573,B-Disease
renal,2573,I-Disease
disease,2573,I-Disease
(,2573,O
ESRD,2573,B-Disease
),2573,O
.,2573,O
This,2574,O
retrospective,2574,O
study,2574,O
examines,2574,O
the,2574,O
incidence,2574,O
and,2574,O
treatment,2574,O
of,2574,O
ESRD,2574,B-Disease
and,2574,O
chronic,2574,B-Disease
renal,2574,I-Disease
failure,2574,I-Disease
(,2574,O
CRF,2574,B-Disease
),2574,O
in,2574,O
OLTX,2574,O
patients,2574,O
.,2574,O
METHODS,2575,O
:,2575,O
Patients,2575,O
receiving,2575,O
an,2575,O
OLTX,2575,O
only,2575,O
from,2575,O
June,2575,O
1985,2575,O
through,2575,O
December,2575,O
of,2575,O
1994,2575,O
who,2575,O
survived,2575,O
6,2575,O
months,2575,O
postoperatively,2575,O
were,2575,O
studied,2575,O
(,2575,O
n=834,2575,O
),2575,O
.,2575,O
Our,2576,O
prospectively,2576,O
collected,2576,O
database,2576,O
was,2576,O
the,2576,O
source,2576,O
of,2576,O
information,2576,O
.,2576,O
Patients,2577,O
were,2577,O
divided,2577,O
into,2577,O
three,2577,O
groups,2577,O
:,2577,O
Controls,2577,O
",",2577,O
no,2577,O
CRF,2577,B-Disease
or,2577,O
ESRD,2577,B-Disease
",",2577,O
n=748,2577,O
;,2577,O
CRF,2577,B-Disease
",",2577,O
sustained,2577,O
serum,2577,O
creatinine,2577,B-Chemical
>,2577,O
2.5,2577,O
mg/dl,2577,O
",",2577,O
n=41,2577,O
;,2577,O
and,2577,O
ESRD,2577,B-Disease
",",2577,O
n=45,2577,O
.,2577,O
Groups,2578,O
were,2578,O
compared,2578,O
for,2578,O
preoperative,2578,O
laboratory,2578,O
variables,2578,O
",",2578,O
diagnosis,2578,O
",",2578,O
postoperative,2578,O
variables,2578,O
",",2578,O
survival,2578,O
",",2578,O
type,2578,O
of,2578,O
ESRD,2578,B-Disease
therapy,2578,O
",",2578,O
and,2578,O
survival,2578,O
from,2578,O
onset,2578,O
of,2578,O
ESRD,2578,B-Disease
.,2578,O
RESULTS,2579,O
:,2579,O
At,2579,O
13,2579,O
years,2579,O
after,2579,O
OLTX,2579,O
",",2579,O
the,2579,O
incidence,2579,O
of,2579,O
severe,2579,O
renal,2579,B-Disease
dysfunction,2579,I-Disease
was,2579,O
18.1,2579,O
%,2579,O
(,2579,O
CRF,2579,B-Disease
8.6,2579,O
%,2579,O
and,2579,O
ESRD,2579,B-Disease
9.5,2579,O
%,2579,O
),2579,O
.,2579,O
Compared,2580,O
with,2580,O
control,2580,O
patients,2580,O
",",2580,O
CRF,2580,B-Disease
and,2580,O
ESRD,2580,B-Disease
patients,2580,O
had,2580,O
higher,2580,O
preoperative,2580,O
serum,2580,O
creatinine,2580,B-Chemical
levels,2580,O
",",2580,O
a,2580,O
greater,2580,O
percentage,2580,O
of,2580,O
patients,2580,O
with,2580,O
hepatorenal,2580,B-Disease
syndrome,2580,I-Disease
",",2580,O
higher,2580,O
percentage,2580,O
requirement,2580,O
for,2580,O
dialysis,2580,O
in,2580,O
the,2580,O
first,2580,O
3,2580,O
months,2580,O
postoperatively,2580,O
",",2580,O
and,2580,O
a,2580,O
higher,2580,O
1-year,2580,O
serum,2580,O
creatinine,2580,B-Chemical
.,2580,O
Multivariate,2581,O
stepwise,2581,O
logistic,2581,O
regression,2581,O
analysis,2581,O
using,2581,O
preoperative,2581,O
and,2581,O
postoperative,2581,O
variables,2581,O
identified,2581,O
that,2581,O
an,2581,O
increase,2581,O
of,2581,O
serum,2581,O
creatinine,2581,B-Chemical
compared,2581,O
with,2581,O
average,2581,O
at,2581,O
1,2581,O
year,2581,O
",",2581,O
3,2581,O
months,2581,O
",",2581,O
and,2581,O
4,2581,O
weeks,2581,O
postoperatively,2581,O
were,2581,O
independent,2581,O
risk,2581,O
factors,2581,O
for,2581,O
the,2581,O
development,2581,O
of,2581,O
CRF,2581,B-Disease
or,2581,O
ESRD,2581,B-Disease
with,2581,O
odds,2581,O
ratios,2581,O
of,2581,O
2.6,2581,O
",",2581,O
2.2,2581,O
",",2581,O
and,2581,O
1.6,2581,O
",",2581,O
respectively,2581,O
.,2581,O
Overall,2582,O
survival,2582,O
from,2582,O
the,2582,O
time,2582,O
of,2582,O
OLTX,2582,O
was,2582,O
not,2582,O
significantly,2582,O
different,2582,O
among,2582,O
groups,2582,O
",",2582,O
but,2582,O
by,2582,O
year,2582,O
13,2582,O
",",2582,O
the,2582,O
survival,2582,O
of,2582,O
the,2582,O
patients,2582,O
who,2582,O
had,2582,O
ESRD,2582,B-Disease
was,2582,O
only,2582,O
28.2,2582,O
%,2582,O
compared,2582,O
with,2582,O
54.6,2582,O
%,2582,O
in,2582,O
the,2582,O
control,2582,O
group,2582,O
.,2582,O
Patients,2583,O
developing,2583,O
ESRD,2583,B-Disease
had,2583,O
a,2583,O
6-year,2583,O
survival,2583,O
after,2583,O
onset,2583,O
of,2583,O
ESRD,2583,B-Disease
of,2583,O
27,2583,O
%,2583,O
for,2583,O
the,2583,O
patients,2583,O
receiving,2583,O
hemodialysis,2583,O
versus,2583,O
71.4,2583,O
%,2583,O
for,2583,O
the,2583,O
patients,2583,O
developing,2583,O
ESRD,2583,B-Disease
who,2583,O
subsequently,2583,O
received,2583,O
kidney,2583,O
transplants,2583,O
.,2583,O
CONCLUSIONS,2584,O
:,2584,O
Patients,2584,O
who,2584,O
are,2584,O
more,2584,O
than,2584,O
10,2584,O
years,2584,O
post-OLTX,2584,O
have,2584,O
CRF,2584,B-Disease
and,2584,O
ESRD,2584,B-Disease
at,2584,O
a,2584,O
high,2584,O
rate,2584,O
.,2584,O
The,2585,O
development,2585,O
of,2585,O
ESRD,2585,B-Disease
decreases,2585,O
survival,2585,O
",",2585,O
particularly,2585,O
in,2585,O
those,2585,O
patients,2585,O
treated,2585,O
with,2585,O
dialysis,2585,O
only,2585,O
.,2585,O
Patients,2586,O
who,2586,O
develop,2586,O
ESRD,2586,B-Disease
have,2586,O
a,2586,O
higher,2586,O
preoperative,2586,O
and,2586,O
1-year,2586,O
serum,2586,O
creatinine,2586,B-Chemical
and,2586,O
are,2586,O
more,2586,O
likely,2586,O
to,2586,O
have,2586,O
hepatorenal,2586,B-Disease
syndrome,2586,I-Disease
.,2586,O
However,2587,O
",",2587,O
an,2587,O
increase,2587,O
of,2587,O
serum,2587,O
creatinine,2587,B-Chemical
at,2587,O
various,2587,O
times,2587,O
postoperatively,2587,O
is,2587,O
more,2587,O
predictive,2587,O
of,2587,O
the,2587,O
development,2587,O
of,2587,O
CRF,2587,B-Disease
or,2587,O
ESRD,2587,B-Disease
.,2587,O
New,2588,O
strategies,2588,O
for,2588,O
long-term,2588,O
immunosuppression,2588,O
may,2588,O
be,2588,O
needed,2588,O
to,2588,O
decrease,2588,O
this,2588,O
complication,2588,O
.,2588,O
Epileptic,2589,B-Disease
seizures,2589,I-Disease
following,2589,O
cortical,2589,O
application,2589,O
of,2589,O
fibrin,2589,O
sealants,2589,O
containing,2589,O
tranexamic,2589,B-Chemical
acid,2589,I-Chemical
in,2589,O
rats,2589,O
.,2589,O
BACKGROUND,2590,O
:,2590,O
Fibrin,2590,O
sealants,2590,O
(,2590,O
FS,2590,O
),2590,O
derived,2590,O
from,2590,O
human,2590,O
plasma,2590,O
are,2590,O
frequently,2590,O
used,2590,O
in,2590,O
neurosurgery,2590,O
.,2590,O
In,2591,O
order,2591,O
to,2591,O
increase,2591,O
clot,2591,O
stability,2591,O
",",2591,O
FS,2591,O
typically,2591,O
contain,2591,O
aprotinin,2591,O
",",2591,O
a,2591,O
natural,2591,O
fibrinolysis,2591,O
inhibitor,2591,O
.,2591,O
Recently,2592,O
",",2592,O
synthetic,2592,O
fibrinolysis,2592,O
inhibitors,2592,O
such,2592,O
as,2592,O
tranexamic,2592,B-Chemical
acid,2592,I-Chemical
(,2592,O
tAMCA,2592,B-Chemical
),2592,O
have,2592,O
been,2592,O
considered,2592,O
as,2592,O
substitutes,2592,O
for,2592,O
aprotinin,2592,O
.,2592,O
However,2593,O
",",2593,O
tAMCA,2593,B-Chemical
has,2593,O
been,2593,O
shown,2593,O
to,2593,O
cause,2593,O
epileptic,2593,B-Disease
seizures,2593,I-Disease
.,2593,O
We,2594,O
wanted,2594,O
to,2594,O
study,2594,O
whether,2594,O
tAMCA,2594,B-Chemical
retains,2594,O
its,2594,O
convulsive,2594,B-Disease
action,2594,O
if,2594,O
incorporated,2594,O
into,2594,O
a,2594,O
FS,2594,O
.,2594,O
METHOD,2595,O
:,2595,O
FS,2595,O
containing,2595,O
aprotinin,2595,O
or,2595,O
different,2595,O
concentrations,2595,O
of,2595,O
tAMCA,2595,B-Chemical
(,2595,O
0.5-47.5,2595,O
mg/ml,2595,O
),2595,O
were,2595,O
applied,2595,O
to,2595,O
the,2595,O
pial,2595,O
surface,2595,O
of,2595,O
the,2595,O
cortex,2595,O
of,2595,O
anaesthetized,2595,O
rats,2595,O
.,2595,O
The,2596,O
response,2596,O
of,2596,O
the,2596,O
animals,2596,O
was,2596,O
evaluated,2596,O
using,2596,O
electroencephalography,2596,O
and,2596,O
by,2596,O
monitoring,2596,O
the,2596,O
clinical,2596,O
behaviour,2596,O
during,2596,O
and,2596,O
after,2596,O
recovery,2596,O
from,2596,O
anaesthesia,2596,O
.,2596,O
FINDINGS,2597,O
:,2597,O
FS,2597,O
containing,2597,O
tAMCA,2597,B-Chemical
caused,2597,O
paroxysmal,2597,O
brain,2597,O
activity,2597,O
which,2597,O
was,2597,O
associated,2597,O
with,2597,O
distinct,2597,O
convulsive,2597,B-Disease
behaviours,2597,O
.,2597,O
The,2598,O
degree,2598,O
of,2598,O
these,2598,O
seizures,2598,B-Disease
increased,2598,O
with,2598,O
increasing,2598,O
concentration,2598,O
of,2598,O
tAMCA,2598,B-Chemical
.,2598,O
Thus,2599,O
",",2599,O
FS,2599,O
containing,2599,O
47.5,2599,O
mg/ml,2599,O
tAMCA,2599,B-Chemical
evoked,2599,O
generalized,2599,B-Disease
seizures,2599,I-Disease
in,2599,O
all,2599,O
tested,2599,O
rats,2599,O
(,2599,O
n=6,2599,O
),2599,O
while,2599,O
the,2599,O
lowest,2599,O
concentration,2599,O
of,2599,O
tAMCA,2599,B-Chemical
(,2599,O
0.5,2599,O
mg/ml,2599,O
),2599,O
only,2599,O
evoked,2599,O
brief,2599,O
episodes,2599,O
of,2599,O
jerk-correlated,2599,O
convulsive,2599,B-Disease
potentials,2599,O
in,2599,O
1,2599,O
of,2599,O
6,2599,O
rats,2599,O
.,2599,O
In,2600,O
contrast,2600,O
",",2600,O
FS,2600,O
containing,2600,O
aprotinin,2600,O
did,2600,O
not,2600,O
evoke,2600,O
any,2600,O
paroxysmal,2600,O
activity,2600,O
.,2600,O
INTERPRETATION,2601,O
:,2601,O
Tranexamic,2601,B-Chemical
acid,2601,I-Chemical
retains,2601,O
its,2601,O
convulsive,2601,B-Disease
action,2601,O
within,2601,O
FS,2601,O
.,2601,O
Thus,2602,O
",",2602,O
use,2602,O
of,2602,O
FS,2602,O
containing,2602,O
tAMCA,2602,B-Chemical
for,2602,O
surgery,2602,O
within,2602,O
or,2602,O
close,2602,O
to,2602,O
the,2602,O
CNS,2602,O
may,2602,O
pose,2602,O
a,2602,O
substantial,2602,O
risk,2602,O
to,2602,O
the,2602,O
patient,2602,O
.,2602,O
Sequential,2603,O
observations,2603,O
of,2603,O
exencephaly,2603,B-Disease
and,2603,O
subsequent,2603,O
morphological,2603,O
changes,2603,O
by,2603,O
mouse,2603,O
exo,2603,O
utero,2603,O
development,2603,O
system,2603,O
:,2603,O
analysis,2603,O
of,2603,O
the,2603,O
mechanism,2603,O
of,2603,O
transformation,2603,O
from,2603,O
exencephaly,2603,B-Disease
to,2603,O
anencephaly,2603,B-Disease
.,2603,O
Anencephaly,2604,B-Disease
has,2604,O
been,2604,O
suggested,2604,O
to,2604,O
develop,2604,O
from,2604,O
exencephaly,2604,B-Disease
;,2604,O
however,2604,O
",",2604,O
there,2604,O
is,2604,O
little,2604,O
direct,2604,O
experimental,2604,O
evidence,2604,O
to,2604,O
support,2604,O
this,2604,O
",",2604,O
and,2604,O
the,2604,O
mechanism,2604,O
of,2604,O
transformation,2604,O
remains,2604,O
unclear,2604,O
.,2604,O
We,2605,O
examined,2605,O
this,2605,O
theory,2605,O
using,2605,O
the,2605,O
exo,2605,O
utero,2605,O
development,2605,O
system,2605,O
that,2605,O
allows,2605,O
direct,2605,O
and,2605,O
sequential,2605,O
observations,2605,O
of,2605,O
mid-,2605,O
to,2605,O
late-gestation,2605,O
mouse,2605,O
embryos,2605,O
.,2605,O
We,2606,O
observed,2606,O
the,2606,O
exencephaly,2606,B-Disease
induced,2606,O
by,2606,O
5-azacytidine,2606,B-Chemical
at,2606,O
embryonic,2606,O
day,2606,O
13.5,2606,O
(,2606,O
E13.5,2606,O
),2606,O
",",2606,O
let,2606,O
the,2606,O
embryos,2606,O
develop,2606,O
exo,2606,O
utero,2606,O
until,2606,O
E18.5,2606,O
",",2606,O
and,2606,O
re-observed,2606,O
the,2606,O
same,2606,O
embryos,2606,O
at,2606,O
E18.5,2606,O
.,2606,O
We,2607,O
confirmed,2607,O
several,2607,O
cases,2607,O
of,2607,O
transformation,2607,O
from,2607,O
exencephaly,2607,B-Disease
to,2607,O
anencephaly,2607,B-Disease
.,2607,O
However,2608,O
",",2608,O
in,2608,O
many,2608,O
cases,2608,O
",",2608,O
the,2608,O
exencephalic,2608,B-Disease
brain,2608,O
tissue,2608,O
was,2608,O
preserved,2608,O
with,2608,O
more,2608,O
or,2608,O
less,2608,O
reduction,2608,O
during,2608,O
this,2608,O
period,2608,O
.,2608,O
To,2609,O
analyze,2609,O
the,2609,O
transformation,2609,O
patterns,2609,O
",",2609,O
we,2609,O
classified,2609,O
the,2609,O
exencephaly,2609,B-Disease
by,2609,O
size,2609,O
and,2609,O
shape,2609,O
of,2609,O
the,2609,O
exencephalic,2609,B-Disease
tissue,2609,O
into,2609,O
several,2609,O
types,2609,O
at,2609,O
E13.5,2609,O
and,2609,O
E18.5,2609,O
.,2609,O
It,2610,O
was,2610,O
found,2610,O
that,2610,O
the,2610,O
transformation,2610,O
of,2610,O
exencephalic,2610,B-Disease
tissue,2610,O
was,2610,O
not,2610,O
simply,2610,O
size-dependent,2610,O
",",2610,O
and,2610,O
all,2610,O
cases,2610,O
of,2610,O
anencephaly,2610,B-Disease
at,2610,O
E18.5,2610,O
resulted,2610,O
from,2610,O
embryos,2610,O
with,2610,O
a,2610,O
large,2610,O
amount,2610,O
of,2610,O
exencephalic,2610,B-Disease
tissue,2610,O
at,2610,O
E13.5,2610,O
.,2610,O
Microscopic,2611,O
observation,2611,O
showed,2611,O
the,2611,O
configuration,2611,O
of,2611,O
exencephaly,2611,B-Disease
at,2611,O
E13.5,2611,O
",",2611,O
frequent,2611,O
hemorrhaging,2611,B-Disease
and,2611,O
detachment,2611,O
of,2611,O
the,2611,O
neural,2611,O
plate,2611,O
from,2611,O
surface,2611,O
ectoderm,2611,O
in,2611,O
the,2611,O
exencephalic,2611,B-Disease
head,2611,O
at,2611,O
E15.5,2611,O
",",2611,O
and,2611,O
multiple,2611,O
modes,2611,O
of,2611,O
reduction,2611,O
in,2611,O
the,2611,O
exencephalic,2611,B-Disease
tissue,2611,O
at,2611,O
E18.5,2611,O
.,2611,O
From,2612,O
observations,2612,O
of,2612,O
the,2612,O
vasculature,2612,O
",",2612,O
altered,2612,O
distribution,2612,O
patterns,2612,O
of,2612,O
vessels,2612,O
were,2612,O
identified,2612,O
in,2612,O
the,2612,O
exencephalic,2612,B-Disease
head,2612,O
.,2612,O
These,2613,O
findings,2613,O
suggest,2613,O
that,2613,O
overgrowth,2613,O
of,2613,O
the,2613,O
exencephalic,2613,B-Disease
neural,2613,O
tissue,2613,O
causes,2613,O
the,2613,O
altered,2613,O
distribution,2613,O
patterns,2613,O
of,2613,O
vessels,2613,O
",",2613,O
subsequent,2613,O
peripheral,2613,O
circulatory,2613,B-Disease
failure,2613,I-Disease
and/or,2613,O
hemorrhaging,2613,B-Disease
in,2613,O
various,2613,O
parts,2613,O
of,2613,O
the,2613,O
exencephalic,2613,B-Disease
head,2613,O
",",2613,O
leading,2613,O
to,2613,O
the,2613,O
multiple,2613,O
modes,2613,O
of,2613,O
tissue,2613,O
reduction,2613,O
during,2613,O
transformation,2613,O
from,2613,O
exencephaly,2613,B-Disease
to,2613,O
anencephaly,2613,B-Disease
.,2613,O
99mTc-glucarate,2614,B-Chemical
for,2614,O
detection,2614,O
of,2614,O
isoproterenol-induced,2614,B-Chemical
myocardial,2614,B-Disease
infarction,2614,I-Disease
in,2614,O
rats,2614,O
.,2614,O
Infarct-avid,2615,B-Disease
radiopharmaceuticals,2615,O
are,2615,O
necessary,2615,O
for,2615,O
rapid,2615,O
and,2615,O
timely,2615,O
diagnosis,2615,O
of,2615,O
acute,2615,O
myocardial,2615,B-Disease
infarction,2615,I-Disease
.,2615,O
The,2616,O
animal,2616,O
model,2616,O
used,2616,O
to,2616,O
produce,2616,O
infarction,2616,B-Disease
implies,2616,O
artery,2616,O
ligation,2616,O
but,2616,O
chemical,2616,O
induction,2616,O
can,2616,O
be,2616,O
easily,2616,O
obtained,2616,O
with,2616,O
isoproterenol,2616,B-Chemical
.,2616,O
A,2617,O
new,2617,O
infarct-avid,2617,B-Disease
radiopharmaceutical,2617,O
based,2617,O
on,2617,O
glucaric,2617,B-Chemical
acid,2617,I-Chemical
was,2617,O
prepared,2617,O
in,2617,O
the,2617,O
hospital,2617,O
radiopharmacy,2617,O
of,2617,O
the,2617,O
INCMNSZ,2617,O
.,2617,O
99mTc-glucarate,2618,B-Chemical
was,2618,O
easy,2618,O
to,2618,O
prepare,2618,O
",",2618,O
stable,2618,O
for,2618,O
96,2618,O
h,2618,O
and,2618,O
was,2618,O
used,2618,O
to,2618,O
study,2618,O
its,2618,O
biodistribution,2618,O
in,2618,O
rats,2618,O
with,2618,O
isoproterenol-induced,2618,B-Chemical
acute,2618,O
myocardial,2618,B-Disease
infarction,2618,I-Disease
.,2618,O
Histological,2619,O
studies,2619,O
demonstrated,2619,O
that,2619,O
the,2619,O
rats,2619,O
developed,2619,O
an,2619,O
infarct,2619,B-Disease
18,2619,O
h,2619,O
after,2619,O
isoproterenol,2619,B-Chemical
administration,2619,O
.,2619,O
The,2620,O
rat,2620,O
biodistribution,2620,O
studies,2620,O
showed,2620,O
a,2620,O
rapid,2620,O
blood,2620,O
clearance,2620,O
via,2620,O
the,2620,O
kidneys,2620,O
.,2620,O
Thirty,2621,O
minutes,2621,O
after,2621,O
99mTc-glucarate,2621,B-Chemical
administration,2621,O
the,2621,O
standardised,2621,O
heart,2621,O
uptake,2621,O
value,2621,O
S,2621,O
(,2621,O
h,2621,O
),2621,O
UV,2621,O
was,2621,O
4.7,2621,O
in,2621,O
infarcted,2621,O
rat,2621,O
heart,2621,O
which,2621,O
is,2621,O
six,2621,O
times,2621,O
more,2621,O
than,2621,O
in,2621,O
normal,2621,O
rats,2621,O
.,2621,O
ROIs,2622,O
drawn,2622,O
over,2622,O
the,2622,O
gamma,2622,O
camera,2622,O
images,2622,O
showed,2622,O
a,2622,O
ratio,2622,O
of,2622,O
4.4,2622,O
.,2622,O
The,2623,O
high,2623,O
image,2623,O
quality,2623,O
suggests,2623,O
that,2623,O
high,2623,O
contrast,2623,O
images,2623,O
can,2623,O
be,2623,O
obtained,2623,O
in,2623,O
humans,2623,O
and,2623,O
the,2623,O
96,2623,O
h,2623,O
stability,2623,O
makes,2623,O
it,2623,O
an,2623,O
ideal,2623,O
agent,2623,O
to,2623,O
detect,2623,O
",",2623,O
in,2623,O
patients,2623,O
",",2623,O
early,2623,O
cardiac,2623,B-Disease
infarction,2623,I-Disease
.,2623,O
Bupropion,2624,B-Chemical
(,2624,O
Zyban,2624,B-Chemical
),2624,O
toxicity,2624,B-Disease
.,2624,O
Bupropion,2625,B-Chemical
is,2625,O
a,2625,O
monocyclic,2625,O
antidepressant,2625,B-Chemical
structurally,2625,O
related,2625,O
to,2625,O
amphetamine,2625,B-Chemical
.,2625,O
Zyban,2626,B-Chemical
",",2626,O
a,2626,O
sustained-release,2626,O
formulation,2626,O
of,2626,O
bupropion,2626,B-Chemical
hydrochloride,2626,I-Chemical
",",2626,O
was,2626,O
recently,2626,O
released,2626,O
in,2626,O
Ireland,2626,O
",",2626,O
as,2626,O
a,2626,O
smoking,2626,O
cessation,2626,O
aid,2626,O
.,2626,O
In,2627,O
the,2627,O
initial,2627,O
6,2627,O
months,2627,O
since,2627,O
it,2627,O
's,2627,O
introduction,2627,O
",",2627,O
12,2627,O
overdose,2627,B-Disease
cases,2627,O
have,2627,O
been,2627,O
reported,2627,O
to,2627,O
The,2627,O
National,2627,O
Poisons,2627,O
Information,2627,O
Centre,2627,O
.,2627,O
8,2628,O
patients,2628,O
developed,2628,O
symptoms,2628,O
of,2628,O
toxicity,2628,B-Disease
.,2628,O
Common,2629,O
features,2629,O
included,2629,O
tachycardia,2629,B-Disease
",",2629,O
drowsiness,2629,O
",",2629,O
hallucinations,2629,B-Disease
and,2629,O
convulsions,2629,B-Disease
.,2629,O
Two,2630,O
patients,2630,O
developed,2630,O
severe,2630,O
cardiac,2630,B-Disease
arrhythmias,2630,I-Disease
",",2630,O
including,2630,O
one,2630,O
patient,2630,O
who,2630,O
was,2630,O
resuscitated,2630,O
following,2630,O
a,2630,O
cardiac,2630,B-Disease
arrest,2630,I-Disease
.,2630,O
All,2631,O
patients,2631,O
recovered,2631,O
without,2631,O
sequelae,2631,O
.,2631,O
We,2632,O
report,2632,O
a,2632,O
case,2632,O
of,2632,O
a,2632,O
31,2632,O
year,2632,O
old,2632,O
female,2632,O
who,2632,O
required,2632,O
admission,2632,O
to,2632,O
the,2632,O
Intensive,2632,O
Care,2632,O
Unit,2632,O
for,2632,O
ventilation,2632,O
and,2632,O
full,2632,O
supportive,2632,O
therapy,2632,O
",",2632,O
following,2632,O
ingestion,2632,O
of,2632,O
13.5g,2632,O
bupropion,2632,B-Chemical
.,2632,O
Recurrent,2633,O
seizures,2633,B-Disease
were,2633,O
treated,2633,O
with,2633,O
diazepam,2633,B-Chemical
and,2633,O
broad,2633,O
complex,2633,O
tachycardia,2633,B-Disease
was,2633,O
successfully,2633,O
treated,2633,O
with,2633,O
adenosine,2633,B-Chemical
.,2633,O
Zyban,2634,B-Chemical
caused,2634,O
significant,2634,O
neurological,2634,O
and,2634,O
cardiovascular,2634,O
toxicity,2634,O
in,2634,O
overdose,2634,B-Disease
.,2634,O
The,2635,O
potential,2635,O
toxic,2635,O
effects,2635,O
should,2635,O
be,2635,O
considered,2635,O
when,2635,O
prescribing,2635,O
it,2635,O
as,2635,O
a,2635,O
smoking,2635,O
cessation,2635,O
aid,2635,O
.,2635,O
GLEPP1,2636,O
receptor,2636,O
tyrosine,2636,B-Chemical
phosphatase,2636,O
(,2636,O
Ptpro,2636,O
),2636,O
in,2636,O
rat,2636,O
PAN,2636,B-Chemical
nephrosis,2636,B-Disease
.,2636,O
A,2637,O
marker,2637,O
of,2637,O
acute,2637,O
podocyte,2637,O
injury,2637,O
.,2637,O
Glomerular,2638,O
epithelial,2638,O
protein,2638,O
1,2638,O
(,2638,O
GLEPP1,2638,O
),2638,O
is,2638,O
a,2638,O
podocyte,2638,O
receptor,2638,O
membrane,2638,O
protein,2638,O
tyrosine,2638,B-Chemical
phosphatase,2638,O
located,2638,O
on,2638,O
the,2638,O
apical,2638,O
cell,2638,O
membrane,2638,O
of,2638,O
visceral,2638,O
glomerular,2638,O
epithelial,2638,O
cell,2638,O
and,2638,O
foot,2638,O
processes,2638,O
.,2638,O
This,2639,O
receptor,2639,O
plays,2639,O
a,2639,O
role,2639,O
in,2639,O
regulating,2639,O
the,2639,O
structure,2639,O
and,2639,O
function,2639,O
of,2639,O
podocyte,2639,O
foot,2639,O
process,2639,O
.,2639,O
To,2640,O
better,2640,O
understand,2640,O
the,2640,O
utility,2640,O
of,2640,O
GLEPP1,2640,O
as,2640,O
a,2640,O
marker,2640,O
of,2640,O
glomerular,2640,B-Disease
injury,2640,I-Disease
",",2640,O
the,2640,O
amount,2640,O
and,2640,O
distribution,2640,O
of,2640,O
GLEPP1,2640,O
protein,2640,O
and,2640,O
mRNA,2640,O
were,2640,O
examined,2640,O
by,2640,O
immunohistochemistry,2640,O
",",2640,O
Western,2640,O
blot,2640,O
and,2640,O
RNase,2640,O
protection,2640,O
assay,2640,O
in,2640,O
a,2640,O
model,2640,O
of,2640,O
podocyte,2640,O
injury,2640,O
in,2640,O
the,2640,O
rat,2640,O
.,2640,O
Puromycin,2641,B-Chemical
aminonucleoside,2641,I-Chemical
nephrosis,2641,B-Disease
was,2641,O
induced,2641,O
by,2641,O
single,2641,O
intraperitoneal,2641,O
injection,2641,O
of,2641,O
puromycin,2641,B-Chemical
aminonucleoside,2641,I-Chemical
(,2641,O
PAN,2641,B-Chemical
",",2641,O
20,2641,O
mg/100g,2641,O
BW,2641,O
),2641,O
.,2641,O
Tissues,2642,O
were,2642,O
analyzed,2642,O
at,2642,O
0,2642,O
",",2642,O
5,2642,O
",",2642,O
7,2642,O
",",2642,O
11,2642,O
",",2642,O
21,2642,O
",",2642,O
45,2642,O
",",2642,O
80,2642,O
and,2642,O
126,2642,O
days,2642,O
after,2642,O
PAN,2642,B-Chemical
injection,2642,O
so,2642,O
as,2642,O
to,2642,O
include,2642,O
both,2642,O
the,2642,O
acute,2642,O
phase,2642,O
of,2642,O
proteinuria,2642,B-Disease
associated,2642,O
with,2642,O
foot,2642,O
process,2642,O
effacement,2642,O
(,2642,O
days,2642,O
5-11,2642,O
),2642,O
and,2642,O
the,2642,O
chronic,2642,O
phase,2642,O
of,2642,O
proteinuria,2642,B-Disease
associated,2642,O
with,2642,O
glomerulosclerosis,2642,B-Disease
(,2642,O
days,2642,O
45-126,2642,O
),2642,O
.,2642,O
At,2643,O
day,2643,O
5,2643,O
",",2643,O
GLEPP1,2643,O
protein,2643,O
and,2643,O
mRNA,2643,O
were,2643,O
reduced,2643,O
from,2643,O
the,2643,O
normal,2643,O
range,2643,O
(,2643,O
265.2,2643,O
+/-,2643,O
79.6,2643,O
x,2643,O
10,2643,O
(,2643,O
6,2643,O
),2643,O
moles/glomerulus,2643,O
and,2643,O
100,2643,O
%,2643,O
),2643,O
to,2643,O
15,2643,O
%,2643,O
of,2643,O
normal,2643,O
(,2643,O
41.8,2643,O
+/-,2643,O
4.8,2643,O
x,2643,O
10,2643,O
(,2643,O
6,2643,O
),2643,O
moles/glomerulus,2643,O
",",2643,O
p,2643,O
<,2643,O
0.005,2643,O
),2643,O
.,2643,O
This,2644,O
occurred,2644,O
in,2644,O
association,2644,O
with,2644,O
an,2644,O
increase,2644,O
in,2644,O
urinary,2644,O
protein,2644,O
content,2644,O
from,2644,O
1.8,2644,O
+/-,2644,O
1,2644,O
to,2644,O
99.0,2644,O
+/-,2644,O
61,2644,O
mg/day,2644,O
(,2644,O
p,2644,O
<,2644,O
0.001,2644,O
),2644,O
.,2644,O
In,2645,O
contrast,2645,O
",",2645,O
podocalyxin,2645,O
did,2645,O
not,2645,O
change,2645,O
significantly,2645,O
at,2645,O
this,2645,O
time,2645,O
.,2645,O
By,2646,O
day,2646,O
11,2646,O
",",2646,O
GLEPP1,2646,O
protein,2646,O
and,2646,O
mRNA,2646,O
had,2646,O
begun,2646,O
to,2646,O
return,2646,O
towards,2646,O
baseline,2646,O
.,2646,O
By,2647,O
day,2647,O
45-126,2647,O
",",2647,O
at,2647,O
a,2647,O
time,2647,O
when,2647,O
glomerular,2647,O
scarring,2647,O
was,2647,O
present,2647,O
",",2647,O
GLEPP1,2647,O
was,2647,O
absent,2647,O
from,2647,O
glomerulosclerotic,2647,O
areas,2647,O
although,2647,O
the,2647,O
total,2647,O
glomerular,2647,O
content,2647,O
of,2647,O
GLEPP1,2647,O
was,2647,O
not,2647,O
different,2647,O
from,2647,O
normal,2647,O
.,2647,O
We,2648,O
conclude,2648,O
that,2648,O
GLEPP1,2648,O
expression,2648,O
",",2648,O
unlike,2648,O
podocalyxin,2648,O
",",2648,O
reflects,2648,O
podocyte,2648,O
injury,2648,O
induced,2648,O
by,2648,O
PAN,2648,B-Chemical
.,2648,O
GLEPP1,2649,O
expression,2649,O
may,2649,O
be,2649,O
a,2649,O
useful,2649,O
marker,2649,O
of,2649,O
podocyte,2649,O
injury,2649,O
.,2649,O
Antithymocyte,2650,B-Chemical
globulin,2650,I-Chemical
in,2650,O
the,2650,O
treatment,2650,O
of,2650,O
D-penicillamine-induced,2650,B-Chemical
aplastic,2650,B-Disease
anemia,2650,I-Disease
.,2650,O
A,2651,O
patient,2651,O
who,2651,O
received,2651,O
antithymocyte,2651,B-Chemical
globulin,2651,I-Chemical
therapy,2651,O
for,2651,O
aplastic,2651,B-Disease
anemia,2651,I-Disease
due,2651,O
to,2651,O
D-penicillamine,2651,B-Chemical
therapy,2651,O
is,2651,O
described,2651,O
.,2651,O
Bone,2652,O
marrow,2652,O
recovery,2652,O
and,2652,O
peripheral,2652,O
blood,2652,O
recovery,2652,O
were,2652,O
complete,2652,O
1,2652,O
month,2652,O
and,2652,O
3,2652,O
months,2652,O
",",2652,O
respectively,2652,O
",",2652,O
after,2652,O
treatment,2652,O
",",2652,O
and,2652,O
blood,2652,O
transfusion,2652,O
or,2652,O
other,2652,O
therapies,2652,O
were,2652,O
not,2652,O
necessary,2652,O
in,2652,O
a,2652,O
follow-up,2652,O
period,2652,O
of,2652,O
more,2652,O
than,2652,O
2,2652,O
years,2652,O
.,2652,O
Use,2653,O
of,2653,O
antithymocyte,2653,B-Chemical
globulin,2653,I-Chemical
may,2653,O
be,2653,O
the,2653,O
optimal,2653,O
treatment,2653,O
of,2653,O
D-penicillamine-induced,2653,B-Chemical
aplastic,2653,B-Disease
anemia,2653,I-Disease
.,2653,O
Metamizol,2654,B-Chemical
potentiates,2654,O
morphine,2654,B-Chemical
antinociception,2654,O
but,2654,O
not,2654,O
constipation,2654,B-Disease
after,2654,O
chronic,2654,O
treatment,2654,O
.,2654,O
This,2655,O
work,2655,O
evaluates,2655,O
the,2655,O
antinociceptive,2655,O
and,2655,O
constipating,2655,B-Disease
effects,2655,O
of,2655,O
the,2655,O
combination,2655,O
of,2655,O
3.2,2655,O
mg/kg,2655,O
s.c.,2655,O
morphine,2655,B-Chemical
with,2655,O
177.8,2655,O
mg/kg,2655,O
s.c.,2655,O
metamizol,2655,B-Chemical
in,2655,O
acutely,2655,O
and,2655,O
chronically,2655,O
treated,2655,O
(,2655,O
once,2655,O
a,2655,O
day,2655,O
for,2655,O
12,2655,O
days,2655,O
),2655,O
rats,2655,O
.,2655,O
On,2656,O
the,2656,O
13th,2656,O
day,2656,O
",",2656,O
antinociceptive,2656,O
effects,2656,O
were,2656,O
assessed,2656,O
using,2656,O
a,2656,O
model,2656,O
of,2656,O
inflammatory,2656,O
nociception,2656,O
",",2656,O
pain-induced,2656,B-Disease
functional,2656,O
impairment,2656,O
model,2656,O
",",2656,O
and,2656,O
the,2656,O
charcoal,2656,B-Chemical
meal,2656,O
test,2656,O
was,2656,O
used,2656,O
to,2656,O
evaluate,2656,O
the,2656,O
intestinal,2656,O
transit,2656,O
.,2656,O
Simultaneous,2657,O
administration,2657,O
of,2657,O
morphine,2657,B-Chemical
with,2657,O
metamizol,2657,B-Chemical
resulted,2657,O
in,2657,O
a,2657,O
markedly,2657,O
antinociceptive,2657,O
potentiation,2657,O
and,2657,O
an,2657,O
increasing,2657,O
of,2657,O
the,2657,O
duration,2657,O
of,2657,O
action,2657,O
after,2657,O
a,2657,O
single,2657,O
(,2657,O
298+/-7,2657,O
vs.,2657,O
139+/-36,2657,O
units,2657,O
area,2657,O
(,2657,O
ua,2657,O
),2657,O
;,2657,O
P,2657,O
<,2657,O
0.001,2657,O
),2657,O
and,2657,O
repeated,2657,O
administration,2657,O
(,2657,O
280+/-17,2657,O
vs.,2657,O
131+/-22,2657,O
ua,2657,O
;,2657,O
P,2657,O
<,2657,O
0.001,2657,O
),2657,O
.,2657,O
Antinociceptive,2658,O
effect,2658,O
of,2658,O
morphine,2658,B-Chemical
was,2658,O
reduced,2658,O
in,2658,O
chronically,2658,O
treated,2658,O
rats,2658,O
(,2658,O
39+/-10,2658,O
vs.,2658,O
18+/-5,2658,O
au,2658,O
),2658,O
while,2658,O
the,2658,O
combination-induced,2658,O
antinociception,2658,O
was,2658,O
remained,2658,O
similar,2658,O
as,2658,O
an,2658,O
acute,2658,O
treatment,2658,O
(,2658,O
298+/-7,2658,O
vs.,2658,O
280+/-17,2658,O
au,2658,O
),2658,O
.,2658,O
Acute,2659,O
antinociceptive,2659,O
effects,2659,O
of,2659,O
the,2659,O
combination,2659,O
were,2659,O
partially,2659,O
prevented,2659,O
by,2659,O
3.2,2659,O
mg/kg,2659,O
naloxone,2659,B-Chemical
s.c.,2659,O
(,2659,O
P,2659,O
<,2659,O
0.05,2659,O
),2659,O
",",2659,O
suggesting,2659,O
the,2659,O
partial,2659,O
involvement,2659,O
of,2659,O
the,2659,O
opioidergic,2659,O
system,2659,O
in,2659,O
the,2659,O
synergism,2659,O
observed,2659,O
.,2659,O
In,2660,O
independent,2660,O
groups,2660,O
",",2660,O
morphine,2660,B-Chemical
inhibited,2660,O
the,2660,O
intestinal,2660,O
transit,2660,O
in,2660,O
48+/-4,2660,O
%,2660,O
and,2660,O
38+/-4,2660,O
%,2660,O
after,2660,O
acute,2660,O
and,2660,O
chronic,2660,O
treatment,2660,O
",",2660,O
respectively,2660,O
",",2660,O
suggesting,2660,O
that,2660,O
tolerance,2660,O
did,2660,O
not,2660,O
develop,2660,O
to,2660,O
the,2660,O
constipating,2660,B-Disease
effects,2660,O
.,2660,O
The,2661,O
combination,2661,O
inhibited,2661,O
intestinal,2661,O
transit,2661,O
similar,2661,O
to,2661,O
that,2661,O
produced,2661,O
by,2661,O
morphine,2661,B-Chemical
regardless,2661,O
of,2661,O
the,2661,O
time,2661,O
of,2661,O
treatment,2661,O
",",2661,O
suggesting,2661,O
that,2661,O
metamizol,2661,B-Chemical
did,2661,O
not,2661,O
potentiate,2661,O
morphine-induced,2661,B-Chemical
constipation,2661,B-Disease
.,2661,O
These,2662,O
findings,2662,O
show,2662,O
a,2662,O
significant,2662,O
interaction,2662,O
between,2662,O
morphine,2662,B-Chemical
and,2662,O
metamizol,2662,B-Chemical
in,2662,O
chronically,2662,O
treated,2662,O
rats,2662,O
",",2662,O
suggesting,2662,O
that,2662,O
this,2662,O
combination,2662,O
could,2662,O
be,2662,O
useful,2662,O
for,2662,O
the,2662,O
treatment,2662,O
of,2662,O
chronic,2662,B-Disease
pain,2662,I-Disease
.,2662,O
Ifosfamide,2663,B-Chemical
encephalopathy,2663,B-Disease
presenting,2663,O
with,2663,O
asterixis,2663,B-Disease
.,2663,O
CNS,2664,O
toxic,2664,O
effects,2664,O
of,2664,O
the,2664,O
antineoplastic,2664,O
agent,2664,O
ifosfamide,2664,B-Chemical
(,2664,O
IFX,2664,B-Chemical
),2664,O
are,2664,O
frequent,2664,O
and,2664,O
include,2664,O
a,2664,O
variety,2664,O
of,2664,O
neurological,2664,O
symptoms,2664,O
that,2664,O
can,2664,O
limit,2664,O
drug,2664,O
use,2664,O
.,2664,O
We,2665,O
report,2665,O
a,2665,O
case,2665,O
of,2665,O
a,2665,O
51-year-old,2665,O
man,2665,O
who,2665,O
developed,2665,O
severe,2665,O
",",2665,O
disabling,2665,O
negative,2665,O
myoclonus,2665,B-Disease
of,2665,O
the,2665,O
upper,2665,O
and,2665,O
lower,2665,O
extremities,2665,O
after,2665,O
the,2665,O
infusion,2665,O
of,2665,O
ifosfamide,2665,B-Chemical
for,2665,O
plasmacytoma,2665,B-Disease
.,2665,O
He,2666,O
was,2666,O
awake,2666,O
",",2666,O
revealed,2666,O
no,2666,O
changes,2666,O
of,2666,O
mental,2666,O
status,2666,O
and,2666,O
at,2666,O
rest,2666,O
there,2666,O
were,2666,O
no,2666,O
further,2666,O
motor,2666,O
symptoms,2666,O
.,2666,O
Cranial,2667,O
magnetic,2667,O
resonance,2667,O
imaging,2667,O
and,2667,O
extensive,2667,O
laboratory,2667,O
studies,2667,O
failed,2667,O
to,2667,O
reveal,2667,O
structural,2667,B-Disease
lesions,2667,I-Disease
of,2667,I-Disease
the,2667,I-Disease
brain,2667,I-Disease
and,2667,O
metabolic,2667,B-Disease
abnormalities,2667,I-Disease
.,2667,O
An,2668,O
electroencephalogram,2668,O
showed,2668,O
continuous,2668,O
",",2668,O
generalized,2668,O
irregular,2668,O
slowing,2668,O
with,2668,O
admixed,2668,O
periodic,2668,O
triphasic,2668,O
waves,2668,O
indicating,2668,O
symptomatic,2668,O
encephalopathy,2668,B-Disease
.,2668,O
The,2669,O
administration,2669,O
of,2669,O
ifosfamide,2669,B-Chemical
was,2669,O
discontinued,2669,O
and,2669,O
within,2669,O
12,2669,O
h,2669,O
the,2669,O
asterixis,2669,B-Disease
resolved,2669,O
completely,2669,O
.,2669,O
In,2670,O
the,2670,O
patient,2670,O
described,2670,O
",",2670,O
the,2670,O
presence,2670,O
of,2670,O
asterixis,2670,B-Disease
during,2670,O
infusion,2670,O
of,2670,O
ifosfamide,2670,B-Chemical
",",2670,O
normal,2670,O
laboratory,2670,O
findings,2670,O
and,2670,O
imaging,2670,O
studies,2670,O
and,2670,O
the,2670,O
resolution,2670,O
of,2670,O
symptoms,2670,O
following,2670,O
the,2670,O
discontinuation,2670,O
of,2670,O
the,2670,O
drug,2670,O
suggest,2670,O
that,2670,O
negative,2670,O
myoclonus,2670,B-Disease
is,2670,O
associated,2670,O
with,2670,O
the,2670,O
use,2670,O
of,2670,O
IFX,2670,B-Chemical
.,2670,O
Antagonism,2671,O
between,2671,O
interleukin,2671,O
3,2671,O
and,2671,O
erythropoietin,2671,O
in,2671,O
mice,2671,O
with,2671,O
azidothymidine-induced,2671,B-Chemical
anemia,2671,B-Disease
and,2671,O
in,2671,O
bone,2671,O
marrow,2671,O
endothelial,2671,O
cells,2671,O
.,2671,O
Azidothymidine,2672,B-Chemical
(,2672,O
AZT,2672,B-Chemical
),2672,O
-induced,2672,O
anemia,2672,B-Disease
in,2672,O
mice,2672,O
can,2672,O
be,2672,O
reversed,2672,O
by,2672,O
the,2672,O
administration,2672,O
of,2672,O
IGF-IL-3,2672,O
(,2672,O
fusion,2672,O
protein,2672,O
of,2672,O
insulin-like,2672,O
growth,2672,O
factor,2672,O
II,2672,O
(,2672,O
IGF,2672,O
II,2672,O
),2672,O
and,2672,O
interleukin,2672,O
3,2672,O
),2672,O
.,2672,O
Although,2673,O
interleukin,2673,O
3,2673,O
(,2673,O
IL-3,2673,O
),2673,O
and,2673,O
erythropoietin,2673,O
(,2673,O
EPO,2673,O
),2673,O
are,2673,O
known,2673,O
to,2673,O
act,2673,O
synergistically,2673,O
on,2673,O
hematopoietic,2673,O
cell,2673,O
proliferation,2673,O
in,2673,O
vitro,2673,O
",",2673,O
injection,2673,O
of,2673,O
IGF-IL-3,2673,O
and,2673,O
EPO,2673,O
in,2673,O
AZT-treated,2673,B-Chemical
mice,2673,O
resulted,2673,O
in,2673,O
a,2673,O
reduction,2673,O
of,2673,O
red,2673,O
cells,2673,O
and,2673,O
an,2673,O
increase,2673,O
of,2673,O
plasma,2673,O
EPO,2673,O
levels,2673,O
as,2673,O
compared,2673,O
to,2673,O
animals,2673,O
treated,2673,O
with,2673,O
IGF-IL-3,2673,O
or,2673,O
EPO,2673,O
alone,2673,O
.,2673,O
We,2674,O
tested,2674,O
the,2674,O
hypothesis,2674,O
that,2674,O
the,2674,O
antagonistic,2674,O
effect,2674,O
of,2674,O
IL-3,2674,O
and,2674,O
EPO,2674,O
on,2674,O
erythroid,2674,O
cells,2674,O
may,2674,O
be,2674,O
mediated,2674,O
by,2674,O
endothelial,2674,O
cells,2674,O
.,2674,O
Bovine,2675,O
liver,2675,O
erythroid,2675,O
cells,2675,O
were,2675,O
cultured,2675,O
on,2675,O
monolayers,2675,O
of,2675,O
human,2675,O
bone,2675,O
marrow,2675,O
endothelial,2675,O
cells,2675,O
previously,2675,O
treated,2675,O
with,2675,O
EPO,2675,O
and,2675,O
IGF-IL-3,2675,O
.,2675,O
There,2676,O
was,2676,O
a,2676,O
significant,2676,O
reduction,2676,O
of,2676,O
thymidine,2676,B-Chemical
incorporation,2676,O
into,2676,O
both,2676,O
erythroid,2676,O
and,2676,O
endothelial,2676,O
cells,2676,O
in,2676,O
cultures,2676,O
pre-treated,2676,O
with,2676,O
IGF-IL-3,2676,O
and,2676,O
EPO,2676,O
.,2676,O
Endothelial,2677,O
cell,2677,O
culture,2677,O
supernatants,2677,O
separated,2677,O
by,2677,O
ultrafiltration,2677,O
and,2677,O
ultracentrifugation,2677,O
from,2677,O
cells,2677,O
treated,2677,O
with,2677,O
EPO,2677,O
and,2677,O
IL-3,2677,O
significantly,2677,O
reduced,2677,O
thymidine,2677,B-Chemical
incorporation,2677,O
into,2677,O
erythroid,2677,O
cells,2677,O
as,2677,O
compared,2677,O
to,2677,O
identical,2677,O
fractions,2677,O
obtained,2677,O
from,2677,O
the,2677,O
media,2677,O
of,2677,O
cells,2677,O
cultured,2677,O
with,2677,O
EPO,2677,O
alone,2677,O
.,2677,O
These,2678,O
results,2678,O
suggest,2678,O
that,2678,O
endothelial,2678,O
cells,2678,O
treated,2678,O
simultaneously,2678,O
with,2678,O
EPO,2678,O
and,2678,O
IL-3,2678,O
have,2678,O
a,2678,O
negative,2678,O
effect,2678,O
on,2678,O
erythroid,2678,O
cell,2678,O
production,2678,O
.,2678,O
The,2679,O
relationship,2679,O
between,2679,O
hippocampal,2679,O
acetylcholine,2679,B-Chemical
release,2679,O
and,2679,O
cholinergic,2679,O
convulsant,2679,O
sensitivity,2679,O
in,2679,O
withdrawal,2679,O
seizure-prone,2679,B-Disease
and,2679,O
withdrawal,2679,O
seizure-resistant,2679,B-Disease
selected,2679,O
mouse,2679,O
lines,2679,O
.,2679,O
BACKGROUND,2680,O
:,2680,O
The,2680,O
septo-hippocampal,2680,O
cholinergic,2680,O
pathway,2680,O
has,2680,O
been,2680,O
implicated,2680,O
in,2680,O
epileptogenesis,2680,O
",",2680,O
and,2680,O
genetic,2680,O
factors,2680,O
influence,2680,O
the,2680,O
response,2680,O
to,2680,O
cholinergic,2680,O
agents,2680,O
",",2680,O
but,2680,O
limited,2680,O
data,2680,O
are,2680,O
available,2680,O
on,2680,O
cholinergic,2680,O
involvement,2680,O
in,2680,O
alcohol,2680,B-Chemical
withdrawal,2680,O
severity,2680,O
.,2680,O
Thus,2681,O
",",2681,O
the,2681,O
relationship,2681,O
between,2681,O
cholinergic,2681,O
activity,2681,O
and,2681,O
responsiveness,2681,O
and,2681,O
alcohol,2681,B-Chemical
withdrawal,2681,O
was,2681,O
investigated,2681,O
in,2681,O
a,2681,O
genetic,2681,O
animal,2681,O
model,2681,O
of,2681,O
ethanol,2681,B-Chemical
withdrawal,2681,O
severity,2681,O
.,2681,O
METHODS,2682,O
:,2682,O
Cholinergic,2682,O
convulsant,2682,O
sensitivity,2682,O
was,2682,O
examined,2682,O
in,2682,O
alcohol-na,2682,B-Chemical
ve,2682,O
Withdrawal,2682,O
Seizure-Prone,2682,B-Disease
(,2682,O
WSP,2682,O
),2682,O
and-Resistant,2682,O
(,2682,O
WSR,2682,O
),2682,O
mice,2682,O
.,2682,O
Animals,2683,O
were,2683,O
administered,2683,O
nicotine,2683,B-Chemical
",",2683,O
carbachol,2683,B-Chemical
",",2683,O
or,2683,O
neostigmine,2683,B-Chemical
via,2683,O
timed,2683,O
tail,2683,O
vein,2683,O
infusion,2683,O
",",2683,O
and,2683,O
the,2683,O
latencies,2683,O
to,2683,O
onset,2683,O
of,2683,O
tremor,2683,B-Disease
and,2683,O
clonus,2683,O
were,2683,O
recorded,2683,O
and,2683,O
converted,2683,O
to,2683,O
threshold,2683,O
dose,2683,O
.,2683,O
We,2684,O
also,2684,O
used,2684,O
microdialysis,2684,O
to,2684,O
measure,2684,O
basal,2684,O
and,2684,O
potassium-stimulated,2684,B-Chemical
acetylcholine,2684,B-Chemical
(,2684,O
ACh,2684,B-Chemical
),2684,O
release,2684,O
in,2684,O
the,2684,O
CA1,2684,O
region,2684,O
of,2684,O
the,2684,O
hippocampus,2684,O
.,2684,O
Potassium,2685,B-Chemical
was,2685,O
applied,2685,O
by,2685,O
reverse,2685,O
dialysis,2685,O
twice,2685,O
",",2685,O
separated,2685,O
by,2685,O
75,2685,O
min,2685,O
.,2685,O
Hippocampal,2686,O
ACh,2686,B-Chemical
also,2686,O
was,2686,O
measured,2686,O
during,2686,O
testing,2686,O
for,2686,O
handling-induced,2686,O
convulsions,2686,B-Disease
.,2686,O
RESULTS,2687,O
:,2687,O
Sensitivity,2687,O
to,2687,O
several,2687,O
convulsion,2687,B-Disease
endpoints,2687,O
induced,2687,O
by,2687,O
nicotine,2687,B-Chemical
",",2687,O
carbachol,2687,B-Chemical
",",2687,O
and,2687,O
neostigmine,2687,B-Chemical
were,2687,O
significantly,2687,O
greater,2687,O
in,2687,O
WSR,2687,O
versus,2687,O
WSP,2687,O
mice,2687,O
.,2687,O
In,2688,O
microdialysis,2688,O
experiments,2688,O
",",2688,O
the,2688,O
lines,2688,O
did,2688,O
not,2688,O
differ,2688,O
in,2688,O
basal,2688,O
release,2688,O
of,2688,O
ACh,2688,B-Chemical
",",2688,O
and,2688,O
50,2688,O
mM,2688,O
KCl,2688,B-Chemical
increased,2688,O
ACh,2688,B-Chemical
output,2688,O
in,2688,O
both,2688,O
lines,2688,O
of,2688,O
mice,2688,O
.,2688,O
However,2689,O
",",2689,O
the,2689,O
increase,2689,O
in,2689,O
release,2689,O
of,2689,O
ACh,2689,B-Chemical
produced,2689,O
by,2689,O
the,2689,O
first,2689,O
application,2689,O
of,2689,O
KCl,2689,B-Chemical
was,2689,O
2-fold,2689,O
higher,2689,O
in,2689,O
WSP,2689,O
versus,2689,O
WSR,2689,O
mice,2689,O
.,2689,O
When,2690,O
hippocampal,2690,O
ACh,2690,B-Chemical
was,2690,O
measured,2690,O
during,2690,O
testing,2690,O
for,2690,O
handling-induced,2690,O
convulsions,2690,B-Disease
",",2690,O
extracellular,2690,O
ACh,2690,B-Chemical
was,2690,O
significantly,2690,O
elevated,2690,O
(,2690,O
192,2690,O
%,2690,O
),2690,O
in,2690,O
WSP,2690,O
mice,2690,O
",",2690,O
but,2690,O
was,2690,O
nonsignificantly,2690,O
elevated,2690,O
(,2690,O
59,2690,O
%,2690,O
),2690,O
in,2690,O
WSR,2690,O
mice,2690,O
.,2690,O
CONCLUSIONS,2691,O
:,2691,O
These,2691,O
results,2691,O
suggest,2691,O
that,2691,O
differences,2691,O
in,2691,O
cholinergic,2691,O
activity,2691,O
and,2691,O
postsynaptic,2691,O
sensitivity,2691,O
to,2691,O
cholinergic,2691,O
convulsants,2691,B-Disease
may,2691,O
be,2691,O
associated,2691,O
with,2691,O
ethanol,2691,B-Chemical
withdrawal,2691,O
severity,2691,O
and,2691,O
implicate,2691,O
cholinergic,2691,O
mechanisms,2691,O
in,2691,O
alcohol,2691,B-Chemical
withdrawal,2691,O
.,2691,O
Specifically,2692,O
",",2692,O
WSP,2692,O
mice,2692,O
may,2692,O
have,2692,O
lower,2692,O
sensitivity,2692,O
to,2692,O
cholinergic,2692,O
convulsants,2692,B-Disease
compared,2692,O
with,2692,O
WSR,2692,O
because,2692,O
of,2692,O
postsynaptic,2692,O
receptor,2692,O
desensitization,2692,O
brought,2692,O
on,2692,O
by,2692,O
higher,2692,O
activity,2692,O
of,2692,O
cholinergic,2692,O
neurons,2692,O
.,2692,O
Capsaicin-induced,2693,B-Chemical
muscle,2693,B-Disease
pain,2693,I-Disease
alters,2693,O
the,2693,O
excitability,2693,O
of,2693,O
the,2693,O
human,2693,O
jaw-stretch,2693,O
reflex,2693,O
.,2693,O
The,2694,O
pathophysiology,2694,O
of,2694,O
painful,2694,O
temporomandibular,2694,B-Disease
disorders,2694,I-Disease
is,2694,O
not,2694,O
fully,2694,O
understood,2694,O
",",2694,O
but,2694,O
evidence,2694,O
suggests,2694,O
that,2694,O
muscle,2694,B-Disease
pain,2694,I-Disease
modulates,2694,O
motor,2694,O
function,2694,O
in,2694,O
characteristic,2694,O
ways,2694,O
.,2694,O
This,2695,O
study,2695,O
tested,2695,O
the,2695,O
hypothesis,2695,O
that,2695,O
activation,2695,O
of,2695,O
nociceptive,2695,B-Disease
muscle,2695,I-Disease
afferent,2695,O
fibers,2695,O
would,2695,O
be,2695,O
linked,2695,O
to,2695,O
an,2695,O
increased,2695,O
excitability,2695,O
of,2695,O
the,2695,O
human,2695,O
jaw-stretch,2695,O
reflex,2695,O
and,2695,O
whether,2695,O
this,2695,O
process,2695,O
would,2695,O
be,2695,O
sensitive,2695,O
to,2695,O
length,2695,O
and,2695,O
velocity,2695,O
of,2695,O
the,2695,O
stretch,2695,O
.,2695,O
Capsaicin,2696,B-Chemical
(,2696,O
10,2696,O
micro,2696,O
g,2696,O
),2696,O
was,2696,O
injected,2696,O
into,2696,O
the,2696,O
masseter,2696,O
muscle,2696,O
to,2696,O
induce,2696,O
pain,2696,B-Disease
in,2696,O
11,2696,O
healthy,2696,O
volunteers,2696,O
.,2696,O
Short-latency,2697,O
reflex,2697,O
responses,2697,O
were,2697,O
evoked,2697,O
in,2697,O
the,2697,O
masseter,2697,O
and,2697,O
temporalis,2697,O
muscles,2697,O
by,2697,O
a,2697,O
stretch,2697,O
device,2697,O
with,2697,O
different,2697,O
velocities,2697,O
and,2697,O
displacements,2697,O
before,2697,O
",",2697,O
during,2697,O
",",2697,O
and,2697,O
after,2697,O
the,2697,O
pain,2697,B-Disease
.,2697,O
The,2698,O
normalized,2698,O
reflex,2698,O
amplitude,2698,O
increased,2698,O
with,2698,O
an,2698,O
increase,2698,O
in,2698,O
velocity,2698,O
at,2698,O
a,2698,O
given,2698,O
displacement,2698,O
",",2698,O
but,2698,O
remained,2698,O
constant,2698,O
with,2698,O
different,2698,O
displacements,2698,O
at,2698,O
a,2698,O
given,2698,O
velocity,2698,O
.,2698,O
The,2699,O
normalized,2699,O
reflex,2699,O
amplitude,2699,O
was,2699,O
significantly,2699,O
higher,2699,O
during,2699,O
pain,2699,B-Disease
",",2699,O
but,2699,O
only,2699,O
at,2699,O
faster,2699,O
stretches,2699,O
in,2699,O
the,2699,O
painful,2699,B-Disease
muscle,2699,I-Disease
.,2699,O
Increased,2700,O
sensitivity,2700,O
of,2700,O
the,2700,O
fusimotor,2700,O
system,2700,O
during,2700,O
acute,2700,O
muscle,2700,B-Disease
pain,2700,I-Disease
could,2700,O
be,2700,O
one,2700,O
likely,2700,O
mechanism,2700,O
to,2700,O
explain,2700,O
the,2700,O
findings,2700,O
.,2700,O
Effects,2701,O
of,2701,O
5-HT1B,2701,O
receptor,2701,O
ligands,2701,O
microinjected,2701,O
into,2701,O
the,2701,O
accumbal,2701,O
shell,2701,O
or,2701,O
core,2701,O
on,2701,O
the,2701,O
cocaine-induced,2701,B-Chemical
locomotor,2701,B-Disease
hyperactivity,2701,I-Disease
in,2701,O
rats,2701,O
.,2701,O
The,2702,O
present,2702,O
study,2702,O
was,2702,O
designed,2702,O
to,2702,O
examine,2702,O
the,2702,O
effect,2702,O
of,2702,O
5-HT1B,2702,O
receptor,2702,O
ligands,2702,O
microinjected,2702,O
into,2702,O
the,2702,O
subregions,2702,O
of,2702,O
the,2702,O
nucleus,2702,O
accumbens,2702,O
(,2702,O
the,2702,O
shell,2702,O
and,2702,O
the,2702,O
core,2702,O
),2702,O
on,2702,O
the,2702,O
locomotor,2702,B-Disease
hyperactivity,2702,I-Disease
induced,2702,O
by,2702,O
cocaine,2702,B-Chemical
in,2702,O
rats,2702,O
.,2702,O
Male,2703,O
Wistar,2703,O
rats,2703,O
were,2703,O
implanted,2703,O
bilaterally,2703,O
with,2703,O
cannulae,2703,O
into,2703,O
the,2703,O
accumbens,2703,O
shell,2703,O
or,2703,O
core,2703,O
",",2703,O
and,2703,O
then,2703,O
were,2703,O
locally,2703,O
injected,2703,O
with,2703,O
GR,2703,B-Chemical
55562,2703,I-Chemical
(,2703,O
an,2703,O
antagonist,2703,O
of,2703,O
5-HT1B,2703,O
receptors,2703,O
),2703,O
or,2703,O
CP,2703,B-Chemical
93129,2703,I-Chemical
(,2703,O
an,2703,O
agonist,2703,O
of,2703,O
5-HT1B,2703,O
receptors,2703,O
),2703,O
.,2703,O
Given,2704,O
alone,2704,O
to,2704,O
any,2704,O
accumbal,2704,O
subregion,2704,O
",",2704,O
GR,2704,B-Chemical
55562,2704,I-Chemical
(,2704,O
0.1-10,2704,O
microg/side,2704,O
),2704,O
or,2704,O
CP,2704,B-Chemical
93129,2704,I-Chemical
(,2704,O
0.1-10,2704,O
microg/side,2704,O
),2704,O
did,2704,O
not,2704,O
change,2704,O
basal,2704,O
locomotor,2704,O
activity,2704,O
.,2704,O
Systemic,2705,O
cocaine,2705,B-Chemical
(,2705,O
10,2705,O
mg/kg,2705,O
),2705,O
significantly,2705,O
increased,2705,O
the,2705,O
locomotor,2705,O
activity,2705,O
of,2705,O
rats,2705,O
.,2705,O
GR,2706,B-Chemical
55562,2706,I-Chemical
(,2706,O
0.1-10,2706,O
microg/side,2706,O
),2706,O
",",2706,O
administered,2706,O
intra-accumbens,2706,O
shell,2706,O
prior,2706,O
to,2706,O
cocaine,2706,B-Chemical
",",2706,O
dose-dependently,2706,O
attenuated,2706,O
the,2706,O
psychostimulant-induced,2706,O
locomotor,2706,B-Disease
hyperactivity,2706,I-Disease
.,2706,O
Such,2707,O
attenuation,2707,O
was,2707,O
not,2707,O
found,2707,O
in,2707,O
animals,2707,O
which,2707,O
had,2707,O
been,2707,O
injected,2707,O
with,2707,O
GR,2707,B-Chemical
55562,2707,I-Chemical
into,2707,O
the,2707,O
accumbens,2707,O
core,2707,O
.,2707,O
When,2708,O
injected,2708,O
into,2708,O
the,2708,O
accumbens,2708,O
shell,2708,O
(,2708,O
but,2708,O
not,2708,O
the,2708,O
core,2708,O
),2708,O
before,2708,O
cocaine,2708,B-Chemical
",",2708,O
CP,2708,B-Chemical
93129,2708,I-Chemical
(,2708,O
0.1-10,2708,O
microg/side,2708,O
),2708,O
enhanced,2708,O
the,2708,O
locomotor,2708,O
response,2708,O
to,2708,O
cocaine,2708,B-Chemical
;,2708,O
the,2708,O
maximum,2708,O
effect,2708,O
being,2708,O
observed,2708,O
after,2708,O
10,2708,O
microg/side,2708,O
of,2708,O
the,2708,O
agonist,2708,O
.,2708,O
The,2709,O
later,2709,O
enhancement,2709,O
was,2709,O
attenuated,2709,O
after,2709,O
intra-accumbens,2709,O
shell,2709,O
treatment,2709,O
with,2709,O
GR,2709,B-Chemical
55562,2709,I-Chemical
(,2709,O
1,2709,O
microg/side,2709,O
),2709,O
.,2709,O
Our,2710,O
findings,2710,O
indicate,2710,O
that,2710,O
cocaine,2710,B-Chemical
induced,2710,O
hyperlocomotion,2710,B-Disease
is,2710,O
modified,2710,O
by,2710,O
5-HT1B,2710,O
receptor,2710,O
ligands,2710,O
microinjected,2710,O
into,2710,O
the,2710,O
accumbens,2710,O
shell,2710,O
",",2710,O
but,2710,O
not,2710,O
core,2710,O
",",2710,O
this,2710,O
modification,2710,O
consisting,2710,O
in,2710,O
inhibitory,2710,O
and,2710,O
facilitatory,2710,O
effects,2710,O
of,2710,O
the,2710,O
5-HT1B,2710,O
receptor,2710,O
antagonist,2710,O
(,2710,O
GR,2710,B-Chemical
55562,2710,I-Chemical
),2710,O
and,2710,O
agonist,2710,O
(,2710,O
CP,2710,B-Chemical
93129,2710,I-Chemical
),2710,O
",",2710,O
respectively,2710,O
.,2710,O
In,2711,O
other,2711,O
words,2711,O
",",2711,O
the,2711,O
present,2711,O
results,2711,O
suggest,2711,O
that,2711,O
the,2711,O
accumbal,2711,O
shell,2711,O
5-HT1B,2711,O
receptors,2711,O
play,2711,O
a,2711,O
permissive,2711,O
role,2711,O
in,2711,O
the,2711,O
behavioural,2711,O
response,2711,O
to,2711,O
the,2711,O
psychostimulant,2711,O
.,2711,O
Cocaine,2712,B-Chemical
related,2712,O
chest,2712,B-Disease
pain,2712,I-Disease
:,2712,O
are,2712,O
we,2712,O
seeing,2712,O
the,2712,O
tip,2712,O
of,2712,O
an,2712,O
iceberg,2712,O
?,2712,O
The,2713,O
recreational,2713,O
use,2713,O
of,2713,O
cocaine,2713,B-Chemical
is,2713,O
on,2713,O
the,2713,O
increase,2713,O
.,2713,O
The,2714,O
emergency,2714,O
nurse,2714,O
ought,2714,O
to,2714,O
be,2714,O
familiar,2714,O
with,2714,O
some,2714,O
of,2714,O
the,2714,O
cardiovascular,2714,O
consequences,2714,O
of,2714,O
cocaine,2714,B-Chemical
use,2714,O
.,2714,O
In,2715,O
particular,2715,O
",",2715,O
the,2715,O
tendency,2715,O
of,2715,O
cocaine,2715,B-Chemical
to,2715,O
produce,2715,O
chest,2715,B-Disease
pain,2715,I-Disease
ought,2715,O
to,2715,O
be,2715,O
in,2715,O
the,2715,O
mind,2715,O
of,2715,O
the,2715,O
emergency,2715,O
nurse,2715,O
when,2715,O
faced,2715,O
with,2715,O
a,2715,O
young,2715,O
victim,2715,O
of,2715,O
chest,2715,B-Disease
pain,2715,I-Disease
who,2715,O
is,2715,O
otherwise,2715,O
at,2715,O
low,2715,O
risk,2715,O
.,2715,O
The,2716,O
mechanism,2716,O
of,2716,O
chest,2716,B-Disease
pain,2716,I-Disease
related,2716,O
to,2716,O
cocaine,2716,B-Chemical
use,2716,O
is,2716,O
discussed,2716,O
and,2716,O
treatment,2716,O
dilemmas,2716,O
are,2716,O
discussed,2716,O
.,2716,O
Finally,2717,O
",",2717,O
moral,2717,O
issues,2717,O
relating,2717,O
to,2717,O
the,2717,O
testing,2717,O
of,2717,O
potential,2717,O
cocaine,2717,B-Chemical
users,2717,O
will,2717,O
be,2717,O
addressed,2717,O
.,2717,O
Crossover,2718,O
comparison,2718,O
of,2718,O
efficacy,2718,O
and,2718,O
preference,2718,O
for,2718,O
rizatriptan,2718,B-Chemical
10,2718,O
mg,2718,O
versus,2718,O
ergotamine/caffeine,2718,B-Chemical
in,2718,O
migraine,2718,B-Disease
.,2718,O
Rizatriptan,2719,B-Chemical
is,2719,O
a,2719,O
selective,2719,O
5-HT,2719,B-Chemical
(,2719,O
1B/1D,2719,O
),2719,O
receptor,2719,O
agonist,2719,O
with,2719,O
rapid,2719,O
oral,2719,O
absorption,2719,O
and,2719,O
early,2719,O
onset,2719,O
of,2719,O
action,2719,O
in,2719,O
the,2719,O
acute,2719,O
treatment,2719,O
of,2719,O
migraine,2719,B-Disease
.,2719,O
This,2720,O
randomized,2720,O
double-,2720,O
blind,2720,O
crossover,2720,O
outpatient,2720,O
study,2720,O
assessed,2720,O
the,2720,O
preference,2720,O
for,2720,O
1,2720,O
rizatriptan,2720,B-Chemical
10,2720,O
mg,2720,O
tablet,2720,O
to,2720,O
2,2720,O
ergotamine,2720,B-Chemical
1,2720,O
mg/caffeine,2720,O
100,2720,O
mg,2720,O
tablets,2720,O
in,2720,O
439,2720,O
patients,2720,O
treating,2720,O
a,2720,O
single,2720,O
migraine,2720,B-Disease
attack,2720,O
with,2720,O
each,2720,O
therapy,2720,O
.,2720,O
Of,2721,O
patients,2721,O
expressing,2721,O
a,2721,O
preference,2721,O
(,2721,O
89.1,2721,O
%,2721,O
),2721,O
",",2721,O
more,2721,O
than,2721,O
twice,2721,O
as,2721,O
many,2721,O
preferred,2721,O
rizatriptan,2721,B-Chemical
to,2721,O
ergotamine/caffeine,2721,B-Chemical
(,2721,O
69.9,2721,O
vs.,2721,O
30.1,2721,O
%,2721,O
",",2721,O
p,2721,O
<,2721,O
or,2721,O
=,2721,O
0.001,2721,O
),2721,O
.,2721,O
Faster,2722,O
relief,2722,O
of,2722,O
headache,2722,B-Disease
was,2722,O
the,2722,O
most,2722,O
important,2722,O
reason,2722,O
for,2722,O
preference,2722,O
",",2722,O
cited,2722,O
by,2722,O
67.3,2722,O
%,2722,O
of,2722,O
patients,2722,O
preferring,2722,O
rizatriptan,2722,B-Chemical
and,2722,O
54.2,2722,O
%,2722,O
of,2722,O
patients,2722,O
who,2722,O
preferred,2722,O
ergotamine/caffeine,2722,B-Chemical
.,2722,O
The,2723,O
co-primary,2723,O
endpoint,2723,O
of,2723,O
being,2723,O
pain,2723,B-Disease
free,2723,O
at,2723,O
2,2723,O
h,2723,O
was,2723,O
also,2723,O
in,2723,O
favor,2723,O
of,2723,O
rizatriptan,2723,B-Chemical
.,2723,O
Forty-nine,2724,O
percent,2724,O
of,2724,O
patients,2724,O
were,2724,O
pain,2724,B-Disease
free,2724,O
2,2724,O
h,2724,O
after,2724,O
rizatriptan,2724,B-Chemical
",",2724,O
compared,2724,O
with,2724,O
24.3,2724,O
%,2724,O
treated,2724,O
with,2724,O
ergotamine/caffeine,2724,B-Chemical
(,2724,O
p,2724,O
<,2724,O
or,2724,O
=,2724,O
0.001,2724,O
),2724,O
",",2724,O
rizatriptan,2724,B-Chemical
being,2724,O
superior,2724,O
within,2724,O
1,2724,O
h,2724,O
of,2724,O
treatment,2724,O
.,2724,O
Headache,2725,B-Disease
relief,2725,O
at,2725,O
2,2725,O
h,2725,O
was,2725,O
75.9,2725,O
%,2725,O
for,2725,O
rizatriptan,2725,B-Chemical
and,2725,O
47.3,2725,O
%,2725,O
for,2725,O
ergotamine/caffeine,2725,B-Chemical
(,2725,O
p,2725,O
<,2725,O
or,2725,O
=,2725,O
0.001,2725,O
),2725,O
",",2725,O
with,2725,O
rizatriptan,2725,B-Chemical
being,2725,O
superior,2725,O
to,2725,O
ergotamine/caffeine,2725,B-Chemical
within,2725,O
30,2725,O
min,2725,O
of,2725,O
dosing,2725,O
.,2725,O
Almost,2726,O
36,2726,O
%,2726,O
of,2726,O
patients,2726,O
taking,2726,O
rizatriptan,2726,B-Chemical
were,2726,O
pain,2726,B-Disease
free,2726,O
at,2726,O
2,2726,O
h,2726,O
and,2726,O
had,2726,O
no,2726,O
recurrence,2726,O
or,2726,O
need,2726,O
for,2726,O
additional,2726,O
medication,2726,O
within,2726,O
24,2726,O
h,2726,O
",",2726,O
compared,2726,O
to,2726,O
20,2726,O
%,2726,O
of,2726,O
patients,2726,O
on,2726,O
ergotamine/caffeine,2726,B-Chemical
(,2726,O
p,2726,O
<,2726,O
or,2726,O
=,2726,O
0.001,2726,O
),2726,O
.,2726,O
Rizatriptan,2727,B-Chemical
was,2727,O
also,2727,O
superior,2727,O
to,2727,O
ergotamine/caffeine,2727,B-Chemical
in,2727,O
the,2727,O
proportions,2727,O
of,2727,O
patients,2727,O
with,2727,O
no,2727,O
nausea,2727,B-Disease
",",2727,O
vomiting,2727,B-Disease
",",2727,O
phonophobia,2727,B-Disease
or,2727,O
photophobia,2727,B-Disease
and,2727,O
for,2727,O
patients,2727,O
with,2727,O
normal,2727,O
function,2727,O
2,2727,O
h,2727,O
after,2727,O
drug,2727,O
intake,2727,O
(,2727,O
p,2727,O
<,2727,O
or,2727,O
=,2727,O
0.001,2727,O
),2727,O
.,2727,O
More,2728,O
patients,2728,O
were,2728,O
(,2728,O
completely,2728,O
",",2728,O
very,2728,O
or,2728,O
somewhat,2728,O
),2728,O
satisfied,2728,O
2,2728,O
h,2728,O
after,2728,O
treatment,2728,O
with,2728,O
rizatriptan,2728,B-Chemical
(,2728,O
69.8,2728,O
%,2728,O
),2728,O
than,2728,O
at,2728,O
2,2728,O
h,2728,O
after,2728,O
treatment,2728,O
with,2728,O
ergotamine/caffeine,2728,B-Chemical
(,2728,O
38.6,2728,O
%,2728,O
",",2728,O
p,2728,O
<,2728,O
or,2728,O
=,2728,O
0.001,2728,O
),2728,O
.,2728,O
Recurrence,2729,O
rates,2729,O
were,2729,O
31.4,2729,O
%,2729,O
with,2729,O
rizatriptan,2729,B-Chemical
and,2729,O
15.3,2729,O
%,2729,O
with,2729,O
ergotamine/caffeine,2729,B-Chemical
.,2729,O
Both,2730,O
active,2730,O
treatments,2730,O
were,2730,O
well,2730,O
tolerated,2730,O
.,2730,O
The,2731,O
most,2731,O
common,2731,O
adverse,2731,O
events,2731,O
(,2731,O
incidence,2731,O
>,2731,O
or,2731,O
=,2731,O
5,2731,O
%,2731,O
in,2731,O
one,2731,O
group,2731,O
),2731,O
after,2731,O
rizatriptan,2731,B-Chemical
and,2731,O
ergotamine/caffeine,2731,B-Chemical
",",2731,O
respectively,2731,O
",",2731,O
were,2731,O
dizziness,2731,B-Disease
(,2731,O
6.7,2731,O
and,2731,O
5.3,2731,O
%,2731,O
),2731,O
",",2731,O
nausea,2731,B-Disease
(,2731,O
4.2,2731,O
and,2731,O
8.5,2731,O
%,2731,O
),2731,O
and,2731,O
somnolence,2731,B-Disease
(,2731,O
5.5,2731,O
and,2731,O
2.3,2731,O
%,2731,O
),2731,O
.,2731,O
Severe,2732,O
ocular,2732,O
and,2732,O
orbital,2732,O
toxicity,2732,O
after,2732,O
intracarotid,2732,O
injection,2732,O
of,2732,O
carboplatin,2732,B-Chemical
for,2732,O
recurrent,2732,O
glioblastomas,2732,B-Disease
.,2732,O
BACKGROUND,2733,O
:,2733,O
Glioblastoma,2733,B-Disease
is,2733,O
a,2733,O
malignant,2733,B-Disease
tumor,2733,I-Disease
that,2733,O
occurs,2733,O
in,2733,O
the,2733,O
cerebrum,2733,O
during,2733,O
adulthood,2733,O
.,2733,O
With,2734,O
current,2734,O
treatment,2734,O
regimens,2734,O
including,2734,O
combined,2734,O
surgery,2734,O
",",2734,O
radiation,2734,O
and,2734,O
chemotherapy,2734,O
",",2734,O
the,2734,O
average,2734,O
life,2734,O
expectancy,2734,O
of,2734,O
the,2734,O
patients,2734,O
is,2734,O
limited,2734,O
to,2734,O
approximately,2734,O
1,2734,O
year,2734,O
.,2734,O
Therefore,2735,O
",",2735,O
patients,2735,O
with,2735,O
glioblastoma,2735,B-Disease
sometimes,2735,O
have,2735,O
intracarotid,2735,O
injection,2735,O
of,2735,O
carcinostatics,2735,O
added,2735,O
to,2735,O
the,2735,O
treatment,2735,O
regimen,2735,O
.,2735,O
Generally,2736,O
",",2736,O
carboplatin,2736,B-Chemical
is,2736,O
said,2736,O
to,2736,O
have,2736,O
milder,2736,O
side,2736,O
effects,2736,O
than,2736,O
cisplatin,2736,B-Chemical
",",2736,O
whose,2736,O
ocular,2736,O
and,2736,O
orbital,2736,O
toxicity,2736,O
are,2736,O
well,2736,O
known,2736,O
.,2736,O
However,2737,O
",",2737,O
we,2737,O
experienced,2737,O
a,2737,O
case,2737,O
of,2737,O
severe,2737,O
ocular,2737,O
and,2737,O
orbital,2737,O
toxicity,2737,O
after,2737,O
intracarotid,2737,O
injection,2737,O
of,2737,O
carboplatin,2737,B-Chemical
",",2737,O
which,2737,O
is,2737,O
infrequently,2737,O
reported,2737,O
.,2737,O
CASE,2738,O
:,2738,O
A,2738,O
58-year-old,2738,O
man,2738,O
received,2738,O
an,2738,O
intracarotid,2738,O
injection,2738,O
of,2738,O
carboplatin,2738,B-Chemical
for,2738,O
recurrent,2738,O
glioblastomas,2738,B-Disease
in,2738,O
his,2738,O
left,2738,O
temporal,2738,O
lobe,2738,O
.,2738,O
He,2739,O
complained,2739,O
of,2739,O
pain,2739,O
and,2739,O
visual,2739,O
disturbance,2739,O
in,2739,O
the,2739,O
ipsilateral,2739,O
eye,2739,O
30,2739,O
h,2739,O
after,2739,O
the,2739,O
injection,2739,O
.,2739,O
Various,2740,O
ocular,2740,O
symptoms,2740,O
and,2740,O
findings,2740,O
caused,2740,O
by,2740,O
carboplatin,2740,B-Chemical
toxicity,2740,B-Disease
were,2740,O
seen,2740,O
.,2740,O
RESULTS,2741,O
:,2741,O
He,2741,O
was,2741,O
treated,2741,O
with,2741,O
intravenous,2741,O
administration,2741,O
of,2741,O
corticosteroids,2741,O
and,2741,O
glycerin,2741,B-Chemical
for,2741,O
6,2741,O
days,2741,O
after,2741,O
the,2741,O
injection,2741,O
.,2741,O
Although,2742,O
the,2742,O
intraocular,2742,O
pressure,2742,O
elevation,2742,O
caused,2742,O
by,2742,O
secondary,2742,O
acute,2742,O
angle-closure,2742,O
glaucoma,2742,B-Disease
decreased,2742,O
and,2742,O
ocular,2742,B-Disease
pain,2742,I-Disease
diminished,2742,O
",",2742,O
inexorable,2742,O
papilledema,2742,B-Disease
and,2742,O
exudative,2742,O
retinal,2742,B-Disease
detachment,2742,I-Disease
continued,2742,O
for,2742,O
3,2742,O
weeks,2742,O
.,2742,O
Finally,2743,O
",",2743,O
6,2743,O
weeks,2743,O
later,2743,O
",",2743,O
diffuse,2743,O
chorioretinal,2743,B-Disease
atrophy,2743,I-Disease
with,2743,O
optic,2743,B-Disease
atrophy,2743,I-Disease
occurred,2743,O
and,2743,O
the,2743,O
vision,2743,O
in,2743,O
his,2743,O
left,2743,O
eye,2743,O
was,2743,O
lost,2743,O
.,2743,O
CONCLUSION,2744,O
:,2744,O
When,2744,O
performing,2744,O
intracarotid,2744,O
injection,2744,O
of,2744,O
carboplatin,2744,B-Chemical
",",2744,O
we,2744,O
must,2744,O
be,2744,O
aware,2744,O
of,2744,O
its,2744,O
potentially,2744,O
blinding,2744,O
ocular,2744,B-Disease
toxicity,2744,I-Disease
.,2744,O
It,2745,O
is,2745,O
recommended,2745,O
that,2745,O
further,2745,O
studies,2745,O
and,2745,O
investigations,2745,O
are,2745,O
undertaken,2745,O
in,2745,O
the,2745,O
effort,2745,O
to,2745,O
minimize,2745,O
such,2745,O
severe,2745,O
side,2745,O
effects,2745,O
.,2745,O
Visual,2746,B-Disease
hallucinations,2746,I-Disease
associated,2746,O
with,2746,O
zonisamide,2746,B-Chemical
.,2746,O
Zonisamide,2747,B-Chemical
is,2747,O
a,2747,O
broad-spectrum,2747,O
antiepileptic,2747,O
drug,2747,O
used,2747,O
to,2747,O
treat,2747,O
various,2747,O
types,2747,O
of,2747,O
seizures,2747,B-Disease
.,2747,O
Although,2748,O
visual,2748,B-Disease
hallucinations,2748,I-Disease
have,2748,O
not,2748,O
been,2748,O
reported,2748,O
as,2748,O
an,2748,O
adverse,2748,O
effect,2748,O
of,2748,O
this,2748,O
agent,2748,O
",",2748,O
we,2748,O
describe,2748,O
three,2748,O
patients,2748,O
who,2748,O
experienced,2748,O
complex,2748,O
visual,2748,B-Disease
hallucinations,2748,I-Disease
and,2748,O
altered,2748,O
mental,2748,O
status,2748,O
after,2748,O
zonisamide,2748,B-Chemical
treatment,2748,O
was,2748,O
begun,2748,O
or,2748,O
its,2748,O
dosage,2748,O
increased,2748,O
.,2748,O
All,2749,O
three,2749,O
had,2749,O
been,2749,O
diagnosed,2749,O
earlier,2749,O
with,2749,O
epilepsy,2749,B-Disease
",",2749,O
and,2749,O
their,2749,O
electroencephalogram,2749,O
(,2749,O
EEG,2749,O
),2749,O
findings,2749,O
were,2749,O
abnormal,2749,O
.,2749,O
During,2750,O
monitoring,2750,O
",",2750,O
visual,2750,B-Disease
hallucinations,2750,I-Disease
did,2750,O
not,2750,O
correlate,2750,O
with,2750,O
EEG,2750,O
readings,2750,O
",",2750,O
nor,2750,O
did,2750,O
video,2750,O
recording,2750,O
capture,2750,O
any,2750,O
of,2750,O
the,2750,O
described,2750,O
events,2750,O
.,2750,O
None,2751,O
of,2751,O
the,2751,O
patients,2751,O
had,2751,O
experienced,2751,O
visual,2751,B-Disease
hallucinations,2751,I-Disease
before,2751,O
this,2751,O
event,2751,O
.,2751,O
The,2752,O
only,2752,O
recent,2752,O
change,2752,O
in,2752,O
their,2752,O
treatment,2752,O
was,2752,O
the,2752,O
introduction,2752,O
or,2752,O
increased,2752,O
dosage,2752,O
of,2752,O
zonisamide,2752,B-Chemical
.,2752,O
With,2753,O
either,2753,O
discontinuation,2753,O
or,2753,O
decreased,2753,O
dosage,2753,O
of,2753,O
the,2753,O
drug,2753,O
the,2753,O
symptoms,2753,O
disappeared,2753,O
and,2753,O
did,2753,O
not,2753,O
recur,2753,O
.,2753,O
Further,2754,O
observations,2754,O
and,2754,O
reports,2754,O
will,2754,O
help,2754,O
clarify,2754,O
this,2754,O
adverse,2754,O
effect,2754,O
.,2754,O
Until,2755,O
then,2755,O
",",2755,O
clinicians,2755,O
need,2755,O
to,2755,O
be,2755,O
aware,2755,O
of,2755,O
this,2755,O
possible,2755,O
complication,2755,O
associated,2755,O
with,2755,O
zonisamide,2755,B-Chemical
.,2755,O
Anti-epileptic,2756,O
drugs-induced,2756,O
de,2756,O
novo,2756,O
absence,2756,B-Disease
seizures,2756,I-Disease
.,2756,O
The,2757,O
authors,2757,O
present,2757,O
three,2757,O
patients,2757,O
with,2757,O
de,2757,O
novo,2757,O
absence,2757,B-Disease
epilepsy,2757,I-Disease
after,2757,O
administration,2757,O
of,2757,O
carbamazepine,2757,B-Chemical
and,2757,O
vigabatrin,2757,B-Chemical
.,2757,O
Despite,2758,O
the,2758,O
underlying,2758,O
diseases,2758,O
",",2758,O
the,2758,O
prognosis,2758,O
for,2758,O
drug-induced,2758,O
de,2758,O
novo,2758,O
absence,2758,B-Disease
seizure,2758,I-Disease
is,2758,O
good,2758,O
because,2758,O
it,2758,O
subsides,2758,O
rapidly,2758,O
after,2758,O
discontinuing,2758,O
the,2758,O
use,2758,O
of,2758,O
the,2758,O
offending,2758,O
drugs,2758,O
.,2758,O
The,2759,O
gamma-aminobutyric,2759,B-Chemical
acid-transmitted,2759,O
thalamocortical,2759,O
circuitry,2759,O
accounts,2759,O
for,2759,O
a,2759,O
major,2759,O
part,2759,O
of,2759,O
the,2759,O
underlying,2759,O
neurophysiology,2759,O
of,2759,O
the,2759,O
absence,2759,B-Disease
epilepsy,2759,I-Disease
.,2759,O
Because,2760,O
drug-induced,2760,O
de,2760,O
novo,2760,O
absence,2760,B-Disease
seizure,2760,I-Disease
is,2760,O
rare,2760,O
",",2760,O
pro-absence,2760,O
drugs,2760,O
can,2760,O
only,2760,O
be,2760,O
considered,2760,O
a,2760,O
promoting,2760,O
factor,2760,O
.,2760,O
The,2761,O
underlying,2761,O
epileptogenecity,2761,O
of,2761,O
the,2761,O
patients,2761,O
or,2761,O
the,2761,O
synergistic,2761,O
effects,2761,O
of,2761,O
the,2761,O
accompanying,2761,O
drugs,2761,O
is,2761,O
required,2761,O
to,2761,O
trigger,2761,O
the,2761,O
de,2761,O
novo,2761,O
absence,2761,B-Disease
seizure,2761,I-Disease
.,2761,O
The,2762,O
possibility,2762,O
of,2762,O
drug-induced,2762,O
aggravation,2762,O
should,2762,O
be,2762,O
considered,2762,O
whenever,2762,O
an,2762,O
unexpected,2762,O
increase,2762,O
in,2762,O
seizure,2762,B-Disease
frequency,2762,O
and/or,2762,O
new,2762,O
seizure,2762,B-Disease
types,2762,O
appear,2762,O
following,2762,O
a,2762,O
change,2762,O
in,2762,O
drug,2762,O
treatment,2762,O
.,2762,O
By,2763,O
understanding,2763,O
the,2763,O
underlying,2763,O
mechanism,2763,O
of,2763,O
absence,2763,B-Disease
epilepsy,2763,I-Disease
",",2763,O
we,2763,O
can,2763,O
avoid,2763,O
the,2763,O
inappropriate,2763,O
use,2763,O
of,2763,O
anticonvulsants,2763,O
in,2763,O
children,2763,O
with,2763,O
epilepsy,2763,B-Disease
and,2763,O
prevent,2763,O
drug-induced,2763,O
absence,2763,B-Disease
seizures,2763,I-Disease
.,2763,O
Prenatal,2764,O
dexamethasone,2764,B-Chemical
programs,2764,O
hypertension,2764,B-Disease
and,2764,O
renal,2764,B-Disease
injury,2764,I-Disease
in,2764,O
the,2764,O
rat,2764,O
.,2764,O
Dexamethasone,2765,O
is,2765,O
frequently,2765,O
administered,2765,O
to,2765,O
the,2765,O
developing,2765,O
fetus,2765,O
to,2765,O
accelerate,2765,O
pulmonary,2765,O
development,2765,O
.,2765,O
The,2766,O
purpose,2766,O
of,2766,O
the,2766,O
present,2766,O
study,2766,O
was,2766,O
to,2766,O
determine,2766,O
if,2766,O
prenatal,2766,O
dexamethasone,2766,B-Chemical
programmed,2766,O
a,2766,O
progressive,2766,O
increase,2766,B-Disease
in,2766,I-Disease
blood,2766,I-Disease
pressure,2766,I-Disease
and,2766,O
renal,2766,B-Disease
injury,2766,I-Disease
in,2766,O
rats,2766,O
.,2766,O
Pregnant,2767,O
rats,2767,O
were,2767,O
given,2767,O
either,2767,O
vehicle,2767,O
or,2767,O
2,2767,O
daily,2767,O
intraperitoneal,2767,O
injections,2767,O
of,2767,O
dexamethasone,2767,B-Chemical
(,2767,O
0.2,2767,O
mg/kg,2767,O
body,2767,O
weight,2767,O
),2767,O
on,2767,O
gestational,2767,O
days,2767,O
11,2767,O
and,2767,O
12,2767,O
",",2767,O
13,2767,O
and,2767,O
14,2767,O
",",2767,O
15,2767,O
and,2767,O
16,2767,O
",",2767,O
17,2767,O
and,2767,O
18,2767,O
",",2767,O
or,2767,O
19,2767,O
and,2767,O
20,2767,O
.,2767,O
Offspring,2768,O
of,2768,O
rats,2768,O
administered,2768,O
dexamethasone,2768,B-Chemical
on,2768,O
days,2768,O
15,2768,O
and,2768,O
16,2768,O
gestation,2768,O
had,2768,O
a,2768,O
20,2768,O
%,2768,O
reduction,2768,B-Disease
in,2768,I-Disease
glomerular,2768,I-Disease
number,2768,I-Disease
compared,2768,O
with,2768,O
control,2768,O
at,2768,O
6,2768,O
to,2768,O
9,2768,O
months,2768,O
of,2768,O
age,2768,O
(,2768,O
22,2768,O
527+/-509,2768,O
versus,2768,O
28,2768,O
050+/-561,2768,O
",",2768,O
P,2768,O
<,2768,O
0.05,2768,O
),2768,O
",",2768,O
which,2768,O
was,2768,O
comparable,2768,O
to,2768,O
the,2768,O
percent,2768,O
reduction,2768,O
in,2768,O
glomeruli,2768,O
measured,2768,O
at,2768,O
3,2768,O
weeks,2768,O
of,2768,O
age,2768,O
.,2768,O
Six-,2769,O
to,2769,O
9-month,2769,O
old,2769,O
rats,2769,O
receiving,2769,O
prenatal,2769,O
dexamethasone,2769,B-Chemical
on,2769,O
days,2769,O
17,2769,O
and,2769,O
18,2769,O
of,2769,O
gestation,2769,O
had,2769,O
a,2769,O
17,2769,O
%,2769,O
reduction,2769,O
in,2769,O
glomeruli,2769,O
(,2769,O
23,2769,O
380+/-587,2769,O
),2769,O
compared,2769,O
with,2769,O
control,2769,O
rats,2769,O
(,2769,O
P,2769,O
<,2769,O
0.05,2769,O
),2769,O
.,2769,O
Male,2770,O
rats,2770,O
that,2770,O
received,2770,O
prenatal,2770,O
dexamethasone,2770,B-Chemical
on,2770,O
days,2770,O
15,2770,O
and,2770,O
16,2770,O
",",2770,O
17,2770,O
and,2770,O
18,2770,O
",",2770,O
and,2770,O
13,2770,O
and,2770,O
14,2770,O
of,2770,O
gestation,2770,O
had,2770,O
elevated,2770,B-Disease
blood,2770,I-Disease
pressures,2770,I-Disease
at,2770,O
6,2770,O
months,2770,O
of,2770,O
age,2770,O
;,2770,O
the,2770,O
latter,2770,O
group,2770,O
did,2770,O
not,2770,O
have,2770,O
a,2770,O
reduction,2770,B-Disease
in,2770,I-Disease
glomerular,2770,I-Disease
number,2770,I-Disease
.,2770,O
Adult,2771,O
rats,2771,O
given,2771,O
dexamethasone,2771,B-Chemical
on,2771,O
days,2771,O
15,2771,O
and,2771,O
16,2771,O
of,2771,O
gestation,2771,O
had,2771,O
more,2771,O
glomeruli,2771,O
with,2771,O
glomerulosclerosis,2771,B-Disease
than,2771,O
control,2771,O
rats,2771,O
.,2771,O
This,2772,O
study,2772,O
shows,2772,O
that,2772,O
prenatal,2772,O
dexamethasone,2772,B-Chemical
in,2772,O
rats,2772,O
results,2772,O
in,2772,O
a,2772,O
reduction,2772,B-Disease
in,2772,I-Disease
glomerular,2772,I-Disease
number,2772,I-Disease
",",2772,O
glomerulosclerosis,2772,B-Disease
",",2772,O
and,2772,O
hypertension,2772,B-Disease
when,2772,O
administered,2772,O
at,2772,O
specific,2772,O
points,2772,O
during,2772,O
gestation,2772,O
.,2772,O
Hypertension,2773,B-Disease
was,2773,O
observed,2773,O
in,2773,O
animals,2773,O
that,2773,O
had,2773,O
a,2773,O
reduction,2773,O
in,2773,O
glomeruli,2773,O
as,2773,O
well,2773,O
as,2773,O
in,2773,O
a,2773,O
group,2773,O
that,2773,O
did,2773,O
not,2773,O
have,2773,O
a,2773,O
reduction,2773,B-Disease
in,2773,I-Disease
glomerular,2773,I-Disease
number,2773,I-Disease
",",2773,O
suggesting,2773,O
that,2773,O
a,2773,O
reduction,2773,B-Disease
in,2773,I-Disease
glomerular,2773,I-Disease
number,2773,I-Disease
is,2773,O
not,2773,O
the,2773,O
sole,2773,O
cause,2773,O
for,2773,O
the,2773,O
development,2773,O
of,2773,O
hypertension,2773,B-Disease
.,2773,O
Kidney,2774,O
function,2774,O
and,2774,O
morphology,2774,O
after,2774,O
short-term,2774,O
combination,2774,O
therapy,2774,O
with,2774,O
cyclosporine,2774,B-Chemical
A,2774,I-Chemical
",",2774,O
tacrolimus,2774,B-Chemical
and,2774,O
sirolimus,2774,B-Chemical
in,2774,O
the,2774,O
rat,2774,O
.,2774,O
BACKGROUND,2775,O
:,2775,O
Sirolimus,2775,B-Chemical
(,2775,O
SRL,2775,B-Chemical
),2775,O
may,2775,O
supplement,2775,O
calcineurin,2775,O
inhibitors,2775,O
in,2775,O
clinical,2775,O
organ,2775,O
transplantation,2775,O
.,2775,O
These,2776,O
are,2776,O
nephrotoxic,2776,B-Disease
",",2776,O
but,2776,O
SRL,2776,B-Chemical
seems,2776,O
to,2776,O
act,2776,O
differently,2776,O
displaying,2776,O
only,2776,O
minor,2776,O
nephrotoxic,2776,B-Disease
effects,2776,O
",",2776,O
although,2776,O
this,2776,O
question,2776,O
is,2776,O
still,2776,O
open,2776,O
.,2776,O
In,2777,O
a,2777,O
number,2777,O
of,2777,O
treatment,2777,O
protocols,2777,O
where,2777,O
SRL,2777,B-Chemical
was,2777,O
combined,2777,O
with,2777,O
a,2777,O
calcineurin,2777,O
inhibitor,2777,O
indications,2777,O
of,2777,O
a,2777,O
synergistic,2777,O
nephrotoxic,2777,B-Disease
effect,2777,O
were,2777,O
described,2777,O
.,2777,O
The,2778,O
aim,2778,O
of,2778,O
this,2778,O
study,2778,O
was,2778,O
to,2778,O
examine,2778,O
further,2778,O
the,2778,O
renal,2778,O
function,2778,O
",",2778,O
including,2778,O
morphological,2778,O
analysis,2778,O
of,2778,O
the,2778,O
kidneys,2778,O
of,2778,O
male,2778,O
Sprague-Dawley,2778,O
rats,2778,O
treated,2778,O
with,2778,O
either,2778,O
cyclosporine,2778,B-Chemical
A,2778,I-Chemical
(,2778,O
CsA,2778,B-Chemical
),2778,O
",",2778,O
tacrolimus,2778,B-Chemical
(,2778,O
FK506,2778,B-Chemical
),2778,O
or,2778,O
SRL,2778,B-Chemical
as,2778,O
monotherapies,2778,O
or,2778,O
in,2778,O
different,2778,O
combinations,2778,O
.,2778,O
METHODS,2779,O
:,2779,O
For,2779,O
a,2779,O
period,2779,O
of,2779,O
2,2779,O
weeks,2779,O
",",2779,O
CsA,2779,B-Chemical
15,2779,O
mg/kg/day,2779,O
(,2779,O
given,2779,O
orally,2779,O
),2779,O
",",2779,O
FK506,2779,B-Chemical
3.0,2779,O
mg/kg/day,2779,O
(,2779,O
given,2779,O
orally,2779,O
),2779,O
or,2779,O
SRL,2779,B-Chemical
0.4,2779,O
mg/kg/day,2779,O
(,2779,O
given,2779,O
intraperitoneally,2779,O
),2779,O
was,2779,O
administered,2779,O
once,2779,O
a,2779,O
day,2779,O
as,2779,O
these,2779,O
doses,2779,O
have,2779,O
earlier,2779,O
been,2779,O
found,2779,O
to,2779,O
achieve,2779,O
a,2779,O
significant,2779,O
immunosuppressive,2779,O
effect,2779,O
in,2779,O
Sprague-Dawley,2779,O
rats,2779,O
.,2779,O
In,2780,O
the,2780,O
'conscious,2780,O
catheterized,2780,O
rat,2780,O
',2780,O
model,2780,O
",",2780,O
the,2780,O
glomerular,2780,O
filtration,2780,O
rate,2780,O
(,2780,O
GFR,2780,O
),2780,O
was,2780,O
measured,2780,O
as,2780,O
the,2780,O
clearance,2780,O
of,2780,O
Cr,2780,O
(,2780,O
EDTA,2780,O
),2780,O
.,2780,O
The,2781,O
morphological,2781,O
analysis,2781,O
of,2781,O
the,2781,O
kidneys,2781,O
included,2781,O
a,2781,O
semi-quantitative,2781,O
scoring,2781,O
system,2781,O
analysing,2781,O
the,2781,O
degree,2781,O
of,2781,O
striped,2781,O
fibrosis,2781,B-Disease
",",2781,O
subcapsular,2781,O
fibrosis,2781,B-Disease
and,2781,O
the,2781,O
number,2781,O
of,2781,O
basophilic,2781,O
tubules,2781,O
",",2781,O
plus,2781,O
an,2781,O
additional,2781,O
stereological,2781,O
analysis,2781,O
of,2781,O
the,2781,O
total,2781,O
grade,2781,O
of,2781,O
fibrosis,2781,B-Disease
in,2781,O
the,2781,O
cortex,2781,O
stained,2781,O
with,2781,O
Sirius,2781,O
Red,2781,O
.,2781,O
RESULTS,2782,O
:,2782,O
CsA,2782,B-Chemical
",",2782,O
FK506,2782,B-Chemical
and,2782,O
SRL,2782,B-Chemical
all,2782,O
significantly,2782,O
decreased,2782,O
the,2782,O
GFR,2782,O
.,2782,O
A,2783,O
further,2783,O
deterioration,2783,O
was,2783,O
seen,2783,O
when,2783,O
CsA,2783,B-Chemical
was,2783,O
combined,2783,O
with,2783,O
either,2783,O
FK506,2783,B-Chemical
or,2783,O
SRL,2783,B-Chemical
",",2783,O
whereas,2783,O
the,2783,O
GFR,2783,O
remained,2783,O
unchanged,2783,O
in,2783,O
the,2783,O
group,2783,O
treated,2783,O
with,2783,O
FK506,2783,B-Chemical
plus,2783,O
SRL,2783,B-Chemical
when,2783,O
compared,2783,O
with,2783,O
treatment,2783,O
with,2783,O
any,2783,O
of,2783,O
the,2783,O
single,2783,O
substances,2783,O
.,2783,O
The,2784,O
morphological,2784,O
changes,2784,O
presented,2784,O
a,2784,O
similar,2784,O
pattern,2784,O
.,2784,O
The,2785,O
semi-quantitative,2785,O
scoring,2785,O
was,2785,O
significantly,2785,O
worst,2785,O
in,2785,O
the,2785,O
group,2785,O
treated,2785,O
with,2785,O
CsA,2785,B-Chemical
plus,2785,O
SRL,2785,B-Chemical
(,2785,O
P,2785,O
<,2785,O
0.001,2785,O
compared,2785,O
with,2785,O
controls,2785,O
),2785,O
and,2785,O
the,2785,O
analysis,2785,O
of,2785,O
the,2785,O
total,2785,O
grade,2785,O
of,2785,O
fibrosis,2785,B-Disease
also,2785,O
showed,2785,O
the,2785,O
highest,2785,O
proportion,2785,O
in,2785,O
the,2785,O
same,2785,O
group,2785,O
and,2785,O
was,2785,O
significantly,2785,O
different,2785,O
from,2785,O
controls,2785,O
(,2785,O
P,2785,O
<,2785,O
0.02,2785,O
),2785,O
.,2785,O
The,2786,O
FK506,2786,B-Chemical
plus,2786,O
SRL,2786,B-Chemical
combination,2786,O
showed,2786,O
only,2786,O
a,2786,O
marginally,2786,O
higher,2786,O
degree,2786,O
of,2786,O
fibrosis,2786,B-Disease
as,2786,O
compared,2786,O
with,2786,O
controls,2786,O
(,2786,O
P=0.05,2786,O
),2786,O
.,2786,O
CONCLUSION,2787,O
:,2787,O
This,2787,O
rat,2787,O
study,2787,O
demonstrated,2787,O
a,2787,O
synergistic,2787,O
nephrotoxic,2787,B-Disease
effect,2787,O
of,2787,O
CsA,2787,B-Chemical
plus,2787,O
SRL,2787,B-Chemical
",",2787,O
whereas,2787,O
FK506,2787,B-Chemical
plus,2787,O
SRL,2787,B-Chemical
was,2787,O
better,2787,O
tolerated,2787,O
.,2787,O
Evaluation,2788,O
of,2788,O
cardiac,2788,O
troponin,2788,O
I,2788,O
and,2788,O
T,2788,O
levels,2788,O
as,2788,O
markers,2788,O
of,2788,O
myocardial,2788,B-Disease
damage,2788,I-Disease
in,2788,O
doxorubicin-induced,2788,B-Chemical
cardiomyopathy,2788,B-Disease
rats,2788,O
",",2788,O
and,2788,O
their,2788,O
relationship,2788,O
with,2788,O
echocardiographic,2788,O
and,2788,O
histological,2788,O
findings,2788,O
.,2788,O
BACKGROUND,2789,O
:,2789,O
Cardiac,2789,O
troponins,2789,O
I,2789,O
(,2789,O
cTnI,2789,O
),2789,O
and,2789,O
T,2789,O
(,2789,O
cTnT,2789,O
),2789,O
have,2789,O
been,2789,O
shown,2789,O
to,2789,O
be,2789,O
highly,2789,O
sensitive,2789,O
and,2789,O
specific,2789,O
markers,2789,O
of,2789,O
myocardial,2789,B-Disease
cell,2789,I-Disease
injury,2789,I-Disease
.,2789,O
We,2790,O
investigated,2790,O
the,2790,O
diagnostic,2790,O
value,2790,O
of,2790,O
cTnI,2790,O
and,2790,O
cTnT,2790,O
for,2790,O
the,2790,O
diagnosis,2790,O
of,2790,O
myocardial,2790,B-Disease
damage,2790,I-Disease
in,2790,O
a,2790,O
rat,2790,O
model,2790,O
of,2790,O
doxorubicin,2790,B-Chemical
(,2790,O
DOX,2790,B-Chemical
),2790,O
-induced,2790,O
cardiomyopathy,2790,B-Disease
",",2790,O
and,2790,O
we,2790,O
examined,2790,O
the,2790,O
relationship,2790,O
between,2790,O
serial,2790,O
cTnI,2790,O
and,2790,O
cTnT,2790,O
with,2790,O
the,2790,O
development,2790,O
of,2790,O
cardiac,2790,B-Disease
disorders,2790,I-Disease
monitored,2790,O
by,2790,O
echocardiography,2790,O
and,2790,O
histological,2790,O
examinations,2790,O
in,2790,O
this,2790,O
model,2790,O
.,2790,O
METHODS,2791,O
:,2791,O
Thirty-five,2791,O
Wistar,2791,O
rats,2791,O
were,2791,O
given,2791,O
1.5,2791,O
mg/kg,2791,O
DOX,2791,B-Chemical
",",2791,O
i.v.,2791,O
",",2791,O
weekly,2791,O
for,2791,O
up,2791,O
to,2791,O
8,2791,O
weeks,2791,O
for,2791,O
a,2791,O
total,2791,O
cumulative,2791,O
dose,2791,O
of,2791,O
12,2791,O
mg/kg,2791,O
BW,2791,O
.,2791,O
Ten,2792,O
rats,2792,O
received,2792,O
saline,2792,O
as,2792,O
a,2792,O
control,2792,O
group,2792,O
.,2792,O
cTnI,2793,O
was,2793,O
measured,2793,O
with,2793,O
Access,2793,O
(,2793,O
R,2793,O
),2793,O
(,2793,O
ng/ml,2793,O
),2793,O
and,2793,O
a,2793,O
research,2793,O
immunoassay,2793,O
(,2793,O
pg/ml,2793,O
),2793,O
",",2793,O
and,2793,O
compared,2793,O
with,2793,O
cTnT,2793,O
",",2793,O
CK-MB,2793,O
mass,2793,O
and,2793,O
CK,2793,O
.,2793,O
By,2794,O
using,2794,O
transthoracic,2794,O
echocardiography,2794,O
",",2794,O
anterior,2794,O
and,2794,O
posterior,2794,O
wall,2794,O
thickness,2794,O
",",2794,O
LV,2794,O
diameters,2794,O
and,2794,O
LV,2794,O
fractional,2794,O
shortening,2794,O
(,2794,O
FS,2794,O
),2794,O
were,2794,O
measured,2794,O
in,2794,O
all,2794,O
rats,2794,O
before,2794,O
DOX,2794,B-Chemical
or,2794,O
saline,2794,O
",",2794,O
and,2794,O
at,2794,O
weeks,2794,O
6,2794,O
and,2794,O
9,2794,O
after,2794,O
treatment,2794,O
in,2794,O
all,2794,O
surviving,2794,O
rats,2794,O
.,2794,O
Histology,2795,O
was,2795,O
performed,2795,O
in,2795,O
DOX-rats,2795,B-Chemical
at,2795,O
6,2795,O
and,2795,O
9,2795,O
weeks,2795,O
after,2795,O
the,2795,O
last,2795,O
DOX,2795,B-Chemical
dose,2795,O
and,2795,O
in,2795,O
all,2795,O
controls,2795,O
.,2795,O
RESULTS,2796,O
:,2796,O
Eighteen,2796,O
of,2796,O
the,2796,O
DOX,2796,B-Chemical
rats,2796,O
died,2796,O
prematurely,2796,O
of,2796,O
general,2796,O
toxicity,2796,B-Disease
during,2796,O
the,2796,O
9-week,2796,O
period,2796,O
.,2796,O
End-diastolic,2797,O
(,2797,O
ED,2797,O
),2797,O
and,2797,O
end-systolic,2797,O
(,2797,O
ES,2797,O
),2797,O
LV,2797,O
diameters/BW,2797,O
significantly,2797,O
increased,2797,O
",",2797,O
whereas,2797,O
LV,2797,O
FS,2797,O
was,2797,O
decreased,2797,O
after,2797,O
9,2797,O
weeks,2797,O
in,2797,O
the,2797,O
DOX,2797,B-Chemical
group,2797,O
(,2797,O
p,2797,O
<,2797,O
0.001,2797,O
),2797,O
.,2797,O
These,2798,O
parameters,2798,O
remained,2798,O
unchanged,2798,O
in,2798,O
controls,2798,O
.,2798,O
Histological,2799,O
evaluation,2799,O
of,2799,O
hearts,2799,O
from,2799,O
all,2799,O
rats,2799,O
given,2799,O
DOX,2799,B-Chemical
revealed,2799,O
significant,2799,O
slight,2799,O
degrees,2799,O
of,2799,O
perivascular,2799,O
and,2799,O
interstitial,2799,O
fibrosis,2799,B-Disease
.,2799,O
In,2800,O
7,2800,O
of,2800,O
the,2800,O
18,2800,O
rats,2800,O
",",2800,O
degeneration,2800,O
and,2800,O
myocyte,2800,O
vacuolisation,2800,O
were,2800,O
found,2800,O
.,2800,O
Only,2801,O
five,2801,O
of,2801,O
the,2801,O
controls,2801,O
exhibited,2801,O
evidence,2801,O
of,2801,O
very,2801,O
slight,2801,O
perivascular,2801,O
fibrosis,2801,B-Disease
.,2801,O
A,2802,O
significant,2802,O
rise,2802,O
in,2802,O
cTnT,2802,O
was,2802,O
found,2802,O
in,2802,O
DOX,2802,B-Chemical
rats,2802,O
after,2802,O
cumulative,2802,O
doses,2802,O
of,2802,O
7.5,2802,O
and,2802,O
12,2802,O
mg/kg,2802,O
in,2802,O
comparison,2802,O
with,2802,O
baseline,2802,O
(,2802,O
p,2802,O
<,2802,O
0.05,2802,O
),2802,O
.,2802,O
cTnT,2803,O
found,2803,O
in,2803,O
rats,2803,O
after,2803,O
12,2803,O
mg/kg,2803,O
were,2803,O
significantly,2803,O
greater,2803,O
than,2803,O
that,2803,O
found,2803,O
after,2803,O
7.5,2803,O
mg/kg,2803,O
DOX,2803,B-Chemical
.,2803,O
Maximal,2804,O
cTnI,2804,O
(,2804,O
pg/ml,2804,O
),2804,O
and,2804,O
cTnT,2804,O
levels,2804,O
were,2804,O
significantly,2804,O
increased,2804,O
in,2804,O
DOX,2804,B-Chemical
rats,2804,O
compared,2804,O
with,2804,O
controls,2804,O
(,2804,O
p=0.006,2804,O
",",2804,O
0.007,2804,O
),2804,O
.,2804,O
cTnI,2805,O
(,2805,O
ng/ml,2805,O
),2805,O
",",2805,O
CK-MB,2805,O
mass,2805,O
and,2805,O
CK,2805,O
remained,2805,O
unchanged,2805,O
in,2805,O
DOX,2805,B-Chemical
rats,2805,O
compared,2805,O
with,2805,O
controls,2805,O
.,2805,O
All,2806,O
markers,2806,O
remained,2806,O
stable,2806,O
in,2806,O
controls,2806,O
.,2806,O
Analysis,2807,O
of,2807,O
data,2807,O
revealed,2807,O
a,2807,O
significant,2807,O
correlation,2807,O
between,2807,O
maximal,2807,O
cTnT,2807,O
and,2807,O
ED,2807,O
and,2807,O
ES,2807,O
LV,2807,O
diameters/BW,2807,O
(,2807,O
r=0.81,2807,O
and,2807,O
0.65,2807,O
;,2807,O
p,2807,O
<,2807,O
0.0001,2807,O
),2807,O
.,2807,O
A,2808,O
significant,2808,O
relationship,2808,O
was,2808,O
observed,2808,O
between,2808,O
maximal,2808,O
cTnT,2808,O
and,2808,O
the,2808,O
extent,2808,O
of,2808,O
myocardial,2808,O
morphological,2808,O
changes,2808,O
",",2808,O
and,2808,O
between,2808,O
LV,2808,O
diameters/BW,2808,O
and,2808,O
histological,2808,O
findings,2808,O
.,2808,O
CONCLUSIONS,2809,O
:,2809,O
Among,2809,O
markers,2809,O
of,2809,O
ischemic,2809,B-Disease
injury,2809,I-Disease
after,2809,O
DOX,2809,B-Chemical
in,2809,O
rats,2809,O
",",2809,O
cTnT,2809,O
showed,2809,O
the,2809,O
greatest,2809,O
ability,2809,O
to,2809,O
detect,2809,O
myocardial,2809,B-Disease
damage,2809,I-Disease
assessed,2809,O
by,2809,O
echocardiographic,2809,O
detection,2809,O
and,2809,O
histological,2809,O
changes,2809,O
.,2809,O
Although,2810,O
there,2810,O
was,2810,O
a,2810,O
discrepancy,2810,O
between,2810,O
the,2810,O
amount,2810,O
of,2810,O
cTnI,2810,O
and,2810,O
cTnT,2810,O
after,2810,O
DOX,2810,B-Chemical
",",2810,O
probably,2810,O
due,2810,O
to,2810,O
heterogeneity,2810,O
in,2810,O
cross-reactivities,2810,O
of,2810,O
mAbs,2810,O
to,2810,O
various,2810,O
cTnI,2810,O
and,2810,O
cTnT,2810,O
forms,2810,O
",",2810,O
it,2810,O
is,2810,O
likely,2810,O
that,2810,O
cTnT,2810,O
in,2810,O
rats,2810,O
after,2810,O
DOX,2810,B-Chemical
indicates,2810,O
cell,2810,O
damage,2810,O
determined,2810,O
by,2810,O
the,2810,O
magnitude,2810,O
of,2810,O
injury,2810,O
induced,2810,O
and,2810,O
that,2810,O
cTnT,2810,O
should,2810,O
be,2810,O
a,2810,O
useful,2810,O
marker,2810,O
for,2810,O
the,2810,O
prediction,2810,O
of,2810,O
experimentally,2810,O
induced,2810,O
cardiotoxicity,2810,B-Disease
and,2810,O
possibly,2810,O
for,2810,O
cardioprotective,2810,O
experiments,2810,O
.,2810,O
Octreotide-induced,2811,B-Chemical
hypoxemia,2811,B-Disease
and,2811,O
pulmonary,2811,B-Disease
hypertension,2811,I-Disease
in,2811,O
premature,2811,O
neonates,2811,O
.,2811,O
The,2812,O
authors,2812,O
report,2812,O
2,2812,O
cases,2812,O
of,2812,O
premature,2812,O
neonates,2812,O
who,2812,O
had,2812,O
enterocutaneous,2812,O
fistula,2812,B-Disease
complicating,2812,O
necrotizing,2812,B-Disease
enterocolitis,2812,I-Disease
.,2812,O
Pulmonary,2813,B-Disease
hypertension,2813,I-Disease
developed,2813,O
after,2813,O
administration,2813,O
of,2813,O
a,2813,O
somatostatin,2813,O
analogue,2813,O
",",2813,O
octreotide,2813,B-Chemical
",",2813,O
to,2813,O
enhance,2813,O
resolution,2813,O
of,2813,O
the,2813,O
fistula,2813,B-Disease
.,2813,O
The,2814,O
authors,2814,O
discuss,2814,O
the,2814,O
mechanism,2814,O
of,2814,O
the,2814,O
occurrence,2814,O
of,2814,O
this,2814,O
complication,2814,O
and,2814,O
recommend,2814,O
caution,2814,O
of,2814,O
its,2814,O
use,2814,O
in,2814,O
high-risk,2814,O
premature,2814,O
neonates,2814,O
.,2814,O
The,2815,O
risk,2815,O
of,2815,O
venous,2815,B-Disease
thromboembolism,2815,I-Disease
in,2815,O
women,2815,O
prescribed,2815,O
cyproterone,2815,B-Chemical
acetate,2815,I-Chemical
in,2815,O
combination,2815,O
with,2815,O
ethinyl,2815,B-Chemical
estradiol,2815,I-Chemical
:,2815,O
a,2815,O
nested,2815,O
cohort,2815,O
analysis,2815,O
and,2815,O
case-control,2815,O
study,2815,O
.,2815,O
BACKGROUND,2816,O
:,2816,O
Cyproterone,2816,B-Chemical
acetate,2816,I-Chemical
combined,2816,O
with,2816,O
ethinyl,2816,B-Chemical
estradiol,2816,I-Chemical
(,2816,O
CPA/EE,2816,B-Chemical
),2816,O
is,2816,O
licensed,2816,O
in,2816,O
the,2816,O
UK,2816,O
for,2816,O
the,2816,O
treatment,2816,O
of,2816,O
women,2816,O
with,2816,O
acne,2816,B-Disease
and,2816,O
hirsutism,2816,B-Disease
and,2816,O
is,2816,O
also,2816,O
a,2816,O
treatment,2816,O
option,2816,O
for,2816,O
polycystic,2816,B-Disease
ovary,2816,I-Disease
syndrome,2816,I-Disease
(,2816,O
PCOS,2816,B-Disease
),2816,O
.,2816,O
Previous,2817,O
studies,2817,O
have,2817,O
demonstrated,2817,O
an,2817,O
increased,2817,O
risk,2817,O
of,2817,O
venous,2817,B-Disease
thromboembolism,2817,I-Disease
(,2817,O
VTE,2817,B-Disease
),2817,O
associated,2817,O
with,2817,O
CPA/EE,2817,B-Chemical
compared,2817,O
with,2817,O
conventional,2817,O
combined,2817,O
oral,2817,B-Chemical
contraceptives,2817,I-Chemical
(,2817,O
COCs,2817,O
),2817,O
.,2817,O
We,2818,O
believe,2818,O
the,2818,O
results,2818,O
of,2818,O
those,2818,O
studies,2818,O
may,2818,O
have,2818,O
been,2818,O
affected,2818,O
by,2818,O
residual,2818,O
confounding,2818,O
.,2818,O
METHODS,2819,O
:,2819,O
Using,2819,O
the,2819,O
General,2819,O
Practice,2819,O
Research,2819,O
Database,2819,O
we,2819,O
conducted,2819,O
a,2819,O
cohort,2819,O
analysis,2819,O
and,2819,O
case-control,2819,O
study,2819,O
nested,2819,O
within,2819,O
a,2819,O
population,2819,O
of,2819,O
women,2819,O
aged,2819,O
between,2819,O
15,2819,O
and,2819,O
39,2819,O
years,2819,O
with,2819,O
acne,2819,B-Disease
",",2819,O
hirsutism,2819,B-Disease
or,2819,O
PCOS,2819,B-Disease
to,2819,O
estimate,2819,O
the,2819,O
risk,2819,O
of,2819,O
VTE,2819,B-Disease
associated,2819,O
with,2819,O
CPA/EE,2819,B-Chemical
.,2819,O
RESULTS,2820,O
:,2820,O
The,2820,O
age-adjusted,2820,O
incidence,2820,O
rate,2820,O
ratio,2820,O
for,2820,O
CPA/EE,2820,B-Chemical
versus,2820,O
conventional,2820,O
COCs,2820,O
was,2820,O
2.20,2820,O
[,2820,O
95,2820,O
%,2820,O
confidence,2820,O
interval,2820,O
(,2820,O
CI,2820,O
),2820,O
1.35-3.58,2820,O
],2820,O
.,2820,O
Using,2821,O
as,2821,O
the,2821,O
reference,2821,O
group,2821,O
women,2821,O
who,2821,O
were,2821,O
not,2821,O
using,2821,O
oral,2821,O
contraception,2821,O
",",2821,O
had,2821,O
no,2821,O
recent,2821,O
pregnancy,2821,O
or,2821,O
menopausal,2821,O
symptoms,2821,O
",",2821,O
the,2821,O
case-control,2821,O
analysis,2821,O
gave,2821,O
an,2821,O
adjusted,2821,O
odds,2821,O
ratio,2821,O
(,2821,O
OR,2821,O
(,2821,O
adj,2821,O
),2821,O
),2821,O
of,2821,O
7.44,2821,O
(,2821,O
95,2821,O
%,2821,O
CI,2821,O
3.67-15.08,2821,O
),2821,O
for,2821,O
CPA/EE,2821,B-Chemical
use,2821,O
compared,2821,O
with,2821,O
an,2821,O
OR,2821,O
(,2821,O
adj,2821,O
),2821,O
of,2821,O
2.58,2821,O
(,2821,O
95,2821,O
%,2821,O
CI,2821,O
1.60-4.18,2821,O
),2821,O
for,2821,O
use,2821,O
of,2821,O
conventional,2821,O
COCs,2821,O
.,2821,O
CONCLUSIONS,2822,O
:,2822,O
We,2822,O
have,2822,O
demonstrated,2822,O
an,2822,O
increased,2822,O
risk,2822,O
of,2822,O
VTE,2822,B-Disease
associated,2822,O
with,2822,O
the,2822,O
use,2822,O
of,2822,O
CPA/EE,2822,B-Chemical
in,2822,O
women,2822,O
with,2822,O
acne,2822,B-Disease
",",2822,O
hirsutism,2822,B-Disease
or,2822,O
PCOS,2822,B-Disease
although,2822,O
residual,2822,O
confounding,2822,O
by,2822,O
indication,2822,O
can,2822,O
not,2822,O
be,2822,O
excluded,2822,O
.,2822,O
The,2823,O
effect,2823,O
of,2823,O
treatment,2823,O
with,2823,O
gum,2823,B-Chemical
Arabic,2823,I-Chemical
on,2823,O
gentamicin,2823,B-Chemical
nephrotoxicity,2823,B-Disease
in,2823,O
rats,2823,O
:,2823,O
a,2823,O
preliminary,2823,O
study,2823,O
.,2823,O
In,2824,O
the,2824,O
present,2824,O
work,2824,O
we,2824,O
assessed,2824,O
the,2824,O
effect,2824,O
of,2824,O
treatment,2824,O
of,2824,O
rats,2824,O
with,2824,O
gum,2824,B-Chemical
Arabic,2824,I-Chemical
on,2824,O
acute,2824,B-Disease
renal,2824,I-Disease
failure,2824,I-Disease
induced,2824,O
by,2824,O
gentamicin,2824,B-Chemical
(,2824,O
GM,2824,B-Chemical
),2824,O
nephrotoxicity,2824,B-Disease
.,2824,O
Rats,2825,O
were,2825,O
treated,2825,O
with,2825,O
the,2825,O
vehicle,2825,O
(,2825,O
2,2825,O
mL/kg,2825,O
of,2825,O
distilled,2825,O
water,2825,O
and,2825,O
5,2825,O
%,2825,O
w/v,2825,O
cellulose,2825,O
",",2825,O
10,2825,O
days,2825,O
),2825,O
",",2825,O
gum,2825,B-Chemical
Arabic,2825,I-Chemical
(,2825,O
2,2825,O
mL/kg,2825,O
of,2825,O
a,2825,O
10,2825,O
%,2825,O
w/v,2825,O
aqueous,2825,O
suspension,2825,O
of,2825,O
gum,2825,B-Chemical
Arabic,2825,I-Chemical
powder,2825,O
",",2825,O
orally,2825,O
for,2825,O
10,2825,O
days,2825,O
),2825,O
",",2825,O
or,2825,O
gum,2825,B-Chemical
Arabic,2825,I-Chemical
concomitantly,2825,O
with,2825,O
GM,2825,B-Chemical
(,2825,O
80mg/kg/day,2825,O
intramuscularly,2825,O
",",2825,O
during,2825,O
the,2825,O
last,2825,O
six,2825,O
days,2825,O
of,2825,O
the,2825,O
treatment,2825,O
period,2825,O
),2825,O
.,2825,O
Nephrotoxicity,2826,B-Disease
was,2826,O
assessed,2826,O
by,2826,O
measuring,2826,O
the,2826,O
concentrations,2826,O
of,2826,O
creatinine,2826,B-Chemical
and,2826,O
urea,2826,B-Chemical
in,2826,O
the,2826,O
plasma,2826,O
and,2826,O
reduced,2826,O
glutathione,2826,B-Chemical
(,2826,O
GSH,2826,B-Chemical
),2826,O
in,2826,O
the,2826,O
kidney,2826,O
cortex,2826,O
",",2826,O
and,2826,O
by,2826,O
light,2826,O
microscopic,2826,O
examination,2826,O
of,2826,O
kidney,2826,O
sections,2826,O
.,2826,O
The,2827,O
results,2827,O
indicated,2827,O
that,2827,O
concomitant,2827,O
treatment,2827,O
with,2827,O
gum,2827,B-Chemical
Arabic,2827,I-Chemical
and,2827,O
GM,2827,B-Chemical
significantly,2827,O
increased,2827,O
creatinine,2827,B-Chemical
and,2827,O
urea,2827,B-Chemical
by,2827,O
about,2827,O
183,2827,O
and,2827,O
239,2827,O
%,2827,O
",",2827,O
respectively,2827,O
(,2827,O
compared,2827,O
to,2827,O
432,2827,O
and,2827,O
346,2827,O
%,2827,O
",",2827,O
respectively,2827,O
",",2827,O
in,2827,O
rats,2827,O
treated,2827,O
with,2827,O
cellulose,2827,O
and,2827,O
GM,2827,B-Chemical
),2827,O
",",2827,O
and,2827,O
decreased,2827,O
that,2827,O
of,2827,O
cortical,2827,O
GSH,2827,B-Chemical
by,2827,O
21,2827,O
%,2827,O
(,2827,O
compared,2827,O
to,2827,O
27,2827,O
%,2827,O
in,2827,O
the,2827,O
cellulose,2827,O
plus,2827,O
GM,2827,B-Chemical
group,2827,O
),2827,O
The,2827,O
GM-induced,2827,B-Chemical
proximal,2827,O
tubular,2827,B-Disease
necrosis,2827,I-Disease
appeared,2827,O
to,2827,O
be,2827,O
slightly,2827,O
less,2827,O
severe,2827,O
in,2827,O
rats,2827,O
given,2827,O
GM,2827,B-Chemical
together,2827,O
with,2827,O
gum,2827,B-Chemical
Arabic,2827,I-Chemical
than,2827,O
in,2827,O
those,2827,O
given,2827,O
GM,2827,B-Chemical
and,2827,O
cellulose,2827,O
.,2827,O
It,2828,O
could,2828,O
be,2828,O
inferred,2828,O
that,2828,O
gum,2828,B-Chemical
Arabic,2828,I-Chemical
treatment,2828,O
has,2828,O
induced,2828,O
a,2828,O
modest,2828,O
amelioration,2828,O
of,2828,O
some,2828,O
of,2828,O
the,2828,O
histological,2828,O
and,2828,O
biochemical,2828,O
indices,2828,O
of,2828,O
GM,2828,B-Chemical
nephrotoxicity,2828,B-Disease
.,2828,O
Further,2829,O
work,2829,O
is,2829,O
warranted,2829,O
on,2829,O
the,2829,O
effect,2829,O
of,2829,O
the,2829,O
treatments,2829,O
on,2829,O
renal,2829,O
functional,2829,O
aspects,2829,O
in,2829,O
models,2829,O
of,2829,O
chronic,2829,B-Disease
renal,2829,I-Disease
failure,2829,I-Disease
",",2829,O
and,2829,O
on,2829,O
the,2829,O
mechanism,2829,O
(,2829,O
s,2829,O
),2829,O
involved,2829,O
.,2829,O
Increased,2830,O
frequency,2830,O
of,2830,O
venous,2830,B-Disease
thromboembolism,2830,I-Disease
with,2830,O
the,2830,O
combination,2830,O
of,2830,O
docetaxel,2830,B-Chemical
and,2830,O
thalidomide,2830,B-Chemical
in,2830,O
patients,2830,O
with,2830,O
metastatic,2830,O
androgen-independent,2830,O
prostate,2830,B-Disease
cancer,2830,I-Disease
.,2830,O
STUDY,2831,O
OBJECTIVE,2831,O
:,2831,O
To,2831,O
evaluate,2831,O
the,2831,O
frequency,2831,O
of,2831,O
venous,2831,B-Disease
thromboembolism,2831,I-Disease
(,2831,O
VTE,2831,B-Disease
),2831,O
in,2831,O
patients,2831,O
with,2831,O
advanced,2831,O
androgen-independent,2831,O
prostate,2831,B-Disease
cancer,2831,I-Disease
who,2831,O
were,2831,O
treated,2831,O
with,2831,O
docetaxel,2831,B-Chemical
alone,2831,O
or,2831,O
in,2831,O
combination,2831,O
with,2831,O
thalidomide,2831,B-Chemical
.,2831,O
DESIGN,2832,O
:,2832,O
Retrospective,2832,O
analysis,2832,O
of,2832,O
a,2832,O
randomized,2832,O
phase,2832,O
II,2832,O
trial,2832,O
.,2832,O
SETTING,2833,O
:,2833,O
National,2833,O
Institutes,2833,O
of,2833,O
Health,2833,O
clinical,2833,O
research,2833,O
center,2833,O
.,2833,O
PATIENTS,2834,O
:,2834,O
Seventy,2834,O
men,2834,O
",",2834,O
aged,2834,O
50-80,2834,O
years,2834,O
",",2834,O
with,2834,O
advanced,2834,O
androgen-independent,2834,O
prostate,2834,B-Disease
cancer,2834,I-Disease
.,2834,O
INTERVENTION,2835,O
:,2835,O
Each,2835,O
patient,2835,O
received,2835,O
either,2835,O
intravenous,2835,O
docetaxel,2835,B-Chemical
30,2835,O
mg/m2/week,2835,O
for,2835,O
3,2835,O
consecutive,2835,O
weeks,2835,O
",",2835,O
followed,2835,O
by,2835,O
1,2835,O
week,2835,O
off,2835,O
",",2835,O
or,2835,O
the,2835,O
combination,2835,O
of,2835,O
continuous,2835,O
oral,2835,O
thalidomide,2835,B-Chemical
200,2835,O
mg,2835,O
every,2835,O
evening,2835,O
plus,2835,O
the,2835,O
same,2835,O
docetaxel,2835,B-Chemical
regimen,2835,O
.,2835,O
This,2836,O
4-week,2836,O
cycle,2836,O
was,2836,O
repeated,2836,O
until,2836,O
there,2836,O
was,2836,O
evidence,2836,O
of,2836,O
excessive,2836,O
toxicity,2836,B-Disease
or,2836,O
disease,2836,O
progression,2836,O
.,2836,O
MEASUREMENTS,2837,O
AND,2837,O
MAIN,2837,O
RESULTS,2837,O
:,2837,O
None,2837,O
of,2837,O
23,2837,O
patients,2837,O
who,2837,O
received,2837,O
docetaxel,2837,B-Chemical
alone,2837,O
developed,2837,O
VTE,2837,B-Disease
",",2837,O
whereas,2837,O
9,2837,O
of,2837,O
47,2837,O
patients,2837,O
(,2837,O
19,2837,O
%,2837,O
),2837,O
who,2837,O
received,2837,O
docetaxel,2837,B-Chemical
plus,2837,O
thalidomide,2837,B-Chemical
developed,2837,O
VTE,2837,B-Disease
(,2837,O
p=0.025,2837,O
),2837,O
.,2837,O
CONCLUSION,2838,O
:,2838,O
The,2838,O
addition,2838,O
of,2838,O
thalidomide,2838,B-Chemical
to,2838,O
docetaxel,2838,B-Chemical
in,2838,O
the,2838,O
treatment,2838,O
of,2838,O
prostate,2838,B-Disease
cancer,2838,I-Disease
significantly,2838,O
increases,2838,O
the,2838,O
frequency,2838,O
of,2838,O
VTE,2838,B-Disease
.,2838,O
Clinicians,2839,O
should,2839,O
be,2839,O
aware,2839,O
of,2839,O
this,2839,O
potential,2839,O
complication,2839,O
when,2839,O
adding,2839,O
thalidomide,2839,B-Chemical
to,2839,O
chemotherapeutic,2839,O
regimens,2839,O
.,2839,O
Ticlopidine-induced,2840,B-Chemical
cholestatic,2840,O
hepatitis,2840,O
.,2840,O
OBJECTIVE,2841,O
:,2841,O
To,2841,O
report,2841,O
2,2841,O
cases,2841,O
of,2841,O
ticlopidine-induced,2841,B-Chemical
cholestatic,2841,O
hepatitis,2841,O
",",2841,O
investigate,2841,O
its,2841,O
mechanism,2841,O
",",2841,O
and,2841,O
compare,2841,O
the,2841,O
observed,2841,O
main,2841,O
characteristics,2841,O
with,2841,O
those,2841,O
of,2841,O
the,2841,O
published,2841,O
cases,2841,O
.,2841,O
CASE,2842,O
SUMMARIES,2842,O
:,2842,O
Two,2842,O
patients,2842,O
developed,2842,O
prolonged,2842,O
cholestatic,2842,O
hepatitis,2842,O
after,2842,O
receiving,2842,O
ticlopidine,2842,B-Chemical
following,2842,O
percutaneous,2842,O
coronary,2842,O
angioplasty,2842,O
",",2842,O
with,2842,O
complete,2842,O
remission,2842,O
during,2842,O
the,2842,O
follow-up,2842,O
period,2842,O
.,2842,O
T-cell,2843,O
stimulation,2843,O
by,2843,O
therapeutic,2843,O
concentration,2843,O
of,2843,O
ticlopidine,2843,B-Chemical
was,2843,O
demonstrated,2843,O
in,2843,O
vitro,2843,O
in,2843,O
the,2843,O
patients,2843,O
",",2843,O
but,2843,O
not,2843,O
in,2843,O
healthy,2843,O
controls,2843,O
.,2843,O
DISCUSSION,2844,O
:,2844,O
Cholestatic,2844,O
hepatitis,2844,O
is,2844,O
a,2844,O
rare,2844,O
complication,2844,O
of,2844,O
the,2844,O
antiplatelet,2844,O
agent,2844,O
ticlopidine,2844,B-Chemical
;,2844,O
several,2844,O
cases,2844,O
have,2844,O
been,2844,O
reported,2844,O
but,2844,O
few,2844,O
in,2844,O
the,2844,O
English,2844,O
literature,2844,O
.,2844,O
Our,2845,O
patients,2845,O
developed,2845,O
jaundice,2845,B-Disease
following,2845,O
treatment,2845,O
with,2845,O
ticlopidine,2845,B-Chemical
and,2845,O
showed,2845,O
the,2845,O
clinical,2845,O
and,2845,O
laboratory,2845,O
characteristics,2845,O
of,2845,O
cholestatic,2845,O
hepatitis,2845,O
",",2845,O
which,2845,O
resolved,2845,O
after,2845,O
discontinuation,2845,O
of,2845,O
the,2845,O
drug,2845,O
.,2845,O
Hepatitis,2846,B-Disease
may,2846,O
develop,2846,O
weeks,2846,O
after,2846,O
discontinuation,2846,O
of,2846,O
the,2846,O
drug,2846,O
and,2846,O
may,2846,O
run,2846,O
a,2846,O
prolonged,2846,O
course,2846,O
",",2846,O
but,2846,O
complete,2846,O
remission,2846,O
was,2846,O
observed,2846,O
in,2846,O
all,2846,O
reported,2846,O
cases,2846,O
.,2846,O
An,2847,O
objective,2847,O
causality,2847,O
assessment,2847,O
revealed,2847,O
that,2847,O
the,2847,O
adverse,2847,O
drug,2847,O
event,2847,O
was,2847,O
probably,2847,O
related,2847,O
to,2847,O
the,2847,O
use,2847,O
of,2847,O
ticlopidine,2847,B-Chemical
.,2847,O
The,2848,O
mechanisms,2848,O
of,2848,O
this,2848,O
ticlopidine-induced,2848,B-Chemical
cholestasis,2848,B-Disease
are,2848,O
unclear,2848,O
.,2848,O
Immune,2849,O
mechanisms,2849,O
may,2849,O
be,2849,O
involved,2849,O
in,2849,O
the,2849,O
drug,2849,O
's,2849,O
hepatotoxicity,2849,B-Disease
",",2849,O
as,2849,O
suggested,2849,O
by,2849,O
the,2849,O
T-cell,2849,O
stimulation,2849,O
study,2849,O
reported,2849,O
here,2849,O
.,2849,O
CONCLUSIONS,2850,O
:,2850,O
Cholestatic,2850,O
hepatitis,2850,O
is,2850,O
a,2850,O
rare,2850,O
adverse,2850,O
effect,2850,O
of,2850,O
ticlopidine,2850,B-Chemical
that,2850,O
may,2850,O
be,2850,O
immune,2850,O
mediated,2850,O
.,2850,O
Patients,2851,O
receiving,2851,O
the,2851,O
drug,2851,O
should,2851,O
be,2851,O
monitored,2851,O
with,2851,O
liver,2851,O
function,2851,O
tests,2851,O
along,2851,O
with,2851,O
complete,2851,O
blood,2851,O
cell,2851,O
counts,2851,O
.,2851,O
This,2852,O
complication,2852,O
will,2852,O
be,2852,O
observed,2852,O
even,2852,O
less,2852,O
often,2852,O
in,2852,O
the,2852,O
future,2852,O
as,2852,O
ticlopidine,2852,B-Chemical
is,2852,O
being,2852,O
replaced,2852,O
by,2852,O
the,2852,O
newer,2852,O
antiplatelet,2852,O
agent,2852,O
clopidogrel,2852,B-Chemical
.,2852,O
Epithelial,2853,O
sodium,2853,B-Chemical
channel,2853,O
(,2853,O
ENaC,2853,O
),2853,O
subunit,2853,O
mRNA,2853,O
and,2853,O
protein,2853,O
expression,2853,O
in,2853,O
rats,2853,O
with,2853,O
puromycin,2853,B-Chemical
aminonucleoside-induced,2853,O
nephrotic,2853,B-Disease
syndrome,2853,I-Disease
.,2853,O
In,2854,O
experimental,2854,O
nephrotic,2854,B-Disease
syndrome,2854,I-Disease
",",2854,O
urinary,2854,O
sodium,2854,B-Chemical
excretion,2854,O
is,2854,O
decreased,2854,O
during,2854,O
the,2854,O
early,2854,O
phase,2854,O
of,2854,O
the,2854,O
disease,2854,O
.,2854,O
The,2855,O
molecular,2855,O
mechanism,2855,O
(,2855,O
s,2855,O
),2855,O
leading,2855,O
to,2855,O
salt,2855,O
retention,2855,O
has,2855,O
not,2855,O
been,2855,O
completely,2855,O
elucidated,2855,O
.,2855,O
The,2856,O
rate-limiting,2856,O
constituent,2856,O
of,2856,O
collecting,2856,O
duct,2856,O
sodium,2856,B-Chemical
transport,2856,O
is,2856,O
the,2856,O
epithelial,2856,O
sodium,2856,B-Chemical
channel,2856,O
(,2856,O
ENaC,2856,O
),2856,O
.,2856,O
We,2857,O
examined,2857,O
the,2857,O
abundance,2857,O
of,2857,O
ENaC,2857,O
subunit,2857,O
mRNAs,2857,O
and,2857,O
proteins,2857,O
in,2857,O
puromycin,2857,B-Chemical
aminonucleoside,2857,I-Chemical
(,2857,O
PAN,2857,B-Chemical
),2857,O
-induced,2857,O
nephrotic,2857,B-Disease
syndrome,2857,I-Disease
.,2857,O
The,2858,O
time,2858,O
courses,2858,O
of,2858,O
urinary,2858,O
sodium,2858,B-Chemical
excretion,2858,O
",",2858,O
plasma,2858,O
aldosterone,2858,B-Chemical
concentration,2858,O
and,2858,O
proteinuria,2858,B-Disease
were,2858,O
studied,2858,O
in,2858,O
male,2858,O
Sprague-Dawley,2858,O
rats,2858,O
treated,2858,O
with,2858,O
a,2858,O
single,2858,O
dose,2858,O
of,2858,O
either,2858,O
PAN,2858,B-Chemical
or,2858,O
vehicle,2858,O
.,2858,O
The,2859,O
relative,2859,O
amounts,2859,O
of,2859,O
alphaENaC,2859,O
",",2859,O
betaENaC,2859,O
and,2859,O
gammaENaC,2859,O
mRNAs,2859,O
were,2859,O
determined,2859,O
in,2859,O
kidneys,2859,O
from,2859,O
these,2859,O
rats,2859,O
by,2859,O
real-time,2859,O
quantitative,2859,O
TaqMan,2859,O
PCR,2859,O
",",2859,O
and,2859,O
the,2859,O
amounts,2859,O
of,2859,O
proteins,2859,O
by,2859,O
Western,2859,O
blot,2859,O
.,2859,O
The,2860,O
kinetics,2860,O
of,2860,O
urinary,2860,O
sodium,2860,B-Chemical
excretion,2860,O
and,2860,O
the,2860,O
appearance,2860,O
of,2860,O
proteinuria,2860,B-Disease
were,2860,O
comparable,2860,O
with,2860,O
those,2860,O
reported,2860,O
previously,2860,O
.,2860,O
Sodium,2861,B-Chemical
retention,2861,O
occurred,2861,O
on,2861,O
days,2861,O
2,2861,O
",",2861,O
3,2861,O
and,2861,O
6,2861,O
after,2861,O
PAN,2861,B-Chemical
injection,2861,O
.,2861,O
A,2862,O
significant,2862,O
up-regulation,2862,O
of,2862,O
alphaENaC,2862,O
and,2862,O
betaENaC,2862,O
mRNA,2862,O
abundance,2862,O
on,2862,O
days,2862,O
1,2862,O
and,2862,O
2,2862,O
preceded,2862,O
sodium,2862,B-Chemical
retention,2862,O
on,2862,O
days,2862,O
2,2862,O
and,2862,O
3,2862,O
.,2862,O
Conversely,2863,O
",",2863,O
down-regulation,2863,O
of,2863,O
alphaENaC,2863,O
",",2863,O
betaENaC,2863,O
and,2863,O
gammaENaC,2863,O
mRNA,2863,O
expression,2863,O
on,2863,O
day,2863,O
3,2863,O
occurred,2863,O
in,2863,O
the,2863,O
presence,2863,O
of,2863,O
high,2863,O
aldosterone,2863,B-Chemical
concentrations,2863,O
",",2863,O
and,2863,O
was,2863,O
followed,2863,O
by,2863,O
a,2863,O
return,2863,O
of,2863,O
sodium,2863,B-Chemical
excretion,2863,O
to,2863,O
control,2863,O
values,2863,O
.,2863,O
The,2864,O
amounts,2864,O
of,2864,O
alphaENaC,2864,O
",",2864,O
betaENaC,2864,O
and,2864,O
gammaENaC,2864,O
proteins,2864,O
were,2864,O
not,2864,O
increased,2864,O
during,2864,O
PAN-induced,2864,B-Chemical
sodium,2864,B-Chemical
retention,2864,O
.,2864,O
In,2865,O
conclusion,2865,O
",",2865,O
ENaC,2865,O
mRNA,2865,O
expression,2865,O
",",2865,O
especially,2865,O
alphaENaC,2865,O
",",2865,O
is,2865,O
increased,2865,O
in,2865,O
the,2865,O
very,2865,O
early,2865,O
phase,2865,O
of,2865,O
the,2865,O
experimental,2865,O
model,2865,O
of,2865,O
PAN-induced,2865,B-Chemical
nephrotic,2865,B-Disease
syndrome,2865,I-Disease
in,2865,O
rats,2865,O
",",2865,O
but,2865,O
appears,2865,O
to,2865,O
escape,2865,O
from,2865,O
the,2865,O
regulation,2865,O
by,2865,O
aldosterone,2865,B-Chemical
after,2865,O
day,2865,O
3,2865,O
.,2865,O
Sub-chronic,2866,O
low,2866,O
dose,2866,O
gamma-vinyl,2866,B-Chemical
GABA,2866,I-Chemical
(,2866,O
vigabatrin,2866,B-Chemical
),2866,O
inhibits,2866,O
cocaine-induced,2866,B-Chemical
increases,2866,O
in,2866,O
nucleus,2866,O
accumbens,2866,O
dopamine,2866,B-Chemical
.,2866,O
RATIONALE,2867,O
:,2867,O
gamma-Vinyl,2867,B-Chemical
GABA,2867,I-Chemical
(,2867,O
GVG,2867,B-Chemical
),2867,O
irreversibly,2867,O
inhibits,2867,O
GABA-transaminase,2867,B-Chemical
.,2867,O
This,2868,O
non-receptor,2868,O
mediated,2868,O
inhibition,2868,O
requires,2868,O
de,2868,O
novo,2868,O
synthesis,2868,O
for,2868,O
restoration,2868,O
of,2868,O
functional,2868,O
GABA,2868,B-Chemical
catabolism,2868,O
.,2868,O
OBJECTIVES,2869,O
:,2869,O
Given,2869,O
its,2869,O
preclinical,2869,O
success,2869,O
for,2869,O
treating,2869,O
substance,2869,B-Disease
abuse,2869,I-Disease
and,2869,O
the,2869,O
increased,2869,O
risk,2869,O
of,2869,O
visual,2869,B-Disease
field,2869,I-Disease
defects,2869,I-Disease
(,2869,O
VFD,2869,B-Disease
),2869,O
associated,2869,O
with,2869,O
cumulative,2869,O
lifetime,2869,O
exposure,2869,O
",",2869,O
we,2869,O
explored,2869,O
the,2869,O
effects,2869,O
of,2869,O
sub-chronic,2869,O
low,2869,O
dose,2869,O
GVG,2869,B-Chemical
on,2869,O
cocaine-induced,2869,B-Chemical
increases,2869,O
in,2869,O
nucleus,2869,O
accumbens,2869,O
(,2869,O
NAcc,2869,O
),2869,O
dopamine,2869,B-Chemical
(,2869,O
DA,2869,B-Chemical
),2869,O
.,2869,O
METHODS,2870,O
:,2870,O
Using,2870,O
in,2870,O
vivo,2870,O
microdialysis,2870,O
",",2870,O
we,2870,O
compared,2870,O
acute,2870,O
exposure,2870,O
(,2870,O
450,2870,O
mg/kg,2870,O
),2870,O
to,2870,O
an,2870,O
identical,2870,O
sub-chronic,2870,O
exposure,2870,O
(,2870,O
150,2870,O
mg/kg,2870,O
per,2870,O
day,2870,O
for,2870,O
3,2870,O
days,2870,O
),2870,O
",",2870,O
followed,2870,O
by,2870,O
1-,2870,O
or,2870,O
3-day,2870,O
washout,2870,O
.,2870,O
Finally,2871,O
",",2871,O
we,2871,O
examined,2871,O
the,2871,O
low,2871,O
dose,2871,O
of,2871,O
150,2871,O
mg/kg,2871,O
(,2871,O
50,2871,O
mg/kg,2871,O
per,2871,O
day,2871,O
),2871,O
using,2871,O
a,2871,O
similar,2871,O
washout,2871,O
period,2871,O
.,2871,O
RESULTS,2872,O
:,2872,O
Sub-chronic,2872,O
GVG,2872,B-Chemical
exposure,2872,O
inhibited,2872,O
the,2872,O
effect,2872,O
of,2872,O
cocaine,2872,B-Chemical
for,2872,O
3,2872,O
days,2872,O
",",2872,O
which,2872,O
exceeded,2872,O
in,2872,O
magnitude,2872,O
and,2872,O
duration,2872,O
the,2872,O
identical,2872,O
acute,2872,O
dose,2872,O
.,2872,O
CONCLUSIONS,2873,O
:,2873,O
Sub-chronic,2873,O
low,2873,O
dose,2873,O
GVG,2873,B-Chemical
potentiates,2873,O
and,2873,O
extends,2873,O
the,2873,O
inhibition,2873,O
of,2873,O
cocaine-induced,2873,B-Chemical
increases,2873,O
in,2873,O
dopamine,2873,B-Chemical
",",2873,O
effectively,2873,O
reducing,2873,O
cumulative,2873,O
exposures,2873,O
and,2873,O
the,2873,O
risk,2873,O
for,2873,O
VFDS,2873,O
.,2873,O
MR,2874,O
imaging,2874,O
with,2874,O
quantitative,2874,O
diffusion,2874,O
mapping,2874,O
of,2874,O
tacrolimus-induced,2874,B-Chemical
neurotoxicity,2874,B-Disease
in,2874,O
organ,2874,O
transplant,2874,O
patients,2874,O
.,2874,O
Our,2875,O
objective,2875,O
was,2875,O
to,2875,O
investigate,2875,O
brain,2875,O
MR,2875,O
imaging,2875,O
findings,2875,O
and,2875,O
the,2875,O
utility,2875,O
of,2875,O
diffusion-weighted,2875,O
(,2875,O
DW,2875,O
),2875,O
imaging,2875,O
in,2875,O
organ,2875,O
transplant,2875,O
patients,2875,O
who,2875,O
developed,2875,O
neurologic,2875,O
symptoms,2875,O
during,2875,O
tacrolimus,2875,B-Chemical
therapy,2875,O
.,2875,O
Brain,2876,O
MR,2876,O
studies,2876,O
",",2876,O
including,2876,O
DW,2876,O
imaging,2876,O
",",2876,O
were,2876,O
prospectively,2876,O
performed,2876,O
in,2876,O
14,2876,O
organ,2876,O
transplant,2876,O
patients,2876,O
receiving,2876,O
tacrolimus,2876,B-Chemical
who,2876,O
developed,2876,O
neurologic,2876,B-Disease
complications,2876,I-Disease
.,2876,O
In,2877,O
each,2877,O
patient,2877,O
who,2877,O
had,2877,O
abnormalities,2877,O
on,2877,O
the,2877,O
initial,2877,O
MR,2877,O
study,2877,O
",",2877,O
a,2877,O
follow-up,2877,O
MR,2877,O
study,2877,O
was,2877,O
performed,2877,O
1,2877,O
month,2877,O
later,2877,O
.,2877,O
Apparent,2878,O
diffusion,2878,O
coefficient,2878,O
(,2878,O
ADC,2878,O
),2878,O
values,2878,O
on,2878,O
the,2878,O
initial,2878,O
MR,2878,O
study,2878,O
were,2878,O
correlated,2878,O
with,2878,O
reversibility,2878,O
of,2878,O
the,2878,O
lesions,2878,O
.,2878,O
Of,2879,O
the,2879,O
14,2879,O
patients,2879,O
",",2879,O
5,2879,O
(,2879,O
35.7,2879,O
%,2879,O
),2879,O
had,2879,O
white,2879,B-Disease
matter,2879,I-Disease
abnormalities,2879,I-Disease
",",2879,O
1,2879,O
(,2879,O
7.1,2879,O
%,2879,O
),2879,O
had,2879,O
putaminal,2879,B-Disease
hemorrhage,2879,I-Disease
",",2879,O
and,2879,O
8,2879,O
(,2879,O
57.1,2879,O
%,2879,O
),2879,O
had,2879,O
normal,2879,O
findings,2879,O
on,2879,O
initial,2879,O
MR,2879,O
images,2879,O
.,2879,O
Among,2880,O
the,2880,O
5,2880,O
patients,2880,O
with,2880,O
white,2880,B-Disease
matter,2880,I-Disease
abnormalities,2880,I-Disease
",",2880,O
4,2880,O
patients,2880,O
(,2880,O
80.0,2880,O
%,2880,O
),2880,O
showed,2880,O
higher,2880,O
than,2880,O
normal,2880,O
ADC,2880,O
values,2880,O
on,2880,O
initial,2880,O
MR,2880,O
images,2880,O
",",2880,O
and,2880,O
all,2880,O
showed,2880,O
complete,2880,O
resolution,2880,O
on,2880,O
follow-up,2880,O
images,2880,O
.,2880,O
The,2881,O
remaining,2881,O
1,2881,O
patient,2881,O
(,2881,O
20.0,2881,O
%,2881,O
),2881,O
showed,2881,O
lower,2881,O
than,2881,O
normal,2881,O
ADC,2881,O
value,2881,O
and,2881,O
showed,2881,O
incomplete,2881,O
resolution,2881,O
with,2881,O
cortical,2881,B-Disease
laminar,2881,I-Disease
necrosis,2881,I-Disease
.,2881,O
Diffusion-weighted,2882,O
imaging,2882,O
may,2882,O
be,2882,O
useful,2882,O
in,2882,O
predicting,2882,O
the,2882,O
outcomes,2882,O
of,2882,O
the,2882,O
lesions,2882,O
of,2882,O
tacrolimus-induced,2882,B-Chemical
neurotoxicity,2882,B-Disease
.,2882,O
L-arginine,2883,B-Chemical
transport,2883,O
in,2883,O
humans,2883,O
with,2883,O
cortisol-induced,2883,B-Chemical
hypertension,2883,B-Disease
.,2883,O
A,2884,O
deficient,2884,O
L-arginine-nitric,2884,B-Chemical
oxide,2884,I-Chemical
system,2884,O
is,2884,O
implicated,2884,O
in,2884,O
cortisol-induced,2884,B-Chemical
hypertension,2884,B-Disease
.,2884,O
We,2885,O
investigate,2885,O
whether,2885,O
abnormalities,2885,O
in,2885,O
L-arginine,2885,B-Chemical
uptake,2885,O
contribute,2885,O
to,2885,O
this,2885,O
deficiency,2885,O
.,2885,O
Eight,2886,O
healthy,2886,O
men,2886,O
were,2886,O
recruited,2886,O
.,2886,O
Hydrocortisone,2887,B-Chemical
acetate,2887,I-Chemical
(,2887,O
50,2887,O
mg,2887,O
),2887,O
was,2887,O
given,2887,O
orally,2887,O
every,2887,O
6,2887,O
hours,2887,O
for,2887,O
24,2887,O
hours,2887,O
after,2887,O
a,2887,O
5-day,2887,O
fixed-salt,2887,O
diet,2887,O
(,2887,O
150,2887,O
mmol/d,2887,O
),2887,O
.,2887,O
Crossover,2888,O
studies,2888,O
were,2888,O
performed,2888,O
2,2888,O
weeks,2888,O
apart,2888,O
.,2888,O
Thirty,2889,O
milliliters,2889,O
of,2889,O
blood,2889,O
was,2889,O
obtained,2889,O
for,2889,O
isolation,2889,O
of,2889,O
peripheral,2889,O
blood,2889,O
mononuclear,2889,O
cells,2889,O
after,2889,O
each,2889,O
treatment,2889,O
period,2889,O
.,2889,O
L-arginine,2890,B-Chemical
uptake,2890,O
was,2890,O
assessed,2890,O
in,2890,O
mononuclear,2890,O
cells,2890,O
incubated,2890,O
with,2890,O
L-arginine,2890,B-Chemical
(,2890,O
1,2890,O
to,2890,O
300,2890,O
micromol/L,2890,O
),2890,O
",",2890,O
incorporating,2890,O
100,2890,O
nmol/L,2890,O
[,2890,B-Chemical
3H,2890,I-Chemical
],2890,I-Chemical
-l-arginine,2890,I-Chemical
for,2890,O
a,2890,O
period,2890,O
of,2890,O
5,2890,O
minutes,2890,O
at,2890,O
37,2890,O
degrees,2890,O
C.,2890,O
Forearm,2890,O
[,2890,B-Chemical
3H,2890,I-Chemical
],2890,I-Chemical
-L-arginine,2890,I-Chemical
extraction,2890,O
was,2890,O
calculated,2890,O
after,2890,O
infusion,2890,O
of,2890,O
[,2890,B-Chemical
3H,2890,I-Chemical
],2890,I-Chemical
-L-arginine,2890,I-Chemical
into,2890,O
the,2890,O
brachial,2890,O
artery,2890,O
at,2890,O
a,2890,O
rate,2890,O
of,2890,O
100,2890,O
nCi/min,2890,O
for,2890,O
80,2890,O
minutes,2890,O
.,2890,O
Deep,2891,O
forearm,2891,O
venous,2891,O
samples,2891,O
were,2891,O
collected,2891,O
for,2891,O
determination,2891,O
of,2891,O
L-arginine,2891,B-Chemical
extraction,2891,O
.,2891,O
Plasma,2892,O
cortisol,2892,B-Chemical
concentrations,2892,O
were,2892,O
significantly,2892,O
raised,2892,O
during,2892,O
the,2892,O
active,2892,O
phase,2892,O
(,2892,O
323+/-43,2892,O
to,2892,O
1082+/-245,2892,O
mmol/L,2892,O
",",2892,O
P,2892,O
<,2892,O
0.05,2892,O
),2892,O
.,2892,O
Systolic,2893,O
blood,2893,O
pressure,2893,O
was,2893,O
elevated,2893,O
by,2893,O
an,2893,O
average,2893,O
of,2893,O
7,2893,O
mm,2893,O
Hg,2893,O
.,2893,O
Neither,2894,O
L-arginine,2894,B-Chemical
transport,2894,O
into,2894,O
mononuclear,2894,O
cells,2894,O
(,2894,O
placebo,2894,O
vs,2894,O
active,2894,O
",",2894,O
26.3+/-3.6,2894,O
vs,2894,O
29.0+/-2.1,2894,O
pmol/10,2894,O
000,2894,O
cells,2894,O
per,2894,O
5,2894,O
minutes,2894,O
",",2894,O
respectively,2894,O
",",2894,O
at,2894,O
an,2894,O
l-arginine,2894,B-Chemical
concentration,2894,O
of,2894,O
300,2894,O
micromol/L,2894,O
),2894,O
nor,2894,O
L-arginine,2894,B-Chemical
extraction,2894,O
in,2894,O
the,2894,O
forearm,2894,O
(,2894,O
at,2894,O
80,2894,O
minutes,2894,O
",",2894,O
placebo,2894,O
vs,2894,O
active,2894,O
",",2894,O
1,2894,O
868,2894,O
904+/-434,2894,O
962,2894,O
vs,2894,O
2,2894,O
013,2894,O
910+/-770,2894,O
619,2894,O
disintegrations,2894,O
per,2894,O
minute,2894,O
),2894,O
was,2894,O
affected,2894,O
by,2894,O
cortisol,2894,B-Chemical
treatment,2894,O
;,2894,O
ie,2894,O
",",2894,O
that,2894,O
L-arginine,2894,B-Chemical
uptake,2894,O
is,2894,O
not,2894,O
affected,2894,O
by,2894,O
short-term,2894,O
cortisol,2894,B-Chemical
treatment,2894,O
.,2894,O
We,2895,O
conclude,2895,O
that,2895,O
cortisol-induced,2895,B-Chemical
increases,2895,B-Disease
in,2895,I-Disease
blood,2895,I-Disease
pressure,2895,I-Disease
are,2895,O
not,2895,O
associated,2895,O
with,2895,O
abnormalities,2895,O
in,2895,O
the,2895,O
l-arginine,2895,B-Chemical
transport,2895,O
system,2895,O
.,2895,O
Amount,2896,O
of,2896,O
bleeding,2896,B-Disease
and,2896,O
hematoma,2896,B-Disease
size,2896,O
in,2896,O
the,2896,O
collagenase-induced,2896,O
intracerebral,2896,B-Disease
hemorrhage,2896,I-Disease
rat,2896,O
model,2896,O
.,2896,O
The,2897,O
aggravated,2897,O
risk,2897,O
on,2897,O
intracerebral,2897,B-Disease
hemorrhage,2897,I-Disease
(,2897,O
ICH,2897,B-Disease
),2897,O
with,2897,O
drugs,2897,O
used,2897,O
for,2897,O
stroke,2897,B-Disease
patients,2897,O
should,2897,O
be,2897,O
estimated,2897,O
carefully,2897,O
.,2897,O
We,2898,O
therefore,2898,O
established,2898,O
sensitive,2898,O
quantification,2898,O
methods,2898,O
and,2898,O
provided,2898,O
a,2898,O
rat,2898,O
ICH,2898,B-Disease
model,2898,O
for,2898,O
detection,2898,O
of,2898,O
ICH,2898,B-Disease
deterioration,2898,O
.,2898,O
In,2899,O
ICH,2899,B-Disease
intrastriatally,2899,O
induced,2899,O
by,2899,O
0.014-unit,2899,O
",",2899,O
0.070-unit,2899,O
",",2899,O
and,2899,O
0.350-unit,2899,O
collagenase,2899,O
",",2899,O
the,2899,O
amount,2899,O
of,2899,O
bleeding,2899,B-Disease
was,2899,O
measured,2899,O
using,2899,O
a,2899,O
hemoglobin,2899,O
assay,2899,O
developed,2899,O
in,2899,O
the,2899,O
present,2899,O
study,2899,O
and,2899,O
was,2899,O
compared,2899,O
with,2899,O
the,2899,O
morphologically,2899,O
determined,2899,O
hematoma,2899,B-Disease
volume,2899,O
.,2899,O
The,2900,O
blood,2900,O
amounts,2900,O
and,2900,O
hematoma,2900,B-Disease
volumes,2900,O
were,2900,O
significantly,2900,O
correlated,2900,O
",",2900,O
and,2900,O
the,2900,O
hematoma,2900,B-Disease
induced,2900,O
by,2900,O
0.014-unit,2900,O
collagenase,2900,O
was,2900,O
adequate,2900,O
to,2900,O
detect,2900,O
ICH,2900,B-Disease
deterioration,2900,O
.,2900,O
In,2901,O
ICH,2901,B-Disease
induction,2901,O
using,2901,O
0.014-unit,2901,O
collagenase,2901,O
",",2901,O
heparin,2901,B-Chemical
enhanced,2901,O
the,2901,O
hematoma,2901,B-Disease
volume,2901,O
3.4-fold,2901,O
over,2901,O
that,2901,O
seen,2901,O
in,2901,O
control,2901,O
ICH,2901,B-Disease
animals,2901,O
and,2901,O
the,2901,O
bleeding,2901,B-Disease
7.6-fold,2901,O
.,2901,O
Data,2902,O
suggest,2902,O
that,2902,O
this,2902,O
sensitive,2902,O
hemoglobin,2902,O
assay,2902,O
is,2902,O
useful,2902,O
for,2902,O
ICH,2902,B-Disease
detection,2902,O
",",2902,O
and,2902,O
that,2902,O
a,2902,O
model,2902,O
with,2902,O
a,2902,O
small,2902,O
ICH,2902,B-Disease
induced,2902,O
with,2902,O
a,2902,O
low-dose,2902,O
collagenase,2902,O
should,2902,O
be,2902,O
used,2902,O
for,2902,O
evaluation,2902,O
of,2902,O
drugs,2902,O
that,2902,O
may,2902,O
affect,2902,O
ICH,2902,B-Disease
.,2902,O
Estradiol,2903,B-Chemical
reduces,2903,O
seizure-induced,2903,B-Disease
hippocampal,2903,B-Disease
injury,2903,I-Disease
in,2903,O
ovariectomized,2903,O
female,2903,O
but,2903,O
not,2903,O
in,2903,O
male,2903,O
rats,2903,O
.,2903,O
Estrogens,2904,O
protect,2904,O
ovariectomized,2904,O
rats,2904,O
from,2904,O
hippocampal,2904,B-Disease
injury,2904,I-Disease
induced,2904,O
by,2904,O
kainic,2904,B-Chemical
acid-induced,2904,O
status,2904,B-Disease
epilepticus,2904,I-Disease
(,2904,O
SE,2904,B-Disease
),2904,O
.,2904,O
We,2905,O
compared,2905,O
the,2905,O
effects,2905,O
of,2905,O
17beta-estradiol,2905,B-Chemical
in,2905,O
adult,2905,O
male,2905,O
and,2905,O
ovariectomized,2905,O
female,2905,O
rats,2905,O
subjected,2905,O
to,2905,O
lithium-pilocarpine-induced,2905,B-Chemical
SE,2905,B-Disease
.,2905,O
Rats,2906,O
received,2906,O
subcutaneous,2906,O
injections,2906,O
of,2906,O
17beta-estradiol,2906,B-Chemical
(,2906,O
2,2906,O
microg/rat,2906,O
),2906,O
or,2906,O
oil,2906,O
once,2906,O
daily,2906,O
for,2906,O
four,2906,O
consecutive,2906,O
days,2906,O
.,2906,O
SE,2907,B-Disease
was,2907,O
induced,2907,O
20,2907,O
h,2907,O
following,2907,O
the,2907,O
second,2907,O
injection,2907,O
and,2907,O
terminated,2907,O
3,2907,O
h,2907,O
later,2907,O
.,2907,O
The,2908,O
extent,2908,O
of,2908,O
silver-stained,2908,B-Chemical
CA3,2908,O
and,2908,O
CA1,2908,O
hippocampal,2908,O
neurons,2908,O
was,2908,O
evaluated,2908,O
2,2908,O
days,2908,O
after,2908,O
SE,2908,B-Disease
.,2908,O
17beta-Estradiol,2909,B-Chemical
did,2909,O
not,2909,O
alter,2909,O
the,2909,O
onset,2909,O
of,2909,O
first,2909,O
clonus,2909,O
in,2909,O
ovariectomized,2909,O
rats,2909,O
but,2909,O
accelerated,2909,O
it,2909,O
in,2909,O
males,2909,O
.,2909,O
17beta-Estradiol,2910,B-Chemical
reduced,2910,O
the,2910,O
argyrophilic,2910,O
neurons,2910,O
in,2910,O
the,2910,O
CA1,2910,O
and,2910,O
CA3-C,2910,O
sectors,2910,O
of,2910,O
ovariectomized,2910,O
rats,2910,O
.,2910,O
In,2911,O
males,2911,O
",",2911,O
estradiol,2911,B-Chemical
increased,2911,O
the,2911,O
total,2911,O
damage,2911,O
score,2911,O
.,2911,O
These,2912,O
findings,2912,O
suggest,2912,O
that,2912,O
the,2912,O
effects,2912,O
of,2912,O
estradiol,2912,B-Chemical
on,2912,O
seizure,2912,B-Disease
threshold,2912,O
and,2912,O
damage,2912,O
may,2912,O
be,2912,O
altered,2912,O
by,2912,O
sex-related,2912,O
differences,2912,O
in,2912,O
the,2912,O
hormonal,2912,O
environment,2912,O
.,2912,O
Pseudoacromegaly,2913,B-Disease
induced,2913,O
by,2913,O
the,2913,O
long-term,2913,O
use,2913,O
of,2913,O
minoxidil,2913,B-Chemical
.,2913,O
Acromegaly,2914,B-Disease
is,2914,O
an,2914,O
endocrine,2914,B-Disease
disorder,2914,I-Disease
caused,2914,O
by,2914,O
chronic,2914,O
excessive,2914,O
growth,2914,O
hormone,2914,O
secretion,2914,O
from,2914,O
the,2914,O
anterior,2914,O
pituitary,2914,O
gland,2914,O
.,2914,O
Significant,2915,O
disfiguring,2915,O
changes,2915,O
occur,2915,O
as,2915,O
a,2915,O
result,2915,O
of,2915,O
bone,2915,O
",",2915,O
cartilage,2915,O
",",2915,O
and,2915,O
soft,2915,O
tissue,2915,O
hypertrophy,2915,B-Disease
",",2915,O
including,2915,O
the,2915,O
thickening,2915,O
of,2915,O
the,2915,O
skin,2915,O
",",2915,O
coarsening,2915,O
of,2915,O
facial,2915,O
features,2915,O
",",2915,O
and,2915,O
cutis,2915,B-Disease
verticis,2915,I-Disease
gyrata,2915,I-Disease
.,2915,O
Pseudoacromegaly,2916,B-Disease
",",2916,O
on,2916,O
the,2916,O
other,2916,O
hand,2916,O
",",2916,O
is,2916,O
the,2916,O
presence,2916,O
of,2916,O
similar,2916,O
acromegaloid,2916,O
features,2916,O
in,2916,O
the,2916,O
absence,2916,O
of,2916,O
elevated,2916,O
growth,2916,O
hormone,2916,O
or,2916,O
insulin-like,2916,O
growth,2916,O
factor,2916,O
levels,2916,O
.,2916,O
We,2917,O
present,2917,O
a,2917,O
patient,2917,O
with,2917,O
pseudoacromegaly,2917,B-Disease
that,2917,O
resulted,2917,O
from,2917,O
the,2917,O
long-term,2917,O
use,2917,O
of,2917,O
minoxidil,2917,B-Chemical
at,2917,O
an,2917,O
unusually,2917,O
high,2917,O
dose,2917,O
.,2917,O
This,2918,O
is,2918,O
the,2918,O
first,2918,O
case,2918,O
report,2918,O
of,2918,O
pseudoacromegaly,2918,B-Disease
as,2918,O
a,2918,O
side,2918,O
effect,2918,O
of,2918,O
minoxidil,2918,B-Chemical
use,2918,O
.,2918,O
Combined,2919,O
androgen,2919,O
blockade-induced,2919,O
anemia,2919,B-Disease
in,2919,O
prostate,2919,B-Disease
cancer,2919,I-Disease
patients,2919,O
without,2919,O
bone,2919,O
involvement,2919,O
.,2919,O
BACKGROUND,2920,O
:,2920,O
To,2920,O
determine,2920,O
the,2920,O
onset,2920,O
and,2920,O
extent,2920,O
of,2920,O
combined,2920,O
androgen,2920,O
blockade,2920,O
(,2920,O
CAB,2920,O
),2920,O
-induced,2920,O
anemia,2920,B-Disease
in,2920,O
prostate,2920,B-Disease
cancer,2920,I-Disease
patients,2920,O
without,2920,O
bone,2920,O
involvement,2920,O
.,2920,O
PATIENTS,2921,O
AND,2921,O
METHODS,2921,O
:,2921,O
Forty-two,2921,O
patients,2921,O
with,2921,O
biopsy-proven,2921,O
prostatic,2921,B-Disease
adenocarcinoma,2921,I-Disease
[,2921,O
26,2921,O
with,2921,O
stage,2921,O
C,2921,O
(,2921,O
T3N0M0,2921,O
),2921,O
and,2921,O
16,2921,O
with,2921,O
stage,2921,O
D1,2921,O
(,2921,O
T3N1M0,2921,O
),2921,O
],2921,O
were,2921,O
included,2921,O
in,2921,O
this,2921,O
study,2921,O
.,2921,O
All,2922,O
patients,2922,O
received,2922,O
CAB,2922,O
[,2922,O
leuprolide,2922,B-Chemical
acetate,2922,I-Chemical
(,2922,O
LHRH-A,2922,B-Chemical
),2922,O
3.75,2922,O
mg,2922,O
",",2922,O
intramuscularly,2922,O
",",2922,O
every,2922,O
28,2922,O
days,2922,O
plus,2922,O
250,2922,O
mg,2922,O
flutamide,2922,B-Chemical
",",2922,O
tid,2922,O
",",2922,O
per,2922,O
Os,2922,O
],2922,O
and,2922,O
were,2922,O
evaluated,2922,O
for,2922,O
anemia,2922,B-Disease
by,2922,O
physical,2922,O
examination,2922,O
and,2922,O
laboratory,2922,O
tests,2922,O
at,2922,O
baseline,2922,O
and,2922,O
4,2922,O
subsequent,2922,O
intervals,2922,O
(,2922,O
1,2922,O
",",2922,O
2,2922,O
",",2922,O
3,2922,O
and,2922,O
6,2922,O
months,2922,O
post-CAB,2922,O
),2922,O
.,2922,O
Hb,2923,O
",",2923,O
PSA,2923,O
and,2923,O
Testosterone,2923,B-Chemical
measurements,2923,O
were,2923,O
recorded,2923,O
.,2923,O
Patients,2924,O
with,2924,O
stage,2924,O
D2-3,2924,O
disease,2924,O
",",2924,O
abnormal,2924,O
hemoglobin,2924,O
level,2924,O
or,2924,O
renal,2924,O
and,2924,O
liver,2924,O
function,2924,O
tests,2924,O
that,2924,O
were,2924,O
higher,2924,O
than,2924,O
the,2924,O
upper,2924,O
limits,2924,O
were,2924,O
excluded,2924,O
from,2924,O
the,2924,O
study,2924,O
.,2924,O
The,2925,O
duration,2925,O
of,2925,O
the,2925,O
study,2925,O
was,2925,O
six,2925,O
months,2925,O
.,2925,O
RESULTS,2926,O
:,2926,O
The,2926,O
mean,2926,O
hemoglobin,2926,O
(,2926,O
Hb,2926,O
),2926,O
levels,2926,O
were,2926,O
significantly,2926,O
declined,2926,O
in,2926,O
all,2926,O
patients,2926,O
from,2926,O
baseline,2926,O
of,2926,O
14.2,2926,O
g/dl,2926,O
to,2926,O
14.0,2926,O
g/dl,2926,O
",",2926,O
13.5,2926,O
g/dl,2926,O
",",2926,O
13.2,2926,O
g/dl,2926,O
and,2926,O
12.7,2926,O
g/dl,2926,O
at,2926,O
1,2926,O
",",2926,O
2,2926,O
",",2926,O
3,2926,O
and,2926,O
6,2926,O
months,2926,O
post-CAB,2926,O
",",2926,O
respectively,2926,O
.,2926,O
Severe,2927,O
and,2927,O
clinically,2927,O
evident,2927,O
anemia,2927,B-Disease
of,2927,O
Hb,2927,O
<,2927,O
11,2927,O
g/dl,2927,O
with,2927,O
clinical,2927,O
symptoms,2927,O
was,2927,O
detected,2927,O
in,2927,O
6,2927,O
patients,2927,O
(,2927,O
14.3,2927,O
%,2927,O
),2927,O
.,2927,O
This,2928,O
CAB-induced,2928,O
anemia,2928,B-Disease
was,2928,O
normochromic,2928,O
and,2928,O
normocytic,2928,O
.,2928,O
At,2929,O
six,2929,O
months,2929,O
post-CAB,2929,O
",",2929,O
patients,2929,O
with,2929,O
severe,2929,O
anemia,2929,B-Disease
had,2929,O
a,2929,O
Hb,2929,O
mean,2929,O
value,2929,O
of,2929,O
10.2,2929,O
+/-,2929,O
0.1,2929,O
g/dl,2929,O
(,2929,O
X,2929,O
+/-,2929,O
SE,2929,O
),2929,O
",",2929,O
whereas,2929,O
the,2929,O
other,2929,O
patients,2929,O
had,2929,O
mild,2929,O
anemia,2929,B-Disease
with,2929,O
Hb,2929,O
mean,2929,O
value,2929,O
of,2929,O
13.2,2929,O
+/-,2929,O
0.17,2929,O
(,2929,O
X,2929,O
+/-,2929,O
SE,2929,O
),2929,O
.,2929,O
The,2930,O
development,2930,O
of,2930,O
severe,2930,O
anemia,2930,B-Disease
at,2930,O
6,2930,O
months,2930,O
post-CAB,2930,O
was,2930,O
predictable,2930,O
by,2930,O
the,2930,O
reduction,2930,O
of,2930,O
Hb,2930,O
baseline,2930,O
value,2930,O
of,2930,O
more,2930,O
than,2930,O
2.5,2930,O
g/dl,2930,O
after,2930,O
3,2930,O
months,2930,O
of,2930,O
CAB,2930,O
(,2930,O
p,2930,O
=,2930,O
0.01,2930,O
),2930,O
.,2930,O
The,2931,O
development,2931,O
of,2931,O
severe,2931,O
CAB-induced,2931,O
anemia,2931,B-Disease
in,2931,O
prostate,2931,B-Disease
cancer,2931,I-Disease
patients,2931,O
did,2931,O
not,2931,O
correlate,2931,O
with,2931,O
T,2931,O
baseline,2931,O
values,2931,O
(,2931,O
T,2931,O
<,2931,O
3,2931,O
ng/ml,2931,O
versus,2931,O
T,2931,O
>,2931,O
or,2931,O
=,2931,O
3,2931,O
ng/ml,2931,O
),2931,O
",",2931,O
with,2931,O
age,2931,O
(,2931,O
<,2931,O
76,2931,O
yrs,2931,O
versus,2931,O
>,2931,O
or,2931,O
=,2931,O
76,2931,O
yrs,2931,O
),2931,O
",",2931,O
and,2931,O
clinical,2931,O
stage,2931,O
(,2931,O
stage,2931,O
C,2931,O
versus,2931,O
stage,2931,O
D1,2931,O
),2931,O
.,2931,O
Severe,2932,O
and,2932,O
clinically,2932,O
evident,2932,O
anemia,2932,B-Disease
was,2932,O
easily,2932,O
corrected,2932,O
by,2932,O
subcutaneous,2932,O
injections,2932,O
(,2932,O
3,2932,O
times/week,2932,O
for,2932,O
1,2932,O
month,2932,O
),2932,O
of,2932,O
recombinant,2932,O
erythropoietin,2932,O
(,2932,O
rHuEPO-beta,2932,O
),2932,O
.,2932,O
CONCLUSION,2933,O
:,2933,O
Our,2933,O
data,2933,O
suggest,2933,O
that,2933,O
rHuEPO-beta,2933,O
correctable,2933,O
CAB-induced,2933,O
anemia,2933,B-Disease
occurs,2933,O
in,2933,O
14.3,2933,O
%,2933,O
of,2933,O
prostate,2933,B-Disease
cancer,2933,I-Disease
patients,2933,O
after,2933,O
6,2933,O
months,2933,O
of,2933,O
therapy,2933,O
.,2933,O
Delirium,2934,B-Disease
during,2934,O
clozapine,2934,B-Chemical
treatment,2934,O
:,2934,O
incidence,2934,O
and,2934,O
associated,2934,O
risk,2934,O
factors,2934,O
.,2934,O
BACKGROUND,2935,O
:,2935,O
Incidence,2935,O
and,2935,O
risk,2935,O
factors,2935,O
for,2935,O
delirium,2935,B-Disease
during,2935,O
clozapine,2935,B-Chemical
treatment,2935,O
require,2935,O
further,2935,O
clarification,2935,O
.,2935,O
METHODS,2936,O
:,2936,O
We,2936,O
used,2936,O
computerized,2936,O
pharmacy,2936,O
records,2936,O
to,2936,O
identify,2936,O
all,2936,O
adult,2936,O
psychiatric,2936,B-Disease
inpatients,2936,O
treated,2936,O
with,2936,O
clozapine,2936,B-Chemical
(,2936,O
1995-96,2936,O
),2936,O
",",2936,O
reviewed,2936,O
their,2936,O
medical,2936,O
records,2936,O
to,2936,O
score,2936,O
incidence,2936,O
and,2936,O
severity,2936,O
of,2936,O
delirium,2936,B-Disease
",",2936,O
and,2936,O
tested,2936,O
associations,2936,O
with,2936,O
potential,2936,O
risk,2936,O
factors,2936,O
.,2936,O
RESULTS,2937,O
:,2937,O
Subjects,2937,O
(,2937,O
n,2937,O
=,2937,O
139,2937,O
),2937,O
were,2937,O
72,2937,O
women,2937,O
and,2937,O
67,2937,O
men,2937,O
",",2937,O
aged,2937,O
40.8,2937,O
+/-,2937,O
12.1,2937,O
years,2937,O
",",2937,O
hospitalized,2937,O
for,2937,O
24.9,2937,O
+/-,2937,O
23.3,2937,O
days,2937,O
",",2937,O
and,2937,O
given,2937,O
clozapine,2937,B-Chemical
",",2937,O
gradually,2937,O
increased,2937,O
to,2937,O
an,2937,O
average,2937,O
daily,2937,O
dose,2937,O
of,2937,O
282,2937,O
+/-,2937,O
203,2937,O
mg,2937,O
(,2937,O
3.45,2937,O
+/-,2937,O
2.45,2937,O
mg/kg,2937,O
),2937,O
for,2937,O
18.9,2937,O
+/-,2937,O
16.4,2937,O
days,2937,O
.,2937,O
Delirium,2938,B-Disease
was,2938,O
diagnosed,2938,O
in,2938,O
14,2938,O
(,2938,O
10.1,2938,O
%,2938,O
incidence,2938,O
",",2938,O
or,2938,O
1.48,2938,O
cases/person-years,2938,O
of,2938,O
exposure,2938,O
),2938,O
;,2938,O
71.4,2938,O
%,2938,O
of,2938,O
cases,2938,O
were,2938,O
moderate,2938,O
or,2938,O
severe,2938,O
.,2938,O
Associated,2939,O
factors,2939,O
were,2939,O
co-treatment,2939,O
with,2939,O
other,2939,O
centrally,2939,O
antimuscarinic,2939,O
agents,2939,O
",",2939,O
poor,2939,O
clinical,2939,O
outcome,2939,O
",",2939,O
older,2939,O
age,2939,O
",",2939,O
and,2939,O
longer,2939,O
hospitalization,2939,O
(,2939,O
by,2939,O
17.5,2939,O
days,2939,O
",",2939,O
increasing,2939,O
cost,2939,O
),2939,O
;,2939,O
sex,2939,O
",",2939,O
diagnosis,2939,O
or,2939,O
medical,2939,O
co-morbidity,2939,O
",",2939,O
and,2939,O
daily,2939,O
clozapine,2939,B-Chemical
dose,2939,O
",",2939,O
which,2939,O
fell,2939,O
with,2939,O
age,2939,O
",",2939,O
were,2939,O
unrelated,2939,O
.,2939,O
CONCLUSIONS,2940,O
:,2940,O
Delirium,2940,B-Disease
was,2940,O
found,2940,O
in,2940,O
10,2940,O
%,2940,O
of,2940,O
clozapine-treated,2940,B-Chemical
inpatients,2940,O
",",2940,O
particularly,2940,O
in,2940,O
older,2940,O
patients,2940,O
exposed,2940,O
to,2940,O
other,2940,O
central,2940,O
anticholinergics,2940,O
.,2940,O
Delirium,2941,B-Disease
was,2941,O
inconsistently,2941,O
recognized,2941,O
clinically,2941,O
in,2941,O
milder,2941,O
cases,2941,O
and,2941,O
was,2941,O
associated,2941,O
with,2941,O
increased,2941,O
length-of-stay,2941,O
and,2941,O
higher,2941,O
costs,2941,O
",",2941,O
and,2941,O
inferior,2941,O
clinical,2941,O
outcome,2941,O
.,2941,O
Neuroprotective,2942,O
action,2942,O
of,2942,O
MPEP,2942,B-Chemical
",",2942,O
a,2942,O
selective,2942,O
mGluR5,2942,O
antagonist,2942,O
",",2942,O
in,2942,O
methamphetamine-induced,2942,B-Chemical
dopaminergic,2942,O
neurotoxicity,2942,B-Disease
is,2942,O
associated,2942,O
with,2942,O
a,2942,O
decrease,2942,O
in,2942,O
dopamine,2942,B-Chemical
outflow,2942,O
and,2942,O
inhibition,2942,O
of,2942,O
hyperthermia,2942,B-Disease
in,2942,O
rats,2942,O
.,2942,O
The,2943,O
aim,2943,O
of,2943,O
this,2943,O
study,2943,O
was,2943,O
to,2943,O
examine,2943,O
the,2943,O
role,2943,O
of,2943,O
metabotropic,2943,O
glutamate,2943,B-Chemical
receptor,2943,O
5,2943,O
(,2943,O
mGluR5,2943,O
),2943,O
in,2943,O
the,2943,O
toxic,2943,O
action,2943,O
of,2943,O
methamphetamine,2943,B-Chemical
on,2943,O
dopaminergic,2943,O
neurones,2943,O
in,2943,O
rats,2943,O
.,2943,O
Methamphetamine,2944,B-Chemical
(,2944,O
10,2944,O
mg/kg,2944,O
sc,2944,O
),2944,O
",",2944,O
administered,2944,O
five,2944,O
times,2944,O
",",2944,O
reduced,2944,O
the,2944,O
levels,2944,O
of,2944,O
dopamine,2944,B-Chemical
and,2944,O
its,2944,O
metabolites,2944,O
in,2944,O
striatal,2944,O
tissue,2944,O
when,2944,O
measured,2944,O
72,2944,O
h,2944,O
after,2944,O
the,2944,O
last,2944,O
injection,2944,O
.,2944,O
A,2945,O
selective,2945,O
antagonist,2945,O
of,2945,O
mGluR5,2945,O
",",2945,O
2-methyl-6-,2945,B-Chemical
(,2945,I-Chemical
phenylethynyl,2945,I-Chemical
),2945,I-Chemical
pyridine,2945,I-Chemical
(,2945,O
MPEP,2945,B-Chemical
;,2945,O
5,2945,O
mg/kg,2945,O
ip,2945,O
),2945,O
",",2945,O
when,2945,O
administered,2945,O
five,2945,O
times,2945,O
immediately,2945,O
before,2945,O
each,2945,O
methamphetamine,2945,B-Chemical
injection,2945,O
reversed,2945,O
the,2945,O
above-mentioned,2945,O
methamphetamine,2945,B-Chemical
effects,2945,O
.,2945,O
A,2946,O
single,2946,O
MPEP,2946,B-Chemical
(,2946,O
5,2946,O
mg/kg,2946,O
ip,2946,O
),2946,O
injection,2946,O
reduced,2946,O
the,2946,O
basal,2946,O
extracellular,2946,O
dopamine,2946,B-Chemical
level,2946,O
in,2946,O
the,2946,O
striatum,2946,O
",",2946,O
as,2946,O
well,2946,O
as,2946,O
dopamine,2946,B-Chemical
release,2946,O
stimulated,2946,O
either,2946,O
by,2946,O
methamphetamine,2946,B-Chemical
(,2946,O
10,2946,O
mg/kg,2946,O
sc,2946,O
),2946,O
or,2946,O
by,2946,O
intrastriatally,2946,O
administered,2946,O
veratridine,2946,B-Chemical
(,2946,O
100,2946,O
microM,2946,O
),2946,O
.,2946,O
Moreover,2947,O
",",2947,O
it,2947,O
transiently,2947,O
diminished,2947,O
the,2947,O
methamphetamine,2947,B-Chemical
(,2947,O
10,2947,O
mg/kg,2947,O
sc,2947,O
),2947,O
-induced,2947,O
hyperthermia,2947,B-Disease
and,2947,O
reduced,2947,O
basal,2947,O
body,2947,O
temperature,2947,O
.,2947,O
MPEP,2948,B-Chemical
administered,2948,O
into,2948,O
the,2948,O
striatum,2948,O
at,2948,O
high,2948,O
concentrations,2948,O
(,2948,O
500,2948,O
microM,2948,O
),2948,O
increased,2948,O
extracellular,2948,O
dopamine,2948,B-Chemical
levels,2948,O
",",2948,O
while,2948,O
lower,2948,O
concentrations,2948,O
(,2948,O
50-100,2948,O
microM,2948,O
),2948,O
were,2948,O
devoid,2948,O
of,2948,O
any,2948,O
effect,2948,O
.,2948,O
The,2949,O
results,2949,O
of,2949,O
this,2949,O
study,2949,O
suggest,2949,O
that,2949,O
the,2949,O
blockade,2949,O
of,2949,O
mGluR5,2949,O
by,2949,O
MPEP,2949,B-Chemical
may,2949,O
protect,2949,O
dopaminergic,2949,O
neurones,2949,O
against,2949,O
methamphetamine-induced,2949,B-Chemical
toxicity,2949,B-Disease
.,2949,O
Neuroprotection,2950,O
rendered,2950,O
by,2950,O
MPEP,2950,B-Chemical
may,2950,O
be,2950,O
associated,2950,O
with,2950,O
the,2950,O
reduction,2950,O
of,2950,O
the,2950,O
methamphetamine-induced,2950,B-Chemical
dopamine,2950,B-Chemical
efflux,2950,O
in,2950,O
the,2950,O
striatum,2950,O
due,2950,O
to,2950,O
the,2950,O
blockade,2950,O
of,2950,O
extrastriatal,2950,O
mGluR5,2950,O
",",2950,O
and,2950,O
with,2950,O
a,2950,O
decrease,2950,O
in,2950,O
hyperthermia,2950,B-Disease
.,2950,O
Protective,2951,O
efficacy,2951,O
of,2951,O
neuroactive,2951,O
steroids,2951,B-Chemical
against,2951,O
cocaine,2951,B-Chemical
kindled-seizures,2951,O
in,2951,O
mice,2951,O
.,2951,O
Neuroactive,2952,O
steroids,2952,B-Chemical
demonstrate,2952,O
pharmacological,2952,O
actions,2952,O
that,2952,O
have,2952,O
relevance,2952,O
for,2952,O
a,2952,O
host,2952,O
of,2952,O
neurological,2952,O
and,2952,O
psychiatric,2952,O
disorders,2952,O
.,2952,O
They,2953,O
offer,2953,O
protection,2953,O
against,2953,O
seizures,2953,B-Disease
in,2953,O
a,2953,O
range,2953,O
of,2953,O
models,2953,O
and,2953,O
seem,2953,O
to,2953,O
inhibit,2953,O
certain,2953,O
stages,2953,O
of,2953,O
drug,2953,B-Disease
dependence,2953,I-Disease
in,2953,O
preclinical,2953,O
assessments,2953,O
.,2953,O
The,2954,O
present,2954,O
study,2954,O
was,2954,O
designed,2954,O
to,2954,O
evaluate,2954,O
two,2954,O
endogenous,2954,O
and,2954,O
one,2954,O
synthetic,2954,O
neuroactive,2954,O
steroid,2954,B-Chemical
that,2954,O
positively,2954,O
modulate,2954,O
the,2954,O
gamma-aminobutyric,2954,B-Chemical
acid,2954,I-Chemical
(,2954,O
GABA,2954,B-Chemical
(,2954,O
A,2954,O
),2954,O
),2954,O
receptor,2954,O
against,2954,O
the,2954,O
increase,2954,O
in,2954,O
sensitivity,2954,O
to,2954,O
the,2954,O
convulsant,2954,O
effects,2954,O
of,2954,O
cocaine,2954,B-Chemical
engendered,2954,O
by,2954,O
repeated,2954,O
cocaine,2954,B-Chemical
administration,2954,O
(,2954,O
seizure,2954,B-Disease
kindling,2954,O
),2954,O
.,2954,O
Allopregnanolone,2955,B-Chemical
(,2955,O
3alpha-hydroxy-5alpha-pregnan-20-one,2955,B-Chemical
),2955,O
",",2955,O
pregnanolone,2955,B-Chemical
(,2955,O
3alpha-hydroxy-5beta-pregnan-20-one,2955,B-Chemical
),2955,O
and,2955,O
ganaxolone,2955,B-Chemical
(,2955,O
a,2955,O
synthetic,2955,O
derivative,2955,O
of,2955,O
allopregnanolone,2955,B-Chemical
3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one,2955,B-Chemical
),2955,O
were,2955,O
tested,2955,O
for,2955,O
their,2955,O
ability,2955,O
to,2955,O
suppress,2955,O
the,2955,O
expression,2955,O
(,2955,O
anticonvulsant,2955,O
effect,2955,O
),2955,O
and,2955,O
development,2955,O
(,2955,O
antiepileptogenic,2955,O
effect,2955,O
),2955,O
of,2955,O
cocaine-kindled,2955,B-Chemical
seizures,2955,B-Disease
in,2955,O
male,2955,O
",",2955,O
Swiss-Webster,2955,O
mice,2955,O
.,2955,O
Kindled,2956,O
seizures,2956,B-Disease
were,2956,O
induced,2956,O
by,2956,O
daily,2956,O
administration,2956,O
of,2956,O
60,2956,O
mg/kg,2956,O
cocaine,2956,B-Chemical
for,2956,O
5,2956,O
days,2956,O
.,2956,O
All,2957,O
of,2957,O
these,2957,O
positive,2957,O
GABA,2957,B-Chemical
(,2957,O
A,2957,O
),2957,O
modulators,2957,O
suppressed,2957,O
the,2957,O
expression,2957,O
of,2957,O
kindled,2957,O
seizures,2957,B-Disease
",",2957,O
whereas,2957,O
only,2957,O
allopregnanolone,2957,B-Chemical
and,2957,O
ganaxolone,2957,B-Chemical
inhibited,2957,O
the,2957,O
development,2957,O
of,2957,O
kindling,2957,O
.,2957,O
Allopregnanolone,2958,B-Chemical
and,2958,O
pregnanolone,2958,B-Chemical
",",2958,O
but,2958,O
not,2958,O
ganaxolone,2958,B-Chemical
",",2958,O
also,2958,O
reduced,2958,O
cumulative,2958,O
lethality,2958,O
associated,2958,O
with,2958,O
kindling,2958,O
.,2958,O
These,2959,O
findings,2959,O
demonstrate,2959,O
that,2959,O
some,2959,O
neuroactive,2959,O
steroids,2959,B-Chemical
attenuate,2959,O
convulsant,2959,O
and,2959,O
sensitizing,2959,O
properties,2959,O
of,2959,O
cocaine,2959,B-Chemical
and,2959,O
add,2959,O
to,2959,O
a,2959,O
growing,2959,O
literature,2959,O
on,2959,O
their,2959,O
potential,2959,O
use,2959,O
in,2959,O
the,2959,O
modulation,2959,O
of,2959,O
effects,2959,O
of,2959,O
drugs,2959,O
of,2959,O
abuse,2959,O
.,2959,O
Ketoconazole-induced,2960,B-Chemical
neurologic,2960,B-Disease
sequelae,2960,I-Disease
.,2960,O
A,2961,O
77-y-old,2961,O
patient,2961,O
developed,2961,O
weakness,2961,B-Disease
of,2961,I-Disease
extremities,2961,I-Disease
",",2961,O
legs,2961,B-Disease
paralysis,2961,I-Disease
",",2961,O
dysarthria,2961,B-Disease
and,2961,O
tremor,2961,B-Disease
1,2961,O
h,2961,O
after,2961,O
ingestion,2961,O
of,2961,O
200,2961,O
mg,2961,O
ketoconazole,2961,B-Chemical
for,2961,O
the,2961,O
first,2961,O
time,2961,O
in,2961,O
his,2961,O
life,2961,O
.,2961,O
All,2962,O
complaints,2962,O
faded,2962,O
away,2962,O
within,2962,O
24,2962,O
h.,2962,O
Few,2962,O
days,2962,O
later,2962,O
",",2962,O
the,2962,O
patient,2962,O
used,2962,O
another,2962,O
200,2962,O
mg,2962,O
ketoconazole,2962,B-Chemical
tablet,2962,O
",",2962,O
and,2962,O
within,2962,O
an,2962,O
hour,2962,O
experienced,2962,O
a,2962,O
similar,2962,O
clinical,2962,O
picture,2962,O
",",2962,O
which,2962,O
resolved,2962,O
again,2962,O
spontaneously,2962,O
within,2962,O
hours,2962,O
.,2962,O
Laboratory,2963,O
evaluations,2963,O
",",2963,O
including,2963,O
head,2963,O
CT,2963,O
scan,2963,O
",",2963,O
were,2963,O
normal,2963,O
.,2963,O
This,2964,O
case,2964,O
illustrates,2964,O
the,2964,O
need,2964,O
for,2964,O
close,2964,O
vigilance,2964,O
in,2964,O
adverse,2964,B-Disease
drug,2964,I-Disease
reactions,2964,I-Disease
",",2964,O
particularly,2964,O
in,2964,O
the,2964,O
elderly,2964,O
.,2964,O
Development,2965,O
of,2965,O
levodopa-induced,2965,B-Chemical
dyskinesias,2965,B-Disease
in,2965,O
parkinsonian,2965,B-Disease
monkeys,2965,O
may,2965,O
depend,2965,O
upon,2965,O
rate,2965,O
of,2965,O
symptom,2965,O
onset,2965,O
and/or,2965,O
duration,2965,O
of,2965,O
symptoms,2965,O
.,2965,O
Levodopa-induced,2966,B-Chemical
dyskinesias,2966,B-Disease
(,2966,O
LIDs,2966,B-Disease
),2966,O
present,2966,O
a,2966,O
major,2966,O
problem,2966,O
for,2966,O
the,2966,O
long-term,2966,O
management,2966,O
of,2966,O
Parkinson,2966,B-Disease
's,2966,I-Disease
disease,2966,I-Disease
(,2966,O
PD,2966,B-Disease
),2966,O
patients,2966,O
.,2966,O
Due,2967,O
to,2967,O
the,2967,O
interdependence,2967,O
of,2967,O
risk,2967,O
factors,2967,O
in,2967,O
clinical,2967,O
populations,2967,O
",",2967,O
it,2967,O
is,2967,O
difficult,2967,O
to,2967,O
independently,2967,O
examine,2967,O
factors,2967,O
that,2967,O
may,2967,O
influence,2967,O
the,2967,O
development,2967,O
of,2967,O
LIDs,2967,B-Disease
.,2967,O
Using,2968,O
macaque,2968,O
monkeys,2968,O
with,2968,O
different,2968,O
types,2968,O
of,2968,O
MPTP-induced,2968,B-Chemical
parkinsonism,2968,B-Disease
",",2968,O
the,2968,O
current,2968,O
study,2968,O
evaluated,2968,O
the,2968,O
degree,2968,O
to,2968,O
which,2968,O
rate,2968,O
of,2968,O
symptom,2968,O
progression,2968,O
",",2968,O
symptom,2968,O
severity,2968,O
",",2968,O
and,2968,O
response,2968,O
to,2968,O
and,2968,O
duration,2968,O
of,2968,O
levodopa,2968,B-Chemical
therapy,2968,O
may,2968,O
be,2968,O
involved,2968,O
in,2968,O
the,2968,O
development,2968,O
of,2968,O
LIDs,2968,B-Disease
.,2968,O
Monkeys,2969,O
with,2969,O
acute,2969,O
(,2969,O
short-term,2969,O
),2969,O
MPTP,2969,B-Chemical
exposure,2969,O
",",2969,O
rapid,2969,O
symptom,2969,O
onset,2969,O
and,2969,O
short,2969,O
symptom,2969,O
duration,2969,O
prior,2969,O
to,2969,O
initiation,2969,O
of,2969,O
levodopa,2969,B-Chemical
therapy,2969,O
developed,2969,O
dyskinesia,2969,B-Disease
between,2969,O
11,2969,O
and,2969,O
24,2969,O
days,2969,O
of,2969,O
daily,2969,O
levodopa,2969,B-Chemical
administration,2969,O
.,2969,O
In,2970,O
contrast,2970,O
",",2970,O
monkeys,2970,O
with,2970,O
long-term,2970,O
MPTP,2970,B-Chemical
exposure,2970,O
",",2970,O
slow,2970,O
symptom,2970,O
progression,2970,O
and/or,2970,O
long,2970,O
symptom,2970,O
duration,2970,O
prior,2970,O
to,2970,O
initiation,2970,O
of,2970,O
levodopa,2970,B-Chemical
therapy,2970,O
were,2970,O
more,2970,O
resistant,2970,O
to,2970,O
developing,2970,O
LIDs,2970,B-Disease
(,2970,O
e.g.,2970,O
",",2970,O
dyskinesia,2970,B-Disease
developed,2970,O
no,2970,O
sooner,2970,O
than,2970,O
146,2970,O
days,2970,O
of,2970,O
chronic,2970,O
levodopa,2970,B-Chemical
administration,2970,O
),2970,O
.,2970,O
All,2971,O
animals,2971,O
were,2971,O
similarly,2971,O
symptomatic,2971,O
at,2971,O
the,2971,O
start,2971,O
of,2971,O
levodopa,2971,B-Chemical
treatment,2971,O
and,2971,O
had,2971,O
similar,2971,O
therapeutic,2971,O
responses,2971,O
to,2971,O
the,2971,O
drug,2971,O
.,2971,O
These,2972,O
data,2972,O
suggest,2972,O
distinct,2972,O
differences,2972,O
in,2972,O
the,2972,O
propensity,2972,O
to,2972,O
develop,2972,O
LIDs,2972,B-Disease
in,2972,O
monkeys,2972,O
with,2972,O
different,2972,O
rates,2972,O
of,2972,O
symptom,2972,O
progression,2972,O
or,2972,O
symptom,2972,O
durations,2972,O
prior,2972,O
to,2972,O
levodopa,2972,B-Chemical
and,2972,O
demonstrate,2972,O
the,2972,O
value,2972,O
of,2972,O
these,2972,O
models,2972,O
for,2972,O
further,2972,O
studying,2972,O
the,2972,O
pathophysiology,2972,O
of,2972,O
LIDs,2972,B-Disease
.,2972,O
A,2973,O
diet,2973,O
promoting,2973,O
sugar,2973,B-Disease
dependency,2973,I-Disease
causes,2973,O
behavioral,2973,B-Disease
cross-sensitization,2973,I-Disease
to,2973,O
a,2973,O
low,2973,O
dose,2973,O
of,2973,O
amphetamine,2973,B-Chemical
.,2973,O
Previous,2974,O
research,2974,O
in,2974,O
this,2974,O
laboratory,2974,O
has,2974,O
shown,2974,O
that,2974,O
a,2974,O
diet,2974,O
of,2974,O
intermittent,2974,O
excessive,2974,O
sugar,2974,O
consumption,2974,O
produces,2974,O
a,2974,O
state,2974,O
with,2974,O
neurochemical,2974,O
and,2974,O
behavioral,2974,O
similarities,2974,O
to,2974,O
drug,2974,B-Disease
dependency,2974,I-Disease
.,2974,O
The,2975,O
present,2975,O
study,2975,O
examined,2975,O
whether,2975,O
female,2975,O
rats,2975,O
on,2975,O
various,2975,O
regimens,2975,O
of,2975,O
sugar,2975,O
access,2975,O
would,2975,O
show,2975,O
behavioral,2975,B-Disease
cross-sensitization,2975,I-Disease
to,2975,O
a,2975,O
low,2975,O
dose,2975,O
of,2975,O
amphetamine,2975,B-Chemical
.,2975,O
After,2976,O
a,2976,O
30-min,2976,O
baseline,2976,O
measure,2976,O
of,2976,O
locomotor,2976,O
activity,2976,O
(,2976,O
day,2976,O
0,2976,O
),2976,O
",",2976,O
animals,2976,O
were,2976,O
maintained,2976,O
on,2976,O
a,2976,O
cyclic,2976,O
diet,2976,O
of,2976,O
12-h,2976,O
deprivation,2976,O
followed,2976,O
by,2976,O
12-h,2976,O
access,2976,O
to,2976,O
10,2976,O
%,2976,O
sucrose,2976,B-Chemical
solution,2976,O
and,2976,O
chow,2976,O
pellets,2976,O
(,2976,O
12,2976,O
h,2976,O
access,2976,O
starting,2976,O
4,2976,O
h,2976,O
after,2976,O
onset,2976,O
of,2976,O
the,2976,O
dark,2976,O
period,2976,O
),2976,O
for,2976,O
21,2976,O
days,2976,O
.,2976,O
Locomotor,2977,O
activity,2977,O
was,2977,O
measured,2977,O
again,2977,O
for,2977,O
30,2977,O
min,2977,O
at,2977,O
the,2977,O
beginning,2977,O
of,2977,O
days,2977,O
1,2977,O
and,2977,O
21,2977,O
of,2977,O
sugar,2977,O
access,2977,O
.,2977,O
Beginning,2978,O
on,2978,O
day,2978,O
22,2978,O
",",2978,O
all,2978,O
rats,2978,O
were,2978,O
maintained,2978,O
on,2978,O
ad,2978,O
libitum,2978,O
chow,2978,O
.,2978,O
Nine,2979,O
days,2979,O
later,2979,O
locomotor,2979,O
activity,2979,O
was,2979,O
measured,2979,O
in,2979,O
response,2979,O
to,2979,O
a,2979,O
single,2979,O
low,2979,O
dose,2979,O
of,2979,O
amphetamine,2979,B-Chemical
(,2979,O
0.5,2979,O
mg/kg,2979,O
),2979,O
.,2979,O
The,2980,O
animals,2980,O
that,2980,O
had,2980,O
experienced,2980,O
cyclic,2980,O
sucrose,2980,B-Chemical
and,2980,O
chow,2980,O
were,2980,O
hyperactive,2980,B-Disease
in,2980,O
response,2980,O
to,2980,O
amphetamine,2980,B-Chemical
compared,2980,O
with,2980,O
four,2980,O
control,2980,O
groups,2980,O
(,2980,O
ad,2980,O
libitum,2980,O
10,2980,O
%,2980,O
sucrose,2980,B-Chemical
and,2980,O
chow,2980,O
followed,2980,O
by,2980,O
amphetamine,2980,B-Chemical
injection,2980,O
",",2980,O
cyclic,2980,O
chow,2980,O
followed,2980,O
by,2980,O
amphetamine,2980,B-Chemical
injection,2980,O
",",2980,O
ad,2980,O
libitum,2980,O
chow,2980,O
with,2980,O
amphetamine,2980,B-Chemical
",",2980,O
or,2980,O
cyclic,2980,O
10,2980,O
%,2980,O
sucrose,2980,B-Chemical
and,2980,O
chow,2980,O
with,2980,O
a,2980,O
saline,2980,O
injection,2980,O
),2980,O
.,2980,O
These,2981,O
results,2981,O
suggest,2981,O
that,2981,O
a,2981,O
diet,2981,O
comprised,2981,O
of,2981,O
alternating,2981,O
deprivation,2981,O
and,2981,O
access,2981,O
to,2981,O
a,2981,O
sugar,2981,O
solution,2981,O
and,2981,O
chow,2981,O
produces,2981,O
bingeing,2981,O
on,2981,O
sugar,2981,O
that,2981,O
leads,2981,O
to,2981,O
a,2981,O
long,2981,O
lasting,2981,O
state,2981,O
of,2981,O
increased,2981,O
sensitivity,2981,O
to,2981,O
amphetamine,2981,B-Chemical
",",2981,O
possibly,2981,O
due,2981,O
to,2981,O
a,2981,O
lasting,2981,O
alteration,2981,O
in,2981,O
the,2981,O
dopamine,2981,B-Chemical
system,2981,O
.,2981,O
Reversible,2982,O
dilated,2982,B-Disease
cardiomyopathy,2982,I-Disease
related,2982,O
to,2982,O
amphotericin,2982,B-Chemical
B,2982,I-Chemical
therapy,2982,O
.,2982,O
We,2983,O
describe,2983,O
a,2983,O
patient,2983,O
who,2983,O
developed,2983,O
dilated,2983,B-Disease
cardiomyopathy,2983,I-Disease
and,2983,O
clinical,2983,O
congestive,2983,O
heart,2983,B-Disease
failure,2983,I-Disease
after,2983,O
2,2983,O
months,2983,O
of,2983,O
therapy,2983,O
with,2983,O
amphotericin,2983,B-Chemical
B,2983,I-Chemical
(,2983,O
AmB,2983,B-Chemical
),2983,O
for,2983,O
disseminated,2983,O
coccidioidomycosis,2983,B-Disease
.,2983,O
His,2984,O
echocardiographic,2984,O
abnormalities,2984,O
and,2984,O
heart,2984,B-Disease
failure,2984,I-Disease
resolved,2984,O
after,2984,O
posaconazole,2984,B-Chemical
was,2984,O
substituted,2984,O
for,2984,O
AmB,2984,B-Chemical
.,2984,O
It,2985,O
is,2985,O
important,2985,O
to,2985,O
recognize,2985,O
the,2985,O
rare,2985,O
and,2985,O
potentially,2985,O
reversible,2985,O
toxicity,2985,B-Disease
of,2985,O
AmB,2985,B-Chemical
.,2985,O
NO-induced,2986,B-Chemical
migraine,2986,B-Disease
attack,2986,O
:,2986,O
strong,2986,O
increase,2986,O
in,2986,O
plasma,2986,O
calcitonin,2986,B-Chemical
gene-related,2986,I-Chemical
peptide,2986,I-Chemical
(,2986,O
CGRP,2986,B-Chemical
),2986,O
concentration,2986,O
and,2986,O
negative,2986,O
correlation,2986,O
with,2986,O
platelet,2986,O
serotonin,2986,B-Chemical
release,2986,O
.,2986,O
The,2987,O
aim,2987,O
of,2987,O
the,2987,O
present,2987,O
study,2987,O
was,2987,O
to,2987,O
investigate,2987,O
changes,2987,O
in,2987,O
the,2987,O
plasma,2987,O
calcitonin,2987,B-Chemical
gene-related,2987,I-Chemical
peptide,2987,I-Chemical
(,2987,O
CGRP,2987,B-Chemical
),2987,O
concentration,2987,O
and,2987,O
platelet,2987,O
serotonin,2987,B-Chemical
(,2987,O
5-hydroxytriptamine,2987,B-Chemical
",",2987,O
5-HT,2987,B-Chemical
),2987,O
content,2987,O
during,2987,O
the,2987,O
immediate,2987,O
headache,2987,B-Disease
and,2987,O
the,2987,O
delayed,2987,O
genuine,2987,O
migraine,2987,B-Disease
attack,2987,O
provoked,2987,O
by,2987,O
nitroglycerin,2987,B-Chemical
.,2987,O
Fifteen,2988,O
female,2988,O
migraineurs,2988,B-Disease
(,2988,I-Disease
without,2988,I-Disease
aura,2988,I-Disease
),2988,I-Disease
and,2988,O
eight,2988,O
controls,2988,O
participated,2988,O
in,2988,O
the,2988,O
study,2988,O
.,2988,O
Sublingual,2989,O
nitroglycerin,2989,B-Chemical
(,2989,O
0.5,2989,O
mg,2989,O
),2989,O
was,2989,O
administered,2989,O
.,2989,O
Blood,2990,O
was,2990,O
collected,2990,O
from,2990,O
the,2990,O
antecubital,2990,O
vein,2990,O
four,2990,O
times,2990,O
:,2990,O
60,2990,O
min,2990,O
before,2990,O
and,2990,O
after,2990,O
the,2990,O
nitroglycerin,2990,B-Chemical
application,2990,O
",",2990,O
and,2990,O
60,2990,O
and,2990,O
120,2990,O
min,2990,O
after,2990,O
the,2990,O
beginning,2990,O
of,2990,O
the,2990,O
migraine,2990,B-Disease
attack,2990,O
(,2990,O
mean,2990,O
344,2990,O
and,2990,O
404,2990,O
min,2990,O
;,2990,O
12,2990,O
subjects,2990,O
),2990,O
.,2990,O
In,2991,O
those,2991,O
subjects,2991,O
who,2991,O
had,2991,O
no,2991,O
migraine,2991,B-Disease
attack,2991,O
(,2991,O
11,2991,O
subjects,2991,O
),2991,O
a,2991,O
similar,2991,O
time,2991,O
schedule,2991,O
was,2991,O
used,2991,O
.,2991,O
Plasma,2992,O
CGRP,2992,B-Chemical
concentration,2992,O
increased,2992,O
significantly,2992,O
(,2992,O
P,2992,O
<,2992,O
0.01,2992,O
),2992,O
during,2992,O
the,2992,O
migraine,2992,B-Disease
attack,2992,O
and,2992,O
returned,2992,O
to,2992,O
baseline,2992,O
after,2992,O
the,2992,O
cessation,2992,O
of,2992,O
the,2992,O
migraine,2992,B-Disease
.,2992,O
In,2993,O
addition,2993,O
",",2993,O
both,2993,O
change,2993,O
and,2993,O
peak,2993,O
",",2993,O
showed,2993,O
significant,2993,O
positive,2993,O
correlations,2993,O
with,2993,O
migraine,2993,B-Disease
headache,2993,B-Disease
intensity,2993,O
(,2993,O
P,2993,O
<,2993,O
0.001,2993,O
),2993,O
.,2993,O
However,2994,O
",",2994,O
plasma,2994,O
CGRP,2994,B-Chemical
concentrations,2994,O
failed,2994,O
to,2994,O
change,2994,O
during,2994,O
immediate,2994,O
headache,2994,B-Disease
and,2994,O
in,2994,O
the,2994,O
subjects,2994,O
with,2994,O
no,2994,O
migraine,2994,B-Disease
attack,2994,O
.,2994,O
Basal,2995,O
CGRP,2995,B-Chemical
concentration,2995,O
was,2995,O
significantly,2995,O
higher,2995,O
and,2995,O
platelet,2995,O
5-HT,2995,B-Chemical
content,2995,O
tended,2995,O
to,2995,O
be,2995,O
lower,2995,O
in,2995,O
subjects,2995,O
who,2995,O
experienced,2995,O
a,2995,O
migraine,2995,B-Disease
attack,2995,O
.,2995,O
Platelet,2996,O
serotonin,2996,B-Chemical
content,2996,O
decreased,2996,O
significantly,2996,O
(,2996,O
P,2996,O
<,2996,O
0.01,2996,O
),2996,O
after,2996,O
nitroglycerin,2996,B-Chemical
in,2996,O
subjects,2996,O
with,2996,O
no,2996,O
migraine,2996,B-Disease
attack,2996,O
but,2996,O
no,2996,O
consistent,2996,O
change,2996,O
was,2996,O
observed,2996,O
in,2996,O
patients,2996,O
with,2996,O
migraine,2996,B-Disease
attack,2996,O
.,2996,O
In,2997,O
conclusion,2997,O
",",2997,O
the,2997,O
fact,2997,O
that,2997,O
plasma,2997,O
CGRP,2997,B-Chemical
concentration,2997,O
correlates,2997,O
with,2997,O
the,2997,O
timing,2997,O
and,2997,O
severity,2997,O
of,2997,O
a,2997,O
migraine,2997,B-Disease
headache,2997,B-Disease
suggests,2997,O
a,2997,O
direct,2997,O
relationship,2997,O
between,2997,O
CGRP,2997,B-Chemical
and,2997,O
migraine,2997,B-Disease
.,2997,O
In,2998,O
contrast,2998,O
",",2998,O
serotonin,2998,B-Chemical
release,2998,O
from,2998,O
platelets,2998,O
does,2998,O
not,2998,O
provoke,2998,O
migraine,2998,B-Disease
",",2998,O
it,2998,O
may,2998,O
even,2998,O
counteract,2998,O
the,2998,O
headache,2998,B-Disease
and,2998,O
the,2998,O
concomitant,2998,O
CGRP,2998,B-Chemical
release,2998,O
in,2998,O
this,2998,O
model,2998,O
.,2998,O
Acute,2999,B-Disease
psychosis,2999,I-Disease
due,2999,O
to,2999,O
treatment,2999,O
with,2999,O
phenytoin,2999,B-Chemical
in,2999,O
a,2999,O
nonepileptic,2999,O
patient,2999,O
.,2999,O
The,3000,O
development,3000,O
of,3000,O
psychosis,3000,B-Disease
related,3000,O
to,3000,O
antiepileptic,3000,O
drug,3000,O
treatment,3000,O
is,3000,O
usually,3000,O
attributed,3000,O
to,3000,O
the,3000,O
interaction,3000,O
between,3000,O
the,3000,O
epileptic,3000,B-Disease
brain,3000,O
substratum,3000,O
and,3000,O
the,3000,O
antiepileptic,3000,O
drugs,3000,O
.,3000,O
The,3001,O
case,3001,O
of,3001,O
a,3001,O
nonepileptic,3001,O
patient,3001,O
who,3001,O
developed,3001,O
psychosis,3001,B-Disease
following,3001,O
phenytoin,3001,B-Chemical
treatment,3001,O
for,3001,O
trigeminal,3001,B-Disease
neuralgia,3001,I-Disease
is,3001,O
described,3001,O
.,3001,O
This,3002,O
case,3002,O
suggests,3002,O
that,3002,O
the,3002,O
psychotic,3002,B-Disease
symptoms,3002,I-Disease
that,3002,O
occur,3002,O
following,3002,O
phenytoin,3002,B-Chemical
treatment,3002,O
in,3002,O
some,3002,O
epileptic,3002,B-Disease
patients,3002,O
may,3002,O
be,3002,O
the,3002,O
direct,3002,O
result,3002,O
of,3002,O
medication,3002,O
",",3002,O
unrelated,3002,O
to,3002,O
seizures,3002,B-Disease
.,3002,O
Risks,3003,O
of,3003,O
the,3003,O
consumption,3003,O
of,3003,O
beverages,3003,O
containing,3003,O
quinine,3003,B-Chemical
.,3003,O
Although,3004,O
the,3004,O
United,3004,O
States,3004,O
Food,3004,O
and,3004,O
Drug,3004,O
Administration,3004,O
banned,3004,O
its,3004,O
use,3004,O
for,3004,O
nocturnal,3004,B-Disease
leg,3004,I-Disease
cramps,3004,I-Disease
due,3004,O
to,3004,O
lack,3004,O
of,3004,O
safety,3004,O
and,3004,O
efficacy,3004,O
",",3004,O
quinine,3004,B-Chemical
is,3004,O
widely,3004,O
available,3004,O
in,3004,O
beverages,3004,O
including,3004,O
tonic,3004,O
water,3004,O
and,3004,O
bitter,3004,O
lemon,3004,O
.,3004,O
Numerous,3005,O
anecdotal,3005,O
reports,3005,O
suggest,3005,O
that,3005,O
products,3005,O
containing,3005,O
quinine,3005,B-Chemical
may,3005,O
produce,3005,O
neurological,3005,B-Disease
complications,3005,I-Disease
",",3005,O
including,3005,O
confusion,3005,B-Disease
",",3005,O
altered,3005,O
mental,3005,O
status,3005,O
",",3005,O
seizures,3005,B-Disease
",",3005,O
and,3005,O
coma,3005,B-Disease
",",3005,O
particularly,3005,O
in,3005,O
older,3005,O
women,3005,O
.,3005,O
Psychologists,3006,O
need,3006,O
to,3006,O
inquire,3006,O
about,3006,O
consumption,3006,O
of,3006,O
quinine-containing,3006,B-Chemical
beverages,3006,O
as,3006,O
part,3006,O
of,3006,O
an,3006,O
evaluation,3006,O
process,3006,O
.,3006,O
Transient,3007,O
platypnea-orthodeoxia-like,3007,B-Disease
syndrome,3007,I-Disease
induced,3007,O
by,3007,O
propafenone,3007,B-Chemical
overdose,3007,B-Disease
in,3007,O
a,3007,O
young,3007,O
woman,3007,O
with,3007,O
Ebstein,3007,B-Disease
's,3007,I-Disease
anomaly,3007,I-Disease
.,3007,O
In,3008,O
this,3008,O
report,3008,O
we,3008,O
describe,3008,O
the,3008,O
case,3008,O
of,3008,O
a,3008,O
37-year-old,3008,O
white,3008,O
woman,3008,O
with,3008,O
Ebstein,3008,B-Disease
's,3008,I-Disease
anomaly,3008,I-Disease
",",3008,O
who,3008,O
developed,3008,O
a,3008,O
rare,3008,O
syndrome,3008,O
called,3008,O
platypnea-orthodeoxia,3008,B-Disease
",",3008,O
characterized,3008,O
by,3008,O
massive,3008,O
right-to-left,3008,O
interatrial,3008,O
shunting,3008,O
with,3008,O
transient,3008,O
profound,3008,O
hypoxia,3008,B-Disease
and,3008,O
cyanosis,3008,B-Disease
.,3008,O
This,3009,O
shunt,3009,O
of,3009,O
blood,3009,O
via,3009,O
a,3009,O
patent,3009,B-Disease
foramen,3009,I-Disease
ovale,3009,I-Disease
occurred,3009,O
in,3009,O
the,3009,O
presence,3009,O
of,3009,O
a,3009,O
normal,3009,O
pulmonary,3009,O
artery,3009,O
pressure,3009,O
",",3009,O
and,3009,O
was,3009,O
probably,3009,O
precipitated,3009,O
by,3009,O
a,3009,O
propafenone,3009,B-Chemical
overdose,3009,B-Disease
.,3009,O
This,3010,O
drug,3010,O
caused,3010,O
biventricular,3010,B-Disease
dysfunction,3010,I-Disease
",",3010,O
due,3010,O
to,3010,O
its,3010,O
negative,3010,O
inotropic,3010,O
effect,3010,O
",",3010,O
and,3010,O
hypotension,3010,B-Disease
",",3010,O
due,3010,O
to,3010,O
its,3010,O
peripheral,3010,O
vasodilatory,3010,O
effect,3010,O
.,3010,O
These,3011,O
effects,3011,O
gave,3011,O
rise,3011,O
to,3011,O
an,3011,O
increase,3011,O
in,3011,O
the,3011,O
right,3011,O
atrial,3011,O
pressure,3011,O
and,3011,O
a,3011,O
decrease,3011,O
in,3011,O
the,3011,O
left,3011,O
one,3011,O
with,3011,O
a,3011,O
consequent,3011,O
stretching,3011,O
of,3011,O
the,3011,O
foramen,3011,O
ovale,3011,O
and,3011,O
the,3011,O
creation,3011,O
of,3011,O
massive,3011,O
right-to-left,3011,O
shunting,3011,O
.,3011,O
In,3012,O
our,3012,O
case,3012,O
this,3012,O
interatrial,3012,O
shunt,3012,O
was,3012,O
very,3012,O
accurately,3012,O
detected,3012,O
at,3012,O
bubble,3012,O
contrast,3012,O
echocardiography,3012,O
.,3012,O
Noxious,3013,O
chemical,3013,O
stimulation,3013,O
of,3013,O
rat,3013,O
facial,3013,O
mucosa,3013,O
increases,3013,O
intracranial,3013,O
blood,3013,O
flow,3013,O
through,3013,O
a,3013,O
trigemino-parasympathetic,3013,O
reflex,3013,O
--,3013,O
an,3013,O
experimental,3013,O
model,3013,O
for,3013,O
vascular,3013,B-Disease
dysfunctions,3013,I-Disease
in,3013,O
cluster,3013,B-Disease
headache,3013,I-Disease
.,3013,O
Cluster,3014,B-Disease
headache,3014,I-Disease
is,3014,O
characterized,3014,O
by,3014,O
typical,3014,O
autonomic,3014,O
dysfunctions,3014,O
including,3014,O
facial,3014,O
and,3014,O
intracranial,3014,B-Disease
vascular,3014,I-Disease
disturbances,3014,I-Disease
.,3014,O
Both,3015,O
the,3015,O
trigeminal,3015,O
and,3015,O
the,3015,O
cranial,3015,O
parasympathetic,3015,O
systems,3015,O
may,3015,O
be,3015,O
involved,3015,O
in,3015,O
mediating,3015,O
these,3015,O
dysfunctions,3015,O
.,3015,O
An,3016,O
experimental,3016,O
model,3016,O
was,3016,O
developed,3016,O
in,3016,O
the,3016,O
rat,3016,O
to,3016,O
measure,3016,O
changes,3016,O
in,3016,O
lacrimation,3016,O
and,3016,O
intracranial,3016,O
blood,3016,O
flow,3016,O
following,3016,O
noxious,3016,O
chemical,3016,O
stimulation,3016,O
of,3016,O
facial,3016,O
mucosa,3016,O
.,3016,O
Blood,3017,O
flow,3017,O
was,3017,O
monitored,3017,O
in,3017,O
arteries,3017,O
of,3017,O
the,3017,O
exposed,3017,O
cranial,3017,O
dura,3017,O
mater,3017,O
and,3017,O
the,3017,O
parietal,3017,O
cortex,3017,O
using,3017,O
laser,3017,O
Doppler,3017,O
flowmetry,3017,O
.,3017,O
Capsaicin,3018,B-Chemical
(,3018,O
0.01-1,3018,O
mm,3018,O
),3018,O
applied,3018,O
to,3018,O
oral,3018,O
or,3018,O
nasal,3018,O
mucosa,3018,O
induced,3018,O
increases,3018,B-Disease
in,3018,I-Disease
dural,3018,I-Disease
and,3018,I-Disease
cortical,3018,I-Disease
blood,3018,I-Disease
flow,3018,I-Disease
and,3018,O
provoked,3018,O
lacrimation,3018,O
.,3018,O
These,3019,O
responses,3019,O
were,3019,O
blocked,3019,O
by,3019,O
systemic,3019,O
pre-administration,3019,O
of,3019,O
hexamethonium,3019,B-Chemical
chloride,3019,I-Chemical
(,3019,O
20,3019,O
mg/kg,3019,O
),3019,O
.,3019,O
The,3020,O
evoked,3020,O
increases,3020,B-Disease
in,3020,I-Disease
dural,3020,I-Disease
blood,3020,I-Disease
flow,3020,I-Disease
were,3020,O
also,3020,O
abolished,3020,O
by,3020,O
topical,3020,O
pre-administration,3020,O
of,3020,O
atropine,3020,B-Chemical
(,3020,O
1,3020,O
mm,3020,O
),3020,O
and,3020,O
[,3020,O
Lys1,3020,O
",",3020,O
"Pro2,5",3020,O
",",3020,O
"Arg3,4",3020,O
",",3020,O
Tyr6,3020,O
],3020,O
-VIP,3020,O
(,3020,O
0.1,3020,O
mm,3020,O
),3020,O
",",3020,O
a,3020,O
vasoactive,3020,O
intestinal,3020,O
polypeptide,3020,O
(,3020,O
VIP,3020,O
),3020,O
antagonist,3020,O
",",3020,O
onto,3020,O
the,3020,O
exposed,3020,O
dura,3020,O
mater,3020,O
.,3020,O
We,3021,O
conclude,3021,O
that,3021,O
noxious,3021,O
stimulation,3021,O
of,3021,O
facial,3021,O
mucosa,3021,O
increases,3021,O
intracranial,3021,O
blood,3021,O
flow,3021,O
and,3021,O
lacrimation,3021,O
via,3021,O
a,3021,O
trigemino-parasympathetic,3021,O
reflex,3021,O
.,3021,O
The,3022,O
blood,3022,O
flow,3022,O
responses,3022,O
seem,3022,O
to,3022,O
be,3022,O
mediated,3022,O
by,3022,O
the,3022,O
release,3022,O
of,3022,O
acetylcholine,3022,B-Chemical
and,3022,O
VIP,3022,O
within,3022,O
the,3022,O
meninges,3022,O
.,3022,O
Similar,3023,O
mechanisms,3023,O
may,3023,O
be,3023,O
involved,3023,O
in,3023,O
the,3023,O
pathogenesis,3023,O
of,3023,O
cluster,3023,B-Disease
headache,3023,I-Disease
.,3023,O
Organophosphate-induced,3024,B-Chemical
convulsions,3024,B-Disease
and,3024,O
prevention,3024,O
of,3024,O
neuropathological,3024,B-Disease
damages,3024,I-Disease
.,3024,O
Such,3025,O
organophosphorus,3025,B-Chemical
(,3025,O
OP,3025,B-Chemical
),3025,O
compounds,3025,O
as,3025,O
diisopropylfluorophosphate,3025,B-Chemical
(,3025,O
DFP,3025,B-Chemical
),3025,O
",",3025,O
sarin,3025,B-Chemical
and,3025,O
soman,3025,B-Chemical
are,3025,O
potent,3025,O
inhibitors,3025,O
of,3025,O
acetylcholinesterases,3025,O
(,3025,O
AChEs,3025,O
),3025,O
and,3025,O
butyrylcholinesterases,3025,O
(,3025,O
BChEs,3025,O
),3025,O
.,3025,O
The,3026,O
acute,3026,O
toxicity,3026,B-Disease
of,3026,O
OPs,3026,B-Chemical
is,3026,O
the,3026,O
result,3026,O
of,3026,O
their,3026,O
irreversible,3026,O
binding,3026,O
with,3026,O
AChEs,3026,O
in,3026,O
the,3026,O
central,3026,O
nervous,3026,O
system,3026,O
(,3026,O
CNS,3026,O
),3026,O
",",3026,O
which,3026,O
elevates,3026,O
acetylcholine,3026,B-Chemical
(,3026,O
ACh,3026,B-Chemical
),3026,O
levels,3026,O
.,3026,O
The,3027,O
protective,3027,O
action,3027,O
of,3027,O
subcutaneously,3027,O
(,3027,O
SC,3027,O
),3027,O
administered,3027,O
antidotes,3027,O
or,3027,O
their,3027,O
combinations,3027,O
in,3027,O
DFP,3027,B-Chemical
(,3027,O
2.0,3027,O
mg/kg,3027,O
BW,3027,O
),3027,O
intoxication,3027,O
was,3027,O
studied,3027,O
in,3027,O
9-10-weeks-old,3027,O
Han-Wistar,3027,O
male,3027,O
rats,3027,O
.,3027,O
The,3028,O
rats,3028,O
received,3028,O
AChE,3028,O
reactivator,3028,O
pralidoxime-2-chloride,3028,B-Chemical
(,3028,O
2PAM,3028,B-Chemical
),3028,O
(,3028,O
30.0,3028,O
mg/kg,3028,O
BW,3028,O
),3028,O
",",3028,O
anticonvulsant,3028,O
diazepam,3028,B-Chemical
(,3028,O
2.0,3028,O
mg/kg,3028,O
BW,3028,O
),3028,O
",",3028,O
A,3028,O
(,3028,O
1,3028,O
),3028,O
-adenosine,3028,O
receptor,3028,O
agonist,3028,O
N,3028,B-Chemical
(,3028,I-Chemical
6,3028,I-Chemical
),3028,I-Chemical
-cyclopentyl,3028,I-Chemical
adenosine,3028,I-Chemical
(,3028,O
CPA,3028,B-Chemical
),3028,O
(,3028,O
2.0,3028,O
mg/kg,3028,O
BW,3028,O
),3028,O
",",3028,O
NMDA-receptor,3028,B-Chemical
antagonist,3028,O
dizocilpine,3028,B-Chemical
maleate,3028,I-Chemical
(,3028,O
+-MK801,3028,O
hydrogen,3028,O
maleate,3028,O
),3028,O
(,3028,O
2.0,3028,O
mg/kg,3028,O
BW,3028,O
),3028,O
or,3028,O
their,3028,O
combinations,3028,O
with,3028,O
cholinolytic,3028,O
drug,3028,O
atropine,3028,B-Chemical
sulfate,3028,I-Chemical
(,3028,O
50.0,3028,O
mg/kg,3028,O
BW,3028,O
),3028,O
immediately,3028,O
or,3028,O
30,3028,O
min,3028,O
after,3028,O
the,3028,O
single,3028,O
SC,3028,O
injection,3028,O
of,3028,O
DFP,3028,B-Chemical
.,3028,O
The,3029,O
control,3029,O
rats,3029,O
received,3029,O
atropine,3029,B-Chemical
sulfate,3029,I-Chemical
",",3029,O
but,3029,O
also,3029,O
saline,3029,O
and,3029,O
olive,3029,O
oil,3029,O
instead,3029,O
of,3029,O
other,3029,O
antidotes,3029,O
and,3029,O
DFP,3029,B-Chemical
",",3029,O
respectively,3029,O
.,3029,O
All,3030,O
rats,3030,O
were,3030,O
terminated,3030,O
either,3030,O
24,3030,O
h,3030,O
or,3030,O
3,3030,O
weeks,3030,O
after,3030,O
the,3030,O
DFP,3030,B-Chemical
injection,3030,O
.,3030,O
The,3031,O
rats,3031,O
treated,3031,O
with,3031,O
DFP-atropine,3031,B-Chemical
showed,3031,O
severe,3031,O
typical,3031,O
OP-induced,3031,B-Chemical
toxicity,3031,B-Disease
signs,3031,O
.,3031,O
When,3032,O
CPA,3032,B-Chemical
",",3032,O
diazepam,3032,B-Chemical
or,3032,O
2PAM,3032,B-Chemical
was,3032,O
given,3032,O
immediately,3032,O
after,3032,O
DFP-atropine,3032,B-Chemical
",",3032,O
these,3032,O
treatments,3032,O
prevented,3032,O
",",3032,O
delayed,3032,O
or,3032,O
shortened,3032,O
the,3032,O
occurrence,3032,O
of,3032,O
serious,3032,O
signs,3032,O
of,3032,O
poisoning,3032,B-Disease
.,3032,O
Atropine-MK801,3033,B-Chemical
did,3033,O
not,3033,O
offer,3033,O
any,3033,O
additional,3033,O
protection,3033,O
against,3033,O
DFP,3033,B-Chemical
toxicity,3033,B-Disease
.,3033,O
In,3034,O
conclusion,3034,O
",",3034,O
CPA,3034,B-Chemical
",",3034,O
diazepam,3034,B-Chemical
and,3034,O
2PAM,3034,B-Chemical
in,3034,O
combination,3034,O
with,3034,O
atropine,3034,B-Chemical
prevented,3034,O
the,3034,O
occurrence,3034,O
of,3034,O
serious,3034,O
signs,3034,O
of,3034,O
poisoning,3034,B-Disease
and,3034,O
thus,3034,O
reduced,3034,O
the,3034,O
toxicity,3034,B-Disease
of,3034,O
DFP,3034,B-Chemical
in,3034,O
rat,3034,O
.,3034,O
Recurrent,3035,O
excitation,3035,O
in,3035,O
the,3035,O
dentate,3035,O
gyrus,3035,O
of,3035,O
a,3035,O
murine,3035,O
model,3035,O
of,3035,O
temporal,3035,B-Disease
lobe,3035,I-Disease
epilepsy,3035,I-Disease
.,3035,O
Similar,3036,O
to,3036,O
rats,3036,O
",",3036,O
systemic,3036,O
pilocarpine,3036,B-Chemical
injection,3036,O
causes,3036,O
status,3036,B-Disease
epilepticus,3036,I-Disease
(,3036,O
SE,3036,B-Disease
),3036,O
and,3036,O
the,3036,O
eventual,3036,O
development,3036,O
of,3036,O
spontaneous,3036,O
seizures,3036,B-Disease
and,3036,O
mossy,3036,O
fiber,3036,O
sprouting,3036,O
in,3036,O
C57BL/6,3036,O
and,3036,O
CD1,3036,O
mice,3036,O
",",3036,O
but,3036,O
the,3036,O
physiological,3036,O
correlates,3036,O
of,3036,O
these,3036,O
events,3036,O
have,3036,O
not,3036,O
been,3036,O
identified,3036,O
in,3036,O
mice,3036,O
.,3036,O
Population,3037,O
responses,3037,O
in,3037,O
granule,3037,O
cells,3037,O
of,3037,O
the,3037,O
dentate,3037,O
gyrus,3037,O
were,3037,O
examined,3037,O
in,3037,O
transverse,3037,O
slices,3037,O
of,3037,O
the,3037,O
ventral,3037,O
hippocampus,3037,O
from,3037,O
pilocarpine-treated,3037,B-Chemical
and,3037,O
untreated,3037,O
mice,3037,O
.,3037,O
In,3038,O
Mg,3038,B-Chemical
(,3038,O
2+,3038,O
),3038,O
-free,3038,O
bathing,3038,O
medium,3038,O
containing,3038,O
bicuculline,3038,B-Chemical
",",3038,O
conditions,3038,O
designed,3038,O
to,3038,O
increase,3038,O
excitability,3038,O
in,3038,O
the,3038,O
slices,3038,O
",",3038,O
electrical,3038,O
stimulation,3038,O
of,3038,O
the,3038,O
hilus,3038,O
resulted,3038,O
in,3038,O
a,3038,O
single,3038,O
population,3038,O
spike,3038,O
in,3038,O
granule,3038,O
cells,3038,O
from,3038,O
control,3038,O
mice,3038,O
and,3038,O
pilocarpine-treated,3038,B-Chemical
mice,3038,O
that,3038,O
did,3038,O
not,3038,O
experience,3038,O
SE,3038,B-Disease
.,3038,O
In,3039,O
SE,3039,B-Disease
survivors,3039,O
",",3039,O
similar,3039,O
stimulation,3039,O
resulted,3039,O
in,3039,O
a,3039,O
population,3039,O
spike,3039,O
followed,3039,O
",",3039,O
at,3039,O
a,3039,O
variable,3039,O
latency,3039,O
",",3039,O
by,3039,O
negative,3039,O
DC,3039,O
shifts,3039,O
and,3039,O
repetitive,3039,O
afterdischarges,3039,O
of,3039,O
3-60,3039,O
s,3039,O
duration,3039,O
",",3039,O
which,3039,O
were,3039,O
blocked,3039,O
by,3039,O
ionotropic,3039,O
glutamate,3039,B-Chemical
receptor,3039,O
antagonists,3039,O
.,3039,O
Focal,3040,O
glutamate,3040,B-Chemical
photostimulation,3040,O
of,3040,O
the,3040,O
granule,3040,O
cell,3040,O
layer,3040,O
at,3040,O
sites,3040,O
distant,3040,O
from,3040,O
the,3040,O
recording,3040,O
pipette,3040,O
resulted,3040,O
in,3040,O
population,3040,O
responses,3040,O
of,3040,O
1-30,3040,O
s,3040,O
duration,3040,O
in,3040,O
slices,3040,O
from,3040,O
SE,3040,B-Disease
survivors,3040,O
but,3040,O
not,3040,O
other,3040,O
groups,3040,O
.,3040,O
These,3041,O
data,3041,O
support,3041,O
the,3041,O
hypothesis,3041,O
that,3041,O
SE-induced,3041,B-Disease
mossy,3041,O
fiber,3041,O
sprouting,3041,O
and,3041,O
synaptic,3041,O
reorganization,3041,O
are,3041,O
relevant,3041,O
characteristics,3041,O
of,3041,O
seizure,3041,B-Disease
development,3041,O
in,3041,O
these,3041,O
murine,3041,O
strains,3041,O
",",3041,O
resembling,3041,O
rat,3041,O
models,3041,O
of,3041,O
human,3041,O
temporal,3041,B-Disease
lobe,3041,I-Disease
epilepsy,3041,I-Disease
.,3041,O
Urinary,3042,B-Disease
bladder,3042,I-Disease
cancer,3042,I-Disease
in,3042,O
Wegener,3042,B-Disease
's,3042,I-Disease
granulomatosis,3042,I-Disease
:,3042,O
risks,3042,O
and,3042,O
relation,3042,O
to,3042,O
cyclophosphamide,3042,B-Chemical
.,3042,O
OBJECTIVE,3043,O
:,3043,O
To,3043,O
assess,3043,O
and,3043,O
characterise,3043,O
the,3043,O
risk,3043,O
of,3043,O
bladder,3043,B-Disease
cancer,3043,I-Disease
",",3043,O
and,3043,O
its,3043,O
relation,3043,O
to,3043,O
cyclophosphamide,3043,B-Chemical
",",3043,O
in,3043,O
patients,3043,O
with,3043,O
Wegener,3043,B-Disease
's,3043,I-Disease
granulomatosis,3043,I-Disease
.,3043,O
METHODS,3044,O
:,3044,O
In,3044,O
the,3044,O
population,3044,O
based,3044,O
",",3044,O
nationwide,3044,O
Swedish,3044,O
Inpatient,3044,O
Register,3044,O
a,3044,O
cohort,3044,O
of,3044,O
1065,3044,O
patients,3044,O
with,3044,O
Wegener,3044,B-Disease
's,3044,I-Disease
granulomatosis,3044,I-Disease
",",3044,O
1969-95,3044,O
",",3044,O
was,3044,O
identified,3044,O
.,3044,O
Through,3045,O
linkage,3045,O
with,3045,O
the,3045,O
Swedish,3045,O
Cancer,3045,B-Disease
Register,3045,O
",",3045,O
all,3045,O
subjects,3045,O
in,3045,O
this,3045,O
cohort,3045,O
diagnosed,3045,O
with,3045,O
bladder,3045,B-Disease
cancer,3045,I-Disease
were,3045,O
identified,3045,O
.,3045,O
Nested,3046,O
within,3046,O
the,3046,O
cohort,3046,O
",",3046,O
a,3046,O
matched,3046,O
case-control,3046,O
study,3046,O
was,3046,O
performed,3046,O
to,3046,O
estimate,3046,O
the,3046,O
association,3046,O
between,3046,O
cyclophosphamide,3046,B-Chemical
and,3046,O
bladder,3046,B-Disease
cancer,3046,I-Disease
using,3046,O
odds,3046,O
ratios,3046,O
(,3046,O
ORs,3046,O
),3046,O
as,3046,O
relative,3046,O
risk,3046,O
.,3046,O
In,3047,O
the,3047,O
cohort,3047,O
the,3047,O
cumulative,3047,O
risk,3047,O
of,3047,O
bladder,3047,B-Disease
cancer,3047,I-Disease
after,3047,O
Wegener,3047,B-Disease
's,3047,I-Disease
granulomatosis,3047,I-Disease
",",3047,O
and,3047,O
the,3047,O
relative,3047,O
prevalence,3047,O
of,3047,O
a,3047,O
history,3047,O
of,3047,O
bladder,3047,B-Disease
cancer,3047,I-Disease
at,3047,O
the,3047,O
time,3047,O
of,3047,O
diagnosis,3047,O
of,3047,O
Wegener,3047,B-Disease
's,3047,I-Disease
granulomatosis,3047,I-Disease
",",3047,O
were,3047,O
also,3047,O
estimated,3047,O
.,3047,O
RESULTS,3048,O
:,3048,O
The,3048,O
median,3048,O
cumulative,3048,O
doses,3048,O
of,3048,O
cyclophosphamide,3048,B-Chemical
among,3048,O
cases,3048,O
(,3048,O
n,3048,O
=,3048,O
11,3048,O
),3048,O
and,3048,O
controls,3048,O
(,3048,O
n,3048,O
=,3048,O
25,3048,O
),3048,O
were,3048,O
113,3048,O
g,3048,O
and,3048,O
25,3048,O
g,3048,O
",",3048,O
respectively,3048,O
.,3048,O
The,3049,O
risk,3049,O
of,3049,O
bladder,3049,B-Disease
cancer,3049,I-Disease
doubled,3049,O
for,3049,O
every,3049,O
10,3049,O
g,3049,O
increment,3049,O
in,3049,O
cyclophosphamide,3049,B-Chemical
(,3049,O
OR,3049,O
=,3049,O
2.0,3049,O
",",3049,O
95,3049,O
%,3049,O
confidence,3049,O
interval,3049,O
(,3049,O
CI,3049,O
),3049,O
0.8,3049,O
to,3049,O
4.9,3049,O
),3049,O
.,3049,O
Treatment,3050,O
duration,3050,O
longer,3050,O
than,3050,O
1,3050,O
year,3050,O
was,3050,O
associated,3050,O
with,3050,O
an,3050,O
eightfold,3050,O
increased,3050,O
risk,3050,O
(,3050,O
OR,3050,O
=,3050,O
7.7,3050,O
",",3050,O
95,3050,O
%,3050,O
CI,3050,O
0.9,3050,O
to,3050,O
69,3050,O
),3050,O
.,3050,O
The,3051,O
absolute,3051,O
risk,3051,O
for,3051,O
bladder,3051,B-Disease
cancer,3051,I-Disease
in,3051,O
the,3051,O
cohort,3051,O
reached,3051,O
10,3051,O
%,3051,O
16,3051,O
years,3051,O
after,3051,O
diagnosis,3051,O
of,3051,O
Wegener,3051,B-Disease
's,3051,I-Disease
granulomatosis,3051,I-Disease
",",3051,O
and,3051,O
a,3051,O
history,3051,O
of,3051,O
bladder,3051,B-Disease
cancer,3051,I-Disease
was,3051,O
(,3051,O
non-significantly,3051,O
),3051,O
twice,3051,O
as,3051,O
common,3051,O
as,3051,O
expected,3051,O
at,3051,O
the,3051,O
time,3051,O
of,3051,O
diagnosis,3051,O
of,3051,O
Wegener,3051,B-Disease
's,3051,I-Disease
granulomatosis,3051,I-Disease
.,3051,O
CONCLUSION,3052,O
:,3052,O
The,3052,O
results,3052,O
indicate,3052,O
a,3052,O
dose-response,3052,O
relationship,3052,O
between,3052,O
cyclophosphamide,3052,B-Chemical
and,3052,O
the,3052,O
risk,3052,O
of,3052,O
bladder,3052,B-Disease
cancer,3052,I-Disease
",",3052,O
high,3052,O
cumulative,3052,O
risks,3052,O
in,3052,O
the,3052,O
entire,3052,O
cohort,3052,O
",",3052,O
and,3052,O
also,3052,O
the,3052,O
possibility,3052,O
of,3052,O
risk,3052,O
factors,3052,O
operating,3052,O
even,3052,O
before,3052,O
Wegener,3052,B-Disease
's,3052,I-Disease
granulomatosis,3052,I-Disease
.,3052,O
Differential,3053,O
modulation,3053,O
by,3053,O
estrogen,3053,B-Chemical
of,3053,O
alpha2-adrenergic,3053,O
and,3053,O
I1-imidazoline,3053,O
receptor-mediated,3053,O
hypotension,3053,B-Disease
in,3053,O
female,3053,O
rats,3053,O
.,3053,O
We,3054,O
have,3054,O
recently,3054,O
shown,3054,O
that,3054,O
estrogen,3054,B-Chemical
negatively,3054,O
modulates,3054,O
the,3054,O
hypotensive,3054,B-Disease
effect,3054,O
of,3054,O
clonidine,3054,B-Chemical
(,3054,O
mixed,3054,O
alpha2-/I1-receptor,3054,O
agonist,3054,O
),3054,O
in,3054,O
female,3054,O
rats,3054,O
and,3054,O
implicates,3054,O
the,3054,O
cardiovascular,3054,O
autonomic,3054,O
control,3054,O
in,3054,O
this,3054,O
interaction,3054,O
.,3054,O
The,3055,O
present,3055,O
study,3055,O
investigated,3055,O
whether,3055,O
this,3055,O
effect,3055,O
of,3055,O
estrogen,3055,B-Chemical
involves,3055,O
interaction,3055,O
with,3055,O
alpha2-,3055,O
and/or,3055,O
I1-receptors,3055,O
.,3055,O
Changes,3056,O
evoked,3056,O
by,3056,O
a,3056,O
single,3056,O
intraperitoneal,3056,O
injection,3056,O
of,3056,O
rilmenidine,3056,B-Chemical
(,3056,O
600,3056,O
microg/kg,3056,O
),3056,O
or,3056,O
alpha-methyldopa,3056,B-Chemical
(,3056,O
100,3056,O
mg/kg,3056,O
),3056,O
",",3056,O
selective,3056,O
I1-,3056,O
and,3056,O
alpha2-receptor,3056,O
agonists,3056,O
",",3056,O
respectively,3056,O
",",3056,O
in,3056,O
blood,3056,O
pressure,3056,O
",",3056,O
hemodynamic,3056,O
variability,3056,O
",",3056,O
and,3056,O
locomotor,3056,O
activity,3056,O
were,3056,O
assessed,3056,O
in,3056,O
radiotelemetered,3056,O
sham-operated,3056,O
and,3056,O
ovariectomized,3056,O
(,3056,O
Ovx,3056,O
),3056,O
Sprague-Dawley,3056,O
female,3056,O
rats,3056,O
with,3056,O
or,3056,O
without,3056,O
12-wk,3056,O
estrogen,3056,B-Chemical
replacement,3056,O
.,3056,O
Three,3057,O
time,3057,O
domain,3057,O
indexes,3057,O
of,3057,O
hemodynamic,3057,O
variability,3057,O
were,3057,O
employed,3057,O
:,3057,O
the,3057,O
standard,3057,O
deviation,3057,O
of,3057,O
mean,3057,O
arterial,3057,O
pressure,3057,O
as,3057,O
a,3057,O
measure,3057,O
of,3057,O
blood,3057,O
pressure,3057,O
variability,3057,O
and,3057,O
the,3057,O
standard,3057,O
deviation,3057,O
of,3057,O
beat-to-beat,3057,O
intervals,3057,O
(,3057,O
SDRR,3057,O
),3057,O
and,3057,O
the,3057,O
root,3057,O
mean,3057,O
square,3057,O
of,3057,O
successive,3057,O
differences,3057,O
in,3057,O
R-wave-to-R-wave,3057,O
intervals,3057,O
as,3057,O
measures,3057,O
of,3057,O
heart,3057,O
rate,3057,O
variability,3057,O
.,3057,O
In,3058,O
sham-operated,3058,O
rats,3058,O
",",3058,O
rilmenidine,3058,B-Chemical
or,3058,O
alpha-methyldopa,3058,B-Chemical
elicited,3058,O
similar,3058,O
hypotension,3058,B-Disease
that,3058,O
lasted,3058,O
at,3058,O
least,3058,O
5,3058,O
h,3058,O
and,3058,O
was,3058,O
associated,3058,O
with,3058,O
reductions,3058,O
in,3058,O
standard,3058,O
deviation,3058,O
of,3058,O
mean,3058,O
arterial,3058,O
pressure,3058,O
.,3058,O
SDRR,3059,O
was,3059,O
reduced,3059,O
only,3059,O
by,3059,O
alpha-methyldopa,3059,B-Chemical
.,3059,O
Ovx,3060,O
significantly,3060,O
enhanced,3060,O
the,3060,O
hypotensive,3060,B-Disease
response,3060,O
to,3060,O
alpha-methyldopa,3060,B-Chemical
",",3060,O
in,3060,O
contrast,3060,O
to,3060,O
no,3060,O
effect,3060,O
on,3060,O
rilmenidine,3060,B-Chemical
hypotension,3060,B-Disease
.,3060,O
The,3061,O
enhanced,3061,O
alpha-methyldopa,3061,B-Chemical
hypotension,3061,B-Disease
in,3061,O
Ovx,3061,O
rats,3061,O
was,3061,O
paralleled,3061,O
with,3061,O
further,3061,O
reduction,3061,O
in,3061,O
SDRR,3061,O
and,3061,O
a,3061,B-Disease
reduced,3061,I-Disease
locomotor,3061,I-Disease
activity,3061,I-Disease
.,3061,O
Estrogen,3062,O
replacement,3062,O
(,3062,O
17beta-estradiol,3062,B-Chemical
subcutaneous,3062,O
pellet,3062,O
",",3062,O
14.2,3062,O
microg/day,3062,O
",",3062,O
12,3062,O
wk,3062,O
),3062,O
of,3062,O
Ovx,3062,O
rats,3062,O
restored,3062,O
the,3062,O
hemodynamic,3062,O
and,3062,O
locomotor,3062,O
effects,3062,O
of,3062,O
alpha-methyldopa,3062,B-Chemical
to,3062,O
sham-operated,3062,O
levels,3062,O
.,3062,O
These,3063,O
findings,3063,O
suggest,3063,O
that,3063,O
estrogen,3063,B-Chemical
downregulates,3063,O
alpha2-,3063,O
but,3063,O
not,3063,O
I1-receptor-mediated,3063,O
hypotension,3063,B-Disease
and,3063,O
highlight,3063,O
a,3063,O
role,3063,O
for,3063,O
the,3063,O
cardiac,3063,O
autonomic,3063,O
control,3063,O
in,3063,O
alpha-methyldopa-estrogen,3063,B-Chemical
interaction,3063,O
.,3063,O
Severe,3064,O
reversible,3064,O
left,3064,B-Disease
ventricular,3064,I-Disease
systolic,3064,I-Disease
and,3064,I-Disease
diastolic,3064,I-Disease
dysfunction,3064,I-Disease
due,3064,O
to,3064,O
accidental,3064,O
iatrogenic,3064,O
epinephrine,3064,B-Chemical
overdose,3064,B-Disease
.,3064,O
Catecholamine-induced,3065,B-Chemical
cardiomyopathy,3065,B-Disease
due,3065,O
to,3065,O
chronic,3065,O
excess,3065,O
of,3065,O
endogenous,3065,O
catecholamines,3065,B-Chemical
has,3065,O
been,3065,O
recognized,3065,O
for,3065,O
decades,3065,O
as,3065,O
a,3065,O
clinical,3065,O
phenomenon,3065,O
.,3065,O
In,3066,O
contrast,3066,O
",",3066,O
reports,3066,O
of,3066,O
myocardial,3066,B-Disease
dysfunction,3066,I-Disease
due,3066,O
to,3066,O
acute,3066,O
iatrogenic,3066,O
overdose,3066,B-Disease
are,3066,O
rare,3066,O
.,3066,O
A,3067,O
35-year-old,3067,O
woman,3067,O
whose,3067,O
cervix,3067,O
uteri,3067,O
was,3067,O
inadvertently,3067,O
injected,3067,O
with,3067,O
8,3067,O
mg,3067,O
of,3067,O
epinephrine,3067,B-Chemical
developed,3067,O
myocardial,3067,B-Disease
stunning,3067,I-Disease
that,3067,O
was,3067,O
characterized,3067,O
by,3067,O
severe,3067,O
hemodynamic,3067,O
compromise,3067,O
",",3067,O
profound,3067,O
",",3067,O
albeit,3067,O
transient,3067,O
",",3067,O
left,3067,B-Disease
ventricular,3067,I-Disease
systolic,3067,I-Disease
and,3067,I-Disease
diastolic,3067,I-Disease
dysfunction,3067,I-Disease
",",3067,O
and,3067,O
only,3067,O
modestly,3067,O
elevated,3067,O
biochemical,3067,O
markers,3067,O
of,3067,O
myocardial,3067,B-Disease
necrosis,3067,I-Disease
.,3067,O
Our,3068,O
case,3068,O
illustrates,3068,O
the,3068,O
serious,3068,O
consequences,3068,O
of,3068,O
medical,3068,O
errors,3068,O
that,3068,O
can,3068,O
be,3068,O
avoided,3068,O
through,3068,O
improved,3068,O
medication,3068,O
labeling,3068,O
and,3068,O
staff,3068,O
supervision,3068,O
.,3068,O
Cardioprotective,3069,O
effect,3069,O
of,3069,O
tincture,3069,B-Chemical
of,3069,I-Chemical
Crataegus,3069,I-Chemical
on,3069,O
isoproterenol-induced,3069,B-Chemical
myocardial,3069,B-Disease
infarction,3069,I-Disease
in,3069,O
rats,3069,O
.,3069,O
Tincture,3070,B-Chemical
of,3070,I-Chemical
Crataegus,3070,I-Chemical
(,3070,O
TCR,3070,B-Chemical
),3070,O
",",3070,O
an,3070,O
alcoholic,3070,B-Chemical
extract,3070,I-Chemical
of,3070,I-Chemical
the,3070,I-Chemical
berries,3070,I-Chemical
of,3070,I-Chemical
hawthorn,3070,I-Chemical
(,3070,O
Crataegus,3070,B-Chemical
oxycantha,3070,I-Chemical
),3070,O
",",3070,O
is,3070,O
used,3070,O
in,3070,O
herbal,3070,O
and,3070,O
homeopathic,3070,O
medicine,3070,O
.,3070,O
The,3071,O
present,3071,O
study,3071,O
was,3071,O
done,3071,O
to,3071,O
investigate,3071,O
the,3071,O
protective,3071,O
effect,3071,O
of,3071,O
TCR,3071,B-Chemical
on,3071,O
experimentally,3071,O
induced,3071,O
myocardial,3071,B-Disease
infarction,3071,I-Disease
in,3071,O
rats,3071,O
.,3071,O
Pretreatment,3072,O
of,3072,O
TCR,3072,B-Chemical
",",3072,O
at,3072,O
a,3072,O
dose,3072,O
of,3072,O
0.5,3072,O
mL/100,3072,O
g,3072,O
bodyweight,3072,O
per,3072,O
day,3072,O
",",3072,O
orally,3072,O
for,3072,O
30,3072,O
days,3072,O
",",3072,O
prevented,3072,O
the,3072,O
increase,3072,O
in,3072,O
lipid,3072,O
peroxidation,3072,O
and,3072,O
activity,3072,O
of,3072,O
marker,3072,O
enzymes,3072,O
observed,3072,O
in,3072,O
isoproterenol-induced,3072,B-Chemical
rats,3072,O
(,3072,O
85,3072,O
mg,3072,O
kg,3072,O
(,3072,O
-1,3072,O
),3072,O
s.,3072,O
c.,3072,O
for,3072,O
2,3072,O
days,3072,O
at,3072,O
an,3072,O
interval,3072,O
of,3072,O
24,3072,O
h,3072,O
),3072,O
.,3072,O
TCR,3073,B-Chemical
prevented,3073,O
the,3073,O
isoproterenol-induced,3073,B-Chemical
decrease,3073,O
in,3073,O
antioxidant,3073,O
enzymes,3073,O
in,3073,O
the,3073,O
heart,3073,O
and,3073,O
increased,3073,O
the,3073,O
rate,3073,O
of,3073,O
ADP-stimulated,3073,B-Chemical
oxygen,3073,B-Chemical
uptake,3073,O
and,3073,O
respiratory,3073,O
coupling,3073,O
ratio,3073,O
.,3073,O
TCR,3074,B-Chemical
protected,3074,O
against,3074,O
pathological,3074,O
changes,3074,O
induced,3074,O
by,3074,O
isoproterenol,3074,B-Chemical
in,3074,O
rat,3074,O
heart,3074,O
.,3074,O
The,3075,O
results,3075,O
show,3075,O
that,3075,O
pretreatment,3075,O
with,3075,O
TCR,3075,B-Chemical
may,3075,O
be,3075,O
useful,3075,O
in,3075,O
preventing,3075,O
the,3075,O
damage,3075,O
induced,3075,O
by,3075,O
isoproterenol,3075,B-Chemical
in,3075,O
rat,3075,O
heart,3075,O
.,3075,O
The,3076,O
alpha3,3076,O
and,3076,O
beta4,3076,O
nicotinic,3076,O
acetylcholine,3076,B-Chemical
receptor,3076,O
subunits,3076,O
are,3076,O
necessary,3076,O
for,3076,O
nicotine-induced,3076,B-Chemical
seizures,3076,B-Disease
and,3076,O
hypolocomotion,3076,B-Disease
in,3076,O
mice,3076,O
.,3076,O
Binding,3077,O
of,3077,O
nicotine,3077,B-Chemical
to,3077,O
nicotinic,3077,O
acetylcholine,3077,B-Chemical
receptors,3077,O
(,3077,O
nAChRs,3077,O
),3077,O
elicits,3077,O
a,3077,O
series,3077,O
of,3077,O
dose-dependent,3077,O
behaviors,3077,O
that,3077,O
go,3077,O
from,3077,O
altered,3077,O
exploration,3077,O
",",3077,O
sedation,3077,O
",",3077,O
and,3077,O
tremors,3077,B-Disease
",",3077,O
to,3077,O
seizures,3077,B-Disease
and,3077,O
death,3077,B-Disease
.,3077,O
nAChRs,3078,O
are,3078,O
pentameric,3078,O
ion,3078,O
channels,3078,O
usually,3078,O
composed,3078,O
of,3078,O
alpha,3078,O
and,3078,O
beta,3078,O
subunits,3078,O
.,3078,O
A,3079,O
gene,3079,O
cluster,3079,O
comprises,3079,O
the,3079,O
alpha3,3079,O
",",3079,O
alpha5,3079,O
and,3079,O
beta4,3079,O
subunits,3079,O
",",3079,O
which,3079,O
coassemble,3079,O
to,3079,O
form,3079,O
functional,3079,O
receptors,3079,O
.,3079,O
We,3080,O
examined,3080,O
the,3080,O
role,3080,O
of,3080,O
the,3080,O
beta4,3080,O
subunits,3080,O
in,3080,O
nicotine-induced,3080,B-Chemical
seizures,3080,B-Disease
and,3080,O
hypolocomotion,3080,B-Disease
in,3080,O
beta4,3080,O
homozygous,3080,O
null,3080,O
(,3080,O
beta4,3080,O
-/-,3080,O
),3080,O
and,3080,O
alpha3,3080,O
heterozygous,3080,O
(,3080,O
+/-,3080,O
),3080,O
mice,3080,O
.,3080,O
beta4,3081,O
-/-,3081,O
mice,3081,O
were,3081,O
less,3081,O
sensitive,3081,O
to,3081,O
the,3081,O
effects,3081,O
of,3081,O
nicotine,3081,B-Chemical
both,3081,O
at,3081,O
low,3081,O
doses,3081,O
",",3081,O
measured,3081,O
as,3081,O
decreased,3081,O
exploration,3081,O
in,3081,O
an,3081,O
open,3081,O
field,3081,O
",",3081,O
and,3081,O
at,3081,O
high,3081,O
doses,3081,O
",",3081,O
measured,3081,O
as,3081,O
sensitivity,3081,O
to,3081,O
nicotine-induced,3081,B-Chemical
seizures,3081,B-Disease
.,3081,O
Using,3082,O
in,3082,O
situ,3082,O
hybridization,3082,O
probes,3082,O
for,3082,O
the,3082,O
alpha3,3082,O
and,3082,O
alpha5,3082,O
subunits,3082,O
",",3082,O
we,3082,O
showed,3082,O
that,3082,O
alpha5,3082,O
mRNA,3082,O
levels,3082,O
are,3082,O
unchanged,3082,O
",",3082,O
whereas,3082,O
alpha3,3082,O
mRNA,3082,O
levels,3082,O
are,3082,O
selectively,3082,O
decreased,3082,O
in,3082,O
the,3082,O
mitral,3082,O
cell,3082,O
layer,3082,O
of,3082,O
the,3082,O
olfactory,3082,O
bulb,3082,O
",",3082,O
and,3082,O
the,3082,O
inferior,3082,O
and,3082,O
the,3082,O
superior,3082,O
colliculus,3082,O
of,3082,O
beta4,3082,O
-/-,3082,O
brains,3082,O
.,3082,O
alpha3,3083,O
+/-,3083,O
mice,3083,O
were,3083,O
partially,3083,O
resistant,3083,O
to,3083,O
nicotine-induced,3083,B-Chemical
seizures,3083,B-Disease
when,3083,O
compared,3083,O
to,3083,O
wild-type,3083,O
littermates,3083,O
.,3083,O
mRNA,3084,O
levels,3084,O
for,3084,O
the,3084,O
alpha5,3084,O
and,3084,O
the,3084,O
beta4,3084,O
subunits,3084,O
were,3084,O
unchanged,3084,O
in,3084,O
alpha3,3084,O
+/-,3084,O
brains,3084,O
.,3084,O
Together,3085,O
",",3085,O
these,3085,O
results,3085,O
suggest,3085,O
that,3085,O
the,3085,O
beta4,3085,O
and,3085,O
the,3085,O
alpha3,3085,O
subunits,3085,O
are,3085,O
mediators,3085,O
of,3085,O
nicotine-induced,3085,B-Chemical
seizures,3085,B-Disease
and,3085,O
hypolocomotion,3085,B-Disease
.,3085,O
The,3086,O
effects,3086,O
of,3086,O
sevoflurane,3086,B-Chemical
on,3086,O
lidocaine-induced,3086,B-Chemical
convulsions,3086,B-Disease
.,3086,O
The,3087,O
influence,3087,O
of,3087,O
sevoflurane,3087,B-Chemical
on,3087,O
lidocaine-induced,3087,B-Chemical
convulsions,3087,B-Disease
was,3087,O
studied,3087,O
in,3087,O
cats,3087,O
.,3087,O
The,3088,O
convulsive,3088,B-Disease
threshold,3088,O
(,3088,O
mean,3088,O
+/-,3088,O
SD,3088,O
),3088,O
was,3088,O
41.4,3088,O
+/-,3088,O
6.5,3088,O
mg.,3088,O
l,3088,O
(,3088,O
-1,3088,O
),3088,O
with,3088,O
lidocaine,3088,B-Chemical
infusion,3088,O
(,3088,O
6,3088,O
mg.kg,3088,O
(,3088,O
-1,3088,O
),3088,O
.min,3088,O
(,3088,O
-1,3088,O
),3088,O
),3088,O
",",3088,O
increasing,3088,O
significantly,3088,O
to,3088,O
66.6,3088,O
+/-,3088,O
10.9,3088,O
mg.,3088,O
l,3088,O
(,3088,O
-1,3088,O
),3088,O
when,3088,O
the,3088,O
end-tidal,3088,O
concentration,3088,O
of,3088,O
sevoflurane,3088,B-Chemical
was,3088,O
0.8,3088,O
%,3088,O
.,3088,O
However,3089,O
",",3089,O
the,3089,O
threshold,3089,O
(,3089,O
61.6,3089,O
+/-,3089,O
8.7,3089,O
mg.,3089,O
l,3089,O
(,3089,O
-1,3089,O
),3089,O
),3089,O
during,3089,O
1.6,3089,O
%,3089,O
sevoflurane,3089,B-Chemical
was,3089,O
not,3089,O
significant,3089,O
from,3089,O
that,3089,O
during,3089,O
0.8,3089,O
%,3089,O
sevoflurane,3089,B-Chemical
",",3089,O
indicating,3089,O
a,3089,O
celling,3089,O
effect,3089,O
.,3089,O
There,3090,O
was,3090,O
no,3090,O
significant,3090,O
difference,3090,O
in,3090,O
the,3090,O
convulsive,3090,B-Disease
threshold,3090,O
between,3090,O
sevoflurane,3090,B-Chemical
and,3090,O
enflurane,3090,B-Chemical
.,3090,O
The,3091,O
rise,3091,O
in,3091,O
blood,3091,O
pressure,3091,O
became,3091,O
less,3091,O
marked,3091,O
when,3091,O
higher,3091,O
concentrations,3091,O
of,3091,O
sevoflurane,3091,B-Chemical
or,3091,O
enflurane,3091,B-Chemical
were,3091,O
administered,3091,O
and,3091,O
the,3091,O
blood,3091,O
pressure,3091,O
at,3091,O
convulsions,3091,B-Disease
decreased,3091,O
significantly,3091,O
in,3091,O
1.6,3091,O
%,3091,O
sevoflurane,3091,B-Chemical
",",3091,O
and,3091,O
in,3091,O
0.8,3091,O
%,3091,O
and,3091,O
1.6,3091,O
%,3091,O
enflurane,3091,B-Chemical
.,3091,O
However,3092,O
",",3092,O
there,3092,O
was,3092,O
no,3092,O
significant,3092,O
difference,3092,O
in,3092,O
the,3092,O
lidocaine,3092,B-Chemical
concentrations,3092,O
measured,3092,O
when,3092,O
the,3092,O
systolic,3092,O
blood,3092,O
pressure,3092,O
became,3092,O
70,3092,O
mmHg,3092,O
.,3092,O
Apamin,3093,B-Chemical
",",3093,O
a,3093,O
selective,3093,O
blocker,3093,O
of,3093,O
calcium-dependent,3093,B-Chemical
potassium,3093,B-Chemical
channels,3093,O
",",3093,O
was,3093,O
administered,3093,O
intracerebroventricularly,3093,O
in,3093,O
rats,3093,O
anesthetized,3093,O
with,3093,O
0.8,3093,O
%,3093,O
sevoflurane,3093,B-Chemical
to,3093,O
investigate,3093,O
the,3093,O
mechanism,3093,O
of,3093,O
the,3093,O
anticonvulsive,3093,O
effects,3093,O
.,3093,O
Apamin,3094,B-Chemical
(,3094,O
10,3094,O
ng,3094,O
),3094,O
had,3094,O
a,3094,O
tendency,3094,O
to,3094,O
decrease,3094,O
the,3094,O
convulsive,3094,B-Disease
threshold,3094,O
(,3094,O
21.6,3094,O
+/-,3094,O
2.2,3094,O
to,3094,O
19.9,3094,O
+/-,3094,O
2.5,3094,O
mg.,3094,O
l,3094,O
(,3094,O
-1,3094,O
),3094,O
),3094,O
but,3094,O
this,3094,O
was,3094,O
not,3094,O
statistically,3094,O
significant,3094,O
.,3094,O
It,3095,O
is,3095,O
suggested,3095,O
that,3095,O
sevoflurane,3095,B-Chemical
reduces,3095,O
the,3095,O
convulsive,3095,B-Disease
effect,3095,O
of,3095,O
lidocaine,3095,B-Chemical
toxicity,3095,B-Disease
but,3095,O
carries,3095,O
some,3095,O
risk,3095,O
due,3095,O
to,3095,O
circulatory,3095,O
depression,3095,B-Disease
.,3095,O
Cardiac,3096,B-Disease
toxicity,3096,I-Disease
observed,3096,O
in,3096,O
association,3096,O
with,3096,O
high-dose,3096,O
cyclophosphamide-based,3096,B-Chemical
chemotherapy,3096,O
for,3096,O
metastatic,3096,O
breast,3096,B-Disease
cancer,3096,I-Disease
.,3096,O
INTRODUCTION,3097,O
:,3097,O
Cyclophosphamide,3097,B-Chemical
is,3097,O
an,3097,O
alkylating,3097,O
agent,3097,O
given,3097,O
frequently,3097,O
as,3097,O
a,3097,O
component,3097,O
of,3097,O
many,3097,O
conditioning,3097,O
regimens,3097,O
.,3097,O
In,3098,O
high,3098,O
doses,3098,O
",",3098,O
its,3098,O
nonhematological,3098,O
dose-limiting,3098,O
toxicity,3098,B-Disease
is,3098,O
cardiomyopathy,3098,B-Disease
.,3098,O
STUDY,3099,O
DESIGN,3099,O
:,3099,O
We,3099,O
combined,3099,O
paclitaxel,3099,B-Chemical
",",3099,O
melphalan,3099,B-Chemical
and,3099,O
high-dose,3099,O
cyclophosphamide,3099,B-Chemical
",",3099,O
thiotepa,3099,B-Chemical
",",3099,O
and,3099,O
carboplatin,3099,B-Chemical
in,3099,O
a,3099,O
triple,3099,O
sequential,3099,O
high-dose,3099,O
regimen,3099,O
for,3099,O
patients,3099,O
with,3099,O
metastatic,3099,O
breast,3099,B-Disease
cancer,3099,I-Disease
.,3099,O
Analysis,3100,O
was,3100,O
performed,3100,O
on,3100,O
61,3100,O
women,3100,O
with,3100,O
chemotherapy-responsive,3100,O
metastatic,3100,O
breast,3100,B-Disease
cancer,3100,I-Disease
receiving,3100,O
96-h,3100,O
infusional,3100,O
cyclophosphamide,3100,B-Chemical
as,3100,O
part,3100,O
of,3100,O
a,3100,O
triple,3100,O
sequential,3100,O
high-dose,3100,O
regimen,3100,O
to,3100,O
assess,3100,O
association,3100,O
between,3100,O
presence,3100,O
of,3100,O
peritransplant,3100,O
congestive,3100,B-Disease
heart,3100,I-Disease
failure,3100,I-Disease
(,3100,O
CHF,3100,B-Disease
),3100,O
and,3100,O
the,3100,O
following,3100,O
pretreatment,3100,O
characteristics,3100,O
:,3100,O
presence,3100,O
of,3100,O
electrocardiogram,3100,O
(,3100,O
EKG,3100,O
),3100,O
abnormalities,3100,O
",",3100,O
age,3100,O
",",3100,O
hypertension,3100,B-Disease
",",3100,O
prior,3100,O
cardiac,3100,O
history,3100,O
",",3100,O
smoking,3100,O
",",3100,O
diabetes,3100,B-Disease
mellitus,3100,I-Disease
",",3100,O
prior,3100,O
use,3100,O
of,3100,O
anthracyclines,3100,B-Chemical
",",3100,O
and,3100,O
left-sided,3100,O
chest,3100,O
irradiation,3100,O
.,3100,O
RESULTS,3101,O
:,3101,O
Six,3101,O
of,3101,O
61,3101,O
women,3101,O
(,3101,O
10,3101,O
%,3101,O
),3101,O
developed,3101,O
clinically,3101,O
reversible,3101,O
grade,3101,O
3,3101,O
CHF,3101,B-Disease
following,3101,O
infusional,3101,O
cyclophosphamide,3101,B-Chemical
with,3101,O
a,3101,O
median,3101,O
percent,3101,O
decline,3101,O
in,3101,O
ejection,3101,O
fraction,3101,O
of,3101,O
31,3101,O
%,3101,O
.,3101,O
Incidence,3102,O
of,3102,O
transient,3102,O
cyclophosphamide-related,3102,B-Chemical
cardiac,3102,B-Disease
toxicity,3102,I-Disease
(,3102,O
10,3102,O
%,3102,O
),3102,O
is,3102,O
comparable,3102,O
to,3102,O
previous,3102,O
recorded,3102,O
literature,3102,O
.,3102,O
Older,3103,O
age,3103,O
was,3103,O
significantly,3103,O
correlated,3103,O
with,3103,O
the,3103,O
CHF,3103,B-Disease
development,3103,O
;,3103,O
with,3103,O
median,3103,O
ages,3103,O
for,3103,O
the,3103,O
entire,3103,O
group,3103,O
and,3103,O
for,3103,O
patients,3103,O
developing,3103,O
CHF,3103,B-Disease
of,3103,O
45,3103,O
and,3103,O
59,3103,O
",",3103,O
respectively,3103,O
.,3103,O
No,3104,O
association,3104,O
was,3104,O
found,3104,O
with,3104,O
other,3104,O
pretreatment,3104,O
characteristics,3104,O
.,3104,O
CONCLUSIONS,3105,O
:,3105,O
As,3105,O
a,3105,O
result,3105,O
of,3105,O
these,3105,O
findings,3105,O
",",3105,O
oncologists,3105,O
should,3105,O
carefully,3105,O
monitor,3105,O
fluid,3105,O
balance,3105,O
in,3105,O
older,3105,O
patients,3105,O
.,3105,O
Routine,3106,O
EKG,3106,O
monitoring,3106,O
during,3106,O
infusional,3106,O
cyclophosphamide,3106,B-Chemical
did,3106,O
not,3106,O
predict,3106,O
CHF,3106,B-Disease
development,3106,O
.,3106,O
Tremor,3107,B-Disease
side,3107,O
effects,3107,O
of,3107,O
salbutamol,3107,B-Chemical
",",3107,O
quantified,3107,O
by,3107,O
a,3107,O
laser,3107,O
pointer,3107,O
technique,3107,O
.,3107,O
OBJECTIVE,3108,O
:,3108,O
To,3108,O
study,3108,O
tremor,3108,B-Disease
side,3108,O
effects,3108,O
of,3108,O
salbutamol,3108,B-Chemical
an,3108,O
easily,3108,O
applicable,3108,O
",",3108,O
quick,3108,O
and,3108,O
low-priced,3108,O
method,3108,O
is,3108,O
needed,3108,O
.,3108,O
A,3109,O
new,3109,O
method,3109,O
using,3109,O
a,3109,O
commercially,3109,O
available,3109,O
",",3109,O
pen-shaped,3109,O
laser,3109,O
pointer,3109,O
was,3109,O
developed,3109,O
.,3109,O
Aim,3110,O
of,3110,O
the,3110,O
study,3110,O
was,3110,O
to,3110,O
determine,3110,O
sensitivity,3110,O
",",3110,O
reproducibility,3110,O
",",3110,O
reference,3110,O
values,3110,O
and,3110,O
the,3110,O
agreement,3110,O
with,3110,O
a,3110,O
questionnaire,3110,O
.,3110,O
METHODS,3111,O
:,3111,O
Tremor,3111,B-Disease
was,3111,O
measured,3111,O
using,3111,O
a,3111,O
laser,3111,O
pointer,3111,O
technique,3111,O
.,3111,O
To,3112,O
determine,3112,O
sensitivity,3112,O
we,3112,O
assessed,3112,O
tremor,3112,B-Disease
in,3112,O
44,3112,O
patients,3112,O
with,3112,O
obstructive,3112,B-Disease
lung,3112,I-Disease
disease,3112,I-Disease
after,3112,O
administration,3112,O
of,3112,O
cumulative,3112,O
doses,3112,O
of,3112,O
salbutamol,3112,B-Chemical
.,3112,O
Subjects,3113,O
were,3113,O
asked,3113,O
to,3113,O
aim,3113,O
at,3113,O
the,3113,O
centre,3113,O
of,3113,O
a,3113,O
target,3113,O
",",3113,O
subdivided,3113,O
in,3113,O
concentric,3113,O
circles,3113,O
",",3113,O
from,3113,O
5,3113,O
m,3113,O
distance,3113,O
.,3113,O
The,3114,O
circle,3114,O
in,3114,O
which,3114,O
the,3114,O
participant,3114,O
succeeded,3114,O
to,3114,O
aim,3114,O
was,3114,O
recorded,3114,O
in,3114,O
millimetres,3114,O
radius,3114,O
.,3114,O
In,3115,O
another,3115,O
series,3115,O
of,3115,O
measurements,3115,O
",",3115,O
reproducibility,3115,O
and,3115,O
reference,3115,O
values,3115,O
of,3115,O
the,3115,O
tremor,3115,B-Disease
was,3115,O
assessed,3115,O
in,3115,O
65,3115,O
healthy,3115,O
subjects,3115,O
in,3115,O
three,3115,O
sessions,3115,O
",",3115,O
at,3115,O
9,3115,O
a.m.,3115,O
",",3115,O
4,3115,O
p.m.,3115,O
and,3115,O
9,3115,O
a.m.,3115,O
",",3115,O
respectively,3115,O
",",3115,O
1,3115,O
week,3115,O
later,3115,O
.,3115,O
Postural,3116,O
tremor,3116,B-Disease
was,3116,O
measured,3116,O
with,3116,O
the,3116,O
arm,3116,O
horizontally,3116,O
outstretched,3116,O
rest,3116,O
tremor,3116,B-Disease
with,3116,O
the,3116,O
arm,3116,O
supported,3116,O
by,3116,O
an,3116,O
armrest,3116,O
and,3116,O
finally,3116,O
tremor,3116,B-Disease
was,3116,O
measured,3116,O
after,3116,O
holding,3116,O
a,3116,O
2-kg,3116,O
weight,3116,O
until,3116,O
exhaustion,3116,O
.,3116,O
Inter-observer,3117,O
variability,3117,O
was,3117,O
measured,3117,O
in,3117,O
a,3117,O
series,3117,O
of,3117,O
10,3117,O
healthy,3117,O
subjects,3117,O
.,3117,O
Tremor,3118,B-Disease
was,3118,O
measured,3118,O
simultaneously,3118,O
by,3118,O
two,3118,O
independent,3118,O
observers,3118,O
.,3118,O
RESULTS,3119,O
:,3119,O
Salbutamol,3119,B-Chemical
significantly,3119,O
increased,3119,O
tremor,3119,B-Disease
severity,3119,O
in,3119,O
patients,3119,O
in,3119,O
a,3119,O
dose-dependent,3119,O
way,3119,O
.,3119,O
Within,3120,O
healthy,3120,O
adults,3120,O
no,3120,O
age-dependency,3120,O
could,3120,O
be,3120,O
found,3120,O
(,3120,O
b,3120,O
=,3120,O
0.262,3120,O
mm/year,3120,O
;,3120,O
P,3120,O
=,3120,O
0.72,3120,O
),3120,O
.,3120,O
There,3121,O
was,3121,O
no,3121,O
agreement,3121,O
between,3121,O
the,3121,O
questionnaire,3121,O
and,3121,O
tremor,3121,B-Disease
severity,3121,O
(,3121,O
r,3121,O
=,3121,O
0.093,3121,O
;,3121,O
P,3121,O
=,3121,O
0.53,3121,O
),3121,O
.,3121,O
Postural,3122,O
tremor,3122,B-Disease
showed,3122,O
no,3122,O
significant,3122,O
difference,3122,O
between,3122,O
the,3122,O
first,3122,O
and,3122,O
third,3122,O
session,3122,O
(,3122,O
P,3122,O
=,3122,O
0.07,3122,O
),3122,O
.,3122,O
Support,3123,O
of,3123,O
the,3123,O
arm,3123,O
decreased,3123,O
tremor,3123,B-Disease
severity,3123,O
",",3123,O
exhaustion,3123,O
increased,3123,O
tremor,3123,B-Disease
severity,3123,O
significantly,3123,O
.,3123,O
A,3124,O
good,3124,O
agreement,3124,O
was,3124,O
found,3124,O
between,3124,O
two,3124,O
independent,3124,O
observers,3124,O
(,3124,O
interclass,3124,O
correlation,3124,O
coefficient,3124,O
0.72,3124,O
),3124,O
.,3124,O
DISCUSSION,3125,O
:,3125,O
Quantifying,3125,O
tremor,3125,B-Disease
by,3125,O
using,3125,O
an,3125,O
inexpensive,3125,O
laser,3125,O
pointer,3125,O
is,3125,O
",",3125,O
with,3125,O
the,3125,O
exception,3125,O
of,3125,O
children,3125,O
(,3125,O
<,3125,O
12,3125,O
years,3125,O
),3125,O
a,3125,O
sensitive,3125,O
and,3125,O
reproducible,3125,O
method,3125,O
.,3125,O
Safety,3126,O
and,3126,O
adverse,3126,O
effects,3126,O
associated,3126,O
with,3126,O
raloxifene,3126,B-Chemical
:,3126,O
multiple,3126,O
outcomes,3126,O
of,3126,O
raloxifene,3126,B-Chemical
evaluation,3126,O
.,3126,O
OBJECTIVE,3127,O
:,3127,O
To,3127,O
examine,3127,O
the,3127,O
effect,3127,O
of,3127,O
raloxifene,3127,B-Chemical
on,3127,O
major,3127,O
adverse,3127,O
events,3127,O
that,3127,O
occur,3127,O
with,3127,O
postmenopausal,3127,O
estrogen,3127,B-Chemical
therapy,3127,O
or,3127,O
tamoxifen,3127,B-Chemical
.,3127,O
METHODS,3128,O
:,3128,O
The,3128,O
Multiple,3128,O
Outcomes,3128,O
of,3128,O
Raloxifene,3128,B-Chemical
Evaluation,3128,O
",",3128,O
a,3128,O
multicenter,3128,O
",",3128,O
randomized,3128,O
",",3128,O
double-blind,3128,O
trial,3128,O
",",3128,O
enrolled,3128,O
"7,705",3128,O
postmenopausal,3128,O
women,3128,O
with,3128,O
osteoporosis,3128,B-Disease
.,3128,O
Women,3129,O
were,3129,O
randomly,3129,O
assigned,3129,O
to,3129,O
raloxifene,3129,B-Chemical
60,3129,O
mg/d,3129,O
or,3129,O
120,3129,O
mg/d,3129,O
or,3129,O
placebo,3129,O
.,3129,O
Outcomes,3130,O
included,3130,O
venous,3130,B-Disease
thromboembolism,3130,I-Disease
",",3130,O
cataracts,3130,B-Disease
",",3130,O
gallbladder,3130,B-Disease
disease,3130,I-Disease
",",3130,O
and,3130,O
endometrial,3130,O
hyperplasia,3130,O
or,3130,O
cancer,3130,O
.,3130,O
RESULTS,3131,O
:,3131,O
During,3131,O
a,3131,O
mean,3131,O
follow-up,3131,O
of,3131,O
3.3,3131,O
years,3131,O
",",3131,O
raloxifene,3131,B-Chemical
was,3131,O
associated,3131,O
with,3131,O
an,3131,O
increased,3131,O
risk,3131,O
for,3131,O
venous,3131,B-Disease
thromboembolism,3131,I-Disease
(,3131,O
relative,3131,O
risk,3131,O
[,3131,O
RR,3131,O
],3131,O
2.1,3131,O
;,3131,O
95,3131,O
%,3131,O
confidence,3131,O
interval,3131,O
[,3131,O
CI,3131,O
],3131,O
1.2-3.8,3131,O
),3131,O
.,3131,O
The,3132,O
excess,3132,O
event,3132,O
rate,3132,O
was,3132,O
1.8,3132,O
per,3132,O
"1,000",3132,O
woman-years,3132,O
(,3132,O
95,3132,O
%,3132,O
CI,3132,O
-0.5-4.1,3132,O
),3132,O
",",3132,O
and,3132,O
the,3132,O
number,3132,O
needed,3132,O
to,3132,O
treat,3132,O
to,3132,O
cause,3132,O
1,3132,O
event,3132,O
was,3132,O
170,3132,O
(,3132,O
95,3132,O
%,3132,O
CI,3132,O
100-582,3132,O
),3132,O
over,3132,O
3.3,3132,O
years,3132,O
.,3132,O
Risk,3133,O
in,3133,O
the,3133,O
raloxifene,3133,B-Chemical
group,3133,O
was,3133,O
higher,3133,O
than,3133,O
in,3133,O
the,3133,O
placebo,3133,O
group,3133,O
for,3133,O
the,3133,O
first,3133,O
2,3133,O
years,3133,O
",",3133,O
but,3133,O
decreased,3133,O
to,3133,O
about,3133,O
the,3133,O
same,3133,O
rate,3133,O
as,3133,O
in,3133,O
the,3133,O
placebo,3133,O
group,3133,O
thereafter,3133,O
.,3133,O
Raloxifene,3134,B-Chemical
did,3134,O
not,3134,O
increase,3134,O
risk,3134,O
for,3134,O
cataracts,3134,B-Disease
(,3134,O
RR,3134,O
0.9,3134,O
;,3134,O
95,3134,O
%,3134,O
CI,3134,O
0.8-1.1,3134,O
),3134,O
",",3134,O
gallbladder,3134,B-Disease
disease,3134,I-Disease
(,3134,O
RR,3134,O
1.0,3134,O
;,3134,O
95,3134,O
%,3134,O
CI,3134,O
0.7-1.3,3134,O
),3134,O
",",3134,O
endometrial,3134,B-Disease
hyperplasia,3134,I-Disease
(,3134,O
RR,3134,O
1.3,3134,O
;,3134,O
95,3134,O
%,3134,O
CI,3134,O
0.4-5.1,3134,O
),3134,O
",",3134,O
or,3134,O
endometrial,3134,B-Disease
cancer,3134,I-Disease
(,3134,O
RR,3134,O
0.9,3134,O
;,3134,O
95,3134,O
%,3134,O
CI,3134,O
0.3-2.7,3134,O
),3134,O
.,3134,O
CONCLUSION,3135,O
:,3135,O
Raloxifene,3135,B-Chemical
was,3135,O
associated,3135,O
with,3135,O
an,3135,O
increased,3135,O
risk,3135,O
for,3135,O
venous,3135,B-Disease
thromboembolism,3135,I-Disease
",",3135,O
but,3135,O
there,3135,O
was,3135,O
no,3135,O
increased,3135,O
risk,3135,O
for,3135,O
cataracts,3135,B-Disease
",",3135,O
gallbladder,3135,B-Disease
disease,3135,I-Disease
",",3135,O
endometrial,3135,B-Disease
hyperplasia,3135,I-Disease
",",3135,O
or,3135,O
endometrial,3135,B-Disease
cancer,3135,I-Disease
.,3135,O
LEVEL,3136,O
OF,3136,O
EVIDENCE,3136,O
:,3136,O
I,3136,O
Long,3137,O
term,3137,O
audiological,3137,O
evaluation,3137,O
of,3137,O
beta-thalassemic,3137,B-Disease
patients,3137,O
.,3137,O
OBJECTIVE,3138,O
:,3138,O
The,3138,O
objective,3138,O
of,3138,O
this,3138,O
study,3138,O
was,3138,O
to,3138,O
identify,3138,O
the,3138,O
incidence,3138,O
and,3138,O
to,3138,O
monitor,3138,O
the,3138,O
progression,3138,O
of,3138,O
hearing,3138,B-Disease
loss,3138,I-Disease
in,3138,O
children,3138,O
and,3138,O
young,3138,O
adults,3138,O
with,3138,O
beta-thalassemia,3138,B-Disease
major,3138,O
.,3138,O
METHODS,3139,O
:,3139,O
One,3139,O
hundred,3139,O
and,3139,O
four,3139,O
(,3139,O
104,3139,O
),3139,O
patients,3139,O
aged,3139,O
6-35,3139,O
years,3139,O
(,3139,O
mean,3139,O
"17,2",3139,O
years,3139,O
),3139,O
participated,3139,O
in,3139,O
the,3139,O
study,3139,O
.,3139,O
All,3140,O
patients,3140,O
were,3140,O
on,3140,O
a,3140,O
regular,3140,O
transfusion-chelation,3140,O
program,3140,O
maintaining,3140,O
a,3140,O
mean,3140,O
hemoglobin,3140,O
level,3140,O
of,3140,O
9.5,3140,O
gr/dl,3140,O
.,3140,O
Subjects,3141,O
were,3141,O
receiving,3141,O
desferrioxamine,3141,B-Chemical
(,3141,O
DFO,3141,B-Chemical
),3141,O
chelation,3141,O
treatment,3141,O
with,3141,O
a,3141,O
mean,3141,O
daily,3141,O
dose,3141,O
of,3141,O
50-60,3141,O
mg/kg,3141,O
",",3141,O
5-6,3141,O
days,3141,O
a,3141,O
week,3141,O
during,3141,O
the,3141,O
first,3141,O
six,3141,O
years,3141,O
of,3141,O
the,3141,O
study,3141,O
",",3141,O
which,3141,O
was,3141,O
then,3141,O
reduced,3141,O
to,3141,O
40-50,3141,O
mg/kg,3141,O
for,3141,O
the,3141,O
following,3141,O
eight,3141,O
years,3141,O
.,3141,O
Patients,3142,O
were,3142,O
followed,3142,O
for,3142,O
8-14,3142,O
years,3142,O
.,3142,O
RESULTS,3143,O
:,3143,O
Overall,3143,O
",",3143,O
21,3143,O
out,3143,O
of,3143,O
104,3143,O
patients,3143,O
(,3143,O
20.2,3143,O
%,3143,O
),3143,O
presented,3143,O
with,3143,O
high,3143,O
frequency,3143,O
sensorineural,3143,B-Disease
hearing,3143,I-Disease
loss,3143,I-Disease
(,3143,O
SNHL,3143,B-Disease
),3143,O
",",3143,O
either,3143,O
unilateral,3143,O
or,3143,O
bilateral,3143,O
.,3143,O
No,3144,O
ototoxic,3144,B-Disease
factor,3144,O
",",3144,O
other,3144,O
than,3144,O
DFO,3144,B-Chemical
",",3144,O
was,3144,O
present,3144,O
in,3144,O
any,3144,O
of,3144,O
the,3144,O
patients,3144,O
.,3144,O
Patients,3145,O
with,3145,O
SNHL,3145,B-Disease
presented,3145,O
with,3145,O
relatively,3145,O
lower,3145,O
serum,3145,O
ferritin,3145,O
levels,3145,O
than,3145,O
those,3145,O
with,3145,O
normal,3145,O
hearing,3145,O
",",3145,O
however,3145,O
",",3145,O
no,3145,O
statistically,3145,O
significant,3145,O
difference,3145,O
was,3145,O
observed,3145,O
.,3145,O
Subjects,3146,O
with,3146,O
SNHL,3146,B-Disease
were,3146,O
submitted,3146,O
to,3146,O
DFO,3146,B-Chemical
reduction,3146,O
or,3146,O
temporary,3146,O
withdrawal,3146,O
.,3146,O
Following,3147,O
intervention,3147,O
",",3147,O
7,3147,O
out,3147,O
of,3147,O
21,3147,O
affected,3147,O
patients,3147,O
recovered,3147,O
",",3147,O
10,3147,O
remained,3147,O
stable,3147,O
and,3147,O
4,3147,O
demonstrated,3147,O
aggravation,3147,O
.,3147,O
CONCLUSION,3148,O
:,3148,O
The,3148,O
findings,3148,O
are,3148,O
indicative,3148,O
of,3148,O
DFO,3148,B-Chemical
's,3148,O
contributing,3148,O
role,3148,O
in,3148,O
the,3148,O
development,3148,O
of,3148,O
hearing,3148,B-Disease
impairment,3148,I-Disease
.,3148,O
Regular,3149,O
audiologic,3149,O
evaluation,3149,O
is,3149,O
imperative,3149,O
in,3149,O
all,3149,O
thalassemic,3149,B-Disease
patients,3149,O
so,3149,O
that,3149,O
early,3149,O
changes,3149,O
may,3149,O
be,3149,O
recognized,3149,O
and,3149,O
treatment,3149,O
may,3149,O
be,3149,O
judiciously,3149,O
adjusted,3149,O
in,3149,O
order,3149,O
to,3149,O
prevent,3149,O
or,3149,O
reverse,3149,O
hearing,3149,B-Disease
impairment,3149,I-Disease
.,3149,O
Individual,3150,O
differences,3150,O
in,3150,O
renal,3150,O
ACE,3150,O
activity,3150,O
in,3150,O
healthy,3150,O
rats,3150,O
predict,3150,O
susceptibility,3150,O
to,3150,O
adriamycin-induced,3150,B-Chemical
renal,3150,B-Disease
damage,3150,I-Disease
.,3150,O
BACKGROUND,3151,O
:,3151,O
In,3151,O
man,3151,O
",",3151,O
differences,3151,O
in,3151,O
angiotensin-converting,3151,B-Chemical
enzyme,3151,O
(,3151,O
ACE,3151,O
),3151,O
levels,3151,O
",",3151,O
related,3151,O
to,3151,O
ACE,3151,O
(,3151,O
I/D,3151,O
),3151,O
genotype,3151,O
",",3151,O
are,3151,O
associated,3151,O
with,3151,O
renal,3151,O
prognosis,3151,O
.,3151,O
This,3152,O
raises,3152,O
the,3152,O
hypothesis,3152,O
that,3152,O
individual,3152,O
differences,3152,O
in,3152,O
renal,3152,O
ACE,3152,O
activity,3152,O
are,3152,O
involved,3152,O
in,3152,O
renal,3152,O
susceptibility,3152,O
to,3152,O
inflicted,3152,O
damage,3152,O
.,3152,O
Therefore,3153,O
",",3153,O
we,3153,O
studied,3153,O
the,3153,O
predictive,3153,O
effect,3153,O
of,3153,O
renal,3153,O
ACE,3153,O
activity,3153,O
for,3153,O
the,3153,O
severity,3153,O
of,3153,O
renal,3153,B-Disease
damage,3153,I-Disease
induced,3153,O
by,3153,O
a,3153,O
single,3153,O
injection,3153,O
of,3153,O
adriamycin,3153,B-Chemical
in,3153,O
rats,3153,O
.,3153,O
METHODS,3154,O
:,3154,O
Renal,3154,O
ACE,3154,O
activity,3154,O
(,3154,O
Hip-His-Leu,3154,B-Chemical
cleavage,3154,O
by,3154,O
cortical,3154,O
homogenates,3154,O
),3154,O
was,3154,O
determined,3154,O
by,3154,O
renal,3154,O
biopsy,3154,O
in,3154,O
27,3154,O
adult,3154,O
male,3154,O
Wistar,3154,O
rats,3154,O
.,3154,O
After,3155,O
1,3155,O
week,3155,O
of,3155,O
recovery,3155,O
",",3155,O
proteinuria,3155,B-Disease
was,3155,O
induced,3155,O
by,3155,O
adriamycin,3155,B-Chemical
[,3155,O
1.5,3155,O
mg/kg,3155,O
intravenously,3155,O
(,3155,O
i.v,3155,O
.,3155,O
),3155,O
n,3156,O
=,3156,O
18,3156,O
;,3156,O
controls,3156,O
",",3156,O
saline,3156,O
i.v,3156,O
.,3156,O
n,3157,O
=,3157,O
9,3157,O
],3157,O
.,3157,O
Proteinuria,3158,B-Disease
was,3158,O
measured,3158,O
every,3158,O
2,3158,O
weeks,3158,O
.,3158,O
After,3159,O
12,3159,O
weeks,3159,O
",",3159,O
rats,3159,O
were,3159,O
sacrificed,3159,O
and,3159,O
their,3159,O
kidneys,3159,O
harvested,3159,O
.,3159,O
RESULTS,3160,O
:,3160,O
As,3160,O
anticipated,3160,O
",",3160,O
adriamycin,3160,B-Chemical
elicited,3160,O
nephrotic,3160,B-Disease
range,3160,O
proteinuria,3160,B-Disease
",",3160,O
renal,3160,B-Disease
interstitial,3160,I-Disease
damage,3160,I-Disease
and,3160,O
mild,3160,O
focal,3160,B-Disease
glomerulosclerosis,3160,I-Disease
.,3160,O
Baseline,3161,O
renal,3161,O
ACE,3161,O
positively,3161,O
correlated,3161,O
with,3161,O
the,3161,O
relative,3161,O
rise,3161,O
in,3161,O
proteinuria,3161,B-Disease
after,3161,O
adriamycin,3161,B-Chemical
(,3161,O
r,3161,O
=,3161,O
0.62,3161,O
",",3161,O
P,3161,O
<,3161,O
0.01,3161,O
),3161,O
",",3161,O
renal,3161,O
interstitial,3161,O
alpha-smooth,3161,O
muscle,3161,O
actin,3161,O
(,3161,O
r,3161,O
=,3161,O
0.49,3161,O
",",3161,O
P,3161,O
<,3161,O
0.05,3161,O
),3161,O
",",3161,O
interstitial,3161,O
macrophage,3161,O
influx,3161,O
(,3161,O
r,3161,O
=,3161,O
0.56,3161,O
",",3161,O
P,3161,O
<,3161,O
0.05,3161,O
),3161,O
",",3161,O
interstitial,3161,O
collagen,3161,O
III,3161,O
(,3161,O
r,3161,O
=,3161,O
0.53,3161,O
",",3161,O
P,3161,O
<,3161,O
0.05,3161,O
),3161,O
",",3161,O
glomerular,3161,O
alpha-smooth,3161,O
muscle,3161,O
actin,3161,O
(,3161,O
r,3161,O
=,3161,O
0.74,3161,O
",",3161,O
P,3161,O
<,3161,O
0.01,3161,O
),3161,O
and,3161,O
glomerular,3161,O
desmin,3161,O
(,3161,O
r,3161,O
=,3161,O
0.48,3161,O
",",3161,O
P,3161,O
<,3161,O
0.05,3161,O
),3161,O
.,3161,O
Baseline,3162,O
renal,3162,O
ACE,3162,O
did,3162,O
not,3162,O
correlate,3162,O
with,3162,O
focal,3162,B-Disease
glomerulosclerosis,3162,I-Disease
(,3162,O
r,3162,O
=,3162,O
0.22,3162,O
",",3162,O
NS,3162,O
),3162,O
.,3162,O
In,3163,O
controls,3163,O
",",3163,O
no,3163,O
predictive,3163,O
values,3163,O
for,3163,O
renal,3163,O
parameters,3163,O
were,3163,O
observed,3163,O
.,3163,O
CONCLUSION,3164,O
:,3164,O
Individual,3164,O
differences,3164,O
in,3164,O
renal,3164,O
ACE,3164,O
activity,3164,O
predict,3164,O
the,3164,O
severity,3164,O
of,3164,O
adriamycin-induced,3164,B-Chemical
renal,3164,B-Disease
damage,3164,I-Disease
in,3164,O
this,3164,O
outbred,3164,O
rat,3164,O
strain,3164,O
.,3164,O
This,3165,O
supports,3165,O
the,3165,O
assumption,3165,O
that,3165,O
differences,3165,O
in,3165,O
renal,3165,O
ACE,3165,O
activity,3165,O
predispose,3165,O
to,3165,O
a,3165,O
less,3165,O
favourable,3165,O
course,3165,O
of,3165,O
renal,3165,B-Disease
damage,3165,I-Disease
.,3165,O
Recurrent,3166,O
acute,3166,O
interstitial,3166,B-Disease
nephritis,3166,I-Disease
induced,3166,O
by,3166,O
azithromycin,3166,B-Chemical
.,3166,O
A,3167,O
14-year-old,3167,O
girl,3167,O
is,3167,O
reported,3167,O
with,3167,O
recurrent,3167,O
",",3167,O
azithromycin-induced,3167,B-Chemical
",",3167,O
acute,3167,O
interstitial,3167,B-Disease
nephritis,3167,I-Disease
.,3167,O
The,3168,O
second,3168,O
episode,3168,O
was,3168,O
more,3168,O
severe,3168,O
than,3168,O
the,3168,O
first,3168,O
;,3168,O
and,3168,O
although,3168,O
both,3168,O
were,3168,O
treated,3168,O
with,3168,O
intensive,3168,O
corticosteroid,3168,O
therapy,3168,O
",",3168,O
renal,3168,O
function,3168,O
remained,3168,O
impaired,3168,O
.,3168,O
Although,3169,O
most,3169,O
cases,3169,O
of,3169,O
antibiotic,3169,O
induced,3169,O
acute,3169,O
interstitial,3169,B-Disease
nephritis,3169,I-Disease
are,3169,O
benign,3169,O
and,3169,O
self-limited,3169,O
",",3169,O
some,3169,O
patients,3169,O
are,3169,O
at,3169,O
risk,3169,O
for,3169,O
permanent,3169,O
renal,3169,B-Disease
injury,3169,I-Disease
.,3169,O
Spironolactone-induced,3170,B-Chemical
renal,3170,B-Disease
insufficiency,3170,I-Disease
and,3170,O
hyperkalemia,3170,B-Disease
in,3170,O
patients,3170,O
with,3170,O
heart,3170,B-Disease
failure,3170,I-Disease
.,3170,O
BACKGROUND,3171,O
:,3171,O
A,3171,O
previous,3171,O
randomized,3171,O
controlled,3171,O
trial,3171,O
evaluating,3171,O
the,3171,O
use,3171,O
of,3171,O
spironolactone,3171,B-Chemical
in,3171,O
heart,3171,B-Disease
failure,3171,I-Disease
patients,3171,O
reported,3171,O
a,3171,O
low,3171,O
risk,3171,O
of,3171,O
hyperkalemia,3171,B-Disease
(,3171,O
2,3171,O
%,3171,O
),3171,O
and,3171,O
renal,3171,B-Disease
insufficiency,3171,I-Disease
(,3171,O
0,3171,O
%,3171,O
),3171,O
.,3171,O
Because,3172,O
treatments,3172,O
for,3172,O
heart,3172,B-Disease
failure,3172,I-Disease
have,3172,O
changed,3172,O
since,3172,O
the,3172,O
benefits,3172,O
of,3172,O
spironolactone,3172,B-Chemical
were,3172,O
reported,3172,O
",",3172,O
the,3172,O
prevalence,3172,O
of,3172,O
these,3172,O
complications,3172,O
may,3172,O
differ,3172,O
in,3172,O
current,3172,O
clinical,3172,O
practice,3172,O
.,3172,O
We,3173,O
therefore,3173,O
sought,3173,O
to,3173,O
determine,3173,O
the,3173,O
prevalence,3173,O
and,3173,O
clinical,3173,O
associations,3173,O
of,3173,O
hyperkalemia,3173,B-Disease
and,3173,O
renal,3173,B-Disease
insufficiency,3173,I-Disease
in,3173,O
heart,3173,B-Disease
failure,3173,I-Disease
patients,3173,O
treated,3173,O
with,3173,O
spironolactone,3173,B-Chemical
.,3173,O
METHODS,3174,O
:,3174,O
We,3174,O
performed,3174,O
a,3174,O
case,3174,O
control,3174,O
study,3174,O
of,3174,O
heart,3174,B-Disease
failure,3174,I-Disease
patients,3174,O
treated,3174,O
with,3174,O
spironolactone,3174,B-Chemical
in,3174,O
our,3174,O
clinical,3174,O
practice,3174,O
.,3174,O
Cases,3175,O
were,3175,O
patients,3175,O
who,3175,O
developed,3175,O
hyperkalemia,3175,B-Disease
(,3175,O
K,3175,B-Chemical
(,3175,O
+,3175,O
),3175,O
>,3175,O
5.0,3175,O
mEq/L,3175,O
),3175,O
or,3175,O
renal,3175,B-Disease
insufficiency,3175,I-Disease
(,3175,O
Cr,3175,B-Chemical
>,3175,O
or=2.5,3175,O
mg/dL,3175,O
),3175,O
",",3175,O
and,3175,O
they,3175,O
were,3175,O
compared,3175,O
to,3175,O
2,3175,O
randomly,3175,O
selected,3175,O
controls,3175,O
per,3175,O
case,3175,O
.,3175,O
Clinical,3176,O
characteristics,3176,O
",",3176,O
medications,3176,O
",",3176,O
and,3176,O
serum,3176,O
chemistries,3176,O
at,3176,O
baseline,3176,O
and,3176,O
follow-up,3176,O
time,3176,O
periods,3176,O
were,3176,O
compared,3176,O
.,3176,O
RESULTS,3177,O
:,3177,O
Sixty-seven,3177,O
of,3177,O
926,3177,O
patients,3177,O
(,3177,O
7.2,3177,O
%,3177,O
),3177,O
required,3177,O
discontinuation,3177,O
of,3177,O
spironolactone,3177,B-Chemical
due,3177,O
to,3177,O
hyperkalemia,3177,B-Disease
(,3177,O
n,3177,O
=,3177,O
33,3177,O
),3177,O
or,3177,O
renal,3177,B-Disease
failure,3177,I-Disease
(,3177,O
n,3177,O
=,3177,O
34,3177,O
),3177,O
.,3177,O
Patients,3178,O
who,3178,O
developed,3178,O
hyperkalemia,3178,B-Disease
were,3178,O
older,3178,O
and,3178,O
more,3178,O
likely,3178,O
to,3178,O
have,3178,O
diabetes,3178,B-Disease
",",3178,O
had,3178,O
higher,3178,O
baseline,3178,O
serum,3178,O
potassium,3178,B-Chemical
levels,3178,O
and,3178,O
lower,3178,O
baseline,3178,O
potassium,3178,B-Chemical
supplement,3178,O
doses,3178,O
",",3178,O
and,3178,O
were,3178,O
more,3178,O
likely,3178,O
to,3178,O
be,3178,O
treated,3178,O
with,3178,O
beta-blockers,3178,O
than,3178,O
controls,3178,O
(,3178,O
n,3178,O
=,3178,O
134,3178,O
),3178,O
.,3178,O
Patients,3179,O
who,3179,O
developed,3179,O
renal,3179,B-Disease
insufficiency,3179,I-Disease
had,3179,O
lower,3179,O
baseline,3179,O
body,3179,O
weight,3179,O
and,3179,O
higher,3179,O
baseline,3179,O
serum,3179,O
creatinine,3179,B-Chemical
",",3179,O
required,3179,O
higher,3179,O
doses,3179,O
of,3179,O
loop,3179,O
diuretics,3179,O
",",3179,O
and,3179,O
were,3179,O
more,3179,O
likely,3179,O
to,3179,O
be,3179,O
treated,3179,O
with,3179,O
thiazide,3179,B-Chemical
diuretics,3179,O
than,3179,O
controls,3179,O
.,3179,O
CONCLUSIONS,3180,O
:,3180,O
Spironolactone-induced,3180,B-Chemical
hyperkalemia,3180,B-Disease
and,3180,O
renal,3180,B-Disease
insufficiency,3180,I-Disease
are,3180,O
more,3180,O
common,3180,O
in,3180,O
our,3180,O
clinical,3180,O
experience,3180,O
than,3180,O
reported,3180,O
previously,3180,O
.,3180,O
This,3181,O
difference,3181,O
is,3181,O
explained,3181,O
by,3181,O
patient,3181,O
comorbidities,3181,O
and,3181,O
more,3181,O
frequent,3181,O
use,3181,O
of,3181,O
beta-blockers,3181,O
.,3181,O
Acute,3182,O
reserpine,3182,B-Chemical
and,3182,O
subchronic,3182,O
haloperidol,3182,B-Chemical
treatments,3182,O
change,3182,O
synaptosomal,3182,O
brain,3182,O
glutamate,3182,B-Chemical
uptake,3182,O
and,3182,O
elicit,3182,O
orofacial,3182,B-Disease
dyskinesia,3182,I-Disease
in,3182,O
rats,3182,O
.,3182,O
Reserpine-,3183,B-Chemical
and,3183,O
haloperidol-induced,3183,B-Chemical
orofacial,3183,B-Disease
dyskinesia,3183,I-Disease
are,3183,O
putative,3183,O
animal,3183,O
models,3183,O
of,3183,O
tardive,3183,B-Disease
dyskinesia,3183,I-Disease
(,3183,O
TD,3183,B-Disease
),3183,O
whose,3183,O
pathophysiology,3183,O
has,3183,O
been,3183,O
related,3183,O
to,3183,O
free,3183,O
radical,3183,O
generation,3183,O
and,3183,O
oxidative,3183,O
stress,3183,O
.,3183,O
In,3184,O
the,3184,O
present,3184,O
study,3184,O
",",3184,O
the,3184,O
authors,3184,O
induced,3184,O
orofacial,3184,B-Disease
dyskinesia,3184,I-Disease
by,3184,O
acute,3184,O
reserpine,3184,B-Chemical
and,3184,O
subchronic,3184,O
haloperidol,3184,B-Chemical
administration,3184,O
to,3184,O
rats,3184,O
.,3184,O
Reserpine,3185,B-Chemical
injection,3185,O
(,3185,O
one,3185,O
dose,3185,O
of,3185,O
1,3185,O
mg/kg,3185,O
s.c.,3185,O
),3185,O
every,3185,O
other,3185,O
day,3185,O
for,3185,O
3,3185,O
days,3185,O
caused,3185,O
a,3185,O
significant,3185,O
increase,3185,O
in,3185,O
vacuous,3185,O
chewing,3185,O
",",3185,O
tongue,3185,O
protrusion,3185,O
and,3185,O
duration,3185,O
of,3185,O
facial,3185,O
twitching,3185,O
",",3185,O
compared,3185,O
to,3185,O
the,3185,O
control,3185,O
.,3185,O
Haloperidol,3186,B-Chemical
administration,3186,O
(,3186,O
one,3186,O
dose,3186,O
of,3186,O
12,3186,O
mg/kg,3186,O
once,3186,O
a,3186,O
week,3186,O
s.c.,3186,O
),3186,O
for,3186,O
4,3186,O
weeks,3186,O
caused,3186,O
an,3186,O
increase,3186,O
in,3186,O
vacuous,3186,O
chewing,3186,O
",",3186,O
tongue,3186,O
protrusion,3186,O
and,3186,O
duration,3186,O
of,3186,O
facial,3186,O
twitching,3186,O
observed,3186,O
in,3186,O
four,3186,O
weekly,3186,O
evaluations,3186,O
.,3186,O
After,3187,O
the,3187,O
treatments,3187,O
and,3187,O
behavioral,3187,O
observation,3187,O
",",3187,O
glutamate,3187,B-Chemical
uptake,3187,O
by,3187,O
segments,3187,O
of,3187,O
the,3187,O
brain,3187,O
was,3187,O
analyzed,3187,O
.,3187,O
A,3188,O
decreased,3188,O
glutamate,3188,B-Chemical
uptake,3188,O
was,3188,O
observed,3188,O
in,3188,O
the,3188,O
subcortical,3188,O
parts,3188,O
of,3188,O
animals,3188,O
treated,3188,O
with,3188,O
reserpine,3188,B-Chemical
and,3188,O
haloperidol,3188,B-Chemical
",",3188,O
compared,3188,O
to,3188,O
the,3188,O
control,3188,O
.,3188,O
Importantly,3189,O
",",3189,O
a,3189,O
decrease,3189,O
in,3189,O
glutamate,3189,B-Chemical
uptake,3189,O
correlates,3189,O
negatively,3189,O
with,3189,O
an,3189,O
increase,3189,O
in,3189,O
the,3189,O
incidence,3189,O
of,3189,O
orofacial,3189,B-Disease
diskinesia,3189,I-Disease
.,3189,O
These,3190,O
results,3190,O
indicate,3190,O
that,3190,O
early,3190,O
changes,3190,O
in,3190,O
glutamate,3190,B-Chemical
transport,3190,O
may,3190,O
be,3190,O
related,3190,O
to,3190,O
the,3190,O
development,3190,O
of,3190,O
vacuous,3190,O
chewing,3190,O
movements,3190,O
in,3190,O
rats,3190,O
.,3190,O
Ceftriaxone-associated,3191,B-Chemical
biliary,3191,B-Disease
pseudolithiasis,3191,I-Disease
in,3191,O
paediatric,3191,O
surgical,3191,O
patients,3191,O
.,3191,O
It,3192,O
is,3192,O
well,3192,O
known,3192,O
that,3192,O
ceftriaxone,3192,B-Chemical
leads,3192,O
to,3192,O
pseudolithiasis,3192,B-Disease
in,3192,O
some,3192,O
patients,3192,O
.,3192,O
Clinical,3193,O
and,3193,O
experimental,3193,O
studies,3193,O
also,3193,O
suggest,3193,O
that,3193,O
situations,3193,O
causing,3193,O
gallbladder,3193,B-Disease
dysfunction,3193,I-Disease
",",3193,O
such,3193,O
as,3193,O
fasting,3193,O
",",3193,O
may,3193,O
have,3193,O
a,3193,O
role,3193,O
for,3193,O
the,3193,O
development,3193,O
of,3193,O
pseudolithiasis,3193,B-Disease
.,3193,O
In,3194,O
this,3194,O
study,3194,O
",",3194,O
we,3194,O
prospectively,3194,O
evaluated,3194,O
the,3194,O
incidence,3194,O
and,3194,O
clinical,3194,O
importance,3194,O
of,3194,O
pseudolithiasis,3194,B-Disease
in,3194,O
paediatric,3194,O
surgical,3194,O
patients,3194,O
receiving,3194,O
ceftriaxone,3194,B-Chemical
treatment,3194,O
",",3194,O
who,3194,O
often,3194,O
had,3194,O
to,3194,O
fast,3194,O
in,3194,O
the,3194,O
post-operative,3194,O
period,3194,O
.,3194,O
Fifty,3195,O
children,3195,O
who,3195,O
were,3195,O
given,3195,O
ceftriaxone,3195,B-Chemical
were,3195,O
evaluated,3195,O
by,3195,O
serial,3195,O
abdominal,3195,O
sonograms,3195,O
.,3195,O
Of,3196,O
those,3196,O
",",3196,O
13,3196,O
(,3196,O
26,3196,O
%,3196,O
),3196,O
developed,3196,O
biliary,3196,O
pathology,3196,O
.,3196,O
Comparison,3197,O
of,3197,O
the,3197,O
patients,3197,O
with,3197,O
or,3197,O
without,3197,O
pseudolithiasis,3197,B-Disease
revealed,3197,O
no,3197,O
significant,3197,O
difference,3197,O
with,3197,O
respect,3197,O
to,3197,O
age,3197,O
",",3197,O
sex,3197,O
",",3197,O
duration,3197,O
of,3197,O
the,3197,O
treatment,3197,O
and,3197,O
starvation,3197,O
variables,3197,O
.,3197,O
After,3198,O
cessation,3198,O
of,3198,O
the,3198,O
treatment,3198,O
",",3198,O
pseudolithiasis,3198,B-Disease
resolved,3198,O
spontaneously,3198,O
within,3198,O
a,3198,O
short,3198,O
period,3198,O
.,3198,O
The,3199,O
incidence,3199,O
of,3199,O
pseudolithiasis,3199,B-Disease
is,3199,O
not,3199,O
affected,3199,O
by,3199,O
fasting,3199,O
.,3199,O
Coronary,3200,B-Disease
aneurysm,3200,I-Disease
after,3200,O
implantation,3200,O
of,3200,O
a,3200,O
paclitaxel-eluting,3200,B-Chemical
stent,3200,O
.,3200,O
Formation,3201,O
of,3201,O
coronary,3201,B-Disease
aneurysm,3201,I-Disease
is,3201,O
a,3201,O
rare,3201,O
complication,3201,O
of,3201,O
stenting,3201,O
with,3201,O
bare,3201,O
metal,3201,O
stents,3201,O
",",3201,O
but,3201,O
based,3201,O
on,3201,O
experimental,3201,O
studies,3201,O
drug-eluting,3201,O
stents,3201,O
may,3201,O
induce,3201,O
toxic,3201,O
effects,3201,O
on,3201,O
the,3201,O
vessel,3201,O
wall,3201,O
with,3201,O
incomplete,3201,O
stent,3201,O
apposition,3201,O
",",3201,O
aneurysm,3201,B-Disease
formation,3201,O
and,3201,O
with,3201,O
the,3201,O
potential,3201,O
of,3201,O
stent,3201,O
thrombosis,3201,B-Disease
or,3201,O
vessel,3201,B-Disease
rupture,3201,I-Disease
.,3201,O
We,3202,O
present,3202,O
a,3202,O
43-year-old,3202,O
man,3202,O
who,3202,O
developed,3202,O
a,3202,O
coronary,3202,B-Disease
aneurysm,3202,I-Disease
in,3202,O
the,3202,O
right,3202,O
coronary,3202,O
artery,3202,O
6,3202,O
months,3202,O
after,3202,O
receiving,3202,O
a,3202,O
paclitaxel-eluting,3202,B-Chemical
stent,3202,O
.,3202,O
The,3203,O
patient,3203,O
was,3203,O
asymptomatic,3203,O
and,3203,O
the,3203,O
aneurysm,3203,B-Disease
was,3203,O
detected,3203,O
in,3203,O
a,3203,O
routine,3203,O
control,3203,O
.,3203,O
Angiography,3204,O
and,3204,O
intracoronary,3204,O
ultrasound,3204,O
demonstrated,3204,O
lack,3204,O
of,3204,O
contact,3204,O
between,3204,O
stent,3204,O
and,3204,O
vessel,3204,O
wall,3204,O
in,3204,O
a,3204,O
15-mm,3204,O
long,3204,O
segment,3204,O
with,3204,O
maximal,3204,O
aneurysm,3204,B-Disease
diameter,3204,O
of,3204,O
6.0,3204,O
mm,3204,O
.,3204,O
The,3205,O
patient,3205,O
was,3205,O
successfully,3205,O
treated,3205,O
with,3205,O
a,3205,O
graft,3205,O
stent,3205,O
.,3205,O
Causes,3206,O
of,3206,O
acute,3206,O
thrombotic,3206,B-Disease
microangiopathy,3206,I-Disease
in,3206,O
patients,3206,O
receiving,3206,O
kidney,3206,O
transplantation,3206,O
.,3206,O
OBJECTIVES,3207,O
:,3207,O
Thrombotic,3207,B-Disease
microangiopathy,3207,I-Disease
is,3207,O
a,3207,O
well-known,3207,O
problem,3207,O
in,3207,O
patients,3207,O
following,3207,O
renal,3207,O
transplantation,3207,O
.,3207,O
In,3208,O
postrenal,3208,O
transplantation,3208,O
",",3208,O
thrombotic,3208,B-Disease
microangiopathy,3208,I-Disease
is,3208,O
often,3208,O
a,3208,O
reflection,3208,O
of,3208,O
hemolytic,3208,B-Disease
uremic,3208,I-Disease
syndrome,3208,I-Disease
.,3208,O
We,3209,O
aimed,3209,O
to,3209,O
determine,3209,O
the,3209,O
causes,3209,O
of,3209,O
thrombotic,3209,B-Disease
microangiopathy,3209,I-Disease
in,3209,O
a,3209,O
population,3209,O
of,3209,O
renal,3209,O
transplantation,3209,O
recipients,3209,O
and,3209,O
discuss,3209,O
the,3209,O
literature,3209,O
.,3209,O
MATERIALS,3210,O
AND,3210,O
METHODS,3210,O
:,3210,O
We,3210,O
investigated,3210,O
the,3210,O
causes,3210,O
of,3210,O
thrombotic,3210,B-Disease
microangiopathy,3210,I-Disease
during,3210,O
a,3210,O
1-year,3210,O
period,3210,O
",",3210,O
from,3210,O
June,3210,O
2003,3210,O
to,3210,O
June,3210,O
2004,3210,O
",",3210,O
at,3210,O
the,3210,O
King,3210,O
Fahad,3210,O
National,3210,O
Guard,3210,O
Hospital,3210,O
in,3210,O
Riyadh,3210,O
",",3210,O
Saudi,3210,O
Arabia,3210,O
",",3210,O
by,3210,O
reviewing,3210,O
the,3210,O
slides,3210,O
of,3210,O
all,3210,O
transplant,3210,O
biopsies,3210,O
(,3210,O
n=25,3210,O
),3210,O
performed,3210,O
during,3210,O
this,3210,O
interval,3210,O
.,3210,O
Pre-,3211,O
and,3211,O
posttransplant,3211,O
crossmatching,3211,O
was,3211,O
done,3211,O
when,3211,O
possible,3211,O
.,3211,O
RESULTS,3212,O
:,3212,O
Five,3212,O
cases,3212,O
of,3212,O
thrombotic,3212,B-Disease
microangiopathy,3212,I-Disease
were,3212,O
found,3212,O
.,3212,O
Three,3213,O
of,3213,O
these,3213,O
cases,3213,O
were,3213,O
from,3213,O
the,3213,O
25,3213,O
transplantations,3213,O
performed,3213,O
at,3213,O
King,3213,O
Fahad,3213,O
National,3213,O
Guard,3213,O
Hospital,3213,O
",",3213,O
while,3213,O
the,3213,O
other,3213,O
2,3213,O
transplantations,3213,O
had,3213,O
been,3213,O
performed,3213,O
abroad,3213,O
and,3213,O
were,3213,O
referred,3213,O
to,3213,O
us,3213,O
for,3213,O
follow-up,3213,O
.,3213,O
Three,3214,O
cases,3214,O
were,3214,O
related,3214,O
to,3214,O
cyclosporine,3214,B-Chemical
",",3214,O
and,3214,O
1,3214,O
case,3214,O
was,3214,O
secondary,3214,O
to,3214,O
both,3214,O
cyclosporine,3214,B-Chemical
and,3214,O
tacrolimus,3214,B-Chemical
.,3214,O
The,3215,O
fifth,3215,O
case,3215,O
had,3215,O
features,3215,O
of,3215,O
thrombotic,3215,B-Disease
microangiopathy,3215,I-Disease
related,3215,O
to,3215,O
an,3215,O
antiphospholipid,3215,B-Disease
syndrome,3215,I-Disease
in,3215,O
a,3215,O
patient,3215,O
with,3215,O
systemic,3215,B-Disease
lupus,3215,I-Disease
erythematosus,3215,I-Disease
.,3215,O
CONCLUSIONS,3216,O
:,3216,O
In,3216,O
the,3216,O
literature,3216,O
",",3216,O
the,3216,O
most-frequent,3216,O
cause,3216,O
of,3216,O
hemolytic,3216,B-Disease
uremic,3216,I-Disease
syndrome,3216,I-Disease
in,3216,O
patients,3216,O
following,3216,O
renal,3216,O
transplantation,3216,O
is,3216,O
recurrence,3216,O
of,3216,O
the,3216,O
hemolytic,3216,B-Disease
uremic,3216,I-Disease
syndrome,3216,I-Disease
.,3216,O
Other,3217,O
causes,3217,O
include,3217,O
drug-related,3217,O
(,3217,O
cyclosporine,3217,B-Chemical
",",3217,O
tacrolimus,3217,B-Chemical
),3217,O
toxicity,3217,B-Disease
",",3217,O
procoagulant,3217,O
status,3217,O
",",3217,O
and,3217,O
antibody-mediated,3217,O
rejection,3217,O
.,3217,O
We,3218,O
found,3218,O
that,3218,O
the,3218,O
most-frequent,3218,O
cause,3218,O
of,3218,O
thrombotic,3218,B-Disease
microangiopathy,3218,I-Disease
was,3218,O
drug,3218,O
related,3218,O
",",3218,O
secondary,3218,O
mainly,3218,O
to,3218,O
cyclosporine,3218,B-Chemical
.,3218,O
In,3219,O
the,3219,O
current,3219,O
study,3219,O
",",3219,O
the,3219,O
frequency,3219,O
of,3219,O
thrombotic,3219,B-Disease
microangiopathy,3219,I-Disease
was,3219,O
similar,3219,O
to,3219,O
the,3219,O
percentage,3219,O
reported,3219,O
in,3219,O
the,3219,O
literature,3219,O
(,3219,O
20,3219,O
%,3219,O
),3219,O
.,3219,O
Comparison,3220,O
of,3220,O
developmental,3220,O
toxicity,3220,B-Disease
of,3220,O
selective,3220,O
and,3220,O
non-selective,3220,O
cyclooxygenase-2,3220,O
inhibitors,3220,O
in,3220,O
CRL,3220,O
:,3220,O
(,3220,O
WI,3220,O
),3220,O
WUBR,3220,O
Wistar,3220,O
rats,3220,O
--,3220,O
DFU,3220,B-Chemical
and,3220,O
piroxicam,3220,B-Chemical
study,3220,O
.,3220,O
BACKGROUND,3221,O
:,3221,O
Cyclooxygenase,3221,O
(,3221,O
COX,3221,O
),3221,O
inhibitors,3221,O
are,3221,O
one,3221,O
of,3221,O
the,3221,O
most,3221,O
often,3221,O
ingested,3221,O
drugs,3221,O
during,3221,O
pregnancy,3221,O
.,3221,O
Unlike,3222,O
general,3222,O
toxicity,3222,B-Disease
data,3222,O
",",3222,O
their,3222,O
prenatal,3222,O
toxic,3222,O
effects,3222,O
were,3222,O
not,3222,O
extensively,3222,O
studied,3222,O
before,3222,O
.,3222,O
The,3223,O
aim,3223,O
of,3223,O
the,3223,O
experiment,3223,O
was,3223,O
to,3223,O
evaluate,3223,O
the,3223,O
developmental,3223,O
toxicity,3223,B-Disease
of,3223,O
the,3223,O
non-selective,3223,O
(,3223,O
piroxicam,3223,B-Chemical
),3223,O
and,3223,O
selective,3223,O
(,3223,O
DFU,3223,B-Chemical
;,3223,O
"5,5-dimethyl-3-",3223,B-Chemical
(,3223,I-Chemical
3-fluorophenyl,3223,I-Chemical
),3223,I-Chemical
-4-,3223,I-Chemical
(,3223,I-Chemical
4-methylsulphonyl,3223,I-Chemical
),3223,I-Chemical
phenyl-2,3223,I-Chemical
(,3223,I-Chemical
5H,3223,I-Chemical
),3223,I-Chemical
-furanon,3223,I-Chemical
),3223,O
COX-2,3223,O
inhibitors,3223,O
.,3223,O
METHODS,3224,O
:,3224,O
Drugs,3224,O
were,3224,O
separately,3224,O
",",3224,O
orally,3224,O
once,3224,O
daily,3224,O
dosed,3224,O
to,3224,O
pregnant,3224,O
rats,3224,O
from,3224,O
day,3224,O
8,3224,O
to,3224,O
21,3224,O
(,3224,O
GD1=plug,3224,O
day,3224,O
),3224,O
.,3224,O
Doses,3225,O
were,3225,O
set,3225,O
at,3225,O
0.3,3225,O
",",3225,O
3.0,3225,O
and,3225,O
30.0mg/kg,3225,O
for,3225,O
piroxicam,3225,B-Chemical
and,3225,O
0.2,3225,O
",",3225,O
2.0,3225,O
and,3225,O
20.0mg/kg,3225,O
for,3225,O
DFU,3225,B-Chemical
.,3225,O
Fetuses,3226,O
were,3226,O
delivered,3226,O
on,3226,O
GD,3226,O
21,3226,O
and,3226,O
routinely,3226,O
examined,3226,O
.,3226,O
Comprehensive,3227,O
clinical,3227,O
and,3227,O
developmental,3227,O
measurements,3227,O
were,3227,O
done,3227,O
.,3227,O
The,3228,O
pooled,3228,O
statistical,3228,O
analysis,3228,O
for,3228,O
ventricular,3228,O
septal,3228,O
(,3228,O
VSD,3228,O
),3228,O
and,3228,O
midline,3228,O
(,3228,O
MD,3228,O
),3228,O
defects,3228,O
was,3228,O
performed,3228,O
for,3228,O
rat,3228,O
fetuses,3228,O
exposed,3228,O
to,3228,O
piroxicam,3228,B-Chemical
",",3228,O
selective,3228,O
and,3228,O
non-selective,3228,O
COX-2,3228,O
inhibitor,3228,O
based,3228,O
on,3228,O
present,3228,O
and,3228,O
historic,3228,O
data,3228,O
.,3228,O
RESULTS,3229,O
:,3229,O
Maternal,3229,O
toxicity,3229,B-Disease
",",3229,O
intrauterine,3229,B-Disease
growth,3229,I-Disease
retardation,3229,I-Disease
",",3229,O
and,3229,O
increase,3229,B-Disease
of,3229,I-Disease
external,3229,I-Disease
and,3229,I-Disease
skeletal,3229,I-Disease
variations,3229,I-Disease
were,3229,O
found,3229,O
in,3229,O
rats,3229,O
treated,3229,O
with,3229,O
the,3229,O
highest,3229,O
dose,3229,O
of,3229,O
piroxicam,3229,B-Chemical
.,3229,O
Decrease,3230,O
of,3230,O
fetal,3230,O
length,3230,O
was,3230,O
the,3230,O
only,3230,O
signs,3230,O
of,3230,O
the,3230,O
DFU,3230,B-Chemical
developmental,3230,O
toxicity,3230,B-Disease
observed,3230,O
in,3230,O
pups,3230,O
exposed,3230,O
to,3230,O
the,3230,O
highest,3230,O
compound,3230,O
dose,3230,O
.,3230,O
Lack,3231,O
of,3231,O
teratogenicity,3231,O
was,3231,O
found,3231,O
in,3231,O
piroxicam,3231,B-Chemical
and,3231,O
DFU-exposed,3231,B-Chemical
groups,3231,O
.,3231,O
Prenatal,3232,O
exposure,3232,O
to,3232,O
non-selective,3232,O
COX,3232,O
inhibitors,3232,O
increases,3232,O
the,3232,O
risk,3232,O
of,3232,O
VSD,3232,O
and,3232,O
MD,3232,O
when,3232,O
compared,3232,O
to,3232,O
historic,3232,O
control,3232,O
but,3232,O
not,3232,O
with,3232,O
selective,3232,O
COX-2,3232,O
inhibitors,3232,O
.,3232,O
CONCLUSION,3233,O
:,3233,O
Both,3233,O
selective,3233,O
and,3233,O
non-selective,3233,O
COX-2,3233,O
inhibitors,3233,O
were,3233,O
toxic,3233,O
for,3233,O
rats,3233,O
fetuses,3233,O
when,3233,O
administered,3233,O
in,3233,O
the,3233,O
highest,3233,O
dose,3233,O
.,3233,O
Unlike,3234,O
DFU,3234,B-Chemical
",",3234,O
piroxicam,3234,B-Chemical
was,3234,O
also,3234,O
highly,3234,O
toxic,3234,O
to,3234,O
the,3234,O
dams,3234,O
.,3234,O
Prenatal,3235,O
exposure,3235,O
to,3235,O
selective,3235,O
COX-2,3235,O
inhibitors,3235,O
does,3235,O
not,3235,O
increase,3235,O
the,3235,O
risk,3235,O
of,3235,O
ventricular,3235,O
septal,3235,O
and,3235,O
midline,3235,O
defects,3235,O
in,3235,O
rat,3235,O
when,3235,O
compared,3235,O
to,3235,O
non-selective,3235,O
drugs,3235,O
and,3235,O
historic,3235,O
control,3235,O
.,3235,O
Lone,3236,O
atrial,3236,B-Disease
fibrillation,3236,I-Disease
associated,3236,O
with,3236,O
creatine,3236,B-Chemical
monohydrate,3236,O
supplementation,3236,O
.,3236,O
Atrial,3237,B-Disease
fibrillation,3237,I-Disease
in,3237,O
young,3237,O
patients,3237,O
without,3237,O
structural,3237,O
heart,3237,B-Disease
disease,3237,I-Disease
is,3237,O
rare,3237,O
.,3237,O
Therefore,3238,O
",",3238,O
when,3238,O
the,3238,O
arrhythmia,3238,B-Disease
is,3238,O
present,3238,O
in,3238,O
this,3238,O
population,3238,O
",",3238,O
reversible,3238,O
causes,3238,O
must,3238,O
be,3238,O
identified,3238,O
and,3238,O
resolved,3238,O
.,3238,O
Thyroid,3239,B-Disease
disorders,3239,I-Disease
",",3239,O
illicit,3239,O
drug,3239,O
or,3239,O
stimulant,3239,O
use,3239,O
",",3239,O
and,3239,O
acute,3239,B-Disease
alcohol,3239,I-Disease
intoxication,3239,I-Disease
are,3239,O
among,3239,O
these,3239,O
causes,3239,O
.,3239,O
We,3240,O
report,3240,O
the,3240,O
case,3240,O
of,3240,O
a,3240,O
30-year-old,3240,O
Caucasian,3240,O
man,3240,O
who,3240,O
came,3240,O
to,3240,O
the,3240,O
emergency,3240,O
department,3240,O
in,3240,O
atrial,3240,B-Disease
fibrillation,3240,I-Disease
with,3240,O
rapid,3240,O
ventricular,3240,O
response,3240,O
.,3240,O
His,3241,O
medical,3241,O
history,3241,O
was,3241,O
unremarkable,3241,O
",",3241,O
except,3241,O
for,3241,O
minor,3241,O
fractures,3241,B-Disease
of,3241,O
the,3241,O
fingers,3241,O
and,3241,O
foot,3241,O
.,3241,O
Thyroid-stimulating,3242,O
hormone,3242,O
",",3242,O
magnesium,3242,B-Chemical
",",3242,O
and,3242,O
potassium,3242,B-Chemical
levels,3242,O
were,3242,O
within,3242,O
normal,3242,O
limits,3242,O
",",3242,O
urine,3242,O
drug,3242,O
screen,3242,O
was,3242,O
negative,3242,O
",",3242,O
and,3242,O
alcohol,3242,B-Chemical
use,3242,O
was,3242,O
denied,3242,O
.,3242,O
However,3243,O
",",3243,O
when,3243,O
the,3243,O
patient,3243,O
was,3243,O
questioned,3243,O
about,3243,O
use,3243,O
of,3243,O
herbal,3243,O
products,3243,O
and,3243,O
supplements,3243,O
",",3243,O
the,3243,O
use,3243,O
of,3243,O
creatine,3243,B-Chemical
monohydrate,3243,O
was,3243,O
revealed,3243,O
.,3243,O
The,3244,O
patient,3244,O
was,3244,O
admitted,3244,O
to,3244,O
the,3244,O
hospital,3244,O
",",3244,O
anticoagulated,3244,O
with,3244,O
unfractionated,3244,O
heparin,3244,B-Chemical
",",3244,O
and,3244,O
given,3244,O
intravenous,3244,O
diltiazem,3244,B-Chemical
for,3244,O
rate,3244,O
control,3244,O
and,3244,O
intravenous,3244,O
amiodarone,3244,B-Chemical
for,3244,O
rate,3244,O
and,3244,O
rhythm,3244,O
control,3244,O
.,3244,O
When,3245,O
discharged,3245,O
less,3245,O
than,3245,O
24,3245,O
hours,3245,O
later,3245,O
",",3245,O
he,3245,O
was,3245,O
receiving,3245,O
metoprolol,3245,B-Chemical
and,3245,O
aspirin,3245,B-Chemical
",",3245,O
with,3245,O
follow-up,3245,O
plans,3245,O
for,3245,O
echocardiography,3245,O
and,3245,O
nuclear,3245,O
imaging,3245,O
to,3245,O
assess,3245,O
perfusion,3245,O
.,3245,O
Exogenous,3246,O
creatine,3246,B-Chemical
is,3246,O
used,3246,O
by,3246,O
athletes,3246,O
to,3246,O
theoretically,3246,O
improve,3246,O
exercise,3246,O
performance,3246,O
.,3246,O
Vegetarians,3247,O
may,3247,O
also,3247,O
take,3247,O
creatine,3247,B-Chemical
to,3247,O
replace,3247,O
what,3247,O
they,3247,O
are,3247,O
not,3247,O
consuming,3247,O
from,3247,O
meat,3247,O
",",3247,O
fish,3247,O
",",3247,O
and,3247,O
other,3247,O
animal,3247,O
products,3247,O
.,3247,O
Previous,3248,O
anecdotal,3248,O
reports,3248,O
have,3248,O
linked,3248,O
creatine,3248,B-Chemical
to,3248,O
the,3248,O
development,3248,O
of,3248,O
arrhythmia,3248,B-Disease
.,3248,O
Clinicians,3249,O
must,3249,O
be,3249,O
diligent,3249,O
when,3249,O
interviewing,3249,O
patients,3249,O
about,3249,O
their,3249,O
drug,3249,O
therapy,3249,O
histories,3249,O
and,3249,O
include,3249,O
questions,3249,O
about,3249,O
their,3249,O
use,3249,O
of,3249,O
herbal,3249,O
products,3249,O
and,3249,O
dietary,3249,O
supplements,3249,O
.,3249,O
In,3250,O
addition,3250,O
",",3250,O
it,3250,O
is,3250,O
important,3250,O
to,3250,O
report,3250,O
adverse,3250,O
effects,3250,O
associated,3250,O
with,3250,O
frequently,3250,O
consumed,3250,O
supplements,3250,O
and,3250,O
herbal,3250,O
products,3250,O
to,3250,O
the,3250,O
Food,3250,O
and,3250,O
Drug,3250,O
Administration,3250,O
and,3250,O
in,3250,O
the,3250,O
literature,3250,O
.,3250,O
The,3251,O
selective,3251,O
5-HT6,3251,O
receptor,3251,O
antagonist,3251,O
Ro4368554,3251,B-Chemical
restores,3251,O
memory,3251,O
performance,3251,O
in,3251,O
cholinergic,3251,O
and,3251,O
serotonergic,3251,O
models,3251,O
of,3251,O
memory,3251,B-Disease
deficiency,3251,I-Disease
in,3251,O
the,3251,O
rat,3251,O
.,3251,O
Antagonists,3252,O
at,3252,O
serotonin,3252,B-Chemical
type,3252,O
6,3252,O
(,3252,O
5-HT,3252,B-Chemical
(,3252,O
6,3252,O
),3252,O
),3252,O
receptors,3252,O
show,3252,O
activity,3252,O
in,3252,O
models,3252,O
of,3252,O
learning,3252,O
and,3252,O
memory,3252,O
.,3252,O
Although,3253,O
the,3253,O
underlying,3253,O
mechanism,3253,O
(,3253,O
s,3253,O
),3253,O
are,3253,O
not,3253,O
well,3253,O
understood,3253,O
",",3253,O
these,3253,O
effects,3253,O
may,3253,O
involve,3253,O
an,3253,O
increase,3253,O
in,3253,O
acetylcholine,3253,B-Chemical
(,3253,O
ACh,3253,B-Chemical
),3253,O
levels,3253,O
.,3253,O
The,3254,O
present,3254,O
study,3254,O
sought,3254,O
to,3254,O
characterize,3254,O
the,3254,O
cognitive-enhancing,3254,O
effects,3254,O
of,3254,O
the,3254,O
5-HT,3254,B-Chemical
(,3254,O
6,3254,O
),3254,O
antagonist,3254,O
Ro4368554,3254,B-Chemical
(,3254,O
3-benzenesulfonyl-7-,3254,B-Chemical
(,3254,I-Chemical
4-methyl-piperazin-1-yl,3254,I-Chemical
),3254,I-Chemical
1H-indole,3254,I-Chemical
),3254,O
in,3254,O
a,3254,O
rat,3254,O
object,3254,O
recognition,3254,O
task,3254,O
employing,3254,O
a,3254,O
cholinergic,3254,O
(,3254,O
scopolamine,3254,B-Chemical
pretreatment,3254,O
),3254,O
and,3254,O
a,3254,O
serotonergic-,3254,O
(,3254,O
tryptophan,3254,B-Chemical
(,3254,O
TRP,3254,B-Chemical
),3254,O
depletion,3254,O
),3254,O
deficient,3254,O
model,3254,O
",",3254,O
and,3254,O
compared,3254,O
its,3254,O
pattern,3254,O
of,3254,O
action,3254,O
with,3254,O
that,3254,O
of,3254,O
the,3254,O
acetylcholinesterase,3254,O
inhibitor,3254,O
metrifonate,3254,B-Chemical
.,3254,O
Initial,3255,O
testing,3255,O
in,3255,O
a,3255,O
time-dependent,3255,O
forgetting,3255,O
task,3255,O
employing,3255,O
a,3255,O
24-h,3255,O
delay,3255,O
between,3255,O
training,3255,O
and,3255,O
testing,3255,O
showed,3255,O
that,3255,O
metrifonate,3255,B-Chemical
improved,3255,O
object,3255,O
recognition,3255,O
(,3255,O
at,3255,O
10,3255,O
and,3255,O
30,3255,O
mg/kg,3255,O
",",3255,O
p.o,3255,O
.,3255,O
),3256,O
",",3256,O
whereas,3256,O
Ro4368554,3256,O
was,3256,O
inactive,3256,O
.,3256,O
Both,3257,O
",",3257,O
Ro4368554,3257,O
(,3257,O
3,3257,O
and,3257,O
10,3257,O
mg/kg,3257,O
",",3257,O
intraperitoneally,3257,O
(,3257,O
i.p,3257,O
.,3257,O
),3257,O
),3257,O
and,3258,O
metrifonate,3258,O
(,3258,O
10,3258,O
mg/kg,3258,O
",",3258,O
p.o.,3258,O
",",3258,O
respectively,3258,O
),3258,O
reversed,3258,O
memory,3258,I-Disease
deficits,3258,O
induced,3258,O
by,3258,O
scopolamine,3258,O
and,3258,O
TRP,3258,O
depletion,3258,O
(,3258,O
10,3258,O
mg/kg,3258,O
",",3258,O
i.p.,3258,O
",",3258,O
and,3258,O
3,3258,O
mg/kg,3258,O
",",3258,O
p.o.,3258,O
",",3258,O
respectively,3258,O
),3258,O
.,3258,O
In,3259,O
conclusion,3259,O
",",3259,O
although,3259,O
Ro4368554,3259,O
did,3259,O
not,3259,O
improve,3259,O
a,3259,O
time-related,3259,O
retention,3259,O
deficit,3259,O
",",3259,O
it,3259,O
reversed,3259,O
a,3259,O
cholinergic,3259,O
and,3259,O
a,3259,O
serotonergic,3259,O
memory,3259,I-Disease
deficit,3259,O
",",3259,O
suggesting,3259,O
that,3259,O
both,3259,O
mechanisms,3259,O
may,3259,O
be,3259,O
involved,3259,O
in,3259,O
the,3259,O
facilitation,3259,O
of,3259,O
object,3259,O
memory,3259,O
by,3259,O
Ro4368554,3259,O
and,3259,O
",",3259,O
possibly,3259,O
",",3259,O
other,3259,O
5-HT,3259,O
(,3259,O
6,3259,O
),3259,O
receptor,3259,O
antagonists,3259,O
.,3259,O
Evaluation,3260,O
of,3260,O
the,3260,O
anticocaine,3260,O
monoclonal,3260,O
antibody,3260,O
GNC92H2,3260,B-Chemical
as,3260,O
an,3260,O
immunotherapy,3260,O
for,3260,O
cocaine,3260,B-Disease
overdose,3260,I-Disease
.,3260,O
The,3261,O
illicit,3261,O
use,3261,O
of,3261,O
cocaine,3261,B-Chemical
continues,3261,O
in,3261,O
epidemic,3261,O
proportions,3261,O
and,3261,O
treatment,3261,O
for,3261,O
cocaine,3261,B-Disease
overdose,3261,I-Disease
remains,3261,O
elusive,3261,O
.,3261,O
Current,3262,O
protein-based,3262,O
technology,3262,O
offers,3262,O
a,3262,O
new,3262,O
therapeutic,3262,O
venue,3262,O
by,3262,O
which,3262,O
antibodies,3262,O
bind,3262,O
the,3262,O
drug,3262,O
in,3262,O
the,3262,O
blood,3262,O
stream,3262,O
",",3262,O
inactivating,3262,O
its,3262,O
toxic,3262,O
effects,3262,O
.,3262,O
The,3263,O
therapeutic,3263,O
potential,3263,O
of,3263,O
the,3263,O
anticocaine,3263,O
antibody,3263,O
GNC92H2,3263,B-Chemical
was,3263,O
examined,3263,O
using,3263,O
a,3263,O
model,3263,O
of,3263,O
cocaine,3263,B-Disease
overdose,3263,I-Disease
.,3263,O
Swiss,3264,O
albino,3264,O
mice,3264,O
prepared,3264,O
with,3264,O
intrajugular,3264,O
catheters,3264,O
were,3264,O
tested,3264,O
in,3264,O
photocell,3264,O
cages,3264,O
after,3264,O
administration,3264,O
of,3264,O
93,3264,O
mg/kg,3264,O
(,3264,O
LD50,3264,O
),3264,O
of,3264,O
cocaine,3264,B-Chemical
and,3264,O
GNC92H2,3264,B-Chemical
infusions,3264,O
ranging,3264,O
from,3264,O
30,3264,O
to,3264,O
190,3264,O
mg/kg,3264,O
.,3264,O
GNC92H2,3265,B-Chemical
was,3265,O
delivered,3265,O
30,3265,O
min,3265,O
before,3265,O
",",3265,O
concomitantly,3265,O
or,3265,O
3,3265,O
min,3265,O
after,3265,O
cocaine,3265,B-Chemical
treatment,3265,O
.,3265,O
Significant,3266,O
blockade,3266,O
of,3266,O
cocaine,3266,B-Chemical
toxicity,3266,B-Disease
was,3266,O
observed,3266,O
with,3266,O
the,3266,O
higher,3266,O
dose,3266,O
of,3266,O
GNC92H2,3266,B-Chemical
(,3266,O
190,3266,O
mg/kg,3266,O
),3266,O
",",3266,O
where,3266,O
premorbid,3266,O
behaviors,3266,O
were,3266,O
reduced,3266,O
up,3266,O
to,3266,O
40,3266,O
%,3266,O
",",3266,O
seizures,3266,B-Disease
up,3266,O
to,3266,O
77,3266,O
%,3266,O
and,3266,O
death,3266,B-Disease
by,3266,O
72,3266,O
%,3266,O
.,3266,O
Importantly,3267,O
",",3267,O
GNC92H2,3267,B-Chemical
prevented,3267,O
death,3267,B-Disease
even,3267,O
post-cocaine,3267,O
injection,3267,O
.,3267,O
The,3268,O
results,3268,O
support,3268,O
the,3268,O
important,3268,O
potential,3268,O
of,3268,O
GNC92H2,3268,B-Chemical
as,3268,O
a,3268,O
therapeutic,3268,O
tool,3268,O
against,3268,O
cocaine,3268,B-Disease
overdose,3268,I-Disease
.,3268,O
Behavioral,3269,O
effects,3269,O
of,3269,O
urotensin-II,3269,B-Chemical
centrally,3269,O
administered,3269,O
in,3269,O
mice,3269,O
.,3269,O
Urotensin-II,3270,B-Chemical
(,3270,O
U-II,3270,B-Chemical
),3270,O
receptors,3270,O
are,3270,O
widely,3270,O
distributed,3270,O
in,3270,O
the,3270,O
central,3270,O
nervous,3270,O
system,3270,O
.,3270,O
Intracerebroventricular,3271,O
(,3271,O
i.c.v,3271,O
.,3271,O
),3271,O
injection,3272,O
of,3272,O
U-II,3272,B-Chemical
causes,3272,O
hypertension,3272,B-Disease
and,3272,O
bradycardia,3272,B-Disease
and,3272,O
stimulates,3272,O
prolactin,3272,O
and,3272,O
thyrotropin,3272,O
secretion,3272,O
.,3272,O
However,3273,O
",",3273,O
the,3273,O
behavioral,3273,O
effects,3273,O
of,3273,O
centrally,3273,O
administered,3273,O
U-II,3273,B-Chemical
have,3273,O
received,3273,O
little,3273,O
attention,3273,O
.,3273,O
In,3274,O
the,3274,O
present,3274,O
study,3274,O
",",3274,O
we,3274,O
tested,3274,O
the,3274,O
effects,3274,O
of,3274,O
i.c.v,3274,O
.,3274,O
injections,3275,O
of,3275,O
U-II,3275,B-Chemical
on,3275,O
behavioral,3275,O
",",3275,O
metabolic,3275,O
",",3275,O
and,3275,O
endocrine,3275,O
responses,3275,O
in,3275,O
mice,3275,O
.,3275,O
Administration,3276,O
of,3276,O
graded,3276,O
doses,3276,O
of,3276,O
U-II,3276,B-Chemical
(,3276,O
"1-10,000",3276,O
ng/mouse,3276,O
),3276,O
provoked,3276,O
:,3276,O
(,3276,O
1,3276,O
),3276,O
a,3276,O
dose-dependent,3276,O
reduction,3276,O
in,3276,O
the,3276,O
number,3276,O
of,3276,O
head,3276,O
dips,3276,O
in,3276,O
the,3276,O
hole-board,3276,O
test,3276,O
;,3276,O
(,3276,O
2,3276,O
),3276,O
a,3276,O
dose-dependent,3276,O
reduction,3276,O
in,3276,O
the,3276,O
number,3276,O
of,3276,O
entries,3276,O
in,3276,O
the,3276,O
white,3276,O
chamber,3276,O
in,3276,O
the,3276,O
black-and-white,3276,O
compartment,3276,O
test,3276,O
",",3276,O
and,3276,O
in,3276,O
the,3276,O
number,3276,O
of,3276,O
entries,3276,O
in,3276,O
the,3276,O
central,3276,O
platform,3276,O
and,3276,O
open,3276,O
arms,3276,O
in,3276,O
the,3276,O
plus-maze,3276,O
test,3276,O
;,3276,O
and,3276,O
(,3276,O
3,3276,O
),3276,O
a,3276,O
dose-dependent,3276,O
increase,3276,O
in,3276,O
the,3276,O
duration,3276,O
of,3276,O
immobility,3276,O
in,3276,O
the,3276,O
forced-swimming,3276,O
test,3276,O
and,3276,O
tail,3276,O
suspension,3276,O
test,3276,O
.,3276,O
Intracerebroventricular,3277,O
injection,3277,O
of,3277,O
U-II,3277,B-Chemical
also,3277,O
caused,3277,O
an,3277,O
increase,3277,O
in,3277,O
:,3277,O
food,3277,O
intake,3277,O
at,3277,O
doses,3277,O
of,3277,O
100,3277,O
and,3277,O
"1,000",3277,O
ng/mouse,3277,O
",",3277,O
water,3277,O
intake,3277,O
at,3277,O
doses,3277,O
of,3277,O
"100-10,000",3277,O
ng/mouse,3277,O
",",3277,O
and,3277,O
horizontal,3277,O
locomotion,3277,O
activity,3277,O
at,3277,O
a,3277,O
dose,3277,O
of,3277,O
"10,000",3277,O
ng/mouse,3277,O
.,3277,O
Whatever,3278,O
was,3278,O
the,3278,O
dose,3278,O
",",3278,O
the,3278,O
central,3278,O
administration,3278,O
of,3278,O
U-II,3278,B-Chemical
had,3278,O
no,3278,O
effect,3278,O
on,3278,O
body,3278,O
temperature,3278,O
",",3278,O
nociception,3278,O
",",3278,O
apomorphine-induced,3278,B-Chemical
penile,3278,B-Disease
erection,3278,I-Disease
and,3278,O
climbing,3278,O
behavior,3278,O
",",3278,O
and,3278,O
stress-induced,3278,O
plasma,3278,O
corticosterone,3278,B-Chemical
level,3278,O
.,3278,O
Taken,3279,O
together,3279,O
",",3279,O
the,3279,O
present,3279,O
study,3279,O
demonstrates,3279,O
that,3279,O
the,3279,O
central,3279,O
injection,3279,O
of,3279,O
U-II,3279,B-Chemical
at,3279,O
doses,3279,O
of,3279,O
"1-10,000",3279,O
ng/mouse,3279,O
induces,3279,O
anxiogenic-,3279,O
and,3279,O
depressant-like,3279,O
effects,3279,O
in,3279,O
mouse,3279,O
.,3279,O
These,3280,O
data,3280,O
suggest,3280,O
that,3280,O
U-II,3280,B-Chemical
may,3280,O
be,3280,O
involved,3280,O
in,3280,O
some,3280,O
aspects,3280,O
of,3280,O
psychiatric,3280,B-Disease
disorders,3280,I-Disease
.,3280,O
The,3281,O
effects,3281,O
of,3281,O
short-term,3281,O
raloxifene,3281,B-Chemical
therapy,3281,O
on,3281,O
fibrinolysis,3281,O
markers,3281,O
:,3281,O
TAFI,3281,O
",",3281,O
tPA,3281,O
",",3281,O
and,3281,O
PAI-1,3281,O
.,3281,O
BACKGROUND,3282,O
:,3282,O
Markers,3282,O
of,3282,O
fibrinolysis,3282,O
",",3282,O
thrombin-activatable,3282,O
fibrinolysis,3282,O
inhibitor,3282,O
(,3282,O
TAFI,3282,O
),3282,O
",",3282,O
tissue-type,3282,O
plasminogen,3282,O
activator,3282,O
(,3282,O
tPA,3282,O
),3282,O
",",3282,O
and,3282,O
plasminogen,3282,O
activator,3282,O
inhibitor-1,3282,O
(,3282,O
PAI-1,3282,O
),3282,O
levels,3282,O
were,3282,O
studied,3282,O
for,3282,O
the,3282,O
evaluation,3282,O
of,3282,O
short-term,3282,O
effects,3282,O
of,3282,O
raloxifene,3282,B-Chemical
administration,3282,O
in,3282,O
postmenopausal,3282,O
women,3282,O
.,3282,O
METHODS,3283,O
:,3283,O
Thirty-nine,3283,O
postmenopausal,3283,O
women,3283,O
with,3283,O
osteopenia,3283,B-Disease
or,3283,O
osteoporosis,3283,B-Disease
were,3283,O
included,3283,O
in,3283,O
this,3283,O
prospective,3283,O
",",3283,O
controlled,3283,O
clinical,3283,O
study,3283,O
.,3283,O
Twenty-five,3284,O
women,3284,O
were,3284,O
given,3284,O
raloxifene,3284,B-Chemical
hydrochloride,3284,I-Chemical
(,3284,O
60,3284,O
mg/day,3284,O
),3284,O
plus,3284,O
calcium,3284,B-Chemical
(,3284,O
500,3284,O
mg/day,3284,O
),3284,O
.,3284,O
Age-matched,3285,O
controls,3285,O
(,3285,O
n,3285,O
=,3285,O
14,3285,O
),3285,O
were,3285,O
given,3285,O
only,3285,O
calcium,3285,B-Chemical
.,3285,O
Plasma,3286,O
TAFI,3286,O
",",3286,O
tPA,3286,O
",",3286,O
and,3286,O
PAI-1,3286,O
antigen,3286,O
levels,3286,O
were,3286,O
measured,3286,O
at,3286,O
baseline,3286,O
and,3286,O
after,3286,O
3,3286,O
months,3286,O
of,3286,O
treatment,3286,O
by,3286,O
commercially,3286,O
available,3286,O
ELISA,3286,O
kits,3286,O
.,3286,O
Variations,3287,O
of,3287,O
individuals,3287,O
were,3287,O
assessed,3287,O
by,3287,O
Wilcoxon,3287,O
's,3287,O
test,3287,O
.,3287,O
Relationship,3288,O
between,3288,O
those,3288,O
markers,3288,O
and,3288,O
demographic,3288,O
characteristics,3288,O
were,3288,O
investigated,3288,O
.,3288,O
RESULTS,3289,O
:,3289,O
Three,3289,O
months,3289,O
of,3289,O
raloxifene,3289,B-Chemical
treatment,3289,O
was,3289,O
associated,3289,O
with,3289,O
a,3289,O
significant,3289,O
decrease,3289,O
in,3289,O
the,3289,O
plasma,3289,O
TAFI,3289,O
antigen,3289,O
concentrations,3289,O
(,3289,O
16,3289,O
%,3289,O
change,3289,O
",",3289,O
P,3289,O
<,3289,O
0.01,3289,O
),3289,O
",",3289,O
and,3289,O
a,3289,O
significant,3289,O
increase,3289,O
in,3289,O
tPA,3289,O
antigen,3289,O
concentrations,3289,O
(,3289,O
25,3289,O
%,3289,O
change,3289,O
",",3289,O
P,3289,O
<,3289,O
0.05,3289,O
),3289,O
.,3289,O
A,3290,O
significant,3290,O
correlation,3290,O
was,3290,O
found,3290,O
between,3290,O
baseline,3290,O
TAFI,3290,O
antigen,3290,O
concentrations,3290,O
and,3290,O
the,3290,O
duration,3290,O
of,3290,O
amenorrhea,3290,B-Disease
(,3290,O
P,3290,O
<,3290,O
0.05,3290,O
;,3290,O
r,3290,O
=,3290,O
0.33,3290,O
),3290,O
.,3290,O
CONCLUSION,3291,O
:,3291,O
We,3291,O
suggest,3291,O
that,3291,O
the,3291,O
increased,3291,O
risk,3291,O
of,3291,O
venous,3291,B-Disease
thromboembolism,3291,I-Disease
due,3291,O
to,3291,O
raloxifene,3291,B-Chemical
treatment,3291,O
may,3291,O
be,3291,O
related,3291,O
to,3291,O
increased,3291,O
tPA,3291,O
levels,3291,O
",",3291,O
but,3291,O
not,3291,O
TAFI,3291,O
levels,3291,O
.,3291,O
Valproate-induced,3292,B-Chemical
encephalopathy,3292,B-Disease
.,3292,O
Valproate-induced,3293,B-Chemical
encephalopathy,3293,B-Disease
is,3293,O
a,3293,O
rare,3293,O
syndrome,3293,O
that,3293,O
may,3293,O
manifest,3293,O
in,3293,O
otherwise,3293,O
normal,3293,O
epileptic,3293,B-Disease
individuals,3293,O
.,3293,O
It,3294,O
may,3294,O
even,3294,O
present,3294,O
in,3294,O
patients,3294,O
who,3294,O
have,3294,O
tolerated,3294,O
this,3294,O
medicine,3294,O
well,3294,O
in,3294,O
the,3294,O
past,3294,O
.,3294,O
It,3295,O
is,3295,O
usually,3295,O
but,3295,O
not,3295,O
necessarily,3295,O
associated,3295,O
with,3295,O
hyperammonemia,3295,B-Disease
.,3295,O
The,3296,O
EEG,3296,O
shows,3296,O
characteristic,3296,O
triphasic,3296,O
waves,3296,O
in,3296,O
most,3296,O
patients,3296,O
with,3296,O
this,3296,O
complication,3296,O
.,3296,O
A,3297,O
case,3297,O
of,3297,O
valproate-induced,3297,B-Chemical
encephalopathy,3297,B-Disease
is,3297,O
presented,3297,O
.,3297,O
The,3298,O
problems,3298,O
in,3298,O
diagnosing,3298,O
this,3298,O
condition,3298,O
are,3298,O
subsequently,3298,O
discussed,3298,O
.,3298,O
Recurrent,3299,O
dysphonia,3299,B-Disease
and,3299,O
acitretin,3299,B-Chemical
.,3299,O
We,3300,O
report,3300,O
the,3300,O
case,3300,O
of,3300,O
a,3300,O
woman,3300,O
complaining,3300,O
of,3300,O
dysphonia,3300,B-Disease
while,3300,O
she,3300,O
was,3300,O
treated,3300,O
by,3300,O
acitretin,3300,B-Chemical
.,3300,O
Her,3301,O
symptoms,3301,O
totally,3301,O
regressed,3301,O
after,3301,O
drug,3301,O
withdrawal,3301,O
and,3301,O
reappeared,3301,O
when,3301,O
acitretin,3301,B-Chemical
was,3301,O
reintroduced,3301,O
.,3301,O
To,3302,O
our,3302,O
knowledge,3302,O
",",3302,O
this,3302,O
is,3302,O
the,3302,O
first,3302,O
case,3302,O
of,3302,O
acitretin-induced,3302,B-Chemical
dysphonia,3302,B-Disease
.,3302,O
This,3303,O
effect,3303,O
may,3303,O
be,3303,O
related,3303,O
to,3303,O
the,3303,O
pharmacological,3303,O
effect,3303,O
of,3303,O
this,3303,O
drug,3303,O
on,3303,O
mucous,3303,O
membranes,3303,O
.,3303,O
Nitro-L-arginine,3304,B-Chemical
methyl,3304,I-Chemical
ester,3304,I-Chemical
:,3304,O
a,3304,O
potential,3304,O
protector,3304,O
against,3304,O
gentamicin,3304,B-Chemical
ototoxicity,3304,B-Disease
.,3304,O
The,3305,O
nitric,3305,B-Chemical
oxide,3305,I-Chemical
(,3305,O
NO,3305,B-Chemical
),3305,O
inhibitor,3305,O
nitro-L-arginine,3305,B-Chemical
methyl,3305,I-Chemical
ester,3305,I-Chemical
(,3305,O
L-NAME,3305,B-Chemical
),3305,O
may,3305,O
act,3305,O
as,3305,O
an,3305,O
otoprotectant,3305,O
against,3305,O
high-frequency,3305,B-Disease
hearing,3305,I-Disease
loss,3305,I-Disease
caused,3305,O
by,3305,O
gentamicin,3305,B-Chemical
",",3305,O
but,3305,O
further,3305,O
studies,3305,O
are,3305,O
needed,3305,O
to,3305,O
confirm,3305,O
this.Aminoglycoside,3305,O
antibiotics,3305,O
are,3305,O
still,3305,O
widely,3305,O
used,3305,O
by,3305,O
virtue,3305,O
of,3305,O
their,3305,O
efficacy,3305,O
and,3305,O
low,3305,O
cost,3305,O
.,3305,O
Their,3306,O
ototoxicity,3306,B-Disease
is,3306,O
a,3306,O
serious,3306,O
health,3306,O
problem,3306,O
and,3306,O
",",3306,O
as,3306,O
their,3306,O
ototoxic,3306,B-Disease
mechanism,3306,O
involves,3306,O
the,3306,O
production,3306,O
of,3306,O
NO,3306,B-Chemical
",",3306,O
we,3306,O
need,3306,O
to,3306,O
assess,3306,O
the,3306,O
use,3306,O
of,3306,O
NO,3306,B-Chemical
inhibitors,3306,O
for,3306,O
the,3306,O
prevention,3306,O
of,3306,O
aminoglycoside-induced,3306,B-Chemical
sensorineural,3306,B-Disease
hearing,3306,I-Disease
loss,3306,I-Disease
.,3306,O
In,3307,O
this,3307,O
experimental,3307,O
study,3307,O
we,3307,O
used,3307,O
30,3307,O
Sprague-Dawley,3307,O
rats,3307,O
",",3307,O
27,3307,O
of,3307,O
which,3307,O
had,3307,O
gentamicin,3307,B-Chemical
instilled,3307,O
into,3307,O
the,3307,O
middle,3307,O
ear,3307,O
.,3307,O
The,3308,O
otoprotectant,3308,O
L-NAME,3308,B-Chemical
was,3308,O
administered,3308,O
topically,3308,O
to,3308,O
12/27,3308,O
animals,3308,O
.,3308,O
Its,3309,O
effect,3309,O
was,3309,O
determined,3309,O
in,3309,O
terms,3309,O
of,3309,O
attenuation,3309,O
of,3309,O
hearing,3309,B-Disease
loss,3309,I-Disease
",",3309,O
measured,3309,O
by,3309,O
shifts,3309,O
in,3309,O
the,3309,O
auditory,3309,O
brainstem,3309,O
response,3309,O
threshold,3309,O
.,3309,O
L-NAME,3310,B-Chemical
reduced,3310,O
gentamicin-induced,3310,B-Chemical
hearing,3310,B-Disease
loss,3310,I-Disease
in,3310,O
the,3310,O
high-frequency,3310,O
range,3310,O
",",3310,O
but,3310,O
gave,3310,O
no,3310,O
protection,3310,O
in,3310,O
the,3310,O
middle,3310,O
or,3310,O
low,3310,O
frequencies,3310,O
.,3310,O
Safety,3311,O
profile,3311,O
of,3311,O
a,3311,O
nicotine,3311,B-Chemical
lozenge,3311,O
compared,3311,O
with,3311,O
that,3311,O
of,3311,O
nicotine,3311,B-Chemical
gum,3311,O
in,3311,O
adult,3311,O
smokers,3311,O
with,3311,O
underlying,3311,O
medical,3311,O
conditions,3311,O
:,3311,O
a,3311,O
12-week,3311,O
",",3311,O
randomized,3311,O
",",3311,O
open-label,3311,O
study,3311,O
.,3311,O
BACKGROUND,3312,O
:,3312,O
Nicotine,3312,B-Chemical
polacrilex,3312,O
lozenges,3312,O
deliver,3312,O
25,3312,O
%,3312,O
to,3312,O
27,3312,O
%,3312,O
more,3312,O
nicotine,3312,B-Chemical
compared,3312,O
with,3312,O
equivalent,3312,O
doses,3312,O
of,3312,O
nicotine,3312,B-Chemical
polacrilex,3312,O
gum,3312,O
.,3312,O
The,3313,O
increased,3313,O
nicotine,3313,B-Chemical
exposure,3313,O
from,3313,O
the,3313,O
lozenge,3313,O
has,3313,O
raised,3313,O
questions,3313,O
about,3313,O
the,3313,O
relative,3313,O
safety,3313,O
of,3313,O
the,3313,O
lozenge,3313,O
and,3313,O
gum,3313,O
.,3313,O
OBJECTIVE,3314,O
:,3314,O
The,3314,O
objective,3314,O
of,3314,O
this,3314,O
study,3314,O
was,3314,O
to,3314,O
compare,3314,O
the,3314,O
safety,3314,O
profiles,3314,O
of,3314,O
the,3314,O
4-mg,3314,O
nicotine,3314,B-Chemical
lozenge,3314,O
and,3314,O
4-mg,3314,O
nicotine,3314,B-Chemical
gum,3314,O
in,3314,O
smokers,3314,O
with,3314,O
selected,3314,O
label-restricted,3314,O
diseases,3314,O
.,3314,O
METHODS,3315,O
:,3315,O
This,3315,O
was,3315,O
a,3315,O
multicenter,3315,O
",",3315,O
randomized,3315,O
",",3315,O
open-label,3315,O
study,3315,O
in,3315,O
adult,3315,O
smokers,3315,O
with,3315,O
heart,3315,B-Disease
disease,3315,I-Disease
",",3315,O
hypertension,3315,B-Disease
not,3315,O
controlled,3315,O
by,3315,O
medication,3315,O
",",3315,O
and/or,3315,O
diabetes,3315,B-Disease
mellitus,3315,I-Disease
.,3315,O
Patients,3316,O
were,3316,O
randomized,3316,O
in,3316,O
a,3316,O
1:1,3316,O
ratio,3316,O
to,3316,O
receive,3316,O
the,3316,O
4-mg,3316,O
nicotine,3316,B-Chemical
lozenge,3316,O
or,3316,O
4-mg,3316,O
nicotine,3316,B-Chemical
gum,3316,O
.,3316,O
Safety,3317,O
assessments,3317,O
were,3317,O
made,3317,O
at,3317,O
baseline,3317,O
and,3317,O
at,3317,O
2,3317,O
",",3317,O
4,3317,O
",",3317,O
6,3317,O
",",3317,O
and,3317,O
12,3317,O
weeks,3317,O
after,3317,O
the,3317,O
start,3317,O
of,3317,O
product,3317,O
use,3317,O
.,3317,O
RESULTS,3318,O
:,3318,O
Nine,3318,O
hundred,3318,O
one,3318,O
patients,3318,O
were,3318,O
randomized,3318,O
to,3318,O
treatment,3318,O
",",3318,O
447,3318,O
who,3318,O
received,3318,O
the,3318,O
lozenge,3318,O
and,3318,O
454,3318,O
who,3318,O
received,3318,O
the,3318,O
gum,3318,O
(,3318,O
safety,3318,O
population,3318,O
),3318,O
.,3318,O
The,3319,O
majority,3319,O
were,3319,O
women,3319,O
(,3319,O
52.7,3319,O
%,3319,O
),3319,O
.,3319,O
Patients,3320,O
',3320,O
mean,3320,O
age,3320,O
was,3320,O
53.9,3320,O
years,3320,O
",",3320,O
their,3320,O
mean,3320,O
weight,3320,O
was,3320,O
193.9,3320,O
pounds,3320,O
",",3320,O
and,3320,O
they,3320,O
smoked,3320,O
a,3320,O
mean,3320,O
of,3320,O
25.2,3320,O
cigarettes,3320,O
per,3320,O
day,3320,O
at,3320,O
baseline,3320,O
.,3320,O
Five,3321,O
hundred,3321,O
fifty-three,3321,O
patients,3321,O
",",3321,O
264,3321,O
taking,3321,O
the,3321,O
lozenge,3321,O
and,3321,O
289,3321,O
taking,3321,O
the,3321,O
gum,3321,O
",",3321,O
used,3321,O
the,3321,O
study,3321,O
product,3321,O
for,3321,O
>,3321,O
or,3321,O
=4,3321,O
days,3321,O
per,3321,O
week,3321,O
during,3321,O
the,3321,O
first,3321,O
2,3321,O
weeks,3321,O
(,3321,O
evaluable,3321,O
population,3321,O
),3321,O
.,3321,O
The,3322,O
nicotine,3322,B-Chemical
lozenge,3322,O
and,3322,O
nicotine,3322,B-Chemical
gum,3322,O
were,3322,O
equally,3322,O
well,3322,O
tolerated,3322,O
",",3322,O
despite,3322,O
increased,3322,O
nicotine,3322,B-Chemical
exposure,3322,O
from,3322,O
the,3322,O
lozenge,3322,O
.,3322,O
The,3323,O
incidence,3323,O
of,3323,O
adverse,3323,O
events,3323,O
in,3323,O
the,3323,O
2,3323,O
groups,3323,O
was,3323,O
similar,3323,O
during,3323,O
the,3323,O
first,3323,O
2,3323,O
weeks,3323,O
of,3323,O
product,3323,O
use,3323,O
(,3323,O
evaluation,3323,O
population,3323,O
:,3323,O
55.3,3323,O
%,3323,O
lozenge,3323,O
",",3323,O
54.7,3323,O
%,3323,O
gum,3323,O
),3323,O
",",3323,O
as,3323,O
well,3323,O
as,3323,O
during,3323,O
the,3323,O
entire,3323,O
study,3323,O
(,3323,O
safety,3323,O
population,3323,O
:,3323,O
63.8,3323,O
%,3323,O
and,3323,O
58.6,3323,O
%,3323,O
",",3323,O
respectively,3323,O
),3323,O
.,3323,O
Stratification,3324,O
of,3324,O
patients,3324,O
by,3324,O
sex,3324,O
",",3324,O
age,3324,O
",",3324,O
extent,3324,O
of,3324,O
concurrent,3324,O
smoking,3324,O
",",3324,O
extent,3324,O
of,3324,O
product,3324,O
use,3324,O
",",3324,O
and,3324,O
severity,3324,O
of,3324,O
adverse,3324,O
events,3324,O
revealed,3324,O
no,3324,O
clinically,3324,O
significant,3324,O
differences,3324,O
between,3324,O
the,3324,O
lozenge,3324,O
and,3324,O
gum,3324,O
.,3324,O
The,3325,O
most,3325,O
common,3325,O
adverse,3325,O
events,3325,O
were,3325,O
nausea,3325,B-Disease
(,3325,O
17.2,3325,O
%,3325,O
and,3325,O
16.1,3325,O
%,3325,O
;,3325,O
95,3325,O
%,3325,O
CI,3325,O
",",3325,O
-3.7,3325,O
to,3325,O
6.0,3325,O
),3325,O
",",3325,O
hiccups,3325,B-Disease
(,3325,O
10.7,3325,O
%,3325,O
and,3325,O
6.6,3325,O
%,3325,O
;,3325,O
95,3325,O
%,3325,O
CI,3325,O
",",3325,O
0.5,3325,O
to,3325,O
7.8,3325,O
),3325,O
",",3325,O
and,3325,O
headache,3325,B-Disease
(,3325,O
8.7,3325,O
%,3325,O
and,3325,O
9.9,3325,O
%,3325,O
;,3325,O
95,3325,O
%,3325,O
Cl,3325,O
",",3325,O
-5.0,3325,O
to,3325,O
2.6,3325,O
),3325,O
.,3325,O
Serious,3326,O
adverse,3326,O
events,3326,O
were,3326,O
reported,3326,O
in,3326,O
11,3326,O
and,3326,O
13,3326,O
patients,3326,O
in,3326,O
the,3326,O
respective,3326,O
groups,3326,O
.,3326,O
Fewer,3327,O
than,3327,O
6,3327,O
%,3327,O
of,3327,O
patients,3327,O
in,3327,O
either,3327,O
group,3327,O
were,3327,O
considered,3327,O
by,3327,O
the,3327,O
investigator,3327,O
to,3327,O
have,3327,O
a,3327,O
worsening,3327,O
of,3327,O
their,3327,O
overall,3327,O
disease,3327,O
condition,3327,O
during,3327,O
the,3327,O
study,3327,O
.,3327,O
The,3328,O
majority,3328,O
of,3328,O
patients,3328,O
(,3328,O
>,3328,O
60,3328,O
%,3328,O
),3328,O
experienced,3328,O
no,3328,O
change,3328,O
in,3328,O
their,3328,O
disease,3328,O
status,3328,O
from,3328,O
baseline,3328,O
.,3328,O
CONCLUSION,3329,O
:,3329,O
The,3329,O
4-mg,3329,O
nicotine,3329,B-Chemical
lozenge,3329,O
and,3329,O
4-mg,3329,O
nicotine,3329,B-Chemical
gum,3329,O
had,3329,O
comparable,3329,O
safety,3329,O
profiles,3329,O
in,3329,O
these,3329,O
patients,3329,O
with,3329,O
label-restricted,3329,O
medical,3329,O
conditions,3329,O
.,3329,O
Pharmacological,3330,O
modulation,3330,O
of,3330,O
pain-related,3330,B-Disease
brain,3330,O
activity,3330,O
during,3330,O
normal,3330,O
and,3330,O
central,3330,O
sensitization,3330,O
states,3330,O
in,3330,O
humans,3330,O
.,3330,O
Abnormal,3331,O
processing,3331,O
of,3331,O
somatosensory,3331,O
inputs,3331,O
in,3331,O
the,3331,O
central,3331,O
nervous,3331,O
system,3331,O
(,3331,O
central,3331,O
sensitization,3331,O
),3331,O
is,3331,O
the,3331,O
mechanism,3331,O
accounting,3331,O
for,3331,O
the,3331,O
enhanced,3331,O
pain,3331,B-Disease
sensitivity,3331,O
in,3331,O
the,3331,O
skin,3331,O
surrounding,3331,O
tissue,3331,B-Disease
injury,3331,I-Disease
(,3331,O
secondary,3331,B-Disease
hyperalgesia,3331,I-Disease
),3331,O
.,3331,O
Secondary,3332,B-Disease
hyperalgesia,3332,I-Disease
shares,3332,O
clinical,3332,O
characteristics,3332,O
with,3332,O
neurogenic,3332,B-Disease
hyperalgesia,3332,I-Disease
in,3332,O
patients,3332,O
with,3332,O
neuropathic,3332,B-Disease
pain,3332,I-Disease
.,3332,O
Abnormal,3333,O
brain,3333,O
responses,3333,O
to,3333,O
somatosensory,3333,O
stimuli,3333,O
have,3333,O
been,3333,O
found,3333,O
in,3333,O
patients,3333,O
with,3333,O
hyperalgesia,3333,B-Disease
as,3333,O
well,3333,O
as,3333,O
in,3333,O
normal,3333,O
subjects,3333,O
during,3333,O
experimental,3333,O
central,3333,O
sensitization,3333,O
.,3333,O
The,3334,O
aim,3334,O
of,3334,O
this,3334,O
study,3334,O
was,3334,O
to,3334,O
assess,3334,O
the,3334,O
effects,3334,O
of,3334,O
gabapentin,3334,B-Chemical
",",3334,O
a,3334,O
drug,3334,O
effective,3334,O
in,3334,O
neuropathic,3334,B-Disease
pain,3334,I-Disease
patients,3334,O
",",3334,O
on,3334,O
brain,3334,O
processing,3334,O
of,3334,O
nociceptive,3334,O
information,3334,O
in,3334,O
normal,3334,O
and,3334,O
central,3334,O
sensitization,3334,O
states,3334,O
.,3334,O
Using,3335,O
functional,3335,O
magnetic,3335,O
resonance,3335,O
imaging,3335,O
(,3335,O
fMRI,3335,O
),3335,O
in,3335,O
normal,3335,O
volunteers,3335,O
",",3335,O
we,3335,O
studied,3335,O
the,3335,O
gabapentin-induced,3335,B-Chemical
modulation,3335,O
of,3335,O
brain,3335,O
activity,3335,O
in,3335,O
response,3335,O
to,3335,O
nociceptive,3335,O
mechanical,3335,O
stimulation,3335,O
of,3335,O
normal,3335,O
skin,3335,O
and,3335,O
capsaicin-induced,3335,B-Chemical
secondary,3335,B-Disease
hyperalgesia,3335,I-Disease
.,3335,O
The,3336,O
dose,3336,O
of,3336,O
gabapentin,3336,B-Chemical
was,3336,O
"1,800",3336,O
mg,3336,O
per,3336,O
os,3336,O
",",3336,O
in,3336,O
a,3336,O
single,3336,O
administration,3336,O
.,3336,O
We,3337,O
found,3337,O
that,3337,O
(,3337,O
i,3337,O
),3337,O
gabapentin,3337,B-Chemical
reduced,3337,O
the,3337,O
activations,3337,O
in,3337,O
the,3337,O
bilateral,3337,O
operculoinsular,3337,O
cortex,3337,O
",",3337,O
independently,3337,O
of,3337,O
the,3337,O
presence,3337,O
of,3337,O
central,3337,O
sensitization,3337,O
;,3337,O
(,3337,O
ii,3337,O
),3337,O
gabapentin,3337,B-Chemical
reduced,3337,O
the,3337,O
activation,3337,O
in,3337,O
the,3337,O
brainstem,3337,O
",",3337,O
only,3337,O
during,3337,O
central,3337,O
sensitization,3337,O
;,3337,O
(,3337,O
iii,3337,O
),3337,O
gabapentin,3337,B-Chemical
suppressed,3337,O
stimulus-induced,3337,O
deactivations,3337,O
",",3337,O
only,3337,O
during,3337,O
central,3337,O
sensitization,3337,O
;,3337,O
this,3337,O
effect,3337,O
was,3337,O
more,3337,O
robust,3337,O
than,3337,O
the,3337,O
effect,3337,O
on,3337,O
brain,3337,O
activation,3337,O
.,3337,O
The,3338,O
observed,3338,O
drug-induced,3338,O
effects,3338,O
were,3338,O
not,3338,O
due,3338,O
to,3338,O
changes,3338,O
in,3338,O
the,3338,O
baseline,3338,O
fMRI,3338,O
signal,3338,O
.,3338,O
These,3339,O
findings,3339,O
indicate,3339,O
that,3339,O
gabapentin,3339,B-Chemical
has,3339,O
a,3339,O
measurable,3339,O
antinociceptive,3339,O
effect,3339,O
and,3339,O
a,3339,O
stronger,3339,O
antihyperalgesic,3339,O
effect,3339,O
most,3339,O
evident,3339,O
in,3339,O
the,3339,O
brain,3339,O
areas,3339,O
undergoing,3339,O
deactivation,3339,O
",",3339,O
thus,3339,O
supporting,3339,O
the,3339,O
concept,3339,O
that,3339,O
gabapentin,3339,B-Chemical
is,3339,O
more,3339,O
effective,3339,O
in,3339,O
modulating,3339,O
nociceptive,3339,O
transmission,3339,O
when,3339,O
central,3339,O
sensitization,3339,O
is,3339,O
present,3339,O
.,3339,O
Investigation,3340,O
of,3340,O
mitochondrial,3340,O
involvement,3340,O
in,3340,O
the,3340,O
experimental,3340,O
model,3340,O
of,3340,O
epilepsy,3340,B-Disease
induced,3340,O
by,3340,O
pilocarpine,3340,B-Chemical
.,3340,O
Mitochondrial,3341,B-Disease
abnormalities,3341,I-Disease
have,3341,O
been,3341,O
associated,3341,O
with,3341,O
several,3341,O
aspects,3341,O
of,3341,O
epileptogenesis,3341,O
",",3341,O
such,3341,O
as,3341,O
energy,3341,O
generation,3341,O
",",3341,O
control,3341,O
of,3341,O
cell,3341,O
death,3341,B-Disease
",",3341,O
neurotransmitter,3341,O
synthesis,3341,O
",",3341,O
and,3341,O
free,3341,O
radical,3341,O
(,3341,O
FR,3341,O
),3341,O
production,3341,O
.,3341,O
Increased,3342,O
production,3342,O
of,3342,O
FRs,3342,O
may,3342,O
cause,3342,O
mtDNA,3342,O
damage,3342,O
leading,3342,O
to,3342,O
decreased,3342,O
activities,3342,O
of,3342,O
oxidative,3342,O
phosphorylation,3342,O
complexes,3342,O
containing,3342,O
mtDNA-encoded,3342,O
subunits,3342,O
.,3342,O
In,3343,O
this,3343,O
study,3343,O
",",3343,O
we,3343,O
investigated,3343,O
whether,3343,O
increased,3343,O
generation,3343,O
of,3343,O
FR,3343,O
during,3343,O
status,3343,B-Disease
epilepticus,3343,I-Disease
would,3343,O
be,3343,O
sufficient,3343,O
to,3343,O
provoke,3343,O
abnormalities,3343,O
in,3343,O
mtDNA,3343,O
and,3343,O
in,3343,O
the,3343,O
expression,3343,O
and,3343,O
activity,3343,O
of,3343,O
cytochrome,3343,O
c,3343,O
oxidase,3343,O
(,3343,O
CCO,3343,O
),3343,O
",",3343,O
complex,3343,O
IV,3343,O
of,3343,O
the,3343,O
respiratory,3343,O
chain,3343,O
",",3343,O
in,3343,O
the,3343,O
chronic,3343,O
phase,3343,O
of,3343,O
the,3343,O
pilocarpine,3343,B-Chemical
model,3343,O
of,3343,O
temporal,3343,B-Disease
lobe,3343,I-Disease
epilepsy,3343,I-Disease
.,3343,O
DNA,3344,O
analysis,3344,O
revealed,3344,O
low,3344,O
amounts,3344,O
of,3344,O
a,3344,O
4.8,3344,O
kb,3344,O
mtDNA,3344,O
deletion,3344,O
but,3344,O
with,3344,O
no,3344,O
differences,3344,O
in,3344,O
frequency,3344,O
or,3344,O
quantity,3344,O
in,3344,O
the,3344,O
control,3344,O
and,3344,O
experimental,3344,O
groups,3344,O
.,3344,O
We,3345,O
did,3345,O
not,3345,O
find,3345,O
abnormalities,3345,O
in,3345,O
the,3345,O
expression,3345,O
and,3345,O
distribution,3345,O
of,3345,O
an,3345,O
mtDNA-encoded,3345,O
subunit,3345,O
of,3345,O
CCO,3345,O
(,3345,O
CCO-I,3345,O
),3345,O
or,3345,O
a,3345,O
relative,3345,O
decrease,3345,O
in,3345,O
CCO-I,3345,O
when,3345,O
compared,3345,O
with,3345,O
nuclear-encoded,3345,O
subunits,3345,O
(,3345,O
CCO-IV,3345,O
and,3345,O
SDH-fp,3345,O
),3345,O
.,3345,O
No,3346,O
abnormality,3346,O
in,3346,O
CCO,3346,O
activity,3346,O
was,3346,O
observed,3346,O
through,3346,O
histochemistry,3346,O
.,3346,O
Although,3347,O
evidences,3347,O
of,3347,O
mitochondrial,3347,B-Disease
abnormalities,3347,I-Disease
were,3347,O
found,3347,O
in,3347,O
previously,3347,O
published,3347,O
studies,3347,O
",",3347,O
our,3347,O
results,3347,O
do,3347,O
not,3347,O
suggest,3347,O
that,3347,O
the,3347,O
FRs,3347,O
",",3347,O
generated,3347,O
during,3347,O
the,3347,O
acute,3347,O
phase,3347,O
",",3347,O
determined,3347,O
important,3347,O
abnormalities,3347,O
in,3347,O
mtDNA,3347,O
",",3347,O
in,3347,O
expression,3347,O
of,3347,O
CCO-I,3347,O
",",3347,O
and,3347,O
in,3347,O
CCO,3347,O
activity,3347,O
.,3347,O
Ketoconazole,3348,B-Chemical
induced,3348,O
torsades,3348,B-Disease
de,3348,I-Disease
pointes,3348,I-Disease
without,3348,O
concomitant,3348,O
use,3348,O
of,3348,O
QT,3348,O
interval-prolonging,3348,O
drug,3348,O
.,3348,O
Ketoconazole,3349,B-Chemical
is,3349,O
not,3349,O
known,3349,O
to,3349,O
be,3349,O
proarrhythmic,3349,O
without,3349,O
concomitant,3349,O
use,3349,O
of,3349,O
QT,3349,O
interval-prolonging,3349,O
drugs,3349,O
.,3349,O
We,3350,O
report,3350,O
a,3350,O
woman,3350,O
with,3350,O
coronary,3350,B-Disease
artery,3350,I-Disease
disease,3350,I-Disease
who,3350,O
developed,3350,O
a,3350,O
markedly,3350,O
prolonged,3350,B-Disease
QT,3350,I-Disease
interval,3350,I-Disease
and,3350,O
torsades,3350,B-Disease
de,3350,I-Disease
pointes,3350,I-Disease
(,3350,O
TdP,3350,B-Disease
),3350,O
after,3350,O
taking,3350,O
ketoconazole,3350,B-Chemical
for,3350,O
treatment,3350,O
of,3350,O
fungal,3350,B-Disease
infection,3350,I-Disease
.,3350,O
Her,3351,O
QT,3351,O
interval,3351,O
returned,3351,O
to,3351,O
normal,3351,O
upon,3351,O
withdrawal,3351,O
of,3351,O
ketoconazole,3351,B-Chemical
.,3351,O
Genetic,3352,O
study,3352,O
did,3352,O
not,3352,O
find,3352,O
any,3352,O
mutation,3352,O
in,3352,O
her,3352,O
genes,3352,O
that,3352,O
encode,3352,O
cardiac,3352,O
IKr,3352,O
channel,3352,O
proteins,3352,O
.,3352,O
We,3353,O
postulate,3353,O
that,3353,O
by,3353,O
virtue,3353,O
of,3353,O
its,3353,O
direct,3353,O
blocking,3353,O
action,3353,O
on,3353,O
IKr,3353,O
",",3353,O
ketoconazole,3353,B-Chemical
alone,3353,O
may,3353,O
prolong,3353,O
QT,3353,O
interval,3353,O
and,3353,O
induce,3353,O
TdP,3353,B-Disease
.,3353,O
This,3354,O
calls,3354,O
for,3354,O
attention,3354,O
when,3354,O
ketoconazole,3354,B-Chemical
is,3354,O
administered,3354,O
to,3354,O
patients,3354,O
with,3354,O
risk,3354,O
factors,3354,O
for,3354,O
acquired,3354,O
long,3354,B-Disease
QT,3354,I-Disease
syndrome,3354,I-Disease
.,3354,O
Cerebral,3355,B-Disease
vasculitis,3355,I-Disease
following,3355,O
oral,3355,O
methylphenidate,3355,B-Chemical
intake,3355,O
in,3355,O
an,3355,O
adult,3355,O
:,3355,O
a,3355,O
case,3355,O
report,3355,O
.,3355,O
Methylphenidate,3356,B-Chemical
is,3356,O
structurally,3356,O
and,3356,O
functionally,3356,O
similar,3356,O
to,3356,O
amphetamine,3356,B-Chemical
.,3356,O
Cerebral,3357,B-Disease
vasculitis,3357,I-Disease
associated,3357,O
with,3357,O
amphetamine,3357,B-Disease
abuse,3357,I-Disease
is,3357,O
well,3357,O
documented,3357,O
",",3357,O
and,3357,O
in,3357,O
rare,3357,O
cases,3357,O
ischaemic,3357,B-Disease
stroke,3357,I-Disease
has,3357,O
been,3357,O
reported,3357,O
after,3357,O
methylphenidate,3357,B-Chemical
intake,3357,O
in,3357,O
children,3357,O
.,3357,O
We,3358,O
report,3358,O
the,3358,O
case,3358,O
of,3358,O
a,3358,O
63-year-old,3358,O
female,3358,O
who,3358,O
was,3358,O
treated,3358,O
with,3358,O
methylphenidate,3358,B-Chemical
due,3358,O
to,3358,O
hyperactivity,3358,B-Disease
and,3358,O
suffered,3358,O
from,3358,O
multiple,3358,O
ischaemic,3358,B-Disease
strokes,3358,I-Disease
.,3358,O
We,3359,O
consider,3359,O
drug-induced,3359,O
cerebral,3359,B-Disease
vasculitis,3359,I-Disease
as,3359,O
the,3359,O
most,3359,O
likely,3359,O
cause,3359,O
of,3359,O
recurrent,3359,O
ischaemic,3359,B-Disease
strokes,3359,I-Disease
in,3359,O
the,3359,O
absence,3359,O
of,3359,O
any,3359,O
pathological,3359,O
findings,3359,O
during,3359,O
the,3359,O
diagnostic,3359,O
work-up,3359,O
.,3359,O
We,3360,O
conclude,3360,O
that,3360,O
methylphenidate,3360,B-Chemical
mediated,3360,O
vasculitis,3360,B-Disease
should,3360,O
be,3360,O
considered,3360,O
in,3360,O
patients,3360,O
with,3360,O
neurological,3360,O
symptoms,3360,O
and,3360,O
a,3360,O
history,3360,O
of,3360,O
methylphenidate,3360,B-Chemical
therapy,3360,O
.,3360,O
This,3361,O
potential,3361,O
side-effect,3361,O
",",3361,O
though,3361,O
very,3361,O
rare,3361,O
",",3361,O
represents,3361,O
one,3361,O
more,3361,O
reason,3361,O
to,3361,O
be,3361,O
very,3361,O
restrictive,3361,O
in,3361,O
the,3361,O
use,3361,O
of,3361,O
methylphenidate,3361,B-Chemical
.,3361,O
MDMA,3362,B-Chemical
polydrug,3362,O
users,3362,O
show,3362,O
process-specific,3362,O
central,3362,O
executive,3362,O
impairments,3362,O
coupled,3362,O
with,3362,O
impaired,3362,B-Disease
social,3362,I-Disease
and,3362,I-Disease
emotional,3362,I-Disease
judgement,3362,I-Disease
processes,3362,I-Disease
.,3362,O
In,3363,O
recent,3363,O
years,3363,O
working,3363,O
memory,3363,B-Disease
deficits,3363,I-Disease
have,3363,O
been,3363,O
reported,3363,O
in,3363,O
users,3363,O
of,3363,O
MDMA,3363,B-Chemical
(,3363,O
"3,4-methylenedioxymethamphetamine",3363,B-Chemical
",",3363,O
ecstasy,3363,B-Chemical
),3363,O
.,3363,O
The,3364,O
current,3364,O
study,3364,O
aimed,3364,O
to,3364,O
assess,3364,O
the,3364,O
impact,3364,O
of,3364,O
MDMA,3364,B-Chemical
use,3364,O
on,3364,O
three,3364,O
separate,3364,O
central,3364,O
executive,3364,O
processes,3364,O
(,3364,O
set,3364,O
shifting,3364,O
",",3364,O
inhibition,3364,O
and,3364,O
memory,3364,O
updating,3364,O
),3364,O
and,3364,O
also,3364,O
on,3364,O
``,3364,O
prefrontal,3364,O
'',3364,O
mediated,3364,O
social,3364,O
and,3364,O
emotional,3364,O
judgement,3364,O
processes,3364,O
.,3364,O
Fifteen,3365,O
polydrug,3365,O
ecstasy,3365,B-Chemical
users,3365,O
and,3365,O
15,3365,O
polydrug,3365,O
non-ecstasy,3365,O
user,3365,O
controls,3365,O
completed,3365,O
a,3365,O
general,3365,O
drug,3365,O
use,3365,O
questionnaire,3365,O
",",3365,O
the,3365,O
Brixton,3365,O
Spatial,3365,O
Anticipation,3365,O
task,3365,O
(,3365,O
set,3365,O
shifting,3365,O
),3365,O
",",3365,O
Backward,3365,O
Digit,3365,O
Span,3365,O
procedure,3365,O
(,3365,O
memory,3365,O
updating,3365,O
),3365,O
",",3365,O
Inhibition,3365,O
of,3365,O
Return,3365,O
(,3365,O
inhibition,3365,O
),3365,O
",",3365,O
an,3365,O
emotional,3365,O
intelligence,3365,O
scale,3365,O
",",3365,O
the,3365,O
Tromso,3365,O
Social,3365,O
Intelligence,3365,O
Scale,3365,O
and,3365,O
the,3365,O
Dysexecutive,3365,O
Questionnaire,3365,O
(,3365,O
DEX,3365,O
),3365,O
.,3365,O
Compared,3366,O
with,3366,O
MDMA-free,3366,B-Chemical
polydrug,3366,O
controls,3366,O
",",3366,O
MDMA,3366,B-Chemical
polydrug,3366,O
users,3366,O
showed,3366,O
impairments,3366,O
in,3366,O
set,3366,O
shifting,3366,O
and,3366,O
memory,3366,O
updating,3366,O
",",3366,O
and,3366,O
also,3366,O
in,3366,O
social,3366,O
and,3366,O
emotional,3366,O
judgement,3366,O
processes,3366,O
.,3366,O
The,3367,O
latter,3367,O
two,3367,O
deficits,3367,O
remained,3367,O
significant,3367,O
after,3367,O
controlling,3367,O
for,3367,O
other,3367,O
drug,3367,O
use,3367,O
.,3367,O
These,3368,O
data,3368,O
lend,3368,O
further,3368,O
support,3368,O
to,3368,O
the,3368,O
proposal,3368,O
that,3368,O
cognitive,3368,O
processes,3368,O
mediated,3368,O
by,3368,O
the,3368,O
prefrontal,3368,O
cortex,3368,O
may,3368,O
be,3368,O
impaired,3368,O
by,3368,O
recreational,3368,O
ecstasy,3368,B-Chemical
use,3368,O
.,3368,O
Pharmacokinetics,3369,O
of,3369,O
desipramine,3369,B-Chemical
HCl,3369,I-Chemical
when,3369,O
administered,3369,O
with,3369,O
cinacalcet,3369,B-Chemical
HCl,3369,I-Chemical
.,3369,O
OBJECTIVE,3370,O
:,3370,O
In,3370,O
vitro,3370,O
work,3370,O
has,3370,O
demonstrated,3370,O
that,3370,O
cinacalcet,3370,B-Chemical
is,3370,O
a,3370,O
strong,3370,O
inhibitor,3370,O
of,3370,O
cytochrome,3370,O
P450,3370,O
isoenzyme,3370,O
(,3370,O
CYP,3370,O
),3370,O
2D6,3370,O
.,3370,O
The,3371,O
purpose,3371,O
of,3371,O
this,3371,O
study,3371,O
was,3371,O
to,3371,O
evaluate,3371,O
the,3371,O
effect,3371,O
of,3371,O
cinacalcet,3371,B-Chemical
on,3371,O
CYP2D6,3371,O
activity,3371,O
",",3371,O
using,3371,O
desipramine,3371,B-Chemical
as,3371,O
a,3371,O
probe,3371,O
substrate,3371,O
",",3371,O
in,3371,O
healthy,3371,O
subjects,3371,O
.,3371,O
METHODS,3372,O
:,3372,O
Seventeen,3372,O
subjects,3372,O
who,3372,O
were,3372,O
genotyped,3372,O
as,3372,O
CYP2D6,3372,O
extensive,3372,O
metabolizers,3372,O
were,3372,O
enrolled,3372,O
in,3372,O
this,3372,O
randomized,3372,O
",",3372,O
open-label,3372,O
",",3372,O
crossover,3372,O
study,3372,O
to,3372,O
receive,3372,O
a,3372,O
single,3372,O
oral,3372,O
dose,3372,O
of,3372,O
desipramine,3372,B-Chemical
(,3372,O
50,3372,O
mg,3372,O
),3372,O
on,3372,O
two,3372,O
separate,3372,O
occasions,3372,O
",",3372,O
once,3372,O
alone,3372,O
and,3372,O
once,3372,O
after,3372,O
multiple,3372,O
doses,3372,O
of,3372,O
cinacalcet,3372,B-Chemical
(,3372,O
90,3372,O
mg,3372,O
for,3372,O
7,3372,O
days,3372,O
),3372,O
.,3372,O
Blood,3373,O
samples,3373,O
were,3373,O
obtained,3373,O
predose,3373,O
and,3373,O
up,3373,O
to,3373,O
72,3373,O
h,3373,O
postdose,3373,O
.,3373,O
RESULTS,3374,O
:,3374,O
Fourteen,3374,O
subjects,3374,O
completed,3374,O
both,3374,O
treatment,3374,O
arms,3374,O
.,3374,O
Relative,3375,O
to,3375,O
desipramine,3375,B-Chemical
alone,3375,O
",",3375,O
mean,3375,O
AUC,3375,O
and,3375,O
C,3375,O
(,3375,O
max,3375,O
),3375,O
of,3375,O
desipramine,3375,B-Chemical
increased,3375,O
3.6-,3375,O
and,3375,O
1.8-fold,3375,O
when,3375,O
coadministered,3375,O
with,3375,O
cinacalcet,3375,B-Chemical
.,3375,O
The,3376,O
t,3376,O
(,3376,O
1/2,3376,O
",",3376,O
z,3376,O
),3376,O
of,3376,O
desipramine,3376,B-Chemical
was,3376,O
longer,3376,O
when,3376,O
desipramine,3376,B-Chemical
was,3376,O
coadministered,3376,O
with,3376,O
cinacalcet,3376,B-Chemical
(,3376,O
21.0,3376,O
versus,3376,O
43.3,3376,O
hs,3376,O
),3376,O
.,3376,O
The,3377,O
t,3377,O
(,3377,O
max,3377,O
),3377,O
was,3377,O
similar,3377,O
between,3377,O
the,3377,O
regimens,3377,O
.,3377,O
Fewer,3378,O
subjects,3378,O
reported,3378,O
adverse,3378,O
events,3378,O
following,3378,O
treatment,3378,O
with,3378,O
desipramine,3378,B-Chemical
alone,3378,O
than,3378,O
when,3378,O
receiving,3378,O
desipramine,3378,B-Chemical
with,3378,O
cinacalcet,3378,B-Chemical
(,3378,O
33,3378,O
versus,3378,O
86,3378,O
%,3378,O
),3378,O
",",3378,O
the,3378,O
most,3378,O
frequent,3378,O
of,3378,O
which,3378,O
(,3378,O
nausea,3378,B-Disease
and,3378,O
headache,3378,B-Disease
),3378,O
have,3378,O
been,3378,O
reported,3378,O
for,3378,O
patients,3378,O
treated,3378,O
with,3378,O
either,3378,O
desipramine,3378,B-Chemical
or,3378,O
cinacalcet,3378,B-Chemical
.,3378,O
CONCLUSION,3379,O
:,3379,O
This,3379,O
study,3379,O
demonstrates,3379,O
that,3379,O
cinacalcet,3379,B-Chemical
is,3379,O
a,3379,O
strong,3379,O
inhibitor,3379,O
of,3379,O
CYP2D6,3379,O
.,3379,O
These,3380,O
data,3380,O
suggest,3380,O
that,3380,O
during,3380,O
concomitant,3380,O
treatment,3380,O
with,3380,O
cinacalcet,3380,B-Chemical
",",3380,O
dose,3380,O
adjustment,3380,O
may,3380,O
be,3380,O
necessary,3380,O
for,3380,O
drugs,3380,O
that,3380,O
demonstrate,3380,O
a,3380,O
narrow,3380,O
therapeutic,3380,O
index,3380,O
and,3380,O
are,3380,O
metabolized,3380,O
by,3380,O
CYP2D6,3380,O
.,3380,O
Case,3381,O
report,3381,O
:,3381,O
acute,3381,O
unintentional,3381,O
carbachol,3381,B-Chemical
intoxication,3381,O
.,3381,O
INTRODUCTION,3382,O
:,3382,O
Intoxications,3382,O
with,3382,O
carbachol,3382,B-Chemical
",",3382,O
a,3382,O
muscarinic,3382,O
cholinergic,3382,O
receptor,3382,O
agonist,3382,O
are,3382,O
rare,3382,O
.,3382,O
We,3383,O
report,3383,O
an,3383,O
interesting,3383,O
case,3383,O
investigating,3383,O
a,3383,O
(,3383,O
near,3383,O
),3383,O
fatal,3383,O
poisoning,3383,B-Disease
.,3383,O
METHODS,3384,O
:,3384,O
The,3384,O
son,3384,O
of,3384,O
an,3384,O
84-year-old,3384,O
male,3384,O
discovered,3384,O
a,3384,O
newspaper,3384,O
report,3384,O
stating,3384,O
clinical,3384,O
success,3384,O
with,3384,O
plant,3384,O
extracts,3384,O
in,3384,O
Alzheimer,3384,B-Disease
's,3384,I-Disease
disease,3384,I-Disease
.,3384,O
The,3385,O
mode,3385,O
of,3385,O
action,3385,O
was,3385,O
said,3385,O
to,3385,O
be,3385,O
comparable,3385,O
to,3385,O
that,3385,O
of,3385,O
the,3385,O
synthetic,3385,O
compound,3385,O
'carbamylcholin,3385,O
',3385,O
;,3385,O
that,3385,O
is,3385,O
",",3385,O
carbachol,3385,B-Chemical
.,3385,O
He,3386,O
bought,3386,O
25,3386,O
g,3386,O
of,3386,O
carbachol,3386,B-Chemical
as,3386,O
pure,3386,O
substance,3386,O
in,3386,O
a,3386,O
pharmacy,3386,O
",",3386,O
and,3386,O
the,3386,O
father,3386,O
was,3386,O
administered,3386,O
400,3386,O
to,3386,O
500,3386,O
mg.,3386,O
Carbachol,3386,B-Chemical
concentrations,3386,O
in,3386,O
serum,3386,O
and,3386,O
urine,3386,O
on,3386,O
day,3386,O
1,3386,O
and,3386,O
2,3386,O
of,3386,O
hospital,3386,O
admission,3386,O
were,3386,O
analysed,3386,O
by,3386,O
HPLC-mass,3386,O
spectrometry,3386,O
.,3386,O
RESULTS,3387,O
:,3387,O
Minutes,3387,O
after,3387,O
oral,3387,O
administration,3387,O
",",3387,O
the,3387,O
patient,3387,O
developed,3387,O
nausea,3387,B-Disease
",",3387,O
sweating,3387,O
and,3387,O
hypotension,3387,B-Disease
",",3387,O
and,3387,O
finally,3387,O
collapsed,3387,O
.,3387,O
Bradycardia,3388,B-Disease
",",3388,O
cholinergic,3388,O
symptoms,3388,O
and,3388,O
asystole,3388,B-Disease
occurred,3388,O
.,3388,O
Initial,3389,O
cardiopulmonary,3389,O
resuscitation,3389,O
and,3389,O
immediate,3389,O
treatment,3389,O
with,3389,O
adrenaline,3389,B-Chemical
(,3389,O
epinephrine,3389,B-Chemical
),3389,O
",",3389,O
atropine,3389,B-Chemical
and,3389,O
furosemide,3389,B-Chemical
was,3389,O
successful,3389,O
.,3389,O
On,3390,O
hospital,3390,O
admission,3390,O
",",3390,O
blood,3390,O
pressure,3390,O
of,3390,O
the,3390,O
intubated,3390,O
",",3390,O
bradyarrhythmic,3390,O
patient,3390,O
was,3390,O
100/65,3390,O
mmHg,3390,O
.,3390,O
Further,3391,O
signs,3391,O
were,3391,O
hyperhidrosis,3391,B-Disease
",",3391,O
hypersalivation,3391,B-Disease
",",3391,O
bronchorrhoea,3391,B-Disease
",",3391,O
and,3391,O
severe,3391,O
miosis,3391,B-Disease
;,3391,O
the,3391,O
electrocardiographic,3391,O
finding,3391,O
was,3391,O
atrio-ventricular,3391,B-Disease
dissociation,3391,I-Disease
.,3391,O
High,3392,O
doses,3392,O
of,3392,O
atropine,3392,B-Chemical
(,3392,O
up,3392,O
to,3392,O
50,3392,O
mg,3392,O
per,3392,O
24,3392,O
hours,3392,O
),3392,O
",",3392,O
adrenaline,3392,B-Chemical
and,3392,O
dopamine,3392,B-Chemical
were,3392,O
necessary,3392,O
.,3392,O
The,3393,O
patient,3393,O
was,3393,O
extubated,3393,O
1,3393,O
week,3393,O
later,3393,O
.,3393,O
However,3394,O
",",3394,O
increased,3394,O
dyspnoea,3394,B-Disease
and,3394,O
bronchospasm,3394,B-Disease
necessitated,3394,O
reintubation,3394,O
.,3394,O
Respiratory,3395,B-Disease
insufficiency,3395,I-Disease
was,3395,O
further,3395,O
worsened,3395,O
by,3395,O
Proteus,3395,B-Disease
mirabilis,3395,I-Disease
infection,3395,I-Disease
and,3395,O
severe,3395,O
bronchoconstriction,3395,O
.,3395,O
One,3396,O
week,3396,O
later,3396,O
",",3396,O
the,3396,O
patient,3396,O
was,3396,O
again,3396,O
extubated,3396,O
and,3396,O
3,3396,O
days,3396,O
later,3396,O
was,3396,O
transferred,3396,O
to,3396,O
a,3396,O
peripheral,3396,O
ward,3396,O
.,3396,O
On,3397,O
the,3397,O
next,3397,O
day,3397,O
he,3397,O
died,3397,O
",",3397,O
probably,3397,O
as,3397,O
a,3397,O
result,3397,O
of,3397,O
heart,3397,B-Disease
failure,3397,I-Disease
.,3397,O
Serum,3398,O
samples,3398,O
from,3398,O
the,3398,O
first,3398,O
and,3398,O
second,3398,O
days,3398,O
contained,3398,O
3.6,3398,O
and,3398,O
1.9,3398,O
mg/l,3398,O
carbachol,3398,B-Chemical
",",3398,O
respectively,3398,O
.,3398,O
The,3399,O
corresponding,3399,O
urine,3399,O
concentrations,3399,O
amounted,3399,O
to,3399,O
374,3399,O
and,3399,O
554,3399,O
mg/l,3399,O
.,3399,O
CONCLUSION,3400,O
:,3400,O
This,3400,O
case,3400,O
started,3400,O
with,3400,O
a,3400,O
media,3400,O
report,3400,O
in,3400,O
a,3400,O
popular,3400,O
newspaper,3400,O
",",3400,O
initiated,3400,O
by,3400,O
published,3400,O
",",3400,O
peer-reviewed,3400,O
research,3400,O
on,3400,O
herbals,3400,O
",",3400,O
and,3400,O
involved,3400,O
human,3400,O
failure,3400,O
in,3400,O
a,3400,O
case,3400,O
history,3400,O
",",3400,O
medical,3400,O
examination,3400,O
and,3400,O
clinical,3400,O
treatment,3400,O
.,3400,O
For,3401,O
the,3401,O
first,3401,O
time,3401,O
",",3401,O
an,3401,O
analytical,3401,O
method,3401,O
for,3401,O
the,3401,O
determination,3401,O
of,3401,O
carbachol,3401,B-Chemical
in,3401,O
plasma,3401,O
and,3401,O
urine,3401,O
has,3401,O
been,3401,O
developed,3401,O
.,3401,O
The,3402,O
analysed,3402,O
carbachol,3402,B-Chemical
concentration,3402,O
exceeded,3402,O
the,3402,O
supposed,3402,O
serum,3402,O
level,3402,O
resulting,3402,O
from,3402,O
a,3402,O
therapeutic,3402,O
dose,3402,O
by,3402,O
a,3402,O
factor,3402,O
of,3402,O
130,3402,O
to,3402,O
260,3402,O
.,3402,O
Especially,3403,O
in,3403,O
old,3403,O
patients,3403,O
",",3403,O
intensivists,3403,O
should,3403,O
consider,3403,O
intoxications,3403,O
(,3403,O
with,3403,O
cholinergics,3403,O
),3403,O
as,3403,O
a,3403,O
cause,3403,O
of,3403,O
acute,3403,B-Disease
cardiovascular,3403,I-Disease
failure,3403,I-Disease
.,3403,O
Pharmacological,3404,O
evidence,3404,O
for,3404,O
the,3404,O
potential,3404,O
of,3404,O
Daucus,3404,O
carota,3404,O
in,3404,O
the,3404,O
management,3404,O
of,3404,O
cognitive,3404,B-Disease
dysfunctions,3404,I-Disease
.,3404,O
The,3405,O
present,3405,O
study,3405,O
was,3405,O
aimed,3405,O
at,3405,O
investigating,3405,O
the,3405,O
effects,3405,O
of,3405,O
Daucus,3405,O
carota,3405,O
seeds,3405,O
on,3405,O
cognitive,3405,O
functions,3405,O
",",3405,O
total,3405,O
serum,3405,O
cholesterol,3405,B-Chemical
levels,3405,O
and,3405,O
brain,3405,O
cholinesterase,3405,O
activity,3405,O
in,3405,O
mice,3405,O
.,3405,O
The,3406,O
ethanolic,3406,O
extract,3406,B-Chemical
of,3406,I-Chemical
Daucus,3406,I-Chemical
carota,3406,I-Chemical
seeds,3406,I-Chemical
(,3406,O
DCE,3406,B-Chemical
),3406,O
was,3406,O
administered,3406,O
orally,3406,O
in,3406,O
three,3406,O
doses,3406,O
(,3406,O
100,3406,O
",",3406,O
200,3406,O
",",3406,O
400,3406,O
mg/kg,3406,O
),3406,O
for,3406,O
seven,3406,O
successive,3406,O
days,3406,O
to,3406,O
different,3406,O
groups,3406,O
of,3406,O
young,3406,O
and,3406,O
aged,3406,O
mice,3406,O
.,3406,O
Elevated,3407,O
plus,3407,O
maze,3407,O
and,3407,O
passive,3407,O
avoidance,3407,O
apparatus,3407,O
served,3407,O
as,3407,O
the,3407,O
exteroceptive,3407,O
behavioral,3407,O
models,3407,O
for,3407,O
testing,3407,O
memory,3407,O
.,3407,O
Diazepam-,3408,B-Chemical
",",3408,O
scopolamine-,3408,B-Chemical
and,3408,O
ageing-induced,3408,O
amnesia,3408,B-Disease
served,3408,O
as,3408,O
the,3408,O
interoceptive,3408,O
behavioral,3408,O
models,3408,O
.,3408,O
DCE,3409,B-Chemical
(,3409,O
200,3409,O
",",3409,O
400,3409,O
mg/kg,3409,O
",",3409,O
p.o,3409,O
.,3409,O
),3409,O
showed,3410,O
significant,3410,O
improvement,3410,O
in,3410,O
memory,3410,O
scores,3410,O
of,3410,O
young,3410,O
and,3410,O
aged,3410,O
mice,3410,O
.,3410,O
The,3411,O
extent,3411,O
of,3411,O
memory,3411,O
improvement,3411,O
evoked,3411,O
by,3411,O
DCE,3411,B-Chemical
was,3411,O
23,3411,O
%,3411,O
at,3411,O
the,3411,O
dose,3411,O
of,3411,O
200,3411,O
mg/kg,3411,O
and,3411,O
35,3411,O
%,3411,O
at,3411,O
the,3411,O
dose,3411,O
of,3411,O
400,3411,O
mg/kg,3411,O
in,3411,O
young,3411,O
mice,3411,O
using,3411,O
elevated,3411,O
plus,3411,O
maze,3411,O
.,3411,O
Similarly,3412,O
",",3412,O
significant,3412,O
improvements,3412,O
in,3412,O
memory,3412,O
scores,3412,O
were,3412,O
observed,3412,O
using,3412,O
passive,3412,O
avoidance,3412,O
apparatus,3412,O
and,3412,O
aged,3412,O
mice,3412,O
.,3412,O
Furthermore,3413,O
",",3413,O
DCE,3413,B-Chemical
reversed,3413,O
the,3413,O
amnesia,3413,B-Disease
induced,3413,O
by,3413,O
scopolamine,3413,B-Chemical
(,3413,O
0.4,3413,O
mg/kg,3413,O
",",3413,O
i.p,3413,O
.,3413,O
),3413,O
and,3414,O
diazepam,3414,B-Chemical
(,3414,O
1,3414,O
mg/kg,3414,O
",",3414,O
i.p,3414,O
.,3414,O
),3414,O
.,3414,O
Daucus,3415,B-Chemical
carota,3415,I-Chemical
extract,3415,I-Chemical
(,3415,O
200,3415,O
",",3415,O
400,3415,O
mg/kg,3415,O
",",3415,O
p.o,3415,O
.,3415,O
),3415,O
reduced,3416,O
significantly,3416,O
the,3416,O
brain,3416,O
acetylcholinesterase,3416,O
activity,3416,O
and,3416,O
cholesterol,3416,B-Chemical
levels,3416,O
in,3416,O
young,3416,O
and,3416,O
aged,3416,O
mice,3416,O
.,3416,O
The,3417,O
extent,3417,O
of,3417,O
inhibition,3417,O
of,3417,O
brain,3417,O
cholinesterase,3417,O
activity,3417,O
evoked,3417,O
by,3417,O
DCE,3417,B-Chemical
at,3417,O
the,3417,O
dose,3417,O
of,3417,O
400,3417,O
mg/kg,3417,O
was,3417,O
22,3417,O
%,3417,O
in,3417,O
young,3417,O
and,3417,O
19,3417,O
%,3417,O
in,3417,O
aged,3417,O
mice,3417,O
.,3417,O
There,3418,O
was,3418,O
a,3418,O
remarkable,3418,O
reduction,3418,O
in,3418,O
total,3418,O
cholesterol,3418,B-Chemical
level,3418,O
as,3418,O
well,3418,O
",",3418,O
to,3418,O
the,3418,O
extent,3418,O
of,3418,O
23,3418,O
%,3418,O
in,3418,O
young,3418,O
and,3418,O
21,3418,O
%,3418,O
in,3418,O
aged,3418,O
animals,3418,O
with,3418,O
this,3418,O
dose,3418,O
of,3418,O
DCE,3418,B-Chemical
.,3418,O
Therefore,3419,O
",",3419,O
DCE,3419,B-Chemical
may,3419,O
prove,3419,O
to,3419,O
be,3419,O
a,3419,O
useful,3419,O
remedy,3419,O
for,3419,O
the,3419,O
management,3419,O
of,3419,O
cognitive,3419,B-Disease
dysfunctions,3419,I-Disease
on,3419,O
account,3419,O
of,3419,O
its,3419,O
multifarious,3419,O
beneficial,3419,O
effects,3419,O
such,3419,O
as,3419,O
",",3419,O
memory,3419,O
improving,3419,O
property,3419,O
",",3419,O
cholesterol,3419,B-Chemical
lowering,3419,O
property,3419,O
and,3419,O
anticholinesterase,3419,O
activity,3419,O
.,3419,O
Valproic,3420,B-Chemical
acid,3420,I-Chemical
induced,3420,O
encephalopathy,3420,B-Disease
--,3420,O
19,3420,O
new,3420,O
cases,3420,O
in,3420,O
Germany,3420,O
from,3420,O
1994,3420,O
to,3420,O
2003,3420,O
--,3420,O
a,3420,O
side,3420,O
effect,3420,O
associated,3420,O
to,3420,O
VPA-therapy,3420,B-Chemical
not,3420,O
only,3420,O
in,3420,O
young,3420,O
children,3420,O
.,3420,O
Valproic,3421,B-Chemical
acid,3421,I-Chemical
(,3421,O
VPA,3421,B-Chemical
),3421,O
is,3421,O
a,3421,O
broad-spectrum,3421,O
antiepileptic,3421,O
drug,3421,O
and,3421,O
is,3421,O
usually,3421,O
well-tolerated,3421,O
.,3421,O
Rare,3422,O
serious,3422,O
complications,3422,O
may,3422,O
occur,3422,O
in,3422,O
some,3422,O
patients,3422,O
",",3422,O
including,3422,O
haemorrhagic,3422,O
pancreatitis,3422,B-Disease
",",3422,O
bone,3422,B-Disease
marrow,3422,I-Disease
suppression,3422,I-Disease
",",3422,O
VPA-induced,3422,B-Chemical
hepatotoxicity,3422,B-Disease
and,3422,O
VPA-induced,3422,B-Chemical
encephalopathy,3422,B-Disease
.,3422,O
The,3423,O
typical,3423,O
signs,3423,O
of,3423,O
VPA-induced,3423,B-Chemical
encephalopathy,3423,B-Disease
are,3423,O
impaired,3423,B-Disease
consciousness,3423,I-Disease
",",3423,O
sometimes,3423,O
marked,3423,O
EEG,3423,O
background,3423,O
slowing,3423,O
",",3423,O
increased,3423,O
seizure,3423,B-Disease
frequency,3423,O
",",3423,O
with,3423,O
or,3423,O
without,3423,O
hyperammonemia,3423,B-Disease
.,3423,O
There,3424,O
is,3424,O
still,3424,O
no,3424,O
proof,3424,O
of,3424,O
causative,3424,O
effect,3424,O
of,3424,O
VPA,3424,B-Chemical
in,3424,O
patients,3424,O
with,3424,O
encephalopathy,3424,B-Disease
",",3424,O
but,3424,O
only,3424,O
of,3424,O
an,3424,O
association,3424,O
with,3424,O
an,3424,O
assumed,3424,O
causal,3424,O
relation,3424,O
.,3424,O
We,3425,O
report,3425,O
19,3425,O
patients,3425,O
with,3425,O
VPA-associated,3425,B-Chemical
encephalopathy,3425,B-Disease
in,3425,O
Germany,3425,O
from,3425,O
the,3425,O
years,3425,O
1994,3425,O
to,3425,O
2003,3425,O
",",3425,O
none,3425,O
of,3425,O
whom,3425,O
had,3425,O
been,3425,O
published,3425,O
previously,3425,O
.,3425,O
Cerebral,3426,B-Disease
haemorrhage,3426,I-Disease
induced,3426,O
by,3426,O
warfarin,3426,B-Chemical
-,3426,O
the,3426,O
influence,3426,O
of,3426,O
drug-drug,3426,O
interactions,3426,O
.,3426,O
PURPOSE,3427,O
:,3427,O
To,3427,O
evaluate,3427,O
the,3427,O
frequency,3427,O
",",3427,O
severity,3427,O
and,3427,O
preventability,3427,O
of,3427,O
warfarin-induced,3427,B-Chemical
cerebral,3427,B-Disease
haemorrhages,3427,I-Disease
due,3427,O
to,3427,O
warfarin,3427,B-Chemical
and,3427,O
warfarin-drug,3427,B-Chemical
interactions,3427,O
in,3427,O
patients,3427,O
living,3427,O
in,3427,O
the,3427,O
county,3427,O
of,3427,O
Osterg,3427,O
tland,3427,O
",",3427,O
Sweden,3427,O
.,3427,O
METHODS,3428,O
:,3428,O
All,3428,O
patients,3428,O
with,3428,O
a,3428,O
diagnosed,3428,O
cerebral,3428,B-Disease
haemorrhage,3428,I-Disease
at,3428,O
three,3428,O
hospitals,3428,O
during,3428,O
the,3428,O
period,3428,O
2000-2002,3428,O
were,3428,O
identified,3428,O
.,3428,O
Medical,3429,O
records,3429,O
were,3429,O
studied,3429,O
retrospectively,3429,O
to,3429,O
evaluate,3429,O
whether,3429,O
warfarin,3429,B-Chemical
and,3429,O
warfarin-drug,3429,B-Chemical
interactions,3429,O
could,3429,O
have,3429,O
caused,3429,O
the,3429,O
cerebral,3429,B-Disease
haemorrhage,3429,I-Disease
.,3429,O
The,3430,O
proportion,3430,O
of,3430,O
possibly,3430,O
avoidable,3430,O
cases,3430,O
due,3430,O
to,3430,O
drug,3430,O
interactions,3430,O
was,3430,O
estimated,3430,O
.,3430,O
RESULTS,3431,O
:,3431,O
Among,3431,O
593,3431,O
patients,3431,O
with,3431,O
cerebral,3431,B-Disease
haemorrhage,3431,I-Disease
",",3431,O
59,3431,O
(,3431,O
10,3431,O
%,3431,O
),3431,O
were,3431,O
assessed,3431,O
as,3431,O
related,3431,O
to,3431,O
warfarin,3431,B-Chemical
treatment,3431,O
.,3431,O
This,3432,O
imply,3432,O
an,3432,O
incidence,3432,O
of,3432,O
"1.7/100,000",3432,O
treatment,3432,O
years,3432,O
.,3432,O
Of,3433,O
the,3433,O
59,3433,O
cases,3433,O
",",3433,O
26,3433,O
(,3433,O
44,3433,O
%,3433,O
),3433,O
had,3433,O
a,3433,O
fatal,3433,O
outcome,3433,O
",",3433,O
compared,3433,O
to,3433,O
136,3433,O
(,3433,O
25,3433,O
%,3433,O
),3433,O
among,3433,O
the,3433,O
non-warfarin,3433,O
patients,3433,O
(,3433,O
p,3433,O
<,3433,O
0.01,3433,O
),3433,O
.,3433,O
A,3434,O
warfarin-drug,3434,B-Chemical
interaction,3434,O
could,3434,O
have,3434,O
contributed,3434,O
to,3434,O
the,3434,O
haemorrhage,3434,B-Disease
in,3434,O
24,3434,O
(,3434,O
41,3434,O
%,3434,O
),3434,O
of,3434,O
the,3434,O
warfarin,3434,B-Chemical
patients,3434,O
and,3434,O
in,3434,O
7,3434,O
of,3434,O
these,3434,O
(,3434,O
12,3434,O
%,3434,O
),3434,O
the,3434,O
bleeding,3434,B-Disease
complication,3434,O
was,3434,O
considered,3434,O
being,3434,O
possible,3434,O
to,3434,O
avoid,3434,O
.,3434,O
CONCLUSIONS,3435,O
:,3435,O
Warfarin-induced,3435,B-Chemical
cerebral,3435,B-Disease
haemorrhages,3435,I-Disease
are,3435,O
a,3435,O
major,3435,O
clinical,3435,O
problem,3435,O
with,3435,O
a,3435,O
high,3435,O
fatality,3435,O
rate,3435,O
.,3435,O
Almost,3436,O
half,3436,O
of,3436,O
the,3436,O
cases,3436,O
was,3436,O
related,3436,O
to,3436,O
a,3436,O
warfarin-drug,3436,B-Chemical
interaction,3436,O
.,3436,O
A,3437,O
significant,3437,O
proportion,3437,O
of,3437,O
warfarin-related,3437,B-Chemical
cerebral,3437,B-Disease
haemorrhages,3437,I-Disease
might,3437,O
have,3437,O
been,3437,O
prevented,3437,O
if,3437,O
greater,3437,O
caution,3437,O
had,3437,O
been,3437,O
taken,3437,O
when,3437,O
prescribing,3437,O
drugs,3437,O
known,3437,O
to,3437,O
interact,3437,O
with,3437,O
warfarin,3437,B-Chemical
.,3437,O
Antipsychotic-like,3438,O
profile,3438,O
of,3438,O
thioperamide,3438,B-Chemical
",",3438,O
a,3438,O
selective,3438,O
H3-receptor,3438,O
antagonist,3438,O
in,3438,O
mice,3438,O
.,3438,O
Experimental,3439,O
and,3439,O
clinical,3439,O
evidence,3439,O
points,3439,O
to,3439,O
a,3439,O
role,3439,O
of,3439,O
central,3439,O
histaminergic,3439,O
system,3439,O
in,3439,O
the,3439,O
pathogenesis,3439,O
of,3439,O
schizophrenia,3439,B-Disease
.,3439,O
The,3440,O
present,3440,O
study,3440,O
was,3440,O
designed,3440,O
to,3440,O
study,3440,O
the,3440,O
effect,3440,O
of,3440,O
histamine,3440,B-Chemical
H,3440,O
(,3440,O
3,3440,O
),3440,O
-receptor,3440,O
ligands,3440,O
on,3440,O
neuroleptic-induced,3440,O
catalepsy,3440,B-Disease
",",3440,O
apomorphine-induced,3440,B-Chemical
climbing,3440,O
behavior,3440,O
and,3440,O
amphetamine-induced,3440,B-Chemical
locomotor,3440,O
activities,3440,O
in,3440,O
mice,3440,O
.,3440,O
Catalepsy,3441,B-Disease
was,3441,O
induced,3441,O
by,3441,O
haloperidol,3441,B-Chemical
(,3441,O
2,3441,O
mg/kg,3441,O
p.o,3441,O
.,3441,O
),3442,O
",",3442,O
while,3442,O
apomorphine,3442,O
(,3442,O
1.5,3442,O
mg/kg,3442,O
s.c.,3442,O
),3442,O
and,3442,O
amphetamine,3442,O
(,3442,O
2,3442,O
mg/kg,3442,O
s.c.,3442,O
),3442,O
were,3442,O
used,3442,O
for,3442,O
studying,3442,O
climbing,3442,O
behavior,3442,O
and,3442,O
locomotor,3442,O
activities,3442,O
",",3442,O
respectively,3442,O
.,3442,O
(,3443,O
R,3443,O
),3443,O
-alpha-methylhistamine,3443,O
(,3443,B-Chemical
RAMH,3443,O
),3443,O
(,3443,O
5,3443,O
microg,3443,O
i.c.v,3443,O
.,3443,O
),3443,O
and,3444,O
thioperamide,3444,O
(,3444,B-Chemical
THP,3444,O
),3444,O
(,3444,O
15,3444,O
mg/kg,3444,O
i.p,3444,O
.,3444,O
),3445,O
",",3445,O
per,3445,O
se,3445,O
did,3445,O
not,3445,O
cause,3445,O
catalepsy,3445,O
.,3445,O
Administration,3446,O
of,3446,O
THP,3446,O
(,3446,O
3.75,3446,O
",",3446,O
7.5,3446,O
and,3446,O
15,3446,O
mg/kg,3446,O
i.p,3446,O
.,3446,O
),3446,O
1,3447,O
h,3447,O
prior,3447,O
to,3447,O
haloperidol,3447,O
resulted,3447,O
in,3447,O
a,3447,O
dose-dependent,3447,O
increase,3447,O
in,3447,O
the,3447,O
catalepsy,3447,O
times,3447,O
(,3447,O
P,3447,O
<,3447,O
0.05,3447,O
),3447,O
.,3447,O
However,3448,O
",",3448,O
pretreatment,3448,O
with,3448,O
RAMH,3448,O
significantly,3448,O
reversed,3448,O
such,3448,O
an,3448,O
effect,3448,O
of,3448,O
THP,3448,O
(,3448,O
15,3448,O
mg/kg,3448,O
i.p,3448,O
.,3448,O
),3448,O
.,3448,O
RAMH,3449,O
per,3449,O
se,3449,O
showed,3449,O
significant,3449,O
reduction,3449,O
in,3449,O
locomotor,3449,O
time,3449,O
",",3449,O
distance,3449,O
traveled,3449,O
and,3449,O
average,3449,O
speed,3449,O
but,3449,O
THP,3449,O
(,3449,O
15,3449,O
mg/kg,3449,O
i.p,3449,O
.,3449,O
),3449,O
per,3450,O
se,3450,O
had,3450,O
no,3450,O
effect,3450,O
on,3450,O
these,3450,O
parameters,3450,O
.,3450,O
On,3451,O
amphetamine-induced,3451,O
hyperactivity,3451,O
",",3451,B-Chemical
THP,3451,O
(,3451,O
3.75,3451,O
and,3451,O
7.5,3451,O
mg/kg,3451,O
i.p,3451,O
.,3451,O
),3451,O
reduced,3452,O
locomotor,3452,O
time,3452,O
",",3452,O
distance,3452,O
traveled,3452,O
and,3452,O
average,3452,O
speed,3452,O
(,3452,O
P,3452,O
<,3452,O
0.05,3452,O
),3452,O
.,3452,O
Pretreatment,3453,O
with,3453,O
RAMH,3453,O
(,3453,O
5,3453,O
microg,3453,O
i.c.v,3453,O
.,3453,O
),3453,O
could,3454,O
partially,3454,O
reverse,3454,O
such,3454,O
effects,3454,O
of,3454,O
THP,3454,O
(,3454,O
3.75,3454,O
mg/kg,3454,O
i.p,3454,O
.,3454,O
),3454,O
.,3454,O
Climbing,3455,O
behavior,3455,O
induced,3455,O
by,3455,O
apomorphine,3455,O
was,3455,O
reduced,3455,O
in,3455,O
animals,3455,O
treated,3455,O
with,3455,O
THP,3455,O
.,3455,O
Such,3456,O
an,3456,O
effect,3456,O
was,3456,O
",",3456,O
however,3456,O
",",3456,O
reversed,3456,O
in,3456,O
presence,3456,O
of,3456,O
RAMH,3456,O
.,3456,O
THP,3457,O
exhibited,3457,O
an,3457,O
antipsychotic-like,3457,O
profile,3457,O
by,3457,O
potentiating,3457,O
haloperidol-induced,3457,O
catalepsy,3457,O
",",3457,O
reducing,3457,O
amphetamine-induced,3457,O
hyperactivity,3457,O
and,3457,O
reducing,3457,O
apomorphine-induced,3457,O
climbing,3457,O
in,3457,O
mice,3457,O
.,3457,O
Such,3458,O
effects,3458,O
of,3458,O
THP,3458,O
were,3458,O
reversed,3458,O
by,3458,O
RAMH,3458,O
indicating,3458,O
the,3458,O
involvement,3458,O
of,3458,O
histamine,3458,O
H,3458,O
(,3458,O
3,3458,O
),3458,O
-receptors,3458,O
.,3458,O
Findings,3459,O
suggest,3459,O
a,3459,O
potential,3459,O
for,3459,O
H,3459,O
(,3459,O
3,3459,O
),3459,O
-receptor,3459,O
antagonists,3459,O
in,3459,O
improving,3459,O
the,3459,O
refractory,3459,O
cases,3459,O
of,3459,O
schizophrenia,3459,O
.,3459,O
Cauda,3460,B-Disease
equina,3460,I-Disease
syndrome,3460,I-Disease
after,3460,O
epidural,3460,O
steroid,3460,B-Chemical
injection,3460,O
:,3460,O
a,3460,O
case,3460,O
report,3460,O
.,3460,O
OBJECTIVE,3461,O
:,3461,O
Conventional,3461,O
treatment,3461,O
methods,3461,O
of,3461,O
lumbusacral,3461,O
radiculopathy,3461,B-Disease
are,3461,O
physical,3461,O
therapy,3461,O
",",3461,O
epidural,3461,O
steroid,3461,B-Chemical
injections,3461,O
",",3461,O
oral,3461,O
medications,3461,O
",",3461,O
and,3461,O
spinal,3461,O
manipulative,3461,O
therapy,3461,O
.,3461,O
Cauda,3462,B-Disease
equina,3462,I-Disease
syndrome,3462,I-Disease
is,3462,O
a,3462,O
rare,3462,O
complication,3462,O
of,3462,O
epidural,3462,O
anesthesia,3462,O
.,3462,O
The,3463,O
following,3463,O
case,3463,O
is,3463,O
a,3463,O
report,3463,O
of,3463,O
cauda,3463,B-Disease
equina,3463,I-Disease
syndrome,3463,I-Disease
possibly,3463,O
caused,3463,O
by,3463,O
epidural,3463,O
injection,3463,O
of,3463,O
triamcinolone,3463,B-Chemical
and,3463,O
bupivacaine,3463,B-Chemical
.,3463,O
CLINICAL,3464,O
FEATURES,3464,O
:,3464,O
A,3464,O
50-year-old,3464,O
woman,3464,O
with,3464,O
low,3464,O
back,3464,O
and,3464,O
right,3464,O
leg,3464,O
pain,3464,O
was,3464,O
scheduled,3464,O
for,3464,O
epidural,3464,O
steroid,3464,B-Chemical
injection,3464,O
.,3464,O
INTERVENTION,3465,O
AND,3465,O
OUTCOME,3465,O
:,3465,O
An,3465,O
18-gauge,3465,O
Touhy,3465,O
needle,3465,O
was,3465,O
inserted,3465,O
until,3465,O
loss,3465,O
of,3465,O
resistance,3465,O
occurred,3465,O
at,3465,O
the,3465,O
L4-5,3465,O
level,3465,O
.,3465,O
Spread,3466,O
of,3466,O
the,3466,O
contrast,3466,O
medium,3466,O
within,3466,O
the,3466,O
epidural,3466,O
space,3466,O
was,3466,O
determined,3466,O
by,3466,O
radiographic,3466,O
imaging,3466,O
.,3466,O
After,3467,O
verifying,3467,O
the,3467,O
epidural,3467,O
space,3467,O
",",3467,O
bupivacaine,3467,B-Chemical
and,3467,O
triamcinolone,3467,B-Chemical
diacetate,3467,I-Chemical
were,3467,O
injected,3467,O
.,3467,O
After,3468,O
the,3468,O
injection,3468,O
",",3468,O
there,3468,O
was,3468,O
a,3468,O
reduction,3468,O
in,3468,O
radicular,3468,O
symptoms,3468,O
.,3468,O
Three,3469,O
hours,3469,O
later,3469,O
",",3469,O
she,3469,O
complained,3469,O
of,3469,O
perineal,3469,O
numbness,3469,B-Disease
and,3469,O
lower,3469,B-Disease
extremity,3469,I-Disease
weakness,3469,I-Disease
.,3469,O
The,3470,O
neurologic,3470,O
evaluation,3470,O
revealed,3470,O
loss,3470,B-Disease
of,3470,I-Disease
sensation,3470,I-Disease
in,3470,O
the,3470,O
saddle,3470,O
area,3470,O
and,3470,O
medial,3470,O
aspect,3470,O
of,3470,O
her,3470,O
right,3470,O
leg,3470,O
.,3470,O
There,3471,O
was,3471,O
a,3471,O
decrease,3471,O
in,3471,O
the,3471,O
perception,3471,O
of,3471,O
pinprick,3471,O
test,3471,O
.,3471,O
Deep-tendon,3472,O
reflexes,3472,O
were,3472,O
decreased,3472,O
especially,3472,O
in,3472,O
the,3472,O
right,3472,O
leg,3472,O
.,3472,O
She,3473,O
was,3473,O
unable,3473,O
to,3473,O
urinate,3473,O
.,3473,O
The,3474,O
patient,3474,O
's,3474,O
symptoms,3474,O
improved,3474,O
slightly,3474,O
over,3474,O
the,3474,O
next,3474,O
few,3474,O
hours,3474,O
.,3474,O
She,3475,O
had,3475,O
a,3475,O
gradual,3475,O
return,3475,O
of,3475,O
motor,3475,O
function,3475,O
and,3475,O
ability,3475,O
of,3475,O
feeling,3475,O
Foley,3475,O
catheter,3475,O
.,3475,O
All,3476,O
of,3476,O
the,3476,O
symptoms,3476,O
were,3476,O
completely,3476,O
resolved,3476,O
over,3476,O
the,3476,O
next,3476,O
8,3476,O
hours,3476,O
.,3476,O
CONCLUSION,3477,O
:,3477,O
Complications,3477,O
associated,3477,O
with,3477,O
epidural,3477,O
steroid,3477,B-Chemical
injections,3477,O
are,3477,O
rare,3477,O
.,3477,O
Clinical,3478,O
examination,3478,O
and,3478,O
continued,3478,O
vigilance,3478,O
for,3478,O
neurologic,3478,B-Disease
deterioration,3478,I-Disease
after,3478,O
epidural,3478,O
steroid,3478,B-Chemical
injections,3478,O
is,3478,O
important,3478,O
.,3478,O
High-dose,3479,O
testosterone,3479,B-Chemical
is,3479,O
associated,3479,O
with,3479,O
atherosclerosis,3479,B-Disease
in,3479,O
postmenopausal,3479,O
women,3479,O
.,3479,O
OBJECTIVES,3480,O
:,3480,O
To,3480,O
study,3480,O
the,3480,O
long-term,3480,O
effects,3480,O
of,3480,O
androgen,3480,O
treatment,3480,O
on,3480,O
atherosclerosis,3480,B-Disease
in,3480,O
postmenopausal,3480,O
women,3480,O
.,3480,O
METHODS,3481,O
:,3481,O
In,3481,O
a,3481,O
population-based,3481,O
study,3481,O
in,3481,O
513,3481,O
naturally,3481,O
postmenopausal,3481,O
women,3481,O
aged,3481,O
54-67,3481,O
years,3481,O
",",3481,O
we,3481,O
studied,3481,O
the,3481,O
association,3481,O
between,3481,O
self-reported,3481,O
intramuscularly,3481,O
administered,3481,O
high-dose,3481,O
estrogen-testosterone,3481,B-Chemical
therapy,3481,O
(,3481,O
estradiol-,3481,B-Chemical
and,3481,I-Chemical
testosterone,3481,I-Chemical
esters,3481,I-Chemical
),3481,O
and,3481,O
aortic,3481,O
atherosclerosis,3481,B-Disease
.,3481,O
Aortic,3482,O
atherosclerosis,3482,B-Disease
was,3482,O
diagnosed,3482,O
by,3482,O
radiographic,3482,O
detection,3482,O
of,3482,O
calcified,3482,O
deposits,3482,O
in,3482,O
the,3482,O
abdominal,3482,O
aorta,3482,O
",",3482,O
which,3482,O
have,3482,O
been,3482,O
shown,3482,O
to,3482,O
reflect,3482,O
intima,3482,O
atherosclerosis,3482,B-Disease
.,3482,O
Hormone,3483,O
therapy,3483,O
users,3483,O
were,3483,O
compared,3483,O
with,3483,O
never,3483,O
users,3483,O
.,3483,O
RESULTS,3484,O
:,3484,O
Intramuscular,3484,O
hormone,3484,O
therapy,3484,O
use,3484,O
for,3484,O
1,3484,O
year,3484,O
or,3484,O
longer,3484,O
was,3484,O
reported,3484,O
by,3484,O
25,3484,O
women,3484,O
.,3484,O
In,3485,O
almost,3485,O
half,3485,O
of,3485,O
these,3485,O
women,3485,O
severe,3485,O
atherosclerosis,3485,B-Disease
of,3485,O
the,3485,O
aorta,3485,O
was,3485,O
present,3485,O
(,3485,O
n=11,3485,O
),3485,O
",",3485,O
while,3485,O
in,3485,O
women,3485,O
without,3485,O
hormone,3485,O
use,3485,O
severe,3485,O
atherosclerosis,3485,B-Disease
of,3485,O
the,3485,O
aorta,3485,O
was,3485,O
present,3485,O
in,3485,O
less,3485,O
than,3485,O
20,3485,O
%,3485,O
(,3485,O
OR,3485,O
3.1,3485,O
;,3485,O
95,3485,O
%,3485,O
CI,3485,O
",",3485,O
1.1-8.5,3485,O
",",3485,O
adjusted,3485,O
for,3485,O
age,3485,O
",",3485,O
years,3485,O
since,3485,O
menopause,3485,O
",",3485,O
smoking,3485,O
",",3485,O
and,3485,O
body,3485,O
mass,3485,O
index,3485,O
),3485,O
.,3485,O
The,3486,O
association,3486,O
remained,3486,O
after,3486,O
additional,3486,O
adjustment,3486,O
for,3486,O
diabetes,3486,B-Disease
",",3486,O
cholesterol,3486,B-Chemical
level,3486,O
",",3486,O
systolic,3486,O
blood,3486,O
pressure,3486,O
",",3486,O
or,3486,O
alcohol,3486,B-Chemical
use,3486,O
.,3486,O
No,3487,O
association,3487,O
was,3487,O
found,3487,O
for,3487,O
hormone,3487,O
use,3487,O
less,3487,O
than,3487,O
1,3487,O
year,3487,O
.,3487,O
CONCLUSION,3488,O
:,3488,O
Our,3488,O
results,3488,O
suggest,3488,O
that,3488,O
high-dose,3488,O
testosterone,3488,B-Chemical
therapy,3488,O
may,3488,O
adversely,3488,O
affect,3488,O
atherosclerosis,3488,B-Disease
in,3488,O
postmenopausal,3488,O
women,3488,O
and,3488,O
indicate,3488,O
that,3488,O
androgen,3488,O
replacement,3488,O
in,3488,O
these,3488,O
women,3488,O
may,3488,O
not,3488,O
be,3488,O
harmless,3488,O
.,3488,O
Optimising,3489,O
stroke,3489,B-Disease
prevention,3489,O
in,3489,O
non-valvular,3489,O
atrial,3489,B-Disease
fibrillation,3489,I-Disease
.,3489,O
Atrial,3490,B-Disease
fibrillation,3490,I-Disease
is,3490,O
associated,3490,O
with,3490,O
substantial,3490,O
morbidity,3490,O
and,3490,O
mortality,3490,O
.,3490,O
Pooled,3491,O
data,3491,O
from,3491,O
trials,3491,O
comparing,3491,O
antithrombotic,3491,O
treatment,3491,O
with,3491,O
placebo,3491,O
have,3491,O
shown,3491,O
that,3491,O
warfarin,3491,B-Chemical
reduces,3491,O
the,3491,O
risk,3491,O
of,3491,O
stroke,3491,B-Disease
by,3491,O
62,3491,O
%,3491,O
",",3491,O
and,3491,O
that,3491,O
aspirin,3491,B-Chemical
alone,3491,O
reduces,3491,O
the,3491,O
risk,3491,O
by,3491,O
22,3491,O
%,3491,O
.,3491,O
Overall,3492,O
",",3492,O
in,3492,O
high-risk,3492,O
patients,3492,O
",",3492,O
warfarin,3492,B-Chemical
is,3492,O
superior,3492,O
to,3492,O
aspirin,3492,B-Chemical
in,3492,O
preventing,3492,O
strokes,3492,B-Disease
",",3492,O
with,3492,O
a,3492,O
relative,3492,O
risk,3492,O
reduction,3492,O
of,3492,O
36,3492,O
%,3492,O
.,3492,O
Ximelagatran,3493,B-Chemical
",",3493,O
an,3493,O
oral,3493,O
direct,3493,O
thrombin,3493,O
inhibitor,3493,O
",",3493,O
was,3493,O
found,3493,O
to,3493,O
be,3493,O
as,3493,O
efficient,3493,O
as,3493,O
vitamin,3493,B-Chemical
K,3493,I-Chemical
antagonist,3493,O
drugs,3493,O
in,3493,O
the,3493,O
prevention,3493,O
of,3493,O
embolic,3493,B-Disease
events,3493,I-Disease
",",3493,O
but,3493,O
has,3493,O
been,3493,O
recently,3493,O
withdrawn,3493,O
because,3493,O
of,3493,O
abnormal,3493,B-Disease
liver,3493,I-Disease
function,3493,I-Disease
tests,3493,O
.,3493,O
The,3494,O
ACTIVE-W,3494,O
(,3494,O
Atrial,3494,B-Disease
Fibrillation,3494,I-Disease
Clopidogrel,3494,B-Chemical
Trial,3494,O
with,3494,O
Irbesartan,3494,B-Chemical
for,3494,O
Prevention,3494,O
of,3494,O
Vascular,3494,O
Events,3494,O
),3494,O
study,3494,O
has,3494,O
demonstrated,3494,O
that,3494,O
warfarin,3494,B-Chemical
is,3494,O
superior,3494,O
to,3494,O
platelet,3494,O
therapy,3494,O
(,3494,O
clopidogrel,3494,B-Chemical
plus,3494,O
aspirin,3494,B-Chemical
),3494,O
in,3494,O
the,3494,O
prevention,3494,O
af,3494,O
embolic,3494,B-Disease
events,3494,I-Disease
.,3494,O
Idraparinux,3495,B-Chemical
",",3495,O
a,3495,O
Factor,3495,O
Xa,3495,O
inhibitor,3495,O
",",3495,O
is,3495,O
being,3495,O
evaluated,3495,O
in,3495,O
patients,3495,O
with,3495,O
atrial,3495,B-Disease
fibrillation,3495,I-Disease
.,3495,O
Angiotensin-converting,3496,B-Chemical
enzyme,3496,O
inhibitors,3496,O
and,3496,O
angiotensin,3496,B-Chemical
II,3496,I-Chemical
receptor-blocking,3496,O
drugs,3496,O
hold,3496,O
promise,3496,O
in,3496,O
atrial,3496,B-Disease
fibrillation,3496,I-Disease
through,3496,O
cardiac,3496,B-Disease
remodelling,3496,I-Disease
.,3496,O
Preliminary,3497,O
studies,3497,O
suggest,3497,O
that,3497,O
statins,3497,B-Chemical
could,3497,O
interfere,3497,O
with,3497,O
the,3497,O
risk,3497,O
of,3497,O
recurrence,3497,O
after,3497,O
electrical,3497,O
cardioversion,3497,O
.,3497,O
Finally,3498,O
",",3498,O
percutaneous,3498,O
methods,3498,O
for,3498,O
the,3498,O
exclusion,3498,O
of,3498,O
left,3498,O
atrial,3498,O
appendage,3498,O
are,3498,O
under,3498,O
investigation,3498,O
in,3498,O
high-risk,3498,O
patients,3498,O
.,3498,O
Anti-oxidant,3499,O
effects,3499,O
of,3499,O
atorvastatin,3499,B-Chemical
in,3499,O
dexamethasone-induced,3499,B-Chemical
hypertension,3499,B-Disease
in,3499,O
the,3499,O
rat,3499,O
.,3499,O
1,3500,O
.,3500,O
Dexamethasone,3501,B-Chemical
(,3501,O
Dex,3501,B-Chemical
),3501,O
-induced,3501,O
hypertension,3501,B-Disease
is,3501,O
characterized,3501,O
by,3501,O
endothelial,3501,O
dysfunction,3501,O
associated,3501,O
with,3501,O
nitric,3501,B-Chemical
oxide,3501,I-Chemical
(,3501,O
NO,3501,B-Chemical
),3501,O
deficiency,3501,O
and,3501,O
increased,3501,O
superoxide,3501,B-Chemical
(,3501,O
O2-,3501,B-Chemical
),3501,O
production,3501,O
.,3501,O
Atorvastatin,3502,B-Chemical
(,3502,O
Ato,3502,B-Chemical
),3502,O
possesses,3502,O
pleiotropic,3502,O
properties,3502,O
that,3502,O
have,3502,O
been,3502,O
reported,3502,O
to,3502,O
improve,3502,O
endothelial,3502,O
function,3502,O
through,3502,O
increased,3502,O
availability,3502,O
of,3502,O
NO,3502,B-Chemical
and,3502,O
reduced,3502,O
O2-,3502,B-Chemical
production,3502,O
in,3502,O
various,3502,O
forms,3502,O
of,3502,O
hypertension,3502,B-Disease
.,3502,O
In,3503,O
the,3503,O
present,3503,O
study,3503,O
",",3503,O
we,3503,O
investigated,3503,O
whether,3503,O
50,3503,O
mg/kg,3503,O
per,3503,O
day,3503,O
",",3503,O
p.o.,3503,O
",",3503,O
Ato,3503,B-Chemical
could,3503,O
prevent,3503,O
endothelial,3503,O
NO,3503,B-Chemical
synthase,3503,O
(,3503,O
eNOS,3503,O
),3503,O
downregulation,3503,O
and,3503,O
the,3503,O
increase,3503,O
in,3503,O
O2-,3503,B-Chemical
in,3503,O
Sprague-Dawley,3503,O
(,3503,O
SD,3503,O
),3503,O
rats,3503,O
",",3503,O
thereby,3503,O
reducing,3503,O
blood,3503,O
pressure,3503,O
.,3503,O
2,3504,O
.,3504,O
Male,3505,O
SD,3505,O
rats,3505,O
(,3505,O
n,3505,O
=,3505,O
30,3505,O
),3505,O
were,3505,O
treated,3505,O
with,3505,O
Ato,3505,B-Chemical
(,3505,O
50,3505,O
mg/kg,3505,O
per,3505,O
day,3505,O
in,3505,O
drinking,3505,O
water,3505,O
),3505,O
or,3505,O
tap,3505,O
water,3505,O
for,3505,O
15,3505,O
days,3505,O
.,3505,O
Dexamethasone,3506,B-Chemical
(,3506,O
10,3506,O
microg/kg,3506,O
per,3506,O
day,3506,O
",",3506,O
s.c.,3506,O
),3506,O
or,3506,O
saline,3506,O
was,3506,O
started,3506,O
after,3506,O
4,3506,O
days,3506,O
in,3506,O
Ato-treated,3506,B-Chemical
and,3506,O
non-treated,3506,O
rats,3506,O
and,3506,O
continued,3506,O
for,3506,O
11-13,3506,O
days,3506,O
.,3506,O
Systolic,3507,O
blood,3507,O
pressure,3507,O
(,3507,O
SBP,3507,O
),3507,O
was,3507,O
measured,3507,O
on,3507,O
alternate,3507,O
days,3507,O
using,3507,O
the,3507,O
tail-cuff,3507,O
method,3507,O
.,3507,O
Endothelial,3508,O
function,3508,O
was,3508,O
assessed,3508,O
by,3508,O
acetylcholine-induced,3508,B-Chemical
vasorelaxation,3508,O
and,3508,O
phenylephrine-induced,3508,B-Chemical
vasoconstriction,3508,O
in,3508,O
aortic,3508,O
segments,3508,O
.,3508,O
Vascular,3509,O
eNOS,3509,O
mRNA,3509,O
was,3509,O
assessed,3509,O
by,3509,O
semi-quantitative,3509,O
reverse,3509,O
transcription-polymerase,3509,O
chain,3509,O
reaction,3509,O
.,3509,O
3,3510,O
.,3510,O
In,3511,O
rats,3511,O
treated,3511,O
with,3511,O
Dex,3511,B-Chemical
alone,3511,O
",",3511,O
SBP,3511,O
was,3511,O
increased,3511,O
from,3511,O
109,3511,O
+/-,3511,O
2,3511,O
to,3511,O
133,3511,O
+/-,3511,O
2,3511,O
mmHg,3511,O
on,3511,O
Days,3511,O
4,3511,O
and,3511,O
Day,3511,O
14,3511,O
",",3511,O
respectively,3511,O
(,3511,O
P,3511,O
<,3511,O
0.001,3511,O
),3511,O
.,3511,O
In,3512,O
the,3512,O
Ato,3512,B-Chemical
+,3512,O
Dex,3512,B-Chemical
group,3512,O
",",3512,O
SBP,3512,O
was,3512,O
increased,3512,O
from,3512,O
113,3512,O
+/-,3512,O
2,3512,O
to,3512,O
119,3512,O
+/-,3512,O
2,3512,O
mmHg,3512,O
on,3512,O
Days,3512,O
4,3512,O
to,3512,O
14,3512,O
",",3512,O
respectively,3512,O
(,3512,O
P,3512,O
<,3512,O
0.001,3512,O
),3512,O
",",3512,O
but,3512,O
was,3512,O
significantly,3512,O
lower,3512,O
than,3512,O
SBP,3512,O
in,3512,O
the,3512,O
group,3512,O
treated,3512,O
with,3512,O
Dex,3512,B-Chemical
alone,3512,O
(,3512,O
P,3512,O
<,3512,O
0.05,3512,O
),3512,O
.,3512,O
Endothelial-dependent,3513,O
relaxation,3513,O
and,3513,O
eNOS,3513,O
mRNA,3513,O
expression,3513,O
were,3513,O
greater,3513,O
in,3513,O
the,3513,O
Dex,3513,B-Chemical
+,3513,O
Ato,3513,B-Chemical
group,3513,O
than,3513,O
in,3513,O
the,3513,O
Dex,3513,B-Chemical
only,3513,O
group,3513,O
(,3513,O
P,3513,O
<,3513,O
0.05,3513,O
and,3513,O
P,3513,O
<,3513,O
0.0001,3513,O
",",3513,O
respectively,3513,O
),3513,O
.,3513,O
Aortic,3514,O
superoxide,3514,B-Chemical
production,3514,O
was,3514,O
lower,3514,O
in,3514,O
the,3514,O
Dex,3514,B-Chemical
+,3514,O
Ato,3514,B-Chemical
group,3514,O
compared,3514,O
with,3514,O
the,3514,O
group,3514,O
treated,3514,O
with,3514,O
Dex,3514,B-Chemical
alone,3514,O
(,3514,O
P,3514,O
<,3514,O
0.0001,3514,O
),3514,O
.,3514,O
4,3515,O
.,3515,O
Treatment,3516,O
with,3516,O
Ato,3516,B-Chemical
improved,3516,O
endothelial,3516,O
function,3516,O
",",3516,O
reduced,3516,O
superoxide,3516,B-Chemical
production,3516,O
and,3516,O
reduced,3516,O
SBP,3516,O
in,3516,O
Dex-treated,3516,B-Chemical
SD,3516,O
rats,3516,O
.,3516,O
Severe,3517,O
citrate,3517,B-Chemical
toxicity,3517,B-Disease
complicating,3517,O
volunteer,3517,O
apheresis,3517,O
platelet,3517,O
donation,3517,O
.,3517,O
We,3518,O
report,3518,O
a,3518,O
case,3518,O
of,3518,O
severe,3518,O
citrate,3518,B-Chemical
toxicity,3518,B-Disease
during,3518,O
volunteer,3518,O
donor,3518,O
apheresis,3518,O
platelet,3518,O
collection,3518,O
.,3518,O
The,3519,O
donor,3519,O
was,3519,O
a,3519,O
40-year-old,3519,O
female,3519,O
",",3519,O
first-time,3519,O
apheresis,3519,O
platelet,3519,O
donor,3519,O
.,3519,O
Past,3520,O
medical,3520,O
history,3520,O
was,3520,O
remarkable,3520,O
for,3520,O
hypertension,3520,B-Disease
",",3520,O
hyperlipidemia,3520,B-Disease
",",3520,O
and,3520,O
depression,3520,B-Disease
.,3520,O
Reported,3521,O
medications,3521,O
included,3521,O
bumetanide,3521,B-Chemical
",",3521,O
pravastatin,3521,B-Chemical
",",3521,O
and,3521,O
paroxetine,3521,B-Chemical
.,3521,O
Thirty,3522,O
minutes,3522,O
from,3522,O
the,3522,O
start,3522,O
of,3522,O
the,3522,O
procedure,3522,O
",",3522,O
the,3522,O
donor,3522,O
noted,3522,O
tingling,3522,O
around,3522,O
the,3522,O
mouth,3522,O
",",3522,O
hands,3522,O
",",3522,O
and,3522,O
feet,3522,O
.,3522,O
She,3523,O
then,3523,O
very,3523,O
rapidly,3523,O
developed,3523,O
acute,3523,O
onset,3523,O
of,3523,O
severe,3523,O
facial,3523,O
and,3523,O
extremity,3523,O
tetany,3523,B-Disease
.,3523,O
Empirical,3524,O
treatment,3524,O
with,3524,O
intravenous,3524,O
calcium,3524,B-Chemical
gluconate,3524,I-Chemical
was,3524,O
initiated,3524,O
",",3524,O
and,3524,O
muscle,3524,B-Disease
contractions,3524,I-Disease
slowly,3524,O
subsided,3524,O
over,3524,O
approximately,3524,O
10,3524,O
to,3524,O
15,3524,O
minutes,3524,O
.,3524,O
The,3525,O
events,3525,O
are,3525,O
consistent,3525,O
with,3525,O
a,3525,O
severe,3525,O
reaction,3525,O
to,3525,O
calcium,3525,B-Chemical
chelation,3525,O
by,3525,O
sodium,3525,B-Chemical
citrate,3525,I-Chemical
anticoagulant,3525,O
resulting,3525,O
in,3525,O
symptomatic,3525,O
systemic,3525,O
hypocalcemia,3525,B-Disease
.,3525,O
Upon,3526,O
additional,3526,O
retrospective,3526,O
analysis,3526,O
",",3526,O
it,3526,O
was,3526,O
noted,3526,O
that,3526,O
bumetanide,3526,B-Chemical
is,3526,O
a,3526,O
loop,3526,B-Chemical
diuretic,3526,I-Chemical
that,3526,O
may,3526,O
cause,3526,O
significant,3526,O
hypocalcemia,3526,B-Disease
.,3526,O
We,3527,O
conclude,3527,O
that,3527,O
careful,3527,O
screening,3527,O
for,3527,O
medications,3527,O
and,3527,O
underlying,3527,O
conditions,3527,O
predisposing,3527,O
to,3527,O
hypocalcemia,3527,B-Disease
is,3527,O
recommended,3527,O
to,3527,O
help,3527,O
prevent,3527,O
severe,3527,O
reactions,3527,O
due,3527,O
to,3527,O
citrate,3527,B-Chemical
toxicity,3527,B-Disease
.,3527,O
Laboratory,3528,O
measurement,3528,O
of,3528,O
pre-procedure,3528,O
serum,3528,O
calcium,3528,B-Chemical
levels,3528,O
in,3528,O
selected,3528,O
donors,3528,O
may,3528,O
identify,3528,O
cases,3528,O
requiring,3528,O
heightened,3528,O
vigilance,3528,O
.,3528,O
The,3529,O
case,3529,O
also,3529,O
illustrates,3529,O
the,3529,O
importance,3529,O
of,3529,O
maintaining,3529,O
preparedness,3529,O
for,3529,O
managing,3529,O
rare,3529,O
but,3529,O
serious,3529,O
reactions,3529,O
in,3529,O
volunteer,3529,O
apheresis,3529,O
blood,3529,O
donors,3529,O
.,3529,O
Sirolimus-associated,3530,B-Chemical
proteinuria,3530,B-Disease
and,3530,O
renal,3530,B-Disease
dysfunction,3530,I-Disease
.,3530,O
Sirolimus,3531,B-Chemical
is,3531,O
a,3531,O
novel,3531,O
immunosuppressant,3531,O
with,3531,O
potent,3531,O
antiproliferative,3531,O
actions,3531,O
through,3531,O
its,3531,O
ability,3531,O
to,3531,O
inhibit,3531,O
the,3531,O
raptor-containing,3531,O
mammalian,3531,O
target,3531,O
of,3531,O
rapamycin,3531,B-Chemical
protein,3531,O
kinase,3531,O
.,3531,O
Sirolimus,3532,B-Chemical
represents,3532,O
a,3532,O
major,3532,O
therapeutic,3532,O
advance,3532,O
in,3532,O
the,3532,O
prevention,3532,O
of,3532,O
acute,3532,O
renal,3532,O
allograft,3532,O
rejection,3532,O
and,3532,O
chronic,3532,O
allograft,3532,O
nephropathy,3532,B-Disease
.,3532,O
Its,3533,O
role,3533,O
in,3533,O
the,3533,O
therapy,3533,O
of,3533,O
glomerulonephritis,3533,B-Disease
",",3533,O
autoimmunity,3533,B-Disease
",",3533,O
cystic,3533,B-Disease
renal,3533,I-Disease
diseases,3533,I-Disease
and,3533,O
renal,3533,B-Disease
cancer,3533,I-Disease
is,3533,O
under,3533,O
investigation,3533,O
.,3533,O
Because,3534,O
sirolimus,3534,B-Chemical
does,3534,O
not,3534,O
share,3534,O
the,3534,O
vasomotor,3534,O
renal,3534,O
adverse,3534,O
effects,3534,O
exhibited,3534,O
by,3534,O
calcineurin,3534,O
inhibitors,3534,O
",",3534,O
it,3534,O
has,3534,O
been,3534,O
designated,3534,O
a,3534,O
'non-nephrotoxic,3534,O
drug,3534,O
',3534,O
.,3534,O
However,3535,O
",",3535,O
clinical,3535,O
reports,3535,O
suggest,3535,O
that,3535,O
",",3535,O
under,3535,O
some,3535,O
circumstances,3535,O
",",3535,O
sirolimus,3535,B-Chemical
is,3535,O
associated,3535,O
with,3535,O
proteinuria,3535,B-Disease
and,3535,O
acute,3535,B-Disease
renal,3535,I-Disease
dysfunction,3535,I-Disease
.,3535,O
A,3536,O
common,3536,O
risk,3536,O
factor,3536,O
appears,3536,O
to,3536,O
be,3536,O
presence,3536,O
of,3536,O
pre-existing,3536,O
chronic,3536,B-Disease
renal,3536,I-Disease
damage,3536,I-Disease
.,3536,O
The,3537,O
mechanisms,3537,O
of,3537,O
sirolimus-associated,3537,B-Chemical
proteinuria,3537,B-Disease
are,3537,O
multifactorial,3537,O
and,3537,O
may,3537,O
be,3537,O
due,3537,O
to,3537,O
an,3537,O
increase,3537,O
in,3537,O
glomerular,3537,O
capillary,3537,O
pressure,3537,O
following,3537,O
calcineurin,3537,O
inhibitor,3537,O
withdrawal,3537,O
.,3537,O
It,3538,O
has,3538,O
also,3538,O
been,3538,O
suggested,3538,O
that,3538,O
sirolimus,3538,B-Chemical
directly,3538,O
causes,3538,O
increased,3538,O
glomerular,3538,O
permeability/injury,3538,O
",",3538,O
but,3538,O
evidence,3538,O
for,3538,O
this,3538,O
mechanism,3538,O
is,3538,O
currently,3538,O
inconclusive,3538,O
.,3538,O
The,3539,O
acute,3539,B-Disease
renal,3539,I-Disease
dysfunction,3539,I-Disease
associated,3539,O
with,3539,O
sirolimus,3539,B-Chemical
(,3539,O
such,3539,O
as,3539,O
in,3539,O
delayed,3539,O
graft,3539,O
function,3539,O
),3539,O
may,3539,O
be,3539,O
due,3539,O
to,3539,O
suppression,3539,O
of,3539,O
compensatory,3539,O
renal,3539,O
cell,3539,O
proliferation,3539,O
and,3539,O
survival/repair,3539,O
processes,3539,O
.,3539,O
Although,3540,O
these,3540,O
adverse,3540,O
effects,3540,O
occur,3540,O
in,3540,O
some,3540,O
patients,3540,O
",",3540,O
their,3540,O
occurrence,3540,O
could,3540,O
be,3540,O
minimised,3540,O
by,3540,O
knowledge,3540,O
of,3540,O
the,3540,O
molecular,3540,O
effects,3540,O
of,3540,O
sirolimus,3540,B-Chemical
on,3540,O
the,3540,O
kidney,3540,O
",",3540,O
the,3540,O
use,3540,O
of,3540,O
sirolimus,3540,B-Chemical
in,3540,O
appropriate,3540,O
patient,3540,O
populations,3540,O
",",3540,O
close,3540,O
monitoring,3540,O
of,3540,O
proteinuria,3540,B-Disease
and,3540,O
renal,3540,O
function,3540,O
",",3540,O
use,3540,O
of,3540,O
angiotensin-converting,3540,B-Chemical
enzyme,3540,O
inhibitors,3540,O
or,3540,O
angiotensin,3540,B-Chemical
II,3540,I-Chemical
receptor,3540,O
blockers,3540,O
if,3540,O
proteinuria,3540,B-Disease
occurs,3540,O
and,3540,O
withdrawal,3540,O
if,3540,O
needed,3540,O
.,3540,O
Further,3541,O
long-term,3541,O
analysis,3541,O
of,3541,O
renal,3541,O
allograft,3541,O
studies,3541,O
using,3541,O
sirolimus,3541,B-Chemical
as,3541,O
de,3541,O
novo,3541,O
immunosuppression,3541,O
along,3541,O
with,3541,O
clinical,3541,O
and,3541,O
laboratory,3541,O
studies,3541,O
will,3541,O
refine,3541,O
these,3541,O
issues,3541,O
in,3541,O
the,3541,O
future,3541,O
.,3541,O
Proteinuria,3542,B-Disease
after,3542,O
conversion,3542,O
to,3542,O
sirolimus,3542,B-Chemical
in,3542,O
renal,3542,O
transplant,3542,O
recipients,3542,O
.,3542,O
Sirolimus,3543,B-Chemical
(,3543,O
SRL,3543,B-Chemical
),3543,O
is,3543,O
a,3543,O
new,3543,O
",",3543,O
potent,3543,O
immunosuppressive,3543,O
agent,3543,O
.,3543,O
More,3544,O
recently,3544,O
",",3544,O
proteinuria,3544,B-Disease
has,3544,O
been,3544,O
reported,3544,O
as,3544,O
a,3544,O
consequence,3544,O
of,3544,O
sirolimus,3544,B-Chemical
therapy,3544,O
",",3544,O
although,3544,O
the,3544,O
mechanism,3544,O
has,3544,O
remained,3544,O
unclear,3544,O
.,3544,O
We,3545,O
retrospectively,3545,O
examined,3545,O
the,3545,O
records,3545,O
of,3545,O
25,3545,O
renal,3545,O
transplant,3545,O
patients,3545,O
",",3545,O
who,3545,O
developed,3545,O
or,3545,O
displayed,3545,O
increased,3545,O
proteinuria,3545,B-Disease
after,3545,O
SRL,3545,B-Chemical
conversion,3545,O
.,3545,O
The,3546,O
patient,3546,O
cohort,3546,O
(,3546,O
14,3546,O
men,3546,O
",",3546,O
11,3546,O
women,3546,O
),3546,O
was,3546,O
treated,3546,O
with,3546,O
SRL,3546,B-Chemical
as,3546,O
conversion,3546,O
therapy,3546,O
",",3546,O
due,3546,O
to,3546,O
chronic,3546,B-Disease
allograft,3546,I-Disease
nephropathy,3546,I-Disease
(,3546,O
CAN,3546,B-Disease
),3546,O
(,3546,O
n,3546,O
=,3546,O
15,3546,O
),3546,O
neoplasia,3546,B-Disease
(,3546,O
n,3546,O
=,3546,O
8,3546,O
),3546,O
;,3546,O
Kaposi,3546,B-Disease
's,3546,I-Disease
sarcoma,3546,I-Disease
",",3546,O
Four,3546,O
skin,3546,B-Disease
cancers,3546,I-Disease
",",3546,O
One,3546,O
intestinal,3546,B-Disease
tumors,3546,I-Disease
",",3546,O
One,3546,O
renal,3546,B-Disease
cell,3546,I-Disease
carsinom,3546,I-Disease
),3546,O
or,3546,O
BK,3546,O
virus,3546,O
nephropathy,3546,B-Disease
(,3546,O
n,3546,O
=,3546,O
2,3546,O
),3546,O
.,3546,O
SRL,3547,B-Chemical
was,3547,O
started,3547,O
at,3547,O
a,3547,O
mean,3547,O
of,3547,O
78,3547,O
+/-,3547,O
42,3547,O
(,3547,O
15,3547,O
to,3547,O
163,3547,O
),3547,O
months,3547,O
after,3547,O
transplantation,3547,O
.,3547,O
Mean,3548,O
follow-up,3548,O
on,3548,O
SRL,3548,B-Chemical
therapy,3548,O
was,3548,O
20,3548,O
+/-,3548,O
12,3548,O
(,3548,O
6,3548,O
to,3548,O
43,3548,O
),3548,O
months,3548,O
.,3548,O
Proteinuria,3549,B-Disease
increased,3549,O
from,3549,O
0.445,3549,O
(,3549,O
0,3549,O
to,3549,O
1.5,3549,O
),3549,O
g/d,3549,O
before,3549,O
conversion,3549,O
to,3549,O
3.2,3549,O
g/dL,3549,O
(,3549,O
0.2,3549,O
to,3549,O
12,3549,O
),3549,O
after,3549,O
conversion,3549,O
(,3549,O
P,3549,O
=,3549,O
0.001,3549,O
),3549,O
.,3549,O
Before,3550,O
conversion,3550,O
8,3550,O
(,3550,O
32,3550,O
%,3550,O
),3550,O
patients,3550,O
had,3550,O
no,3550,O
proteinuria,3550,B-Disease
",",3550,O
whereas,3550,O
afterwards,3550,O
all,3550,O
patients,3550,O
had,3550,O
proteinuria,3550,B-Disease
.,3550,O
In,3551,O
28,3551,O
%,3551,O
of,3551,O
patients,3551,O
proteinuria,3551,B-Disease
remained,3551,O
unchanged,3551,O
",",3551,O
whereas,3551,O
it,3551,O
increased,3551,O
in,3551,O
68,3551,O
%,3551,O
of,3551,O
patients,3551,O
.,3551,O
In,3552,O
40,3552,O
%,3552,O
it,3552,O
increased,3552,O
by,3552,O
more,3552,O
than,3552,O
100,3552,O
%,3552,O
.,3552,O
Twenty-eight,3553,O
percent,3553,O
of,3553,O
patients,3553,O
showed,3553,O
increased,3553,O
proteinuria,3553,B-Disease
to,3553,O
the,3553,O
nephrotic,3553,B-Disease
range,3553,O
.,3553,O
Biopsies,3554,O
performed,3554,O
in,3554,O
five,3554,O
patients,3554,O
revealed,3554,O
new,3554,O
pathological,3554,O
changes,3554,O
:,3554,O
One,3554,O
membranoproliferative,3554,B-Disease
glomerulopathy,3554,I-Disease
and,3554,O
interstitial,3554,B-Disease
nephritis,3554,I-Disease
.,3554,O
These,3555,O
patients,3555,O
showed,3555,O
persistently,3555,O
good,3555,O
graft,3555,O
function,3555,O
.,3555,O
Serum,3556,O
creatinine,3556,B-Chemical
values,3556,O
did,3556,O
not,3556,O
change,3556,O
significantly,3556,O
:,3556,O
1.98,3556,O
+/-,3556,O
0.8,3556,O
mg/dL,3556,O
before,3556,O
SRL,3556,B-Chemical
therapy,3556,O
and,3556,O
2.53,3556,O
+/-,3556,O
1.9,3556,O
mg/dL,3556,O
at,3556,O
last,3556,O
follow-up,3556,O
(,3556,O
P,3556,O
=,3556,O
.14,3556,O
),3556,O
.,3556,O
Five,3557,O
grafts,3557,O
were,3557,O
lost,3557,O
and,3557,O
the,3557,O
patients,3557,O
returned,3557,O
to,3557,O
dialysis,3557,O
.,3557,O
Five,3558,O
patients,3558,O
displayed,3558,O
CAN,3558,B-Disease
and,3558,O
Kaposi,3558,B-Disease
's,3558,I-Disease
sarcoma,3558,I-Disease
.,3558,O
Mean,3559,O
urinary,3559,O
protein,3559,O
of,3559,O
patients,3559,O
who,3559,O
returned,3559,O
to,3559,O
dialysis,3559,O
was,3559,O
1.26,3559,O
(,3559,O
0.5,3559,O
to,3559,O
3.5,3559,O
),3559,O
g/d,3559,O
before,3559,O
and,3559,O
4.7,3559,O
(,3559,O
3,3559,O
to,3559,O
12,3559,O
),3559,O
g/d,3559,O
after,3559,O
conversion,3559,O
(,3559,O
P,3559,O
=,3559,O
.01,3559,O
),3559,O
.,3559,O
Mean,3560,O
serum,3560,O
creatinine,3560,B-Chemical
level,3560,O
before,3560,O
conversion,3560,O
was,3560,O
2.21,3560,O
mg/dL,3560,O
and,3560,O
thereafter,3560,O
",",3560,O
4.93,3560,O
mg/dL,3560,O
(,3560,O
P,3560,O
=,3560,O
.02,3560,O
),3560,O
.,3560,O
Heavy,3561,O
proteinuria,3561,B-Disease
was,3561,O
common,3561,O
after,3561,O
the,3561,O
use,3561,O
of,3561,O
SRL,3561,B-Chemical
as,3561,O
rescue,3561,O
therapy,3561,O
for,3561,O
renal,3561,O
transplantation,3561,O
.,3561,O
Therefore,3562,O
",",3562,O
conversion,3562,O
should,3562,O
be,3562,O
considered,3562,O
for,3562,O
patients,3562,O
who,3562,O
have,3562,O
not,3562,O
developed,3562,O
advanced,3562,O
CAN,3562,B-Disease
and,3562,O
proteinuria,3562,B-Disease
.,3562,O
The,3563,O
possibility,3563,O
of,3563,O
de,3563,O
novo,3563,O
glomerular,3563,O
pathology,3563,O
under,3563,O
SRL,3563,B-Chemical
treatment,3563,O
requires,3563,O
further,3563,O
investigation,3563,O
by,3563,O
renal,3563,O
biopsy,3563,O
.,3563,O
Progressive,3564,O
myopathy,3564,B-Disease
with,3564,O
up-regulation,3564,O
of,3564,O
MHC-I,3564,O
associated,3564,O
with,3564,O
statin,3564,B-Chemical
therapy,3564,O
.,3564,O
Statins,3565,B-Chemical
can,3565,O
cause,3565,O
a,3565,O
necrotizing,3565,O
myopathy,3565,B-Disease
and,3565,O
hyperCKaemia,3565,B-Disease
which,3565,O
is,3565,O
reversible,3565,O
on,3565,O
cessation,3565,O
of,3565,O
the,3565,O
drug,3565,O
.,3565,O
What,3566,O
is,3566,O
less,3566,O
well,3566,O
known,3566,O
is,3566,O
a,3566,O
phenomenon,3566,O
whereby,3566,O
statins,3566,B-Chemical
may,3566,O
induce,3566,O
a,3566,O
myopathy,3566,B-Disease
",",3566,O
which,3566,O
persists,3566,O
or,3566,O
may,3566,O
progress,3566,O
after,3566,O
stopping,3566,O
the,3566,O
drug,3566,O
.,3566,O
We,3567,O
investigated,3567,O
the,3567,O
muscle,3567,O
pathology,3567,O
in,3567,O
8,3567,O
such,3567,O
cases,3567,O
.,3567,O
All,3568,O
had,3568,O
myofibre,3568,O
necrosis,3568,B-Disease
but,3568,O
only,3568,O
3,3568,O
had,3568,O
an,3568,O
inflammatory,3568,O
infiltrate,3568,O
.,3568,O
In,3569,O
all,3569,O
cases,3569,O
there,3569,O
was,3569,O
diffuse,3569,O
or,3569,O
multifocal,3569,O
up-regulation,3569,O
of,3569,O
MHC-I,3569,O
expression,3569,O
even,3569,O
in,3569,O
non-necrotic,3569,O
fibres,3569,O
.,3569,O
Progressive,3570,O
improvement,3570,O
occurred,3570,O
in,3570,O
7,3570,O
cases,3570,O
after,3570,O
commencement,3570,O
of,3570,O
prednisolone,3570,B-Chemical
and,3570,O
methotrexate,3570,B-Chemical
",",3570,O
and,3570,O
in,3570,O
one,3570,O
case,3570,O
spontaneously,3570,O
.,3570,O
These,3571,O
observations,3571,O
suggest,3571,O
that,3571,O
statins,3571,B-Chemical
may,3571,O
initiate,3571,O
an,3571,O
immune-mediated,3571,O
myopathy,3571,B-Disease
that,3571,O
persists,3571,O
after,3571,O
withdrawal,3571,O
of,3571,O
the,3571,O
drug,3571,O
and,3571,O
responds,3571,O
to,3571,O
immunosuppressive,3571,O
therapy,3571,O
.,3571,O
The,3572,O
mechanism,3572,O
of,3572,O
this,3572,O
myopathy,3572,B-Disease
is,3572,O
uncertain,3572,O
but,3572,O
may,3572,O
involve,3572,O
the,3572,O
induction,3572,O
by,3572,O
statins,3572,B-Chemical
of,3572,O
an,3572,O
endoplasmic,3572,O
reticulum,3572,O
stress,3572,O
response,3572,O
with,3572,O
associated,3572,O
up-regulation,3572,O
of,3572,O
MHC-I,3572,O
expression,3572,O
and,3572,O
antigen,3572,O
presentation,3572,O
by,3572,O
muscle,3572,O
fibres,3572,O
.,3572,O
Use,3573,O
of,3573,O
chromosome,3573,O
substitution,3573,O
strains,3573,O
to,3573,O
identify,3573,O
seizure,3573,B-Disease
susceptibility,3573,O
loci,3573,O
in,3573,O
mice,3573,O
.,3573,O
Seizure,3574,B-Disease
susceptibility,3574,O
varies,3574,O
among,3574,O
inbred,3574,O
mouse,3574,O
strains,3574,O
.,3574,O
Chromosome,3575,O
substitution,3575,O
strains,3575,O
(,3575,O
CSS,3575,O
),3575,O
",",3575,O
in,3575,O
which,3575,O
a,3575,O
single,3575,O
chromosome,3575,O
from,3575,O
one,3575,O
inbred,3575,O
strain,3575,O
(,3575,O
donor,3575,O
),3575,O
has,3575,O
been,3575,O
transferred,3575,O
onto,3575,O
a,3575,O
second,3575,O
strain,3575,O
(,3575,O
host,3575,O
),3575,O
by,3575,O
repeated,3575,O
backcrossing,3575,O
",",3575,O
may,3575,O
be,3575,O
used,3575,O
to,3575,O
identify,3575,O
quantitative,3575,O
trait,3575,O
loci,3575,O
(,3575,O
QTLs,3575,O
),3575,O
that,3575,O
contribute,3575,O
to,3575,O
seizure,3575,B-Disease
susceptibility,3575,O
.,3575,O
QTLs,3576,O
for,3576,O
susceptibility,3576,O
to,3576,O
pilocarpine-induced,3576,B-Chemical
seizures,3576,B-Disease
",",3576,O
a,3576,O
model,3576,O
of,3576,O
temporal,3576,B-Disease
lobe,3576,I-Disease
epilepsy,3576,I-Disease
",",3576,O
have,3576,O
not,3576,O
been,3576,O
reported,3576,O
",",3576,O
and,3576,O
CSS,3576,O
have,3576,O
not,3576,O
previously,3576,O
been,3576,O
used,3576,O
to,3576,O
localize,3576,O
seizure,3576,B-Disease
susceptibility,3576,O
genes,3576,O
.,3576,O
We,3577,O
report,3577,O
QTLs,3577,O
identified,3577,O
using,3577,O
a,3577,O
B6,3577,O
(,3577,O
host,3577,O
),3577,O
x,3577,O
A/J,3577,O
(,3577,O
donor,3577,O
),3577,O
CSS,3577,O
panel,3577,O
to,3577,O
localize,3577,O
genes,3577,O
involved,3577,O
in,3577,O
susceptibility,3577,O
to,3577,O
pilocarpine-induced,3577,B-Chemical
seizures,3577,B-Disease
.,3577,O
Three,3578,O
hundred,3578,O
fifty-five,3578,O
adult,3578,O
male,3578,O
CSS,3578,O
mice,3578,O
",",3578,O
58,3578,O
B6,3578,O
",",3578,O
and,3578,O
39,3578,O
A/J,3578,O
were,3578,O
tested,3578,O
for,3578,O
susceptibility,3578,O
to,3578,O
pilocarpine-induced,3578,B-Chemical
seizures,3578,B-Disease
.,3578,O
Highest,3579,O
stage,3579,O
reached,3579,O
and,3579,O
latency,3579,O
to,3579,O
each,3579,O
stage,3579,O
were,3579,O
recorded,3579,O
for,3579,O
all,3579,O
mice,3579,O
.,3579,O
B6,3580,O
mice,3580,O
were,3580,O
resistant,3580,O
to,3580,O
seizures,3580,B-Disease
and,3580,O
slower,3580,O
to,3580,O
reach,3580,O
stages,3580,O
compared,3580,O
to,3580,O
A/J,3580,O
mice,3580,O
.,3580,O
The,3581,O
CSS,3581,O
for,3581,O
Chromosomes,3581,O
10,3581,O
and,3581,O
18,3581,O
progressed,3581,O
to,3581,O
the,3581,O
most,3581,O
severe,3581,O
stages,3581,O
",",3581,O
diverging,3581,O
dramatically,3581,O
from,3581,O
the,3581,O
B6,3581,O
phenotype,3581,O
.,3581,O
Latencies,3582,O
to,3582,O
stages,3582,O
were,3582,O
also,3582,O
significantly,3582,O
shorter,3582,O
for,3582,O
CSS10,3582,O
and,3582,O
CSS18,3582,O
mice,3582,O
.,3582,O
CSS,3583,O
mapping,3583,O
suggests,3583,O
seizure,3583,B-Disease
susceptibility,3583,O
loci,3583,O
on,3583,O
mouse,3583,O
Chromosomes,3583,O
10,3583,O
and,3583,O
18,3583,O
.,3583,O
This,3584,O
approach,3584,O
provides,3584,O
a,3584,O
framework,3584,O
for,3584,O
identifying,3584,O
potentially,3584,O
novel,3584,O
homologous,3584,O
candidate,3584,O
genes,3584,O
for,3584,O
human,3584,O
temporal,3584,B-Disease
lobe,3584,I-Disease
epilepsy,3584,I-Disease
.,3584,O
In,3585,O
vitro,3585,O
characterization,3585,O
of,3585,O
parasympathetic,3585,O
and,3585,O
sympathetic,3585,O
responses,3585,O
in,3585,O
cyclophosphamide-induced,3585,B-Chemical
cystitis,3585,B-Disease
in,3585,O
the,3585,O
rat,3585,O
.,3585,O
In,3586,O
cyclophosphamide-induced,3586,B-Chemical
cystitis,3586,B-Disease
in,3586,O
the,3586,O
rat,3586,O
",",3586,O
detrusor,3586,O
function,3586,O
is,3586,O
impaired,3586,O
and,3586,O
the,3586,O
expression,3586,O
and,3586,O
effects,3586,O
of,3586,O
muscarinic,3586,O
receptors,3586,O
altered,3586,O
.,3586,O
Whether,3587,O
or,3587,O
not,3587,O
the,3587,O
neuronal,3587,O
transmission,3587,O
may,3587,O
be,3587,O
affected,3587,O
by,3587,O
cystitis,3587,B-Disease
was,3587,O
presently,3587,O
investigated,3587,O
.,3587,O
Responses,3588,O
of,3588,O
urinary,3588,O
strip,3588,O
preparations,3588,O
from,3588,O
control,3588,O
and,3588,O
cyclophosphamide-pretreated,3588,B-Chemical
rats,3588,O
to,3588,O
electrical,3588,O
field,3588,O
stimulation,3588,O
and,3588,O
to,3588,O
agonists,3588,O
were,3588,O
assessed,3588,O
in,3588,O
the,3588,O
absence,3588,O
and,3588,O
presence,3588,O
of,3588,O
muscarinic,3588,O
",",3588,O
adrenergic,3588,O
and,3588,O
purinergic,3588,O
receptor,3588,O
antagonists,3588,O
.,3588,O
Generally,3589,O
",",3589,O
atropine,3589,B-Chemical
reduced,3589,O
contractions,3589,O
",",3589,O
but,3589,O
in,3589,O
contrast,3589,O
to,3589,O
controls,3589,O
",",3589,O
it,3589,O
also,3589,O
reduced,3589,O
responses,3589,O
to,3589,O
low,3589,O
electrical,3589,O
field,3589,O
stimulation,3589,O
intensity,3589,O
(,3589,O
1-5,3589,O
Hz,3589,O
),3589,O
in,3589,O
inflamed,3589,O
preparations,3589,O
.,3589,O
In,3590,O
both,3590,O
types,3590,O
",",3590,O
purinoceptor,3590,O
desensitization,3590,O
with,3590,O
alpha,3590,B-Chemical
",",3590,I-Chemical
beta-methylene,3590,I-Chemical
adenosine-5'-triphosphate,3590,I-Chemical
(,3590,O
alpha,3590,B-Chemical
",",3590,I-Chemical
beta-meATP,3590,I-Chemical
),3590,O
caused,3590,O
further,3590,O
reductions,3590,O
at,3590,O
low,3590,O
frequencies,3590,O
(,3590,O
<,3590,O
10,3590,O
Hz,3590,O
),3590,O
.,3590,O
The,3591,O
muscarinic,3591,O
receptor,3591,O
antagonists,3591,O
atropine,3591,B-Chemical
",",3591,O
4-diphenylacetoxy-N-methylpiperidine,3591,B-Chemical
(,3591,O
4-DAMP,3591,B-Chemical
),3591,O
(,3591,O
'M,3591,O
(,3591,O
1,3591,O
),3591,O
/M,3591,O
(,3591,O
3,3591,O
),3591,O
/M,3591,O
(,3591,O
5,3591,O
),3591,O
-selective,3591,O
',3591,O
),3591,O
",",3591,O
methoctramine,3591,B-Chemical
(,3591,O
'M,3591,O
(,3591,O
2,3591,O
),3591,O
-selective,3591,O
',3591,O
),3591,O
and,3591,O
pirenzepine,3591,B-Chemical
(,3591,O
'M,3591,O
(,3591,O
1,3591,O
),3591,O
-selective,3591,O
',3591,O
),3591,O
antagonized,3591,O
the,3591,O
tonic,3591,O
component,3591,O
of,3591,O
the,3591,O
electrical,3591,O
field,3591,O
stimulation-evoked,3591,O
contractile,3591,O
response,3591,O
more,3591,O
potently,3591,O
than,3591,O
the,3591,O
phasic,3591,O
component,3591,O
.,3591,O
4-DAMP,3592,B-Chemical
inhibited,3592,O
the,3592,O
tonic,3592,O
contractions,3592,O
in,3592,O
controls,3592,O
more,3592,O
potently,3592,O
than,3592,O
methoctramine,3592,B-Chemical
and,3592,O
pirenzepine,3592,B-Chemical
.,3592,O
In,3593,O
inflamed,3593,O
preparations,3593,O
",",3593,O
the,3593,O
muscarinic,3593,O
receptor,3593,O
antagonism,3593,O
on,3593,O
the,3593,O
phasic,3593,O
component,3593,O
of,3593,O
the,3593,O
electrical,3593,O
field,3593,O
stimulation-evoked,3593,O
contraction,3593,O
was,3593,O
decreased,3593,O
and,3593,O
the,3593,O
pirenzepine,3593,B-Chemical
and,3593,O
4-DAMP,3593,B-Chemical
antagonism,3593,O
on,3593,O
the,3593,O
tonic,3593,O
component,3593,O
was,3593,O
much,3593,O
less,3593,O
efficient,3593,O
than,3593,O
in,3593,O
controls,3593,O
.,3593,O
In,3594,O
contrast,3594,O
to,3594,O
controls,3594,O
",",3594,O
methoctramine,3594,B-Chemical
increased,3594,O
--,3594,O
instead,3594,O
of,3594,O
decreased,3594,O
--,3594,O
the,3594,O
tonic,3594,O
responses,3594,O
at,3594,O
high,3594,O
frequencies,3594,O
.,3594,O
While,3595,O
contractions,3595,O
to,3595,O
carbachol,3595,B-Chemical
and,3595,O
ATP,3595,B-Chemical
were,3595,O
the,3595,O
same,3595,O
in,3595,O
inflamed,3595,O
and,3595,O
in,3595,O
control,3595,O
strips,3595,O
when,3595,O
related,3595,O
to,3595,O
a,3595,O
reference,3595,O
potassium,3595,B-Chemical
response,3595,O
",",3595,O
isoprenaline-induced,3595,B-Chemical
relaxations,3595,O
were,3595,O
smaller,3595,O
in,3595,O
inflamed,3595,O
strips,3595,O
.,3595,O
Thus,3596,O
",",3596,O
in,3596,O
cystitis,3596,B-Disease
substantial,3596,O
changes,3596,O
of,3596,O
the,3596,O
efferent,3596,O
functional,3596,O
responses,3596,O
occur,3596,O
.,3596,O
While,3597,O
postjunctional,3597,O
beta-adrenoceptor-mediated,3597,O
relaxations,3597,O
are,3597,O
reduced,3597,O
",",3597,O
effects,3597,O
by,3597,O
prejunctional,3597,O
inhibitory,3597,O
muscarinic,3597,O
receptors,3597,O
may,3597,O
be,3597,O
increased,3597,O
.,3597,O
Direct,3598,O
inhibition,3598,O
of,3598,O
cardiac,3598,O
hyperpolarization-activated,3598,O
cyclic,3598,B-Chemical
nucleotide-gated,3598,O
pacemaker,3598,O
channels,3598,O
by,3598,O
clonidine,3598,B-Chemical
.,3598,O
BACKGROUND,3599,O
:,3599,O
Inhibition,3599,O
of,3599,O
cardiac,3599,O
sympathetic,3599,O
tone,3599,O
represents,3599,O
an,3599,O
important,3599,O
strategy,3599,O
for,3599,O
treatment,3599,O
of,3599,O
cardiovascular,3599,B-Disease
disease,3599,I-Disease
",",3599,O
including,3599,O
arrhythmia,3599,B-Disease
",",3599,O
coronary,3599,B-Disease
heart,3599,I-Disease
disease,3599,I-Disease
",",3599,O
and,3599,O
chronic,3599,O
heart,3599,B-Disease
failure,3599,I-Disease
.,3599,O
Activation,3600,O
of,3600,O
presynaptic,3600,O
alpha2-adrenoceptors,3600,O
is,3600,O
the,3600,O
most,3600,O
widely,3600,O
accepted,3600,O
mechanism,3600,O
of,3600,O
action,3600,O
of,3600,O
the,3600,O
antisympathetic,3600,O
drug,3600,O
clonidine,3600,B-Chemical
;,3600,O
however,3600,O
",",3600,O
other,3600,O
target,3600,O
proteins,3600,O
have,3600,O
been,3600,O
postulated,3600,O
to,3600,O
contribute,3600,O
to,3600,O
the,3600,O
in,3600,O
vivo,3600,O
actions,3600,O
of,3600,O
clonidine,3600,B-Chemical
.,3600,O
METHODS,3601,O
AND,3601,O
RESULTS,3601,O
:,3601,O
To,3601,O
test,3601,O
whether,3601,O
clonidine,3601,B-Chemical
elicits,3601,O
pharmacological,3601,O
effects,3601,O
independent,3601,O
of,3601,O
alpha2-adrenoceptors,3601,O
",",3601,O
we,3601,O
have,3601,O
generated,3601,O
mice,3601,O
with,3601,O
a,3601,O
targeted,3601,O
deletion,3601,O
of,3601,O
all,3601,O
3,3601,O
alpha2-adrenoceptor,3601,O
subtypes,3601,O
(,3601,O
alpha2ABC-/-,3601,O
),3601,O
.,3601,O
Alpha2ABC-/-,3602,O
mice,3602,O
were,3602,O
completely,3602,O
unresponsive,3602,O
to,3602,O
the,3602,O
analgesic,3602,O
and,3602,O
hypnotic,3602,O
effects,3602,O
of,3602,O
clonidine,3602,B-Chemical
;,3602,O
however,3602,O
",",3602,O
clonidine,3602,B-Chemical
significantly,3602,O
lowered,3602,O
heart,3602,O
rate,3602,O
in,3602,O
alpha2ABC-/-,3602,O
mice,3602,O
by,3602,O
up,3602,O
to,3602,O
150,3602,O
bpm,3602,O
.,3602,O
Clonidine-induced,3603,B-Chemical
bradycardia,3603,B-Disease
in,3603,O
conscious,3603,O
alpha2ABC-/-,3603,O
mice,3603,O
was,3603,O
32.3,3603,O
%,3603,O
(,3603,O
10,3603,O
microg/kg,3603,O
),3603,O
and,3603,O
26.6,3603,O
%,3603,O
(,3603,O
100,3603,O
microg/kg,3603,O
),3603,O
of,3603,O
the,3603,O
effect,3603,O
in,3603,O
wild-type,3603,O
mice,3603,O
.,3603,O
A,3604,O
similar,3604,O
bradycardic,3604,O
effect,3604,O
of,3604,O
clonidine,3604,B-Chemical
was,3604,O
observed,3604,O
in,3604,O
isolated,3604,O
spontaneously,3604,O
beating,3604,O
right,3604,O
atria,3604,O
from,3604,O
alpha2ABC-knockout,3604,O
and,3604,O
wild-type,3604,O
mice,3604,O
.,3604,O
Clonidine,3605,B-Chemical
inhibited,3605,O
the,3605,O
native,3605,O
pacemaker,3605,O
current,3605,O
(,3605,O
I,3605,O
(,3605,O
f,3605,O
),3605,O
),3605,O
in,3605,O
isolated,3605,O
sinoatrial,3605,O
node,3605,O
pacemaker,3605,O
cells,3605,O
and,3605,O
the,3605,O
I,3605,O
(,3605,O
f,3605,O
),3605,O
-generating,3605,O
hyperpolarization-activated,3605,O
cyclic,3605,B-Chemical
nucleotide-gated,3605,O
(,3605,O
HCN,3605,O
),3605,O
2,3605,O
and,3605,O
HCN4,3605,O
channels,3605,O
in,3605,O
transfected,3605,O
HEK293,3605,O
cells,3605,O
.,3605,O
As,3606,O
a,3606,O
consequence,3606,O
of,3606,O
blocking,3606,O
I,3606,O
(,3606,O
f,3606,O
),3606,O
",",3606,O
clonidine,3606,B-Chemical
reduced,3606,O
the,3606,O
slope,3606,O
of,3606,O
the,3606,O
diastolic,3606,O
depolarization,3606,O
and,3606,O
the,3606,O
frequency,3606,O
of,3606,O
pacemaker,3606,O
potentials,3606,O
in,3606,O
sinoatrial,3606,O
node,3606,O
cells,3606,O
from,3606,O
wild-type,3606,O
and,3606,O
alpha2ABC-knockout,3606,O
mice,3606,O
.,3606,O
CONCLUSIONS,3607,O
:,3607,O
Direct,3607,O
inhibition,3607,O
of,3607,O
cardiac,3607,O
HCN,3607,O
pacemaker,3607,O
channels,3607,O
contributes,3607,O
to,3607,O
the,3607,O
bradycardic,3607,O
effects,3607,O
of,3607,O
clonidine,3607,B-Chemical
gene-targeted,3607,O
mice,3607,O
in,3607,O
vivo,3607,O
",",3607,O
and,3607,O
thus,3607,O
",",3607,O
clonidine-like,3607,B-Chemical
drugs,3607,O
represent,3607,O
novel,3607,O
structures,3607,O
for,3607,O
future,3607,O
HCN,3607,O
channel,3607,O
inhibitors,3607,O
.,3607,O
Influence,3608,O
of,3608,O
smoking,3608,B-Chemical
on,3608,O
developing,3608,O
cochlea,3608,O
.,3608,O
Does,3609,O
smoking,3609,B-Chemical
during,3609,O
pregnancy,3609,O
affect,3609,O
the,3609,O
amplitudes,3609,O
of,3609,O
transient,3609,O
evoked,3609,O
otoacoustic,3609,O
emissions,3609,O
in,3609,O
newborns,3609,O
?,3609,O
OBJECTIVE,3610,O
:,3610,O
Maternal,3610,O
tobacco,3610,O
smoking,3610,B-Chemical
has,3610,O
negative,3610,O
effects,3610,O
on,3610,O
fetal,3610,O
growth,3610,O
.,3610,O
The,3611,O
influence,3611,O
of,3611,O
smoking,3611,B-Chemical
during,3611,O
pregnancy,3611,O
on,3611,O
the,3611,O
developing,3611,O
cochlea,3611,O
has,3611,O
not,3611,O
been,3611,O
estimated,3611,O
",",3611,O
although,3611,O
smoking,3611,B-Chemical
has,3611,O
been,3611,O
positively,3611,O
associated,3611,O
with,3611,O
hearing,3611,B-Disease
loss,3611,I-Disease
in,3611,O
adults,3611,O
.,3611,O
The,3612,O
objective,3612,O
of,3612,O
this,3612,O
study,3612,O
was,3612,O
to,3612,O
determine,3612,O
the,3612,O
effects,3612,O
of,3612,O
maternal,3612,O
smoking,3612,B-Chemical
on,3612,O
transient,3612,O
evoked,3612,O
otoacoustic,3612,O
emissions,3612,O
(,3612,O
TEOAEs,3612,O
),3612,O
of,3612,O
healthy,3612,O
neonates,3612,O
.,3612,O
METHODS,3613,O
:,3613,O
This,3613,O
study,3613,O
was,3613,O
undertaken,3613,O
as,3613,O
part,3613,O
of,3613,O
neonatal,3613,O
screening,3613,O
for,3613,O
hearing,3613,B-Disease
impairment,3613,I-Disease
and,3613,O
involved,3613,O
both,3613,O
ears,3613,O
of,3613,O
200,3613,O
newborns,3613,O
.,3613,O
Newborns,3614,O
whose,3614,O
mothers,3614,O
reported,3614,O
smoking,3614,B-Chemical
during,3614,O
pregnancy,3614,O
(,3614,O
n=200,3614,O
ears,3614,O
),3614,O
were,3614,O
compared,3614,O
to,3614,O
a,3614,O
control,3614,O
group,3614,O
of,3614,O
newborns,3614,O
(,3614,O
n=200,3614,O
ears,3614,O
),3614,O
",",3614,O
whose,3614,O
mothers,3614,O
were,3614,O
non-smokers,3614,O
.,3614,O
Exposure,3615,O
to,3615,O
tobacco,3615,O
was,3615,O
characterized,3615,O
as,3615,O
low,3615,O
(,3615,O
<,3615,O
5,3615,O
cigarettes,3615,O
per,3615,O
day,3615,O
",",3615,O
n=88,3615,O
ears,3615,O
),3615,O
",",3615,O
moderate,3615,O
(,3615,O
5,3615,O
<,3615,O
or,3615,O
=cigarettes,3615,O
per,3615,O
day,3615,O
<,3615,O
10,3615,O
",",3615,O
n=76,3615,O
),3615,O
or,3615,O
high,3615,O
(,3615,O
>,3615,O
or,3615,O
=10,3615,O
cigarettes,3615,O
per,3615,O
day,3615,O
",",3615,O
n=36,3615,O
),3615,O
.,3615,O
RESULTS,3616,O
:,3616,O
In,3616,O
exposed,3616,O
neonates,3616,O
",",3616,O
TEOAEs,3616,O
mean,3616,O
response,3616,O
(,3616,O
across,3616,O
frequency,3616,O
),3616,O
and,3616,O
mean,3616,O
amplitude,3616,O
at,3616,O
4000Hz,3616,O
was,3616,O
significantly,3616,O
lower,3616,O
than,3616,O
in,3616,O
non-exposed,3616,O
neonates,3616,O
.,3616,O
Comparisons,3617,O
between,3617,O
exposed,3617,O
newborns,3617,O
',3617,O
subgroups,3617,O
revealed,3617,O
no,3617,O
significant,3617,O
differences,3617,O
.,3617,O
However,3618,O
",",3618,O
by,3618,O
comparing,3618,O
each,3618,O
subgroup,3618,O
to,3618,O
control,3618,O
group,3618,O
",",3618,O
we,3618,O
found,3618,O
statistically,3618,O
significant,3618,O
decreases,3618,B-Disease
of,3618,I-Disease
TEOAEs,3618,I-Disease
amplitudes,3618,I-Disease
at,3618,O
4000Hz,3618,O
for,3618,O
all,3618,O
three,3618,O
groups,3618,O
.,3618,O
Mean,3619,O
TEOAEs,3619,O
responses,3619,O
of,3619,O
highly,3619,O
exposed,3619,O
newborns,3619,O
were,3619,O
also,3619,O
significantly,3619,O
lower,3619,O
in,3619,O
comparison,3619,O
to,3619,O
our,3619,O
control,3619,O
group,3619,O
.,3619,O
CONCLUSION,3620,O
:,3620,O
In,3620,O
utero,3620,O
",",3620,O
exposure,3620,O
to,3620,O
tobacco,3620,O
smoking,3620,B-Chemical
seems,3620,O
to,3620,O
have,3620,O
a,3620,O
small,3620,O
impact,3620,O
on,3620,O
outer,3620,O
hair,3620,O
cells,3620,O
.,3620,O
These,3621,O
effects,3621,O
seem,3621,O
to,3621,O
be,3621,O
equally,3621,O
true,3621,O
for,3621,O
all,3621,O
exposed,3621,O
newborns,3621,O
",",3621,O
regardless,3621,O
of,3621,O
the,3621,O
degree,3621,O
of,3621,O
exposure,3621,O
.,3621,O
Further,3622,O
studies,3622,O
are,3622,O
needed,3622,O
in,3622,O
order,3622,O
to,3622,O
establish,3622,O
a,3622,O
potential,3622,O
negative,3622,O
effect,3622,O
of,3622,O
maternal,3622,O
smoking,3622,B-Chemical
on,3622,O
the,3622,O
neonate,3622,O
's,3622,O
hearing,3622,O
acuity,3622,O
.,3622,O
Simvastatin-induced,3623,B-Chemical
bilateral,3623,O
leg,3623,O
compartment,3623,B-Disease
syndrome,3623,I-Disease
and,3623,O
myonecrosis,3623,B-Disease
associated,3623,O
with,3623,O
hypothyroidism,3623,B-Disease
.,3623,O
A,3624,O
54-year-old,3624,O
hypothyroid,3624,B-Disease
male,3624,O
taking,3624,O
thyroxine,3624,B-Chemical
and,3624,O
simvastatin,3624,B-Chemical
presented,3624,O
with,3624,O
bilateral,3624,O
leg,3624,O
compartment,3624,B-Disease
syndrome,3624,I-Disease
and,3624,O
myonecrosis,3624,B-Disease
.,3624,O
Urgent,3625,O
fasciotomies,3625,O
were,3625,O
performed,3625,O
and,3625,O
the,3625,O
patient,3625,O
made,3625,O
an,3625,O
uneventful,3625,O
recovery,3625,O
with,3625,O
the,3625,O
withdrawal,3625,O
of,3625,O
simvastatin,3625,B-Chemical
.,3625,O
It,3626,O
is,3626,O
likely,3626,O
that,3626,O
this,3626,O
complication,3626,O
will,3626,O
be,3626,O
seen,3626,O
more,3626,O
often,3626,O
with,3626,O
the,3626,O
increased,3626,O
worldwide,3626,O
use,3626,O
of,3626,O
this,3626,O
drug,3626,O
and,3626,O
its,3626,O
approval,3626,O
for,3626,O
all,3626,O
arteriopathic,3626,B-Disease
patients,3626,O
.,3626,O
Neuroinflammation,3627,B-Disease
and,3627,O
behavioral,3627,B-Disease
abnormalities,3627,I-Disease
after,3627,O
neonatal,3627,O
terbutaline,3627,B-Chemical
treatment,3627,O
in,3627,O
rats,3627,O
:,3627,O
implications,3627,O
for,3627,O
autism,3627,B-Disease
.,3627,O
Autism,3628,B-Disease
is,3628,O
a,3628,O
neurodevelopmental,3628,B-Disease
disorder,3628,I-Disease
presenting,3628,O
before,3628,O
3,3628,O
years,3628,O
of,3628,O
age,3628,O
with,3628,O
deficits,3628,B-Disease
in,3628,I-Disease
communication,3628,I-Disease
and,3628,I-Disease
social,3628,I-Disease
skills,3628,I-Disease
and,3628,O
repetitive,3628,B-Disease
behaviors,3628,I-Disease
.,3628,O
In,3629,O
addition,3629,O
to,3629,O
genetic,3629,O
influences,3629,O
",",3629,O
recent,3629,O
studies,3629,O
suggest,3629,O
that,3629,O
prenatal,3629,O
drug,3629,O
or,3629,O
chemical,3629,O
exposures,3629,O
are,3629,O
risk,3629,O
factors,3629,O
for,3629,O
autism,3629,B-Disease
.,3629,O
Terbutaline,3630,B-Chemical
",",3630,O
a,3630,O
beta2-adrenoceptor,3630,O
agonist,3630,O
used,3630,O
to,3630,O
arrest,3630,O
preterm,3630,B-Disease
labor,3630,I-Disease
",",3630,O
has,3630,O
been,3630,O
associated,3630,O
with,3630,O
increased,3630,O
concordance,3630,O
for,3630,O
autism,3630,B-Disease
in,3630,O
dizygotic,3630,O
twins,3630,O
.,3630,O
We,3631,O
studied,3631,O
the,3631,O
effects,3631,O
of,3631,O
terbutaline,3631,B-Chemical
on,3631,O
microglial,3631,O
activation,3631,O
in,3631,O
different,3631,O
brain,3631,O
regions,3631,O
and,3631,O
behavioral,3631,O
outcomes,3631,O
in,3631,O
developing,3631,O
rats,3631,O
.,3631,O
Newborn,3632,O
rats,3632,O
were,3632,O
given,3632,O
terbutaline,3632,B-Chemical
(,3632,O
10,3632,O
mg/kg,3632,O
),3632,O
daily,3632,O
on,3632,O
postnatal,3632,O
days,3632,O
(,3632,O
PN,3632,O
),3632,O
2,3632,O
to,3632,O
5,3632,O
or,3632,O
PN,3632,O
11,3632,O
to,3632,O
14,3632,O
and,3632,O
examined,3632,O
24,3632,O
h,3632,O
after,3632,O
the,3632,O
last,3632,O
dose,3632,O
and,3632,O
at,3632,O
PN,3632,O
30,3632,O
.,3632,O
Immunohistochemical,3633,O
studies,3633,O
showed,3633,O
that,3633,O
administration,3633,O
of,3633,O
terbutaline,3633,B-Chemical
on,3633,O
PN,3633,O
2,3633,O
to,3633,O
5,3633,O
produced,3633,O
a,3633,O
robust,3633,O
increase,3633,O
in,3633,O
microglial,3633,O
activation,3633,O
on,3633,O
PN,3633,O
30,3633,O
in,3633,O
the,3633,O
cerebral,3633,O
cortex,3633,O
",",3633,O
as,3633,O
well,3633,O
as,3633,O
in,3633,O
cerebellar,3633,O
and,3633,O
cerebrocortical,3633,O
white,3633,O
matter,3633,O
.,3633,O
None,3634,O
of,3634,O
these,3634,O
effects,3634,O
occurred,3634,O
in,3634,O
animals,3634,O
given,3634,O
terbutaline,3634,B-Chemical
on,3634,O
PN,3634,O
11,3634,O
to,3634,O
14,3634,O
.,3634,O
In,3635,O
behavioral,3635,O
tests,3635,O
",",3635,O
animals,3635,O
treated,3635,O
with,3635,O
terbutaline,3635,B-Chemical
on,3635,O
PN,3635,O
2,3635,O
to,3635,O
5,3635,O
showed,3635,O
consistent,3635,O
patterns,3635,O
of,3635,O
hyper-reactivity,3635,O
to,3635,O
novelty,3635,O
and,3635,O
aversive,3635,O
stimuli,3635,O
when,3635,O
assessed,3635,O
in,3635,O
a,3635,O
novel,3635,O
open,3635,O
field,3635,O
",",3635,O
as,3635,O
well,3635,O
as,3635,O
in,3635,O
the,3635,O
acoustic,3635,O
startle,3635,O
response,3635,O
test,3635,O
.,3635,O
Our,3636,O
findings,3636,O
indicate,3636,O
that,3636,O
beta2-adrenoceptor,3636,O
overstimulation,3636,O
during,3636,O
an,3636,O
early,3636,O
critical,3636,O
period,3636,O
results,3636,O
in,3636,O
microglial,3636,O
activation,3636,O
associated,3636,O
with,3636,O
innate,3636,O
neuroinflammatory,3636,O
pathways,3636,O
and,3636,O
behavioral,3636,B-Disease
abnormalities,3636,I-Disease
",",3636,O
similar,3636,O
to,3636,O
those,3636,O
described,3636,O
in,3636,O
autism,3636,B-Disease
.,3636,O
This,3637,O
study,3637,O
provides,3637,O
a,3637,O
useful,3637,O
animal,3637,O
model,3637,O
for,3637,O
understanding,3637,O
the,3637,O
neuropathological,3637,O
processes,3637,O
underlying,3637,O
autism,3637,B-Disease
spectrum,3637,I-Disease
disorders,3637,I-Disease
.,3637,O
Upregulation,3638,O
of,3638,O
brain,3638,O
expression,3638,O
of,3638,O
P-glycoprotein,3638,O
in,3638,O
MRP2-deficient,3638,O
TR,3638,O
(,3638,O
-,3638,O
),3638,O
rats,3638,O
resembles,3638,O
seizure-induced,3638,B-Disease
up-regulation,3638,O
of,3638,O
this,3638,O
drug,3638,O
efflux,3638,O
transporter,3638,O
in,3638,O
normal,3638,O
rats,3638,O
.,3638,O
PURPOSE,3639,O
:,3639,O
The,3639,O
multidrug,3639,O
resistance,3639,O
protein,3639,O
2,3639,O
(,3639,O
MRP2,3639,O
),3639,O
is,3639,O
a,3639,O
drug,3639,O
efflux,3639,O
transporter,3639,O
that,3639,O
is,3639,O
expressed,3639,O
predominantly,3639,O
at,3639,O
the,3639,O
apical,3639,O
domain,3639,O
of,3639,O
hepatocytes,3639,O
but,3639,O
seems,3639,O
also,3639,O
to,3639,O
be,3639,O
expressed,3639,O
at,3639,O
the,3639,O
apical,3639,O
membrane,3639,O
of,3639,O
brain,3639,O
capillary,3639,O
endothelial,3639,O
cells,3639,O
that,3639,O
form,3639,O
the,3639,O
blood-brain,3639,O
barrier,3639,O
(,3639,O
BBB,3639,O
),3639,O
.,3639,O
MRP2,3640,O
is,3640,O
absent,3640,O
in,3640,O
the,3640,O
transport-deficient,3640,O
(,3640,O
TR,3640,O
(,3640,O
-,3640,O
),3640,O
),3640,O
Wistar,3640,O
rat,3640,O
mutant,3640,O
",",3640,O
so,3640,O
that,3640,O
this,3640,O
rat,3640,O
strain,3640,O
was,3640,O
very,3640,O
helpful,3640,O
in,3640,O
defining,3640,O
substrates,3640,O
of,3640,O
MRP2,3640,O
by,3640,O
comparing,3640,O
tissue,3640,O
concentrations,3640,O
or,3640,O
functional,3640,O
activities,3640,O
of,3640,O
compounds,3640,O
in,3640,O
MRP2-deficient,3640,O
rats,3640,O
with,3640,O
those,3640,O
in,3640,O
transport-competent,3640,O
Wistar,3640,O
rats,3640,O
.,3640,O
By,3641,O
using,3641,O
this,3641,O
strategy,3641,O
to,3641,O
study,3641,O
the,3641,O
involvement,3641,O
of,3641,O
MRP2,3641,O
in,3641,O
brain,3641,O
access,3641,O
of,3641,O
antiepileptic,3641,O
drugs,3641,O
(,3641,O
AEDs,3641,O
),3641,O
",",3641,O
we,3641,O
recently,3641,O
reported,3641,O
that,3641,O
phenytoin,3641,B-Chemical
is,3641,O
a,3641,O
substrate,3641,O
for,3641,O
MRP2,3641,O
in,3641,O
the,3641,O
BBB,3641,O
.,3641,O
However,3642,O
",",3642,O
one,3642,O
drawback,3642,O
of,3642,O
such,3642,O
studies,3642,O
in,3642,O
genetically,3642,O
deficient,3642,O
rats,3642,O
is,3642,O
the,3642,O
fact,3642,O
that,3642,O
compensatory,3642,O
changes,3642,O
with,3642,O
upregulation,3642,O
of,3642,O
other,3642,O
transporters,3642,O
can,3642,O
occur,3642,O
.,3642,O
This,3643,O
prompted,3643,O
us,3643,O
to,3643,O
study,3643,O
the,3643,O
brain,3643,O
expression,3643,O
of,3643,O
P-glycoprotein,3643,O
(,3643,O
Pgp,3643,O
),3643,O
",",3643,O
a,3643,O
major,3643,O
drug,3643,O
efflux,3643,O
transporter,3643,O
in,3643,O
many,3643,O
tissues,3643,O
",",3643,O
including,3643,O
the,3643,O
BBB,3643,O
",",3643,O
in,3643,O
TR,3643,O
(,3643,O
-,3643,O
),3643,O
rats,3643,O
compared,3643,O
with,3643,O
nonmutant,3643,O
(,3643,O
wild-type,3643,O
),3643,O
Wistar,3643,O
rats,3643,O
.,3643,O
METHODS,3644,O
:,3644,O
The,3644,O
expression,3644,O
of,3644,O
MRP2,3644,O
and,3644,O
Pgp,3644,O
in,3644,O
brain,3644,O
and,3644,O
liver,3644,O
sections,3644,O
of,3644,O
TR,3644,O
(,3644,O
-,3644,O
),3644,O
rats,3644,O
and,3644,O
normal,3644,O
Wistar,3644,O
rats,3644,O
was,3644,O
determined,3644,O
with,3644,O
immunohistochemistry,3644,O
",",3644,O
by,3644,O
using,3644,O
a,3644,O
novel,3644,O
",",3644,O
highly,3644,O
selective,3644,O
monoclonal,3644,O
MRP2,3644,O
antibody,3644,O
and,3644,O
the,3644,O
monoclonal,3644,O
Pgp,3644,O
antibody,3644,O
C219,3644,O
",",3644,O
respectively,3644,O
.,3644,O
RESULTS,3645,O
:,3645,O
Immunofluorescence,3645,O
staining,3645,O
with,3645,O
the,3645,O
MRP2,3645,O
antibody,3645,O
was,3645,O
found,3645,O
to,3645,O
label,3645,O
a,3645,O
high,3645,O
number,3645,O
of,3645,O
microvessels,3645,O
throughout,3645,O
the,3645,O
brain,3645,O
in,3645,O
normal,3645,O
Wistar,3645,O
rats,3645,O
",",3645,O
whereas,3645,O
such,3645,O
labeling,3645,O
was,3645,O
absent,3645,O
in,3645,O
TR,3645,O
(,3645,O
-,3645,O
),3645,O
rats,3645,O
.,3645,O
TR,3646,O
(,3646,O
-,3646,O
),3646,O
rats,3646,O
exhibited,3646,O
a,3646,O
significant,3646,O
up-regulation,3646,O
of,3646,O
Pgp,3646,O
in,3646,O
brain,3646,O
capillary,3646,O
endothelial,3646,O
cells,3646,O
compared,3646,O
with,3646,O
wild-type,3646,O
controls,3646,O
.,3646,O
No,3647,O
such,3647,O
obvious,3647,O
upregulation,3647,O
of,3647,O
Pgp,3647,O
was,3647,O
observed,3647,O
in,3647,O
liver,3647,O
sections,3647,O
.,3647,O
A,3648,O
comparable,3648,O
overexpression,3648,O
of,3648,O
Pgp,3648,O
in,3648,O
the,3648,O
BBB,3648,O
was,3648,O
obtained,3648,O
after,3648,O
pilocarpine-induced,3648,B-Chemical
seizures,3648,B-Disease
in,3648,O
wild-type,3648,O
Wistar,3648,O
rats,3648,O
.,3648,O
Experiments,3649,O
with,3649,O
systemic,3649,O
administration,3649,O
of,3649,O
the,3649,O
Pgp,3649,O
substrate,3649,O
phenobarbital,3649,B-Chemical
and,3649,O
the,3649,O
selective,3649,O
Pgp,3649,O
inhibitor,3649,O
tariquidar,3649,B-Chemical
in,3649,O
TR,3649,O
(,3649,O
-,3649,O
),3649,O
rats,3649,O
substantiated,3649,O
that,3649,O
Pgp,3649,O
is,3649,O
functional,3649,O
and,3649,O
compensates,3649,O
for,3649,O
the,3649,O
lack,3649,O
of,3649,O
MRP2,3649,O
in,3649,O
the,3649,O
BBB,3649,O
.,3649,O
CONCLUSIONS,3650,O
:,3650,O
The,3650,O
data,3650,O
on,3650,O
TR,3650,O
(,3650,O
-,3650,O
),3650,O
rats,3650,O
indicate,3650,O
that,3650,O
Pgp,3650,O
plays,3650,O
an,3650,O
important,3650,O
role,3650,O
in,3650,O
the,3650,O
compensation,3650,O
of,3650,O
MRP2,3650,O
deficiency,3650,O
in,3650,O
the,3650,O
BBB,3650,O
.,3650,O
Because,3651,O
such,3651,O
a,3651,O
compensatory,3651,O
mechanism,3651,O
most,3651,O
likely,3651,O
occurs,3651,O
to,3651,O
reduce,3651,O
injury,3651,B-Disease
to,3651,I-Disease
the,3651,I-Disease
brain,3651,I-Disease
from,3651,O
cytotoxic,3651,O
compounds,3651,O
",",3651,O
the,3651,O
present,3651,O
data,3651,O
substantiate,3651,O
the,3651,O
concept,3651,O
that,3651,O
MRP2,3651,O
performs,3651,O
a,3651,O
protective,3651,O
role,3651,O
in,3651,O
the,3651,O
BBB,3651,O
.,3651,O
Furthermore,3652,O
",",3652,O
our,3652,O
data,3652,O
suggest,3652,O
that,3652,O
TR,3652,O
(,3652,O
-,3652,O
),3652,O
rats,3652,O
are,3652,O
an,3652,O
interesting,3652,O
tool,3652,O
to,3652,O
study,3652,O
consequences,3652,O
of,3652,O
overexpression,3652,O
of,3652,O
Pgp,3652,O
in,3652,O
the,3652,O
BBB,3652,O
on,3652,O
access,3652,O
of,3652,O
drugs,3652,O
in,3652,O
the,3652,O
brain,3652,O
",",3652,O
without,3652,O
the,3652,O
need,3652,O
of,3652,O
inducing,3652,O
seizures,3652,B-Disease
or,3652,O
other,3652,O
Pgp-enhancing,3652,O
events,3652,O
for,3652,O
this,3652,O
purpose,3652,O
.,3652,O
Role,3653,O
of,3653,O
xanthine,3653,B-Chemical
oxidase,3653,O
in,3653,O
dexamethasone-induced,3653,B-Chemical
hypertension,3653,B-Disease
in,3653,O
rats,3653,O
.,3653,O
1,3654,O
.,3654,O
Glucocorticoid-induced,3655,O
hypertension,3655,B-Disease
(,3655,O
GC-HT,3655,O
),3655,O
in,3655,O
the,3655,O
rat,3655,O
is,3655,O
associated,3655,O
with,3655,O
nitric,3655,B-Chemical
oxide-redox,3655,O
imbalance,3655,O
.,3655,O
2,3656,O
.,3656,O
We,3657,O
studied,3657,O
the,3657,O
role,3657,O
of,3657,O
xanthine,3657,B-Chemical
oxidase,3657,O
(,3657,O
XO,3657,O
),3657,O
",",3657,O
which,3657,O
is,3657,O
implicated,3657,O
in,3657,O
the,3657,O
production,3657,O
of,3657,O
reactive,3657,O
oxygen,3657,O
species,3657,O
",",3657,O
in,3657,O
dexamethasone-induced,3657,B-Chemical
hypertension,3657,B-Disease
(,3657,O
dex-HT,3657,B-Chemical
),3657,O
.,3657,O
3,3658,O
.,3658,O
Thirty,3659,O
male,3659,O
Sprague-Dawley,3659,O
rats,3659,O
were,3659,O
divided,3659,O
randomly,3659,O
into,3659,O
four,3659,O
treatment,3659,O
groups,3659,O
:,3659,O
saline,3659,O
",",3659,O
dexamethasone,3659,B-Chemical
(,3659,O
dex,3659,B-Chemical
),3659,O
",",3659,O
allopurinol,3659,B-Chemical
plus,3659,O
saline,3659,O
",",3659,O
and,3659,O
allopurinol,3659,B-Chemical
plus,3659,O
dex,3659,B-Chemical
.,3659,O
4,3660,O
.,3660,O
Systolic,3661,O
blood,3661,O
pressures,3661,O
(,3661,O
SBP,3661,O
),3661,O
and,3661,O
bodyweights,3661,O
were,3661,O
recorded,3661,O
each,3661,O
alternate,3661,O
day,3661,O
.,3661,O
Thymus,3662,O
weight,3662,O
was,3662,O
used,3662,O
as,3662,O
a,3662,O
marker,3662,O
of,3662,O
glucocorticoid,3662,O
activity,3662,O
",",3662,O
and,3662,O
serum,3662,O
urate,3662,B-Chemical
to,3662,O
assess,3662,O
XO,3662,O
inhibition,3662,O
.,3662,O
5,3663,O
.,3663,O
Dex,3664,B-Chemical
increased,3664,B-Disease
SBP,3664,I-Disease
(,3664,O
110,3664,O
+/-,3664,O
2-126,3664,O
+/-,3664,O
3,3664,O
mmHg,3664,O
;,3664,O
P,3664,O
<,3664,O
0.001,3664,O
),3664,O
and,3664,O
decreased,3664,B-Disease
thymus,3664,I-Disease
(,3664,I-Disease
P,3664,I-Disease
<,3664,I-Disease
0.001,3664,I-Disease
),3664,I-Disease
and,3664,I-Disease
bodyweights,3664,I-Disease
(,3664,O
P,3664,O
'',3664,O
<,3664,O
0.01,3664,O
),3664,O
.,3664,O
Allopurinol,3665,B-Chemical
decreased,3665,O
serum,3665,O
urate,3665,B-Chemical
from,3665,O
76,3665,O
+/-,3665,O
5,3665,O
to,3665,O
30,3665,O
+/-,3665,O
3,3665,O
micromol/L,3665,O
(,3665,O
P,3665,O
<,3665,O
0.001,3665,O
),3665,O
in,3665,O
saline,3665,O
and,3665,O
from,3665,O
84,3665,O
+/-,3665,O
13,3665,O
to,3665,O
28,3665,O
+/-,3665,O
2,3665,O
micromol/L,3665,O
in,3665,O
dex-treated,3665,B-Chemical
(,3665,O
P,3665,O
<,3665,O
0.01,3665,O
),3665,O
groups,3665,O
.,3665,O
6,3666,O
.,3666,O
Allopurinol,3667,B-Chemical
did,3667,O
not,3667,O
prevent,3667,O
dex-HT,3667,B-Chemical
.,3667,O
This,3668,O
",",3668,O
together,3668,O
with,3668,O
our,3668,O
previous,3668,O
findings,3668,O
that,3668,O
allopurinol,3668,B-Chemical
failed,3668,O
to,3668,O
prevent,3668,O
adrenocorticotrophic,3668,O
hormone,3668,O
induced,3668,O
hypertension,3668,B-Disease
",",3668,O
suggests,3668,O
that,3668,O
XO,3668,O
activity,3668,O
is,3668,O
not,3668,O
a,3668,O
major,3668,O
determinant,3668,O
of,3668,O
GC-HT,3668,O
in,3668,O
the,3668,O
rat,3668,O
.,3668,O
Side,3669,O
effects,3669,O
of,3669,O
postoperative,3669,O
administration,3669,O
of,3669,O
methylprednisolone,3669,B-Chemical
and,3669,O
gentamicin,3669,B-Chemical
into,3669,O
the,3669,O
posterior,3669,O
sub-Tenon,3669,O
's,3669,O
space,3669,O
.,3669,O
PURPOSE,3670,O
:,3670,O
To,3670,O
assess,3670,O
the,3670,O
incidence,3670,O
of,3670,O
postoperative,3670,O
emetic,3670,O
side,3670,O
effects,3670,O
after,3670,O
the,3670,O
administration,3670,O
of,3670,O
methylprednisolone,3670,B-Chemical
and,3670,O
gentamicin,3670,B-Chemical
into,3670,O
the,3670,O
posterior,3670,O
sub-Tenon,3670,O
's,3670,O
space,3670,O
at,3670,O
the,3670,O
end,3670,O
of,3670,O
routine,3670,O
cataract,3670,B-Disease
surgery,3670,O
.,3670,O
SETTING,3671,O
:,3671,O
St.,3671,O
Luke,3671,O
's,3671,O
Hospital,3671,O
",",3671,O
Gwardamangia,3671,O
",",3671,O
Malta,3671,O
.,3671,O
METHODS,3672,O
:,3672,O
A,3672,O
double-blind,3672,O
double-armed,3672,O
prospective,3672,O
study,3672,O
comprised,3672,O
40,3672,O
patients,3672,O
who,3672,O
had,3672,O
uneventful,3672,O
sutureless,3672,O
phacoemulsification,3672,O
under,3672,O
sub-Tenon,3672,O
's,3672,O
local,3672,O
infiltration,3672,O
of,3672,O
3,3672,O
mL,3672,O
of,3672,O
plain,3672,O
lignocaine,3672,B-Chemical
.,3672,O
At,3673,O
the,3673,O
end,3673,O
of,3673,O
the,3673,O
procedure,3673,O
",",3673,O
Group,3673,O
A,3673,O
(,3673,O
n,3673,O
=,3673,O
20,3673,O
),3673,O
had,3673,O
20,3673,O
mg/0.5,3673,O
mL,3673,O
of,3673,O
methylprednisolone,3673,B-Chemical
and,3673,O
10,3673,O
mg/0.5,3673,O
mL,3673,O
of,3673,O
gentamicin,3673,B-Chemical
injected,3673,O
into,3673,O
the,3673,O
posterior,3673,O
sub-Tenon,3673,O
's,3673,O
space,3673,O
and,3673,O
Group,3673,O
B,3673,O
(,3673,O
n,3673,O
=,3673,O
20,3673,O
),3673,O
had,3673,O
the,3673,O
same,3673,O
combination,3673,O
injected,3673,O
into,3673,O
the,3673,O
anterior,3673,O
sub-Tenon,3673,O
's,3673,O
space,3673,O
.,3673,O
Postoperatively,3674,O
",",3674,O
all,3674,O
patients,3674,O
were,3674,O
assessed,3674,O
for,3674,O
symptoms,3674,O
of,3674,O
nausea,3674,B-Disease
",",3674,I-Disease
vomiting,3674,I-Disease
",",3674,O
and,3674,O
headache,3674,B-Disease
.,3674,O
A,3675,O
chi-square,3675,O
test,3675,O
was,3675,O
used,3675,O
to,3675,O
assess,3675,O
the,3675,O
statistical,3675,O
significance,3675,O
of,3675,O
results,3675,O
.,3675,O
RESULTS,3676,O
:,3676,O
Sixty,3676,O
percent,3676,O
in,3676,O
Group,3676,O
A,3676,O
developed,3676,O
postoperative,3676,B-Disease
emetic,3676,I-Disease
symptoms,3676,I-Disease
",",3676,O
headache,3676,B-Disease
",",3676,O
or,3676,O
both,3676,O
;,3676,O
1,3676,O
patient,3676,O
in,3676,O
Group,3676,O
B,3676,O
developed,3676,O
symptoms,3676,O
.,3676,O
CONCLUSIONS,3677,O
:,3677,O
The,3677,O
administration,3677,O
of,3677,O
methylprednisolone,3677,B-Chemical
and,3677,O
gentamicin,3677,B-Chemical
in,3677,O
the,3677,O
posterior,3677,O
sub-Tenon,3677,O
's,3677,O
space,3677,O
was,3677,O
related,3677,O
to,3677,O
a,3677,O
high,3677,O
incidence,3677,O
of,3677,O
side,3677,O
effects,3677,O
including,3677,O
nausea,3677,B-Disease
",",3677,I-Disease
vomiting,3677,I-Disease
",",3677,O
and,3677,O
headache,3677,B-Disease
.,3677,O
All,3678,O
adverse,3678,O
effects,3678,O
were,3678,O
self-limiting,3678,O
.,3678,O
Assessment,3679,O
of,3679,O
a,3679,O
new,3679,O
non-invasive,3679,O
index,3679,O
of,3679,O
cardiac,3679,O
performance,3679,O
for,3679,O
detection,3679,O
of,3679,O
dobutamine-induced,3679,B-Chemical
myocardial,3679,B-Disease
ischemia,3679,I-Disease
.,3679,O
BACKGROUND,3680,O
:,3680,O
Electrocardiography,3680,O
has,3680,O
a,3680,O
very,3680,O
low,3680,O
sensitivity,3680,O
in,3680,O
detecting,3680,O
dobutamine-induced,3680,B-Chemical
myocardial,3680,B-Disease
ischemia,3680,I-Disease
.,3680,O
OBJECTIVES,3681,O
:,3681,O
To,3681,O
assess,3681,O
the,3681,O
added,3681,O
diagnostic,3681,O
value,3681,O
of,3681,O
a,3681,O
new,3681,O
cardiac,3681,O
performance,3681,O
index,3681,O
(,3681,O
dP/dtejc,3681,O
),3681,O
measurement,3681,O
",",3681,O
based,3681,O
on,3681,O
brachial,3681,O
artery,3681,O
flow,3681,O
changes,3681,O
",",3681,O
as,3681,O
compared,3681,O
to,3681,O
standard,3681,O
12-lead,3681,O
ECG,3681,O
",",3681,O
for,3681,O
detecting,3681,O
dobutamine-induced,3681,B-Chemical
myocardial,3681,B-Disease
ischemia,3681,I-Disease
",",3681,O
using,3681,O
Tc99m-Sestamibi,3681,B-Chemical
single-photon,3681,O
emission,3681,O
computed,3681,O
tomography,3681,O
as,3681,O
the,3681,O
gold,3681,O
standard,3681,O
of,3681,O
comparison,3681,O
to,3681,O
assess,3681,O
the,3681,O
presence,3681,O
or,3681,O
absence,3681,O
of,3681,O
ischemia,3681,B-Disease
.,3681,O
METHODS,3682,O
:,3682,O
The,3682,O
study,3682,O
group,3682,O
comprised,3682,O
40,3682,O
patients,3682,O
undergoing,3682,O
Sestamibi-SPECT/dobutamine,3682,B-Chemical
stress,3682,O
test,3682,O
.,3682,O
Simultaneous,3683,O
measurements,3683,O
of,3683,O
ECG,3683,O
and,3683,O
brachial,3683,O
artery,3683,O
dP/dtejc,3683,O
were,3683,O
performed,3683,O
at,3683,O
each,3683,O
dobutamine,3683,B-Chemical
level,3683,O
.,3683,O
In,3684,O
19,3684,O
of,3684,O
the,3684,O
40,3684,O
patients,3684,O
perfusion,3684,O
defects,3684,O
compatible,3684,O
with,3684,O
ischemia,3684,B-Disease
were,3684,O
detected,3684,O
on,3684,O
SPECT,3684,O
.,3684,O
The,3685,O
increase,3685,O
in,3685,O
dP/dtejc,3685,O
during,3685,O
infusion,3685,O
of,3685,O
dobutamine,3685,B-Chemical
in,3685,O
this,3685,O
group,3685,O
was,3685,O
severely,3685,O
impaired,3685,O
as,3685,O
compared,3685,O
to,3685,O
the,3685,O
non-ischemic,3685,O
group,3685,O
.,3685,O
dP/dtejc,3686,O
outcome,3686,O
was,3686,O
combined,3686,O
with,3686,O
the,3686,O
ECG,3686,O
results,3686,O
",",3686,O
giving,3686,O
an,3686,O
ECG-enhanced,3686,O
value,3686,O
",",3686,O
and,3686,O
compared,3686,O
to,3686,O
ECG,3686,O
alone,3686,O
.,3686,O
RESULTS,3687,O
:,3687,O
The,3687,O
sensitivity,3687,O
improved,3687,O
dramatically,3687,O
from,3687,O
16,3687,O
%,3687,O
to,3687,O
79,3687,O
%,3687,O
",",3687,O
positive,3687,O
predictive,3687,O
value,3687,O
increased,3687,O
from,3687,O
60,3687,O
%,3687,O
to,3687,O
68,3687,O
%,3687,O
and,3687,O
negative,3687,O
predictive,3687,O
value,3687,O
from,3687,O
54,3687,O
%,3687,O
to,3687,O
78,3687,O
%,3687,O
",",3687,O
and,3687,O
specificity,3687,O
decreased,3687,O
from,3687,O
90,3687,O
%,3687,O
to,3687,O
67,3687,O
%,3687,O
.,3687,O
CONCLUSIONS,3688,O
:,3688,O
If,3688,O
ECG,3688,O
alone,3688,O
is,3688,O
used,3688,O
for,3688,O
specificity,3688,O
",",3688,O
the,3688,O
combination,3688,O
with,3688,O
dP/dtejc,3688,O
improved,3688,O
the,3688,O
sensitivity,3688,O
of,3688,O
the,3688,O
test,3688,O
and,3688,O
could,3688,O
be,3688,O
a,3688,O
cost-savings,3688,O
alternative,3688,O
to,3688,O
cardiac,3688,O
imaging,3688,O
or,3688,O
perfusion,3688,O
studies,3688,O
to,3688,O
detect,3688,O
myocardial,3688,B-Disease
ischemia,3688,I-Disease
",",3688,O
especially,3688,O
in,3688,O
patients,3688,O
unable,3688,O
to,3688,O
exercise,3688,O
.,3688,O
Proteomic,3689,O
analysis,3689,O
of,3689,O
striatal,3689,O
proteins,3689,O
in,3689,O
the,3689,O
rat,3689,O
model,3689,O
of,3689,O
L-DOPA-induced,3689,B-Chemical
dyskinesia,3689,B-Disease
.,3689,O
L-DOPA-induced,3690,B-Chemical
dyskinesia,3690,B-Disease
(,3690,O
LID,3690,B-Disease
),3690,O
is,3690,O
among,3690,O
the,3690,O
motor,3690,O
complications,3690,O
that,3690,O
arise,3690,O
in,3690,O
Parkinson,3690,B-Disease
's,3690,I-Disease
disease,3690,I-Disease
(,3690,O
PD,3690,B-Disease
),3690,O
patients,3690,O
after,3690,O
a,3690,O
prolonged,3690,O
treatment,3690,O
with,3690,O
L-DOPA,3690,B-Chemical
.,3690,O
To,3691,O
this,3691,O
day,3691,O
",",3691,O
transcriptome,3691,O
analysis,3691,O
has,3691,O
been,3691,O
performed,3691,O
in,3691,O
a,3691,O
rat,3691,O
model,3691,O
of,3691,O
LID,3691,B-Disease
[,3691,O
Neurobiol,3691,O
.,3691,O
Dis.,3692,O
",",3692,O
17,3692,O
(,3692,O
2004,3692,O
),3692,O
",",3692,O
219,3692,O
],3692,O
but,3692,O
information,3692,O
regarding,3692,O
the,3692,O
proteome,3692,O
is,3692,O
still,3692,O
lacking,3692,O
.,3692,O
In,3693,O
the,3693,O
present,3693,O
study,3693,O
",",3693,O
we,3693,O
investigated,3693,O
the,3693,O
changes,3693,O
occurring,3693,O
at,3693,O
the,3693,O
protein,3693,O
level,3693,O
in,3693,O
striatal,3693,O
samples,3693,O
obtained,3693,O
from,3693,O
the,3693,O
unilaterally,3693,O
6-hydroxydopamine-lesion,3693,B-Chemical
rat,3693,O
model,3693,O
of,3693,O
PD,3693,B-Disease
treated,3693,O
with,3693,O
saline,3693,O
",",3693,O
L-DOPA,3693,B-Chemical
or,3693,O
bromocriptine,3693,B-Chemical
using,3693,O
two-dimensional,3693,O
difference,3693,O
gel,3693,O
electrophoresis,3693,O
and,3693,O
mass,3693,O
spectrometry,3693,O
(,3693,O
MS,3693,O
),3693,O
.,3693,O
Rats,3694,O
treated,3694,O
with,3694,O
L-DOPA,3694,B-Chemical
were,3694,O
allocated,3694,O
to,3694,O
two,3694,O
groups,3694,O
based,3694,O
on,3694,O
the,3694,O
presence,3694,O
or,3694,O
absence,3694,O
of,3694,O
LID,3694,B-Disease
.,3694,O
Among,3695,O
the,3695,O
2000,3695,O
spots,3695,O
compared,3695,O
for,3695,O
statistical,3695,O
difference,3695,O
",",3695,O
67,3695,O
spots,3695,O
were,3695,O
significantly,3695,O
changed,3695,O
in,3695,O
abundance,3695,O
and,3695,O
identified,3695,O
using,3695,O
matrix-assisted,3695,O
laser,3695,O
desorption/ionization,3695,O
time-of-flight,3695,O
MS,3695,O
",",3695,O
atmospheric,3695,O
pressure,3695,O
matrix-assisted,3695,O
laser,3695,O
desorption/ionization,3695,O
and,3695,O
HPLC,3695,O
coupled,3695,O
tandem,3695,O
MS,3695,O
(,3695,O
LC/MS/MS,3695,O
),3695,O
.,3695,O
Out,3696,O
of,3696,O
these,3696,O
67,3696,O
proteins,3696,O
",",3696,O
LID,3696,B-Disease
significantly,3696,O
changed,3696,O
the,3696,O
expression,3696,O
level,3696,O
of,3696,O
five,3696,O
proteins,3696,O
:,3696,O
alphabeta-crystalin,3696,O
",",3696,O
gamma-enolase,3696,O
",",3696,O
guanidoacetate,3696,O
methyltransferase,3696,O
",",3696,O
vinculin,3696,O
",",3696,O
and,3696,O
proteasome,3696,O
alpha-2,3696,O
subunit,3696,O
.,3696,O
Complementary,3697,O
techniques,3697,O
such,3697,O
as,3697,O
western,3697,O
immunoblotting,3697,O
and,3697,O
immunohistochemistry,3697,O
were,3697,O
performed,3697,O
to,3697,O
investigate,3697,O
the,3697,O
validity,3697,O
of,3697,O
the,3697,O
data,3697,O
obtained,3697,O
using,3697,O
the,3697,O
proteomic,3697,O
approach,3697,O
.,3697,O
In,3698,O
conclusion,3698,O
",",3698,O
this,3698,O
study,3698,O
provides,3698,O
new,3698,O
insights,3698,O
into,3698,O
the,3698,O
protein,3698,O
changes,3698,O
occurring,3698,O
in,3698,O
LID,3698,B-Disease
.,3698,O
Cardiac,3699,O
Angiography,3699,O
in,3699,O
Renally,3699,O
Impaired,3699,O
Patients,3699,O
(,3699,O
CARE,3699,O
),3699,O
study,3699,O
:,3699,O
a,3699,O
randomized,3699,O
double-blind,3699,O
trial,3699,O
of,3699,O
contrast-induced,3699,O
nephropathy,3699,B-Disease
in,3699,O
patients,3699,O
with,3699,O
chronic,3699,B-Disease
kidney,3699,I-Disease
disease,3699,I-Disease
.,3699,O
BACKGROUND,3700,O
:,3700,O
No,3700,O
direct,3700,O
comparisons,3700,O
exist,3700,O
of,3700,O
the,3700,O
renal,3700,O
tolerability,3700,O
of,3700,O
the,3700,O
low-osmolality,3700,O
contrast,3700,B-Chemical
medium,3700,I-Chemical
iopamidol,3700,B-Chemical
with,3700,O
that,3700,O
of,3700,O
the,3700,O
iso-osmolality,3700,O
contrast,3700,B-Chemical
medium,3700,I-Chemical
iodixanol,3700,B-Chemical
in,3700,O
high-risk,3700,O
patients,3700,O
.,3700,O
METHODS,3701,O
AND,3701,O
RESULTS,3701,O
:,3701,O
The,3701,O
present,3701,O
study,3701,O
is,3701,O
a,3701,O
multicenter,3701,O
",",3701,O
randomized,3701,O
",",3701,O
double-blind,3701,O
comparison,3701,O
of,3701,O
iopamidol,3701,B-Chemical
and,3701,O
iodixanol,3701,B-Chemical
in,3701,O
patients,3701,O
with,3701,O
chronic,3701,B-Disease
kidney,3701,I-Disease
disease,3701,I-Disease
(,3701,O
estimated,3701,O
glomerular,3701,O
filtration,3701,O
rate,3701,O
",",3701,O
20,3701,O
to,3701,O
59,3701,O
mL/min,3701,O
),3701,O
who,3701,O
underwent,3701,O
cardiac,3701,O
angiography,3701,O
or,3701,O
percutaneous,3701,O
coronary,3701,O
interventions,3701,O
.,3701,O
Serum,3702,O
creatinine,3702,B-Chemical
(,3702,O
SCr,3702,O
),3702,O
levels,3702,O
and,3702,O
estimated,3702,O
glomerular,3702,O
filtration,3702,O
rate,3702,O
were,3702,O
assessed,3702,O
at,3702,O
baseline,3702,O
and,3702,O
2,3702,O
to,3702,O
5,3702,O
days,3702,O
after,3702,O
receiving,3702,O
medications,3702,O
.,3702,O
The,3703,O
primary,3703,O
outcome,3703,O
was,3703,O
a,3703,O
postdose,3703,O
SCr,3703,O
increase,3703,O
>,3703,O
or,3703,O
=,3703,O
0.5,3703,O
mg/dL,3703,O
(,3703,O
44.2,3703,O
micromol/L,3703,O
),3703,O
over,3703,O
baseline,3703,O
.,3703,O
Secondary,3704,O
outcomes,3704,O
were,3704,O
a,3704,O
postdose,3704,O
SCr,3704,O
increase,3704,O
>,3704,O
or,3704,O
=,3704,O
25,3704,O
%,3704,O
",",3704,O
a,3704,O
postdose,3704,O
estimated,3704,O
glomerular,3704,O
filtration,3704,O
rate,3704,O
decrease,3704,O
of,3704,O
>,3704,O
or,3704,O
=,3704,O
25,3704,O
%,3704,O
",",3704,O
and,3704,O
the,3704,O
mean,3704,O
peak,3704,O
change,3704,O
in,3704,O
SCr,3704,O
.,3704,O
In,3705,O
414,3705,O
patients,3705,O
",",3705,O
contrast,3705,O
volume,3705,O
",",3705,O
presence,3705,O
of,3705,O
diabetes,3705,B-Disease
mellitus,3705,I-Disease
",",3705,O
use,3705,O
of,3705,O
N-acetylcysteine,3705,B-Chemical
",",3705,O
mean,3705,O
baseline,3705,O
SCr,3705,O
",",3705,O
and,3705,O
estimated,3705,O
glomerular,3705,O
filtration,3705,O
rate,3705,O
were,3705,O
comparable,3705,O
in,3705,O
the,3705,O
2,3705,O
groups,3705,O
.,3705,O
SCr,3706,O
increases,3706,O
>,3706,O
or,3706,O
=,3706,O
0.5,3706,O
mg/dL,3706,O
occurred,3706,O
in,3706,O
4.4,3706,O
%,3706,O
(,3706,O
9,3706,O
of,3706,O
204,3706,O
patients,3706,O
),3706,O
after,3706,O
iopamidol,3706,B-Chemical
and,3706,O
6.7,3706,O
%,3706,O
(,3706,O
14,3706,O
of,3706,O
210,3706,O
patients,3706,O
),3706,O
after,3706,O
iodixanol,3706,B-Chemical
(,3706,O
P=0.39,3706,O
),3706,O
",",3706,O
whereas,3706,O
rates,3706,O
of,3706,O
SCr,3706,O
increases,3706,O
>,3706,O
or,3706,O
=,3706,O
25,3706,O
%,3706,O
were,3706,O
9.8,3706,O
%,3706,O
and,3706,O
12.4,3706,O
%,3706,O
",",3706,O
respectively,3706,O
(,3706,O
P=0.44,3706,O
),3706,O
.,3706,O
In,3707,O
patients,3707,O
with,3707,O
diabetes,3707,B-Disease
",",3707,O
SCr,3707,O
increases,3707,O
>,3707,O
or,3707,O
=,3707,O
0.5,3707,O
mg/dL,3707,O
were,3707,O
5.1,3707,O
%,3707,O
(,3707,O
4,3707,O
of,3707,O
78,3707,O
patients,3707,O
),3707,O
with,3707,O
iopamidol,3707,B-Chemical
and,3707,O
13.0,3707,O
%,3707,O
(,3707,O
12,3707,O
of,3707,O
92,3707,O
patients,3707,O
),3707,O
with,3707,O
iodixanol,3707,B-Chemical
(,3707,O
P=0.11,3707,O
),3707,O
",",3707,O
whereas,3707,O
SCr,3707,O
increases,3707,O
>,3707,O
or,3707,O
=,3707,O
25,3707,O
%,3707,O
were,3707,O
10.3,3707,O
%,3707,O
and,3707,O
15.2,3707,O
%,3707,O
",",3707,O
respectively,3707,O
(,3707,O
P=0.37,3707,O
),3707,O
.,3707,O
Mean,3708,O
post-SCr,3708,O
increases,3708,O
were,3708,O
significantly,3708,O
less,3708,O
with,3708,O
iopamidol,3708,B-Chemical
(,3708,O
all,3708,O
patients,3708,O
:,3708,O
0.07,3708,O
versus,3708,O
0.12,3708,O
mg/dL,3708,O
",",3708,O
6.2,3708,O
versus,3708,O
10.6,3708,O
micromol/L,3708,O
",",3708,O
P=0.03,3708,O
;,3708,O
patients,3708,O
with,3708,O
diabetes,3708,B-Disease
:,3708,O
0.07,3708,O
versus,3708,O
0.16,3708,O
mg/dL,3708,O
",",3708,O
6.2,3708,O
versus,3708,O
14.1,3708,O
micromol/L,3708,O
",",3708,O
P=0.01,3708,O
),3708,O
.,3708,O
CONCLUSIONS,3709,O
:,3709,O
The,3709,O
rate,3709,O
of,3709,O
contrast-induced,3709,O
nephropathy,3709,B-Disease
",",3709,O
defined,3709,O
by,3709,O
multiple,3709,O
end,3709,O
points,3709,O
",",3709,O
is,3709,O
not,3709,O
statistically,3709,O
different,3709,O
after,3709,O
the,3709,O
intraarterial,3709,O
administration,3709,O
of,3709,O
iopamidol,3709,B-Chemical
or,3709,O
iodixanol,3709,B-Chemical
to,3709,O
high-risk,3709,O
patients,3709,O
",",3709,O
with,3709,O
or,3709,O
without,3709,O
diabetes,3709,B-Disease
mellitus,3709,I-Disease
.,3709,O
Any,3710,O
true,3710,O
difference,3710,O
between,3710,O
the,3710,O
agents,3710,O
is,3710,O
small,3710,O
and,3710,O
not,3710,O
likely,3710,O
to,3710,O
be,3710,O
clinically,3710,O
significant,3710,O
.,3710,O
A,3711,O
novel,3711,O
compound,3711,O
",",3711,O
maltolyl,3711,B-Chemical
p-coumarate,3711,I-Chemical
",",3711,O
attenuates,3711,O
cognitive,3711,B-Disease
deficits,3711,I-Disease
and,3711,O
shows,3711,O
neuroprotective,3711,O
effects,3711,O
in,3711,O
vitro,3711,O
and,3711,O
in,3711,O
vivo,3711,O
dementia,3711,B-Disease
models,3711,O
.,3711,O
To,3712,O
develop,3712,O
a,3712,O
novel,3712,O
and,3712,O
effective,3712,O
drug,3712,O
that,3712,O
could,3712,O
enhance,3712,O
cognitive,3712,O
function,3712,O
and,3712,O
neuroprotection,3712,O
",",3712,O
we,3712,O
newly,3712,O
synthesized,3712,O
maltolyl,3712,B-Chemical
p-coumarate,3712,I-Chemical
by,3712,O
the,3712,O
esterification,3712,O
of,3712,O
maltol,3712,B-Chemical
and,3712,O
p-coumaric,3712,B-Chemical
acid,3712,I-Chemical
.,3712,O
In,3713,O
the,3713,O
present,3713,O
study,3713,O
",",3713,O
we,3713,O
investigated,3713,O
whether,3713,O
maltolyl,3713,B-Chemical
p-coumarate,3713,I-Chemical
could,3713,O
improve,3713,O
cognitive,3713,B-Disease
decline,3713,I-Disease
in,3713,O
scopolamine-injected,3713,B-Chemical
rats,3713,O
and,3713,O
in,3713,O
amyloid,3713,B-Chemical
beta,3713,I-Chemical
peptide,3713,I-Chemical
(,3713,I-Chemical
1-42,3713,I-Chemical
),3713,I-Chemical
-infused,3713,O
rats,3713,O
.,3713,O
Maltolyl,3714,B-Chemical
p-coumarate,3714,I-Chemical
was,3714,O
found,3714,O
to,3714,O
attenuate,3714,O
cognitive,3714,B-Disease
deficits,3714,I-Disease
in,3714,O
both,3714,O
rat,3714,O
models,3714,O
using,3714,O
passive,3714,O
avoidance,3714,O
test,3714,O
and,3714,O
to,3714,O
reduce,3714,O
apoptotic,3714,O
cell,3714,O
death,3714,O
observed,3714,O
in,3714,O
the,3714,O
hippocampus,3714,O
of,3714,O
the,3714,O
amyloid,3714,B-Chemical
beta,3714,I-Chemical
peptide,3714,I-Chemical
(,3714,I-Chemical
1-42,3714,I-Chemical
),3714,I-Chemical
-infused,3714,O
rats,3714,O
.,3714,O
We,3715,O
also,3715,O
examined,3715,O
the,3715,O
neuroprotective,3715,O
effects,3715,O
of,3715,O
maltolyl,3715,B-Chemical
p-coumarate,3715,I-Chemical
in,3715,O
vitro,3715,O
using,3715,O
SH-SY5Y,3715,O
cells,3715,O
.,3715,O
Cells,3716,O
were,3716,O
pretreated,3716,O
with,3716,O
maltolyl,3716,B-Chemical
p-coumarate,3716,I-Chemical
",",3716,O
before,3716,O
exposed,3716,O
to,3716,O
amyloid,3716,B-Chemical
beta,3716,I-Chemical
peptide,3716,I-Chemical
(,3716,I-Chemical
1-42,3716,I-Chemical
),3716,I-Chemical
",",3716,O
glutamate,3716,B-Chemical
or,3716,O
H2O2,3716,B-Chemical
.,3716,O
We,3717,O
found,3717,O
that,3717,O
maltolyl,3717,B-Chemical
p-coumarate,3717,I-Chemical
significantly,3717,O
decreased,3717,O
apoptotic,3717,O
cell,3717,O
death,3717,O
and,3717,O
reduced,3717,O
reactive,3717,O
oxygen,3717,O
species,3717,O
",",3717,O
cytochrome,3717,O
c,3717,O
release,3717,O
",",3717,O
and,3717,O
caspase,3717,O
3,3717,O
activation,3717,O
.,3717,O
Taking,3718,O
these,3718,O
in,3718,O
vitro,3718,O
and,3718,O
in,3718,O
vivo,3718,O
results,3718,O
together,3718,O
",",3718,O
our,3718,O
study,3718,O
suggests,3718,O
that,3718,O
maltolyl,3718,B-Chemical
p-coumarate,3718,I-Chemical
is,3718,O
a,3718,O
potentially,3718,O
effective,3718,O
candidate,3718,O
against,3718,O
Alzheimer,3718,B-Disease
's,3718,I-Disease
disease,3718,I-Disease
that,3718,O
is,3718,O
characterized,3718,O
by,3718,O
wide,3718,O
spread,3718,O
neuronal,3718,B-Disease
death,3718,I-Disease
and,3718,O
progressive,3718,O
decline,3718,B-Disease
of,3718,I-Disease
cognitive,3718,I-Disease
function,3718,I-Disease
.,3718,O
Attenuation,3719,O
of,3719,O
methamphetamine-induced,3719,B-Chemical
nigrostriatal,3719,O
dopaminergic,3719,O
neurotoxicity,3719,B-Disease
in,3719,O
mice,3719,O
by,3719,O
lipopolysaccharide,3719,B-Chemical
pretreatment,3719,O
.,3719,O
Immunological,3720,O
activation,3720,O
has,3720,O
been,3720,O
proposed,3720,O
to,3720,O
play,3720,O
a,3720,O
role,3720,O
in,3720,O
methamphetamine-induced,3720,B-Chemical
dopaminergic,3720,B-Disease
terminal,3720,I-Disease
damage,3720,I-Disease
.,3720,O
In,3721,O
this,3721,O
study,3721,O
",",3721,O
we,3721,O
examined,3721,O
the,3721,O
roles,3721,O
of,3721,O
lipopolysaccharide,3721,B-Chemical
",",3721,O
a,3721,O
pro-inflammatory,3721,O
and,3721,O
inflammatory,3721,O
factor,3721,O
",",3721,O
treatment,3721,O
in,3721,O
modulating,3721,O
the,3721,O
methamphetamine-induced,3721,B-Chemical
nigrostriatal,3721,O
dopamine,3721,B-Chemical
neurotoxicity,3721,B-Disease
.,3721,O
Lipopolysaccharide,3722,B-Chemical
pretreatment,3722,O
did,3722,O
not,3722,O
affect,3722,O
the,3722,O
basal,3722,O
body,3722,O
temperature,3722,O
or,3722,O
methamphetamine-elicited,3722,B-Chemical
hyperthermia,3722,B-Disease
three,3722,O
days,3722,O
later,3722,O
.,3722,O
Such,3723,O
systemic,3723,O
lipopolysaccharide,3723,B-Chemical
treatment,3723,O
mitigated,3723,O
methamphetamine-induced,3723,B-Chemical
striatal,3723,O
dopamine,3723,B-Chemical
and,3723,O
"3,4-dihydroxyphenylacetic",3723,B-Chemical
acid,3723,I-Chemical
depletions,3723,O
in,3723,O
a,3723,O
dose-dependent,3723,O
manner,3723,O
.,3723,O
As,3724,O
the,3724,O
most,3724,O
potent,3724,O
dose,3724,O
(,3724,O
1,3724,O
mg/kg,3724,O
),3724,O
of,3724,O
lipopolysaccharide,3724,B-Chemical
was,3724,O
administered,3724,O
two,3724,O
weeks,3724,O
",",3724,O
one,3724,O
day,3724,O
before,3724,O
or,3724,O
after,3724,O
the,3724,O
methamphetamine,3724,B-Chemical
dosing,3724,O
regimen,3724,O
",",3724,O
methamphetamine-induced,3724,B-Chemical
striatal,3724,O
dopamine,3724,B-Chemical
and,3724,O
"3,4-dihydroxyphenylacetic",3724,B-Chemical
acid,3724,I-Chemical
depletions,3724,O
remained,3724,O
unaltered,3724,O
.,3724,O
Moreover,3725,O
",",3725,O
systemic,3725,O
lipopolysaccharide,3725,B-Chemical
pretreatment,3725,O
(,3725,O
1,3725,O
mg/kg,3725,O
),3725,O
attenuated,3725,O
local,3725,O
methamphetamine,3725,B-Chemical
infusion-produced,3725,O
dopamine,3725,B-Chemical
and,3725,O
"3,4-dihydroxyphenylacetic",3725,B-Chemical
acid,3725,I-Chemical
depletions,3725,O
in,3725,O
the,3725,O
striatum,3725,O
",",3725,O
indicating,3725,O
that,3725,O
the,3725,O
protective,3725,O
effect,3725,O
of,3725,O
lipopolysaccharide,3725,B-Chemical
is,3725,O
less,3725,O
likely,3725,O
due,3725,O
to,3725,O
interrupted,3725,O
peripheral,3725,O
distribution,3725,O
or,3725,O
metabolism,3725,O
of,3725,O
methamphetamine,3725,B-Chemical
.,3725,O
We,3726,O
concluded,3726,O
a,3726,O
critical,3726,O
time,3726,O
window,3726,O
for,3726,O
systemic,3726,O
lipopolysaccharide,3726,B-Chemical
pretreatment,3726,O
in,3726,O
exerting,3726,O
effective,3726,O
protection,3726,O
against,3726,O
methamphetamine-induced,3726,B-Chemical
nigrostriatal,3726,O
dopamine,3726,B-Chemical
neurotoxicity,3726,B-Disease
.,3726,O
Acute,3727,O
myocarditis,3727,B-Disease
associated,3727,O
with,3727,O
clozapine,3727,B-Chemical
.,3727,O
OBJECTIVE,3728,O
:,3728,O
A,3728,O
case,3728,O
of,3728,O
acute,3728,O
myocarditis,3728,B-Disease
associated,3728,O
with,3728,O
the,3728,O
commencement,3728,O
of,3728,O
clozapine,3728,B-Chemical
is,3728,O
described,3728,O
",",3728,O
highlighting,3728,O
the,3728,O
onset,3728,O
",",3728,O
course,3728,O
and,3728,O
possible,3728,O
contributing,3728,O
factors,3728,O
.,3728,O
There,3729,O
is,3729,O
an,3729,O
urgent,3729,O
need,3729,O
to,3729,O
raise,3729,O
awareness,3729,O
about,3729,O
this,3729,O
potentially,3729,O
fatal,3729,O
complication,3729,O
of,3729,O
clozapine,3729,B-Chemical
use,3729,O
.,3729,O
RESULTS,3730,O
:,3730,O
A,3730,O
20-year-old,3730,O
male,3730,O
with,3730,O
schizophrenia,3730,B-Disease
developed,3730,O
a,3730,O
sudden,3730,O
onset,3730,O
of,3730,O
myocarditis,3730,B-Disease
after,3730,O
commencement,3730,O
of,3730,O
clozapine,3730,B-Chemical
.,3730,O
The,3731,O
patient,3731,O
recovered,3731,O
with,3731,O
intensive,3731,O
medical,3731,O
support,3731,O
.,3731,O
The,3732,O
symptoms,3732,O
occurred,3732,O
around,3732,O
2,3732,O
weeks,3732,O
after,3732,O
starting,3732,O
clozapine,3732,B-Chemical
in,3732,O
an,3732,O
inpatient,3732,O
setting,3732,O
.,3732,O
Possible,3733,O
contributing,3733,O
factors,3733,O
may,3733,O
have,3733,O
been,3733,O
concomitant,3733,O
antidepressant,3733,B-Chemical
use,3733,O
and,3733,O
unaccustomed,3733,O
physical,3733,O
activity,3733,O
.,3733,O
CONCLUSIONS,3734,O
:,3734,O
Myocarditis,3734,B-Disease
is,3734,O
an,3734,O
increasingly,3734,O
recognized,3734,O
complication,3734,O
associated,3734,O
with,3734,O
the,3734,O
use,3734,O
of,3734,O
clozapine,3734,B-Chemical
.,3734,O
It,3735,O
can,3735,O
be,3735,O
fatal,3735,O
if,3735,O
not,3735,O
recognized,3735,O
and,3735,O
treated,3735,O
early,3735,O
.,3735,O
Considering,3736,O
that,3736,O
clozapine,3736,B-Chemical
remains,3736,O
the,3736,O
gold,3736,O
standard,3736,O
in,3736,O
treatment,3736,O
of,3736,O
resistant,3736,O
psychosis,3736,B-Disease
",",3736,O
there,3736,O
is,3736,O
an,3736,O
urgent,3736,O
need,3736,O
to,3736,O
raise,3736,O
awareness,3736,O
among,3736,O
medical,3736,O
and,3736,O
paramedical,3736,O
staff,3736,O
involved,3736,O
in,3736,O
the,3736,O
care,3736,O
of,3736,O
these,3736,O
patients,3736,O
.,3736,O
There,3737,O
are,3737,O
also,3737,O
implications,3737,O
for,3737,O
recommendations,3737,O
and,3737,O
regulations,3737,O
regarding,3737,O
the,3737,O
use,3737,O
of,3737,O
clozapine,3737,B-Chemical
.,3737,O
Severe,3738,O
rhabdomyolysis,3738,B-Disease
and,3738,O
acute,3738,B-Disease
renal,3738,I-Disease
failure,3738,I-Disease
secondary,3738,O
to,3738,O
concomitant,3738,O
use,3738,O
of,3738,O
simvastatin,3738,B-Chemical
",",3738,O
amiodarone,3738,B-Chemical
",",3738,O
and,3738,O
atazanavir,3738,B-Chemical
.,3738,O
OBJECTIVE,3739,O
:,3739,O
To,3739,O
report,3739,O
a,3739,O
case,3739,O
of,3739,O
a,3739,O
severe,3739,O
interaction,3739,O
between,3739,O
simvastatin,3739,B-Chemical
",",3739,O
amiodarone,3739,B-Chemical
",",3739,O
and,3739,O
atazanavir,3739,B-Chemical
resulting,3739,O
in,3739,O
rhabdomyolysis,3739,B-Disease
and,3739,O
acute,3739,B-Disease
renal,3739,I-Disease
failure,3739,I-Disease
.,3739,O
BACKGROUND,3740,O
:,3740,O
A,3740,O
72-year-old,3740,O
white,3740,O
man,3740,O
with,3740,O
underlying,3740,O
human,3740,B-Disease
immunodeficiency,3740,I-Disease
virus,3740,I-Disease
",",3740,O
atrial,3740,B-Disease
fibrillation,3740,I-Disease
",",3740,O
coronary,3740,B-Disease
artery,3740,I-Disease
disease,3740,I-Disease
",",3740,O
and,3740,O
hyperlipidemia,3740,B-Disease
presented,3740,O
with,3740,O
generalized,3740,O
pain,3740,B-Disease
",",3740,O
fatigue,3740,B-Disease
",",3740,O
and,3740,O
dark,3740,O
orange,3740,O
urine,3740,O
for,3740,O
3,3740,O
days,3740,O
.,3740,O
The,3741,O
patient,3741,O
was,3741,O
taking,3741,O
80,3741,O
mg,3741,O
simvastatin,3741,B-Chemical
at,3741,O
bedtime,3741,O
(,3741,O
initiated,3741,O
27,3741,O
days,3741,O
earlier,3741,O
),3741,O
;,3741,O
amiodarone,3741,B-Chemical
at,3741,O
a,3741,O
dose,3741,O
of,3741,O
400,3741,O
mg,3741,O
daily,3741,O
for,3741,O
7,3741,O
days,3741,O
",",3741,O
then,3741,O
200,3741,O
mg,3741,O
daily,3741,O
(,3741,O
initiated,3741,O
19,3741,O
days,3741,O
earlier,3741,O
),3741,O
;,3741,O
and,3741,O
400,3741,O
mg,3741,O
atazanavir,3741,B-Chemical
daily,3741,O
(,3741,O
initiated,3741,O
at,3741,O
least,3741,O
2,3741,O
years,3741,O
previously,3741,O
),3741,O
.,3741,O
Laboratory,3742,O
evaluation,3742,O
revealed,3742,O
"66,680",3742,O
U/L,3742,O
creatine,3742,B-Chemical
kinase,3742,O
",",3742,O
93,3742,O
mg/dL,3742,O
blood,3742,B-Chemical
urea,3742,I-Chemical
nitrogen,3742,I-Chemical
",",3742,O
4.6,3742,O
mg/dL,3742,O
creatinine,3742,B-Chemical
",",3742,O
1579,3742,O
U/L,3742,O
aspartate,3742,B-Chemical
aminotransferase,3742,O
",",3742,O
and,3742,O
738,3742,O
U/L,3742,O
alanine,3742,B-Chemical
aminotransferase,3742,O
.,3742,O
Simvastatin,3743,B-Chemical
",",3743,O
amiodarone,3743,B-Chemical
",",3743,O
and,3743,O
the,3743,O
patient,3743,O
's,3743,O
human,3743,B-Disease
immunodeficiency,3743,I-Disease
virus,3743,I-Disease
medications,3743,O
were,3743,O
all,3743,O
temporarily,3743,O
discontinued,3743,O
and,3743,O
the,3743,O
patient,3743,O
was,3743,O
given,3743,O
forced,3743,O
alkaline,3743,O
diuresis,3743,O
and,3743,O
started,3743,O
on,3743,O
dialysis,3743,O
.,3743,O
Nine,3744,O
days,3744,O
later,3744,O
the,3744,O
patient,3744,O
's,3744,O
creatine,3744,B-Chemical
kinase,3744,O
had,3744,O
dropped,3744,O
to,3744,O
1695,3744,O
U/L,3744,O
and,3744,O
creatinine,3744,B-Chemical
was,3744,O
3.3,3744,O
mg/dL,3744,O
.,3744,O
The,3745,O
patient,3745,O
was,3745,O
discharged,3745,O
and,3745,O
continued,3745,O
outpatient,3745,O
dialysis,3745,O
for,3745,O
1,3745,O
month,3745,O
until,3745,O
his,3745,O
renal,3745,O
function,3745,O
recovered,3745,O
.,3745,O
DISCUSSION,3746,O
:,3746,O
The,3746,O
risk,3746,O
of,3746,O
rhabdomyolysis,3746,B-Disease
is,3746,O
increased,3746,O
in,3746,O
the,3746,O
presence,3746,O
of,3746,O
concomitant,3746,O
drugs,3746,O
that,3746,O
inhibit,3746,O
simvastatin,3746,B-Chemical
metabolism,3746,O
.,3746,O
Simvastatin,3747,B-Chemical
is,3747,O
metabolized,3747,O
by,3747,O
CYP3A4,3747,O
.,3747,O
Amiodarone,3748,B-Chemical
and,3748,O
atazanavir,3748,B-Chemical
are,3748,O
recognized,3748,O
CYP3A4,3748,O
inhibitors,3748,O
.,3748,O
CONCLUSIONS,3749,O
:,3749,O
Pharmacokinetic,3749,O
differences,3749,O
in,3749,O
statins,3749,B-Chemical
are,3749,O
an,3749,O
important,3749,O
consideration,3749,O
for,3749,O
assessing,3749,O
the,3749,O
risk,3749,O
of,3749,O
potential,3749,O
drug,3749,O
interactions,3749,O
.,3749,O
In,3750,O
patients,3750,O
requiring,3750,O
the,3750,O
concurrent,3750,O
use,3750,O
of,3750,O
statins,3750,B-Chemical
and,3750,O
CYP3A4,3750,O
inhibitors,3750,O
",",3750,O
pravastatin,3750,B-Chemical
",",3750,O
fluvastatin,3750,B-Chemical
",",3750,O
and,3750,O
rosuvastatin,3750,B-Chemical
carry,3750,O
the,3750,O
lowest,3750,O
risk,3750,O
of,3750,O
drug,3750,O
interactions,3750,O
;,3750,O
atorvastatin,3750,B-Chemical
carries,3750,O
moderate,3750,O
risk,3750,O
",",3750,O
whereas,3750,O
simvastatin,3750,B-Chemical
and,3750,O
lovastatin,3750,B-Chemical
have,3750,O
the,3750,O
highest,3750,O
risk,3750,O
and,3750,O
should,3750,O
be,3750,O
avoided,3750,O
in,3750,O
patients,3750,O
taking,3750,O
concomitant,3750,O
CYP3A4,3750,O
inhibitors,3750,O
.,3750,O
Interaction,3751,O
between,3751,O
warfarin,3751,B-Chemical
and,3751,O
levofloxacin,3751,B-Chemical
:,3751,O
case,3751,O
series,3751,O
.,3751,O
Warfarin,3752,B-Chemical
is,3752,O
the,3752,O
most,3752,O
widely,3752,O
used,3752,O
oral,3752,O
anticoagulant,3752,O
and,3752,O
is,3752,O
indicated,3752,O
for,3752,O
many,3752,O
clinical,3752,O
conditions,3752,O
.,3752,O
Levofloxacin,3753,B-Chemical
",",3753,O
a,3753,O
fluoroquinolone,3753,B-Chemical
",",3753,O
is,3753,O
one,3753,O
of,3753,O
the,3753,O
most,3753,O
commonly,3753,O
prescribed,3753,O
antibiotics,3753,O
in,3753,O
clinical,3753,O
practice,3753,O
and,3753,O
is,3753,O
effective,3753,O
against,3753,O
Gram-positive,3753,O
",",3753,O
Gram-negative,3753,O
",",3753,O
and,3753,O
atypical,3753,O
bacteria,3753,O
.,3753,O
While,3754,O
small,3754,O
prospective,3754,O
studies,3754,O
have,3754,O
not,3754,O
revealed,3754,O
any,3754,O
significant,3754,O
drug-drug,3754,O
interaction,3754,O
between,3754,O
warfarin,3754,B-Chemical
and,3754,O
levofloxacin,3754,B-Chemical
",",3754,O
several,3754,O
case,3754,O
reports,3754,O
have,3754,O
indicated,3754,O
that,3754,O
levofloxacin,3754,B-Chemical
may,3754,O
significantly,3754,O
potentiate,3754,O
the,3754,O
anticoagulation,3754,O
effect,3754,O
of,3754,O
warfarin,3754,B-Chemical
.,3754,O
We,3755,O
report,3755,O
3,3755,O
cases,3755,O
of,3755,O
serious,3755,O
bleeding,3755,B-Disease
complications,3755,O
that,3755,O
appear,3755,O
to,3755,O
be,3755,O
the,3755,O
result,3755,O
of,3755,O
the,3755,O
interaction,3755,O
between,3755,O
warfarin,3755,B-Chemical
and,3755,O
levofloxacin,3755,B-Chemical
.,3755,O
Physicians,3756,O
should,3756,O
be,3756,O
aware,3756,O
of,3756,O
this,3756,O
potential,3756,O
interaction,3756,O
and,3756,O
use,3756,O
caution,3756,O
when,3756,O
prescribing,3756,O
levofloxacin,3756,B-Chemical
to,3756,O
patients,3756,O
taking,3756,O
warfarin,3756,B-Chemical
.,3756,O
Mutations,3757,O
associated,3757,O
with,3757,O
lamivudine-resistance,3757,B-Chemical
in,3757,O
therapy-na,3757,O
ve,3757,O
hepatitis,3757,B-Disease
B,3757,I-Disease
virus,3757,I-Disease
(,3757,I-Disease
HBV,3757,I-Disease
),3757,I-Disease
infected,3757,I-Disease
patients,3757,O
with,3757,O
and,3757,O
without,3757,O
HIV,3757,B-Disease
co-infection,3757,I-Disease
:,3757,O
implications,3757,O
for,3757,O
antiretroviral,3757,O
therapy,3757,O
in,3757,O
HBV,3757,O
and,3757,O
HIV,3757,O
co-infected,3757,O
South,3757,O
African,3757,O
patients,3757,O
.,3757,O
This,3758,O
was,3758,O
an,3758,O
exploratory,3758,O
study,3758,O
to,3758,O
investigate,3758,O
lamivudine-resistant,3758,B-Chemical
hepatitis,3758,B-Disease
B,3758,I-Disease
virus,3758,O
(,3758,O
HBV,3758,O
),3758,O
strains,3758,O
in,3758,O
selected,3758,O
lamivudine-na,3758,B-Chemical
ve,3758,O
HBV,3758,O
carriers,3758,O
with,3758,O
and,3758,O
without,3758,O
human,3758,B-Disease
immunodeficiency,3758,I-Disease
virus,3758,I-Disease
(,3758,I-Disease
HIV,3758,I-Disease
),3758,I-Disease
co-infection,3758,I-Disease
in,3758,O
South,3758,O
African,3758,O
patients,3758,O
.,3758,O
Thirty-five,3759,O
lamivudine-na,3759,B-Chemical
ve,3759,O
HBV,3759,B-Disease
infected,3759,I-Disease
patients,3759,O
with,3759,O
or,3759,O
without,3759,O
HIV,3759,B-Disease
co-infection,3759,I-Disease
were,3759,O
studied,3759,O
:,3759,O
15,3759,O
chronic,3759,O
HBV,3759,B-Disease
mono-infected,3759,I-Disease
patients,3759,O
and,3759,O
20,3759,O
HBV-HIV,3759,O
co-infected,3759,O
patients,3759,O
.,3759,O
The,3760,O
latter,3760,O
group,3760,O
was,3760,O
further,3760,O
sub-divided,3760,O
into,3760,O
13,3760,O
occult,3760,O
HBV,3760,O
(,3760,O
HBsAg-negative,3760,B-Chemical
),3760,O
and,3760,O
7,3760,O
overt,3760,O
HBV,3760,O
(,3760,O
HBsAg-,3760,B-Chemical
positive,3760,O
),3760,O
patients,3760,O
.,3760,O
HBsAg,3761,B-Chemical
",",3761,O
anti-HBs,3761,O
",",3761,O
anti-HBc,3761,O
",",3761,O
and,3761,O
anti-HIV,3761,O
1/2,3761,O
were,3761,O
determined,3761,O
as,3761,O
part,3761,O
of,3761,O
routine,3761,O
diagnosis,3761,O
using,3761,O
Axsym,3761,O
assays,3761,O
(,3761,O
Abbott,3761,O
Laboratories,3761,O
",",3761,O
North,3761,O
Chicago,3761,O
",",3761,O
IL,3761,O
),3761,O
.,3761,O
Serum,3762,O
samples,3762,O
were,3762,O
PCR,3762,O
amplified,3762,O
with,3762,O
HBV,3762,O
reverse,3762,O
transcriptase,3762,O
(,3762,O
RT,3762,O
),3762,O
primers,3762,O
",",3762,O
followed,3762,O
by,3762,O
direct,3762,O
sequencing,3762,O
across,3762,O
the,3762,O
tyrosine-methionine-aspartate-aspartate,3762,B-Chemical
(,3762,O
YMDD,3762,O
),3762,O
motif,3762,O
of,3762,O
the,3762,O
major,3762,O
catalytic,3762,O
region,3762,O
in,3762,O
the,3762,O
C,3762,O
domain,3762,O
of,3762,O
the,3762,O
HBV,3762,O
RT,3762,O
enzyme,3762,O
.,3762,O
HBV,3763,O
viral,3763,O
load,3763,O
was,3763,O
performed,3763,O
with,3763,O
Amplicor,3763,O
HBV,3763,O
Monitor,3763,O
test,3763,O
v2.0,3763,O
(,3763,O
Roche,3763,O
Diagnostics,3763,O
",",3763,O
Penzberg,3763,O
",",3763,O
Germany,3763,O
),3763,O
.,3763,O
HBV,3764,O
lamivudine-resistant,3764,B-Chemical
strains,3764,O
were,3764,O
detected,3764,O
in,3764,O
3,3764,O
of,3764,O
15,3764,O
mono-infected,3764,O
chronic,3764,O
hepatitis,3764,B-Disease
B,3764,I-Disease
patients,3764,O
and,3764,O
10,3764,O
of,3764,O
20,3764,O
HBV-HIV,3764,O
co-infected,3764,O
patients,3764,O
.,3764,O
To,3765,O
the,3765,O
best,3765,O
of,3765,O
our,3765,O
knowledge,3765,O
",",3765,O
this,3765,O
constitutes,3765,O
the,3765,O
first,3765,O
report,3765,O
of,3765,O
HBV,3765,O
lamivudine-resistant,3765,B-Chemical
strains,3765,O
in,3765,O
therapy-na,3765,O
ve,3765,O
HBV-HIV,3765,O
co-infected,3765,O
patients,3765,O
.,3765,O
The,3766,O
HBV,3766,O
viral,3766,O
loads,3766,O
for,3766,O
mono-infected,3766,O
and,3766,O
co-infected,3766,O
patients,3766,O
ranged,3766,O
from,3766,O
3.32,3766,O
x,3766,O
10,3766,O
(,3766,O
2,3766,O
),3766,O
to,3766,O
3.82,3766,O
x,3766,O
10,3766,O
(,3766,O
7,3766,O
),3766,O
and,3766,O
<,3766,O
200,3766,O
to,3766,O
4.40,3766,O
x,3766,O
10,3766,O
(,3766,O
3,3766,O
),3766,O
copies/ml,3766,O
",",3766,O
respectively,3766,O
.,3766,O
It,3767,O
remains,3767,O
to,3767,O
be,3767,O
seen,3767,O
whether,3767,O
such,3767,O
pre-existing,3767,O
antiviral,3767,O
mutations,3767,O
could,3767,O
result,3767,O
in,3767,O
widespread,3767,O
emergence,3767,O
of,3767,O
HBV,3767,O
resistant,3767,O
strains,3767,O
when,3767,O
lamivudine-containing,3767,B-Chemical
highly,3767,O
active,3767,O
antiretroviral,3767,O
(,3767,O
ARV,3767,O
),3767,O
treatment,3767,O
(,3767,O
HAART,3767,O
),3767,O
regimens,3767,O
become,3767,O
widely,3767,O
applied,3767,O
in,3767,O
South,3767,O
Africa,3767,O
",",3767,O
as,3767,O
this,3767,O
is,3767,O
likely,3767,O
to,3767,O
have,3767,O
potential,3767,O
implications,3767,O
in,3767,O
the,3767,O
management,3767,O
of,3767,O
HBV-HIV,3767,O
co-infected,3767,O
patients,3767,O
.,3767,O
Estrogen,3768,O
prevents,3768,O
cholesteryl,3768,B-Chemical
ester,3768,I-Chemical
accumulation,3768,O
in,3768,O
macrophages,3768,O
induced,3768,O
by,3768,O
the,3768,O
HIV,3768,O
protease,3768,O
inhibitor,3768,O
ritonavir,3768,B-Chemical
.,3768,O
Individuals,3769,O
with,3769,O
HIV,3769,O
can,3769,O
now,3769,O
live,3769,O
long,3769,O
lives,3769,O
with,3769,O
drug,3769,O
therapy,3769,O
that,3769,O
often,3769,O
includes,3769,O
protease,3769,O
inhibitors,3769,O
such,3769,O
as,3769,O
ritonavir,3769,B-Chemical
.,3769,O
Many,3770,O
patients,3770,O
",",3770,O
however,3770,O
",",3770,O
develop,3770,O
negative,3770,O
long-term,3770,O
side,3770,O
effects,3770,O
such,3770,O
as,3770,O
premature,3770,B-Disease
atherosclerosis,3770,I-Disease
.,3770,O
We,3771,O
have,3771,O
previously,3771,O
demonstrated,3771,O
that,3771,O
ritonavir,3771,B-Chemical
treatment,3771,O
increases,3771,O
atherosclerotic,3771,B-Disease
lesion,3771,I-Disease
formation,3771,O
in,3771,O
male,3771,O
mice,3771,O
to,3771,O
a,3771,O
greater,3771,O
extent,3771,O
than,3771,O
in,3771,O
female,3771,O
mice,3771,O
.,3771,O
Furthermore,3772,O
",",3772,O
peripheral,3772,O
blood,3772,O
monocytes,3772,O
isolated,3772,O
from,3772,O
ritonavir-treated,3772,B-Chemical
females,3772,O
had,3772,O
less,3772,O
cholesteryl,3772,B-Chemical
ester,3772,I-Chemical
accumulation,3772,O
.,3772,O
In,3773,O
the,3773,O
present,3773,O
study,3773,O
",",3773,O
we,3773,O
have,3773,O
investigated,3773,O
the,3773,O
molecular,3773,O
mechanisms,3773,O
by,3773,O
which,3773,O
female,3773,O
hormones,3773,O
influence,3773,O
cholesterol,3773,B-Chemical
metabolism,3773,O
in,3773,O
macrophages,3773,O
in,3773,O
response,3773,O
to,3773,O
the,3773,O
HIV,3773,O
protease,3773,O
inhibitor,3773,O
ritonavir,3773,B-Chemical
.,3773,O
We,3774,O
have,3774,O
utilized,3774,O
the,3774,O
human,3774,O
monocyte,3774,O
cell,3774,O
line,3774,O
",",3774,O
THP-1,3774,O
as,3774,O
a,3774,O
model,3774,O
to,3774,O
address,3774,O
this,3774,O
question,3774,O
.,3774,O
Briefly,3775,O
",",3775,O
cells,3775,O
were,3775,O
differentiated,3775,O
for,3775,O
72,3775,O
h,3775,O
with,3775,O
100,3775,O
nM,3775,O
PMA,3775,O
to,3775,O
obtain,3775,O
a,3775,O
macrophage-like,3775,O
phenotype,3775,O
in,3775,O
the,3775,O
presence,3775,O
or,3775,O
absence,3775,O
of,3775,O
1,3775,O
nM,3775,O
17beta-estradiol,3775,B-Chemical
(,3775,O
E2,3775,B-Chemical
),3775,O
",",3775,O
100,3775,O
nM,3775,O
progesterone,3775,B-Chemical
or,3775,O
vehicle,3775,O
(,3775,O
0.01,3775,O
%,3775,O
ethanol,3775,B-Chemical
),3775,O
.,3775,O
Cells,3776,O
were,3776,O
then,3776,O
treated,3776,O
with,3776,O
30,3776,O
ng/ml,3776,O
ritonavir,3776,B-Chemical
or,3776,O
vehicle,3776,O
in,3776,O
the,3776,O
presence,3776,O
of,3776,O
aggregated,3776,O
LDL,3776,O
for,3776,O
24,3776,O
h.,3776,O
Cell,3776,O
extracts,3776,O
were,3776,O
harvested,3776,O
",",3776,O
and,3776,O
lipid,3776,O
or,3776,O
total,3776,O
RNA,3776,O
was,3776,O
isolated,3776,O
.,3776,O
E2,3777,B-Chemical
decreased,3777,O
the,3777,O
accumulation,3777,O
of,3777,O
cholesteryl,3777,B-Chemical
esters,3777,I-Chemical
in,3777,O
macrophages,3777,O
following,3777,O
ritonavir,3777,B-Chemical
treatment,3777,O
.,3777,O
Ritonavir,3778,B-Chemical
increased,3778,O
the,3778,O
expression,3778,O
of,3778,O
the,3778,O
scavenger,3778,O
receptor,3778,O
",",3778,O
CD36,3778,O
mRNA,3778,O
",",3778,O
responsible,3778,O
for,3778,O
the,3778,O
uptake,3778,O
of,3778,O
LDL,3778,O
.,3778,O
Additionally,3779,O
",",3779,O
ritonavir,3779,B-Chemical
treatment,3779,O
selectively,3779,O
increased,3779,O
the,3779,O
relative,3779,O
levels,3779,O
of,3779,O
PPARgamma,3779,O
mRNA,3779,O
",",3779,O
a,3779,O
transcription,3779,O
factor,3779,O
responsible,3779,O
for,3779,O
the,3779,O
regulation,3779,O
of,3779,O
CD36,3779,O
mRNA,3779,O
expression,3779,O
.,3779,O
Treatment,3780,O
with,3780,O
E2,3780,B-Chemical
",",3780,O
however,3780,O
",",3780,O
failed,3780,O
to,3780,O
prevent,3780,O
these,3780,O
increases,3780,O
at,3780,O
the,3780,O
mRNA,3780,O
level,3780,O
.,3780,O
E2,3781,B-Chemical
did,3781,O
",",3781,O
however,3781,O
",",3781,O
significantly,3781,O
suppress,3781,O
CD36,3781,O
protein,3781,O
levels,3781,O
as,3781,O
measured,3781,O
by,3781,O
fluorescent,3781,O
immunocytochemistry,3781,O
.,3781,O
This,3782,O
data,3782,O
suggests,3782,O
that,3782,O
E2,3782,B-Chemical
modifies,3782,O
the,3782,O
expression,3782,O
of,3782,O
CD36,3782,O
at,3782,O
the,3782,O
level,3782,O
of,3782,O
protein,3782,O
expression,3782,O
in,3782,O
monocyte-derived,3782,O
macrophages,3782,O
resulting,3782,O
in,3782,O
reduced,3782,O
cholesteryl,3782,B-Chemical
ester,3782,I-Chemical
accumulation,3782,O
following,3782,O
ritonavir,3782,B-Chemical
treatment,3782,O
.,3782,O
Acute,3783,O
hepatitis,3783,B-Disease
attack,3783,O
after,3783,O
exposure,3783,O
to,3783,O
telithromycin,3783,B-Chemical
.,3783,O
INTRODUCTION,3784,O
:,3784,O
Antibiotic-associated,3784,O
hepatotoxicity,3784,B-Disease
is,3784,O
rare,3784,O
.,3784,O
With,3785,O
widespread,3785,O
use,3785,O
of,3785,O
antimicrobial,3785,O
agents,3785,O
",",3785,O
however,3785,O
",",3785,O
hepatic,3785,B-Disease
injury,3785,I-Disease
occurs,3785,O
frequently,3785,O
",",3785,O
and,3785,O
among,3785,O
adverse,3785,B-Disease
drug,3785,I-Disease
reactions,3785,I-Disease
",",3785,O
idiosyncratic,3785,O
reactions,3785,O
are,3785,O
the,3785,O
most,3785,O
serious,3785,O
.,3785,O
CASE,3786,O
SUMMARY,3786,O
:,3786,O
A,3786,O
25-year-old,3786,O
male,3786,O
patient,3786,O
",",3786,O
with,3786,O
a,3786,O
height,3786,O
of,3786,O
175,3786,O
cm,3786,O
and,3786,O
weight,3786,O
of,3786,O
72,3786,O
kg,3786,O
presented,3786,O
to,3786,O
Marmara,3786,O
University,3786,O
Hospital,3786,O
Emergency,3786,O
Department,3786,O
",",3786,O
Istanbul,3786,O
",",3786,O
Turkey,3786,O
",",3786,O
with,3786,O
5,3786,O
days,3786,O
',3786,O
history,3786,O
of,3786,O
jaundice,3786,B-Disease
",",3786,O
malaise,3786,O
",",3786,O
nausea,3786,B-Disease
",",3786,O
and,3786,O
vomiting,3786,B-Disease
.,3786,O
He,3787,O
had,3787,O
been,3787,O
prescribed,3787,O
telithromycin,3787,B-Chemical
400,3787,O
mg/d,3787,O
PO,3787,O
to,3787,O
treat,3787,O
an,3787,O
upper,3787,B-Disease
respiratory,3787,I-Disease
tract,3787,I-Disease
infection,3787,I-Disease
7,3787,O
days,3787,O
prior,3787,O
.,3787,O
Admission,3788,O
laboratory,3788,O
tests,3788,O
were,3788,O
as,3788,O
follows,3788,O
:,3788,O
alanine,3788,B-Chemical
aminotransferase,3788,O
",",3788,O
67,3788,O
U/L,3788,O
(,3788,O
reference,3788,O
range,3788,O
",",3788,O
10-37,3788,O
U/L,3788,O
),3788,O
;,3788,O
aspartate,3788,B-Chemical
aminotransferase,3788,O
",",3788,O
98,3788,O
U/L,3788,O
(,3788,O
10-40,3788,O
U/L,3788,O
),3788,O
;,3788,O
alkaline,3788,O
phosphatase,3788,O
",",3788,O
513,3788,O
U/L,3788,O
(,3788,O
0-270,3788,O
U/L,3788,O
),3788,O
;,3788,O
gamma-glutamyltransferase,3788,O
",",3788,O
32,3788,O
U/L,3788,O
(,3788,O
7-49,3788,O
U/L,3788,O
),3788,O
;,3788,O
amylase,3788,O
",",3788,O
46,3788,O
U/L,3788,O
(,3788,O
0-220,3788,O
U/L,3788,O
),3788,O
;,3788,O
total,3788,O
bilirubin,3788,B-Chemical
",",3788,O
20.1,3788,O
mg/dL,3788,O
(,3788,O
0.2-1.0,3788,O
mg/dL,3788,O
),3788,O
;,3788,O
direct,3788,O
bilirubin,3788,B-Chemical
",",3788,O
14.8,3788,O
mg/dL,3788,O
(,3788,O
0-0.3,3788,O
mg/dL,3788,O
),3788,O
;,3788,O
and,3788,O
albumin,3788,O
",",3788,O
4.7,3788,O
mg/dL,3788,O
(,3788,O
3.5-5.4,3788,O
mg/dL,3788,O
),3788,O
.,3788,O
No,3789,O
toxin,3789,O
",",3789,O
alcohol,3789,B-Chemical
",",3789,O
or,3789,O
other,3789,O
drugs,3789,O
were,3789,O
reported,3789,O
.,3789,O
The,3790,O
patient,3790,O
had,3790,O
suffered,3790,O
a,3790,O
previous,3790,O
episode,3790,O
of,3790,O
``,3790,O
acute,3790,O
hepatitis,3790,B-Disease
of,3790,O
unknown,3790,O
origin,3790,O
",",3790,O
'',3790,O
that,3790,O
occurred,3790,O
after,3790,O
telithromycin,3790,B-Chemical
usage,3790,O
.,3790,O
Both,3791,O
incidents,3791,O
occurred,3791,O
within,3791,O
a,3791,O
year,3791,O
.,3791,O
DISCUSSION,3792,O
:,3792,O
Telithromycin,3792,B-Chemical
is,3792,O
the,3792,O
first,3792,O
of,3792,O
the,3792,O
ketolide,3792,O
antibacterials,3792,O
to,3792,O
receive,3792,O
US,3792,O
Food,3792,O
and,3792,O
Drug,3792,O
Administration,3792,O
approval,3792,O
for,3792,O
clinical,3792,O
use,3792,O
.,3792,O
It,3793,O
has,3793,O
been,3793,O
associated,3793,O
with,3793,O
infrequent,3793,O
and,3793,O
usually,3793,O
reversible,3793,O
severe,3793,O
hepatic,3793,B-Disease
dysfunction,3793,I-Disease
.,3793,O
Based,3794,O
on,3794,O
a,3794,O
score,3794,O
of,3794,O
8,3794,O
on,3794,O
the,3794,O
Naranjo,3794,O
adverse,3794,B-Disease
drug,3794,I-Disease
reaction,3794,I-Disease
probability,3794,O
scale,3794,O
",",3794,O
telithromycin,3794,B-Chemical
was,3794,O
the,3794,O
probable,3794,O
cause,3794,O
of,3794,O
acute,3794,O
hepatitis,3794,B-Disease
in,3794,O
this,3794,O
patient,3794,O
",",3794,O
and,3794,O
pathological,3794,O
findings,3794,O
suggested,3794,O
drug-induced,3794,O
toxic,3794,B-Disease
hepatitis,3794,I-Disease
.,3794,O
Recurrence,3795,O
of,3795,O
hepatitis,3795,B-Disease
attack,3795,O
might,3795,O
have,3795,O
been,3795,O
avoided,3795,O
if,3795,O
the,3795,O
initial,3795,O
incident,3795,O
had,3795,O
been,3795,O
communicated,3795,O
to,3795,O
the,3795,O
attending,3795,O
physician,3795,O
who,3795,O
prescribed,3795,O
telithromycin,3795,B-Chemical
the,3795,O
second,3795,O
time,3795,O
.,3795,O
CONCLUSION,3796,O
:,3796,O
Here,3796,O
we,3796,O
report,3796,O
a,3796,O
case,3796,O
of,3796,O
acute,3796,O
hepatitis,3796,B-Disease
probably,3796,O
associated,3796,O
with,3796,O
the,3796,O
administration,3796,O
of,3796,O
telithromycin,3796,B-Chemical
.,3796,O
A,3797,O
study,3797,O
on,3797,O
the,3797,O
effect,3797,O
of,3797,O
the,3797,O
duration,3797,O
of,3797,O
subcutaneous,3797,O
heparin,3797,B-Chemical
injection,3797,O
on,3797,O
bruising,3797,B-Disease
and,3797,O
pain,3797,B-Disease
.,3797,O
AIM,3798,O
:,3798,O
This,3798,O
study,3798,O
was,3798,O
carried,3798,O
out,3798,O
to,3798,O
determine,3798,O
the,3798,O
effect,3798,O
of,3798,O
injection,3798,O
duration,3798,O
on,3798,O
bruising,3798,B-Disease
and,3798,O
pain,3798,B-Disease
following,3798,O
the,3798,O
administration,3798,O
of,3798,O
the,3798,O
subcutaneous,3798,O
injection,3798,O
of,3798,O
heparin,3798,B-Chemical
.,3798,O
BACKGROUND,3799,O
:,3799,O
Although,3799,O
different,3799,O
methods,3799,O
to,3799,O
prevent,3799,O
bruising,3799,B-Disease
and,3799,O
pain,3799,B-Disease
following,3799,O
the,3799,O
subcutaneous,3799,O
injection,3799,O
of,3799,O
heparin,3799,B-Chemical
have,3799,O
been,3799,O
widely,3799,O
studied,3799,O
and,3799,O
described,3799,O
",",3799,O
the,3799,O
effect,3799,O
of,3799,O
injection,3799,O
duration,3799,O
on,3799,O
the,3799,O
occurrence,3799,O
of,3799,O
bruising,3799,B-Disease
and,3799,O
pain,3799,B-Disease
is,3799,O
little,3799,O
documented,3799,O
.,3799,O
DESIGN,3800,O
:,3800,O
This,3800,O
study,3800,O
was,3800,O
designed,3800,O
as,3800,O
within-subject,3800,O
",",3800,O
quasi-experimental,3800,O
research,3800,O
.,3800,O
METHOD,3801,O
:,3801,O
The,3801,O
sample,3801,O
for,3801,O
the,3801,O
study,3801,O
consisted,3801,O
of,3801,O
50,3801,O
patients,3801,O
to,3801,O
whom,3801,O
subcutaneous,3801,O
heparin,3801,B-Chemical
was,3801,O
administered,3801,O
.,3801,O
Heparin,3802,B-Chemical
was,3802,O
injected,3802,O
over,3802,O
10,3802,O
seconds,3802,O
on,3802,O
the,3802,O
right,3802,O
abdominal,3802,O
site,3802,O
and,3802,O
30,3802,O
seconds,3802,O
on,3802,O
the,3802,O
left,3802,O
abdominal,3802,O
site,3802,O
.,3802,O
Injections,3803,O
areas,3803,O
were,3803,O
assessed,3803,O
for,3803,O
the,3803,O
presence,3803,O
of,3803,O
bruising,3803,B-Disease
at,3803,O
48,3803,O
and,3803,O
72,3803,O
hours,3803,O
after,3803,O
each,3803,O
injection,3803,O
.,3803,O
Dimensions,3804,O
of,3804,O
the,3804,O
bruising,3804,B-Disease
on,3804,O
the,3804,O
heparin,3804,B-Chemical
applied,3804,O
areas,3804,O
were,3804,O
measured,3804,O
using,3804,O
transparent,3804,O
millimetric,3804,O
measuring,3804,O
paper,3804,O
.,3804,O
The,3805,O
visual,3805,O
analog,3805,O
scale,3805,O
(,3805,O
VAS,3805,O
),3805,O
was,3805,O
used,3805,O
to,3805,O
measure,3805,O
pain,3805,B-Disease
intensity,3805,O
and,3805,O
a,3805,O
stop-watch,3805,O
was,3805,O
used,3805,O
to,3805,O
time,3805,O
the,3805,O
pain,3805,B-Disease
period,3805,O
.,3805,O
Data,3806,O
were,3806,O
analysed,3806,O
using,3806,O
chi-square,3806,O
test,3806,O
",",3806,O
Mann-Whitney,3806,O
U,3806,O
",",3806,O
Wilcoxon,3806,O
signed,3806,O
ranks,3806,O
tests,3806,O
and,3806,O
correlation,3806,O
.,3806,O
RESULTS,3807,O
:,3807,O
The,3807,O
percentage,3807,O
of,3807,O
bruising,3807,B-Disease
occurrence,3807,O
was,3807,O
64,3807,O
%,3807,O
with,3807,O
the,3807,O
injection,3807,O
of,3807,O
10,3807,O
seconds,3807,O
duration,3807,O
and,3807,O
42,3807,O
%,3807,O
in,3807,O
the,3807,O
30-second,3807,O
injection,3807,O
.,3807,O
It,3808,O
was,3808,O
determined,3808,O
that,3808,O
the,3808,O
size,3808,O
of,3808,O
the,3808,O
bruising,3808,B-Disease
was,3808,O
smaller,3808,O
in,3808,O
the,3808,O
30-second,3808,O
injection,3808,O
.,3808,O
Pain,3809,B-Disease
intensity,3809,O
and,3809,O
pain,3809,B-Disease
period,3809,O
were,3809,O
statistically,3809,O
significantly,3809,O
lower,3809,O
for,3809,O
the,3809,O
30-second,3809,O
injection,3809,O
than,3809,O
for,3809,O
the,3809,O
10-second,3809,O
injection,3809,O
.,3809,O
CONCLUSIONS,3810,O
:,3810,O
It,3810,O
was,3810,O
determined,3810,O
that,3810,O
injection,3810,O
duration,3810,O
had,3810,O
an,3810,O
effect,3810,O
on,3810,O
bruising,3810,B-Disease
and,3810,O
pain,3810,B-Disease
following,3810,O
the,3810,O
subcutaneous,3810,O
administration,3810,O
of,3810,O
heparin,3810,B-Chemical
.,3810,O
This,3811,O
study,3811,O
should,3811,O
be,3811,O
repeated,3811,O
on,3811,O
a,3811,O
larger,3811,O
sample,3811,O
.,3811,O
RELEVANCE,3812,O
TO,3812,O
CLINICAL,3812,O
PRACTICE,3812,O
:,3812,O
When,3812,O
administering,3812,O
subcutaneous,3812,O
heparin,3812,B-Chemical
injections,3812,O
",",3812,O
it,3812,O
is,3812,O
important,3812,O
to,3812,O
extend,3812,O
the,3812,O
duration,3812,O
of,3812,O
the,3812,O
injection,3812,O
.,3812,O
Acute,3813,B-Disease
liver,3813,I-Disease
failure,3813,I-Disease
in,3813,O
two,3813,O
patients,3813,O
with,3813,O
regular,3813,O
alcohol,3813,B-Chemical
consumption,3813,O
ingesting,3813,O
paracetamol,3813,B-Chemical
at,3813,O
therapeutic,3813,O
dosage,3813,O
.,3813,O
BACKGROUND,3814,O
:,3814,O
The,3814,O
possible,3814,O
role,3814,O
of,3814,O
alcohol,3814,B-Chemical
in,3814,O
the,3814,O
development,3814,O
of,3814,O
hepatotoxicity,3814,B-Disease
associated,3814,O
with,3814,O
therapeutic,3814,O
doses,3814,O
of,3814,O
paracetamol,3814,B-Chemical
(,3814,O
acetaminophen,3814,B-Chemical
),3814,O
is,3814,O
currently,3814,O
debated,3814,O
.,3814,O
CASE,3815,O
REPORT,3815,O
:,3815,O
We,3815,O
describe,3815,O
2,3815,O
patients,3815,O
who,3815,O
were,3815,O
regular,3815,O
consumers,3815,O
of,3815,O
alcohol,3815,B-Chemical
and,3815,O
who,3815,O
developed,3815,O
liver,3815,B-Disease
failure,3815,I-Disease
within,3815,O
3-5,3815,O
days,3815,O
after,3815,O
hospitalization,3815,O
and,3815,O
stopping,3815,O
alcohol,3815,B-Chemical
consumption,3815,O
while,3815,O
being,3815,O
treated,3815,O
with,3815,O
4,3815,O
g,3815,O
paracetamol/day,3815,B-Chemical
.,3815,O
A,3816,O
paracetamol,3816,B-Chemical
serum,3816,O
level,3816,O
obtained,3816,O
in,3816,O
one,3816,O
of,3816,O
these,3816,O
patients,3816,O
was,3816,O
not,3816,O
in,3816,O
the,3816,O
toxic,3816,O
range,3816,O
.,3816,O
Possible,3817,O
risk,3817,O
factors,3817,O
for,3817,O
the,3817,O
development,3817,O
of,3817,O
hepatotoxicity,3817,B-Disease
in,3817,O
patients,3817,O
treated,3817,O
with,3817,O
therapeutic,3817,O
doses,3817,O
of,3817,O
paracetamol,3817,B-Chemical
are,3817,O
discussed,3817,O
.,3817,O
CONCLUSION,3818,O
:,3818,O
In,3818,O
patients,3818,O
with,3818,O
risk,3818,O
factors,3818,O
",",3818,O
e.g,3818,O
.,3818,O
regular,3819,O
consumption,3819,O
of,3819,O
alcohol,3819,B-Chemical
",",3819,O
liver,3819,B-Disease
failure,3819,I-Disease
is,3819,O
possible,3819,O
when,3819,O
therapeutic,3819,O
doses,3819,O
are,3819,O
ingested,3819,O
.,3819,O
We,3820,O
propose,3820,O
that,3820,O
the,3820,O
paracetamol,3820,B-Chemical
dose,3820,O
should,3820,O
not,3820,O
exceed,3820,O
2,3820,O
g/day,3820,O
in,3820,O
such,3820,O
patients,3820,O
and,3820,O
that,3820,O
their,3820,O
liver,3820,O
function,3820,O
should,3820,O
be,3820,O
monitored,3820,O
closely,3820,O
while,3820,O
being,3820,O
treated,3820,O
with,3820,O
paracetamol,3820,B-Chemical
.,3820,O
Associations,3821,O
between,3821,O
use,3821,O
of,3821,O
benzodiazepines,3821,B-Chemical
or,3821,O
related,3821,O
drugs,3821,O
and,3821,O
health,3821,O
",",3821,O
physical,3821,O
abilities,3821,O
and,3821,O
cognitive,3821,O
function,3821,O
:,3821,O
a,3821,O
non-randomised,3821,O
clinical,3821,O
study,3821,O
in,3821,O
the,3821,O
elderly,3821,O
.,3821,O
OBJECTIVE,3822,O
:,3822,O
To,3822,O
describe,3822,O
associations,3822,O
between,3822,O
the,3822,O
use,3822,O
of,3822,O
benzodiazepines,3822,B-Chemical
or,3822,O
related,3822,O
drugs,3822,O
(,3822,O
BZDs/RDs,3822,B-Chemical
),3822,O
and,3822,O
health,3822,O
",",3822,O
functional,3822,O
abilities,3822,O
and,3822,O
cognitive,3822,O
function,3822,O
in,3822,O
the,3822,O
elderly,3822,O
.,3822,O
METHODS,3823,O
:,3823,O
A,3823,O
non-randomised,3823,O
clinical,3823,O
study,3823,O
of,3823,O
patients,3823,O
aged,3823,O
>,3823,O
or,3823,O
=65,3823,O
years,3823,O
admitted,3823,O
to,3823,O
acute,3823,O
hospital,3823,O
wards,3823,O
during,3823,O
1,3823,O
month,3823,O
.,3823,O
164,3824,O
patients,3824,O
(,3824,O
mean,3824,O
age,3824,O
+/-,3824,O
standard,3824,O
deviation,3824,O
[,3824,O
SD,3824,O
],3824,O
81.6,3824,O
+/-,3824,O
6.8,3824,O
years,3824,O
),3824,O
were,3824,O
admitted,3824,O
.,3824,O
Of,3825,O
these,3825,O
",",3825,O
nearly,3825,O
half,3825,O
(,3825,O
n,3825,O
=,3825,O
78,3825,O
),3825,O
had,3825,O
used,3825,O
BZDs/RDs,3825,B-Chemical
before,3825,O
admission,3825,O
",",3825,O
and,3825,O
the,3825,O
remainder,3825,O
(,3825,O
n,3825,O
=,3825,O
86,3825,O
),3825,O
were,3825,O
non-users,3825,O
.,3825,O
Cognitive,3826,O
ability,3826,O
was,3826,O
assessed,3826,O
by,3826,O
the,3826,O
Mini-Mental,3826,O
State,3826,O
Examination,3826,O
(,3826,O
MMSE,3826,O
),3826,O
.,3826,O
Patients,3827,O
scoring,3827,O
>,3827,O
or,3827,O
=20,3827,O
MMSE,3827,O
sum,3827,O
points,3827,O
were,3827,O
interviewed,3827,O
(,3827,O
n,3827,O
=,3827,O
79,3827,O
),3827,O
and,3827,O
questioned,3827,O
regarding,3827,O
symptoms,3827,O
and,3827,O
functional,3827,O
abilities,3827,O
during,3827,O
the,3827,O
week,3827,O
prior,3827,O
to,3827,O
admission,3827,O
.,3827,O
Data,3828,O
on,3828,O
use,3828,O
of,3828,O
BZDs/RDs,3828,B-Chemical
before,3828,O
admission,3828,O
",",3828,O
current,3828,O
medications,3828,O
and,3828,O
discharge,3828,O
diagnoses,3828,O
were,3828,O
collected,3828,O
from,3828,O
medical,3828,O
records,3828,O
.,3828,O
Health,3829,O
",",3829,O
physical,3829,O
abilities,3829,O
and,3829,O
cognitive,3829,O
function,3829,O
were,3829,O
compared,3829,O
between,3829,O
BZD/RD,3829,O
users,3829,O
and,3829,O
non-users,3829,O
",",3829,O
and,3829,O
adjustments,3829,O
were,3829,O
made,3829,O
for,3829,O
confounding,3829,O
variables,3829,O
.,3829,O
The,3830,O
residual,3830,O
serum,3830,O
concentrations,3830,O
of,3830,O
oxazepam,3830,B-Chemical
",",3830,O
temazepam,3830,B-Chemical
and,3830,O
zopiclone,3830,B-Chemical
were,3830,O
analysed,3830,O
.,3830,O
RESULTS,3831,O
:,3831,O
The,3831,O
mean,3831,O
+/-,3831,O
SD,3831,O
duration,3831,O
of,3831,O
BZD/RD,3831,O
use,3831,O
was,3831,O
7,3831,O
+/-,3831,O
7,3831,O
years,3831,O
(,3831,O
range,3831,O
1-31,3831,O
),3831,O
.,3831,O
Two,3832,O
or,3832,O
three,3832,O
BZDs/RDs,3832,B-Chemical
were,3832,O
concomitantly,3832,O
taken,3832,O
by,3832,O
26,3832,O
%,3832,O
of,3832,O
users,3832,O
(,3832,O
n,3832,O
=,3832,O
20,3832,O
),3832,O
.,3832,O
Long-term,3833,O
use,3833,O
of,3833,O
these,3833,O
drugs,3833,O
was,3833,O
associated,3833,O
with,3833,O
female,3833,O
sex,3833,O
and,3833,O
use,3833,O
of,3833,O
a,3833,O
higher,3833,O
number,3833,O
of,3833,O
drugs,3833,O
with,3833,O
effects,3833,O
on,3833,O
the,3833,O
CNS,3833,O
",",3833,O
which,3833,O
tended,3833,O
to,3833,O
be,3833,O
related,3833,O
to,3833,O
diagnosed,3833,O
dementia,3833,B-Disease
.,3833,O
After,3834,O
adjustment,3834,O
for,3834,O
these,3834,O
variables,3834,O
as,3834,O
confounders,3834,O
",",3834,O
use,3834,O
of,3834,O
BZDs/RDs,3834,B-Chemical
was,3834,O
not,3834,O
associated,3834,O
with,3834,O
cognitive,3834,O
function,3834,O
as,3834,O
measured,3834,O
by,3834,O
the,3834,O
MMSE,3834,O
.,3834,O
However,3835,O
",",3835,O
use,3835,O
of,3835,O
BZDs/RDs,3835,B-Chemical
was,3835,O
associated,3835,O
with,3835,O
dizziness,3835,B-Disease
",",3835,O
inability,3835,B-Disease
to,3835,I-Disease
sleep,3835,I-Disease
after,3835,O
awaking,3835,O
at,3835,O
night,3835,O
and,3835,O
tiredness,3835,B-Disease
in,3835,O
the,3835,O
mornings,3835,O
during,3835,O
the,3835,O
week,3835,O
prior,3835,O
to,3835,O
admission,3835,O
and,3835,O
with,3835,O
stronger,3835,O
depressive,3835,B-Disease
symptoms,3835,I-Disease
measured,3835,O
at,3835,O
the,3835,O
beginning,3835,O
of,3835,O
the,3835,O
hospital,3835,O
stay,3835,O
.,3835,O
Use,3836,O
of,3836,O
BZDs/RDs,3836,B-Chemical
tended,3836,O
to,3836,O
be,3836,O
associated,3836,O
with,3836,O
a,3836,O
reduced,3836,O
ability,3836,O
to,3836,O
walk,3836,O
and,3836,O
shorter,3836,O
night-time,3836,O
sleep,3836,O
during,3836,O
the,3836,O
week,3836,O
prior,3836,O
to,3836,O
admission,3836,O
.,3836,O
A,3837,O
higher,3837,O
residual,3837,O
serum,3837,O
concentration,3837,O
of,3837,O
temazepam,3837,B-Chemical
correlated,3837,O
with,3837,O
a,3837,O
lower,3837,O
MMSE,3837,O
sum,3837,O
score,3837,O
after,3837,O
adjustment,3837,O
for,3837,O
confounding,3837,O
variables,3837,O
.,3837,O
CONCLUSIONS,3838,O
:,3838,O
Long-term,3838,O
use,3838,O
and,3838,O
concomitant,3838,O
use,3838,O
of,3838,O
more,3838,O
than,3838,O
one,3838,O
BZD/RD,3838,O
were,3838,O
common,3838,O
in,3838,O
elderly,3838,O
patients,3838,O
hospitalised,3838,O
because,3838,O
of,3838,O
acute,3838,O
illnesses,3838,O
.,3838,O
Long-term,3839,O
use,3839,O
was,3839,O
associated,3839,O
with,3839,O
daytime,3839,O
and,3839,O
night-time,3839,O
symptoms,3839,O
indicative,3839,O
of,3839,O
poorer,3839,O
health,3839,O
and,3839,O
potentially,3839,O
caused,3839,O
by,3839,O
the,3839,O
adverse,3839,O
effects,3839,O
of,3839,O
these,3839,O
drugs,3839,O
.,3839,O
Acute,3840,O
vocal,3840,B-Disease
fold,3840,I-Disease
palsy,3840,I-Disease
after,3840,O
acute,3840,O
disulfiram,3840,B-Chemical
intoxication,3840,O
.,3840,O
Acute,3841,O
peripheral,3841,B-Disease
neuropathy,3841,I-Disease
caused,3841,O
by,3841,O
a,3841,O
disulfiram,3841,B-Chemical
overdose,3841,B-Disease
is,3841,O
very,3841,O
rare,3841,O
and,3841,O
there,3841,O
is,3841,O
no,3841,O
report,3841,O
of,3841,O
it,3841,O
leading,3841,O
to,3841,O
vocal,3841,B-Disease
fold,3841,I-Disease
palsy,3841,I-Disease
.,3841,O
A,3842,O
49-year-old,3842,O
woman,3842,O
was,3842,O
transferred,3842,O
to,3842,O
our,3842,O
department,3842,O
because,3842,O
of,3842,O
quadriparesis,3842,B-Disease
",",3842,O
lancinating,3842,O
pain,3842,B-Disease
",",3842,O
sensory,3842,B-Disease
loss,3842,I-Disease
",",3842,O
and,3842,O
paresthesia,3842,B-Disease
of,3842,O
the,3842,O
distal,3842,O
limbs,3842,O
.,3842,O
One,3843,O
month,3843,O
previously,3843,O
",",3843,O
she,3843,O
had,3843,O
taken,3843,O
a,3843,O
single,3843,O
high,3843,O
dose,3843,O
of,3843,O
disulfiram,3843,B-Chemical
(,3843,O
130,3843,O
tablets,3843,O
of,3843,O
ALCOHOL,3843,B-Chemical
STOP,3843,O
TAB,3843,O
",",3843,O
Shin-Poong,3843,O
Pharm,3843,O
.,3843,O
Co.,3844,O
",",3844,O
Ansan,3844,O
",",3844,O
Korea,3844,O
),3844,O
in,3844,O
a,3844,O
suicide,3844,O
attempt,3844,O
.,3844,O
She,3845,O
was,3845,O
not,3845,O
an,3845,O
alcoholic,3845,O
.,3845,O
For,3846,O
the,3846,O
first,3846,O
few,3846,O
days,3846,O
after,3846,O
ingestion,3846,O
",",3846,O
she,3846,O
was,3846,O
in,3846,O
a,3846,O
confused,3846,O
state,3846,O
and,3846,O
had,3846,O
mild,3846,O
to,3846,O
moderate,3846,O
ataxia,3846,B-Disease
and,3846,O
giddiness,3846,B-Disease
.,3846,O
She,3847,O
noticed,3847,O
hoarseness,3847,B-Disease
and,3847,O
distally,3847,O
accentuated,3847,O
motor,3847,O
and,3847,O
sensory,3847,O
dysfunction,3847,O
after,3847,O
she,3847,O
had,3847,O
recovered,3847,O
from,3847,O
this,3847,O
state,3847,O
.,3847,O
A,3848,O
nerve,3848,O
conduction,3848,O
study,3848,O
was,3848,O
consistent,3848,O
with,3848,O
severe,3848,O
sensorimotor,3848,O
axonal,3848,O
polyneuropathy,3848,B-Disease
.,3848,O
Laryngeal,3849,O
electromyography,3849,O
(,3849,O
thyroarytenoid,3849,O
muscle,3849,O
),3849,O
showed,3849,O
ample,3849,O
denervation,3849,O
potentials,3849,O
.,3849,O
Laryngoscopy,3850,O
revealed,3850,O
asymmetric,3850,O
vocal,3850,O
fold,3850,O
movements,3850,O
during,3850,O
phonation,3850,O
.,3850,O
Her,3851,O
vocal,3851,O
change,3851,O
and,3851,O
weakness,3851,O
began,3851,O
to,3851,O
improve,3851,O
spontaneously,3851,O
about,3851,O
3,3851,O
weeks,3851,O
after,3851,O
transfer,3851,O
.,3851,O
This,3852,O
was,3852,O
a,3852,O
case,3852,O
of,3852,O
acute,3852,O
palsy,3852,B-Disease
of,3852,O
the,3852,O
recurrent,3852,O
laryngeal,3852,O
nerve,3852,O
and,3852,O
superimposed,3852,O
severe,3852,O
acute,3852,O
sensorimotor,3852,O
axonal,3852,O
polyneuropathy,3852,B-Disease
caused,3852,O
by,3852,O
high-dose,3852,O
disulfiram,3852,B-Chemical
intoxication,3852,O
.,3852,O
Encephalopathy,3853,B-Disease
induced,3853,O
by,3853,O
levetiracetam,3853,B-Chemical
added,3853,O
to,3853,O
valproate,3853,B-Chemical
.,3853,O
BACKGROUND,3854,O
:,3854,O
We,3854,O
report,3854,O
on,3854,O
the,3854,O
manifestation,3854,O
of,3854,O
a,3854,O
levetiracetam,3854,B-Chemical
(,3854,O
LEV,3854,B-Chemical
),3854,O
-induced,3854,O
encephalopathy,3854,B-Disease
.,3854,O
FINDINGS,3855,O
:,3855,O
A,3855,O
28-year-old,3855,O
man,3855,O
suffering,3855,O
from,3855,O
idiopathic,3855,B-Disease
epilepsy,3855,I-Disease
with,3855,O
generalized,3855,O
seizures,3855,B-Disease
was,3855,O
treated,3855,O
with,3855,O
LEV,3855,B-Chemical
(,3855,O
3000,3855,O
mg,3855,O
),3855,O
added,3855,O
to,3855,O
valproate,3855,B-Chemical
(,3855,O
VPA,3855,B-Chemical
),3855,O
(,3855,O
2000,3855,O
mg,3855,O
),3855,O
.,3855,O
Frequency,3856,O
of,3856,O
generalized,3856,O
tonic-clonic,3856,B-Disease
seizures,3856,I-Disease
increased,3856,O
from,3856,O
one,3856,O
per,3856,O
6,3856,O
months,3856,O
to,3856,O
two,3856,O
per,3856,O
month,3856,O
.,3856,O
Neuropsychological,3857,O
testing,3857,O
showed,3857,O
impaired,3857,B-Disease
word,3857,I-Disease
fluency,3857,I-Disease
",",3857,I-Disease
psychomotor,3857,I-Disease
speed,3857,I-Disease
and,3857,I-Disease
working,3857,I-Disease
memory,3857,I-Disease
.,3857,O
The,3858,O
interictal,3858,O
electroencephalogram,3858,O
(,3858,O
EEG,3858,O
),3858,O
showed,3858,O
a,3858,O
generalized,3858,O
slowing,3858,O
to,3858,O
5,3858,O
per,3858,O
second,3858,O
theta,3858,O
rhythms,3858,O
with,3858,O
bilateral,3858,O
generalized,3858,O
high-amplitude,3858,O
discharges,3858,O
.,3858,O
OUTCOME,3859,O
:,3859,O
Following,3859,O
discontinuation,3859,O
of,3859,O
LEV,3859,B-Chemical
",",3859,O
EEG,3859,O
and,3859,O
neuropsychological,3859,O
findings,3859,O
improved,3859,O
and,3859,O
seizure,3859,B-Disease
frequency,3859,O
decreased,3859,O
.,3859,O
Norepinephrine,3860,B-Chemical
signaling,3860,O
through,3860,O
beta-adrenergic,3860,O
receptors,3860,O
is,3860,O
critical,3860,O
for,3860,O
expression,3860,O
of,3860,O
cocaine-induced,3860,B-Chemical
anxiety,3860,B-Disease
.,3860,O
BACKGROUND,3861,O
:,3861,O
Cocaine,3861,B-Chemical
is,3861,O
a,3861,O
widely,3861,O
abused,3861,O
psychostimulant,3861,O
that,3861,O
has,3861,O
both,3861,O
rewarding,3861,O
and,3861,O
aversive,3861,O
properties,3861,O
.,3861,O
While,3862,O
the,3862,O
mechanisms,3862,O
underlying,3862,O
cocaine,3862,B-Chemical
's,3862,O
rewarding,3862,O
effects,3862,O
have,3862,O
been,3862,O
studied,3862,O
extensively,3862,O
",",3862,O
less,3862,O
attention,3862,O
has,3862,O
been,3862,O
paid,3862,O
to,3862,O
the,3862,O
unpleasant,3862,O
behavioral,3862,O
states,3862,O
induced,3862,O
by,3862,O
cocaine,3862,B-Chemical
",",3862,O
such,3862,O
as,3862,O
anxiety,3862,B-Disease
.,3862,O
METHODS,3863,O
:,3863,O
In,3863,O
this,3863,O
study,3863,O
",",3863,O
we,3863,O
evaluated,3863,O
the,3863,O
performance,3863,O
of,3863,O
dopamine,3863,B-Chemical
beta-hydroxylase,3863,O
knockout,3863,O
(,3863,O
Dbh,3863,O
-/-,3863,O
),3863,O
mice,3863,O
",",3863,O
which,3863,O
lack,3863,O
norepinephrine,3863,B-Chemical
(,3863,O
NE,3863,B-Chemical
),3863,O
",",3863,O
in,3863,O
the,3863,O
elevated,3863,O
plus,3863,O
maze,3863,O
(,3863,O
EPM,3863,O
),3863,O
to,3863,O
examine,3863,O
the,3863,O
contribution,3863,O
of,3863,O
noradrenergic,3863,O
signaling,3863,O
to,3863,O
cocaine-induced,3863,B-Chemical
anxiety,3863,B-Disease
.,3863,O
RESULTS,3864,O
:,3864,O
We,3864,O
found,3864,O
that,3864,O
cocaine,3864,B-Chemical
dose-dependently,3864,O
increased,3864,O
anxiety-like,3864,B-Disease
behavior,3864,O
in,3864,O
control,3864,O
(,3864,O
Dbh,3864,O
+/-,3864,O
),3864,O
mice,3864,O
",",3864,O
as,3864,O
measured,3864,O
by,3864,O
a,3864,O
decrease,3864,O
in,3864,O
open,3864,O
arm,3864,O
exploration,3864,O
.,3864,O
The,3865,O
Dbh,3865,O
-/-,3865,O
mice,3865,O
had,3865,O
normal,3865,O
baseline,3865,O
performance,3865,O
in,3865,O
the,3865,O
EPM,3865,O
but,3865,O
were,3865,O
completely,3865,O
resistant,3865,O
to,3865,O
the,3865,O
anxiogenic,3865,O
effects,3865,O
of,3865,O
cocaine,3865,B-Chemical
.,3865,O
Cocaine-induced,3866,B-Chemical
anxiety,3866,B-Disease
was,3866,O
also,3866,O
attenuated,3866,O
in,3866,O
Dbh,3866,O
+/-,3866,O
mice,3866,O
following,3866,O
administration,3866,O
of,3866,O
disulfiram,3866,B-Chemical
",",3866,O
a,3866,O
dopamine,3866,B-Chemical
beta-hydroxylase,3866,O
(,3866,O
DBH,3866,O
),3866,O
inhibitor,3866,O
.,3866,O
In,3867,O
experiments,3867,O
using,3867,O
specific,3867,O
adrenergic,3867,O
antagonists,3867,O
",",3867,O
we,3867,O
found,3867,O
that,3867,O
pretreatment,3867,O
with,3867,O
the,3867,O
beta-adrenergic,3867,O
receptor,3867,O
antagonist,3867,O
propranolol,3867,B-Chemical
blocked,3867,O
cocaine-induced,3867,B-Chemical
anxiety-like,3867,B-Disease
behavior,3867,O
in,3867,O
Dbh,3867,O
+/-,3867,O
and,3867,O
wild-type,3867,O
C57BL6/J,3867,O
mice,3867,O
",",3867,O
while,3867,O
the,3867,O
alpha,3867,O
(,3867,O
1,3867,O
),3867,O
antagonist,3867,O
prazosin,3867,B-Chemical
and,3867,O
the,3867,O
alpha,3867,O
(,3867,O
2,3867,O
),3867,O
antagonist,3867,O
yohimbine,3867,B-Chemical
had,3867,O
no,3867,O
effect,3867,O
.,3867,O
CONCLUSIONS,3868,O
:,3868,O
These,3868,O
results,3868,O
indicate,3868,O
that,3868,O
noradrenergic,3868,O
signaling,3868,O
via,3868,O
beta-adrenergic,3868,O
receptors,3868,O
is,3868,O
required,3868,O
for,3868,O
cocaine-induced,3868,B-Chemical
anxiety,3868,B-Disease
in,3868,O
mice,3868,O
.,3868,O
Hypothalamic,3869,O
prolactin,3869,O
receptor,3869,O
messenger,3869,O
ribonucleic,3869,B-Chemical
acid,3869,I-Chemical
levels,3869,O
",",3869,O
prolactin,3869,O
signaling,3869,O
",",3869,O
and,3869,O
hyperprolactinemic,3869,B-Disease
inhibition,3869,O
of,3869,O
pulsatile,3869,O
luteinizing,3869,O
hormone,3869,O
secretion,3869,O
are,3869,O
dependent,3869,O
on,3869,O
estradiol,3869,B-Chemical
.,3869,O
Hyperprolactinemia,3870,B-Disease
can,3870,O
reduce,3870,O
fertility,3870,O
and,3870,O
libido,3870,O
.,3870,O
Although,3871,O
central,3871,O
prolactin,3871,O
actions,3871,O
are,3871,O
thought,3871,O
to,3871,O
contribute,3871,O
to,3871,O
this,3871,O
",",3871,O
the,3871,O
mechanisms,3871,O
are,3871,O
poorly,3871,O
understood,3871,O
.,3871,O
We,3872,O
first,3872,O
tested,3872,O
whether,3872,O
chronic,3872,O
hyperprolactinemia,3872,B-Disease
inhibited,3872,O
two,3872,O
neuroendocrine,3872,O
parameters,3872,O
necessary,3872,O
for,3872,O
female,3872,O
fertility,3872,O
:,3872,O
pulsatile,3872,O
LH,3872,O
secretion,3872,O
and,3872,O
the,3872,O
estrogen-induced,3872,B-Chemical
LH,3872,O
surge,3872,O
.,3872,O
Chronic,3873,O
hyperprolactinemia,3873,B-Disease
induced,3873,O
by,3873,O
the,3873,O
dopamine,3873,B-Chemical
antagonist,3873,O
sulpiride,3873,B-Chemical
caused,3873,O
a,3873,O
40,3873,O
%,3873,O
reduction,3873,O
LH,3873,O
pulse,3873,O
frequency,3873,O
in,3873,O
ovariectomized,3873,O
rats,3873,O
",",3873,O
but,3873,O
only,3873,O
in,3873,O
the,3873,O
presence,3873,O
of,3873,O
chronic,3873,O
low,3873,O
levels,3873,O
of,3873,O
estradiol,3873,B-Chemical
.,3873,O
Sulpiride,3874,B-Chemical
did,3874,O
not,3874,O
affect,3874,O
the,3874,O
magnitude,3874,O
of,3874,O
a,3874,O
steroid-induced,3874,B-Chemical
LH,3874,O
surge,3874,O
or,3874,O
the,3874,O
percentage,3874,O
of,3874,O
GnRH,3874,O
neurons,3874,O
activated,3874,O
during,3874,O
the,3874,O
surge,3874,O
.,3874,O
Estradiol,3875,B-Chemical
is,3875,O
known,3875,O
to,3875,O
influence,3875,O
expression,3875,O
of,3875,O
the,3875,O
long,3875,O
form,3875,O
of,3875,O
prolactin,3875,O
receptors,3875,O
(,3875,O
PRL-R,3875,O
),3875,O
and,3875,O
components,3875,O
of,3875,O
prolactin,3875,O
's,3875,O
signaling,3875,O
pathway,3875,O
.,3875,O
To,3876,O
test,3876,O
the,3876,O
hypothesis,3876,O
that,3876,O
estrogen,3876,B-Chemical
increases,3876,O
PRL-R,3876,O
expression,3876,O
and,3876,O
sensitivity,3876,O
to,3876,O
prolactin,3876,O
",",3876,O
we,3876,O
next,3876,O
demonstrated,3876,O
that,3876,O
estradiol,3876,B-Chemical
greatly,3876,O
augments,3876,O
prolactin-induced,3876,O
STAT5,3876,O
activation,3876,O
.,3876,O
Lastly,3877,O
",",3877,O
we,3877,O
measured,3877,O
PRL-R,3877,O
and,3877,O
suppressor,3877,O
of,3877,O
cytokine,3877,O
signaling,3877,O
(,3877,O
SOCS-1,3877,O
and,3877,O
-3,3877,O
and,3877,O
CIS,3877,O
",",3877,O
which,3877,O
reflect,3877,O
the,3877,O
level,3877,O
of,3877,O
prolactin,3877,O
signaling,3877,O
),3877,O
mRNAs,3877,O
in,3877,O
response,3877,O
to,3877,O
sulpiride,3877,B-Chemical
and,3877,O
estradiol,3877,B-Chemical
.,3877,O
Sulpiride,3878,B-Chemical
induced,3878,O
only,3878,O
SOCS-1,3878,O
in,3878,O
the,3878,O
medial,3878,O
preoptic,3878,O
area,3878,O
",",3878,O
where,3878,O
GnRH,3878,O
neurons,3878,O
are,3878,O
regulated,3878,O
",",3878,O
but,3878,O
in,3878,O
the,3878,O
arcuate,3878,O
nucleus,3878,O
and,3878,O
choroid,3878,O
plexus,3878,O
",",3878,O
PRL-R,3878,O
",",3878,O
SOCS-3,3878,O
",",3878,O
and,3878,O
CIS,3878,O
mRNA,3878,O
levels,3878,O
were,3878,O
also,3878,O
induced,3878,O
.,3878,O
Estradiol,3879,B-Chemical
enhanced,3879,O
these,3879,O
effects,3879,O
on,3879,O
SOCS-3,3879,O
and,3879,O
CIS,3879,O
.,3879,O
Interestingly,3880,O
",",3880,O
estradiol,3880,B-Chemical
also,3880,O
induced,3880,O
PRL-R,3880,O
",",3880,O
SOCS-3,3880,O
",",3880,O
and,3880,O
CIS,3880,O
mRNA,3880,O
levels,3880,O
independently,3880,O
.,3880,O
These,3881,O
data,3881,O
show,3881,O
that,3881,O
GnRH,3881,O
pulse,3881,O
frequency,3881,O
is,3881,O
inhibited,3881,O
by,3881,O
chronic,3881,O
hyperprolactinemia,3881,B-Disease
in,3881,O
a,3881,O
steroid-dependent,3881,B-Chemical
manner,3881,O
.,3881,O
They,3882,O
also,3882,O
provide,3882,O
evidence,3882,O
for,3882,O
estradiol-dependent,3882,B-Chemical
and,3882,O
brain,3882,O
region-specific,3882,O
regulation,3882,O
of,3882,O
PRL-R,3882,O
expression,3882,O
and,3882,O
signaling,3882,O
responses,3882,O
by,3882,O
prolactin,3882,O
.,3882,O
Clonidine,3883,B-Chemical
for,3883,O
attention-deficit/hyperactivity,3883,B-Disease
disorder,3883,I-Disease
:,3883,O
II,3883,O
.,3883,O
ECG,3884,O
changes,3884,O
and,3884,O
adverse,3884,O
events,3884,O
analysis,3884,O
.,3884,O
OBJECTIVE,3885,O
:,3885,O
To,3885,O
examine,3885,O
the,3885,O
safety,3885,O
and,3885,O
tolerability,3885,O
of,3885,O
clonidine,3885,B-Chemical
used,3885,O
alone,3885,O
or,3885,O
with,3885,O
methylphenidate,3885,B-Chemical
in,3885,O
children,3885,O
with,3885,O
attention-deficit/hyperactivity,3885,B-Disease
disorder,3885,I-Disease
(,3885,O
ADHD,3885,B-Disease
),3885,O
.,3885,O
METHOD,3886,O
:,3886,O
In,3886,O
a,3886,O
16-week,3886,O
multicenter,3886,O
",",3886,O
double-blind,3886,O
trial,3886,O
",",3886,O
122,3886,O
children,3886,O
with,3886,O
ADHD,3886,B-Disease
were,3886,O
randomly,3886,O
assigned,3886,O
to,3886,O
clonidine,3886,B-Chemical
(,3886,O
n,3886,O
=,3886,O
31,3886,O
),3886,O
",",3886,O
methylphenidate,3886,B-Chemical
(,3886,O
n,3886,O
=,3886,O
29,3886,O
),3886,O
",",3886,O
clonidine,3886,B-Chemical
and,3886,O
methylphenidate,3886,B-Chemical
(,3886,O
n,3886,O
=,3886,O
32,3886,O
),3886,O
",",3886,O
or,3886,O
placebo,3886,O
(,3886,O
n,3886,O
=,3886,O
30,3886,O
),3886,O
.,3886,O
Doses,3887,O
were,3887,O
flexibly,3887,O
titrated,3887,O
up,3887,O
to,3887,O
0.6,3887,O
mg/day,3887,O
for,3887,O
clonidine,3887,B-Chemical
and,3887,O
60,3887,O
mg/day,3887,O
for,3887,O
methylphenidate,3887,B-Chemical
(,3887,O
both,3887,O
with,3887,O
divided,3887,O
dosing,3887,O
),3887,O
.,3887,O
Groups,3888,O
were,3888,O
compared,3888,O
regarding,3888,O
adverse,3888,O
events,3888,O
and,3888,O
changes,3888,O
from,3888,O
baseline,3888,O
to,3888,O
week,3888,O
16,3888,O
in,3888,O
electrocardiograms,3888,O
and,3888,O
vital,3888,O
signs,3888,O
.,3888,O
RESULTS,3889,O
:,3889,O
There,3889,O
were,3889,O
more,3889,O
incidents,3889,O
of,3889,O
bradycardia,3889,B-Disease
in,3889,O
subjects,3889,O
treated,3889,O
with,3889,O
clonidine,3889,B-Chemical
compared,3889,O
with,3889,O
those,3889,O
not,3889,O
treated,3889,O
with,3889,O
clonidine,3889,B-Chemical
(,3889,O
17.5,3889,O
%,3889,O
versus,3889,O
3.4,3889,O
%,3889,O
;,3889,O
p,3889,O
=.02,3889,O
),3889,O
",",3889,O
but,3889,O
no,3889,O
other,3889,O
significant,3889,O
group,3889,O
differences,3889,O
regarding,3889,O
electrocardiogram,3889,O
and,3889,O
other,3889,O
cardiovascular,3889,O
outcomes,3889,O
.,3889,O
There,3890,O
were,3890,O
no,3890,O
suggestions,3890,O
of,3890,O
interactions,3890,O
between,3890,O
clonidine,3890,B-Chemical
and,3890,O
methylphenidate,3890,B-Chemical
regarding,3890,O
cardiovascular,3890,O
outcomes,3890,O
.,3890,O
Moderate,3891,O
or,3891,O
severe,3891,O
adverse,3891,O
events,3891,O
were,3891,O
more,3891,O
common,3891,O
in,3891,O
subjects,3891,O
on,3891,O
clonidine,3891,B-Chemical
(,3891,O
79.4,3891,O
%,3891,O
versus,3891,O
49.2,3891,O
%,3891,O
;,3891,O
p,3891,O
=.0006,3891,O
),3891,O
but,3891,O
not,3891,O
associated,3891,O
with,3891,O
higher,3891,O
rates,3891,O
of,3891,O
early,3891,O
study,3891,O
withdrawal,3891,O
.,3891,O
Drowsiness,3892,B-Disease
was,3892,O
common,3892,O
on,3892,O
clonidine,3892,B-Chemical
",",3892,O
but,3892,O
generally,3892,O
resolved,3892,O
by,3892,O
6,3892,O
to,3892,O
8,3892,O
weeks,3892,O
.,3892,O
CONCLUSIONS,3893,O
:,3893,O
Clonidine,3893,B-Chemical
",",3893,O
used,3893,O
alone,3893,O
or,3893,O
with,3893,O
methylphenidate,3893,B-Chemical
",",3893,O
appears,3893,O
safe,3893,O
and,3893,O
well,3893,O
tolerated,3893,O
in,3893,O
childhood,3893,O
ADHD,3893,B-Disease
.,3893,O
Physicians,3894,O
prescribing,3894,O
clonidine,3894,B-Chemical
should,3894,O
monitor,3894,O
for,3894,O
bradycardia,3894,B-Disease
and,3894,O
advise,3894,O
patients,3894,O
about,3894,O
the,3894,O
high,3894,O
likelihood,3894,O
of,3894,O
initial,3894,O
drowsiness,3894,B-Disease
.,3894,O
Renal,3895,B-Disease
Fanconi,3895,I-Disease
syndrome,3895,I-Disease
and,3895,O
myopathy,3895,B-Disease
after,3895,O
liver,3895,O
transplantation,3895,O
:,3895,O
drug-related,3895,O
mitochondrial,3895,B-Disease
cytopathy,3895,I-Disease
?,3895,O
Advances,3896,O
in,3896,O
the,3896,O
field,3896,O
of,3896,O
transplantation,3896,O
provide,3896,O
a,3896,O
better,3896,O
quality,3896,O
of,3896,O
life,3896,O
and,3896,O
allow,3896,O
more,3896,O
favorable,3896,O
conditions,3896,O
for,3896,O
growth,3896,O
and,3896,O
development,3896,O
in,3896,O
children,3896,O
.,3896,O
However,3897,O
",",3897,O
combinations,3897,O
of,3897,O
different,3897,O
therapeutic,3897,O
regimens,3897,O
require,3897,O
consideration,3897,O
of,3897,O
potential,3897,O
adverse,3897,O
reactions,3897,O
.,3897,O
We,3898,O
describe,3898,O
a,3898,O
15-yr-old,3898,O
girl,3898,O
who,3898,O
had,3898,O
orthotopic,3898,O
liver,3898,O
transplantation,3898,O
because,3898,O
of,3898,O
Wilson,3898,B-Disease
's,3898,I-Disease
disease,3898,I-Disease
.,3898,O
Tacrolimus,3899,B-Chemical
",",3899,O
MMF,3899,B-Chemical
",",3899,O
and,3899,O
steroids,3899,B-Chemical
were,3899,O
given,3899,O
as,3899,O
immunosuppressant,3899,O
.,3899,O
Lamivudine,3900,B-Chemical
was,3900,O
added,3900,O
because,3900,O
of,3900,O
de,3900,O
nova,3900,O
hepatitis,3900,B-Disease
B,3900,I-Disease
infection,3900,I-Disease
during,3900,O
her,3900,O
follow-up,3900,O
.,3900,O
Three,3901,O
yr,3901,O
after,3901,O
transplantation,3901,O
she,3901,O
developed,3901,O
renal,3901,B-Disease
Fanconi,3901,I-Disease
syndrome,3901,I-Disease
with,3901,O
severe,3901,O
metabolic,3901,B-Disease
acidosis,3901,I-Disease
",",3901,O
hypophosphatemia,3901,B-Disease
",",3901,O
glycosuria,3901,B-Disease
",",3901,O
and,3901,O
aminoaciduria,3901,B-Disease
.,3901,O
Although,3902,O
tacrolimus,3902,B-Chemical
was,3902,O
suspected,3902,O
to,3902,O
be,3902,O
the,3902,O
cause,3902,O
of,3902,O
late,3902,O
post-transplant,3902,O
renal,3902,O
acidosis,3902,B-Disease
and,3902,O
was,3902,O
replaced,3902,O
by,3902,O
sirolimus,3902,B-Chemical
",",3902,O
acidosis,3902,B-Disease
",",3902,O
and,3902,O
electrolyte,3902,O
imbalance,3902,O
got,3902,O
worse,3902,O
.,3902,O
Proximal,3903,O
muscle,3903,B-Disease
weakness,3903,I-Disease
has,3903,O
developed,3903,O
during,3903,O
her,3903,O
follow-up,3903,O
.,3903,O
Fanconi,3904,B-Disease
syndrome,3904,I-Disease
",",3904,O
as,3904,O
well,3904,O
as,3904,O
myopathy,3904,B-Disease
",",3904,O
is,3904,O
well,3904,O
recognized,3904,O
in,3904,O
patients,3904,O
with,3904,O
mitochondrial,3904,B-Disease
disorders,3904,I-Disease
and,3904,O
caused,3904,O
by,3904,O
depletion,3904,O
of,3904,O
mtDNA,3904,O
.,3904,O
We,3905,O
suggest,3905,O
that,3905,O
our,3905,O
patient,3905,O
's,3905,O
tubular,3905,B-Disease
dysfunction,3905,I-Disease
and,3905,O
myopathy,3905,B-Disease
may,3905,O
have,3905,O
resulted,3905,O
from,3905,O
mitochondrial,3905,B-Disease
dysfunction,3905,I-Disease
which,3905,O
is,3905,O
triggered,3905,O
by,3905,O
tacrolimus,3905,B-Chemical
and,3905,O
augmented,3905,O
by,3905,O
lamivudine,3905,B-Chemical
.,3905,O
Higher,3906,O
optical,3906,O
density,3906,O
of,3906,O
an,3906,O
antigen,3906,O
assay,3906,O
predicts,3906,O
thrombosis,3906,B-Disease
in,3906,O
patients,3906,O
with,3906,O
heparin-induced,3906,B-Chemical
thrombocytopenia,3906,B-Disease
.,3906,O
OBJECTIVES,3907,O
:,3907,O
To,3907,O
correlate,3907,O
optical,3907,O
density,3907,O
and,3907,O
percent,3907,O
inhibition,3907,O
of,3907,O
a,3907,O
two-step,3907,O
heparin-induced,3907,B-Chemical
thrombocytopenia,3907,B-Disease
(,3907,O
HIT,3907,B-Disease
),3907,O
antigen,3907,O
assay,3907,O
with,3907,O
thrombosis,3907,B-Disease
;,3907,O
the,3907,O
assay,3907,O
utilizes,3907,O
reaction,3907,O
inhibition,3907,O
characteristics,3907,O
of,3907,O
a,3907,O
high,3907,O
heparin,3907,B-Chemical
concentration,3907,O
.,3907,O
PATIENTS,3908,O
AND,3908,O
METHODS,3908,O
:,3908,O
Patients,3908,O
with,3908,O
more,3908,O
than,3908,O
50,3908,O
%,3908,O
decrease,3908,O
in,3908,O
platelet,3908,O
count,3908,O
or,3908,O
thrombocytopenia,3908,B-Disease
(,3908,O
<,3908,O
150,3908,O
x,3908,O
10,3908,O
(,3908,O
9,3908,O
),3908,O
/L,3908,O
),3908,O
after,3908,O
exposure,3908,O
to,3908,O
heparin,3908,B-Chemical
",",3908,O
who,3908,O
had,3908,O
a,3908,O
positive,3908,O
two-step,3908,O
antigen,3908,O
assay,3908,O
[,3908,O
optical,3908,O
density,3908,O
(,3908,O
OD,3908,O
),3908,O
>,3908,O
0.4,3908,O
and,3908,O
>,3908,O
50,3908,O
inhibition,3908,O
with,3908,O
high,3908,O
concentration,3908,O
of,3908,O
heparin,3908,B-Chemical
],3908,O
were,3908,O
included,3908,O
in,3908,O
the,3908,O
study,3908,O
.,3908,O
RESULTS,3909,O
:,3909,O
Forty,3909,O
of,3909,O
94,3909,O
HIT,3909,B-Disease
patients,3909,O
had,3909,O
thrombosis,3909,B-Disease
at,3909,O
diagnosis,3909,O
;,3909,O
54/94,3909,O
had,3909,O
isolated-HIT,3909,O
without,3909,O
thrombosis,3909,B-Disease
.,3909,O
Eight,3910,O
of,3910,O
the,3910,O
isolated-HIT,3910,O
patients,3910,O
developed,3910,O
thrombosis,3910,B-Disease
within,3910,O
the,3910,O
next,3910,O
30,3910,O
d,3910,O
;,3910,O
thus,3910,O
",",3910,O
a,3910,O
total,3910,O
of,3910,O
48,3910,O
patients,3910,O
had,3910,O
thrombosis,3910,B-Disease
at,3910,O
day,3910,O
30,3910,O
.,3910,O
At,3911,O
diagnosis,3911,O
there,3911,O
was,3911,O
no,3911,O
significant,3911,O
difference,3911,O
in,3911,O
OD,3911,O
between,3911,O
HIT,3911,B-Disease
patients,3911,O
with,3911,O
thrombosis,3911,B-Disease
and,3911,O
those,3911,O
with,3911,O
isolated-HIT,3911,O
.,3911,O
However,3912,O
",",3912,O
OD,3912,O
was,3912,O
significantly,3912,O
higher,3912,O
in,3912,O
all,3912,O
patients,3912,O
with,3912,O
thrombosis,3912,B-Disease
(,3912,O
n,3912,O
=,3912,O
48,3912,O
",",3912,O
1.34,3912,O
+/-,3912,O
0.89,3912,O
),3912,O
",",3912,O
including,3912,O
isolated-HIT,3912,O
patients,3912,O
who,3912,O
later,3912,O
developed,3912,O
thrombosis,3912,B-Disease
within,3912,O
30,3912,O
d,3912,O
(,3912,O
n,3912,O
=,3912,O
8,3912,O
",",3912,O
1.84,3912,O
+/-,3912,O
0.64,3912,O
),3912,O
as,3912,O
compared,3912,O
to,3912,O
isolated-HIT,3912,O
patients,3912,O
who,3912,O
did,3912,O
not,3912,O
develop,3912,O
thrombosis,3912,B-Disease
(,3912,O
0.96,3912,O
+/-,3912,O
0.75,3912,O
;,3912,O
P,3912,O
=,3912,O
0.011,3912,O
and,3912,O
P,3912,O
=,3912,O
0.008,3912,O
),3912,O
.,3912,O
The,3913,O
Receiver,3913,O
Operative,3913,O
Characteristic,3913,O
Curve,3913,O
showed,3913,O
that,3913,O
OD,3913,O
>,3913,O
1.27,3913,O
in,3913,O
the,3913,O
isolated-HIT,3913,O
group,3913,O
had,3913,O
a,3913,O
significantly,3913,O
higher,3913,O
chance,3913,O
of,3913,O
developing,3913,O
thrombosis,3913,B-Disease
by,3913,O
day,3913,O
30,3913,O
.,3913,O
None,3914,O
of,3914,O
these,3914,O
groups,3914,O
showed,3914,O
significant,3914,O
difference,3914,O
in,3914,O
percent,3914,O
inhibition,3914,O
.,3914,O
Multivariate,3915,O
analysis,3915,O
showed,3915,O
a,3915,O
2.8-fold,3915,O
increased,3915,O
risk,3915,O
of,3915,O
thrombosis,3915,B-Disease
in,3915,O
females,3915,O
.,3915,O
Similarly,3916,O
",",3916,O
thrombotic,3916,B-Disease
risk,3916,O
increased,3916,O
with,3916,O
age,3916,O
and,3916,O
OD,3916,O
values,3916,O
.,3916,O
CONCLUSION,3917,O
:,3917,O
Higher,3917,O
OD,3917,O
is,3917,O
associated,3917,O
with,3917,O
significant,3917,O
risk,3917,O
of,3917,O
subsequent,3917,O
thrombosis,3917,B-Disease
in,3917,O
patients,3917,O
with,3917,O
isolated-HIT,3917,O
;,3917,O
percent,3917,O
inhibition,3917,O
",",3917,O
however,3917,O
",",3917,O
was,3917,O
not,3917,O
predictive,3917,O
.,3917,O
Thalidomide,3918,B-Chemical
has,3918,O
limited,3918,O
single-agent,3918,O
activity,3918,O
in,3918,O
relapsed,3918,O
or,3918,O
refractory,3918,O
indolent,3918,O
non-Hodgkin,3918,B-Disease
lymphomas,3918,I-Disease
:,3918,O
a,3918,O
phase,3918,O
II,3918,O
trial,3918,O
of,3918,O
the,3918,O
Cancer,3918,B-Disease
and,3918,O
Leukemia,3918,B-Disease
Group,3918,O
B.,3918,O
Thalidomide,3918,B-Chemical
is,3918,O
an,3918,O
immunomodulatory,3918,O
agent,3918,O
with,3918,O
demonstrated,3918,O
activity,3918,O
in,3918,O
multiple,3918,B-Disease
myeloma,3918,I-Disease
",",3918,O
mantle,3918,B-Disease
cell,3918,I-Disease
lymphoma,3918,I-Disease
and,3918,O
lymphoplasmacytic,3918,B-Disease
lymphoma,3918,I-Disease
.,3918,O
Its,3919,O
activity,3919,O
is,3919,O
believed,3919,O
to,3919,O
be,3919,O
due,3919,O
modulation,3919,O
of,3919,O
the,3919,O
tumour,3919,B-Disease
milieu,3919,O
",",3919,O
including,3919,O
downregulation,3919,O
of,3919,O
angiogenesis,3919,O
and,3919,O
inflammatory,3919,O
cytokines,3919,O
.,3919,O
Between,3920,O
July,3920,O
2001,3920,O
and,3920,O
April,3920,O
2004,3920,O
",",3920,O
24,3920,O
patients,3920,O
with,3920,O
relapsed/refractory,3920,O
indolent,3920,O
lymphomas,3920,B-Disease
received,3920,O
thalidomide,3920,B-Chemical
200,3920,O
mg,3920,O
daily,3920,O
with,3920,O
escalation,3920,O
by,3920,O
100,3920,O
mg,3920,O
daily,3920,O
every,3920,O
1-2,3920,O
weeks,3920,O
as,3920,O
tolerated,3920,O
",",3920,O
up,3920,O
to,3920,O
a,3920,O
maximum,3920,O
of,3920,O
800,3920,O
mg,3920,O
daily,3920,O
.,3920,O
Patients,3921,O
had,3921,O
received,3921,O
a,3921,O
median,3921,O
of,3921,O
2,3921,O
(,3921,O
range,3921,O
",",3921,O
1-4,3921,O
),3921,O
prior,3921,O
regimens,3921,O
.,3921,O
Of,3922,O
24,3922,O
evaluable,3922,O
patients,3922,O
",",3922,O
two,3922,O
achieved,3922,O
a,3922,O
complete,3922,O
remission,3922,O
and,3922,O
one,3922,O
achieved,3922,O
a,3922,O
partial,3922,O
remission,3922,O
for,3922,O
an,3922,O
overall,3922,O
response,3922,O
rate,3922,O
of,3922,O
12.5,3922,O
%,3922,O
(,3922,O
95,3922,O
%,3922,O
confidence,3922,O
interval,3922,O
:,3922,O
2.6-32.4,3922,O
%,3922,O
),3922,O
.,3922,O
Eleven,3923,O
patients,3923,O
progressed,3923,O
during,3923,O
therapy,3923,O
.,3923,O
Grade,3924,O
3-4,3924,O
adverse,3924,O
effects,3924,O
included,3924,O
myelosuppression,3924,B-Disease
",",3924,O
fatigue,3924,B-Disease
",",3924,O
somnolence/depressed,3924,B-Disease
mood,3924,I-Disease
",",3924,O
neuropathy,3924,B-Disease
and,3924,O
dyspnea,3924,B-Disease
.,3924,O
Of,3925,O
concern,3925,O
was,3925,O
the,3925,O
occurrence,3925,O
of,3925,O
four,3925,O
thromboembolic,3925,B-Disease
events,3925,O
.,3925,O
Our,3926,O
results,3926,O
failed,3926,O
to,3926,O
demonstrate,3926,O
an,3926,O
important,3926,O
response,3926,O
rate,3926,O
to,3926,O
single,3926,O
agent,3926,O
thalidomide,3926,B-Chemical
in,3926,O
indolent,3926,O
lymphomas,3926,B-Disease
and,3926,O
contrast,3926,O
with,3926,O
the,3926,O
higher,3926,O
activity,3926,O
level,3926,O
reported,3926,O
with,3926,O
the,3926,O
second,3926,O
generation,3926,O
immunomodulatory,3926,O
agent,3926,O
",",3926,O
lenalidomide,3926,B-Chemical
.,3926,O
Sex,3927,O
differences,3927,O
in,3927,O
NMDA,3927,B-Chemical
antagonist,3927,O
enhancement,3927,O
of,3927,O
morphine,3927,B-Chemical
antihyperalgesia,3927,O
in,3927,O
a,3927,O
capsaicin,3927,B-Chemical
model,3927,O
of,3927,O
persistent,3927,O
pain,3927,B-Disease
:,3927,O
comparisons,3927,O
to,3927,O
two,3927,O
models,3927,O
of,3927,O
acute,3927,B-Disease
pain,3927,I-Disease
.,3927,O
In,3928,O
acute,3928,B-Disease
pain,3928,I-Disease
models,3928,O
",",3928,O
N-methyl-D-aspartate,3928,B-Chemical
(,3928,O
NMDA,3928,B-Chemical
),3928,O
antagonists,3928,O
enhance,3928,O
the,3928,O
antinociceptive,3928,O
effects,3928,O
of,3928,O
morphine,3928,B-Chemical
to,3928,O
a,3928,O
greater,3928,O
extent,3928,O
in,3928,O
males,3928,O
than,3928,O
females,3928,O
.,3928,O
The,3929,O
purpose,3929,O
of,3929,O
this,3929,O
investigation,3929,O
was,3929,O
to,3929,O
extend,3929,O
these,3929,O
findings,3929,O
to,3929,O
a,3929,O
persistent,3929,O
pain,3929,B-Disease
model,3929,O
which,3929,O
could,3929,O
be,3929,O
distinguished,3929,O
from,3929,O
acute,3929,B-Disease
pain,3929,I-Disease
models,3929,O
on,3929,O
the,3929,O
basis,3929,O
of,3929,O
the,3929,O
nociceptive,3929,O
fibers,3929,O
activated,3929,O
",",3929,O
neurochemical,3929,O
substrates,3929,O
",",3929,O
and,3929,O
duration,3929,O
of,3929,O
the,3929,O
nociceptive,3929,O
stimulus,3929,O
.,3929,O
To,3930,O
this,3930,O
end,3930,O
",",3930,O
persistent,3930,O
hyperalgesia,3930,B-Disease
was,3930,O
induced,3930,O
by,3930,O
administration,3930,O
of,3930,O
capsaicin,3930,B-Chemical
in,3930,O
the,3930,O
tail,3930,O
of,3930,O
gonadally,3930,O
intact,3930,O
F344,3930,O
rats,3930,O
",",3930,O
following,3930,O
which,3930,O
the,3930,O
tail,3930,O
was,3930,O
immersed,3930,O
in,3930,O
a,3930,O
mildly,3930,O
noxious,3930,O
thermal,3930,O
stimulus,3930,O
",",3930,O
and,3930,O
tail-withdrawal,3930,O
latencies,3930,O
measured,3930,O
.,3930,O
For,3931,O
comparison,3931,O
",",3931,O
tests,3931,O
were,3931,O
conducted,3931,O
in,3931,O
two,3931,O
acute,3931,B-Disease
pain,3931,I-Disease
models,3931,O
",",3931,O
the,3931,O
hotplate,3931,O
and,3931,O
warm,3931,O
water,3931,O
tail-withdrawal,3931,O
procedures,3931,O
.,3931,O
In,3932,O
males,3932,O
",",3932,O
the,3932,O
non-competitive,3932,O
NMDA,3932,B-Chemical
antagonist,3932,O
dextromethorphan,3932,B-Chemical
enhanced,3932,O
the,3932,O
antihyperalgesic,3932,O
effect,3932,O
of,3932,O
low,3932,O
to,3932,O
moderate,3932,O
doses,3932,O
of,3932,O
morphine,3932,B-Chemical
in,3932,O
a,3932,O
dose-and,3932,O
time-dependent,3932,O
manner,3932,O
.,3932,O
Across,3933,O
the,3933,O
doses,3933,O
and,3933,O
pretreatment,3933,O
times,3933,O
examined,3933,O
",",3933,O
enhancement,3933,O
was,3933,O
not,3933,O
observed,3933,O
in,3933,O
females,3933,O
.,3933,O
Enhancement,3934,O
of,3934,O
morphine,3934,B-Chemical
antinociception,3934,O
by,3934,O
dextromethorphan,3934,B-Chemical
was,3934,O
seen,3934,O
in,3934,O
both,3934,O
males,3934,O
and,3934,O
females,3934,O
in,3934,O
the,3934,O
acute,3934,B-Disease
pain,3934,I-Disease
models,3934,O
",",3934,O
with,3934,O
the,3934,O
magnitude,3934,O
of,3934,O
this,3934,O
effect,3934,O
being,3934,O
greater,3934,O
in,3934,O
males,3934,O
.,3934,O
These,3935,O
findings,3935,O
demonstrate,3935,O
a,3935,O
sexually-dimorphic,3935,O
interaction,3935,O
between,3935,O
NMDA,3935,B-Chemical
antagonists,3935,O
and,3935,O
morphine,3935,B-Chemical
in,3935,O
a,3935,O
persistent,3935,O
pain,3935,B-Disease
model,3935,O
that,3935,O
can,3935,O
be,3935,O
distinguished,3935,O
from,3935,O
those,3935,O
observed,3935,O
in,3935,O
acute,3935,B-Disease
pain,3935,I-Disease
models,3935,O
.,3935,O
Development,3936,O
of,3936,O
proteinuria,3936,B-Disease
after,3936,O
switch,3936,O
to,3936,O
sirolimus-based,3936,B-Chemical
immunosuppression,3936,O
in,3936,O
long-term,3936,O
cardiac,3936,O
transplant,3936,O
patients,3936,O
.,3936,O
Calcineurin-inhibitor,3937,O
therapy,3937,O
can,3937,O
lead,3937,O
to,3937,O
renal,3937,B-Disease
dysfunction,3937,I-Disease
in,3937,O
heart,3937,O
transplantation,3937,O
patients,3937,O
.,3937,O
The,3938,O
novel,3938,O
immunosuppressive,3938,O
(,3938,O
IS,3938,O
),3938,O
drug,3938,O
sirolmus,3938,B-Chemical
(,3938,O
Srl,3938,B-Chemical
),3938,O
lacks,3938,O
nephrotoxic,3938,B-Disease
effects,3938,O
;,3938,O
however,3938,O
",",3938,O
proteinuria,3938,B-Disease
associated,3938,O
with,3938,O
Srl,3938,B-Chemical
has,3938,O
been,3938,O
reported,3938,O
following,3938,O
renal,3938,O
transplantation,3938,O
.,3938,O
In,3939,O
cardiac,3939,O
transplantation,3939,O
",",3939,O
the,3939,O
incidence,3939,O
of,3939,O
proteinuria,3939,B-Disease
associated,3939,O
with,3939,O
Srl,3939,B-Chemical
is,3939,O
unknown,3939,O
.,3939,O
In,3940,O
this,3940,O
study,3940,O
",",3940,O
long-term,3940,O
cardiac,3940,O
transplant,3940,O
patients,3940,O
were,3940,O
switched,3940,O
from,3940,O
cyclosporine,3940,B-Chemical
to,3940,O
Srl-based,3940,B-Chemical
IS,3940,O
.,3940,O
Concomitant,3941,O
IS,3941,O
consisted,3941,O
of,3941,O
mycophenolate,3941,B-Chemical
mofetil,3941,I-Chemical
+/-,3941,O
steroids,3941,B-Chemical
.,3941,O
Proteinuria,3942,O
increased,3942,O
significantly,3942,O
from,3942,O
a,3942,O
median,3942,O
of,3942,O
0.13,3942,O
g/day,3942,O
(,3942,O
range,3942,O
0-5.7,3942,O
),3942,O
preswitch,3942,O
to,3942,O
0.23,3942,O
g/day,3942,O
(,3942,O
0-9.88,3942,O
),3942,O
at,3942,O
24,3942,O
months,3942,O
postswitch,3942,O
(,3942,O
p,3942,O
=,3942,O
0.0024,3942,O
),3942,O
.,3942,O
Before,3943,O
the,3943,O
switch,3943,O
",",3943,O
11.5,3943,O
%,3943,O
of,3943,O
patients,3943,O
had,3943,O
high-grade,3943,O
proteinuria,3943,B-Disease
(,3943,O
>,3943,O
1.0,3943,O
g/day,3943,O
),3943,O
;,3943,O
this,3943,O
increased,3943,O
to,3943,O
22.9,3943,O
%,3943,O
postswitch,3943,O
(,3943,O
p,3943,O
=,3943,O
0.006,3943,O
),3943,O
.,3943,O
ACE,3944,B-Chemical
inhibitor,3944,I-Chemical
and,3944,O
angiotensin-releasing,3944,B-Chemical
blocker,3944,I-Chemical
(,3944,O
ARB,3944,B-Chemical
),3944,O
therapy,3944,O
reduced,3944,O
proteinuria,3944,B-Disease
development,3944,O
.,3944,O
Patients,3945,O
without,3945,O
proteinuria,3945,B-Disease
had,3945,O
increased,3945,O
renal,3945,O
function,3945,O
(,3945,O
median,3945,O
42.5,3945,O
vs.,3945,O
64.1,3945,O
",",3945,O
p,3945,O
=,3945,O
0.25,3945,O
),3945,O
",",3945,O
whereas,3945,O
patients,3945,O
who,3945,O
developed,3945,O
high-grade,3945,O
proteinuria,3945,B-Disease
showed,3945,O
decreased,3945,O
renal,3945,O
function,3945,O
at,3945,O
the,3945,O
end,3945,O
of,3945,O
follow-up,3945,O
(,3945,O
median,3945,O
39.6,3945,O
vs.,3945,O
29.2,3945,O
",",3945,O
p,3945,O
=,3945,O
0.125,3945,O
),3945,O
.,3945,O
Thus,3946,O
",",3946,O
proteinuria,3946,B-Disease
may,3946,O
develop,3946,O
in,3946,O
cardiac,3946,O
transplant,3946,O
patients,3946,O
after,3946,O
switch,3946,O
to,3946,O
Srl,3946,B-Chemical
",",3946,O
which,3946,O
may,3946,O
have,3946,O
an,3946,O
adverse,3946,O
effect,3946,O
on,3946,O
renal,3946,O
function,3946,O
in,3946,O
these,3946,O
patients,3946,O
.,3946,O
Srl,3947,B-Chemical
should,3947,O
be,3947,O
used,3947,O
with,3947,O
ACEi/ARB,3947,B-Chemical
therapy,3947,O
and,3947,O
patients,3947,O
monitored,3947,O
for,3947,O
proteinuria,3947,B-Disease
and,3947,O
increased,3947,O
renal,3947,B-Disease
dysfunction,3947,I-Disease
.,3947,O
Ginsenoside,3948,B-Chemical
Rg1,3948,I-Chemical
restores,3948,O
the,3948,O
impairment,3948,B-Disease
of,3948,I-Disease
learning,3948,I-Disease
induced,3948,O
by,3948,O
chronic,3948,O
morphine,3948,B-Chemical
administration,3948,O
in,3948,O
rats,3948,O
.,3948,O
Rg1,3949,B-Chemical
",",3949,O
as,3949,O
a,3949,O
ginsenoside,3949,B-Chemical
extracted,3949,O
from,3949,O
Panax,3949,O
ginseng,3949,O
",",3949,O
could,3949,O
ameliorate,3949,O
spatial,3949,O
learning,3949,B-Disease
impairment,3949,I-Disease
.,3949,O
Previous,3950,O
studies,3950,O
have,3950,O
demonstrated,3950,O
that,3950,O
Rg1,3950,B-Chemical
might,3950,O
be,3950,O
a,3950,O
useful,3950,O
agent,3950,O
for,3950,O
the,3950,O
prevention,3950,O
and,3950,O
treatment,3950,O
of,3950,O
the,3950,O
adverse,3950,O
effects,3950,O
of,3950,O
morphine,3950,B-Chemical
.,3950,O
The,3951,O
aim,3951,O
of,3951,O
this,3951,O
study,3951,O
was,3951,O
to,3951,O
investigate,3951,O
the,3951,O
effect,3951,O
of,3951,O
Rg1,3951,B-Chemical
on,3951,O
learning,3951,B-Disease
impairment,3951,I-Disease
by,3951,O
chronic,3951,O
morphine,3951,B-Chemical
administration,3951,O
and,3951,O
the,3951,O
mechanism,3951,O
responsible,3951,O
for,3951,O
this,3951,O
effect,3951,O
.,3951,O
Male,3952,O
rats,3952,O
were,3952,O
subcutaneously,3952,O
injected,3952,O
with,3952,O
morphine,3952,B-Chemical
(,3952,O
10,3952,O
mg/kg,3952,O
),3952,O
twice,3952,O
a,3952,O
day,3952,O
at,3952,O
12,3952,O
hour,3952,O
intervals,3952,O
for,3952,O
10,3952,O
days,3952,O
",",3952,O
and,3952,O
Rg1,3952,B-Chemical
(,3952,O
30,3952,O
mg/kg,3952,O
),3952,O
was,3952,O
intraperitoneally,3952,O
injected,3952,O
2,3952,O
hours,3952,O
after,3952,O
the,3952,O
second,3952,O
injection,3952,O
of,3952,O
morphine,3952,B-Chemical
once,3952,O
a,3952,O
day,3952,O
for,3952,O
10,3952,O
days,3952,O
.,3952,O
Spatial,3953,O
learning,3953,O
capacity,3953,O
was,3953,O
assessed,3953,O
in,3953,O
the,3953,O
Morris,3953,O
water,3953,O
maze,3953,O
.,3953,O
The,3954,O
results,3954,O
showed,3954,O
that,3954,O
rats,3954,O
treated,3954,O
with,3954,O
Morphine/Rg1,3954,B-Chemical
decreased,3954,O
escape,3954,O
latency,3954,O
and,3954,O
increased,3954,O
the,3954,O
time,3954,O
spent,3954,O
in,3954,O
platform,3954,O
quadrant,3954,O
and,3954,O
entering,3954,O
frequency,3954,O
.,3954,O
By,3955,O
implantation,3955,O
of,3955,O
electrodes,3955,O
and,3955,O
electrophysiological,3955,O
recording,3955,O
in,3955,O
vivo,3955,O
",",3955,O
the,3955,O
results,3955,O
showed,3955,O
that,3955,O
Rg1,3955,B-Chemical
restored,3955,O
the,3955,O
long-term,3955,O
potentiation,3955,O
(,3955,O
LTP,3955,O
),3955,O
impaired,3955,O
by,3955,O
morphine,3955,B-Chemical
in,3955,O
both,3955,O
freely,3955,O
moving,3955,O
and,3955,O
anaesthetised,3955,O
rats,3955,O
.,3955,O
The,3956,O
electrophysiological,3956,O
recording,3956,O
in,3956,O
vitro,3956,O
showed,3956,O
that,3956,O
Rg1,3956,B-Chemical
restored,3956,O
the,3956,O
LTP,3956,O
in,3956,O
slices,3956,O
from,3956,O
the,3956,O
rats,3956,O
treated,3956,O
with,3956,O
morphine,3956,B-Chemical
",",3956,O
but,3956,O
not,3956,O
changed,3956,O
LTP,3956,O
in,3956,O
the,3956,O
slices,3956,O
from,3956,O
normal,3956,O
saline-,3956,O
or,3956,O
morphine/Rg1-treated,3956,B-Chemical
rats,3956,O
;,3956,O
this,3956,O
restoration,3956,O
could,3956,O
be,3956,O
inhibited,3956,O
by,3956,O
N-methyl-D-aspartate,3956,B-Chemical
(,3956,O
NMDA,3956,B-Chemical
),3956,O
receptor,3956,O
antagonist,3956,O
MK801,3956,B-Chemical
.,3956,O
We,3957,O
conclude,3957,O
that,3957,O
Rg1,3957,B-Chemical
may,3957,O
significantly,3957,O
improve,3957,O
the,3957,O
spatial,3957,O
learning,3957,O
capacity,3957,O
impaired,3957,O
by,3957,O
chonic,3957,O
morphine,3957,B-Chemical
administration,3957,O
and,3957,O
restore,3957,O
the,3957,O
morphine-inhibited,3957,B-Chemical
LTP,3957,O
.,3957,O
This,3958,O
effect,3958,O
is,3958,O
NMDA,3958,B-Chemical
receptor,3958,O
dependent,3958,O
.,3958,O
Synthesis,3959,O
of,3959,O
N-pyrimidinyl-2-phenoxyacetamides,3959,B-Chemical
as,3959,O
adenosine,3959,B-Chemical
A2A,3959,O
receptor,3959,O
antagonists,3959,O
.,3959,O
A,3960,O
series,3960,O
of,3960,O
N-pyrimidinyl-2-phenoxyacetamide,3960,B-Chemical
adenosine,3960,B-Chemical
A,3960,O
(,3960,O
2A,3960,O
),3960,O
antagonists,3960,O
is,3960,O
described,3960,O
.,3960,O
SAR,3961,O
studies,3961,O
led,3961,O
to,3961,O
compound,3961,O
14,3961,O
with,3961,O
excellent,3961,O
potency,3961,O
(,3961,O
K,3961,O
(,3961,O
i,3961,O
),3961,O
=,3961,O
0.4,3961,O
nM,3961,O
),3961,O
",",3961,O
selectivity,3961,O
(,3961,O
A,3961,O
(,3961,O
1,3961,O
),3961,O
/A,3961,O
(,3961,O
2A,3961,O
),3961,O
>,3961,O
100,3961,O
),3961,O
",",3961,O
and,3961,O
efficacy,3961,O
(,3961,O
MED,3961,O
10,3961,O
mg/kg,3961,O
p.o,3961,O
.,3961,O
),3961,O
in,3962,O
the,3962,O
rat,3962,O
haloperidol-induced,3962,B-Chemical
catalepsy,3962,B-Disease
model,3962,O
for,3962,O
Parkinson,3962,B-Disease
's,3962,I-Disease
disease,3962,I-Disease
.,3962,O
Central,3963,O
retinal,3963,B-Disease
vein,3963,I-Disease
occlusion,3963,I-Disease
associated,3963,O
with,3963,O
clomiphene-induced,3963,B-Chemical
ovulation,3963,O
.,3963,O
OBJECTIVE,3964,O
:,3964,O
To,3964,O
report,3964,O
a,3964,O
case,3964,O
of,3964,O
central,3964,O
retinal,3964,B-Disease
vein,3964,I-Disease
occlusion,3964,I-Disease
associated,3964,O
with,3964,O
clomiphene,3964,B-Chemical
citrate,3964,I-Chemical
(,3964,O
CC,3964,B-Chemical
),3964,O
.,3964,O
DESIGN,3965,O
:,3965,O
Case,3965,O
study,3965,O
.,3965,O
SETTING,3966,O
:,3966,O
Ophthalmology,3966,O
clinic,3966,O
of,3966,O
an,3966,O
academic,3966,O
hospital,3966,O
.,3966,O
PATIENT,3967,O
(,3967,O
S,3967,O
),3967,O
:,3967,O
A,3967,O
36-year-old,3967,O
woman,3967,O
referred,3967,O
from,3967,O
the,3967,O
infertility,3967,B-Disease
clinic,3967,O
for,3967,O
blurred,3967,B-Disease
vision,3967,I-Disease
.,3967,O
INTERVENTION,3968,O
(,3968,O
S,3968,O
),3968,O
:,3968,O
Ophthalmic,3968,O
examination,3968,O
after,3968,O
CC,3968,B-Chemical
therapy,3968,O
.,3968,O
MAIN,3969,O
OUTCOME,3969,O
MEASURE,3969,O
(,3969,O
S,3969,O
),3969,O
:,3969,O
Central,3969,O
retinal,3969,B-Disease
vein,3969,I-Disease
occlusion,3969,I-Disease
after,3969,O
ovulation,3969,O
induction,3969,O
with,3969,O
CC,3969,B-Chemical
.,3969,O
RESULT,3970,O
(,3970,O
S,3970,O
),3970,O
:,3970,O
A,3970,O
36-year-old,3970,O
Chinese,3970,O
woman,3970,O
developed,3970,O
central,3970,O
retinal,3970,B-Disease
vein,3970,I-Disease
occlusion,3970,I-Disease
after,3970,O
eight,3970,O
courses,3970,O
of,3970,O
CC,3970,B-Chemical
.,3970,O
A,3971,O
search,3971,O
of,3971,O
the,3971,O
literature,3971,O
on,3971,O
the,3971,O
thromboembolic,3971,B-Disease
complications,3971,O
of,3971,O
CC,3971,B-Chemical
does,3971,O
not,3971,O
include,3971,O
this,3971,O
severe,3971,O
ophthalmic,3971,O
complication,3971,O
",",3971,O
although,3971,O
mild,3971,O
visual,3971,B-Disease
disturbance,3971,I-Disease
after,3971,O
CC,3971,B-Chemical
intake,3971,O
is,3971,O
not,3971,O
uncommon,3971,O
.,3971,O
CONCLUSION,3972,O
(,3972,O
S,3972,O
),3972,O
:,3972,O
This,3972,O
is,3972,O
the,3972,O
first,3972,O
reported,3972,O
case,3972,O
of,3972,O
central,3972,O
retinal,3972,B-Disease
vein,3972,I-Disease
occlusion,3972,I-Disease
after,3972,O
treatment,3972,O
with,3972,O
CC,3972,B-Chemical
.,3972,O
Extra,3973,O
caution,3973,O
is,3973,O
warranted,3973,O
in,3973,O
treating,3973,O
infertility,3973,B-Disease
patients,3973,O
with,3973,O
CC,3973,B-Chemical
",",3973,O
and,3973,O
patients,3973,O
should,3973,O
be,3973,O
well,3973,O
informed,3973,O
of,3973,O
this,3973,O
side,3973,O
effect,3973,O
before,3973,O
commencement,3973,O
of,3973,O
therapy,3973,O
.,3973,O
Methamphetamine-induced,3974,B-Chemical
neurotoxicity,3974,B-Disease
and,3974,O
microglial,3974,O
activation,3974,O
are,3974,O
not,3974,O
mediated,3974,O
by,3974,O
fractalkine,3974,O
receptor,3974,O
signaling,3974,O
.,3974,O
Methamphetamine,3975,B-Chemical
(,3975,O
METH,3975,B-Chemical
),3975,O
damages,3975,O
dopamine,3975,B-Chemical
(,3975,O
DA,3975,B-Chemical
),3975,O
nerve,3975,O
endings,3975,O
by,3975,O
a,3975,O
process,3975,O
that,3975,O
has,3975,O
been,3975,O
linked,3975,O
to,3975,O
microglial,3975,O
activation,3975,O
but,3975,O
the,3975,O
signaling,3975,O
pathways,3975,O
that,3975,O
mediate,3975,O
this,3975,O
response,3975,O
have,3975,O
not,3975,O
yet,3975,O
been,3975,O
delineated,3975,O
.,3975,O
Cardona,3976,O
et,3976,O
al,3976,O
.,3976,O
[,3977,O
Nat,3977,O
.,3977,O
Neurosci,3978,O
.,3978,O
9,3979,O
(,3979,O
2006,3979,O
),3979,O
",",3979,O
917,3979,O
],3979,O
recently,3979,O
identified,3979,O
the,3979,O
microglial-specific,3979,O
fractalkine,3979,O
receptor,3979,O
(,3979,O
CX3CR1,3979,O
),3979,O
as,3979,O
an,3979,O
important,3979,O
mediator,3979,O
of,3979,O
MPTP-induced,3979,B-Chemical
neurodegeneration,3979,B-Disease
of,3979,O
DA,3979,B-Chemical
neurons,3979,O
.,3979,O
Because,3980,O
the,3980,O
CNS,3980,B-Disease
damage,3980,I-Disease
caused,3980,O
by,3980,O
METH,3980,B-Chemical
and,3980,O
MPTP,3980,B-Chemical
is,3980,O
highly,3980,O
selective,3980,O
for,3980,O
the,3980,O
DA,3980,B-Chemical
neuronal,3980,O
system,3980,O
in,3980,O
mouse,3980,O
models,3980,O
of,3980,O
neurotoxicity,3980,B-Disease
",",3980,O
we,3980,O
hypothesized,3980,O
that,3980,O
the,3980,O
CX3CR1,3980,O
plays,3980,O
a,3980,O
role,3980,O
in,3980,O
METH-induced,3980,B-Chemical
neurotoxicity,3980,B-Disease
and,3980,O
microglial,3980,O
activation,3980,O
.,3980,O
Mice,3981,O
in,3981,O
which,3981,O
the,3981,O
CX3CR1,3981,O
gene,3981,O
has,3981,O
been,3981,O
deleted,3981,O
and,3981,O
replaced,3981,O
with,3981,O
a,3981,O
cDNA,3981,O
encoding,3981,O
enhanced,3981,O
green,3981,O
fluorescent,3981,O
protein,3981,O
(,3981,O
eGFP,3981,O
),3981,O
were,3981,O
treated,3981,O
with,3981,O
METH,3981,B-Chemical
and,3981,O
examined,3981,O
for,3981,O
striatal,3981,O
neurotoxicity,3981,B-Disease
.,3981,O
METH,3982,B-Chemical
depleted,3982,O
DA,3982,B-Chemical
",",3982,O
caused,3982,O
microglial,3982,O
activation,3982,O
",",3982,O
and,3982,O
increased,3982,O
body,3982,O
temperature,3982,O
in,3982,O
CX3CR1,3982,O
knockout,3982,O
mice,3982,O
to,3982,O
the,3982,O
same,3982,O
extent,3982,O
and,3982,O
over,3982,O
the,3982,O
same,3982,O
time,3982,O
course,3982,O
seen,3982,O
in,3982,O
wild-type,3982,O
controls,3982,O
.,3982,O
The,3983,O
effects,3983,O
of,3983,O
METH,3983,B-Chemical
in,3983,O
CX3CR1,3983,O
knockout,3983,O
mice,3983,O
were,3983,O
not,3983,O
gender-dependent,3983,O
and,3983,O
did,3983,O
not,3983,O
extend,3983,O
beyond,3983,O
the,3983,O
striatum,3983,O
.,3983,O
Striatal,3984,O
microglia,3984,O
expressing,3984,O
eGFP,3984,O
constitutively,3984,O
show,3984,O
morphological,3984,O
changes,3984,O
after,3984,O
METH,3984,B-Chemical
that,3984,O
are,3984,O
characteristic,3984,O
of,3984,O
activation,3984,O
.,3984,O
This,3985,O
response,3985,O
was,3985,O
restricted,3985,O
to,3985,O
the,3985,O
striatum,3985,O
and,3985,O
contrasted,3985,O
sharply,3985,O
with,3985,O
unresponsive,3985,O
eGFP-microglia,3985,O
in,3985,O
surrounding,3985,O
brain,3985,O
areas,3985,O
that,3985,O
are,3985,O
not,3985,O
damaged,3985,O
by,3985,O
METH,3985,B-Chemical
.,3985,O
We,3986,O
conclude,3986,O
from,3986,O
these,3986,O
studies,3986,O
that,3986,O
CX3CR1,3986,O
signaling,3986,O
does,3986,O
not,3986,O
modulate,3986,O
METH,3986,B-Chemical
neurotoxicity,3986,B-Disease
or,3986,O
microglial,3986,O
activation,3986,O
.,3986,O
Furthermore,3987,O
",",3987,O
it,3987,O
appears,3987,O
that,3987,O
striatal-resident,3987,O
microglia,3987,O
respond,3987,O
to,3987,O
METH,3987,B-Chemical
with,3987,O
an,3987,O
activation,3987,O
cascade,3987,O
and,3987,O
then,3987,O
return,3987,O
to,3987,O
a,3987,O
surveying,3987,O
state,3987,O
without,3987,O
undergoing,3987,O
apoptosis,3987,O
or,3987,O
migration,3987,O
.,3987,O
Nicotine-induced,3988,B-Chemical
nystagmus,3988,B-Disease
correlates,3988,O
with,3988,O
midpontine,3988,O
activation,3988,O
.,3988,O
The,3989,O
pathomechanism,3989,O
of,3989,O
nicotine-induced,3989,B-Chemical
nystagmus,3989,B-Disease
(,3989,O
NIN,3989,B-Disease
),3989,O
is,3989,O
unknown,3989,O
.,3989,O
The,3990,O
aim,3990,O
of,3990,O
this,3990,O
study,3990,O
was,3990,O
to,3990,O
delineate,3990,O
brain,3990,O
structures,3990,O
that,3990,O
are,3990,O
involved,3990,O
in,3990,O
NIN,3990,B-Disease
generation,3990,O
.,3990,O
Eight,3991,O
healthy,3991,O
volunteers,3991,O
inhaled,3991,O
nicotine,3991,B-Chemical
in,3991,O
darkness,3991,O
during,3991,O
a,3991,O
functional,3991,O
magnetic,3991,O
resonance,3991,O
imaging,3991,O
(,3991,O
fMRI,3991,O
),3991,O
experiment,3991,O
;,3991,O
eye,3991,O
movements,3991,O
were,3991,O
registered,3991,O
using,3991,O
video-oculography,3991,O
.,3991,O
NIN,3992,B-Disease
correlated,3992,O
with,3992,O
blood,3992,O
oxygen,3992,B-Chemical
level-dependent,3992,O
(,3992,O
BOLD,3992,O
),3992,O
activity,3992,O
levels,3992,O
in,3992,O
a,3992,O
midpontine,3992,O
site,3992,O
in,3992,O
the,3992,O
posterior,3992,O
basis,3992,O
pontis,3992,O
.,3992,O
NIN-induced,3993,B-Disease
midpontine,3993,O
activation,3993,O
may,3993,O
correspond,3993,O
to,3993,O
activation,3993,O
of,3993,O
the,3993,O
dorsomedial,3993,O
pontine,3993,O
nuclei,3993,O
and,3993,O
the,3993,O
nucleus,3993,O
reticularis,3993,O
tegmenti,3993,O
pontis,3993,O
",",3993,O
structures,3993,O
known,3993,O
to,3993,O
participate,3993,O
in,3993,O
the,3993,O
generation,3993,O
of,3993,O
multidirectional,3993,O
saccades,3993,O
and,3993,O
smooth,3993,O
pursuit,3993,O
eye,3993,O
movements,3993,O
.,3993,O
Acute,3994,O
effects,3994,O
of,3994,O
N-,3994,B-Chemical
(,3994,I-Chemical
2-propylpentanoyl,3994,I-Chemical
),3994,I-Chemical
urea,3994,I-Chemical
on,3994,O
hippocampal,3994,O
amino,3994,B-Chemical
acid,3994,I-Chemical
neurotransmitters,3994,O
in,3994,O
pilocarpine-induced,3994,B-Chemical
seizure,3994,B-Disease
in,3994,O
rats,3994,O
.,3994,O
The,3995,O
present,3995,O
study,3995,O
aimed,3995,O
to,3995,O
investigate,3995,O
the,3995,O
anticonvulsant,3995,O
activity,3995,O
as,3995,O
well,3995,O
as,3995,O
the,3995,O
effects,3995,O
on,3995,O
the,3995,O
level,3995,O
of,3995,O
hippocampal,3995,O
amino,3995,B-Chemical
acid,3995,I-Chemical
neurotransmitters,3995,O
(,3995,O
glutamate,3995,B-Chemical
",",3995,O
aspartate,3995,B-Chemical
",",3995,O
glycine,3995,B-Chemical
and,3995,O
GABA,3995,B-Chemical
),3995,O
of,3995,O
N-,3995,B-Chemical
(,3995,I-Chemical
2-propylpentanoyl,3995,I-Chemical
),3995,I-Chemical
urea,3995,I-Chemical
(,3995,O
VPU,3995,B-Chemical
),3995,O
in,3995,O
comparison,3995,O
to,3995,O
its,3995,O
parent,3995,O
compound,3995,O
",",3995,O
valproic,3995,B-Chemical
acid,3995,I-Chemical
(,3995,O
VPA,3995,B-Chemical
),3995,O
.,3995,O
VPU,3996,B-Chemical
was,3996,O
more,3996,O
potent,3996,O
than,3996,O
VPA,3996,B-Chemical
",",3996,O
exhibiting,3996,O
the,3996,O
median,3996,O
effective,3996,O
dose,3996,O
(,3996,O
ED,3996,O
(,3996,O
50,3996,O
),3996,O
),3996,O
of,3996,O
49,3996,O
mg/kg,3996,O
in,3996,O
protecting,3996,O
rats,3996,O
against,3996,O
pilocarpine-induced,3996,B-Chemical
seizure,3996,B-Disease
whereas,3996,O
the,3996,O
corresponding,3996,O
value,3996,O
for,3996,O
VPA,3996,B-Chemical
was,3996,O
322,3996,O
mg/kg,3996,O
.,3996,O
In,3997,O
vivo,3997,O
microdialysis,3997,O
demonstrated,3997,O
that,3997,O
an,3997,O
intraperitoneal,3997,O
administration,3997,O
of,3997,O
pilocarpine,3997,B-Chemical
induced,3997,O
a,3997,O
pronounced,3997,O
increment,3997,O
of,3997,O
hippocampal,3997,O
glutamate,3997,B-Chemical
and,3997,O
aspartate,3997,B-Chemical
whereas,3997,O
no,3997,O
significant,3997,O
change,3997,O
was,3997,O
observed,3997,O
on,3997,O
the,3997,O
level,3997,O
of,3997,O
glycine,3997,B-Chemical
and,3997,O
GABA,3997,B-Chemical
.,3997,O
Pretreatment,3998,O
with,3998,O
either,3998,O
VPU,3998,B-Chemical
(,3998,O
50,3998,O
and,3998,O
100,3998,O
mg/kg,3998,O
),3998,O
or,3998,O
VPA,3998,B-Chemical
(,3998,O
300,3998,O
and,3998,O
600,3998,O
mg/kg,3998,O
),3998,O
completely,3998,O
abolished,3998,O
pilocarpine-evoked,3998,B-Chemical
increases,3998,O
in,3998,O
extracellular,3998,O
glutamate,3998,B-Chemical
and,3998,O
aspartate,3998,B-Chemical
.,3998,O
In,3999,O
addition,3999,O
",",3999,O
a,3999,O
statistically,3999,O
significant,3999,O
reduction,3999,O
was,3999,O
also,3999,O
observed,3999,O
on,3999,O
the,3999,O
level,3999,O
of,3999,O
GABA,3999,B-Chemical
and,3999,O
glycine,3999,B-Chemical
but,3999,O
less,3999,O
than,3999,O
a,3999,O
drastic,3999,O
reduction,3999,O
of,3999,O
glutamate,3999,B-Chemical
and,3999,O
aspartate,3999,B-Chemical
level,3999,O
.,3999,O
Based,4000,O
on,4000,O
the,4000,O
finding,4000,O
that,4000,O
VPU,4000,B-Chemical
and,4000,O
VPA,4000,B-Chemical
could,4000,O
protect,4000,O
the,4000,O
animals,4000,O
against,4000,O
pilocarpine-induced,4000,B-Chemical
seizure,4000,B-Disease
it,4000,O
is,4000,O
suggested,4000,O
that,4000,O
the,4000,O
reduction,4000,O
of,4000,O
inhibitory,4000,O
amino,4000,B-Chemical
acid,4000,I-Chemical
neurotransmitters,4000,O
was,4000,O
comparatively,4000,O
minor,4000,O
and,4000,O
offset,4000,O
by,4000,O
a,4000,O
pronounced,4000,O
reduction,4000,O
of,4000,O
glutamate,4000,B-Chemical
and,4000,O
aspartate,4000,B-Chemical
.,4000,O
Therefore,4001,O
",",4001,O
like,4001,O
VPA,4001,B-Chemical
",",4001,O
the,4001,O
finding,4001,O
that,4001,O
VPU,4001,B-Chemical
could,4001,O
drastically,4001,O
reduce,4001,O
pilocarpine-induced,4001,B-Chemical
increases,4001,O
in,4001,O
glutamate,4001,B-Chemical
and,4001,O
aspartate,4001,B-Chemical
should,4001,O
account,4001,O
",",4001,O
at,4001,O
least,4001,O
partly,4001,O
",",4001,O
for,4001,O
its,4001,O
anticonvulsant,4001,O
activity,4001,O
observed,4001,O
in,4001,O
pilocarpine-induced,4001,B-Chemical
seizure,4001,B-Disease
in,4001,O
experimental,4001,O
animals,4001,O
.,4001,O
Some,4002,O
other,4002,O
mechanism,4002,O
than,4002,O
those,4002,O
being,4002,O
reported,4002,O
herein,4002,O
should,4002,O
be,4002,O
further,4002,O
investigated,4002,O
.,4002,O
Protective,4003,O
effect,4003,O
of,4003,O
verapamil,4003,B-Chemical
on,4003,O
gastric,4003,B-Disease
hemorrhagic,4003,I-Disease
ulcers,4003,B-Disease
in,4003,O
severe,4003,O
atherosclerotic,4003,B-Disease
rats,4003,O
.,4003,O
Studies,4004,O
concerning,4004,O
with,4004,O
pathogenesis,4004,O
of,4004,O
gastric,4004,B-Disease
hemorrhage,4004,I-Disease
and,4004,O
mucosal,4004,O
ulceration,4004,O
produced,4004,O
in,4004,O
atherosclerotic,4004,B-Disease
rats,4004,O
are,4004,O
lacking,4004,O
.,4004,O
The,4005,O
aim,4005,O
of,4005,O
this,4005,O
study,4005,O
is,4005,O
to,4005,O
examine,4005,O
the,4005,O
role,4005,O
of,4005,O
gastric,4005,O
acid,4005,O
back-diffusion,4005,O
",",4005,O
mast,4005,O
cell,4005,O
histamine,4005,B-Chemical
release,4005,O
",",4005,O
lipid,4005,O
peroxide,4005,O
(,4005,O
LPO,4005,O
),4005,O
generation,4005,O
and,4005,O
mucosal,4005,O
microvascular,4005,O
permeability,4005,O
in,4005,O
modulating,4005,O
gastric,4005,B-Disease
hemorrhage,4005,I-Disease
and,4005,O
ulcer,4005,B-Disease
in,4005,O
rats,4005,O
with,4005,O
atherosclerosis,4005,B-Disease
induced,4005,O
by,4005,O
coadministration,4005,O
of,4005,O
vitamin,4005,B-Chemical
D2,4005,I-Chemical
and,4005,O
cholesterol,4005,B-Chemical
.,4005,O
Additionally,4006,O
",",4006,O
the,4006,O
protective,4006,O
effect,4006,O
of,4006,O
verapamil,4006,B-Chemical
on,4006,O
this,4006,O
ulcer,4006,B-Disease
model,4006,O
was,4006,O
evaluated,4006,O
.,4006,O
Male,4007,O
Wistar,4007,O
rats,4007,O
were,4007,O
challenged,4007,O
intragastrically,4007,O
once,4007,O
daily,4007,O
for,4007,O
9,4007,O
days,4007,O
with,4007,O
1.0,4007,O
ml/kg,4007,O
of,4007,O
corn,4007,O
oil,4007,O
containing,4007,O
vitamin,4007,B-Chemical
D2,4007,I-Chemical
and,4007,O
cholesterol,4007,B-Chemical
to,4007,O
induce,4007,O
atherosclerosis,4007,B-Disease
.,4007,O
Control,4008,O
rats,4008,O
received,4008,O
corn,4008,O
oil,4008,O
only,4008,O
.,4008,O
After,4009,O
gastric,4009,O
surgery,4009,O
",",4009,O
rat,4009,O
stomachs,4009,O
were,4009,O
irrigated,4009,O
for,4009,O
3,4009,O
h,4009,O
with,4009,O
either,4009,O
simulated,4009,O
gastric,4009,O
juice,4009,O
or,4009,O
normal,4009,O
saline,4009,O
.,4009,O
Gastric,4010,O
acid,4010,O
back-diffusion,4010,O
",",4010,O
mucosal,4010,O
LPO,4010,O
generation,4010,O
",",4010,O
histamine,4010,B-Chemical
concentration,4010,O
",",4010,O
microvascular,4010,O
permeability,4010,O
",",4010,O
luminal,4010,B-Chemical
hemoglobin,4010,O
content,4010,O
and,4010,O
ulcer,4010,B-Disease
areas,4010,O
were,4010,O
determined,4010,O
.,4010,O
Elevated,4011,O
atherosclerotic,4011,B-Disease
parameters,4011,O
",",4011,O
such,4011,O
as,4011,O
serum,4011,O
calcium,4011,B-Chemical
",",4011,O
total,4011,O
cholesterol,4011,B-Chemical
and,4011,O
low-density,4011,O
lipoprotein,4011,O
concentration,4011,O
were,4011,O
obtained,4011,O
in,4011,O
atherosclerotic,4011,B-Disease
rats,4011,O
.,4011,O
Severe,4012,O
gastric,4012,O
ulcers,4012,B-Disease
accompanied,4012,O
with,4012,O
increased,4012,O
ulcerogenic,4012,O
factors,4012,O
",",4012,O
including,4012,O
gastric,4012,O
acid,4012,O
back-diffusion,4012,O
",",4012,O
histamine,4012,B-Chemical
release,4012,O
",",4012,O
LPO,4012,O
generation,4012,O
and,4012,O
luminal,4012,B-Chemical
hemoglobin,4012,O
content,4012,O
were,4012,O
also,4012,O
observed,4012,O
in,4012,O
these,4012,O
rats,4012,O
.,4012,O
Moreover,4013,O
",",4013,O
a,4013,O
positive,4013,O
correlation,4013,O
of,4013,O
histamine,4013,B-Chemical
to,4013,O
gastric,4013,B-Disease
hemorrhage,4013,I-Disease
and,4013,O
to,4013,O
ulcer,4013,B-Disease
was,4013,O
found,4013,O
in,4013,O
those,4013,O
atherosclerotic,4013,B-Disease
rats,4013,O
.,4013,O
This,4014,O
hemorrhagic,4014,B-Disease
ulcer,4014,B-Disease
and,4014,O
various,4014,O
ulcerogenic,4014,O
parameters,4014,O
were,4014,O
dose-dependently,4014,O
ameliorated,4014,O
by,4014,O
daily,4014,O
intragastric,4014,O
verapamil,4014,B-Chemical
.,4014,O
Atherosclerosis,4015,B-Disease
could,4015,O
produce,4015,O
gastric,4015,B-Disease
hemorrhagic,4015,I-Disease
ulcer,4015,B-Disease
via,4015,O
aggravation,4015,O
of,4015,O
gastric,4015,O
acid,4015,O
back-diffusion,4015,O
",",4015,O
LPO,4015,O
generation,4015,O
",",4015,O
histamine,4015,B-Chemical
release,4015,O
and,4015,O
microvascular,4015,O
permeability,4015,O
that,4015,O
could,4015,O
be,4015,O
ameliorated,4015,O
by,4015,O
verapamil,4015,B-Chemical
in,4015,O
rats,4015,O
.,4015,O
Lamivudine,4016,B-Chemical
for,4016,O
the,4016,O
prevention,4016,O
of,4016,O
hepatitis,4016,B-Disease
B,4016,I-Disease
virus,4016,O
reactivation,4016,O
in,4016,O
hepatitis-B,4016,B-Chemical
surface,4016,I-Chemical
antigen,4016,I-Chemical
(,4016,O
HBSAG,4016,B-Chemical
),4016,O
seropositive,4016,O
cancer,4016,B-Disease
patients,4016,O
undergoing,4016,O
cytotoxic,4016,O
chemotherapy,4016,O
.,4016,O
Hepatitis,4017,B-Disease
B,4017,I-Disease
virus,4017,O
(,4017,O
HBV,4017,O
),4017,O
is,4017,O
one,4017,O
of,4017,O
the,4017,O
major,4017,O
causes,4017,O
of,4017,O
chronic,4017,O
liver,4017,B-Disease
disease,4017,I-Disease
worldwide,4017,O
.,4017,O
Cancer,4018,B-Disease
patients,4018,O
who,4018,O
are,4018,O
chronic,4018,O
carriers,4018,O
of,4018,O
HBV,4018,O
have,4018,O
a,4018,O
higher,4018,O
hepatic,4018,B-Disease
complication,4018,I-Disease
rate,4018,O
while,4018,O
receiving,4018,O
cytotoxic,4018,O
chemotherapy,4018,O
(,4018,O
CT,4018,O
),4018,O
and,4018,O
this,4018,O
has,4018,O
mainly,4018,O
been,4018,O
attributed,4018,O
to,4018,O
HBV,4018,O
reactivation,4018,O
.,4018,O
In,4019,O
this,4019,O
study,4019,O
",",4019,O
cancer,4019,B-Disease
patients,4019,O
who,4019,O
have,4019,O
solid,4019,O
and,4019,O
hematological,4019,B-Disease
malignancies,4019,I-Disease
with,4019,O
chronic,4019,O
HBV,4019,B-Disease
infection,4019,I-Disease
received,4019,O
the,4019,O
antiviral,4019,O
agent,4019,O
lamivudine,4019,B-Chemical
prior,4019,O
and,4019,O
during,4019,O
CT,4019,O
compared,4019,O
with,4019,O
historical,4019,O
control,4019,O
group,4019,O
who,4019,O
did,4019,O
not,4019,O
receive,4019,O
lamivudine,4019,B-Chemical
.,4019,O
The,4020,O
objectives,4020,O
were,4020,O
to,4020,O
assess,4020,O
the,4020,O
efficacy,4020,O
of,4020,O
lamivudine,4020,B-Chemical
in,4020,O
reducing,4020,O
the,4020,O
incidence,4020,O
of,4020,O
HBV,4020,O
reactivation,4020,O
",",4020,O
and,4020,O
diminishing,4020,O
morbidity,4020,O
and,4020,O
mortality,4020,O
during,4020,O
CT.,4020,O
Two,4020,O
groups,4020,O
were,4020,O
compared,4020,O
in,4020,O
this,4020,O
study,4020,O
.,4020,O
The,4021,O
prophylactic,4021,O
lamivudin,4021,B-Chemical
group,4021,O
consisted,4021,O
of,4021,O
37,4021,O
patients,4021,O
who,4021,O
received,4021,O
prophylactic,4021,O
lamivudine,4021,B-Chemical
treatment,4021,O
.,4021,O
The,4022,O
historical,4022,O
controls,4022,O
consisted,4022,O
of,4022,O
50,4022,O
consecutive,4022,O
patients,4022,O
who,4022,O
underwent,4022,O
CT,4022,O
without,4022,O
prophylactic,4022,O
lamivudine,4022,B-Chemical
.,4022,O
They,4023,O
were,4023,O
followed,4023,O
up,4023,O
during,4023,O
and,4023,O
for,4023,O
8,4023,O
weeks,4023,O
after,4023,O
CT,4023,O
.,4023,O
The,4024,O
outcomes,4024,O
were,4024,O
compared,4024,O
for,4024,O
both,4024,O
groups,4024,O
.,4024,O
Of,4025,O
our,4025,O
control,4025,O
group,4025,O
(,4025,O
n=,4025,O
50,4025,O
),4025,O
",",4025,O
21,4025,O
patients,4025,O
(,4025,O
42,4025,O
%,4025,O
),4025,O
were,4025,O
established,4025,O
hepatitis,4025,B-Disease
.,4025,O
Twelve,4026,O
(,4026,O
24,4026,O
%,4026,O
),4026,O
of,4026,O
them,4026,O
were,4026,O
evaluated,4026,O
as,4026,O
severe,4026,O
hepatitis,4026,B-Disease
.,4026,O
In,4027,O
the,4027,O
prophylactic,4027,O
lamivudine,4027,B-Chemical
group,4027,O
severe,4027,O
hepatitis,4027,B-Disease
were,4027,O
observed,4027,O
only,4027,O
in,4027,O
1,4027,O
patient,4027,O
(,4027,O
2.7,4027,O
%,4027,O
),4027,O
of,4027,O
37,4027,O
patients,4027,O
(,4027,O
p,4027,O
<,4027,O
0.006,4027,O
),4027,O
.,4027,O
Comparison,4028,O
of,4028,O
the,4028,O
mean,4028,O
ALT,4028,O
values,4028,O
revealed,4028,O
significantly,4028,O
higher,4028,O
mean,4028,O
alanine,4028,B-Chemical
aminotransferase,4028,O
(,4028,O
ALT,4028,O
),4028,O
values,4028,O
in,4028,O
the,4028,O
control,4028,O
group,4028,O
than,4028,O
the,4028,O
prophylactic,4028,O
lamivudine,4028,B-Chemical
group,4028,O
;,4028,O
154:64,4028,O
(,4028,O
p,4028,O
<,4028,O
0.32,4028,O
),4028,O
.,4028,O
Our,4029,O
study,4029,O
suggests,4029,O
that,4029,O
prophylactic,4029,O
lamivudine,4029,B-Chemical
significantly,4029,O
decreases,4029,O
the,4029,O
incidence,4029,O
of,4029,O
HBV,4029,O
reactivation,4029,O
and,4029,O
overall,4029,O
morbidity,4029,O
in,4029,O
cancer,4029,B-Disease
patients,4029,O
during,4029,O
and,4029,O
after,4029,O
immunosuppressive,4029,O
therapy,4029,O
.,4029,O
Further,4030,O
studies,4030,O
are,4030,O
needed,4030,O
to,4030,O
determine,4030,O
the,4030,O
most,4030,O
appropriate,4030,O
nucleoside,4030,B-Chemical
or,4030,O
nucleotide,4030,B-Chemical
analogue,4030,O
for,4030,O
antiviral,4030,O
prophylaxis,4030,O
during,4030,O
CT,4030,O
and,4030,O
the,4030,O
optimal,4030,O
duration,4030,O
of,4030,O
administration,4030,O
after,4030,O
completion,4030,O
of,4030,O
CT,4030,O
.,4030,O
Recovery,4031,O
of,4031,O
tacrolimus-associated,4031,B-Chemical
brachial,4031,B-Disease
neuritis,4031,I-Disease
after,4031,O
conversion,4031,O
to,4031,O
everolimus,4031,B-Chemical
in,4031,O
a,4031,O
pediatric,4031,O
renal,4031,O
transplant,4031,O
recipient,4031,O
--,4031,O
case,4031,O
report,4031,O
and,4031,O
review,4031,O
of,4031,O
the,4031,O
literature,4031,O
.,4031,O
TAC,4032,B-Chemical
has,4032,O
been,4032,O
shown,4032,O
to,4032,O
be,4032,O
a,4032,O
potent,4032,O
immunosuppressive,4032,O
agent,4032,O
for,4032,O
solid,4032,O
organ,4032,O
transplantation,4032,O
in,4032,O
pediatrics,4032,O
.,4032,O
Neurotoxicity,4033,B-Disease
is,4033,O
a,4033,O
potentially,4033,O
serious,4033,O
toxic,4033,O
effect,4033,O
.,4033,O
It,4034,O
is,4034,O
characterized,4034,O
by,4034,O
encephalopathy,4034,B-Disease
",",4034,O
headaches,4034,B-Disease
",",4034,O
seizures,4034,B-Disease
",",4034,O
or,4034,O
neurological,4034,B-Disease
deficits,4034,I-Disease
.,4034,O
Here,4035,O
",",4035,O
we,4035,O
describe,4035,O
an,4035,O
eight-and-a-half-yr-old,4035,O
male,4035,O
renal,4035,O
transplant,4035,O
recipient,4035,O
with,4035,O
right,4035,O
BN,4035,O
.,4035,O
MRI,4036,O
demonstrated,4036,O
hyperintense,4036,O
T2,4036,O
signals,4036,O
in,4036,O
the,4036,O
cervical,4036,O
cord,4036,O
and,4036,O
right,4036,O
brachial,4036,O
plexus,4036,O
roots,4036,O
indicative,4036,O
of,4036,O
both,4036,O
myelitis,4036,B-Disease
and,4036,O
right,4036,O
brachial,4036,B-Disease
plexitis,4036,I-Disease
.,4036,O
Symptoms,4037,O
persisted,4037,O
for,4037,O
three,4037,O
months,4037,O
despite,4037,O
TAC,4037,B-Chemical
dose,4037,O
reduction,4037,O
",",4037,O
administration,4037,O
of,4037,O
IVIG,4037,O
and,4037,O
four,4037,O
doses,4037,O
of,4037,O
methylprednisolone,4037,B-Chemical
pulse,4037,O
therapy,4037,O
.,4037,O
Improvement,4038,O
and,4038,O
eventually,4038,O
full,4038,O
recovery,4038,O
only,4038,O
occurred,4038,O
after,4038,O
TAC,4038,B-Chemical
was,4038,O
completely,4038,O
discontinued,4038,O
and,4038,O
successfully,4038,O
replaced,4038,O
by,4038,O
everolimus,4038,B-Chemical
.,4038,O
Omitting,4039,O
fentanyl,4039,B-Chemical
reduces,4039,O
nausea,4039,B-Disease
and,4039,O
vomiting,4039,B-Disease
",",4039,O
without,4039,O
increasing,4039,O
pain,4039,B-Disease
",",4039,O
after,4039,O
sevoflurane,4039,B-Chemical
for,4039,O
day,4039,O
surgery,4039,O
.,4039,O
BACKGROUND,4040,O
AND,4040,O
OBJECTIVE,4040,O
:,4040,O
Despite,4040,O
advantages,4040,O
of,4040,O
induction,4040,O
and,4040,O
maintenance,4040,O
of,4040,O
anaesthesia,4040,O
with,4040,O
sevoflurane,4040,B-Chemical
",",4040,O
postoperative,4040,B-Disease
nausea,4040,I-Disease
and,4040,I-Disease
vomiting,4040,I-Disease
occurs,4040,O
frequently,4040,O
.,4040,O
Fentanyl,4041,B-Chemical
is,4041,O
a,4041,O
commonly,4041,O
used,4041,O
supplement,4041,O
that,4041,O
may,4041,O
contribute,4041,O
to,4041,O
this,4041,O
",",4041,O
although,4041,O
it,4041,O
may,4041,O
also,4041,O
improve,4041,O
analgesia,4041,O
.,4041,O
METHODS,4042,O
:,4042,O
This,4042,O
double-blind,4042,O
study,4042,O
examined,4042,O
the,4042,O
incidence,4042,O
and,4042,O
severity,4042,O
of,4042,O
postoperative,4042,B-Disease
nausea,4042,I-Disease
and,4042,I-Disease
vomiting,4042,I-Disease
and,4042,O
pain,4042,B-Disease
in,4042,O
the,4042,O
first,4042,O
24,4042,O
h,4042,O
after,4042,O
sevoflurane,4042,B-Chemical
anaesthesia,4042,O
in,4042,O
216,4042,O
adult,4042,O
day,4042,O
surgery,4042,O
patients,4042,O
.,4042,O
Patients,4043,O
were,4043,O
randomly,4043,O
allocated,4043,O
to,4043,O
either,4043,O
receive,4043,O
or,4043,O
not,4043,O
receive,4043,O
1,4043,O
1,4043,O
fentanyl,4043,B-Chemical
",",4043,O
while,4043,O
a,4043,O
third,4043,O
group,4043,O
received,4043,O
dexamethasone,4043,B-Chemical
in,4043,O
addition,4043,O
to,4043,O
fentanyl,4043,B-Chemical
.,4043,O
RESULTS,4044,O
:,4044,O
Omission,4044,O
of,4044,O
fentanyl,4044,B-Chemical
did,4044,O
not,4044,O
reduce,4044,O
the,4044,O
overall,4044,O
incidence,4044,O
of,4044,O
postoperative,4044,B-Disease
nausea,4044,I-Disease
and,4044,I-Disease
vomiting,4044,I-Disease
",",4044,O
but,4044,O
did,4044,O
reduce,4044,O
the,4044,O
incidence,4044,O
of,4044,O
vomiting,4044,B-Disease
and/or,4044,O
moderate,4044,O
to,4044,O
severe,4044,O
nausea,4044,B-Disease
prior,4044,O
to,4044,O
discharge,4044,O
from,4044,O
20,4044,O
%,4044,O
and,4044,O
17,4044,O
%,4044,O
with,4044,O
fentanyl,4044,B-Chemical
and,4044,O
fentanyl-dexamethasone,4044,B-Chemical
",",4044,O
respectively,4044,O
",",4044,O
to,4044,O
5,4044,O
%,4044,O
(,4044,O
P,4044,O
=,4044,O
0.013,4044,O
),4044,O
.,4044,O
Antiemetic,4045,O
requirements,4045,O
were,4045,O
reduced,4045,O
from,4045,O
24,4045,O
%,4045,O
and,4045,O
31,4045,O
%,4045,O
to,4045,O
7,4045,O
%,4045,O
(,4045,O
P,4045,O
=,4045,O
0.0012,4045,O
),4045,O
.,4045,O
Dexamethasone,4046,B-Chemical
had,4046,O
no,4046,O
significant,4046,O
effect,4046,O
on,4046,O
the,4046,O
incidence,4046,O
or,4046,O
severity,4046,O
of,4046,O
postoperative,4046,B-Disease
nausea,4046,I-Disease
and,4046,I-Disease
vomiting,4046,I-Disease
.,4046,O
Combining,4047,O
the,4047,O
two,4047,O
fentanyl,4047,B-Chemical
groups,4047,O
revealed,4047,O
further,4047,O
significant,4047,O
benefits,4047,O
from,4047,O
the,4047,O
avoidance,4047,O
of,4047,O
opioids,4047,O
",",4047,O
reducing,4047,O
postoperative,4047,B-Disease
nausea,4047,I-Disease
and,4047,I-Disease
vomiting,4047,I-Disease
and,4047,O
nausea,4047,B-Disease
prior,4047,O
to,4047,O
discharge,4047,O
from,4047,O
35,4047,O
%,4047,O
and,4047,O
33,4047,O
%,4047,O
to,4047,O
22,4047,O
%,4047,O
and,4047,O
19,4047,O
%,4047,O
(,4047,O
P,4047,O
=,4047,O
0.049,4047,O
and,4047,O
P,4047,O
=,4047,O
0.035,4047,O
),4047,O
",",4047,O
respectively,4047,O
",",4047,O
while,4047,O
nausea,4047,B-Disease
in,4047,O
the,4047,O
first,4047,O
24,4047,O
h,4047,O
was,4047,O
decreased,4047,O
from,4047,O
42,4047,O
%,4047,O
to,4047,O
27,4047,O
%,4047,O
(,4047,O
P,4047,O
=,4047,O
0.034,4047,O
),4047,O
.,4047,O
Pain,4048,B-Disease
severity,4048,O
and,4048,O
analgesic,4048,O
requirements,4048,O
were,4048,O
unaffected,4048,O
by,4048,O
the,4048,O
omission,4048,O
of,4048,O
fentanyl,4048,B-Chemical
.,4048,O
Fentanyl,4049,B-Chemical
did,4049,O
reduce,4049,O
minor,4049,O
intraoperative,4049,O
movement,4049,O
but,4049,O
had,4049,O
no,4049,O
sevoflurane-sparing,4049,B-Chemical
effect,4049,O
and,4049,O
increased,4049,O
respiratory,4049,B-Disease
depression,4049,I-Disease
",",4049,O
hypotension,4049,B-Disease
and,4049,O
bradycardia,4049,B-Disease
.,4049,O
CONCLUSION,4050,O
:,4050,O
As,4050,O
fentanyl,4050,B-Chemical
exacerbated,4050,O
postoperative,4050,B-Disease
nausea,4050,I-Disease
and,4050,I-Disease
vomiting,4050,I-Disease
without,4050,O
an,4050,O
improvement,4050,O
in,4050,O
postoperative,4050,B-Disease
pain,4050,I-Disease
and,4050,O
also,4050,O
had,4050,O
adverse,4050,O
cardiorespiratory,4050,O
effects,4050,O
",",4050,O
it,4050,O
appears,4050,O
to,4050,O
be,4050,O
an,4050,O
unnecessary,4050,O
and,4050,O
possibly,4050,O
detrimental,4050,O
supplement,4050,O
to,4050,O
sevoflurane,4050,B-Chemical
in,4050,O
day,4050,O
surgery,4050,O
.,4050,O
Valvular,4051,B-Disease
heart,4051,I-Disease
disease,4051,I-Disease
in,4051,O
patients,4051,O
with,4051,O
Parkinson,4051,B-Disease
's,4051,I-Disease
disease,4051,I-Disease
treated,4051,O
with,4051,O
pergolide,4051,B-Chemical
.,4051,O
Course,4052,O
following,4052,O
treatment,4052,O
modifications,4052,O
.,4052,O
Valvular,4053,B-Disease
heart,4053,I-Disease
abnormalities,4053,I-Disease
have,4053,O
been,4053,O
reported,4053,O
in,4053,O
patients,4053,O
with,4053,O
Parkinson,4053,B-Disease
's,4053,I-Disease
disease,4053,I-Disease
(,4053,O
PD,4053,B-Disease
),4053,O
treated,4053,O
with,4053,O
pergolide,4053,B-Chemical
.,4053,O
However,4054,O
",",4054,O
the,4054,O
incidence,4054,O
and,4054,O
severity,4054,O
of,4054,O
these,4054,O
abnormalities,4054,O
vary,4054,O
from,4054,O
study,4054,O
to,4054,O
study,4054,O
and,4054,O
their,4054,O
course,4054,O
after,4054,O
drug,4054,O
withdrawal,4054,O
has,4054,O
not,4054,O
been,4054,O
systematically,4054,O
assessed,4054,O
.,4054,O
OBJECTIVES,4055,O
:,4055,O
To,4055,O
estimate,4055,O
the,4055,O
frequency,4055,O
and,4055,O
severity,4055,O
of,4055,O
valvular,4055,B-Disease
heart,4055,I-Disease
abnormality,4055,I-Disease
and,4055,O
its,4055,O
possible,4055,O
reversibility,4055,O
after,4055,O
drug,4055,O
withdrawal,4055,O
in,4055,O
a,4055,O
case-control,4055,O
study,4055,O
.,4055,O
METHODS,4056,O
:,4056,O
All,4056,O
PD,4056,B-Disease
patients,4056,O
in,4056,O
the,4056,O
Amiens,4056,O
area,4056,O
treated,4056,O
with,4056,O
pergolide,4056,B-Chemical
were,4056,O
invited,4056,O
to,4056,O
attend,4056,O
a,4056,O
cardiologic,4056,O
assessment,4056,O
including,4056,O
transthoracic,4056,O
echocardiography,4056,O
.,4056,O
Thirty,4057,O
PD,4057,B-Disease
patients,4057,O
participated,4057,O
in,4057,O
the,4057,O
study,4057,O
.,4057,O
A,4058,O
second,4058,O
echocardiography,4058,O
was,4058,O
performed,4058,O
(,4058,O
median,4058,O
interval,4058,O
:,4058,O
13,4058,O
months,4058,O
),4058,O
after,4058,O
pergolide,4058,B-Chemical
withdrawal,4058,O
(,4058,O
n=10,4058,O
patients,4058,O
),4058,O
.,4058,O
Controls,4059,O
were,4059,O
age-,4059,O
and,4059,O
sex-matched,4059,O
non-PD,4059,O
patients,4059,O
referred,4059,O
to,4059,O
the,4059,O
cardiology,4059,O
department,4059,O
.,4059,O
RESULTS,4060,O
:,4060,O
Compared,4060,O
to,4060,O
controls,4060,O
",",4060,O
aortic,4060,B-Disease
regurgitation,4060,I-Disease
(,4060,O
OR,4060,O
:,4060,O
3.1,4060,O
;,4060,O
95,4060,O
%,4060,O
IC,4060,O
:,4060,O
1.1-8.8,4060,O
),4060,O
and,4060,O
mitral,4060,B-Disease
regurgitation,4060,I-Disease
(,4060,O
OR,4060,O
:,4060,O
10.7,4060,O
;,4060,O
95,4060,O
%,4060,O
IC,4060,O
:,4060,O
2.1-53,4060,O
),4060,O
were,4060,O
more,4060,O
frequent,4060,O
in,4060,O
PD,4060,B-Disease
patients,4060,O
(,4060,O
tricuspid,4060,O
:,4060,O
NS,4060,O
),4060,O
.,4060,O
The,4061,O
number,4061,O
of,4061,O
affected,4061,O
valves,4061,O
(,4061,O
n=2.4+/-0.7,4061,O
),4061,O
and,4061,O
the,4061,O
sum,4061,O
of,4061,O
regurgitation,4061,O
grades,4061,O
(,4061,O
n=2.8+/-1.09,4061,O
),4061,O
were,4061,O
higher,4061,O
(,4061,O
p=0.008,4061,O
and,4061,O
p=0.006,4061,O
",",4061,O
respectively,4061,O
),4061,O
in,4061,O
the,4061,O
pergolide,4061,B-Chemical
group,4061,O
.,4061,O
Severity,4062,O
of,4062,O
regurgitation,4062,O
was,4062,O
not,4062,O
correlated,4062,O
with,4062,O
pergolide,4062,B-Chemical
cumulative,4062,O
dose,4062,O
.,4062,O
A,4063,O
restrictive,4063,O
pattern,4063,O
of,4063,O
valvular,4063,B-Disease
regurgitation,4063,I-Disease
",",4063,O
suggestive,4063,O
of,4063,O
the,4063,O
role,4063,O
of,4063,O
pergolide,4063,B-Chemical
",",4063,O
was,4063,O
observed,4063,O
in,4063,O
12/30,4063,O
(,4063,O
40,4063,O
%,4063,O
),4063,O
patients,4063,O
including,4063,O
two,4063,O
with,4063,O
heart,4063,B-Disease
failure,4063,I-Disease
.,4063,O
Pergolide,4064,B-Chemical
was,4064,O
discontinued,4064,O
in,4064,O
10,4064,O
patients,4064,O
with,4064,O
valvular,4064,B-Disease
heart,4064,I-Disease
disease,4064,I-Disease
",",4064,O
resulting,4064,O
in,4064,O
a,4064,O
lower,4064,O
regurgitation,4064,O
grade,4064,O
(,4064,O
p=0.01,4064,O
),4064,O
at,4064,O
the,4064,O
second,4064,O
transthoracic,4064,O
echocardiography,4064,O
and,4064,O
the,4064,O
two,4064,O
patients,4064,O
with,4064,O
heart,4064,B-Disease
failure,4064,I-Disease
returned,4064,O
to,4064,O
nearly,4064,O
normal,4064,O
clinical,4064,O
examination,4064,O
.,4064,O
This,4065,O
study,4065,O
supports,4065,O
the,4065,O
high,4065,O
frequency,4065,O
of,4065,O
restrictive,4065,O
valve,4065,B-Disease
regurgitation,4065,I-Disease
in,4065,O
PD,4065,B-Disease
patients,4065,O
treated,4065,O
with,4065,O
pergolide,4065,B-Chemical
and,4065,O
reveals,4065,O
that,4065,O
a,4065,O
significant,4065,O
improvement,4065,O
is,4065,O
usual,4065,O
when,4065,O
the,4065,O
treatment,4065,O
is,4065,O
converted,4065,O
to,4065,O
non-ergot,4065,O
dopamine,4065,B-Chemical
agonists,4065,O
.,4065,O
Adriamycin-induced,4066,B-Chemical
autophagic,4066,O
cardiomyocyte,4066,O
death,4066,B-Disease
plays,4066,O
a,4066,O
pathogenic,4066,O
role,4066,O
in,4066,O
a,4066,O
rat,4066,O
model,4066,O
of,4066,O
heart,4066,B-Disease
failure,4066,I-Disease
.,4066,O
BACKGROUND,4067,O
:,4067,O
The,4067,O
mechanisms,4067,O
underlying,4067,O
heart,4067,B-Disease
failure,4067,I-Disease
induced,4067,O
by,4067,O
adriamycin,4067,B-Chemical
are,4067,O
very,4067,O
complicated,4067,O
and,4067,O
still,4067,O
unclear,4067,O
.,4067,O
The,4068,O
aim,4068,O
of,4068,O
this,4068,O
study,4068,O
was,4068,O
to,4068,O
investigate,4068,O
whether,4068,O
autophagy,4068,O
was,4068,O
involved,4068,O
in,4068,O
the,4068,O
progression,4068,O
of,4068,O
heart,4068,B-Disease
failure,4068,I-Disease
induced,4068,O
by,4068,O
adriamycin,4068,B-Chemical
",",4068,O
so,4068,O
that,4068,O
we,4068,O
can,4068,O
develop,4068,O
a,4068,O
novel,4068,O
treatment,4068,O
strategy,4068,O
for,4068,O
heart,4068,B-Disease
failure,4068,I-Disease
.,4068,O
METHODS,4069,O
:,4069,O
3-methyladenine,4069,B-Chemical
(,4069,O
3MA,4069,B-Chemical
),4069,O
",",4069,O
a,4069,O
specific,4069,O
inhibitor,4069,O
on,4069,O
autophagy,4069,O
was,4069,O
used,4069,O
in,4069,O
a,4069,O
heart,4069,B-Disease
failure,4069,I-Disease
model,4069,O
of,4069,O
rats,4069,O
induced,4069,O
by,4069,O
adriamycin,4069,B-Chemical
.,4069,O
Neonatal,4070,O
cardiomyocytes,4070,O
were,4070,O
isolated,4070,O
from,4070,O
Sprague-Dawley,4070,O
rat,4070,O
hearts,4070,O
and,4070,O
randomly,4070,O
divided,4070,O
into,4070,O
controls,4070,O
",",4070,O
an,4070,O
adriamycin-treated,4070,B-Chemical
group,4070,O
",",4070,O
and,4070,O
a,4070,O
3MA,4070,B-Chemical
plus,4070,O
adriamycin-treated,4070,B-Chemical
group,4070,O
.,4070,O
We,4071,O
then,4071,O
examined,4071,O
the,4071,O
morphology,4071,O
",",4071,O
expression,4071,O
of,4071,O
beclin,4071,O
1,4071,O
gene,4071,O
",",4071,O
mitochondrial,4071,O
permeability,4071,O
transition,4071,O
(,4071,O
MPT,4071,O
),4071,O
",",4071,O
and,4071,O
Na+-K+,4071,O
ATPase,4071,O
activity,4071,O
in,4071,O
vivo,4071,O
.,4071,O
We,4072,O
also,4072,O
assessed,4072,O
cell,4072,O
viability,4072,O
",",4072,O
mitochondrial,4072,O
membrane,4072,O
potential,4072,O
changes,4072,O
and,4072,O
counted,4072,O
autophagic,4072,O
vacuoles,4072,O
in,4072,O
cultured,4072,O
cardiomyocytes,4072,O
.,4072,O
In,4073,O
addition,4073,O
",",4073,O
we,4073,O
analyzed,4073,O
the,4073,O
expression,4073,O
of,4073,O
autophagy,4073,O
associated,4073,O
gene,4073,O
",",4073,O
beclin,4073,O
1,4073,O
using,4073,O
RT-PCR,4073,O
and,4073,O
Western,4073,O
blotting,4073,O
in,4073,O
an,4073,O
animal,4073,O
model,4073,O
.,4073,O
RESULTS,4074,O
:,4074,O
3MA,4074,B-Chemical
significantly,4074,O
improved,4074,O
cardiac,4074,O
function,4074,O
and,4074,O
reduced,4074,O
mitochondrial,4074,O
injury,4074,O
.,4074,O
Furthermore,4075,O
",",4075,O
adriamycin,4075,B-Chemical
induced,4075,O
the,4075,O
formation,4075,O
of,4075,O
autophagic,4075,O
vacuoles,4075,O
",",4075,O
and,4075,O
3MA,4075,B-Chemical
strongly,4075,O
downregulated,4075,O
the,4075,O
expression,4075,O
of,4075,O
beclin,4075,O
1,4075,O
in,4075,O
adriamycin-induced,4075,B-Chemical
failing,4075,O
heart,4075,O
and,4075,O
inhibited,4075,O
the,4075,O
formation,4075,O
of,4075,O
autophagic,4075,O
vacuoles,4075,O
.,4075,O
CONCLUSION,4076,O
:,4076,O
Autophagic,4076,O
cardiomyocyte,4076,O
death,4076,B-Disease
plays,4076,O
an,4076,O
important,4076,O
role,4076,O
in,4076,O
the,4076,O
pathogenesis,4076,O
of,4076,O
heart,4076,B-Disease
failure,4076,I-Disease
in,4076,O
rats,4076,O
induced,4076,O
by,4076,O
adriamycin,4076,B-Chemical
.,4076,O
Mitochondrial,4077,O
injury,4077,O
may,4077,O
be,4077,O
involved,4077,O
in,4077,O
the,4077,O
progression,4077,O
of,4077,O
heart,4077,B-Disease
failure,4077,I-Disease
caused,4077,O
by,4077,O
adriamycin,4077,B-Chemical
via,4077,O
the,4077,O
autophagy,4077,O
pathway,4077,O
.,4077,O
mToR,4078,O
inhibitors-induced,4078,O
proteinuria,4078,B-Disease
:,4078,O
mechanisms,4078,O
",",4078,O
significance,4078,O
",",4078,O
and,4078,O
management,4078,O
.,4078,O
Massive,4079,O
urinary,4079,O
protein,4079,O
excretion,4079,O
has,4079,O
been,4079,O
observed,4079,O
after,4079,O
conversion,4079,O
from,4079,O
calcineurin,4079,O
inhibitors,4079,O
to,4079,O
mammalian,4079,O
target,4079,O
of,4079,O
rapamycin,4079,B-Chemical
(,4079,O
mToR,4079,O
),4079,O
inhibitors,4079,O
",",4079,O
especially,4079,O
sirolimus,4079,B-Chemical
",",4079,O
in,4079,O
renal,4079,O
transplant,4079,O
recipients,4079,O
with,4079,O
chronic,4079,B-Disease
allograft,4079,I-Disease
nephropathy,4079,I-Disease
.,4079,O
Because,4080,O
proteinuria,4080,B-Disease
is,4080,O
a,4080,O
major,4080,O
predictive,4080,O
factor,4080,O
of,4080,O
poor,4080,O
transplantation,4080,O
outcome,4080,O
",",4080,O
many,4080,O
studies,4080,O
focused,4080,O
on,4080,O
this,4080,O
adverse,4080,O
event,4080,O
during,4080,O
the,4080,O
past,4080,O
years,4080,O
.,4080,O
Whether,4081,O
proteinuria,4081,B-Disease
was,4081,O
due,4081,O
to,4081,O
sirolimus,4081,B-Chemical
or,4081,O
only,4081,O
a,4081,O
consequence,4081,O
of,4081,O
calcineurin,4081,O
inhibitors,4081,O
withdrawal,4081,O
remained,4081,O
unsolved,4081,O
until,4081,O
high,4081,O
range,4081,O
proteinuria,4081,B-Disease
has,4081,O
been,4081,O
observed,4081,O
during,4081,O
sirolimus,4081,B-Chemical
therapy,4081,O
in,4081,O
islet,4081,O
transplantation,4081,O
and,4081,O
in,4081,O
patients,4081,O
who,4081,O
received,4081,O
sirolimus,4081,B-Chemical
de,4081,O
novo,4081,O
.,4081,O
Podocyte,4082,O
injury,4082,O
and,4082,O
focal,4082,O
segmental,4082,O
glomerulosclerosis,4082,B-Disease
have,4082,O
been,4082,O
related,4082,O
to,4082,O
mToR,4082,O
inhibition,4082,O
in,4082,O
some,4082,O
patients,4082,O
",",4082,O
but,4082,O
the,4082,O
pathways,4082,O
underlying,4082,O
these,4082,O
lesions,4082,O
remain,4082,O
hypothetic,4082,O
.,4082,O
We,4083,O
discuss,4083,O
herein,4083,O
the,4083,O
possible,4083,O
mechanisms,4083,O
and,4083,O
the,4083,O
significance,4083,O
of,4083,O
mToR,4083,O
blockade-induced,4083,O
proteinuria,4083,B-Disease
.,4083,O
Prenatal,4084,O
protein,4084,O
deprivation,4084,O
alters,4084,O
dopamine-mediated,4084,B-Chemical
behaviors,4084,O
and,4084,O
dopaminergic,4084,O
and,4084,O
glutamatergic,4084,O
receptor,4084,O
binding,4084,O
.,4084,O
Epidemiological,4085,O
evidence,4085,O
indicates,4085,O
that,4085,O
prenatal,4085,O
nutritional,4085,O
deprivation,4085,O
may,4085,O
increase,4085,O
the,4085,O
risk,4085,O
of,4085,O
schizophrenia,4085,B-Disease
.,4085,O
The,4086,O
goal,4086,O
of,4086,O
these,4086,O
studies,4086,O
was,4086,O
to,4086,O
use,4086,O
an,4086,O
animal,4086,O
model,4086,O
to,4086,O
examine,4086,O
the,4086,O
effects,4086,O
of,4086,O
prenatal,4086,O
protein,4086,O
deprivation,4086,O
on,4086,O
behaviors,4086,O
and,4086,O
receptor,4086,O
binding,4086,O
with,4086,O
relevance,4086,O
to,4086,O
schizophrenia,4086,B-Disease
.,4086,O
We,4087,O
report,4087,O
that,4087,O
prenatally,4087,O
protein,4087,O
deprived,4087,O
(,4087,O
PD,4087,O
),4087,O
female,4087,O
rats,4087,O
showed,4087,O
an,4087,O
increased,4087,O
stereotypic,4087,O
response,4087,O
to,4087,O
apomorphine,4087,B-Chemical
and,4087,O
an,4087,O
increased,4087,O
locomotor,4087,O
response,4087,O
to,4087,O
amphetamine,4087,B-Chemical
in,4087,O
adulthood,4087,O
.,4087,O
These,4088,O
differences,4088,O
were,4088,O
not,4088,O
observed,4088,O
during,4088,O
puberty,4088,O
.,4088,O
No,4089,O
changes,4089,O
in,4089,O
haloperidol-induced,4089,B-Chemical
catalepsy,4089,B-Disease
or,4089,O
MK-801-induced,4089,B-Chemical
locomotion,4089,O
were,4089,O
seen,4089,O
following,4089,O
PD,4089,O
.,4089,O
In,4090,O
addition,4090,O
",",4090,O
PD,4090,O
female,4090,O
rats,4090,O
showed,4090,O
increased,4090,O
(,4090,O
3,4090,O
),4090,O
H-MK-801,4090,B-Chemical
binding,4090,O
in,4090,O
the,4090,O
striatum,4090,O
and,4090,O
hippocampus,4090,O
",",4090,O
but,4090,O
not,4090,O
in,4090,O
the,4090,O
cortex,4090,O
.,4090,O
PD,4091,O
female,4091,O
rats,4091,O
also,4091,O
showed,4091,O
increased,4091,O
(,4091,O
3,4091,O
),4091,O
H-haloperidol,4091,B-Chemical
binding,4091,O
and,4091,O
decreased,4091,O
dopamine,4091,B-Chemical
transporter,4091,O
binding,4091,O
in,4091,O
striatum,4091,O
.,4091,O
No,4092,O
statistically,4092,O
significant,4092,O
changes,4092,O
in,4092,O
behavior,4092,O
or,4092,O
receptor,4092,O
binding,4092,O
were,4092,O
found,4092,O
in,4092,O
PD,4092,O
males,4092,O
with,4092,O
the,4092,O
exception,4092,O
of,4092,O
increased,4092,O
(,4092,O
3,4092,O
),4092,O
H-MK-801,4092,B-Chemical
binding,4092,O
in,4092,O
cortex,4092,O
.,4092,O
This,4093,O
animal,4093,O
model,4093,O
may,4093,O
be,4093,O
useful,4093,O
to,4093,O
explore,4093,O
the,4093,O
mechanisms,4093,O
by,4093,O
which,4093,O
prenatal,4093,O
nutritional,4093,B-Disease
deficiency,4093,I-Disease
enhances,4093,O
risk,4093,O
for,4093,O
schizophrenia,4093,B-Disease
in,4093,O
humans,4093,O
and,4093,O
may,4093,O
also,4093,O
have,4093,O
implications,4093,O
for,4093,O
developmental,4093,O
processes,4093,O
leading,4093,O
to,4093,O
differential,4093,O
sensitivity,4093,O
to,4093,O
drugs,4093,O
of,4093,O
abuse,4093,O
.,4093,O
Adverse,4094,O
effects,4094,O
of,4094,O
topical,4094,O
papaverine,4094,B-Chemical
on,4094,O
auditory,4094,O
nerve,4094,O
function,4094,O
.,4094,O
BACKGROUND,4095,O
:,4095,O
Papaverine,4095,B-Chemical
hydrochloride,4095,I-Chemical
is,4095,O
a,4095,O
direct-acting,4095,O
vasodilator,4095,O
used,4095,O
to,4095,O
manage,4095,O
vasospasm,4095,B-Disease
during,4095,O
various,4095,O
neurosurgical,4095,O
operations,4095,O
.,4095,O
Transient,4096,O
cranial,4096,B-Disease
nerve,4096,I-Disease
dysfunction,4096,I-Disease
has,4096,O
been,4096,O
described,4096,O
in,4096,O
a,4096,O
few,4096,O
cases,4096,O
with,4096,O
topical,4096,O
papaverine,4096,B-Chemical
.,4096,O
This,4097,O
study,4097,O
supports,4097,O
previous,4097,O
reports,4097,O
and,4097,O
provides,4097,O
neurophysiological,4097,O
evidence,4097,O
of,4097,O
an,4097,O
adverse,4097,O
effect,4097,O
on,4097,O
the,4097,O
auditory,4097,O
nerve,4097,O
.,4097,O
METHODS,4098,O
:,4098,O
We,4098,O
conducted,4098,O
a,4098,O
retrospective,4098,O
review,4098,O
of,4098,O
70,4098,O
consecutive,4098,O
microvascular,4098,O
decompression,4098,O
operations,4098,O
and,4098,O
studied,4098,O
those,4098,O
patients,4098,O
who,4098,O
received,4098,O
topical,4098,O
papaverine,4098,B-Chemical
for,4098,O
vasospasm,4098,B-Disease
.,4098,O
Topical,4099,O
papaverine,4099,B-Chemical
was,4099,O
used,4099,O
as,4099,O
a,4099,O
direct,4099,O
therapeutic,4099,O
action,4099,O
to,4099,O
manage,4099,O
vasospasm,4099,B-Disease
in,4099,O
a,4099,O
total,4099,O
of,4099,O
11,4099,O
patients,4099,O
.,4099,O
The,4100,O
timing,4100,O
of,4100,O
papaverine,4100,B-Chemical
application,4100,O
and,4100,O
ongoing,4100,O
operative,4100,O
events,4100,O
was,4100,O
reviewed,4100,O
relative,4100,O
to,4100,O
changes,4100,O
in,4100,O
neurophysiological,4100,O
recordings,4100,O
.,4100,O
Brainstem,4101,O
auditory,4101,O
evoked,4101,O
potentials,4101,O
(,4101,O
BAEPs,4101,O
),4101,O
were,4101,O
routinely,4101,O
used,4101,O
to,4101,O
monitor,4101,O
cochlear,4101,O
nerve,4101,O
function,4101,O
during,4101,O
these,4101,O
operations,4101,O
.,4101,O
FINDINGS,4102,O
:,4102,O
A,4102,O
temporal,4102,O
relationship,4102,O
was,4102,O
found,4102,O
between,4102,O
topical,4102,O
papaverine,4102,B-Chemical
and,4102,O
BAEP,4102,O
changes,4102,O
leading,4102,O
to,4102,O
complete,4102,O
waveform,4102,O
loss,4102,O
.,4102,O
The,4103,O
average,4103,O
temporal,4103,O
delay,4103,O
between,4103,O
papaverine,4103,B-Chemical
and,4103,O
the,4103,O
onset,4103,O
of,4103,O
an,4103,O
adverse,4103,O
BAEP,4103,O
change,4103,O
was,4103,O
5,4103,O
min,4103,O
.,4103,O
In,4104,O
10,4104,O
of,4104,O
11,4104,O
patients,4104,O
",",4104,O
BAEP,4104,O
waves,4104,O
II/III-V,4104,O
completely,4104,O
disappeared,4104,O
within,4104,O
2,4104,O
to,4104,O
25,4104,O
min,4104,O
after,4104,O
papaverine,4104,B-Chemical
.,4104,O
Eight,4105,O
of,4105,O
these,4105,O
10,4105,O
patients,4105,O
had,4105,O
complete,4105,O
loss,4105,O
of,4105,O
BAEP,4105,O
waveforms,4105,O
within,4105,O
10,4105,O
min,4105,O
.,4105,O
One,4106,O
patient,4106,O
showed,4106,O
no,4106,O
recovery,4106,O
of,4106,O
later,4106,O
waves,4106,O
and,4106,O
a,4106,O
delayed,4106,O
profound,4106,O
sensorineural,4106,B-Disease
hearing,4106,I-Disease
loss,4106,I-Disease
.,4106,O
The,4107,O
average,4107,O
recovery,4107,O
time,4107,O
of,4107,O
BAEP,4107,O
waveforms,4107,O
to,4107,O
pre-papaverine,4107,O
baseline,4107,O
values,4107,O
was,4107,O
39,4107,O
min,4107,O
.,4107,O
CONCLUSIONS,4108,O
:,4108,O
Topical,4108,O
papaverine,4108,B-Chemical
for,4108,O
the,4108,O
treatment,4108,O
of,4108,O
vasospasm,4108,B-Disease
was,4108,O
associated,4108,O
with,4108,O
the,4108,O
onset,4108,O
of,4108,O
a,4108,O
transient,4108,O
disturbance,4108,O
in,4108,O
neurophysiological,4108,O
function,4108,O
of,4108,O
the,4108,O
ascending,4108,O
auditory,4108,O
brainstem,4108,O
pathway,4108,O
.,4108,O
The,4109,O
complete,4109,O
disappearance,4109,O
of,4109,O
BAEP,4109,O
waveforms,4109,O
with,4109,O
a,4109,O
consistent,4109,O
temporal,4109,O
delay,4109,O
suggests,4109,O
a,4109,O
possible,4109,O
adverse,4109,B-Disease
effect,4109,I-Disease
on,4109,I-Disease
the,4109,I-Disease
proximal,4109,I-Disease
eighth,4109,I-Disease
nerve,4109,I-Disease
.,4109,O
Recommendations,4110,O
to,4110,O
avoid,4110,O
potential,4110,O
cranial,4110,B-Disease
nerve,4110,I-Disease
deficits,4110,I-Disease
from,4110,O
papaverine,4110,B-Chemical
are,4110,O
provided,4110,O
.,4110,O
Simvastatin-ezetimibe-induced,4111,B-Chemical
hepatic,4111,B-Disease
failure,4111,I-Disease
necessitating,4111,O
liver,4111,O
transplantation,4111,O
.,4111,O
Abstract,4112,O
Serum,4112,O
aminotransferase,4112,O
elevations,4112,O
are,4112,O
a,4112,O
commonly,4112,O
known,4112,O
adverse,4112,O
effect,4112,O
of,4112,O
3-hydroxy-3-methylglutaryl,4112,O
coenzyme,4112,O
A,4112,O
reductase,4112,O
inhibitor,4112,O
(,4112,O
statin,4112,B-Chemical
),4112,O
therapy,4112,O
.,4112,O
However,4113,O
",",4113,O
hepatotoxic,4113,B-Disease
events,4113,O
have,4113,O
not,4113,O
been,4113,O
widely,4113,O
published,4113,O
with,4113,O
ezetimibe,4113,B-Chemical
or,4113,O
the,4113,O
combination,4113,O
agent,4113,O
simvastatin-ezetimibe,4113,B-Chemical
.,4113,O
We,4114,O
describe,4114,O
a,4114,O
70-year-old,4114,O
Hispanic,4114,O
woman,4114,O
who,4114,O
developed,4114,O
fulminant,4114,B-Disease
hepatic,4114,I-Disease
failure,4114,I-Disease
necessitating,4114,O
liver,4114,O
transplantation,4114,O
10,4114,O
weeks,4114,O
after,4114,O
conversion,4114,O
from,4114,O
simvastatin,4114,B-Chemical
40,4114,O
mg/day,4114,O
to,4114,O
simvastatin,4114,B-Chemical
10,4114,I-Chemical
mg-ezetimibe,4114,I-Chemical
40,4114,I-Chemical
mg/day,4114,O
.,4114,O
The,4115,O
patient,4115,O
's,4115,O
lipid,4115,O
panel,4115,O
had,4115,O
been,4115,O
maintained,4115,O
with,4115,O
simvastatin,4115,B-Chemical
for,4115,O
18,4115,O
months,4115,O
before,4115,O
the,4115,O
conversion,4115,O
without,4115,O
evidence,4115,O
of,4115,O
hepatotoxicity,4115,B-Disease
.,4115,O
A,4116,O
routine,4116,O
laboratory,4116,O
work-up,4116,O
10,4116,O
weeks,4116,O
after,4116,O
conversion,4116,O
revealed,4116,O
elevated,4116,O
serum,4116,O
aminotransferase,4116,O
levels,4116,O
.,4116,O
Simvastatinezetimibe,4117,B-Chemical
and,4117,O
escitalopram,4117,B-Chemical
(,4117,O
which,4117,O
she,4117,O
was,4117,O
taking,4117,O
for,4117,O
depression,4117,B-Disease
),4117,O
were,4117,O
discontinued,4117,O
",",4117,O
and,4117,O
other,4117,O
potential,4117,O
causes,4117,O
of,4117,O
hepatotoxicity,4117,B-Disease
were,4117,O
excluded,4117,O
.,4117,O
A,4118,O
repeat,4118,O
work-up,4118,O
revealed,4118,O
further,4118,O
elevations,4118,O
in,4118,O
aminotransferase,4118,O
levels,4118,O
",",4118,O
and,4118,O
liver,4118,O
biopsy,4118,O
revealed,4118,O
evidence,4118,O
of,4118,O
moderate-to-severe,4118,O
drug,4118,B-Disease
toxicity,4118,I-Disease
.,4118,O
She,4119,O
underwent,4119,O
liver,4119,O
transplantation,4119,O
with,4119,O
an,4119,O
uneventful,4119,O
postoperative,4119,O
course,4119,O
.,4119,O
Her,4120,O
aminotransferase,4120,O
levels,4120,O
returned,4120,O
to,4120,O
normal,4120,O
by,4120,O
postoperative,4120,O
day,4120,O
23,4120,O
",",4120,O
and,4120,O
her,4120,O
2-year,4120,O
follow-up,4120,O
showed,4120,O
no,4120,O
adverse,4120,O
events,4120,O
.,4120,O
Ezetimibe,4121,B-Chemical
undergoes,4121,O
extensive,4121,O
glucuronidation,4121,O
by,4121,O
uridine,4121,B-Chemical
diphosphate,4121,I-Chemical
glucoronosyltransferases,4121,O
(,4121,O
UGT,4121,O
),4121,O
in,4121,O
the,4121,O
intestine,4121,O
and,4121,O
liver,4121,O
and,4121,O
may,4121,O
have,4121,O
inhibited,4121,O
the,4121,O
glucuronidation,4121,O
of,4121,O
simvastatin,4121,B-Chemical
hydroxy,4121,I-Chemical
acid,4121,I-Chemical
",",4121,O
resulting,4121,O
in,4121,O
increased,4121,O
simvastatin,4121,B-Chemical
exposure,4121,O
and,4121,O
subsequent,4121,O
hepatotoxicity,4121,B-Disease
.,4121,O
To,4122,O
our,4122,O
knowledge,4122,O
",",4122,O
this,4122,O
is,4122,O
the,4122,O
first,4122,O
case,4122,O
report,4122,O
of,4122,O
simvastatin-ezetimibe-induced,4122,B-Chemical
liver,4122,B-Disease
failure,4122,I-Disease
that,4122,O
resulted,4122,O
in,4122,O
liver,4122,O
transplantation,4122,O
.,4122,O
We,4123,O
postulate,4123,O
that,4123,O
the,4123,O
mechanism,4123,O
of,4123,O
the,4123,O
simvastatinezetimibe-induced,4123,B-Chemical
hepatotoxicity,4123,B-Disease
is,4123,O
the,4123,O
increased,4123,O
simvastatin,4123,B-Chemical
exposure,4123,O
by,4123,O
ezetimibe,4123,B-Chemical
inhibition,4123,O
of,4123,O
UGT,4123,O
enzymes,4123,O
.,4123,O
Clinicians,4124,O
should,4124,O
be,4124,O
aware,4124,O
of,4124,O
potential,4124,O
hepatotoxicity,4124,B-Disease
with,4124,O
simvastatin-ezetimibe,4124,B-Chemical
especially,4124,O
in,4124,O
elderly,4124,O
patients,4124,O
and,4124,O
should,4124,O
carefully,4124,O
monitor,4124,O
serum,4124,O
aminotransferase,4124,O
levels,4124,O
when,4124,O
starting,4124,O
therapy,4124,O
and,4124,O
titrating,4124,O
the,4124,O
dosage,4124,O
.,4124,O
Massive,4125,O
proteinuria,4125,B-Disease
and,4125,O
acute,4125,B-Disease
renal,4125,I-Disease
failure,4125,I-Disease
after,4125,O
oral,4125,O
bisphosphonate,4125,B-Chemical
(,4125,O
alendronate,4125,B-Chemical
),4125,O
administration,4125,O
in,4125,O
a,4125,O
patient,4125,O
with,4125,O
focal,4125,B-Disease
segmental,4125,I-Disease
glomerulosclerosis,4125,I-Disease
.,4125,O
A,4126,O
61-year-old,4126,O
Japanese,4126,O
man,4126,O
with,4126,O
nephrotic,4126,B-Disease
syndrome,4126,I-Disease
due,4126,O
to,4126,O
focal,4126,B-Disease
segmental,4126,I-Disease
glomerulosclerosis,4126,I-Disease
was,4126,O
initially,4126,O
responding,4126,O
well,4126,O
to,4126,O
steroid,4126,B-Chemical
therapy,4126,O
.,4126,O
The,4127,O
amount,4127,O
of,4127,O
daily,4127,O
urinary,4127,O
protein,4127,O
decreased,4127,O
from,4127,O
15.6,4127,O
to,4127,O
2.8,4127,O
g.,4127,O
Within,4127,O
14,4127,O
days,4127,O
of,4127,O
the,4127,O
oral,4127,O
bisphosphonate,4127,B-Chemical
(,4127,O
alendronate,4127,B-Chemical
sodium,4127,I-Chemical
),4127,O
administration,4127,O
",",4127,O
the,4127,O
amount,4127,O
of,4127,O
daily,4127,O
urinary,4127,O
protein,4127,O
increased,4127,O
rapidly,4127,O
up,4127,O
to,4127,O
12.8,4127,O
g,4127,O
with,4127,O
acute,4127,B-Disease
renal,4127,I-Disease
failure,4127,I-Disease
.,4127,O
After,4128,O
discontinuing,4128,O
the,4128,O
oral,4128,O
alendronate,4128,B-Chemical
",",4128,O
the,4128,O
patient,4128,O
underwent,4128,O
six,4128,O
cycles,4128,O
of,4128,O
hemodialysis,4128,O
and,4128,O
four,4128,O
cycles,4128,O
of,4128,O
LDL,4128,O
apheresis,4128,O
.,4128,O
Urinary,4129,O
volume,4129,O
and,4129,O
serum,4129,O
creatinine,4129,B-Chemical
levels,4129,O
recovered,4129,O
to,4129,O
the,4129,O
normal,4129,O
range,4129,O
",",4129,O
with,4129,O
urinary,4129,O
protein,4129,O
disappearing,4129,O
completely,4129,O
within,4129,O
40,4129,O
days,4129,O
.,4129,O
This,4130,O
report,4130,O
demonstrates,4130,O
that,4130,O
not,4130,O
only,4130,O
intravenous,4130,O
",",4130,O
but,4130,O
also,4130,O
oral,4130,O
bisphosphonates,4130,B-Chemical
can,4130,O
aggravate,4130,O
proteinuria,4130,B-Disease
and,4130,O
acute,4130,B-Disease
renal,4130,I-Disease
failure,4130,I-Disease
.,4130,O
Serum-,4131,O
and,4131,O
glucocorticoid-inducible,4131,O
kinase,4131,O
1,4131,O
in,4131,O
doxorubicin-induced,4131,B-Chemical
nephrotic,4131,B-Disease
syndrome,4131,I-Disease
.,4131,O
Doxorubicin-induced,4132,B-Chemical
nephropathy,4132,B-Disease
leads,4132,O
to,4132,O
epithelial,4132,O
sodium,4132,B-Chemical
channel,4132,O
(,4132,O
ENaC,4132,O
),4132,O
-dependent,4132,O
volume,4132,B-Disease
retention,4132,I-Disease
and,4132,O
renal,4132,O
fibrosis,4132,B-Disease
.,4132,O
The,4133,O
aldosterone-sensitive,4133,B-Chemical
serum-,4133,O
and,4133,O
glucocorticoid-inducible,4133,O
kinase,4133,O
SGK1,4133,O
has,4133,O
been,4133,O
shown,4133,O
to,4133,O
participate,4133,O
in,4133,O
the,4133,O
stimulation,4133,O
of,4133,O
ENaC,4133,O
and,4133,O
to,4133,O
mediate,4133,O
renal,4133,O
fibrosis,4133,B-Disease
following,4133,O
mineralocorticoid,4133,O
and,4133,O
salt,4133,O
excess,4133,O
.,4133,O
The,4134,O
present,4134,O
study,4134,O
was,4134,O
performed,4134,O
to,4134,O
elucidate,4134,O
the,4134,O
role,4134,O
of,4134,O
SGK1,4134,O
in,4134,O
the,4134,O
volume,4134,B-Disease
retention,4134,I-Disease
and,4134,O
fibrosis,4134,B-Disease
during,4134,O
nephrotic,4134,B-Disease
syndrome,4134,I-Disease
.,4134,O
To,4135,O
this,4135,O
end,4135,O
",",4135,O
doxorubicin,4135,B-Chemical
(,4135,O
15,4135,O
mug/g,4135,O
body,4135,O
wt,4135,O
),4135,O
was,4135,O
injected,4135,O
intravenously,4135,O
into,4135,O
gene-targeted,4135,O
mice,4135,O
lacking,4135,O
SGK1,4135,O
(,4135,O
sgk1,4135,O
(,4135,O
-/-,4135,O
),4135,O
),4135,O
and,4135,O
their,4135,O
wild-type,4135,O
littermates,4135,O
(,4135,O
sgk1,4135,O
(,4135,O
+/+,4135,O
),4135,O
),4135,O
.,4135,O
Doxorubicin,4136,B-Chemical
treatment,4136,O
resulted,4136,O
in,4136,O
heavy,4136,O
proteinuria,4136,B-Disease
(,4136,O
>,4136,O
100,4136,O
mg,4136,O
protein/mg,4136,O
crea,4136,O
),4136,O
in,4136,O
15/44,4136,O
of,4136,O
sgk1,4136,O
(,4136,O
+/+,4136,O
),4136,O
and,4136,O
15/44,4136,O
of,4136,O
sgk1,4136,O
(,4136,O
-/-,4136,O
),4136,O
mice,4136,O
leading,4136,O
to,4136,O
severe,4136,O
nephrotic,4136,B-Disease
syndrome,4136,I-Disease
with,4136,O
ascites,4136,B-Disease
",",4136,O
lipidemia,4136,B-Disease
",",4136,O
and,4136,O
hypoalbuminemia,4136,B-Disease
in,4136,O
both,4136,O
genotypes,4136,O
.,4136,O
Plasma,4137,O
aldosterone,4137,B-Chemical
levels,4137,O
increased,4137,O
in,4137,O
nephrotic,4137,B-Disease
mice,4137,O
of,4137,O
both,4137,O
genotypes,4137,O
and,4137,O
was,4137,O
followed,4137,O
by,4137,O
increased,4137,O
SGK1,4137,O
protein,4137,O
expression,4137,O
in,4137,O
sgk1,4137,O
(,4137,O
+/+,4137,O
),4137,O
mice,4137,O
.,4137,O
Urinary,4138,O
sodium,4138,B-Chemical
excretion,4138,O
reached,4138,O
signficantly,4138,O
lower,4138,O
values,4138,O
in,4138,O
sgk1,4138,O
(,4138,O
+/+,4138,O
),4138,O
mice,4138,O
(,4138,O
15,4138,O
+/-,4138,O
5,4138,O
mumol/mg,4138,O
crea,4138,O
),4138,O
than,4138,O
in,4138,O
sgk1,4138,O
(,4138,O
-/-,4138,O
),4138,O
mice,4138,O
(,4138,O
35,4138,O
+/-,4138,O
5,4138,O
mumol/mg,4138,O
crea,4138,O
),4138,O
and,4138,O
was,4138,O
associated,4138,O
with,4138,O
a,4138,O
significantly,4138,O
higher,4138,O
body,4138,O
weight,4138,B-Disease
gain,4138,I-Disease
in,4138,O
sgk1,4138,O
(,4138,O
+/+,4138,O
),4138,O
compared,4138,O
with,4138,O
sgk1,4138,O
(,4138,O
-/-,4138,O
),4138,O
mice,4138,O
(,4138,O
+6.6,4138,O
+/-,4138,O
0.7,4138,O
vs.,4138,O
+4.1,4138,O
+/-,4138,O
0.8,4138,O
g,4138,O
),4138,O
.,4138,O
During,4139,O
the,4139,O
course,4139,O
of,4139,O
nephrotic,4139,B-Disease
syndrome,4139,I-Disease
",",4139,O
serum,4139,O
urea,4139,B-Chemical
concentrations,4139,O
increased,4139,O
significantly,4139,O
faster,4139,O
in,4139,O
sgk1,4139,O
(,4139,O
-/-,4139,O
),4139,O
mice,4139,O
than,4139,O
in,4139,O
sgk1,4139,O
(,4139,O
+/+,4139,O
),4139,O
mice,4139,O
leading,4139,O
to,4139,O
uremia,4139,B-Disease
and,4139,O
a,4139,O
reduced,4139,O
median,4139,O
survival,4139,O
in,4139,O
sgk1,4139,O
(,4139,O
-/-,4139,O
),4139,O
mice,4139,O
(,4139,O
29,4139,O
vs.,4139,O
40,4139,O
days,4139,O
in,4139,O
sgk1,4139,O
(,4139,O
+/+,4139,O
),4139,O
mice,4139,O
),4139,O
.,4139,O
In,4140,O
conclusion,4140,O
",",4140,O
gene-targeted,4140,O
mice,4140,O
lacking,4140,O
SGK1,4140,O
showed,4140,O
blunted,4140,O
volume,4140,B-Disease
retention,4140,I-Disease
",",4140,O
yet,4140,O
were,4140,O
not,4140,O
protected,4140,O
against,4140,O
renal,4140,O
fibrosis,4140,B-Disease
during,4140,O
experimental,4140,O
nephrotic,4140,B-Disease
syndrome,4140,I-Disease
.,4140,O
Severe,4141,O
thrombocytopenia,4141,B-Disease
and,4141,O
haemolytic,4141,B-Disease
anaemia,4141,I-Disease
associated,4141,O
with,4141,O
ciprofloxacin,4141,B-Chemical
:,4141,O
a,4141,O
case,4141,O
report,4141,O
with,4141,O
fatal,4141,O
outcome,4141,O
.,4141,O
Haematological,4142,O
adverse,4142,O
reactions,4142,O
associated,4142,O
with,4142,O
fatal,4142,O
outcome,4142,O
are,4142,O
rare,4142,O
during,4142,O
treatment,4142,O
with,4142,O
ciprofloxacin,4142,B-Chemical
.,4142,O
A,4143,O
30-year,4143,O
old,4143,O
Caucasian,4143,O
man,4143,O
reported,4143,O
with,4143,O
abdominal,4143,B-Disease
pain,4143,I-Disease
and,4143,O
jaundice,4143,B-Disease
after,4143,O
3-day,4143,O
administration,4143,O
of,4143,O
oral,4143,O
ciprofloxacin,4143,B-Chemical
for,4143,O
a,4143,O
suspect,4143,O
of,4143,O
urinary,4143,B-Disease
tract,4143,I-Disease
infection,4143,I-Disease
.,4143,O
Clinical,4144,O
evaluations,4144,O
suggested,4144,O
an,4144,O
initial,4144,O
diagnosis,4144,O
of,4144,O
severe,4144,O
thrombocytopenia,4144,B-Disease
and,4144,O
haemolysis,4144,B-Disease
.,4144,O
The,4145,O
patient,4145,O
progressively,4145,O
developed,4145,O
petechiae,4145,B-Disease
and,4145,O
purpura,4145,B-Disease
on,4145,O
thorax,4145,O
and,4145,O
lower,4145,O
limbs,4145,O
.,4145,O
Despite,4146,O
pharmacological,4146,O
and,4146,O
supportive,4146,O
interventions,4146,O
",",4146,O
laboratory,4146,O
parameters,4146,O
worsened,4146,O
and,4146,O
the,4146,O
patient,4146,O
died,4146,O
17,4146,O
hours,4146,O
after,4146,O
admission,4146,O
.,4146,O
An,4147,O
accurate,4147,O
autopsy,4147,O
revealed,4147,O
most,4147,O
organs,4147,O
with,4147,O
diffuse,4147,O
petechial,4147,O
haemorrhages,4147,B-Disease
.,4147,O
No,4148,O
signs,4148,O
of,4148,O
bone,4148,B-Disease
marrow,4148,I-Disease
depression,4148,I-Disease
were,4148,O
found,4148,O
.,4148,O
No,4149,O
thrombi,4149,B-Disease
or,4149,O
signs,4149,O
of,4149,O
microangiopathies,4149,B-Disease
were,4149,O
observed,4149,O
in,4149,O
arterial,4149,O
vessels,4149,O
.,4149,O
Blood,4150,O
and,4150,O
urine,4150,O
cultures,4150,O
did,4150,O
not,4150,O
show,4150,O
any,4150,O
bacterial,4150,O
growth,4150,O
.,4150,O
This,4151,O
case,4151,O
report,4151,O
shows,4151,O
that,4151,O
ciprofloxacin,4151,B-Chemical
may,4151,O
precipitate,4151,O
life-threatening,4151,O
thrombocytopenia,4151,B-Disease
and,4151,O
haemolytic,4151,B-Disease
anaemia,4151,I-Disease
",",4151,O
even,4151,O
in,4151,O
the,4151,O
early,4151,O
phases,4151,O
of,4151,O
treatment,4151,O
and,4151,O
without,4151,O
apparent,4151,O
previous,4151,O
exposures,4151,O
.,4151,O
Alpha-lipoic,4152,B-Chemical
acid,4152,I-Chemical
prevents,4152,O
mitochondrial,4152,B-Disease
damage,4152,I-Disease
and,4152,O
neurotoxicity,4152,B-Disease
in,4152,O
experimental,4152,O
chemotherapy,4152,O
neuropathy,4152,B-Disease
.,4152,O
The,4153,O
study,4153,O
investigates,4153,O
if,4153,O
alpha-lipoic,4153,B-Chemical
acid,4153,I-Chemical
is,4153,O
neuroprotective,4153,O
against,4153,O
chemotherapy,4153,O
induced,4153,O
neurotoxicity,4153,B-Disease
",",4153,O
if,4153,O
mitochondrial,4153,B-Disease
damage,4153,I-Disease
plays,4153,O
a,4153,O
critical,4153,O
role,4153,O
in,4153,O
toxic,4153,B-Disease
neurodegenerative,4153,I-Disease
cascade,4153,I-Disease
",",4153,O
and,4153,O
if,4153,O
neuroprotective,4153,O
effects,4153,O
of,4153,O
alpha-lipoic,4153,B-Chemical
acid,4153,I-Chemical
depend,4153,O
on,4153,O
mitochondria,4153,O
protection,4153,O
.,4153,O
We,4154,O
used,4154,O
an,4154,O
in,4154,O
vitro,4154,O
model,4154,O
of,4154,O
chemotherapy,4154,O
induced,4154,O
peripheral,4154,B-Disease
neuropathy,4154,I-Disease
that,4154,O
closely,4154,O
mimic,4154,O
the,4154,O
in,4154,O
vivo,4154,O
condition,4154,O
by,4154,O
exposing,4154,O
primary,4154,O
cultures,4154,O
of,4154,O
dorsal,4154,O
root,4154,O
ganglion,4154,O
(,4154,O
DRG,4154,O
),4154,O
sensory,4154,O
neurons,4154,O
to,4154,O
paclitaxel,4154,B-Chemical
and,4154,O
cisplatin,4154,B-Chemical
",",4154,O
two,4154,O
widely,4154,O
used,4154,O
and,4154,O
highly,4154,O
effective,4154,O
chemotherapeutic,4154,O
drugs,4154,O
.,4154,O
This,4155,O
approach,4155,O
allowed,4155,O
investigating,4155,O
the,4155,O
efficacy,4155,O
of,4155,O
alpha-lipoic,4155,B-Chemical
acid,4155,I-Chemical
in,4155,O
preventing,4155,O
axonal,4155,B-Disease
damage,4155,I-Disease
and,4155,O
apoptosis,4155,O
and,4155,O
the,4155,O
function,4155,O
and,4155,O
ultrastructural,4155,O
morphology,4155,O
of,4155,O
mitochondria,4155,O
after,4155,O
exposure,4155,O
to,4155,O
toxic,4155,O
agents,4155,O
and,4155,O
alpha-lipoic,4155,B-Chemical
acid,4155,I-Chemical
.,4155,O
Our,4156,O
results,4156,O
demonstrate,4156,O
that,4156,O
both,4156,O
cisplatin,4156,B-Chemical
and,4156,O
paclitaxel,4156,B-Chemical
cause,4156,O
early,4156,O
mitochondrial,4156,B-Disease
impairment,4156,I-Disease
with,4156,O
loss,4156,O
of,4156,O
membrane,4156,O
potential,4156,O
and,4156,O
induction,4156,O
of,4156,O
autophagic,4156,O
vacuoles,4156,O
in,4156,O
neurons,4156,O
.,4156,O
Alpha-lipoic,4157,B-Chemical
acid,4157,I-Chemical
exerts,4157,O
neuroprotective,4157,O
effects,4157,O
against,4157,O
chemotherapy,4157,O
induced,4157,O
neurotoxicity,4157,B-Disease
in,4157,O
sensory,4157,O
neurons,4157,O
:,4157,O
it,4157,O
rescues,4157,O
the,4157,O
mitochondrial,4157,B-Disease
toxicity,4157,I-Disease
and,4157,O
induces,4157,O
the,4157,O
expression,4157,O
of,4157,O
frataxin,4157,O
",",4157,O
an,4157,O
essential,4157,O
mitochondrial,4157,O
protein,4157,O
with,4157,O
anti-oxidant,4157,O
and,4157,O
chaperone,4157,O
properties,4157,O
.,4157,O
In,4158,O
conclusion,4158,O
mitochondrial,4158,B-Disease
toxicity,4158,I-Disease
is,4158,O
an,4158,O
early,4158,O
common,4158,O
event,4158,O
both,4158,O
in,4158,O
paclitaxel,4158,B-Chemical
and,4158,O
cisplatin,4158,B-Chemical
induced,4158,O
neurotoxicity,4158,B-Disease
.,4158,O
Alpha-lipoic,4159,B-Chemical
acid,4159,I-Chemical
protects,4159,O
sensory,4159,O
neurons,4159,O
through,4159,O
its,4159,O
anti-oxidant,4159,O
and,4159,O
mitochondrial,4159,O
regulatory,4159,O
functions,4159,O
",",4159,O
possibly,4159,O
inducing,4159,O
the,4159,O
expression,4159,O
of,4159,O
frataxin,4159,O
.,4159,O
These,4160,O
findings,4160,O
suggest,4160,O
that,4160,O
alpha-lipoic,4160,B-Chemical
acid,4160,I-Chemical
might,4160,O
reduce,4160,O
the,4160,O
risk,4160,O
of,4160,O
developing,4160,O
peripheral,4160,B-Disease
nerve,4160,I-Disease
toxicity,4160,I-Disease
in,4160,O
patients,4160,O
undergoing,4160,O
chemotherapy,4160,O
and,4160,O
encourage,4160,O
further,4160,O
confirmatory,4160,O
clinical,4160,O
trials,4160,O
.,4160,O
Toxicity,4161,B-Disease
in,4161,O
rhesus,4161,O
monkeys,4161,O
following,4161,O
administration,4161,O
of,4161,O
the,4161,O
8-aminoquinoline,4161,B-Chemical
8-,4161,B-Chemical
[,4161,I-Chemical
(,4161,I-Chemical
4-amino-l-methylbutyl,4161,I-Chemical
),4161,I-Chemical
amino,4161,I-Chemical
],4161,I-Chemical
-,4161,I-Chemical
5-,4161,I-Chemical
(,4161,I-Chemical
l-hexyloxy,4161,I-Chemical
),4161,I-Chemical
-6-methoxy-4-methylquinoline,4161,I-Chemical
(,4161,O
WR242511,4161,B-Chemical
),4161,O
.,4161,O
INTRODUCTION,4162,O
:,4162,O
Many,4162,O
substances,4162,O
that,4162,O
form,4162,O
methemoglobin,4162,O
(,4162,O
MHb,4162,O
),4162,O
effectively,4162,O
counter,4162,O
cyanide,4162,O
(,4162,O
CN,4162,O
),4162,O
toxicity,4162,B-Disease
.,4162,O
Although,4163,O
MHb,4163,O
formers,4163,O
are,4163,O
generally,4163,O
applied,4163,O
as,4163,O
treatments,4163,O
for,4163,O
CN,4163,O
poisoning,4163,B-Disease
",",4163,O
it,4163,O
has,4163,O
been,4163,O
proposed,4163,O
that,4163,O
a,4163,O
stable,4163,O
",",4163,O
long-acting,4163,O
MHb,4163,O
former,4163,O
could,4163,O
serve,4163,O
as,4163,O
a,4163,O
CN,4163,O
pretreatment,4163,O
.,4163,O
Using,4164,O
this,4164,O
rationale,4164,O
",",4164,O
the,4164,O
8-aminoquinoline,4164,B-Chemical
WR242511,4164,B-Chemical
",",4164,O
a,4164,O
potent,4164,O
long-lasting,4164,O
MHb,4164,O
former,4164,O
in,4164,O
rodents,4164,O
and,4164,O
beagle,4164,O
dogs,4164,O
",",4164,O
was,4164,O
studied,4164,O
in,4164,O
the,4164,O
rhesus,4164,O
monkey,4164,O
for,4164,O
advanced,4164,O
development,4164,O
as,4164,O
a,4164,O
potential,4164,O
CN,4164,O
pretreatment,4164,O
.,4164,O
METHODS,4165,O
:,4165,O
In,4165,O
this,4165,O
study,4165,O
",",4165,O
WR242511,4165,B-Chemical
was,4165,O
administered,4165,O
intravenously,4165,O
(,4165,O
IV,4165,O
),4165,O
in,4165,O
2,4165,O
female,4165,O
and,4165,O
4,4165,O
male,4165,O
rhesus,4165,O
monkeys,4165,O
in,4165,O
doses,4165,O
of,4165,O
3.5,4165,O
and/or,4165,O
7.0,4165,O
mg/kg,4165,O
;,4165,O
a,4165,O
single,4165,O
male,4165,O
also,4165,O
received,4165,O
WR242511,4165,B-Chemical
orally,4165,O
(,4165,O
PO,4165,O
),4165,O
at,4165,O
7.0,4165,O
mg/kg,4165,O
.,4165,O
Health,4166,O
status,4166,O
and,4166,O
MHb,4166,O
levels,4166,O
were,4166,O
monitored,4166,O
following,4166,O
exposure,4166,O
.,4166,O
RESULTS,4167,O
:,4167,O
The,4167,O
selected,4167,O
doses,4167,O
of,4167,O
WR242511,4167,B-Chemical
",",4167,O
which,4167,O
produced,4167,O
significant,4167,O
methemoglobinemia,4167,B-Disease
in,4167,O
beagle,4167,O
dogs,4167,O
in,4167,O
earlier,4167,O
studies,4167,O
conducted,4167,O
elsewhere,4167,O
",",4167,O
produced,4167,O
very,4167,O
little,4167,O
MHb,4167,O
(,4167,O
mean,4167,O
<,4167,O
2.0,4167,O
%,4167,O
),4167,O
in,4167,O
the,4167,O
rhesus,4167,O
monkey,4167,O
.,4167,O
Furthermore,4168,O
",",4168,O
transient,4168,O
hemoglobinuria,4168,B-Disease
was,4168,O
noted,4168,O
approximately,4168,O
60,4168,O
minutes,4168,O
postinjection,4168,O
of,4168,O
WR242511,4168,B-Chemical
(,4168,O
3.5,4168,O
or,4168,O
7.0,4168,O
mg/kg,4168,O
),4168,O
",",4168,O
and,4168,O
2,4168,O
lethalities,4168,O
occurred,4168,O
(,4168,O
one,4168,O
IV,4168,O
and,4168,O
one,4168,O
PO,4168,O
),4168,O
following,4168,O
the,4168,O
7.0,4168,O
mg/kg,4168,O
dose,4168,O
.,4168,O
Myoglobinuria,4169,B-Disease
was,4169,O
also,4169,O
observed,4169,O
following,4169,O
the,4169,O
7.0,4169,O
mg/kg,4169,O
dose,4169,O
.,4169,O
Histopathology,4170,O
analyses,4170,O
in,4170,O
the,4170,O
2,4170,O
animals,4170,O
that,4170,O
died,4170,O
revealed,4170,O
liver,4170,O
and,4170,O
kidney,4170,O
toxicity,4170,O
",",4170,O
with,4170,O
greater,4170,O
severity,4170,O
in,4170,O
the,4170,O
orally-treated,4170,O
animal,4170,O
.,4170,O
CONCLUSIONS,4171,O
:,4171,O
These,4171,O
data,4171,O
demonstrate,4171,O
direct,4171,O
and/or,4171,O
indirect,4171,O
drug-induced,4171,O
toxicity,4171,B-Disease
.,4171,O
It,4172,O
is,4172,O
concluded,4172,O
that,4172,O
WR242511,4172,B-Chemical
should,4172,O
not,4172,O
be,4172,O
pursued,4172,O
as,4172,O
a,4172,O
pretreatment,4172,O
for,4172,O
CN,4172,O
poisoning,4172,B-Disease
unless,4172,O
the,4172,O
anti-CN,4172,O
characteristics,4172,O
of,4172,O
this,4172,O
compound,4172,O
can,4172,O
be,4172,O
successfully,4172,O
dissociated,4172,O
from,4172,O
those,4172,O
producing,4172,O
undesirable,4172,O
toxicity,4172,B-Disease
.,4172,O
Repetitive,4173,O
transcranial,4173,O
magnetic,4173,O
stimulation,4173,O
for,4173,O
levodopa-induced,4173,B-Chemical
dyskinesias,4173,B-Disease
in,4173,O
Parkinson,4173,B-Disease
's,4173,I-Disease
disease,4173,I-Disease
.,4173,O
In,4174,O
a,4174,O
placebo-controlled,4174,O
",",4174,O
single-blinded,4174,O
",",4174,O
crossover,4174,O
study,4174,O
",",4174,O
we,4174,O
assessed,4174,O
the,4174,O
effect,4174,O
of,4174,O
``,4174,O
real,4174,O
'',4174,O
repetitive,4174,O
transcranial,4174,O
magnetic,4174,O
stimulation,4174,O
(,4174,O
rTMS,4174,O
),4174,O
versus,4174,O
``,4174,O
sham,4174,O
'',4174,O
rTMS,4174,O
(,4174,O
placebo,4174,O
),4174,O
on,4174,O
peak,4174,O
dose,4174,O
dyskinesias,4174,B-Disease
in,4174,O
patients,4174,O
with,4174,O
Parkinson,4174,B-Disease
's,4174,I-Disease
disease,4174,I-Disease
(,4174,O
PD,4174,B-Disease
),4174,O
.,4174,O
Ten,4175,O
patients,4175,O
with,4175,O
PD,4175,B-Disease
and,4175,O
prominent,4175,O
dyskinesias,4175,B-Disease
had,4175,O
rTMS,4175,O
(,4175,O
"1,800",4175,O
pulses,4175,O
;,4175,O
1,4175,O
Hz,4175,O
rate,4175,O
),4175,O
delivered,4175,O
over,4175,O
the,4175,O
motor,4175,O
cortex,4175,O
for,4175,O
4,4175,O
consecutive,4175,O
days,4175,O
twice,4175,O
",",4175,O
once,4175,O
real,4175,O
stimuli,4175,O
and,4175,O
once,4175,O
sham,4175,O
stimulation,4175,O
were,4175,O
used,4175,O
;,4175,O
evaluations,4175,O
were,4175,O
done,4175,O
at,4175,O
the,4175,O
baseline,4175,O
and,4175,O
1,4175,O
day,4175,O
after,4175,O
the,4175,O
end,4175,O
of,4175,O
each,4175,O
of,4175,O
the,4175,O
treatment,4175,O
series,4175,O
.,4175,O
Direct,4176,O
comparison,4176,O
between,4176,O
sham,4176,O
and,4176,O
real,4176,O
rTMS,4176,O
effects,4176,O
showed,4176,O
no,4176,O
significant,4176,O
difference,4176,O
in,4176,O
clinician-assessed,4176,O
dyskinesia,4176,B-Disease
severity,4176,O
.,4176,O
However,4177,O
",",4177,O
comparison,4177,O
with,4177,O
the,4177,O
baseline,4177,O
showed,4177,O
small,4177,O
but,4177,O
significant,4177,O
reduction,4177,O
in,4177,O
dyskinesia,4177,B-Disease
severity,4177,O
following,4177,O
real,4177,O
rTMS,4177,O
but,4177,O
not,4177,O
placebo,4177,O
.,4177,O
The,4178,O
major,4178,O
effect,4178,O
was,4178,O
on,4178,O
dystonia,4178,B-Disease
subscore,4178,O
.,4178,O
Similarly,4179,O
",",4179,O
in,4179,O
patient,4179,O
diaries,4179,O
",",4179,O
although,4179,O
both,4179,O
treatments,4179,O
caused,4179,O
reduction,4179,O
in,4179,O
subjective,4179,O
dyskinesia,4179,B-Disease
scores,4179,O
during,4179,O
the,4179,O
days,4179,O
of,4179,O
intervention,4179,O
",",4179,O
the,4179,O
effect,4179,O
was,4179,O
sustained,4179,O
for,4179,O
3,4179,O
days,4179,O
after,4179,O
the,4179,O
intervention,4179,O
for,4179,O
the,4179,O
real,4179,O
rTMS,4179,O
only,4179,O
.,4179,O
Following,4180,O
rTMS,4180,O
",",4180,O
no,4180,O
side,4180,O
effects,4180,O
and,4180,O
no,4180,O
adverse,4180,O
effects,4180,O
on,4180,O
motor,4180,O
function,4180,O
and,4180,O
PD,4180,B-Disease
symptoms,4180,O
were,4180,O
noted,4180,O
.,4180,O
The,4181,O
results,4181,O
suggest,4181,O
the,4181,O
existence,4181,O
of,4181,O
residual,4181,O
beneficial,4181,O
clinical,4181,O
aftereffects,4181,O
of,4181,O
consecutive,4181,O
daily,4181,O
applications,4181,O
of,4181,O
low-frequency,4181,O
rTMS,4181,O
on,4181,O
dyskinesias,4181,B-Disease
in,4181,O
PD,4181,B-Disease
.,4181,O
The,4182,O
effects,4182,O
may,4182,O
be,4182,O
further,4182,O
exploited,4182,O
for,4182,O
potential,4182,O
therapeutic,4182,O
uses,4182,O
.,4182,O
Intracavernous,4183,O
epinephrine,4183,B-Chemical
:,4183,O
a,4183,O
minimally,4183,O
invasive,4183,O
treatment,4183,O
for,4183,O
priapism,4183,B-Disease
in,4183,O
the,4183,O
emergency,4183,O
department,4183,O
.,4183,O
Priapism,4184,B-Disease
is,4184,O
the,4184,O
prolonged,4184,O
erection,4184,O
of,4184,O
the,4184,O
penis,4184,O
in,4184,O
the,4184,O
absence,4184,O
of,4184,O
sexual,4184,O
arousal,4184,O
.,4184,O
A,4185,O
45-year-old,4185,O
man,4185,O
",",4185,O
an,4185,O
admitted,4185,O
frequent,4185,O
cocaine,4185,B-Chemical
user,4185,O
",",4185,O
presented,4185,O
to,4185,O
the,4185,O
Emergency,4185,O
Department,4185,O
(,4185,O
ED,4185,O
),4185,O
on,4185,O
two,4185,O
separate,4185,O
occasions,4185,O
with,4185,O
a,4185,O
history,4185,O
of,4185,O
priapism,4185,B-Disease
after,4185,O
cocaine,4185,B-Chemical
use,4185,O
.,4185,O
The,4186,O
management,4186,O
options,4186,O
in,4186,O
the,4186,O
ED,4186,O
",",4186,O
as,4186,O
exemplified,4186,O
by,4186,O
four,4186,O
individual,4186,O
case,4186,O
reports,4186,O
",",4186,O
in,4186,O
particular,4186,O
the,4186,O
use,4186,O
of,4186,O
a,4186,O
minimally,4186,O
invasive,4186,O
method,4186,O
of,4186,O
intracorporal,4186,O
epinephrine,4186,B-Chemical
instillation,4186,O
",",4186,O
are,4186,O
discussed,4186,O
.,4186,O
Prophylactic,4187,O
use,4187,O
of,4187,O
lamivudine,4187,B-Chemical
with,4187,O
chronic,4187,O
immunosuppressive,4187,O
therapy,4187,O
for,4187,O
rheumatologic,4187,B-Disease
disorders,4187,I-Disease
.,4187,O
The,4188,O
objective,4188,O
of,4188,O
this,4188,O
study,4188,O
was,4188,O
to,4188,O
report,4188,O
our,4188,O
experience,4188,O
concerning,4188,O
the,4188,O
effectiveness,4188,O
of,4188,O
the,4188,O
prophylactic,4188,O
administration,4188,O
of,4188,O
lamivudine,4188,B-Chemical
in,4188,O
hepatitis,4188,B-Chemical
B,4188,I-Chemical
virus,4188,I-Chemical
surface,4188,I-Chemical
antigen,4188,I-Chemical
(,4188,O
HBs,4188,B-Chemical
Ag,4188,I-Chemical
),4188,O
positive,4188,O
patients,4188,O
with,4188,O
rheumatologic,4188,B-Disease
disease,4188,I-Disease
.,4188,O
From,4189,O
June,4189,O
2004,4189,O
to,4189,O
October,4189,O
2006,4189,O
",",4189,O
11,4189,O
HBs,4189,B-Chemical
Ag,4189,I-Chemical
positive,4189,O
patients,4189,O
with,4189,O
rheumatologic,4189,B-Disease
diseases,4189,I-Disease
",",4189,O
who,4189,O
were,4189,O
on,4189,O
both,4189,O
immunosuppressive,4189,O
and,4189,O
prophylactic,4189,O
lamivudine,4189,B-Chemical
therapies,4189,O
",",4189,O
were,4189,O
retrospectively,4189,O
assessed,4189,O
.,4189,O
Liver,4190,O
function,4190,O
tests,4190,O
",",4190,O
hepatitis,4190,B-Disease
B,4190,I-Disease
virus,4190,O
(,4190,O
HBV,4190,O
),4190,O
serologic,4190,O
markers,4190,O
",",4190,O
and,4190,O
HBV,4190,O
DNA,4190,O
levels,4190,O
of,4190,O
the,4190,O
patients,4190,O
during,4190,O
follow-up,4190,O
were,4190,O
obtained,4190,O
from,4190,O
hospital,4190,O
file,4190,O
records,4190,O
.,4190,O
Eleven,4191,O
patients,4191,O
(,4191,O
six,4191,O
male,4191,O
),4191,O
with,4191,O
median,4191,O
age,4191,O
47,4191,O
years,4191,O
(,4191,O
range,4191,O
27-73,4191,O
),4191,O
",",4191,O
median,4191,O
disease,4191,O
duration,4191,O
50,4191,O
months,4191,O
(,4191,O
range,4191,O
9-178,4191,O
),4191,O
and,4191,O
median,4191,O
follow-up,4191,O
period,4191,O
of,4191,O
patients,4191,O
13.8,4191,O
months,4191,O
(,4191,O
range,4191,O
5-27,4191,O
),4191,O
were,4191,O
enrolled,4191,O
in,4191,O
this,4191,O
study,4191,O
.,4191,O
Lamivudine,4192,B-Chemical
therapy,4192,O
was,4192,O
started,4192,O
3-7,4192,O
days,4192,O
prior,4192,O
to,4192,O
immunosuppressive,4192,O
therapy,4192,O
in,4192,O
all,4192,O
patients,4192,O
.,4192,O
Baseline,4193,O
",",4193,O
liver,4193,O
function,4193,O
tests,4193,O
were,4193,O
elevated,4193,O
in,4193,O
two,4193,O
patients,4193,O
(,4193,O
fourth,4193,O
patient,4193,O
:,4193,O
ALT:122,4193,O
IU/l,4193,O
",",4193,O
AST:111,4193,O
IU/l,4193,O
",",4193,O
tenth,4193,O
patient,4193,O
:,4193,O
ALT:294,4193,O
IU/l,4193,O
",",4193,O
AST:274,4193,O
IU/l,4193,O
",",4193,O
with,4193,O
minimal,4193,O
changes,4193,O
in,4193,O
the,4193,O
liver,4193,O
biopsy,4193,O
in,4193,O
both,4193,O
),4193,O
.,4193,O
Shortly,4194,O
after,4194,O
treatment,4194,O
their,4194,O
tests,4194,O
normalized,4194,O
and,4194,O
during,4194,O
follow-up,4194,O
period,4194,O
none,4194,O
of,4194,O
the,4194,O
patients,4194,O
had,4194,O
abnormal,4194,B-Disease
liver,4194,I-Disease
function,4194,I-Disease
tests,4194,O
.,4194,O
In,4195,O
four,4195,O
patients,4195,O
HBV,4195,O
DNA,4195,O
levels,4195,O
were,4195,O
higher,4195,O
than,4195,O
normal,4195,O
at,4195,O
baseline,4195,O
.,4195,O
Two,4196,O
of,4196,O
these,4196,O
normalized,4196,O
and,4196,O
the,4196,O
others,4196,O
increased,4196,O
later,4196,O
.,4196,O
In,4197,O
three,4197,O
additional,4197,O
patients,4197,O
",",4197,O
HBV,4197,O
DNA,4197,O
levels,4197,O
were,4197,O
increased,4197,O
during,4197,O
follow-up,4197,O
.,4197,O
None,4198,O
of,4198,O
the,4198,O
patients,4198,O
had,4198,O
significant,4198,O
clinical,4198,O
sings,4198,O
of,4198,O
HBV,4198,O
activation,4198,O
.,4198,O
Lamivudine,4199,B-Chemical
was,4199,O
well,4199,O
tolerated,4199,O
and,4199,O
was,4199,O
continued,4199,O
in,4199,O
all,4199,O
patients,4199,O
.,4199,O
Prophylactic,4200,O
administration,4200,O
of,4200,O
lamivudine,4200,B-Chemical
in,4200,O
patients,4200,O
who,4200,O
required,4200,O
immunosuppressive,4200,O
therapy,4200,O
seems,4200,O
to,4200,O
be,4200,O
safe,4200,O
",",4200,O
well,4200,O
tolerated,4200,O
and,4200,O
effective,4200,O
in,4200,O
preventing,4200,O
HBV,4200,O
reactivation,4200,O
.,4200,O
Effect,4201,O
of,4201,O
green,4201,B-Chemical
tea,4201,I-Chemical
and,4201,O
vitamin,4201,B-Chemical
E,4201,I-Chemical
combination,4201,O
in,4201,O
isoproterenol,4201,B-Chemical
induced,4201,O
myocardial,4201,B-Disease
infarction,4201,I-Disease
in,4201,O
rats,4201,O
.,4201,O
The,4202,O
present,4202,O
study,4202,O
was,4202,O
aimed,4202,O
to,4202,O
investigate,4202,O
the,4202,O
combined,4202,O
effects,4202,O
of,4202,O
green,4202,B-Chemical
tea,4202,I-Chemical
and,4202,O
vitamin,4202,B-Chemical
E,4202,I-Chemical
on,4202,O
heart,4202,O
weight,4202,O
",",4202,O
body,4202,O
weight,4202,O
",",4202,O
serum,4202,O
marker,4202,O
enzymes,4202,O
",",4202,O
lipid,4202,O
peroxidation,4202,O
",",4202,O
endogenous,4202,O
antioxidants,4202,O
and,4202,O
membrane,4202,O
bound,4202,O
ATPases,4202,O
in,4202,O
isoproterenol,4202,B-Chemical
(,4202,O
ISO,4202,B-Chemical
),4202,O
-induced,4202,O
myocardial,4202,B-Disease
infarction,4202,I-Disease
in,4202,O
rats,4202,O
.,4202,O
Adult,4203,O
male,4203,O
albino,4203,O
rats,4203,O
",",4203,O
treated,4203,O
with,4203,O
ISO,4203,B-Chemical
(,4203,O
200,4203,O
mg/kg,4203,O
",",4203,O
s.c.,4203,O
),4203,O
for,4203,O
2,4203,O
days,4203,O
at,4203,O
an,4203,O
interval,4203,O
of,4203,O
24,4203,O
h,4203,O
caused,4203,O
a,4203,O
significant,4203,O
(,4203,O
P,4203,O
<,4203,O
0.05,4203,O
),4203,O
elevation,4203,O
of,4203,O
heart,4203,O
weight,4203,O
",",4203,O
serum,4203,O
marker,4203,O
enzymes,4203,O
",",4203,O
lipid,4203,O
peroxidation,4203,O
and,4203,O
Ca+2,4203,B-Chemical
ATPase,4203,O
level,4203,O
whereas,4203,O
there,4203,O
was,4203,O
a,4203,O
significant,4203,O
(,4203,O
P,4203,O
<,4203,O
0.05,4203,O
),4203,O
decrease,4203,O
in,4203,O
body,4203,O
weight,4203,O
",",4203,O
endogenous,4203,O
antioxidants,4203,O
",",4203,O
Na+/,4203,B-Chemical
K+,4203,B-Chemical
ATPase,4203,O
and,4203,O
Mg+2,4203,B-Chemical
ATPase,4203,O
levels,4203,O
.,4203,O
Administration,4204,O
of,4204,O
green,4204,B-Chemical
tea,4204,I-Chemical
(,4204,O
100,4204,O
mg/kg/day,4204,O
",",4204,O
p.o,4204,O
.,4204,O
),4204,O
and,4205,O
vitamin,4205,B-Chemical
E,4205,I-Chemical
(,4205,O
100,4205,O
mg/kg/day,4205,O
",",4205,O
p.o,4205,O
.,4205,O
),4205,O
together,4206,O
for,4206,O
30,4206,O
consecutive,4206,O
days,4206,O
and,4206,O
challenged,4206,O
with,4206,O
ISO,4206,B-Chemical
on,4206,O
the,4206,O
day,4206,O
29th,4206,O
and,4206,O
30th,4206,O
",",4206,O
showed,4206,O
a,4206,O
significant,4206,O
(,4206,O
P,4206,O
<,4206,O
0.05,4206,O
),4206,O
decrease,4206,O
in,4206,O
heart,4206,O
weight,4206,O
",",4206,O
serum,4206,O
marker,4206,O
enzymes,4206,O
",",4206,O
lipid,4206,O
peroxidation,4206,O
",",4206,O
Ca+2,4206,B-Chemical
ATPase,4206,O
and,4206,O
a,4206,O
significant,4206,O
increase,4206,O
in,4206,O
the,4206,O
body,4206,O
weight,4206,O
",",4206,O
endogenous,4206,O
antioxidants,4206,O
",",4206,O
Na+/K+,4206,B-Chemical
ATPase,4206,O
and,4206,O
Mg+2,4206,B-Chemical
ATPase,4206,O
when,4206,O
compared,4206,O
with,4206,O
ISO,4206,B-Chemical
treated,4206,O
group,4206,O
and,4206,O
green,4206,B-Chemical
tea,4206,I-Chemical
or,4206,O
vitamin,4206,B-Chemical
E,4206,I-Chemical
alone,4206,O
treated,4206,O
groups,4206,O
.,4206,O
These,4207,O
findings,4207,O
indicate,4207,O
the,4207,O
synergistic,4207,O
protective,4207,O
effect,4207,O
of,4207,O
green,4207,B-Chemical
tea,4207,I-Chemical
and,4207,O
vitamin,4207,B-Chemical
E,4207,I-Chemical
during,4207,O
ISO,4207,B-Chemical
induced,4207,O
myocardial,4207,B-Disease
infarction,4207,I-Disease
in,4207,O
rats,4207,O
.,4207,O
Testosterone-dependent,4208,B-Chemical
hypertension,4208,B-Disease
and,4208,O
upregulation,4208,O
of,4208,O
intrarenal,4208,O
angiotensinogen,4208,O
in,4208,O
Dahl,4208,O
salt-sensitive,4208,B-Chemical
rats,4208,O
.,4208,O
Blood,4209,O
pressure,4209,O
(,4209,O
BP,4209,O
),4209,O
is,4209,O
more,4209,O
salt,4209,B-Chemical
sensitive,4209,O
in,4209,O
men,4209,O
than,4209,O
in,4209,O
premenopausal,4209,O
women,4209,O
.,4209,O
In,4210,O
Dahl,4210,O
salt-sensitive,4210,B-Chemical
rats,4210,O
(,4210,O
DS,4210,O
),4210,O
",",4210,O
high-salt,4210,O
(,4210,O
HS,4210,O
),4210,O
diet,4210,O
increases,4210,O
BP,4210,O
more,4210,O
in,4210,O
males,4210,O
than,4210,O
females,4210,O
.,4210,O
In,4211,O
contrast,4211,O
to,4211,O
the,4211,O
systemic,4211,O
renin-angiotensin,4211,O
system,4211,O
",",4211,O
which,4211,O
is,4211,O
suppressed,4211,O
in,4211,O
response,4211,O
to,4211,O
HS,4211,O
in,4211,O
male,4211,O
DS,4211,O
",",4211,O
intrarenal,4211,O
angiotensinogen,4211,O
expression,4211,O
is,4211,O
increased,4211,O
",",4211,O
and,4211,O
intrarenal,4211,O
levels,4211,O
of,4211,O
ANG,4211,O
II,4211,O
are,4211,O
not,4211,O
suppressed,4211,O
.,4211,O
In,4212,O
this,4212,O
study,4212,O
",",4212,O
the,4212,O
hypothesis,4212,O
was,4212,O
tested,4212,O
that,4212,O
there,4212,O
is,4212,O
a,4212,O
sexual,4212,O
dimorphism,4212,O
in,4212,O
HS-induced,4212,O
upregulation,4212,O
of,4212,O
intrarenal,4212,O
angiotensinogen,4212,O
mediated,4212,O
by,4212,O
testosterone,4212,B-Chemical
that,4212,O
also,4212,O
causes,4212,O
increases,4212,O
in,4212,O
BP,4212,O
and,4212,O
renal,4212,B-Disease
injury,4212,I-Disease
.,4212,O
On,4213,O
a,4213,O
low-salt,4213,O
(,4213,O
LS,4213,O
),4213,O
diet,4213,O
",",4213,O
male,4213,O
DS,4213,O
had,4213,O
higher,4213,O
levels,4213,O
of,4213,O
intrarenal,4213,O
angiotensinogen,4213,O
mRNA,4213,O
than,4213,O
females,4213,O
.,4213,O
HS,4214,O
diet,4214,O
for,4214,O
4,4214,O
wk,4214,O
increased,4214,O
renal,4214,O
cortical,4214,O
angiotensinogen,4214,O
mRNA,4214,O
and,4214,O
protein,4214,O
only,4214,O
in,4214,O
male,4214,O
DS,4214,O
",",4214,O
which,4214,O
was,4214,O
prevented,4214,O
by,4214,O
castration,4214,O
.,4214,O
Ovariectomy,4215,O
of,4215,O
female,4215,O
DS,4215,O
had,4215,O
no,4215,O
effect,4215,O
on,4215,O
intrarenal,4215,O
angiotensinogen,4215,O
expression,4215,O
on,4215,O
either,4215,O
diet,4215,O
.,4215,O
Radiotelemetric,4216,O
BP,4216,O
was,4216,O
similar,4216,O
between,4216,O
males,4216,O
and,4216,O
castrated,4216,O
rats,4216,O
on,4216,O
LS,4216,O
diet,4216,O
.,4216,O
HS,4217,O
diet,4217,O
for,4217,O
4,4217,O
wk,4217,O
caused,4217,O
a,4217,O
progressive,4217,O
increase,4217,O
in,4217,O
BP,4217,O
",",4217,O
protein,4217,O
and,4217,O
albumin,4217,O
excretion,4217,O
",",4217,O
and,4217,O
glomerular,4217,B-Disease
sclerosis,4217,I-Disease
in,4217,O
male,4217,O
DS,4217,O
rats,4217,O
",",4217,O
which,4217,O
were,4217,O
attenuated,4217,O
by,4217,O
castration,4217,O
.,4217,O
Testosterone,4218,B-Chemical
replacement,4218,O
in,4218,O
castrated,4218,O
DS,4218,O
rats,4218,O
increased,4218,O
BP,4218,O
",",4218,O
renal,4218,B-Disease
injury,4218,I-Disease
",",4218,O
and,4218,O
upregulation,4218,O
of,4218,O
renal,4218,O
angiotensinogen,4218,O
associated,4218,O
with,4218,O
HS,4218,O
diet,4218,O
.,4218,O
Testosterone,4219,B-Chemical
contributes,4219,O
to,4219,O
the,4219,O
development,4219,O
of,4219,O
hypertension,4219,B-Disease
and,4219,O
renal,4219,B-Disease
injury,4219,I-Disease
in,4219,O
male,4219,O
DS,4219,O
rats,4219,O
on,4219,O
HS,4219,O
diet,4219,O
possibly,4219,O
through,4219,O
upregulation,4219,O
of,4219,O
the,4219,O
intrarenal,4219,O
renin-angiotensin,4219,O
system,4219,O
.,4219,O
Explicit,4220,O
episodic,4220,O
memory,4220,O
for,4220,O
sensory-discriminative,4220,O
components,4220,O
of,4220,O
capsaicin-induced,4220,B-Chemical
pain,4220,B-Disease
:,4220,O
immediate,4220,O
and,4220,O
delayed,4220,O
ratings,4220,O
.,4220,O
Pain,4221,B-Disease
memory,4221,O
is,4221,O
thought,4221,O
to,4221,O
affect,4221,O
future,4221,O
pain,4221,B-Disease
sensitivity,4221,O
and,4221,O
thus,4221,O
contribute,4221,O
to,4221,O
clinical,4221,O
pain,4221,B-Disease
conditions,4221,O
.,4221,O
Systematic,4222,O
investigations,4222,O
of,4222,O
the,4222,O
human,4222,O
capacity,4222,O
to,4222,O
remember,4222,O
sensory,4222,O
features,4222,O
of,4222,O
experimental,4222,O
pain,4222,B-Disease
are,4222,O
sparse,4222,O
.,4222,O
In,4223,O
order,4223,O
to,4223,O
address,4223,O
long-term,4223,O
pain,4223,B-Disease
memory,4223,O
",",4223,O
nine,4223,O
healthy,4223,O
male,4223,O
volunteers,4223,O
received,4223,O
intradermal,4223,O
injections,4223,O
of,4223,O
three,4223,O
doses,4223,O
of,4223,O
capsaicin,4223,B-Chemical
(,4223,O
0.05,4223,O
",",4223,O
1,4223,O
and,4223,O
20,4223,O
microg,4223,O
",",4223,O
separated,4223,O
by,4223,O
15,4223,O
min,4223,O
breaks,4223,O
),4223,O
",",4223,O
each,4223,O
given,4223,O
three,4223,O
times,4223,O
in,4223,O
a,4223,O
balanced,4223,O
design,4223,O
across,4223,O
three,4223,O
sessions,4223,O
at,4223,O
one,4223,O
week,4223,O
intervals,4223,O
.,4223,O
Pain,4224,B-Disease
rating,4224,O
was,4224,O
performed,4224,O
using,4224,O
a,4224,O
computerized,4224,O
visual,4224,O
analogue,4224,O
scale,4224,O
(,4224,O
0-100,4224,O
),4224,O
digitized,4224,O
at,4224,O
1/s,4224,O
",",4224,O
either,4224,O
immediately,4224,O
online,4224,O
or,4224,O
one,4224,O
hour,4224,O
or,4224,O
one,4224,O
day,4224,O
after,4224,O
injection,4224,O
.,4224,O
Subjects,4225,O
also,4225,O
recalled,4225,O
their,4225,O
pains,4225,B-Disease
one,4225,O
week,4225,O
later,4225,O
.,4225,O
Capsaicin,4226,B-Chemical
injection,4226,O
reliably,4226,O
induced,4226,O
a,4226,O
dose-dependent,4226,O
flare,4226,O
(,4226,O
p,4226,O
<,4226,O
0.001,4226,O
),4226,O
without,4226,O
any,4226,O
difference,4226,O
within,4226,O
or,4226,O
across,4226,O
sessions,4226,O
.,4226,O
The,4227,O
strong,4227,O
burning,4227,O
pain,4227,B-Disease
decayed,4227,O
exponentially,4227,O
within,4227,O
a,4227,O
few,4227,O
minutes,4227,O
.,4227,O
Subjects,4228,O
were,4228,O
able,4228,O
to,4228,O
reliably,4228,O
discriminate,4228,O
pain,4228,B-Disease
magnitude,4228,O
and,4228,O
duration,4228,O
across,4228,O
capsaicin,4228,B-Chemical
doses,4228,O
(,4228,O
both,4228,O
p,4228,O
<,4228,O
0.001,4228,O
),4228,O
",",4228,O
regardless,4228,O
of,4228,O
whether,4228,O
first-time,4228,O
ratings,4228,O
were,4228,O
requested,4228,O
immediately,4228,O
",",4228,O
after,4228,O
one,4228,O
hour,4228,O
or,4228,O
after,4228,O
one,4228,O
day,4228,O
.,4228,O
Pain,4229,B-Disease
recall,4229,O
after,4229,O
one,4229,O
week,4229,O
was,4229,O
similarly,4229,O
precise,4229,O
(,4229,O
magnitude,4229,O
:,4229,O
p,4229,O
<,4229,O
0.01,4229,O
",",4229,O
duration,4229,O
:,4229,O
p,4229,O
<,4229,O
0.05,4229,O
),4229,O
.,4229,O
Correlation,4230,O
with,4230,O
rating,4230,O
recall,4230,O
after,4230,O
one,4230,O
week,4230,O
was,4230,O
best,4230,O
when,4230,O
first-time,4230,O
ratings,4230,O
were,4230,O
requested,4230,O
as,4230,O
late,4230,O
as,4230,O
one,4230,O
day,4230,O
after,4230,O
injection,4230,O
(,4230,O
R,4230,O
(,4230,O
2,4230,O
),4230,O
=0.79,4230,O
),4230,O
indicating,4230,O
that,4230,O
both,4230,O
rating,4230,O
retrievals,4230,O
utilized,4230,O
similar,4230,O
memory,4230,O
traces,4230,O
.,4230,O
These,4231,O
results,4231,O
indicate,4231,O
a,4231,O
reliable,4231,O
memory,4231,O
for,4231,O
magnitude,4231,O
and,4231,O
duration,4231,O
of,4231,O
experimentally,4231,O
induced,4231,O
pain,4231,B-Disease
.,4231,O
The,4232,O
data,4232,O
further,4232,O
suggest,4232,O
that,4232,O
the,4232,O
consolidation,4232,O
of,4232,O
this,4232,O
memory,4232,O
is,4232,O
an,4232,O
important,4232,O
interim,4232,O
stage,4232,O
",",4232,O
and,4232,O
may,4232,O
take,4232,O
up,4232,O
to,4232,O
one,4232,O
day,4232,O
.,4232,O
Severe,4233,O
and,4233,O
long,4233,O
lasting,4233,O
cholestasis,4233,B-Disease
after,4233,O
high-dose,4233,O
co-trimoxazole,4233,B-Chemical
treatment,4233,O
for,4233,O
Pneumocystis,4233,B-Disease
pneumonia,4233,I-Disease
in,4233,O
HIV-infected,4233,B-Disease
patients,4233,O
--,4233,O
a,4233,O
report,4233,O
of,4233,O
two,4233,O
cases,4233,O
.,4233,O
Pneumocystis,4234,B-Disease
pneumonia,4234,I-Disease
(,4234,O
PCP,4234,B-Disease
),4234,O
",",4234,O
a,4234,O
common,4234,O
opportunistic,4234,B-Disease
infection,4234,I-Disease
in,4234,O
HIV-infected,4234,B-Disease
individuals,4234,O
",",4234,O
is,4234,O
generally,4234,O
treated,4234,O
with,4234,O
high,4234,O
doses,4234,O
of,4234,O
co-trimoxazole,4234,B-Chemical
.,4234,O
However,4235,O
",",4235,O
treatment,4235,O
is,4235,O
often,4235,O
limited,4235,O
by,4235,O
adverse,4235,O
effects,4235,O
.,4235,O
Here,4236,O
",",4236,O
we,4236,O
report,4236,O
two,4236,O
cases,4236,O
of,4236,O
severely,4236,O
immunocompromised,4236,O
HIV-infected,4236,B-Disease
patients,4236,O
who,4236,O
developed,4236,O
severe,4236,O
intrahepatic,4236,B-Disease
cholestasis,4236,I-Disease
",",4236,O
and,4236,O
in,4236,O
one,4236,O
patient,4236,O
lesions,4236,O
mimicking,4236,O
liver,4236,B-Disease
abscess,4236,I-Disease
formation,4236,O
on,4236,O
radiologic,4236,O
exams,4236,O
",",4236,O
during,4236,O
co-trimoxazole,4236,B-Chemical
treatment,4236,O
for,4236,O
PCP,4236,B-Disease
.,4236,O
Whereas,4237,O
patient,4237,O
1,4237,O
showed,4237,O
lesions,4237,O
of,4237,O
up,4237,O
to,4237,O
1,4237,O
cm,4237,O
readily,4237,O
detectable,4237,O
on,4237,O
magnetic,4237,O
resonance,4237,O
imaging,4237,O
under,4237,O
prolonged,4237,O
co-trimoxazole,4237,B-Chemical
treatment,4237,O
",",4237,O
therapy,4237,O
of,4237,O
patient,4237,O
2,4237,O
was,4237,O
switched,4237,O
early,4237,O
.,4237,O
Bradykinin,4238,B-Chemical
receptors,4238,O
antagonists,4238,O
and,4238,O
nitric,4238,B-Chemical
oxide,4238,I-Chemical
synthase,4238,O
inhibitors,4238,O
in,4238,O
vincristine,4238,B-Chemical
and,4238,O
streptozotocin,4238,B-Chemical
induced,4238,O
hyperalgesia,4238,B-Disease
in,4238,O
chemotherapy,4238,O
and,4238,O
diabetic,4238,B-Disease
neuropathy,4238,I-Disease
rat,4238,O
model,4238,O
.,4238,O
PURPOSE,4239,O
:,4239,O
The,4239,O
influence,4239,O
of,4239,O
an,4239,O
irreversible,4239,O
inhibitor,4239,O
of,4239,O
constitutive,4239,O
NO,4239,B-Chemical
synthase,4239,O
(,4239,O
L-NOArg,4239,O
;,4239,O
1.0,4239,O
mg/kg,4239,O
ip,4239,O
),4239,O
",",4239,O
a,4239,O
relatively,4239,O
selective,4239,O
inhibitor,4239,O
of,4239,O
inducible,4239,O
NO,4239,B-Chemical
synthase,4239,O
(,4239,O
L-NIL,4239,O
;,4239,O
1.0,4239,O
mg/kg,4239,O
ip,4239,O
),4239,O
and,4239,O
a,4239,O
relatively,4239,O
specific,4239,O
inhibitor,4239,O
of,4239,O
neuronal,4239,O
NO,4239,B-Chemical
synthase,4239,O
(,4239,O
7-NI,4239,O
;,4239,O
0.1,4239,O
mg/kg,4239,O
ip,4239,O
),4239,O
",",4239,O
on,4239,O
antihyperalgesic,4239,O
action,4239,O
of,4239,O
selective,4239,O
antagonists,4239,O
of,4239,O
B2,4239,O
and,4239,O
B1,4239,O
receptors,4239,O
:,4239,O
D-Arg-,4239,O
[,4239,O
Hyp3,4239,O
",",4239,O
Thi5,4239,O
",",4239,O
D-Tic7,4239,O
",",4239,O
Oic8,4239,O
],4239,O
bradykinin,4239,B-Chemical
(,4239,O
HOE,4239,B-Chemical
140,4239,I-Chemical
;,4239,O
70,4239,O
nmol/kg,4239,O
ip,4239,O
),4239,O
or,4239,O
des,4239,B-Chemical
Arg10,4239,I-Chemical
HOE,4239,I-Chemical
140,4239,I-Chemical
(,4239,O
70,4239,O
nmol/kg,4239,O
ip,4239,O
),4239,O
respectively,4239,O
",",4239,O
in,4239,O
model,4239,O
of,4239,O
diabetic,4239,O
(,4239,O
streptozotocin-induced,4239,O
),4239,O
and,4239,O
toxic,4239,O
(,4239,O
vincristine-induced,4239,O
),4239,O
neuropathy,4239,O
was,4239,O
investigated,4239,O
.,4239,O
METHODS,4240,O
:,4240,O
The,4240,O
changes,4240,O
in,4240,O
pain,4240,B-Disease
thresholds,4240,O
were,4240,O
determined,4240,O
using,4240,O
mechanical,4240,O
stimuli,4240,O
--,4240,O
the,4240,O
modification,4240,O
of,4240,O
the,4240,O
classic,4240,O
paw,4240,O
withdrawal,4240,O
test,4240,O
described,4240,O
by,4240,O
Randall-Selitto,4240,O
.,4240,O
RESULTS,4241,O
:,4241,O
The,4241,O
results,4241,O
of,4241,O
this,4241,O
paper,4241,O
confirm,4241,O
that,4241,O
inhibition,4241,O
of,4241,O
bradykinin,4241,B-Chemical
receptors,4241,O
and,4241,O
inducible,4241,O
NO,4241,B-Chemical
synthase,4241,O
but,4241,O
not,4241,O
neuronal,4241,O
NO,4241,B-Chemical
synthase,4241,O
activity,4241,O
reduces,4241,O
diabetic,4241,B-Disease
hyperalgesia,4241,I-Disease
.,4241,O
Pretreatment,4242,O
with,4242,O
L-NOArg,4242,O
and,4242,O
L-NIL,4242,O
but,4242,O
not,4242,O
7-NI,4242,O
",",4242,O
significantly,4242,O
increases,4242,O
antihyperalgesic,4242,O
activity,4242,O
both,4242,O
HOE,4242,B-Chemical
140,4242,I-Chemical
and,4242,O
des,4242,B-Chemical
Arg10,4242,I-Chemical
HOE,4242,I-Chemical
140,4242,I-Chemical
.,4242,O
It,4243,O
was,4243,O
also,4243,O
shown,4243,O
that,4243,O
both,4243,O
products,4243,O
of,4243,O
inducible,4243,O
NO,4243,B-Chemical
synthase,4243,O
and,4243,O
neuronal,4243,O
NO,4243,B-Chemical
synthase,4243,O
activation,4243,O
as,4243,O
well,4243,O
as,4243,O
bradykinin,4243,B-Chemical
are,4243,O
involved,4243,O
in,4243,O
hyperalgesia,4243,B-Disease
produced,4243,O
by,4243,O
vincristine,4243,B-Chemical
.,4243,O
Moreover,4244,O
",",4244,O
L-NOArg,4244,O
and,4244,O
7-NI,4244,O
but,4244,O
not,4244,O
L-NIL,4244,O
intensify,4244,O
antihyperalgesic,4244,O
activity,4244,O
of,4244,O
HOE,4244,B-Chemical
140,4244,I-Chemical
or,4244,O
des-Arg10HOE,4244,B-Chemical
140,4244,I-Chemical
in,4244,O
toxic,4244,B-Disease
neuropathy,4244,I-Disease
.,4244,O
CONCLUSIONS,4245,O
:,4245,O
Results,4245,O
of,4245,O
these,4245,O
studies,4245,O
suggest,4245,O
that,4245,O
B1,4245,O
and,4245,O
B2,4245,O
receptors,4245,O
are,4245,O
engaged,4245,O
in,4245,O
transmission,4245,O
of,4245,O
nociceptive,4245,O
stimuli,4245,O
in,4245,O
both,4245,O
diabetic,4245,O
and,4245,O
toxic,4245,O
neuropathy,4245,O
.,4245,O
In,4246,O
streptozotocin-induced,4246,B-Chemical
hyperalgesia,4246,B-Disease
",",4246,O
inducible,4246,O
NO,4246,B-Chemical
synthase,4246,O
participates,4246,O
in,4246,O
pronociceptive,4246,O
activity,4246,O
of,4246,O
bradykinin,4246,B-Chemical
",",4246,O
whereas,4246,O
in,4246,O
vincristine-induced,4246,B-Chemical
hyperalgesia,4246,B-Disease
bradykinin,4246,B-Chemical
seemed,4246,O
to,4246,O
activate,4246,O
neuronal,4246,O
NO,4246,B-Chemical
synthase,4246,O
pathway,4246,O
.,4246,O
Therefore,4247,O
",",4247,O
concomitant,4247,O
administration,4247,O
of,4247,O
small,4247,O
doses,4247,O
of,4247,O
bradykinin,4247,B-Chemical
receptor,4247,O
antagonists,4247,O
and,4247,O
NO,4247,B-Chemical
synthase,4247,O
inhibitors,4247,O
can,4247,O
be,4247,O
effective,4247,O
in,4247,O
alleviation,4247,O
of,4247,O
neuropathic,4247,B-Disease
pain,4247,I-Disease
",",4247,O
even,4247,O
in,4247,O
hospital,4247,O
care,4247,O
.,4247,O
Confusion,4248,B-Disease
",",4248,O
a,4248,O
rather,4248,O
serious,4248,O
adverse,4248,O
drug,4248,O
reaction,4248,O
with,4248,O
valproic,4248,B-Chemical
acid,4248,I-Chemical
:,4248,O
a,4248,O
review,4248,O
of,4248,O
the,4248,O
French,4248,O
Pharmacovigilance,4248,O
database,4248,O
.,4248,O
INTRODUCTION,4249,O
:,4249,O
Confusion,4249,B-Disease
is,4249,O
an,4249,O
adverse,4249,O
drug,4249,O
reaction,4249,O
frequently,4249,O
observed,4249,O
with,4249,O
valproic,4249,B-Chemical
acid,4249,I-Chemical
.,4249,O
Some,4250,O
case,4250,O
reports,4250,O
are,4250,O
published,4250,O
in,4250,O
the,4250,O
literature,4250,O
but,4250,O
no,4250,O
systematic,4250,O
study,4250,O
from,4250,O
a,4250,O
sample,4250,O
of,4250,O
patients,4250,O
has,4250,O
been,4250,O
published,4250,O
.,4250,O
We,4251,O
performed,4251,O
this,4251,O
study,4251,O
in,4251,O
order,4251,O
to,4251,O
describe,4251,O
the,4251,O
main,4251,O
characteristics,4251,O
of,4251,O
this,4251,O
adverse,4251,O
drug,4251,O
reaction,4251,O
.,4251,O
METHODS,4252,O
:,4252,O
Using,4252,O
the,4252,O
French,4252,O
Pharmacovigilance,4252,O
database,4252,O
",",4252,O
we,4252,O
selected,4252,O
the,4252,O
cases,4252,O
of,4252,O
confusion,4252,B-Disease
reported,4252,O
since,4252,O
1985,4252,O
with,4252,O
valproic,4252,B-Chemical
acid,4252,I-Chemical
.,4252,O
RESULTS,4253,O
:,4253,O
272,4253,O
cases,4253,O
of,4253,O
confusion,4253,B-Disease
were,4253,O
reported,4253,O
with,4253,O
valproic,4253,B-Chemical
acid,4253,I-Chemical
:,4253,O
153,4253,O
women,4253,O
and,4253,O
119,4253,O
men,4253,O
.,4253,O
Confusion,4254,B-Disease
mostly,4254,O
occurred,4254,O
during,4254,O
the,4254,O
two,4254,O
first,4254,O
weeks,4254,O
following,4254,O
valproic,4254,B-Chemical
acid,4254,I-Chemical
exposure,4254,O
(,4254,O
39.7,4254,O
%,4254,O
),4254,O
.,4254,O
It,4255,O
was,4255,O
``,4255,O
serious,4255,O
'',4255,O
for,4255,O
almost,4255,O
2/3,4255,O
of,4255,O
the,4255,O
patients,4255,O
(,4255,O
62.5,4255,O
%,4255,O
),4255,O
and,4255,O
its,4255,O
outcome,4255,O
favourable,4255,O
in,4255,O
most,4255,O
of,4255,O
the,4255,O
cases,4255,O
(,4255,O
82,4255,O
%,4255,O
),4255,O
.,4255,O
The,4256,O
occurrence,4256,O
of,4256,O
this,4256,O
ADR,4256,O
was,4256,O
more,4256,O
frequent,4256,O
in,4256,O
patients,4256,O
aged,4256,O
between,4256,O
61,4256,O
and,4256,O
80,4256,O
years,4256,O
.,4256,O
CONCLUSION,4257,O
:,4257,O
This,4257,O
work,4257,O
shows,4257,O
that,4257,O
confusion,4257,B-Disease
with,4257,O
valproic,4257,B-Chemical
acid,4257,I-Chemical
is,4257,O
a,4257,O
serious,4257,O
",",4257,O
rather,4257,O
frequent,4257,O
but,4257,O
reversible,4257,O
adverse,4257,O
drug,4257,O
reaction,4257,O
.,4257,O
It,4258,O
occurs,4258,O
especially,4258,O
in,4258,O
older,4258,O
patients,4258,O
and,4258,O
during,4258,O
the,4258,O
first,4258,O
two,4258,O
weeks,4258,O
of,4258,O
treatment,4258,O
.,4258,O
Reversible,4259,O
inferior,4259,B-Disease
colliculus,4259,I-Disease
lesion,4259,I-Disease
in,4259,O
metronidazole-induced,4259,B-Chemical
encephalopathy,4259,B-Disease
:,4259,O
magnetic,4259,O
resonance,4259,O
findings,4259,O
on,4259,O
diffusion-weighted,4259,O
and,4259,O
fluid,4259,O
attenuated,4259,O
inversion,4259,O
recovery,4259,O
imaging,4259,O
.,4259,O
OBJECTIVE,4260,O
:,4260,O
This,4260,O
is,4260,O
to,4260,O
present,4260,O
reversible,4260,O
inferior,4260,B-Disease
colliculus,4260,I-Disease
lesions,4260,I-Disease
in,4260,O
metronidazole-induced,4260,B-Chemical
encephalopathy,4260,B-Disease
",",4260,O
to,4260,O
focus,4260,O
on,4260,O
the,4260,O
diffusion-weighted,4260,O
imaging,4260,O
(,4260,O
DWI,4260,O
),4260,O
and,4260,O
fluid,4260,O
attenuated,4260,O
inversion,4260,O
recovery,4260,O
(,4260,O
FLAIR,4260,O
),4260,O
imaging,4260,O
.,4260,O
MATERIALS,4261,O
AND,4261,O
METHODS,4261,O
:,4261,O
From,4261,O
November,4261,O
2005,4261,O
to,4261,O
September,4261,O
2007,4261,O
",",4261,O
8,4261,O
patients,4261,O
(,4261,O
5,4261,O
men,4261,O
and,4261,O
3,4261,O
women,4261,O
),4261,O
were,4261,O
diagnosed,4261,O
as,4261,O
having,4261,O
metronidazole-induced,4261,B-Chemical
encephalopathy,4261,B-Disease
(,4261,O
age,4261,O
range,4261,O
;,4261,O
43-78,4261,O
years,4261,O
),4261,O
.,4261,O
They,4262,O
had,4262,O
been,4262,O
taking,4262,O
metronidazole,4262,B-Chemical
(,4262,O
total,4262,O
dosage,4262,O
",",4262,O
45-120,4262,O
g,4262,O
;,4262,O
duration,4262,O
",",4262,O
30,4262,O
days,4262,O
to,4262,O
2,4262,O
months,4262,O
),4262,O
to,4262,O
treat,4262,O
the,4262,O
infection,4262,B-Disease
in,4262,O
various,4262,O
organs,4262,O
.,4262,O
Initial,4263,O
brain,4263,O
magnetic,4263,O
resonance,4263,O
imaging,4263,O
(,4263,O
MRI,4263,O
),4263,O
were,4263,O
obtained,4263,O
after,4263,O
the,4263,O
hospitalization,4263,O
",",4263,O
including,4263,O
DWI,4263,O
(,4263,O
8/8,4263,O
),4263,O
",",4263,O
apparent,4263,O
diffusion,4263,O
coefficient,4263,O
(,4263,O
ADC,4263,O
),4263,O
map,4263,O
(,4263,O
4/8,4263,O
),4263,O
",",4263,O
FLAIR,4263,O
(,4263,O
7/8,4263,O
),4263,O
",",4263,O
and,4263,O
T2-weighted,4263,O
image,4263,O
(,4263,O
8/8,4263,O
),4263,O
.,4263,O
Follow-up,4264,O
MRIs,4264,O
were,4264,O
performed,4264,O
on,4264,O
5,4264,O
patients,4264,O
from,4264,O
third,4264,O
to,4264,O
14th,4264,O
days,4264,O
after,4264,O
discontinuation,4264,O
of,4264,O
metronidazole,4264,B-Chemical
administration,4264,O
.,4264,O
Findings,4265,O
of,4265,O
initial,4265,O
and,4265,O
follow-up,4265,O
MRIs,4265,O
were,4265,O
retrospectively,4265,O
evaluated,4265,O
by,4265,O
2,4265,O
neuroradiologists,4265,O
by,4265,O
consensus,4265,O
",",4265,O
to,4265,O
analyze,4265,O
the,4265,O
presence,4265,O
of,4265,O
abnormal,4265,O
signal,4265,O
intensities,4265,O
",",4265,O
their,4265,O
locations,4265,O
",",4265,O
and,4265,O
signal,4265,O
changes,4265,O
on,4265,O
follow-up,4265,O
images,4265,O
.,4265,O
RESULTS,4266,O
:,4266,O
Initial,4266,O
MRIs,4266,O
showed,4266,O
abnormal,4266,O
high,4266,O
signal,4266,O
intensities,4266,O
on,4266,O
DWI,4266,O
and,4266,O
FLAIR,4266,O
(,4266,O
or,4266,O
T2-weighted,4266,O
image,4266,O
),4266,O
at,4266,O
the,4266,O
dentate,4266,O
nucleus,4266,O
(,4266,O
8/8,4266,O
),4266,O
",",4266,O
inferior,4266,O
colliculus,4266,O
(,4266,O
6/8,4266,O
),4266,O
",",4266,O
corpus,4266,O
callosum,4266,O
(,4266,O
2/8,4266,O
),4266,O
",",4266,O
pons,4266,O
(,4266,O
2/8,4266,O
),4266,O
",",4266,O
medulla,4266,O
(,4266,O
1/8,4266,O
),4266,O
",",4266,O
and,4266,O
bilateral,4266,O
cerebral,4266,O
white,4266,O
matter,4266,O
(,4266,O
1/8,4266,O
),4266,O
.,4266,O
High-signal,4267,O
intensity,4267,O
lesions,4267,O
on,4267,O
DWI,4267,O
tended,4267,O
to,4267,O
show,4267,O
low,4267,O
signal,4267,O
intensity,4267,O
on,4267,O
ADC,4267,O
map,4267,O
(,4267,O
3/4,4267,O
),4267,O
",",4267,O
but,4267,O
in,4267,O
one,4267,O
patient,4267,O
",",4267,O
high,4267,O
signal,4267,O
intensity,4267,O
was,4267,O
shown,4267,O
at,4267,O
bilateral,4267,O
dentate,4267,O
nuclei,4267,O
on,4267,O
not,4267,O
only,4267,O
DWI,4267,O
but,4267,O
also,4267,O
ADC,4267,O
map,4267,O
.,4267,O
All,4268,O
the,4268,O
lesions,4268,O
in,4268,O
dentate,4268,O
",",4268,O
inferior,4268,O
colliculus,4268,O
",",4268,O
pons,4268,O
",",4268,O
and,4268,O
medullas,4268,O
had,4268,O
been,4268,O
resolved,4268,O
completely,4268,O
on,4268,O
follow-up,4268,O
MRIs,4268,O
in,4268,O
5,4268,O
patients,4268,O
",",4268,O
but,4268,O
in,4268,O
1,4268,O
patient,4268,O
of,4268,O
them,4268,O
",",4268,O
corpus,4268,O
callosal,4268,B-Disease
lesion,4268,I-Disease
persisted,4268,O
.,4268,O
CONCLUSIONS,4269,O
:,4269,O
Reversible,4269,O
inferior,4269,B-Disease
colliculus,4269,I-Disease
lesions,4269,I-Disease
could,4269,O
be,4269,O
considered,4269,O
as,4269,O
the,4269,O
characteristic,4269,O
for,4269,O
metronidazole-induced,4269,B-Chemical
encephalopathy,4269,B-Disease
",",4269,O
next,4269,O
to,4269,O
the,4269,O
dentate,4269,O
nucleus,4269,O
involvement,4269,O
.,4269,O
Clinically,4270,O
significant,4270,O
proteinuria,4270,B-Disease
following,4270,O
the,4270,O
administration,4270,O
of,4270,O
sirolimus,4270,B-Chemical
to,4270,O
renal,4270,O
transplant,4270,O
recipients,4270,O
.,4270,O
BACKGROUND,4271,O
:,4271,O
Sirolimus,4271,B-Chemical
is,4271,O
the,4271,O
latest,4271,O
immunosuppressive,4271,O
agent,4271,O
used,4271,O
to,4271,O
prevent,4271,O
rejection,4271,O
",",4271,O
and,4271,O
may,4271,O
have,4271,O
less,4271,O
nephrotoxicity,4271,B-Disease
than,4271,O
calcineurin,4271,O
inhibitor,4271,O
(,4271,O
CNI,4271,O
),4271,O
-based,4271,O
regimens,4271,O
.,4271,O
To,4272,O
date,4272,O
there,4272,O
has,4272,O
been,4272,O
little,4272,O
documentation,4272,O
of,4272,O
clinically,4272,O
significant,4272,O
proteinuria,4272,B-Disease
linked,4272,O
with,4272,O
the,4272,O
use,4272,O
of,4272,O
sirolimus,4272,B-Chemical
.,4272,O
We,4273,O
have,4273,O
encountered,4273,O
several,4273,O
patients,4273,O
who,4273,O
developed,4273,O
substantial,4273,O
proteinuria,4273,B-Disease
associated,4273,O
with,4273,O
sirolimus,4273,B-Chemical
use,4273,O
.,4273,O
In,4274,O
each,4274,O
patient,4274,O
",",4274,O
the,4274,O
close,4274,O
temporal,4274,O
association,4274,O
between,4274,O
the,4274,O
commencement,4274,O
of,4274,O
sirolimus,4274,B-Chemical
therapy,4274,O
and,4274,O
proteinuria,4274,B-Disease
implicated,4274,O
sirolimus,4274,B-Chemical
as,4274,O
the,4274,O
most,4274,O
likely,4274,O
etiology,4274,O
of,4274,O
the,4274,O
proteinuria,4274,B-Disease
.,4274,O
METHODS,4275,O
:,4275,O
We,4275,O
analyzed,4275,O
the,4275,O
clinical,4275,O
and,4275,O
laboratory,4275,O
information,4275,O
available,4275,O
for,4275,O
all,4275,O
119,4275,O
patients,4275,O
transplanted,4275,O
at,4275,O
the,4275,O
Washington,4275,O
Hospital,4275,O
Center,4275,O
between,4275,O
1999-2003,4275,O
for,4275,O
whom,4275,O
sirolimus,4275,B-Chemical
was,4275,O
a,4275,O
component,4275,O
of,4275,O
their,4275,O
immunosuppressant,4275,O
regimen,4275,O
.,4275,O
In,4276,O
these,4276,O
patients,4276,O
",",4276,O
the,4276,O
magnitude,4276,O
of,4276,O
proteinuria,4276,B-Disease
was,4276,O
assessed,4276,O
on,4276,O
morning,4276,O
urine,4276,O
samples,4276,O
by,4276,O
turbidometric,4276,O
measurement,4276,O
or,4276,O
random,4276,O
urine,4276,O
protein,4276,O
:,4276,O
creatinine,4276,B-Chemical
ratios,4276,O
",",4276,O
an,4276,O
estimate,4276,O
of,4276,O
grams,4276,O
of,4276,O
proteinuria/day,4276,B-Disease
.,4276,O
Laboratory,4277,O
results,4277,O
were,4277,O
compared,4277,O
between,4277,O
prior,4277,O
",",4277,O
during,4277,O
and,4277,O
following,4277,O
sirolimus,4277,B-Chemical
use,4277,O
.,4277,O
RESULTS,4278,O
:,4278,O
Twenty-eight,4278,O
patients,4278,O
(,4278,O
24,4278,O
%,4278,O
),4278,O
developed,4278,O
increased,4278,O
proteinuria,4278,B-Disease
from,4278,O
baseline,4278,O
during,4278,O
their,4278,O
post-transplantation,4278,O
course,4278,O
.,4278,O
In,4279,O
21,4279,O
patients,4279,O
an,4279,O
alternative,4279,O
cause,4279,O
of,4279,O
proteinuria,4279,B-Disease
was,4279,O
either,4279,O
obvious,4279,O
or,4279,O
insufficient,4279,O
data,4279,O
was,4279,O
available,4279,O
to,4279,O
be,4279,O
conclusive,4279,O
.,4279,O
In,4280,O
7,4280,O
of,4280,O
the,4280,O
28,4280,O
patients,4280,O
there,4280,O
was,4280,O
a,4280,O
striking,4280,O
temporal,4280,O
association,4280,O
between,4280,O
the,4280,O
initiation,4280,O
of,4280,O
sirolimus,4280,B-Chemical
and,4280,O
the,4280,O
development,4280,O
of,4280,O
nephrotic-range,4280,B-Disease
proteinuria,4280,B-Disease
.,4280,O
Proteinuria,4281,B-Disease
correlated,4281,O
most,4281,O
strongly,4281,O
with,4281,O
sirolimus,4281,B-Chemical
therapy,4281,O
when,4281,O
compared,4281,O
to,4281,O
other,4281,O
demographic,4281,O
and,4281,O
clinical,4281,O
variables,4281,O
.,4281,O
In,4282,O
most,4282,O
patients,4282,O
",",4282,O
discontinuation,4282,O
of,4282,O
sirolimus,4282,B-Chemical
resulted,4282,O
in,4282,O
a,4282,O
decrease,4282,O
",",4282,O
but,4282,O
not,4282,O
resolution,4282,O
",",4282,O
of,4282,O
proteinuria,4282,B-Disease
.,4282,O
CONCLUSIONS,4283,O
:,4283,O
Sirolimus,4283,B-Chemical
induces,4283,O
or,4283,O
aggravates,4283,O
pre-existing,4283,O
proteinuria,4283,B-Disease
in,4283,O
an,4283,O
unpredictable,4283,O
subset,4283,O
of,4283,O
renal,4283,O
allograft,4283,O
recipients,4283,O
.,4283,O
Proteinuria,4284,B-Disease
may,4284,O
improve,4284,O
",",4284,O
but,4284,O
does,4284,O
not,4284,O
resolve,4284,O
",",4284,O
when,4284,O
sirolimus,4284,B-Chemical
is,4284,O
withdrawn,4284,O
.,4284,O
Components,4285,O
of,4285,O
lemon,4285,O
essential,4285,O
oil,4285,O
attenuate,4285,O
dementia,4285,B-Disease
induced,4285,O
by,4285,O
scopolamine,4285,B-Chemical
.,4285,O
The,4286,O
anti-dementia,4286,O
effects,4286,O
of,4286,O
s-limonene,4286,B-Chemical
and,4286,O
s-perillyl,4286,B-Chemical
alcohol,4286,I-Chemical
were,4286,O
observed,4286,O
using,4286,O
the,4286,O
passive,4286,O
avoidance,4286,O
test,4286,O
(,4286,O
PA,4286,O
),4286,O
and,4286,O
the,4286,O
open,4286,O
field,4286,O
habituation,4286,O
test,4286,O
(,4286,O
OFH,4286,O
),4286,O
.,4286,O
These,4287,O
lemon,4287,O
essential,4287,O
oils,4287,O
showed,4287,O
strong,4287,O
ability,4287,O
to,4287,O
improve,4287,O
memory,4287,B-Disease
impaired,4287,I-Disease
by,4287,O
scopolamine,4287,B-Chemical
;,4287,O
however,4287,O
",",4287,O
s-perillyl,4287,B-Chemical
alcohol,4287,I-Chemical
relieved,4287,O
the,4287,O
deficit,4287,B-Disease
of,4287,I-Disease
associative,4287,I-Disease
memory,4287,I-Disease
in,4287,O
PA,4287,O
only,4287,O
",",4287,O
and,4287,O
did,4287,O
not,4287,O
improve,4287,O
non-associative,4287,O
memory,4287,O
significantly,4287,O
in,4287,O
OFH,4287,O
.,4287,O
Analysis,4288,O
of,4288,O
neurotransmitter,4288,O
concentration,4288,O
in,4288,O
some,4288,O
brain,4288,O
regions,4288,O
on,4288,O
the,4288,O
test,4288,O
day,4288,O
showed,4288,O
that,4288,O
dopamine,4288,B-Chemical
concentration,4288,O
of,4288,O
the,4288,O
vehicle/scopolamine,4288,O
group,4288,O
was,4288,O
significantly,4288,O
lower,4288,O
than,4288,O
that,4288,O
of,4288,O
the,4288,O
vehicle/vehicle,4288,O
group,4288,O
",",4288,O
but,4288,O
this,4288,O
phenomenon,4288,O
was,4288,O
reversed,4288,O
when,4288,O
s-limonene,4288,B-Chemical
or,4288,O
s-perillyl,4288,B-Chemical
alcohol,4288,I-Chemical
were,4288,O
administered,4288,O
before,4288,O
the,4288,O
injection,4288,O
of,4288,O
scopolamine,4288,B-Chemical
.,4288,O
Simultaneously,4289,O
",",4289,O
we,4289,O
found,4289,O
that,4289,O
these,4289,O
two,4289,O
lemon,4289,O
essential,4289,O
oil,4289,O
components,4289,O
could,4289,O
inhibit,4289,O
acetylcholinesterase,4289,O
activity,4289,O
in,4289,O
vitro,4289,O
using,4289,O
the,4289,O
Ellman,4289,O
method,4289,O
.,4289,O
Attentional,4290,O
modulation,4290,O
of,4290,O
perceived,4290,O
pain,4290,B-Disease
intensity,4290,O
in,4290,O
capsaicin-induced,4290,B-Chemical
secondary,4290,O
hyperalgesia,4290,B-Disease
.,4290,O
Perceived,4291,O
pain,4291,B-Disease
intensity,4291,O
is,4291,O
modulated,4291,O
by,4291,O
attention,4291,O
.,4291,O
However,4292,O
",",4292,O
it,4292,O
is,4292,O
not,4292,O
known,4292,O
that,4292,O
how,4292,O
pain,4292,B-Disease
intensity,4292,O
ratings,4292,O
are,4292,O
affected,4292,O
by,4292,O
attention,4292,O
in,4292,O
capsaicin-induced,4292,B-Chemical
secondary,4292,O
hyperalgesia,4292,B-Disease
.,4292,O
Here,4293,O
we,4293,O
show,4293,O
that,4293,O
perceived,4293,O
pain,4293,B-Disease
intensity,4293,O
in,4293,O
secondary,4293,O
hyperalgesia,4293,B-Disease
is,4293,O
decreased,4293,O
when,4293,O
attention,4293,O
is,4293,O
distracted,4293,O
away,4293,O
from,4293,O
the,4293,O
painful,4293,O
pinprick,4293,O
stimulus,4293,O
with,4293,O
a,4293,O
visual,4293,O
task,4293,O
.,4293,O
Furthermore,4294,O
",",4294,O
it,4294,O
was,4294,O
found,4294,O
that,4294,O
the,4294,O
magnitude,4294,O
of,4294,O
attentional,4294,O
modulation,4294,O
in,4294,O
secondary,4294,O
hyperalgesia,4294,B-Disease
is,4294,O
very,4294,O
similar,4294,O
to,4294,O
that,4294,O
of,4294,O
capsaicin-untreated,4294,B-Chemical
",",4294,O
control,4294,O
condition,4294,O
.,4294,O
Our,4295,O
findings,4295,O
",",4295,O
showing,4295,O
no,4295,O
interaction,4295,O
between,4295,O
capsaicin,4295,B-Chemical
treatment,4295,O
and,4295,O
attentional,4295,O
modulation,4295,O
suggest,4295,O
that,4295,O
capsaicin-induced,4295,B-Chemical
secondary,4295,O
hyperalgesia,4295,B-Disease
and,4295,O
attention,4295,O
might,4295,O
affect,4295,O
mechanical,4295,O
pain,4295,B-Disease
through,4295,O
independent,4295,O
mechanisms,4295,O
.,4295,O
Cardioprotective,4296,O
effect,4296,O
of,4296,O
salvianolic,4296,B-Chemical
acid,4296,I-Chemical
A,4296,I-Chemical
on,4296,O
isoproterenol-induced,4296,B-Chemical
myocardial,4296,B-Disease
infarction,4296,I-Disease
in,4296,O
rats,4296,O
.,4296,O
The,4297,O
present,4297,O
study,4297,O
was,4297,O
designed,4297,O
to,4297,O
evaluate,4297,O
the,4297,O
cardioprotective,4297,O
potential,4297,O
of,4297,O
salvianolic,4297,B-Chemical
acid,4297,I-Chemical
A,4297,I-Chemical
on,4297,O
isoproterenol-induced,4297,B-Chemical
myocardial,4297,B-Disease
infarction,4297,I-Disease
in,4297,O
rats,4297,O
.,4297,O
Hemodynamic,4298,O
parameters,4298,O
and,4298,O
lead,4298,O
II,4298,O
electrocardiograph,4298,O
were,4298,O
monitored,4298,O
and,4298,O
recorded,4298,O
continuously,4298,O
.,4298,O
Cardiac,4299,O
marker,4299,O
enzymes,4299,O
and,4299,O
antioxidative,4299,O
parameters,4299,O
in,4299,O
serum,4299,O
and,4299,O
heart,4299,O
tissues,4299,O
were,4299,O
measured,4299,O
.,4299,O
Assay,4300,O
for,4300,O
mitochondrial,4300,O
respiratory,4300,O
function,4300,O
and,4300,O
histopathological,4300,O
examination,4300,O
of,4300,O
heart,4300,O
tissues,4300,O
were,4300,O
performed,4300,O
.,4300,O
Isoproterenol-treated,4301,B-Chemical
rats,4301,O
showed,4301,O
significant,4301,O
increases,4301,O
in,4301,O
the,4301,O
levels,4301,O
of,4301,O
lactate,4301,B-Chemical
dehydrogenase,4301,O
",",4301,O
aspartate,4301,B-Chemical
transaminase,4301,O
",",4301,O
creatine,4301,B-Chemical
kinase,4301,O
and,4301,O
malondialdehyde,4301,B-Chemical
and,4301,O
significant,4301,O
decreases,4301,O
in,4301,O
the,4301,O
activities,4301,O
of,4301,O
superoxide,4301,B-Chemical
dismutase,4301,O
",",4301,O
catalase,4301,O
and,4301,O
glutathione,4301,B-Chemical
peroxidase,4301,O
in,4301,O
serum,4301,O
and,4301,O
heart,4301,O
.,4301,O
These,4302,O
rats,4302,O
also,4302,O
showed,4302,O
declines,4302,O
in,4302,O
left,4302,O
ventricular,4302,O
systolic,4302,O
pressure,4302,O
",",4302,O
maximum,4302,O
and,4302,O
minimum,4302,O
rate,4302,O
of,4302,O
developed,4302,O
left,4302,O
ventricular,4302,O
pressure,4302,O
",",4302,O
and,4302,O
elevation,4302,O
of,4302,O
left,4302,O
ventricular,4302,O
end-diastolic,4302,O
pressure,4302,O
and,4302,O
ST-segment,4302,O
.,4302,O
In,4303,O
addition,4303,O
",",4303,O
mitochondrial,4303,O
respiratory,4303,B-Disease
dysfunction,4303,I-Disease
characterized,4303,O
by,4303,O
decreased,4303,O
respiratory,4303,O
control,4303,O
ratio,4303,O
and,4303,O
ADP/O,4303,B-Chemical
was,4303,O
observed,4303,O
in,4303,O
isoproterenol-treated,4303,B-Chemical
rats,4303,O
.,4303,O
Administration,4304,O
of,4304,O
salvianolic,4304,B-Chemical
acid,4304,I-Chemical
A,4304,I-Chemical
for,4304,O
a,4304,O
period,4304,O
of,4304,O
8,4304,O
days,4304,O
significantly,4304,O
attenuated,4304,O
isoproterenol-induced,4304,B-Chemical
cardiac,4304,B-Disease
dysfunction,4304,I-Disease
and,4304,O
myocardial,4304,B-Disease
injury,4304,I-Disease
and,4304,O
improved,4304,O
mitochondrial,4304,O
respiratory,4304,O
function,4304,O
.,4304,O
The,4305,O
protective,4305,O
role,4305,O
of,4305,O
salvianolic,4305,B-Chemical
acid,4305,I-Chemical
A,4305,I-Chemical
against,4305,O
isoproterenol-induced,4305,B-Chemical
myocardial,4305,B-Disease
damage,4305,I-Disease
was,4305,O
further,4305,O
confirmed,4305,O
by,4305,O
histopathological,4305,O
examination,4305,O
.,4305,O
The,4306,O
results,4306,O
of,4306,O
our,4306,O
study,4306,O
suggest,4306,O
that,4306,O
salvianolic,4306,B-Chemical
acid,4306,I-Chemical
A,4306,I-Chemical
possessing,4306,O
antioxidant,4306,O
activity,4306,O
has,4306,O
a,4306,O
significant,4306,O
protective,4306,O
effect,4306,O
against,4306,O
isoproterenol-induced,4306,B-Chemical
myocardial,4306,B-Disease
infarction,4306,I-Disease
.,4306,O
Long-term,4307,O
glutamate,4307,B-Chemical
supplementation,4307,O
failed,4307,O
to,4307,O
protect,4307,O
against,4307,O
peripheral,4307,B-Disease
neurotoxicity,4307,I-Disease
of,4307,O
paclitaxel,4307,B-Chemical
.,4307,O
Toxic,4308,O
peripheral,4308,B-Disease
neuropathy,4308,I-Disease
is,4308,O
still,4308,O
a,4308,O
significant,4308,O
limiting,4308,O
factor,4308,O
for,4308,O
chemotherapy,4308,O
with,4308,O
paclitaxel,4308,B-Chemical
(,4308,O
PAC,4308,B-Chemical
),4308,O
",",4308,O
although,4308,O
glutamate,4308,B-Chemical
and,4308,O
its,4308,O
closely,4308,O
related,4308,O
amino,4308,B-Chemical
acid,4308,I-Chemical
glutamine,4308,B-Chemical
were,4308,O
claimed,4308,O
to,4308,O
ameliorate,4308,O
PAC,4308,B-Chemical
neurotoxicity,4308,B-Disease
.,4308,O
This,4309,O
pilot,4309,O
trial,4309,O
aimed,4309,O
to,4309,O
evaluate,4309,O
the,4309,O
role,4309,O
of,4309,O
glutamate,4309,B-Chemical
supplementation,4309,O
for,4309,O
preventing,4309,O
PAC-induced,4309,B-Chemical
peripheral,4309,B-Disease
neuropathy,4309,I-Disease
in,4309,O
a,4309,O
randomized,4309,O
",",4309,O
placebo-controlled,4309,O
",",4309,O
double-blinded,4309,O
clinical,4309,O
and,4309,O
electro-diagnostic,4309,O
study,4309,O
.,4309,O
Forty-three,4310,O
ovarian,4310,B-Disease
cancer,4310,I-Disease
patients,4310,O
were,4310,O
available,4310,O
for,4310,O
analysis,4310,O
following,4310,O
six,4310,O
cycles,4310,O
of,4310,O
the,4310,O
same,4310,O
PAC-containing,4310,B-Chemical
regimen,4310,O
:,4310,O
23,4310,O
had,4310,O
been,4310,O
supplemented,4310,O
by,4310,O
glutamate,4310,B-Chemical
all,4310,O
along,4310,O
the,4310,O
treatment,4310,O
period,4310,O
",",4310,O
at,4310,O
a,4310,O
daily,4310,O
dose,4310,O
of,4310,O
three,4310,O
times,4310,O
500,4310,O
mg,4310,O
(,4310,O
group,4310,O
G,4310,O
),4310,O
",",4310,O
and,4310,O
20,4310,O
had,4310,O
received,4310,O
a,4310,O
placebo,4310,O
(,4310,O
group,4310,O
P,4310,O
),4310,O
.,4310,O
Patients,4311,O
were,4311,O
evaluated,4311,O
by,4311,O
neurological,4311,O
examinations,4311,O
",",4311,O
questionnaires,4311,O
and,4311,O
sensory-motor,4311,O
nerve,4311,O
conduction,4311,O
studies,4311,O
.,4311,O
There,4312,O
was,4312,O
no,4312,O
significant,4312,O
difference,4312,O
in,4312,O
the,4312,O
frequency,4312,O
of,4312,O
signs,4312,O
or,4312,O
symptoms,4312,O
between,4312,O
the,4312,O
two,4312,O
groups,4312,O
although,4312,O
neurotoxicity,4312,B-Disease
symptoms,4312,O
presented,4312,O
mostly,4312,O
with,4312,O
lower,4312,O
scores,4312,O
of,4312,O
severity,4312,O
in,4312,O
group,4312,O
G.,4312,O
However,4312,O
",",4312,O
this,4312,O
difference,4312,O
reached,4312,O
statistical,4312,O
significance,4312,O
only,4312,O
with,4312,O
regard,4312,O
to,4312,O
reported,4312,O
pain,4312,B-Disease
sensation,4312,O
(,4312,O
P,4312,O
=,4312,O
0.011,4312,O
),4312,O
.,4312,O
Also,4313,O
the,4313,O
frequency,4313,O
of,4313,O
abnormal,4313,O
electro-diagnostic,4313,O
findings,4313,O
showed,4313,O
similarity,4313,O
between,4313,O
the,4313,O
two,4313,O
groups,4313,O
(,4313,O
G,4313,O
:,4313,O
7/23,4313,O
=,4313,O
30.4,4313,O
%,4313,O
;,4313,O
P,4313,O
:,4313,O
6/20,4313,O
=,4313,O
30,4313,O
%,4313,O
),4313,O
.,4313,O
This,4314,O
pilot,4314,O
study,4314,O
leads,4314,O
to,4314,O
the,4314,O
conclusion,4314,O
that,4314,O
glutamate,4314,B-Chemical
supplementation,4314,O
at,4314,O
the,4314,O
chosen,4314,O
regimen,4314,O
fails,4314,O
to,4314,O
protect,4314,O
against,4314,O
peripheral,4314,B-Disease
neurotoxicity,4314,I-Disease
of,4314,O
PAC,4314,B-Chemical
.,4314,O
Development,4315,O
of,4315,O
ocular,4315,B-Disease
myasthenia,4315,I-Disease
during,4315,O
pegylated,4315,B-Chemical
interferon,4315,I-Chemical
and,4315,O
ribavirin,4315,B-Chemical
treatment,4315,O
for,4315,O
chronic,4315,B-Disease
hepatitis,4315,I-Disease
C.,4315,O
A,4315,O
63-year-old,4315,O
male,4315,O
experienced,4315,O
sudden,4315,O
diplopia,4315,B-Disease
after,4315,O
9,4315,O
weeks,4315,O
of,4315,O
administration,4315,O
of,4315,O
pegylated,4315,B-Chemical
interferon,4315,I-Chemical
(,4315,I-Chemical
IFN,4315,I-Chemical
),4315,I-Chemical
alpha-2b,4315,I-Chemical
and,4315,O
ribavirin,4315,B-Chemical
for,4315,O
chronic,4315,B-Disease
hepatitis,4315,I-Disease
C,4315,I-Disease
(,4315,O
CHC,4315,B-Disease
),4315,O
.,4315,O
Ophthalmologic,4316,O
examinations,4316,O
showed,4316,O
ptosis,4316,B-Disease
on,4316,I-Disease
the,4316,I-Disease
right,4316,I-Disease
upper,4316,I-Disease
lid,4316,I-Disease
and,4316,O
restricted,4316,B-Disease
right,4316,I-Disease
eye,4316,I-Disease
movement,4316,I-Disease
without,4316,O
any,4316,O
other,4316,O
neurological,4316,O
signs,4316,O
.,4316,O
A,4317,O
brain,4317,O
imaging,4317,O
study,4317,O
and,4317,O
repetitive,4317,O
nerve,4317,O
stimulation,4317,O
test,4317,O
indicated,4317,O
no,4317,O
abnormality,4317,O
.,4317,O
The,4318,O
acetylcholine,4318,B-Chemical
receptor,4318,O
antibody,4318,O
titer,4318,O
and,4318,O
response,4318,O
to,4318,O
acetylcholinesterase,4318,O
inhibitors,4318,O
were,4318,O
negative,4318,O
",",4318,O
and,4318,O
the,4318,O
results,4318,O
of,4318,O
thyroid,4318,O
function,4318,O
tests,4318,O
were,4318,O
normal,4318,O
.,4318,O
The,4319,O
patient,4319,O
's,4319,O
ophthalmological,4319,O
symptoms,4319,O
improved,4319,O
rapidly,4319,O
3,4319,O
weeks,4319,O
after,4319,O
discontinuation,4319,O
of,4319,O
pegylated,4319,B-Chemical
IFN,4319,I-Chemical
alpha-2b,4319,I-Chemical
and,4319,O
ribavirin,4319,B-Chemical
.,4319,O
The,4320,O
ocular,4320,B-Disease
myasthenia,4320,I-Disease
associated,4320,O
with,4320,O
combination,4320,O
therapy,4320,O
of,4320,O
pegylated,4320,B-Chemical
IFN,4320,I-Chemical
alpha-2b,4320,I-Chemical
and,4320,O
ribavirin,4320,B-Chemical
for,4320,O
CHC,4320,B-Disease
is,4320,O
very,4320,O
rarely,4320,O
reported,4320,O
;,4320,O
therefore,4320,O
",",4320,O
we,4320,O
present,4320,O
this,4320,O
case,4320,O
with,4320,O
a,4320,O
review,4320,O
of,4320,O
the,4320,O
various,4320,O
eye,4320,O
complications,4320,O
of,4320,O
IFN,4320,B-Chemical
therapy,4320,O
.,4320,O
Learning,4321,O
and,4321,O
memory,4321,O
deficits,4321,O
in,4321,O
ecstasy,4321,B-Chemical
users,4321,O
and,4321,O
their,4321,O
neural,4321,O
correlates,4321,O
during,4321,O
a,4321,O
face-learning,4321,O
task,4321,O
.,4321,O
It,4322,O
has,4322,O
been,4322,O
consistently,4322,O
shown,4322,O
that,4322,O
ecstasy,4322,B-Chemical
users,4322,O
display,4322,O
impairments,4322,O
in,4322,O
learning,4322,O
and,4322,O
memory,4322,O
performance,4322,O
.,4322,O
In,4323,O
addition,4323,O
",",4323,O
working,4323,O
memory,4323,O
processing,4323,O
in,4323,O
ecstasy,4323,B-Chemical
users,4323,O
has,4323,O
been,4323,O
shown,4323,O
to,4323,O
be,4323,O
associated,4323,O
with,4323,O
neural,4323,O
alterations,4323,O
in,4323,O
hippocampal,4323,O
and/or,4323,O
cortical,4323,O
regions,4323,O
as,4323,O
measured,4323,O
by,4323,O
functional,4323,O
magnetic,4323,O
resonance,4323,O
imaging,4323,O
(,4323,O
fMRI,4323,O
),4323,O
.,4323,O
Using,4324,O
functional,4324,O
imaging,4324,O
and,4324,O
a,4324,O
face-learning,4324,O
task,4324,O
",",4324,O
we,4324,O
investigated,4324,O
neural,4324,O
correlates,4324,O
of,4324,O
encoding,4324,O
and,4324,O
recalling,4324,O
face-name,4324,O
associations,4324,O
in,4324,O
20,4324,O
recreational,4324,O
drug,4324,O
users,4324,O
whose,4324,O
predominant,4324,O
drug,4324,O
use,4324,O
was,4324,O
ecstasy,4324,B-Chemical
and,4324,O
20,4324,O
controls,4324,O
.,4324,O
To,4325,O
address,4325,O
the,4325,O
potential,4325,O
confounding,4325,O
effects,4325,O
of,4325,O
the,4325,O
cannabis,4325,B-Chemical
use,4325,O
of,4325,O
the,4325,O
ecstasy,4325,B-Chemical
using,4325,O
group,4325,O
",",4325,O
a,4325,O
second,4325,O
analysis,4325,O
included,4325,O
14,4325,O
previously,4325,O
tested,4325,O
cannabis,4325,B-Chemical
users,4325,O
(,4325,O
Nestor,4325,O
",",4325,O
L.,4325,O
",",4325,O
Roberts,4325,O
",",4325,O
G.,4325,O
",",4325,O
Garavan,4325,O
",",4325,O
H.,4325,O
",",4325,O
Hester,4325,O
",",4325,O
R.,4325,O
",",4325,O
2008,4325,O
.,4325,O
Deficits,4326,O
in,4326,O
learning,4326,O
and,4326,O
memory,4326,O
:,4326,O
parahippocampal,4326,O
hyperactivity,4326,B-Disease
and,4326,O
frontocortical,4326,O
hypoactivity,4326,O
in,4326,O
cannabis,4326,B-Chemical
users,4326,O
.,4326,O
Neuroimage,4327,O
40,4327,O
",",4327,O
1328-1339,4327,O
),4327,O
.,4327,O
Ecstasy,4328,B-Chemical
users,4328,O
performed,4328,O
significantly,4328,O
worse,4328,O
in,4328,O
learning,4328,O
and,4328,O
memory,4328,O
compared,4328,O
to,4328,O
controls,4328,O
and,4328,O
cannabis,4328,B-Chemical
users,4328,O
.,4328,O
A,4329,O
conjunction,4329,O
analysis,4329,O
of,4329,O
the,4329,O
encode,4329,O
and,4329,O
recall,4329,O
phases,4329,O
of,4329,O
the,4329,O
task,4329,O
revealed,4329,O
ecstasy-specific,4329,B-Chemical
hyperactivity,4329,B-Disease
in,4329,O
bilateral,4329,O
frontal,4329,O
regions,4329,O
",",4329,O
left,4329,O
temporal,4329,O
",",4329,O
right,4329,O
parietal,4329,O
",",4329,O
bilateral,4329,O
temporal,4329,O
",",4329,O
and,4329,O
bilateral,4329,O
occipital,4329,O
brain,4329,O
regions,4329,O
.,4329,O
Ecstasy-specific,4330,B-Chemical
hypoactivity,4330,O
was,4330,O
evident,4330,O
in,4330,O
the,4330,O
right,4330,O
dorsal,4330,O
anterior,4330,O
cingulated,4330,O
cortex,4330,O
(,4330,O
ACC,4330,O
),4330,O
and,4330,O
left,4330,O
posterior,4330,O
cingulated,4330,O
cortex,4330,O
.,4330,O
In,4331,O
both,4331,O
ecstasy,4331,B-Chemical
and,4331,O
cannabis,4331,B-Chemical
groups,4331,O
brain,4331,O
activation,4331,O
was,4331,O
decreased,4331,O
in,4331,O
the,4331,O
right,4331,O
medial,4331,O
frontal,4331,O
gyrus,4331,O
",",4331,O
left,4331,O
parahippocampal,4331,O
gyrus,4331,O
",",4331,O
left,4331,O
dorsal,4331,O
cingulate,4331,O
gyrus,4331,O
",",4331,O
and,4331,O
left,4331,O
caudate,4331,O
.,4331,O
These,4332,O
results,4332,O
elucidated,4332,O
ecstasy-related,4332,B-Chemical
deficits,4332,O
",",4332,O
only,4332,O
some,4332,O
of,4332,O
which,4332,O
might,4332,O
be,4332,O
attributed,4332,O
to,4332,O
cannabis,4332,B-Chemical
use,4332,O
.,4332,O
These,4333,O
ecstasy-specific,4333,B-Chemical
effects,4333,O
may,4333,O
be,4333,O
related,4333,O
to,4333,O
the,4333,O
vulnerability,4333,O
of,4333,O
isocortical,4333,O
and,4333,O
allocortical,4333,O
regions,4333,O
to,4333,O
the,4333,O
neurotoxic,4333,B-Disease
effects,4333,O
of,4333,O
ecstasy,4333,B-Chemical
.,4333,O
Disulfiram-like,4334,B-Chemical
syndrome,4334,O
after,4334,O
hydrogen,4334,B-Chemical
cyanamide,4334,I-Chemical
professional,4334,O
skin,4334,O
exposure,4334,O
:,4334,O
two,4334,O
case,4334,O
reports,4334,O
in,4334,O
France,4334,O
.,4334,O
Hydrogen,4335,B-Chemical
cyanamide,4335,I-Chemical
is,4335,O
a,4335,O
plant,4335,O
growth,4335,O
regulator,4335,O
used,4335,O
in,4335,O
agriculture,4335,O
to,4335,O
induce,4335,O
bud,4335,O
break,4335,O
in,4335,O
fruit,4335,O
trees,4335,O
.,4335,O
Contact,4336,O
with,4336,O
the,4336,O
skin,4336,O
can,4336,O
result,4336,O
in,4336,O
percutaneous,4336,O
absorption,4336,O
of,4336,O
the,4336,O
substance,4336,O
that,4336,O
inhibits,4336,O
aldehyde,4336,B-Chemical
dehydrogenase,4336,O
and,4336,O
can,4336,O
induce,4336,O
acetaldehyde,4336,B-Chemical
syndrome,4336,O
in,4336,O
case,4336,O
of,4336,O
alcohol,4336,B-Chemical
use,4336,O
.,4336,O
The,4337,O
purpose,4337,O
of,4337,O
this,4337,O
report,4337,O
is,4337,O
to,4337,O
describe,4337,O
two,4337,O
cases,4337,O
of,4337,O
a,4337,O
disulfiram-like,4337,B-Chemical
syndrome,4337,O
following,4337,O
occupational,4337,O
exposure,4337,O
to,4337,O
hydrogen,4337,B-Chemical
cyanamide,4337,I-Chemical
.,4337,O
The,4338,O
first,4338,O
case,4338,O
involved,4338,O
a,4338,O
59-year-old,4338,O
man,4338,O
who,4338,O
used,4338,O
Dormex,4338,B-Chemical
",",4338,O
which,4338,O
contains,4338,O
hydrogen,4338,B-Chemical
cyanamide,4338,I-Chemical
",",4338,O
without,4338,O
protection,4338,O
after,4338,O
consuming,4338,O
a,4338,O
large,4338,O
amount,4338,O
of,4338,O
alcohol,4338,B-Chemical
during,4338,O
a,4338,O
meal,4338,O
.,4338,O
In,4339,O
less,4339,O
than,4339,O
1,4339,O
hour,4339,O
after,4339,O
the,4339,O
ingestion,4339,O
of,4339,O
alcohol,4339,B-Chemical
",",4339,O
he,4339,O
developed,4339,O
malaise,4339,O
with,4339,O
flushing,4339,B-Disease
of,4339,I-Disease
the,4339,I-Disease
face,4339,I-Disease
",",4339,O
tachycardia,4339,B-Disease
",",4339,O
and,4339,O
dyspnea,4339,B-Disease
.,4339,O
Manifestations,4340,O
regressed,4340,O
spontaneously,4340,O
under,4340,O
surveillance,4340,O
in,4340,O
the,4340,O
hospital,4340,O
.,4340,O
The,4341,O
second,4341,O
case,4341,O
occurred,4341,O
in,4341,O
a,4341,O
55-year-old,4341,O
farmer,4341,O
following,4341,O
cutaneous,4341,O
contact,4341,O
with,4341,O
Dormex,4341,B-Chemical
.,4341,O
Five,4342,O
hours,4342,O
after,4342,O
exposure,4342,O
",",4342,O
he,4342,O
developed,4342,O
disulfiram-like,4342,B-Chemical
syndrome,4342,O
with,4342,O
flushing,4342,B-Disease
",",4342,O
tachycardia,4342,B-Disease
",",4342,O
and,4342,O
arterial,4342,B-Disease
hypotension,4342,I-Disease
after,4342,O
consuming,4342,O
three,4342,O
glasses,4342,O
of,4342,O
wine,4342,O
.,4342,O
The,4343,O
patient,4343,O
recovered,4343,O
spontaneously,4343,O
in,4343,O
3,4343,O
hours,4343,O
under,4343,O
surveillance,4343,O
in,4343,O
the,4343,O
hospital,4343,O
.,4343,O
These,4344,O
cases,4344,O
confirm,4344,O
the,4344,O
necessity,4344,O
of,4344,O
avoiding,4344,O
alcohol,4344,B-Chemical
consumption,4344,O
as,4344,O
recommended,4344,O
in,4344,O
the,4344,O
instructions,4344,O
for,4344,O
use,4344,O
of,4344,O
Dormex,4344,B-Chemical
and,4344,O
of,4344,O
preventing,4344,O
cutaneous,4344,O
contact,4344,O
during,4344,O
use,4344,O
.,4344,O
Comparative,4345,O
cognitive,4345,O
and,4345,O
subjective,4345,O
side,4345,O
effects,4345,O
of,4345,O
immediate-release,4345,O
oxycodone,4345,B-Chemical
in,4345,O
healthy,4345,O
middle-aged,4345,O
and,4345,O
older,4345,O
adults,4345,O
.,4345,O
This,4346,O
study,4346,O
measured,4346,O
the,4346,O
objective,4346,O
and,4346,O
subjective,4346,O
neurocognitive,4346,O
effects,4346,O
of,4346,O
a,4346,O
single,4346,O
10-mg,4346,O
dose,4346,O
of,4346,O
immediate-release,4346,O
oxycodone,4346,B-Chemical
in,4346,O
healthy,4346,O
",",4346,O
older,4346,O
(,4346,O
>,4346,O
65,4346,O
years,4346,O
),4346,O
",",4346,O
and,4346,O
middle-aged,4346,O
(,4346,O
35,4346,O
to,4346,O
55,4346,O
years,4346,O
),4346,O
adults,4346,O
who,4346,O
were,4346,O
not,4346,O
suffering,4346,O
from,4346,O
chronic,4346,O
or,4346,O
significant,4346,O
daily,4346,O
pain,4346,B-Disease
.,4346,O
Seventy-one,4347,O
participants,4347,O
completed,4347,O
2,4347,O
separate,4347,O
study,4347,O
days,4347,O
and,4347,O
were,4347,O
blind,4347,O
to,4347,O
medication,4347,O
condition,4347,O
(,4347,O
placebo,4347,O
",",4347,O
10-mg,4347,O
oxycodone,4347,B-Chemical
),4347,O
.,4347,O
Plasma,4348,O
oxycodone,4348,B-Chemical
concentration,4348,O
peaked,4348,O
between,4348,O
60,4348,O
and,4348,O
90,4348,O
minutes,4348,O
postdose,4348,O
(,4348,O
P,4348,O
<,4348,O
.01,4348,O
),4348,O
and,4348,O
pupil,4348,O
size,4348,O
",",4348,O
an,4348,O
indication,4348,O
of,4348,O
physiological,4348,O
effects,4348,O
of,4348,O
the,4348,O
medication,4348,O
",",4348,O
peaked,4348,O
at,4348,O
approximately,4348,O
90,4348,O
to,4348,O
120,4348,O
minutes,4348,O
postdose,4348,O
(,4348,O
P,4348,O
<,4348,O
.01,4348,O
),4348,O
.,4348,O
Significant,4349,O
declines,4349,O
in,4349,O
simple,4349,O
and,4349,O
sustained,4349,O
attention,4349,O
",",4349,O
working,4349,O
memory,4349,O
",",4349,O
and,4349,O
verbal,4349,O
memory,4349,O
were,4349,O
observed,4349,O
at,4349,O
1,4349,O
hour,4349,O
postdose,4349,O
compared,4349,O
to,4349,O
baseline,4349,O
for,4349,O
both,4349,O
age,4349,O
groups,4349,O
with,4349,O
a,4349,O
trend,4349,O
toward,4349,O
return,4349,O
to,4349,O
baseline,4349,O
by,4349,O
5,4349,O
hours,4349,O
postdose,4349,O
.,4349,O
For,4350,O
almost,4350,O
all,4350,O
cognitive,4350,O
measures,4350,O
",",4350,O
there,4350,O
were,4350,O
no,4350,O
medication,4350,O
by,4350,O
age-interaction,4350,O
effects,4350,O
",",4350,O
which,4350,O
indicates,4350,O
that,4350,O
the,4350,O
2,4350,O
age,4350,O
groups,4350,O
exhibited,4350,O
similar,4350,O
responses,4350,O
to,4350,O
the,4350,O
medication,4350,O
challenge,4350,O
.,4350,O
This,4351,O
study,4351,O
suggests,4351,O
that,4351,O
for,4351,O
healthy,4351,O
older,4351,O
adults,4351,O
who,4351,O
are,4351,O
not,4351,O
suffering,4351,O
from,4351,O
chronic,4351,B-Disease
pain,4351,I-Disease
",",4351,O
neurocognitive,4351,O
and,4351,O
pharmacodynamic,4351,O
changes,4351,O
in,4351,O
response,4351,O
to,4351,O
a,4351,O
10-mg,4351,O
dose,4351,O
of,4351,O
immediate-release,4351,O
oxycodone,4351,B-Chemical
are,4351,O
similar,4351,O
to,4351,O
those,4351,O
observed,4351,O
for,4351,O
middle-aged,4351,O
adults,4351,O
.,4351,O
PERSPECTIVE,4352,O
:,4352,O
Study,4352,O
findings,4352,O
indicate,4352,O
that,4352,O
the,4352,O
metabolism,4352,O
",",4352,O
neurocognitive,4352,O
effects,4352,O
",",4352,O
and,4352,O
physical,4352,O
side,4352,O
effects,4352,O
of,4352,O
oral,4352,O
oxycodone,4352,B-Chemical
are,4352,O
similar,4352,O
for,4352,O
healthy,4352,O
middle-aged,4352,O
and,4352,O
older,4352,O
adults,4352,O
.,4352,O
Therefore,4353,O
",",4353,O
clinicians,4353,O
should,4353,O
not,4353,O
avoid,4353,O
prescribing,4353,O
oral,4353,O
opioids,4353,O
to,4353,O
older,4353,O
adults,4353,O
based,4353,O
on,4353,O
the,4353,O
belief,4353,O
that,4353,O
older,4353,O
adults,4353,O
are,4353,O
at,4353,O
higher,4353,O
risk,4353,O
for,4353,O
side,4353,O
effects,4353,O
than,4353,O
younger,4353,O
adults,4353,O
.,4353,O
The,4354,O
glycine,4354,B-Chemical
transporter-1,4354,O
inhibitor,4354,O
SSR103800,4354,B-Chemical
displays,4354,O
a,4354,O
selective,4354,O
and,4354,O
specific,4354,O
antipsychotic-like,4354,O
profile,4354,O
in,4354,O
normal,4354,O
and,4354,O
transgenic,4354,O
mice,4354,O
.,4354,O
Schizophrenia,4355,B-Disease
has,4355,O
been,4355,O
initially,4355,O
associated,4355,O
with,4355,O
dysfunction,4355,O
in,4355,O
dopamine,4355,B-Chemical
neurotransmission,4355,O
.,4355,O
However,4356,O
",",4356,O
the,4356,O
observation,4356,O
that,4356,O
antagonists,4356,O
of,4356,O
the,4356,O
glutamate,4356,B-Chemical
N-methyl-D-aspartate,4356,B-Chemical
(,4356,O
NMDA,4356,B-Chemical
),4356,O
receptor,4356,O
produce,4356,O
schizophrenic-like,4356,B-Disease
symptoms,4356,O
in,4356,O
humans,4356,O
has,4356,O
led,4356,O
to,4356,O
the,4356,O
idea,4356,O
of,4356,O
a,4356,O
dysfunctioning,4356,O
of,4356,O
the,4356,O
glutamatergic,4356,O
system,4356,O
via,4356,O
its,4356,O
NMDA,4356,B-Chemical
receptor,4356,O
.,4356,O
As,4357,O
a,4357,O
result,4357,O
",",4357,O
there,4357,O
is,4357,O
a,4357,O
growing,4357,O
interest,4357,O
in,4357,O
the,4357,O
development,4357,O
of,4357,O
pharmacological,4357,O
agents,4357,O
with,4357,O
potential,4357,O
antipsychotic,4357,O
properties,4357,O
that,4357,O
enhance,4357,O
the,4357,O
activity,4357,O
of,4357,O
the,4357,O
glutamatergic,4357,O
system,4357,O
via,4357,O
a,4357,O
modulation,4357,O
of,4357,O
the,4357,O
NMDA,4357,B-Chemical
receptor,4357,O
.,4357,O
Among,4358,O
them,4358,O
are,4358,O
glycine,4358,B-Chemical
transporter-1,4358,O
(,4358,O
GlyT1,4358,O
),4358,O
inhibitors,4358,O
such,4358,O
as,4358,O
SSR103800,4358,B-Chemical
",",4358,O
which,4358,O
indirectly,4358,O
enhance,4358,O
NMDA,4358,B-Chemical
receptor,4358,O
function,4358,O
by,4358,O
increasing,4358,O
the,4358,O
glycine,4358,B-Chemical
(,4358,O
a,4358,O
co-agonist,4358,O
for,4358,O
the,4358,O
NMDA,4358,B-Chemical
receptor,4358,O
),4358,O
levels,4358,O
in,4358,O
the,4358,O
synapse,4358,O
.,4358,O
This,4359,O
study,4359,O
aimed,4359,O
at,4359,O
investigating,4359,O
the,4359,O
potential,4359,O
antipsychotic-like,4359,O
properties,4359,O
of,4359,O
SSR103800,4359,B-Chemical
",",4359,O
with,4359,O
a,4359,O
particular,4359,O
focus,4359,O
on,4359,O
models,4359,O
of,4359,O
hyperactivity,4359,B-Disease
",",4359,O
involving,4359,O
either,4359,O
drug,4359,O
challenge,4359,O
(,4359,O
ie,4359,O
",",4359,O
amphetamine,4359,B-Chemical
and,4359,O
MK-801,4359,B-Chemical
),4359,O
or,4359,O
transgenic,4359,O
mice,4359,O
(,4359,O
ie,4359,O
",",4359,O
NMDA,4359,B-Chemical
Nr1,4359,O
(,4359,O
neo-/-,4359,O
),4359,O
and,4359,O
DAT,4359,O
(,4359,O
-/-,4359,O
),4359,O
),4359,O
.,4359,O
Results,4360,O
showed,4360,O
that,4360,O
SSR103800,4360,B-Chemical
(,4360,O
10-30,4360,O
mg/kg,4360,O
p.o,4360,O
.,4360,O
),4360,O
blocked,4361,O
hyperactivity,4361,B-Disease
induced,4361,O
by,4361,O
the,4361,O
non-competitive,4361,O
NMDA,4361,B-Chemical
receptor,4361,O
antagonist,4361,O
",",4361,O
MK-801,4361,B-Chemical
and,4361,O
partially,4361,O
reversed,4361,O
spontaneous,4361,O
hyperactivity,4361,B-Disease
of,4361,O
NMDA,4361,B-Chemical
Nr1,4361,O
(,4361,O
neo-/-,4361,O
),4361,O
mice,4361,O
.,4361,O
In,4362,O
contrast,4362,O
",",4362,O
SSR103800,4362,B-Chemical
failed,4362,O
to,4362,O
affect,4362,O
hyperactivity,4362,B-Disease
induced,4362,O
by,4362,O
amphetamine,4362,B-Chemical
or,4362,O
naturally,4362,O
observed,4362,O
in,4362,O
dopamine,4362,B-Chemical
transporter,4362,O
(,4362,O
DAT,4362,O
(,4362,O
-/-,4362,O
),4362,O
),4362,O
knockout,4362,O
mice,4362,O
(,4362,O
10-30,4362,O
mg/kg,4362,O
p.o,4362,O
.,4362,O
),4362,O
.,4362,O
Importantly,4363,O
",",4363,O
both,4363,O
classical,4363,O
(,4363,O
haloperidol,4363,B-Chemical
),4363,O
and,4363,O
atypical,4363,O
(,4363,O
olanzapine,4363,B-Chemical
",",4363,O
clozapine,4363,B-Chemical
and,4363,O
aripiprazole,4363,B-Chemical
),4363,O
antipsychotics,4363,O
were,4363,O
effective,4363,O
in,4363,O
all,4363,O
these,4363,O
models,4363,O
of,4363,O
hyperactivity,4363,B-Disease
.,4363,O
However,4364,O
",",4364,O
unlike,4364,O
these,4364,O
latter,4364,O
",",4364,O
SSR103800,4364,B-Chemical
did,4364,O
not,4364,O
produce,4364,O
catalepsy,4364,B-Disease
(,4364,O
retention,4364,O
on,4364,O
the,4364,O
bar,4364,O
test,4364,O
),4364,O
up,4364,O
to,4364,O
30,4364,O
mg/kg,4364,O
p.o,4364,O
.,4364,O
Together,4365,O
these,4365,O
findings,4365,O
show,4365,O
that,4365,O
the,4365,O
GlyT1,4365,O
inhibitor,4365,O
",",4365,O
SSR103800,4365,B-Chemical
",",4365,O
produces,4365,O
antipsychotic-like,4365,O
effects,4365,O
",",4365,O
which,4365,O
differ,4365,O
from,4365,O
those,4365,O
observed,4365,O
with,4365,O
compounds,4365,O
primarily,4365,O
targeting,4365,O
the,4365,O
dopaminergic,4365,O
system,4365,O
",",4365,O
and,4365,O
has,4365,O
a,4365,O
reduced,4365,O
side-effect,4365,O
potential,4365,O
as,4365,O
compared,4365,O
with,4365,O
these,4365,O
latter,4365,O
drugs,4365,O
.,4365,O
Pyrrolidine,4366,B-Chemical
dithiocarbamate,4366,I-Chemical
protects,4366,O
the,4366,O
piriform,4366,O
cortex,4366,O
in,4366,O
the,4366,O
pilocarpine,4366,B-Chemical
status,4366,B-Disease
epilepticus,4366,I-Disease
model,4366,O
.,4366,O
Pyrrolidine,4367,B-Chemical
dithiocarbamate,4367,I-Chemical
(,4367,O
PDTC,4367,B-Chemical
),4367,O
has,4367,O
a,4367,O
dual,4367,O
mechanism,4367,O
of,4367,O
action,4367,O
as,4367,O
an,4367,O
antioxidant,4367,O
and,4367,O
an,4367,O
inhibitor,4367,O
of,4367,O
the,4367,O
transcription,4367,O
factor,4367,O
kappa-beta,4367,O
.,4367,O
Both,4368,O
",",4368,O
production,4368,O
of,4368,O
reactive,4368,O
oxygen,4368,B-Chemical
species,4368,O
as,4368,O
well,4368,O
as,4368,O
activation,4368,O
of,4368,O
NF-kappaB,4368,O
have,4368,O
been,4368,O
implicated,4368,O
in,4368,O
severe,4368,O
neuronal,4368,B-Disease
damage,4368,I-Disease
in,4368,O
different,4368,O
sub-regions,4368,O
of,4368,O
the,4368,O
hippocampus,4368,O
as,4368,O
well,4368,O
as,4368,O
in,4368,O
the,4368,O
surrounding,4368,O
cortices,4368,O
.,4368,O
The,4369,O
effect,4369,O
of,4369,O
PDTC,4369,B-Chemical
on,4369,O
status,4369,B-Disease
epilepticus-associated,4369,O
cell,4369,O
loss,4369,O
in,4369,O
the,4369,O
hippocampus,4369,O
and,4369,O
piriform,4369,O
cortex,4369,O
was,4369,O
evaluated,4369,O
in,4369,O
the,4369,O
rat,4369,O
fractionated,4369,O
pilocarpine,4369,B-Chemical
model,4369,O
.,4369,O
Treatment,4370,O
with,4370,O
150,4370,O
mg/kg,4370,O
PDTC,4370,B-Chemical
before,4370,O
and,4370,O
following,4370,O
status,4370,B-Disease
epilepticus,4370,I-Disease
significantly,4370,O
increased,4370,O
the,4370,O
mortality,4370,O
rate,4370,O
to,4370,O
100,4370,O
%,4370,O
.,4370,O
Administration,4371,O
of,4371,O
50,4371,O
mg/kg,4371,O
PDTC,4371,B-Chemical
(,4371,O
low-dose,4371,O
),4371,O
did,4371,O
not,4371,O
exert,4371,O
major,4371,O
effects,4371,O
on,4371,O
the,4371,O
development,4371,O
of,4371,O
a,4371,O
status,4371,B-Disease
epilepticus,4371,I-Disease
or,4371,O
the,4371,O
mortality,4371,O
rate,4371,O
.,4371,O
In,4372,O
vehicle-treated,4372,O
rats,4372,O
",",4372,O
status,4372,B-Disease
epilepticus,4372,I-Disease
caused,4372,O
pronounced,4372,O
neuronal,4372,B-Disease
damage,4372,I-Disease
in,4372,O
the,4372,O
piriform,4372,O
cortex,4372,O
comprising,4372,O
both,4372,O
pyramidal,4372,O
cells,4372,O
and,4372,O
interneurons,4372,O
.,4372,O
Low-dose,4373,O
PDTC,4373,B-Chemical
treatment,4373,O
almost,4373,O
completely,4373,O
protected,4373,O
from,4373,O
lesions,4373,O
in,4373,O
the,4373,O
piriform,4373,O
cortex,4373,O
.,4373,O
A,4374,O
significant,4374,O
decrease,4374,O
in,4374,O
neuronal,4374,O
density,4374,O
of,4374,O
the,4374,O
hippocampal,4374,O
hilar,4374,O
formation,4374,O
was,4374,O
identified,4374,O
in,4374,O
vehicle-,4374,O
and,4374,O
PDTC-treated,4374,B-Chemical
rats,4374,O
following,4374,O
status,4374,B-Disease
epilepticus,4374,I-Disease
.,4374,O
In,4375,O
conclusion,4375,O
",",4375,O
the,4375,O
NF-kappaB,4375,O
inhibitor,4375,O
and,4375,O
antioxidant,4375,O
PDTC,4375,B-Chemical
protected,4375,O
the,4375,O
piriform,4375,O
cortex,4375,O
",",4375,O
whereas,4375,O
it,4375,O
did,4375,O
not,4375,O
affect,4375,O
hilar,4375,O
neuronal,4375,B-Disease
loss,4375,I-Disease
.,4375,O
These,4376,O
data,4376,O
might,4376,O
indicate,4376,O
that,4376,O
the,4376,O
generation,4376,O
of,4376,O
reactive,4376,O
oxygen,4376,B-Chemical
species,4376,O
and,4376,O
activation,4376,O
of,4376,O
NF-kappaB,4376,O
plays,4376,O
a,4376,O
more,4376,O
central,4376,O
role,4376,O
in,4376,O
seizure-associated,4376,B-Disease
neuronal,4376,B-Disease
damage,4376,I-Disease
in,4376,O
the,4376,O
temporal,4376,O
cortex,4376,O
as,4376,O
compared,4376,O
to,4376,O
the,4376,O
hippocampal,4376,O
hilus,4376,O
.,4376,O
However,4377,O
",",4377,O
future,4377,O
investigations,4377,O
are,4377,O
necessary,4377,O
to,4377,O
exactly,4377,O
analyze,4377,O
the,4377,O
biochemical,4377,O
mechanisms,4377,O
by,4377,O
which,4377,O
PDTC,4377,B-Chemical
exerted,4377,O
its,4377,O
beneficial,4377,O
effects,4377,O
in,4377,O
the,4377,O
piriform,4377,O
cortex,4377,O
.,4377,O
Anaesthetists,4378,O
',4378,O
nightmare,4378,O
:,4378,O
masseter,4378,B-Disease
spasm,4378,I-Disease
after,4378,O
induction,4378,O
in,4378,O
an,4378,O
undiagnosed,4378,O
case,4378,O
of,4378,O
myotonia,4378,B-Disease
congenita,4378,I-Disease
.,4378,O
We,4379,O
report,4379,O
an,4379,O
undiagnosed,4379,O
case,4379,O
of,4379,O
myotonia,4379,B-Disease
congenita,4379,I-Disease
in,4379,O
a,4379,O
24-year-old,4379,O
previously,4379,O
healthy,4379,O
primigravida,4379,O
",",4379,O
who,4379,O
developed,4379,O
life,4379,O
threatening,4379,O
masseter,4379,B-Disease
spasm,4379,I-Disease
following,4379,O
a,4379,O
standard,4379,O
dose,4379,O
of,4379,O
intravenous,4379,O
suxamethonium,4379,B-Chemical
for,4379,O
induction,4379,O
of,4379,O
anaesthesia,4379,O
.,4379,O
Neither,4380,O
the,4380,O
patient,4380,O
nor,4380,O
the,4380,O
anaesthetist,4380,O
was,4380,O
aware,4380,O
of,4380,O
the,4380,O
diagnosis,4380,O
before,4380,O
this,4380,O
potentially,4380,O
lethal,4380,O
complication,4380,O
occurred,4380,O
.,4380,O
Twin,4381,O
preterm,4381,O
neonates,4381,O
with,4381,O
cardiac,4381,B-Disease
toxicity,4381,I-Disease
related,4381,O
to,4381,O
lopinavir/ritonavir,4381,B-Chemical
therapy,4381,O
.,4381,O
We,4382,O
report,4382,O
twin,4382,O
neonates,4382,O
who,4382,O
were,4382,O
born,4382,O
prematurely,4382,O
at,4382,O
32,4382,O
weeks,4382,O
of,4382,O
gestation,4382,O
to,4382,O
a,4382,O
mother,4382,O
with,4382,O
human,4382,B-Disease
immunodeficiency,4382,I-Disease
virus,4382,I-Disease
infection,4382,I-Disease
.,4382,O
One,4383,O
of,4383,O
the,4383,O
twins,4383,O
developed,4383,O
complete,4383,O
heart,4383,B-Disease
block,4383,I-Disease
and,4383,O
dilated,4383,B-Disease
cardiomyopathy,4383,I-Disease
related,4383,O
to,4383,O
lopinavir/ritonavir,4383,B-Chemical
therapy,4383,O
",",4383,O
a,4383,O
boosted,4383,O
protease-inhibitor,4383,O
agent,4383,O
",",4383,O
while,4383,O
the,4383,O
other,4383,O
twin,4383,O
developed,4383,O
mild,4383,O
bradycardia,4383,B-Disease
.,4383,O
We,4384,O
recommend,4384,O
caution,4384,O
in,4384,O
the,4384,O
use,4384,O
of,4384,O
lopinavir/ritonavir,4384,B-Chemical
in,4384,O
the,4384,O
immediate,4384,O
neonatal,4384,O
period,4384,O
.,4384,O
When,4385,O
drugs,4385,O
disappear,4385,O
from,4385,O
the,4385,O
patient,4385,O
:,4385,O
elimination,4385,O
of,4385,O
intravenous,4385,O
medication,4385,O
by,4385,O
hemodiafiltration,4385,O
.,4385,O
Twenty-three,4386,O
hours,4386,O
after,4386,O
heart,4386,O
transplantation,4386,O
",",4386,O
life-threatening,4386,O
acute,4386,O
right,4386,B-Disease
heart,4386,I-Disease
failure,4386,I-Disease
was,4386,O
diagnosed,4386,O
in,4386,O
a,4386,O
patient,4386,O
requiring,4386,O
continuous,4386,O
venovenous,4386,O
hemodiafiltration,4386,O
(,4386,O
CVVHDF,4386,O
),4386,O
.,4386,O
Increasing,4387,O
doses,4387,O
of,4387,O
catecholamines,4387,B-Chemical
",",4387,O
sedatives,4387,O
",",4387,O
and,4387,O
muscle,4387,O
relaxants,4387,O
administered,4387,O
through,4387,O
a,4387,O
central,4387,O
venous,4387,O
catheter,4387,O
were,4387,O
ineffective,4387,O
.,4387,O
However,4388,O
",",4388,O
a,4388,O
bolus,4388,O
of,4388,O
epinephrine,4388,B-Chemical
injected,4388,O
through,4388,O
an,4388,O
alternative,4388,O
catheter,4388,O
provoked,4388,O
a,4388,O
hypertensive,4388,B-Disease
crisis,4388,O
.,4388,O
Thus,4389,O
",",4389,O
interference,4389,O
with,4389,O
the,4389,O
central,4389,O
venous,4389,O
infusion,4389,O
by,4389,O
the,4389,O
dialysis,4389,O
catheter,4389,O
was,4389,O
suspected,4389,O
.,4389,O
The,4390,O
catheters,4390,O
were,4390,O
changed,4390,O
",",4390,O
and,4390,O
hemodynamics,4390,O
stabilized,4390,O
at,4390,O
lower,4390,O
catecholamine,4390,B-Chemical
doses,4390,O
.,4390,O
When,4391,O
the,4391,O
effects,4391,O
of,4391,O
IV,4391,O
drugs,4391,O
are,4391,O
inadequate,4391,O
in,4391,O
patients,4391,O
receiving,4391,O
CVVHDF,4391,O
",",4391,O
interference,4391,O
with,4391,O
adjacent,4391,O
catheters,4391,O
resulting,4391,O
in,4391,O
elimination,4391,O
of,4391,O
the,4391,O
drug,4391,O
by,4391,O
CVVHDF,4391,O
should,4391,O
be,4391,O
suspected,4391,O
.,4391,O
Antibacterial,4392,O
medication,4392,O
use,4392,O
during,4392,O
pregnancy,4392,O
and,4392,O
risk,4392,O
of,4392,O
birth,4392,B-Disease
defects,4392,I-Disease
:,4392,O
National,4392,O
Birth,4392,B-Disease
Defects,4392,I-Disease
Prevention,4392,O
Study,4392,O
.,4392,O
OBJECTIVE,4393,O
:,4393,O
To,4393,O
estimate,4393,O
the,4393,O
association,4393,O
between,4393,O
antibacterial,4393,O
medications,4393,O
and,4393,O
selected,4393,O
birth,4393,B-Disease
defects,4393,I-Disease
.,4393,O
DESIGN,4394,O
",",4394,O
SETTING,4394,O
",",4394,O
AND,4394,O
PARTICIPANTS,4394,O
:,4394,O
Population-based,4394,O
",",4394,O
multisite,4394,O
",",4394,O
case-control,4394,O
study,4394,O
of,4394,O
women,4394,O
who,4394,O
had,4394,O
pregnancies,4394,O
affected,4394,O
by,4394,O
1,4394,O
of,4394,O
more,4394,O
than,4394,O
30,4394,O
eligible,4394,O
major,4394,O
birth,4394,B-Disease
defects,4394,I-Disease
identified,4394,O
via,4394,O
birth,4394,B-Disease
defect,4394,I-Disease
surveillance,4394,O
programs,4394,O
in,4394,O
10,4394,O
states,4394,O
(,4394,O
n,4394,O
=,4394,O
13,4394,O
155,4394,O
),4394,O
and,4394,O
control,4394,O
women,4394,O
randomly,4394,O
selected,4394,O
from,4394,O
the,4394,O
same,4394,O
geographical,4394,O
regions,4394,O
(,4394,O
n,4394,O
=,4394,O
4941,4394,O
),4394,O
.,4394,O
MAIN,4395,O
EXPOSURE,4395,O
:,4395,O
Reported,4395,O
maternal,4395,O
use,4395,O
of,4395,O
antibacterials,4395,O
(,4395,O
1,4395,O
month,4395,O
before,4395,O
pregnancy,4395,O
through,4395,O
the,4395,O
end,4395,O
of,4395,O
the,4395,O
first,4395,O
trimester,4395,O
),4395,O
.,4395,O
MAIN,4396,O
OUTCOME,4396,O
MEASURE,4396,O
:,4396,O
Odds,4396,O
ratios,4396,O
(,4396,O
ORs,4396,O
),4396,O
measuring,4396,O
the,4396,O
association,4396,O
between,4396,O
antibacterial,4396,O
use,4396,O
and,4396,O
selected,4396,O
birth,4396,B-Disease
defects,4396,I-Disease
adjusted,4396,O
for,4396,O
potential,4396,O
confounders,4396,O
.,4396,O
RESULTS,4397,O
:,4397,O
The,4397,O
reported,4397,O
use,4397,O
of,4397,O
antibacterials,4397,O
increased,4397,O
during,4397,O
pregnancy,4397,O
",",4397,O
peaking,4397,O
during,4397,O
the,4397,O
third,4397,O
month,4397,O
.,4397,O
Sulfonamides,4398,B-Chemical
were,4398,O
associated,4398,O
with,4398,O
anencephaly,4398,B-Disease
(,4398,O
adjusted,4398,O
OR,4398,O
[,4398,O
AOR,4398,O
],4398,O
=,4398,O
3.4,4398,O
;,4398,O
95,4398,O
%,4398,O
confidence,4398,O
interval,4398,O
[,4398,O
CI,4398,O
],4398,O
",",4398,O
1.3-8.8,4398,O
),4398,O
",",4398,O
hypoplastic,4398,B-Disease
left,4398,I-Disease
heart,4398,I-Disease
syndrome,4398,I-Disease
(,4398,O
AOR,4398,O
=,4398,O
3.2,4398,O
;,4398,O
95,4398,O
%,4398,O
CI,4398,O
",",4398,O
1.3-7.6,4398,O
),4398,O
",",4398,O
coarctation,4398,B-Disease
of,4398,I-Disease
the,4398,I-Disease
aorta,4398,I-Disease
(,4398,O
AOR,4398,O
=,4398,O
2.7,4398,O
;,4398,O
95,4398,O
%,4398,O
CI,4398,O
",",4398,O
1.3-5.6,4398,O
),4398,O
",",4398,O
choanal,4398,B-Disease
atresia,4398,I-Disease
(,4398,O
AOR,4398,O
=,4398,O
8.0,4398,O
;,4398,O
95,4398,O
%,4398,O
CI,4398,O
",",4398,O
2.7-23.5,4398,O
),4398,O
",",4398,O
transverse,4398,B-Disease
limb,4398,I-Disease
deficiency,4398,I-Disease
(,4398,O
AOR,4398,O
=,4398,O
2.5,4398,O
;,4398,O
95,4398,O
%,4398,O
CI,4398,O
",",4398,O
1.0-5.9,4398,O
),4398,O
",",4398,O
and,4398,O
diaphragmatic,4398,B-Disease
hernia,4398,I-Disease
(,4398,O
AOR,4398,O
=,4398,O
2.4,4398,O
;,4398,O
95,4398,O
%,4398,O
CI,4398,O
",",4398,O
1.1-5.4,4398,O
),4398,O
.,4398,O
Nitrofurantoins,4399,B-Chemical
were,4399,O
associated,4399,O
with,4399,O
anophthalmia,4399,B-Disease
or,4399,O
microphthalmos,4399,B-Disease
(,4399,O
AOR,4399,O
=,4399,O
3.7,4399,O
;,4399,O
95,4399,O
%,4399,O
CI,4399,O
",",4399,O
1.1-12.2,4399,O
),4399,O
",",4399,O
hypoplastic,4399,B-Disease
left,4399,I-Disease
heart,4399,I-Disease
syndrome,4399,I-Disease
(,4399,O
AOR,4399,O
=,4399,O
4.2,4399,O
;,4399,O
95,4399,O
%,4399,O
CI,4399,O
",",4399,O
1.9-9.1,4399,O
),4399,O
",",4399,O
atrial,4399,B-Disease
septal,4399,I-Disease
defects,4399,I-Disease
(,4399,O
AOR,4399,O
=,4399,O
1.9,4399,O
;,4399,O
95,4399,O
%,4399,O
CI,4399,O
",",4399,O
1.1-3.4,4399,O
),4399,O
",",4399,O
and,4399,O
cleft,4399,B-Disease
lip,4399,I-Disease
with,4399,O
cleft,4399,B-Disease
palate,4399,I-Disease
(,4399,O
AOR,4399,O
=,4399,O
2.1,4399,O
;,4399,O
95,4399,O
%,4399,O
CI,4399,O
",",4399,O
1.2-3.9,4399,O
),4399,O
.,4399,O
Other,4400,O
antibacterial,4400,O
agents,4400,O
that,4400,O
showed,4400,O
associations,4400,O
included,4400,O
erythromycins,4400,B-Chemical
(,4400,O
2,4400,O
defects,4400,O
),4400,O
",",4400,O
penicillins,4400,B-Chemical
(,4400,O
1,4400,O
defect,4400,O
),4400,O
",",4400,O
cephalosporins,4400,B-Chemical
(,4400,O
1,4400,O
defect,4400,O
),4400,O
",",4400,O
and,4400,O
quinolones,4400,B-Chemical
(,4400,O
1,4400,O
defect,4400,O
),4400,O
.,4400,O
CONCLUSIONS,4401,O
:,4401,O
Reassuringly,4401,O
",",4401,O
penicillins,4401,B-Chemical
",",4401,O
erythromycins,4401,B-Chemical
",",4401,O
and,4401,O
cephalosporins,4401,B-Chemical
",",4401,O
although,4401,O
used,4401,O
commonly,4401,O
by,4401,O
pregnant,4401,O
women,4401,O
",",4401,O
were,4401,O
not,4401,O
associated,4401,O
with,4401,O
many,4401,O
birth,4401,B-Disease
defects,4401,I-Disease
.,4401,O
Sulfonamides,4402,B-Chemical
and,4402,O
nitrofurantoins,4402,B-Chemical
were,4402,O
associated,4402,O
with,4402,O
several,4402,O
birth,4402,B-Disease
defects,4402,I-Disease
",",4402,O
indicating,4402,O
a,4402,O
need,4402,O
for,4402,O
additional,4402,O
scrutiny,4402,O
.,4402,O
Differential,4403,O
impact,4403,O
of,4403,O
immune,4403,O
escape,4403,O
mutations,4403,O
G145R,4403,O
and,4403,O
P120T,4403,O
on,4403,O
the,4403,O
replication,4403,O
of,4403,O
lamivudine-resistant,4403,B-Chemical
hepatitis,4403,B-Chemical
B,4403,I-Chemical
virus,4403,I-Chemical
e,4403,I-Chemical
antigen-positive,4403,O
and,4403,O
-negative,4403,O
strains,4403,O
.,4403,O
Immune,4404,O
escape,4404,O
variants,4404,O
of,4404,O
the,4404,O
hepatitis,4404,B-Disease
B,4404,I-Disease
virus,4404,O
(,4404,O
HBV,4404,O
),4404,O
represent,4404,O
an,4404,O
emerging,4404,O
clinical,4404,O
challenge,4404,O
",",4404,O
because,4404,O
they,4404,O
can,4404,O
be,4404,O
associated,4404,O
with,4404,O
vaccine,4404,O
escape,4404,O
",",4404,O
HBV,4404,O
reactivation,4404,O
",",4404,O
and,4404,O
failure,4404,O
of,4404,O
diagnostic,4404,O
tests,4404,O
.,4404,O
Recent,4405,O
data,4405,O
suggest,4405,O
a,4405,O
preferential,4405,O
selection,4405,O
of,4405,O
immune,4405,O
escape,4405,O
mutants,4405,O
in,4405,O
distinct,4405,O
peripheral,4405,O
blood,4405,O
leukocyte,4405,O
compartments,4405,O
of,4405,O
infected,4405,O
individuals,4405,O
.,4405,O
We,4406,O
therefore,4406,O
systematically,4406,O
analyzed,4406,O
the,4406,O
functional,4406,O
impact,4406,O
of,4406,O
the,4406,O
most,4406,O
prevalent,4406,O
immune,4406,O
escape,4406,O
variants,4406,O
",",4406,O
the,4406,O
sG145R,4406,O
and,4406,O
sP120T,4406,O
mutants,4406,O
",",4406,O
on,4406,O
the,4406,O
viral,4406,O
replication,4406,O
efficacy,4406,O
and,4406,O
antiviral,4406,O
drug,4406,O
susceptibility,4406,O
of,4406,O
common,4406,O
treatment-associated,4406,O
mutants,4406,O
with,4406,O
resistance,4406,O
to,4406,O
lamivudine,4406,B-Chemical
(,4406,O
LAM,4406,B-Chemical
),4406,O
and/or,4406,O
HBeAg,4406,B-Chemical
negativity,4406,O
.,4406,O
Replication-competent,4407,O
HBV,4407,O
strains,4407,O
with,4407,O
sG145R,4407,O
or,4407,O
sP120T,4407,O
and,4407,O
LAM,4407,B-Chemical
resistance,4407,O
(,4407,O
rtM204I,4407,O
or,4407,O
rtL180M/rtM204V,4407,O
),4407,O
were,4407,O
generated,4407,O
on,4407,O
an,4407,O
HBeAg-positive,4407,B-Chemical
and,4407,O
an,4407,O
HBeAg-negative,4407,B-Chemical
background,4407,O
with,4407,O
precore,4407,O
(,4407,O
PC,4407,O
),4407,O
and,4407,O
basal,4407,O
core,4407,O
promoter,4407,O
(,4407,O
BCP,4407,O
),4407,O
mutants,4407,O
.,4407,O
The,4408,O
sG145R,4408,O
mutation,4408,O
strongly,4408,O
reduced,4408,O
HBsAg,4408,B-Chemical
levels,4408,O
and,4408,O
was,4408,O
able,4408,O
to,4408,O
fully,4408,O
restore,4408,O
the,4408,O
impaired,4408,O
replication,4408,O
of,4408,O
LAM-resistant,4408,B-Chemical
HBV,4408,O
mutants,4408,O
to,4408,O
the,4408,O
levels,4408,O
of,4408,O
wild-type,4408,O
HBV,4408,O
",",4408,O
and,4408,O
PC,4408,O
or,4408,O
BCP,4408,O
mutations,4408,O
further,4408,O
enhanced,4408,O
viral,4408,O
replication,4408,O
.,4408,O
Although,4409,O
the,4409,O
sP120T,4409,O
substitution,4409,O
also,4409,O
impaired,4409,O
HBsAg,4409,B-Chemical
secretion,4409,O
",",4409,O
it,4409,O
did,4409,O
not,4409,O
enhance,4409,O
the,4409,O
replication,4409,O
of,4409,O
LAM-resistant,4409,B-Chemical
clones,4409,O
.,4409,O
However,4410,O
",",4410,O
the,4410,O
concomitant,4410,O
occurrence,4410,O
of,4410,O
HBeAg,4410,B-Chemical
negativity,4410,O
(,4410,O
PC/BCP,4410,O
),4410,O
",",4410,O
sP120T,4410,O
",",4410,O
and,4410,O
LAM,4410,B-Chemical
resistance,4410,O
resulted,4410,O
in,4410,O
the,4410,O
restoration,4410,O
of,4410,O
replication,4410,O
to,4410,O
levels,4410,O
of,4410,O
wild-type,4410,O
HBV,4410,O
.,4410,O
In,4411,O
all,4411,O
clones,4411,O
with,4411,O
combined,4411,O
immune,4411,O
escape,4411,O
and,4411,O
LAM,4411,B-Chemical
resistance,4411,O
mutations,4411,O
",",4411,O
the,4411,O
nucleotide,4411,B-Chemical
analogues,4411,O
adefovir,4411,B-Chemical
and,4411,O
tenofovir,4411,B-Chemical
remained,4411,O
effective,4411,O
in,4411,O
suppressing,4411,O
viral,4411,O
replication,4411,O
in,4411,O
vitro,4411,O
.,4411,O
These,4412,O
findings,4412,O
reveal,4412,O
the,4412,O
differential,4412,O
impact,4412,O
of,4412,O
immune,4412,O
escape,4412,O
variants,4412,O
on,4412,O
the,4412,O
replication,4412,O
and,4412,O
drug,4412,O
susceptibility,4412,O
of,4412,O
complex,4412,O
HBV,4412,O
mutants,4412,O
",",4412,O
supporting,4412,O
the,4412,O
need,4412,O
of,4412,O
close,4412,O
surveillance,4412,O
and,4412,O
treatment,4412,O
adjustment,4412,O
in,4412,O
response,4412,O
to,4412,O
the,4412,O
selection,4412,O
of,4412,O
distinct,4412,O
mutational,4412,O
patterns,4412,O
.,4412,O
Phenylephrine,4413,B-Chemical
but,4413,O
not,4413,O
ephedrine,4413,B-Chemical
reduces,4413,B-Disease
frontal,4413,I-Disease
lobe,4413,I-Disease
oxygenation,4413,I-Disease
following,4413,O
anesthesia-induced,4413,O
hypotension,4413,B-Disease
.,4413,O
BACKGROUND,4414,O
:,4414,O
Vasopressor,4414,O
agents,4414,O
are,4414,O
used,4414,O
to,4414,O
correct,4414,O
anesthesia-induced,4414,O
hypotension,4414,B-Disease
.,4414,O
We,4415,O
describe,4415,O
the,4415,O
effect,4415,O
of,4415,O
phenylephrine,4415,B-Chemical
and,4415,O
ephedrine,4415,B-Chemical
on,4415,O
frontal,4415,O
lobe,4415,O
oxygenation,4415,O
(,4415,O
S,4415,O
(,4415,O
c,4415,O
),4415,O
O,4415,O
(,4415,O
2,4415,O
),4415,O
),4415,O
following,4415,O
anesthesia-induced,4415,O
hypotension,4415,B-Disease
.,4415,O
METHODS,4416,O
:,4416,O
Following,4416,O
induction,4416,O
of,4416,O
anesthesia,4416,O
by,4416,O
fentanyl,4416,B-Chemical
(,4416,O
0.15,4416,O
mg,4416,O
kg,4416,O
(,4416,O
-1,4416,O
),4416,O
),4416,O
and,4416,O
propofol,4416,B-Chemical
(,4416,O
2.0,4416,O
mg,4416,O
kg,4416,O
(,4416,O
-1,4416,O
),4416,O
),4416,O
",",4416,O
13,4416,O
patients,4416,O
received,4416,O
phenylephrine,4416,B-Chemical
(,4416,O
0.1,4416,O
mg,4416,O
iv,4416,O
),4416,O
and,4416,O
12,4416,O
patients,4416,O
received,4416,O
ephedrine,4416,B-Chemical
(,4416,O
10,4416,O
mg,4416,O
iv,4416,O
),4416,O
to,4416,O
restore,4416,O
mean,4416,O
arterial,4416,O
pressure,4416,O
(,4416,O
MAP,4416,O
),4416,O
.,4416,O
Heart,4417,O
rate,4417,O
(,4417,O
HR,4417,O
),4417,O
",",4417,O
MAP,4417,O
",",4417,O
stroke,4417,B-Disease
volume,4417,O
(,4417,O
SV,4417,O
),4417,O
",",4417,O
cardiac,4417,O
output,4417,O
(,4417,O
CO,4417,O
),4417,O
",",4417,O
and,4417,O
frontal,4417,O
lobe,4417,O
oxygenation,4417,O
(,4417,O
S,4417,O
(,4417,O
c,4417,O
),4417,O
O,4417,O
(,4417,O
2,4417,O
),4417,O
),4417,O
were,4417,O
registered,4417,O
.,4417,O
RESULTS,4418,O
:,4418,O
Induction,4418,O
of,4418,O
anesthesia,4418,O
was,4418,O
followed,4418,O
by,4418,O
a,4418,O
decrease,4418,O
in,4418,O
MAP,4418,O
",",4418,O
HR,4418,O
",",4418,O
SV,4418,O
",",4418,O
and,4418,O
CO,4418,O
concomitant,4418,O
with,4418,O
an,4418,O
elevation,4418,O
in,4418,O
S,4418,O
(,4418,O
c,4418,O
),4418,O
O,4418,O
(,4418,O
2,4418,O
),4418,O
.,4418,O
After,4419,O
administration,4419,O
of,4419,O
phenylephrine,4419,B-Chemical
",",4419,O
MAP,4419,O
increased,4419,O
(,4419,O
51,4419,O
+/-,4419,O
12,4419,O
to,4419,O
81,4419,O
+/-,4419,O
13,4419,O
mmHg,4419,O
;,4419,O
P,4419,O
<,4419,O
0.001,4419,O
;,4419,O
mean,4419,O
+/-,4419,O
SD,4419,O
),4419,O
.,4419,O
However,4420,O
",",4420,O
a,4420,O
14,4420,O
%,4420,O
(,4420,O
from,4420,O
70,4420,O
+/-,4420,O
8,4420,O
%,4420,O
to,4420,O
60,4420,O
+/-,4420,O
7,4420,O
%,4420,O
),4420,O
reduction,4420,O
in,4420,O
S,4420,O
(,4420,O
c,4420,O
),4420,O
O,4420,O
(,4420,O
2,4420,O
),4420,O
(,4420,O
P,4420,O
<,4420,O
0.05,4420,O
),4420,O
followed,4420,O
with,4420,O
no,4420,O
change,4420,O
in,4420,O
CO,4420,O
(,4420,O
3.7,4420,O
+/-,4420,O
1.1,4420,O
to,4420,O
3.4,4420,O
+/-,4420,O
0.9,4420,O
l,4420,O
min,4420,O
(,4420,O
-1,4420,O
),4420,O
),4420,O
.,4420,O
The,4421,O
administration,4421,O
of,4421,O
ephedrine,4421,B-Chemical
led,4421,O
to,4421,O
a,4421,O
similar,4421,O
increase,4421,O
in,4421,O
MAP,4421,O
(,4421,O
53,4421,O
+/-,4421,O
9,4421,O
to,4421,O
79,4421,O
+/-,4421,O
8,4421,O
mmHg,4421,O
;,4421,O
P,4421,O
<,4421,O
0.001,4421,O
),4421,O
",",4421,O
restored,4421,O
CO,4421,O
(,4421,O
3.2,4421,O
+/-,4421,O
1.2,4421,O
to,4421,O
5.0,4421,O
+/-,4421,O
1.3,4421,O
l,4421,O
min,4421,O
(,4421,O
-1,4421,O
),4421,O
),4421,O
",",4421,O
and,4421,O
preserved,4421,O
S,4421,O
(,4421,O
c,4421,O
),4421,O
O,4421,O
(,4421,O
2,4421,O
),4421,O
.,4421,O
CONCLUSIONS,4422,O
:,4422,O
The,4422,O
utilization,4422,O
of,4422,O
phenylephrine,4422,B-Chemical
to,4422,O
correct,4422,O
hypotension,4422,B-Disease
induced,4422,O
by,4422,O
anesthesia,4422,O
has,4422,O
a,4422,O
negative,4422,O
impact,4422,O
on,4422,O
S,4422,O
(,4422,O
c,4422,O
),4422,O
O,4422,O
(,4422,O
2,4422,O
),4422,O
while,4422,O
ephedrine,4422,B-Chemical
maintains,4422,O
frontal,4422,O
lobe,4422,O
oxygenation,4422,O
potentially,4422,O
related,4422,O
to,4422,O
an,4422,O
increase,4422,O
in,4422,O
CO,4422,O
.,4422,O
Prolonged,4423,O
elevation,4423,O
of,4423,O
plasma,4423,O
argatroban,4423,B-Chemical
in,4423,O
a,4423,O
cardiac,4423,O
transplant,4423,O
patient,4423,O
with,4423,O
a,4423,O
suspected,4423,O
history,4423,O
of,4423,O
heparin-induced,4423,B-Chemical
thrombocytopenia,4423,B-Disease
with,4423,O
thrombosis,4423,B-Disease
.,4423,O
BACKGROUND,4424,O
:,4424,O
Direct,4424,O
thrombin,4424,O
inhibitors,4424,O
(,4424,O
DTIs,4424,O
),4424,O
provide,4424,O
an,4424,O
alternative,4424,O
method,4424,O
of,4424,O
anticoagulation,4424,O
for,4424,O
patients,4424,O
with,4424,O
a,4424,O
history,4424,O
of,4424,O
heparin-induced,4424,B-Chemical
thrombocytopenia,4424,B-Disease
(,4424,O
HIT,4424,B-Disease
),4424,O
or,4424,O
HIT,4424,B-Disease
with,4424,O
thrombosis,4424,B-Disease
(,4424,O
HITT,4424,B-Disease
),4424,O
undergoing,4424,O
cardiopulmonary,4424,O
bypass,4424,O
(,4424,O
CPB,4424,O
),4424,O
.,4424,O
In,4425,O
the,4425,O
following,4425,O
report,4425,O
",",4425,O
a,4425,O
65-year-old,4425,O
critically,4425,B-Disease
ill,4425,I-Disease
patient,4425,O
with,4425,O
a,4425,O
suspected,4425,O
history,4425,O
of,4425,O
HITT,4425,B-Disease
was,4425,O
administered,4425,O
argatroban,4425,B-Chemical
for,4425,O
anticoagulation,4425,O
on,4425,O
bypass,4425,O
during,4425,O
heart,4425,O
transplantation,4425,O
.,4425,O
The,4426,O
patient,4426,O
required,4426,O
massive,4426,O
transfusion,4426,O
support,4426,O
(,4426,O
55,4426,O
units,4426,O
of,4426,O
red,4426,O
blood,4426,O
cells,4426,O
",",4426,O
42,4426,O
units,4426,O
of,4426,O
fresh-frozen,4426,O
plasma,4426,O
",",4426,O
40,4426,O
units,4426,O
of,4426,O
cryoprecipitate,4426,O
",",4426,O
40,4426,O
units,4426,O
of,4426,O
platelets,4426,O
",",4426,O
and,4426,O
three,4426,O
doses,4426,O
of,4426,O
recombinant,4426,O
Factor,4426,O
VIIa,4426,O
),4426,O
for,4426,O
severe,4426,O
intraoperative,4426,O
and,4426,O
postoperative,4426,O
bleeding,4426,O
.,4426,O
STUDY,4427,O
DESIGN,4427,O
AND,4427,O
METHODS,4427,O
:,4427,O
Plasma,4427,O
samples,4427,O
from,4427,O
before,4427,O
and,4427,O
after,4427,O
CPB,4427,O
were,4427,O
analyzed,4427,O
postoperatively,4427,O
for,4427,O
argatroban,4427,B-Chemical
concentration,4427,O
using,4427,O
a,4427,O
modified,4427,O
ecarin,4427,O
clotting,4427,O
time,4427,O
(,4427,O
ECT,4427,O
),4427,O
assay,4427,O
.,4427,O
RESULTS,4428,O
:,4428,O
Unexpectedly,4428,O
high,4428,O
concentrations,4428,O
of,4428,O
argatroban,4428,B-Chemical
were,4428,O
measured,4428,O
in,4428,O
these,4428,O
samples,4428,O
(,4428,O
range,4428,O
",",4428,O
0-32,4428,O
microg/mL,4428,O
),4428,O
",",4428,O
and,4428,O
a,4428,O
prolonged,4428,O
plasma,4428,O
argatroban,4428,B-Chemical
half,4428,O
life,4428,O
(,4428,O
t,4428,O
(,4428,O
1/2,4428,O
),4428,O
),4428,O
of,4428,O
514,4428,O
minutes,4428,O
was,4428,O
observed,4428,O
(,4428,O
published,4428,O
elimination,4428,O
t,4428,O
(,4428,O
1/2,4428,O
),4428,O
is,4428,O
39-51,4428,O
minutes,4428,O
[,4428,O
<,4428,O
or,4428,O
=,4428,O
181,4428,O
minutes,4428,O
with,4428,O
hepatic,4428,B-Disease
impairment,4428,I-Disease
],4428,O
),4428,O
.,4428,O
CONCLUSIONS,4429,O
:,4429,O
Correlation,4429,O
of,4429,O
plasma,4429,O
argatroban,4429,B-Chemical
concentration,4429,O
versus,4429,O
the,4429,O
patient,4429,O
's,4429,O
coagulation,4429,O
variables,4429,O
and,4429,O
clinical,4429,O
course,4429,O
suggest,4429,O
that,4429,O
prolonged,4429,O
elevated,4429,O
levels,4429,O
of,4429,O
plasma,4429,O
argatroban,4429,B-Chemical
may,4429,O
have,4429,O
contributed,4429,O
to,4429,O
the,4429,O
patient,4429,O
's,4429,O
extended,4429,O
coagulopathy,4429,B-Disease
.,4429,O
Because,4430,O
DTIs,4430,O
do,4430,O
not,4430,O
have,4430,O
reversal,4430,O
agents,4430,O
",",4430,O
surgical,4430,O
teams,4430,O
and,4430,O
transfusion,4430,O
services,4430,O
should,4430,O
remain,4430,O
aware,4430,O
of,4430,O
the,4430,O
possibility,4430,O
of,4430,O
massive,4430,O
transfusion,4430,O
events,4430,O
during,4430,O
anticoagulation,4430,O
with,4430,O
these,4430,O
agents,4430,O
.,4430,O
This,4431,O
is,4431,O
the,4431,O
first,4431,O
report,4431,O
to,4431,O
measure,4431,O
plasma,4431,O
argatroban,4431,B-Chemical
concentration,4431,O
in,4431,O
the,4431,O
context,4431,O
of,4431,O
CPB,4431,O
and,4431,O
extended,4431,O
coagulopathy,4431,B-Disease
.,4431,O
The,4432,O
effects,4432,O
of,4432,O
the,4432,O
adjunctive,4432,O
bupropion,4432,B-Chemical
on,4432,O
male,4432,O
sexual,4432,B-Disease
dysfunction,4432,I-Disease
induced,4432,O
by,4432,O
a,4432,O
selective,4432,B-Chemical
serotonin,4432,I-Chemical
reuptake,4432,I-Chemical
inhibitor,4432,I-Chemical
:,4432,O
a,4432,O
double-blind,4432,O
placebo-controlled,4432,O
and,4432,O
randomized,4432,O
study,4432,O
.,4432,O
OBJECTIVE,4433,O
:,4433,O
To,4433,O
determine,4433,O
the,4433,O
safety,4433,O
and,4433,O
efficacy,4433,O
of,4433,O
adjunctive,4433,O
bupropion,4433,B-Chemical
sustained-release,4433,O
(,4433,O
SR,4433,O
),4433,O
on,4433,O
male,4433,O
sexual,4433,B-Disease
dysfunction,4433,I-Disease
(,4433,O
SD,4433,B-Disease
),4433,O
induced,4433,O
by,4433,O
a,4433,O
selective,4433,B-Chemical
serotonin,4433,I-Chemical
reuptake,4433,I-Chemical
inhibitor,4433,I-Chemical
(,4433,O
SSRI,4433,B-Chemical
),4433,O
",",4433,O
as,4433,O
SD,4433,B-Disease
is,4433,O
a,4433,O
common,4433,O
side-effect,4433,O
of,4433,O
SSRIs,4433,B-Chemical
and,4433,O
the,4433,O
most,4433,O
effective,4433,O
treatments,4433,O
have,4433,O
yet,4433,O
to,4433,O
be,4433,O
determined,4433,O
.,4433,O
PATIENTS,4434,O
AND,4434,O
METHODS,4434,O
:,4434,O
The,4434,O
randomized,4434,O
sample,4434,O
consisted,4434,O
of,4434,O
234,4434,O
euthymic,4434,O
men,4434,O
who,4434,O
were,4434,O
receiving,4434,O
some,4434,O
type,4434,O
of,4434,O
SSRI,4434,B-Chemical
.,4434,O
The,4435,O
men,4435,O
were,4435,O
randomly,4435,O
assigned,4435,O
to,4435,O
bupropion,4435,B-Chemical
SR,4435,O
(,4435,O
150,4435,O
mg,4435,O
twice,4435,O
daily,4435,O
",",4435,O
117,4435,O
),4435,O
or,4435,O
placebo,4435,O
(,4435,O
twice,4435,O
daily,4435,O
",",4435,O
117,4435,O
),4435,O
for,4435,O
12,4435,O
weeks,4435,O
.,4435,O
Efficacy,4436,O
was,4436,O
evaluated,4436,O
using,4436,O
the,4436,O
Clinical,4436,O
Global,4436,O
Impression-Sexual,4436,O
Function,4436,O
(,4436,O
CGI-SF,4436,O
;,4436,O
the,4436,O
primary,4436,O
outcome,4436,O
measure,4436,O
),4436,O
",",4436,O
the,4436,O
International,4436,O
Index,4436,O
of,4436,O
Erectile,4436,O
Function,4436,O
(,4436,O
IIEF,4436,O
),4436,O
",",4436,O
Arizona,4436,O
Sexual,4436,O
Experience,4436,O
Scale,4436,O
(,4436,O
ASEX,4436,O
),4436,O
",",4436,O
and,4436,O
Erectile,4436,B-Disease
Dysfunction,4436,I-Disease
Inventory,4436,O
of,4436,O
Treatment,4436,O
Satisfaction,4436,O
(,4436,O
EDITS,4436,O
),4436,O
(,4436,O
secondary,4436,O
outcome,4436,O
measures,4436,O
),4436,O
.,4436,O
Participants,4437,O
were,4437,O
followed,4437,O
biweekly,4437,O
during,4437,O
study,4437,O
period,4437,O
.,4437,O
RESULTS,4438,O
:,4438,O
After,4438,O
12,4438,O
weeks,4438,O
of,4438,O
treatment,4438,O
",",4438,O
the,4438,O
mean,4438,O
(,4438,O
sd,4438,O
),4438,O
scores,4438,O
for,4438,O
CGI-SF,4438,O
were,4438,O
significantly,4438,O
lower,4438,O
",",4438,O
i.e,4438,O
.,4438,O
better,4439,O
",",4439,O
in,4439,O
patients,4439,O
on,4439,O
bupropion,4439,B-Chemical
SR,4439,O
",",4439,O
at,4439,O
2.4,4439,O
(,4439,O
1.2,4439,O
),4439,O
",",4439,O
than,4439,O
in,4439,O
the,4439,O
placebo,4439,O
group,4439,O
",",4439,O
at,4439,O
3.9,4439,O
(,4439,O
1.1,4439,O
),4439,O
(,4439,O
P=,4439,O
0.01,4439,O
),4439,O
.,4439,O
Men,4440,O
who,4440,O
received,4440,O
bupropion,4440,B-Chemical
had,4440,O
a,4440,O
significant,4440,O
increase,4440,O
in,4440,O
the,4440,O
total,4440,O
IIEF,4440,O
score,4440,O
(,4440,O
54.4,4440,O
%,4440,O
vs,4440,O
1.2,4440,O
%,4440,O
;,4440,O
P=,4440,O
0.003,4440,O
),4440,O
",",4440,O
and,4440,O
in,4440,O
the,4440,O
five,4440,O
different,4440,O
domains,4440,O
of,4440,O
the,4440,O
IIEF,4440,O
.,4440,O
Total,4441,O
ASEX,4441,O
scores,4441,O
were,4441,O
significantly,4441,O
lower,4441,O
",",4441,O
i.e,4441,O
.,4441,O
better,4442,O
",",4442,O
among,4442,O
men,4442,O
who,4442,O
received,4442,O
bupropion,4442,B-Chemical
than,4442,O
placebo,4442,O
",",4442,O
at,4442,O
15.5,4442,O
(,4442,O
4.3,4442,O
),4442,O
vs,4442,O
21.5,4442,O
(,4442,O
4.7,4442,O
),4442,O
(,4442,O
P=,4442,O
0.002,4442,O
),4442,O
.,4442,O
The,4443,O
EDITS,4443,O
scores,4443,O
were,4443,O
67.4,4443,O
(,4443,O
10.2,4443,O
),4443,O
for,4443,O
the,4443,O
bupropion,4443,B-Chemical
and,4443,O
36.3,4443,O
(,4443,O
11.7,4443,O
),4443,O
for,4443,O
the,4443,O
placebo,4443,O
group,4443,O
(,4443,O
P=,4443,O
0.001,4443,O
),4443,O
.,4443,O
The,4444,O
ASEX,4444,O
score,4444,O
and,4444,O
CGI-SF,4444,O
score,4444,O
were,4444,O
correlated,4444,O
(,4444,O
P=,4444,O
0.003,4444,O
),4444,O
.,4444,O
In,4445,O
linear,4445,O
regression,4445,O
analyses,4445,O
the,4445,O
CGI-SF,4445,O
score,4445,O
was,4445,O
not,4445,O
affected,4445,O
significantly,4445,O
by,4445,O
the,4445,O
duration,4445,O
of,4445,O
SD,4445,B-Disease
",",4445,O
type,4445,O
of,4445,O
SSRI,4445,B-Chemical
used,4445,O
and,4445,O
age,4445,O
.,4445,O
CONCLUSIONS,4446,O
:,4446,O
Bupropion,4446,B-Chemical
is,4446,O
an,4446,O
effective,4446,O
treatment,4446,O
for,4446,O
male,4446,O
SD,4446,B-Disease
induced,4446,O
by,4446,O
SSRIs,4446,B-Chemical
.,4446,O
These,4447,O
results,4447,O
provide,4447,O
empirical,4447,O
support,4447,O
for,4447,O
conducting,4447,O
a,4447,O
further,4447,O
study,4447,O
of,4447,O
bupropion,4447,B-Chemical
.,4447,O
Prevention,4448,O
of,4448,O
seizures,4448,B-Disease
and,4448,O
reorganization,4448,O
of,4448,O
hippocampal,4448,O
functions,4448,O
by,4448,O
transplantation,4448,O
of,4448,O
bone,4448,O
marrow,4448,O
cells,4448,O
in,4448,O
the,4448,O
acute,4448,O
phase,4448,O
of,4448,O
experimental,4448,O
epilepsy,4448,B-Disease
.,4448,O
In,4449,O
this,4449,O
study,4449,O
",",4449,O
we,4449,O
investigated,4449,O
the,4449,O
therapeutic,4449,O
potential,4449,O
of,4449,O
bone,4449,O
marrow,4449,O
mononuclear,4449,O
cells,4449,O
(,4449,O
BMCs,4449,O
),4449,O
in,4449,O
a,4449,O
model,4449,O
of,4449,O
epilepsy,4449,B-Disease
induced,4449,O
by,4449,O
pilocarpine,4449,B-Chemical
in,4449,O
rats,4449,O
.,4449,O
BMCs,4450,O
obtained,4450,O
from,4450,O
green,4450,O
fluorescent,4450,O
protein,4450,O
(,4450,O
GFP,4450,O
),4450,O
transgenic,4450,O
mice,4450,O
or,4450,O
rats,4450,O
were,4450,O
transplanted,4450,O
intravenously,4450,O
after,4450,O
induction,4450,O
of,4450,O
status,4450,B-Disease
epilepticus,4450,I-Disease
(,4450,O
SE,4450,B-Disease
),4450,O
.,4450,O
Spontaneous,4451,B-Disease
recurrent,4451,I-Disease
seizures,4451,I-Disease
(,4451,O
SRS,4451,B-Disease
),4451,O
were,4451,O
monitored,4451,O
using,4451,O
Racine,4451,O
's,4451,O
seizure,4451,B-Disease
severity,4451,O
scale,4451,O
.,4451,O
All,4452,O
of,4452,O
the,4452,O
rats,4452,O
in,4452,O
the,4452,O
saline-treated,4452,O
epileptic,4452,B-Disease
control,4452,O
group,4452,O
developed,4452,O
SRS,4452,B-Disease
",",4452,O
whereas,4452,O
none,4452,O
of,4452,O
the,4452,O
BMC-treated,4452,O
epileptic,4452,B-Disease
animals,4452,O
had,4452,O
seizures,4452,B-Disease
in,4452,O
the,4452,O
short,4452,O
term,4452,O
(,4452,O
15,4452,O
days,4452,O
after,4452,O
transplantation,4452,O
),4452,O
",",4452,O
regardless,4452,O
of,4452,O
the,4452,O
BMC,4452,O
source,4452,O
.,4452,O
Over,4453,O
the,4453,O
long-term,4453,O
chronic,4453,O
phase,4453,O
(,4453,O
120,4453,O
days,4453,O
after,4453,O
transplantation,4453,O
),4453,O
",",4453,O
only,4453,O
25,4453,O
%,4453,O
of,4453,O
BMC-treated,4453,O
epileptic,4453,B-Disease
animals,4453,O
had,4453,O
seizures,4453,B-Disease
",",4453,O
but,4453,O
with,4453,O
a,4453,O
lower,4453,O
frequency,4453,O
and,4453,O
duration,4453,O
compared,4453,O
to,4453,O
the,4453,O
epileptic,4453,B-Disease
control,4453,O
group,4453,O
.,4453,O
The,4454,O
density,4454,O
of,4454,O
hippocampal,4454,O
neurons,4454,O
in,4454,O
the,4454,O
brains,4454,O
of,4454,O
animals,4454,O
treated,4454,O
with,4454,O
BMCs,4454,O
was,4454,O
markedly,4454,O
preserved,4454,O
.,4454,O
At,4455,O
hippocampal,4455,O
Schaeffer,4455,O
collateral-CA1,4455,O
synapses,4455,O
",",4455,O
long-term,4455,O
potentiation,4455,O
was,4455,O
preserved,4455,O
in,4455,O
BMC-transplanted,4455,O
rats,4455,O
compared,4455,O
to,4455,O
epileptic,4455,B-Disease
controls,4455,O
.,4455,O
The,4456,O
donor-derived,4456,O
GFP,4456,O
(,4456,O
+,4456,O
),4456,O
cells,4456,O
were,4456,O
rarely,4456,O
found,4456,O
in,4456,O
the,4456,O
brains,4456,O
of,4456,O
transplanted,4456,O
epileptic,4456,B-Disease
rats,4456,O
.,4456,O
In,4457,O
conclusion,4457,O
",",4457,O
treatment,4457,O
with,4457,O
BMCs,4457,O
can,4457,O
prevent,4457,O
the,4457,O
development,4457,O
of,4457,O
chronic,4457,O
seizures,4457,B-Disease
",",4457,O
reduce,4457,O
neuronal,4457,B-Disease
loss,4457,I-Disease
",",4457,O
and,4457,O
influence,4457,O
the,4457,O
reorganization,4457,O
of,4457,O
the,4457,O
hippocampal,4457,O
neuronal,4457,O
network,4457,O
.,4457,O
Normalizing,4458,O
effects,4458,O
of,4458,O
modafinil,4458,B-Chemical
on,4458,O
sleep,4458,O
in,4458,O
chronic,4458,O
cocaine,4458,B-Chemical
users,4458,O
.,4458,O
OBJECTIVE,4459,O
:,4459,O
The,4459,O
purpose,4459,O
of,4459,O
the,4459,O
present,4459,O
study,4459,O
was,4459,O
to,4459,O
determine,4459,O
the,4459,O
effect,4459,O
of,4459,O
morning-dosed,4459,O
modafinil,4459,B-Chemical
on,4459,O
sleep,4459,O
and,4459,O
daytime,4459,B-Disease
sleepiness,4459,I-Disease
in,4459,O
chronic,4459,O
cocaine,4459,B-Chemical
users,4459,O
.,4459,O
METHOD,4460,O
:,4460,O
Twenty,4460,O
cocaine-dependent,4460,B-Chemical
participants,4460,O
were,4460,O
randomly,4460,O
assigned,4460,O
to,4460,O
receive,4460,O
modafinil,4460,B-Chemical
",",4460,O
400,4460,O
mg,4460,O
(,4460,O
N=10,4460,O
),4460,O
",",4460,O
or,4460,O
placebo,4460,O
(,4460,O
N=10,4460,O
),4460,O
every,4460,O
morning,4460,O
at,4460,O
7:30,4460,O
a.m.,4460,O
for,4460,O
16,4460,O
days,4460,O
in,4460,O
an,4460,O
inpatient,4460,O
",",4460,O
double-blind,4460,O
randomized,4460,O
trial,4460,O
.,4460,O
Participants,4461,O
underwent,4461,O
polysomnographic,4461,O
sleep,4461,O
recordings,4461,O
on,4461,O
days,4461,O
1,4461,O
to,4461,O
3,4461,O
",",4461,O
7,4461,O
to,4461,O
9,4461,O
",",4461,O
and,4461,O
14,4461,O
to,4461,O
16,4461,O
(,4461,O
first,4461,O
",",4461,O
second,4461,O
",",4461,O
and,4461,O
third,4461,O
weeks,4461,O
of,4461,O
abstinence,4461,O
),4461,O
.,4461,O
The,4462,O
Multiple,4462,O
Sleep,4462,O
Latency,4462,O
Test,4462,O
was,4462,O
performed,4462,O
at,4462,O
11:30,4462,O
a.m.,4462,O
",",4462,O
2:00,4462,O
p.m.,4462,O
",",4462,O
and,4462,O
4:30,4462,O
p.m.,4462,O
on,4462,O
days,4462,O
2,4462,O
",",4462,O
8,4462,O
",",4462,O
and,4462,O
15,4462,O
.,4462,O
For,4463,O
comparison,4463,O
of,4463,O
sleep,4463,O
architecture,4463,O
variables,4463,O
",",4463,O
12,4463,O
healthy,4463,O
comparison,4463,O
participants,4463,O
underwent,4463,O
a,4463,O
single,4463,O
night,4463,O
of,4463,O
experimental,4463,O
polysomnography,4463,O
that,4463,O
followed,4463,O
1,4463,O
night,4463,O
of,4463,O
accommodation,4463,O
polysomnography,4463,O
.,4463,O
RESULTS,4464,O
:,4464,O
Progressive,4464,O
abstinence,4464,O
from,4464,O
cocaine,4464,B-Chemical
was,4464,O
associated,4464,O
with,4464,O
worsening,4464,O
of,4464,O
all,4464,O
measured,4464,O
polysomnographic,4464,O
sleep,4464,O
outcomes,4464,O
.,4464,O
Compared,4465,O
with,4465,O
placebo,4465,O
",",4465,O
modafinil,4465,B-Chemical
decreased,4465,O
nighttime,4465,O
sleep,4465,O
latency,4465,O
and,4465,O
increased,4465,O
slow-wave,4465,O
sleep,4465,O
time,4465,O
in,4465,O
cocaine-dependent,4465,B-Chemical
participants,4465,O
.,4465,O
The,4466,O
effect,4466,O
of,4466,O
modafinil,4466,B-Chemical
interacted,4466,O
with,4466,O
the,4466,O
abstinence,4466,O
week,4466,O
and,4466,O
was,4466,O
associated,4466,O
with,4466,O
longer,4466,O
total,4466,O
sleep,4466,O
time,4466,O
and,4466,O
shorter,4466,O
REM,4466,O
sleep,4466,O
latency,4466,O
in,4466,O
the,4466,O
third,4466,O
week,4466,O
of,4466,O
abstinence,4466,O
.,4466,O
Comparison,4467,O
of,4467,O
slow-wave,4467,O
sleep,4467,O
time,4467,O
",",4467,O
total,4467,O
sleep,4467,O
time,4467,O
",",4467,O
and,4467,O
sleep,4467,O
latency,4467,O
in,4467,O
cocaine-dependent,4467,B-Chemical
and,4467,O
healthy,4467,O
participants,4467,O
revealed,4467,O
a,4467,O
normalizing,4467,O
effect,4467,O
of,4467,O
modafinil,4467,B-Chemical
in,4467,O
cocaine-dependent,4467,B-Chemical
participants,4467,O
.,4467,O
Modafinil,4468,B-Chemical
was,4468,O
associated,4468,O
with,4468,O
increased,4468,O
daytime,4468,O
sleep,4468,O
latency,4468,O
",",4468,O
as,4468,O
measured,4468,O
by,4468,O
the,4468,O
Multiple,4468,O
Sleep,4468,O
Latency,4468,O
Test,4468,O
",",4468,O
and,4468,O
a,4468,O
nearly,4468,O
significant,4468,O
decrease,4468,O
in,4468,O
subjective,4468,O
daytime,4468,B-Disease
sleepiness,4468,I-Disease
.,4468,O
CONCLUSIONS,4469,O
:,4469,O
Morning-dosed,4469,O
modafinil,4469,B-Chemical
promotes,4469,O
nocturnal,4469,O
sleep,4469,O
",",4469,O
normalizes,4469,O
sleep,4469,O
architecture,4469,O
",",4469,O
and,4469,O
decreases,4469,O
daytime,4469,B-Disease
sleepiness,4469,I-Disease
in,4469,O
abstinent,4469,O
cocaine,4469,B-Chemical
users,4469,O
.,4469,O
These,4470,O
effects,4470,O
may,4470,O
be,4470,O
relevant,4470,O
in,4470,O
the,4470,O
treatment,4470,O
of,4470,O
cocaine,4470,B-Chemical
dependence,4470,O
.,4470,O
Safety,4471,O
of,4471,O
transesophageal,4471,O
echocardiography,4471,O
in,4471,O
adults,4471,O
:,4471,O
study,4471,O
in,4471,O
a,4471,O
multidisciplinary,4471,O
hospital,4471,O
.,4471,O
BACKGROUND,4472,O
:,4472,O
TEE,4472,O
is,4472,O
a,4472,O
semi-invasive,4472,O
tool,4472,O
broadly,4472,O
used,4472,O
and,4472,O
its,4472,O
utilization,4472,O
associated,4472,O
to,4472,O
sedatives,4472,O
drugs,4472,O
might,4472,O
to,4472,O
affect,4472,O
the,4472,O
procedure,4472,O
safety,4472,O
.,4472,O
OBJECTIVE,4473,O
:,4473,O
to,4473,O
analyze,4473,O
aspects,4473,O
of,4473,O
TEE,4473,O
safety,4473,O
associated,4473,O
to,4473,O
the,4473,O
use,4473,O
of,4473,O
Midazolan,4473,B-Chemical
(,4473,O
MZ,4473,B-Chemical
),4473,O
and,4473,O
Flumazenil,4473,B-Chemical
(,4473,O
FL,4473,B-Chemical
),4473,O
and,4473,O
the,4473,O
influence,4473,O
of,4473,O
the,4473,O
clinical,4473,O
variables,4473,O
on,4473,O
the,4473,O
event,4473,O
rate,4473,O
.,4473,O
METHOD,4474,O
:,4474,O
prospective,4474,O
study,4474,O
with,4474,O
137,4474,O
patients,4474,O
that,4474,O
underwent,4474,O
TEE,4474,O
with,4474,O
MZ,4474,B-Chemical
associated,4474,O
to,4474,O
moderate,4474,O
sedation,4474,O
.,4474,O
We,4475,O
analyzed,4475,O
the,4475,O
following,4475,O
events,4475,O
:,4475,O
complications,4475,O
related,4475,O
with,4475,O
the,4475,O
topical,4475,O
anesthesia,4475,O
",",4475,O
with,4475,O
MZ,4475,B-Chemical
use,4475,O
and,4475,O
with,4475,O
the,4475,O
procedure,4475,O
.,4475,O
Uni-,4476,O
and,4476,O
multivariate,4476,O
analyses,4476,O
were,4476,O
used,4476,O
to,4476,O
test,4476,O
the,4476,O
influence,4476,O
of,4476,O
the,4476,O
clinical,4476,O
variables,4476,O
:,4476,O
age,4476,O
",",4476,O
sex,4476,O
",",4476,O
stroke,4476,B-Disease
",",4476,O
myocardiopathy,4476,B-Disease
(,4476,O
MP,4476,B-Disease
),4476,O
",",4476,O
duration,4476,O
of,4476,O
the,4476,O
test,4476,O
",",4476,O
mitral,4476,B-Disease
regurgitation,4476,I-Disease
(,4476,O
MR,4476,B-Disease
),4476,O
and,4476,O
the,4476,O
MZ,4476,B-Chemical
dose,4476,O
.,4476,O
RESULTS,4477,O
:,4477,O
All,4477,O
patients,4477,O
(,4477,O
65+/-16,4477,O
yrs,4477,O
;,4477,O
58,4477,O
%,4477,O
males,4477,O
),4477,O
finished,4477,O
the,4477,O
examination,4477,O
.,4477,O
The,4478,O
mean,4478,O
doses,4478,O
of,4478,O
MZ,4478,B-Chemical
and,4478,O
FL,4478,B-Chemical
were,4478,O
4.3+/-1.9,4478,O
mg,4478,O
and,4478,O
0.28+/-0.2,4478,O
mg,4478,O
",",4478,O
respectively,4478,O
.,4478,O
The,4479,O
duration,4479,O
of,4479,O
the,4479,O
examination,4479,O
and,4479,O
the,4479,O
mean,4479,O
ejection,4479,O
fraction,4479,O
(,4479,O
EF,4479,O
),4479,O
were,4479,O
16.4+/-6.1,4479,O
minutes,4479,O
and,4479,O
60+/-9,4479,O
%,4479,O
",",4479,O
respectively,4479,O
.,4479,O
Mild,4480,O
hypoxia,4480,B-Disease
(,4480,O
SO2,4480,O
<,4480,O
90,4480,O
%,4480,O
),4480,O
was,4480,O
the,4480,O
most,4480,O
common,4480,O
event,4480,O
(,4480,O
11,4480,O
patients,4480,O
),4480,O
;,4480,O
3,4480,O
patients,4480,O
(,4480,O
2,4480,O
%,4480,O
),4480,O
presented,4480,O
transient,4480,O
hypoxia,4480,B-Disease
due,4480,O
to,4480,O
upper,4480,O
airway,4480,B-Disease
obstruction,4480,I-Disease
by,4480,O
probe,4480,O
introduction,4480,O
and,4480,O
8,4480,O
(,4480,O
5.8,4480,O
%,4480,O
),4480,O
due,4480,O
to,4480,O
hypoxia,4480,B-Disease
caused,4480,O
by,4480,O
MZ,4480,B-Chemical
use,4480,O
.,4480,O
Transient,4481,O
hypotension,4481,B-Disease
(,4481,O
SAP,4481,O
<,4481,O
90mmHg,4481,O
),4481,O
occurred,4481,O
in,4481,O
1,4481,O
patient,4481,O
(,4481,O
0.7,4481,O
%,4481,O
),4481,O
.,4481,O
The,4482,O
multivariate,4482,O
analysis,4482,O
showed,4482,O
that,4482,O
severe,4482,O
MR,4482,B-Disease
",",4482,O
MP,4482,B-Disease
(,4482,O
EF,4482,O
<,4482,O
45,4482,O
%,4482,O
),4482,O
and,4482,O
high,4482,O
doses,4482,O
of,4482,O
MZ,4482,B-Chemical
(,4482,O
>,4482,O
5mg,4482,O
),4482,O
were,4482,O
associated,4482,O
with,4482,O
events,4482,O
(,4482,O
p,4482,O
<,4482,O
0.001,4482,O
),4482,O
.,4482,O
The,4483,O
EF,4483,O
was,4483,O
40,4483,O
%,4483,O
",",4483,O
in,4483,O
the,4483,O
group,4483,O
with,4483,O
MP,4483,B-Disease
and,4483,O
44,4483,O
%,4483,O
in,4483,O
the,4483,O
group,4483,O
with,4483,O
severe,4483,O
MR,4483,B-Disease
and,4483,O
it,4483,O
can,4483,O
be,4483,O
a,4483,O
factor,4483,O
associated,4483,O
with,4483,O
clinical,4483,O
events,4483,O
in,4483,O
the,4483,O
last,4483,O
group,4483,O
.,4483,O
CONCLUSION,4484,O
:,4484,O
TEE,4484,O
with,4484,O
sedation,4484,O
presents,4484,O
a,4484,O
low,4484,O
rate,4484,O
of,4484,O
events,4484,O
.,4484,O
There,4485,O
were,4485,O
no,4485,O
severe,4485,O
events,4485,O
and,4485,O
there,4485,O
was,4485,O
no,4485,O
need,4485,O
to,4485,O
interrupt,4485,O
the,4485,O
examinations,4485,O
.,4485,O
Oral,4486,O
manifestations,4486,O
of,4486,O
``,4486,O
meth,4486,B-Disease
mouth,4486,I-Disease
'',4486,O
:,4486,O
a,4486,O
case,4486,O
report,4486,O
.,4486,O
AIM,4487,O
:,4487,O
The,4487,O
aim,4487,O
of,4487,O
the,4487,O
documentation,4487,O
of,4487,O
this,4487,O
clinical,4487,O
case,4487,O
is,4487,O
to,4487,O
make,4487,O
clinicians,4487,O
aware,4487,O
of,4487,O
``,4487,O
meth,4487,B-Disease
mouth,4487,I-Disease
'',4487,O
and,4487,O
the,4487,O
medical,4487,O
risks,4487,O
associated,4487,O
with,4487,O
this,4487,O
serious,4487,O
condition,4487,O
.,4487,O
BACKGROUND,4488,O
:,4488,O
Methamphetamine,4488,B-Chemical
is,4488,O
a,4488,O
very,4488,O
addictive,4488,O
",",4488,O
powerful,4488,O
stimulant,4488,O
that,4488,O
increases,4488,O
wakefulness,4488,O
and,4488,O
physical,4488,O
activity,4488,O
and,4488,O
can,4488,O
produce,4488,O
other,4488,O
effects,4488,O
such,4488,O
as,4488,O
cardiac,4488,B-Disease
dysrhythmias,4488,I-Disease
",",4488,O
hypertension,4488,B-Disease
",",4488,O
hallucinations,4488,B-Disease
",",4488,O
and,4488,O
violent,4488,B-Disease
behavior,4488,I-Disease
.,4488,O
Dental,4489,O
patients,4489,O
abusing,4489,O
methamphetamine,4489,B-Chemical
can,4489,O
present,4489,O
with,4489,O
poor,4489,O
oral,4489,O
hygiene,4489,O
",",4489,O
xerostomia,4489,B-Disease
",",4489,O
rampant,4489,O
caries,4489,B-Disease
(,4489,O
``,4489,O
meth,4489,B-Chemical
mouth,4489,I-Disease
'',4489,O
),4489,O
",",4489,O
and,4489,O
excessive,4489,O
tooth,4489,B-Disease
wear,4489,I-Disease
.,4489,O
Oral,4490,O
rehabilitation,4490,O
of,4490,O
patients,4490,O
using,4490,O
methamphetamine,4490,B-Chemical
can,4490,O
be,4490,O
challenging,4490,O
.,4490,O
CASE,4491,O
DESCRIPTION,4491,O
:,4491,O
A,4491,O
30-year-old,4491,O
Caucasian,4491,O
woman,4491,O
presented,4491,O
with,4491,O
dental,4491,O
pain,4491,B-Disease
",",4491,O
bad,4491,B-Disease
breath,4491,I-Disease
",",4491,O
and,4491,O
self-reported,4491,O
poor,4491,O
esthetics,4491,O
.,4491,O
A,4492,O
comprehensive,4492,O
examination,4492,O
including,4492,O
her,4492,O
medical,4492,O
history,4492,O
",",4492,O
panoramic,4492,O
radiograph,4492,O
",",4492,O
and,4492,O
intraoral,4492,O
examination,4492,O
revealed,4492,O
19,4492,O
carious,4492,B-Disease
lesions,4492,I-Disease
",",4492,O
which,4492,O
is,4492,O
not,4492,O
very,4492,O
common,4492,O
for,4492,O
a,4492,O
healthy,4492,O
adult,4492,O
.,4492,O
She,4493,O
reported,4493,O
her,4493,O
use,4493,O
of,4493,O
methamphetamine,4493,B-Chemical
for,4493,O
five,4493,O
years,4493,O
and,4493,O
had,4493,O
not,4493,O
experienced,4493,O
any,4493,O
major,4493,O
carious,4493,B-Disease
episodes,4493,I-Disease
before,4493,O
she,4493,O
started,4493,O
using,4493,O
the,4493,O
drug,4493,O
.,4493,O
SUMMARY,4494,O
:,4494,O
The,4494,O
patient,4494,O
's,4494,O
medical,4494,O
and,4494,O
dental,4494,O
histories,4494,O
along,4494,O
with,4494,O
radiographic,4494,O
and,4494,O
clinical,4494,O
findings,4494,O
lead,4494,O
to,4494,O
a,4494,O
diagnosis,4494,O
of,4494,O
``,4494,O
meth,4494,B-Disease
mouth,4494,I-Disease
.,4494,O
'',4494,O
Although,4495,O
three,4495,O
different,4495,O
dental,4495,O
treatment,4495,O
modalities,4495,O
(,4495,O
either,4495,O
conventional,4495,O
or,4495,O
implant-supported,4495,O
),4495,O
have,4495,O
been,4495,O
offered,4495,O
to,4495,O
the,4495,O
patient,4495,O
since,4495,O
August,4495,O
2007,4495,O
",",4495,O
the,4495,O
patient,4495,O
has,4495,O
yet,4495,O
to,4495,O
initiate,4495,O
any,4495,O
treatment,4495,O
.,4495,O
CLINICAL,4496,O
SIGNIFICANCE,4496,O
:,4496,O
This,4496,O
clinical,4496,O
case,4496,O
showing,4496,O
oral,4496,O
manifestations,4496,O
of,4496,O
meth,4496,B-Disease
mouth,4496,I-Disease
was,4496,O
presented,4496,O
to,4496,O
help,4496,O
dental,4496,O
practitioners,4496,O
recognize,4496,O
and,4496,O
manage,4496,O
patients,4496,O
who,4496,O
may,4496,O
be,4496,O
abusing,4496,O
methamphetamines,4496,B-Chemical
.,4496,O
Dental,4497,O
practitioners,4497,O
also,4497,O
may,4497,O
be,4497,O
skeptical,4497,O
about,4497,O
the,4497,O
reliability,4497,O
of,4497,O
appointment,4497,O
keeping,4497,O
by,4497,O
these,4497,O
patients,4497,O
",",4497,O
as,4497,O
they,4497,O
frequently,4497,O
miss,4497,O
their,4497,O
appointments,4497,O
without,4497,O
reasonable,4497,O
justification,4497,O
.,4497,O
Antituberculosis,4498,B-Chemical
therapy-induced,4498,O
acute,4498,B-Disease
liver,4498,I-Disease
failure,4498,I-Disease
:,4498,O
magnitude,4498,O
",",4498,O
profile,4498,O
",",4498,O
prognosis,4498,O
",",4498,O
and,4498,O
predictors,4498,O
of,4498,O
outcome,4498,O
.,4498,O
Antituberculosis,4499,B-Chemical
therapy,4499,O
(,4499,O
ATT,4499,O
),4499,O
-associated,4499,O
acute,4499,B-Disease
liver,4499,I-Disease
failure,4499,I-Disease
(,4499,O
ATT-ALF,4499,O
),4499,O
is,4499,O
the,4499,O
commonest,4499,O
drug-induced,4499,O
ALF,4499,B-Disease
in,4499,O
South,4499,O
Asia,4499,O
.,4499,O
Prospective,4500,O
studies,4500,O
on,4500,O
ATT-ALF,4500,O
are,4500,O
lacking,4500,O
.,4500,O
The,4501,O
current,4501,O
study,4501,O
prospectively,4501,O
evaluated,4501,O
the,4501,O
magnitude,4501,O
",",4501,O
clinical,4501,O
course,4501,O
",",4501,O
outcome,4501,O
",",4501,O
and,4501,O
prognostic,4501,O
factors,4501,O
in,4501,O
ATT-ALF,4501,O
.,4501,O
From,4502,O
January,4502,O
1986,4502,O
to,4502,O
January,4502,O
2009,4502,O
",",4502,O
1223,4502,O
consecutive,4502,O
ALF,4502,B-Disease
patients,4502,O
were,4502,O
evaluated,4502,O
:,4502,O
ATT,4502,O
alone,4502,O
was,4502,O
the,4502,O
cause,4502,O
in,4502,O
70,4502,O
(,4502,O
5.7,4502,O
%,4502,O
),4502,O
patients,4502,O
.,4502,O
Another,4503,O
15,4503,O
(,4503,O
1.2,4503,O
%,4503,O
),4503,O
had,4503,O
ATT,4503,O
and,4503,O
simultaneous,4503,O
hepatitis,4503,B-Disease
virus,4503,I-Disease
infection,4503,I-Disease
.,4503,O
In,4504,O
44,4504,O
(,4504,O
62.8,4504,O
%,4504,O
),4504,O
patients,4504,O
",",4504,O
ATT,4504,O
was,4504,O
prescribed,4504,O
empirically,4504,O
without,4504,O
definitive,4504,O
evidence,4504,O
of,4504,O
tuberculosis,4504,B-Disease
.,4504,O
ATT-ALF,4505,O
patients,4505,O
were,4505,O
younger,4505,O
(,4505,O
32.87,4505,O
[,4505,O
+/-15.8,4505,O
],4505,O
years,4505,O
),4505,O
",",4505,O
and,4505,O
49,4505,O
(,4505,O
70,4505,O
%,4505,O
),4505,O
of,4505,O
them,4505,O
were,4505,O
women,4505,O
.,4505,O
Most,4506,O
had,4506,O
hyperacute,4506,O
presentation,4506,O
;,4506,O
the,4506,O
median,4506,O
icterus,4506,B-Disease
encephalopathy,4506,B-Disease
interval,4506,O
was,4506,O
4.5,4506,O
(,4506,O
0-30,4506,O
),4506,O
days,4506,O
.,4506,O
The,4507,O
median,4507,O
duration,4507,O
of,4507,O
ATT,4507,O
before,4507,O
ALF,4507,B-Disease
was,4507,O
30,4507,O
(,4507,O
7-350,4507,O
),4507,O
days,4507,O
.,4507,O
At,4508,O
presentation,4508,O
",",4508,O
advanced,4508,O
encephalopathy,4508,B-Disease
and,4508,O
cerebral,4508,B-Disease
edema,4508,I-Disease
were,4508,O
present,4508,O
in,4508,O
51,4508,O
(,4508,O
76,4508,O
%,4508,O
),4508,O
and,4508,O
29,4508,O
(,4508,O
41.4,4508,O
%,4508,O
),4508,O
patients,4508,O
",",4508,O
respectively,4508,O
.,4508,O
Gastrointestinal,4509,B-Disease
bleed,4509,I-Disease
",",4509,O
seizures,4509,B-Disease
",",4509,O
infection,4509,B-Disease
",",4509,O
and,4509,O
acute,4509,B-Disease
renal,4509,I-Disease
failure,4509,I-Disease
were,4509,O
documented,4509,O
in,4509,O
seven,4509,O
(,4509,O
10,4509,O
%,4509,O
),4509,O
",",4509,O
five,4509,O
(,4509,O
7.1,4509,O
%,4509,O
),4509,O
",",4509,O
26,4509,O
(,4509,O
37.1,4509,O
%,4509,O
),4509,O
",",4509,O
and,4509,O
seven,4509,O
(,4509,O
10,4509,O
%,4509,O
),4509,O
patients,4509,O
",",4509,O
respectively,4509,O
.,4509,O
Compared,4510,O
with,4510,O
hepatitis,4510,B-Disease
E,4510,I-Disease
virus,4510,O
(,4510,O
HEV,4510,O
),4510,O
and,4510,O
non-A,4510,O
non-E-induced,4510,O
ALF,4510,B-Disease
",",4510,O
ATT-ALF,4510,O
patients,4510,O
had,4510,O
nearly,4510,O
similar,4510,O
presentations,4510,O
except,4510,O
for,4510,O
older,4510,O
age,4510,O
and,4510,O
less,4510,O
elevation,4510,O
of,4510,O
liver,4510,O
enzymes,4510,O
.,4510,O
The,4511,O
mortality,4511,O
rate,4511,O
among,4511,O
patients,4511,O
with,4511,O
ATT-ALF,4511,O
was,4511,O
high,4511,O
(,4511,O
67.1,4511,O
%,4511,O
",",4511,O
n,4511,O
=,4511,O
47,4511,O
),4511,O
",",4511,O
and,4511,O
only,4511,O
23,4511,O
(,4511,O
32.9,4511,O
%,4511,O
),4511,O
patients,4511,O
recovered,4511,O
with,4511,O
medical,4511,O
treatment,4511,O
.,4511,O
In,4512,O
multivariate,4512,O
analysis,4512,O
",",4512,O
three,4512,O
factors,4512,O
independently,4512,O
predicted,4512,O
mortality,4512,O
:,4512,O
serum,4512,O
bilirubin,4512,B-Chemical
(,4512,O
>,4512,O
or=10.8,4512,O
mg/dL,4512,O
),4512,O
",",4512,O
prothrombin,4512,O
time,4512,O
(,4512,O
PT,4512,O
),4512,O
prolongation,4512,O
(,4512,O
>,4512,O
or=26,4512,O
seconds,4512,O
),4512,O
",",4512,O
and,4512,O
grade,4512,O
III/IV,4512,O
encephalopathy,4512,B-Disease
at,4512,O
presentation,4512,O
.,4512,O
CONCLUSION,4513,O
:,4513,O
ATT-ALF,4513,O
constituted,4513,O
5.7,4513,O
%,4513,O
of,4513,O
ALF,4513,B-Disease
at,4513,O
our,4513,O
center,4513,O
and,4513,O
had,4513,O
a,4513,O
high,4513,O
mortality,4513,O
rate,4513,O
.,4513,O
Because,4514,O
the,4514,O
mortality,4514,O
rate,4514,O
is,4514,O
so,4514,O
high,4514,O
",",4514,O
determining,4514,O
which,4514,O
factors,4514,O
are,4514,O
predictors,4514,O
is,4514,O
less,4514,O
important,4514,O
.,4514,O
A,4515,O
high,4515,O
proportion,4515,O
of,4515,O
patients,4515,O
had,4515,O
consumed,4515,O
ATT,4515,O
empirically,4515,O
",",4515,O
which,4515,O
could,4515,O
have,4515,O
been,4515,O
prevented,4515,O
.,4515,O
Central,4516,B-Disease
nervous,4516,I-Disease
system,4516,I-Disease
complications,4516,I-Disease
during,4516,O
treatment,4516,O
of,4516,O
acute,4516,B-Disease
lymphoblastic,4516,I-Disease
leukemia,4516,I-Disease
in,4516,O
a,4516,O
single,4516,O
pediatric,4516,O
institution,4516,O
.,4516,O
Central,4517,B-Disease
nervous,4517,I-Disease
system,4517,I-Disease
(,4517,I-Disease
CNS,4517,I-Disease
),4517,I-Disease
complications,4517,I-Disease
during,4517,O
treatment,4517,O
of,4517,O
childhood,4517,O
acute,4517,B-Disease
lymphoblastic,4517,I-Disease
leukemia,4517,I-Disease
(,4517,O
ALL,4517,B-Disease
),4517,O
remain,4517,O
a,4517,O
challenging,4517,O
clinical,4517,O
problem,4517,O
.,4517,O
Outcome,4518,O
improvement,4518,O
with,4518,O
more,4518,O
intensive,4518,O
chemotherapy,4518,O
has,4518,O
significantly,4518,O
increased,4518,O
the,4518,O
incidence,4518,O
and,4518,O
severity,4518,O
of,4518,O
adverse,4518,O
events,4518,O
.,4518,O
This,4519,O
study,4519,O
analyzed,4519,O
the,4519,O
incidence,4519,O
of,4519,O
neurological,4519,B-Disease
complications,4519,I-Disease
during,4519,O
ALL,4519,B-Disease
treatment,4519,O
in,4519,O
a,4519,O
single,4519,O
pediatric,4519,O
institution,4519,O
",",4519,O
focusing,4519,O
on,4519,O
clinical,4519,O
",",4519,O
radiological,4519,O
",",4519,O
and,4519,O
electrophysiological,4519,O
findings,4519,O
.,4519,O
Exclusion,4520,O
criteria,4520,O
included,4520,O
CNS,4520,O
leukemic,4520,B-Disease
infiltration,4520,I-Disease
at,4520,O
diagnosis,4520,O
",",4520,O
therapy-related,4520,O
peripheral,4520,B-Disease
neuropathy,4520,I-Disease
",",4520,O
late-onset,4520,O
encephalopathy,4520,B-Disease
",",4520,O
or,4520,O
long-term,4520,O
neurocognitive,4520,B-Disease
defects,4520,I-Disease
.,4520,O
During,4521,O
a,4521,O
9-year,4521,O
period,4521,O
",",4521,O
we,4521,O
retrospectively,4521,O
collected,4521,O
27,4521,O
neurological,4521,O
events,4521,O
(,4521,O
11,4521,O
%,4521,O
),4521,O
in,4521,O
as,4521,O
many,4521,O
patients,4521,O
",",4521,O
from,4521,O
253,4521,O
children,4521,O
enrolled,4521,O
in,4521,O
the,4521,O
ALL,4521,B-Disease
front-line,4521,O
protocol,4521,O
.,4521,O
CNS,4522,O
complications,4522,O
included,4522,O
posterior,4522,O
reversible,4522,O
leukoencephalopathy,4522,B-Disease
syndrome,4522,O
(,4522,O
n,4522,O
=,4522,O
10,4522,O
),4522,O
",",4522,O
stroke,4522,B-Disease
(,4522,O
n,4522,O
=,4522,O
5,4522,O
),4522,O
",",4522,O
temporal,4522,B-Disease
lobe,4522,I-Disease
epilepsy,4522,I-Disease
(,4522,O
n,4522,O
=,4522,O
2,4522,O
),4522,O
",",4522,O
high-dose,4522,O
methotrexate,4522,B-Chemical
toxicity,4522,B-Disease
(,4522,O
n,4522,O
=,4522,O
2,4522,O
),4522,O
",",4522,O
syndrome,4522,O
of,4522,O
inappropriate,4522,B-Disease
antidiuretic,4522,I-Disease
hormone,4522,I-Disease
secretion,4522,I-Disease
(,4522,O
n,4522,O
=,4522,O
1,4522,O
),4522,O
",",4522,O
and,4522,O
other,4522,O
unclassified,4522,O
events,4522,O
(,4522,O
n,4522,O
=,4522,O
7,4522,O
),4522,O
.,4522,O
In,4523,O
conclusion,4523,O
",",4523,O
CNS,4523,O
complications,4523,O
are,4523,O
frequent,4523,O
events,4523,O
during,4523,O
ALL,4523,B-Disease
therapy,4523,O
",",4523,O
and,4523,O
require,4523,O
rapid,4523,O
detection,4523,O
and,4523,O
prompt,4523,O
treatment,4523,O
to,4523,O
limit,4523,O
permanent,4523,O
damage,4523,O
.,4523,O
Cocaine,4524,B-Chemical
causes,4524,O
memory,4524,O
and,4524,O
learning,4524,O
impairments,4524,O
in,4524,O
rats,4524,O
:,4524,O
involvement,4524,O
of,4524,O
nuclear,4524,O
factor,4524,O
kappa,4524,O
B,4524,O
and,4524,O
oxidative,4524,O
stress,4524,O
",",4524,O
and,4524,O
prevention,4524,O
by,4524,O
topiramate,4524,B-Chemical
.,4524,O
Different,4525,O
mechanisms,4525,O
have,4525,O
been,4525,O
suggested,4525,O
for,4525,O
cocaine,4525,B-Chemical
toxicity,4525,B-Disease
including,4525,O
an,4525,O
increase,4525,O
in,4525,O
oxidative,4525,O
stress,4525,O
but,4525,O
the,4525,O
association,4525,O
between,4525,O
oxidative,4525,O
status,4525,O
in,4525,O
the,4525,O
brain,4525,O
and,4525,O
cocaine,4525,B-Chemical
induced-behaviour,4525,O
is,4525,O
poorly,4525,O
understood,4525,O
.,4525,O
Nuclear,4526,O
factor,4526,O
kappa,4526,O
B,4526,O
(,4526,O
NFkappaB,4526,O
),4526,O
is,4526,O
a,4526,O
sensor,4526,O
of,4526,O
oxidative,4526,O
stress,4526,O
and,4526,O
participates,4526,O
in,4526,O
memory,4526,O
formation,4526,O
that,4526,O
could,4526,O
be,4526,O
involved,4526,O
in,4526,O
drug,4526,O
toxicity,4526,B-Disease
and,4526,O
addiction,4526,O
mechanisms,4526,O
.,4526,O
Therefore,4527,O
NFkappaB,4527,O
activity,4527,O
",",4527,O
oxidative,4527,O
stress,4527,O
",",4527,O
neuronal,4527,O
nitric,4527,B-Chemical
oxide,4527,I-Chemical
synthase,4527,O
(,4527,O
nNOS,4527,O
),4527,O
activity,4527,O
",",4527,O
spatial,4527,O
learning,4527,O
and,4527,O
memory,4527,O
as,4527,O
well,4527,O
as,4527,O
the,4527,O
effect,4527,O
of,4527,O
topiramate,4527,B-Chemical
",",4527,O
a,4527,O
previously,4527,O
proposed,4527,O
therapy,4527,O
for,4527,O
cocaine,4527,B-Disease
addiction,4527,I-Disease
",",4527,O
were,4527,O
evaluated,4527,O
in,4527,O
an,4527,O
experimental,4527,O
model,4527,O
of,4527,O
cocaine,4527,B-Chemical
administration,4527,O
in,4527,O
rats,4527,O
.,4527,O
NFkappaB,4528,O
activity,4528,O
was,4528,O
decreased,4528,O
in,4528,O
the,4528,O
frontal,4528,O
cortex,4528,O
of,4528,O
cocaine,4528,B-Chemical
treated,4528,O
rats,4528,O
",",4528,O
as,4528,O
well,4528,O
as,4528,O
GSH,4528,B-Chemical
concentration,4528,O
and,4528,O
glutathione,4528,B-Chemical
peroxidase,4528,O
activity,4528,O
in,4528,O
the,4528,O
hippocampus,4528,O
",",4528,O
whereas,4528,O
nNOS,4528,O
activity,4528,O
in,4528,O
the,4528,O
hippocampus,4528,O
was,4528,O
increased,4528,O
.,4528,O
Memory,4529,O
retrieval,4529,O
of,4529,O
experiences,4529,O
acquired,4529,O
prior,4529,O
to,4529,O
cocaine,4529,B-Chemical
administration,4529,O
was,4529,O
impaired,4529,O
and,4529,O
negatively,4529,O
correlated,4529,O
with,4529,O
NFkappaB,4529,O
activity,4529,O
in,4529,O
the,4529,O
frontal,4529,O
cortex,4529,O
.,4529,O
In,4530,O
contrast,4530,O
",",4530,O
learning,4530,O
of,4530,O
new,4530,O
tasks,4530,O
was,4530,O
enhanced,4530,O
and,4530,O
correlated,4530,O
with,4530,O
the,4530,O
increase,4530,O
of,4530,O
nNOS,4530,O
activity,4530,O
and,4530,O
the,4530,O
decrease,4530,O
of,4530,O
glutathione,4530,B-Chemical
peroxidase,4530,O
.,4530,O
These,4531,O
results,4531,O
provide,4531,O
evidence,4531,O
for,4531,O
a,4531,O
possible,4531,O
mechanistic,4531,O
role,4531,O
of,4531,O
oxidative,4531,O
and,4531,O
nitrosative,4531,O
stress,4531,O
and,4531,O
NFkappaB,4531,O
in,4531,O
the,4531,O
alterations,4531,O
induced,4531,O
by,4531,O
cocaine,4531,B-Chemical
.,4531,O
Topiramate,4532,B-Chemical
prevented,4532,O
all,4532,O
the,4532,O
alterations,4532,O
observed,4532,O
",",4532,O
showing,4532,O
novel,4532,O
neuroprotective,4532,O
properties,4532,O
.,4532,O
Efficacy,4533,O
and,4533,O
safety,4533,O
of,4533,O
asenapine,4533,B-Chemical
in,4533,O
a,4533,O
placebo-,4533,O
and,4533,O
haloperidol-controlled,4533,B-Chemical
trial,4533,O
in,4533,O
patients,4533,O
with,4533,O
acute,4533,O
exacerbation,4533,O
of,4533,O
schizophrenia,4533,B-Disease
.,4533,O
Asenapine,4534,B-Chemical
is,4534,O
approved,4534,O
by,4534,O
the,4534,O
Food,4534,O
and,4534,O
Drugs,4534,O
Administration,4534,O
in,4534,O
adults,4534,O
for,4534,O
acute,4534,O
treatment,4534,O
of,4534,O
schizophrenia,4534,B-Disease
or,4534,O
of,4534,O
manic,4534,B-Disease
or,4534,O
mixed,4534,O
episodes,4534,O
associated,4534,O
with,4534,O
bipolar,4534,B-Disease
I,4534,I-Disease
disorder,4534,I-Disease
with,4534,O
or,4534,O
without,4534,O
psychotic,4534,B-Disease
features,4534,O
.,4534,O
In,4535,O
a,4535,O
double-blind,4535,O
6-week,4535,O
trial,4535,O
",",4535,O
458,4535,O
patients,4535,O
with,4535,O
acute,4535,O
schizophrenia,4535,B-Disease
were,4535,O
randomly,4535,O
assigned,4535,O
to,4535,O
fixed-dose,4535,O
treatment,4535,O
with,4535,O
asenapine,4535,B-Chemical
at,4535,O
5,4535,O
mg,4535,O
twice,4535,O
daily,4535,O
(,4535,O
BID,4535,O
),4535,O
",",4535,O
asenapine,4535,B-Chemical
at,4535,O
10,4535,O
mg,4535,O
BID,4535,O
",",4535,O
placebo,4535,O
",",4535,O
or,4535,O
haloperidol,4535,B-Chemical
at,4535,O
4,4535,O
mg,4535,O
BID,4535,O
(,4535,O
to,4535,O
verify,4535,O
assay,4535,O
sensitivity,4535,O
),4535,O
.,4535,O
With,4536,O
last,4536,O
observations,4536,O
carried,4536,O
forward,4536,O
(,4536,O
LOCF,4536,O
),4536,O
",",4536,O
mean,4536,O
Positive,4536,O
and,4536,O
Negative,4536,O
Syndrome,4536,O
Scale,4536,O
total,4536,O
score,4536,O
reductions,4536,O
from,4536,O
baseline,4536,O
to,4536,O
endpoint,4536,O
were,4536,O
significantly,4536,O
greater,4536,O
with,4536,O
asenapine,4536,B-Chemical
at,4536,O
5,4536,O
mg,4536,O
BID,4536,O
(,4536,O
-16.2,4536,O
),4536,O
and,4536,O
haloperidol,4536,B-Chemical
(,4536,O
-15.4,4536,O
),4536,O
than,4536,O
placebo,4536,O
(,4536,O
-10.7,4536,O
;,4536,O
both,4536,O
P,4536,O
<,4536,O
0.05,4536,O
),4536,O
;,4536,O
using,4536,O
mixed,4536,O
model,4536,O
for,4536,O
repeated,4536,O
measures,4536,O
(,4536,O
MMRM,4536,O
),4536,O
",",4536,O
changes,4536,O
at,4536,O
day,4536,O
42,4536,O
were,4536,O
significantly,4536,O
greater,4536,O
with,4536,O
asenapine,4536,B-Chemical
at,4536,O
5,4536,O
and,4536,O
10,4536,O
mg,4536,O
BID,4536,O
(,4536,O
-21.3,4536,O
and,4536,O
-19.4,4536,O
",",4536,O
respectively,4536,O
),4536,O
and,4536,O
haloperidol,4536,B-Chemical
(,4536,O
-20.0,4536,O
),4536,O
than,4536,O
placebo,4536,O
(,4536,O
-14.6,4536,O
;,4536,O
all,4536,O
P,4536,O
<,4536,O
0.05,4536,O
),4536,O
.,4536,O
On,4537,O
the,4537,O
Positive,4537,O
and,4537,O
Negative,4537,O
Syndrome,4537,O
Scale,4537,O
positive,4537,O
subscale,4537,O
",",4537,O
all,4537,O
treatments,4537,O
were,4537,O
superior,4537,O
to,4537,O
placebo,4537,O
with,4537,O
LOCF,4537,O
and,4537,O
MMRM,4537,O
;,4537,O
asenapine,4537,B-Chemical
at,4537,O
5,4537,O
mg,4537,O
BID,4537,O
was,4537,O
superior,4537,O
to,4537,O
placebo,4537,O
on,4537,O
the,4537,O
negative,4537,O
subscale,4537,O
with,4537,O
MMRM,4537,O
and,4537,O
on,4537,O
the,4537,O
general,4537,O
psychopathology,4537,O
subscale,4537,O
with,4537,O
LOCF,4537,O
and,4537,O
MMRM,4537,O
.,4537,O
Treatment-related,4538,O
adverse,4538,O
events,4538,O
(,4538,O
AEs,4538,O
),4538,O
occurred,4538,O
in,4538,O
44,4538,O
%,4538,O
and,4538,O
52,4538,O
%,4538,O
",",4538,O
57,4538,O
%,4538,O
",",4538,O
and,4538,O
41,4538,O
%,4538,O
of,4538,O
the,4538,O
asenapine,4538,B-Chemical
at,4538,O
5,4538,O
and,4538,O
10,4538,O
mg,4538,O
BID,4538,O
",",4538,O
haloperidol,4538,B-Chemical
",",4538,O
and,4538,O
placebo,4538,O
groups,4538,O
",",4538,O
respectively,4538,O
.,4538,O
Extrapyramidal,4539,B-Disease
symptoms,4539,I-Disease
reported,4539,O
as,4539,O
AEs,4539,O
occurred,4539,O
in,4539,O
15,4539,O
%,4539,O
and,4539,O
18,4539,O
%,4539,O
",",4539,O
34,4539,O
%,4539,O
",",4539,O
and,4539,O
10,4539,O
%,4539,O
of,4539,O
the,4539,O
asenapine,4539,B-Chemical
at,4539,O
5,4539,O
and,4539,O
10,4539,O
mg,4539,O
BID,4539,O
",",4539,O
haloperidol,4539,B-Chemical
",",4539,O
and,4539,O
placebo,4539,O
groups,4539,O
",",4539,O
respectively,4539,O
.,4539,O
Across,4540,O
all,4540,O
groups,4540,O
",",4540,O
no,4540,O
more,4540,O
than,4540,O
5,4540,O
%,4540,O
of,4540,O
patients,4540,O
had,4540,O
clinically,4540,O
significant,4540,O
weight,4540,O
change,4540,O
.,4540,O
Post,4541,O
hoc,4541,O
analyses,4541,O
indicated,4541,O
that,4541,O
efficacy,4541,O
was,4541,O
similar,4541,O
with,4541,O
asenapine,4541,B-Chemical
and,4541,O
haloperidol,4541,B-Chemical
;,4541,O
greater,4541,O
contrasts,4541,O
were,4541,O
seen,4541,O
in,4541,O
AEs,4541,O
",",4541,O
especially,4541,O
extrapyramidal,4541,B-Disease
symptoms,4541,I-Disease
.,4541,O
Salvage,4542,O
therapy,4542,O
with,4542,O
nelarabine,4542,B-Chemical
",",4542,O
etoposide,4542,B-Chemical
",",4542,O
and,4542,O
cyclophosphamide,4542,B-Chemical
in,4542,O
relapsed/refractory,4542,O
paediatric,4542,O
T-cell,4542,O
lymphoblastic,4542,O
leukaemia,4542,O
and,4542,O
lymphoma,4542,O
.,4542,O
A,4543,O
combination,4543,O
of,4543,O
5,4543,O
d,4543,O
of,4543,O
nelarabine,4543,B-Chemical
(,4543,O
AraG,4543,B-Chemical
),4543,O
with,4543,O
5,4543,O
d,4543,O
of,4543,O
etoposide,4543,B-Chemical
(,4543,O
VP,4543,B-Chemical
),4543,O
and,4543,O
cyclophosphamide,4543,B-Chemical
(,4543,O
CPM,4543,B-Chemical
),4543,O
and,4543,O
prophylactic,4543,O
intrathecal,4543,O
chemotherapy,4543,O
was,4543,O
used,4543,O
as,4543,O
salvage,4543,O
therapy,4543,O
in,4543,O
seven,4543,O
children,4543,O
with,4543,O
refractory,4543,O
or,4543,O
relapsed,4543,O
T-cell,4543,O
leukaemia,4543,O
or,4543,O
lymphoma,4543,O
.,4543,O
The,4544,O
most,4544,O
common,4544,O
side,4544,O
effects,4544,O
attributable,4544,O
to,4544,O
the,4544,O
AraG,4544,B-Chemical
included,4544,O
Grade,4544,O
2,4544,O
and,4544,O
3,4544,O
sensory,4544,O
and,4544,O
motor,4544,O
neuropathy,4544,B-Disease
and,4544,O
musculoskeletal,4544,B-Disease
pain,4544,I-Disease
.,4544,O
Haematological,4545,B-Disease
toxicity,4545,I-Disease
was,4545,O
greater,4545,O
for,4545,O
the,4545,O
combination,4545,O
than,4545,O
AraG,4545,B-Chemical
alone,4545,O
",",4545,O
although,4545,O
median,4545,O
time,4545,O
to,4545,O
neutrophil,4545,O
and,4545,O
platelet,4545,O
recovery,4545,O
was,4545,O
consistent,4545,O
with,4545,O
other,4545,O
salvage,4545,O
therapies,4545,O
.,4545,O
All,4546,O
patients,4546,O
had,4546,O
some,4546,O
response,4546,O
to,4546,O
the,4546,O
combined,4546,O
therapy,4546,O
and,4546,O
five,4546,O
of,4546,O
the,4546,O
seven,4546,O
went,4546,O
into,4546,O
complete,4546,O
remission,4546,O
after,4546,O
one,4546,O
or,4546,O
two,4546,O
courses,4546,O
of,4546,O
AraG/VP/CPM,4546,B-Chemical
.,4546,O
Our,4547,O
experience,4547,O
supports,4547,O
the,4547,O
safety,4547,O
of,4547,O
giving,4547,O
AraG,4547,B-Chemical
as,4547,O
salvage,4547,O
therapy,4547,O
in,4547,O
synchrony,4547,O
with,4547,O
etoposide,4547,B-Chemical
and,4547,O
cyclophosphamide,4547,B-Chemical
",",4547,O
although,4547,O
neurological,4547,B-Disease
toxicity,4547,I-Disease
must,4547,O
be,4547,O
closely,4547,O
monitored,4547,O
.,4547,O
Permeability,4548,O
",",4548,O
ultrastructural,4548,O
changes,4548,O
",",4548,O
and,4548,O
distribution,4548,O
of,4548,O
novel,4548,O
proteins,4548,O
in,4548,O
the,4548,O
glomerular,4548,O
barrier,4548,O
in,4548,O
early,4548,O
puromycin,4548,B-Chemical
aminonucleoside,4548,I-Chemical
nephrosis,4548,B-Disease
.,4548,O
BACKGROUND/AIMS,4549,O
:,4549,O
It,4549,O
is,4549,O
still,4549,O
unclear,4549,O
what,4549,O
happens,4549,O
in,4549,O
the,4549,O
glomerulus,4549,O
when,4549,O
proteinuria,4549,B-Disease
starts,4549,O
.,4549,O
Using,4550,O
puromycin,4550,B-Chemical
aminonucleoside,4550,I-Chemical
nephrosis,4550,B-Disease
(,4550,O
PAN,4550,O
),4550,O
rats,4550,O
",",4550,O
we,4550,O
studied,4550,O
early,4550,O
ultrastructural,4550,O
and,4550,O
permeability,4550,O
changes,4550,O
in,4550,O
relation,4550,O
to,4550,O
the,4550,O
expression,4550,O
of,4550,O
the,4550,O
podocyte-associated,4550,O
molecules,4550,O
nephrin,4550,O
",",4550,O
a-actinin,4550,O
",",4550,O
dendrin,4550,O
",",4550,O
and,4550,O
plekhh2,4550,O
",",4550,O
the,4550,O
last,4550,O
two,4550,O
of,4550,O
which,4550,O
were,4550,O
only,4550,O
recently,4550,O
discovered,4550,O
in,4550,O
podocytes,4550,O
.,4550,O
METHODS,4551,O
:,4551,O
Using,4551,O
immune,4551,O
stainings,4551,O
",",4551,O
semiquantitative,4551,O
measurement,4551,O
was,4551,O
performed,4551,O
under,4551,O
the,4551,O
electron,4551,O
microscope,4551,O
.,4551,O
Permeability,4552,O
was,4552,O
assessed,4552,O
using,4552,O
isolated,4552,O
kidney,4552,O
perfusion,4552,O
with,4552,O
tracers,4552,O
.,4552,O
Possible,4553,O
effects,4553,O
of,4553,O
ACE,4553,O
inhibition,4553,O
were,4553,O
tested,4553,O
.,4553,O
RESULTS,4554,O
:,4554,O
By,4554,O
day,4554,O
2,4554,O
",",4554,O
some,4554,O
patchy,4554,O
foot,4554,O
process,4554,O
effacement,4554,O
",",4554,O
but,4554,O
no,4554,O
proteinuria,4554,B-Disease
",",4554,O
appeared,4554,O
.,4554,O
The,4555,O
amount,4555,O
of,4555,O
nephrin,4555,O
was,4555,O
reduced,4555,O
in,4555,O
both,4555,O
diseased,4555,O
and,4555,O
normal,4555,O
areas,4555,O
.,4555,O
The,4556,O
other,4556,O
proteins,4556,O
showed,4556,O
few,4556,O
changes,4556,O
",",4556,O
which,4556,O
were,4556,O
limited,4556,O
to,4556,O
diseased,4556,O
areas,4556,O
.,4556,O
By,4557,O
day,4557,O
4,4557,O
",",4557,O
foot,4557,O
process,4557,O
effacement,4557,O
was,4557,O
complete,4557,O
and,4557,O
proteinuria,4557,B-Disease
appeared,4557,O
in,4557,O
parallel,4557,O
with,4557,O
signs,4557,O
of,4557,O
size,4557,O
barrier,4557,O
damage,4557,O
.,4557,O
Nephrin,4558,O
decreased,4558,O
further,4558,O
",",4558,O
while,4558,O
dendrin,4558,O
and,4558,O
plekhh2,4558,O
also,4558,O
decreased,4558,O
but,4558,O
a-actinin,4558,O
remained,4558,O
unchanged,4558,O
.,4558,O
ACE,4559,O
inhibition,4559,O
had,4559,O
no,4559,O
significant,4559,O
protective,4559,O
effect,4559,O
.,4559,O
CONCLUSIONS,4560,O
:,4560,O
PAN,4560,O
glomeruli,4560,O
already,4560,O
showed,4560,O
significant,4560,O
pathology,4560,O
by,4560,O
day,4560,O
4,4560,O
",",4560,O
despite,4560,O
relatively,4560,O
mild,4560,O
proteinuria,4560,B-Disease
.,4560,O
This,4561,O
was,4561,O
preceded,4561,O
by,4561,O
altered,4561,O
nephrin,4561,O
expression,4561,O
",",4561,O
supporting,4561,O
its,4561,O
pivotal,4561,O
role,4561,O
in,4561,O
podocyte,4561,O
morphology,4561,O
.,4561,O
The,4562,O
novel,4562,O
proteins,4562,O
dendrin,4562,O
and,4562,O
plekhh2,4562,O
were,4562,O
both,4562,O
reduced,4562,O
",",4562,O
suggesting,4562,O
roles,4562,O
in,4562,O
PAN,4562,O
",",4562,O
whereas,4562,O
a-actinin,4562,O
was,4562,O
unchanged,4562,O
.,4562,O
A,4563,O
novel,4563,O
",",4563,O
multiple,4563,O
symptom,4563,O
model,4563,O
of,4563,O
obsessive-compulsive-like,4563,B-Disease
behaviors,4563,I-Disease
in,4563,O
animals,4563,O
.,4563,O
BACKGROUND,4564,O
:,4564,O
Current,4564,O
animal,4564,O
models,4564,O
of,4564,O
obsessive-compulsive,4564,B-Disease
disorder,4564,I-Disease
(,4564,O
OCD,4564,B-Disease
),4564,O
typically,4564,O
involve,4564,O
acute,4564,O
",",4564,O
drug-induced,4564,O
symptom,4564,O
provocation,4564,O
or,4564,O
a,4564,O
genetic,4564,O
association,4564,O
with,4564,O
stereotypies,4564,O
or,4564,O
anxiety,4564,B-Disease
.,4564,O
None,4565,O
of,4565,O
these,4565,O
current,4565,O
models,4565,O
demonstrate,4565,O
multiple,4565,O
OCD-like,4565,B-Disease
behaviors,4565,O
.,4565,O
METHODS,4566,O
:,4566,O
Neonatal,4566,O
rats,4566,O
were,4566,O
treated,4566,O
with,4566,O
the,4566,O
tricyclic,4566,O
antidepressant,4566,B-Chemical
clomipramine,4566,B-Chemical
or,4566,O
vehicle,4566,O
between,4566,O
days,4566,O
9,4566,O
and,4566,O
16,4566,O
twice,4566,O
daily,4566,O
and,4566,O
behaviorally,4566,O
tested,4566,O
in,4566,O
adulthood,4566,O
.,4566,O
RESULTS,4567,O
:,4567,O
Clomipramine,4567,B-Chemical
exposure,4567,O
in,4567,O
immature,4567,O
rats,4567,O
produced,4567,O
significant,4567,O
behavioral,4567,O
and,4567,O
biochemical,4567,O
changes,4567,O
that,4567,O
include,4567,O
enhanced,4567,O
anxiety,4567,B-Disease
(,4567,O
elevated,4567,O
plus,4567,O
maze,4567,O
and,4567,O
marble,4567,O
burying,4567,O
),4567,O
",",4567,O
behavioral,4567,B-Disease
inflexibility,4567,I-Disease
(,4567,O
perseveration,4567,O
in,4567,O
the,4567,O
spontaneous,4567,O
alternation,4567,O
task,4567,O
and,4567,O
impaired,4567,O
reversal,4567,O
learning,4567,O
),4567,O
",",4567,O
working,4567,O
memory,4567,B-Disease
impairment,4567,I-Disease
(,4567,O
e.g.,4567,O
",",4567,O
win-shift,4567,O
paradigm,4567,O
),4567,O
",",4567,O
hoarding,4567,B-Disease
",",4567,O
and,4567,O
corticostriatal,4567,B-Disease
dysfunction,4567,I-Disease
.,4567,O
Dopamine,4568,B-Chemical
D2,4568,O
receptors,4568,O
were,4568,O
elevated,4568,O
in,4568,O
the,4568,O
striatum,4568,O
",",4568,O
whereas,4568,O
serotonin,4568,B-Chemical
2C,4568,O
",",4568,O
but,4568,O
not,4568,O
serotonin,4568,B-Chemical
1A,4568,O
",",4568,O
receptors,4568,O
were,4568,O
elevated,4568,O
in,4568,O
the,4568,O
orbital,4568,O
frontal,4568,O
cortex,4568,O
.,4568,O
CONCLUSIONS,4569,O
:,4569,O
This,4569,O
is,4569,O
the,4569,O
first,4569,O
demonstration,4569,O
of,4569,O
multiple,4569,O
symptoms,4569,O
consistent,4569,O
with,4569,O
an,4569,O
OCD-like,4569,B-Disease
profile,4569,O
in,4569,O
animals,4569,O
.,4569,O
Moreover,4570,O
",",4570,O
these,4570,O
behaviors,4570,O
are,4570,O
accompanied,4570,O
by,4570,O
biochemical,4570,O
changes,4570,O
in,4570,O
brain,4570,O
regions,4570,O
previously,4570,O
identified,4570,O
as,4570,O
relevant,4570,O
to,4570,O
OCD,4570,B-Disease
.,4570,O
This,4571,O
novel,4571,O
model,4571,O
of,4571,O
OCD,4571,B-Disease
demonstrates,4571,O
that,4571,O
drug,4571,O
exposure,4571,O
during,4571,O
a,4571,O
sensitive,4571,O
period,4571,O
can,4571,O
program,4571,O
disease-like,4571,O
systems,4571,O
permanently,4571,O
",",4571,O
which,4571,O
could,4571,O
have,4571,O
implications,4571,O
for,4571,O
current,4571,O
and,4571,O
future,4571,O
therapeutic,4571,O
strategies,4571,O
for,4571,O
this,4571,O
and,4571,O
other,4571,O
psychiatric,4571,B-Disease
disorders,4571,I-Disease
.,4571,O
Elevation,4572,O
of,4572,O
ADAM10,4572,O
",",4572,O
ADAM17,4572,O
",",4572,O
MMP-2,4572,O
and,4572,O
MMP-9,4572,O
expression,4572,O
with,4572,O
media,4572,O
degeneration,4572,O
features,4572,O
CaCl2-induced,4572,B-Chemical
thoracic,4572,B-Disease
aortic,4572,I-Disease
aneurysm,4572,I-Disease
in,4572,O
a,4572,O
rat,4572,O
model,4572,O
.,4572,O
PURPOSE,4573,O
:,4573,O
This,4573,O
study,4573,O
was,4573,O
designed,4573,O
to,4573,O
establish,4573,O
a,4573,O
rat,4573,O
model,4573,O
of,4573,O
thoracic,4573,B-Disease
aortic,4573,I-Disease
aneurysm,4573,I-Disease
(,4573,O
TAA,4573,B-Disease
),4573,O
by,4573,O
calcium,4573,B-Chemical
chloride,4573,I-Chemical
(,4573,O
CaCl,4573,B-Chemical
(,4573,I-Chemical
2,4573,I-Chemical
),4573,I-Chemical
),4573,O
-induced,4573,O
arterial,4573,B-Disease
injury,4573,I-Disease
and,4573,O
to,4573,O
explore,4573,O
the,4573,O
potential,4573,O
role,4573,O
of,4573,O
a,4573,O
disintegrin,4573,O
and,4573,O
metalloproteinase,4573,O
(,4573,O
ADAM,4573,O
),4573,O
",",4573,O
matrix,4573,O
metalloproteinases,4573,O
(,4573,O
MMPs,4573,O
),4573,O
and,4573,O
their,4573,O
endogenous,4573,O
inhibitors,4573,O
(,4573,O
TIMPs,4573,O
),4573,O
in,4573,O
TAA,4573,B-Disease
formation,4573,O
.,4573,O
METHODS,4574,O
:,4574,O
Thoracic,4574,O
aorta,4574,O
of,4574,O
male,4574,O
Sprague-Dawley,4574,O
rats,4574,O
was,4574,O
exposed,4574,O
to,4574,O
0.5M,4574,O
CaCl,4574,B-Chemical
(,4574,I-Chemical
2,4574,I-Chemical
),4574,I-Chemical
or,4574,O
normal,4574,O
saline,4574,O
(,4574,O
NaCl,4574,B-Chemical
),4574,O
.,4574,O
After,4575,O
12weeks,4575,O
",",4575,O
animals,4575,O
were,4575,O
euthanized,4575,O
",",4575,O
and,4575,O
CaCl,4575,B-Chemical
(,4575,I-Chemical
2,4575,I-Chemical
),4575,I-Chemical
-treated,4575,O
",",4575,O
CaCl,4575,B-Chemical
(,4575,I-Chemical
2,4575,I-Chemical
),4575,I-Chemical
-untreated,4575,O
(,4575,O
n=12,4575,O
),4575,O
and,4575,O
NaCl-treated,4575,B-Chemical
aortic,4575,O
segments,4575,O
(,4575,O
n=12,4575,O
),4575,O
were,4575,O
collected,4575,O
for,4575,O
histological,4575,O
and,4575,O
molecular,4575,O
assessments,4575,O
.,4575,O
MMP-TIMP,4576,O
and,4576,O
ADAM,4576,O
mRNAs,4576,O
were,4576,O
semi-quantitatively,4576,O
analyzed,4576,O
and,4576,O
protein,4576,O
expressions,4576,O
were,4576,O
determined,4576,O
by,4576,O
immunohistochemistry,4576,O
.,4576,O
RESULTS,4577,O
:,4577,O
Despite,4577,O
similar,4577,O
external,4577,O
diameters,4577,O
among,4577,O
CaCl,4577,B-Chemical
(,4577,I-Chemical
2,4577,I-Chemical
),4577,I-Chemical
-treated,4577,O
",",4577,O
non-CaCl,4577,O
(,4577,I-Chemical
2,4577,I-Chemical
),4577,I-Chemical
-treated,4577,O
and,4577,O
NaCl-treated,4577,B-Chemical
segments,4577,O
",",4577,O
aneurymal,4577,O
alteration,4577,O
(,4577,O
n=6,4577,O
",",4577,O
50,4577,O
%,4577,O
),4577,O
",",4577,O
media,4577,O
degeneration,4577,O
with,4577,O
regional,4577,O
disruption,4577,O
",",4577,O
fragmentation,4577,O
of,4577,O
elastic,4577,O
fiber,4577,O
",",4577,O
and,4577,O
increased,4577,O
collagen,4577,O
deposition,4577,O
(,4577,O
n=12,4577,O
",",4577,O
100,4577,O
%,4577,O
),4577,O
were,4577,O
demonstrated,4577,O
in,4577,O
CaCl,4577,B-Chemical
(,4577,I-Chemical
2,4577,I-Chemical
),4577,I-Chemical
-treated,4577,O
segments,4577,O
.,4577,O
MMP-2,4578,O
",",4578,O
MMP-9,4578,O
",",4578,O
ADAM-10,4578,O
and,4578,O
ADAM-17,4578,O
mRNA,4578,O
levels,4578,O
were,4578,O
increased,4578,O
in,4578,O
CaCl,4578,B-Chemical
(,4578,I-Chemical
2,4578,I-Chemical
),4578,I-Chemical
-treated,4578,O
segments,4578,O
(,4578,O
all,4578,O
p,4578,O
<,4578,O
0.01,4578,O
),4578,O
",",4578,O
with,4578,O
trends,4578,O
of,4578,O
elevation,4578,O
in,4578,O
CaCl,4578,B-Chemical
(,4578,I-Chemical
2,4578,I-Chemical
),4578,I-Chemical
-untreated,4578,O
segments,4578,O
",",4578,O
as,4578,O
compared,4578,O
with,4578,O
NaCl-treated,4578,B-Chemical
segments,4578,O
.,4578,O
Immunohistochemistry,4579,O
displayed,4579,O
significantly,4579,O
increased,4579,O
expressions,4579,O
of,4579,O
MMP-2,4579,O
",",4579,O
MMP-9,4579,O
",",4579,O
ADAM-10,4579,O
and,4579,O
ADAM-17,4579,O
(,4579,O
all,4579,O
p,4579,O
<,4579,O
0.01,4579,O
),4579,O
in,4579,O
intima,4579,O
and,4579,O
media,4579,O
for,4579,O
CaCl,4579,B-Chemical
(,4579,I-Chemical
2,4579,I-Chemical
),4579,I-Chemical
-treated,4579,O
segments,4579,O
.,4579,O
TIMP,4580,O
mRNA,4580,O
and,4580,O
tissue,4580,O
levels,4580,O
did,4580,O
not,4580,O
differ,4580,O
obviously,4580,O
among,4580,O
the,4580,O
three,4580,O
aortic,4580,O
segments,4580,O
.,4580,O
CONCLUSION,4581,O
:,4581,O
This,4581,O
study,4581,O
establishes,4581,O
a,4581,O
TAA,4581,B-Disease
model,4581,O
by,4581,O
periarterial,4581,O
CaCl,4581,B-Chemical
(,4581,I-Chemical
2,4581,I-Chemical
),4581,I-Chemical
exposure,4581,O
in,4581,O
rats,4581,O
",",4581,O
and,4581,O
demonstrates,4581,O
a,4581,O
significant,4581,O
elevation,4581,O
of,4581,O
expression,4581,O
of,4581,O
MMP-2,4581,O
",",4581,O
MMP-9,4581,O
",",4581,O
ADAM10,4581,O
and,4581,O
ADAM17,4581,O
in,4581,O
the,4581,O
pathogenesis,4581,O
of,4581,O
vascular,4581,O
remodeling,4581,O
.,4581,O
Suxamethonium,4582,B-Chemical
induced,4582,O
prolonged,4582,O
apnea,4582,B-Disease
in,4582,O
a,4582,O
patient,4582,O
receiving,4582,O
electroconvulsive,4582,O
therapy,4582,O
.,4582,O
Suxamethonium,4583,B-Chemical
causes,4583,O
prolonged,4583,O
apnea,4583,B-Disease
in,4583,O
patients,4583,O
in,4583,O
whom,4583,O
pseudocholinesterase,4583,O
enzyme,4583,O
gets,4583,O
deactivated,4583,O
by,4583,O
organophosphorus,4583,B-Chemical
(,4583,I-Chemical
OP,4583,I-Chemical
),4583,I-Chemical
poisons,4583,I-Chemical
.,4583,O
Here,4584,O
",",4584,O
we,4584,O
present,4584,O
a,4584,O
similar,4584,O
incident,4584,O
in,4584,O
a,4584,O
severely,4584,O
depressed,4584,B-Disease
patient,4584,O
who,4584,O
received,4584,O
electroconvulsive,4584,O
therapy,4584,O
(,4584,O
ECT,4584,O
),4584,O
.,4584,O
Prolonged,4585,O
apnea,4585,B-Disease
in,4585,O
our,4585,O
case,4585,O
ensued,4585,O
because,4585,O
the,4585,O
information,4585,O
about,4585,O
suicidal,4585,O
attempt,4585,O
by,4585,O
OP,4585,B-Chemical
compound,4585,I-Chemical
was,4585,O
concealed,4585,O
from,4585,O
the,4585,O
treating,4585,O
team,4585,O
.,4585,O
Curcumin,4586,B-Chemical
ameliorates,4586,O
cognitive,4586,B-Disease
dysfunction,4586,I-Disease
and,4586,O
oxidative,4586,O
damage,4586,O
in,4586,O
phenobarbitone,4586,B-Chemical
and,4586,O
carbamazepine,4586,B-Chemical
administered,4586,O
rats,4586,O
.,4586,O
The,4587,O
antiepileptic,4587,O
drugs,4587,O
",",4587,O
phenobarbitone,4587,B-Chemical
and,4587,O
carbamazepine,4587,B-Chemical
are,4587,O
well,4587,O
known,4587,O
to,4587,O
cause,4587,O
cognitive,4587,B-Disease
impairment,4587,I-Disease
on,4587,O
chronic,4587,O
use,4587,O
.,4587,O
The,4588,O
increase,4588,O
in,4588,O
free,4588,O
radical,4588,O
generation,4588,O
has,4588,O
been,4588,O
implicated,4588,O
as,4588,O
one,4588,O
of,4588,O
the,4588,O
important,4588,O
mechanisms,4588,O
of,4588,O
cognitive,4588,B-Disease
impairment,4588,I-Disease
by,4588,O
antiepileptic,4588,O
drugs,4588,O
.,4588,O
Curcumin,4589,B-Chemical
has,4589,O
shown,4589,O
antioxidant,4589,O
",",4589,O
anti-inflammatory,4589,O
and,4589,O
neuro-protective,4589,O
properties,4589,O
.,4589,O
Therefore,4590,O
",",4590,O
the,4590,O
present,4590,O
study,4590,O
was,4590,O
carried,4590,O
out,4590,O
to,4590,O
investigate,4590,O
the,4590,O
effect,4590,O
of,4590,O
chronic,4590,O
curcumin,4590,B-Chemical
administration,4590,O
on,4590,O
phenobarbitone-,4590,B-Chemical
and,4590,O
carbamazepine-induced,4590,B-Chemical
cognitive,4590,B-Disease
impairment,4590,I-Disease
and,4590,O
oxidative,4590,O
stress,4590,O
in,4590,O
rats,4590,O
.,4590,O
Pharmacokinetic,4591,O
interactions,4591,O
of,4591,O
curcumin,4591,B-Chemical
with,4591,O
phenobarbitone,4591,B-Chemical
and,4591,O
carbamazepine,4591,B-Chemical
were,4591,O
also,4591,O
studied,4591,O
.,4591,O
Vehicle/drugs,4592,O
were,4592,O
administered,4592,O
daily,4592,O
for,4592,O
21days,4592,O
to,4592,O
male,4592,O
Wistar,4592,O
rats,4592,O
.,4592,O
Passive,4593,O
avoidance,4593,O
paradigm,4593,O
and,4593,O
elevated,4593,O
plus,4593,O
maze,4593,O
test,4593,O
were,4593,O
used,4593,O
to,4593,O
assess,4593,O
cognitive,4593,O
function,4593,O
.,4593,O
At,4594,O
the,4594,O
end,4594,O
of,4594,O
study,4594,O
period,4594,O
",",4594,O
serum,4594,O
phenobarbitone,4594,B-Chemical
and,4594,O
carbamazepine,4594,B-Chemical
",",4594,O
whole,4594,O
brain,4594,O
malondialdehyde,4594,B-Chemical
and,4594,O
reduced,4594,O
glutathione,4594,B-Chemical
levels,4594,O
were,4594,O
estimated,4594,O
.,4594,O
The,4595,O
administration,4595,O
of,4595,O
phenobarbitone,4595,B-Chemical
and,4595,O
carbamazepine,4595,B-Chemical
for,4595,O
21days,4595,O
caused,4595,O
a,4595,O
significant,4595,O
impairment,4595,B-Disease
of,4595,I-Disease
learning,4595,I-Disease
and,4595,I-Disease
memory,4595,I-Disease
as,4595,O
well,4595,O
as,4595,O
an,4595,O
increased,4595,O
oxidative,4595,O
stress,4595,O
.,4595,O
Concomitant,4596,O
curcumin,4596,B-Chemical
administration,4596,O
prevented,4596,O
the,4596,O
cognitive,4596,B-Disease
impairment,4596,I-Disease
and,4596,O
decreased,4596,O
the,4596,O
increased,4596,O
oxidative,4596,O
stress,4596,O
induced,4596,O
by,4596,O
these,4596,O
antiepileptic,4596,O
drugs,4596,O
.,4596,O
Curcumin,4597,B-Chemical
co-administration,4597,O
did,4597,O
not,4597,O
cause,4597,O
any,4597,O
significant,4597,O
alteration,4597,O
in,4597,O
the,4597,O
serum,4597,O
concentrations,4597,O
of,4597,O
both,4597,O
phenobarbitone,4597,B-Chemical
as,4597,O
well,4597,O
as,4597,O
carbamazepine,4597,B-Chemical
.,4597,O
These,4598,O
results,4598,O
show,4598,O
that,4598,O
curcumin,4598,B-Chemical
has,4598,O
beneficial,4598,O
effect,4598,O
in,4598,O
mitigating,4598,O
the,4598,O
deterioration,4598,B-Disease
of,4598,I-Disease
cognitive,4598,I-Disease
functions,4598,I-Disease
and,4598,O
oxidative,4598,O
damage,4598,O
in,4598,O
rats,4598,O
treated,4598,O
with,4598,O
phenobarbitone,4598,B-Chemical
and,4598,O
carbamazepine,4598,B-Chemical
without,4598,O
significantly,4598,O
altering,4598,O
their,4598,O
serum,4598,O
concentrations,4598,O
.,4598,O
The,4599,O
findings,4599,O
suggest,4599,O
that,4599,O
curcumin,4599,B-Chemical
can,4599,O
be,4599,O
considered,4599,O
as,4599,O
a,4599,O
potential,4599,O
safe,4599,O
and,4599,O
effective,4599,O
adjuvant,4599,O
to,4599,O
phenobarbitone,4599,B-Chemical
and,4599,O
carbamazepine,4599,B-Chemical
therapy,4599,O
in,4599,O
preventing,4599,O
cognitive,4599,B-Disease
impairment,4599,I-Disease
associated,4599,O
with,4599,O
these,4599,O
drugs,4599,O
.,4599,O
Can,4600,O
angiogenesis,4600,O
be,4600,O
a,4600,O
target,4600,O
of,4600,O
treatment,4600,O
for,4600,O
ribavirin,4600,B-Chemical
associated,4600,O
hemolytic,4600,B-Disease
anemia,4600,I-Disease
?,4600,O
BACKGROUND/AIMS,4601,O
:,4601,O
Recently,4601,O
ribavirin,4601,B-Chemical
has,4601,O
been,4601,O
found,4601,O
to,4601,O
inhibit,4601,O
angiogenesis,4601,O
and,4601,O
a,4601,O
number,4601,O
of,4601,O
angiogenesis,4601,O
inhibitors,4601,O
such,4601,O
as,4601,O
sunitinib,4601,B-Chemical
and,4601,O
sorafenib,4601,B-Chemical
have,4601,O
been,4601,O
found,4601,O
to,4601,O
cause,4601,O
acute,4601,O
hemolysis,4601,B-Disease
.,4601,O
We,4602,O
aimed,4602,O
to,4602,O
investigate,4602,O
whether,4602,O
there,4602,O
is,4602,O
a,4602,O
relation,4602,O
between,4602,O
hemoglobin,4602,O
",",4602,O
haptoglobin,4602,O
and,4602,O
angiogenesis,4602,O
soluble,4602,O
markers,4602,O
which,4602,O
are,4602,O
modifiable,4602,O
and,4602,O
can,4602,O
help,4602,O
in,4602,O
developing,4602,O
strategies,4602,O
against,4602,O
anemia,4602,B-Disease
.,4602,O
METHODS,4603,O
:,4603,O
Fourteen,4603,O
patients,4603,O
chronically,4603,B-Disease
infected,4603,I-Disease
with,4603,I-Disease
hepatitis,4603,I-Disease
C,4603,I-Disease
virus,4603,I-Disease
were,4603,O
treated,4603,O
by,4603,O
pegylated,4603,B-Chemical
interferon,4603,I-Chemical
alpha,4603,I-Chemical
2a,4603,I-Chemical
and,4603,O
ribavirin,4603,B-Chemical
.,4603,O
Serum,4604,O
hemoglobin,4604,O
",",4604,O
haptoglobin,4604,O
and,4604,O
angiogenesis,4604,O
markers,4604,O
of,4604,O
vascular,4604,O
endothelial,4604,O
growth,4604,O
factor,4604,O
and,4604,O
angiopoetin-2,4604,O
were,4604,O
investigated,4604,O
before,4604,O
and,4604,O
after,4604,O
therapy,4604,O
.,4604,O
RESULTS,4605,O
:,4605,O
We,4605,O
observed,4605,O
a,4605,O
significant,4605,O
decrease,4605,O
in,4605,O
haptoglobin,4605,O
levels,4605,O
at,4605,O
the,4605,O
end,4605,O
of,4605,O
the,4605,O
treatment,4605,O
period,4605,O
.,4605,O
Hemoglobin,4606,O
levels,4606,O
also,4606,O
decreased,4606,O
but,4606,O
insignificantly,4606,O
by,4606,O
treatment,4606,O
.,4606,O
In,4607,O
contrast,4607,O
with,4607,O
the,4607,O
literature,4607,O
",",4607,O
serum,4607,O
levels,4607,O
of,4607,O
angiogenesis,4607,O
factors,4607,O
did,4607,O
not,4607,O
change,4607,O
significantly,4607,O
by,4607,O
pegylated,4607,B-Chemical
interferon,4607,I-Chemical
and,4607,O
ribavirin,4607,B-Chemical
therapy,4607,O
.,4607,O
We,4608,O
found,4608,O
no,4608,O
correlation,4608,O
of,4608,O
angiogenesis,4608,O
soluble,4608,O
markers,4608,O
with,4608,O
either,4608,O
hemoglobin,4608,O
or,4608,O
haptoglobin,4608,O
.,4608,O
CONCLUSION,4609,O
:,4609,O
This,4609,O
is,4609,O
the,4609,O
first,4609,O
study,4609,O
in,4609,O
the,4609,O
literature,4609,O
investigating,4609,O
a,4609,O
link,4609,O
between,4609,O
angiogenesis,4609,O
soluble,4609,O
markers,4609,O
and,4609,O
ribavirin,4609,B-Chemical
induced,4609,O
anemia,4609,B-Disease
in,4609,O
patients,4609,O
with,4609,O
hepatitis,4609,B-Disease
C,4609,I-Disease
and,4609,O
we,4609,O
could,4609,O
not,4609,O
find,4609,O
any,4609,O
relation,4609,O
.,4609,O
Future,4610,O
research,4610,O
with,4610,O
larger,4610,O
number,4610,O
of,4610,O
patients,4610,O
is,4610,O
needed,4610,O
to,4610,O
find,4610,O
out,4610,O
modifiable,4610,O
factors,4610,O
that,4610,O
will,4610,O
improve,4610,O
the,4610,O
safety,4610,O
of,4610,O
ribavirin,4610,B-Chemical
therapy,4610,O
.,4610,O
Safety,4611,O
of,4611,O
capecitabine,4611,B-Chemical
:,4611,O
a,4611,O
review,4611,O
.,4611,O
IMPORTANCE,4612,O
OF,4612,O
THE,4612,O
FIELD,4612,O
:,4612,O
Fluoropyrimidines,4612,B-Chemical
",",4612,O
in,4612,O
particular,4612,O
5-fluorouracil,4612,B-Chemical
(,4612,O
5-FU,4612,B-Chemical
),4612,O
",",4612,O
have,4612,O
been,4612,O
the,4612,O
mainstay,4612,O
of,4612,O
treatment,4612,O
for,4612,O
several,4612,O
solid,4612,O
tumors,4612,B-Disease
",",4612,O
including,4612,O
colorectal,4612,O
",",4612,O
breast,4612,O
and,4612,O
head,4612,O
and,4612,O
neck,4612,O
cancers,4612,O
",",4612,O
for,4612,O
>,4612,O
40,4612,O
years,4612,O
.,4612,O
AREAS,4613,O
COVERED,4613,O
IN,4613,O
THIS,4613,O
REVIEW,4613,O
:,4613,O
This,4613,O
article,4613,O
reviews,4613,O
the,4613,O
pharmacology,4613,O
and,4613,O
efficacy,4613,O
of,4613,O
capecitabine,4613,B-Chemical
with,4613,O
a,4613,O
special,4613,O
emphasis,4613,O
on,4613,O
its,4613,O
safety,4613,O
.,4613,O
WHAT,4614,O
THE,4614,O
READER,4614,O
WILL,4614,O
GAIN,4614,O
:,4614,O
The,4614,O
reader,4614,O
will,4614,O
gain,4614,O
better,4614,O
insight,4614,O
into,4614,O
the,4614,O
safety,4614,O
of,4614,O
capecitabine,4614,B-Chemical
in,4614,O
special,4614,O
populations,4614,O
such,4614,O
as,4614,O
patients,4614,O
with,4614,O
advanced,4614,O
age,4614,O
",",4614,O
renal,4614,B-Disease
and,4614,I-Disease
kidney,4614,I-Disease
disease,4614,I-Disease
.,4614,O
We,4615,O
also,4615,O
explore,4615,O
different,4615,O
dosing,4615,O
and,4615,O
schedules,4615,O
of,4615,O
capecitabine,4615,B-Chemical
administration,4615,O
.,4615,O
TAKE,4616,O
HOME,4616,O
MESSAGE,4616,O
:,4616,O
Capecitabine,4616,B-Chemical
is,4616,O
an,4616,O
oral,4616,O
prodrug,4616,O
of,4616,O
5-FU,4616,B-Chemical
and,4616,O
was,4616,O
developed,4616,O
to,4616,O
fulfill,4616,O
the,4616,O
need,4616,O
for,4616,O
a,4616,O
more,4616,O
convenient,4616,O
therapy,4616,O
and,4616,O
provide,4616,O
an,4616,O
improved,4616,O
safety/efficacy,4616,O
profile,4616,O
.,4616,O
It,4617,O
has,4617,O
shown,4617,O
promising,4617,O
results,4617,O
alone,4617,O
or,4617,O
in,4617,O
combination,4617,O
with,4617,O
other,4617,O
chemotherapeutic,4617,O
agents,4617,O
in,4617,O
colorectal,4617,O
",",4617,O
breast,4617,O
",",4617,O
pancreaticobiliary,4617,O
",",4617,O
gastric,4617,O
",",4617,O
renal,4617,O
cell,4617,O
and,4617,O
head,4617,O
and,4617,O
neck,4617,O
cancers,4617,O
.,4617,O
The,4618,O
most,4618,O
commonly,4618,O
reported,4618,O
toxic,4618,O
effects,4618,O
of,4618,O
capecitabine,4618,B-Chemical
are,4618,O
diarrhea,4618,B-Disease
",",4618,O
nausea,4618,B-Disease
",",4618,O
vomiting,4618,B-Disease
",",4618,O
stomatitis,4618,B-Disease
and,4618,O
hand-foot,4618,B-Disease
syndrome,4618,I-Disease
.,4618,O
Capecitabine,4619,B-Chemical
has,4619,O
a,4619,O
well-established,4619,O
safety,4619,O
profile,4619,O
and,4619,O
can,4619,O
be,4619,O
given,4619,O
safely,4619,O
to,4619,O
patients,4619,O
with,4619,O
advanced,4619,O
age,4619,O
",",4619,O
hepatic,4619,O
and,4619,O
renal,4619,O
dysfunctions,4619,O
.,4619,O
Levodopa-induced,4620,B-Chemical
dyskinesias,4620,B-Disease
in,4620,O
patients,4620,O
with,4620,O
Parkinson,4620,B-Disease
's,4620,I-Disease
disease,4620,I-Disease
:,4620,O
filling,4620,O
the,4620,O
bench-to-bedside,4620,O
gap,4620,O
.,4620,O
Levodopa,4621,B-Chemical
is,4621,O
the,4621,O
most,4621,O
effective,4621,O
drug,4621,O
for,4621,O
the,4621,O
treatment,4621,O
of,4621,O
Parkinson,4621,B-Disease
's,4621,I-Disease
disease,4621,I-Disease
.,4621,O
However,4622,O
",",4622,O
the,4622,O
long-term,4622,O
use,4622,O
of,4622,O
this,4622,O
dopamine,4622,B-Chemical
precursor,4622,O
is,4622,O
complicated,4622,O
by,4622,O
highly,4622,O
disabling,4622,O
fluctuations,4622,O
and,4622,O
dyskinesias,4622,B-Disease
.,4622,O
Although,4623,O
preclinical,4623,O
and,4623,O
clinical,4623,O
findings,4623,O
suggest,4623,O
pulsatile,4623,O
stimulation,4623,O
of,4623,O
striatal,4623,O
postsynaptic,4623,O
receptors,4623,O
as,4623,O
a,4623,O
key,4623,O
mechanism,4623,O
underlying,4623,O
levodopa-induced,4623,B-Chemical
dyskinesias,4623,B-Disease
",",4623,O
their,4623,O
pathogenesis,4623,O
is,4623,O
still,4623,O
unclear,4623,O
.,4623,O
In,4624,O
recent,4624,O
years,4624,O
",",4624,O
evidence,4624,O
from,4624,O
animal,4624,O
models,4624,O
of,4624,O
Parkinson,4624,B-Disease
's,4624,I-Disease
disease,4624,I-Disease
has,4624,O
provided,4624,O
important,4624,O
information,4624,O
to,4624,O
understand,4624,O
the,4624,O
effect,4624,O
of,4624,O
specific,4624,O
receptor,4624,O
and,4624,O
post-receptor,4624,O
molecular,4624,O
mechanisms,4624,O
underlying,4624,O
the,4624,O
development,4624,O
of,4624,O
dyskinetic,4624,B-Disease
movements,4624,I-Disease
.,4624,O
Recent,4625,O
preclinical,4625,O
and,4625,O
clinical,4625,O
data,4625,O
from,4625,O
promising,4625,O
lines,4625,O
of,4625,O
research,4625,O
focus,4625,O
on,4625,O
the,4625,O
differential,4625,O
role,4625,O
of,4625,O
presynaptic,4625,O
versus,4625,O
postsynaptic,4625,O
mechanisms,4625,O
",",4625,O
dopamine,4625,B-Chemical
receptor,4625,O
subtypes,4625,O
",",4625,O
ionotropic,4625,O
and,4625,O
metabotropic,4625,O
glutamate,4625,B-Chemical
receptors,4625,O
",",4625,O
and,4625,O
non-dopaminergic,4625,O
neurotransmitter,4625,O
systems,4625,O
in,4625,O
the,4625,O
pathophysiology,4625,O
of,4625,O
levodopa-induced,4625,B-Chemical
dyskinesias,4625,B-Disease
.,4625,O
Effects,4626,O
of,4626,O
pallidal,4626,O
neurotensin,4626,B-Chemical
on,4626,O
haloperidol-induced,4626,B-Chemical
parkinsonian,4626,B-Disease
catalepsy,4626,I-Disease
:,4626,O
behavioral,4626,O
and,4626,O
electrophysiological,4626,O
studies,4626,O
.,4626,O
OBJECTIVE,4627,O
:,4627,O
The,4627,O
globus,4627,O
pallidus,4627,O
plays,4627,O
a,4627,O
critical,4627,O
role,4627,O
in,4627,O
movement,4627,O
regulation,4627,O
.,4627,O
Previous,4628,O
studies,4628,O
have,4628,O
indicated,4628,O
that,4628,O
the,4628,O
globus,4628,O
pallidus,4628,O
receives,4628,O
neurotensinergic,4628,O
innervation,4628,O
from,4628,O
the,4628,O
striatum,4628,O
",",4628,O
and,4628,O
systemic,4628,O
administration,4628,O
of,4628,O
a,4628,O
neurotensin,4628,B-Chemical
analog,4628,O
could,4628,O
produce,4628,O
antiparkinsonian,4628,O
effects,4628,O
.,4628,O
The,4629,O
present,4629,O
study,4629,O
aimed,4629,O
to,4629,O
investigate,4629,O
the,4629,O
effects,4629,O
of,4629,O
pallidal,4629,O
neurotensin,4629,B-Chemical
on,4629,O
haloperidol-induced,4629,B-Chemical
parkinsonian,4629,B-Disease
symptoms,4629,I-Disease
.,4629,O
METHODS,4630,O
:,4630,O
Behavioral,4630,O
experiments,4630,O
and,4630,O
electrophysiological,4630,O
recordings,4630,O
were,4630,O
performed,4630,O
in,4630,O
the,4630,O
present,4630,O
study,4630,O
.,4630,O
RESULTS,4631,O
:,4631,O
Bilateral,4631,O
infusions,4631,O
of,4631,O
neurotensin,4631,B-Chemical
into,4631,O
the,4631,O
globus,4631,O
pallidus,4631,O
reversed,4631,O
haloperidol-induced,4631,B-Chemical
parkinsonian,4631,B-Disease
catalepsy,4631,I-Disease
in,4631,O
rats,4631,O
.,4631,O
Electrophysiological,4632,O
recordings,4632,O
showed,4632,O
that,4632,O
microinjection,4632,O
of,4632,O
neurotensin,4632,B-Chemical
induced,4632,O
excitation,4632,O
of,4632,O
pallidal,4632,O
neurons,4632,O
in,4632,O
the,4632,O
presence,4632,O
of,4632,O
systemic,4632,O
haloperidol,4632,B-Chemical
administration,4632,O
.,4632,O
The,4633,O
neurotensin,4633,B-Chemical
type-1,4633,I-Chemical
receptor,4633,I-Chemical
antagonist,4633,I-Chemical
SR48692,4633,B-Chemical
blocked,4633,O
both,4633,O
the,4633,O
behavioral,4633,O
and,4633,O
the,4633,O
electrophysiological,4633,O
effects,4633,O
induced,4633,O
by,4633,O
neurotensin,4633,B-Chemical
.,4633,O
CONCLUSION,4634,O
:,4634,O
Activation,4634,O
of,4634,O
pallidal,4634,O
neurotensin,4634,B-Chemical
receptors,4634,O
may,4634,O
be,4634,O
involved,4634,O
in,4634,O
neurotensin-induced,4634,B-Chemical
antiparkinsonian,4634,O
effects,4634,O
.,4634,O
Butyrylcholinesterase,4635,O
gene,4635,O
mutations,4635,O
in,4635,O
patients,4635,O
with,4635,O
prolonged,4635,O
apnea,4635,B-Disease
after,4635,O
succinylcholine,4635,B-Chemical
for,4635,O
electroconvulsive,4635,O
therapy,4635,O
.,4635,O
BACKGROUND,4636,O
:,4636,O
patients,4636,O
undergoing,4636,O
electroconvulsive,4636,O
therapy,4636,O
(,4636,O
ECT,4636,O
),4636,O
often,4636,O
receive,4636,O
succinylcholine,4636,B-Chemical
as,4636,O
part,4636,O
of,4636,O
the,4636,O
anesthetic,4636,O
procedure,4636,O
.,4636,O
The,4637,O
duration,4637,O
of,4637,O
action,4637,O
may,4637,O
be,4637,O
prolonged,4637,O
in,4637,O
patients,4637,O
with,4637,O
genetic,4637,O
variants,4637,O
of,4637,O
the,4637,O
butyrylcholinesterase,4637,O
enzyme,4637,O
(,4637,O
BChE,4637,O
),4637,O
",",4637,O
the,4637,O
most,4637,O
common,4637,O
being,4637,O
the,4637,O
K-,4637,O
and,4637,O
the,4637,O
A-variants,4637,O
.,4637,O
The,4638,O
aim,4638,O
of,4638,O
the,4638,O
study,4638,O
was,4638,O
to,4638,O
assess,4638,O
the,4638,O
clinical,4638,O
significance,4638,O
of,4638,O
genetic,4638,O
variants,4638,O
in,4638,O
butyrylcholinesterase,4638,O
gene,4638,O
(,4638,O
BCHE,4638,O
),4638,O
in,4638,O
patients,4638,O
with,4638,O
a,4638,O
suspected,4638,O
prolonged,4638,O
duration,4638,O
of,4638,O
action,4638,O
of,4638,O
succinylcholine,4638,B-Chemical
after,4638,O
ECT,4638,O
.,4638,O
METHODS,4639,O
:,4639,O
a,4639,O
total,4639,O
of,4639,O
13,4639,O
patients,4639,O
were,4639,O
referred,4639,O
to,4639,O
the,4639,O
Danish,4639,O
Cholinesterase,4639,O
Research,4639,O
Unit,4639,O
after,4639,O
ECT,4639,O
during,4639,O
38,4639,O
months,4639,O
.,4639,O
We,4640,O
determined,4640,O
the,4640,O
BChE,4640,O
activity,4640,O
and,4640,O
the,4640,O
BCHE,4640,O
genotype,4640,O
using,4640,O
molecular,4640,O
genetic,4640,O
methods,4640,O
",",4640,O
the,4640,O
duration,4640,O
of,4640,O
apnea,4640,B-Disease
",",4640,O
time,4640,O
to,4640,O
sufficient,4640,O
spontaneous,4640,O
ventilation,4640,O
and,4640,O
whether,4640,O
neuromuscular,4640,O
monitoring,4640,O
was,4640,O
used,4640,O
.,4640,O
The,4641,O
duration,4641,O
of,4641,O
apnea,4641,B-Disease
was,4641,O
compared,4641,O
with,4641,O
published,4641,O
data,4641,O
on,4641,O
normal,4641,O
subjects,4641,O
.,4641,O
RESULTS,4642,O
:,4642,O
in,4642,O
11,4642,O
patients,4642,O
",",4642,O
mutations,4642,O
were,4642,O
found,4642,O
in,4642,O
the,4642,O
BCHE,4642,O
gene,4642,O
",",4642,O
the,4642,O
K-variant,4642,O
being,4642,O
the,4642,O
most,4642,O
frequent,4642,O
.,4642,O
The,4643,O
duration,4643,O
of,4643,O
apnea,4643,B-Disease
was,4643,O
5-15,4643,O
min,4643,O
compared,4643,O
with,4643,O
3-5.3,4643,O
min,4643,O
from,4643,O
the,4643,O
literature,4643,O
.,4643,O
Severe,4644,O
distress,4644,O
was,4644,O
noted,4644,O
in,4644,O
the,4644,O
recovery,4644,O
phase,4644,O
in,4644,O
two,4644,O
patients,4644,O
.,4644,O
Neuromuscular,4645,O
monitoring,4645,O
was,4645,O
used,4645,O
in,4645,O
two,4645,O
patients,4645,O
.,4645,O
CONCLUSION,4646,O
:,4646,O
eleven,4646,O
of,4646,O
13,4646,O
patients,4646,O
with,4646,O
a,4646,O
prolonged,4646,O
duration,4646,O
of,4646,O
action,4646,O
of,4646,O
succinylcholine,4646,B-Chemical
had,4646,O
mutations,4646,O
in,4646,O
BCHE,4646,O
",",4646,O
indicating,4646,O
that,4646,O
this,4646,O
is,4646,O
the,4646,O
possible,4646,O
reason,4646,O
for,4646,O
a,4646,O
prolonged,4646,O
period,4646,O
of,4646,O
apnea,4646,B-Disease
.,4646,O
We,4647,O
recommend,4647,O
objective,4647,O
neuromuscular,4647,O
monitoring,4647,O
during,4647,O
the,4647,O
first,4647,O
ECT,4647,O
.,4647,O
